PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Cominetti, M; Terruggi, CHB; Ramos, OHP; Fox, JW; Mariano-Oliveira, A; De Freitas, MS; Figueiredo, CC; Morandi, V; Selistre-de-Araujo, HS				Cominetti, M; Terruggi, CHB; Ramos, OHP; Fox, JW; Mariano-Oliveira, A; De Freitas, MS; Figueiredo, CC; Morandi, V; Selistre-de-Araujo, HS			Alternagin-C, a disintegrin-like protein, induces vascular endothelial cell growth factor (VEGF) expression and endothelial cell proliferation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM DISINTEGRIN; CYSTEINE-RICH DOMAIN; PLATELET-AGGREGATION; MELANOMA-CELLS; INTEGRIN ALPHA(V)BETA(3); EXPERIMENTAL METASTASIS; ANGIOGENESIS INVITRO; NEUTROPHIL MIGRATION; MATRIX INTERACTIONS; AKT PROTOONCOGENE	Alternagin-C (ALT-C), a disintegrin-like protein purified from the venom of the Brazilian snake Bothrops alternatus, interacts with the major collagen I receptor, the alpha(2)beta(1) integrin, inhibiting collagen binding. Here we show that ALT-C also inhibits the adhesion of a mouse fibroblast cell line (NIH-3T3) to collagen I (IC50 2.2 muM). In addition, when immobilized on plate wells, ALT-C supports the adhesion of this cell line as well as of human vein endothelial cell (HUVEC). ALT-C (3 muM) does not detach cells that were previously bound to collagen I. ALT-C (5 nM) induces HUVEC proliferation in vitro, and it inhibits the positive effect of vascular endothelial growth factor (VEGF) or FGF-2 on the proliferation of these cells, thus suggesting a common mechanism for these proteins. Gene expression analysis of human fibroblasts growing on ALT-C- or collagen-coated plates showed that ALT-C and collagen I induce a very similar pattern of gene expression. When compared with cells growing on plastic only, ALT-C up-regulates the expression of 45 genes including the VEGF gene and downregulates the expression of 30 genes. Fibroblast VEGF expression was confirmed by RT-PCR and ELISA assay. Up-regulation of the VEGF gene and other growth factors could explain the positive effect on HUVEC proliferation. ALT-C also strongly activates Akt/PKB phosphorylation, a signaling event involved in endothelial survival and angiogenesis. In conclusion, ALT-C acts as a survival factor, promoting adhesion and endothelial cell proliferation.	Univ Fed Sao Carlos, Dept Ciencias Fisiol, BR-13565905 Sao Carlos, SP, Brazil; Univ Estado Rio de Janeiro, Inst Biol, Dept Biol Celular & Genet, BR-20550013 Rio De Janeiro, Brazil; Univ Estado Rio de Janeiro, Inst Biol, Dept Farmacol, BR-20550013 Rio De Janeiro, Brazil; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA	Universidade Federal de Sao Carlos; Universidade do Estado do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; University of Virginia	Selistre-de-Araujo, HS (corresponding author), Univ Fed Sao Carlos, Dept Ciencias Fisiol, Rodovia Washington Luis,Km 235, BR-13565905 Sao Carlos, SP, Brazil.	hsaraujo@power.ufscar.br	Ramos, Oscar HP/E-1862-2013; de Freitas, Marta Sampaio/AAE-8422-2021; Cominetti, Marcia Regina/B-8080-2012; Morandi, Verônica/C-5837-2013; Selistre-de-Araujo, Heloisa S/A-3792-2016	Ramos, Oscar HP/0000-0002-5788-4500; Cominetti, Marcia Regina/0000-0001-6385-7392; 				Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Araki S, 2002, TOXICON, V40, P535, DOI 10.1016/S0041-0101(01)00249-5; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Belisario MA, 2000, BBA-MOL CELL RES, V1497, P227, DOI 10.1016/S0167-4889(00)00061-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Castel S, 2000, EUR J CELL BIOL, V79, P502, DOI 10.1078/0171-9335-00067; Coelho ALJ, 1999, EXP CELL RES, V251, P379, DOI 10.1006/excr.1999.4583; Cominetti MR, 2003, ARCH BIOCHEM BIOPHYS, V416, P171, DOI 10.1016/S0003-9861(03)00298-4; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Curti A, 2002, HAEMATOLOGICA, V87, P373; Danen EHJ, 1998, EXP CELL RES, V238, P188, DOI 10.1006/excr.1997.3821; Della Morte R, 2000, EUR J BIOCHEM, V267, P5047, DOI 10.1046/j.1432-1327.2000.01561.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FOX JW, 1998, SNAKE VENOM ENZYMES, P151; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; Hong SY, 2003, BIOCHEM BIOPH RES CO, V302, P502, DOI 10.1016/S0006-291X(03)00213-4; Hong SY, 2002, THROMB RES, V105, P79, DOI 10.1016/S0049-3848(01)00416-9; HUANG TF, 1987, J BIOL CHEM, V262, P16157; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Ilan N, 1998, J CELL SCI, V111, P3621; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Kamiguti AS, 2003, FEBS LETT, V549, P129, DOI 10.1016/S0014-5793(03)00799-3; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LaFlamme SE, 1996, SEMIN CANCER BIOL, V7, P111, DOI 10.1006/scbi.1996.0016; Leng SX, 1997, INT J BIOCHEM CELL B, V29, P1059, DOI 10.1016/S1357-2725(97)00017-4; LLOYD RV, 1997, ENDOCR PATHOL, V8, P2121; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; Mariano-Oliveira A, 2003, EUR J BIOCHEM, V270, P4799, DOI 10.1046/j.1432-1033.2003.03867.x; MITJANS F, 1995, J CELL SCI, V108, P2825; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1987, J CELL PHYSIOL, V130, P284, DOI 10.1002/jcp.1041300215; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; SAIKI I, 1989, BRIT J CANCER, V59, P194, DOI 10.1038/bjc.1989.40; Sheu JR, 1997, BBA-GEN SUBJECTS, V1336, P445, DOI 10.1016/S0304-4165(97)00057-3; SHOIJIMA I, 2002, CIRC RES, V90, P1243; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Souza DHF, 2000, ARCH BIOCHEM BIOPHYS, V384, P341, DOI 10.1006/abbi.2000.2120; TRIKHA M, 1994, CANCER RES, V54, P4993; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Yeh CH, 1998, BBA-GEN SUBJECTS, V1425, P493, DOI 10.1016/S0304-4165(98)00104-4; Yeh CH, 1998, BLOOD, V92, P3268, DOI 10.1182/blood.V92.9.3268.421k41_3268_3276; Zeng XR, 2003, CELLS TISSUES ORGANS, V174, P63, DOI 10.1159/000070575; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	62	57	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18247	18255		10.1074/jbc.M311771200	http://dx.doi.org/10.1074/jbc.M311771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14766757	hybrid			2022-12-27	WOS:000221041500020
J	Hisatsune, C; Kuroda, Y; Nakamura, K; Inoue, T; Nakamura, T; Michikawa, T; Mizutani, A; Mikoshiba, K				Hisatsune, C; Kuroda, Y; Nakamura, K; Inoue, T; Nakamura, T; Michikawa, T; Mizutani, A; Mikoshiba, K			Regulation of TRPC6 channel activity by tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; OPERATED HTRP3 CHANNELS; CALCIUM-ENTRY CHANNEL; SMOOTH-MUSCLE CELLS; TRANSIENT RECEPTOR; G-PROTEIN; STORE DEPLETION; IP3 RECEPTOR; CA2+ ENTRY	Various hormonal stimuli and growth factors activate the mammalian canonical transient receptor potential ( TRPC) channel through phospholipase C ( PLC) activation. However, the precise mechanism of the regulation of TRPC channel activity remains unknown. Here, we provide the first evidence that direct tyrosine phosphorylation by Src family protein-tyrosine kinases (PTKs) is a novel mechanism for modulating TRPC6 channel activity. We found that TRPC6 is tyrosine-phosphorylated in COS-7 cells when coexpressed with Fyn, a member of the Src family PTKs. We also found that Fyn interacts with TRPC6 and that the interaction is mediated by the SH2 domain of Fyn and the N-terminal region of TRPC6 in a phosphorylation-independent manner. In addition, we demonstrated the physical association of TRPC6 with Fyn in the mammalian brain. Moreover, we showed that stimulation of the epidermal growth factor receptor induced rapid tyrosine phosphorylation of TRPC6 in COS-7 cells. This epidermal growth factor-induced tyrosine phosphorylation of TRPC6 was significantly blocked by PP2, a specific inhibitor of Src family PTKs, and by a dominant negative form of Fyn, suggesting that the direct phosphorylation of TRPC6 by Src family PTKs could be caused by physiological stimulation. Furthermore, using single channel recording, we showed that Fyn modulates TRPC6 channel activity via tyrosine phosphorylation. Thus, our findings demonstrated that tyrosine phosphorylation by Src family PTKs is a novel regulatory mechanism of TRPC6 channel activity.	RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, ICORP, Calcium Oscillat Project, Chiyoda Ku, Tokyo 1020084, Japan	RIKEN; University of Tokyo; Japan Science & Technology Agency (JST)	Hisatsune, C (corresponding author), RIKEN, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	chihiro@brain.riken.go.jp	Inoue, Takafumi/AAM-9533-2020; Hisatsune, Chihiro/C-6661-2017; Mikoshiba, Katsuhiko/N-7943-2015; Kuroda, Yukiko/L-6332-2013; Mizutani, Akihiro/GPS-4809-2022; Kuroda, Yukiko/L-6332-2013	Inoue, Takafumi/0000-0002-2728-0060; Hisatsune, Chihiro/0000-0001-7811-7784; Kuroda, Yukiko/0000-0002-5335-4238; Mizutani, Akihiro/0000-0003-4155-802X; Kuroda, Yukiko/0000-0001-7713-9471				Albert AP, 2001, J PHYSIOL-LONDON, V530, P207, DOI 10.1111/j.1469-7793.2001.0207l.x; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; Fusaki N, 1996, J IMMUNOL, V156, P1369; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Hassock SR, 2002, BLOOD, V100, P2801, DOI 10.1182/blood-2002-03-0723; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Itoh T, 1996, J BIOL CHEM, V271, P27931, DOI 10.1074/jbc.271.44.27931; Jiang XP, 2003, J BIOL CHEM, V278, P42867, DOI 10.1074/jbc.M304487200; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C., 2001, SCI STKE; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Onishi-Haraikawa Y, 2001, BIOCHEM BIOPH RES CO, V288, P476, DOI 10.1006/bbrc.2001.5791; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Putney JW, 1999, BIOESSAYS, V21, P38; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Yokoyama K, 2002, EMBO J, V21, P83, DOI 10.1093/emboj/21.1.83; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	45	150	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18887	18894		10.1074/jbc.M311274200	http://dx.doi.org/10.1074/jbc.M311274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14761972	hybrid			2022-12-27	WOS:000221041500098
J	Yan, Q; Sun, W; McNew, JA; Vida, TA; Bean, AJ				Yan, Q; Sun, W; McNew, JA; Vida, TA; Bean, AJ			Ca2+ and N-ethylmaleimide-sensitive factor differentially regulate disassembly of SNARE complexes on early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MEMBRANE-FUSION; VACUOLAR H+-ATPASE; IN-VITRO; EXOCYTOSIS; PROTEIN; NSF; DISTINCT; CALMODULIN; HRS-2; CELLS	The endosome-associated protein Hrs inhibits the homotypic fusion of early endosomes. A helical region of Hrs containing a Q-SNARE motif mediates this effect as well as its endosomal membrane association via SNAP-25, an endosomal receptor for Hrs. Hrs inhibits formation of an early endosomal SNARE complex by displacing VAMP-2 from the complex, suggesting a mechanism by which Hrs inhibits early endosome fusion. We examined the regulation of endosomal SNARE complexes to probe how Hrs may function as a negative regulator. We show that although NSF dissociates the VAMP-2 . SNAP-25 . syntaxin 13 complex, it has no effect on the Hrs-containing complex. Whereas Ca2+ dissociates the Hrs-containing complex but not the VAMP-2-containing SNARE complex. This is the first demonstration of differential regulation of R/Q-SNARE and all Q-SNARE-containing SNARE complexes. Ca2+ also reverses the Hrs-induced inhibition of early endosome fusion in a tetanus toxin-sensitive manner and removes Hrs from early endosomal membranes. Moreover, Hrs inhibition of endosome fusion and its endosomal localization are sensitive to bafilomycin, implying a role for luminal Ca2+. Thus, Hrs may bind a SNARE protein on early endosomal membranes negatively regulating trans-SNARE pairing and endosomal fusion. The release of Ca2+ from the endosome lumen dissociates Hrs, allowing a VAMP-2-containing complex to form enabling fusion.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; Rice University; University of Texas System	Bean, AJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept NBA, 6431 Fannin St,MSB 7-208, Houston, TX 77030 USA.	a.bean@uth.tmc.edu	McNew, James/ABD-8081-2020; McNew, James/AAV-4911-2020	McNew, James/0000-0001-8459-3664	NIMH NIH HHS [MH58920] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058920] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; Chemello ME, 2002, J VIROL, V76, P13083, DOI 10.1128/JVI.76.24.13083-13087.2002; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Gerasimenko JV, 1998, CURR BIOL, V8, P1335, DOI 10.1016/S0960-9822(07)00565-9; Hanley JG, 2002, NEURON, V34, P53, DOI 10.1016/S0896-6273(02)00638-4; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Holroyd C, 1999, MOL BIOL CELL, V10, P3035, DOI 10.1091/mbc.10.9.3035; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kwong J, 2000, J CELL SCI, V113, P2273; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Martinez-Arca S, 2000, BIOL CELL, V92, P449, DOI 10.1016/S0248-4900(00)01096-0; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Muller JMM, 1999, NAT CELL BIOL, V1, P335, DOI 10.1038/14025; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; Muzerelle A, 2003, NEUROSCIENCE, V122, P59, DOI 10.1016/S0306-4522(03)00567-0; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053; Quetglas S, 2002, EMBO J, V21, P3970, DOI 10.1093/emboj/cdf404; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SMITH SJ, 1993, J PHYSIOL-LONDON, V472, P573, DOI 10.1113/jphysiol.1993.sp019963; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; Sun W, 2003, J CELL BIOL, V162, P125, DOI 10.1083/jcb.200302083; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tsujimoto S, 1999, EUR J NEUROSCI, V11, P3047, DOI 10.1046/j.1460-9568.1999.00716.x; Tsujimoto S, 2000, J BIOL CHEM, V275, P2938, DOI 10.1074/jbc.275.4.2938; Van Baelen K, 2003, BIOCHEM BIOPH RES CO, V306, P430, DOI 10.1016/S0006-291X(03)00977-X; Ward DM, 2000, MOL BIOL CELL, V11, P2327, DOI 10.1091/mbc.11.7.2327; Weber T, 2000, J CELL BIOL, V149, P1063, DOI 10.1083/jcb.149.5.1063; Zhao CM, 1997, CELL TISSUE RES, V290, P539, DOI 10.1007/s004410050960	39	25	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18270	18276		10.1074/jbc.M400093200	http://dx.doi.org/10.1074/jbc.M400093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14769786	hybrid			2022-12-27	WOS:000221041500023
J	Park, YN; Arvan, P				Park, YN; Arvan, P			The acetylcholinesterase homology region is essential for normal conformational maturation and secretion of thyroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; RETICULUM STORAGE DISEASE; CONGENITAL GOITER COG/COG; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; DISULFIDE BONDS; MICE; IDENTIFICATION; HYPOTHYROIDISM; DEGRADATION	Secretion of thyroglobulin (Tg, a large homodimeric glycoprotein) is essential to deliver Tg to its site of iodination for thyroxine biosynthesis. An L2263P missense mutation in Tg has been proposed as the molecular defect causing congenital goitrous hypothyroidism in cog/cog mice due to perturbed Tg homodimerization, resulting in its retention within the endoplasmic reticulum. The mutation falls within a carboxyl-terminal region of Tg with high structural similarity to the entirety of acetylcholinesterase (AChE), a secretory protein that also forms homodimers. We provide new evidence that authentic AChE and the cholinesterase-like domain of Tg share a common tertiary structure. Moreover, we find that a Tg truncation, deleted of the cholinesterase-like region (but not a comparably sized deletion of internal Tg regions), blocks Tg export. Appending to this truncation a cDNA encoding authentic AChE results in translation of a chimeric protein in which AChE is present in a native, enzymatically active (albeit latent) conformation, and this fully rescues Tg secretion. Introduction of the cog mutation inhibits AChE enzyme activity, and established denaturing mutations of AChE block secretion of the Tg. Additional studies show that the native structure of the AChE region functions as a "dimerization domain,"facilitating intracellular transport of Tg to the site of thyroid hormonogenesis.	Univ Michigan, Div Endocrinol Diabet & Metab, Med Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Arvan, P (corresponding author), Univ Michigan, Div Endocrinol Diabet & Metab, Med Ctr, 5560 MSRB2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	parvan@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040344, R29DK040344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADKISON LR, 1990, J ENDOCRINOL, V126, P51, DOI 10.1677/joe.0.1260051; BASCHE M, 1989, ENDOCRINOLOGY, V124, P1822, DOI 10.1210/endo-124-4-1822; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Di Jeso B, 2003, BIOCHEM J, V370, P449, DOI 10.1042/BJ20021257; Dunn AD, 1998, J BIOL CHEM, V273, P25223, DOI 10.1074/jbc.273.39.25223; Dunn JT, 1999, BIOCHIMIE, V81, P505, DOI 10.1016/S0300-9084(99)80102-3; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FOGELFELD L, 1992, THYROID, V2, P329, DOI 10.1089/thy.1992.2.329; Galesa K, 2003, FEBS LETT, V539, P120, DOI 10.1016/S0014-5793(03)00215-1; GENTILE F, 1993, EUR J BIOCHEM, V218, P603, DOI 10.1111/j.1432-1033.1993.tb18414.x; KEREM A, 1993, J BIOL CHEM, V268, P180; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1993, J BIOL CHEM, V268, P4873; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; LAMAS L, 1977, ENDOCRINOLOGY, V100, P1129; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MALTHIERY Y, 1989, BIOCHIMIE, V71, P195, DOI 10.1016/0300-9084(89)90057-6; MARRIQ C, 1991, MOL CELL ENDOCRINOL, V81, P155, DOI 10.1016/0303-7207(91)90214-D; MAURIZIS J, 1981, FEBS LETT, V132, P29, DOI 10.1016/0014-5793(81)80420-6; MedeirosNeto G, 1996, J CLIN INVEST, V98, P2838, DOI 10.1172/JCI119112; MEDEIROSNETO G, 1989, J ENDOCRINOL INVEST, V12, P805, DOI 10.1007/BF03350067; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; MICHELBECHET M, 1969, ACTA ANAT, V73, P389; Morel N, 2001, J BIOL CHEM, V276, P37379, DOI 10.1074/jbc.M103192200; MORI N, 1987, P NATL ACAD SCI USA, V84, P2813, DOI 10.1073/pnas.84.9.2813; Pungercic G, 2002, BIOL CHEM, V383, P1809, DOI 10.1515/BC.2002.202; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SWILLENS S, 1986, BIOCHEM BIOPH RES CO, V137, P142, DOI 10.1016/0006-291X(86)91187-3; Thrasyvoulides A, 2001, EUR J ENDOCRINOL, V145, P119, DOI 10.1530/eje.0.1450119; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; van de Graaf SAR, 2001, J ENDOCRINOL, V170, P307, DOI 10.1677/joe.0.1700307; VANHERLE AJ, 1979, NEW ENGL J MED, V301, P307, DOI 10.1056/NEJM197908093010605; VANHERLE AJ, 1979, NEW ENGL J MED, V301, P239, DOI 10.1056/NEJM197908023010504; VELAN B, 1991, J BIOL CHEM, V266, P23977	39	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17085	17089		10.1074/jbc.M314042200	http://dx.doi.org/10.1074/jbc.M314042200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14764582	hybrid			2022-12-27	WOS:000220870400026
J	Taylor, KR; Trowbridge, JM; Rudisill, JA; Termeer, CC; Simon, JC; Gallo, RL				Taylor, KR; Trowbridge, JM; Rudisill, JA; Termeer, CC; Simon, JC; Gallo, RL			Hyaluronan fragments stimulate endothelial recognition of injury through TLR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; ANGIOGENIC OLIGOSACCHARIDES; CYTOKINE REGULATION; DENDRITIC CELLS; SULFATE; INFLAMMATION; DEGRADATION; CHEMOKINES; RESPONSES; IMMUNITY	Tissues must quickly recognize injury to respond to the rapid pace of microbial growth. In skin, dermal microvascular endothelial cells must also react to danger signals from the surrounding tissue and immediately participate by initiating the wound repair process. Components of the extracellular matrix such as hyaluronan are rapidly broken down into smaller molecular weight oligosaccharides in a wound, and these can activate a variety of biological processes. This study set out to determine if hyaluronan fragments released following injury can stimulate endothelial cells and what mechanism is responsible for this response. Using genechip microarray analysis, a response to hyaluronan fragments was detected in endothelial cells with the most significant increase observed for the chemokine IL-8. This observation was verified with qualitative reverse transcriptase-PCR and ELISA in human endothelial cell culture, and in a mouse model by observing serum levels of MIP-2 and KC following hyaluronan fragment administration in vivo. Activation was TLR4-dependent, as shown by use of TLR4 blocking antibody and TLR4-deficient mice, but not due to the presence of undetected contaminants as shown by inactivation following digestion with the hyaluronan-degrading enzyme chondroitinase ABC or incubation with the hyaluronan-specific blocking peptide Pep-1. Inactivation of LPS activity failed to diminish the action of hyaluronan fragments. These observations suggest that endogenous components of the extracellular matrix can stimulate endothelia to trigger recognition of injury in the initial stages of the wound defense and repair response.	Univ Calif San Diego, Dept Dermatol, San Diego, CA 92161 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA; Fujisawa Deutschland GmbH, D-81610 Munich, Germany; Univ Leipzig, Dept Dermatol, D-04103 Leipzig, Germany	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Leipzig University	Gallo, RL (corresponding author), Univ Calif San Diego, Dept Dermatol, San Diego, CA 92161 USA.	rgallo@vapop.ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL7261] Funding Source: Medline; NIAMS NIH HHS [AR45676] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Chen WYJ, 1999, WOUND REPAIR REGEN, V7, P79, DOI 10.1046/j.1524-475X.1999.00079.x; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; FRASER JRE, 1989, CIBA F SYMP, V143, P41; Garcia-Ramallo E, 2002, J IMMUNOL, V169, P6467, DOI 10.4049/jimmunol.169.11.6467; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Guidolin DD, 2001, OSTEOARTHR CARTILAGE, V9, P371, DOI 10.1053/joca.2000.0398; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Juhlin L, 1997, J INTERN MED, V242, P61, DOI 10.1046/j.1365-2796.1997.00175.x; Krishnaswamy G, 1999, J INTERF CYTOK RES, V19, P91, DOI 10.1089/107999099314234; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li XM, 2002, MICROCIRCULATION, V9, P13, DOI 10.1038/sj.mn.7800118; Mancardi S, 2003, IMMUNOLOGY, V108, P523, DOI 10.1046/j.1365-2567.2003.01613.x; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McCourt PAG, 1999, MATRIX BIOL, V18, P427, DOI 10.1016/S0945-053X(99)00045-1; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Penc SF, 1999, J CLIN INVEST, V103, P1329, DOI 10.1172/JCI4742; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; Roman JA, 2000, CLIN RHEUMATOL, V19, P204, DOI 10.1007/s100670050157; SAARI H, 1991, ANN RHEUM DIS, V50, P389, DOI 10.1136/ard.50.6.389; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Slevin M, 1998, LAB INVEST, V78, P987; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; Termeer C, 2003, TRENDS IMMUNOL, V24, P112, DOI 10.1016/S1471-4906(03)00029-2; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; VanDamme J, 1997, J LEUKOCYTE BIOL, V62, P563, DOI 10.1002/jlb.62.5.563; Yager DR, 1999, WOUND REPAIR REGEN, V7, P433, DOI 10.1046/j.1524-475X.1999.00433.x; [No title captured]	40	429	440	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17079	17084		10.1074/jbc.M310859200	http://dx.doi.org/10.1074/jbc.M310859200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14764599	hybrid			2022-12-27	WOS:000220870400025
J	Dhami, GK; Dale, LB; Anborgh, PH; O'Connor-Halligan, KE; Sterne-Marr, R; Ferguson, SSG				Dhami, GK; Dale, LB; Anborgh, PH; O'Connor-Halligan, KE; Sterne-Marr, R; Ferguson, SSG			G protein-coupled receptor kinase 2 regulator of G protein signaling homology domain binds to both metabotropic glutamate receptor 1a and G alpha(q) to attenuate signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DESENSITIZATION; PHOSPHORYLATION; ARRESTIN; INTERNALIZATION; ENDOCYTOSIS; SUBUNITS; MEMBRANE; GAMMA	Heterotrimeric guanine nucleotide-binding (G) protein-coupled receptor kinases (GRKs) are cytosolic proteins that contribute to the adaptation of G protein-coupled receptor signaling. The canonical model for GRK-dependent receptor desensitization involves GRK-mediated receptor phosphorylation to promote the binding of arrestin proteins that sterically block receptor coupling to G proteins. However, GRK-mediated desensitization, in the absence of phosphorylation and arrestin binding, has been reported for metabotropic glutamate receptor 1 (mGluR1) and gamma-aminobutyric acid B receptors. Here we show that GRK2 mutants impaired in Galpha(q/11) binding (R106A, D110A, and M114A), bind effectively to mGluR1a, but do not mediate mGluR1a adaptation. Galpha(q/11) is immunoprecipitated as a complex with mGluR1a in the absence of agonist, and either agonist treatment or GRK2 overexpression promotes the dissociation of the receptor/Galpha(q/11) complex. However, these mGluR1a/Galpha(q/11) interactions are not antagonized by the overexpression of either GRK2 mutants defective in Galpha(q/11) binding or RGS4. We have also identified a GRK2-D527A mutant that binds Galpha(q/11) in an AlF4--dependent manner but is unable to either bind mGluR1a or attenuate mGluR1a signaling. We conclude that the mechanism underlying GRK2 phosphorylation-independent attenuation of mGluR1a signaling is RH domain-dependent, requiring the binding of GRK2 to both Galpha(q/11) and mGluR1a. This serves to coordinate GRK2 interactions with Galpha(q/11) and to disrupt receptor/Galpha(q/11) complexes. Our findings indicate that GRK2 regulates receptor/G protein interactions, in addition to its traditional role as a receptor kinase.	Univ Western Ontario, Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5K8, Canada; Sienna Coll, Dept Biol, Giza 12211, Egypt	Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), Univ Western Ontario, Robarts Res Inst, Cell Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	ferguson@robarts.ca						ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PAO CS, 2002, SCI STKE, V153, pPE42; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Saugstad JA, 1998, J NEUROSCI, V18, P905; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153	25	69	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16614	16620		10.1074/jbc.M314090200	http://dx.doi.org/10.1074/jbc.M314090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764583	hybrid			2022-12-27	WOS:000220747900112
J	Kreikemeyer, B; Oehmcke, S; Nakata, M; Hoffrogge, R; Podbielski, A				Kreikemeyer, B; Oehmcke, S; Nakata, M; Hoffrogge, R; Podbielski, A			Streptococcus pyogenes fibronectin-binding protein F2 - Expression profile, binding characteristics, and impact on eukaryotic cell interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; 2 DIFFERENT GENES; GENOME SEQUENCE; CYSTEINE PROTEASE; SURFACE PROTEIN; ADHESIN; STRAINS; SFBI; INTERNALIZATION; ADHERENCE	Some Streptococcus pyogenes ( group A streptococci, GAS) strains have previously been shown to express the fibronectin-binding protein F2 instead of the functionally related but structurally dissimilar protein F1/SfbI. In this study, recombinant N-terminal and C-terminal portions and the two fibronectin-binding domains of protein F2 were used to assess affinity parameters of the interaction with fibronectin and its N-terminal 70-, 30-, and 45-kDa fragments. The association and dissociation equilibrium constants for both binding domains were in the nanomolar range, although the repeat domain of protein F2 exceeded the affinity of the unique domain by up to one order magnitude. Both domains primarily interacted with the 30-kDa fibronectin fragment. Using a prtF2 gene isogenic mutant of a serotype M49 GAS strain that does not harbor the protein F1/SfbI gene, the attachment values of whole bacteria to immobilized fibronectin and to HEp-2 epithelial cells were found to be 6- and 2-fold decreased, respectively. Reduction of prtF2 mutant internalization rates for eukaryotic cells exceeded the reduction of attachment rates, indicating an independent contribution of protein F2 to both processes. The prtF2 transcription and protein F2 expression profiles documented maximum expression at the transition to the stationary phase especially under aerobic growth condition. The protein F2 function as the major fibronectin-binding adhesin in a subset of GAS strains, its expression pattern, and highly specific interaction with fibronectin would be consistent with a status as an indispensable virulence factor for both earlier and later pathogenetic stages of GAS superficial infections.	Rostock Univ Hosp, Dept Med Microbiol & Hosp Hyg, D-18057 Rostock, Germany; Univ Rostock, Fac Med, Proteome Ctr Rostock, D-18059 Rostock, Germany	University of Rostock; University of Rostock	Podbielski, A (corresponding author), Rostock Univ Hosp, Dept Med Microbiol & Hosp Hyg, Schillingallee 70, D-18057 Rostock, Germany.	andreas.podbielski@med.unirostock.de		Hoffrogge, Raimund/0000-0003-0118-0990; Nakata, Masanobu/0000-0003-1686-5415; Kreikemeyer, Bernd/0000-0001-9527-5098				Baev D, 1999, INFECT IMMUN, V67, P4510, DOI 10.1128/IAI.67.9.4510-4516.1999; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; Bessen DE, 2002, INFECT IMMUN, V70, P1159, DOI 10.1128/IAI.70.3.1159-1167.2002; Brandt CM, 2001, J INFECT DIS, V183, P670, DOI 10.1086/318542; Chaussee MS, 1999, INFECT IMMUN, V67, P1715; Courtney HS, 2002, ANN MED, V34, P77, DOI 10.1080/07853890252953464; COURTNEY HS, 2004, IN PRESS BACTERIAL I; Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897; Delvecchio A, 2002, EPIDEMIOL INFECT, V128, P391, DOI 10.1017/S0950268802006787; Ensenberger MG, 2001, J BIOL CHEM, V276, P35606, DOI 10.1074/jbc.M105417200; Facinelli B, 2001, LANCET, V358, P30, DOI 10.1016/S0140-6736(00)05253-3; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; FRICK IM, 1994, MOL MICROBIOL, V12, P143, DOI 10.1111/j.1365-2958.1994.tb01003.x; Goodfellow AM, 2000, J CLIN MICROBIOL, V38, P389; HousePompeo K, 1996, J BIOL CHEM, V271, P1379, DOI 10.1074/jbc.271.3.1379; Jaffe J, 1996, MOL MICROBIOL, V21, P373, DOI 10.1046/j.1365-2958.1996.6331356.x; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; JOH HJ, 1994, BIOCHEMISTRY-US, V33, P6086, DOI 10.1021/bi00186a007; Kreikemeyer B, 2003, TRENDS MICROBIOL, V11, P224, DOI 10.1016/S0966-842X(03)00098-2; Kreikemeyer B, 2002, MICROBIOL-SGM, V148, P1501, DOI 10.1099/00221287-148-5-1501; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; LINDGREN PE, 1993, EUR J BIOCHEM, V214, P819, DOI 10.1111/j.1432-1033.1993.tb17985.x; LINDGREN PE, 1992, J BIOL CHEM, V267, P1924; McIver KS, 1997, J BACTERIOL, V179, P5178, DOI 10.1128/jb.179.16.5178-5187.1997; Molinari G, 2001, MOL MICROBIOL, V40, P99, DOI 10.1046/j.1365-2958.2001.02373.x; Molinari G, 1999, J INFECT DIS, V179, P1049, DOI 10.1086/314681; Molinari G, 1998, J INFECT DIS, V177, P1600, DOI 10.1086/515310; Musumeci R, 2003, CLIN INFECT DIS, V37, P173, DOI 10.1086/375589; Nakagawa I, 2001, CELL MICROBIOL, V3, P395, DOI 10.1046/j.1462-5822.2001.00122.x; Nakagawa I, 2003, GENOME RES, V13, P1042, DOI 10.1101/gr.1096703; NATANSON S, 1995, J INFECT DIS, V171, P871, DOI 10.1093/infdis/171.4.871; Neeman R, 1998, LANCET, V352, P1974, DOI 10.1016/S0140-6736(97)12452-7; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; Ozeri V, 2001, MOL MICROBIOL, V41, P561, DOI 10.1046/j.1365-2958.2001.02535.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; Podbielski A, 1999, MED MICROBIOL IMMUN, V188, P99, DOI 10.1007/s004300050111; Podbielski A, 1999, MOL MICROBIOL, V31, P1051, DOI 10.1046/j.1365-2958.1999.01241.x; Raeder R, 1998, RES MICROBIOL, V149, P539, DOI 10.1016/S0923-2508(99)80001-1; Rasmussen M, 2002, MOL MICROBIOL, V43, P537, DOI 10.1046/j.1365-2958.2002.02766.x; Rocha CL, 1999, INFECT IMMUN, V67, P2720, DOI 10.1128/IAI.67.6.2720-2728.1999; SCHMIDT KH, 1990, ZBL BAKT-INT J MED M, V273, P216; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Sela S, 2000, J MED MICROBIOL, V49, P499, DOI 10.1099/0022-1317-49-6-499; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; Talay SR, 2000, CELL MICROBIOL, V2, P521, DOI 10.1046/j.1462-5822.2000.00076.x; Terao Y, 2002, J BIOL CHEM, V277, P47428, DOI 10.1074/jbc.M209133200; Terao Y, 2001, MOL MICROBIOL, V42, P75, DOI 10.1046/j.1365-2958.2001.02579.x; Tomasini-Johansson BR, 2001, J BIOL CHEM, V276, P23430, DOI 10.1074/jbc.M103467200; Unnikrishnan M, 1999, INFECT IMMUN, V67, P5495, DOI 10.1128/IAI.67.10.5495-5499.1999; VALENTINWEIGAND P, 1994, MICROB PATHOGENESIS, V17, P111, DOI 10.1006/mpat.1994.1057; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980	55	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15850	15859		10.1074/jbc.M313613200	http://dx.doi.org/10.1074/jbc.M313613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14749329	hybrid			2022-12-27	WOS:000220747900021
J	Nomura, T; Tanikawa, J; Akimaru, H; Kanei-Ishii, C; Ichikawa-Iwata, E; Khan, MM; Ito, H; Ishii, S				Nomura, T; Tanikawa, J; Akimaru, H; Kanei-Ishii, C; Ichikawa-Iwata, E; Khan, MM; Ito, H; Ishii, S			Oncogenic activation of c-Myb correlates with a loss of negative regulation by TIF1 beta and Ski	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; THYROID-HORMONE RECEPTOR; DNA-BINDING DOMAIN; V-MYB; TRANSCRIPTIONAL REPRESSION; NUCLEAR RECEPTOR; N-COR; CELLULAR PROGENITOR; GENE; PROTEIN	The c-myb proto-oncogene product (c-Myb) regulates proliferation of hematopoietic cells by inducing the transcription of a group of target genes. Removal or mutations of the negative regulatory domain (NRD) in the C-terminal half of c-Myb leads to increased transactivating capacity and oncogenic activation. Here we report that TIF1beta directly binds to the NRD and negatively regulates the c-Myb-dependent trans-activation. In addition, three corepressors (Ski, N-CoR, and mSin3A) bind to the DNA-binding domain of c-Myb together with TIF1beta and recruit the histone deacetylase complex to c-Myb. Furthermore, the Drosophila TIF1beta homolog, Bonus, negatively regulates Drosophila Myb activity. The Ski corepressor competes with the coactivator CBP for binding to c-Myb, indicating that the selection of coactivators and corepressors is a key event for c-Myb-dependent transcription. Mutations or deletion of the NRD of c-Myb and the mutations found in the DNA-binding domain of v-Myb decrease the interaction with these corepressors and weaken the corepressor-induced negative regulation of Myb activity. These observations have conceptual implications for understanding how the nuclear oncogene is activated.	RIKEN, Tsukuba Inst, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan	RIKEN	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.jp	Ito, Hiroki/E-4858-2017; Ito, Hiroki/ABC-9621-2020; Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478; Ito, Hiroki/0000-0003-4745-5750				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Allen RD, 2001, MOL CELL BIOL, V21, P3071, DOI 10.1128/MCB.21.9.3071-3082.2001; Beckstead R, 2001, MOL CELL, V7, P753, DOI 10.1016/S1097-2765(01)00220-9; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Dai P, 2002, GENE DEV, V16, P2843, DOI 10.1101/gad.1017302; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HU YL, 1991, ONCOGENE, V6, P1549; Huang EY, 2000, GENE DEV, V14, P45; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kao HY, 2000, GENE DEV, V14, P55; Katzen AL, 1998, GENE DEV, V12, P831, DOI 10.1101/gad.12.6.831; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Ladendorff NE, 2001, ONCOGENE, V20, P125, DOI 10.1038/sj.onc.1204048; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Okada M, 2002, EMBO J, V21, P675, DOI 10.1093/emboj/21.4.675; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Shinagawa T, 2001, ONCOGENE, V20, P8100, DOI 10.1038/sj.onc.1204987; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	53	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16715	16726		10.1074/jbc.M313069200	http://dx.doi.org/10.1074/jbc.M313069200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761981	hybrid			2022-12-27	WOS:000220747900124
J	Rakhit, R; Crow, JP; Lepock, JR; Kondejewski, LH; Cashman, NR; Chakrabartty, A				Rakhit, R; Crow, JP; Lepock, JR; Kondejewski, LH; Cashman, NR; Chakrabartty, A			Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU/ZN-SUPEROXIDE-DISMUTASE; ASTROCYTIC HYALINE INCLUSIONS; BODY-LIKE INCLUSIONS; TRANSGENIC MICE; PROTEIN AGGREGATION; MOTOR-NEURONS; MUTANT SOD1; COPPER; ENZYME; SUPEROXIDE-DISMUTASE-1	Proteinacious intracellular aggregates in motor neurons are a key feature of both sporadic and familial amyotrophic lateral sclerosis (ALS). These inclusion bodies are often immunoreactive for Cu, Zn-superoxide dismutase (SOD1) and are implicated in the pathology of ALS. On the basis of this and a similar clinical presentation of symptoms in the familial (fALS) and sporadic forms of ALS, we sought to investigate the possibility that there exists a common disease-related aggregation pathway for fALS-associated mutant SODs and wild type SOD1. We have previously shown that oxidation of fALS-associated mutant SODs produces aggregates that have the same morphological, structural, and tinctorial features as those found in SOD1 inclusion bodies in ALS. Here, we show that oxidative damage of wild type SOD at physiological concentrations (similar to 40 muM) results in destabilization and aggregation in vitro. Oxidation of either mutant or wild type SOD1 causes the enzyme to dissociate to monomers prior to aggregation. Only small changes in secondary and tertiary structure are associated with monomer formation. These results indicate a common aggregation prone monomeric intermediate for wild type and fALS-associated mutant SODs and provides a link between sporadic and familial ALS.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 2M9, Canada; Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; Caprion Pharmaceut Inc, St Laurent, PQ H4S 2C8, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Sunnybrook & Womens Coll Hosp, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Arkansas System; University of Arkansas Medical Sciences; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Chakrabartty, A (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.	chakrab@uhnres.utoronto.ca		Chakrabartty, Avi/0000-0001-7002-8381				Andrus PK, 1998, J NEUROCHEM, V71, P2041; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chou SM, 1999, J NEUROL SCI, V169, P87, DOI 10.1016/S0022-510X(99)00222-1; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crow JP, 1997, J NEUROCHEM, V69, P1936; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Kato S, 2001, NEUROPATHOLOGY, V21, P67, DOI 10.1046/j.1440-1789.2001.00359.x; Kato S, 1999, HISTOL HISTOPATHOL, V14, P973, DOI 10.14670/HH-14.973; Kato S, 1997, AM J PATHOL, V151, P611; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; Koide T, 1998, NEUROSCI LETT, V257, P29, DOI 10.1016/S0304-3940(98)00800-3; KUROBE N, 1990, CLIN CHIM ACTA, V187, P11, DOI 10.1016/0009-8981(90)90257-S; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Liu HB, 2000, BIOCHEMISTRY-US, V39, P8125, DOI 10.1021/bi000846f; Majoor-Krakauer D, 2003, CLIN GENET, V63, P83, DOI 10.1046/j.0009-9163.2002.00001.x; Matsumoto S, 1996, CLIN NEUROPATHOL, V15, P41; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; NOBLE J, 2001, NOBLE TXB PRIMARY CA, P1089; OKAMOTO K, 1991, NEUROSCI LETT, V129, P233, DOI 10.1016/0304-3940(91)90469-A; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; Piao YS, 2003, BRAIN PATHOL, V13, P10; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; SHIBATA N, 1994, NEUROSCI LETT, V179, P149, DOI 10.1016/0304-3940(94)90956-3; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; UCHINO M, 1994, J NEUROL SCI, V127, P61, DOI 10.1016/0022-510X(94)90136-8; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	40	259	269	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15499	15504		10.1074/jbc.M313295200	http://dx.doi.org/10.1074/jbc.M313295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14734542	hybrid			2022-12-27	WOS:000220594700121
J	Suzuki, M; Kobayashi, H; Kanayama, N; Saga, Y; Suzuki, M; Lin, CY; Dickson, RB; Terao, T				Suzuki, M; Kobayashi, H; Kanayama, N; Saga, Y; Suzuki, M; Lin, CY; Dickson, RB; Terao, T			Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY TRYPSIN-INHIBITOR; UROKINASE PLASMINOGEN-ACTIVATOR; MEMBRANE SERINE-PROTEASE; OVARIAN-CANCER; CELL-LINE; BINDING-PROTEIN; GENE-EXPRESSION; BIKUNIN; SYSTEM; IDENTIFICATION	Urokinase-type plasminogen activator (uPA) degrades the extracellular matrix and plays critical roles in tumor invasion and metastasis. Matriptase, a membrane-bound serine protease, was shown to activate uPA in a uPA receptor-free, solution-based study. We now investigate whether matriptase affects activation of receptor-bound uPA and contributes to the invasiveness of HRA human ovarian cancer cells in vitro and tumor behavior in nude mice. Here we show the following. 1) uPA expression was effectively stimulated by TGF-beta1 in HRA cells. 2) Antisense (AS)-matriptase transfection achieved a marked inhibition of receptor-bound pro-uPA activation without altering expression of uPA and uPA receptor mRNA and proteins, irrespective of whether cells were stimulated with TGF-beta1. 3) Tumor cell receptor-bound pro-uPA could be efficiently cleaved by matriptase to generate enzymatically active two-chain uPA. Thus, matriptase can substitute for plasmin in the proteolytic activation of pro-uPA to enzymatically active uPA. 4) The AS-matriptase-treated cells had a decreased ability to invade an extracellular matrix layer, as compared with control cells. 5) When the AS-matriptase-treated cells were injected intraperitoneally into nude mice, the mice developed smaller tumors. Our data identify a novel role for matriptase for activation of receptor-bound uPA.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Shizuoka 4313192, Japan; Jichi Med Sch, Dept Obstet & Gynecol, Tochigi 3290498, Japan; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA	Hamamatsu University School of Medicine; Jichi Medical University; Georgetown University	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handayama 1-20-1, Shizuoka 4313192, Japan.	hirokoba@hama-med.ac.jp						ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772; Cho EG, 2001, J BIOL CHEM, V276, P44581, DOI 10.1074/jbc.M107059200; Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/BST0300207; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Haeckel C, 1998, INT J CANCER, V77, P153, DOI 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.3.CO;2-2; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Hirashima Y, 2001, J BIOL CHEM, V276, P13650, DOI 10.1074/jbc.M009906200; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; JARRARD DF, 1995, INVAS METAST, V15, P34; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; Kobayashi H, 2003, J BIOL CHEM, V278, P7790, DOI 10.1074/jbc.M210407200; Kobayashi H, 2002, EUR J BIOCHEM, V269, P3945, DOI 10.1046/j.1432-1033.2002.03068.x; Kobayashi H, 2001, Hum Cell, V14, P233; Kobayashi H, 1998, BBA-PROTEIN STRUCT M, V1383, P253, DOI 10.1016/S0167-4838(97)00215-X; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kobayashi H, 2000, J BIOL CHEM, V275, P21185, DOI 10.1074/jbc.M907862199; KOHN EC, 1995, CANCER RES, V55, P1856; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Mohanam S, 2001, CLIN CANCER RES, V7, P2519; Morrissey D, 1999, CLIN EXP METASTAS, V17, P77; Muehlenweg B, 2001, EXPERT OPIN BIOL TH, V1, P683; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; Ploug M, 2002, BIOCHEM SOC T, V30, P177, DOI 10.1042/BST0300177; Reuning U, 1998, INT J ONCOL, V13, P893; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Suzuki M, 2003, J BIOL CHEM, V278, P14640, DOI 10.1074/jbc.M300239200; Suzuki M, 2002, J BIOL CHEM, V277, P8022, DOI 10.1074/jbc.M108545200; Suzuki M, 2001, BBA-PROTEIN STRUCT M, V1547, P26, DOI 10.1016/S0167-4838(01)00167-4; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tanaka Y, 2003, CANCER-AM CANCER SOC, V98, P424, DOI 10.1002/cncr.11506; Tanimoto H, 2001, TUMOR BIOL, V22, P104, DOI 10.1159/000050604	43	67	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14899	14908		10.1074/jbc.M313130200	http://dx.doi.org/10.1074/jbc.M313130200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747469	hybrid			2022-12-27	WOS:000220594700051
J	Hanique, S; Colombo, ML; Goormaghtigh, E; Soumillion, P; Frere, JM; Joris, B				Hanique, S; Colombo, ML; Goormaghtigh, E; Soumillion, P; Frere, JM; Joris, B			Evidence of an intramolecular interaction between the two domains of the BlaR1 penicillin receptor during the signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAMASE SYNTHESIS; TRANSFORM INFRARED-SPECTROSCOPY; RESISTANT STAPHYLOCOCCUS-AUREUS; BACILLUS-LICHENIFORMIS; PHAGE DISPLAY; METHICILLIN RESISTANCE; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; REPRESSOR BLAL	The BlaR1 protein is a penicillin-sensory transducer involved in the induction of the Bacillus licheniformis beta-lactamase. The amino-terminal domain of the protein exhibits four transmembrane segments (TM1-TM4) that form a four-alpha-helix bundle embedded in the plasma bilayer. The carboxyl-terminal domain of 250 amino acids (BlaR-CTD) fused at the carboxyl end of TM4 possesses the amino acid sequence signature of penicillin-binding proteins. This membrane topology suggests that BlaR-CTD and the BlaR-amino-terminal domain are responsible for signal reception and signal transduction, respectively. With the use of phage display experiments, we highlight herein an interaction between BlaR-CTD and the extracellular, 63-amino acid L2 loop connecting TM2 and TM3. This interaction does not occur in the presence of penicillin. This result suggests that binding of the antibiotic to BlaR1 might entail the release of the interaction between L2 and BlaR-CTD, causing a motion of the alpha-helix bundle and transfer of the information to the cytoplasm of the cell. In addition, fluorescence spectroscopy, CD, and Fourier transform IR spectroscopy experiments indicate that in contrast to the behavior of the corresponding Staphylococcus aureus protein, the beta-lactam antibiotic does not induce a drastic conformational change in B. licheniformis BlaR-CTD.	Univ Liege, Inst Chim, Ctr Ingn Prot, B-4000 Sart Tilman Par Liege, Belgium; Free Univ Brussels, Ctr Struct Biol & Bioinformat, Lab Struct & Funct Biol Membranes, B-1050 Brussels, Belgium; Catholic Univ Louvain, Inst Sci Vie, Lab Biochim Phys & Biopolymeres, B-1348 Louvain, Belgium	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain	Joris, B (corresponding author), Univ Liege, Inst Chim, Ctr Ingn Prot, B-4000 Sart Tilman Par Liege, Belgium.	bjoris@ulg.ac.be		Goormaghtigh, Erik/0000-0002-2071-2262				BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Clarke SR, 2001, MICROBIOL-UK, V147, P803, DOI 10.1099/00221287-147-4-803; Duval V, 2003, MOL MICROBIOL, V48, P1553, DOI 10.1046/j.1365-2958.2003.03520.x; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Filee P, 2002, MOL MICROBIOL, V44, P685, DOI 10.1046/j.1365-2958.2002.02888.x; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; Garcia-Castellanos R, 2003, J BIOL CHEM, V278, P39897, DOI 10.1074/jbc.M307199200; Golemi-Kotra D, 2003, J BIOL CHEM, V278, P18419, DOI 10.1074/jbc.M300611200; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Gordon E, 2000, J MOL BIOL, V299, P477, DOI 10.1006/jmbi.2000.3740; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Gregory PD, 1997, MOL MICROBIOL, V24, P1025, DOI 10.1046/j.1365-2958.1997.4051770.x; HACKBARTH CJ, 1993, ANTIMICROB AGENTS CH, V37, P1144, DOI 10.1128/AAC.37.5.1144; Hardt K, 1997, MOL MICROBIOL, V23, P935, DOI 10.1046/j.1365-2958.1997.2761642.x; HOESS RH, 1993, CURR OPIN STRUC BIOL, V3, P572, DOI 10.1016/0959-440X(93)90085-Y; JORIS B, 1990, FEMS MICROBIOL LETT, V70, P107, DOI 10.1016/0378-1097(90)90111-3; JORIS B, 1994, N COMP BIOC, V27, P505; Kerff F, 2003, BIOCHEMISTRY-US, V42, P12835, DOI 10.1021/bi034976a; KOBAYASHI T, 1987, J BACTERIOL, V169, P3873, DOI 10.1128/jb.169.9.3873-3878.1987; Legendre D, 2000, J MOL BIOL, V296, P87, DOI 10.1006/jmbi.1999.3437; Lewis RA, 1999, FEMS MICROBIOL LETT, V178, P271, DOI 10.1016/S0378-1097(99)00366-3; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; McKinney TK, 2001, J BACTERIOL, V183, P6862, DOI 10.1128/JB.183.23.6862-6868.2001; MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Philippon A, 1998, CELL MOL LIFE SCI, V54, P341, DOI 10.1007/s000180050161; Rossenu S, 1997, J PROTEIN CHEM, V16, P499, DOI 10.1023/A:1026317612554; SALERNO AJ, 1988, FEBS LETT, V227, P61, DOI 10.1016/0014-5793(88)81414-5; SHERRATT DJ, 1973, J GEN MICROBIOL, V76, P217, DOI 10.1099/00221287-76-1-217; SOUMILLION P, 1994, J MOL BIOL, V237, P415, DOI 10.1006/jmbi.1994.1244; Van Melckebeke H, 2003, J MOL BIOL, V333, P711, DOI 10.1016/j/jmb.2003.09.005; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144	38	27	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14264	14272		10.1074/jbc.M313488200	http://dx.doi.org/10.1074/jbc.M313488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736870	hybrid			2022-12-27	WOS:000220478500120
J	Hoard-Fruchey, HM; Goetzman, E; Benson, L; Naylor, S; Vockley, J				Hoard-Fruchey, HM; Goetzman, E; Benson, L; Naylor, S; Vockley, J			Mammalian electron transferring flavoprotein center dot flavoprotein dehydrogenase complexes observed by microelectrospray ionization-mass spectrometry and surface plasmon resonance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; IRON-SULFUR FLAVOPROTEIN; FOLATE-BINDING PROTEINS; RAT-LIVER MITOCHONDRIA; DIMETHYLGLYCINE DEHYDROGENASE; SARCOSINE DEHYDROGENASE; TRIMETHYLAMINE DEHYDROGENASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; COENZYME-A	Microelectrospray ionization-mass spectrometry was used to directly observe electron transferring flavoprotein . flavoprotein dehydrogenase interactions. When electron transferring flavoprotein and porcine dimethylglycine dehydrogenase or sarcosine dehydrogenase were incubated together in the absence of substrate, a relative molecular mass corresponding to the flavoprotein . electron transferring flavoprotein complex was observed, providing the first direct observation of these mammalian complexes. When an acyl-CoA dehydrogenase family member, human short chain acyl-CoA dehydrogenase, was incubated with dimethylglycine dehydrogenase and electron transferring flavoprotein, the microelectrospray ionization-mass spectrometry signal for the dimethylglycine dehydrogenase . electron transferring flavoprotein complex decreased, indicating that the acyl-CoA dehydrogenases have the ability to compete with the dimethylglycine dehydrogenase/sarcosine dehydrogenase family for access to electron transferring flavoprotein. Surface plasmon resonance solution competition experiments revealed affinity constants of 2.0 and 5.0 muM for the dimethylglycine dehydrogenase-electron transferring flavoprotein and short chain acyl-CoA dehydrogenase-electron transferring flavoprotein interactions, respectively, suggesting the same or closely overlapping binding motif(s) on electron transferring flavoprotein for dehydrogenase interaction.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Proteom Res Ctr, Rochester, MN 55905 USA; Beyond Genom Inc, Waltham, MA 02451 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Vockley, J (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.	Gerard.vockley@chp.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045482] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK45482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamczyk M, 2000, METHODS, V20, P319, DOI 10.1006/meth.1999.0925; BECKMANN JD, 1983, J BIOL CHEM, V258, P7563; Bergeron F, 1998, EUR J BIOCHEM, V257, P556, DOI 10.1046/j.1432-1327.1998.2570556.x; Binzak BA, 2000, MOL GENET METAB, V69, P181, DOI 10.1006/mgme.2000.2980; Binzak BA, 2001, AM J HUM GENET, V68, P839, DOI 10.1086/319520; Craig TA, 1999, NAT BIOTECHNOL, V17, P1214, DOI 10.1038/70767; CRANE FL, 1956, J BIOL CHEM, V218, P717; Cummings JG, 1994, FLAVINS AND FLAVOPROTEINS 1993, P313; CUMMINGS JG, 1994, BIOCHEMISTRY-US, V33, P788, DOI 10.1021/bi00169a021; Demmers JAA, 2003, FEBS LETT, V541, P28, DOI 10.1016/S0014-5793(03)00282-5; EDMONDS CG, 1989, J CHROMATOGR, V474, P21, DOI 10.1016/S0021-9673(01)93899-3; Ehring H, 1999, ANAL BIOCHEM, V267, P252, DOI 10.1006/abio.1998.3000; Engel P. C., 1992, CHEM BIOCH FLAVOENZY, P597; Eschenbrenner M, 1999, GENOMICS, V59, P300, DOI 10.1006/geno.1999.5886; FRERMAN FE, 1985, BIOCHEM MED METAB B, V33, P38, DOI 10.1016/0006-2944(85)90124-3; Gehrig PM, 2000, PROTEIN SCI, V9, P395; GRIMM R, 1993, J BIOL CHEM, V268, P5220; HALL CL, 1980, J BIOL CHEM, V255, P3591; He M, 2003, J BIOL CHEM, V278, P37974, DOI 10.1074/jbc.M306882200; Hoard HM, 2001, BIOCHEM BIOPH RES CO, V282, P297, DOI 10.1006/bbrc.2001.4537; Johnson KL, 1997, RAPID COMMUN MASS SP, V11, P939, DOI 10.1002/(SICI)1097-0231(199705)11:8<939::AID-RCM936>3.0.CO;2-3; Jones M, 2002, J BIOL CHEM, V277, P8457, DOI 10.1074/jbc.M111105200; Kebarle P., 1993, ANAL CHEM, V65, P972; KIM JJ, 1988, P NATL ACAD SCI USA, V84, P6677; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KUBO T, 1993, J BIOL CHEM, V268, P19346; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; LIGHTWAHL KJ, 1993, BIOL MASS SPECTROM, V22, P112, DOI 10.1002/bms.1200220203; LOO JA, 1995, J MASS SPECTROM, V30, P180, DOI 10.1002/jms.1190300127; Mohsen A.-W.A., 1999, FLAVINS FLAVOPROTEIN, P515; MOHSEN AWA, 1995, BIOCHEMISTRY-US, V34, P10146, DOI 10.1021/bi00032a007; MOHSEN AWA, 1995, GENE, V160, P263, DOI 10.1016/0378-1119(95)00256-6; Mohsen AWA, 2001, MOL GENET METAB, V73, P126, DOI 10.1006/mgme.2001.3183; Nedelkov D, 2003, TRENDS BIOTECHNOL, V21, P301, DOI 10.1016/S0167-7799(03)00141-0; Nesatyy VJ, 2001, J MASS SPECTROM, V36, P950, DOI 10.1002/jms.199; Nguyen TV, 2002, BIOCHEMISTRY-US, V41, P11126, DOI 10.1021/bi026030r; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Rich RL, 2002, J MOL RECOGNIT, V15, P352, DOI 10.1002/jmr.598; RUZICKA FJ, 1975, BIOCHEM BIOPH RES CO, V66, P622, DOI 10.1016/0006-291X(75)90555-0; RUZICKA FJ, 1977, J BIOL CHEM, V252, P8440; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; Vockley J, 2000, METHOD ENZYMOL, V324, P241; WILLIAMSON G, 1982, J BIOL CHEM, V257, P4314; Wilson EK, 1997, EUR J BIOCHEM, V243, P393, DOI 10.1111/j.1432-1033.1997.0393a.x; WITTWER AJ, 1980, P NATL ACAD SCI-BIOL, V77, P4484, DOI 10.1073/pnas.77.8.4484; WITTWER AJ, 1981, J BIOL CHEM, V256, P4109; WITTWER AJ, 1981, J BIOL CHEM, V256, P4102; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Xu NX, 1999, ANAL BIOCHEM, V272, P26, DOI 10.1006/abio.1999.4143; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113	53	8	8	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13786	13791		10.1074/jbc.M313914200	http://dx.doi.org/10.1074/jbc.M313914200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14744856	hybrid			2022-12-27	WOS:000220478500063
J	Jarving, R; Jarving, I; Kurg, R; Brash, AR; Samel, N				Jarving, R; Jarving, I; Kurg, R; Brash, AR; Samel, N			On the evolutionary origin of cyclooxygenase (COX) isozymes - Characterization of marine invertebrate COX genes points to independent duplication events in vertebrate and invertebrate lineages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; 3'-UNTRANSLATED REGION; POSTTRANSCRIPTIONAL REGULATION; CIONA-INTESTINALIS; PLEXAURA-HOMOMALLA; MOLECULAR-CLONING; BINDING PROTEIN; H SYNTHASE-1; G/H SYNTHASE	In vertebrates, COX-1 and COX-2, two cyclooxygenase isozymes with different physiological functions and gene regulation, catalyze identical reactions in prostaglandin synthesis. It is still not understood why there are multiple forms of COX enzyme in the same cell type and when the evolutionary duplication of the COX gene occurred. Here we report the structure of two genes encoding for COX isozymes in the coral Gersemia fruticosa, the first non-vertebrate organism from which a cyclooxygenase was characterized. Both genes are about 20 kb in size and consist of nine exons. Intron/exon boundaries are well conserved between coral and mammalian COX genes. mRNAs of the previously reported G. fruticosa COX-A (GenBank(TM) accession number AY004222) and the novel COX-B share 94% sequence identity in the coding regions and less than 30% in the 5'- and 3'-untranslated region. Transcripts of both COX genes are detectable in coral cells, although the transcriptional level of COX-A is 2 orders of magnitude higher than COX-B. Expression of both coral genes in mammalian cells gave functional proteins with similar catalytic properties. By data base analyses we also detected and constructed different pairs of COX genes from the primitive chordates, Ciona savignyi and Ciona intestinalis. These two gene pairs encode proteins with 50% intra-species and only 70% cross-species sequence identity. Our results suggest that invertebrate COX gene pairs do not correspond to vertebrate COX-1 and COX-2 and are consistent with duplication of the COX gene having occurred independently in corals, ascidians, and vertebrates. It is evident that due to the importance and complexity of its regulatory role, COX has multiple isoforms in all organisms known to express it, and the genes encoding for the isozymes may to be regulated differently.	Tallinn Univ Technol, Dept Chem, EE-12618 Tallinn, Estonia; Univ Tartu, Inst Technol, EE-51010 Tartu, Estonia; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Tallinn University of Technology; University of Tartu; Vanderbilt University	Samel, N (corresponding author), Tallinn Univ Technol, Dept Chem, Akad Tee 15, EE-12618 Tallinn, Estonia.	samel@chemnet.ee	Samel, Nigulas/A-1420-2019; Kurg, Reet/J-2829-2015	Kurg, Reet/0000-0001-7188-9693	NIGMS NIH HHS [GM-53638] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Boerboom D, 1998, ENDOCRINOLOGY, V139, P1662, DOI 10.1210/en.139.4.1662; BRASH AR, 1987, J BIOL CHEM, V262, P15829; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; COREY EJ, 1973, J AM CHEM SOC, V95, P2054, DOI 10.1021/ja00787a079; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Deutsch M, 1999, NUCLEIC ACIDS RES, V27, P3219, DOI 10.1093/nar/27.15.3219; DEWITT DL, 1989, ADV PROSTAG THROMB L, V19, P454; Duquette M, 2002, J BIOL CHEM, V277, P44631, DOI 10.1074/jbc.M207007200; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; Grosser T, 2002, P NATL ACAD SCI USA, V99, P8418, DOI 10.1073/pnas.112217799; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Kaldalu N, 2000, BIOTECHNIQUES, V28, P456, DOI 10.2144/00283st02; Knight J, 1999, BBA-MOL CELL BIOL L, V1436, P467, DOI 10.1016/S0005-2760(98)00153-2; Koljak R, 2001, J BIOL CHEM, V276, P7033, DOI 10.1074/jbc.M009803200; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; Kulmacz RJ, 2003, PROG LIPID RES, V42, P377, DOI 10.1016/S0163-7827(03)00023-7; Kurg R, 1999, J VIROL, V73, P4670, DOI 10.1128/JVI.73.6.4670-4677.1999; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai EC, 1997, DEVELOPMENT, V124, P4847; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MARNETT LJ, 1999, COMPREHENSIVE NATURA, V5, P225; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Muller WEG, 2002, GENE, V295, P299, DOI 10.1016/S0378-1119(02)00690-X; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Pope EC, 2002, J EXP BIOL, V205, P1577; Reed DW, 1996, PROSTAGLANDINS, V52, P269, DOI 10.1016/S0090-6980(96)00089-5; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Scott BT, 2002, BLOOD COAGUL FIBRIN, V13, P519, DOI 10.1097/00001721-200209000-00007; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SU X, 1988, ANAL BIOCHEM, V174, P650, DOI 10.1016/0003-2697(88)90068-1; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Valmsen K, 2001, P NATL ACAD SCI USA, V98, P7700, DOI 10.1073/pnas.131022398; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Varvas K, 1999, J BIOL CHEM, V274, P9923, DOI 10.1074/jbc.274.15.9923; WEISING K, 1995, DNA FINGERPRINTING P, P251; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; Yuasa HJ, 2001, GENE, V279, P205, DOI 10.1016/S0378-1119(01)00755-7	61	53	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13624	13633		10.1074/jbc.M313258200	http://dx.doi.org/10.1074/jbc.M313258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732711	hybrid			2022-12-27	WOS:000220478500043
J	Jiang, YF; Minet, E; Zhang, ZX; Silver, PA; Bai, M				Jiang, YF; Minet, E; Zhang, ZX; Silver, PA; Bai, M			Modulation of interprotomer relationships is important for activation of dimeric calcium-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; INTERMOLECULAR INTERACTIONS; BRAIN-FUNCTION; SWISS-MODEL; DIMERIZATION; DOMAIN; MUTAGENESIS; INTERFACE; CELLS; SITE	The extracellular calcium-sensing receptor (CaR) forms a disulfide-linked dimer through cysteine residues within its N-terminal extracellular domain (ECD). However, these disulfide linkages are dispensable for the formation of the dimeric CaR and for the functional reconstitution of two inactive CaRs. In this study, using molecular modeling, mutagenesis, and biochemical and biophysical analyses, we examined the importance of two leucine residues, Leu-112 and Leu-156, in the ECD of the CaR for the non-covalent dimerization and functional reconstitution. We found that the mutant receptor carrying L112S and L156S still exists mostly as a covalently linked dimer and has a significantly higher apparent affinity for calcium than the wild-type receptor. However, a combination of four mutations, L112S, L156S, C129S, and C131S, significantly reduces receptor dimerization and markedly inactivates the CaR. We also found that L112S and L156S mediate the non-covalent intermolecular interactions important for functional reconstitution. Because mutating either the two cysteines or the two leucines enhances the apparent ligand affinity of the CaR, it is likely that the changes in intermolecular relationships between two receptor protomers linked by these leucines and cysteines are essential for receptor activation. Moreover, these mutations are unlikely to have negative effects on the secondary structure of each protomer of the dimeric receptor. Thus, the detrimental effects of the combined mutations on the function of the CaR further suggest that CaR dimerization through its ECD is essential for the formation of a functional tertiary structure of the CaR.	Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Bai, M (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA.	mbai@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054934] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54934] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Jin TQ, 2001, J BIOL CHEM, V276, P12879, DOI 10.1074/jbc.M010513200; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Yamauchi M, 2002, J BONE MINER RES, V17, P2174, DOI 10.1359/jbmr.2002.17.12.2174; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200	23	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14147	14156		10.1074/jbc.M307422200	http://dx.doi.org/10.1074/jbc.M307422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729680	hybrid			2022-12-27	WOS:000220478500105
J	Korotkova, N; Lidstrom, ME				Korotkova, N; Lidstrom, ME			MeaB is a component of the methylmalonyl-CoA mutase complex required for protection of the enzyme from inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP; GLUTAMATE MUTASE; IDENTIFICATION; CLONING; COBALAMIN; PROTEIN; EXPRESSION; METHANOL; GENES; PURIFICATION	Adenosylcobalamin-dependent methylmalonyl-CoA mutase catalyzes the interconversion of methylmalonyl-CoA and succinyl-CoA. In humans, deficiencies in the mutase lead to methylmalonic aciduria, a rare disease that is fatal in the first year of life. Such inherited deficiencies can result from mutations in the mutase structural gene or from mutations that impair the acquisition of cobalamins. Recently, a human gene of unknown function, MMAA, has been implicated in methylmalonic aciduria (Dobson, C. M., Wai, T., Leclerc, D., Wilson, A., Wu, X., Dore, C., Hudson, T., Rosenblatt, D. S., and Gravel, R. A. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 15554 - 15559). MMAA orthologs are widespread in bacteria, archaea, and eukaryotes. In Methylobacterium extorquens AM1, a mutant defective in the MMAA homolog meaB was unable to grow on C-1 and C-2 compounds because of the inability to convert methylmalonyl-CoA to succinyl-CoA (Korotkova N., Chistoserdova, L., Kuksa, V., and Lidstrom, M. E. ( 2002) J. Bacteriol. 184, 1750 1758). Here we demonstrate that this defect is not due to the absence of adenosylcobalamin but due to an inactive form of methylmalonyl-CoA mutase. The presence of active mutase in double mutants defective in MeaB and in the synthesis of either R-methylmalonyl-CoA or adenosylcobalamin indicates that MeaB is necessary for protection of mutase from inactivation during catalysis. MeaB and methylmalonyl-CoA mutase from M. extorquens were cloned and purified in their active forms. We demonstrated that MeaB forms a complex with methylmalonyl-CoA mutase and stimulates in vitro mutase activity. These results support the hypothesis that MeaB functions to protect methylmalonyl-CoA mutase from irreversible inactivation.	Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lidstrom, ME (corresponding author), Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA.	lidstrom@u.washington.edu		Korotkova, Natalia/0000-0002-8696-4892	NIGMS NIH HHS [GM58933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee R., 1999, Chemistry and biochemistry of B12., P707; Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; BEATRIX B, 1994, EUR J BIOCHEM, V221, P101, DOI 10.1111/j.1432-1033.1994.tb18718.x; BIRCH A, 1993, J BACTERIOL, V175, P3511, DOI 10.1128/jb.175.11.3511-3519.1993; Bobik TA, 2003, ANAL BIOANAL CHEM, V375, P344, DOI 10.1007/s00216-002-1696-x; Bobik TA, 2001, J BIOL CHEM, V276, P37194, DOI 10.1074/jbc.M107232200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Celis RTF, 1998, J BACTERIOL, V180, P4828, DOI 10.1128/JB.180.18.4828-4833.1998; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DITTA G, 1985, PLASMID, V13, P149, DOI 10.1016/0147-619X(85)90068-X; Dobson CM, 2002, HUM MOL GENET, V11, P3361, DOI 10.1093/hmg/11.26.3361; Dobson CM, 2002, P NATL ACAD SCI USA, V99, P15554, DOI 10.1073/pnas.242614799; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Fenton WA, 2001, METABOLIC MOL BASES, P2165; FRANCALANCI F, 1986, BIOCHEM J, V236, P489, DOI 10.1042/bj2360489; Haller T, 2000, BIOCHEMISTRY-US, V39, P4622, DOI 10.1021/bi992888d; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HARDER W, 1973, J GEN MICROBIOL, V78, P155, DOI 10.1099/00221287-78-1-155; JANSEN R, 1989, GENOMICS, V4, P198, DOI 10.1016/0888-7543(89)90300-5; Kajiura H, 2001, J BIOL CHEM, V276, P36514, DOI 10.1074/jbc.M105182200; KAMOUN P, 1992, TRENDS BIOCHEM SCI, V17, P175, DOI 10.1016/0968-0004(92)90258-B; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; Korotkova N, 2002, J BACTERIOL, V184, P1750, DOI 10.1128/JB.184.6.1750-1758.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leal NA, 2003, J BIOL CHEM, V278, P9227, DOI 10.1074/jbc.M212739200; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Mancia F, 1998, STRUCTURE, V6, P711, DOI 10.1016/S0969-2126(98)00073-2; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Maniatis T., 1982, MOL CLONING; MARSH EN, 1989, BIOCHEM J, V260, P353, DOI 10.1042/bj2600353; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; Marx CJ, 2003, J BACTERIOL, V185, P669, DOI 10.1128/JB.185.2.669-673.2003; Marx CJ, 2002, BIOTECHNIQUES, V33, P1062, DOI 10.2144/02335rr01; MATSUI SM, 1983, NEW ENGL J MED, V308, P857, DOI 10.1056/NEJM198304143081501; Miyamoto E, 2002, J NUTR SCI VITAMINOL, V48, P242; Ratnatilleke A, 1999, J BIOL CHEM, V274, P31679, DOI 10.1074/jbc.274.44.31679; Rosenblatt D. S., 1999, Chemistry and biochemistry of B12., P367; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Seifert C, 2001, EUR J BIOCHEM, V268, P2369, DOI 10.1046/j.1432-1327.2001.02123.x; Simon R., 1983, MOL GENETICS BACTERI, V1st ed., P98; Smith LM, 1996, MICROBIOL-UK, V142, P675, DOI 10.1099/13500872-142-3-675; Thoma NH, 2000, BIOCHEMISTRY-US, V39, P9213, DOI 10.1021/bi0004302; Toraya T, 2000, CELL MOL LIFE SCI, V57, P106, DOI 10.1007/s000180050502; Watkins D, 2001, ENDOCRINOLOGIST, V11, P98, DOI 10.1097/00019616-200103000-00005; Watkins D, 2000, J MED GENET, V37, P510, DOI 10.1136/jmg.37.7.510; WILKEMEYER MF, 1990, BIOCHEM J, V271, P449, DOI 10.1042/bj2710449; ZAGALAK B, 1974, EUR J BIOCHEM, V44, P529, DOI 10.1111/j.1432-1033.1974.tb03512.x; ZELDER O, 1994, EUR J BIOCHEM, V226, P577, DOI 10.1111/j.1432-1033.1994.tb20083.x	49	72	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13652	13658		10.1074/jbc.M312852200	http://dx.doi.org/10.1074/jbc.M312852200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734568	hybrid			2022-12-27	WOS:000220478500047
J	Kariko, K; Ni, HP; Capodici, J; Lamphier, M; Weissman, D				Kariko, K; Ni, HP; Capodici, J; Lamphier, M; Weissman, D			mRNA is an endogenous ligand for Toll-like receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; CYTOTOXIC T-LYMPHOCYTES; HEAT-SHOCK PROTEINS; MHC CLASS-I; NF-KAPPA-B; DENDRITIC CELLS; CROSS-PRESENTATION; TRANSCRIPTION FACTORS; ADAPTER MOLECULE; GENE-EXPRESSION	Toll-like receptors (TLRs) are the basic signaling receptors of the innate immune system. They are activated by molecules associated with pathogens or injured host cells and tissue. TLR3 has been shown to respond to double stranded (ds) RNA, a replication intermediary for many viruses. Here we present evidence that heterologous RNA released from or associated with necrotic cells or generated by in vitro transcription also stimulates TLR3 and induces immune activation. To assess RNA-mediated TLR3 activation, human embryonic kidney 293 cells stably expressing TLR3 and containing a nuclear factor-kappaB-dependent luciferase reporter were generated. Exposing these cells to in vitro transcribed RNA resulted in a TLR3-dependent induction of luciferase activity and interleukin-8 secretion. Treatment with in vitro transcribed mRNA activated nuclear factor-kappaB via TLR3 through a process that was dose-dependent and involved tyrosine phosphorylation. Furthermore, in vitro transcribed natural or 2'-fluoro-substituted mRNA induced the expression of TLR3, interferon regulatory factor-1, tumor necrosis factor-alpha, and interleukin-1 receptor-associated kinase-M mRNA in human dendritic cells (DCs). DCs responded to mRNA treatment by expressing activation markers, and this maturation was inhibited by antagonistic TLR3-specific antibody. Endogenous RNA released from or associated with necrotic cells also stimulated DCs, leading to interferon-alpha secretion, which could be abolished by pretreatment of necrotic cells with RNase. These results demonstrate that RNA, likely through secondary structure, is a potent host-derived activator of TLR3. This finding has potential physiologic relevance because RNA escaping from damaged tissue or contained within endocytosed cells could serve as an endogenous ligand for TLR3 that induces or otherwise modulates immune responses.	Univ Penn, Div Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA; Eisai Res Inst, Andover, MA 01810 USA	University of Pennsylvania; University of Pennsylvania; Eisai Co Ltd	Kariko, K (corresponding author), Univ Penn, Div Neurosurg, 3610 Hamilton Walk, Philadelphia, PA 19104 USA.	kariko@mail.med.upenn.edu			NHLBI NIH HHS [HL 62060-04] Funding Source: Medline; NIAID NIH HHS [AI 50484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Armant MA, 2002, GENOME BIOL, V3; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Belz GT, 2002, CRIT REV IMMUNOL, V22, P439; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Datta SK, 2003, J IMMUNOL, V170, P4102, DOI 10.4049/jimmunol.170.8.4102; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; EILAT D, 1994, MOL IMMUNOL, V31, P1377, DOI 10.1016/0161-5890(94)90154-6; Ginsberg SD, 1999, ANN NEUROL, V45, P174, DOI 10.1002/1531-8249(199902)45:2<174::AID-ANA7>3.0.CO;2-E; Ginsberg SD, 1998, ACTA NEUROPATHOL, V96, P487, DOI 10.1007/s004010050923; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Grentzmann G, 1998, RNA, V4, P479; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; Heiser A, 2002, J CLIN INVEST, V109, P409, DOI 10.1172/JCI14364; Heiser A, 2001, J IMMUNOL, V166, P2953, DOI 10.4049/jimmunol.166.5.2953; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kariko K, 1998, BBA-BIOMEMBRANES, V1369, P320, DOI 10.1016/S0005-2736(97)00238-1; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Larsson M, 2003, CURR TOP MICROBIOL, V276, P261; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Marcinkiewicz M, 2002, J NEUROPATH EXP NEUR, V61, P815, DOI 10.1093/jnen/61.9.915; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2002, ANN NY ACAD SCI, V961, P341, DOI 10.1111/j.1749-6632.2002.tb03118.x; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; Miettinen M, 2001, GENES IMMUN, V2, P349, DOI 10.1038/sj.gene.6363791; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nair SK, 2002, ANN SURG, V235, P540, DOI 10.1097/00000658-200204000-00013; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Ni HP, 2002, J BIOL CHEM, V277, P12689, DOI 10.1074/jbc.M110729200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; Sato M, 2001, CYTOKINE GROWTH F R, V12, P133, DOI 10.1016/S1359-6101(00)00032-0; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Shinobu N, 2002, FEBS LETT, V517, P251, DOI 10.1016/S0014-5793(02)02636-4; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Vabulas RM, 2002, CURR TOP MICROBIOL, V270, P169; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; Weissman D, 2000, J IMMUNOL, V165, P4710, DOI 10.4049/jimmunol.165.8.4710; Werling D, 2003, VET IMMUNOL IMMUNOP, V91, P1, DOI 10.1016/S0165-2427(02)00228-3; Williams B.R., 2001, SCI STKE, V2001, pre2; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yasutomo K, 2001, NAT GENET, V28, P313, DOI 10.1038/91070; Zinkernagel RM, 2002, EUR J IMMUNOL, V32, P2385, DOI 10.1002/1521-4141(200209)32:9<2385::AID-IMMU2385>3.0.CO;2-V; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	64	777	868	6	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12542	12550		10.1074/jbc.M310175200	http://dx.doi.org/10.1074/jbc.M310175200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729660	hybrid			2022-12-27	WOS:000220334900066
J	van Meeteren, LA; Frederiks, F; Giepmans, BNG; Pedrosa, MFF; Billington, SJ; Jost, BH; Tambourgi, DV; Moolenaar, WH				van Meeteren, LA; Frederiks, F; Giepmans, BNG; Pedrosa, MFF; Billington, SJ; Jost, BH; Tambourgi, DV; Moolenaar, WH			Spider and bacterial sphingomyelinases D target cellular lysophosphatidic acid receptors by hydrolyzing lysophosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN RECLUSE SPIDER; PHOSPHOLIPASE-D; CORYNEBACTERIUM-PSEUDOTUBERCULOSIS; LYSOPHOSPHOLIPASE-D; ACTIVATION; CERAMIDE; CLONING; VENOM; IDENTIFICATION; LYMPHADENITIS	Bites by Loxosceles spiders can produce severe clinical symptoms, including dermonecrosis, thrombosis, vascular leakage, hemolysis, and persistent inflammation. The causative factor is a sphingomyelinase D (SMaseD) that cleaves sphingomyelin into choline and ceramide 1-phosphate. A similar enzyme, showing comparable bioactivity, is secreted by certain pathogenic corynebacteria and acts as a potent virulence factor. However, the molecular basis for SMaseD toxicity is not well understood, which hampers effective therapy. Here we show that the spider and bacterial SMases D hydrolyze albumin-bound lysophosphatidylcholine (LPC), but not sphingosylphosphorylcholine, with K-m values (similar to20-40 muM) well below the normal LPC levels in blood. Thus, toxic SMases D have intrinsic lysophospholipase D activity toward LPC. LPC hydrolysis yields the lipid mediator lysophosphatidic acid (LPA), a known inducer of platelet aggregation, endothelial hyperpermeability, and pro-inflammatory responses. Introduction of LPA(1) receptor cDNA into LPA receptor-negative cells renders non-susceptible cells susceptible to SmaseD, but only in LPC-containing media. Degradation of circulating LPC to LPA with consequent activation of LPA receptors may have a previously unappreciated role in the pathophysiology of secreted SMases D.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Inst Butantan, Lab Imunoquim, BR-05503900 Sao Paulo, Brazil; Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ 85721 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Instituto Butantan; University of Arizona	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	w.moolenaar@nki.nl	Fernandes-Pedrosa, Matheus/C-6398-2014; van Meeteren, Laurens/A-9890-2008; Van Meeteren, Laurens A./AGQ-6139-2022; Tambourgi, Denise/H-7114-2016; Giepmans, Ben N.G./R-4564-2016	Fernandes-Pedrosa, Matheus/0000-0003-4221-9580; van Meeteren, Laurens/0000-0001-9885-0668; Tambourgi, Denise/0000-0003-1896-9074; Giepmans, Ben N.G./0000-0001-5105-5915				Amerongen GPV, 2000, ARTERIOSCL THROM VAS, V20, pE127, DOI 10.1161/01.ATV.20.12.e127; BATEY RG, 1986, AUST VET J, V63, P269, DOI 10.1111/j.1751-0813.1986.tb08064.x; BERNHEIMER AW, 1985, SCIENCE, V228, P590, DOI 10.1126/science.3983643; CARNE HR, 1978, NATURE, V271, P246, DOI 10.1038/271246a0; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Feldhaus MJ, 2002, J BIOL CHEM, V277, P4285, DOI 10.1074/jbc.M106653200; FORRESTER LJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P355, DOI 10.1016/0003-9861(78)90046-2; Fueller M, 2003, CELL SIGNAL, V15, P367, DOI 10.1016/S0898-6568(02)00117-1; FUTRELL JM, 1992, AM J MED SCI, V304, P261, DOI 10.1097/00000441-199210000-00008; Geng D, 1998, J BIOL CHEM, V273, P12195, DOI 10.1074/jbc.273.20.12195; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; HASERUECK N, 2004, IN PRESS BLOOD; Hashimoto T, 2003, J PHARMACOL SCI, V91, P8, DOI 10.1254/jphs.91.8; KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8; LILIOM K, 2004, BIOCHEM J, V355, P189; LIPSKY BA, 1982, REV INFECT DIS, V4, P1220; MCNAMARA PJ, 1995, GENE, V156, P113, DOI 10.1016/0378-1119(95)00002-N; MCNAMARA PJ, 1994, MOL MICROBIOL, V12, P921, DOI 10.1111/j.1365-2958.1994.tb01080.x; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; Pedrosa MD, 2002, BIOCHEM BIOPH RES CO, V298, P638, DOI 10.1016/S0006-291X(02)02521-4; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; REES RS, 1983, J SURG RES, V35, P1, DOI 10.1016/0022-4804(83)90119-1; Sams HH, 2001, J AM ACAD DERMATOL, V44, P561, DOI 10.1067/mjd.2001.112385; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Siess W, 2002, BBA-MOL CELL BIOL L, V1582, P204, DOI 10.1016/S1388-1981(02)00173-7; Songer JG, 1997, TRENDS MICROBIOL, V5, P156, DOI 10.1016/S0966-842X(97)01005-6; SOUCEK A, 1967, BIOCHIM BIOPHYS ACTA, V144, P180; SOUCEK A, 1971, BIOCHIM BIOPHYS ACTA, V227, P116, DOI 10.1016/0005-2744(71)90173-2; Subbaiah PV, 2003, J LIPID RES, V44, P1574, DOI 10.1194/jlr.M300103-JLR200; SUBBAIAH PV, 1985, J BIOL CHEM, V260, P5308; Tachedjian M, 1995, VACCINE, V13, P1785, DOI 10.1016/0264-410X(95)00144-P; Tambourgi DV, 1998, BIOCHEM BIOPH RES CO, V251, P366, DOI 10.1006/bbrc.1998.9474; Tambourgi DV, 2002, IMMUNOLOGY, V107, P93, DOI 10.1046/j.1365-2567.2002.01483.x; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; TRUETT AP, 1993, ADV LIPID RES, V26, P275; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Yang HY, 2002, PROTEIN SCI, V11, P2958, DOI 10.1110/ps.0225302; Yang L, 2000, BLOOD, V95, P2420, DOI 10.1182/blood.V95.7.2420.007k12_2420_2425	45	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10833	10836		10.1074/jbc.C300563200	http://dx.doi.org/10.1074/jbc.C300563200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14732720	hybrid			2022-12-27	WOS:000220157600002
J	Bowen, RL; Verdile, G; Liu, TB; Parlow, AF; Perry, G; Smith, MA; Martins, RN; Atwood, CS				Bowen, RL; Verdile, G; Liu, TB; Parlow, AF; Perry, G; Smith, MA; Martins, RN; Atwood, CS			Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; HUMAN NEUROBLASTOMA-CELLS; A-BETA; GONADOTROPIN RECEPTORS; CEREBROSPINAL-FLUID; GENDER-DIFFERENCES; TRANSGENIC MICE; DOWN-SYNDROME; FEMALE RATS; IN-VIVO	Hormonal changes associated with the dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis following menopause/andropause have been implicated in the pathogenesis of Alzheimer's disease ( AD). Experimental support for this has come from studies demonstrating an increase in amyloid-beta(Abeta) deposition following ovariectomy/castration. Because sex steroids and gonadotropins are both part of the HPG feedback loop, any loss in sex steroids results in a proportionate increase in gonadotropins. To assess whether Abeta generation was due to the loss of serum 17beta-estradiol or to the up-regulation of serum gonadotropins, we treated C57Bl/6J mice with the anti-gonadotropin leuprolide acetate, which suppresses both sex steroids and gonadotropins. Leuprolide acetate treatment resulted in a 3.5-fold ( p < 0.0001) and a 1.5-fold ( p < 0.024) reduction in total brain Abeta1-42 and Abeta1-40 concentrations, respectively, after 8 weeks of treatment. To further explore the role of gonadotropins in promoting amyloidogenesis, M17 neuroblastoma cells were treated with the gonadotropin luteinizing hormone (LH) at concentrations equivalent to early adulthood ( 10 mIU/ml) or post-menopause/andropause ( 30 mIU/ml). LH did not alter amyloid-beta precursor protein (AbetaPP) expression but did alter AbetaPP processing toward the amyloidogenic pathway as evidenced by increased secretion and insolubility of Abeta, decreased alphaAbetaPP secretion, and increased AbetaPP-C99 levels. These results suggest the marked increases in serum LH following menopause/andropause as a physiologically relevant signal that could promote Abeta secretion and deposition in the aging brain. Suppression of the age-related increase in serum gonadotropins using anti-gonadotropin agents may represent a novel therapeutic strategy for AD.	Voyager Pharmaceut Corp, Raleigh, NC 27615 USA; Edith Cowan Univ, Sch Biomed & Sports Sci, Ctr Aging & Alzheimers Dis, Joondalup, WA 6027, Australia; Univ Western Australia, Dept Psychiat & Clin Neurosci, Perth, WA 6009, Australia; Hollywood Private Hosp, Sir James McCusker Alzheimsers Dis Res Unit, Perth, WA 6009, Australia; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA; Harbor UCLA Med Ctr, Natl Hormone & Peptide Program, Torrance, CA 90509 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	Edith Cowan University; University of Western Australia; University of Western Australia; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Case Western Reserve University; University of Wisconsin System; University of Wisconsin Madison	Atwood, CS (corresponding author), Univ Wisconsin, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA.	csa@medicine.wisc.edu	, Craig/AAB-3963-2022; Perry, George/A-8611-2009; Smith, Mark A/A-9053-2009	Perry, George/0000-0002-6547-0172; Martins, Ralph/0000-0002-4828-9363; Verdile, Giuseppe/0000-0003-2475-0124	NIA NIH HHS [R01 AG 19356] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019356] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AlHader AA, 1997, BIOL REPROD, V56, P501, DOI 10.1095/biolreprod56.2.501; AlHader AA, 1997, BIOL REPROD, V56, P1071, DOI 10.1095/biolreprod56.5.1071; Andersson AM, 1998, J CLIN ENDOCR METAB, V83, P675, DOI 10.1210/jc.83.2.675; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; ATWOOD CS, 2003, MENOPAUSE ANDROPAUSE, P29; Beffert U, 1999, BRAIN RES, V843, P87, DOI 10.1016/S0006-8993(99)01894-6; Berezovska O, 1997, J NEUROPATH EXP NEUR, V56, P40, DOI 10.1097/00005072-199701000-00004; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bowen RL, 2002, J NEUROSCI RES, V70, P514, DOI 10.1002/jnr.10452; Bowen RL, 2000, J NEUROENDOCRINOL, V12, P351; BOYAR R, 1972, NEW ENGL J MED, V287, P582, DOI 10.1056/NEJM197209212871203; BUKOVSKY A, 1993, BIOL REPROD, V48, P1367, DOI 10.1095/biolreprod48.6.1367; Bukovsky Antonin, 2003, Reprod Biol Endocrinol, V1, P46, DOI 10.1186/1477-7827-1-46; Burger LL, 2001, ENDOCRINOLOGY, V142, P3435, DOI 10.1210/en.142.8.3435; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHAKRAVARTI S, 1976, BRIT MED J, V2, P784, DOI 10.1136/bmj.2.6039.784; Chang D, 1997, ADV EXP MED BIOL, V429, P261; CLAYTON RN, 1981, ENDOCR REV, V2, P186, DOI 10.1210/edrv-2-2-186; COUZINET B, 1993, HUM REPROD, V8, P97, DOI 10.1093/humrep/8.suppl_2.97; Gawronska B, 1999, J REPROD FERTIL, V115, P293, DOI 10.1530/jrf.0.1150293; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GOLDE TE, 1993, ANN NY ACAD SCI, V695, P103, DOI 10.1111/j.1749-6632.1993.tb23036.x; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; HAASS C, 1994, J BIOL CHEM, V269, P17741; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; Hogervorst E, 2001, NEUROENDOCRINOL LETT, V22, P163; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; INDRAPICHATE K, 1992, BIOL REPROD, V46, P265, DOI 10.1095/biolreprod46.2.265; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Konishi I, 1999, ONCOLOGY-BASEL, V57, P45, DOI 10.1159/000055274; LARSON J, 2002, WILLIAMS TXB ENDOCRI; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; LEI ZM, 1993, ENDOCRINOLOGY, V132, P2262, DOI 10.1210/en.132.5.2262; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levin-Allerhand JA, 2002, J ALZHEIMERS DIS, V4, P449; LUKACS H, 1995, HORM BEHAV, V29, P42, DOI 10.1006/hbeh.1995.1004; Manly JJ, 2000, NEUROLOGY, V54, P833, DOI 10.1212/WNL.54.4.833; Manthey D, 2001, EUR J BIOCHEM, V268, P4285, DOI 10.1046/j.1432-1327.2001.02346.x; Martins RH, 1995, NEUROREPORT, V7, P217, DOI 10.1097/00001756-199512290-00052; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mathews PM, 2002, J BIOL CHEM, V277, P5299, DOI 10.1074/jbc.M108161200; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785, DOI 10.1152/jappl.2001.91.6.2785; MCGONIGAL G, 1993, BRIT MED J, V306, P680, DOI 10.1136/bmj.306.6879.680; Mehta PD, 1998, NEUROSCI LETT, V241, P13, DOI 10.1016/S0304-3940(97)00966-X; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MINEGISHI T, 1989, P NATL ACAD SCI USA, V86, P1470, DOI 10.1073/pnas.86.5.1470; Misonou H, 2000, BIOCHEMISTRY-US, V39, P6951, DOI 10.1021/bi000169p; MONROE SE, 1972, J CLIN ENDOCR METAB, V34, P420, DOI 10.1210/jcem-34-2-420; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; NEAVES WB, 1984, J CLIN ENDOCR METAB, V59, P756, DOI 10.1210/jcem-59-4-756; Okada H, 1996, J PHARM SCI, V85, P1044, DOI 10.1021/js960123a; OKADA H, 1994, PHARMACEUT RES, V11, P1199, DOI 10.1023/A:1018905403359; OLSON DR, 1991, NEUROENDOCRINOLOGY, V53, P124, DOI 10.1159/000125709; PARLOW AF, 1964, ENDOCRINOLOGY, V74, P102, DOI 10.1210/endo-74-1-102; Petanceska SS, 2000, EXP GERONTOL, V35, P1317, DOI 10.1016/S0531-5565(00)00157-1; Schally AV, 2001, FRONT NEUROENDOCRIN, V22, P248, DOI 10.1006/frne.2001.0217; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Short RA, 2001, MAYO CLIN PROC, V76, P906; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAKASHIMA S, 1990, BRAIN DEV-JPN, V12, P367, DOI 10.1016/S0387-7604(12)80066-0; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; THOMAS DM, 1994, ENDOCRINOLOGY, V135, P1902, DOI 10.1210/en.135.5.1902; Vaucher E, 2001, J CHEM NEUROANAT, V21, P323, DOI 10.1016/S0891-0618(01)00120-X; Verdile G, 1999, ALZHEIMERS REP, V2, P231; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Wang J, 2003, NEUROBIOL DIS, V14, P318, DOI 10.1016/j.nbd.2003.08.009; West A. P., 1992, Biochemical Society Transactions, V20, p320S; WISE PM, 1980, NEUROENDOCRINOLOGY, V30, P15, DOI 10.1159/000122968; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yarram SJ, 2003, ENDOCRINOLOGY, V144, P3555, DOI 10.1210/en.2003-0036; Zheng H, 2002, J NEUROCHEM, V80, P191, DOI 10.1046/j.0022-3042.2001.00690.x	77	143	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20539	20545		10.1074/jbc.M311993200	http://dx.doi.org/10.1074/jbc.M311993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14871891	hybrid			2022-12-27	WOS:000221164500133
J	Donnini, M; Lapucci, A; Papucci, L; Witort, E; Jacquier, A; Brewer, G; Nicolin, A; Capaccioli, S; Schiavone, N				Donnini, M; Lapucci, A; Papucci, L; Witort, E; Jacquier, A; Brewer, G; Nicolin, A; Capaccioli, S; Schiavone, N			Identification of TINO - A new evolutionarily conserved BCL-2 Au-rich element RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS EMBRYOS; MESSENGER-RNA; SEQUENCE FEATURES; KH DOMAIN; GENE; DESTABILIZATION; DEADENYLATION; DEGRADATION; APOPTOSIS; COMPLEXES	Modulation of mRNA stability by regulatory cis-acting AU-rich elements (AREs) and ARE-binding proteins is an important posttranscriptional mechanism of gene expression control. We previously demonstrated that the 3'-untranslated region of BCL-2 mRNA contains an ARE that accounts for rapid BCL-2 down-regulation in response to apoptotic stimuli. We also demonstrated that the BCL-2 ARE core interacts with a number of ARE-binding proteins, one of which is AU-rich factor 1/heterogeneous nuclear ribonucleoprotein D, known for its interaction with mRNA elements of others genes. In an attempt to search for other BCL-2 mRNA-binding proteins, we used the yeast RNA three-hybrid system assay and identified a novel human protein that interacts with BCL-2 ARE. We refer to it as TINO. The predicted protein sequence of TINO reveals two amino-terminal heterogeneous nuclear ribonucleoprotein K homology motifs for nucleic acid binding and a carboxyl-terminal RING domain, endowed with a putative E3 ubiquitin-protein ligase activity. In addition the novel protein is evolutionarily conserved; the two following orthologous proteins have been identified with protein-protein BLAST: posterior end mark-3 (PEM-3) of Ciona savignyi and muscle excess protein-3 (MEX-3) of Caenorhabditis elegans. Upon binding, TINO destabilizes a chimeric reporter construct containing the BCL-2 ARE sequence, revealing a negative regulatory action on BCL-2 gene expression at the posttranscriptional level.	Univ Florence, Sch Med, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Univ Milan, Sch Med, Dept Pharmacol, I-20129 Milan, Italy; Inst Pasteur, Unite Genet Interact Macromol, CNRS, URA 2171, F-75724 Paris, France; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA	University of Florence; University of Milan; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Rutgers State University New Brunswick; Rutgers State University Medical Center	Capaccioli, S (corresponding author), Univ Florence, Sch Med, Dept Expt Pathol & Oncol, I-50134 Florence, Italy.	sergio@unifi.it; nicola@unifi.it	Lapucci, Andrea/AAA-6645-2019	JACQUIER, ALAIN/0000-0001-5707-9184; Papucci, Laura/0000-0002-8450-7428; Schiavone, Nicola/0000-0002-1592-4244; LAPUCCI, Andrea/0000-0001-9613-7164	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; Brooks S A, 2000, Nucleic Acids Res, V28, pE49, DOI 10.1093/nar/28.10.e49; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Burge CB, 1998, MOL CELL, V2, P773, DOI 10.1016/S1097-2765(00)80292-0; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Dominov JA, 1998, J CELL BIOL, V142, P537, DOI 10.1083/jcb.142.2.537; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P638, DOI 10.1093/nar/29.3.638; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; HUTNER CH, 1999, 12 INT C EL M MAD WI; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kikuno R, 2002, NUCLEIC ACIDS RES, V30, P166, DOI 10.1093/nar/30.1.166; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; LEGNADO CA, 1994, MOL CELL BIOL, V14, P7984; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Satou Y, 1999, DEV BIOL, V212, P337, DOI 10.1006/dbio.1999.9336; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Schisa JA, 2001, DEVELOPMENT, V128, P1287; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Stoecklin G, 2001, RNA, V7, P1578; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	37	47	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20154	20166		10.1074/jbc.M314071200	http://dx.doi.org/10.1074/jbc.M314071200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14769789	hybrid			2022-12-27	WOS:000221164500092
J	Khor, HK; Fisher, MT; Schoneich, C				Khor, HK; Fisher, MT; Schoneich, C			Potential role of methionine sulfoxide in the inactivation of the chaperone GroEL by hypochlorous acid (HOCl) and peroxynitrite (ONOO-)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; LOW-DENSITY-LIPOPROTEIN; ESCHERICHIA-COLI; HYDROGEN-PEROXIDE; AMINO-ACID; SACCHAROMYCES-CEREVISIAE; ANTIMICROBIAL SYSTEM; GLUTAMINE-SYNTHETASE; BACTERICIDAL ACTION; OXIDATIVE STRESS	GroEL is an Escherichia coli molecular chaperone that functions in vivo to fold newly synthesized polypeptides as well as to bind and refold denatured proteins during stress. This protein is a suitable model for its eukaryotic homolog, heat shock protein 60 (Hsp60), due to the high number of conserved amino acid sequences and similar function. Here, we will provide evidence that GroEL is rather insensitive to oxidants produced endogenously during metabolism, such as nitric oxide ((NO)-N-circle) or hydrogen peroxide (H2O2), but is efficiently modified and inactivated by reactive species generated by phagocytes, such as peroxynitrite (ONOO-) and hypochlorous acid (HOCl). For the exposure of 17.5 muM GroEL to 100-250 muM HOCl, the major pathway of inactivation was through the oxidation of methionine to methionine sulfoxide, established through mass spectrometric detection of methionine sulfoxide and the reactivation of a significant fraction of inactivated GroEL by the enzyme methionine sulfoxide reductase B/A (MsrB/A). In addition to the oxidation of methionine, HOCl caused the conversion of cysteine to cysteic acid and this product may account for the remainder of inactivated GroEL not recoverable through MsrB/A. In contrast, HOCl produced only negligible yields of 3-chlorotyrosine. A remarkable finding was the conversion of Met(111) and Met(114) to Met sulfone, which suggests a rather low reduction potential of these 2 residues in GroEL. The high sensitivity of GroEL toward HOCl and ONOO- suggests that this protein may be a target for bacterial killing by phagocytes.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas; University of Kansas Medical Center	Schoneich, C (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.	schoneic@ku.edu			NATIONAL INSTITUTE ON AGING [P01AG012993] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12993] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bochkareva E, 1999, J BIOL CHEM, V274, P20756, DOI 10.1074/jbc.274.30.20756; Brennan ML, 2003, AMINO ACIDS, V25, P365, DOI 10.1007/s00726-003-0023-y; Brocchieri L, 2000, PROTEIN SCI, V9, P476; BROT N, 1991, BIOFACTORS, V3, P91; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; Buchanan Michelle V., 2002, OMICS A Journal of Integrative Biology, V6, P287, DOI 10.1089/153623102321112737; BUZY A, 1995, J PROTEIN CHEM, V14, P59, DOI 10.1007/BF01888363; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Cabiscol E, 2002, J BIOL CHEM, V277, P44531, DOI 10.1074/jbc.M206525200; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DOLLA A, 1994, J BIOL CHEM, V269, P6340; EZZELL C, 1996, J NATL I HLTH RES, V8, P31; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Fu XY, 2002, BIOCHEMISTRY-US, V41, P1293, DOI 10.1021/bi015777z; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Gustavsson N, 1999, PROTEIN SCI, V8, P2506; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hansel A, 2002, FASEB J, V16, P911, DOI 10.1096/fj.01-0737fje; Harndahl U, 2001, BBA-PROTEIN STRUCT M, V1545, P227, DOI 10.1016/S0167-4838(00)00280-6; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; Jung S, 2002, FEBS LETT, V527, P91, DOI 10.1016/S0014-5793(02)03171-X; KLEBANOFF SJ, 1984, INFECT IMMUN, V44, P534, DOI 10.1128/IAI.44.2.534-536.1984; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Levy-Rimler G, 2001, EUR J BIOCHEM, V268, P3465, DOI 10.1046/j.1432-1327.2001.02243.x; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; Maguire M, 2002, CELL STRESS CHAPERON, V7, P317, DOI 10.1379/1466-1268(2002)007<0317:CUISOC>2.0.CO;2; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Martin J, 1998, J BIOL CHEM, V273, P7351, DOI 10.1074/jbc.273.13.7351; MAXWELL SRJ, 1995, DRUGS, V49, P345, DOI 10.2165/00003495-199549030-00003; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Napoli C, 2001, J CELL BIOCHEM, V82, P674, DOI 10.1002/jcb.1198; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; PRYOR WA, 1995, FREE RADICAL BIO MED, V18, P75, DOI 10.1016/0891-5849(94)00105-S; ROSEN H, 1987, J BIOL CHEM, V262, P15004; ROSEN H, 1985, INFECT IMMUN, V47, P613, DOI 10.1128/IAI.47.3.613-618.1985; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SIPS HJ, 1981, INFECT IMMUN, V31, P11, DOI 10.1128/IAI.31.1.11-16.1981; THOMAS EL, 1979, INFECT IMMUN, V23, P522, DOI 10.1128/IAI.23.2.522-531.1979; Tieman BC, 2001, J BIOL CHEM, V276, P44541, DOI 10.1074/jbc.M106693200; Voziyan PA, 2000, PROTEIN SCI, V9, P2405, DOI 10.1110/ps.9.12.2405; WANG F, 2002, BIOCHEMISTRY MOSC, V67, P656; Wick G, 1999, EXP GERONTOL, V34, P559, DOI 10.1016/S0531-5565(99)00035-2; XU QB, 1994, CIRC RES, V75, P1078, DOI 10.1161/01.RES.75.6.1078; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	61	78	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19486	19493		10.1074/jbc.M310045200	http://dx.doi.org/10.1074/jbc.M310045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14757771	hybrid			2022-12-27	WOS:000221164500015
J	Grazide, S; Terrisse, AD; Lerouge, S; Laurent, G; Jaffrezou, JP				Grazide, S; Terrisse, AD; Lerouge, S; Laurent, G; Jaffrezou, JP			Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT CANCER-CELLS; CULTURED FIBROBLASTS; GD3 GANGLIOSIDE; P-GLYCOPROTEIN; CERAMIDE; SPHINGOMYELINASE; ACTIVATION; MITOCHONDRIA; SPHINGOSINE; PROLIFERATION	Several studies have shown that ceramide (CER) glucosylation contributes to drug resistance in multidrug-resistant cells and that inhibition of glucosylceramide synthase sensitizes cells to various drug treatments. However, the role of glucosylceramide synthase has not been studied in drug-sensitive cancer cells. We have demonstrated previously that the anthracycline daunorubicin (DNR) rapidly induces interphasic apoptosis through neutral sphingomyelinase-mediated CER generation in human leukemic cell lines. We now report that inhibition of glucosylceramide synthase using D, L-threo-1-phenyl- 2-decanoylamino-3-morpholino-1-propanol (PDMP) or 1-phenyl-2-palmitoylamino-3-morpholino-1- propanol ( PPMP) protected U937 and HL-60 cells from DNR-induced apoptosis. Moreover, blocking CER glucosylation did not lead to increased CER levels but to increased CER galactosylation. We also observed that pretreating cells with galactosylceramide (GalCER) significantly inhibited DNR-induced apoptosis. Finally, we show that GalCER-enriched lymphoblast cells ( Krabbe's disease) were significantly more resistant to DNR- and cytosine arabinoside-induced apoptosis as compared with normal lymphoblasts, whereas glucosylceramide-enriched cells ( Gaucher's disease) were more sensitive. In conclusion, this study suggests that sphingomyelin-derived CER in itself is not a second messenger but rather a precursor of both an apoptosis second messenger (GD3) and an apoptosis "protector" (GalCER).	Inst Claudius Regaud, CPTP, INSERM, U563, F-31059 Toulouse, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jaffrezou, JP (corresponding author), Inst Claudius Regaud, CPTP, INSERM, U563, 20 Rue Pont St Pierre, F-31059 Toulouse, France.	jaffrezou@icr.fnclcc.fr		Terrisse, Anne Dominique/0000-0001-9202-8569				Bezombes C, 2001, FASEB J, V15, P1583, DOI 10.1096/fj.00-0787fje; Bezombes C, 2001, FASEB J, V15, P297; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; CHABNER BA, 1975, NEW ENGL J MED, V292, P1159, DOI 10.1056/NEJM197505292922206; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Di Bartolomeo S, 2001, BIOCHEM PHARMACOL, V61, P851, DOI 10.1016/S0006-2952(01)00569-X; di Bartolomeo S, 2001, BIOCHEM BIOPH RES CO, V288, P269, DOI 10.1006/bbrc.2001.5748; Durrieu F, 1999, CYTOMETRY, V36, P140, DOI 10.1002/(SICI)1097-0320(19990601)36:2<140::AID-CYTO8>3.0.CO;2-P; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; HARDY B, 1987, BIOMED PHARMACOTHER, V41, P40; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jaffrezou JP, 1998, FASEB J, V12, P999, DOI 10.1096/fasebj.12.11.999; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kleuser B, 1998, CANCER RES, V58, P1817; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Lavie Y, 1999, LIPIDS, V34, pS57, DOI 10.1007/BF02562229; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; LING V, 1992, CANCER-AM CANCER SOC, V69, P2603, DOI 10.1002/1097-0142(19920515)69:10<2603::AID-CNCR2820691034>3.0.CO;2-E; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Nicholson KM, 1999, BRIT J CANCER, V81, P423, DOI 10.1038/sj.bjc.6690711; NILSSON O, 1982, J LIPID RES, V23, P327; OBRIEN JS, 1975, ARCH NEUROL-CHICAGO, V32, P592, DOI 10.1001/archneur.1975.00490510048002; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Plo I, 2002, MOL PHARMACOL, V62, P304, DOI 10.1124/mol.62.2.304; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Veldman RJ, 2002, FASEB J, V16, P1111, DOI 10.1096/fj.01-0863fje	42	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18256	18261		10.1074/jbc.M314105200	http://dx.doi.org/10.1074/jbc.M314105200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14766899	hybrid			2022-12-27	WOS:000221041500021
J	de Breyne, S; Monney, RS; Curran, J				de Breyne, S; Monney, RS; Curran, J			Proteolytic processing and translation initiation - Two independent mechanisms for the expression of the sendai virus Y proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P/C MESSENGER-RNA; FACTOR 4G EIF4G; C-PROTEINS; RIBOSOMAL INITIATION; MAMMALIAN TRANSLATION; FACTOR EIF-4A; HEPATITIS-C; CELL-DEATH; X-PROTEIN; APOPTOSIS	The four Sendai virus C-proteins (C', C, Y1, and Y2) represent an N-terminal nested set of non-structural proteins whose expression modulates both the readout of the viral genome and the host cell response. In particular, they modulate the innate immune response by perturbing the signaling of type 1 interferons. The initiation codons for the four C-proteins have been mapped in vitro, and it has been proposed that the Y proteins are initiated by ribosomal shunting. A number of mutations were reported that significantly enhanced Y expression, and this was attributed to increased shunt-mediated initiation. However, we demonstrate that this arises due to enhanced proteolytic processing of C', an event that requires its very N terminus. Curiously, although Y expression in vitro is mediated almost exclusively by initiation, Y proteins in vivo can arise both by translation initiation and processing of the C' protein. To our knowledge this is the first example of two apparently independent pathways leading to the expression of the same polypeptide chain. This dual pathway explains several features of Y expression.	Univ Geneva, Sch Med, Ctr Med Univ, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Curran, J (corresponding author), Univ Geneva, Sch Med, Ctr Med Univ, Dept Microbiol & Mol Med, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Joseph.Curran@medecine.unige.ch	de Breyne, Sylvain/M-6489-2014	de Breyne, Sylvain/0000-0002-1632-3475				Best SM, 2003, J VIROL, V77, P5305, DOI 10.1128/JVI.77.9.5305-5312.2003; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; BOECK R, 1994, EMBO J, V13, P3608, DOI 10.1002/j.1460-2075.1994.tb06668.x; Bontron S, 2002, J BIOL CHEM, V277, P38847, DOI 10.1074/jbc.M205722200; Cadd T, 1996, J VIROL, V70, P5067, DOI 10.1128/JVI.70.8.5067-5074.1996; Chiu R, 2002, J CELL BIOL, V159, P637, DOI 10.1083/jcb.200208013; CHRISTENSEN J, 1995, J VIROL, V69, P5422, DOI 10.1128/JVI.69.9.5422-5430.1995; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Collier AJ, 1998, J GEN VIROL, V79, P2359, DOI 10.1099/0022-1317-79-10-2359; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; CURRAN J, 1989, EMBO J, V8, P521, DOI 10.1002/j.1460-2075.1989.tb03406.x; CURRAN J, 1992, VIROLOGY, V189, P647, DOI 10.1016/0042-6822(92)90588-G; Curran J, 1998, SEMIN VIROL, V8, P351, DOI 10.1006/smvy.1997.0138; Curran J, 1999, ADV VIRUS RES, V54, P403, DOI 10.1016/S0065-3527(08)60373-5; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; de Breyne S, 2003, NUCLEIC ACIDS RES, V31, P608, DOI 10.1093/nar/gkg143; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Garcin D, 2000, J VIROL, V74, P8823, DOI 10.1128/JVI.74.19.8823-8830.2000; Garcin D, 2003, J VIROL, V77, P2321, DOI 10.1128/JVI.77.4.2321-2329.2003; Garcin D, 2002, VIROLOGY, V295, P256, DOI 10.1006/viro.2001.1342; Garcin D, 2001, J VIROL, V75, P6800, DOI 10.1128/JVI.75.15.6800-6807.2001; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; GUPTA KC, 1988, J BIOL CHEM, V263, P8553; HANN SR, 1994, BIOCHIMIE, V76, P880, DOI 10.1016/0300-9084(94)90190-2; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Itoh M, 1998, J VIROL, V72, P2927, DOI 10.1128/JVI.72.4.2927-2934.1998; Koyama AH, 2003, MICROBES INFECT, V5, P373, DOI 10.1016/S1286-4579(03)00043-1; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lane JD, 2002, J CELL BIOL, V156, P495, DOI 10.1083/jcb.200110007; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; Lobedanz S, 2003, GENE DEV, V17, P2151, DOI 10.1101/gad.274203; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mottet G, 1999, J GEN VIROL, V80, P2977, DOI 10.1099/0022-1317-80-11-2977; Park HS, 2001, CELL, V106, P723, DOI 10.1016/S0092-8674(01)00487-1; PATWARDHAN S, 1988, J BIOL CHEM, V263, P4907; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Sasaki J, 2000, P NATL ACAD SCI USA, V97, P1512, DOI 10.1073/pnas.010426997; Sesso A, 1999, TISSUE CELL, V31, P357, DOI 10.1054/tice.1999.0042; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Yueh A, 2000, GENE DEV, V14, P414; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	52	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16571	16580		10.1074/jbc.M312391200	http://dx.doi.org/10.1074/jbc.M312391200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14739274	hybrid			2022-12-27	WOS:000220747900107
J	Patel, DR; Wallweber, HJA; Yin, JP; Shriver, SK; Marsters, SA; Gordon, NC; Starovasnik, MA; Kelley, RF				Patel, DR; Wallweber, HJA; Yin, JP; Shriver, SK; Marsters, SA; Gordon, NC; Starovasnik, MA; Kelley, RF			Engineering an APRIL-specific B cell maturation antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR FAMILY; TNF RECEPTOR; BAFF-R; CRYSTAL-STRUCTURE; PROTEIN; LIGAND; BINDING; MEMBER; BCMA; BLYS	B cell maturation antigen ( BCMA) is a tumor necrosis factor receptor family member whose physiological role remains unclear. BCMA has been implicated as a receptor for both a proliferation-inducing ligand (APRIL) and B cell-activating factor (BAFF), tumor necrosis factor ligands that bind to multiple tumor necrosis factor receptor and have been reported to play a role in autoimmune disease and cancer. The results presented herein provide a dual perspective analysis of BCMA binding to both APRIL and BAFF. First, we characterized the binding affinity of monomeric BCMA for its ligands; BAFF binding affinity (IC50 = 8 +/- 5 muM) is about 1000-fold reduced compared with the high affinity interaction of APRIL (IC50 = 11 +/- 3 nM). Second, shotgun alanine scanning of BCMA was used to map critical residues for either APRIL or BAFF binding. In addition to a previously described "DXL" motif (Gordon, N. C., Pan, B., Hymowitz, S. G., Yin, J., Kelley, R. F., Cochran, A. G., Yan, M., Dixit, V. M., Fairbrother, W. J., and Starovasnik, M. A. (2003) Biochemistry 42, 5977 - 5983), the alanine scanning results predicted four amino acid positions in BCMA (Tyr(13), Ile(22), Gln(25), and Arg(27)) that could impart ligand specificity. Substitution of Tyr13 was tolerated for BAFF binding but not APRIL binding. Arg27 was required for high affinity binding to APRIL, whereas substitutions of this residue had minimal effect on affinity for BAFF. Further phage display experiments suggested the single mutations of I22K, Q25D, and R27Y as providing the greatest difference in APRIL versus BAFF binding affinity. Incorporation of the Q25D and R27Y substitutions into BCMA produced a dual specificity variant, since it has comparable binding affinity for both APRIL and BAFF, IC50 = 350 and 700 nM, respectively. Binding of the I22K mutant of monomeric BCMA to BAFF was undetectable (IC50 > 100 muM), but affinity for binding to APRIL was similar to wild-type BCMA. Based on these results, a BCMA-Fc fusion with the single I22K mutation was produced that binds APRIL, IC50 = 12 nM, and has no measurable affinity for BAFF. These results suggest that APRIL is the preferred ligand for BCMA and show that specificity can be further modified through amino acid substitutions.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Kelley, RF (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way,MS 27, San Francisco, CA 94080 USA.	rk@gene.com						Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Gordon NC, 2003, BIOCHEMISTRY-US, V42, P5977, DOI 10.1021/bi034017g; Gorelik L, 2003, J EXP MED, V198, P937, DOI 10.1084/jem.20030789; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Hatzoglou A, 2000, J IMMUNOL, V165, P1322, DOI 10.4049/jimmunol.165.3.1322; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kelly K, 2000, CANCER RES, V60, P1021; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Kim HM, 2003, NAT STRUCT BIOL, V10, P342, DOI 10.1038/nsb925; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABEAN TH, 1993, PROTEIN SCI, V2, P1249, DOI 10.1002/pro.5560020807; Lee GF, 1998, J BIOL CHEM, V273, P4149, DOI 10.1074/jbc.273.7.4149; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Liu YF, 2002, CELL, V108, P383, DOI 10.1016/S0092-8674(02)00631-1; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Nardelli B, 2001, BLOOD, V97, P198, DOI 10.1182/blood.V97.1.198; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Oren DA, 2002, NAT STRUCT BIOL, V9, P288, DOI 10.1038/nsb769; Pelletier M, 2003, J BIOL CHEM, V278, P33127, DOI 10.1074/jbc.M305754200; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Scapini P, 2003, J EXP MED, V197, P297, DOI 10.1084/jem.20021343; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Sidhu SS, 2000, J MOL BIOL, V296, P487, DOI 10.1006/jmbi.1999.3465; Sidhu SS, 2001, BIOMOL ENG, V18, P57, DOI 10.1016/S1389-0344(01)00087-9; Skelton NJ, 2003, J BIOL CHEM, V278, P7645, DOI 10.1074/jbc.M209751200; Starovasnik MA, 1996, BIOCHEMISTRY-US, V35, P15558, DOI 10.1021/bi961409x; Starovasnik MA, 1999, PROTEIN SCI, V8, P1423, DOI 10.1110/ps.8.7.1423; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Varfolomeev E, 2004, MOL CELL BIOL, V24, P997, DOI 10.1128/MCB.24.3.997-1006.2004; Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Xu SL, 2001, MOL CELL BIOL, V21, P4067, DOI 10.1128/MCB.21.12.4067-4074.2001; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802	43	47	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16727	16735		10.1074/jbc.M312316200	http://dx.doi.org/10.1074/jbc.M312316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764606	hybrid			2022-12-27	WOS:000220747900125
J	Scobey, MJ; Fix, CA; Walker, WH				Scobey, MJ; Fix, CA; Walker, WH			The Id2 transcriptional repressor is induced by follicle-stimulating hormone and cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; NF-KAPPA-B; RESPONSE ELEMENT; ENHANCER-BINDING; DNA-BINDING; E-BOX; REGULATE TRANSCRIPTION; GENE-TRANSCRIPTION; C-FOS; PROMOTER	Id (inhibitor of DNA binding/differentiation) proteins repress differentiation and promote cell division by dimerizing with and inhibiting the action of basic helix-loop-helix transcription factors including those that bind to E-box motifs. Of the four characterized Id proteins, only Id2 is found in the nucleus of Sertoli cells that support the development of spermatozoa in the testis. Differential display analysis of rat primary Sertoli cell mRNA identified Id2 as being inducible by forskolin, a stimulator of cAMP production. Northern blot analysis confirmed that Id2 mRNA expression peaked in Sertoli cells 6 - 12 h after stimulation with forskolin or follicle-stimulating hormone (FSH), the major physiological stimulator of cAMP in Sertoli cells. Similarly, Id2 promoter activity in Sertoli cells was induced after forskolin or FSH stimulation as well as by overexpression of protein kinase A. Forskolin induction of the Id2 promoter required sequences located between positions - 122 and - 82. Protein(s) of 40 - 45 kDa were found to bind two activated transcription factor/cAMP-response element-like sites and a GATA motif within the regulatory region. The induction of the Id2 gene by FSH corresponded with a decrease in protein binding to an E-box consensus motif and decreased E-box-mediated transcription. Together, these findings raise the possibility that FSH-mediated induction of Id2 and resultant inhibition of basic helix-loop-helix transcription factor-regulated genes in Sertoli cells may contribute to the regulation of spermatogenesis.	Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Walker, WH (corresponding author), Univ Pittsburgh, Dept Cell Biol & Physiol, 820 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	walkerw@pitt.edu			NICHD NIH HHS [F32 HD0861, K02 HD01206, R29-HD34913] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K02HD001206, R29HD034913] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS JR, 1995, J CELL PHYSIOL, V164, P249, DOI 10.1002/jcp.1041640205; Chaudhary J, 1997, ENDOCRINOLOGY, V138, P667, DOI 10.1210/en.138.2.667; Chaudhary J, 2001, ENDOCRINOLOGY, V142, P1727, DOI 10.1210/en.142.5.1727; Chaudhary J, 1999, MOL ENDOCRINOL, V13, P774, DOI 10.1210/me.13.5.774; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Delfino F, 1998, MOL ENDOCRINOL, V12, P1696, DOI 10.1210/me.12.11.1696; Delfino FJ, 1999, J BIOL CHEM, V274, P35607, DOI 10.1074/jbc.274.50.35607; Goetz TL, 1996, J BIOL CHEM, V271, P33317, DOI 10.1074/jbc.271.52.33317; Griswold MD, 2001, MOL CELL ENDOCRINOL, V173, P95, DOI 10.1016/S0303-7207(00)00412-3; Heckert LL, 2000, MOL ENDOCRINOL, V14, P1836, DOI 10.1210/me.14.11.1836; Heckert LL, 1998, MOL ENDOCRINOL, V12, P1499, DOI 10.1210/me.12.10.1499; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; KANGASNIEMI M, 1990, J ANDROL, V11, P336; KANGASNIEMI M, 1990, ANAT RECORD, V227, P62, DOI 10.1002/ar.1092270108; KURABAYASHI M, 1994, J BIOL CHEM, V269, P31162; KURABAYASHI M, 1995, MOL CELL BIOL, V15, P6386; KURABAYASHI M, 1995, GENE, V156, P311, DOI 10.1016/0378-1119(95)00017-Z; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LaVoie HA, 2003, EXP BIOL MED, V228, P1282, DOI 10.1177/153537020322801107; Maguire SM, 1997, BIOL REPROD, V56, P1106, DOI 10.1095/biolreprod56.5.1106; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCGUINNESS MP, 1994, BIOL REPROD, V51, P116, DOI 10.1095/biolreprod51.1.116; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; NEUMAN K, 1995, FEBS LETT, V374, P279, DOI 10.1016/0014-5793(95)01128-2; Norton JD, 2000, J CELL SCI, V113, P3897; RIECHMAN V, 1994, NUCLEIC ACIDS RES, V21, P215; Sablitzky F, 1998, CELL GROWTH DIFFER, V9, P1015; Sharpe Richard M., 1994, P1363; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; WALKER WH, 1995, ENDOCRINOLOGY, V136, P3534, DOI 10.1210/en.136.8.3534; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	41	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16064	16070		10.1074/jbc.M309298200	http://dx.doi.org/10.1074/jbc.M309298200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761970	hybrid			2022-12-27	WOS:000220747900046
J	Zhang, Z; Wang, H; Li, M; Agrawal, S; Chen, XB; Zhang, RW				Zhang, Z; Wang, H; Li, M; Agrawal, S; Chen, XB; Zhang, RW			MDM2 is a negative regulator of p21(WAF1/CIP1), independent of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; IN-VIVO ACTIVITIES; DEGRADATION; EXPRESSION; P21; APOPTOSIS; THERAPY; LIGASE; GENE; OLIGONUCLEOTIDES	The MDM2 oncogene has both p53-dependent and p53-independent activities. We have previously reported that antisense MDM2 inhibitors have significant antitumor activity in multiple human cancer models with various p53 statuses (Zhang, Z., Li, M., Wang, H., Agrawal, S., and Zhang, R. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 11636 - 11641). We have also provided evidence that MDM2 has a direct role in the regulation of p21, a cyclin-dependent kinase inhibitor. Here we provide evidence supporting functional interaction between MDM2 and p21 in vitro and in vivo. The inhibition of MDM2 with anti-MDM2 antisense oligonucleotide or Short Interference RNA targeting MDM2 significantly elevated p21 protein levels in PC3 cells ( p53 null). In contrast, overexpression of MDM2 diminished the p21 level in the same cells by shortening the p21 half-life, an effect reversed by MDM2 antisense inhibition. MDM2 facilitates p21 degradation independent of ubiquitination and the E3 ligase function of MDM2. Instead, MDM2 promotes p21 degradation by facilitating binding of p21 with the proteasomal C8 subunit. The physical interaction between p21 and MDM2 was demonstrated both in vitro and in vivo with the binding region in amino acids 180 - 298 of the MDM2 protein. In summary, we provide evidence supporting a physical interaction between MDM2 and p21. We also demonstrate that, by reducing p21 protein stability via proteasome-mediated degradation, MDM2 functions as a negative regulator of p21, an effect independent of both p53 and ubiquitination.	Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Div Clin Pharmacol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Hybridon Inc, Cambridge, MA 02139 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhang, RW (corresponding author), Univ Alabama, Dept Pharmacol & Toxicol, VH 113,1670 Univ Blvd, Birmingham, AL 35294 USA.	ruiwen.zhang@ccc.uab.edu	高, 雨莉/HGU-8187-2022	Agrawal, Sudhir/0000-0003-4275-2510	NCI NIH HHS [CA 80698] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Audo I, 2003, INVEST OPHTH VIS SCI, V44, P4192, DOI 10.1167/iovs.02-1198; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fokkema E, 2003, VIRCHOWS ARCH, V442, P349, DOI 10.1007/s00428-003-0763-9; Ganansia-Leymarie Valerie, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P291, DOI 10.2174/1568011033482422; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gerards WLH, 1998, J MOL BIOL, V275, P113, DOI 10.1006/jmbi.1997.1429; Gotoh A, 2003, BJU INT, V92, P314, DOI 10.1046/j.1464-410X.2003.04318.x; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu XM, 2003, BRIT J CANCER, V89, P1566, DOI 10.1038/sj.bjc.6601317; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; Wang H, 2001, CLIN CANCER RES, V7, P3613; Yang HL, 2003, J CLIN ENDOCR METAB, V88, P763, DOI 10.1210/jc.2002-020992; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100	31	210	218	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16000	16006		10.1074/jbc.M312264200	http://dx.doi.org/10.1074/jbc.M312264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761977	hybrid			2022-12-27	WOS:000220747900038
J	Nair, AK; Menon, KMJ				Nair, AK; Menon, KMJ			Isolation and characterization of a novel trans-factor for luteinizing hormone receptor mRNA from ovary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC BINDING; INDUCED DOWN-REGULATION; MEVALONATE KINASE; CODING REGION; CHORIOGONADOTROPIN RECEPTOR; RIBONUCLEIC-ACID; HALF-LIFE; PROTEIN; TRANSLATION; STABILITY	Post-transcriptional mechanisms play a major role in regulating luteinizing hormone (LH) receptor mRNA expression in the ovary. An ovarian cytosolic protein that we have identified in rats and humans, which binds to a polypyrimidine-rich bipartitate sequence in the coding region of LHR mRNA, acts as a trans-acting factor in this process. In the present study, we isolated and characterized this LH receptor mRNA-binding protein (LRBP) from rat ovary. LRBP was purified to homogeneity by cation exchange chromatography followed by Northwestern analysis and subsequent elution of the single protein band from SDS-polyacrylamide gel. Purified LRBP was subjected to N-terminal microsequencing followed by homology search, which revealed its identity as mevalonate kinase. Purified rat mevalonate kinase antibody recognized the gel-purified LRBP on Western blots performed with one- and two-dimensional SDS-polyacrylamide gels. When recombinant mevalonate kinase produced in human embryonic kidney cells (293 cells) was tested, it showed all of the characteristics of LRBP with respect to specificity of LHR mRNA binding sequence, as examined by gel mobility shift analysis. Inhibition of LHR mRNA binding activity of mevalonate kinase in the presence of ATP and mevalonate indicates that the RNA recognition site of mevalonate kinase might involve the ATP/mevalonate binding region of the protein. Treatment of 293 cells with mevastatin to deplete cellular mevalonate resulted in an increase in LHR mRNA binding activity of mevalonate kinase. Collectively, the data support the novel function of rat mevalonate kinase as a LHR mRNA-binding protein in the post-transcriptional regulation of LH receptor expression in the ovary.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Obstet Gynecol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Menon, KMJ (corresponding author), 6428 Med Sci Bldg 1,1301 Catherine, Ann Arbor, MI 48109 USA.				NICHD NIH HHS [HD-06656] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD006656] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006656] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BIARDI L, 1994, J BIOL CHEM, V269, P1197; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAMP TA, 1991, MOL ENDOCRINOL, V5, P1405, DOI 10.1210/mend-5-10-1405; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; Cho YK, 2001, J BIOL CHEM, V276, P12573, DOI 10.1074/jbc.M011478200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fu ZJ, 2002, J BIOL CHEM, V277, P18134, DOI 10.1074/jbc.M200912200; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; HOFFMAN YM, 1991, ENDOCRINOLOGY, V128, P388, DOI 10.1210/endo-128-1-388; Holcik M., 1997, MRNA FORMATION FUNCT, P195; Kash JC, 1998, J BIOL CHEM, V273, P10658, DOI 10.1074/jbc.273.17.10658; Kash JC, 1999, BIOCHEMISTRY-US, V38, P16889, DOI 10.1021/bi9915770; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAPOLT PS, 1990, ENDOCRINOLOGY, V126, P3277, DOI 10.1210/endo-126-6-3277; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; LU DL, 1993, ENDOCRINOLOGY, V132, P235, DOI 10.1210/en.132.1.235; Luz JG, 2003, GENE DEV, V17, P977, DOI 10.1101/gad.1082303; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MENON KMJ, 1974, FERTIL STERIL, V25, P732; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Nair AK, 2002, J BIOL CHEM, V277, P21468, DOI 10.1074/jbc.M111653200; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OSSIPOW V, 1993, NUCLEIC ACIDS RES, V21, P6040, DOI 10.1093/nar/21.25.6040; PEEGEL H, 1994, ENDOCRINOLOGY, V135, P1044, DOI 10.1210/en.135.3.1044; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pioli PA, 2002, J BIOL CHEM, V277, P35738, DOI 10.1074/jbc.M204002200; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SACHS AB, 1985, MOL CELL BIOL, V5, P1993, DOI 10.1128/MCB.5.8.1993; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; Zhang MC, 1999, MOL CELL BIOL, V19, P7314; Zhou T, 2000, STRUCTURE, V8, P1247, DOI 10.1016/S0969-2126(00)00533-5	52	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14937	14944		10.1074/jbc.M309484200	http://dx.doi.org/10.1074/jbc.M309484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749336	hybrid			2022-12-27	WOS:000220594700056
J	Stevens, TA; Iacovoni, JS; Edelman, DB; Meech, R				Stevens, TA; Iacovoni, JS; Edelman, DB; Meech, R			Identification of novel binding elements and gene targets for the homeodomain protein BARX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; ADHESION MOLECULE GENE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TERRITORIES; IN-VIVO; EXPRESSION; TRANSCRIPTION; ESTROGEN; GENOME; SITES	BARX2 is a homeobox transcription factor that influences cellular differentiation in various developmental contexts. To begin to identify the gene targets that mediate its effects, chromatin immunoprecipitation (ChIP) was used to isolate BARX2 binding sites from the human MCF7 breast cancer cell line. Cloning and sequencing of BARX2-ChIP-derived DNA fragments identified 60 potential BARX2 target loci that were proximal to or within introns of genes involved in cytoskeletal organization, cell adhesion, growth factor signaling, transcriptional regulation, and RNA metabolism. The sequences of over half of the fragments showed homology with the mouse genome, and several sequences could be mapped to orthologous human and mouse genes. Binding of BARX2 to 21 genomic loci examined was confirmed quantitatively by replicate ChIP assays. A combination of sequence analysis and electrophoretic mobility shift assays revealed homeodomain binding sites within several fragments that bind to BARX2 in vitro. The majority of BARX2 binding fragments tested (14/19), also affected transcription in luciferase reporter gene assays. Mutation analyses of three fragments showed that their transcriptional activities required the HBS, and suggested that BARX2 regulates gene expression by binding to DNA elements containing paired TAAT motifs that are separated by a poly( T) sequence. Inhibition of BARX2 expression in MCF7 cells led to reduced expression of eight genes associated with BARX2 binding sites, indicating that BARX2 directly regulates their expression. The data suggest that BARX2 can coordinate the expression of a network of genes that influence the growth of MCF7 cells.	Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA; Inst Neurosci, San Diego, CA 92121 USA; CHU Rangueil, Inst Fed Rech Louis bugnard, INSERM, U Hormones Facteurs Croissance & Physiopathol Vas, F-31403 Toulouse 04, France	Scripps Research Institute; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Meech, R (corresponding author), Scripps Res Inst, Dept Neurobiol, La Jolla, CA 92037 USA.	rmeech@scripps.edu		Meech, Robyn/0000-0002-6831-0801	NINDS NIH HHS [NS39837] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039837] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAILEY TL, 1994, ISMB, V2, P28; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; Edelman DB, 2000, J BIOL CHEM, V275, P21737, DOI 10.1074/jbc.M909998199; Edelman GM, 2000, P NATL ACAD SCI USA, V97, P3038, DOI 10.1073/pnas.040569897; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; FIENBERG AA, 1987, CURR TOP DEV BIOL, V23, P233; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hall BK, 1995, INT J DEV BIOL, V39, P881; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Hardison RC, 2000, TRENDS GENET, V16, P369, DOI 10.1016/S0168-9525(00)02081-3; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Jones FS, 1997, P NATL ACAD SCI USA, V94, P2632, DOI 10.1073/pnas.94.6.2632; Jones FS, 2001, CIRC RES, V89, P131, DOI 10.1161/hh1401.093582; Krasner A, 2000, GENE, V250, P171, DOI 10.1016/S0378-1119(00)00169-4; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; Ma B, 2002, BIOINFORMATICS, V18, P440, DOI 10.1093/bioinformatics/18.3.440; Mahy NL, 2002, J CELL BIOL, V159, P753, DOI 10.1083/jcb.200207115; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Meech R, 2003, J BIOL CHEM, V278, P8269, DOI 10.1074/jbc.M207617200; Meech R, 1999, P NATL ACAD SCI USA, V96, P2420, DOI 10.1073/pnas.96.5.2420; Nakashiba T, 2002, MECH DEVELOP, V111, P47, DOI 10.1016/S0925-4773(01)00600-1; Oegema K, 2000, J CELL BIOL, V150, P539, DOI 10.1083/jcb.150.3.539; Pombo A, 2000, CRIT REV EUKAR GENE, V10, P21; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Sellar GC, 2001, CANCER RES, V61, P6977; Shabalina SA, 2001, TRENDS GENET, V17, P373, DOI 10.1016/S0168-9525(01)02344-7; Solano PJ, 2003, DEVELOPMENT, V130, P1243, DOI 10.1242/dev.00348; Stein GS, 2000, J CELL BIOCHEM, P84; Tucker SC, 1999, J BIOL CHEM, V274, P32325, DOI 10.1074/jbc.274.45.32325; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Verschure PJ, 1999, J CELL BIOL, V147, P13, DOI 10.1083/jcb.147.1.13; Wang YB, 1996, P NATL ACAD SCI USA, V93, P1892, DOI 10.1073/pnas.93.5.1892; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001	45	31	31	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14520	14530		10.1074/jbc.M310259200	http://dx.doi.org/10.1074/jbc.M310259200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744868	hybrid			2022-12-27	WOS:000220594700009
J	Vinci, F; Catharino, S; Frey, S; Buchner, J; Marino, G; Pucci, P; Ruoppolo, M				Vinci, F; Catharino, S; Frey, S; Buchner, J; Marino, G; Pucci, P; Ruoppolo, M			Hierarchical formation of disulfide bonds in the immunoglobulin Fc fragment is assisted by protein-disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; CONSTANT FRAGMENT; DOMAIN; PDI; RENATURATION; STABILITY; CHAIN	Antibodies provide an excellent system to study the folding and assembly of all beta-sheet proteins and to elucidate the hierarchy of intra/inter chain disulfide bonds formation during the folding process of multimeric and multidomain proteins. Here, the folding process of the Fc fragment of the heavy chain of the antibody MAK33 was investigated. The Fc fragment consists of the C(H)3 and C(H)2 domains of the immunoglobulin heavy chain, both containing a single S-S bond. The folding process was investigated both in the absence and presence of the folding catalyst protein-disulfide isomerase (PDI), monitoring the evolution of intermediates by electrospray mass spectrometry. Moreover, the disulfide bonds present at different times in the folding mixture were identified by mass mapping to determine the hierarchy of disulfide bond formation. The analysis of the uncatalyzed folding showed that the species containing one intramolecular disulfide predominated throughout the entire process, whereas the fully oxidized Fc fragment never accumulated in significant amounts. This result suggests the presence of a kinetic trap during the Fc folding, preventing the one-disulfide-containing species (1S2H) to reach the fully oxidized protein (2S). The assignment of disulfide bonds revealed that 1S2H is a homogeneous species characterized by the presence of a single disulfide bond (Cys-130-Cys-188) belonging to the CH3 domain. When the folding experiments were carried out in the presence of PDI, the completely oxidized species accumulated and predominated at later stages of the process. This species contained the two native S-S bonds of the Fc protein. Our results indicate that the two domains of the Fc fragment fold independently, with a precise hierarchy of disulfide formation in which the disulfide bond, especially, of the CH2 domain requires catalysis by PDI.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Fac Med & Chirurg, I-80131 Naples, Italy; Univ Monte S Angelo, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Munich, Germany; CEINGE, I-80131 Naples, Italy; Univ Naples Federico II, Sch Biotechnol Sci, I-80126 Naples, Italy	University of Naples Federico II; Technical University of Munich; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Ruoppolo, M (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Fac Med & Chirurg, Via Pansini 5, I-80131 Naples, Italy.	ruoppolo@dbbm.unina.it	Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737; PUCCI, Pietro/0000-0002-5885-1495				Augustine JG, 2001, J BIOL CHEM, V276, P3287, DOI 10.1074/jbc.M005221200; Bolivar F, 1979, Methods Enzymol, V68, P245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CHOWDHURY SK, 1990, J AM CHEM SOC, V112, P9012, DOI 10.1021/ja00180a074; Clark PL, 1997, NAT STRUCT BIOL, V4, P883, DOI 10.1038/nsb1197-883; Creighton Thomas E., 1992, P301; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1995, METHOD ENZYMOL, V251, P397, DOI 10.1016/0076-6879(95)51143-1; Frisch C, 1996, FOLD DES, V1, P431, DOI 10.1016/S1359-0278(96)00059-4; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; Iwaoka M, 1998, BIOCHEMISTRY-US, V37, P4490, DOI 10.1021/bi9725327; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KIM PS, 1992, ANNU REV BIOCHEM, V51, P247; LILIE H, 1994, J BIOL CHEM, V269, P14290; LOO JA, 1991, RAPID COMMUN MASS SP, V62, P693; Mayer M, 2000, J BIOL CHEM, V275, P29421, DOI 10.1074/jbc.M002655200; Navon A, 2002, BIOCHEMISTRY-US, V41, P14225, DOI 10.1021/bi020506p; Rudolph R, 1997, PROTEIN FUNCTION PRA, P57; RUDOLPH R, MODERN METHODS PROTE, P14990; Ruoppolo M, 2000, BIOCHEMISTRY-US, V39, P12033, DOI 10.1021/bi001044n; Ruoppolo M, 1998, BIOCHEMISTRY-US, V37, P16060, DOI 10.1021/bi981492j; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; Thies MJW, 1999, J MOL BIOL, V293, P67, DOI 10.1006/jmbi.1999.3128; Thies MJW, 2002, J MOL BIOL, V319, P1267, DOI 10.1016/S0022-2836(02)00375-3; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Vinci F, 2000, PROTEIN SCI, V9, P525; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	34	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15059	15066		10.1074/jbc.M311480200	http://dx.doi.org/10.1074/jbc.M311480200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729662	hybrid			2022-12-27	WOS:000220594700070
J	Yamagishi, A; Masuda, M; Ohki, T; Onishi, H; Mochizuki, N				Yamagishi, A; Masuda, M; Ohki, T; Onishi, H; Mochizuki, N			A novel actin bundling/filopodium-forming domain conserved in insulin receptor tyrosine kinase substrate p53 and missing in metastasis protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUNDLING PROTEINS; DENDRITIC NETWORK; ALPHA-ACTININ; FILOPODIA; FILAMENTS; COMPLEX; IRSP53; BINDING; WAVE; MIM	Insulin receptor tyrosine kinase substrate p53 (IRSp53) has been identified as an SH3 domain-containing adaptor that links Rac1 with a Wiskott-Aldrich syndrome family verprolin-homologous protein 2 (WAVE2) to induce lamellipodia or Cdc42 with Mena to induce filopodia. The recruitment of these SH3-binding partners by IRSp53 is thought to be crucial for F-actin rearrangements. Here, we show that the N-terminal predicted helical stretch of 250 amino acids of IRSp53 is an evolutionarily conserved F-actin bundling domain involved in filopodium formation. Five proteins including IRSp53 and missing in metastasis (MIM) protein share this unique domain and are highly conserved in vertebrates. We named the conserved domain IRSp53/MIM homology domain (IMD). The IMD has domain relatives in invertebrates but does not show obvious homology to any known actin interacting proteins. The IMD alone, derived from either IRSp53 or MIM, induced filopodia in HeLa cells and the formation of tightly packed parallel F-actin bundles in vitro. These results suggest that IRSp53 and MIM belong to a novel actin bundling protein family. Furthermore, we found that filopodium-inducing IMD activity in the full-length IRSp53 was regulated by active Cdc42 and Rac1. The SH3 domain was not necessary for IMD-induced filopodium formation. Our results indicate that IRSp53, when activated by small GTPases, participates in F-actin reorganization not only in an SH3-dependent manner but also in a manner dependent on the activity of the IMD.	Natl Cardiovasc Ctr, Dept Struct Anal, Res Inst, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Masuda, M (corresponding author), Natl Cardiovasc Ctr, Dept Struct Anal, Res Inst, 5-7-1 Fujishiro Dai, Osaka 5658565, Japan.	masuda61@ri.ncvc.go.jp						Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Alvarez CE, 2002, J BIOL CHEM, V277, P24728, DOI 10.1074/jbc.M202512200; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bartles JR, 2000, CURR OPIN CELL BIOL, V12, P72, DOI 10.1016/S0955-0674(99)00059-9; Bartles JR, 1996, J CELL SCI, V109, P1229; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; DEROSIER DJ, 1981, COLD SPRING HARB SYM, V46, P525, DOI 10.1101/SQB.1982.046.01.049; DeRosier DJ, 2000, J CELL BIOL, V148, P1; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Katoh K, 1998, MOL BIOL CELL, V9, P1919, DOI 10.1091/mbc.9.7.1919; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 2002, BIOCHEM BIOPH RES CO, V293, P93, DOI 10.1016/S0006-291X(02)00218-8; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nakagawa H, 2003, J CELL SCI, V116, P2577, DOI 10.1242/jcs.00462; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nozumi M, 2003, J CELL SCI, V116, P239, DOI 10.1242/jcs.00233; Oda K, 1999, CYTOGENET CELL GENET, V84, P75, DOI 10.1159/000015219; Sekerkova G, 2003, J NEUROSCI, V23, P1310, DOI 10.1523/JNEUROSCI.23-04-01310.2003; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Takenawa T, 2001, J CELL SCI, V114, P1801; Taylor KA, 2000, J CELL BIOL, V149, P635, DOI 10.1083/jcb.149.3.635; Vignjevic D, 2003, J CELL BIOL, V160, P951, DOI 10.1083/jcb.200208059; Volkmann N, 2001, J CELL BIOL, V153, P947, DOI 10.1083/jcb.153.5.947; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921	34	156	168	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14929	14936		10.1074/jbc.M309408200	http://dx.doi.org/10.1074/jbc.M309408200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752106	hybrid			2022-12-27	WOS:000220594700055
J	Chang, KJ; Wang, CC				Chang, KJ; Wang, CC			Translation initiation from a naturally occurring non-AUG codon in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASES; MAMMALIAN-CELLS; LEADER PEPTIDE; MESSENGER-RNAS; GENE ENCODES; MITOCHONDRIAL; YEAST; PROTEIN; SELECTION; REGION	Although previous studies have already shown that both cytoplasmic and mitochondrial activities of glycyl-tRNA synthetase are provided by a single gene, GRS1, in the yeast Saccharomyces cerevisiae, the mechanism by which this occurs remains unclear. Evidence presented here indicates that this bifunctional property is actually a result of two distinct translational products alternatively generated from a single transcript of this gene. Except for an amino-terminal 23-amino acid extension, these two isoforms have the same polypeptide sequence and function exclusively in their respective compartments under normal conditions. Reporter gene assays further suggest that this leader peptide can function independently as a mitochondrial targeting signal and plays the major role in the subcellular localization of the isoforms. Additionally, whereas the short protein is translationally initiated from a traditional AUG triplet, the longer isoform is generated from an upstream inframe UUG codon. To our knowledge, GRS1 appears to be the first example in the yeast wherein a functional protein isoform is initiated from a naturally occurring non-AUG codon. The results suggest that non-AUG initiation might be a mechanism existing throughout all kingdoms.	Natl Cent Univ, Dept Life Sci, Chungli 32054, Taiwan	National Central University	Wang, CC (corresponding author), Natl Cent Univ, Dept Life Sci, 300 Jung Da, Chungli 32054, Taiwan.	dukewang@cc.ncu.edu.tw	Chang, Kuang-Jung/J-2193-2012					Abramczyk D, 2003, YEAST, V20, P1045, DOI 10.1002/yea.1020; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CHATTON B, 1988, J BIOL CHEM, V263, P52; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; CLEMENTS JM, 1988, MOL CELL BIOL, V8, P4533, DOI 10.1128/MCB.8.10.4533; DIRCKS LK, 1990, MOL CELL BIOL, V10, P4984, DOI 10.1128/MCB.10.9.4984; DONAHUE TF, 1988, MOL CELL BIOL, V8, P2955, DOI 10.1128/MCB.8.7.2955; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; MARECHALDROUARD L, 1992, ANN REV CELL BIOL, V8, P115; Martinis SA, 1999, BIOCHIMIE, V81, P683, DOI 10.1016/S0300-9084(99)80126-6; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, P887; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; Pelchat M, 1999, BIOCHEM CELL BIOL, V77, P343, DOI 10.1139/bcb-77-4-343; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; RIECHMANN JL, 1990, VIROLOGY, V177, P170; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Schimmel P, 1999, TRENDS BIOCHEM SCI, V24, P127, DOI 10.1016/S0968-0004(99)01369-9; SHERMAN F, 1980, CELL, V20, P215, DOI 10.1016/0092-8674(80)90249-4; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; Turner RJ, 2000, J BIOL CHEM, V275, P27681; Wang CC, 2003, BIOCHEMISTRY-US, V42, P1646, DOI 10.1021/bi025964c; WOLFE CL, 1994, J BIOL CHEM, V269, P13361; WU M, 1987, J BIOL CHEM, V262, P12275; Zhou W, 2001, P NATL ACAD SCI USA, V98, P1531, DOI 10.1073/pnas.98.4.1531	41	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13778	13785		10.1074/jbc.M311269200	http://dx.doi.org/10.1074/jbc.M311269200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734560	hybrid			2022-12-27	WOS:000220478500062
J	Chen, SC; Gardner, DG				Chen, SC; Gardner, DG			Suppression of WEE1 and stimulation of CDC25A correlates with endothelin-dependent proliferation of rat aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INHIBITORY KINASE; PHOSPHORYLATES CDC2; NEGATIVE REGULATION; CYCLE REGULATION; ANGIOTENSIN-II; DNA-DAMAGE; HUMAN MYT1; GROWTH; CDK2	Proliferation of vascular smooth muscle cells plays a key role in the pathogenesis of several disorders of the vascular wall. Endothelin ( ET), a vasoactive peptide that signals through a G protein-coupled receptor, has been linked to mitogenesis in vascular smooth muscle cells, but the mechanistic details underlying this activity remain incompletely understood. In the present study, we demonstrate that ET-dependent mitogenesis in rat neonatal and adult aortic smooth muscle (RASM) cells is accompanied by an increase ( up to 10-fold) in CDK2 activity, but not CDK2 protein levels. This effect is blocked almost entirely by PD98059 and UO126, implying involvement of the MEK/ERK signal transduction cascade in the activation. Extracts of ET-treated cells phosphorylate the N terminus of WEE1, an inhibitory kinase, which negatively regulates CDK2 activity through phosphorylation at Tyr(15), leading to a decrease in WEE1 activity and a reduction in levels of phospho-Tyr(15) in the CDK2 protein. ET also increases expression and activity of CDC25A, the regulatory phosphatase responsible for dephosphorylating Tyr15. All of these effects are reversible following treatment with the MEK inhibitor PD98059. ET also increases levels of CDC2 activity in these cells in association with a decrease in levels of phospho-Tyr(15) on the CDC2 molecule. Phosphorylation of WEE1 is linked to ERK while phosphorylation of MYT1 (CDC2-selective inhibitory kinase) is tied to the ribosomal S6 kinase (RSK). In summary, ET controls progression through the cell cycle, in part, by increasing CDK2 and CDC2 activity through the MEK/ERK/RSK signal transduction pathway(s). This results from the phosphorylation and subsequent inactivation of two inhibitory kinases ( WEE1 and MYT1) that tonically suppress CDK2 and CDC2 activity and activation of a phosphatase ( CDC25A) that increases CDK2 activity.	Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Ctr Diabet, 1109 HSW, San Francisco, CA 94143 USA.	gardner@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45637] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER RF, 1976, IN VITRO CELL DEV B, V12, P558; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Chen SC, 1998, J CLIN INVEST, V102, P653, DOI 10.1172/JCI3483; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Demoliou-Mason CD, 1998, BIOL SIGNAL RECEPT, V7, P90; Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32; Harris BZ, 2003, BIOCHEMISTRY-US, V42, P2797, DOI 10.1021/bi027061p; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONDA R, 1995, CHROMOSOME RES, V3, P300, DOI 10.1007/BF00713068; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Jahan H, 1996, EUR J PHARMACOL, V295, P261, DOI 10.1016/0014-2999(95)00653-2; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaldis P, 2000, J BIOL CHEM, V275, P32578, DOI 10.1074/jbc.M003212200; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Ma J, 2003, EUR J PHARMACOL, V464, P79, DOI 10.1016/S0014-2999(03)01373-6; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Neylon CB, 1999, CLIN EXP PHARMACOL P, V26, P149, DOI 10.1046/j.1440-1681.1999.03013.x; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Qiang YW, 2000, EXP HEMATOL, V28, P1147, DOI 10.1016/S0301-472X(00)00521-X; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; SCOTTBURDEN T, 1991, J CARDIOVASC PHARM, V17, pS96, DOI 10.1097/00005344-199100177-00025; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Walter SA, 2000, MOL BIOL CELL, V11, P887, DOI 10.1091/mbc.11.3.887; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wells NJ, 1999, J CELL SCI, V112, P3361; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589, DOI 10.1165/ajrcmb.16.5.9160841; Wu CL, 2001, CANCER RES, V61, P7325; Yang ZH, 1999, CIRCULATION, V100, P5, DOI 10.1161/01.CIR.100.1.5; Zhang WY, 1999, J BONE MINER RES, V14, P528, DOI 10.1359/jbmr.1999.14.4.528	41	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13755	13763		10.1074/jbc.M310064200	http://dx.doi.org/10.1074/jbc.M310064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14742443	hybrid			2022-12-27	WOS:000220478500059
J	Katafuchi, A; Nakano, T; Masaoka, A; Terato, H; Iwai, S; Hanaoka, F; Ide, H				Katafuchi, A; Nakano, T; Masaoka, A; Terato, H; Iwai, S; Hanaoka, F; Ide, H			Differential specificity of human and Escherichia coli endonuclease III and VIII homologues for oxidative base lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA GLYCOSYLASE; MAMMALIAN 5-FORMYLURACIL-DNA GLYCOSYLASE; THYMINE GLYCOL LESIONS; DAMAGED DNA; NITROUS-ACID; 8-OXOGUANINE-DNA GLYCOSYLASE; STEREOSELECTIVE EXCISION; REPAIR ACTIVITIES; NITRIC-OXIDE; HUMAN NTH1	In human cells, oxidative pyrimidine lesions are restored by the base excision repair pathway initiated by homologues of Endo III (hNTH1) and Endo VIII (hNEIL1 and hNEIL2). In this study we have quantitatively analyzed and compared their activity toward nine oxidative base lesions and an apurinic/apyrimidinic (AP) site using defined oligonucleotide substrates. hNTH1 and hNEIL1 but not hNEIL2 excised the two stereoisomers of thymine glycol (5R-Tg and 5S-Tg), but their isomer specificity was markedly different: the relative activity for 5R-Tg: 5S-Tg was 13: 1 for hNTH1 and 1.5: 1 for hNEIL1. This was also the case for their Escherichia coli homologues: the relative activity for 5R-Tg: 5S-Tg was 1: 2.5 for Endo III and 3.2: 1 for Endo VIII. Among other tested lesions for hNTH1, an AP site was a significantly better substrate than urea, 5-hydroxyuracil (hoU), and guanine-derived formamidopyrimidine (mFapyG), whereas for hNEIL1 these base lesions and an AP site were comparable substrates. In contrast, hNEIL2 recognized an AP site exclusively, and the activity for hoU and mFapyG was marginal. hNEIL1, hNEIL2, and Endo VIII but not hNTH1 and Endo III formed cross-links to oxanine, suggesting conservation of the - fold of the active site of the Endo VIII homologues. The profiles of the excision of the Tg isomers with HeLa and E. coli cell extracts closely resembled those of hNTH1 and Endo III, confirming their major contribution to the repair of Tg isomers in cells. However, detailed analysis of the cellular activity suggests that hNEIL1 has a significant role in the repair of 5S-Tg in human cells.	Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan; Osaka Univ, Grad Sch Engn Sci, Div Chem, Osaka 5608531, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Hiroshima University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Ide, H (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan.	ideh@hiroshima-u.ac.jp		Nakano, Toshiaki/0000-0002-5274-2909; Terato, Hiroaki/0000-0002-7070-5263				Arai T, 2003, CANCER RES, V63, P4287; Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l; Asagoshi K, 2000, J BIOL CHEM, V275, P24781, DOI 10.1074/jbc.M000576200; Asagoshi K, 2000, J BIOL CHEM, V275, P4956, DOI 10.1074/jbc.275.7.4956; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dizdaroglu M, 1999, BIOCHEMISTRY-US, V38, P243, DOI 10.1021/bi9819071; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fromme JC, 2003, EMBO J, V22, P3461, DOI 10.1093/emboj/cdg311; Fromme JC, 2003, NAT STRUCT BIOL, V10, P204, DOI 10.1038/nsb902; Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hazra TK, 2000, J BIOL CHEM, V275, P27762; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Iwai S, 2000, ANGEW CHEM INT EDIT, V39, P3874, DOI 10.1002/1521-3773(20001103)39:21<3874::AID-ANIE3874>3.0.CO;2-O; Iwai S, 2001, CHEM-EUR J, V7, P4343, DOI 10.1002/1521-3765(20011015)7:20<4343::AID-CHEM4343>3.0.CO;2-H; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; Karahalil B, 2003, J BIOL CHEM, V278, P33701, DOI 10.1074/jbc.M301617200; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Kusumoto R, 2002, BIOCHEMISTRY-US, V41, P6090, DOI 10.1021/bi025549k; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LUSTIG MJ, 1992, NUCLEIC ACIDS RES, V20, P4839, DOI 10.1093/nar/20.18.4839; Masaoka A, 2001, J BIOL CHEM, V276, P16501, DOI 10.1074/jbc.M008598200; Masaoka A, 2003, BIOCHEMISTRY-US, V42, P5003, DOI 10.1021/bi0273213; Matsubara M, 2003, BIOCHEMISTRY-US, V42, P4993, DOI 10.1021/bi027322v; McTigue MM, 2004, DNA REPAIR, V3, P313, DOI 10.1016/j.dnarep.2003.11.009; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Miller H, 2004, NUCLEIC ACIDS RES, V32, P338, DOI 10.1093/nar/gkh190; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nakano T, 2003, J BIOL CHEM, V278, P25264, DOI 10.1074/jbc.M212847200; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Suzuki T, 2000, NUCLEIC ACIDS RES, V28, P544, DOI 10.1093/nar/28.2.544; Suzuki T, 1996, J AM CHEM SOC, V118, P2515, DOI 10.1021/ja952550g; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; Teebor G, 1987, Free Radic Res Commun, V2, P303, DOI 10.3109/10715768709065296; Terato H, 2002, NUCLEIC ACIDS RES, V30, P4975, DOI 10.1093/nar/gkf630; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wallace SS, 2003, DNA REPAIR, V2, P441, DOI 10.1016/S1568-7864(02)00182-9; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200; Zharkov DO, 2003, DNA REPAIR, V2, P839, DOI 10.1016/S1568-7864(03)00084-3; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789	57	104	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14464	14471		10.1074/jbc.M400393200	http://dx.doi.org/10.1074/jbc.M400393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734554	hybrid			2022-12-27	WOS:000220478500143
J	Liu, ZY; Fisher, RA				Liu, ZY; Fisher, RA			RGS6 interacts with DMAP1 and DNMT1 and inhibits DMAP1 transcriptional repressor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HUMAN CANCER-CELLS; SUBCELLULAR-LOCALIZATION; REPLICATION FOCI; DOMAIN; DNA; REGULATOR; NUCLEAR; COMPLEX; DESENSITIZATION	RGS6 is a member of a subfamily of mammalian RGS proteins that possess DEP (disheveled, Egl-10, pleckstrin) and GGL (G protein gamma subunit-like) domains in addition to the hallmark RGS domain. RGS proteins negatively regulate heterotrimeric G protein signaling by virtue of the GTPase-activating protein activity of their RGS domains. RGS6 exists in multiple splice forms with a long (6L) or short (6S) N terminus, a complete or incomplete GGL domain, in combination with various C-terminal domains. Green fluorescent protein-tagged RGS6L and RGS6S forms exhibit predominantly cytoplasmic and nuclear patterns of distribution in COS-7 cells, respectively, and traffic from these sites to nucleoli in response to stress signaling. We undertook a yeast two-hybrid screen for nuclear RGS6-binding proteins and here identify DMAP1 as an RGS6-interacting protein. DMAP1 is a component of the Dnmt1 complex involved in repression of newly replicated genes. The domains of interaction were mapped to the N-terminal region of the GGL domain of RGS6, a region distinct from its Gbeta5 binding region, and the C-terminal domain of DMAP1. Gbeta5 and DMAP1 did not compete for each other's interaction with RGS6. Co-immunoprecipitation studies in COS-7 cells showed that RGS6L and RGS6S, but not RGS6L Delta 258 - 293 deletion mutant lacking a DMAP1-binding module, co-immunoprecipitate DMAP1 as well as Dnmt1 in a DMAP1-dependent manner. A recombinant GGL domain of RGS6 precipitated endogenous DMAP1 and Dnmt1 in neuroblastoma cell lysates and endogenous DMAP1 co-immunoprecipitated with RGS6L from mouse brain. Co-expression of DMAP1 with RGS6L promoted nuclear migration of RGS6L and its co-localization with DMAP1, a response not observed with RGS6LDelta258 - 293. RGS6 inhibited the transcriptional repressor activity of DMAP1. RGS6 is the first member of the RGS protein family shown to interact with proteins involved in transcriptional regulation.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.	rory-fisher@uiowa.edu		Fisher, Rory/0000-0003-3108-4836	NIGMS NIH HHS [GM-067881] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067881] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 2003, J BIOL CHEM, V278, P30272, DOI 10.1074/jbc.M212688200; Chatterjee TK, 2003, J BIOL CHEM, V278, P30261, DOI 10.1074/jbc.M212687200; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Liu K, 2003, MOL CELL BIOL, V23, P2709, DOI 10.1128/MCB.23.8.2709-2719.2003; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross SA, 2003, ANN NY ACAD SCI, V983, P197, DOI 10.1111/j.1749-6632.2003.tb05974.x; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	30	46	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14120	14128		10.1074/jbc.M309547200	http://dx.doi.org/10.1074/jbc.M309547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734556	hybrid			2022-12-27	WOS:000220478500102
J	Saito, K; Ohara, N; Hotokezaka, H; Fukumoto, S; Yuasa, K; Naito, M; Fujiwara, T; Nakayama, K				Saito, K; Ohara, N; Hotokezaka, H; Fukumoto, S; Yuasa, K; Naito, M; Fujiwara, T; Nakayama, K			Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; FACTOR LIGAND FAMILY; BONE-RESORPTION; OSTEOPROTEGERIN LIGAND; PARATHYROID-HORMONE; IMMUNE-RESPONSES; ANABOLIC ACTIONS; MICE LACKING	Bacterial infection sometimes impairs bone metabolism. In this study, we infected the osteoblastic cell line MC3T3-E1 with Mycobacterium bovis bacillus Calmette-Guerin (BCG) and identified genes that were up-regulated in the BCG-infected cells by the suppression subtractive hybridization method. A gene encoding 4-1BB (CD137), a member of the tumor necrosis factor-alpha receptor family, was found to be one of the up-regulated genes. Up-regulation of 4-1BB was also observed by infection with Escherichia coli, Salmonella typhimurium, and Staphylococcus aureus, and by treatment with lipopolysaccharides and heat-killed BCG. Bone marrow cells and the macrophage-like cell lines J774 and RAW264.7 were found to express 4-1BB ligand (4-1BBL). Recombinant 4-1BB (r4-1BB) that was immobilized on culture plates strongly inhibited macrophage colony stimulating factor (M-CSF)/receptor activator of nuclear factor-kappaB ligand (RANKL)-induced in vitro osteoclast formation from bone marrow cells. Anti-4-1BBL antibody also inhibited osteoclast formation to a lesser extent, indicating involvement of reverse signaling through 4-1BBL during inhibition of osteoclast formation. A casein kinase I (CKI) inhibitor markedly suppressed the inhibitory effect of r4-1BB on M-CSF/ RANKL-induced osteoclast formation, suggesting that CKI might be involved in 4-1BB/4-1BBL reverse signaling. r4-1BB showed no effects on M-CSF- or RANKL-induced phosphorylation of I-kappaB, ERK1/2, p38, or JNK, whereas RANKL-induced phosphorylation of Akt, a downstream target of phosphatidylinositol 3-kinase (PI3K), was completely abolished by r4-1BB, suggesting that 4-1BB/4-1BBL reverse signaling may interfere with PI3K/Akt pathway. r4-1BB also abolished RANKL-mediated induction of nuclear factor of activated T cells-2. This study may elucidate a novel role of 4-1BB in cell metabolism, especially osteoclastogenesis.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Microbiol & Oral Infect, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Orthodont & Biomed Engn, Nagasaki 8528588, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Nakayama, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Microbiol & Oral Infect, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	knak@net.nagasaki-u.ac.jp	Saito, Kan/AFS-5564-2022; OHARA, Naoya/B-2481-2011; Saito, Kan/AAG-3507-2020	Saito, Kan/0000-0002-2151-6204; Saito, Kan/0000-0002-2151-6204; Fukumoto, Satoshi/0000-0002-5046-6891				Abu-Nader R, 2002, MAYO CLIN PROC, V77, P393, DOI 10.4065/77.4.393; ALDERSON MR, 1994, EUR J IMMUNOL, V24, P2219, DOI 10.1002/eji.1830240943; ANBIN JE, 1996, PRINCIPLES BONE BIOL, P51; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Boyce BF, 1999, LAB INVEST, V79, P83; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cannons JL, 2001, J IMMUNOL, V167, P1313, DOI 10.4049/jimmunol.167.3.1313; Chambers TJ, 2000, J PATHOL, V192, P4; Chu NR, 1997, J IMMUNOL, V158, P3081; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; DeBenedette MA, 1999, J IMMUNOL, V163, P4833; DELANY AM, 1994, J CELL BIOCHEM, V56, P295, DOI 10.1002/jcb.240560304; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DEMPSTER DW, 1995, ENDOCRINE REV MONOGR, V4, P247; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200; Hotokezaka H, 1998, SCAND J IMMUNOL, V47, P453; Hurtado JC, 1997, J IMMUNOL, V158, P2600; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822; Iwamoto T, 2001, J BIOL CHEM, V276, P46031, DOI 10.1074/jbc.M104464200; Kawabata Y, 1998, FEMS IMMUNOL MED MIC, V22, P293, DOI 10.1016/S0928-8244(98)00100-X; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 2000, IMMUNOL TODAY, V21, P495, DOI 10.1016/S0167-5699(00)01718-7; Kwon BS, 2002, J IMMUNOL, V168, P5483, DOI 10.4049/jimmunol.168.11.5483; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Langstein J, 1999, BLOOD, V94, P3161, DOI 10.1182/blood.V94.9.3161.421k31_3161_3168; Langstein J, 1999, J LEUKOCYTE BIOL, V65, P829, DOI 10.1002/jlb.65.6.829; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Lian JB, 1999, VITAM HORM, V55, P443; Lin CJ, 1999, J BONE JOINT SURG AM, V81A, P1305, DOI 10.2106/00004623-199909000-00012; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBEN RA, 1976, ENDOCRINOLOGY, V99, P526, DOI 10.1210/endo-99-2-526; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Meghji S, 1997, J EXP MED, V186, P1241, DOI 10.1084/jem.186.8.1241; Melero I, 1998, CELL IMMUNOL, V190, P167, DOI 10.1006/cimm.1998.1396; Moon MS, 1997, SPINE, V22, P1791, DOI 10.1097/00007632-199708010-00022; Nau GJ, 1999, INFECT IMMUN, V67, P4223, DOI 10.1128/IAI.67.8.4223-4230.1999; Nau GJ, 1997, P NATL ACAD SCI USA, V94, P6414, DOI 10.1073/pnas.94.12.6414; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; POLLOK KE, 1993, J IMMUNOL, V150, P771; Sakai H, 2000, BIOCHEM BIOPH RES CO, V270, P550, DOI 10.1006/bbrc.2000.2485; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tsurukai T, 1998, J CELL PHYSIOL, V177, P26, DOI 10.1002/(SICI)1097-4652(199810)177:1<26::AID-JCP3>3.0.CO;2-G; TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275; ULSTRUP JC, 1995, INFECT IMMUN, V63, P672, DOI 10.1128/IAI.63.2.672-675.1995; Valledor AF, 1999, J IMMUNOL, V163, P2452; Vinay DS, 1998, SEMIN IMMUNOL, V10, P481, DOI 10.1006/smim.1998.0157; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhang ZY, 2003, J IMMUNOL, V171, P3620, DOI 10.4049/jimmunol.171.7.3620	68	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13555	13563		10.1074/jbc.M303791200	http://dx.doi.org/10.1074/jbc.M303791200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729681	hybrid			2022-12-27	WOS:000220478500035
J	Silvennoinen, L; Myllyharju, J; Ruoppolo, M; Orru, S; Caterino, M; Kivirikko, KI; Koivunen, P				Silvennoinen, L; Myllyharju, J; Ruoppolo, M; Orru, S; Caterino, M; Kivirikko, KI; Koivunen, P			Identification and characterization of structural domains of human ERp57 - Association with calreticulin requires several domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOL-DEPENDENT REDUCTASE; PROLYL 4-HYDROXYLASES; ENDOPLASMIC-RETICULUM; N-15 RESONANCES; TERMINAL DOMAIN; SUBUNIT; ASSIGNMENT; A'; EXPRESSION	The amino acid sequence of ERp57, which functions in the endoplasmic reticulum together with the lectins calreticulin and calnexin to achieve folding of newly synthesized glycoproteins, is highly similar to that of protein disulfide isomerase (PDI), but they have their own distinct roles in protein folding. We have characterized the domain structure of ERp57 by limited proteolysis and N-terminal sequencing and have found it to be similar but not identical to that of PDI. ERp57 had three major protease-sensitive regions, the first of which was located between residues 120 and 150, the second between 201 and 215, and the third between 313 and 341, the data thus being consistent with a four-domain structure abb 'a'. Recombinant expression in Escherichia coli was used to verify the domain boundaries. Each single domain and a b 'a' double domain could be produced in the form of soluble, folded polypeptides, as verified by circular dichroism spectra and urea gradient gel electrophoresis. When the ability of ERp57 and its a and a' domains to fold denatured RNase A was studied by electrospray mass analyses, ERp57 markedly enhanced the folding rate at early time points, although less effectively than PDI, but was an ineffective catalyst of the overall process. The a and a' domains produced only minor, if any, increases in the folding rate at the early stages and no increase at the late stages. Interaction of the soluble ERp57 domains with the P domain of calreticulin was studied by chemical cross-linking in vitro. None of the single ERp57 domains nor the b' a' double domain could be cross-linked to the P domain, whereas cross-linking was obtained with a hybrid ERpabb' PDIa' c polypeptide but not with ERpabPDIb' a' c, indicating that multiple domains are involved in this protein-protein interaction and that the b' domain of ERp57 cannot be replaced by that of PDI.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80138 Naples, Italy; Ctr Ingn Genet Biotecnol Avanzate, Scrl, I-80138 Naples, Italy	University of Oulu; University of Oulu; University of Naples Federico II	Koivunen, P (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	peppi.koivunen@oulu.fi	Caterino, Marianna/AAR-3526-2020; Orrù, Stefania/A-2895-2015; Caterino, Marianna/K-4531-2016; Stefania, Orrù/ABH-2178-2020	Caterino, Marianna/0000-0001-6035-8213				Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Dijkstra K, 1999, J BIOMOL NMR, V14, P195, DOI 10.1023/A:1008331225208; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; GRUENWALD S, 1994, BACULOVIRUS EXPRESSI; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 1997, GENOMICS, V42, P397, DOI 10.1006/geno.1997.4750; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Peterson JR, 1999, J CELL SCI, V112, P2775; Pirneskoski A, 2001, J BIOL CHEM, V276, P11287, DOI 10.1074/jbc.M010656200; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Ruoppolo M, 2000, BIOCHEMISTRY-US, V39, P12033, DOI 10.1021/bi001044n; Ruoppolo M, 2003, PROTEIN SCI, V12, P939, DOI 10.1110/ps.0242803; Silvennoinen L, 2001, J BIOMOL NMR, V20, P385, DOI 10.1023/A:1011291316810; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; TORELLA C, 1994, FEBS LETT, V352, P301; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	38	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13607	13615		10.1074/jbc.M313054200	http://dx.doi.org/10.1074/jbc.M313054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732712	hybrid			2022-12-27	WOS:000220478500041
J	Sullivan, PG; Dragicevic, NB; Deng, JH; Bai, YD; Dimayuga, E; Ding, QX; Chen, QH; Bruce-Keller, AJ; Keller, JN				Sullivan, PG; Dragicevic, NB; Deng, JH; Bai, YD; Dimayuga, E; Ding, QX; Chen, QH; Bruce-Keller, AJ; Keller, JN			Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; RESPIRATORY-FUNCTION; PARKINSONS-DISEASE; OXIDATIVE STRESS; MECHANISMS; DYSFUNCTION; APOPTOSIS; BRAIN; DEATH	Inhibition of proteasome activity occurs in normal aging and in a wide variety of neurodegenerative conditions including Alzheimer's disease and Parkinson's disease. Although each of these conditions is also associated with mitochondrial dysfunction potentially mediated by proteasome inhibition, the relationship between proteasome inhibition and the loss of mitochondrial homeostasis in each of these conditions has not been fully elucidated. In this study, we conducted experimentation in order to begin to develop a more complete understanding of the effects proteasome inhibition has on neural mitochondrial homeostasis. Mitochondria within neural SH-SY5Y cells exposed to low level proteasome inhibition possessed similar morphological features and similar rates of electron transport chain activity under basal conditions as compared with untreated neural cultures of equal passage number. Despite such similarities, maximal complex I and complex II activities were dramatically reduced in neural cells subject to proteasome inhibition. Proteasome inhibition also increased mitochondrial reactive oxygen species production, reduced intramitochondrial protein translation, and increased cellular dependence on glycolysis. Finally, whereas proteasome inhibition generated cells that consistently possessed mitochondria located in close proximity to lysosomes with mitochondria present in the cellular debris located within autophagosomes, increased levels of lipofuscin suggest that impairments in mitochondrial turnover may occur following proteasome inhibition. Taken together, these data demonstrate that proteasome inhibition dramatically alters specific aspects of neural mitochondrial homeostasis and alters lysosomal-mediated degradation of mitochondria with both of these alterations potentially contributing to aging and age-related disease in the nervous system.	Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	University of Kentucky; University of Kentucky; University of Texas System; University of Texas Health San Antonio	Keller, JN (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, 205 Sanders Brown Bldg, Lexington, KY 40536 USA.	Jnkell0@pop.uky.edu	Keller, Jeffrey N/N-1975-2017; Bai, Yidong/A-4959-2012; Bruce-Keller, Annadora/N-1954-2017	keller, jeffrey/0000-0002-9892-7423	NIA NIH HHS [AG/NS 018302, AG 005119, AG 08437] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albers DS, 2000, J NEURAL TRANSM-SUPP, P133; Aliev G, 2003, NEUROL RES, V25, P665, DOI 10.1179/016164103101201977; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BLASS JP, 1988, REV NEUROL, V144, P543; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Castellani R, 2002, J NEUROSCI RES, V70, P357, DOI 10.1002/jnr.10389; Chai YH, 1999, J NEUROSCI, V19, P10338; Cooper JM, 1997, J BIOENERG BIOMEMBR, V29, P175, DOI 10.1023/A:1022642114734; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DING Q, 2003, IN PRESS FREE RADIC; Ding QX, 2003, J NEUROCHEM, V86, P489, DOI 10.1046/j.1471-4159.2003.01885.x; Ding QX, 2002, J BIOL CHEM, V277, P13935, DOI 10.1074/jbc.M107706200; Ding QX, 2001, FREE RADICAL BIO MED, V31, P574, DOI 10.1016/S0891-5849(01)00635-9; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Gibson GE, 1998, J NEURAL TRANSM, V105, P855, DOI 10.1007/s007020050099; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg AL, 1997, BIOL CHEM, V378, P131; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Holtsberg FW, 1998, J NEUROSCI RES, V53, P685, DOI 10.1002/(SICI)1097-4547(19980915)53:6<685::AID-JNR7>3.0.CO;2-1; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Keller JN, 2000, J NEUROSCI RES, V61, P436, DOI 10.1002/1097-4547(20000815)61:4<436::AID-JNR10>3.0.CO;2-Z; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee MH, 2001, J NEUROCHEM, V78, P32, DOI 10.1046/j.1471-4159.2001.00416.x; Manfredi G, 2000, BRAIN PATHOL, V10, P462; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; RIDEOUT HJ, 2003, IN PRESS J NEUROSCI; Salon ML, 2000, J NEUROSCI RES, V62, P302, DOI 10.1002/1097-4547(20001015)62:2<302::AID-JNR15>3.0.CO;2-L; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WALLACE DC, 1998, BIOCHIM BIOPHYS ACTA, V1271, P141; Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x	40	160	165	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					20699	20707		10.1074/jbc.M313579200	http://dx.doi.org/10.1074/jbc.M313579200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14742431	hybrid			2022-12-27	WOS:000221273800021
J	Ladd, AN; Nguyen, NH; Malhotra, K; Cooper, TA				Ladd, AN; Nguyen, NH; Malhotra, K; Cooper, TA			CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MYOTONIC-DYSTROPHY; MOLECULAR-BASIS; TRIPLET REPEAT; CANDIDATE GENE; CTG REPEAT; EXPRESSION; REGION; IDENTIFICATION; EXPANSION	We previously described a family of five RNA-binding proteins: CUG-binding protein, embryonic lethal abnormal vision-type RNA-binding protein 3, and the CUG-binding protein and embryonic lethal abnormal vision-type RNA-binding protein 3-like factors (CELFs) 3, 4, and 5. We demonstrated that all five of these proteins specifically activate exon inclusion of cardiac troponin T minigenes in vivo via muscle-specific splicing enhancer (MSE) sequences. We also predicted that a sixth family member, CELF6, was located on chromosome 15. Here, we describe the isolation and characterization of CELF6. Like the previously described CELF proteins, CELF6 shares a domain structure containing three RNA-binding domains and a divergent domain of unknown function. CELF6 is strongly expressed in kidney, brain, and testis and is expressed at very low levels in most other tissues. In the brain, expression is widespread and maintained from the fetus to the adult. CELF6 activates exon inclusion of a cardiac troponin T minigene in transient transfection assays in an MSE-dependent manner and can activate inclusion via multiple copies of a single element, MSE2. These results place CELF6 in a functional subfamily of CELF proteins that includes CELFs 3, 4, and 5. CELF6 also promotes skipping of exon 11 of insulin receptor, a known target of CELF activity that is expressed in kidney.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine	Cooper, TA (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza,Rm 268B, Houston, TX 77030 USA.	tcooper@bcm.tmc.edu		Ladd, Andrea/0000-0003-4725-5644	NIAMS NIH HHS [AR45653] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045653] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; Cooper TA, 1998, MOL CELL BIOL, V18, P4519, DOI 10.1128/MCB.18.8.4519; Delacourte Andre, 2000, Current Opinion in Neurology, V13, P371, DOI 10.1097/00019052-200008000-00002; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; Good PJ, 2000, J BIOL CHEM, V275, P28583, DOI 10.1074/jbc.M003083200; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; Harper PS, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P115; Kaminski A, 1995, RNA, V1, P924; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kosaki A, 1998, J BIOL CHEM, V273, P10331, DOI 10.1074/jbc.273.17.10331; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Li DX, 2001, GENOMICS, V74, P396, DOI 10.1006/geno.2001.6558; Lichtner P, 2002, J MOL MED, V80, P431, DOI 10.1007/s00109-002-0331-9; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; Sergeant N, 2001, HUM MOL GENET, V10, P2143, DOI 10.1093/hmg/10.19.2143; Seznec H, 2001, HUM MOL GENET, V10, P2717, DOI 10.1093/hmg/10.23.2717; Singh G, 2004, NUCLEIC ACIDS RES, V32, P1232, DOI 10.1093/nar/gkh275; Sironi M, 2003, FEBS LETT, V537, P30, DOI 10.1016/S0014-5793(03)00066-8; Sun XL, 2000, EMBO J, V19, P4734, DOI 10.1093/emboj/19.17.4734; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; Timchenko NA, 2001, MOL CELL BIOL, V21, P6927, DOI 10.1128/MCB.21.20.6927-6938.2001; Vermersch P, 1996, NEUROLOGY, V47, P711, DOI 10.1212/WNL.47.3.711; Zhang WQ, 2002, RNA, V8, P671, DOI 10.1017/S1355838202027036	35	69	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17756	17764		10.1074/jbc.M310687200	http://dx.doi.org/10.1074/jbc.M310687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761971	hybrid			2022-12-27	WOS:000220870400107
J	Fang, QH; Peng, JH; Dierks, T				Fang, QH; Peng, JH; Dierks, T			Post-translational formylglycine modification of bacterial sulfatases by the radical S-adenosylmethionine protein AtsB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; EUKARYOTIC SULFATASES; HUMAN ARYLSULFATASE; ESCHERICHIA-COLI; CYSTEINE; GENE; CONVERSION; DEFICIENCY; GENERATION	C-alpha-Formylglycine (FGly) is the catalytic residue of sulfatases. FGly is generated by post-translational modification of a cysteine ( prokaryotes and eukaryotes) or serine ( prokaryotes) located in a conserved (C/S) XPXR motif. AtsB of Klebsiella pneumoniae is directly involved in FGly generation from serine. AtsB is predicted to belong to the newly discovered radical S-adenosylmethionine (SAM) superfamily. By in vivo and in vitro studies we show that SAM is the critical co-factor for formation of a functional AtsB . SAM . sulfatase complex and for FGly formation by AtsB. The SAM-binding site of AtsB involves (83)GGE(85) and possibly also a juxtaposed FeS center coordinated by Cys(39) and Cys(42), as indicated by alanine scanning mutagenesis. Mutation of these and other conserved cysteines as well as treatment with metal chelators fully impaired FGly formation, indicating that all three predicted FeS centers are crucial for AtsB function. It is concluded that AtsB oxidizes serine to FGly by a radical mechanism that is initiated through reductive cleavage of SAM, thereby generating the highly oxidizing deoxyadenosyl radical, which abstracts a hydrogen from the serine-CbetaH2-OH side chain.	Univ Gottingen, Biochem Abt 2, Inst Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Dierks, T (corresponding author), Univ Gottingen, Biochem Abt 2, Inst Biochem & Mol Zellbiol, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	tdierks@gwdg.de	Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Cosper NJ, 2000, BIOCHEMISTRY-US, V39, P15668, DOI 10.1021/bi0022184; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; DIERKS T, 2001, ENCY MOL MED, P974; Fey J, 2001, J BIOL CHEM, V276, P47021, DOI 10.1074/jbc.M108943200; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; Hopwood JJ, 2001, METABOLIC MOL BASES, P3725; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; Layer G, 2002, J BIOL CHEM, V277, P34136, DOI 10.1074/jbc.M205247200; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Marquordt C, 2003, J BIOL CHEM, V278, P2212, DOI 10.1074/jbc.M209435200; Miech C, 1998, J BIOL CHEM, V273, P4835, DOI 10.1074/jbc.273.9.4835; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Peng JH, 2003, J MASS SPECTROM, V38, P80, DOI 10.1002/jms.404; Recksiek R, 1998, J BIOL CHEM, V273, P6096, DOI 10.1074/jbc.273.11.6096; Schirmer A, 1998, CHEM BIOL, V5, pR181, DOI 10.1016/S1074-5521(98)90154-5; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shields DJ, 2003, J BIOL CHEM, V278, P35826, DOI 10.1074/jbc.M306308200; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; Ugulava NB, 2003, BIOCHEMISTRY-US, V42, P2708, DOI 10.1021/bi0261084; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	36	52	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14570	14578		10.1074/jbc.M313855200	http://dx.doi.org/10.1074/jbc.M313855200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749327	hybrid			2022-12-27	WOS:000220594700014
J	Kahl, CR; Means, AR				Kahl, CR; Means, AR			Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT PHOSPHORYLATION; NIH 3T3 CELLS; CAMK-II; G1 ARREST; ACTIVATION; PROGRESSION; CALMODULIN; CDK4; INHIBITORS; IDENTIFICATION	The selective inhibitor of the multifunctional calcium/calmodulin-dependent kinases (CaMK), KN-93, arrests a variety of cell types in G(1). However, the biochemical nature of this G(1) arrest point and the physiological target of KN-93 in G(1) remain controversial. Here we show that in WI-38 human diploid fibroblasts KN-93 reversibly arrested cells in late G(1) prior to detectable cyclin-dependent kinase 4 (cdk4) activation. At the KN-93 arrest point, we found that cyclin D1/cdk4 complexes had assembled with p21/p27, accumulated in the nucleus, and become phosphorylated on Thr-172, yet were relatively inactive. Additional examination of cdk4 complexes by gel filtration analysis demonstrated that, in late G(1), cyclin D1-containing complexes migrated toward lower molecular weight (M-r) fractions and this altered migration was accompanied by the appearance of two peaks of cdk4 activity, at 150-200 and 70 kDa, respectively. KN-93 prevented both the activation of cdk4, and this shift in cyclin D1 migration and overexpression of cyclin D1/cdk4 overcame the KN-93 arrest. To determine which multifunctional CaMK acts in G(1), we expressed kinase-deficient forms of CaMKI and CaMKII. Overexpression of kinase-deficient CaMKI, but not CaMKII, prevented cdk4 activation, mimicking the KN-93 arrest point. Therefore, we hypothesize that KN-93 prevents a very late, uncharacterized step in cyclin D/cdk4 activation that involves CaMKI and follows complex assembly, nuclear entry, and phosphorylation.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	means001@mc.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; BOYNTON AL, 1977, CANCER RES, V37, P2657; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; Hidaka H, 1996, Adv Pharmacol, V36, P193, DOI 10.1016/S1054-3589(08)60583-9; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morris TA, 1998, EXP CELL RES, V240, P218, DOI 10.1006/excr.1997.3925; Obaya AJ, 2002, J BIOL CHEM, V277, P31263, DOI 10.1074/jbc.M202528200; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Parry D, 1999, MOL CELL BIOL, V19, P1775; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; RASMUSSEN G, 1995, BIOCHEM CELL BIOL, V73, P201, DOI 10.1139/o95-024; Sheaff RJ, 1997, METHOD ENZYMOL, V283, P173; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; TAKUWA N, 1993, J BIOL CHEM, V268, P138; TAKUWA N, 1992, FEBS LETT, V306, P173, DOI 10.1016/0014-5793(92)80993-Q; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Tombes RM, 1997, BBA-MOL CELL RES, V1355, P281, DOI 10.1016/S0167-4889(96)00141-3; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WHITFIELD J F, 1992, Critical Reviews in Oncogenesis, V3, P55; Ye QR, 1997, BBA-MOL CELL RES, V1359, P89, DOI 10.1016/S0167-4889(97)00086-4	33	55	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15411	15419		10.1074/jbc.M312543200	http://dx.doi.org/10.1074/jbc.M312543200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14754892	hybrid			2022-12-27	WOS:000220594700111
J	Takanaga, H; Yoshitake, T; Hara, S; Yamasaki, C; Kunimoto, M				Takanaga, H; Yoshitake, T; Hara, S; Yamasaki, C; Kunimoto, M			cAMP-induced astrocytic differentiation of C6 glioma cells is mediated by autocrine interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLARY ACIDIC PROTEIN; CYCLASE-ACTIVATING POLYPEPTIDE; FETAL NEUROEPITHELIAL CELLS; ADENYLATE-CYCLASE; NERVOUS-SYSTEM; TRANSCRIPTIONAL REGULATION; MESSENGER-RNAS; GLIAL-CELLS; RAT-BRAIN; EXPRESSION	Elevation in the level of intracellular cAMP is known to induce the astrocytic differentiation of C6 glioma cells by unknown mechanisms. In this report, we show that cAMP-induced autocrine interleukin 6 (IL-6) promoted astrocytic differentiation of C6 cells. Treatment of cells with N-6,2'-O-dibutyryl cAMP (Bt(2)AMP) and theophylline caused the delayed phosphorylation of signal transducer and activator of transcription 3 (STAT3), as well as the expression of an astrocyte marker, glial fibrillary acidic protein (GFAP). Overexpression of the dominant-negative form of STAT3 leads to the suppression of GFAP promoter activity, suggesting that STAT3 activity was essential for cAMP-induced GFAP promoter activation. On the other hand, the IL-6 gene was quickly induced by Bt(2)AMP/theophylline, and subsequent IL-6 protein secretion was stimulated. In addition, recombinant IL-6 induced GFAP expression and STAT3 phosphorylation. Most importantly, treatment with IL-6-neutralizing antibody dramatically reduced the cAMP-induced GFAP expression and STAT3 phosphorylation and reversed the cellular morphological changes that had been caused by Bt(2)AMP/theophylline. Taken together, these results indicated that Bt(2)AMP/ theophylline lead to delayed STAT3 activation via autocrine IL-6. These processes subsequently led to the induction of GFAP. IL-6 secretion is thus thought to be a key event in controlling the astrocytic differentiation of C6 cells.	Kitasato Univ, Sch Pharmaceut Sci, Dept Publ Hlth & Mol Toxicol, Sch Pharmaceut Sci, Tokyo 1088641, Japan	Kitasato University	Takanaga, H (corresponding author), Univ Cambridge, Ctr Brain Repair, ED Adrian Bldg,Forvie Site,Robinson Way, Cambridge CB2 2PY, England.							Anciaux K, 1997, J NEUROSCI RES, V48, P324, DOI 10.1002/(SICI)1097-4547(19970515)48:4<324::AID-JNR4>3.0.CO;2-D; Basille M, 2000, J COMP NEUROL, V425, P495; Brodie C, 1998, MOL BRAIN RES, V56, P108, DOI 10.1016/S0169-328X(98)00035-7; CHEN WJ, 1994, J CELL BIOL, V127, P813, DOI 10.1083/jcb.127.3.813; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVIES DL, 1986, BRAIN RES, V378, P251, DOI 10.1016/0006-8993(86)90928-5; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; GADIENT RA, 1994, BRAIN RES, V637, P10, DOI 10.1016/0006-8993(94)91211-4; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Jaworski DM, 2000, DEV BRAIN RES, V120, P27, DOI 10.1016/S0165-3806(99)00192-3; Mabie PC, 1997, J NEUROSCI, V17, P4112; MESSENS J, 1992, J NEUROCHEM, V58, P2071, DOI 10.1111/j.1471-4159.1992.tb10948.x; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Nagashima AC, 2003, MOL CELL ENDOCRINOL, V201, P47, DOI 10.1016/S0303-7207(02)00435-5; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nakashima K, 2002, MOL NEUROBIOL, V25, P233; Ochiai W, 2001, CYTOKINE, V14, P264, DOI 10.1006/cyto.2001.0883; PARKER KK, 1980, SCIENCE, V208, P179, DOI 10.1126/science.6102413; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEGOVIA J, 1994, J NEUROCHEM, V63, P1218; Takanaga H, 2001, J NEUROSCI RES, V64, P402, DOI 10.1002/jnr.1091; Vallejo I, 2002, MOL CELL NEUROSCI, V21, P671, DOI 10.1006/mcne.2002.1189; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Yanagisawa M, 1999, NEUROSCI LETT, V269, P169, DOI 10.1016/S0304-3940(99)00447-4; Yoshimura S, 1997, MOL BRAIN RES, V45, P90, DOI 10.1016/S0169-328X(96)00239-2	33	68	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15441	15447		10.1074/jbc.M311844200	http://dx.doi.org/10.1074/jbc.M311844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14754894	hybrid			2022-12-27	WOS:000220594700115
J	Huang, HJ; Muddiman, DC; Tindall, DJ				Huang, HJ; Muddiman, DC; Tindall, DJ			Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTEN TUMOR-SUPPRESSOR; PROTEIN-KINASE B/AKT; CYCLE ARREST; PHOSPHATIDYLINOSITOL 3'-KINASE; PROTEASOME INHIBITORS; PHOSPHATASE-ACTIVITY; SIGNALING PATHWAY; CARCINOMA-CELLS; GENE-EXPRESSION; APOPTOSIS	The ability of androgens to inhibit apoptosis in both normal and malignant prostatic cells has been well documented. However, the underlying mechanisms are understood poorly. Here we demonstrated that forkhead transcription factor FKHR (FOXO1)-induced death of LNCaP cells was blocked by a synthetic androgen R1881. Androgen treatment also resulted in a reduction in transcriptional activity of FKHR in these cells. Moreover, treatment of LNCaP cells with R1881 led to a decrease in the intact FKHR protein (70 kDa) and an increase in a faster migrating protein band (60 kDa). Androgen-enhanced appearance of the 60-kDa protein was diminished specifically by lysosomal acidic cysteine protease inhibitors. Mass spectrometry analyses of the purified FLAG-tagged 70- and 60-kDa proteins demonstrated that the 60-kDa species is a FKHR protein product that lacks about 120 amino acid residues of the C-terminal end. Mutagenesis of the basic amino acid Arg(537) in the protease cleavage region, as suggested by mass spectrometry, abrogated both the androgen-induced accumulation of the 60-kDa product and decrease in cell death induced by FKHR, suggesting that the residue Arg(537) is a potential protease cleavage site. Finally, ectopic expression of the first 537 amino acids of FKHR produced an inhibitory effect on transcriptional activity of the intact protein. Together, these results suggest that androgens induce increased activity of an acidic cysteine protease, which in turn cleaves FKHR. This provides a mechanism by which androgens protect prostate cancer cells from the killing effect of FKHR.	Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Mayo Proteom Res Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Tindall, DJ (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Biochem Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	tindall.donald@mayo.edu		Muddiman, David/0000-0003-2216-499X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065236] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065236] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; BERCHEM GJ, 1995, CANCER RES, V55, P735; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; BRANDSTROM A, 1994, CANCER RES, V54, P3594; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardillo M, 1997, J UROLOGY, V158, P212, DOI 10.1097/00005392-199707000-00073; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carson JP, 1999, CANCER RES, V59, P1449; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Georgescu MM, 2000, CANCER RES, V60, P7033; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang HJ, 1999, CANCER RES, V59, P2981; ISAACS JT, 1994, VITAM HORM, V49, P433; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; Kimura K, 2001, CANCER RES, V61, P5611; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kuratsukuri K, 1999, PROSTATE, V41, P121; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Lin JQ, 1999, CANCER RES, V59, P2891; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McMenamin ME, 1999, CANCER RES, V59, P4291; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Musial A, 2001, J BIOL CHEM, V276, P24268, DOI 10.1074/jbc.M100725200; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WESTIN P, 1995, AM J PATHOL, V146, P1368; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	66	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13866	13877		10.1074/jbc.M314143200	http://dx.doi.org/10.1074/jbc.M314143200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726521	hybrid			2022-12-27	WOS:000220478500073
J	Rosker, C; Graziani, A; Lukas, M; Eder, P; Zhu, MX; Romanin, C; Groschner, K				Rosker, C; Graziani, A; Lukas, M; Eder, P; Zhu, MX; Romanin, C; Groschner, K			Ca2+ signaling by TRPC3 involves Na+ entry and local coupling to the Na+/Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; OPERATED CATION CHANNELS; HAMSTER OVARY CELLS; CARDIAC MYOCYTES; NITRIC-OXIDE; RYANODINE RECEPTORS; NA+-CA2+ EXCHANGER; HTRP3 CHANNELS; IONIC CURRENTS; EXPRESSION	TRPC3 has been suggested as a key component of phospholipase C-dependent Ca2+ signaling. Here we investigated the role of TRPC3-mediated Na+ entry as a determinant of plasmalemmal Na+/Ca2+ exchange. Ca2+ signals generated by TRPC3 overexpression in HEK293 cells were found to be dependent on extracellular Na+, in that carbachol-stimulated Ca2+ entry into TRPC3 expressing cells was significantly suppressed when extracellular Na+ was reduced to 5 mM. Moreover, KB-R9743 ( 5 muM) an inhibitor of the Na+/Ca2+ exchanger (NCX) strongly suppressed TRPC3-mediated Ca2+ entry but not TRPC3-mediated Na+ currents. NCX1 immunoreactivity was detectable in HEK293 as well as in TRPC3-overexpressing HEK293 cells, and reduction of extracellular Na+ after Na+ loading with monensin resulted in significant rises in intracellular free Ca2+ (Ca-i(2+)) of HEK293 cells. Similar rises in Ca-i(2+) were recorded in TRPC3-overexpressing cells upon the reduction of extracellular Na+ subsequent to stimulation with carbachol. These increases in Ca-i(2+) were associated with outward membrane currents at positive potentials and inhibited by KB-R7943 ( 5 muM), chelation of extracellular Ca2+, or dominant negative suppression of TRPC3 channel function. This suggests that Ca2+ entry into TRPC3-expressing cells involves reversed mode Na+/Ca2+ exchange. Cell fractionation experiments demonstrated co-localization of TRPC3 and NCX1 in low density membrane fractions, and co-immunoprecipitation experiments provided evidence for association of TRPC3 and NCX1. Glutathione S-transferase pull-down experiments revealed that NCX1 interacts with the cytosolic C terminus of TRPC3. We suggest functional and physical interaction of nonselective TRPC cation channels with NCX proteins as a novel principle of TRPC-mediated Ca2+ signaling.	Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, A-8010 Graz, Austria; Johannes Kepler Univ, Dept Biochem, A-4040 Linz, Austria; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA	University of Graz; Johannes Kepler University Linz; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Groschner, K (corresponding author), Karl Franzens Univ Graz, Dept Pharmacol & Toxicol, A-8010 Graz, Austria.	klaus.groschner@uni-graz.at	Romanin, Christoph/D-5399-2009; Groschner, Klaus/A-2550-2010	Romanin, Christoph/0000-0003-3756-4136; Groschner, Klaus/0000-0002-8659-377X				Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Billman G E, 2001, Curr Opin Investig Drugs, V2, P1740; Bossuyt J, 2002, ANN NY ACAD SCI, V976, P197; Brini M, 2002, J BIOL CHEM, V277, P38693, DOI 10.1074/jbc.M206075200; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; Cutaia M, 1996, J APPL PHYSIOL, V81, P509, DOI 10.1152/jappl.1996.81.1.509; Dong H, 2002, ANN NY ACAD SCI, V976, P159; Frank JS, 1996, ANN NY ACAD SCI, V779, P532, DOI 10.1111/j.1749-6632.1996.tb44829.x; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; GROSCHNER K, 1994, CIRC RES, V75, P304, DOI 10.1161/01.RES.75.2.304; He LP, 2003, J PHYSIOL-LONDON, V548, P677, DOI 10.1113/jphysiol.2002.036426; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Poteser M, 2003, CIRC RES, V92, P888, DOI 10.1161/01.RES.0000069216.80612.66; SAGE SO, 1991, J PHYSIOL-LONDON, V440, P569, DOI 10.1113/jphysiol.1991.sp018725; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Slodzinski MK, 1998, AM J PHYSIOL-CELL PH, V275, pC459, DOI 10.1152/ajpcell.1998.275.2.C459; Teubl M, 1999, J BIOL CHEM, V274, P29529, DOI 10.1074/jbc.274.41.29529; Thyagarajan B, 2001, J BIOL CHEM, V276, P48149, DOI 10.1074/jbc.M103977200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Van Eylen F, 1998, DIABETES, V47, P1873, DOI 10.2337/diabetes.47.12.1873; Van Eylen F, 2001, CELL CALCIUM, V30, P191, DOI 10.1054/ceca.2001.0223; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Vennekens R, 2002, CELL CALCIUM, V31, P253, DOI 10.1016/S0143-4160(02)00055-6; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	33	142	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13696	13704		10.1074/jbc.M308108200	http://dx.doi.org/10.1074/jbc.M308108200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736881	hybrid			2022-12-27	WOS:000220478500052
J	Pagan-Rodriguez, D; Zhou, X; Simmons, R; Bethel, CR; Hujer, AM; Helfand, MS; Jin, ZY; Guo, BC; Anderson, VE; Ng, LM; Bonomo, RA				Pagan-Rodriguez, D; Zhou, X; Simmons, R; Bethel, CR; Hujer, AM; Helfand, MS; Jin, ZY; Guo, BC; Anderson, VE; Ng, LM; Bonomo, RA			Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser(130)-> Gly SHV-1 beta-lactamase - Insights into the mechanism of inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; STANDARD NUMBERING SCHEME; ESCHERICHIA-COLI; CLAVULANIC ACID; TEM-1; MUTAGENESIS; VARIANT; MUTANT; SELECTION	The increasing number of bacteria resistant to combinations of beta-lactam and beta-lactamase inhibitors is creating great difficulties in the treatment of serious hospital-acquired infections. Understanding the mechanisms and structural basis for the inactivation of these inhibitor-resistant beta-lactamases provides a rationale for the design of novel compounds. In the present work, SHV-1 and the Ser(130)-->Gly inhibitor-resistant variant of SHV-1 beta-lactamase were inactivated with tazobactam, a potent class A beta-lactamase inhibitor. Apoenzymes and inhibited beta-lactamases were analyzed by liquid chromatography-electrospray ionization mass spectrometry (LC-ESI/MS), digested with trypsin, and the products resolved using LC-ESI/MS and matrix-assisted laser desorption ionization-time of flight mass spectrometry. The mass increases observed for SHV-1 and Ser(130)-->Gly (+ Delta88 Da and + Delta70 Da, respectively) suggest that fragmentation of tazobactam readily occurs in the inhibitor-resistant variant to yield an inactive beta-lactamase. These two mass increments are consistent with the formation of an aldehyde (+ Delta70 Da) and a hydrated aldehyde (+ Delta88 Da) as stable products of inhibition. Our results reveal that the Ser-->Gly substitution at amino acid position 130 is not essential for enzyme inactivation. By examining the inhibitor-resistant Ser(130)-->Gly beta-lactamase, our data are the first to show that tazobactam undergoes fragmentation while still attached to the active site Ser(70) in this enzyme. After acylation of tazobactam by Ser(130)-->Gly, inactivation proceeds independent of any additional covalent interactions.	Vet Adm Med Ctr, Infect Dis Sect, Cleveland, OH 44106 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Ohio; Cleveland State University; Case Western Reserve University	Bonomo, RA (corresponding author), Vet Adm Med Ctr, Infect Dis Sect, 10701 East Blvd, Cleveland, OH 44106 USA.	robert.bonomo@med.va.gov	Anderson, Vernon/W-2673-2019	Anderson, Vernon Emmett/0000-0002-1699-7621				Alonso R, 2002, ANTIMICROB AGENTS CH, V46, P3627, DOI 10.1128/AAC.46.11.3627-3629.2002; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; APLIN RT, 1990, FEBS LETT, V277, P212, DOI 10.1016/0014-5793(90)80847-C; Bonomo RA, 2001, BBA-PROTEIN STRUCT M, V1547, P196, DOI 10.1016/S0167-4838(01)00175-3; BROWN RP, 1996, BIOCHEMISTRY-US, V24, P12421; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610; Bush Karen, 2002, Curr Opin Investig Drugs, V3, P1284; Canica MM, 1997, ANTIMICROB AGENTS CH, V41, P374, DOI 10.1128/AAC.41.2.374; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Helfand Marion S., 2003, Current Drug Targets - Infectious Disorders, V3, P9, DOI 10.2174/1568005033342181; Helfand MS, 2003, J BIOL CHEM, V278, P52724, DOI 10.1074/jbc.M306059200; Helfand MS, 2002, J BIOL CHEM, V277, P47719, DOI 10.1074/jbc.M207271200; Helfand MS, 2003, BIOCHEMISTRY-US, V42, P13386, DOI 10.1021/bi035716w; Hujer AM, 2001, BBA-PROTEIN STRUCT M, V1547, P37, DOI 10.1016/S0167-4838(01)00164-9; IMTIAZ U, 1994, BIOCHEMISTRY-US, V33, P5728, DOI 10.1021/bi00185a009; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Kuzin AP, 2001, BIOCHEMISTRY-US, V40, P1861, DOI 10.1021/bi0022745; Meroueh SO, 2002, J AM CHEM SOC, V124, P9422, DOI 10.1021/ja026547q; Page MGF, 2000, DRUG RESIST UPDATE, V3, P109, DOI 10.1054/drup.2000.0137; Payne DJ, 1996, BIOCHEM J, V314, P457, DOI 10.1042/bj3140457; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SAVES I, 1995, J BIOL CHEM, V270, P18240, DOI 10.1074/jbc.270.31.18240; Swaren P, 1999, BIOCHEMISTRY-US, V38, P9570, DOI 10.1021/bi990758z; Vakulenko SB, 1998, ANTIMICROB AGENTS CH, V42, P1542, DOI 10.1128/AAC.42.7.1542; Wang XJ, 2002, J BIOL CHEM, V277, P32149, DOI 10.1074/jbc.M204212200; Yang Y, 2000, J BIOL CHEM, V275, P26674; Zervosen A, 2001, EUR J BIOCHEM, V268, P3840, DOI 10.1046/j.1432-1327.2001.02298.x	28	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19494	19501		10.1074/jbc.M311669200	http://dx.doi.org/10.1074/jbc.M311669200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14757767	hybrid			2022-12-27	WOS:000221164500016
J	Frickel, EM; Frei, P; Bouvier, M; Stafford, WF; Helenius, A; Glockshuber, R; Ellgaard, L				Frickel, EM; Frei, P; Bouvier, M; Stafford, WF; Helenius, A; Glockshuber, R; Ellgaard, L			ERp57 is a multifunctional thiol-disulfide oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-LIKE DOMAINS; CALRETICULIN P-DOMAIN; ESCHERICHIA-COLI THIOREDOXIN; BOND FORMATION INVIVO; ENDOPLASMIC-RETICULUM; REDOX PROPERTIES; ACTIVE-SITE; SEDIMENTATION-VELOCITY; DEPENDENT REDUCTASE; STRUCTURAL DOMAIN	The thiol-disulfide oxidoreductase ERp57 is a soluble protein of the endoplasmic reticulum and the closest known homologue of protein disulfide isomerase. The protein interacts with the two lectin chaperones calnexin and calreticulin and thereby promotes the oxidative folding of newly synthesized glycoproteins. Here we have characterized several fundamental structural and functional properties of ERp57 in vitro, such as the domain organization, shape, redox potential, and the ability to catalyze different thiol-disulfide exchange reactions. Like protein disulfide isomerase, we find ERp57 to be comprised of four structural domains. The protein has an elongated shape of 3.4 +/- 0.1 nm in diameter and 16.8 +/- 0.5 nm in length. The two redox-active a and a' domains were determined to have redox potentials of - 0.167 and - 0.156 V, respectively. Furthermore, ERp57 was shown to efficiently catalyze disulfide reduction, disulfide isomerization, and dithiol oxidation in substrate proteins. The implications of these findings for the function of the protein in vivo are discussed.	ETH, Inst Biochem, CH-8093 Zurich, Switzerland; ETH, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Boston Biomed Res Inst, Watertown, MA 02472 USA; Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Boston Biomedical Research Institute; University of Connecticut	Ellgaard, L (corresponding author), ETH, Inst Biochem, CH-8093 Zurich, Switzerland.	lars.ellgaard@bc.biol.ethz.ch	Stafford, Walter/ABC-6553-2020; Ellgaard, Lars/I-9034-2014	Ellgaard, Lars/0000-0002-7018-0137	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045070, R56AI045070] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45070] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Antoniou AN, 2003, ANTIOXID REDOX SIGN, V5, P375, DOI 10.1089/152308603768295104; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Blasko B, 2003, BIOCHEM BIOPH RES CO, V303, P1142, DOI 10.1016/S0006-291X(03)00490-X; Bonfils C, 1998, EUR J BIOCHEM, V254, P420, DOI 10.1046/j.1432-1327.1998.2540420.x; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; Bouvier M, 2003, MOL IMMUNOL, V39, P697, DOI 10.1016/S0161-5890(02)00261-4; BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Darby NJ, 1999, FEBS LETT, V448, P167, DOI 10.1016/S0014-5793(99)00374-9; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Ellgaard L, 2002, J MOL BIOL, V322, P773, DOI 10.1016/S0022-2836(02)00812-4; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Eschenlauer SCP, 2003, J BIOL CHEM, V278, P4227, DOI 10.1074/jbc.M210510200; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hennecke J, 1999, J MOL BIOL, V286, P1197, DOI 10.1006/jmbi.1998.2531; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Jacobi A, 1997, J BIOL CHEM, V272, P21692, DOI 10.1074/jbc.272.35.21692; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Kramer B, 2001, BIOCHEM J, V357, P83, DOI 10.1042/0264-6021:3570083; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; Matsuo Y, 2001, J BIOL CHEM, V276, P10032, DOI 10.1074/jbc.M011037200; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Mossner E, 1998, PROTEIN SCI, V7, P1233; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P155, DOI 10.1111/j.1432-1033.1986.tb09652.x; Pirneskoski A, 2001, J BIOL CHEM, V276, P11287, DOI 10.1074/jbc.M010656200; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; SILHAVY TJ, 1976, P NATL ACAD SCI USA, V73, P3423, DOI 10.1073/pnas.73.10.3423; Silvennoinen L, 2001, J BIOMOL NMR, V20, P385, DOI 10.1023/A:1011291316810; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 2004, BIOPHYS CHEM, V108, P231, DOI 10.1016/j.bpc.2003.10.028; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; STAFFORD WF, 1995, HYDRODYNAMIC TRANSPO, P111; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	80	159	168	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18277	18287		10.1074/jbc.M314089200	http://dx.doi.org/10.1074/jbc.M314089200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14871896	hybrid			2022-12-27	WOS:000221041500024
J	Lakaye, B; Wirtzfeld, B; Wins, P; Grisar, T; Bettendorff, L				Lakaye, B; Wirtzfeld, B; Wins, P; Grisar, T; Bettendorff, L			Thiamine triphosphate, a new signal required for optimal growth of Escherichia coli during amino acid starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE REGULATOR PROTEINS; INORGANIC POLYPHOSPHATE; HISTIDINE KINASES; EXPRESSION; PHOSPHORYLATION; DEGRADATION; BACTERIA; RAPSYN; CELLS	Thiamine triphosphate (ThTP) is present in low amounts in most organisms from bacteria to humans, but its biological role remains unknown. Escherichia coli grown aerobically in LB medium contain no detectable amounts of ThTP, but when they are transferred to M9 minimal medium with a substrate such as glucose or pyruvate, there is a rapid but transient accumulation of relatively high amounts of ThTP (about 20% of total thiamine). If a mixture of amino acids is present in addition to glucose, ThTP accumulation is impaired, suggesting that the latter may occur in response to amino acid starvation. To test the importance of ThTP for bacterial growth, we used an E. coli strain overexpressing a specific human recombinant thiamine triphosphatase as a glutathione S-transferase (GST) fusion protein (GST-ThTPase). Those bacteria were unable to accumulate measurable amounts of ThTP. On minimal medium supplemented with glucose, pyruvate, or acetate, they exhibited an intermediate plateau in cell growth compared with control bacteria expressing GST alone or a GST fusion protein unrelated to thiamine metabolism. These results suggest that the early accumulation of ThTP initiates a reaction cascade involved in the adaptation of bacteria to stringent conditions such as amino acid starvation. This is the first demonstration of a physiological role of this ubiquitous compound in any organism.	Univ Liege, Ctr Cellular & Mol Neurobiol, B-4020 Liege, Belgium	University of Liege	Bettendorff, L (corresponding author), Univ Liege, Ctr Cellular & Mol Neurobiol, 17 Pl Delcour, B-4020 Liege, Belgium.	L.Bettendorff@ulg.ac.be						Ault-Riche D, 1998, J BACTERIOL, V180, P1841; Besant PG, 2003, INT J BIOCHEM CELL B, V35, P297, DOI 10.1016/S1357-2725(02)00257-1; BETTENDORFF L, 1991, ANAL BIOCHEM, V198, P52, DOI 10.1016/0003-2697(91)90505-N; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; HILL M, 1987, METHOD ENZYMOL, V148, P132; Jones KL, 2000, METAB ENG, V2, P328, DOI 10.1006/mben.2000.0161; Kuroda A, 1997, J BIOL CHEM, V272, P21240, DOI 10.1074/jbc.272.34.21240; Kuroda A, 2001, SCIENCE, V293, P705, DOI 10.1126/science.1061315; Kuroda A, 1999, P NATL ACAD SCI USA, V96, P14264, DOI 10.1073/pnas.96.25.14264; Lakaye B, 2002, J BIOL CHEM, V277, P13771, DOI 10.1074/jbc.M111241200; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Makarchikov AF, 2003, CELL MOL LIFE SCI, V60, P1477, DOI 10.1007/s00018-003-3098-4; Nghiem HO, 2000, FASEB J, V14, P543, DOI 10.1096/fasebj.14.3.543; NISHIMUNE T, 1987, J NUTR SCI VITAMINOL, V33, P113; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Peng L, 2003, APPL MICROBIOL BIOT, V61, P163, DOI 10.1007/s00253-002-1202-6; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; SPIRA B, 1995, J BACTERIOL, V177, P4053, DOI 10.1128/jb.177.14.4053-4058.1995; Wang LH, 2003, P NATL ACAD SCI USA, V100, P11249, DOI 10.1073/pnas.1534805100; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145	23	42	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17142	17147		10.1074/jbc.M313569200	http://dx.doi.org/10.1074/jbc.M313569200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769791	hybrid			2022-12-27	WOS:000220870400033
J	Ibarrola, N; Molina, H; Iwahori, A; Pandey, A				Ibarrola, N; Molina, H; Iwahori, A; Pandey, A			A novel proteomic approach for specific identification of tyrosine kinase substrates using [C-13]tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE; TRANSCRIPT-RELEASE FACTOR; GROWTH-FACTOR-I; MASS-SPECTROMETRY; SIGNALING PATHWAYS; MAP KINASE; PHOSPHORYLATION SITES; CONTAINING MOLECULE; POLYMERASE-I; CELL-CULTURE	Proteomic studies to find substrates of tyrosine kinases generally rely on identification of protein bands that are "pulled down" by antiphosphotyrosine antibodies from ligand-stimulated samples. One can obtain erroneous results from such experiments because of two major reasons. First, some proteins might be basally phosphorylated on tyrosine residues in the absence of ligand stimulation. Second, proteins can bind non-specifically to the antibodies or the affinity matrix. Induction of phosphorylation of proteins by ligand must therefore be confirmed by a different approach, which is not always feasible. We have developed a novel proteomic approach to identify substrates of tyrosine kinases in signaling pathways studies based on in vivo labeling of proteins with "light" (C-12-labeled) or "heavy" (C-13-labeled) tyrosine. This stable isotope labeling in cell culture method enables the unequivocal identification of tyrosine kinase substrates, as peptides derived from true substrates give rise to a unique signature in a mass spectrometry experiment. By using this approach, from a single experiment, we have successfully identified several known substrates of insulin signaling pathway and a novel substrate, polymerase I and transcript release factor, a protein that is implicated in the control of RNA metabolism and regulation of type I collagen promoters. This approach is amenable to high throughput global studies as it simplifies the specific identification of substrates of tyrosine kinases as well as serine/threonine kinases using mass spectrometry.	Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21205 USA; Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	Johns Hopkins University; Johns Hopkins University; University of Southern Denmark	Pandey, A (corresponding author), Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Broadway Res Bldg,733 N Broadway, Baltimore, MD 21205 USA.	pandey@jhmi.edu	Pandey, Akhilesh/B-4127-2009	Pandey, Akhilesh/0000-0001-9943-6127	NCI NIH HHS [CA88843] Funding Source: Medline; NHLBI NIH HHS [HV-28180] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028180] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA088843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed Z, 1999, BIOCHEM J, V341, P665, DOI 10.1042/0264-6021:3410665; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bevan P, 2001, J CELL SCI, V114, P1429; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; Butch ER, 1996, J BIOL CHEM, V271, P4230; Campbell HD, 2000, GENOMICS, V68, P89, DOI 10.1006/geno.2000.6259; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; GOLDSTEIN RH, 1989, ENDOCRINOLOGY, V124, P964, DOI 10.1210/endo-124-2-964; Goshe MB, 2003, CURR OPIN BIOTECH, V14, P101, DOI 10.1016/S0958-1669(02)00014-9; Hamdan M, 2002, MASS SPECTROM REV, V21, P287, DOI 10.1002/mas.10032; Hasegawa T, 2000, BIOCHEM J, V347, P55, DOI 10.1042/0264-6021:3470055; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hresko RC, 2000, J BIOL CHEM, V275, P18114, DOI 10.1074/jbc.M001937200; Hresko RC, 2002, J BIOL CHEM, V277, P25233, DOI 10.1074/jbc.M202556200; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Ibarrola N, 2003, ANAL CHEM, V75, P6043, DOI 10.1021/ac034931f; Jansa P, 1998, EMBO J, V17, P2855, DOI 10.1093/emboj/17.10.2855; Jansa P, 2001, NUCLEIC ACIDS RES, V29, P423, DOI 10.1093/nar/29.2.423; Lehr S, 2000, BIOCHEMISTRY-US, V39, P10898, DOI 10.1021/bi000982k; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Mizutani A, 2000, J BIOL CHEM, V275, P9823, DOI 10.1074/jbc.275.13.9823; Moodie SA, 1999, J BIOL CHEM, V274, P11186, DOI 10.1074/jbc.274.16.11186; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Pandey A, 2002, ONCOGENE, V21, P8029, DOI 10.1038/sj.onc.1205988; PANDEY A, 2000, SCI STKE; Patton WF, 2002, J CHROMATOGR B, V771, P3, DOI 10.1016/S1570-0232(02)00043-0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Rae FK, 2001, GENOMICS, V77, P200, DOI 10.1006/geno.2001.6629; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; SCHLESSINGER J, 2003, SCI STKE; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Steen H, 2002, TRENDS BIOTECHNOL, V20, P361, DOI 10.1016/S0167-7799(02)02009-7; Steen H, 2002, J BIOL CHEM, V277, P1031, DOI 10.1074/jbc.M109992200; STEEN H, 2002, SCI STKE; Summers SA, 1999, ANN NY ACAD SCI, V892, P169, DOI 10.1111/j.1749-6632.1999.tb07795.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Van Obberghen E, 2001, EUR J CLIN INVEST, V31, P966, DOI 10.1046/j.1365-2362.2001.00896.x; Wang QH, 1998, MOL BIOL CELL, V9, P3057, DOI 10.1091/mbc.9.11.3057; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	55	78	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15805	15813		10.1074/jbc.M311714200	http://dx.doi.org/10.1074/jbc.M311714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14739304	hybrid			2022-12-27	WOS:000220747900016
J	Lahdesmaki, A; Taylor, AMR; Chrzanowska, KH; Pan-Hammarstrom, Q				Lahdesmaki, A; Taylor, AMR; Chrzanowska, KH; Pan-Hammarstrom, Q			Delineation of the role of the Mre11 complex in class switch recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; TELANGIECTASIA-LIKE DISORDER; CYTIDINE DEAMINASE AID; DNA-DAMAGE RESPONSE; RNA EDITING ENZYME; S-MU REGION; SOMATIC HYPERMUTATION; ATAXIA-TELANGIECTASIA; B-CELLS; V(D)J RECOMBINATION	Class switch recombination (CSR) is a region-specific, transcriptionally regulated, nonhomologous recombinational process that is initiated by activation-induced cytidine deaminase ( AID). The initial lesions in the switch ( S) regions are processed and resolved, leading to a recombination of the two S regions involved. The mechanism involved in the repair and ligation of the broken DNA ends is however still unclear. Here, we describe that switching is less efficient in cells from patients with Mre11 deficiency (Ataxia-Telangiectasia-like disorder, ATLD) and, more importantly, that the switch recombination junctions resulting from the in vivo switching events are aberrant. There was a trend toward an increased usage of microhomology (greater than or equal to 4 bp) at the switch junctions in both ATLD and Nijmegen breakage syndrome (NBS) patients. However, the DNA ends were not joined as "perfectly" as those from Ataxia-Telangiectasia (A-T) patients and 1 - 2 bp mutations or insertions were often observed. In switch junctions from ATLD patients, there were fewer base substitutions due to transitions and, most strikingly, the substitutions that occurred most often in controls, C 3 T transitions, never occurred at, or close to, the junctions derived from the ATLD patients. In switch junctions from NBS patients, all base substitutions were observed at the G/C nucleotides, and transitions were preferred. These data suggest that the Mre11-Rad50-Nbs1 complex ( Mre11 complex) is involved in the nonhomologous end joining pathway in CSR and that Mre11, Nbs1, and protein mutated in ataxia-telangiectasia (ATM) might have both common and independent roles in this process.	Huddinge Hosp, Karolinska Inst, Div Clin Immunol, Dept Lab Med, SE-14186 Stockholm, Sweden; NOVUM, Ctr Biotechnol, SE-14157 Huddinge, Sweden; Univ Birmingham, Canc Res UK Inst Canc Studies, Med Sch Edghaston, Birmingham B15 2TT, W Midlands, England; Childrens Mem Hlth Inst, Dept Med Genet, PL-04736 Warsaw, Poland	Karolinska Institutet; Karolinska Institutet; Cancer Research UK; University of Birmingham; Children's Memorial Health Institute	Pan-Hammarstrom, Q (corresponding author), Huddinge Hosp, Karolinska Inst, Div Clin Immunol, Dept Lab Med, F79, SE-14186 Stockholm, Sweden.	qipa@biosci.ki.se	hammarstrom, qiang pan/ABA-4589-2021	pan-hammarstrom, qiang/0000-0003-1990-8804; Chrzanowska, Krystyna/0000-0003-3888-0624				Bemark M, 2000, J EXP MED, V192, P1509, DOI 10.1084/jem.192.10.1509; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Cook AJL, 2003, J IMMUNOL, V171, P6556, DOI 10.4049/jimmunol.171.12.6556; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; de Jager M, 2002, NUCLEIC ACIDS RES, V30, P4425, DOI 10.1093/nar/gkf574; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Ehrenstein MR, 1999, EMBO J, V18, P3484, DOI 10.1093/emboj/18.12.3484; Ehrenstein MR, 2001, P NATL ACAD SCI USA, V98, P14553, DOI 10.1073/pnas.241525998; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; HERNANDEZ D, 1993, J MED GENET, V30, P135, DOI 10.1136/jmg.30.2.135; ISLAM KB, 1994, J IMMUNOL, V152, P1442; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Klein C, 1996, MOVEMENT DISORD, V11, P217, DOI 10.1002/mds.870110217; Laake K, 2000, HUM MUTAT, V16, P232, DOI 10.1002/1098-1004(200009)16:3<232::AID-HUMU6>3.0.CO;2-L; LAHDESMAKI A, 2000, J SWED DRS ASS, V97, P4461; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2002, IMMUNITY, V16, P607, DOI 10.1016/S1074-7613(02)00306-0; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagaoka H, 2002, J EXP MED, V195, P529, DOI 10.1084/jem.20012144; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; Pan Q, 1997, J IMMUNOL, V158, P5849; Pan Q, 1997, EUR J IMMUNOL, V27, P2920, DOI 10.1002/eji.1830271126; Pan Q, 2002, EUR J IMMUNOL, V32, P1300, DOI 10.1002/1521-4141(200205)32:5<1300::AID-IMMU1300>3.0.CO;2-L; Pan Q, 1999, EUR J IMMUNOL, V29, P2779; PAN Q, 2001, EUR J IMMUNOL, V32; Pan-Hammarstrom Q, 2003, J IMMUNOL, V170, P3707, DOI 10.4049/jimmunol.170.7.3707; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Paull TT, 2001, CELL, V107, P563, DOI 10.1016/S0092-8674(01)00591-8; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pitts SA, 2001, HUM MOL GENET, V10, P1155, DOI 10.1093/hmg/10.11.1155; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Schrader CE, 2003, EMBO J, V22, P5893, DOI 10.1093/emboj/cdg550; Schrader CE, 1999, J EXP MED, V190, P323, DOI 10.1084/jem.190.3.323; Schrader CE, 2002, J EXP MED, V195, P367, DOI 10.1084/jem.20011877; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; SUN Z, 1991, J DNA SEQ MAP, V1, P347; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yavuz S, 2002, J IMMUNOL, V169, P3825, DOI 10.4049/jimmunol.169.7.3825; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	69	60	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16479	16487		10.1074/jbc.M312796200	http://dx.doi.org/10.1074/jbc.M312796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14747472	hybrid			2022-12-27	WOS:000220747900096
J	Wosten, MMSM; Wagenaar, JA; van Putten, JPM				Wosten, MMSM; Wagenaar, JA; van Putten, JPM			The FlgS/FlgR two-component signal transduction system regulates the fla regulon in Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI; FUNCTIONAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; PSEUDOMONAS-AERUGINOSA; FLAGELLIN EXPRESSION; HOUSEKEEPING GENES; MOTILITY; IDENTIFICATION; COLONIZATION; PROMOTER	The human pathogen Campylobacter jejuni is a highly motile organism that carries a flagellum on each pole. The flagellar motility is regarded as an important trait in C. jejuni colonization of the intestinal tract, however, the knowledge of the regulation of this important colonization factor is rudimentary. We demonstrate by phosphorylation assays that the sensor FlgS and the response regulator FlgR form a two-component system that is on the top of the Campylobacter flagellum hierarchy. Phosphorylated FlgR is needed to activate RpoN-dependent genes of which the products form the hook-basal body filament complex. By real-time reverse transcriptase-PCR we identified that FlgS, FlgR, RpoN, and FliA belong to the early flagellar genes and are regulated by sigma(70). FliD and the putative anti-sigma-factor FlgM are regulated by a sigma(54)- and sigma(28)-dependent promoters. Activation of the fla regulon is growth phase-dependent, a 100-fold rpoN mRNA reduction is seen in the early stationary phase compared with the early logarithmic phase. Whereas flaB transcription decreases, flaA transcription increases in early stationary phase. Our data show that the C. jejuni flagellar hierarchy largely differs from that of other bacteria. Phenotypical analysis revealed that unflagellated C. jejuni mutants grow three times faster in broth medium compared with wild-type bacteria. In vivo the C. jejuni flagella are needed to pass the gastrointestinal tract of chickens, but not to colonize the ceaca of the chicken.	Univ Utrecht, Dept Immunol & Infect Dis, NL-3584 CL Utrecht, Netherlands; Anim Sci Grp, Div Infect Dis, NL-8219 PH Lelystad, Netherlands	Utrecht University; Animal Sciences Group of Wageningen UR	Wosten, MMSM (corresponding author), Univ Utrecht, Dept Immunol & Infect Dis, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.	M.Wosten@vet.uu.nl		Wosten, Marc/0000-0002-7464-7232; van Putten, Jos/0000-0002-4126-8172				Aldridge P, 2002, CURR OPIN MICROBIOL, V5, P160, DOI 10.1016/S1369-5274(02)00302-8; ALM RA, 1993, J BACTERIOL, V175, P4448, DOI 10.1128/JB.175.14.4448-4455.1993; Beier D, 2000, J BACTERIOL, V182, P2068, DOI 10.1128/JB.182.8.2068-2076.2000; Bleumink-Pluym NMC, 1999, MICROBIOL-UK, V145, P2145, DOI 10.1099/13500872-145-8-2145; BRAZIER JS, 1989, J CLIN PATHOL, V42, P640, DOI 10.1136/jcp.42.6.640; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Dasgupta N, 2003, MOL MICROBIOL, V50, P809, DOI 10.1046/j.1365-2958.2003.03740.x; de Boer P, 2002, MOL MICROBIOL, V44, P351, DOI 10.1046/j.1365-2958.2002.02930.x; FERRERO RL, 1988, J GEN MICROBIOL, V134, P53; Frisk A, 2002, J BACTERIOL, V184, P1514, DOI 10.1128/JB.184.6.1514-1521.2002; GILLEN KL, 1991, J BACTERIOL, V173, P6453, DOI 10.1128/jb.173.20.6453-6459.1991; Golden NJ, 2002, INFECT IMMUN, V70, P1761, DOI 10.1128/IAI.70.4.1761-1771.2002; Gray SA, 1999, ADV EXP MED BIOL, V473, P231; GUERRY P, 2000, CAMPYLOBACTER, P405; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hendrixson DR, 2003, MOL MICROBIOL, V50, P687, DOI 10.1046/j.1365-2958.2003.03731.x; Hendrixson DR, 2001, MOL MICROBIOL, V40, P214, DOI 10.1046/j.1365-2958.2001.02376.x; Jacobs C, 2003, MOL MICROBIOL, V47, P1279, DOI 10.1046/j.1365-2958.2003.03379.x; Jagannathan A, 2001, J BACTERIOL, V183, P2937, DOI 10.1128/JB.183.9.2937-2942.2001; Josenhans C, 2002, MOL MICROBIOL, V43, P307, DOI 10.1046/j.1365-2958.2002.02765.x; Jyot J, 2002, J BACTERIOL, V184, P5251, DOI 10.1128/JB.184.19.5251-5260.2002; Kinsella N, 1997, J BACTERIOL, V179, P4647, DOI 10.1128/jb.179.15.4647-4653.1997; KOHLER T, 1994, FEMS MICROBIOL LETT, V115, P177, DOI 10.1016/0378-1097(94)90010-8; KOSTRZYNSKA M, 1991, J BACTERIOL, V173, P937, DOI 10.1128/jb.173.3.937-946.1991; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; KUTSUKAKE K, 1995, MOL GEN GENET, V247, P275, DOI 10.1007/BF00293195; Leach S, 1997, J APPL MICROBIOL, V82, P631; LIAKING NG, 1985, J BACTERIOL, V164, P338; Macnab RM, 2003, ANNU REV MICROBIOL, V57, P77, DOI 10.1146/annurev.micro.57.030502.090832; McCarter LL, 2001, MICROBIOL MOL BIOL R, V65, P445, DOI 10.1128/MMBR.65.3.445-462.2001; Miller WG, 2000, APPL ENVIRON MICROB, V66, P5426, DOI 10.1128/AEM.66.12.5426-5436.2000; NACHAMKIN I, 1993, APPL ENVIRON MICROB, V59, P1269, DOI 10.1128/AEM.59.5.1269-1273.1993; Newell DG, 2003, APPL ENVIRON MICROB, V69, P4343, DOI 10.1128/AEM.69.8.4343-4351.2003; Niehus E, 2002, MICROBIOL-SGM, V148, P3827, DOI 10.1099/00221287-148-12-3827; NUIJTEN PJM, 1989, INFECT IMMUN, V57, P1084, DOI 10.1128/IAI.57.4.1084-1088.1989; NUIJTEN PJM, 1990, J BIOL CHEM, V265, P17798; NUIJTEN PJM, 1991, INFECT IMMUN, V59, P1100, DOI 10.1128/IAI.59.3.1100-1105.1991; PALMER SR, 1983, LANCET, V1, P287, DOI 10.1016/S0140-6736(83)91698-7; Park SF, 2002, INT J FOOD MICROBIOL, V74, P177, DOI 10.1016/S0168-1605(01)00678-X; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Perraud AL, 1999, TRENDS MICROBIOL, V7, P115, DOI 10.1016/S0966-842X(99)01458-4; Prouty MG, 2001, MOL MICROBIOL, V39, P1595, DOI 10.1046/j.1365-2958.2001.02348.x; Pruss BM, 1996, J BACTERIOL, V178, P668; PURDY D, 1993, FEMS MICROBIOL LETT, V111, P233, DOI 10.1016/0378-1097(93)90386-G; Savli H, 2003, J MED MICROBIOL, V52, P403, DOI 10.1099/jmm.0.05132-0; Shigematsu M, 1998, J MED MICROBIOL, V47, P521, DOI 10.1099/00222615-47-6-521; Shreeve JE, 2000, AVIAN DIS, V44, P983, DOI 10.2307/1593076; Spohn G, 1999, J BACTERIOL, V181, P593, DOI 10.1128/JB.181.2.593-599.1999; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; van Vliet AHM, 1998, J BACTERIOL, V180, P5291, DOI 10.1128/JB.180.20.5291-5298.1998; Vandecasteele SJ, 2001, J BACTERIOL, V183, P7094, DOI 10.1128/JB.183.24.7094-7101.2001; WASSENAAR TM, 1994, INFECT IMMUN, V62, P3901, DOI 10.1128/IAI.62.9.3901-3906.1994; WASSENAAR TM, 1993, J GEN MICROBIOL, V139, P1171, DOI 10.1099/00221287-139-6-1171; WASSENAAR TM, 1991, EMBO J, V10, P2055, DOI 10.1002/j.1460-2075.1991.tb07736.x; WASSENAAR TM, 1993, GENE, V132, P131, DOI 10.1016/0378-1119(93)90525-8; WOSTEN MM, 1997, INITIATION TRANSCRIP, P63; Wosten MMSM, 1998, J BACTERIOL, V180, P594; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Young CR, 1999, AVIAN DIS, V43, P763, DOI 10.2307/1592745	63	112	117	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16214	16222		10.1074/jbc.M400357200	http://dx.doi.org/10.1074/jbc.M400357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14960570	hybrid			2022-12-27	WOS:000220747900064
J	Covian, R; Gutierrez-Cirlos, EB; Trumpower, BL				Covian, R; Gutierrez-Cirlos, EB; Trumpower, BL			Anti-cooperative oxidation of ubiquinol by the yeast cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; BOVINE HEART-MITOCHONDRIA; ELECTRON-TRANSFER; SACCHAROMYCES-CEREVISIAE; RESPIRATORY-CHAIN; CRYSTAL-STRUCTURE; 2FE-2S CLUSTER; BC1 COMPLEX; MECHANISM; INHIBITOR	We have investigated the interaction between monomers of the dimeric yeast cytochrome bc(1) complex by analyzing the pre-steady and steady state activities of the isolated enzyme in the presence of antimycin under conditions that allow the first turnover of ubiquinol oxidation to be observable in cytochrome c(1) reduction. At pH 8.8, where the redox potential of the iron-sulfur protein is similar to 200 mV and in a bc(1) complex with a mutated iron-sulfur protein of equally low redox potential, the amount of cytochrome c(1) reduced by several equivalents of decyl-ubiquinol in the presence of antimycin corresponded to only half of that present in the bc(1) complex. Similar experiments in the presence of several equivalents of cytochrome c also showed only half of the bc(1) complex participating in quinol oxidation. The extent of cytochrome b reduced corresponded to two b(H) hemes undergoing reduction through one center P per dimer, indicating electron transfer between the two cytochrome b subunits. Antimycin stimulated the ubiquinol-cytochrome c reductase activity of the bc(1) complex at low inhibitor/enzyme ratios. This stimulation could only be fitted to a model in which half of the bc(1) dimer is inactive when both center N sites are free, becoming active upon binding of one center N inhibitor molecule per dimer, and there is electron transfer between the cytochrome b subunits of the dimer. These results are consistent with an alternating half-of-the-sites mechanism of ubiquinol oxidation in the bc(1) complex dimer.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 72000 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Gutierrez Cirlos, Emma Berta/D-4463-2011; Gutiérrez, Emma/AAG-5191-2021	Gutierrez Cirlos, Emma Berta/0000-0002-6672-1711	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECHMANN G, 1992, EUR J BIOCHEM, V208, P315, DOI 10.1111/j.1432-1033.1992.tb17189.x; BECKMANN JD, 1989, J BIOL CHEM, V264, P3713; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BOWYER JR, 1981, J BIOL CHEM, V256, P2245; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DEVRIES S, 1986, J BIOENERG BIOMEMBR, V18, P195, DOI 10.1007/BF00743464; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; Gutierrez-Cirlos EB, 2004, J BIOL CHEM, V279, P8708, DOI 10.1074/jbc.M311805200; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P50703, DOI 10.1074/jbc.M208556200; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; Merbitz-Zahradnik T, 2003, BIOCHEMISTRY-US, V42, P13637, DOI 10.1021/bi035344r; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; Shinkarev VP, 2001, BIOCHEMISTRY-US, V40, P12584, DOI 10.1021/bi011334j; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1983, BIOCHIM BIOPHYS ACTA, V722, P349, DOI 10.1016/0005-2728(83)90083-X; Valkova-Valchanova M, 2000, BIOCHEMISTRY-US, V39, P15484, DOI 10.1021/bi000751d; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU CA, 1972, J BIOL CHEM, V247, P1012; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	32	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15040	15049		10.1074/jbc.M400193200	http://dx.doi.org/10.1074/jbc.M400193200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14761953	hybrid			2022-12-27	WOS:000220594700068
J	Hedfalk, K; Bill, RM; Mullins, JGL; Karlgren, S; Filipsson, C; Bergstrom, J; Tamas, MJ; Rydstrom, J; Hohmann, S				Hedfalk, K; Bill, RM; Mullins, JGL; Karlgren, S; Filipsson, C; Bergstrom, J; Tamas, MJ; Rydstrom, J; Hohmann, S			A regulatory domain in the C-terminal extension of the yeast glycerol channel Fps1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER; TRANSPORT; STRESS; AQUAPORINS; PROTEINS; FAMILY; OSMOADAPTATION; PERMEABILITY; HOMOLOG; GROWTH	The Saccharomyces cerevisiae gene FPS1 encodes an aquaglyceroporin of the major intrinsic protein (MIP) family. The main function of Fps1p seems to be the efflux of glycerol in the adaptation of the yeast cell to lower external osmolarity. Fps1p is an atypical member of the family, because the protein is much larger (669 amino acids) than most MIPs due to long hydrophilic extensions in both termini. We have shown previously that a short domain in the N-terminal extension of the protein is required for restricting glycerol transport through the channel (Tama's, M.J., Karlgren, S., Bill, R. M., Hedfalk, K., Allegri, L., Ferreira, M., Thevelein, J.M., Rydstrom, J., Mullins, J. G. L., and Hohmann, S. (2003) J. Biol. Chem. 278, 6337-6345). Deletion of the N-terminal domain results in an unregulated channel, loss of glycerol, and osmosensitivity. In this work we have investigated the role of the Fps1p C terminus (139 amino acids). A set of eight truncations has been constructed and tested in vivo in a yeast fps1Delta strain. We have performed growth tests, membrane localization following cell fractionation, and glycerol accumulation measurements as well as an investigation of the osmotic stress response. Our results show that the C-terminal extension is also involved in restricting transport through Fps1p. We have identified a sequence of 12 amino acids, residues 535-546, close to the sixth transmembrane domain. This element seems to be important for controlling Fps1p function. Similar to the N-terminal domain, the C-terminal domain is amphiphilic and has a potential to dip into the membrane.	Univ Gothenburg, Dept Cell & Mol Biol Microbiol, Gothenburg, Sweden; Univ Gothenburg, Dept Chem Biochem & Biophys, Gothenburg, Sweden; Chalmers Univ Technol, Dept Chem & Biosci Mol Biotechnol, S-40530 Gothenburg, Sweden; Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; Univ Coll Swansea, Swansea Clin Sch, Swansea SA2 8PP, W Glam, Wales	University of Gothenburg; University of Gothenburg; Chalmers University of Technology; Aston University; Swansea University	Hedfalk, K (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol Microbiol, Gothenburg, Sweden.	kristina.hedfalk@molbiotech.chalmers.se	Bill, Roslyn M/D-4554-2012; Hohmann, Stefan/K-9895-2013; Hedfalk, Kristina/A-8244-2010; Rydström, Jan/A-7683-2010; Tamas, Markus J/E-8183-2010	Bill, Roslyn M/0000-0003-1331-0852; Hohmann, Stefan/0000-0002-0809-1985; Tamas, Markus J/0000-0002-0762-7848; Mullins, Jonathan/0000-0003-0144-2962				Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Bill RM, 2001, J BIOL CHEM, V276, P36543, DOI 10.1074/jbc.M105045200; Calamita G, 1998, P NATL ACAD SCI USA, V95, P3627, DOI 10.1073/pnas.95.7.3627; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Ferreira MCD, 2001, CURR GENET, V40, P27, DOI 10.1007/s002940100237; Fotiadis D, 2001, J BIOL CHEM, V276, P1707, DOI 10.1074/jbc.M009383200; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P281; Hedfalk K., 2000, MOL BIOL PHYSL WATER, P29; Heymann JB, 1999, NEWS PHYSIOL SCI, V14, P187; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; HOHMANN S, 2001, AQUAPORINS; Holst B, 2000, MOL MICROBIOL, V37, P108, DOI 10.1046/j.1365-2958.2000.01968.x; Johansson I, 1998, PLANT CELL, V10, P451, DOI 10.1105/tpc.10.3.451; Karlgren S, 2004, EUR J BIOCHEM, V271, P771, DOI 10.1111/j.1432-1033.2004.03980.x; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777; Sherman F., 1983, METHODS YEAST GENETI; Stroud RM, 2003, FEBS LETT, V555, P79, DOI 10.1016/S0014-5793(03)01195-5; Sugiyama Y, 2001, BBA-GENE STRUCT EXPR, V1522, P82, DOI 10.1016/S0167-4781(01)00320-7; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Tamas MJ, 2003, J BIOL CHEM, V278, P6337, DOI 10.1074/jbc.M209792200; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VANAELST L, 1991, EMBO J, V10, P2095, DOI 10.1002/j.1460-2075.1991.tb07742.x; Warringer J, 2003, YEAST, V20, P53, DOI 10.1002/yea.931; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	34	44	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14954	14960		10.1074/jbc.M313126200	http://dx.doi.org/10.1074/jbc.M313126200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752103	hybrid, Green Accepted			2022-12-27	WOS:000220594700058
J	Rostovtseva, TK; Antonsson, B; Suzuki, M; Youle, RJ; Colombini, M; Bezrukov, SM				Rostovtseva, TK; Antonsson, B; Suzuki, M; Youle, RJ; Colombini, M; Bezrukov, SM			Bid, but not Bax, regulates VDAC channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; BCL-2 FAMILY-MEMBER; NEUROSPORA-CRASSA; CONTACT SITES; ION-CHANNEL; CONFORMATIONAL-CHANGE; ANTIAPOPTOTIC BCL-2; BRAIN MITOCHONDRIA	During apoptosis, cytochrome c is released from mitochondria into the cytosol, where it participates in caspase activation. Various and often conflicting mechanisms have been proposed to account for the increased permeability of the mitochondrial outer membrane that is responsible for this process. The voltage-dependent anion channel (VDAC) is the major permeability pathway for metabolites in the mitochondrial outer membrane and therefore is a very attractive candidate for cytochrome c translocation. Here, we report that properties of VDAC channels reconstituted into planar phospholipid membranes are unaffected by addition of the pro-apoptotic protein Bax under a variety of conditions. Contrary to other reports (Shimizu, S., Narita, M., and Tsujimoto, Y. (1999) Nature 399, 483 - 487; Shimizu, S., Ide, T., Yanagida, T., and Tsujimoto, Y. (2000) J. Biol. Chem. 275, 12321 - 12325; Shimizu, S., Konishi, A., Kodama, T., and Tsujimoto, Y. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 3100 - 3105), we found no electrophysiologically detectable interaction between VDAC channels isolated from mammalian mitochondria and either monomeric or oligomeric forms of Bax. We conclude that Bax does not induce cytochrome c release by acting on VDAC. In contrast to Bax, another pro-apoptotic protein ( Bid) proteolytically cleaved with caspase-8 affected the voltage gating of VDAC by inducing channel closure. We speculate that by decreasing the probability of VDAC opening, Bid reduces metabolite exchange between mitochondria and the cytosol, leading to mitochondrial dysfunction.	NICHD, Lab Phys & Struct Biol, NIH, Bethesda, MD 20892 USA; NICHD, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Univ Maryland, Dept Biol, College Pk, MD 20742 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University System of Maryland; University of Maryland College Park	Rostovtseva, TK (corresponding author), NICHD, Lab Phys & Struct Biol, NIH, Bldg 9,Rm 1E-106, Bethesda, MD 20892 USA.	rostovts@helix.nih.gov	Colombini, Marco/A-1540-2014		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000072] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002859, ZIANS002859] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Bezrukov SM, 2000, CURR OPIN COLLOID IN, V5, P237, DOI 10.1016/S1359-0294(00)00061-3; BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DEKROON AIP, 1997, BIOCHIM BIOPHYS ACTA, V1325, pA108; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Goforth RL, 2003, J GEN PHYSIOL, V121, P477, DOI 10.1085/jgp.200308797; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Montessuit S, 1999, PROTEIN EXPRES PURIF, V15, P202, DOI 10.1006/prep.1998.1010; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; Polster BM, 2003, J NEUROSCI, V23, P2735; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Rostovtseva TK, 2002, BIOPHYS J, V82, P160, DOI 10.1016/S0006-3495(02)75383-6; Rostovtseva TK, 2002, J MEMBRANE BIOL, V187, P147, DOI 10.1007/s00232-001-0159-1; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; Siskind LJ, 2003, BIOPHYS J, V85, P1560, DOI 10.1016/S0006-3495(03)74588-3; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Wei MC, 2000, GENE DEV, V14, P2060; Xu XF, 1996, J BIOL CHEM, V271, P23675, DOI 10.1074/jbc.271.39.23675; Xu XF, 1997, BIOPHYS J, V72, P2129, DOI 10.1016/S0006-3495(97)78855-6; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; ZALMAN LS, 1980, J BIOL CHEM, V255, P1771; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhai DY, 2000, FEBS LETT, V472, P293, DOI 10.1016/S0014-5793(00)01471-X	69	158	166	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13575	13583		10.1074/jbc.M310593200	http://dx.doi.org/10.1074/jbc.M310593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729675	hybrid			2022-12-27	WOS:000220478500037
J	Sondag, CM; Combs, CK				Sondag, CM; Combs, CK			Amyloid precursor protein mediates proinflammatory activation of monocytic lineage cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; TYROSINE PHOSPHORYLATION; BETA(1) INTEGRIN; CDNA CLONING; FE65 PROTEIN; KINASE; COLLAGEN; INDUCTION	Alzheimer's disease is a progressive neurodegenerative disorder characterized by extracellular deposition of beta-amyloid (Abeta) peptide containing neuritic plaques. Abeta peptides are proteolytically derived from the membrane-bound amyloid precursor protein (APP). Although the function of APP is not entirely clear, previous studies demonstrate that neuronal APP colocalizes with beta(1) integrin receptors at sites of focal adhesion, suggesting that APP is involved in mediating neuronal process adhesion. Integrin-dependent adhesion is also a well-characterized component of immune cell proinflammatory activation. Using primary mouse microglia and the human monocytic cell line, THP-1, we have begun investigating the role of APP in integrin-dependent activation. Co-immunoprecipitation studies demonstrate that APP is recruited into a multi-receptor signaling complex during beta(1) integrin-mediated adhesion of monocytes. Stimulation induces a subsequent, specific recruitment of tyrosine phosphorylated proteins to APP, including Lyn and Syk. Antibody cross-linking of cell surface APP leads to a similar response characterized by activation and recruitment of tyrosine kinases to APP as well as subsequent activation of mitogen-activated protein kinases and increased proinflammatory protein levels. These data demonstrate that APP can act as a proinflammatory receptor in monocytic lineage cells and provide insight into the contribution of this protein to the inflammatory conditions described in Alzheimer's disease.	Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA	University of North Dakota Grand Forks	Combs, CK (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, 501 N Columbia Rd, Grand Forks, ND 58202 USA.	ccombs@medicine.nodak.edu			NCRR NIH HHS [1 P20 RR17699-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017699] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Brouillet E, 1999, J NEUROSCI, V19, P1717; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howell BW, 1999, MOL CELL BIOL, V19, P5179; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Jung SS, 1999, NEUROBIOL AGING, V20, P249, DOI 10.1016/S0197-4580(99)00051-2; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; McGilvray ID, 1997, J BIOL CHEM, V272, P10287; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miller LA, 1999, EUR J IMMUNOL, V29, P1426, DOI 10.1002/(SICI)1521-4141(199905)29:05<1426::AID-IMMU1426>3.0.CO;2-J; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MONNING U, 1992, J BIOL CHEM, V267, P23950; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Reyes-Reyes M, 2002, BIOCHEM J, V363, P273, DOI 10.1042/0264-6021:3630273; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; SELKOE DJ, 1991, NATURE, V354, P432, DOI 10.1038/354432a0; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Wang JF, 2001, J BIOL CHEM, V276, P41950, DOI 10.1074/jbc.M101370200; Yamazaki T, 1997, J NEUROSCI, V17, P1004; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200	40	44	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14456	14463		10.1074/jbc.M313747200	http://dx.doi.org/10.1074/jbc.M313747200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732706	hybrid			2022-12-27	WOS:000220478500142
J	Burden, JJ; Sun, XM; Garcia, ABG; Soutar, AK				Burden, JJ; Sun, XM; Garcia, ABG; Soutar, AK			Sorting motifs in the intracellular domain of the low density lipoprotein receptor interact with a novel domain of sorting nexin-17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; EPIDERMAL-GROWTH-FACTOR; LDL RECEPTOR; PROTEIN; FAMILY; IDENTIFICATION; ENDOCYTOSIS; ASSOCIATION; PHENOTYPE; COMPLEX	The low density lipoprotein (LDL) receptor plays a major role in maintaining human plasma cholesterol levels and mutations in the gene cause familial hypercholesterolemia. The LDL receptor (LDLR) pathway has been well characterized, but little is known of proteins involved in its complex intracellular sorting and trafficking. Sorting nexin 17 (SNX17) has recently been implicated in LDLR intracellular trafficking. We show here that endogenous SNX17 is highly expressed in several cell types and is localized partially in early endosomes. We found that the PX domain of SNX17 is required for its endosomal localization but does not interact directly with the LDL receptor. A novel domain containing a FERM-like domain of SNX17 is needed for its interaction with the LDL receptor. Mutations in the NPXY motif of the LDL-receptor cytoplasmic tail that disrupt internalization also disrupt its interaction with SNX17, whereas mutations elsewhere had little effect. When transiently overexpressed in Chinese hamster ovary cells, SNX17 localized to large vesicular structures and disrupted normal trafficking of the LDL receptor in a PX domain-dependent manner. These results suggest that SNX17 plays a role in the cellular trafficking of the LDL receptor through interaction with the NPVY motif in its cytoplasmic domain and interaction of the PX domain with subcellular membrane compartments.	Hammersmith Hosp, Imperial Coll Sch Med, MRC, Clin Sci Ctr,Lipoprot Grp, London W12 0NN, England	Imperial College London	Soutar, AK (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, MRC, Clin Sci Ctr,Lipoprot Grp, Ducane Rd, London W12 0NN, England.	anne.soutar@csc.mrc.ac.uk	Burden, Jemima/Q-1228-2017	Burden, Jemima/0000-0001-5894-7043; garcia-garcia, ana barbara/0000-0002-2162-6606	Medical Research Council [MC_U120074271] Funding Source: Medline; MRC [MC_U120074271] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Barr VA, 2000, TRAFFIC, V1, P904, DOI 10.1034/j.1600-0854.2000.011109.x; BURDEN J, 2000, ATHEROSCLEROSIS, V151, P242; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Cozier GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; Florian V, 2001, BIOCHEM BIOPH RES CO, V281, P1045, DOI 10.1006/bbrc.2001.4467; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Koivisto UM, 2001, CELL, V105, P575, DOI 10.1016/S0092-8674(01)00371-3; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lundmark R, 2002, BIOCHEM J, V362, P597, DOI 10.1042/0264-6021:3620597; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Otsuki T, 1999, BIOCHEM BIOPH RES CO, V265, P630, DOI 10.1006/bbrc.1999.1731; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; SUN XM, 1995, ARTERIOSCL THROM VAS, V15, P219, DOI 10.1161/01.ATV.15.2.219; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; VANCRIEKINGE W, 1999, BIOL P ONLINE, V1, P1; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39	32	62	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16237	16245		10.1074/jbc.M313689200	http://dx.doi.org/10.1074/jbc.M313689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14739284	hybrid			2022-12-27	WOS:000220747900067
J	Chen, X; Stitt, BL				Chen, X; Stitt, BL			The binding of C-10 oligomers to Escherichia coli transcription termination factor Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNP1-LIKE SEQUENCE MOTIF; RNA-BINDING; PROTEIN-RHO; OLIGONUCLEOTIDE COFACTORS; FUNCTIONAL INTERACTIONS; PHYSICAL-PROPERTIES; HYDROLYTIC SITES; LIGAND COFACTORS; ATP HYDROLYSIS; MESSENGER-RNA	The binding of C-10 RNA oligomers to wild type and mutant Escherichia coli transcription termination factor Rho provides a model for the enzyme-RNA interactions that lead to transcription termination. One surprising finding is that wild type Rho binds between five and six C-10 oligomers per hexamer with K-D=0.3 muM, and five to six additional C-10 molecules with K-D=7 muM. Previously, approximately half this number of oligomer-binding sites was reported (Wang, Y., and von Hippel, P. H. (1993) J. Biol. Chem. 268, 13947-13955); however, the E155K mutant form of Rho, thought at the time to be wild type, was used in that work. The present results with E155K Rho agree with the earlier work. C-10 binding with mutant forms of Rho that are altered in RNA interactions, bearing amino acid changes F62S, G99V, F232C, T286A, or K352E, indicate that the higher affinity binding sites constitute what has been termed the primary RNA site, and the lower affinity sites constitute the secondary sites. The binding data together with the crystal structures for wild type Rho (Skordalakes, E., and Berger, J. M. (2003) Cell 114, 135-146) support structurally distinct locations on Rho for the two classes of C-10-binding sites. The results are consistent with participation of residues 33 Angstrom apart in secondary site RNA interactions. The data further indicate that not all RNA sites on Rho must be filled for full ATPase and transcription termination activity, and suggest a model in which RNA binding to the higher affinity sites leads to a protein conformation change that exposes the previously hidden lower affinity sites.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stitt, BL (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3420 N Broad St, Philadelphia, PA 19140 USA.	stitt@temple.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; BROIDO MS, 1982, J AM CHEM SOC, V104, P5207, DOI 10.1021/ja00383a036; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; Cleland W W, 1979, Methods Enzymol, V63, P103; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1990, J BACTERIOL, V172, P2477, DOI 10.1128/jb.172.5.2477-2484.1990; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HASCHEMEYER AE, 1967, J MOL BIOL, V27, P369, DOI 10.1016/0022-2836(67)90026-5; Kim DE, 1999, J BIOL CHEM, V274, P32667, DOI 10.1074/jbc.274.46.32667; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; Kim DE, 2001, J BIOL CHEM, V276, P13902, DOI 10.1074/jbc.M011043200; KLOTZ IM, 1979, ARCH BIOCHEM BIOPHYS, V193, P314, DOI 10.1016/0003-9861(79)90036-5; KLOTZ IM, 1997, LIGAND RECEPTOR ENER, P1; LOLL PJ, 1990, BIOCHEMISTRY-US, V29, P6866, DOI 10.1021/bi00481a016; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; Magyar A, 1996, J BIOL CHEM, V271, P25369, DOI 10.1074/jbc.271.41.25369; Martinez A, 1996, J MOL BIOL, V257, P895, DOI 10.1006/jmbi.1996.0210; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MODRAK D, 1994, BIOCHEMISTRY-US, V33, P8292, DOI 10.1021/bi00193a016; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEHRKE KW, 1992, NUCLEIC ACIDS RES, V20, P6107, DOI 10.1093/nar/20.22.6107; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; PEREIRA S, 1995, J MOL BIOL, V251, P30, DOI 10.1006/jmbi.1995.0413; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5767; Saenger W., 1984, PRINCIPLES NUCL ACID; SEIFRIED SE, 1991, J MOL BIOL, V221, P1139; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STITT BL, 1988, J BIOL CHEM, V263, P11130; Vincent F, 2000, BIOCHEMISTRY-US, V39, P9067, DOI 10.1021/bi000503h; VONHIPPEL PH, 1987, RNA POLYM REGULATION, P325; WANG Y, 1993, J BIOL CHEM, V268, P13940; WANG Y, 1993, J BIOL CHEM, V268, P13947; Washburn RS, 1996, J MOL BIOL, V260, P332, DOI 10.1006/jmbi.1996.0404; Wei RR, 2001, J MOL BIOL, V314, P1007, DOI 10.1006/jmbi.2000.5207; Wei RR, 2001, J BIOL CHEM, V276, P28380, DOI 10.1074/jbc.M102444200; Xu Y, 2002, J BIOL CHEM, V277, P30023, DOI 10.1074/jbc.M111009200	66	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16301	16310		10.1074/jbc.M313640200	http://dx.doi.org/10.1074/jbc.M313640200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761943	hybrid			2022-12-27	WOS:000220747900075
J	Fien, K; Cho, YS; Lee, JK; Raychaudhuri, S; Tappin, I; Hurwitz, J				Fien, K; Cho, YS; Lee, JK; Raychaudhuri, S; Tappin, I; Hurwitz, J			Primer utilization by DNA polymerase alpha-primase is influenced by its interaction with Mcm10p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; CELL-CYCLE; INITIATION; COMPLEX; SUBUNIT; ELONGATION; ORIGINS; PURIFICATION; CDC7P-DBF4P; CHROMATIN	Models of DNA replication in yeast and Xenopus suggest that Mcm10p is required to generate the pre-initiation complex as well as progression of the replication fork during the elongation of DNA chains. In this report, we show that the Schizosaccharomyces pombe Mcm10p/Cdc23p binds to the S. pombe DNA polymerase (pol) alpha-primase complex in vitro by interacting specifically with the catalytic p180 subunit and stimulates DNA synthesis catalyzed by the pol alpha-primase complex with various primed DNA templates. We investigated the mechanism by which Mcm10p activates the polymerase activity of the pol alpha-primase complex by generating truncated derivatives of the full-length 593-amino acid Mcm10p. Their ability to stimulate pol alpha polymerase activity and bind to single-stranded DNA and to pol alpha were compared. Concomitant with increased deletion of the N-terminal region (from amino acids 95 to 415), Mcm10p derivatives lost their ability to stimulate pol alpha polymerase activity and bind to single-stranded DNA. Truncated derivatives of Mcm10p containing amino acids 1-416 retained the pol alpha binding activity, whereas the C terminus, amino acids 496-593, did not. These results demonstrate that both the single-stranded DNA binding and the pol alpha binding properties of Mcm10p play important roles in the activation. In accord with these findings, Mcm10p facilitated the binding of pol alpha-primase complex to primed DNA and formed a stable complex with pol alpha-primase on primed templates. A mutant that failed to activate or bind to DNA and pol alpha, was not observed in this complex. We suggest that the interaction of Mcm10p with the pol alpha-primase complex, its binding to single-stranded DNA, and its activation of the polymerase complex together contribute to its role in the elongation phase of DNA replication.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Seoul Natl Univ, Dept Biol Educ, Seoul 151748, South Korea; Ajou Univ, Sch Med, Dept Biochem, Suwon 442749, South Korea; Univ Calif Los Angeles, Sch Med Microbiol & Immunol, Ctr Hlth Sci, Los Angeles, CA 90024 USA	Memorial Sloan Kettering Cancer Center; Seoul National University (SNU); Ajou University; University of California System; University of California Los Angeles	Hurwitz, J (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.	j-hurwitz@ski.mskcc.org						Araki Y, 2003, GENES CELLS, V8, P465, DOI 10.1046/j.1365-2443.2003.00648.x; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; De Saro FJL, 2003, P NATL ACAD SCI USA, V100, P14689, DOI 10.1073/pnas.2435454100; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FOIANI M, 1995, MOL CELL BIOL, V15, P883; Formosa T, 1999, GENETICS, V151, P1459; Gregan J, 2003, MOL BIOL CELL, V14, P3876, DOI 10.1091/mbc.E03-02-0090; Hart EA, 2002, CURR GENET, V41, P342, DOI 10.1007/s00294-002-0316-9; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Homesley L, 2000, GENE DEV, V14, P913; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Kukimoto I, 1999, EUR J BIOCHEM, V265, P936, DOI 10.1046/j.1432-1327.1999.00791.x; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Liang DT, 2001, GENETICS, V159, P471; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; Schneider A, 1998, J BIOL CHEM, V273, P21608, DOI 10.1074/jbc.273.34.21608; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; Sclafani RA, 2000, J CELL SCI, V113, P2111; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Tanaka H, 1999, MOL CELL BIOL, V19, P1038; WANG TSF, 1996, DNA REPLICATION EUKA, V31, P461; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Zerbe LK, 2002, BIOCHEMISTRY-US, V41, P4891, DOI 10.1021/bi016030b; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	40	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16144	16153		10.1074/jbc.M400142200	http://dx.doi.org/10.1074/jbc.M400142200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14766746				2022-12-27	WOS:000220747900056
J	O'Connor, V; Genin, A; Davis, S; Karishma, KK; Doyere, V; De Zeeuw, CI; Sanger, G; Hunt, SP; Richter-Levin, G; Mallet, J; Laroche, S; Bliss, TVP; French, PJ				O'Connor, V; Genin, A; Davis, S; Karishma, KK; Doyere, V; De Zeeuw, CI; Sanger, G; Hunt, SP; Richter-Levin, G; Mallet, J; Laroche, S; Bliss, TVP; French, PJ			Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific Pde10A phosphodiesterase splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DEPENDENT PROTEIN-KINASE; TISSUE-PLASMINOGEN ACTIVATOR; NITRIC-OXIDE SYNTHASE; II MUTANT MICE; MESSENGER-RNA; DENTATE GYRUS; SYNAPTIC PLASTICITY; LATE-PHASE; RAT-BRAIN	We employed differential display of expressed mRNAs (Liang, P., and Pardee, A. B. (1992) Science 257, 967-971) to identify genes up-regulated after long term potentiation (LTP) induction in the hippocampus of awake adult rats. In situ hybridization confirmed the differential expression of five independently amplified clones representing two distinct transcripts, cl13/19/90 and cl95/96. Neither cl13/19/90 nor cl95/96 showed significant sequence homology to known transcripts (mRNA or expressed sequence tag) or to the mouse or human genome. However, comparison with the rat genome revealed that they are localized to a predicted intron of the phosphodiesterase Pde10A gene. cl13/19/90 and cl95/96 are likely to be part of the Pde10A primary transcript as, using reverse transcriptase-PCR, we could specifically amplify distinct introns of the Pde10A primary transcript, and in situ hybridization demonstrated that a subset of Pde10A splice variants are also up-regulated after LTP induction. These results indicate that amplification of a primary transcript can faithfully report gene activity and that differential display can be used to identify differential expression of RNA species other than mRNA. In transiently transfected Cos7 cells, Pde10A3 reduces the atrial natriuretic peptide-induced elevation in cGMP levels without affecting basal cGMP levels. This cellular function of LTP-associated Pde10A transcripts argues for a role of the cGMP/cGMP-dependent kinase pathway in long term synaptic plasticity.	Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England; Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR 9923, F-75013 Paris, France; Univ Paris 11, Lab Neurobiol Apprentisage Memoire & Commun, CNRS, UMR 8620, Orsay, France; Natl Inst Med Res, Div Neurophysiol, London NW7 1AA, England; Glaxo SmithKline, Harlow CM19 5AW, Essex, England; UCL, Dept Anat, London WC1E 6BT, England; Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel; Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands	University of Southampton; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; MRC National Institute for Medical Research; GlaxoSmithKline; University of London; University College London; University of Haifa; Erasmus University Rotterdam; Erasmus MC	French, PJ (corresponding author), Erasmus MC, Dept Neurol, NL-3000 DR Rotterdam, Netherlands.		Sanger, Gareth/AAA-4099-2022; Sanger, Gareth J/AFP-2450-2022; Richter Levin, Gal/GVT-4050-2022; HUNT, STEPHEN P/C-1646-2008	Sanger, Gareth/0000-0002-4231-1945; Richter Levin, Gal/0000-0001-7980-5212; French, Pim/0000-0002-0668-9529; Doyere, Valerie/0000-0002-3851-669X; Hunt, Stephen/0000-0001-9453-5505; O'Connor, Vincent/0000-0003-3185-5709				Ahmed T, 2003, NEUROSCIENCE, V117, P627, DOI 10.1016/S0306-4522(02)00838-2; Arancio O, 2001, J NEUROSCI, V21, P143, DOI 10.1523/JNEUROSCI.21-01-00143.2001; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bon CLM, 2003, J NEUROSCI, V23, P1941; Bottai D, 2002, J NEUROSCI, V22, P167, DOI 10.1523/JNEUROSCI.22-01-00167.2002; BOULTON CL, 1995, NEUROSCIENCE, V69, P699, DOI 10.1016/0306-4522(95)00349-N; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; Dai RJ, 2003, GENE, V311, P111, DOI 10.1016/S0378-1119(03)00564-X; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Deller T, 2003, P NATL ACAD SCI USA, V100, P10494, DOI 10.1073/pnas.1832384100; Dytrych L, 1998, J BIOL CHEM, V273, P5794, DOI 10.1074/jbc.273.10.5794; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; French PJ, 2001, EUR J NEUROSCI, V14, P2037, DOI 10.1046/j.0953-816x.2001.01818.x; French PJ, 2001, NEUROSCIENCE, V108, P207, DOI 10.1016/S0306-4522(01)00408-0; French PJ, 2001, EUR J NEUROSCI, V13, P968, DOI 10.1046/j.0953-816x.2001.01467.x; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Frey U, 1996, J NEUROSCI, V16, P2057; Fujishige K, 1999, EUR J BIOCHEM, V266, P1118, DOI 10.1046/j.1432-1327.1999.00963.x; Fujishige K, 2000, EUR J BIOCHEM, V267, P5943, DOI 10.1046/j.1432-1327.2000.01661.x; Fujishige K, 1999, J BIOL CHEM, V274, P18438, DOI 10.1074/jbc.274.26.18438; Genin A, 2003, EUR J NEUROSCI, V17, P331, DOI 10.1046/j.1460-9568.2003.02462.x; Gnatt A, 2002, BBA-GENE STRUCT EXPR, V1577, P175, DOI 10.1016/S0167-4781(02)00451-7; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Hall J, 2000, NAT NEUROSCI, V3, P533, DOI 10.1038/75698; Hall J, 2001, J NEUROSCI, V21, P2186, DOI 10.1523/JNEUROSCI.21-06-02186.2001; Hawkins RD, 1998, PROG BRAIN RES, V118, P155; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kleppisch T, 1999, J NEUROSCI, V19, P48, DOI 10.1523/JNEUROSCI.19-01-00048.1999; Kleppisch T, 2003, J NEUROSCI, V23, P6005, DOI 10.1523/JNEUROSCI.23-14-06005.2003; Ko GY, 1999, J NEUROSCI, V19, P6784, DOI 10.1523/JNEUROSCI.19-16-06784.1999; Konietzko U, 1999, EMBO J, V18, P3359, DOI 10.1093/emboj/18.12.3359; Kotera J, 1999, BIOCHEM BIOPH RES CO, V261, P551, DOI 10.1006/bbrc.1999.1013; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; Lanahan A, 1998, NEUROBIOL LEARN MEM, V70, P37, DOI 10.1006/nlme.1998.3836; LAROCHE S, 1989, NEUROSCIENCE, V28, P375, DOI 10.1016/0306-4522(89)90184-X; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734; Loughney K, 1999, GENE, V234, P109, DOI 10.1016/S0378-1119(99)00171-7; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; Lu YF, 1999, J NEUROSCI, V19, P10250; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Moita MAP, 2002, NAT NEUROSCI, V5, P837, DOI 10.1038/nn901; Monfort P, 2002, J NEUROSCI, V22, P10116; Montag-Sallaz M, 2003, LEARN MEMORY, V10, P99, DOI 10.1101/lm.53403; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; Nguyen PV, 1996, J NEUROSCI, V16, P3189; Pandey KN, 2000, MOL PHARMACOL, V57, P259; Pyne NJ, 2003, DIABETOLOGIA, V46, P1179, DOI 10.1007/s00125-003-1176-7; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Rodger J, 1998, J NEUROCHEM, V71, P666; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Sambrook J., 2002, MOL CLONING LAB MANU; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Son H, 1998, LEARN MEMORY, V5, P231; STEWARD O, 1994, MOL BRAIN RES, V25, P217, DOI 10.1016/0169-328X(94)90156-2; Suda S, 1998, J NEUROCHEM, V71, P1554; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; THOMAS KL, 1994, NEUROREPORT, V6, P119, DOI 10.1097/00001756-199412300-00031; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Unsworth BR, 1999, INT J DEV NEUROSCI, V17, P45, DOI 10.1016/S0736-5748(98)00058-6; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	74	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15841	15849		10.1074/jbc.M312500200	http://dx.doi.org/10.1074/jbc.M312500200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14752115	Green Accepted, hybrid			2022-12-27	WOS:000220747900020
J	Satake, Y; Diaz, BL; Balestrieri, B; Lam, BK; Kanaoka, Y; Grusby, MJ; Arm, JP				Satake, Y; Diaz, BL; Balestrieri, B; Lam, BK; Kanaoka, Y; Grusby, MJ; Arm, JP			Role of group V phospholipase A(2) in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; RECOMBINANT EXPRESSION; PROSTAGLANDIN PRODUCTION; P388D(1) MACROPHAGES; NUCLEAR-ENVELOPE; GROUP-IV; CLONING; CALCIUM; CELLS; MICE	Conclusions regarding the contribution of low molecular weight secretory phospholipase A(2) (sPLA(2)) enzymes in eicosanoid generation have relied on data obtained from transfected cells or the use of inhibitors that fail to discriminate between individual members of the large family of mammalian sPLA(2) enzymes. To elucidate the role of group V sPLA(2), we used targeted gene disruption to generate mice lacking this enzyme. Zymosan-induced generation of leukotriene C-4 and prostaglandin E-2 was attenuated similar to50% in peritoneal macrophages from group V sPLA(2)-null mice compared with macrophages from wild-type littermates. Furthermore, the early phase of plasma exudation in response to intraperitoneal injection of zymosan and the accompanying in vivo generation of cysteinyl leukotrienes were markedly attenuated in group V sPLA(2)-null mice compared with wild-type controls. These data provide clear evidence of a role for group V sPLA(2) in regulating eicosanoid generation in response to an acute innate stimulus of the immune response both in vitro and in vivo, suggesting a role for this enzyme in innate immunity.	Brigham & Womens Hosp, Partners Asthma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Inst Nacl Canc, Div Biol Celular Coordenacao Pesquisa, BR-20231050 Rio De Janeiro, Brazil; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; National Cancer Institute (Inca); Harvard University; Harvard T.H. Chan School of Public Health	Arm, JP (corresponding author), Brigham & Womens Hosp, Partners Asthma Ctr, Smith Res Bldg,Room 638B,1 Jimmy Fund Way, Boston, MA 02115 USA.	jarm@rics.bwh.harvard.edu	Balestrieri, Barbara/Y-2547-2018; Diaz, Bruno L./A-5673-2009	Balestrieri, Barbara/0000-0002-0323-3278; Diaz, Bruno L./0000-0001-8393-3823	NHLBI NIH HHS [P01 HL036110, HL07718, P01 HL036110-190012, T35 HL007718, HL070946, R01 HL070946, HL36110, R01 HL070946-02] Funding Source: Medline; NIAID NIH HHS [R01 AI040171, AI40171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007718, R01HL070946, P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040171, R21AI040171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Arm JP, 1997, J IMMUNOL, V159, P2342; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Diaz BL, 2003, PROSTAG LEUKOTR ESS, V69, P87, DOI 10.1016/S0952-3278(03)00069-3; DOHERTY NS, 1985, PROSTAGLANDINS, V30, P769, DOI 10.1016/0090-6980(85)90006-1; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GROSS RW, 1995, J LIPID MEDIAT CELL, V12, P131, DOI 10.1016/0929-7855(95)00014-H; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Mejia ROS, 2000, AM J RESP CELL MOL, V22, P557, DOI 10.1165/ajrcmb.22.5.3902; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nakatani N, 2000, BIOCHEM J, V352, P311, DOI 10.1042/0264-6021:3520311; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tjoelker LW, 2000, BBA-MOL CELL BIOL L, V1488, P102, DOI 10.1016/S1388-1981(00)00114-1; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	51	132	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16488	16494		10.1074/jbc.M313748200	http://dx.doi.org/10.1074/jbc.M313748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761945	hybrid, Green Accepted			2022-12-27	WOS:000220747900097
J	Christian, M; Tullet, JMA; Parker, MG				Christian, M; Tullet, JMA; Parker, MG			Characterization of four autonomous repression domains in the corepressor receptor interacting protein 140	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COREPRESSOR; FEMALE FERTILITY; RIP140; MOTIF; CTBP; ACTIVATION; BINDING; FAMILY	Receptor interacting protein (RIP) 140 is a corepressor that can be recruited to nuclear receptors by means of LXXLL motifs. We have characterized four distinct autonomous repression domains in RIP140, termed RD1-4, that are highly conserved in mammals and birds. RD1 at the N terminus represses transcription in the presence of trichostatin A, suggesting that it functions by a histone deacetylase (HDAC)-independent mechanism. The repressive activity of RD2 is dependent upon carboxyl-terminal binding protein recruitment to two specific binding sites. Use of specific inhibitors indicates that RD2, RD3, and RD4 are capable of functioning by HDAC-dependent and HDAC-independent mechanisms, depending upon cell type.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, London W12 ONN, England	Imperial College London	Parker, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, London W12 ONN, England.	m.parker@imperial.ac.uk	Tullet, Jennifer/C-1779-2008	Christian, Mark/0000-0002-1616-4179; Tullet, Jennifer/0000-0002-2037-526X				Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Leonardsson G, 2002, ENDOCRINOLOGY, V143, P700, DOI 10.1210/en.143.2.700; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Tazawa H, 2003, MOL CELL BIOL, V23, P4187, DOI 10.1128/MCB.23.12.4187-4198.2003; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; White R, 2000, NAT MED, V6, P1368, DOI 10.1038/82183; Zhang QH, 2002, SCIENCE, V295, P1895	23	56	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15645	15651		10.1074/jbc.M313906200	http://dx.doi.org/10.1074/jbc.M313906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736873	hybrid			2022-12-27	WOS:000220594700137
J	Garcia, R; Bermejo, C; Grau, C; Perez, R; Rodriguez-Pena, JM; Francois, J; Nombela, C; Arroyo, J				Garcia, R; Bermejo, C; Grau, C; Perez, R; Rodriguez-Pena, JM; Francois, J; Nombela, C; Arroyo, J			The global transcriptional response to transient cell wall damage in Saccharomyces cerevisiae and its regulation by the cell integrity signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; MAP KINASE PATHWAY; GENE-EXPRESSION; CHITIN SYNTHESIS; CYCLE REGULATOR; YEAST; PROTEIN; GROWTH; IDENTIFICATION; ORGANIZATION	In the yeast Saccharomyces cerevisiae, environmental stress conditions that damage the cell wall lead to activation of the so-called "compensatory mechanism," aimed at preserving cell integrity through a remodeling of this extracellular matrix. Here we used DNA microarrays to investigate the molecular basis of this response to two agents that induce transient cell wall damage; namely Congo Red and Zymolyase. Treatment of the cells with these two agents elicited the up-regulation of 132 and 101 genes respectively, the main functional groups among them being involved in cell wall construction and metabolism. The main response does not occur until hours after exposure to the cell wall-perturbing agent. In some cases, this response was transient, but more sustained in others, especially in the case of the genes involved in cell wall remodeling. Clustering of these data together with those from the response to constitutive cell wall damage, revealed the existence of a cluster of co-regulated genes that was strongly induced under all conditions assayed. Those genes induced by cell wall damage showed an enrichment in DNA binding motifs for Rlm1p, Crz1p, SBF (Swi4p/ Swi6p), Msn2p/Msn4p, Ste12p, and Tec1p transcription factors, suggesting a complex regulation of this response together with the possible involvement of several signaling pathways. With the exception of PHO89 and FKS2, none of the genes induced by Congo Red was up-regulated in a slt2 strain. Moreover, characterization of the transcriptional response to Congo Red in a rlm1 mutant strain revealed that only a few genes (i.e. PHO89, FKS2, YLR042C, and CHA1) were induced at least partially independently of the transcription factor Rlm1p, the rest being totally dependent on this transcription factor for their activation. Our findings consistently demonstrate that the cell integrity signaling pathway regulates the cell wall damage compensatory response, mainly through transcriptional activation mediated by Rlm1p.	Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain; Univ Complutense Madrid, Ctr Gen & Prote, E-28040 Madrid, Spain; CNRS, Ctr Bioingn Gilbert Durand, UMR 5504, Toulouse, France; INRA, Toulouse, France	Complutense University of Madrid; Complutense University of Madrid; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; INRAE	Arroyo, J (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain.	jarroyo@farm.ucm.es	Nombela Cano, César/H-2565-2015; Rodriguez-Peña, Jose M/E-9624-2016; Sanchez, Raúl García/E-9303-2016; Arroyo, Javier/E-9308-2016	Nombela Cano, César/0000-0003-0757-4034; Rodriguez-Peña, Jose M/0000-0002-8792-362X; Sanchez, Raúl García/0000-0002-7389-4696; Arroyo, Javier/0000-0002-1971-1721; Francois, Jean marie/0000-0001-9884-5535				Agarwal AK, 2003, J BIOL CHEM, V278, P34998, DOI 10.1074/jbc.M306291200; Baetz K, 2001, MOL CELL BIOL, V21, P6515, DOI 10.1128/MCB.21.19.6515-6528.2001; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; CORREA J, 1992, CURR GENET, V22, P283, DOI 10.1007/BF00317922; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GROOT PWJ, 2001, COMP FUNCT GENOM, V2, P124; Hashimoto H, 1997, J BIOL CHEM, V272, P16308, DOI 10.1074/jbc.272.26.16308; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Jung US, 2002, MOL MICROBIOL, V46, P781, DOI 10.1046/j.1365-2958.2002.03198.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Kapteyn JC, 2001, MOL MICROBIOL, V39, P469, DOI 10.1046/j.1365-2958.2001.02242.x; Kapteyn JC, 1999, MOL MICROBIOL, V31, P1835, DOI 10.1046/j.1365-2958.1999.01320.x; Kapteyn JC, 1997, J BACTERIOL, V179, P6279, DOI 10.1128/JB.179.20.6279-6284.1997; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kitagaki H, 2002, MOL MICROBIOL, V46, P1011, DOI 10.1046/j.1365-2958.2002.03244.x; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; KOPECKA M, 1992, ARCH MICROBIOL, V158, P115, DOI 10.1007/BF00245214; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lussier M, 1997, GENETICS, V147, P435; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; Molina M, 2000, MICROSC RES TECHNIQ, V51, P601, DOI 10.1002/1097-0029(20001215)51:6<601::AID-JEMT9>3.3.CO;2-9; MRSA V, 1993, J BACTERIOL, V175, P2102, DOI 10.1128/JB.175.7.2102-2106.1993; Mrsa V, 1999, YEAST, V15, P813, DOI 10.1002/(SICI)1097-0061(199907)15:10A<813::AID-YEA421>3.0.CO;2-Y; Pardo M, 1999, YEAST, V15, P459, DOI 10.1002/(SICI)1097-0061(199904)15:6<459::AID-YEA387>3.0.CO;2-L; PETERSEN JGL, 1988, GENETICS, V119, P527; Popolo L, 1999, BBA-GEN SUBJECTS, V1426, P385, DOI 10.1016/S0304-4165(98)00138-X; Popolo L, 2001, MED MYCOL, V39, P111, DOI 10.1080/744118881; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Rodriguez-Pena JM, 2002, J CELL SCI, V115, P2549; Rodriguez-Pena JM, 2000, MOL CELL BIOL, V20, P3245, DOI 10.1128/MCB.20.9.3245-3255.2000; Santos B, 2000, MOL BIOL CELL, V11, P435, DOI 10.1091/mbc.11.2.435; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; Smits GJ, 1999, CURR OPIN MICROBIOL, V2, P348; Valdivieso MH, 2000, J BACTERIOL, V182, P4752, DOI 10.1128/JB.182.17.4752-4757.2000; van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; WATZELE G, 1989, J BIOL CHEM, V264, P8753; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wykoff DD, 2001, GENETICS, V159, P1491; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Yun DJ, 1997, P NATL ACAD SCI USA, V94, P7082, DOI 10.1073/pnas.94.13.7082; Zu T, 2001, MOL GENET GENOMICS, V266, P142, DOI 10.1007/s004380100537	63	273	284	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15183	15195		10.1074/jbc.M312954200	http://dx.doi.org/10.1074/jbc.M312954200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739279	hybrid			2022-12-27	WOS:000220594700085
J	Gov, Y; Borovok, I; Korem, M; Singh, VK; Jayaswal, RK; Wilkinson, BJ; Rich, SM; Balaban, N				Gov, Y; Borovok, I; Korem, M; Singh, VK; Jayaswal, RK; Wilkinson, BJ; Rich, SM; Balaban, N			Quorum sensing in staphylococci is regulated via phosphorylation of three conserved histidine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNAIII-INHIBITING PEPTIDE; GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; VIRULENCE DETERMINANTS; TRANSMEMBRANE TOPOLOGY; AUTOINDUCING PEPTIDES; SIGNAL-TRANSDUCTION; AUREUS PATHOGENESIS; BACILLUS-SUBTILIS; BIOFILM FORMATION	Staphylococcus aureus cause infections by producing toxins, a process regulated by cell-cell communication ( quorum sensing) through the histidine-phosphorylation of the target of RNAIII-activating protein ( TRAP). We show here that TRAP is highly conserved in staphylococci and contains three completely conserved histidine residues (His-66, His-79, His-154) that are phosphorylated and essential for its activity. This was tested by constructing a TRAP(-) strain with each of the conserved histidine residues changed to alanine by site-directed mutagenesis. All mutants were tested for pathogenesis in vitro ( expression of RNAIII and hemolytic activity) and in vivo ( murine cellulitis model). Results show that RNAIII is not expressed in the TRAP(-) strain, that it is non hemolytic, and that it does not cause disease in vivo. These pathogenic phenotypes could be rescued in the strain containing the recovered traP, confirming the importance of TRAP in S. aureus pathogenesis. The phosphorylation of TRAP mutated in any of the conserved histidine residues was significantly reduced, and mutants defective in any one of these residues were non-pathogenic in vitro or in vivo, whereas those mutated in a non-conserved histidine residue (His-124) were as pathogenic as the wild type. These results confirm the importance of the three conserved histidine residues in TRAP activity. The phosphorylation pattern, structure, and gene organization of TRAP deviates from signaling molecules known to date, suggesting that TRAP belongs to a novel class of signal transducers.	Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Illinois State Univ, Dept Biol Sci, Microbiol Grp, Normal, IL 61790 USA	Tufts University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Illinois State University	Balaban, N (corresponding author), Tufts Univ, Sch Vet Med, Dept Biomed Sci, 200 Westboro Rd, North Grafton, MA 01536 USA.	naomi.balaban@tufts.edu	BOROVOK, ILYA/ABB-7370-2022; Rich, Stephen/AAX-6953-2020	BOROVOK, ILYA/0000-0003-1602-4499	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043970] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43970] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arvidson S, 2001, INT J MED MICROBIOL, V291, P159, DOI 10.1078/1438-4221-00112; Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Balaban N, 2000, PEPTIDES, V21, P1301, DOI 10.1016/S0196-9781(00)00272-2; BALABAN N, 1995, FEMS MICROBIOL LETT, V133, P155, DOI 10.1016/0378-1097(95)00356-A; Balaban N, 2003, J INFECT DIS, V187, P625, DOI 10.1086/345879; Balaban N, 2003, KIDNEY INT, V63, P340, DOI 10.1046/j.1523-1755.2003.00733.x; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; Balaban N, 2001, J BIOL CHEM, V276, P2658, DOI 10.1074/jbc.M005446200; Benito Y, 2000, RNA, V6, P668, DOI 10.1017/S1355838200992550; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Chen Q, 1998, BIOCHEMISTRY-US, V37, P8714, DOI 10.1021/bi9731652; Cirioni O, 2003, CIRCULATION, V108, P767, DOI 10.1161/01.CIR.0000083717.85060.16; DERBISE A, 1994, PLASMID, V31, P251, DOI 10.1006/plas.1994.1027; Giacometti A, 2003, ANTIMICROB AGENTS CH, V47, P1979, DOI 10.1128/AAC.47.6.1979-1983.2003; Gilot P, 2002, J CLIN MICROBIOL, V40, P4060, DOI 10.1128/JCM.40.11.4060-4067.2002; Gov Y, 2001, PEPTIDES, V22, P1609, DOI 10.1016/S0196-9781(01)00496-X; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hoch JA, 2001, J BACTERIOL, V183, P4941, DOI 10.1128/JB.183.17.4941-4949.2001; Hong-Geller E, 2003, J MOL RECOGNIT, V16, P91, DOI 10.1002/jmr.612; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Korem M, 2003, FEMS MICROBIOL LETT, V223, P167, DOI 10.1016/S0378-1097(03)00326-4; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Lina G, 1998, MOL MICROBIOL, V28, P655, DOI 10.1046/j.1365-2958.1998.00830.x; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Lyon GJ, 2002, BIOCHEMISTRY-US, V41, P10095, DOI 10.1021/bi026049u; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Morfeldt E, 1996, FEMS MICROBIOL LETT, V143, P195, DOI 10.1016/0378-1097(96)00310-2; Nei M., 1987, MOL EVOLUTIONARY GEN; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; Perraud AL, 1999, TRENDS MICROBIOL, V7, P115, DOI 10.1016/S0966-842X(99)01458-4; Saenz HL, 2000, ARCH MICROBIOL, V174, P452, DOI 10.1007/s002030000223; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAFER WM, 1979, INFECT IMMUN, V25, P909; Singh VK, 2001, FEMS MICROBIOL LETT, V199, P79, DOI 10.1016/S0378-1097(01)00163-X; Stephenson K., 2002, Current Drug Targets - Infectious Disorders, V2, P235, DOI 10.2174/1568005023342443; Stephenson K, 2002, CURR OPIN PHARMACOL, V2, P507, DOI 10.1016/S1471-4892(02)00194-7; Sturme MHJ, 2002, ANTON LEEUW INT J G, V81, P233, DOI 10.1023/A:1020522919555; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Throup JP, 2001, BIOCHEMISTRY-US, V40, P10392, DOI 10.1021/bi0102959; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; Varughese KL, 2002, CURR OPIN MICROBIOL, V5, P142, DOI 10.1016/S1369-5274(02)00305-3; Vieira-da-Motta O, 2001, PEPTIDES, V22, P1621, DOI 10.1016/S0196-9781(01)00497-1; Zhang LS, 2002, J BIOL CHEM, V277, P34736, DOI 10.1074/jbc.M205367200	49	49	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14665	14672		10.1074/jbc.M311106200	http://dx.doi.org/10.1074/jbc.M311106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726534	hybrid			2022-12-27	WOS:000220594700025
J	May, JM; Qu, ZC; Cobb, CE				May, JM; Qu, ZC; Cobb, CE			Human erythrocyte recycling of ascorbic acid - Relative contributions from the ascorbate free radical and dehydroascorbic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-ACTIVITY; RAT-LIVER; THIOREDOXIN REDUCTASE; MONODEHYDROASCORBATE REDUCTASE; PLASMA-MEMBRANE; ELECTRON-DONOR; NADH; GLUTATHIONE; PURIFICATION; ANTIOXIDANT	Recycling of ascorbic acid from its oxidized forms helps to maintain the vitamin in human erythrocytes. To determine the relative contributions of recycling from the ascorbate radical and dehydroascorbic acid, we studied erythrocytes exposed to a trans-membrane oxidant stress from ferricyanide. Ferricyanide was used both to induce oxidant stress across the cell membrane and to quantify ascorbate recycling. Erythrocytes reduced ferricyanide with generation of intracellular ascorbate radical, the concentrations of which saturated with increasing intracellular ascorbate and which were sustained over time in cells incubated with glucose. Ferricyanide also generated dehydroascorbic acid that accumulated in the cells and incubation medium to concentrations much higher than those of the radical, especially in the absence of glucose. Ferricyanide-stimulated ascorbate recycling from dehydroascorbic acid depended on intracellular GSH but was well maintained at the expense of intracellular ascorbate when GSH was severely depleted by diethylmaleate. This likely reflects continued radical reduction, which is not dependent on GSH. Erythrocyte hemolysates showed both NAD- and NADPH-dependent ascorbate radical reduction. The latter was partially due to thioredoxin reductase. GSH-dependent dehydroascorbate reduction in hemolysates, which was both direct and enzyme-dependent, was greater than that of the radical reductase activity but of lower apparent affinity. Together, these results suggest an efficient two-tiered system in which high affinity reduction of the ascorbate radical is sufficient to remove low concentrations of the radical that might be encountered by cells not under oxidant stress, with back-up by a high capacity system for reducing dehydroascorbate under conditions of more severe oxidant stress.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	May, JM (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 715 Med Res Bldg 2, Nashville, TN 37232 USA.	james.may@vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050435] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50435] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BIELSKI BHJ, 1981, J AM CHEM SOC, V103, P3516, DOI 10.1021/ja00402a042; BIELSKI BHJ, 1982, ADV CHEM SER, P81; BIELSKI BHJ, 1975, ANN NY ACAD SCI, V258, P231, DOI 10.1111/j.1749-6632.1975.tb29283.x; COASSIN M, 1991, ARCH BIOCHEM BIOPHYS, V290, P458, DOI 10.1016/0003-9861(91)90566-2; DELBELLO B, 1994, BIOCHEM J, V304, P385, DOI 10.1042/bj3040385; DILIBERTO EJ, 1980, MOL PHARMACOL, V17, P421; Drake BB, 1942, J BIOL CHEM, V143, P89; EVANS RM, 1982, BRIT J NUTR, V47, P473, DOI 10.1079/BJN19820059; GOLDENBERG H, 1983, BIOCHEM INT, V6, P1; HARA T, 1971, J BIOCHEM-TOKYO, V69, P325, DOI 10.1093/oxfordjournals.jbchem.a129470; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; ITO A, 1981, BIOCHEM BIOPH RES CO, V101, P591, DOI 10.1016/0006-291X(81)91300-0; IYANAGI T, 1985, BIOCHIM BIOPHYS ACTA, V806, P255, DOI 10.1016/0005-2728(85)90103-3; Jung CH, 1998, ARCH BIOCHEM BIOPHYS, V355, P9, DOI 10.1006/abbi.1998.0713; KOBAYASHI K, 1991, BIOCHEMISTRY-US, V30, P8310, DOI 10.1021/bi00098a005; LAROFF GP, 1972, J AM CHEM SOC, V94, P9062, DOI 10.1021/ja00781a013; Li X, 2001, ARCH BIOCHEM BIOPHYS, V387, P143, DOI 10.1006/abbi.2000.2245; LUMPER L, 1967, H-S Z PHYSIOL CHEM, V348, P323, DOI 10.1515/bchm2.1967.348.1.323; MAELLARO E, 1994, BIOCHEM J, V301, P471, DOI 10.1042/bj3010471; May JM, 1998, J BIOL CHEM, V273, P23039, DOI 10.1074/jbc.273.36.23039; May JM, 1999, FASEB J, V13, P995, DOI 10.1096/fasebj.13.9.995; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; May JM, 2000, BIOCHEM BIOPH RES CO, V267, P118, DOI 10.1006/bbrc.1999.1906; May JM, 1996, FREE RADICAL BIO MED, V20, P543, DOI 10.1016/0891-5849(95)02130-2; May JM, 2001, BBA-GEN SUBJECTS, V1528, P159, DOI 10.1016/S0304-4165(01)00188-X; May JM, 2001, FREE RADICAL BIO MED, V31, P117, DOI 10.1016/S0891-5849(01)00566-4; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; May JM, 1998, ARCH BIOCHEM BIOPHYS, V349, P281, DOI 10.1006/abbi.1997.0473; MAY JM, 1995, BIOCHEMISTRY-US, V34, P12721, DOI 10.1021/bi00039a031; Mendiratta S, 1998, FREE RADICAL BIO MED, V24, P789, DOI 10.1016/S0891-5849(97)00351-1; NAZEMI M, 1968, H-S Z PHYSIOL CHEM, V349, P345, DOI 10.1515/bchm2.1968.349.1.345; NJUS D, 1983, J BIOL CHEM, V258, P27; ORRINGER EP, 1979, J CLIN INVEST, V63, P53, DOI 10.1172/JCI109277; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; ROSE RC, 1993, FASEB J, V7, P1135, DOI 10.1096/fasebj.7.12.8375611; SCHIPFER W, 1985, INT J BIOCHEM, V17, P819, DOI 10.1016/0020-711X(85)90270-8; SCHULZE HU, 1970, H-S Z PHYSIOL CHEM, V351, P809, DOI 10.1515/bchm2.1970.351.2.809; SCHWEINZER E, 1993, EUR J BIOCHEM, V218, P1057, DOI 10.1111/j.1432-1033.1993.tb18465.x; STAHL RL, 1983, ANAL BIOCHEM, V131, P341, DOI 10.1016/0003-2697(83)90180-X; SZEKELY M, 1952, ACTA PHYSIOL HUNG, V3, P571; VanDuijn MM, 2000, J BIOL CHEM, V275, P27720; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Villalba JM, 1997, MOL ASPECTS MED, V18, pS7; Vincent TE, 1999, DIABETES RES CLIN PR, V43, P1, DOI 10.1016/S0168-8227(98)00119-3; WELLS WW, 1995, METHOD ENZYMOL, V252, P30; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Wilson JX, 2002, FEBS LETT, V527, P5, DOI 10.1016/S0014-5793(02)03167-8; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5; Xu DP, 1996, BIOCHEM BIOPH RES CO, V221, P117, DOI 10.1006/bbrc.1996.0555; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9	53	70	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14975	14982		10.1074/jbc.M312548200	http://dx.doi.org/10.1074/jbc.M312548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752116	hybrid			2022-12-27	WOS:000220594700061
J	Oikawa, K; Kimura, S; Aoki, N; Atsuta, Y; Takiyama, Y; Nagato, T; Yanai, M; Kobayashi, H; Sato, K; Sasajima, T; Tateno, M				Oikawa, K; Kimura, S; Aoki, N; Atsuta, Y; Takiyama, Y; Nagato, T; Yanai, M; Kobayashi, H; Sato, K; Sasajima, T; Tateno, M			Neuronal calcium sensor protein visinin-like protein-3 interacts with microsomal cytochrome b(5) in a Ca2+-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DESATURATION; LIVER SULFITE OXIDASE; C REDUCTASE; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; BINDING; FAMILY; EXPRESSION; VESICLES; DOMAIN	Visinin-like protein-3, which is one of the neuronal calcium sensors, has been shown to be mainly expressed in cerebellar Purkinje cells, but cellular function of this protein has not yet been elucidated. We examined the tissue distribution of murine visinin-like protein-3 transcripts using real-time reverse transcription-PCR. Visinin-like protein-3 mRNA was found to be expressed in peripheral tissues. Particularly, the expression of the transcript in the thymus was significantly higher than in other peripheral tissues. In addition, B6RVTC1 thymoma cells robustly expressed visinin-like protein-3 mRNA. To identify a target protein of visinin-like protein-3, we performed a pull-down experiment using glutathione S-transferase-tagged visinin-like protein-3 and two-dimensional electrophoresis. We demonstrated that microsomal cytochrome b(5) was a Ca2+-dependent binding partner of visinin-like protein-3. In a co-immunoprecipitation experiment, it was observed that hippocalcin, as well as visinin-like protein-3, could interact with cytochrome b(5). Furthermore, we confirmed that the sequence Val(114)-Tyr(127) at the C-terminal tail of cytochrome b(5) is the minimal structural requirement for binding to visinin-like protein-3. In addition, the loop His(19)-His(25) at the N terminus of visinin-like protein-3 is essential for binding to cytochrome b(5). Microsomal cytochrome b(5) was also shown to be a potential activator of cytochrome P450. The present findings raise the possibility that visinin-like protein-3 may link Ca2+ signaling to the machinery of microsomal monooxygenase complex composed of cytochrome b5, cytochrome P450, and some reductases. This report provides the first evidence of an interaction between visinin-like protein-3 and microsomal cytochrome b(5).	Asahikawa Med Coll, Dept Pathol, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Sch Nursing, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Surg, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Otolaryngol Head & Neck Surg, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College; Asahikawa Medical College; Asahikawa Medical College	Oikawa, K (corresponding author), Asahikawa Med Coll, Dept Pathol, Midorigaoka Higashi 2-1, Asahikawa, Hokkaido 0788510, Japan.	oiken@asahikawa-med.ac.jp						Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; ARINC E, 1987, J BIOL CHEM, V262, P15563; Bernstein HG, 1999, J NEUROCYTOL, V28, P655, DOI 10.1023/A:1007056731551; BILIMORIA MH, 1973, ANN NY ACAD SCI, V212, P428, DOI 10.1111/j.1749-6632.1973.tb47612.x; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; ENOCH HG, 1979, J BIOL CHEM, V254, P6483; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUIARD B, 1977, EUR J BIOCHEM, V74, P181, DOI 10.1111/j.1432-1033.1977.tb11379.x; Hanlon MR, 2000, BIOCHEM J, V352, P117, DOI 10.1042/0264-6021:3520117; HARA T, 1971, J BIOCHEM-TOKYO, V69, P317, DOI 10.1093/oxfordjournals.jbchem.a129469; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLOWAY PW, 1972, BIOCHEMISTRY-US, V11, P3689, DOI 10.1021/bi00770a005; HOLLOWAY PW, 1970, J BIOL CHEM, V245, P1862; HULTQUIST DE, 1974, BIOCHEM BIOPH RES CO, V60, P28, DOI 10.1016/0006-291X(74)90167-3; Ivanov AS, 2000, VOP MED KHIM, V46, P615; Ivings L, 2002, BIOCHEM J, V363, P599, DOI 10.1042/0264-6021:3630599; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; JANSSON I, 1977, ARCH BIOCHEM BIOPHYS, V178, P89, DOI 10.1016/0003-9861(77)90174-6; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; KRAUT N, 1995, ONCOGENE, V10, P1027; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LADOKHIN AS, 1993, BIOCHEMISTRY-US, V32, P6951, DOI 10.1021/bi00078a020; LIVINGSTON DJ, 1985, J BIOL CHEM, V260, P5699; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; Paterlini M, 2000, NEUROSCIENCE, V99, P205, DOI 10.1016/S0306-4522(00)00201-3; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; Qu W, 2001, J BIOL CHEM, V276, P25467, DOI 10.1074/jbc.M100545200; Spilker C, 2000, NEUROSCIENCE, V96, P121, DOI 10.1016/S0306-4522(99)00536-9; Spilker C, 2002, BBA-PROTEINS PROTEOM, V1600, P118, DOI 10.1016/S1570-9639(02)00452-1; STARON K, 1974, ACTA BIOCHIM POL, V21, P55; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9136; TENNYSON J, 1986, J BIOL CHEM, V261, P14196; VERGERES G, 1995, J BIOL CHEM, V270, P3414, DOI 10.1074/jbc.270.7.3414; VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; VISSER L, 1975, BIOCHEMISTRY-US, V14, P1194, DOI 10.1021/bi00677a015; Zhu H, 1999, P NATL ACAD SCI USA, V96, P14742, DOI 10.1073/pnas.96.26.14742; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	54	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15142	15152		10.1074/jbc.M312766200	http://dx.doi.org/10.1074/jbc.M312766200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739275	hybrid, Green Published			2022-12-27	WOS:000220594700080
J	Ogura, T; Noguchi, T; Murai-Takebe, R; Hosooka, T; Honma, N; Kasuga, M				Ogura, T; Noguchi, T; Murai-Takebe, R; Hosooka, T; Honma, N; Kasuga, M			Resistance of B16 melanoma cells to CD47-induced negative regulation of motility as a result of aberrant N-glycosylation of SHPS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; INTEGRIN-ASSOCIATED PROTEIN; FOCAL-ADHESION-KINASE; TRANSMEMBRANE GLYCOPROTEIN; DOWN-REGULATION; SIRP-ALPHA; E-CADHERIN; T-CELL; CD47; ACTIVATION	The adhesion receptor SHPS-1 activates the protein-tyrosine-phosphatase SHP-2 and thereby promotes integrin-mediated reorganization of the cytoskeleton. SHPS-1 also contributes to cell-cell communication through association with CD47. Although functional alteration of SHPS-1 is implicated in cellular transformation, the role of the CD47-SHPS-1 interaction in carcinogenesis has been unclear. A soluble SHPS-1 ligand (CD47-Fc) has now been shown to bind to Melan-a non-tumorigenic melanocytes but not to syngeneic B16F10 melanoma cells. Treatment of B16F10 cells with 1-deoxymannojirimycin, which prevents N-glycan processing, restored the ability of SHPS-1 derived from these cells to bind CD47-Fc in vitro, indicating that aberrant N-glycosylation of SHPS-1 impairs CD47 binding in B16F10 cells. CD47-Fc inhibited the migration of Melan-a cells but not that of B16F10 cells. However, a monoclonal antibody that reacts with SHPS-1 on both Melan-a and B16F10 cells inhibited the migration of both cell types similarly. CD47 binding induced proteasome-mediated degradation of SHPS-1 in a tyrosine phosphorylation-independent manner. Furthermore, overexpression of SHPS-1 reduced the level of tyrosine phosphorylation of focal adhesion kinase, and this effect was reversed by CD47 binding. These results suggest that CD47 binds to and thereby down-regulates SHPS-1 on adjacent cells, resulting in inhibition of cell motility. Resistance to this inhibitory mechanism may contribute to the highly metastatic potential of B16 melanoma.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kirin Brewery Co Ltd, Pharmaceut Res Labs, Gunma 3701295, Japan	Kobe University; Kirin Brewery Company Limited	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	noguchi@med.kobe-u.ac.jp						Adams S, 1998, J IMMUNOL, V161, P1853; Amin ARMR, 2002, ONCOGENE, V21, P8871, DOI 10.1038/sj.onc.1206018; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Cant CA, 2001, CELL MOL LIFE SCI, V58, P117, DOI 10.1007/PL00000771; Comu S, 1997, J NEUROSCI, V17, P8702; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jamal S, 2002, J CLIN INVEST, V110, P443, DOI 10.1172/JCI200213729; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Johnson FM, 1999, J CELL SCI, V112, P2785; Katakura Y, 1999, CYTOTECHNOLOGY, V31, P103, DOI 10.1023/A:1008048928053; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Latour S, 2001, J IMMUNOL, V167, P2547, DOI 10.4049/jimmunol.167.5.2547; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Machida K, 2000, ONCOGENE, V19, P1710, DOI 10.1038/sj.onc.1203497; Manes S, 1999, MOL CELL BIOL, V19, P3125; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Oshima K, 2002, CANCER RES, V62, P3929; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PASSANITI A, 1990, CANCER RES, V50, P7261; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; van den Nieuwenhof IM, 2001, J CELL SCI, V114, P1321; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	53	20	24	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13711	13720		10.1074/jbc.M310276200	http://dx.doi.org/10.1074/jbc.M310276200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14739297	hybrid			2022-12-27	WOS:000220478500054
J	Zhou, YG; Bennett, ER; Kanner, BI				Zhou, YG; Bennett, ER; Kanner, BI			The aqueous accessibility in the external half of transmembrane domain I of the GABA transporter GAT-1 is modulated by its Ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; RAT-BRAIN; SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; XENOPUS OOCYTES; CALCIUM-PUMP; NEUROTRANSMITTER; EXPRESSION; RESIDUES; SODIUM	The sodium- and chloride-dependent gamma-aminobutyric acid (GABA) transporter GAT-1 is the first identified member of a family of transporters, which maintain low synaptic neurotransmitter levels and thereby enable efficient synaptic transmission. To obtain evidence for the idea that the highly conserved transmembrane domain I (TMD I) participates in the permeation pathway, we have determined the impact of impermeant methanethiosulfonate (MTS) reagents on cysteine residues engineered into this domain. As a background the essentially insensitive but fully active C74A mutant has been used. Transport activity of mutants with a cysteine introduced cytoplasmic to glycine 63 is largely unaffected and is resistant to the impermeant MTS reagents. Conversely, transport activity in mutants extracellular to glycine 63 is strongly impacted. Nevertheless, transport activity could be measured in all but three mutants: G65C, N66C, and R69C. In each of the six active cysteine mutants the activity is highly sensitive to the impermeant MTS reagents. This sensitivity is potentiated by sodium in L64C, F70C, and Y72C, but is protected in V67C and P71C. GABA protects in L64C, W68C, F70C, and P71C. The non-transportable GABA analogue SKF100330A also protects in L64C, W68C, and P71C as well as V67C, but strikingly potentiates inhibition in F70C. Although cysteine substitution in this region may have perturbed the native structure of GAT-1, our observations, taken together with the recently published accessibility study on the related serotonin transporter ( Henry, L. K., Adkins, E. M., Han, Q., and Blakely, R. D. (2003) J. Biol. Chem. 278, 37052 - 37063), suggest that the extracellular part of TMD I is conformationally sensitive, lines the permeation pathway, and forms a more extended structure than expected from a membrane-embedded alpha-helix.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il	Bennett, Estelle R/A-5067-2017					ALI FE, 1985, J MED CHEM, V28, P653, DOI 10.1021/jm50001a020; Barker EL, 1999, J NEUROSCI, V19, P4705; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Bennett ER, 2000, J BIOL CHEM, V275, P34106, DOI 10.1074/jbc.M004229200; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Nelson N, 1998, J NEUROCHEM, V71, P1785; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WANG JB, 1995, J NEUROCHEM, V64, P1416; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	35	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13800	13808		10.1074/jbc.M311579200	http://dx.doi.org/10.1074/jbc.M311579200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14744863	hybrid			2022-12-27	WOS:000220478500065
J	Levengood, J; Ataide, SF; Roy, H; Ibba, M				Levengood, J; Ataide, SF; Roy, H; Ibba, M			Divergence in noncognate amino acid recognition between class I and class II lysyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LYSINE; GENE; BINDING; AMINOACYLATION; SPECIFICITY; BACTERIA	Lysine insertion during coded protein synthesis requires lysyl-tRNALys, which is synthesized by lysyl-tRNA synthetase (LysRS). Two unrelated forms of LysRS are known: LysRS2, which is found in eukaryotes, most bacteria, and a few archaea, and LysRS1, which is found in most archaea and a few bacteria. To compare amino acid recognition between the two forms of LysRS, the effects of L-lysine analogues on aminoacylation were investigated. Both enzymes showed stereospecificity toward the L-enantiomer of lysine and discriminated against noncognate amino acids with different R-groups (arginine, ornithine). Lysine analogues containing substitutions at other positions were generally most effective as inhibitors of LysRS2. For example, the K-i values for aminoacylation of S-(2-aminoethyl)-L-cysteine and L-lysinamide were over 180-fold lower with LysRS2 than with LysRS1. Of the other analogues tested, only gamma-aminobutyric acid showed a significantly higher Ki for LysRS2 than LysRS1. These data indicate that the lysine-binding site is more open in LysRS2 than in LysRS1, in agreement with previous structural studies. The physiological significance of divergent amino acid recognition was reflected by the in vivo resistance to growth inhibition imparted by LysRS1 against S-(2-aminoethyl)-L-cysteine and LysRS2 against gamma-aminobutyric acid. These differences in resistance to naturally occurring noncognate amino acids suggest the distribution of LysRS1 and LysRS2 contributes to quality control during protein synthesis. In addition, the specific inhibition of LysRS1 indicates it is a potential drug target.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Ibba, M (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.	ibba.1@osu.edu	Roy, Hemant/AAC-9096-2020	F Ataide, Sandro/0000-0003-1807-5708				Ambrogelly A, 2002, J BACTERIOL, V184, P4594, DOI 10.1128/JB.184.16.4594-4600.2002; Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; Asahara H, 2002, P NATL ACAD SCI USA, V99, P3499, DOI 10.1073/pnas.052028599; BATURINA ID, 1972, FEBS LETT, V22, P235, DOI 10.1016/0014-5793(72)80053-X; BREVET A, 1995, J BIOL CHEM, V270, P14439, DOI 10.1074/jbc.270.24.14439; CHEN JS, 1994, J BACTERIOL, V176, P2699, DOI 10.1128/JB.176.9.2699-2705.1994; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Christner P, 1996, BBA-PROTEIN STRUCT M, V1294, P37, DOI 10.1016/0167-4838(95)00261-8; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; de Pouplana LR, 2001, TRENDS BIOCHEM SCI, V26, P591, DOI 10.1016/S0968-0004(01)01932-6; de Pouplana LR, 2001, CELL, V104, P191, DOI 10.1016/S0092-8674(01)00204-5; Delagoutte B, 2000, EMBO J, V19, P5599, DOI 10.1093/emboj/19.21.5599; ERIANI G, 1991, NUCLEIC ACIDS RES, V19, P265, DOI 10.1093/nar/19.2.265; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; Grundy FJ, 2003, P NATL ACAD SCI USA, V100, P12057, DOI 10.1073/pnas.2133705100; Harwood C.R., 1990, MOL BIOL METHODS BAC; Hendrickson TL, 2003, MOL B INT U, P34; HUGHES SJ, 2003, BMC BIOCH; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 1999, P NATL ACAD SCI USA, V96, P418, DOI 10.1073/pnas.96.2.418; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; Ibba M, 2000, TRENDS BIOCHEM SCI, V25, P311, DOI 10.1016/S0968-0004(00)01600-5; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; Jester BC, 2003, P NATL ACAD SCI USA, V100, P14351, DOI 10.1073/pnas.2036253100; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Liu JH, 1998, BIOCHEMISTRY-US, V37, P9836, DOI 10.1021/bi980704+; O'Donoghue P, 2003, MICROBIOL MOL BIOL R, V67, P550, DOI 10.1128/MMBR.67.4.550-573.2003; Onesti S, 2000, BIOCHEMISTRY-US, V39, P12853, DOI 10.1021/bi001487r; Polycarpo C, 2003, MOL CELL, V12, P287, DOI 10.1016/S1097-2765(03)00280-6; Raczniak G, 2001, TOXICOLOGY, V160, P181, DOI 10.1016/S0300-483X(00)00454-6; RAUNIO R, 1970, ACTA CHEM SCAND, V24, P2737, DOI 10.3891/acta.chem.scand.24-2737; Roe AJ, 1998, J BACTERIOL, V180, P767, DOI 10.1128/JB.180.4.767-772.1998; Sekine S, 2003, EMBO J, V22, P676, DOI 10.1093/emboj/cdg053; Sherlin LD, 2003, STRUCTURE, V11, P591, DOI 10.1016/S0969-2126(03)00074-1; Soll D, 2000, P NATL ACAD SCI USA, V97, P14224, DOI 10.1073/pnas.97.26.14224; STERN R, 1965, BIOCHEM Z, V342, P400; Sudarsan N, 2003, GENE DEV, V17, P2688, DOI 10.1101/gad.1140003; Takita T, 1996, J BIOCHEM-TOKYO, V119, P680; TEMPEST DW, 1970, J GEN MICROBIOL, V64, P171, DOI 10.1099/00221287-64-2-171; Terada T, 2002, NAT STRUCT BIOL, V9, P257, DOI 10.1038/nsb777; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799	44	36	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17707	17714		10.1074/jbc.M313665200	http://dx.doi.org/10.1074/jbc.M313665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14747465	hybrid, Green Published			2022-12-27	WOS:000220870400101
J	Cui, J; Matkovich, SJ; deSouza, N; Li, SH; Rosemblit, N; Marks, AR				Cui, J; Matkovich, SJ; deSouza, N; Li, SH; Rosemblit, N; Marks, AR			Regulation of the type 1 inositol 1,4,5-trisphosphate receptor by phosphorylation at tyrosine 353	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JURKAT T-LYMPHOCYTES; LIGAND-BINDING SITE; SIGNAL-TRANSDUCTION; CELL-ACTIVATION; CHANNEL; KINASE	The inositol 1,4,5-trisphosphate receptor (IP3R) plays an essential role in Ca2+ signaling during lymphocyte activation. Engagement of the T cell or B cell receptor by antigen initiates a signal transduction cascade that leads to tyrosine phosphorylation of IP3R by Src family nonreceptor protein tyrosine kinases, including Fyn. However, the effect of tyrosine phosphorylation on the IP3R and subsequent Ca2+ release is poorly understood. We have identified tyrosine 353 (Tyr(353)) in the IP3-binding domain of type 1 IP3R (IP(3)R1) as a phosphorylation site for Fyn both in vitro and in vivo. We have developed a phosphoepitope-specific antibody and shown that IP(3)R1-Y353 becomes phosphorylated during T cell and B cell activation. Furthermore, tyrosine phosphorylation of IP(3)R1 increased IP3 binding at low IP3 concentrations (<10 nM). Using wild-type IP(3)R1 or an IP(3)R1-Y353F mutant that cannot be tyrosine phosphorylated at Tyr(353) or expressed in IP3R-deficient DT40 B cells, we demonstrated that tyrosine phosphorylation of Tyr(353) permits prolonged intracellular Ca2+ release during B cell activation. Taken together, these data suggest that one function of tyrosine phosphorylation of IP(3)R1-Y353 is to enhance Ca2+ signaling in lymphocytes by increasing the sensitivity of IP(3)R1 to activation by low levels of IP3.	Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Columbia University	Marks, AR (corresponding author), Columbia Univ Coll Phys & Surg, Dept Physiol, 9-401,630 W 168th St, New York, NY 10032 USA.	arm42@columbia.edu	Matkovich, Scot J/B-9077-2009; Matkovich, Scot J/AFP-0908-2022	Matkovich, Scot J/0000-0002-7398-6857; Matkovich, Scot J/0000-0002-7398-6857	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039794] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI39794] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 2001, J BIOL CHEM, V276, P34722, DOI 10.1074/jbc.M100715200; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; Kennedy JS, 1999, CELL CALCIUM, V26, P227, DOI 10.1054/ceca.1999.0069; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Riley AM, 2002, J BIOL CHEM, V277, P40290, DOI 10.1074/jbc.M206925200; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	23	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16311	16316		10.1074/jbc.M400206200	http://dx.doi.org/10.1074/jbc.M400206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761954	hybrid			2022-12-27	WOS:000220747900076
J	Mandell, KJ; McCall, IC; Parkos, CA				Mandell, KJ; McCall, IC; Parkos, CA			Involvement of the junctional adhesion molecule-1 (JAM1) homodimer interface in regulation of epithelial barrier function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSENDOTHELIAL MIGRATION; INTERACTS; CELLS; IDENTIFICATION; ANTIBODY; PROTEIN; BINDING; ZO-1	Junctional adhesion molecule-1 (JAM1) is a tight junction-associated immunoglobulin superfamily protein implicated in the regulation of tight junctions and leukocyte transmigration. The structural basis for the function of JAM1 has yet to be determined. Here we provide evidence that JAM1 homodimer formation is important for its function in epithelial cells. Experiments were conducted to determine the effects of a panel of JAM1 monoclonal antibodies on epithelial barrier recovery after transient disruption by calcium switch. Two monoclonal antibodies were observed to inhibit barrier recovery in contrast to another monoclonal antibody that had no effect. Epitope mapping by phage display revealed that both inhibitory antibodies bind to a region of JAM1 located within the N-terminal Ig-like loop (residues 111-123). Competition experiments with synthetic peptides and site-directed mutagenesis confirmed the location of this epitope. Analysis of the crystal structure of JAM1 revealed that this epitope includes residues within the putative homodimer interface, and one of the two inhibitory antibodies was then shown to block JAM1 homodimer formation in vitro. Finally, mutations within the homodimer interface were shown to prevent enrichment of JAM1 at points of cell contact, presumably by interference with homophilic interactions. These findings suggest that homodimer formation may be important for localization of JAM1 at tight junctions and for regulation of epithelial barrier function.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA	Emory University	Mandell, KJ (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, 615 Michael St,Rm 125, Atlanta, GA 30322 USA.	kjmande@emory.edu	Parkos, Charles a/B-3896-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054229, R01HL054229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061379, R24DK064399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54229] Funding Source: Medline; NIDDK NIH HHS [R01 DK61379, DK64399] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Babinska A, 2002, THROMB HAEMOSTASIS, V87, P712, DOI 10.1055/s-0037-1613070; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; Cunningham SA, 2002, J BIOL CHEM, V277, P27589, DOI 10.1074/jbc.C200331200; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Ebnet K, 2000, J BIOL CHEM, V275, P27979; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Johnson-Leger CA, 2002, BLOOD, V100, P2479, DOI 10.1182/blood-2001-11-0098; Kostrewa D, 2001, EMBO J, V20, P4391, DOI 10.1093/emboj/20.16.4391; Liang TW, 2002, J IMMUNOL, V168, P1618, DOI 10.4049/jimmunol.168.4.1618; Liang TW, 2000, AM J PHYSIOL-CELL PH, V279, pC1733, DOI 10.1152/ajpcell.2000.279.6.C1733; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Liu Y, 2000, J CELL SCI, V113, P2363; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mazzucchelli L, 1999, BLOOD, V93, P1738, DOI 10.1182/blood.V93.5.1738.405a18_1738_1748; Naik MU, 2003, BLOOD, V102, P2108, DOI 10.1182/blood-2003-04-1114; NAIK UP, 1995, BIOCHEM J, V310, P155, DOI 10.1042/bj3100155; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Prota AE, 2003, P NATL ACAD SCI USA, V100, P5366, DOI 10.1073/pnas.0937718100; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Williams LA, 1999, MOL IMMUNOL, V36, P1175, DOI 10.1016/S0161-5890(99)00122-4	26	97	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16254	16262		10.1074/jbc.M309483200	http://dx.doi.org/10.1074/jbc.M309483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14749337	hybrid			2022-12-27	WOS:000220747900069
J	Morel, F; Rauch, C; Petit, E; Piton, A; Theret, N; Coles, B; Guillouzo, A				Morel, F; Rauch, C; Petit, E; Piton, A; Theret, N; Coles, B; Guillouzo, A			Gene and protein characterization of the human glutathione S-transferase Kappa and evidence for a peroxisomal localization*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-HYDROXYCHROMENE-2-CARBOXYLATE ISOMERASE; CHROMOSOMAL LOCALIZATION; GENOMIC ORGANIZATION; PEROXIDASE ACTIVITY; METABOLISM; SEQUENCE; CLUSTER; BINDING; ENZYME; ALPHA	Kappa class glutathione S-transferase (GST) cDNA sequences have been identified in rat, mouse, and human. In the present study, we determined the structure and chromosomal location of the human GST Kappa 1 (hGSTK1) gene, characterized the protein, and demonstrated its subcellular localization. The human gene spans similar to5 kb, has 8 exons, and maps onto chromosome 7q34. The 5'-flanking region lacks TATA or CCAAT boxes, but there is an initiator element overlapping the transcription start site. hGSTK1 amino acid sequence showed homology to bacterial 2-hydroxychromene-2-carboxylate isomerase, an enzyme involved in naphthalene degradation pathway. hGSTK1 mRNA was expressed in all of the organs examined. Subcellular fractionation of HepG2 cells showed that the protein was located in peroxisomes and mitochondria and was not detectable in cytoplasm. The peroxisomal localization was confirmed by transfection of HepG2 cells with a plasmid coding a green fluorescent protein fused in-frame to the N terminus of hGSTK1. The C terminus of hGSTK1 was essential for localization of the protein to peroxisomes, and the C-terminal sequence Ala-Arg-Leu represents a peroxisome targeting signal. This is the first time that a human GST has been found in peroxisomes, suggesting a new function for this family of enzymes.	Univ Rennes 1, INSERM, U456, F-35043 Rennes, France; Natl Ctr Toxicol Res, Div Mol Epidemiol, Jefferson, AR 72079 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; US Food & Drug Administration (FDA)	Morel, F (corresponding author), Univ Rennes 1, INSERM, U456, 2 Ave Prof Leon Bernard, F-35043 Rennes, France.	Fabrice.Morel@rennes.inserm.fr	theret, nathalie/ABG-6780-2020; GUILLOUZO, Andre/Z-2373-2019; Theret, Nathalie/I-2871-2015; Piton, Amelie/F-1201-2013	theret, nathalie/0000-0002-5857-7828; Theret, Nathalie/0000-0002-5857-7828; Piton, Amelie/0000-0003-0408-7468				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Blackburn AC, 1998, CYTOGENET CELL GENET, V83, P109, DOI 10.1159/000015145; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Coggan M, 1998, BIOCHEM J, V334, P617, DOI 10.1042/bj3340617; DENOME SA, 1993, J BACTERIOL, V175, P6890, DOI 10.1128/jb.175.21.6890-6901.1993; Desmots F, 2002, J BIOL CHEM, V277, P17892, DOI 10.1074/jbc.M112351200; Desmots F, 1998, BIOCHEM J, V336, P437, DOI 10.1042/bj3360437; EATON RW, 1994, J BACTERIOL, V176, P7757, DOI 10.1128/JB.176.24.7757-7762.1994; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Goto S, 2001, FASEB J, V15, P2702, DOI 10.1096/fj.01-0376com; HARRIS JM, 1991, BIOCHEM J, V278, P137, DOI 10.1042/bj2780137; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Holroyd C, 2001, FEBS LETT, V501, P6, DOI 10.1016/S0014-5793(01)02617-5; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; Johansson AS, 2002, J BIOL CHEM, V277, P16648, DOI 10.1074/jbc.M201062200; Jowsey IR, 2003, BIOCHEM J, V373, P559, DOI 10.1042/BJ20030415; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kanaoka Y, 2000, EUR J BIOCHEM, V267, P3315, DOI 10.1046/j.1432-1327.2000.01362.x; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; Ladner JE, 2004, BIOCHEMISTRY-US, V43, P352, DOI 10.1021/bi035832z; Laurie AD, 1999, J BACTERIOL, V181, P531, DOI 10.1128/JB.181.2.531-540.1999; Masters CJ, 1998, BIOCHEM PHARMACOL, V56, P667, DOI 10.1016/S0006-2952(98)00116-6; Morel F, 2002, PHARMACOGENETICS, V12, P277, DOI 10.1097/00008571-200206000-00003; Oakley AJ, 1999, J MOL BIOL, V291, P913, DOI 10.1006/jmbi.1999.3029; Oakley AJ, 1997, FEBS LETT, V419, P32, DOI 10.1016/S0014-5793(97)01424-5; Ohmoto T, 1998, J BIOCHEM-TOKYO, V124, P591, DOI 10.1093/oxfordjournals.jbchem.a022152; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Raza H, 2002, BIOCHEM J, V366, P45, DOI 10.1042/BJ20020533; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Silva C, 1999, EUR J BIOCHEM, V266, P143, DOI 10.1046/j.1432-1327.1999.00838.x; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOBOLL S, 1995, BIOCHEM J, V311, P889, DOI 10.1042/bj3110889; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wanders RJA, 2000, BIOCHEM SOC T, V28, P141, DOI 10.1042/bst0280141; Xu SJ, 1998, J BIOL CHEM, V273, P3517, DOI 10.1074/jbc.273.6.3517	38	103	109	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16246	16253		10.1074/jbc.M313357200	http://dx.doi.org/10.1074/jbc.M313357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14742434	hybrid			2022-12-27	WOS:000220747900068
J	Carniol, K; Eichenberger, P; Losick, R				Carniol, K; Eichenberger, P; Losick, R			A threshold mechanism governing activation of the developmental regulatory protein sigma(F) in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SIGMA(F); CELL-SPECIFIC TRANSCRIPTION; ANTISIGMA FACTOR SPOIIAB; DIFFERENTIATION PROTEIN SPOIIE; DUPLICATED SPORULATION GENES; ASYMMETRIC SEPTATION; CRYSTAL-STRUCTURE; DIVISION PROTEIN; SEPTUM FORMATION; PHOSPHATASE	The RNA polymerase sigma factor sigma(F) is a developmental regulatory protein that is activated in a cell-specific manner following the formation of the polar septum during the process of spore formation in the bacterium Bacillus subtilis. Activation of sigma(F) depends on the membrane-bound phosphatase SpoIIE, which localizes to the septum, and on the formation of the polar septum itself. SpoIIE is responsible for dephosphorylating and thereby activating the phosphoprotein SpoIIAA, which, in turn, triggers the release of sigma(F) from the anti-sigma(F) factor SpoIIAB. Paradoxically, however, the presence of unphosphorylated SpoIIAA is insufficient to cause sigma(F) activation as SpoIIAA reaches substantial levels in mutants blocked in polar septation. We now describe mutants of SpoIIE, SpoIIAA, and SpoIIAB that break the dependence of sigma(F) activation on polar division. Analysis of these mutants indicates that unphosphorylated SpoIIAA must reach a threshold concentration in order to trigger the release of sigma(F) from SpoIIAB. Evidence is presented that this threshold is created by the action of SpoIIAB, which can form an alternative, long lived complex with SpoIIAA. We propose that formation of the SpoIIAA-SpoIIAB complex serves as a sink that traps SpoIIAA in an inactive state and that only when unphosphorylated SpoIIAA is in excess to the sink does activation of sigma(F) take place.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 01238 USA	Harvard University	Losick, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 01238 USA.	losick@mcb.harvard.edu		Eichenberger, Patrick/0000-0002-6027-9651	NIGMS NIH HHS [GM184458] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler E, 1997, MOL MICROBIOL, V23, P57, DOI 10.1046/j.1365-2958.1997.1801552.x; ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; Arigoni F, 1999, MOL MICROBIOL, V31, P1407, DOI 10.1046/j.1365-2958.1999.01282.x; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; Arigoni F, 1996, P NATL ACAD SCI USA, V93, P3238, DOI 10.1073/pnas.93.8.3238; Barak I, 1996, J BACTERIOL, V178, P4984, DOI 10.1128/jb.178.16.4984-4989.1996; Barak I, 1996, MOL MICROBIOL, V19, P1047, DOI 10.1046/j.1365-2958.1996.433963.x; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; Campbell EA, 2002, CELL, V108, P795, DOI 10.1016/S0092-8674(02)00662-1; Daniel RA, 1998, MOL MICROBIOL, V29, P593, DOI 10.1046/j.1365-2958.1998.00954.x; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; Dworkin J, 2001, CELL, V107, P339, DOI 10.1016/S0092-8674(01)00528-1; ERRINGTON J, 1985, FEBS LETT, V188, P184, DOI 10.1016/0014-5793(85)80368-9; Feucht A, 2002, MOL MICROBIOL, V45, P1119, DOI 10.1046/j.1365-2958.2002.03082.x; Feucht A, 1996, GENE DEV, V10, P794, DOI 10.1101/gad.10.7.794; Feucht A, 1999, MOL MICROBIOL, V33, P1015, DOI 10.1046/j.1365-2958.1999.01543.x; FORT P, 1984, J GEN MICROBIOL, V130, P2147; Frandsen N, 1999, GENE DEV, V13, P394, DOI 10.1101/gad.13.4.394; Garsin DA, 1998, J MOL BIOL, V284, P569, DOI 10.1006/jmbi.1998.2202; Garsin DA, 1998, J MOL BIOL, V284, P557, DOI 10.1006/jmbi.1998.2201; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; Gueiros FJ, 2002, GENE DEV, V16, P2544, DOI 10.1101/gad.1014102; GueroutFleury AM, 1996, GENE, V180, P57, DOI 10.1016/S0378-1119(96)00404-0; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; Harwood C.R., 1990, MOL BIOL METHODS BAC; Hilbert DW, 2003, J BACTERIOL, V185, P1590, DOI 10.1128/JB.185.5.1590-1598.2003; Ho MS, 2003, J BIOL CHEM, V278, P20898, DOI 10.1074/jbc.M302305200; KARMAZYNCAMPELLI C, 1992, BIOCHIMIE, V74, P689, DOI 10.1016/0300-9084(92)90141-Z; Kemp JT, 2002, J BACTERIOL, V184, P3856, DOI 10.1128/JB.184.14.3856-3863.2002; King N, 1999, GENE DEV, V13, P1156, DOI 10.1101/gad.13.9.1156; Kovacs H, 1998, P NATL ACAD SCI USA, V95, P5067, DOI 10.1073/pnas.95.9.5067; LEVIN PA, 1994, J BACTERIOL, V176, P1451, DOI 10.1128/jb.176.5.1451-1459.1994; Lewis PJ, 1996, GENES CELLS, V1, P881, DOI 10.1046/j.1365-2443.1996.750275.x; Lucet I, 1999, J BACTERIOL, V181, P3242, DOI 10.1128/JB.181.10.3242-3245.1999; Lucet I, 2000, EMBO J, V19, P1467, DOI 10.1093/emboj/19.7.1467; Magnin T, 1997, J BACTERIOL, V179, P3922, DOI 10.1128/jb.179.12.3922-3927.1997; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; NAJAFI SMA, 1995, J BACTERIOL, V177, P2912, DOI 10.1128/jb.177.10.2912-2913.1995; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; Pan Q, 2001, MOL CELL, V8, P873, DOI 10.1016/S1097-2765(01)00362-8; Piggot P, 2002, BACILLUS SUBTILIS IT, P483; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; STRAGIER P, 1986, FEBS LETT, V195, P9, DOI 10.1016/0014-5793(86)80119-3; VELLANOWETH RL, 1992, MOL MICROBIOL, V6, P1105, DOI 10.1111/j.1365-2958.1992.tb01548.x; Wu LJ, 1998, GENE DEV, V12, P1371, DOI 10.1101/gad.12.9.1371; YOUNGMAN P, 1984, PLASMID, V12, P1, DOI 10.1016/0147-619X(84)90061-1	52	37	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14860	14870		10.1074/jbc.M314274200	http://dx.doi.org/10.1074/jbc.M314274200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744853	hybrid			2022-12-27	WOS:000220594700047
J	Minagawa, A; Takaku, H; Takagi, M; Nashimoto, M				Minagawa, A; Takaku, H; Takagi, M; Nashimoto, M			A novel endonucleolytic mechanism to generate the CCA 3 ' termini of tRNA molecules in Thermotoga maritima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER SUSCEPTIBILITY GENE; PROCESSING ENDORIBONUCLEASE; ESCHERICHIA-COLI; GENOME SEQUENCE; PRECURSORS; CLEAVAGE; EXORIBONUCLEASES; PURIFICATION; MATURATION; 3'-TRNASE	The tRNA 3'-terminal CCA sequence is essential for aminoacylation of the tRNAs and for translation on the ribosome. The tRNAs are transcribed as larger precursor molecules containing 5' and 3' extra sequences. In the tRNAs that do not have the encoded CCA, the 3' extra sequence after the discriminator nucleotide is usually cleaved off by the tRNA 3' processing endoribonuclease (3' tRNase, or RNase Z), and the 3'-terminal CCA residues are added thereto. Here we analyzed Thermotoga maritima 3' tRNase for enzymatic properties using various pre-tRNAs from T. maritima, in which all 46 tRNA genes encode CCA with only one exception. We found that the enzyme has the unprecedented activity that cleaves CCA-containing pre-tRNAs precisely after the CCA sequence, not after the discriminator. The assays for pre-tRNA variants suggest that the CA residues at nucleotides 75 and 76 are required for the enzyme to cleave pre-tRNAs after A at nucleotide 76 and that the cleavage occurs after nucleotide 75 if the sequence is not CA. Intriguingly, the pre-tRNA(Met) that is the only T. maritima pre-tRNA without the encoded CCA was cleaved after the discriminator. The kinetics data imply the existence of a CCA binding domain in T. maritima 3' tRNase. We also identified two amino acid residues critical for the cleavage site selection and several residues essential for the catalysis. Analysis of cleavage sites by 3' tRNases from another eubacteria Escherichia coli and two archaea Thermoplasma acidophilum and Pyrobaculum aerophilum corroborates the importance of the two amino acid residues for the cleavage site selection.	Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Niigata 9568603, Japan	Niigata University	Nashimoto, M (corresponding author), Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Niigata 9568603, Japan.	mnashimoto@niigatayakudai.jp						CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DEUTSCHER MP, 1974, J BIOL CHEM, V249, P6696; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Levinger L, 1998, J BIOL CHEM, V273, P1015, DOI 10.1074/jbc.273.2.1015; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mohan A, 1999, RNA, V5, P245, DOI 10.1017/S1355838299981256; Nashimoto M, 1999, J MOL BIOL, V287, P727, DOI 10.1006/jmbi.1999.2639; Nashimoto M, 1997, NUCLEIC ACIDS RES, V25, P1148, DOI 10.1093/nar/25.6.1148; Nashimoto M, 1999, NUCLEIC ACIDS RES, V27, P2770, DOI 10.1093/nar/27.13.2770; Nashimoto M, 2001, J MOL BIOL, V312, P975, DOI 10.1006/jmbi.2001.5026; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; OOMMEN A, 1992, MOL CELL BIOL, V12, P865, DOI 10.1128/MCB.12.2.865; Papadimitriou A, 1996, EUR J BIOCHEM, V242, P747, DOI 10.1111/j.1432-1033.1996.0747r.x; Paul R, 2001, NUCLEIC ACIDS RES, V29, P880, DOI 10.1093/nar/29.4.880; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; Schiffer S, 2003, BIOL CHEM, V384, P333, DOI 10.1515/BC.2003.039; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schurer H, 2001, BIOL CHEM, V382, P1147, DOI 10.1515/BC.2001.144; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; TAMURA K, 1994, J BIOL CHEM, V269, P22173; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomita K, 2002, J BIOL CHEM, V277, P48192, DOI 10.1074/jbc.M207527200; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	34	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15688	15697		10.1074/jbc.M313951200	http://dx.doi.org/10.1074/jbc.M313951200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749326	hybrid			2022-12-27	WOS:000220594700142
J	Sasaoka, T; Wada, T; Fukui, K; Murakami, S; Ishihara, H; Suzuki, R; Tobe, K; Kadowaki, T; Kobayashi, M				Sasaoka, T; Wada, T; Fukui, K; Murakami, S; Ishihara, H; Suzuki, R; Tobe, K; Kadowaki, T; Kobayashi, M			SH2-containing inositol phosphatase 2 predominantly regulates Akt2, and not Akt1, phosphorylation at the plasma membrane in response to insulin in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; RECEPTOR SUBSTRATE-1; POLYPHOSPHATE 5-PHOSPHATASE; MICE LACKING; GLUT4 TRANSLOCATION; NEGATIVE REGULATION; GROWTH-RETARDATION; BROWN ADIPOCYTES; GLUCOSE-UPTAKE; RESISTANCE	SH2-containing inositol phosphatase 2 (SHIP2) is a physiologically important negative regulator of insulin signaling by hydrolyzing the phosphatidylinositol (PI) 3-kinase product PI 3,4,5-trisphosphate in the target tissues of insulin. Targeted disruption of the SHIP2 gene in mice resulted in increased insulin sensitivity without affecting biological systems other than insulin signaling. Therefore, we investigated the molecular mechanisms by which SHIP2 specifically regulates insulin-induced metabolic signaling in 3T3-L1 adipocytes. Insulin-induced phosphorylation of Akt, one of the molecules downstream of PI3-kinase, was inhibited by expression of wild-type SHIP2, whereas it was increased by expression of 5'-phosphatase- defective (DeltaIP) SHIP2 in whole cell lysates. The regulatory effect of SHIP2 was mainly seen in the plasma membrane (PM) and low density microsomes but not in the cytosol. In this regard, following insulin stimulation, a proportion of Akt2, and not Akt1, appeared to redistribute from the cytosol to the PM. Thus, insulin-induced phosphorylation of Akt2 at the PM was predominantly regulated by SHIP2, whereas the phosphorylation of Akt1 was only minimally affected. Interestingly, insulin also elicited a subcellular redistribution of both wild-type and DeltaIP-SHIP2 from the cytosol to the PM. The degree of this redistribution was inhibited in part by pretreatment with PI3-kinase inhibitor. Although the expression of a constitutively active form of PI3-kinase myr-p110 also elicited a subcellular redistribution of SHIP2 to the PM, expression of SHIP2 appeared to affect the myr-p110-induced phosphorylation, and not the translocation, of Akt2. Furthermore, insulin-induced phosphorylation of Akt was effectively regulated by SHIP2 in embryonic fibroblasts derived from knockout mice lacking either insulin receptor substrate-1 or insulin receptor substrate-2. These results indicate that insulin specifically stimulates the redistribution of SHIP2 from the cytosol to the PM independent of 5'-phosphatase activity, thereby regulating the insulin-induced translocation and phosphorylation of Akt2 at the PM.	Toyama Med & Pharmaceut Univ, Dept Clin Pharmacol, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Dept Internal Med 1, Toyama 9300194, Japan; Sainou Hosp, Toyama 9300887, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan	University of Toyama; University of Toyama; University of Tokyo	Sasaoka, T (corresponding author), Toyama Med & Pharmaceut Univ, Dept Clin Pharmacol, 2630 Sugitani, Toyama 9300194, Japan.	tsasaoka-tym@umin.ac.jp	Wada, Tsutomu/AAY-4450-2020; Suzuki, Ryo/AAA-2736-2019	Wada, Tsutomu/0000-0001-5819-8556; Suzuki, Ryo/0000-0002-2965-6906				Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hori H, 2002, DIABETES, V51, P2387, DOI 10.2337/diabetes.51.8.2387; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; Ishihara H, 2002, MOL ENDOCRINOL, V16, P2371, DOI 10.1210/me.2002-0083; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; Marion E, 2002, DIABETES, V51, P2012, DOI 10.2337/diabetes.51.7.2012; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sasaoka T, 2001, DIABETOLOGIA, V44, P1258, DOI 10.1007/s001250100645; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Vandenbroere I, 2003, BIOCHEM BIOPH RES CO, V300, P494, DOI 10.1016/S0006-291X(02)02894-2; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	47	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14835	14843		10.1074/jbc.M311534200	http://dx.doi.org/10.1074/jbc.M311534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744864	hybrid			2022-12-27	WOS:000220594700044
J	Uchida, T; Rossignol, F; Matthay, MA; Mounier, R; Couette, S; Clottes, E; Clerici, C				Uchida, T; Rossignol, F; Matthay, MA; Mounier, R; Couette, S; Clottes, E; Clerici, C			Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha expression in lung epithelial cells - Implication of natural antisense HIF-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL PAS DOMAIN; TRANSCRIPTION FACTOR; PROLYL HYDROXYLATION/; VEGF EXPRESSION; FACTOR-ALPHA; HIF-ALPHA; FACTOR-1-ALPHA; PROTEIN-1; FAMILY; DESTRUCTION	Transcriptional adaptations to hypoxia are mediated by hypoxia-inducible factor (HIF)-1, a heterodimer of HIF-alpha and aryl hydrocarbon receptor nuclear translocator subunits. The HIF-1alpha and HIF-2alpha subunits both undergo rapid hypoxia-induced protein stabilization and bind identical target DNA sequences. When coexpressed in similar cell types, discriminating control mechanisms may exist for their regulation, explaining why HIF-1alpha and HIF-2alpha do not substitute during embryogenesis. We report that, in a human lung epithelial cell line (A549), HIF-1alpha and HIF-2alpha proteins were similarly induced by acute hypoxia (4 h, 0.5% O-2) at the translational or post-translational level. However, HIF-1alpha and HIF-2alpha were differentially regulated by prolonged hypoxia (12 h, 0.5% O-2) since HIF-1alpha protein stimulation disappeared because of a reduction in its mRNA stability, whereas HIF-2alpha protein stimulation remained high and stable. Prolonged hypoxia also induced an increase in the quantity of natural antisense HIF-1alpha(aHIF), whose gene promoter contains several putative hypoxia response elements to which (as we confirm here) the HIF-1alpha or HIF-2alpha protein can bind. Finally, transient transfection of A549 cells by dominant-negative HIF-2alpha, also acting as a dominant-negative for HIF-1alpha, prevented both the decrease in the HIF-1alpha protein and the increase in the aHIF transcript. Taken together, these data indicate that, during prolonged hypoxia, HIF-alpha proteins negatively regulate HIF-1alpha expression through an increase in aHIF and destabilization of HIF-1alpha mRNA. This transregulation between HIF-1alpha and HIF-2alpha during hypoxia likely conveys target gene specificity.	Univ Paris 07, Fac Med Xavier Bichat, INSERM, U426,Dept Physiol, F-75870 Paris 18, France; Fac Med, Lab Inter Univ Biol Act Phys & Sport, F-63001 Clermont Ferrand, France; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med & Anesthesia, San Francisco, CA 94143 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Clerici, C (corresponding author), Univ Paris 07, Fac Med Xavier Bichat, INSERM, U426,Dept Physiol, 16 Rue Henri Huchard,BP 416, F-75870 Paris 18, France.	christine.clerici@lmr.ap-hop-paris.fr	Clottes, Eric/C-6088-2011					Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Escoubet B, 1999, BIOCHEM BIOPH RES CO, V266, P156, DOI 10.1006/bbrc.1999.1798; Graven KK, 2003, BBA-GENE STRUCT EXPR, V1626, P10, DOI 10.1016/S0167-4781(03)00049-6; Hanze J, 2003, BIOCHEM BIOPH RES CO, V312, P571, DOI 10.1016/j.bbrc.2003.10.153; Heidbreder M, 2003, FASEB J, V17, P1541, DOI 10.1096/fj.02-0963fje; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ouiddir A, 1999, AM J RESP CELL MOL, V21, P710, DOI 10.1165/ajrcmb.21.6.3751; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335; Pham I, 2002, AM J PHYSIOL-LUNG C, V283, pL1133, DOI 10.1152/ajplung.00464.2001; Rossignol F, 2002, GENE, V299, P135, DOI 10.1016/S0378-1119(02)01049-1; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sato M, 2002, AM J RESP CELL MOL, V26, P127, DOI 10.1165/ajrcmb.26.1.4319; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; SIMON LM, 1978, J CLIN INVEST, V61, P1232, DOI 10.1172/JCI109039; Sowter HM, 2003, CANCER RES, V63, P6130; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; SUAREZ F, 1995, J CLIN ENDOCR METAB, V80, P965, DOI 10.1210/jc.80.3.965; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200	40	332	360	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14871	14878		10.1074/jbc.M400461200	http://dx.doi.org/10.1074/jbc.M400461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744852	hybrid			2022-12-27	WOS:000220594700048
J	Cortes-Canteli, M; Wagner, M; Ansorge, W; Perez-Castillo, A				Cortes-Canteli, M; Wagner, M; Ansorge, W; Perez-Castillo, A			Microarray analysis supports a role for CCAAT/enhancer-binding protein-beta in brain injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT BRAIN; TRANSCRIPTIONAL ACTIVATOR PROTEIN; ORNITHINE DECARBOXYLASE GENE; NF-KAPPA-B; C/EBP-BETA; XANTHINE DEHYDROGENASE; MESSENGER-RNA; GROWTH-FACTOR; DIFFERENTIAL EXPRESSION; INFLAMMATORY CYTOKINES	CCAAT/enhancer-binding protein-beta (C/EBPbeta) is a transcription factor that plays an important role in regulating cell growth and differentiation. This protein plays a central role in lymphocyte and adipocyte differentiation and hepatic regeneration and in the control of inflammation and immunity in the liver and in cells of the myelomonocytic lineage. Our previous studies suggested that this protein could also have important functions in the brain. Therefore, we were interested in the identification of downstream targets of this transcription factor in cells of neural origin. We performed cDNA microarray analysis and found that a total of 48 genes were up-regulated in C/EBPbeta-overexpressing neuronal cells. Of the genes that displayed significant changes in expression, several were involved in inflammatory processes and brain injury. Northern blot analysis confirmed the up-regulation of ornithine decarboxylase, 24p3/LCN2, GRO1/KC, spermidine/spermine N-1-acetyltransferase, xanthine dehydrogenase, histidine decarboxylase, decorin, and TM4SF1/L6. Using promoter-luciferase reporter transfection assays, we showed the ornithine decarboxylase and 24p3 genes to be biological downstream targets of C/EBPbeta in neuroblastoma cells. Moreover, the levels of C/EBPbeta protein were significantly induced after neuronal injury, which was accompanied by increased levels of cyclooxygenase-2 enzyme. This strongly supports the concept that C/EBPbeta may play an important role in brain injury.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Madrid 28029, Spain; European Mol Biol Lab, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); European Molecular Biology Laboratory (EMBL)	Perez-Castillo, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.	aperez@iib.uam.es	Ansorge, Wilhelm/AAN-8780-2020; Perez-Castillo, Ana/A-9505-2015; Cortes-Canteli, Marta/L-5449-2014	Cortes-Canteli, Marta/0000-0001-8802-4338; Perez-Castillo, Ana/0000-0002-2632-5853				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.0.CO;2-X; Andreasson KI, 2001, J NEUROSCI, V21, P8198; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Babu GN, 2001, NEUROSCI LETT, V300, P17, DOI 10.1016/S0304-3940(01)01538-5; BATTELLI MG, 1995, DEV BRAIN RES, V86, P340, DOI 10.1016/0165-3806(95)00012-3; BAUDRY M, 1986, J NEUROSCI, V6, P3430; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; Bernstein HG, 1999, PROG NEUROBIOL, V57, P485, DOI 10.1016/S0301-0082(98)00065-3; BOZIC CR, 1995, J IMMUNOL, V154, P6048; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; Cortes-Canteli M, 2002, J BIOL CHEM, V277, P5460, DOI 10.1074/jbc.M108761200; Darlington GJ, 1999, CURR OPIN CELL BIOL, V11, P678, DOI 10.1016/S0955-0674(99)00035-6; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DUPONT GP, 1992, J CLIN INVEST, V89, P197, DOI 10.1172/JCI115563; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; FALUS A, 1992, IMMUNOL TODAY, V13, P154; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Flower DR, 1996, BIOCHEM J, V318, P1; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; HOU YJ, 1995, J NEUROSCI RES, V40, P359, DOI 10.1002/jnr.490400310; Igaz P, 2001, INFLAMM RES, V50, P123, DOI 10.1007/s000110050735; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Katoh Y, 2001, NEUROSCI LETT, V305, P181, DOI 10.1016/S0304-3940(01)01835-3; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kilpelainen P, 2000, J NEUROSCI RES, V62, P675, DOI 10.1002/1097-4547(20001201)62:5<675::AID-JNR6>3.0.CO;2-S; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; Laube G, 2002, J COMP NEUROL, V444, P369, DOI 10.1002/cne.10157; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LINDSAY S, 1991, AM J PHYSIOL, V261, pH2051, DOI 10.1152/ajpheart.1991.261.6.H2051; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mar PK, 1995, MOL CARCINOGEN, V14, P240, DOI 10.1002/mc.2940140404; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; Menard C, 2002, NEURON, V36, P597, DOI 10.1016/S0896-6273(02)01026-7; Menendez-Hurtado A, 2000, ENDOCRINOLOGY, V141, P4164, DOI 10.1210/en.141.11.4164; Muckenthaler M, 1997, RNA, V3, P983; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NATSUKA S, 1992, BLOOD, V79, P460; Niimi M, 1997, J NEUROCHEM, V69, P851; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Osada S, 1996, J BIOL CHEM, V271, P3891; Page S, 1998, BBA-GEN SUBJECTS, V1381, P191, DOI 10.1016/S0304-4165(98)00028-2; Petty HR, 2002, IMMUNOL RES, V25, P75, DOI 10.1385/IR:25:1:75; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rao AM, 2000, J NEUROCHEM, V74, P1106; Rao VLR, 1998, BRAIN RES, V783, P163, DOI 10.1016/S0006-8993(97)01301-2; Sarnesto A, 1996, LAB INVEST, V74, P48; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sterneck E, 1998, J NEUROCHEM, V70, P2424; Stichel CC, 1995, BRAIN RES, V704, P263, DOI 10.1016/0006-8993(95)01131-5; Stipp CS, 2000, J CELL SCI, V113, P1871; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Weiner HL, 2002, NATURE, V420, P879, DOI 10.1038/nature01325; WINROW VR, 1993, BRIT MED BULL, V49, P506, DOI 10.1093/oxfordjournals.bmb.a072627; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xia MQ, 2002, J NEUROIMMUNOL, V122, P55, DOI 10.1016/S0165-5728(01)00463-5; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Yukawa K, 1998, J BIOL CHEM, V273, P31345, DOI 10.1074/jbc.273.47.31345	78	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14409	14417		10.1074/jbc.M313253200	http://dx.doi.org/10.1074/jbc.M313253200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736879	hybrid			2022-12-27	WOS:000220478500137
J	Shukla, S; Dirksen, WP; Joyce, KM; Le Guiner-Blanvillain, C; Breathnach, R; Fisher, SA				Shukla, S; Dirksen, WP; Joyce, KM; Le Guiner-Blanvillain, C; Breathnach, R; Fisher, SA			TIA proteins are necessary but not sufficient for the tissue-specific splicing of the myosin phosphatase targeting subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BINDING; EXPRESSION; MECHANISMS; GRANULES; RECRUITMENT; REGULATOR; DIVERSITY	We are using the tissue-specific splicing of myosin phosphatase targeting subunit (MYPT1) as a model to investigate smooth muscle phenotypic diversity. We previously identified a U-rich intronic enhancer flanking the 5' splice site (IE1), and a bipartite exonic enhancer/ suppressor, that regulate splicing of the MYPT1 central alternative exon. Here we show that T-cell inhibitor of apoptosis (TIA-1) and T-cell inhibitor of apoptosis-related (TIAR) proteins bind to the IE1. Co-transfection of TIA expression vectors with a MYPT1 mini-gene construct increase splicing of the central alternative exon. TIA proteins do not enhance splicing when the palindromic exonic splicing enhancer (ESE) is mutated, indicating that TIAs are necessary but not sufficient for splicing. The ESE specifically binds SRp55 and SRp20 proteins, supporting a model in which both SR and TIA proteins binding to their cis-elements are required for the recruitment of the splicing complex to a weak 5' splice site. Inactivation of TIA proteins in the DT40 cell line (TIA-1(-/-) TIAR(+/-)) reduced the splicing of the central alternative exon of the endogenous MYPT1 as well as stably transfected MYPT1 minigene constructs. Splicing of the MYPT1 3' alternative exon and the MLC17 alternative exon were unaffected, suggesting that TIA proteins regulate a subset of smooth muscle/nonmuscle alternative splicing reactions. Finally, reduced RNA binding and reduced expression of the TIA and SR proteins in phasic (gizzard) smooth muscle around hatching coincided with the switch from exon inclusion to exon skipping, suggesting that loss of TIA and SR enhancer activity may play a role in the developmental switch in MYPT1 splicing.	Case Western Reserve Univ, Sch Med, Dept Med Cardiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Inst Biol CHR, INSERM, U463, F-44093 Nantes 1, France	Case Western Reserve University; Case Western Reserve University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Fisher, SA (corresponding author), BRB 422,2109 Adelbert Rd, Cleveland, OH 44106 USA.	saf9@po.cwru.edu	Breathnach, Richard/K-7599-2015	Shukla, Supriya/0000-0001-7441-6306	NHLBI NIH HHS [R01 HL-66171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson P, 2002, CELL STRESS CHAPERON, V7, P213, DOI 10.1379/1466-1268(2002)007<0213:VSTROE>2.0.CO;2; Beck ARP, 1996, NUCLEIC ACIDS RES, V24, P3829, DOI 10.1093/nar/24.19.3829; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BLYN LB, 1995, J VIROL, V69, P4381, DOI 10.1128/JVI.69.7.4381-4389.1995; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; Dirksen WP, 2003, J BIOL CHEM, V278, P9722, DOI 10.1074/jbc.M207969200; Dirksen WP, 2000, AM J PHYSIOL-CELL PH, V278, pC589, DOI 10.1152/ajpcell.2000.278.3.C589; Fisher SA, 1997, CIRC RES, V80, P885; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; Forch P, 2001, RNA, V7, P1185, DOI 10.1017/S1355838201010536; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; GATTOKONCZAK F, 2000, MOL CELL BIOL, V20, P6287; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gromak N, 2003, RNA, V9, P443, DOI 10.1261/rna.2191903; Hanamura A, 1998, RNA, V4, P430; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Le Guienr C, 2001, J BIOL CHEM, V276, P40638, DOI 10.1074/jbc.M105642200; Le Guiner C, 2003, J BIOL CHEM, V278, P10465, DOI 10.1074/jbc.M212378200; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; PAYNE MC, 2004, IN PRESS AM J PHYSL, V281; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492	33	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13668	13676		10.1074/jbc.M314138200	http://dx.doi.org/10.1074/jbc.M314138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736875	hybrid			2022-12-27	WOS:000220478500049
J	Towpik, J; Chacinska, A; Ciesla, M; Ginalski, K; Boguta, M				Towpik, J; Chacinska, A; Ciesla, M; Ginalski, K; Boguta, M			Mutations in the yeast MRF1 gene encoding mitochondrial release factor inhibit translation on mitochondrial ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COX2 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEAR GENE; CODON RECOGNITION; LARGE SUBUNIT; PROTEIN; TERMINATION; SUPPRESSORS; COMPLEMENT; EXPRESSION	Although the control of mitochondrial translation in the yeast Saccharomyces cerevisiae has been studied extensively, the mechanism of termination remains obscure. Ten mutations isolated in a genetic screen for read-through of premature stop codons in mitochondrial genes were localized in the chromosomal gene encoding the mitochondrial release factor mRF1. The mrf1-13 and mrf1-780 mutant genes, in contrast to other alleles, caused a non-respiratory phenotype that correlated with decreased expression of mitochondrial genes as well as a reporter ARG8(m) gene inserted into mitochondrial DNA. The steady-state levels of several mitochondrially encoded proteins, but not their mRNAs, were dramatically decreased in mrf1-13 and mrf1-780 cells. Structural models of mRF1 were constructed, allowing localization of residues substituted in the mrf1 mutants and offering an insight into the possible mechanism by which these mutations change the mitochondrial translation termination fidelity. Inhibition of mitochondrial translation in mrf1 - 13 and mrf1 - 780 correlated with the three-dimensional localization of the mutated residues close to the PST motif presumably involved in the recognition of stop codons in mitochondrial mRNA.	Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; BioInfoBank Inst, PL-60744 Poznan, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Boguta, M (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.	magda@poczta.ibb.waw.pl		Ciesla, Malgorzata/0000-0003-1795-3409; Chacinska, Agnieszka/0000-0002-2832-2568; Boguta, Magdalena/0000-0002-1545-0691				ALKSNE LE, 1993, P NATL ACAD SCI USA, V90, P9538, DOI 10.1073/pnas.90.20.9538; Askarian-Amiri ME, 2000, J BIOL CHEM, V275, P17241, DOI 10.1074/jbc.M910448199; Barrientos A, 2003, MOL BIOL CELL, V14, P2292, DOI 10.1091/mbc.E02-10-0636; BOGUTA M, 1992, MOL CELL BIOL, V12, P402, DOI 10.1128/MCB.12.1.402; BONITZ SG, 1980, P NATL ACAD SCI-BIOL, V77, P3167, DOI 10.1073/pnas.77.6.3167; Bonnefoy N, 2001, MOL CELL BIOL, V21, P2359, DOI 10.1128/MCB.21.7.2359-2372.2001; Bonnefoy N, 2000, MOL GEN GENET, V262, P1036, DOI 10.1007/PL00008646; Chacinska A, 2000, MOL CELL BIOL, V20, P7220, DOI 10.1128/MCB.20.19.7220-7229.2000; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CLAISSE ML, 1970, EUR J BIOCHEM, V16, P430, DOI 10.1111/j.1432-1033.1970.tb01098.x; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; FEARON K, 1988, MOL CELL BIOL, V8, P3636, DOI 10.1128/MCB.8.9.3636; FEARON K, 1992, J BIOL CHEM, V267, P5162; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; Ginalski K, 2003, PROTEINS, V53, P410, DOI 10.1002/prot.10548; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115; Janzen DM, 2002, MOL CELL BIOL, V22, P8562, DOI 10.1128/MCB.22.24.8562-8570.2002; KAISER C, 1994, METHODS YEAST GENETI, P73; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; KRUSZEWSKA A, 1984, CURR GENET, V9, P1, DOI 10.1007/BF00396198; Li XM, 2002, MOL CELL BIOL, V22, P7701, DOI 10.1128/MCB.22.21.7701-7711.2002; MULERO JJ, 1994, MOL GEN GENET, V242, P383, DOI 10.1007/BF00281787; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; Nakamura Y, 2003, TRENDS BIOCHEM SCI, V28, P99, DOI 10.1016/S0968-0004(03)00006-9; O'Brien TW, 2002, GENE, V286, P73, DOI 10.1016/S0378-1119(01)00808-3; PARTALEDIS JA, 1988, MOL CELL BIOL, V8, P3647, DOI 10.1128/MCB.8.9.3647; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1; Sherman F., 1986, METHODS YEAST GENETI; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; SIKORSKI RS, 1989, GENETICS, V122, P19; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; STANSFIELD I, 1994, CURR GENET, V25, P385, DOI 10.1007/BF00351776; Stribinskis V, 2001, GENETICS, V158, P573; Vestergaard B, 2001, MOL CELL, V8, P1375, DOI 10.1016/S1097-2765(01)00415-4; Williams EH, 2003, RNA, V9, P419, DOI 10.1261/rna.2182903; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZOLADEK T, 1985, CURR GENET, V9, P427, DOI 10.1007/BF00434046	43	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14096	14103		10.1074/jbc.M312856200	http://dx.doi.org/10.1074/jbc.M312856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734569	hybrid			2022-12-27	WOS:000220478500099
J	Andersson, U; Filipsson, K; Abbott, CR; Woods, A; Smith, K; Bloom, SR; Carling, D; Small, CJ				Andersson, U; Filipsson, K; Abbott, CR; Woods, A; Smith, K; Bloom, SR; Carling, D; Small, CJ			AMP-activated protein kinase plays a role in the control of food intake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; SKELETAL-MUSCLE; RAT; INHIBITION; MECHANISM; RECEPTOR; CASCADE; SUBUNIT; OBESITY; ENERGY	AMP-activated protein kinase ( AMPK) is the downstream component of a protein kinase cascade that acts as an intracellular energy sensor maintaining the energy balance within the cell. The finding that leptin and adiponectin activate AMPK to alter metabolic pathways in muscle and liver provides direct evidence for this role in peripheral tissues. The hypothalamus is a key regulator of food intake and energy balance, coordinating body adiposity and nutritional state in response to peripheral hormones, such as leptin, peptide YY-(3-36), and ghrelin. To date the hormonal regulation of AMPK in the hypothalamus, or its potential role in the control of food intake, have not been reported. Here we demonstrate that counter-regulatory hormones involved in appetite control regulate AMPK activity and that pharmacological activation of AMPK in the hypothalamus increases food intake. In vivo administration of leptin, which leads to a reduction in food intake, decreases hypothalamic AMPK activity. By contrast, injection of ghrelin in vivo, which increases food intake, stimulates AMPK activity in the hypothalamus. Consistent with the effect of ghrelin, injection of 5-amino-4-imidazole carboxamide riboside, a pharmacological activator of AMPK, into either the third cerebral ventricle or directly into the paraventricular nucleus of the hypothalamus significantly increased food intake. These results suggest that AMPK is regulated in the hypothalamus by hormones which regulate food intake. Furthermore, direct pharmacological activation of AMPK in the hypothalamus is sufficient to increase food intake. These findings demonstrate that AMPK plays a role in the regulation of feeding and identify AMPK as a novel target for anti-obesity drugs.	Univ London Imperial Coll Sci & Technol, MRC, Ctr Clin Sci, Cellular Stress Grp, London W12 ONN, England; Univ London Imperial Coll Sci & Technol, Endocrine Unit, London W12 ONN, England	Imperial College London; Imperial College London	Carling, D (corresponding author), Univ London Imperial Coll Sci & Technol, MRC, Ctr Clin Sci, Cellular Stress Grp, Hammersmith Campus,Du Cane Rd, London W12 ONN, England.	dcarling@csc.mrc.ac.uk; c.small@imperial.ac.uk	Carling, David/F-1943-2014	Carling, David/0000-0002-2316-1830; Andersson-Hall, Ulrika/0000-0003-3722-3454	Medical Research Council [MC_U120027537] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott CR, 2001, ENDOCRINOLOGY, V142, P3457, DOI 10.1210/en.142.8.3457; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Morgan DGA, 1998, REGUL PEPTIDES, V75-6, P377, DOI 10.1016/S0167-0115(98)00091-3; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; OShea D, 1997, ENDOCRINOLOGY, V138, P196, DOI 10.1210/en.138.1.196; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788	26	598	620	3	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12005	12008		10.1074/jbc.C300557200	http://dx.doi.org/10.1074/jbc.C300557200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14742438	Green Submitted, hybrid			2022-12-27	WOS:000220334900002
J	Zahnd, C; Spinelli, S; Luginbuhl, B; Amstutz, P; Cambillau, C; Pluckthun, A				Zahnd, C; Spinelli, S; Luginbuhl, B; Amstutz, P; Cambillau, C; Pluckthun, A			Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE DOMAINS; DISPLAY; SELECTION; SYSTEM	We generated a single chain Fv fragment of an antibody (scFv) with a binding affinity of about 5 pM to a short peptide by applying rigorous directed evolution. Starting from a high affinity peptide binder, originally obtained by ribosome display from a murine library, we generated libraries of mutants with error-prone PCR and DNA shuffling and applied off-rate selection by using ribosome display. Crystallographic analysis of the scFv in its antigen-bound and free state showed that only few mutations, which do not make direct contact to the antigen, lead to a 500-fold affinity improvement over its potential germ line precursor. These results suggest that the affinity optimization of very high affinity binders is achieved by modulating existing interactions via subtle changes in the framework rather than by introducing new contacts. Off-rate selection in combination with ribosome display can evolve binders to the low picomolar affinity range even for peptide targets.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; CNRS, F-13402 Marseille 20, France	University of Zurich; Centre National de la Recherche Scientifique (CNRS)	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@bioc.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				ADEY NB, 1996, PHAGE DISPLAY PEPTID, P280; Amstutz P, 2001, CURR OPIN BIOTECH, V12, P400, DOI 10.1016/S0958-1669(00)00234-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; Berger C, 1999, FEBS LETT, V450, P149, DOI 10.1016/S0014-5793(99)00458-5; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Ge L, 1995, ANTIBODY ENG, P229; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Honegger A, 2001, J MOL BIOL, V309, P687, DOI 10.1006/jmbi.2001.4664; Honegger A, 2001, J MOL BIOL, V309, P657, DOI 10.1006/jmbi.2001.4662; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; Jung S, 2001, J MOL BIOL, V309, P701, DOI 10.1006/jmbi.2001.4665; Kabat E. A., 1991, SEQUENCES PROTEINS I; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Maur AAD, 2002, J BIOL CHEM, V277, P45075, DOI 10.1074/jbc.M205264200; Mossner E, 2001, J MOL BIOL, V308, P115, DOI 10.1006/jmbi.2001.4575; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1992, MOL REPLACEMENT, P87; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; Roussel A, 1991, SILICON GRAPHICS GEO, P81; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SMITH GP, 1988, VIROLOGY, V167, P156, DOI 10.1016/0042-6822(88)90065-7; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Zaccolo M, 1999, J MOL BIOL, V285, P775, DOI 10.1006/jmbi.1998.2262	36	134	183	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18870	18877		10.1074/jbc.M309169200	http://dx.doi.org/10.1074/jbc.M309169200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14754898	hybrid			2022-12-27	WOS:000221041500096
J	Miyazaki, T; Sanjay, A; Neff, L; Tanaka, S; Horne, WC; Baron, R				Miyazaki, T; Sanjay, A; Neff, L; Tanaka, S; Horne, WC; Baron, R			Src kinase activity is essential for osteoclast function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA(V)BETA(3) INTEGRIN; ADHESION KINASE; FAMILY KINASES; IN-VITRO; CBL; PHOSPHORYLATION; ASSOCIATION	Deletion of the c-src gene impairs osteoclast bone resorbing activity, causing osteopetrosis. Although it has been concluded that restoring only the Src adaptor function at least partly rescues the cell attachment and skeletal phenotypes, the contribution of Src kinase activity remains controversial. Src forms a complex with Pyk2 and Cbl after adhesion-induced stimulation of alpha(v)beta(3) integrin. To demonstrate the importance of the Pyk2-Src association in osteoclasts and to distinguish the contributions of the Src adaptor and kinase activities in cytoskeletal organization and osteoclast function, we expressed mutants of Src and Pyk2 in osteoclasts using adenovirus vectors. Eliminating the Src-binding site on Pyk2 (Pyk2(Y402F)) markedly inhibited bone resorption by osteoclast-like cells, whereas kinasedead Pyk2 had little effect. Kinase-dead Src, unlike kinasedead Pyk2, markedly inhibited the bone-resorbing activity of wild type osteoclasts and failed to significantly restore bone-resorbing activity to Src(-/-) osteoclast-like cells. Activation of Src kinase by overexpressing kinase-dead Csk failed to reverse the inhibitory effect of Pyk2(Y402F), suggesting that osteoclastic bone resorption requires both c-Src kinase activity and the targeting of Src kinase by Pyk2. Src-catalyzed phosphorylation of Cbl on Tyr-731 is reported to induce the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Expressing the Cbl(Y731F) mutant in osteoclasts markedly reduced their bone resorbing activity, suggesting that phosphorylation of Cbl(Y731) and the subsequent recruitment and activation of phosphatidylinositol 3-kinase may be critical signaling events downstream of Src in osteoclasts.	Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1130033, Japan	Yale University; Yale University; University of Tokyo	Baron, R (corresponding author), Yale Univ, Sch Med, Dept Orthopaed, POB 208044, New Haven, CT 06510 USA.	roland.baron@yale.edu	Tanaka, Sakae/Y-3061-2019	Tanaka, Sakae/0000-0001-9210-9414; Miyazaki, Tsuyoshi/0000-0003-0715-9017	NIAMS NIH HHS [AR-42927] Funding Source: Medline; NIDCR NIH HHS [DE-04724] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE004724, R37DE004724] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lowell CA, 1996, BLOOD, V87, P1780; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756-3282(99)00020-4; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Miyazaki T, 2000, J BONE MINER RES, V15, P41, DOI 10.1359/jbmr.2000.15.1.41; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Palacio S, 2001, EUR J ENDOCRINOL, V144, P431, DOI 10.1530/eje.0.1440431; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Tanaka S, 1998, J BONE MINER RES, V13, P1714, DOI 10.1359/jbmr.1998.13.11.1714; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Violette SM, 2000, CHEM BIOL, V7, P225, DOI 10.1016/S1074-5521(00)00090-9; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1	35	225	248	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17660	17666		10.1074/jbc.M311032200	http://dx.doi.org/10.1074/jbc.M311032200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14739300	hybrid			2022-12-27	WOS:000220870400095
J	Jeong, JH; Orvis, J; Kim, JW; McMurtrey, CP; Renne, R; Dittmer, DP				Jeong, JH; Orvis, J; Kim, JW; McMurtrey, CP; Renne, R; Dittmer, DP			Regulation and autoregulation of the promoter for the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; MULTICENTRIC CASTLEMANS-DISEASE; PRIMARY EFFUSION LYMPHOMA; READING FRAME 50; BINDING PROTEIN-ALPHA; II CORE PROMOTER; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; DNA-SEQUENCES; LYTIC-CYCLE	Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 has been established as the etiological agent of Kaposi's sarcoma and certain AIDS-associated lymphomas. KSHV establishes latent infection in these tumors, invariably expressing high levels of the viral latency-associated nuclear antigen (LANA) protein. LANA is necessary and sufficient to maintain the KSHV episome. It also modulates viral and cellular transcription and has been implicated directly in oncogenesis because of its ability to bind to the p53 and pRb tumor suppressor proteins. Previously, we identified the LANA promoter (LANAp) and showed that it was positively regulated by LANA itself. Here, we present a detailed mutational analysis and define cis-acting elements and trans-acting factors for the core LANAp. We found that a downstream promoter element, TATA box, and GC box/Sp1 site at - 29 are all individually required for activity. This architecture places LANAp into the small and unusual group of eukaryotic promoters that contain both the downstream promoter element and TATA element but lack a defined initiation site. Furthermore, we demonstrate that LANA regulates its own promoter via its C-terminal domain and does bind to a defined site within the core promoter.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ N Carolina, Chapel Hill, NC 27599 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill	Dittmer, DP (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	dirk-dittmer@ouhsc.edu	Dittmer, Dirk/AAH-3535-2021; Dittmer, Dirk/GPW-7423-2022	Dittmer, Dirk/0000-0003-4968-5656; 				Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chang J, 2000, VIROLOGY, V266, P17, DOI 10.1006/viro.1999.0077; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen J, 2001, P NATL ACAD SCI USA, V98, P4119, DOI 10.1073/pnas.051004198; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; Damania B, 2001, PHILOS T ROY SOC B, V356, P535, DOI 10.1098/rstb.2000.0782; Decker LL, 1996, J EXP MED, V184, P283, DOI 10.1084/jem.184.1.283; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Garber AC, 2002, J BIOL CHEM, V277, P27401, DOI 10.1074/jbc.M203489200; Garber AC, 2001, J VIROL, V75, P7882, DOI 10.1128/JVI.75.17.7882-7892.2001; Gessain A, 1996, BLOOD, V87, P414; Goryshin IY, 1998, P NATL ACAD SCI USA, V95, P10716, DOI 10.1073/pnas.95.18.10716; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; Gradoville L, 2000, J VIROL, V74, P6207, DOI 10.1128/JVI.74.13.6207-6212.2000; Groves AK, 2001, J VIROL, V75, P9446, DOI 10.1128/JVI.75.19.9446-9457.2001; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Gwack Y, 2003, MOL CELL BIOL, V23, P2055, DOI 10.1128/MCB.23.6.2055-2067.2003; Gwack Y, 2002, J BIOL CHEM, V277, P6438, DOI 10.1074/jbc.M108289200; Gwack Y, 2001, J VIROL, V75, P6245, DOI 10.1128/JVI.75.13.6245-6248.2001; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; Hayward GS, 1999, SEMIN CANCER BIOL, V9, P187, DOI 10.1006/scbi.1998.0116; Hu JH, 2002, J VIROL, V76, P11677, DOI 10.1128/JVI.76.22.11677-11687.2002; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Jeong J, 2001, J VIROL, V75, P1798, DOI 10.1128/JVI.75.4.1798-1807.2001; Jeong JH, 2002, J VIROL, V76, P11024, DOI 10.1128/JVI.76.21.11024-11032.2002; Kadonaga JT, 1990, CURR OPIN CELL BIOL, V2, P496, DOI 10.1016/0955-0674(90)90133-Y; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kellam P, 1997, J Hum Virol, V1, P19; Kliche S, 1998, J VIROL, V72, P8143, DOI 10.1128/JVI.72.10.8143-8149.1998; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Liang YY, 2003, P NATL ACAD SCI USA, V100, P8490, DOI 10.1073/pnas.1432843100; Lim C, 2000, J GEN VIROL, V81, P2645, DOI 10.1099/0022-1317-81-11-2645; Lim C, 2003, J BIOL CHEM, V278, P7397, DOI 10.1074/jbc.M211912200; Lim C, 2002, J VIROL, V76, P10320, DOI 10.1128/JVI.76.20.10320-10331.2002; Lim C, 2001, J BIOL CHEM, V276, P31016, DOI 10.1074/jbc.M102431200; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mannervik M, 1997, FEBS LETT, V414, P111, DOI 10.1016/S0014-5793(97)00982-4; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1998, MONOGR NCI, V23, P65; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; NEIPEL F, 1998, MONOGR NCI, V23, P73; Nonkwelo C, 1997, J VIROL, V71, P354, DOI 10.1128/JVI.71.1.354-361.1997; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Paulose-Murphy M, 2001, J VIROL, V75, P4843, DOI 10.1128/JVI.75.10.4843-4853.2001; Piolot T, 2001, J VIROL, V75, P3948, DOI 10.1128/JVI.75.8.3948-3959.2001; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sakakibara S, 2001, J VIROL, V75, P6894, DOI 10.1128/JVI.75.15.6894-6900.2001; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schwam DR, 2000, J VIROL, V74, P8532, DOI 10.1128/JVI.74.18.8532-8540.2000; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Szekely L, 1999, J GEN VIROL, V80, P2889, DOI 10.1099/0022-1317-80-11-2889; Talbot SJ, 1999, VIROLOGY, V257, P84, DOI 10.1006/viro.1999.9672; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Viejo-Borbolla A, 2003, J VIROL, V77, P7093, DOI 10.1128/JVI.77.12.7093-7100.2003; Wang SE, 2003, J VIROL, V77, P600, DOI 10.1128/JVI.77.1.600-623.2003; Wang SZ, 2001, J VIROL, V75, P11961, DOI 10.1128/JVI.75.24.11961-11973.2001; Wu FY, 2002, P NATL ACAD SCI USA, V99, P10683, DOI 10.1073/pnas.162352299; Zhang L, 1998, DNA CELL BIOL, V17, P735; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; Zhu FX, 1999, J VIROL, V73, P5556, DOI 10.1128/JVI.73.7.5556-5567.1999	84	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16822	16831		10.1074/jbc.M312801200	http://dx.doi.org/10.1074/jbc.M312801200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14742422	Green Published, hybrid			2022-12-27	WOS:000220747900135
J	Notari, S; Capellari, S; Giese, A; Westner, I; Baruzzi, A; Ghetti, B; Gambetti, P; Kretzschmar, HA; Parchi, P				Notari, S; Capellari, S; Giese, A; Westner, I; Baruzzi, A; Ghetti, B; Gambetti, P; Kretzschmar, HA; Parchi, P			Effects of different experimental conditions on the PrPSc core generated by protease digestion - Implications for strain typing and molecular classification of CJD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; NATURAL SCRAPIE; PRION; CONFORMATION; PROTEINASE; BSE; PH; BRAIN	The discovery of molecular subtypes of the pathological prion protein PrPSc has provided the basis for a novel classification of human transmissible spongiform encephalopathies (TSEs) and a potentially powerful method for strain typing. However, there is still a significant disparity regarding the understanding and nomenclature of PrPSc types. In addition, it is still unknown whether a specific PrPSc type is associated with each TSE phenotypic variant. In sporadic Creutzfeldt-Jakob disease (sCJD), five disease phenotypes are known, but only two major types of PrPSc, types 1 and 2, have been consistently reproduced. We further analyzed PrPSc properties in sCJD and variant CJD using a high resolution gel electrophoresis system and varying experimental conditions. We found that pH varies among CJD brain homogenates in standard buffers, thereby influencing the characteristics of protease-treated PrPSc. We also show that PrPSc type 1 and type 2 are heterogeneous species which can be further distinguished into five molecular subtypes that fit the current histopathological classification of sCJD variants. Our results shed light on previous disparities in PrPSc typing, provide a refined classification of human PrPSc types, and support the notion that the pathological TSE phenotype is related to PrPSc structure.	Univ Bologna, Dipartimento Sci Neurol, I-40123 Bologna, Italy; Univ Munich, Inst Neuropathol, D-81377 Munich, Germany; Indiana Univ, Dept Pathol, Indianapolis, IN 46202 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	University of Bologna; University of Munich; Indiana University System; Indiana University-Purdue University Indianapolis; Case Western Reserve University	Parchi, P (corresponding author), Univ Bologna, Dipartimento Sci Neurol, Fia Foscolo 7, I-40123 Bologna, Italy.	parchi@neuro.unibo.it	Parchi, Piero/L-9833-2015; capellari, sabina/F-5545-2012; Giese, Armin/F-3271-2010	Parchi, Piero/0000-0002-9444-9524; capellari, sabina/0000-0003-1631-1439; Giese, Armin/0000-0002-8238-4102	NIA NIH HHS [P30 AG10133] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKSU S, 2000, ELECTROCHEMISTRY MIN, P258; Baron TGM, 2000, NEUROSCI LETT, V284, P175, DOI 10.1016/S0304-3940(00)01047-8; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; Gambetti P, 1999, COLD SPRING HARBOR M, V38, P509; GHETTI B, 2003, NEURODEGENERATION MO, P318; Harrison PJ, 1995, NEUROSCI LETT, V200, P151, DOI 10.1016/0304-3940(95)12102-A; Hope J, 1999, J GEN VIROL, V80, P1, DOI 10.1099/0022-1317-80-1-1; IRONSIDE JW, 2003, NEURODEGENERATION MO, P310; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Korth C, 2003, P NATL ACAD SCI USA, V100, P4784, DOI 10.1073/pnas.2627989100; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; Kuczius T, 1999, MOL MED, V5, P406, DOI 10.1007/BF03402129; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Naureckiene S, 2003, ARCH BIOCHEM BIOPHYS, V420, P55, DOI 10.1016/j.abb.2003.09.011; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P561; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PARCHI P, 2000, NEURODEGENERATIVE DE, P341; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x; Zanusso G, 2001, J BIOL CHEM, V276, P40377, DOI 10.1074/jbc.C100458200	39	112	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16797	16804		10.1074/jbc.M313220200	http://dx.doi.org/10.1074/jbc.M313220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754888	hybrid			2022-12-27	WOS:000220747900132
J	Birgander, PL; Kasrayan, A; Sjoberg, BM				Birgander, PL; Kasrayan, A; Sjoberg, BM			Mutant R1 proteins from Escherichia coli class Ia ribonucleotide reductase with altered responses to dATP inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; DIPHOSPHATE REDUCTASE; SUBSTRATE-SPECIFICITY; ALLOSTERIC REGULATION; PHENOTYPIC SELECTION; COMPREHENSIVE MODEL; SUBUNIT INTERACTION; EFFECTOR-BINDING; PROMOTER SYSTEM; CONSEQUENCES	Aerobic ribonucleotide reductase from Escherichia coli regulates its level of activity by binding of effectors to an allosteric site in R1, located to the proposed interaction area of the two proteins that comprise the class I enzyme. Activity is increased by ATP binding and decreased by dATP binding. To study the mechanism governing this regulation, we have constructed three R1 proteins with mutations at His-59 in the activity site and one R1 protein with a mutation at His-88 close to the activity site and compared their allosteric behavior to that of the wild type R1 protein. All mutant proteins retained about 70% of wild type enzymatic activity. We found that if residue His-59 was replaced with alanine or asparagine, the enzyme lost its normal response to the inhibitory effect of dATP, whereas the enzyme with a glutamine still managed to elicit a normal response. We saw a similar result if residue His-88, which is proposed to hydrogen-bond to His-59, was replaced with alanine. Nucleotide binding experiments ruled out the possibility that the effect is due to an inability of the mutant proteins to bind effector since little difference in binding constants was observed for wild type and mutant proteins. Instead, the interaction between proteins R1 and R2 was perturbed in the mutant proteins. We propose that His-59 is important in the allosteric effect triggered by dATP binding, that the conserved hydrogen bond between His-59 and His-88 is important for the communication of the allosteric effect, and that this effect is exerted on the R1/R2 interaction.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se		Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CARAS IW, 1988, MOL CELL BIOL, V8, P2698, DOI 10.1128/MCB.8.7.2698; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; LARSSON A, 1966, BIOCHIM BIOPHYS ACTA, V113, P407, DOI 10.1016/S0926-6593(66)80083-8; Larsson KM, 2001, STRUCTURE, V9, P739, DOI 10.1016/S0969-2126(01)00627-X; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; Scott CP, 2001, BIOCHEMISTRY-US, V40, P1651, DOI 10.1021/bi002335z; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1973, J BIOL CHEM, V248, P4591; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uppsten M, 2003, J MOL BIOL, V330, P87, DOI 10.1016/S0022-2836(03)00538-2	28	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14496	14501		10.1074/jbc.M310142200	http://dx.doi.org/10.1074/jbc.M310142200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752109	hybrid			2022-12-27	WOS:000220594700006
J	Gutierrez, J; Kremer, L; Zaballos, A; Goya, I; Martinez, C; Marquez, G				Gutierrez, J; Kremer, L; Zaballos, A; Goya, I; Martinez, C; Marquez, G			Analysis of post-translational CCR8 modifications and their influence on receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE SULFATION; CHEMOKINE RECEPTOR-8; AMINO-TERMINUS; CUTTING EDGE; IDENTIFICATION; CONTRIBUTE; MONOCYTE; I-309	Post-translational modifications of the extracellular portions of receptors located in the cell membrane can contribute to modulating their biological activity. Using a mutagenesis approach in which single or multiple Tyr-to-Phe, Thr-to-Ala, Ser-to-Ala, and Asn-to-Gln substitutions were made at the appropriate positions, we analyzed the sulfation and glycosylation state of the murine CCR8 chemokine receptor, and the way in which these post-translational modifications affect CCR8 activity. A Y14Y15-to-F14F15 CCR8 mutant was less sulfated than the wild-type receptor. An N8-to-Q8 mutant was less glycosylated than wild-type, and a double T10T12-toA10A12 mutant showed even less glycosylation. We established a flow cytometric analysis with an Fc-fused form of mouse CCL1 to determine precisely the ligand-binding activity of these mutants. Single mutants at amino acid positions 8, 10 or 12 bound CCL1-Fc similarly to wild-type CCR8, whereas the F14F15 double mutant was essentially inactive and the A10A12 double mutant showed about 65% of wild-type ligand-binding activity. Calcium flux activity assays were performed with these mutants, yielding results consistent with those from the ligand binding assays. These data indicate that sulfation at specific positions of the N-terminal domain of mouse CCR8 is critical for its biological activity, whereas glycosylation has a minor influence.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Marquez, G (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain.	gmarquez@cnb.uam.es	Zaballos, Ángel/O-2853-2015; Kremer, Leonor/L-5445-2015	Kremer, Leonor/0000-0002-2235-2010; Zaballos, Angel/0000-0002-7555-5815				Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Carramolino L, 1999, J LEUKOCYTE BIOL, V66, P837, DOI 10.1002/jlb.66.5.837; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chung CD, 2003, J IMMUNOL, V170, P581, DOI 10.4049/jimmunol.170.1.581; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; De Lisle RC, 2002, J CELL SCI, V115, P2941; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; Goya I, 1998, J IMMUNOL, V160, P1975; Goya I, 2003, J IMMUNOL, V170, P2138, DOI 10.4049/jimmunol.170.4.2138; Harpel PC, 2002, ISRAEL MED ASSOC J, V4, P1025; Holst Peter J, 2003, Contrib Microbiol, V10, P232; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; Kremer L, 2001, J IMMUNOL, V166, P218, DOI 10.4049/jimmunol.166.1.218; LUO Y, 1994, J IMMUNOL, V153, P4616; MINTZ KP, 1994, J BIOL CHEM, V269, P4845; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; Olbrich H, 1999, J LEUKOCYTE BIOL, V65, P281, DOI 10.1002/jlb.65.3.281; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; RANDS E, 1990, J BIOL CHEM, V265, P10759; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Sadeghi H, 1999, GLYCOBIOLOGY, V9, P731, DOI 10.1093/glycob/9.7.731; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Zingoni A, 1998, J IMMUNOL, V161, P547; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	29	34	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14726	14733		10.1074/jbc.M309689200	http://dx.doi.org/10.1074/jbc.M309689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736884	hybrid			2022-12-27	WOS:000220594700032
J	Xavier, S; Piek, E; Fujii, M; Javelaud, D; Mauviel, A; Flanders, KC; Samuni, AM; Felici, A; Reiss, M; Yarkoni, S; Sowers, A; Mitchell, JB; Roberts, AB; Russo, A				Xavier, S; Piek, E; Fujii, M; Javelaud, D; Mauviel, A; Flanders, KC; Samuni, AM; Felici, A; Reiss, M; Yarkoni, S; Sowers, A; Mitchell, JB; Roberts, AB; Russo, A			Amelioration of radiation-induced fibrosis - Inhibition of transforming growth factor-beta signaling by halofuginone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PULMONARY FIBROSIS; TGF-BETA; IONIZING-RADIATION; GENE-REGULATION; IN-VIVO; CELLS; SMAD3; FIBROBLASTS; ACTIVATION; SKIN	Radiation-induced fibrosis is an untoward effect of high dose therapeutic and inadvertent exposure to ionizing radiation. Transforming growth factor-beta (TGF-beta) has been proposed to be critical in tissue repair mechanisms resulting from radiation injury. Previously, we showed that interruption of TGF-beta signaling by deletion of Smad3 results in resistance to radiation-induced injury. In the current study, a small molecular weight molecule, halofuginone ( 100 nM), is demonstrated by reporter assays to inhibit the TGF-beta signaling pathway, by Northern blotting to elevate inhibitory Smad7 expression within 15 min, and by Western blotting to inhibit formation of phospho-Smad2 and phospho-Smad3 and to decrease cytosolic and membrane TGF-beta type II receptor (TbetaRII). Attenuation of TbetaRII levels was noted as early as 1 h and down-regulation persisted for 24 h. Halofuginone blocked TGF-beta-induced delocalization of tight junction ZO-1, a marker of epidermal mesenchymal transition, in NMuMg mammary epithelial cells and suggest halofuginone may have in vivo anti-fibrogenesis characteristics. After documenting the in vitro cellular effects, halofuginone (intraperitoneum injection of 1, 2.5, or 5 mug/mouse/day) efficacy was assessed using ionizing radiation-induced ( single dose, 35 or 45 Gy) hind leg contraction in C3H/Hen mice. Halofuginone treatment alone exerted no toxicity but significantly lessened radiation-induced fibrosis. The effectiveness of radiation treatment ( 2 gray/day for 5 days) of squamous cell carcinoma (SCC) tumors grown in C3H/Hen was not affected by halofuginone. The results detail the molecular effects of halofuginone on the TGF-beta signal pathway and show that halofuginone may lessen radiation-induced fibrosis in humans.	NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Hop St Louis, INSERM, U532, F-75010 Paris, France; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Mol Genet & Microbiol, New Brunswick, NJ 08903 USA; Collgard Biopharmaceut Ltd, IL-49170 Petah Tiqwa, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Russo, A (corresponding author), Bldg 10,Rm B3-B69, Bethesda, MD 20892 USA.	russo@helix.nih.gov	Reiss, Michael/A-8314-2009; Wang, Weili/D-1546-2011; Javelaud, Delphine/B-1129-2019; MAUVIEL, Alain/F-6251-2013	Javelaud, Delphine/0000-0002-7674-7739; Mauviel, Alain/0000-0002-0438-2793	DIVISION OF BASIC SCIENCES - NCI [Z01BC010473, Z01BC005051] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIASC006321, Z01SC006321] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALPER T, 1989, EXPERIENTIA, V45, P21, DOI 10.1007/BF01990449; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bitzer M, 2000, GENE DEV, V14, P187; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bruck R, 2001, HEPATOLOGY, V33, P379, DOI 10.1053/jhep.2001.21408; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CLEMENT JJ, 1980, CANCER RES, V40, P4165; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; Dai CS, 2003, J BIOL CHEM, V278, P12537, DOI 10.1074/jbc.M300777200; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Denton CP, 2003, J BIOL CHEM, V278, P25109, DOI 10.1074/jbc.M300636200; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Elkin M, 1999, CLIN CANCER RES, V5, P1982; Flanders KC, 2003, AM J PATHOL, V163, P2247, DOI 10.1016/S0002-9440(10)63582-1; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GRANOT I, 1993, BIOCHIM BIOPHYS ACTA, V1156, P107, DOI 10.1016/0304-4165(93)90123-P; Hallahan D E, 1993, Important Adv Oncol, P71; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; ILIAKIS G, 1991, BIOESSAYS, V13, P641; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Lui WY, 2003, ENDOCRINOLOGY, V144, P1139, DOI 10.1210/en.2002-0211; Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McGaha T, 2002, AUTOIMMUNITY, V35, P277, DOI 10.1080/0891693021000001235; McGaha TL, 2002, J INVEST DERMATOL, V118, P461, DOI 10.1046/j.0022-202x.2001.01690.x; Nagler A, 1997, KIDNEY INT, V52, P1561, DOI 10.1038/ki.1997.486; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Pines A, 2003, BIOL BLOOD MARROW TR, V9, P417, DOI 10.1016/S1083-8791(03)00151-4; Randall K, 1996, INT J RADIAT BIOL, V70, P351, DOI 10.1080/095530096145085; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Roberts Anita B., 1995, Wound Repair and Regeneration, V3, P408, DOI 10.1046/j.1524-475X.1995.30405.x; RONG GH, 1985, J SURG ONCOL, V28, P131, DOI 10.1002/jso.2930280213; Ruifrok ACC, 1999, INT J RADIAT ONCOL, V43, P877, DOI 10.1016/S0360-3016(98)00495-7; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schiffer M, 2000, KIDNEY INT, V58, pS45, DOI 10.1046/j.1523-1755.2000.07708.x; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schnabl B, 2001, HEPATOLOGY, V34, P89, DOI 10.1053/jhep.2001.25349; Schultze-Mosgau S, 2003, WOUND REPAIR REGEN, V11, P297, DOI 10.1046/j.1524-475X.2003.11410.x; STEWART FA, 1978, BRIT J RADIOL, V51, P307, DOI 10.1259/0007-1285-51-604-307; STONE HB, 1984, INT J RADIAT ONCOL, V10, P1053, DOI 10.1016/0360-3016(84)90177-9; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wells RG, 1997, J BIOL CHEM, V272, P11444; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao JS, 2002, AM J PHYSIOL-LUNG C, V282, pL585, DOI 10.1152/ajplung.00151.2001; Zhao Y, 2002, BIOCHEM BIOPH RES CO, V294, P319, DOI 10.1016/S0006-291X(02)00471-0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	57	164	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15167	15176		10.1074/jbc.M309798200	http://dx.doi.org/10.1074/jbc.M309798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732719	hybrid			2022-12-27	WOS:000220594700083
J	Lawson, VA; Priola, SA; Meade-White, C; Lawson, M; Chesebro, B				Lawson, VA; Priola, SA; Meade-White, C; Lawson, M; Chesebro, B			Flexible N-terminal region of prion protein influences conformation of protease-resistant prion protein isoforms associated with cross-species scrapie infection in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; STRAUSSLER-SCHEINKER-DISEASE; TRANSMISSIBLE MINK ENCEPHALOPATHY; STRAIN VARIATION; AMYLOID PROTEIN; MOLECULAR-BASIS; PRP FRAGMENT; CONVERSION; REPLICATION; VARIANT	Transmissible spongiform encephalopathy (TSE) diseases are characterized by the accumulation in brain of an abnormal protease-resistant form of the host-encoded prion protein (PrP), PrP-res. PrP-res conformation differs among TSE agents derived from various sources, and these conformational differences are thought to influence the biological characteristics of these agents. In this study, we introduced deletions into the flexible N-terminal region of PrP ( residues 34 - 124) and investigated the effect of this region on the conformation of PrP-res generated in an in vitro cell-free conversion assay. PrP deleted from residues 34 to 99 generated 12 - 16-kDa protease-resistant bands with intact C termini but variable N termini. The variable N termini were the result of exposure of new protease cleavage sites in PrP-res between residues 130 and 157, suggesting that these new cleavage sites were caused by alterations in the conformation of the PrP-res generated. Similarly truncated 12 - 16-kDa PrP bands were also identified in brain homogenates from mice infected with mouse-passaged hamster scrapie as well as in the cell-free conversion assay using conditions that mimicked the hamster/mouse species barrier to infection. Thus, by its effects on PrP-res conformation, the flexible N-terminal region of PrP seemed to influence TSE pathogenesis and cross-species TSE transmission.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chesebro, B (corresponding author), 903 S 4th St, Hamilton, MT 59840 USA.	bchesebro@nih.gov	Lawson, Victoria/AAJ-7392-2021	Lawson, Victoria/0000-0002-7362-7176	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000752, ZIAAI000752, ZIAAI000937, Z01AI000937] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Capellari S, 2000, AM J PATHOL, V157, P613, DOI 10.1016/S0002-9440(10)64572-5; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Caughey B, 2000, Curr Issues Mol Biol, V2, P95; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chabry J, 1999, J VIROL, V73, P6245, DOI 10.1128/JVI.73.8.6245-6250.1999; Chen SG, 2000, ARCH VIROL, P209; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Daniels M, 2001, EUR J BIOCHEM, V268, P6155, DOI 10.1046/j.0014-2956.2001.02567.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; HOPE J, 1988, CIBA F SYMP, V135, P146; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Parchi P, 1998, P NATL ACAD SCI USA, V95, P8322, DOI 10.1073/pnas.95.14.8322; Parchi P, 2000, MICROSC RES TECHNIQ, V50, P16, DOI 10.1002/1097-0029(20000701)50:1<16::AID-JEMT4>3.0.CO;2-Y; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Piccardo P, 2001, AM J PATHOL, V158, P2201, DOI 10.1016/S0002-9440(10)64692-5; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; Priola SA, 2001, J VIROL, V75, P4673, DOI 10.1128/JVI.75.10.4673-4680.2001; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; Race R, 2002, J INFECT DIS, V186, pS166, DOI 10.1086/344267; Race R, 2001, J VIROL, V75, P10106, DOI 10.1128/JVI.75.21.10106-10112.2001; RACE RE, 1995, NEURON, V15, P1183, DOI 10.1016/0896-6273(95)90105-1; ROBERTSON MN, 1992, J VIROL, V66, P3271, DOI 10.1128/JVI.66.6.3271-3277.1992; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Supattapone S, 2001, J VIROL, V75, P1408, DOI 10.1128/JVI.75.3.1408-1413.2001; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; Tagliavini F, 2001, J BIOL CHEM, V276, P6009, DOI 10.1074/jbc.M007062200; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; Zou WQ, 2003, J BIOL CHEM, V278, P40429, DOI 10.1074/jbc.M308550200	50	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13689	13695		10.1074/jbc.M303697200	http://dx.doi.org/10.1074/jbc.M303697200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736880	hybrid			2022-12-27	WOS:000220478500051
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Val(133) and Cys(137) in transmembrane segment 2 are close to Arg(935) and Gly(939) in transmembrane segment 11 of human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-BINDING SITE; STIMULATED ATPASE ACTIVITY; CYSTEINE-SCANNING MUTAGENESIS; CROSS-LINKING ANALYSIS; MULTIDRUG-RESISTANCE; COVALENT MODIFICATION; NUCLEOTIDE; DOMAIN; TRANSPORTER; RESIDUES	P-glycoprotein (P-gp; ABCB1) transports a wide variety of structurally diverse compounds out of the cell. The protein has two homologous halves joined by a linker region. Each half consists of a transmembrane (TM) domain with six TM segments and a nucleotide-binding domain. The drug substrate-binding pocket is at the interface between the TM segments in each half of the protein. Preliminary studies suggested that the arrangement of the two halves of P-gp shows rotational symmetry (i.e. "head-to-tail" arrangement). Here, we tested this model by determining whether the cytoplasmic ends of TM2 and TM3 in the N-terminal half are in close contact with TM11 in the C-terminal half. Mutants containing a pair of cysteines in TM2/TM11 or TM3/TM11 were subjected to oxidative cross-linking with copper phenanthroline. Two of the 110 TM2/TM11 mutants, V133C(TM2)/ G939C(TM11) and C137C(TM2)/A935C ( TM11), were cross-linked at 4 degreesC, when thermal motion is reduced. Cross-linking was specific since no crosslinked product was detected in the 100 double Cys TM3/ TM11 mutants. Vanadate trapping of nucleotide or the presence of some drug substrates inhibited cross-linking of mutants V133C( TM2)/ G939C( TM11) and C137C(TM2)/ A935C(TM11). Cross-linking of TM2 and TM11 also blocked drug-stimulated ATPase activity. The close proximity of TM2/TM11 and TM5/TM8 (Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2004) J. Biol. Chem. 279, 7692 - 7697) indicates that these regions between the two halves must enclose the drug-binding pocket at the cytoplasmic side of P-gp. They may form the "hinges" required for conformational changes during the transport cycle.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Med Sci Bldg,Rm 7342,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KATZ BA, 1986, J BIOL CHEM, V261, P5480; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P39706, DOI 10.1074/jbc.M308559200; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, BIOCHEM CELL BIOL, V77, P11, DOI 10.1139/bcb-77-1-11; Loo TW, 2004, J BIOL CHEM, V279, P7692, DOI 10.1074/jbc.M311825200; Loo TW, 2003, J BIOL CHEM, V278, P50136, DOI 10.1074/jbc.M310448200; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Loo TW, 1998, METHOD ENZYMOL, V292, P480; Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Seigneuret M, 2003, J BIOL CHEM, V278, P30115, DOI 10.1074/jbc.M302443200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Thomas Hilary, 2003, Cancer Control, V10, P159; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383	55	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18232	18238		10.1074/jbc.M400229200	http://dx.doi.org/10.1074/jbc.M400229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14749322	hybrid			2022-12-27	WOS:000221041500018
J	Reynolds, LF; de Bettignies, C; Norton, T; Beeser, A; Chernoff, J; Tybulewicz, VLJ				Reynolds, LF; de Bettignies, C; Norton, T; Beeser, A; Chernoff, J; Tybulewicz, VLJ			Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IMMATURE CD4(+)CD8(+) THYMOCYTES; EXCHANGE FACTOR VAV; RHO-FAMILY; NEGATIVE SELECTION; ANTIGEN RECEPTOR; MAP KINASE; PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT	Vav1 is a signaling protein required for both positive and negative selection of CD4(+)CD8(+) double positive thymocytes. Activation of the ERK MAPK pathway is also required for positive selection. Previous work has shown that Vav1 transduces T cell receptor (TCR) signals leading to an intracellular calcium flux. We now show that in double positive thymocytes Vav1 is required for TCR-induced activation of the ERK1 and ERK2 kinases via a pathway involving the Ras GTPase, and B-Raf, MEK1, and MEK2 kinases. Furthermore, we show that Vav1 transduces TCR signals to Ras by controlling the membrane recruitment of two guanine nucleotide exchange factors. First, Vav1 transduces signals via phospholipase Cgamma1 leading to the membrane recruitment of RasGRP1. Second, Vav1 is required for recruitment of Sos1 and - 2 to the transmembrane adapter protein LAT. Finally, we show that Vav1 is required for TCR-induced LAT phosphorylation, a key event for the activation of both phospholipase Cgamma1 and Sos1/2. We propose that reduced LAT phosphorylation is the key reason for defective TCR-induced calcium flux and ERK activation in Vav1-deficient cells.	Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Natl Inst Med Res, Div Mol Immunol, London NW7 1AA, England; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	MRC National Institute for Medical Research; MRC National Institute for Medical Research; Fox Chase Cancer Center	Tybulewicz, VLJ (corresponding author), Natl Inst Med Res, Div Immune Cell Biol, Ridgeway,Mill Hill, London NW7 1AA, England.	vtybule@nimr.mrc.ac.uk	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836; Tybulewicz, Victor/0000-0003-2439-0798	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054168] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54168] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEROLAILA J, 1996, J EXP MED, V184, P9; ABEROLAILA J, 1995, NATURE, V373, P620; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; Bommhardt U, 2000, J IMMUNOL, V164, P2326, DOI 10.4049/jimmunol.164.5.2326; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Caloca MJ, 2003, EMBO J, V22, P3326, DOI 10.1093/emboj/cdg316; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; IZQUIERDO M, 1994, EUR J IMMUNOL, V24, P2462, DOI 10.1002/eji.1830241031; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Liu Y, 2002, BIOCHEM J, V361, P255, DOI 10.1042/bj3610255; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Martin P, 2002, EMBO J, V21, P4049, DOI 10.1093/emboj/cdf407; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Smyth LA, 1998, P NATL ACAD SCI USA, V95, P8193, DOI 10.1073/pnas.95.14.8193; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508; Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	65	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18239	18246		10.1074/jbc.M400257200	http://dx.doi.org/10.1074/jbc.M400257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14764585	hybrid			2022-12-27	WOS:000221041500019
J	Jung, MS; Jin, DH; Chae, HD; Kang, S; Kim, SC; Bang, YJ; Choi, TS; Choi, KS; Shin, DY				Jung, MS; Jin, DH; Chae, HD; Kang, S; Kim, SC; Bang, YJ; Choi, TS; Choi, KS; Shin, DY			Bcl-x(L) and E1B-19K proteins inhibit p53-induced irreversible growth arrest and senescence by preventing reactive oxygen species-dependent p38 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; ONCOGENIC RAS; CHROMOSOMAL BREAKPOINT; REPLICATIVE SENESCENCE; OXIDATIVE STRESS; CELL-SURVIVAL; BCL-2 FAMILY; KINASE; P53; INDUCE	In this study, we describe novel functions of the antiapoptotic Bcl-2 family proteins. Bcl-x(L) and E1B-19K were found to inhibit p53-induced irreversible growth arrest and senescence, but not to inhibit transient growth arrest, implying that Bcl-x(L) and E1B-19K are specifically involved in senescence without participating in growth arrest. We provide several lines of evidences showing that the functions of Bcl-x(L) and E1B-19K to prevent generation of reactive oxygen species (ROS) are important to inhibit senescence induction. First, we found that that ROS are increased during p53-induced senescence. Moreover, Bcl-x(L) and E1B-19K inhibit this p53-induced ROS generation. Second, antioxidants prevent the induction of senescence and ROS by p53, but not the persistence of the senescence phenotype. Third, the anti-senescence functions of Bcl-x(L) and E1B-19K were suppressed by adding exogenous ROS. These results suggest that Bcl-x(L) and E1B-19K inhibit senescence induction by preventing ROS generation. Furthermore, p38 kinase was found to be activated during p53-induced senescence, but not in cells expressing Bcl-x(L) or E1B-19K, or in cells treated with anti-oxidants. Consistently, a chemical inhibitor of p38 kinase, SB203580, was found to inhibit p53-induced senescence, but only when treated before the cellular commitment to senescence, implying that p38 kinase is necessary for senescence induction. Therefore, Bcl-x(L) and E1B-19K inhibit p53-induced senescence by preventing ROS generation, which in turn leads to the activation of p38 kinase. These results also suggest that the oncogenic potential of Bcl-2 is due to its ability to inhibit senescence as well as apoptosis.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab Cell Cycle Control, Cheonan 330714, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305333, South Korea; Sogang Univ, Dept Life Sci, Seoul 121742, South Korea; Ajou Univ, Coll Med, Inst Med Sci, Suwon 442749, South Korea	Dankook University; Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST); Sogang University; Ajou University	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab Cell Cycle Control, Cheonan 330714, South Korea.	dreamer@dku.edu	Chae, Hee-Don/D-2620-2011; Kim, Sun Chang/C-2026-2011; Kim, Sun/GSN-4867-2022; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597; Choi, Kyeong Sook/0000-0003-2331-0856				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Haq R, 2002, CANCER RES, V62, P5076; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hochman A, 1998, J NEUROCHEM, V71, P741; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; MIYASHITA T, 1993, BLOOD, V81, P151; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CLIN PATHOL, V50, P799, DOI 10.1136/jcp.50.10.799; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; Tyurina YY, 1997, ARCH BIOCHEM BIOPHYS, V344, P413, DOI 10.1006/abbi.1997.0201; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Xu H J, 1997, Adv Pharmacol, V40, P369, DOI 10.1016/S1054-3589(08)60145-3; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	46	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17765	17771		10.1074/jbc.M305015200	http://dx.doi.org/10.1074/jbc.M305015200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14764594	hybrid, Green Published			2022-12-27	WOS:000220870400108
J	Ma, DQ; McCorkle, JR; Kaetzel, DM				Ma, DQ; McCorkle, JR; Kaetzel, DM			The metastasis suppressor NM23-H1 possesses 3 '-5 ' exonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; SITE-DIRECTED MUTAGENESIS; WERNER-SYNDROME PROTEIN; DNA-REPLICATION ERRORS; GROWTH-FACTOR; EXONUCLEASE ACTIVITY; PROOFREADING EXONUCLEASE; INHIBITORY-ACTIVITY; CATALYTIC SUBUNIT; POLYMERASE-DELTA	NM23-H1 belongs to a family of eight gene products in humans that have been implicated in cellular differentiation and development, as well as oncogenesis and tumor metastasis. We have defined NM23-H1 biochemically as a 3'-5' exonuclease by virtue of its ability in stoichiometric amounts to excise single nucleotides in a stepwise manner from the 3' terminus of DNA. The activity is dependent upon the presence of Mg2+, is most pronounced with single-stranded substrates or mismatched bases at the 3' terminus of double-stranded substrates, and is inhibited by both ATP and the incorporation of cordycepin, a 2'-deoxyadenosine analogue, into the 3'-terminal position. The 3'- 5' exonuclease activity was assigned to NM23-H1 by virtue of: 1) precise coelution of enzymatic activity with wild-type and mutant forms of NM23-H1 protein during purification by hydroxylapatite and gel filtration column high performance liquid chromatography and 2) significantly diminished activity exhibited by purified recombinant mutant forms of the proteins. Lysine 12 appears to play an important role in the catalytic mechanism, as evidenced by the significant reduction in 3'-5' exonuclease activity resulting from a Lys(12) to glutamine substitution within the protein. 3'-5' Exonucleases are believed to play an important role in DNA repair, a logical candidate function underlying the putative antimetastatic and oncogenic activities of NM23-H1.	Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Kaetzel, DM (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, MS 305,800 Rose St, Lexington, KY 40536 USA.	dmkaetz@uky.edu	McCorkle, Rob/AAH-3759-2019	McCorkle, Rob/0000-0002-5028-8853; ma, deqin/0000-0002-8581-6345	NCI NIH HHS [CA83237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R P, 1978, Methods Enzymol, V51, P376; Anan K, 1996, SURGERY, V119, P333, DOI 10.1016/S0039-6060(96)80120-6; Backer MV, 2000, ANTICANCER RES, V20, P1743; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; BEVILACQUA G, 1989, CANCER RES, V49, P5185; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; ESTEBAN JA, 1994, J BIOL CHEM, V269, P31946; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; FRIEDBERG EC, 1981, ENZYMES, P251; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Hamby CV, 2000, INT J CANCER, V88, P547, DOI 10.1002/1097-0215(20001115)88:4<547::AID-IJC5>3.0.CO;2-L; Hartsough MT, 2002, J BIOL CHEM, V277, P32389, DOI 10.1074/jbc.M203115200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Jackson AL, 1998, GENETICS, V148, P1483; Kaetzel DM, 2003, CYTOKINE GROWTH F R, V14, P427, DOI 10.1016/S1359-6101(03)00051-0; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360; KESTI T, 1993, J BIOL CHEM, V268, P10238; KORANGY F, 1992, J BIOL CHEM, V267, P1733; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; Lee HY, 1999, CANCER LETT, V145, P93, DOI 10.1016/S0304-3835(99)00236-0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; Levit MN, 2002, J BIOL CHEM, V277, P5163, DOI 10.1074/jbc.M111170200; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu B, 1996, J BIOL CHEM, V271, P26281, DOI 10.1074/jbc.271.42.26281; Lombardi D, 2001, CELL DEATH DIFFER, V8, P470, DOI 10.1038/sj.cdd.4400842; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Machwe A, 2002, J BIOL CHEM, V277, P4492, DOI 10.1074/jbc.M108880200; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mazur DJ, 2001, J BIOL CHEM, V276, P17022, DOI 10.1074/jbc.M100623200; Miller H, 1996, BIOCHEMISTRY-US, V35, P12919, DOI 10.1021/bi960326d; Milon L, 2000, J BIOL CHEM, V275, P14264, DOI 10.1074/jbc.275.19.14264; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pisani FM, 1998, BIOCHEMISTRY-US, V37, P15005, DOI 10.1021/bi981127s; Plchova H, 2003, J BIOL CHEM, V278, P44128, DOI 10.1074/jbc.M303891200; Postel EH, 2003, P NATL ACAD SCI USA, V100, P13247, DOI 10.1073/pnas.2333230100; Postel EH, 2002, BIOCHEMISTRY-US, V41, P6330, DOI 10.1021/bi025606+; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Postel EH, 1999, J BIOL CHEM, V274, P22821, DOI 10.1074/jbc.274.32.22821; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; REDDY MK, 1992, J BIOL CHEM, V267, P14157; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SAPORITO SM, 1989, J BACTERIOL, V171, P2542, DOI 10.1128/jb.171.5.2542-2546.1989; Schaertl S, 1996, FEBS LETT, V394, P316, DOI 10.1016/0014-5793(96)00978-7; Shevelev Igor V., 2002, TheScientificWorldJOURNAL, V2, P275; Shevelev IV, 1996, MUTAT RES-FUND MOL M, V352, P51, DOI 10.1016/0027-5107(95)00230-8; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Zhu L, 1999, BIOCHEM BIOPH RES CO, V259, P262, DOI 10.1006/bbrc.1999.0774	81	84	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18073	18084		10.1074/jbc.M400185200	http://dx.doi.org/10.1074/jbc.M400185200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960567	hybrid			2022-12-27	WOS:000220870400143
J	Chinault, SL; Overton, MC; Blumer, KJ				Chinault, SL; Overton, MC; Blumer, KJ			Subunits of a yeast oligomeric G protein-coupled receptor are activated independently by agonist but function in concert to activate G protein heterotrimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; GABA-B RECEPTOR; SACCHAROMYCES-CEREVISIAE; LIGAND-BINDING; TRANSMEMBRANE DOMAIN-1; SIGNAL-TRANSDUCTION; INTRACELLULAR LOOPS; PHEROMONE RECEPTOR; OPIOID RECEPTORS; GB2 SUBUNIT	G protein-coupled receptors (GPCRs) form dimeric or oligomeric complexes in vivo. However, the function of oligomerization in receptor-mediated G protein activation is unclear. Previous studies of the yeast alpha-factor receptor (STE2 gene product) have indicated that oligomerization promotes signaling. Here we have addressed the mechanism by which oligomerization facilitates G protein signaling by examining the ability of ligand binding- and G protein coupling-defective alpha-factor receptors to form complexes in vivo and to correct their signaling defects when co-expressed ( trans complementation). Newly and previously identified receptor mutants indicated that ligand binding involves the exofacial end of transmembrane domain (TM) 4, whereas G protein coupling involves ic1, ic3, the C-terminal tail, and the intracellular ends of TM2 and TM3. Mutant receptors bearing substitutions in these domains formed homo-oligomeric or hetero-oligomeric complexes in vivo, as indicated by results of fluorescence resonance energy transfer experiments. Co-expression of ligand binding- and G protein coupling-defective mutant receptors did not significantly improve signaling. In contrast, co-expression of ic1 and ic3 mutations in trans but not in cis significantly increased signaling efficiency. Therefore, we suggest that subunits of the alpha-factor receptor: 1) are activated independently rather than cooperatively by agonist, and 2) function in a concerted fashion to promote G protein activation, possibly by contacting different subunits or regions of the G protein heterotrimer.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	kblumer@cellbio.wustl.edu	Blumer, Kendall J/C-5268-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044592] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44592] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; CARRILLO JJ, 2003, J BIOL CHEM, V14, P14; Celic A, 2003, BIOCHEMISTRY-US, V42, P3004, DOI 10.1021/bi0269308; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dosil M, 2000, MOL CELL BIOL, V20, P5321, DOI 10.1128/MCB.20.14.5321-5329.2000; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Havlickova M, 2002, MOL PHARMACOL, V62, P343, DOI 10.1124/mol.62.2.343; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Ji IH, 2002, MOL ENDOCRINOL, V16, P1299, DOI 10.1210/me.16.6.1299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; MATTERA R, 1985, J BIOL CHEM, V260, P7410; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parrish W, 2002, GENETICS, V160, P429; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Rieke F, 1998, BIOPHYS J, V75, P1836, DOI 10.1016/S0006-3495(98)77625-8; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; SCHWYZER R, 1977, ANN NY ACAD SCI, V247, P3; Shah A, 1996, BIOCHEM BIOPH RES CO, V226, P242, DOI 10.1006/bbrc.1996.1340; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; WEINER JL, 1993, J BIOL CHEM, V268, P8070; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	55	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16091	16100		10.1074/jbc.M311099200	http://dx.doi.org/10.1074/jbc.M311099200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764600	hybrid			2022-12-27	WOS:000220747900050
J	Dikanov, SA; Samoilova, RI; Kolling, DRJ; Holland, JT; Crofts, AR				Dikanov, SA; Samoilova, RI; Kolling, DRJ; Holland, JT; Crofts, AR			Hydrogen bonds involved in binding the Q(i)-site semiquinone in the bc(1) complex, identified through deuterium exchange using pulsed EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR DOUBLE-RESONANCE; CYTOCHROME BC(1); ELECTRON-TRANSFER; RHODOBACTER-SPHAEROIDES; HYPERFINE COUPLINGS; BOUND SUBSTRATE; DOMAIN MOVEMENT; QUINONE; ENDOR; SITE	Exchangeable protons in the immediate neighborhood of the semiquinone (SQ) at the Q(i)-site of the bc(1) complex (ubihydroquinone: cytochrome c oxidoreductase (EC 1.10.2.2)) from Rhodobacter sphaeroides have been characterized using electron spin echo envelope modulation (ESEEM) and hyperfine sublevel correlation spectroscopy (HYSCORE) and visualized by substitution of H2O by (H2O)-H-2. Three exchangeable protons interact with the electron spin of the SQ. They possess different isotropic and anisotropic hyperfine couplings that allow a clear distinction between them. The strength of interactions indicates that the protons are involved in hydrogen bonds with SQ. The hyperfine couplings differ from values typical for in-plane hydrogen bonds previously observed in model experiments. It is suggested that the two stronger couplings involve formation of hydrogen bonds with carbonyl oxygens, which have a significant out-of-plane character due to the combined influence of bulky substituents and the protein environment. These two hydrogen bonds are most probably to side chains suggested from crystallographic structures (His-217 and Asp-252 in R. sphaeroides). Assignment of the third hydrogen bond is more ambiguous but may involve either a bond between Asn-221 and a methoxy O-atom or a bond to water. The structural and catalytic roles of the exchangeable protons are discussed in the context of three high resolution crystallographic structures for mitochondrial bc1 complexes. Potential H-bonds, including those to water molecules, form a network connecting the quinone (ubiquinone) occupant and its ligands to the propionates of heme b(H) and the external aqueous phase. They provide pathways for exchange of protons within the site and with the exteriors, needed to accommodate the different hydrogen bonding requirements of different quinone species during catalysis.	Univ Illinois, Dept Biochem, Roger Adams Lab 419, Urbana, IL 61801 USA; Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia; Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS; University of Illinois System; University of Illinois Urbana-Champaign	Dikanov, SA (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 419, 600 S Mathews Ave, Urbana, IL 61801 USA.	dikanov@uiuc.edu; a-crofts@life.uiuc.edu	Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487	FOGARTY INTERNATIONAL CENTER [R03TW001495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062954, R01GM035438] Funding Source: NIH RePORTER; FIC NIH HHS [1 R03 TW 01495] Funding Source: Medline; NCRR NIH HHS [S10-RR15878] Funding Source: Medline; NIGMS NIH HHS [GM 62954, GM 35438] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; Crofts AR, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P493; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; de Vries S., 1982, FUNCTION QUINONES EN, P235; DELAROSA FF, 1983, FEBS LETT, V163, P140, DOI 10.1016/0014-5793(83)81181-8; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; Dikanov SA, 2000, J MAGN RESON, V144, P228, DOI 10.1006/jmre.2000.2055; DIKANOV SA, 1995, J MAGN RESON SER A, V116, P125, DOI 10.1006/jmra.1995.1199; Flores M, 2003, CHEM PHYS, V294, P401, DOI 10.1016/S0301-0104(03)00321-5; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; GLASER EG, 1984, FEBS LETT, V178, P336, DOI 10.1016/0014-5793(84)80629-8; HACKER B, 1994, BIOCHEMISTRY-US, V33, P13022, DOI 10.1021/bi00248a011; Hastings SF, 2000, EUR J BIOCHEM, V267, P5638, DOI 10.1046/j.1432-1327.2000.01643.x; HOFER P, 1986, CHEM PHYS LETT, V132, P279, DOI 10.1016/0009-2614(86)80124-5; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Kuras R, 1998, BIOCHEMISTRY-US, V37, P16280, DOI 10.1021/bi9813476; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; MacMillan F, 1995, MAGN RESON CHEM, V33, pS81, DOI 10.1002/mrc.1260331314; MEINHARDT SW, 1984, ADV PHOTOSYNTHESIS R, V1, P649; O'Malley PJ, 1998, CHEM PHYS LETT, V291, P367, DOI 10.1016/S0009-2614(98)00571-5; O'Malley PJ, 1998, J PHYS CHEM A, V102, P248, DOI 10.1021/jp972467a; Okamura MY, 2000, BBA-BIOENERGETICS, V1458, P148, DOI 10.1016/S0005-2728(00)00065-7; OMalley PJ, 1997, J PHYS CHEM A, V101, P6334, DOI 10.1021/jp971238l; OMALLEY PJ, 1986, J AM CHEM SOC, V108, P3995, DOI 10.1021/ja00274a024; OMalley PJ, 1997, J PHYS CHEM A, V101, P9813, DOI 10.1021/jp973032q; REIJERSE EJ, 1991, J CHEM PHYS, V95, P836, DOI 10.1063/1.461091; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006; SALERNO JC, 1989, J BIOL CHEM, V264, P15398; Veselov AV, 2000, BIOCHEMISTRY-US, V39, P3169, DOI 10.1021/bi9926835; Wraight CA, 2004, FRONT BIOSCI-LANDMRK, V9, P309, DOI 10.2741/1236	38	37	39	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15814	15823		10.1074/jbc.M313417200	http://dx.doi.org/10.1074/jbc.M313417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14736869	hybrid			2022-12-27	WOS:000220747900017
J	Feinberg, MW; Watanabe, M; Lebedeva, MA; Depina, AS; Hanai, J; Mammoto, T; Frederick, JP; Wang, XF; Sukhatme, VP; Jain, MK				Feinberg, MW; Watanabe, M; Lebedeva, MA; Depina, AS; Hanai, J; Mammoto, T; Frederick, JP; Wang, XF; Sukhatme, VP; Jain, MK			Transforming growth factor-beta 1 inhibition of vascular smooth muscle cell activation is mediated via Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NF-KAPPA-B; BINDING PROTEIN C/EBP; OXIDE SYNTHASE GENE; C-REACTIVE PROTEIN; TGF-BETA; TRANSCRIPTIONAL REGULATION; INTERLEUKIN-6; EXPRESSION; ATHEROSCLEROSIS	Activation of vascular smooth muscle cells (VSMCs) by proinflammatory cytokines is a key feature of atherosclerotic lesion formation. Transforming growth factor (TGF)-beta1 is a pleiotropic growth factor that can modulate the inflammatory response in diverse cell types including VSMCs. However, the mechanisms by which TGF-beta1 is able to mediate these effects remains incompletely understood. We demonstrate here that the ability of TGF-beta1 to inhibit markers of VSMC activation, inducible nitric-oxide synthase ( iNOS) and interleukin (IL)-6, is mediated through its downstream effector Smad3. In reporter gene transfection studies, we found that among a panel of Smads, Smad3 could inhibit iNOS induction in an analogous manner as exogenous TGF-beta1. Adenoviral overexpression of Smad3 potently repressed inducible expression of endogenous iNOS and IL-6. Conversely, TGF-beta1 inhibition of cytokine-mediated induction of iNOS and IL-6 expression was completely blocked in Smad3-deficient VSMCs. Previous studies demonstrate that CCAAT/enhancer-binding protein (C/EBP) and NF-kappaB sites are critical for cytokine induction of both the iNOS and IL-6 promoters. We demonstrate that the inhibitory effect of Smad3 occurs via a novel antagonistic effect of Smad3 on C/EBP DNA-protein binding and activity. Smad3 mediates this effect in part by inhibiting C/EBP-beta and C/EBP-delta through distinct mechanisms. Furthermore, we find that Smad3 prevents the cooperative induction of the iNOS promoter by C/EBP and NF-kappaB. These data demonstrate that Smad3 plays an essential role in mediating TGF-beta1 anti-inflammatory response in VSMCs.	Brigham & Womens Hosp, Boston, MA 02115 USA; Div Cardiovasc Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA; Duke Univ, Durham, NC 27710 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Duke University	Jain, MK (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	mjain@rics.bwh.harvard.edu	Sukhatme, Vikas/W-2776-2019	Feinberg, Mark/0000-0001-9523-3859	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67755, HL03747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Basu A, 2002, GLIA, V40, P109, DOI 10.1002/glia.10118; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; Blake GJ, 2003, J AM COLL CARDIOL, V41, p37S, DOI 10.1016/S0735-1097(02)02953-4; Chen JQ, 2003, ARTERIOSCL THROM VAS, V23, P97, DOI 10.1161/01.ATV.0000040223.74255.5A; Choy L, 2003, J BIOL CHEM, V278, P9609, DOI 10.1074/jbc.M212259200; Coyle-Rink J, 2002, VIROLOGY, V299, P240, DOI 10.1006/viro.2002.1439; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Detmers PA, 2000, J IMMUNOL, V165, P3430, DOI 10.4049/jimmunol.165.6.3430; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Feinberg MW, 2004, CIRC RES, V94, P601, DOI 10.1161/01.RES.0000119170.70818.4F; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Fukuoka T, 1999, J BIOL CHEM, V274, P25576, DOI 10.1074/jbc.274.36.25576; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200; GUNTHER S, 1980, NATURE, V287, P230, DOI 10.1038/287230a0; Hecker M, 1997, BRIT J PHARMACOL, V120, P1067, DOI 10.1038/sj.bjp.0701026; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hojo Y, 2000, HEART, V84, P83, DOI 10.1136/heart.84.1.83; IKEDA U, 1991, AM J PHYSIOL, V260, pH1713, DOI 10.1152/ajpheart.1991.260.5.H1713; IKEDA U, 1993, ATHEROSCLEROSIS, V104, P61, DOI 10.1016/0021-9150(93)90176-U; Kelkenberg U, 2002, ARTERIOSCL THROM VAS, V22, P949, DOI 10.1161/01.ATV.0000017198.16727.27; Kleemann R, 2003, BLOOD, V101, P545, DOI 10.1182/blood-2002-06-1762; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; LE JM, 1989, LAB INVEST, V61, P588; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Maret A, 1999, ENDOCRINOLOGY, V140, P2876, DOI 10.1210/en.140.6.2876; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; Niu XL, 2001, CIRCULATION, V103, P1115, DOI 10.1161/01.CIR.103.8.1115; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; ROTH M, 1995, P NATL ACAD SCI USA, V92, P1312, DOI 10.1073/pnas.92.5.1312; Sakitani K, 1998, GENES CELLS, V3, P321, DOI 10.1046/j.1365-2443.1998.00193.x; Schwartz RS, 2002, REV CARDIOVASC ME S5, V3, P4; Teng XW, 2002, AM J PHYSIOL-CELL PH, V282, pC144, DOI 10.1152/ajpcell.2002.282.1.C144; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200	51	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16388	16393		10.1074/jbc.M309664200	http://dx.doi.org/10.1074/jbc.M309664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754879	hybrid			2022-12-27	WOS:000220747900085
J	Hipp, MS; Raasi, S; Groettrup, M; Schmidtke, G				Hipp, MS; Raasi, S; Groettrup, M; Schmidtke, G			NEDD8 ultimate Buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26S PROTEASOME; SUBUNIT; SYSTEM; RAD23; GENE; RECOGNITION; EXPRESSION; PARTICLE; IDENTIFICATION; PROTEOLYSIS	FAT10 is an interferon-gamma-inducible ubiquitin-like protein that consists of two ubiquitin-like domains. FAT10 bears a diglycine motif at its C terminus that can form isopeptide bonds to so far unidentified target proteins. Recently we found that FAT10 and its conjugates are rapidly degraded by the proteasome and that the N-terminal fusion of FAT10 to a long lived protein markedly reduces its half-life. FAT10 may hence direct target proteins to the proteasome for degradation. In this study we report a new interaction partner of FAT10 that may link FAT10 to the proteasome. A yeast two-hybrid screen identified NEDD8 ultimate buster-1L (NUB1L) as a non-covalent binding partner of FAT10, and this interaction was confirmed by coimmunoprecipitation and glutathione S-transferase pull-down experiments. NUB1L is also an interferon-inducible protein that has been reported to interact with the ubiquitin-like protein NEDD8, thus leading to accelerated NEDD8 degradation. Here we show that NUB1L binds to FAT10 much stronger than to NEDD8 and that NEDD8 cannot compete with FAT10 for NUB1L binding. The interaction of FAT10 and NUB1L is specific as green fluorescent fusion proteins containing ubiquitin or SUMO-1 do not bind to NUB1L. The coexpression of NUB1L enhanced the degradation rate of FAT10 8-fold, whereas NEDD8 degradation was only accelerated 2-fold. Because NUB1 was shown to bind to the proteasome subunit RPN10 in vitro and to be contained in 26 S proteasome preparations, it may function as a linker that targets FAT10 for degradation by the proteasome.	Univ Konstanz, Dept Biol, Div Immunol, D-78457 Constance, Germany	University of Konstanz	Groettrup, M (corresponding author), Univ Konstanz, Fachbereich Biol Immunol, P1101,Univ Str 10, D-78457 Constance, Germany.	Marcus.Groettrup@uni-konstanz.de	Hipp, Mark/AAA-4238-2022	Hipp, Mark/0000-0002-0497-3016				Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Gao L, 2003, J VIROL, V77, P4149, DOI 10.1128/JVI.77.7.4149-4159.2003; Gietz RD, 2001, BIOTECHNIQUES, V30, P816, DOI 10.2144/01304rv02; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Serebriiskii IG, 2000, ANAL BIOCHEM, V285, P1, DOI 10.1006/abio.2000.4672; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Tanaka T, 2003, J BIOL CHEM, V278, P32905, DOI 10.1074/jbc.M212057200; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y	33	75	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16503	16510		10.1074/jbc.M310114200	http://dx.doi.org/10.1074/jbc.M310114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757770	Green Published, hybrid			2022-12-27	WOS:000220747900099
J	Iijima, M; Huang, YE; Luo, HR; Vazquez, F; Devreotes, PN				Iijima, M; Huang, YE; Luo, HR; Vazquez, F; Devreotes, PN			Novel mechanism of PTEN regulation by its phosphatidylinositol 4,5-bisphosphate binding motif is critical for chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PTEN; PHOSPHATASE-ACTIVITY; LIPID PRODUCTS; CELL MOTILITY; CAMP RECEPTOR; LIVING CELLS; LEADING-EDGE; PDZ DOMAIN; MEMBRANE; ACTIVATION	In chemotaxing cells, localization of phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3) to the leading edge of the cell sets the direction and regulates the formation of pseudopods at the anterior. We show that the lipid phosphatase activity of PTEN mediates chemotaxis and that the sharp localization of PI(3,4,5)P-3 requires localization of PTEN to the rear of the cell. Our data suggest that a phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) binding motif at the N terminus of PTEN serves the dual role of localizing the enzyme to the membrane and regulating its activity. Mutations in this motif enhance catalytic activity but render the enzyme inactive in vivo by preventing membrane association. The key role of this motif may explain the heretofore puzzling tumor-suppressing mutations occurring within the PI(4,5)P-2 binding motif. On the other hand, the localization of PTEN does not depend on its phosphatase activity, the actin cytoskeleton, or the intracellular level of PI(3,4,5)P-3, suggesting that events controlling localization are upstream of phosphoinositide signaling.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA.	pnd@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933, R01GM028007, R37GM028007] Funding Source: NIH RePORTER; NIGMS NIH HHS [GMGM34933, GM28007] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Chen LF, 2003, MOL BIOL CELL, V14, P5028, DOI 10.1091/mbc.E03-05-0339; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; Huang YE, 2003, MOL BIOL CELL, V14, P1913, DOI 10.1091/mbc.E02-10-0703; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; KLEIN P, 1987, J BIOL CHEM, V262, P352; KLEIN P, 1988, METHOD ENZYMOL, V159, P267; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; Miller RT, 1996, FASEB J, V10, P171, DOI 10.1096/fasebj.10.1.8566539; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Niggli V, 2000, FEBS LETT, V473, P217, DOI 10.1016/S0014-5793(00)01534-9; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5	41	159	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16606	16613		10.1074/jbc.M312098200	http://dx.doi.org/10.1074/jbc.M312098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764604	hybrid			2022-12-27	WOS:000220747900111
J	Panda, DK; Miao, DS; Bolivar, I; Li, JR; Huo, RJ; Hendy, GN; Goltzman, D				Panda, DK; Miao, DS; Bolivar, I; Li, JR; Huo, RJ; Hendy, GN; Goltzman, D			Inactivation of the 25-hydroxyvitamin D 1 alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-DEFICIENCY RICKETS; D-DEPENDENT RICKETS; PARATHYROID-HORMONE; ION HOMEOSTASIS; 1,25-DIHYDROXYVITAMIN D-3; BIOMECHANICAL ANALYSES; TARGETED ABLATION; BONE-FORMATION; KNOCKOUT MICE; ANIMAL-MODEL	We employed a genetic approach to determine whether deficiency of 1,25-dihydroxyvitamin D (1,25(OH)(2)D) and deficiency of the vitamin D receptor (VDR) produce the same alterations in skeletal and calcium homeostasis and whether calcium can subserve the skeletal functions of 1,25(OH)(2)D and the VDR. Mice with targeted deletion of the 25-hydroxyvitamin D 1alpha-hydroxylase (1alpha(OH) ase (-/-)) gene, the VDR gene, and both genes were exposed to 1) a high calcium intake, which maintained fertility but left mice hypocalcemic; 2) this intake plus three times weekly injections of 1,25( OH)(2)D-3, which normalized calcium in the 1alpha(OH) ase (-/-) mice only; or 3) a "rescue" diet, which normalized calcium in all mutants. These regimens induced different phenotypic changes, thereby disclosing selective modulation by calcium and the vitamin D system. Parathyroid gland size and the development of the cartilaginous growth plate were each regulated by calcium and by 1,25(OH)(2)D-3 but independent of the VDR. Parathyroid hormone secretion and mineralization of bone reflected ambient calcium levels rather than the 1,25(OH)(2)D/VDR system. In contrast, increased calcium absorption and optimal osteoblastogenesis and osteoclastogenesis were modulated by the 1,25(OH)(2)D/VDR system. These studies indicate that the calcium ion and the 1,25(OH)(2)D/VDR system exert discrete effects on skeletal and calcium homeostasis, which may occur coordinately or independently.	McGill Univ, Ctr Hlth, Dept Med, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Human Genet, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Goltzman, D (corresponding author), Royal Victoria Hosp, Dept Med, Calcium Res Lab, H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	david.goltzman@mcgill.ca		Miao, Dengshun/0000-0002-2682-3502				Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; Bai XY, 2002, MOL ENDOCRINOL, V16, P2913, DOI 10.1210/me.2002-0113; BEER S, 1981, CLIN ENDOCRINOL, V14, P395, DOI 10.1111/j.1365-2265.1981.tb00626.x; BIKLE DD, 1986, J CLIN ENDOCR METAB, V63, P954, DOI 10.1210/jcem-63-4-954; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Dardenne O, 2003, J BONE MINER RES, V18, P637, DOI 10.1359/jbmr.2003.18.4.637; Dardenne O, 2003, BONE, V32, P332, DOI 10.1016/S8756-3282(03)00023-1; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; Donohue MM, 2002, ENDOCRINOLOGY, V143, P3691, DOI 10.1210/en.2002-220454; Eil C, 1986, Adv Exp Med Biol, V196, P407; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; FRASER D, 1973, NEW ENGL J MED, V289, P817, DOI 10.1056/NEJM197310182891601; Fu GK, 1997, DNA CELL BIOL, V16, P1499, DOI 10.1089/dna.1997.16.1499; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Gascon-Barre M., 1997, Vitamin D., P41; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; He B, 2001, ENDOCRINOLOGY, V142, P2070, DOI 10.1210/en.142.5.2070; Johnson LE, 2001, J NUTR, V131, P1787, DOI 10.1093/jn/131.6.1787; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kimmel-Jehan C, 2000, BBA-GEN SUBJECTS, V1475, P109, DOI 10.1016/S0304-4165(00)00065-9; Kitazawa S, 2003, J CELL BIOCHEM, V89, P771, DOI 10.1002/jcb.10567; KREMER R, 1989, ENDOCRINOLOGY, V125, P935, DOI 10.1210/endo-125-2-935; Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002-0225; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; LOPEZDELEON A, 1985, J HISTOCHEM CYTOCHEM, V33, P737, DOI 10.1177/33.8.2410480; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305; Miao DS, 2002, BMC MUSCULOSKELET DI, V3, DOI 10.1186/1471-2474-3-16; Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926; Norman AW, 2002, MOL CELL ENDOCRINOL, V197, P1, DOI 10.1016/S0303-7207(02)00273-3; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Panda DK, 2001, J BONE MINER RES, V16, P46, DOI 10.1359/jbmr.2001.16.1.46; Shinki T, 1997, P NATL ACAD SCI USA, V94, P12920, DOI 10.1073/pnas.94.24.12920; St-Arnaud R, 2000, ENDOCRINOLOGY, V141, P2658, DOI 10.1210/en.141.7.2658; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; Takeda S, 1999, ENDOCRINOLOGY, V140, P1005, DOI 10.1210/en.140.2.1005; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Vegesna V, 2002, ENDOCRINOLOGY, V143, P4389, DOI 10.1210/en.2002-220118; Yagishita N, 2001, ENDOCRINOLOGY, V142, P5332, DOI 10.1210/en.142.12.5332; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	46	282	291	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16754	16766		10.1074/jbc.M310271200	http://dx.doi.org/10.1074/jbc.M310271200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14739296	hybrid			2022-12-27	WOS:000220747900128
J	Pramanik, R; Jorgensen, TN; Xin, H; Kotzin, BL; Choubey, D				Pramanik, R; Jorgensen, TN; Xin, H; Kotzin, BL; Choubey, D			Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD MONONUCLEAR-CELLS; TRANSCRIPTIONAL ACTIVATION; NEGATIVE REGULATOR; STAT3; P202; FAMILY; GROWTH; P53; DIFFERENTIATION; ERYTHEMATOSUS	Systemic lupus erythematosus (SLE) is a prototype autoimmune disease. In human SLE patients, as well as in mouse models of SLE, the development of disease is associated with increased levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6). However, IL-6 target genes contributing to the development of disease remain to be identified. Our previous studies of one mouse model of SLE identified an interferon-inducible gene, Ifi202, as a major contributor to the disease. We now report that IL-6 induces expression of the Ifi202 gene. We found that IL-6 treatment of mouse splenocytes increased levels of Ifi202 mRNA and p202 protein. Furthermore, IL-6 treatment of NIH 3T3 cells or expression of a constitutively active form of STAT3, a known mediator of IL-6 signaling, stimulated the activity of a 202-luc-reporter through a potential STAT3 DNA-binding site ( the 202-SBS) present in the 5'-regulatory region of the Ifi202 gene. Moreover, treatment of cells with IL-6 stimulated binding of the transcription factor STAT3 to an oligonucleotide containing the 202-SBS in gel-mobility shift assays and to the 5'-regulatory region of the Ifi202 gene in chromatin immunoprecipitation assays. Importantly, site-directed mutagenesis of 202-SBS or expression of a dominant negative form of STAT3 significantly reduced constitutive as well as IL-6-stimulated activity of the 202-luc-reporter. Together, our observations support the idea that IL-6 stimulates transcription of the Ifi202 gene through STAT3 activation and predict that increased levels of IL-6 in lupus contribute to upregulation of p202.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; Univ Colorado, Hlth Sci Ctr, Div Clin Immunol, Denver, CO 80262 USA	Loyola University Chicago; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008	Jorgensen, Trine/0000-0001-8566-4647	NCI NIH HHS [CA 69031] Funding Source: Medline; NIAMS NIH HHS [AR37070] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037070] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; ALARCONRIQUELME ME, 1993, CLIN EXP IMMUNOL, V91, P220; Angelo LS, 2002, CANCER RES, V62, P932; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Balomenos D, 2000, IMMUNOL TODAY, V21, P551, DOI 10.1016/S0167-5699(00)01748-5; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; FINCK BK, 1994, J CLIN INVEST, V94, P585, DOI 10.1172/JCI117373; Gu J, 2002, RHEUMATOLOGY, V41, P759, DOI 10.1093/rheumatology/41.7.759; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; Langdon C, 2003, J IMMUNOL, V170, P548, DOI 10.4049/jimmunol.170.1.548; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Li ZJ, 2002, CHINESE MED J-PEKING, V115, P846; LINKERISRAELI M, 1991, J IMMUNOL, V147, P117; McMurray RW, 1997, CLIN IMMUNOL IMMUNOP, V84, P260, DOI 10.1006/clin.1997.4390; Mihara M, 1998, CLIN EXP IMMUNOL, V112, P397; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Peters M, 2001, EXP HEMATOL, V29, P146, DOI 10.1016/S0301-472X(00)00650-0; Rozzo SJ, 2001, IMMUNITY, V15, P435, DOI 10.1016/S1074-7613(01)00196-0; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Salvador JM, 2002, IMMUNITY, V16, P499, DOI 10.1016/S1074-7613(02)00302-3; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Santiago-Raber ML, 2003, J EXP MED, V197, P777, DOI 10.1084/jem.20021996; SEELIG HP, 1994, ARTHRITIS RHEUM-US, V37, P1672, DOI 10.1002/art.1780371117; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; Tsao Betty P, 2002, Curr Rheumatol Rep, V4, P359, DOI 10.1007/s11926-002-0046-5; Tsokos GC, 2000, MOL MED TODAY, V6, P418, DOI 10.1016/S1357-4310(00)01798-6; Vyse TJ, 1998, ANNU REV IMMUNOL, V16, P261, DOI 10.1146/annurev.immunol.16.1.261; Wakeland EK, 2001, IMMUNITY, V15, P397, DOI 10.1016/S1074-7613(01)00201-1; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16121	16127		10.1074/jbc.M313140200	http://dx.doi.org/10.1074/jbc.M313140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764608	hybrid			2022-12-27	WOS:000220747900053
J	Sarfstein, R; Gorzalczany, Y; Mizrahi, A; Berdichevsky, Y; Molshanski-Mor, S; Weinbaum, C; Hirshberg, M; Dagher, MC; Pick, E				Sarfstein, R; Gorzalczany, Y; Mizrahi, A; Berdichevsky, Y; Molshanski-Mor, S; Weinbaum, C; Hirshberg, M; Dagher, MC; Pick, E			Dual role of Rac in the assembly of NADPH oxidase, tethering to the membrane and activation of p67(phox) - A study based on mutagenesis of p67(phox)-Rac1 chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; DEPENDENT SUPEROXIDE PRODUCTION; ADENINE-DINUCLEOTIDE PHOSPHATE; SODIUM DODECYL-SULFATE; CYTOCHROME B(558); IN-VITRO; REDUCED OXIDASE; P47(PHOX); PROTEINS	NADPH oxidase activation involves the assembly of membrane-localized cytochrome b(559) with the cytosolic components p47(phox), p67(phox), and the small GTPase Rac. Assembly is mimicked by a cell-free system consisting of membranes and cytosolic components, activated by an anionic amphiphile. We reported that a chimeric construct, consisting of residues 1 - 212 of p67(phox) and full-lengthRac1, activates the oxidase in vitro in an amphiphile-dependent manner, and when prenylated, in the absence of amphiphile and p47phox. We subjected chimera p67(phox)-(1 - 212)-Rac1 to mutational analysis and found that: 1) replacement of a single basic residue at the C terminus of the Rac1 moiety by glutamine is sufficient for loss of activity by the non-prenylated chimera; replacement of all six basic residues by glutamines is required for loss of activity by the prenylated chimera. 2) A V204A mutation in the activation domain of the p67(phox) moiety leads to a reduction in activity. 3) Mutating residues, known to participate in the interaction between free p67(phox) and Rac1, in the p67(phox)( R102E) or Rac1 (A27K, G30S) moieties of the chimera, leads to a marked decrease in activity, indicating a requirement for intrachimeric bonds, in addition to the engineered fusion. 4) Chimeras, inactive because of mutations A27K or G30S in the Rac1 moiety, are reactivated by supplementation with exogenous Rac1-GTP but not with exogenous p67(phox). This demonstrates that Rac has a dual role in the assembly of NADPH oxidase. One is to tether p67(phox) to the membrane; the other is to induce an "activating" conformational change in p67(phox).	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Ela Kodesz Inst Host Def Infect Dis, IL-69978 Tel Aviv, Israel; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; CEA Grenoble, Lab DBMS BBSI, F-38054 Grenoble 9, France	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Duke University; University of Cambridge; CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel.	epick@post.tau.ac.il	; Pick, Edgar/B-1795-2008	Berdichevsky, Yevgeny/0000-0002-5038-6816; Pick, Edgar/0000-0003-4625-3233; DAGHER, Marie-Claire/0000-0001-6878-3169	NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Ebisu K, 2001, J BIOL CHEM, V276, P24498, DOI 10.1074/jbc.M101122200; Feigin L.A., 1987, STRUCTURE ANAL SMALL; Foubert TR, 2002, BBA-BIOMEMBRANES, V1567, P221, DOI 10.1016/S0005-2736(02)00619-3; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Grizot S, 2001, J BIOL CHEM, V276, P21627, DOI 10.1074/jbc.M100893200; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Leto TL., 1999, INFLAMMATION BASIC P, P769; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; Miyano K, 2001, BIOCHEMISTRY-US, V40, P14089, DOI 10.1021/bi010882u; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Paclet MH, 2000, BIOCHEMISTRY-US, V39, P9302, DOI 10.1021/bi000483j; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; Sigal N, 2003, INFLAMMATION, V27, P147, DOI 10.1023/A:1023869828688; Sigal N, 2003, J BIOL CHEM, V278, P4854, DOI 10.1074/jbc.M211011200; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	47	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16007	16016		10.1074/jbc.M312394200	http://dx.doi.org/10.1074/jbc.M312394200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761978	hybrid			2022-12-27	WOS:000220747900039
J	Yatime, L; Schmitt, E; Blanquet, S; Mechulam, Y				Yatime, L; Schmitt, E; Blanquet, S; Mechulam, Y			Functional molecular mapping of archaeal translation initiation factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR TU; BETA-SUBUNIT; CRYSTAL-STRUCTURE; TERNARY COMPLEX; FACTOR-II; GTP; BINDING; METHIONINE; EIF5	Eukaryotic and archaeal initiation factors 2 (e/aIF2) are heterotrimeric proteins (alphabetagamma) carrying methionylated initiator tRNA to the small subunit of the ribosome. The three-dimensional structure of aIF2gamma from the Archaea Pyrococcus abyssi was previously solved. This subunit forms the core of the heterotrimer. The alpha and beta subunits bind the gamma, but do not interact together. aIF2gamma shows a high resemblance with elongation factor EF1- A. In this study, we characterize the role of each subunit in the binding of the methionylated initiator tRNA. Studying various aminoacyl-tRNA ligands shows that the methionyl group is a major determinant for recognition by aIF2. aIF2gamma alone is able to specifically bind Met-tRNA(i)(Met), although with a reduced affinity as compared with the intact trimer. Site-directed mutagenesis confirms a binding mode of the tRNA molecule similar to that observed with the elongation factor. Under our assay conditions, aIF2beta is not involved in the docking of the tRNA molecule. In contrast, aIF2alpha provides the heterotrimer its full tRNA binding affinity. Furthermore, the isolated C-domain of aIF2alpha is responsible for binding of the alpha subunit to gamma. This binding involves an idiosyncratic loop of domain 2 of aIF2gamma. Association of the C-domain of aIF2alpha to aIF2gamma is enough to retrieve the binding affinity of tRNA for aIF2. The N-terminal and central domains of aIF2alpha do not interfere with tRNA binding. However, the N-domain of aIF2alpha interacts with RNA unspecifically. Based on this property, a possible contribution of aIF2alpha to formation of a productive complex between aIF2 and the small ribosomal subunit is envisaged.	Ecole Polytech, CNRS, Unite MIxte Rech 7654, Biochim Lab, F-91128 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Schmitt, E (corresponding author), Ecole Polytech, CNRS, Unite MIxte Rech 7654, Biochim Lab, F-91128 Palaiseau, France.	emma@botrytis.polytechnique.fr	Yatime, Laure/AAC-8032-2021; SCHMITT, Emmanuelle/F-2605-2019; Mechulam, Yves/F-3313-2019; Emmanuelle, SCHMITT/ABF-8658-2020	Yatime, Laure/0000-0002-3650-8012; SCHMITT, Emmanuelle/0000-0001-7532-338X; Mechulam, Yves/0000-0003-3586-3554; Emmanuelle, SCHMITT/0000-0001-7532-338X				Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; Brock S, 1998, MOL MICROBIOL, V29, P409, DOI 10.1046/j.1365-2958.1998.00893.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Castilho-Valavicius Beatriz, 1992, Gene Expression, V2, P297; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DRABKIN HJ, 1993, J BIOL CHEM, V268, P25221; Erickson FL, 2001, GENETICS, V158, P123; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Farruggio D, 1996, MOL CELL BIOL, V16, P4248; FLYNN A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P117, DOI 10.1016/0167-4781(93)90105-M; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; Kapp LD, 2004, J MOL BIOL, V335, P923, DOI 10.1016/j.jmb.2003.11.025; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P3726, DOI 10.1073/pnas.95.7.3726; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; Lee JH, 1999, P NATL ACAD SCI USA, V96, P4342, DOI 10.1073/pnas.96.8.4342; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MEINNEL T, 1995, J BIOL CHEM, V270, P15908, DOI 10.1074/jbc.270.26.15908; MELLOT P, 1989, J MOL BIOL, V208, P429, DOI 10.1016/0022-2836(89)90507-X; Merrick WC., 1996, TRANSLATION CONTROL, P31; MITSUI KI, 1981, P NATL ACAD SCI-BIOL, V78, P4128, DOI 10.1073/pnas.78.7.4128; Nika J, 2001, J BIOL CHEM, V276, P1051, DOI 10.1074/jbc.M007398200; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nonato MC, 2002, J BIOL CHEM, V277, P17057, DOI 10.1074/jbc.M111804200; Ohtsuki T, 2002, NAT STRUCT BIOL, V9, P669, DOI 10.1038/nsb826; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; PINGOUD A, 1977, EUR J BIOCHEM, V78, P403, DOI 10.1111/j.1432-1033.1977.tb11752.x; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Roll-Mecak A, 2004, J BIOL CHEM, V279, P10634, DOI 10.1074/jbc.M310418200; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Schmitt E, 2002, EMBO J, V21, P1821, DOI 10.1093/emboj/21.7.1821; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; Sette M, 1997, EMBO J, V16, P1436, DOI 10.1093/emboj/16.6.1436; Thompson GM, 2000, BIOCHEM J, V347, P703, DOI 10.1042/0264-6021:3470703; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; VONPAWELRAMMINGEN U, 1992, MOL CELL BIOL, V12, P1432, DOI 10.1128/MCB.12.4.1432; WAGNER T, 1984, J BIOL CHEM, V259, P4706	55	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15984	15993		10.1074/jbc.M311561200	http://dx.doi.org/10.1074/jbc.M311561200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761973	hybrid			2022-12-27	WOS:000220747900036
J	Miki, N; Ikuta, M; Matsui, T				Miki, N; Ikuta, M; Matsui, T			Hypoxia-induced activation of the retinoic acid receptor-related orphan receptor alpha 4 gene by an interaction between hypoxia-inducible factor-1 and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; NUCLEAR RECEPTOR; ROR-ALPHA; FACTOR 1-ALPHA; TRANSCRIPTION FACTORS; STAGGERER MOUSE; FETOPROTEIN GENE; DEFICIENT MICE; MUTANT MICE; DNA-BINDING	Hypoxia plays a key role in the pathophysiology of many disease states, and expression of the retinoic acid receptor-related orphan receptor alpha (RORalpha) gene increases under hypoxia. We investigated the mechanism for this transient hypoxia-induced increase in RORalpha expression. Reverse transcription-coupled PCR analysis revealed that the steady-state level of mRNA for the RORalpha4 isoform, but not the RORalpha1 isoform, increased in HepG2 cells after 3 h of hypoxia. Transient transfection studies showed that the hypoxia-induced increase in RORalpha4 mRNA occurs at the transcriptional level and is dependent on a hypoxia-responsive element (HRE) located downstream of the promoter. A dominant-negative mutant of hypoxia-inducible factor-1alpha (HIF-1alpha) abrogates the transcription activated by hypoxia as well as the transcription activated by exogenously expressed HIF-1alpha, demonstrating the direct involvement of HIF-1alpha in the transcriptional activation. However, HIF-1 alone was not sufficient to activate transcription in hypoxic conditions but, rather, required Sp1/Sp3, which binds to a cluster of GC-rich sequences adjacent to the HRE. Deletion of one or more of these GC boxes reduced or eliminated the HIF-1-dependent transcription. Together, these results suggest that the hypoxia-responsive region of the RORalpha4 promoter is composed of the HRE and GC-rich sequences and that the transcriptional activation under hypoxia is conferred through the cooperation of HIF-1 with Sp1/Sp3.	Fukuyama Univ, Lab Genom & Proteom, Fac Pharm & Pharmaceut Sci, Fukuyama, Hiroshima 7290292, Japan	Fukuyama University	Matsui, T (corresponding author), Fukuyama Univ, Lab Genom & Proteom, Fac Pharm & Pharmaceut Sci, 1 Gakuen Cho, Fukuyama, Hiroshima 7290292, Japan.	matsui@fupharm.fukuyama-u.ac.jp						Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bai LC, 2000, J BIOL CHEM, V275, P30725, DOI 10.1074/jbc.M004249200; Bai LC, 2002, J GASTROINTEST CANC, V31, P79, DOI 10.1385/IJGC:31:1-3:79; Besnard S, 2001, CIRC RES, V89, P1209, DOI 10.1161/hh2401.101755; Besnard S, 2002, FEBS LETT, V511, P36, DOI 10.1016/S0014-5793(01)03275-6; Besnard S, 2002, CIRC RES, V90, P820, DOI 10.1161/01.RES.0000014489.24705.71; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Bois-Joyeux B, 2000, DNA CELL BIOL, V19, P589, DOI 10.1089/104454900750019344; Burris TP, 2001, NUCL RECEPTORS GENET; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Chauvet C, 2002, BIOCHEM J, V364, P449, DOI 10.1042/BJ20011558; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Faraci FM, 2002, CIRC RES, V90, P749, DOI 10.1161/01.RES.0000016833.04130.B6; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fukuda R, 2003, CANCER RES, V63, P2330; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kaluz S, 2003, CANCER RES, V63, P917; Keates AC, 2001, J BIOL CHEM, V276, P43713, DOI 10.1074/jbc.M107838200; KOPMELS B, 1992, J NEUROCHEM, V58, P192, DOI 10.1111/j.1471-4159.1992.tb09295.x; KOPMELS B, 1990, J NEUROCHEM, V55, P1980, DOI 10.1111/j.1471-4159.1990.tb05785.x; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MATSUI T, 1995, MOL BRAIN RES, V33, P217, DOI 10.1016/0169-328X(95)00126-D; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Meyer T, 2000, P NATL ACAD SCI USA, V97, P9197, DOI 10.1073/pnas.150246097; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nacer-Cherif H, 2003, BIOCHEM J, V369, P583, DOI 10.1042/BJ20021229; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sashihara S, 1996, MOL BRAIN RES, V42, P109, DOI 10.1016/S0169-328X(96)00118-0; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2002, P NATL ACAD SCI USA, V99, P11570, DOI 10.1073/pnas.192442299; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Sun ZW, 2002, SHOCK, V18, P99, DOI 10.1097/00024382-200208000-00001; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yoshida E, 1998, GENE, V208, P307, DOI 10.1016/S0378-1119(98)00008-0; Zhang XP, 2003, NUCLEIC ACIDS RES, V31, P2900, DOI 10.1093/nar/gkg380	63	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15025	15031		10.1074/jbc.M313186200	http://dx.doi.org/10.1074/jbc.M313186200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742449	hybrid			2022-12-27	WOS:000220594700066
J	Sunohara, T; Jojima, K; Tagami, H; Inada, T; Aiba, H				Sunohara, T; Jojima, K; Tagami, H; Inada, T; Aiba, H			Ribosome stalling during translation elongation induces cleavage of mRNA being translated in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASCENT-PEPTIDE; STOP CODONS; QUALITY-CONTROL; 10SA RNA; PROTEIN; DEGRADATION; SEQUENCE; SYSTEM; OPERON; TMRNA	Recently, it has been found that ribosome pausing at stop codons caused by certain nascent peptides induces cleavage of mRNA in Escherichia coli cells (1,2). The question we addressed in the present study is whether mRNA cleavage occurs when translation elongation is prevented. We focused on a specific peptide sequence (AS17), derived from SecM, that is known to cause elongation arrest. When the crp-crr fusion gene encoding CRP-AS17-IIA(Glc) was expressed, cAMP receptor protein (CRP) proteins truncated around the arrest sequence were efficiently produced, and they were tagged by the transfer-messenger RNA (tmRNA) system. Northern blot analysis revealed that both truncated upstream crp and downstream crr mRNAs were generated along with reduced amounts of the full-length crp-crr mRNA. The truncated crp mRNA dramatically decreased in the presence of tmRNA due to rapid degradation. The 3' ends of truncated crp mRNA correspond well to the C termini of the truncated CRP proteins. We conclude that ribosome stalling by the arrest sequence induces mRNA cleavage near the arrest point, resulting in nonstop mRNAs that are recognized by tmRNA. We propose that the mRNA cleavage induced by ribosome stalling acts in concert with the tmRNA system as a way to ensure quality control of protein synthesis and possibly to regulate the expression of certain genes.	Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Aiba, H (corresponding author), Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	i45346a@nucc.cc.nagoya-u.ac.jp	Inada, Toshifumi/AAE-1517-2019					Abo T, 2002, GENES CELLS, V7, P629, DOI 10.1046/j.1365-2443.2002.00549.x; Abo T, 2000, EMBO J, V19, P3762, DOI 10.1093/emboj/19.14.3762; AIBA H, 1981, J BIOL CHEM, V256, P1905; AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; Bjornsson A, 1996, NUCLEIC ACIDS RES, V24, P1753, DOI 10.1093/nar/24.9.1753; Christensen SK, 2003, J MOL BIOL, V332, P809, DOI 10.1016/S0022-2836(03)00922-7; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Collier J, 2002, MOL MICROBIOL, V45, P745, DOI 10.1046/j.1365-2958.2002.03045.x; Drider D, 2002, MOL MICROBIOL, V43, P1319, DOI 10.1046/j.1365-2958.2002.02830.x; Gong F, 2002, SCIENCE, V297, P1864, DOI 10.1126/science.1073997; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Hayes CS, 2003, MOL CELL, V12, P903, DOI 10.1016/S1097-2765(03)00385-X; Hayes CS, 2002, J BIOL CHEM, V277, P33825, DOI 10.1074/jbc.M205405200; Hayes CS, 2002, P NATL ACAD SCI USA, V99, P3440, DOI 10.1073/pnas.052707199; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Komine Y, 1996, J BIOCHEM-TOKYO, V119, P463; Loomis WP, 2001, MOL MICROBIOL, V39, P693, DOI 10.1046/j.1365-2958.2001.02241.x; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; McNicholas P, 1997, J MOL BIOL, V265, P128, DOI 10.1006/jmbi.1996.0723; Miller J. H., 1972, EXPT MOL GENETICS, P433; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; Oliver D, 1998, J BACTERIOL, V180, P5240, DOI 10.1128/JB.180.19.5240-5242.1998; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Sunohara T, 2004, RNA, V10, P378, DOI 10.1261/rna.5169404; Sunohara T, 2002, RNA, V8, P1416, DOI 10.1017/S1355838202020198; Tadaki T, 1996, FEBS LETT, V399, P223, DOI 10.1016/S0014-5793(96)01330-0; TAKIFF HE, 1989, J BACTERIOL, V171, P2581, DOI 10.1128/jb.171.5.2581-2590.1989; Ueda K, 2002, GENES CELLS, V7, P509, DOI 10.1046/j.1365-2443.2002.00537.x; Wachi M, 1997, MOL GEN GENET, V253, P515, DOI 10.1007/s004380050352; Withey JH, 2002, CURR OPIN MICROBIOL, V5, P154, DOI 10.1016/S1369-5274(02)00299-0; Yamamoto Y, 2003, RNA, V9, P408, DOI 10.1261/rna.2174803; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7	34	100	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15368	15375		10.1074/jbc.M312805200	http://dx.doi.org/10.1074/jbc.M312805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744860	hybrid			2022-12-27	WOS:000220594700106
J	Narayanaswami, V; Maiorano, JN; Dhanasekaran, P; Ryan, RO; Phillips, MC; Lund-Katz, S; Davidson, WS				Narayanaswami, V; Maiorano, JN; Dhanasekaran, P; Ryan, RO; Phillips, MC; Lund-Katz, S; Davidson, WS			Helix orientation of the functional domains in apolipoprotein E in discoidal high density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; N-TERMINAL DOMAIN; MEMBRANE PENETRATION DEPTH; LIPID-BINDING; ESCHERICHIA-COLI; AQUEOUS-SOLUTION; A-I; CONFORMATION; CHOLESTEROL; PROTEIN	Human apolipoprotein E (apoE) mediates high affinity binding to the low density lipoprotein receptor when present on a lipidated complex. In the absence of lipid, however, apoE does not bind the receptor. Whereas the x-ray structure of lipid-free apoE3 N-terminal (NT) domain is known, the structural organization of its lipid-associated, receptor-active conformation is poorly understood. To study the organization of apoE amphipathic alpha-helices in a lipid-associated state, single tryptophan-containing apoE3 variants were employed in fluorescence quenching studies. The relative positions of the Trp residues with respect to the phospholipid component of apoE/lipid particles were established from the degree of quenching by phospholipids bearing nitroxide groups at various positions along their fatty acyl chains. Four apoE3-NT variants bearing Trp reporter groups at positions 141, 148, 155, or 162 within helix 4 and two apoE3 variants containing single Trp at positions 257 or 264 in the C-terminal (CT) domain, were reconstituted into phospholipid-containing discoidal complexes. Parallax analysis revealed that each engineered Trp residue in helix 4 of apoE3-NT, as well as those in the CT domain of apoE, localized similar to5 Angstrom from the center of the bilayer. Circular dichroism studies revealed that lipid association induces additional helix formation in apoE. Protease protection assays suggest the flexible loop segment between the NT and CT domains may transition from unstructured to helix upon lipid association. Taken together, these data support a model wherein the alpha-helices in the receptor-binding region and the CT domain of apoE align perpendicular to the fatty acyl chains of the phospholipid bilayer. In this alignment, the residues of helix 4 are arrayed in a positively charged, curved helical segment for optimal receptor interaction.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp, Oakland Res Inst, Lipid Biol Hlth & Dis Res Grp, Oakland, CA 94609 USA; Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University System of Ohio; University of Cincinnati	Lund-Katz, S (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst, Abramson Bldg,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Katzs@email.chop.edu		Davidson, William/0000-0003-2756-2989; Narayanaswami, Vasanthy/0000-0001-7088-4057; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064159, R37HL064159, R01HL067093, R01HL056083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67093, HL64159, HL56083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BARATTI J, 1976, BIOCHIM BIOPHYS ACTA, V452, P488, DOI 10.1016/0005-2744(76)90199-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Choy N, 2003, J MOL BIOL, V334, P527, DOI 10.1016/j.jmb.2003.09.059; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; FRERE V, 1995, J BIOL CHEM, V270, P17502, DOI 10.1074/jbc.270.29.17502; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Ladokhin AS, 1999, BIOPHYS J, V76, P946, DOI 10.1016/S0006-3495(99)77258-9; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Maiorano JN, 2000, J BIOL CHEM, V275, P17374, DOI 10.1074/jbc.M000044200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Morrow JA, 2000, J BIOL CHEM, V275, P2576, DOI 10.1074/jbc.275.4.2576; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; PANAGOTOPULOS SE, 2001, J BIOL CHEM; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Raussens V, 2003, J BIOL CHEM, V278, P25998, DOI 10.1074/jbc.M301753200; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; SMALL DM, 1986, PHYS CHEM LIPIDS ALK, P175; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	49	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14273	14279		10.1074/jbc.M313318200	http://dx.doi.org/10.1074/jbc.M313318200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14739281	hybrid			2022-12-27	WOS:000220478500121
J	Ward, IM; Minn, K; Chen, JJ				Ward, IM; Minn, K; Chen, JJ			UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation requires replication stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; HISTONE H2AX; GENOMIC INSTABILITY; REPAIR FACTORS; BINDING; PROTEIN; PHOSPHORYLATION; RECOGNITION; RECRUITMENT; KINASE	Ataxia-telangiectasia-mutated and Rad3-related (ATR) plays an essential role in the maintenance of genome integrity and cell viability. The kinase is activated in response to DNA damage and initiates a checkpoint signaling cascade by phosphorylating a number of downstream substrates including Chk1. Unlike ataxia-telangiectasia-mutated (ATM), which appears to be mainly activated by DNA double-strand breaks, ATR can be activated by a variety of DNA damaging agents. However, it is still unclear what triggers ATR activation in response to such diverse DNA lesions. One model proposes that ATR can directly recognize DNA lesions, while other recent data suggest that ATR is activated by a common single-stranded DNA (ssDNA) intermediate generated during DNA repair. In this study, we show that UV lesions do not directly activate ATR in vivo. In addition, ssDNA lesions created during the repair of UV damage are also not sufficient to activate the ATR-dependent pathway. ATR activation is only observed in replicating cells indicating that replication stress is required to trigger the ATR-mediated checkpoint cascade in response to UV irradiation. Interestingly, H2AX appears to be required for the accumulation of ATR at stalled replication forks. Together our data suggest that ssDNA at arrested replication forks recruits ATR and initiates ATR-mediated phosphorylation of H2AX and Chk1. Phosphorylated H2AX might further facilitate ATR activation by stabilizing ATR at the sites of arrested replication forks.	Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Div Oncol Res, Guggenheim Bldg,Rm 1342,200 1st St SW, Rochester, MN 55905 USA.	Chen.junjie@mayo.edu			NCI NIH HHS [CA92312, CA89239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089239, R01CA092312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	27	169	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9677	9680		10.1074/jbc.C300554200	http://dx.doi.org/10.1074/jbc.C300554200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14742437	hybrid			2022-12-27	WOS:000220050400002
J	Zahringer, U; Lindner, B; Knirel, YA; van den Akker, WMR; Hiestand, R; Heine, H; Dehio, C				Zahringer, U; Lindner, B; Knirel, YA; van den Akker, WMR; Hiestand, R; Heine, H; Dehio, C			Structure and biological activity of the short-chain lipopolysaccharide from Bartonella henselae ATCC 49882(T)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; NF-KAPPA-B; ENDOTHELIAL-CELLS; LIPID-A; BACTERIAL; LEGIONELLA; EXPRESSION; ACID; DECASACCHARIDE; PROLIFERATION	The facultative intracellular pathogen Bartonella henselae is responsible for a broad range of clinical manifestations, including the formation of vascular tumors as a result of increased proliferation and survival of colonized endothelial cells. This remarkable interaction with endotoxin-sensitive endothelial cells and the apparent lack of septic shock are considered to be due to a reduced endotoxic activity of the B. henselae lipopolysaccharide. Here, we show that B. henselae ATCC 49882(T) produces a deep-rough-type lipopolysaccharide devoid of O-chain and report on its complete structure and Toll-like receptor-dependent biological activity. The major short-chain lipopolysaccharide was studied by chemical analyses, electrospray ionization, and matrix-assisted laser desorption/ionization mass spectrometry, as well as by NMR spectroscopy after alkaline deacylation. The carbohydrate portion of the lipopolysaccharide consists of a branched trisaccharide containing a glucose residue attached to position 5 of an alpha-(2-->4)-linked 3-deoxy-D-manno-oct-2-ulosonic acid disaccharide. Lipid A is a pentaacylated beta-(1'-->6)-linked 2,3-diamino 2,3-dideoxy-glucose disaccharide 1,4'-bisphosphate with two amide-linked residues each of 3-hydroxydodecanoic and 3-hydroxyhexadecanoic acids and one residue of either 25-hydroxyhexacosanoic or 27-hydroxyoctacosanoic acid that is O-linked to the acyl group at position 2'. The lipopolysaccharide studied activated Toll-like receptor 4 signaling only to a low extent (1,000-10,000-fold lower compared with that of Salmonella enterica sv. Friedenau) and did not activate Toll-like receptor 2. Some unusual structural features of the B. henselae lipopolysaccharide, including the presence of a long-chain fatty acid, which are shared by the lipopolysaccharides of other bacteria causing chronic intracellular infections ( e. g. Legionella and Chlamydia), may provide the molecular basis for low endotoxic potency.	Leibniz Ctr Med & Biosci, Res Ctr Bortsel, D-23845 Borstel, Germany; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Basel, Biozentrum, Div Mol Microbiol, CH-4056 Basel, Switzerland	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of Basel	Zahringer, U (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr Bortsel, D-23845 Borstel, Germany.	uzaehr@fz-borstel.de	Dehio, Christoph/AAD-5572-2019; Knirel, Yuriy A/E-2058-2014; Heine, Holger/H-4552-2012; Lindner, Buko/G-9731-2014; Dehio, Christoph/R-8277-2016	Dehio, Christoph/0000-0001-7288-1052; Heine, Holger/0000-0001-8128-5068; Dehio, Christoph/0000-0001-7288-1052; van den Akker, Willem M.R./0000-0001-9492-4359				BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BOCK K, 1992, CARBOHYD RES, V229, P213, DOI 10.1016/S0008-6215(00)90571-8; CARRION M, 1990, J BACTERIOL, V172, P1725, DOI 10.1128/jb.172.4.1725-1731.1990; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dehio C, 1997, J CELL SCI, V110, P2141; Dehio C, 2003, CURR OPIN MICROBIOL, V6, P61, DOI 10.1016/S1369-5274(03)00006-7; Dehio C, 2001, TRENDS MICROBIOL, V9, P279, DOI 10.1016/S0966-842X(01)02047-9; Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fuhrmann O, 2001, INFECT IMMUN, V69, P5088, DOI 10.1128/IAI.69.8.5088-5097.2001; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Girard R, 2003, J CELL SCI, V116, P293, DOI 10.1242/jcs.00212; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; Karem KL, 2000, MICROBES INFECT, V2, P1193, DOI 10.1016/S1286-4579(00)01273-9; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; Kirby JE, 2002, P NATL ACAD SCI USA, V99, P4656, DOI 10.1073/pnas.072292699; Knirel YA, 1996, CARBOHYD RES, V283, P129, DOI 10.1016/0008-6215(95)00401-7; Knirel YA, 1995, CARBOHYD RES, V279, P215, DOI 10.1016/0008-6215(95)00274-X; KOSMA P, 1995, J ENDOTOXIN RES, V0002; Kyme P, 2003, MICROBIOL-SGM, V149, P621, DOI 10.1099/mic.0.26014-0; Liberto MC, 2000, MICROBIOLOGICA, V23, P449; Liberto MC, 2003, DIAGN MICR INFEC DIS, V45, P107; Maeno N, 1999, MICROB PATHOGENESIS, V27, P419, DOI 10.1006/mpat.1999.0315; MINNICK MF, 1994, INFECT IMMUN, V62, P2644, DOI 10.1128/IAI.62.6.2644-2648.1994; Neumeister B, 1998, INFECT IMMUN, V66, P4151; QUE NLS, 2002, J ENDOTOXIN RES, V8, P156; Resto-Ruiz SI, 2002, INFECT IMMUN, V70, P4564, DOI 10.1128/IAI.70.8.4564-4570.2002; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Rund S, 1999, J BIOL CHEM, V274, P16819, DOI 10.1074/jbc.274.24.16819; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; Schmid MC, 2004, MOL MICROBIOL, V52, P81, DOI 10.1111/j.1365-2958.2003.03964.x; SONESSON A, 1993, FEMS MICROBIOL LETT, V106, P315, DOI 10.1016/0378-1097(93)90421-W; van den Akker WMR, 1998, MICROBIOL-SGM, V144, P1527, DOI 10.1099/00221287-144-6-1527; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; Zahringer U, 1995, Prog Clin Biol Res, V392, P113; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3	41	72	74	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21046	21054		10.1074/jbc.M313370200	http://dx.doi.org/10.1074/jbc.M313370200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14766898	Green Accepted, hybrid			2022-12-27	WOS:000221273800061
J	Liu, DY; Liu, XY; Robinson, D; Burnett, C; Jackson, C; Seele, L; Veach, RA; Downs, S; Collins, RD; Ballard, DW; Hawiger, J				Liu, DY; Liu, XY; Robinson, D; Burnett, C; Jackson, C; Seele, L; Veach, RA; Downs, S; Collins, RD; Ballard, DW; Hawiger, J			Suppression of staphylococcal enterotoxin B-induced toxicity by a nuclear import inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-ALPHA GENE; T-CELLS; FUNCTIONAL PEPTIDES; LETHAL SHOCK; SUPERANTIGEN; MICE; INTERFERON; RESISTANT; RECEPTOR	Staphylococcal enterotoxin B and related toxins that target T cells have the capacity to elicit systemic inflammation, tissue injury, and death. Genes that encode mediators of inflammation can be globally inhibited by blocking the nuclear import of stress-responsive transcription factors. Here we show that cell-permeant peptides targeting Rch1/importin alpha/karyopherin alpha 2, a nuclear import adaptor protein, are delivered to T cells where they inhibit the staphylococcal enterotoxin B-induced production of inflammatory cytokines ex vivo in cultured primary spleen cells and in vivo. The systemic production of tumor necrosis factor alpha, interferon gamma, and interleukin-6 was attenuated in mice either by a cell-permeant cyclized form of SN50 peptide or by a transgene whose product suppresses the nuclear import of transcription factor nuclear factor kappaB in T cells. The extent of liver apoptosis and hemorrhagic necrosis was also reduced, which correlated with significantly decreased mortality rates. These findings highlight nuclear import inhibitors as a potentially useful countermeasure for staphylococcal enterotoxin B and other toxins that trigger harmful systemic inflammatory responses.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hawiger, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Med Ctr, 1161 21st Ave S,A-5321 MCN, Nashville, TN 37232 USA.	jacek.hawiger@vanderbilt.edu		Veach, Ruth Ann/0000-0003-0038-8802	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA082556] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744, R01HL062356, R43HL069542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054072] Funding Source: NIH RePORTER; NCI NIH HHS [CA82556, 2P30 CA 68485-05] Funding Source: Medline; NHLBI NIH HHS [HL62356, HL69542, HL68744] Funding Source: Medline; NIDDK NIH HHS [DK54072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOKI Y, 1995, J IMMUNOL, V155, P3494; Balaban N, 2000, INT J FOOD MICROBIOL, V61, P1, DOI 10.1016/S0168-1605(00)00377-9; BHARDWAJ N, 1993, J EXP MED, V178, P633, DOI 10.1084/jem.178.2.633; Blank C, 1997, EUR J IMMUNOL, V27, P825, DOI 10.1002/eji.1830270405; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chen CM, 2001, NAT BIOTECHNOL, V19, P921, DOI 10.1038/nbt1001-921; Chen R, 1999, CLIN CHEM, V45, P1693; Clark Nina M, 2003, Curr Opin Crit Care, V9, P403, DOI 10.1097/00075198-200310000-00011; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Fernandez T, 1998, NAT BIOTECHNOL, V16, P418, DOI 10.1038/nbt0598-418; Fey PD, 2003, ANTIMICROB AGENTS CH, V47, P196, DOI 10.1128/AAC.47.1.196-203.2003; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GREEN SJ, 1993, INFECT IMMUN, V61, P689, DOI 10.1128/IAI.61.2.689-698.1993; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; HAWIGER J, 2001, WILEY ENCY MOL MED, P2435; Jezek Z, 1988, HUMAN MONKEYPOX; Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 2000, J BIOL CHEM, V275, P16774; Madsen JM, 2001, CLIN LAB MED, V21, P593; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MATTIX ME, 1995, TOXICOL PATHOL, V23, P262, DOI 10.1177/019262339502300304; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; PEAVY DL, 1970, J IMMUNOL, V105, P1453; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; STILES BG, 1993, INFECT IMMUN, V61, P5333, DOI 10.1128/IAI.61.12.5333-5338.1993; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; TAUB DD, 1992, CELL IMMUNOL, V141, P263, DOI 10.1016/0008-8749(92)90147-H; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Veach RA, 2004, J BIOL CHEM, V279, P11425, DOI 10.1074/jbc.M311089200; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	38	39	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19239	19246		10.1074/jbc.M313442200	http://dx.doi.org/10.1074/jbc.M313442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14732709	hybrid			2022-12-27	WOS:000221041500137
J	Ziebell, MR; Nirthanan, S; Husain, SS; Miller, KW; Cohen, JB				Ziebell, MR; Nirthanan, S; Husain, SS; Miller, KW; Cohen, JB			Identification of binding sites in the nicotinic acetylcholine receptor for [H-3]azietomidate, a photoactivatable general anesthetic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; GATED ION CHANNELS; AMINO-ACIDS; NONCOMPETITIVE ANTAGONIST; H-3 CHLORPROMAZINE; GEL-ELECTROPHORESIS; DELTA-SUBUNIT; GAMMA; ETOMIDATE; BLOCKERS	To identify binding domains in a ligand-gated ion channel for etomidate, an intravenous general anesthetic, we photolabeled nicotinic acetylcholine receptor (nAChR)-rich membranes from Torpedo electric organ with a photoactivatable analog, [H-3]azietomidate. Based upon the inhibition of binding of the noncompetitive antagonist [H-3]phencyclidine, azietomidate and etomidate bind with 10-fold higher affinity to nAChRs in the desensitized state (IC50 = 70 muM) than in the closed channel state. In addition, both drugs between 0.1 and 1 mM produced a concentration-dependent enhancement of [H-3]ACh equilibrium binding affinity, but they inhibited binding at higher concentrations. UV irradiation resulted in preferential [H-3]azietomidate photoincorporation into the nAChR alpha and delta subunits. Photolabeled amino acids in both subunits were identified in the ion channel domain and in the ACh binding sites by Edman degradation. Within the nAChR ion channel in the desensitized state, there was labeling of alphaGlu-262 and deltaGln-276 at the extracellular end and deltaSer-258 and deltaSer-262 toward the cytoplasmic end. Within the acetylcholine binding sites, [H-3]azietomidate photolabeled alphaTyr-93, alphaTyr-190, and alphaTyr-198 in the site at the alpha-gamma interface and deltaAsp-59 (but not the homologous position, gammaGlu-57). Increasing [H-3]azietomidate concentration from 1.8 to 150 muM increased the efficiency of incorporation into amino acids within the ion channel by 10-fold and in the ACh sites by 100-fold, consistent with higher affinity binding within the ion channel. The state dependence and subunit selectivity of [H-3]azietomidate photolabeling are discussed in terms of the structures of the nAChR transmembrane and extracellular domains.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu	Nirthanan, Selvanayagam/ABI-4281-2020	Nirthanan, S. Niru/0000-0001-9888-8447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058448] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addona GH, 2002, J BIOL CHEM, V277, P25685, DOI 10.1074/jbc.M201303200; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; Blanton MP, 2001, BBA-BIOMEMBRANES, V1512, P215, DOI 10.1016/S0005-2736(01)00321-2; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Chiara DC, 2003, BIOCHEMISTRY-US, V42, P13457, DOI 10.1021/bi0351561; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; Chiara DC, 2003, BIOCHEMISTRY-US, V42, P271, DOI 10.1021/bi0269815; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; FLEMING SA, 1995, TETRAHEDRON, V51, P12479; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Gallagher MJ, 1999, MOL PHARMACOL, V56, P300, DOI 10.1124/mol.56.2.300; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; Husain SS, 2003, J MED CHEM, V46, P1257, DOI 10.1021/jm020465v; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; OSWALD RE, 1983, BIOCHEMISTRY-US, V22, P3128, DOI 10.1021/bi00282a015; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Pezacki JP, 1999, J AM CHEM SOC, V121, P6589, DOI 10.1021/ja9840807; Pratt MB, 2000, BIOCHEMISTRY-US, V39, P11452, DOI 10.1021/bi0011680; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; Reynolds DS, 2003, J NEUROSCI, V23, P8608; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tomlin SL, 1998, ANESTHESIOLOGY, V88, P708, DOI 10.1097/00000542-199803000-00022; WACHTEL RE, 1992, BRIT J PHARMACOL, V106, P623, DOI 10.1111/j.1476-5381.1992.tb14385.x; Wakahara T, 2002, J AM CHEM SOC, V124, P9465, DOI 10.1021/ja0116876; Wang D, 2000, J BIOL CHEM, V275, P28666, DOI 10.1074/jbc.M005441200; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1991, J BIOL CHEM, V266, P21595; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23	42	70	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17640	17649		10.1074/jbc.M313886200	http://dx.doi.org/10.1074/jbc.M313886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761946	hybrid			2022-12-27	WOS:000220870400093
J	Hashimoto, Y; Tsuji, O; Kanekura, K; Aiso, S; Niikura, T; Matsuoka, M; Nishimoto, I				Hashimoto, Y; Tsuji, O; Kanekura, K; Aiso, S; Niikura, T; Matsuoka, M; Nishimoto, I			The Gtx homeodomain transcription factor exerts neuroprotection using its homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; P75 NEUROTROPHIN RECEPTOR; RESCUE FACTOR HUMANIN; ALZHEIMERS-DISEASE; REPRESSOR ACTIVITY; BETA-PEPTIDE; CELL-DEATH; NEURONAL DIFFERENTIATION; NEUROTOXIC MECHANISMS; CRYSTAL-STRUCTURE	Certain cases of familial Alzheimer's disease are caused by mutants of amyloid-beta precursor protein (AbetaPP), including V642I-AbetaPP, K595N/M596L-AbetaPP (NL-AbetaPP), A617G-AbetaPP, and L648P-AbetaPP. By using an unbiased functional screening with transfection and expression of a human brain cDNA library, we searched for genes that protect neuronal cells from toxicity by V642I-AbetaPP. One protective clone was identical to the human GTX, a neuronal homeobox gene. Human Gtx (hGtx) inhibited caspase inhibitor-sensitive neuronal cell death not only by V642I-AbetaPP but also by L648P-, NL-, A617G-AbetaPP, apolipoprotein E4, and Abeta. The region of hGtx responsible for this rescue function was specified to be its homeodomain (Lys(148)-His(207)). The rescue function was shared by DLX4, a distal-less family gene with a homeodomain only 38.3% homologous to that of hGtx, suggesting that this function would be generally shared by homeodomains. The neuroprotective function of hGtx was attributable to hGtx-stimulated production and secretion of insulin-like growth factor-I. This study provides molecular clues to understand how neuronal cells developmentally regulate themselves against cell death as well as to develop reagents effective in curative therapeutics of Alzheimer's disease.	Keio Univ, Sch Med, Dept Pharmacol, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Anat, Tokyo 1608582, Japan	Keio University; Keio University	Niikura, T (corresponding author), Keio Univ, Sch Med, Dept Pharmacol, 35 Shinanomachi, Tokyo 1608582, Japan.	niikurat@sc.itc.keio.ac.jp; sakimatu@sc.itc.keio.ac.jp	Hashimoto, Yuichi/N-1508-2015; Tsuji, Osahiko/AHB-2622-2022	Hashimoto, Yuichi/0000-0001-5863-3618; 				Awatramani R, 2000, J NEUROSCI RES, V61, P376, DOI 10.1002/1097-4547(20000815)61:4<376::AID-JNR4>3.0.CO;2-#; Awatramani R, 1997, J NEUROSCI, V17, P6657; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Cai J, 2001, MOL CELL BIOL, V21, P4399, DOI 10.1128/MCB.21.13.4399-4403.2001; Czech C, 1998, NEUROSCIENCE, V87, P325, DOI 10.1016/S0306-4522(98)00162-6; D'Adamio L, 1997, Semin Immunol, V9, P17, DOI 10.1006/smim.1996.0057; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; Guo Q, 1999, J NEUROSCI RES, V56, P457, DOI 10.1002/(SICI)1097-4547(19990601)56:5<457::AID-JNR2>3.0.CO;2-P; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Guo Q, 1999, P NATL ACAD SCI USA, V96, P4125, DOI 10.1073/pnas.96.7.4125; Handler M, 2000, DEVELOPMENT, V127, P2593; Hashimoto Y, 2000, J BIOL CHEM, V275, P34541, DOI 10.1074/jbc.M005332200; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2002, J NEUROCHEM, V80, P426, DOI 10.1046/j.0022-3042.2001.00722.x; Hashimoto Y, 2002, J PHARMACOL EXP THER, V300, P736, DOI 10.1124/jpet.300.3.736; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P460, DOI 10.1006/bbrc.2001.4765; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hong CS, 1999, J NEUROSCI, V19, P637; Inoue H, 1997, GENOMICS, V40, P367, DOI 10.1006/geno.1996.4568; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOMURO I, 1993, EMBO J, V12, P1387, DOI 10.1002/j.1460-2075.1993.tb05783.x; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Kwok JBJ, 2000, ANN NEUROL, V47, P249, DOI 10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.3.CO;2-#; Lee SH, 2001, MAMM GENOME, V12, P157, DOI 10.1007/s003350010247; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niikura T, 2001, J NEUROSCI, V21, P1902, DOI 10.1523/JNEUROSCI.21-06-01902.2001; Niikura T, 2000, BIOCHEM BIOPH RES CO, V274, P445, DOI 10.1006/bbrc.2000.3143; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Perini G, 2002, J EXP MED, V195, P907, DOI 10.1084/jem.20011797; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; Quinn LM, 1997, GENE, V187, P55, DOI 10.1016/S0378-1119(96)00706-8; Raina AK, 2000, J NEUROSCI RES, V61, P128, DOI 10.1002/1097-4547(20000715)61:2<128::AID-JNR2>3.3.CO;2-8; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sim FJ, 2000, NEUROSCIENCE, V100, P131, DOI 10.1016/S0306-4522(00)00252-9; Sudo H, 2001, BIOCHEM BIOPH RES CO, V282, P548, DOI 10.1006/bbrc.2001.4604; Vallstedt A, 2001, NEURON, V31, P743, DOI 10.1016/S0896-6273(01)00412-3; VIOLETTE SM, 1992, P NATL ACAD SCI USA, V89, P3805, DOI 10.1073/pnas.89.9.3805; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200; Weihl CC, 1999, J NEUROSCI, V19, P5360; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; Zhu XW, 2001, MECH AGEING DEV, V123, P39, DOI 10.1016/S0047-6374(01)00342-6	59	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16767	16777		10.1074/jbc.M313630200	http://dx.doi.org/10.1074/jbc.M313630200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754886	hybrid			2022-12-27	WOS:000220747900129
J	Quick, MW; Hu, J; Wang, D; Zhang, HY				Quick, MW; Hu, J; Wang, D; Zhang, HY			Regulation of a gamma-aminobutyric acid transporter by reciprocal tyrosine and serine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA TRANSPORTER; GLUTAMATE TRANSPORTERS; NEUROTRANSMITTER TRANSPORTERS; SEROTONIN TRANSPORTERS; PHORBOL ESTERS; MICE LACKING; EXPRESSION; INHIBITION; REDISTRIBUTION; TRAFFICKING	A feature of the rat brain gamma-aminobutyric acid transporter GAT1, and other members of the neurotransmitter transporter family, is its regulated redistribution between intracellular locations and the plasma membrane. Recent studies have focused upon defining the signaling molecules that facilitate this redistribution. Agents that promote direct tyrosine phosphorylation of GAT1 promote a relative increase in surface GAT1 levels, and this results from a slowing of the transporter internalization rate. Agents that act to increase protein kinase C (PKC) activity promote a relative decrease in surface GAT1 levels; whether this effect is caused by direct transporter phosphorylation is unknown. The opposing actions of tyrosine kinase activity and PKC activity raise the possibility that the subcellular distribution of GAT1 is associated with mutually exclusive transporter phosphorylation events. The present experiments show that GAT1 is phosphorylated on serine residues in a PKC-dependent manner, but this state is only revealed when GAT1 tyrosine phosphorylation is eliminated or greatly reduced. The relative levels of serine phosphorylation and tyrosine phosphorylation are negatively correlated. The amount of serine phosphorylation is regulated by agents that affect tyrosine phosphorylation, and vice versa. In addition, the ability of agents that affect tyrosine kinase activity to regulate GAT1 serine phosphorylation requires a change in its tyrosine phosphorylation state. These data support the ideas that GAT1 can exist in either of two mutually exclusive phosphorylation states and that the relative abundance of these states determines in part the relative subcellular distribution of the transporter.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Grad Program Neurosci, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Quick, MW (corresponding author), Univ So Calif, Dept Biol Sci, HNB 228,3641 Watt Way, Los Angeles, CA 90089 USA.	mquick@usc.edu	Wang, Dan Ohtan/AAF-5704-2019; Wang, Dan Ohtan/E-1953-2011	Wang, Dan Ohtan/0000-0002-3126-8558; 	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010509, R29DA010509] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10509] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Beckman ML, 1998, J NEUROSCI, V18, P6103; Beckman ML, 1999, J NEUROSCI, V19; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; CASADO M, 1993, J BIOL CHEM, V268, P27313; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Chiu CS, 2002, J NEUROSCI, V22, P10251; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; COREY JL, 1994, J BIOL CHEM, V269, P14759; Davis KE, 1998, J NEUROSCI, V18, P2475; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Deken SL, 2003, J NEUROSCI, V23, P1563; DINGLEDINE R, 1985, J PHYSIOL-LONDON, V366, P387, DOI 10.1113/jphysiol.1985.sp015804; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GOMEZA J, 1991, BIOCHEM J, V275, P435, DOI 10.1042/bj2750435; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Horton N, 2001, MOL MEMBR BIOL, V18, P39; Huff RA, 1997, J NEUROCHEM, V68, P225; Ichinose T, 2002, J NEUROSCI, V22, P3285, DOI 10.1523/JNEUROSCI.22-08-03285.2002; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; SATO K, 1995, FEBS LETT, V375, P99, DOI 10.1016/0014-5793(95)01191-G; SOLIS JM, 1992, J NEUROSCI, V12, P3466; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; THOMSEN C, 1995, EPILEPSY RES, V21, P79, DOI 10.1016/0920-1211(95)00010-8; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Uhl GR, 2002, MOL PSYCHIATR, V7, P21, DOI 10.1038/sj/mp/4000964; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9	39	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15961	15967		10.1074/jbc.M306924200	http://dx.doi.org/10.1074/jbc.M306924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761965	hybrid			2022-12-27	WOS:000220747900033
J	Stano, NM; Patel, SS				Stano, NM; Patel, SS			T7 lysozyme represses T7 RNA polymerase transcription by destabilizing the open complex during initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC MECHANISM; STRUCTURAL BASIS; PROMOTER DNA; ELONGATION; BINDING; 2-AMINOPURINE; FLUORESCENCE; INHIBITION; TRANSITION; DYNAMICS	Bacteriophage T7 lysozyme binds to T7 RNA polymerase and inhibits transcription initiation and the transition from initiation to elongation. We have investigated each step of transcription initiation to determine where T7 lysozyme has the most effect. Stopped flow and equilibrium DNA binding studies indicate that T7 lysozyme does not inhibit the formation of the preinitiation open complex (open complex in the absence of initiating nucleotide). T7 lysozyme, however, does prevent the formation of a fully open initiation complex (open complex in the presence of the initiating nucleotide). This is consistent with the results that in the presence of T7 lysozyme the rate of G ladder RNA synthesis is about 5-fold slower and the GTP Kd is about 2-fold higher, but T7 lysozyme does not inhibit the initial rate of RNA synthesis with a premelted bulge-6 promoter (bubble from -4 to +2). Neither the RNA synthesis rate nor the extent of promoter opening is restored by increasing the initiating nucleotide concentration, indicating that T7 lysozyme represses transcription by interfering with the formation of a stable and a fully open initiation bubble or by altering the structure of the DNA in the initiation complex. As a consequence of the unstable initiation bubble and/or the inhibition of the conformational changes in the N-terminal domain of T7 RNAP, T7 lysozyme causes an increased production of abortive products from 2- to 5-mer that delays the transition from the initiation to the elongation phase.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.	patelss@umdnj.edu			NIGMS NIH HHS [GM51966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051966, R01GM051966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2002, BIOCHEMISTRY-US, V41, P3586, DOI 10.1021/bi0158472; Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; BERTRANDBURGGRAF E, 1987, J MOL BIOL, V193, P293, DOI 10.1016/0022-2836(87)90220-8; Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Gardner LP, 1997, BIOCHEMISTRY-US, V36, P2908, DOI 10.1021/bi962397i; Huang JB, 1999, J MOL BIOL, V293, P457, DOI 10.1006/jmbi.1999.3135; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; Kumar A, 1997, BIOCHEMISTRY-US, V36, P13954, DOI 10.1021/bi971432y; MCALLISTER WT, 1993, CELL MOL BIOL RES, V39, P385; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; MCALLISTER WT, 1997, NUCL ACIDS MOL BIOL, V11, P15; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; Stano NM, 2002, J BIOL CHEM, V277, P37292, DOI 10.1074/jbc.M201600200; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Villemain J, 1998, J MOL BIOL, V281, P793, DOI 10.1006/jmbi.1998.1989; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; Zhang X, 1997, J MOL BIOL, V269, P10, DOI 10.1006/jmbi.1997.1016; ZHANG X, 1995, THESIS STATE U NEW Y	30	28	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16136	16143		10.1074/jbc.M400139200	http://dx.doi.org/10.1074/jbc.M400139200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764584	hybrid			2022-12-27	WOS:000220747900055
J	Taniguchi, M; Yoshimi, T; Hongo, K; Mizobata, T; Kawata, Y				Taniguchi, M; Yoshimi, T; Hongo, K; Mizobata, T; Kawata, Y			Stopped-flow fluorescence analysis of the conformational changes in the GroEL apical domain - Relationships between movements in the apical domain and the quaternary structure of GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC CHAPERONIN GROEL; NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; KINETIC-ANALYSIS; PROTEIN; INTERMEDIATE; MECHANISM; ATP; SUBSTRATE	GroEL undergoes numerous conformational alterations in the course of facilitating the folding of various proteins, and the specific movements of the GroEL apical domain are of particular importance in the molecular mechanism. In order to monitor in detail the numerous movements of the GroEL apical domain, we have constructed a mutant chaperonin (GroEL R231W) with wild type-like function and a fluorescent probe introduced into the apical domain. By monitoring the tryptophan fluorescence changes of GroEL R231W upon ATP addition in the presence and absence of the co-chaperonin GroES, we detected a total of four distinct kinetic phases that corresponded to conformational changes of the apical domain and GroES binding. By introducing this mutation into a single ring variant of GroEL ( GroEL SR-1), we determined the extent of inter-ring cooperation that was involved in apical domain movements. Surprisingly, we found that the apical domain movements of GroEL were affected only slightly by the change in quaternary structure. Our experiments provide a number of novel insights regarding the dynamic movements of this protein.	Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6808552, Japan; Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, Tottori 6808552, Japan	Tottori University; Tottori University	Kawata, Y (corresponding author), Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6808552, Japan.	kawata@bio.tottori-u.ac.jp	Kawata, Yasushi/ABA-9608-2021; Mizobata, Tomohiro/V-6672-2019	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Chaudhry C, 2003, EMBO J, V22, P4877, DOI 10.1093/emboj/cdg477; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hayer-Hartl M, 2000, METH MOL B, V140, P127; Inobe T, 2003, J MOL BIOL, V327, P183, DOI 10.1016/S0022-2836(03)00087-1; Inobe T, 2001, BBA-PROTEIN STRUCT M, V1545, P160, DOI 10.1016/S0167-4838(00)00274-0; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; Miyazaki T, 2002, J BIOL CHEM, V277, P50621, DOI 10.1074/jbc.M209183200; Mizobata T, 2000, J BIOL CHEM, V275, P25600, DOI 10.1074/jbc.M000795200; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 2001, CELL, V107, P869, DOI 10.1016/S0092-8674(01)00617-1; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Saibil HR, 2002, TRENDS BIOCHEM SCI, V27, P627, DOI 10.1016/S0968-0004(02)02211-9; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Terada TP, 1999, BBA-PROTEIN STRUCT M, V1431, P269, DOI 10.1016/S0167-4838(99)00049-7; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Wang JM, 2003, J MOL BIOL, V334, P489, DOI 10.1016/j.jmb.2003.09.074; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1998, J AM CHEM SOC, V120, P13262, DOI 10.1021/ja983136u	32	32	32	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16368	16376		10.1074/jbc.M311806200	http://dx.doi.org/10.1074/jbc.M311806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14734563	hybrid			2022-12-27	WOS:000220747900083
J	Brown, TA; Yang, TM; Zaitsevskaia, T; Xia, YP; Dunn, CA; Sigle, RO; Knudsen, B; Carter, WG				Brown, TA; Yang, TM; Zaitsevskaia, T; Xia, YP; Dunn, CA; Sigle, RO; Knudsen, B; Carter, WG			Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; TUMOR-CELLS; INTEGRIN ALPHA-3-BETA-1; FOCAL ADHESION; ACTIVATES SRC; GROWTH-FACTOR; CUB DOMAIN; IN-VITRO; SURAMIN; LAMININ-5	Suspension of cultured human foreskin keratinocytes (HKs) with trypsin phosphorylates tyrosine residues on an 80-kDa membrane glycoprotein, p80 (Xia, Y., Gil, S. G., and Carter, W. G. (1996) J. Cell Biol. 132, 727-740). Read-hesion dephosphorylates p80. Sequencing of a p80 cDNA established identity to CUB domain-containing protein 1 (CDCP1), a gene elevated in carcinomas. CDCP1/p80 cDNA encodes three extracellular CUB domains, a transmembrane domain, and two putative cytoplasmic Tyr phosphorylation sites. Treatment of adherent HKs with suramin, a heparin analogue, or inhibitors of phosphotyrosine phosphatases (PTPs; vanadate or calpeptin) increases phosphorylation of p80 and a novel 140-kDa membrane glycoprotein, gp140. Phosphorylated gp140 was identified as a trypsin-sensitive precursor to p80. Identity was confirmed by digestion and phosphorylation studies with recombinant gp140-GFP. Plasmin, a serum protease, also converts gp140 to p80, providing biological significance to the cleavage in wounds. Phosphorylation of gp140 and p80 are mediated by Src family kinases at multiple Tyr residues including Tyr(734). Dephosphorylation is mediated by PTP(s). Conversion of gp140 to p80 prolongs phosphorylation of p80 in response to suramin and changes in adhesion. This distinguishes gp140 and p80 and explains the relative abundance of phosphorylated p80 in trypsinized HKs. We conclude that phosphorylation of gp140 is dynamic and balanced by Src family kinase and PTPs yielding low equilibrium phosphorylation. We suggest that the balance is altered by conversion of gp140 to p80 and by adhesion, providing a novel transmembrane phosphorylation signal in epithelial wounds.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Carter, WG (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave, Seattle, WA 98109 USA.	wcarter@fhcrc.org			NCI NIH HHS [CA49259] Funding Source: Medline; NIAMS NIH HHS [AR047963] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047963] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JC, 1991, J CELL SCI, V98, P385; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BEHRENDT N, 1993, METHOD ENZYMOL, V223, P207; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; Conze T, 2003, ANN NY ACAD SCI, V996, P222, DOI 10.1111/j.1749-6632.2003.tb03249.x; Dhar S, 2000, EUR J CANCER, V36, P803, DOI 10.1016/S0959-8049(00)00024-1; FRANK D, 2004, IN PRESS J CELL SCI, V117; Fujiyama C, 2001, BRIT J CANCER, V84, P558, DOI 10.1054/bjoc.2000.1641; GARRIDO T, 1995, BRIT J CANCER, V71, P770, DOI 10.1038/bjc.1995.149; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; GHOSH J, 1993, BIOCHEM BIOPH RES CO, V194, P36, DOI 10.1006/bbrc.1993.1781; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gschwendt M, 1998, FEBS LETT, V421, P165, DOI 10.1016/S0014-5793(97)01530-5; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; KONDO H, 1992, EXP CELL RES, V202, P45, DOI 10.1016/0014-4827(92)90402-T; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Lokshin A, 1999, CANCER CHEMOTH PHARM, V43, P341, DOI 10.1007/s002800050905; Mallipeddi R, 2002, CLIN EXP DERMATOL, V27, P616, DOI 10.1046/j.1365-2230.2002.01130.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mollenhauer J, 2003, INT J CANCER, V105, P149, DOI 10.1002/ijc.11072; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; Netzel-Arnett S, 2002, J BIOL CHEM, V277, P45154, DOI 10.1074/jbc.M206354200; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; SARTOR O, 1993, J CLIN ONCOL, V11, P382; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tarui T, 2003, J BIOL CHEM, V278, P29863, DOI 10.1074/jbc.M304694200; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; WOODLEY DT, 1999, PROGR DERMATOLOGY, V33, P1; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281	50	76	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14772	14783		10.1074/jbc.M309678200	http://dx.doi.org/10.1074/jbc.M309678200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739293	hybrid			2022-12-27	WOS:000220594700037
J	Melvin, VS; Harrell, C; Adelman, JS; Kraus, WL; Churchill, M; Edwards, DP				Melvin, VS; Harrell, C; Adelman, JS; Kraus, WL; Churchill, M; Edwards, DP			The role of the C-terminal extension (CTE) of the estrogen receptor alpha and beta DNA binding domain in DNA binding and interaction with HMGB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; ER-ALPHA; TRANSCRIPTIONAL ACTIVITY; STRUCTURAL DETERMINANTS; PROTEINS; PROGESTERONE; SPECIFICITY; ACTIVATION; ANDROGEN; MONOMER	HMGB-1/-2 are coregulatory proteins that facilitate the DNA binding and transcriptional activity of steroid receptor members of the nuclear receptor family of transcription factors. We investigated the influence and mechanism of action of HMGB-1/-2 ( formerly known as HMG-1/-2) on estrogen receptor alpha (ERalpha) and ERbeta. Both ER subtypes were responsive to HMGB-1/-2 with respect to enhancement of receptor DNA binding affinity and transcriptional activity in cells. Responsiveness to HMGB-1/-2 was dependent on the C-terminal extension (CTE) region of the ER DNA binding domain (DBD) and correlated with a direct protein interaction between HMGB-1/-2 and the CTE. Thus the previously reported higher DNA binding affinity and transcription activity of ERalpha as compared with ERbeta is not due to a lack of ERbeta interaction with HMGB-1/-2. Using chimeric receptor DBDs, the higher intrinsic DNA binding affinity of ERalpha than ERbeta was shown to be due to a unique property of the ERalpha CTE, independent of HMGB-1/-2. The CTE of both ER subtypes was also shown to be required for interaction with ERE half-sites. These studies reveal the importance of the CTE and HMGB-1/-2 for ERalpha and ERbeta interaction with their cognate target DNAs.	Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 13853 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cornell University	Edwards, DP (corresponding author), Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Box B-112,4200 E 9th Ave, Denver, CO 80262 USA.	Dean.Edwards@uchsc.edu	Churchill, Mair E. A./C-5549-2014	Churchill, Mair E. A./0000-0003-0862-235X; Harrell, J. Chuck/0000-0003-3541-8418; Adelman, James/0000-0002-5577-8798	NCI NIH HHS [CA46938, P30 CA46934] Funding Source: Medline; NIGMS NIH HHS [R01 GM059456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046938, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agresti A, 2003, BIOCHEM BIOPH RES CO, V302, P421, DOI 10.1016/S0006-291X(03)00184-0; Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Cheung E, 2003, EMBO J, V22, P600, DOI 10.1093/emboj/cdg037; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; CROUSE JF, 1999, ENDOCR REV, V20, P358; Ellwood KB, 2000, MOL CELL BIOL, V20, P4359, DOI 10.1128/MCB.20.12.4359-4370.2000; Gearhart MD, 2003, J MOL BIOL, V327, P819, DOI 10.1016/S0022-2836(03)00183-9; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hyder SM, 1999, BIOCHEM PHARMACOL, V57, P597, DOI 10.1016/S0006-2952(98)00355-4; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Loven MA, 2001, MOL CELL ENDOCRINOL, V181, P151, DOI 10.1016/S0303-7207(01)00491-9; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1994, J BIOL CHEM, V269, P11945; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Melvin VS, 2001, METH MOL B, V176, P39; Melvin VS, 1999, STEROIDS, V64, P576, DOI 10.1016/S0039-128X(99)00036-7; Melvin VS, 2002, J BIOL CHEM, V277, P25115, DOI 10.1074/jbc.M110400200; Mitsouras K, 2002, MOL CELL BIOL, V22, P4390, DOI 10.1128/MCB.22.12.4390-4401.2002; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Schultz JR, 2002, J BIOL CHEM, V277, P8702, DOI 10.1074/jbc.M108491200; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shaffer PL, 2002, EMBO J, V21, P2242, DOI 10.1093/emboj/21.9.2242; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Verrijdt G, 2002, BIOCHEM J, V361, P97, DOI 10.1042/0264-6021:3610097; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632; Zhao Q, 1998, MOL CELL, V1, P849, DOI 10.1016/S1097-2765(00)80084-2; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	46	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14763	14771		10.1074/jbc.M313335200	http://dx.doi.org/10.1074/jbc.M313335200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739282	hybrid			2022-12-27	WOS:000220594700036
J	Zou, JH; Barahmand-pour, F; Blackburn, ML; Matsui, Y; Chansky, HA; Yang, L				Zou, JH; Barahmand-pour, F; Blackburn, ML; Matsui, Y; Chansky, HA; Yang, L			Survival motor neuron (SMN) protein interacts with transcription corepressor mSin3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; DISEASE GENE-PRODUCT; HISTONE DEACETYLASES; SINGLE NUCLEOTIDE; BINDING-PROTEIN; COMPLEX; REPRESSION; SIN3; METHYLTRANSFERASE; IDENTIFICATION	Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA results from loss of survival motor neuron (SMN) expression and subsequent death of motor neuron cells. To study SMN-associated proteins that may be involved in transcriptional regulation, we carried out immunoprecipitation experiments and found that the transcription corepressor mSin3A associates with SMN protein. Deletional analysis localized the mSin3A-interacting domain to the exon 6 region of SMN. When targeted to a promoter, wild-type SMN was able to repress transcription of a downstream luciferase reporter gene. This repression was relieved by treatment with the histone deacetylase inhibitor trichostatin A in a dose-dependent manner, and deletion of exon 6 abolished the ability of SMN to repress the reporter gene. Analysis of SMN missense mutations within the exon 6 region implicated the SMA-associated mutation Y272C with impairment of the mSin3A-interaction. Gel filtration experiments revealed that wild-type SMN, via the exon 6 region, forms protein supra-complexes exceeding 40,000 kDa in size, whereas the Y272C mutation may affect higher order protein assembly, as the mutant SMN was more abundant in smaller complexes. Together, these findings provide a potential mechanism by which lack of fully functional SMN protein is detrimental to motor neuron survival.	Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98108 USA; Univ Washington, Dept Med Hematol, Seattle, WA 98108 USA; Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Yang, L (corresponding author), Univ Washington, Dept Orthoped & Sports Med, 1660 S Columbian Way,GMR-151, Seattle, WA 98108 USA.	lyang@u.washington.edu			NCI NIH HHS [1R01CA90941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; Im H, 2002, BIOCHEMISTRY-US, V41, P15152, DOI 10.1021/bi026786q; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Jones KW, 2001, J BIOL CHEM, V276, P38645, DOI 10.1074/jbc.M106161200; Kerr DA, 2000, P NATL ACAD SCI USA, V97, P13312, DOI 10.1073/pnas.230364197; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Marks PA, 2001, CLIN CANCER RES, V7, P759; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Nicole S, 2002, MUSCLE NERVE, V26, P4, DOI 10.1002/mus.10110; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; RudnikSchoneborn S, 1996, NEUROPEDIATRICS, V27, P8, DOI 10.1055/s-2007-973741; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; Wang J, 2001, J BIOL CHEM, V276, P45387, DOI 10.1074/jbc.M105059200; Whitehead SE, 2002, J BIOL CHEM, V277, P48087, DOI 10.1074/jbc.M204551200; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yang L, 2003, BIOCHEM J, V369, P651, DOI 10.1042/BJ20020854; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869; Young PJ, 2003, MOL BRAIN RES, V119, P37, DOI 10.1016/j.molbrainres.2003.08.011; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang YX, 2003, NUCLEIC ACIDS RES, V31, P2168, DOI 10.1093/nar/gkg318	35	20	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14922	14928		10.1074/jbc.M309218200	http://dx.doi.org/10.1074/jbc.M309218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749338	hybrid			2022-12-27	WOS:000220594700054
J	Gad, A; Thullberg, M; Dannenberg, JH; Riele, HT; Stromblad, S				Gad, A; Thullberg, M; Dannenberg, JH; Riele, HT; Stromblad, S			Retinoblastoma susceptibility gene product (pRb) and p107 functionally separate the requirements for serum and anchorage in the cell cycle G(1)-phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION POINT; DEPENDENT KINASES; DEFICIENT CELLS; G(1) CONTROL; G1 PHASE; GROWTH; PROLIFERATION; EXPRESSION; PROTEIN; PROGRESSION	Growth factors and cell anchorage are both required for cell cycle G(1)-phase progression, but it is unclear whether their function is mediated through the same set of cell cycle components and whether they are both required during the same periods of time. We separately analyzed the requirements of serum and anchorage during G(1)-phase progression and found that human dermal fibroblasts as well as wild type, pRb(-/-), and p107(-/-) mouse embryonic fibroblasts needed serum ( growth factors) until mid-G(1)-phase but required cell anchorage until late G(1)-phase to be competent for S-phase entry. Importantly, however, pRb/p107 double-null mouse embryonic fibroblasts lacked serum requirement in mid-G(1)- phase but still required cell anchorage until late G(1)-phase to enter S-phase. Our results indicate that pRb and p107 do not constitute the last control point for extracellular factors during G(1)-phase progression, and they functionally separate the requirements for serum and cell anchorage in terms of involved cell cycle components.	Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Karolinska Institutet; Netherlands Cancer Institute	Stromblad, S (corresponding author), Karolinska Inst, Huddinge Sjukhjus F46, S-14186 Huddinge, Sweden.	Staffan.Stromblad@labmed.ki.se	Gad, Annica/H-8758-2017; Gad, Annica/X-8294-2018	Gad, Annica/0000-0002-1098-9129; Gad, Annica/0000-0002-1098-9129; Stromblad, Staffan/0000-0002-1236-6339				Assoian Richard K., 1997, Cytokine and Growth Factor Reviews, V8, P165, DOI 10.1016/S1359-6101(97)00011-7; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Kang JS, 1996, MOL CELL BIOL, V16, P3370; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schwartz MA, 2001, J CELL SCI, V114, P2553; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	41	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13640	13644		10.1074/jbc.M314300200	http://dx.doi.org/10.1074/jbc.M314300200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732703	hybrid			2022-12-27	WOS:000220478500045
J	Gatto, L; Berlato, C; Poli, V; Tininini, S; Kinjyo, I; Yoshimura, A; Cassatella, MA; Bazzoni, F				Gatto, L; Berlato, C; Poli, V; Tininini, S; Kinjyo, I; Yoshimura, A; Cassatella, MA; Bazzoni, F			Analysis of SOCS-3 promoter responses to interferon gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE COMPONENTS; MICE LACKING SUPPRESSOR; FACTOR-KAPPA-B; HUMAN NEUTROPHILS; CYTOKINE SIGNALING-3; IFN-GAMMA; SERINE PHOSPHORYLATION; FUNCTIONAL INTERACTION; TARGETED DISRUPTION; NEGATIVE REGULATION	SOCS-3 ( suppressor of cytokine signaling 3) is an intracellular protein that is selectively and rapidly induced by appropriate agonists and that modulates responses of immune cells to cytokines by interfering with the Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway. On the basis of the observations that interferon gamma(IFNgamma) up-regulates SOCS-3 gene and protein expression in primary mouse macrophages, J774 macrophage cell line and embryonal fibroblasts, we investigated which sequences of the 5' SOCS-3 gene are responsive to IFNgamma. By promoter deletion analysis we identified a functional IFNgamma-responsive element, located at nucleotides - 72/ - 64 upstream from the transcription initiation, whose presence and integrity is necessary to ensure responsiveness to IFNgamma. This element contains a STAT consensus binding sequence (SOCS-3/STAT-binding element (SBE)) whose specific mutation totally abolished the responsiveness to IFNgamma. In contrast, discrete deletion of other 5' regions of the SOCS-3 promoter did not substantially modify the inducibility by IFNgamma. Electromobility shift assay analyses revealed that IFNgamma promotes specific DNA binding activities to an oligonucleotide probe containing the SOCS-3/SBE sequence. Even though IFNgamma triggered tyrosine phosphorylation of both STAT1 and STAT3 in macrophages and J774 cells, only STAT1 was appropriately activated and thus found to specifically bind to the SOCS-3/SBE oligonucleotide probe. Accordingly, IFNgamma-induced SOCS-3 protein expression was not impaired in STAT3-deficient embryonal fibroblasts. Taken together, these results demonstrate that the induction of SOCS-3 by IFNgamma depends upon the presence of a STAT-binding element in the SOCS-3 promoter that is specifically activated by STAT1.	Univ Verona, Dept Pathol, Sect Gen Pathol, I-37134 Verona, Italy; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy; Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Fukuoka 8128582, Japan	University of Verona; University of Turin; University of Dundee; Kyushu University	Bazzoni, F (corresponding author), Univ Verona, Dept Pathol, Sect Gen Pathol, Str Grazie 4, I-37134 Verona, Italy.	flavia.bazzoni@univr.it	Yoshimura, Akihiko/K-5515-2013; Poli, Valeria/A-9215-2012; Bazzoni, Flavia/AAB-7674-2019; Cassatella, M A/B-8037-2013	Poli, Valeria/0000-0002-3739-3966; Bazzoni, Flavia/0000-0001-6768-8012; Cassatella, M A/0000-0001-7824-1806; Kinjyo, Ichiko/0000-0001-7051-3790				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Buckley CD, 2001, TRENDS IMMUNOL, V22, P199, DOI 10.1016/S1471-4906(01)01863-4; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; Cassatella MA, 1999, BLOOD, V94, P2880, DOI 10.1182/blood.V94.8.2880.420k31_2880_2889; Corbaz A, 2002, J IMMUNOL, V168, P3608, DOI 10.4049/jimmunol.168.7.3608; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Crepaldi L, 2001, J IMMUNOL, V167, P2312, DOI 10.4049/jimmunol.167.4.2312; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; De Souza D, 2002, BIOCHEMISTRY-US, V41, P9229, DOI 10.1021/bi0259507; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Ding YZ, 2003, J IMMUNOL, V170, P1383, DOI 10.4049/jimmunol.170.3.1383; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Dusi S, 2001, EUR J IMMUNOL, V31, P929, DOI 10.1002/1521-4141(200103)31:3<929::AID-IMMU929>3.0.CO;2-M; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; GHEZZI P, 1988, J IMMUNOL, V140, P4238; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348; Hong F, 2002, J CLIN INVEST, V110, P1503, DOI 10.1172/JCI200215841; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; McDonald PP, 1998, CELL IMMUNOL, V184, P45, DOI 10.1006/cimm.1998.1255; MEDA L, 1994, CELL IMMUNOL, V157, P448, DOI 10.1006/cimm.1994.1241; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Muhl H, 2003, INT IMMUNOPHARMACOL, V3, P1247, DOI 10.1016/S1567-5769(03)00131-0; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; SIHVOLA M, 1989, SCAND J IMMUNOL, V29, P689, DOI 10.1111/j.1365-3083.1989.tb01173.x; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Veenstra KG, 2002, J IMMUNOL, V168, P2282, DOI 10.4049/jimmunol.168.5.2282; Wang JP, 2002, P NATL ACAD SCI USA, V99, P16209, DOI 10.1073/pnas.252454799; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Woldman I, 2001, J BIOL CHEM, V276, P45722, DOI 10.1074/jbc.M105320200; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200; Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	54	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13746	13754		10.1074/jbc.M308999200	http://dx.doi.org/10.1074/jbc.M308999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14742442	hybrid			2022-12-27	WOS:000220478500058
J	Liu, T; Lu, B; Lee, I; Ondrovicova, G; Kutejova, E; Suzuki, CK				Liu, T; Lu, B; Lee, I; Ondrovicova, G; Kutejova, E; Suzuki, CK			DNA and RNA binding by the mitochondrial Lon protease is regulated by nucleotide and protein substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; PIM1 PROTEASE; SACCHAROMYCES-CEREVISIAE; CLPAP PROTEASE; 26S PROTEASOME; DEGRADATION; PROTEOLYSIS; YEAST; LA	The ATP-dependent Lon protease belongs to a unique group of proteases that bind DNA. Eukaryotic Lon is a homo-oligomeric ring-shaped complex localized to the mitochondrial matrix. In vitro, human Lon binds specifically to a single-stranded GT-rich DNA sequence overlapping the light strand promoter of human mitochondrial DNA ( mtDNA). We demonstrate that Lon binds GT-rich DNA sequences found throughout the heavy strand of mtDNA and that it also interacts specifically with GU-rich RNA. ATP inhibits the binding of Lon to DNA or RNA, whereas the presence of protein substrate increases the DNA binding affinity of Lon 3.5-fold. We show that nucleotide inhibition and protein substrate stimulation coordinately regulate DNA binding. In contrast to the wild type enzyme, a Lon mutant lacking both ATPase and protease activity binds nucleic acid; however, protein substrate fails to stimulate binding. These results suggest that conformational changes in the Lon holoenzyme induced by nucleotide and protein substrate modulate the binding affinity for single-stranded mtDNA and RNA in vivo. Co-immunoprecipitation experiments show that Lon interacts with mtDNA polymerase gamma and the Twinkle helicase, which are components of mitochondrial nucleoids. Taken together, these results suggest that Lon participates directly in the metabolism of mtDNA.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Slovak Acad Sci, Inst Mol Biol, Bratislava 84551, Slovakia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Case Western Reserve University; Slovak Academy of Sciences	Suzuki, CK (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	suzukick@umdnj.edu	Kutejova, Eva/K-6550-2014; Lu, Bin/GQQ-3590-2022; Kutejova, Eva/AAI-2544-2021; Lee, Irene/C-6104-2011	Kutejova, Eva/0000-0002-0973-679X; Kutejova, Eva/0000-0002-0973-679X; 	NIGMS NIH HHS [GM067172, GM61095] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067172, R01GM061095] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; ASH DE, 1982, J BIOL CHEM, V257, P9261; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; BONNEFOY E, 1989, P NATL ACAD SCI USA, V86, P7691, DOI 10.1073/pnas.86.20.7691; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bretz J, 2002, MOL MICROBIOL, V45, P397, DOI 10.1046/j.1365-2958.2002.03008.x; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; CHARETTE MF, 1984, J BACTERIOL, V158, P195, DOI 10.1128/JB.158.1.195-201.1984; CHUNG CH, 1982, P NATL ACAD SCI-BIOL, V79, P795, DOI 10.1073/pnas.79.3.795; Ferdous A, 2002, BIOCHEMISTRY-US, V41, P12798, DOI 10.1021/bi020425t; Fu GK, 1997, J BIOL CHEM, V272, P534; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; Maas R, 2001, CELL, V105, P945, DOI 10.1016/S0092-8674(01)00402-0; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P13237, DOI 10.1021/bi0111653; MENON AS, 1987, J BIOL CHEM, V262, P14929; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7; Muise AM, 1999, BIOCHEM J, V343, P341, DOI 10.1042/0264-6021:3430341; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Poon K, 1998, BIOPOLYMERS, V45, P427, DOI 10.1002/(SICI)1097-0282(199805)45:6<427::AID-BIP2>3.0.CO;2-R; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; Robertson GT, 2000, MOL MICROBIOL, V35, P577, DOI 10.1046/j.1365-2958.2000.01726.x; Roudiak SG, 1998, BIOCHEMISTRY-US, V37, P11255, DOI 10.1021/bi980945h; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; Schmidt M, 1999, CURR OPIN CHEM BIOL, V3, P584, DOI 10.1016/S1367-5931(99)00013-7; Shafer RH, 2001, BIOPOLYMERS, V56, P209, DOI 10.1002/1097-0282(2000/2001)56:3<209::AID-BIP10018>3.0.CO;2-Y; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Takaya A, 2003, INFECT IMMUN, V71, P690, DOI 10.1128/IAI.71.2.690-696.2003; Thomas-Wohlever J, 2002, BIOCHEMISTRY-US, V41, P9418, DOI 10.1021/bi0255470; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wagner I, 1997, EMBO J, V16, P7317, DOI 10.1093/emboj/16.24.7317; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; Whistler CA, 2000, APPL ENVIRON MICROB, V66, P2718, DOI 10.1128/AEM.66.7.2718-2725.2000; Wright R, 1996, GENE DEV, V10, P1532, DOI 10.1101/gad.10.12.1532; ZEHNBAUER BA, 1981, P NATL ACAD SCI-BIOL, V78, P2043, DOI 10.1073/pnas.78.4.2043; Zheng WJ, 1998, CELL, V93, P103, DOI 10.1016/S0092-8674(00)81150-2; Zheng WJ, 1998, MOL CELL BIOL, V18, P3580, DOI 10.1128/MCB.18.6.3580; ZOETEWEIJ JP, 1994, BIOCHEM J, V299, P539, DOI 10.1042/bj2990539	66	120	127	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13902	13910		10.1074/jbc.M309642200	http://dx.doi.org/10.1074/jbc.M309642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14739292	hybrid			2022-12-27	WOS:000220478500077
J	Shao, JY; Evers, BM; Sheng, HM				Shao, JY; Evers, BM; Sheng, HM			Prostaglandin E-2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; RAS-MEDIATED TRANSFORMATION; COLORECTAL-CANCER; CARCINOMA CELLS; KNOCKOUT MICE; EGF RECEPTOR; CYCLOOXYGENASE-2; PROTEIN; AMPHIREGULIN	Cyclooxygenase (COX)-generated prostaglandin E-2 (PGE(2)) plays critical roles in colorectal carcinogenesis. Recently, we have shown that PGE2 and transforming growth factor-alpha synergistically induces the expression of amphiregulin (AR) in colon cancer cells (Shao, J., Evers, B. M., and Sheng, H. (2003) Cancer Res. 63, 5218-5223). In this study, we demonstrated synergistic actions of PGE2 and the receptor tyrosine kinase signaling system in AR expression and in tumorigenic potential of colon cancer cells. Activation of the Ras/Raf/MAPK pathway induced AR transcription in colon cancer LS-174 cells that was enhanced by PGE2 in a synergistic fashion. The cAMP-responsive element within the AR promoter was required for the synergistic activation of AR transcription. An Sp1 element was responsible for the basal transcription of AR and significantly enhanced the synergy between PGE(2) and the epidermal growth factor receptor (EGFR) signaling system. Furthermore, activation of both PGE(2) and EGFR signaling pathways synergistically promoted the growth and migration of colon cancer cells. Our results suggest that COX-2/PGE(2) may exert pro-oncogenic effects through synergistic induction of receptor tyrosine kinase-dependent signaling pathway, thus, provide a novel mechanism for the combinatorial treatment of colonic neoplasms targeting both COX-2/PGE(2) and the EGFR system that has demonstrated remarkable advantages.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Sheng, HM (corresponding author), Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA.	hosheng@utmb.edu			NIDDK NIH HHS [DK-065615] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065615] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Breyer MD, 2000, CURR OPIN NEPHROL HY, V9, P23, DOI 10.1097/00041552-200001000-00005; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Damstrup L, 1999, BRIT J CANCER, V80, P1012, DOI 10.1038/sj.bjc.6690456; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; De Luca A, 2000, ONCOGENE, V19, P5863, DOI 10.1038/sj.onc.1203979; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; JONES MK, 1999, FRONT BIOSCI, V4, P303, DOI DOI 10.2741/A428; Karnes WE, 1998, GASTROENTEROLOGY, V114, P930, DOI 10.1016/S0016-5085(98)70312-9; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Mann M, 2001, GASTROENTEROLOGY, V120, P1713, DOI 10.1053/gast.2001.24844; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ozgul C, 1997, Acta Physiol Hung, V85, P121; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Podolsky Daniel K., 1994, P129; POLK DB, 1999, DEV GASTROINTESTINAL, P37; Roh H, 2000, CANCER RES, V60, P560; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Shao JY, 2003, CANCER RES, V63, P5218; Shao JY, 2002, CANCER RES, V62, P3282; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng H, 2003, GUT, V52, P1472, DOI 10.1136/gut.52.10.1472; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sheng HM, 2001, CANCER RES, V61, P2670; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Shirai H, 1995, ANTICANCER RES, V15, P2889; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; THUN MJ, 1993, CANCER RES, V53, P1322; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Wilson AJ, 1999, EXP CELL RES, V250, P187, DOI 10.1006/excr.1999.4496; Yu Y, 1998, J IMMUNOL, V161, P3746	50	73	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14287	14293		10.1074/jbc.M313276200	http://dx.doi.org/10.1074/jbc.M313276200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14742435	hybrid			2022-12-27	WOS:000220478500123
J	Cai, YQ; Anyatonwu, G; Okuhara, D; Lee, KB; Yu, ZH; Onoe, T; Mei, CL; Qian, Q; Geng, L; Wiztgall, R; Ehrlich, BE; Somlo, S				Cai, YQ; Anyatonwu, G; Okuhara, D; Lee, KB; Yu, ZH; Onoe, T; Mei, CL; Qian, Q; Geng, L; Wiztgall, R; Ehrlich, BE; Somlo, S			Calcium dependence of polycystin-2 channel activity is modulated by phosphorylation at Ser(812)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; KIDNEY-DISEASE; CA2+ CHANNELS; INTRACELLULAR CA2+; LLC-PK1 CELLS; EF-HAND; GENE; VASOPRESSIN; PROTEIN; KINASE	Polycystin-2 (PC-2) is a non-selective cation channel that, when mutated, results in autosomal dominant polycystic kidney disease. In an effort to understand the regulation of this channel, we investigated the role of protein phosphorylation in PC-2 function. We demonstrated the direct incorporation of phosphate into PC-2 in cells and tissues and found that this constitutive phosphorylation occurs at Ser(812), a putative casein kinase II (CK2) substrate domain. Ser812 can be phosphorylated by CK2 in vitro and substitution S812A results in failure to incorporate phosphate in cultured epithelial cells. Non-phosphorylated forms of PC-2 traffic normally in the endoplasmic reticulum and cilial compartments and retain homo- and hetero-multimerization interactions with PC-2 and polycystin-1, respectively. Single-channel studies of PC-2, S812A, and a substitution mutant, T721A, not related to phosphorylation show that PC-2 and S812A function as divalent cation channels with similar current amplitudes across a range of holding potentials; the T721A channel is not functional. Channel open probabilities for PC-2 and S812A show a bell-shaped dependence on cytoplasmic Ca2+ but there is a shift in this Ca2+ dependence such that S812A is 10-fold less sensitive to Ca2+ activation/inactivation than the wild type PC-2 channel. In vivo analysis of PC-2-dependent enhanced intracellular Ca2+ transients found that S812A resulted in enhanced transient duration and relative amplitude intermediate between control cells and those overexpressing wild type PC-2. Phosphorylation at Ser812 modulates PC-2 channel activity and factors regulating this phosphorylation are likely to play a role in the pathogenesis of polycystic kidney disease.	Yale Univ, Sch Med, Nephrol Sect, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Heidelberg Univ, Inst Anat & Cell Biol, D-69120 Heidelberg, Germany	Yale University; Yale University; Yale University; Mayo Clinic; Ruprecht Karls University Heidelberg	Somlo, S (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Dept Genet, POB 208029,333 Cedar St, New Haven, CT 06520 USA.	Stefan.somlo@yale.edu	/AAX-8408-2021	/0000-0001-9657-9704	NIDDK NIH HHS [P50 DK 57328, DK 57328, DK 54053] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054053, P50DK057328] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; BURNATOWSKAHLEDIN MA, 1987, AM J PHYSIOL, V253, pF328, DOI 10.1152/ajprenal.1987.253.2.F328; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Dibas AI, 1997, AM J PHYSIOL-CELL PH, V272, pC810, DOI 10.1152/ajpcell.1997.272.3.C810; DICKMAN KG, 1989, AM J PHYSIOL, V257, pC333, DOI 10.1152/ajpcell.1989.257.2.C333; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HIMPENS B, 1993, AM J PHYSIOL, V265, pC966, DOI 10.1152/ajpcell.1993.265.4.C966; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Li Q, 2002, FEBS LETT, V516, P270, DOI 10.1016/S0014-5793(02)02513-9; Li XH, 2002, P NATL ACAD SCI USA, V99, P9260, DOI 10.1073/pnas.132051799; Lieberman DN, 1999, NAT NEUROSCI, V2, P125, DOI 10.1038/5680; Liu SM, 2002, DEVELOPMENT, V129, P5839, DOI 10.1242/dev.00173; Macica CM, 2001, J NEUROSCI, V21, P1160; Marx S, 2003, J MOL CELL CARDIOL, V35, P37, DOI 10.1016/S0022-2828(02)00287-0; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Parnell SC, 1999, BIOCHEM BIOPH RES CO, V259, P539, DOI 10.1006/bbrc.1999.0810; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Reynolds DM, 1999, J AM SOC NEPHROL, V10, P2342; Sweeney WE, 1998, AM J PHYSIOL-RENAL, V275, pF387, DOI 10.1152/ajprenal.1998.275.3.F387; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; WEINBERG JM, 1989, AM J PHYSIOL, V256, pC967, DOI 10.1152/ajpcell.1989.256.5.C967; Wilson PD, 1999, LAB INVEST, V79, P1311; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25	35	110	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19987	19995		10.1074/jbc.M312031200	http://dx.doi.org/10.1074/jbc.M312031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14742446	hybrid			2022-12-27	WOS:000221164500073
J	Becker, CFW; Oblatt-Montal, M; Kochendoerfer, GG; Montal, M				Becker, CFW; Oblatt-Montal, M; Kochendoerfer, GG; Montal, M			Chemical synthesis and single channel properties of tetrameric and pentameric TASPs (template-assembled synthetic proteins) derived from the transmembrane domain of HIV virus protein u (Vpu)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING STRUCTURE; INTEGRAL MEMBRANE-PROTEIN; 4-HELIX BUNDLE PROTEINS; ION-CHANNEL; TYPE-1 VPU; LINING STRUCTURE; MODEL SYSTEMS; FULL-LENGTH; SEGMENT M2; PEPTIDES	Vpu, an 81-residue membrane protein encoded by the genome of HIV-1, is involved in CD4 degradation and facilitates virion budding from infected cells. The latter activity requires an intact transmembrane (TM) domain; however, the mechanism remains unclear. Vpu forms ion channels, an activity linked to the TM domain and envisioned to arise by oligomerization. The precise number of Vpu monomers that structure the channel is not yet known. To address this issue, we have synthesized tetrameric and pentameric proteins consisting of a carrier template to which four or five peptides corresponding to the TM domain of Vpu are attached. Ketoxime-forming chemoselective ligation efficiently ligated four and five copies, respectively, of the linear transmembrane peptide that was solubilized by the addition of a cleavable polyethylene glycol-polyamide auxiliary to a template. Purified tetrameric and pentameric proteins, denoted as T(4)Vpu and T(5)Vpu, exhibit the predicted mass as determined by MS analysis and fold with a high helical content as evidenced by CD. Both T(4)Vpu and T(5)Vpu, after reconstitution in lipid bilayers, form discrete ion channels of distinct conductance and high propensity to be open. The most frequent openings have a single channel conductance of 42 +/- 5 pS for T(4)Vpu and 76 +/- 5 pS for T(5)Vpu in 0.5 M KCl. These findings validate the notion that the channels formed by Vpu result from the self-assembly of monomers. We conclude that a five-helix bundle of the TM of Vpu may approximate the structural motif underlying the oligomeric state of the conductive channel.	Gryphon Therapeut, San Francisco, CA 94080 USA; Univ Calif San Diego, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kochendoerfer, GG (corresponding author), Gryphon Therapeut, 600 Gateway Blvd, San Francisco, CA 94080 USA.	gerd@gryphonRx.com; mmontal@ucsd.edu	Becker, Christian/E-3588-2010; Becker, Christian F/A-4891-2010	Becker, Christian F/0000-0002-8890-7082	NIGMS NIH HHS [GM-49711, GM-56538] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056538] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bour S, 2003, MICROBES INFECT, V5, P1029, DOI 10.1016/S1286-4579(03)00191-6; CAMARERO JA, 1999, CURRENT PROTOCOLS PR, P1; Cordes FS, 2001, BBA-BIOMEMBRANES, V1512, P291, DOI 10.1016/S0005-2736(01)00332-7; De E, 2001, J PEPT SCI, V7, P41, DOI 10.1002/psc.293; Ewart GD, 2002, EUR BIOPHYS J BIOPHY, V31, P26, DOI 10.1007/s002490100177; FIELDS C G, 1991, Peptide Research, V4, P95; GROVE A, 1993, J AM CHEM SOC, V115, P5919, DOI 10.1021/ja00067a004; GROVE A, 1991, P NATL ACAD SCI USA, V88, P6418, DOI 10.1073/pnas.88.15.6418; Henklein P, 2000, FEBS LETT, V482, P220, DOI 10.1016/S0014-5793(00)02060-3; IWAMOTO T, 1994, INT J PEPT PROT RES, V43, P597, DOI 10.1111/j.1399-3011.1994.tb00562.x; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; Kochendoerfer GG, 2004, J AM CHEM SOC, V126, P2439, DOI 10.1021/ja038985i; Kochendoerfer GG, 2002, BIOCONJUGATE CHEM, V13, P474, DOI 10.1021/bc010128l; Kukol A, 1999, BIOPHYS J, V77, P1594, DOI 10.1016/S0006-3495(99)77007-4; Lamb RA, 1997, VIROLOGY, V229, P1, DOI 10.1006/viro.1997.8451; Lopez CF, 2002, BIOPHYS J, V83, P1259, DOI 10.1016/S0006-3495(02)73898-8; Ma C, 2002, PROTEIN SCI, V11, P546, DOI 10.1110/ps.37302; MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993; Marassi FM, 1999, P NATL ACAD SCI USA, V96, P14336, DOI 10.1073/pnas.96.25.14336; Montal M, 2003, FEBS LETT, V552, P47, DOI 10.1016/S0014-5793(03)00849-4; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; Moore PB, 1998, FEBS LETT, V431, P143, DOI 10.1016/S0014-5793(98)00714-5; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; Nishio H, 2000, TETRAHEDRON LETT, V41, P6839, DOI 10.1016/S0040-4039(00)01156-4; OBLATTMONTAL M, 1993, J BIOL CHEM, V268, P14601; OBLATTMONTAL M, 1993, FEBS LETT, V320, P261; Park SH, 2003, J MOL BIOL, V333, P409, DOI 10.1016/j.jmb.2003.08.048; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; REDDY GL, 1993, J BIOL CHEM, V268, P14608; Rose K, 1999, J AM CHEM SOC, V121, P7034, DOI 10.1021/ja9909879; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5; Schubert U, 1996, J VIROL, V70, P809, DOI 10.1128/JVI.70.2.809-819.1996; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992	38	43	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17483	17489		10.1074/jbc.M313212200	http://dx.doi.org/10.1074/jbc.M313212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14752102	hybrid			2022-12-27	WOS:000220870400075
J	Collins, PR; Stack, CM; O'Neill, SM; Doyle, S; Ryan, T; Brennan, GP; Mousley, A; Stewart, M; Maule, AG; Dalton, JP; Donnelly, S				Collins, PR; Stack, CM; O'Neill, SM; Doyle, S; Ryan, T; Brennan, GP; Mousley, A; Stewart, M; Maule, AG; Dalton, JP; Donnelly, S			Cathepsin L1, the major protease involved in liver fluke (Fasciola hepatica) virulence - Propeptide cleavage sites and autoactivation of the zymogen secreted from gastrodermal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROCATHEPSIN-B; L IN-VITRO; SACCHAROMYCES-CEREVISIAE; CYSTEINE PROTEASE; L PROTEINASE; FUNCTIONAL EXPRESSION; BORDETELLA-PERTUSSIS; SCHISTOSOMA-MANSONI; ELECTRON-MICROSCOPE; CRYSTAL-STRUCTURE	The secretion and activation of the major cathepsin L1 cysteine protease involved in the virulence of the helminth pathogen Fasciola hepatica was investigated. Only the fully processed and active mature enzyme can be detected in medium in which adult F. hepatica are cultured. However, immunocytochemical studies revealed that the inactive procathepsin L1 is packaged in secretory vesicles of epithelial cells that line the parasite gut. These observations suggest that processing and activation of procathepsin L1 occurs following secretion from these cells into the acidic gut lumen. Expression of the 37-kDa procathepsin L1 in Pichia pastoris showed that an intermolecular processing event within a conserved GXNXFXD motif in the propeptide generates an active 30-kDa intermediate form. Further activation of the enzyme was initiated by decreasing the pH to 5.0 and involved the progressive processing of the 37 and 30-kDa forms to other intermediates and finally to a fully mature 24.5 kDa cathepsin L with an additional 1 or 2 amino acids. An active site mutant procathepsin L, constructed by replacing the Cys(26) with Gly(26), failed to autoprocess. However, [Gly(26)] procathepsin L was processed by exogenous wild-type cathepsin L to a mature enzyme plus 10 amino acids attached to the N terminus. This exogenous processing occurred without the formation of a 30-kDa intermediate form. The results indicate that activation of procathepsin L1 by removal of the propeptide can occur by different pathways, and that this takes place within the parasite gut where the protease functions in food digestion and from where it is liberated as an active enzyme for additional extracorporeal roles.	Univ Technol Sydney, Inst Biotechnol Infect Dis, St Leonards, NSW 2065, Australia; Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland; Natl Univ Ireland, Dept Biol, Maynooth, Kildare, Ireland; Queens Univ Belfast, Ctr Med Biol, Parasitol Res Grp, Belfast BT9 7BL, Antrim, North Ireland	University of Technology Sydney; Dublin City University; Maynooth University; Queens University Belfast	Dalton, JP (corresponding author), Univ Technol Sydney, Inst Biotechnol Infect Dis, Westbourne St,Gore Hill, St Leonards, NSW 2065, Australia.	john.dalton@uts.edu.au	Stack, Colin M/D-4601-2009; Dalton, John/K-4457-2014; Donnelly, Sheila/H-7733-2014	Doyle, Sean/0000-0003-1679-3247; Maule, Aaron/0000-0003-0862-2667; Donnelly, Sheila/0000-0003-2005-3698; Stack, Colin/0000-0002-7539-7677				BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Berasain P, 1997, J PARASITOL, V83, P1, DOI 10.2307/3284308; Brady CP, 2000, EXP PARASITOL, V94, P75, DOI 10.1006/expr.1999.4478; Brady MT, 1999, INFECT IMMUN, V67, P5372, DOI 10.1128/IAI.67.10.5372-5378.1999; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; Brix K, 2001, BIOL CHEM, V382, P717, DOI 10.1515/BC.2001.087; Cappetta M, 2002, BIOL CHEM, V383, P1215, DOI 10.1515/BC.2002.134; CARMONA C, 1993, MOL BIOCHEM PARASIT, V62, P9, DOI 10.1016/0166-6851(93)90172-T; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DALTON JP, 1989, MOL BIOCHEM PARASIT, V35, P161, DOI 10.1016/0166-6851(89)90118-7; Dalton JP, 2003, INT J PARASITOL, V33, P621, DOI 10.1016/S0020-7519(03)00057-2; Dalton JP, 2001, VET PARASITOL, V98, P149, DOI 10.1016/S0304-4017(01)00430-7; Dalton JP, 1996, INFECT IMMUN, V64, P5066, DOI 10.1128/IAI.64.12.5066-5074.1996; DOWD AJ, 1994, EUR J BIOCHEM, V223, P91, DOI 10.1111/j.1432-1033.1994.tb18969.x; Dowd AJ, 2000, ENZYME MICROB TECH, V27, P599, DOI 10.1016/S0141-0229(00)00259-3; Dowd AJ, 1997, MOL BIOCHEM PARASIT, V88, P163, DOI 10.1016/S0166-6851(97)00090-X; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; Fairweather I, 1999, FASCIOLOSIS, P47; Friedrichs B, 2003, J CLIN INVEST, V111, P1733, DOI 10.1172/JCI200315990; Guillaume-Rousselet N, 2002, BIOCHEM J, V367, P219, DOI 10.1042/BJ20020350; HALTON, 1997, INT J PARASITOL, V57, P693; HALTON DW, 1967, PARASITOLOGY, V57, P639, DOI 10.1017/S003118200007311X; HANNA REB, 1975, EXP PARASITOL, V38, P167, DOI 10.1016/0014-4894(75)90019-3; Higgins DR, 1998, METH MOL B, V103, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ishidoh K, 1998, BIOL CHEM, V379, P131; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; Linder S, 1996, BIOTECHNIQUES, V20, P980; Lipps G, 1996, J BIOL CHEM, V271, P1717, DOI 10.1074/jbc.271.3.1717; Lorenzo K, 2000, CANCER RES, V60, P4070; MACH L, 1994, J BIOL CHEM, V269, P13036; Mas-Coma S, 1999, FASCIOLOSIS, P411; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Mulcahy G, 1998, VACCINE, V16, P932, DOI 10.1016/S0264-410X(97)00289-2; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; O'Neill SM, 2001, PARASITE IMMUNOL, V23, P541, DOI 10.1046/j.1365-3024.2001.00411.x; O'Neill SM, 2000, PARASITE IMMUNOL, V22, P147, DOI 10.1046/j.1365-3024.2000.00290.x; Ogino T, 1999, J BIOCHEM-TOKYO, V126, P78, DOI 10.1093/oxfordjournals.jbchem.a022439; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Quraishi O, 2001, J BIOL CHEM, V276, P8118, DOI 10.1074/jbc.M005851200; ROBINSON G, 1975, EXP PARASITOL, V37, P20, DOI 10.1016/0014-4894(75)90050-8; Roche L, 1997, EUR J BIOCHEM, V245, P373, DOI 10.1111/j.1432-1033.1997.t01-1-00373.x; Roche L, 1999, MOL BIOCHEM PARASIT, V98, P271, DOI 10.1016/S0166-6851(98)00164-9; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; SENFT, 1976, BIOCH PARASITES HOST, P335; SHEAHAN K, 1989, CANCER RES, V49, P3809; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SMITH AM, 1993, MOL BIOCHEM PARASIT, V62, P1, DOI 10.1016/0166-6851(93)90171-S; Smyth J.D., 1983, PHYSL TREMATODES; Spithill TW, 1999, FASCIOLOSIS, P377; Tepel C, 2000, J CELL SCI, V113, P4487; Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2; TRABANDT A, 1990, MATRIX, V10, P349, DOI 10.1016/S0934-8832(11)80142-3; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; YAGEL S, 1989, CANCER RES, V49, P3553; Yamasaki H, 2002, INT J PARASITOL, V32, P1031, DOI 10.1016/S0020-7519(02)00057-7	65	133	139	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17038	17046		10.1074/jbc.M308831200	http://dx.doi.org/10.1074/jbc.M308831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14754899	Green Accepted, hybrid			2022-12-27	WOS:000220870400020
J	Sawka-Verhelle, D; Escoubet-Lozach, L; Fong, AL; Hester, KD; Herzig, S; Lebrun, P; Glass, CK				Sawka-Verhelle, D; Escoubet-Lozach, L; Fong, AL; Hester, KD; Herzig, S; Lebrun, P; Glass, CK			PE-1/METS, an antiproliferative Ets repressor factor, is induced by CREB-1/CREM-1 during macrophage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SCAVENGER RECEPTOR GENE; AMP-RESPONSIVE ELEMENT; TRANSCRIPTION FACTOR; BINDING-PROTEIN; COMBINATORIAL INTERACTIONS; INTERSTITIAL COLLAGENASE; INDUCED PHOSPHORYLATION; C-FOS; CREB	The molecular mechanisms involved in regulating the balance between cellular proliferation and differentiation remain poorly understood. Members of the Ets-domain family of transcription factors are candidates for proteins that might differentially regulate cell cycle control and cell type-specific genes during the differentiation of myeloid progenitor cells. The Ets repressor PE-1/METS has been suggested to contribute to growth arrest during terminal macrophage differentiation by repressing Ets target genes involved in Ras-dependent proliferation. An important feature of this regulatory model is that PE-1/METS is itself induced by the program of macrophage differentiation elicited by M-CSF. Here, we present evidence that the PE-1/METS gene is a transcriptional target of the cyclic AMP response element-binding protein-1 (CREB-1). CREB-1 expression is dramatically up-regulated during macrophage differentiation and phosphorylation of CREB-1 and the related factor CREM-1 are stimulated by M-CSF in a SAPK2/p38-dependent manner. Chromatin immunoprecipitation experiments demonstrate that CREB-1/CREM-1 are recruited to the PE-1/METS promoter as well as to the promoters of other genes that are up-regulated during terminal macrophage differentiation. Overexpression of CREB-1 stimulates the activities of the PE-1/METS, and macrosialin promoters, while expression of a dominant negative form of CREB-1 during macrophage differentiation inhibits expression of the PE-1/METS and macrosialin genes. Inhibition of CREB function also results in reduced expression of CD54 and impaired cell adhesion. Taken together, these findings reveal new roles of CREB-1/CREM-1 as regulators of macrophage differentiation.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute	Glass, CK (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.	cglass@ucsd.edu	Glass, Christopher/AAI-3933-2021; LEBRUN, Patricia/O-5765-2016	Glass, Christopher/0000-0003-4344-3592; Herzig, Stephan/0000-0003-3950-3652	NCI NIH HHS [T32-CA67754] Funding Source: Medline; NHLBI NIH HHS [HL59694-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067754] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Bidder M, 2000, BIOCHEMISTRY-US, V39, P8917, DOI 10.1021/bi000343+; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Cammarota M, 2001, J NEUROCHEM, V79, P1122, DOI 10.1046/j.1471-4159.2001.00666.x; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Guidez F, 1998, MOL CELL BIOL, V18, P3851, DOI 10.1128/MCB.18.7.3851; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; Houglum K, 1997, J CLIN INVEST, V99, P1322, DOI 10.1172/JCI119291; Jiang ZM, 1998, GENOMICS, V50, P199, DOI 10.1006/geno.1998.5327; JIN DI, 1995, MOL CELL BIOL, V15, P693; Klappacher GW, 2002, CELL, V109, P169, DOI 10.1016/S0092-8674(02)00714-6; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1995, HEMATOPOIETIC COLONY; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PAHL HL, 1991, EXP HEMATOL, V19, P1038; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; Saeki K, 2003, J LEUKOCYTE BIOL, V73, P673, DOI 10.1189/jlb.1002512; Sawka-Verhelle D, 2000, ENDOCRINOLOGY, V141, P1977, DOI 10.1210/en.141.6.1977; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Steeber DA, 1999, J IMMUNOL, V163, P2176; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Welch JS, 2002, J BIOL CHEM, V277, P42821, DOI 10.1074/jbc.M205873200; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wolfl S, 1999, MOL ENDOCRINOL, V13, P659, DOI 10.1210/me.13.5.659; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	54	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17772	17784		10.1074/jbc.M311991200	http://dx.doi.org/10.1074/jbc.M311991200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14754893	hybrid			2022-12-27	WOS:000220870400109
J	Souroujon, MC; Yao, LN; Chen, HB; Endemann, G; Khaner, H; Geeraert, V; Schechtman, D; Gordon, AS; Diamond, I; Mochly-Rosen, D				Souroujon, MC; Yao, LN; Chen, HB; Endemann, G; Khaner, H; Geeraert, V; Schechtman, D; Gordon, AS; Diamond, I; Mochly-Rosen, D			State-specific monoclonal antibodies identify an intermediate state in epsilon protein kinase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; CARDIAC MYOCYTES; PHORBOL ESTER; INTRACELLULAR RECEPTOR; SIGNAL-TRANSDUCTION; PKC-EPSILON; LOCALIZATION; TRANSLOCATION; ETHANOL; CELLS	Evaluation of the activation state of protein kinase C (PKC) isozymes relies on analysis of subcellular translocation. A monoclonal antibody, 14E6, specific for the activated conformation of epsilonPKC, was raised using the first variable (V1) domain of epsilonPKC as the immunogen. 14E6 binding is specific for epsilonPKC and is greatly increased in the presence of PKC activators. Immunofluorescence staining by 14E6 of neonatal rat primary cardiac myocytes and the NG108-15 neuroblastoma glioma cell line, NG108-15/D2, increases rapidly following cell activation and is localized to new subcellular sites. However, staining of translocated epsilonPKC with 14E6 is transient, and the epitope disappears 30 min after activation of NG-108/15 cells by a D2 receptor agonist. In contrast, subcellular localization associated with activation, as determined by commercially available polyclonal antibodies, persists for at least 30 min. In vitro, epsilonRACK, the receptor for activated epsilonPKC, inhibits 14E6 binding to epsilonPKC, suggesting that the 14E6 epitope is lost or hidden when active epsilonPKC binds to its RACK. Therefore, the 14E6 antibody appears to identify a transient state of activated but non-anchored epsilonPKC. Moreover, binding of 14E6 to epsilonPKC only after activation suggests that lipid-dependent conformational changes associated with epsilonPKC activation precede binding of the activated isozyme to its specific RACK, epsilonRACK. Further, monoclonal antibody 14E6 should be a powerful tool to study the pathways that control rapid translocation of epsilonPKC from cytosolic to membrane localization on activation.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Calif San Francisco, Sch Med, Ernest Gallo Clin & Res Ctr, Emeryville, CA 94608 USA; Univ Calif San Francisco, Sch Med, Dept Neurol, Emeryville, CA 94608 USA; Open Univ Israel, Dept Nat & Life Sci, IL-61392 Tel Aviv, Israel; CNRS, Ctr Neurochim, Lab Neurobiol Cellulaire, UPR 9009, F-67000 Strasbourg, France	Stanford University; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Open University Israel; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	mochly@stanford.edu	schechtman, deborah/B-7572-2012	Mochly-Rosen, Daria/0000-0002-6691-8733; Schechtman, Deborah/0000-0002-8874-7023	NIAAA NIH HHS [AA11147, AA010030] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA011147, R01AA010030, R37AA010030, R01AA011147] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Akita Y, 2002, J BIOCHEM, V132, P847, DOI 10.1093/oxfordjournals.jbchem.a003296; Asai K, 1998, ALCOHOL CLIN EXP RES, V22, P163, DOI 10.1111/j.1530-0277.1998.tb03633.x; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; Cohen MV, 2000, ANNU REV PHYSIOL, V62, P79, DOI 10.1146/annurev.physiol.62.1.79; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; He JQ, 2000, J PHYSIOL-LONDON, V524, P807, DOI 10.1111/j.1469-7793.2000.00807.x; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LIU JD, 1989, BIOCHEM BIOPH RES CO, V162, P1105, DOI 10.1016/0006-291X(89)90787-0; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1988, ANAL BIOCHEM, V170, P31, DOI 10.1016/0003-2697(88)90085-1; Pi YQ, 1997, CIRC RES, V81, P92, DOI 10.1161/01.RES.81.1.92; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Robia SL, 2001, BIOPHYS J, V80, P2140, DOI 10.1016/S0006-3495(01)76187-5; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schechtinan D., 2004, J BIOL CHEM; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919	30	10	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17617	17624		10.1074/jbc.M400962200	http://dx.doi.org/10.1074/jbc.M400962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761958	hybrid			2022-12-27	WOS:000220870400090
J	Ahmad, S; Ahmad, A; Ghosh, M; Leslie, CC; White, CW				Ahmad, S; Ahmad, A; Ghosh, M; Leslie, CC; White, CW			Extracellular ATP-mediated signaling for survival in Hyperoxia-induced oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ADENINE-NUCLEOTIDE DEPLETION; P2 PURINERGIC RECEPTORS; HUMAN ENDOTHELIAL-CELLS; REGULATED KINASE-1/2; INTRACELLULAR CALCIUM; GLUCOSE-TRANSPORT; ERK ACTIVATION; SHEAR-STRESS; MAP KINASES	Respiratory failure is a serious consequence of lung cell injury caused by treatment with high inhaled oxygen concentrations. Human lung microvascular endothelial cells (HLMVEC) are a principal target of hyperoxic injury (hyperoxia). Cell stress can cause release of ATP, and this extracellular nucleotide can activate purinoreceptors and mediate responses essential for survival. In this investigation, exposure of endothelial cells to an oxidative stress, hyperoxia, caused rapid but transient ATP release (20.03+/-2.00 nM/10(6) cells in 95% O-2 versus 0.08+/-0.01 nM/10(6) cells in 21% O-2 at 30 min) into the extracellular milieu without a concomitant change in intracellular ATP. Endogenously produced extracellular ATP-enhanced mTOR-dependent uptake of glucose (3467+/-102 cpm/mg protein in 95% oxygen versus 2100+/- 112 cpm/mg protein in control). Extracellular addition of ATP-activated important cell survival proteins like PI 3-kinase and extracellular-regulated kinase (ERK-1/2). These events were mediated primarily by P2Y receptors, specifically the P2Y2 and/or P2Y6 subclass of receptors. Extracellular ATP was required for the survival of HLM-VEC in hyperoxia (55+/-10% surviving cells with extracellular ATP scavengers [apyrase + adenosine deaminase] versus 95+/-12% surviving cells without ATP scavengers at 4 d of hyperoxia). Incubation with ATP scavengers abolished ATP-dependent ERK phosphorylation stimulated by hyperoxia. Further, ERK activation also was found to be important for cell survival in hyperoxia, as treatment with PD98059 enhanced hyperoxia-mediated cell death. These findings demonstrate that ATP release and subsequent ATP-mediated signaling events are vital for survival of HLMVEC in hyperoxia.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	White, CW (corresponding author), 1400 Jackson St,Room J309, Denver, CO 80206 USA.	whitec@njc.org	ahmad, shama/GNH-1803-2022; Ahmad, Aftab/ABC-2734-2020	ahmad, shama/0000-0003-1049-5054; Ahmad, Aftab/0000-0003-0686-0987	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL056263, P50HL057144, R01HL052732, U10HL056263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56263, HL52732, HL57144] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTO TK, 1993, AM J PHYSIOL, V264, pC282, DOI 10.1152/ajpcell.1993.264.2.C282; AALTO TK, 1993, FREE RADICAL BIO MED, V14, P177, DOI 10.1016/0891-5849(93)90008-I; AALTO TK, 1990, AM J PHYSIOL, V259, pC883, DOI 10.1152/ajpcell.1990.259.6.C883; Ahmad S, 2003, AM J RESP CELL MOL, V28, P179, DOI 10.1165/rcmb.2002-0004OC; Ahmad S, 2001, AM J PHYSIOL-LUNG C, V280, pL779, DOI 10.1152/ajplung.2001.280.4.L779; Allen CB, 1998, AM J PHYSIOL-LUNG C, V274, pL320, DOI 10.1152/ajplung.1998.274.3.L320; Allen CB, 1998, AM J PHYSIOL-LUNG C, V274, pL159, DOI 10.1152/ajplung.1998.274.1.L159; BARRY BE, 1985, AM REV RESPIR DIS, V132, P548; BECKER B, 1994, ANAL BIOCHEM, V221, P78, DOI 10.1006/abio.1994.1382; Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159, DOI 10.1152/ajplung.1999.277.1.L159; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Cheng TH, 2001, J MOL CELL CARDIOL, V33, P1805, DOI 10.1006/jmcc.2001.1444; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; Dawicki DD, 1997, AM J PHYSIOL-LUNG C, V273, pL485, DOI 10.1152/ajplung.1997.273.2.L485; DAWICKI DD, 1995, AM J PHYSIOL-LUNG C, V268, pL666, DOI 10.1152/ajplung.1995.268.4.L666; DeBosch BJ, 2002, J NEUROCHEM, V81, P728, DOI 10.1046/j.1471-4159.2002.00848.x; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dubyak GR, 2002, AM J PHYSIOL-CELL PH, V282, pC242, DOI 10.1152/ajpcell.00522.2001; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; Feranchak AP, 1999, J BIOL CHEM, V274, P30979, DOI 10.1074/jbc.274.43.30979; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200; Grant MB, 2001, INVEST OPHTH VIS SCI, V42, P2068; Gudmundsdottir IJ, 2001, ATHEROSCLEROSIS, V156, P81, DOI 10.1016/S0021-9150(00)00631-6; Harmon AW, 2003, BIOCHEM BIOPH RES CO, V305, P229, DOI 10.1016/S0006-291X(03)00720-4; HOLTZMAN RB, 1989, PROSTAGLANDINS, V37, P481, DOI 10.1016/0090-6980(89)90097-X; Ikeuchi Y, 1996, BIOCHEM BIOPH RES CO, V218, P428, DOI 10.1006/bbrc.1996.0076; Jankov RP, 2003, FREE RADICAL BIO MED, V35, P200, DOI 10.1016/S0891-5849(03)00305-8; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Kim MS, 2002, ARCH BIOCHEM BIOPHYS, V401, P205; Konduri GG, 2002, AM J PHYSIOL-HEART C, V283, pH1600, DOI 10.1152/ajpheart.00245.2002; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Kribben A, 2003, J LAB CLIN MED, V141, P67, DOI 10.1067/mlc.2003.7; LEE DSC, 1990, AM J PHYSIOL, V259, pL95, DOI 10.1152/ajplung.1990.259.2.L95; Li Y, 2003, AM J RESP CELL MOL, V29, P779, DOI 10.1165/rcmb.2003-0087RC; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; McGrath-Morrow SA, 2002, AM J RESP CELL MOL, V27, P99, DOI 10.1165/ajrcmb.27.1.4664; McMillan MR, 1999, BRIT J PHARMACOL, V128, P543, DOI 10.1038/sj.bjp.0702815; Morse D, 2003, AM J PHYSIOL-LUNG C, V285, pL250, DOI 10.1152/ajplung.00387.2002; Nakano H, 2003, CELL TISSUE RES, V313, P227, DOI 10.1007/s00441-003-0754-9; Narravula S, 2000, J IMMUNOL, V165, P5262, DOI 10.4049/jimmunol.165.9.5262; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; Novak I, 2003, NEWS PHYSIOL SCI, V18, P12, DOI 10.1152/nips.01409.2002; Nyunoya T, 2003, J BIOL CHEM, V278, P36099, DOI 10.1074/jbc.M304370200; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Parinandi NL, 2003, AM J PHYSIOL-LUNG C, V284, pL26, DOI 10.1152/ajplung.00123.2002; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; PHILLIPS PG, 1995, AM J PHYSIOL-LUNG C, V268, pL789, DOI 10.1152/ajplung.1995.268.5.L789; Ralevic V, 1998, PHARMACOL REV, V50, P413; Schafer R, 2003, AM J PHYSIOL-LUNG C, V285, pL376, DOI 10.1152/ajplung.00447.2002; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; SHERIDAN NP, 1988, J CELL PHYSIOL, V134, P117, DOI 10.1002/jcp.1041340114; SMITH LJ, 1986, J LAB CLIN MED, V108, P479; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; WANG DJ, 1992, J CELL PHYSIOL, V153, P221, DOI 10.1002/jcp.1041530202; Waxman AB, 2003, AM J RESP CELL MOL, V29, P513, DOI 10.1165/rcmb.2002-0044OC; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Zager RA, 1996, J AM SOC NEPHROL, V7, P64; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC	70	58	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16317	16325		10.1074/jbc.M313890200	http://dx.doi.org/10.1074/jbc.M313890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761947	hybrid			2022-12-27	WOS:000220747900077
J	Kamao, M; Tatematsu, S; Hatakeyama, S; Sakaki, T; Sawada, N; Inouye, K; Ozono, K; Kubodera, N; Reddy, GS; Okano, T				Kamao, M; Tatematsu, S; Hatakeyama, S; Sakaki, T; Sawada, N; Inouye, K; Ozono, K; Kubodera, N; Reddy, GS; Okano, T			C-3 epimerization of vitamin D-3 metabolites and further metabolism of C-3 epimers - 25-hydroxyvitamin D-3 is metabolized to 3-epi-25-hydroxyvitamin D-3 and subsequently metabolized through C-1 alpha or C-24 hydroxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1-ALPHA,25-DIHYDROXY-3-EPI-VITAMIN D-3; BIOLOGICAL-ACTIVITY; NATURAL METABOLITE; OXIDATION PATHWAY; CALCITROIC ACID; OSTEOSARCOMA; DIFFERENTIATION; ANALOGS	Recently, it was revealed that 1alpha, 25-dihydroxyvitamin D-3 (1alpha,25(OH)(2)D-3) and24R,25-dihydroxyvitamin D-3 (24,25 (OH)(2)D-3) were metabolized to their respective epimers of the hydroxyl group at C-3 of the A-ring. We now report the isolation and structural assignment of 3-epi-25-hydroxyvitamin D-3 (3-epi-25(OH)D-3) as a major metabolite of 25-hydroxyvitamin D-3 (25(OH)D-3) and the further metabolism of C-3 epimers of vitamin D-3 metabolites. When 25(OH) D3 was incubated with various cultured cells including osteosarcoma, colon adenocarcinoma, and hepatoblastoma cell lines, 3-epi-25(OH)D-3 and 24,25 (OH)(2)D-3 were commonly observed as a major and minor metabolite of 25(OH)D-3, respectively. 25(OH)D-3 was at least as sensitive to C-3 epimerization as 1alpha,25(OH)(2)D-3 which has been reported as a substrate for the C-3 epimerization reaction. Unlike these cultured cells, LLC-PK1 cells, a porcine kidney cell line, preferentially produced 24,25(OH)(2)D-3 rather than 3-epi-25(OH)D-3. We also confirmed the existence of 3-epi-25(OH)D-3 in the serum of rats intravenously given pharmacological doses of 25(OH)D-3. The cultured cells metabolized 3-epi-25(OH)D-3 and 3-epi-1alpha,25(OH)(2)D-3 to 3-epi-24,25(OH)(2)D-3 and 3-epi-1alpha,24,25(OH)(3)D-3, respectively. In addition, we demonstrated that 3-epi-25(OH)D-3 was metabolized to 3-epi-1alpha,25(OH)(2)D-3 by CYP27B1 and to 3-epi-24,25(OH)(2)D-3 by CYP24 using recombinant Escherichia coli cell systems. 3-Epi-25(OH)D-3, 3-epi-1alpha,25(OH)(2)D-3, and 3-epi-24,25(OH)(2)D-3 were biologically less active than 25(OH)D-3, 1alpha,25(OH)(2)D-3, and 24,25(OH)(2)D-3, but 3-epi-1alpha,25(OH)(2)D-3 showed to some extent transcriptional activity toward target genes and anti-proliferative/differentiation-inducing activity against human myeloid leukemia cells (HL-60). These results indicate that C-3 epimerization may be a common metabolic pathway for the major metabolites of vitamin D-3.	Kobe Pharmaceut Univ, Dept Hyg Sci, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Nagasaki Univ, Fac Pharmaceut Sci, Nagasaki 8528521, Japan; Kyoto Univ, Lab Enzyme Chem, Kyoto 6068502, Japan; Osaka Univ, Dept Pediat, Suita, Osaka 5650871, Japan; Chugai Pharmaceut Co Ltd, Tokyo 1718301, Japan; Brown Univ, Women & Infants Hosp, Providence, RI 02905 USA	Kobe Pharmaceutical University; Nagasaki University; Kyoto University; Osaka University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Brown University; Women & Infants Hospital Rhode Island	Okano, T (corresponding author), Kobe Pharmaceut Univ, Dept Hyg Sci, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	t-okano@kobepharma-u.ac.jp						AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; Bischof MG, 1998, EXP CELL RES, V241, P194, DOI 10.1006/excr.1998.4044; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown AJ, 1999, J CELL BIOCHEM, V73, P106, DOI 10.1002/(SICI)1097-4644(19990401)73:1&lt;106::AID-JCB12&gt;3.0.CO;2-Q; DELUCA HF, 1976, J LAB CLIN MED, V87, P7; Higashi T, 2000, ANAL SCI, V16, P477, DOI 10.2116/analsci.16.477; Higashi T, 1999, BIOL PHARM BULL, V22, P767; HOLICK SA, 1980, BIOCHEMISTRY-US, V19, P3933, DOI 10.1021/bi00558a007; ISHIZUKA S, 1984, BIOCHEMISTRY-US, V23, P1473, DOI 10.1021/bi00302a021; ISHIZUKA S, 1987, J BIOL CHEM, V262, P7165; ISHIZUKA S, 1981, FEBS LETT, V134, P207, DOI 10.1016/0014-5793(81)80603-5; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kamao M, 2003, J BIOL CHEM, V278, P1463, DOI 10.1074/jbc.M203773200; Kamao M, 2001, J NUTR SCI VITAMINOL, V47, P108, DOI 10.3177/jnsv.47.108; LAWSON DEM, 1979, VITAM HORM, V37, P1; LOHNES D, 1987, J BIOL CHEM, V262, P14394; LORENZ WW, 1991, P NATL ACAD SCI USA, V88, P4438, DOI 10.1073/pnas.88.10.4438; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; Masuda S, 1996, J BIOL CHEM, V271, P8700, DOI 10.1074/jbc.271.15.8700; Masuda S, 2000, BIOL PHARM BULL, V23, P133, DOI 10.1248/bpb.23.133; Nakagawa K, 2000, BIOCHEM PHARMACOL, V60, P1937, DOI 10.1016/S0006-2952(00)00486-X; Napoli JL, 1984, VITAMIN D BASIC CLIN, P91; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; Okano T, 2000, CHEM BIOL, V7, P173, DOI 10.1016/S1074-5521(00)00087-9; OZONO K, 1990, J BIOL CHEM, V265, P21881; Rao DS, 2002, BIOL PHARM BULL, V25, P845, DOI 10.1248/bpb.25.845; Rao DS, 2001, STEROIDS, V66, P423; Reddy GS, 2000, ARCH BIOCHEM BIOPHYS, V383, P197, DOI 10.1006/abbi.2000.2074; Reddy GS, 2001, STEROIDS, V66, P441, DOI 10.1016/S0039-128X(00)00228-2; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; Rehan VK, 2002, MOL GENET METAB, V76, P46, DOI 10.1016/S1096-7192(02)00022-7; Sakaki T, 2000, EUR J BIOCHEM, V267, P6158, DOI 10.1046/j.1432-1327.2000.01680.x; Sawada N, 1999, EUR J BIOCHEM, V265, P950, DOI 10.1046/j.1432-1327.1999.00794.x; Sekimoto H, 1999, FEBS LETT, V448, P278, DOI 10.1016/S0014-5793(99)00377-4; Siu-Caldera ML, 2001, J CELL BIOCHEM, V82, P599, DOI 10.1002/jcb.1189; Siu-Caldera ML, 1999, BONE, V24, P457, DOI 10.1016/S8756-3282(99)00019-8; SIUCALDERA ML, 1995, ENDOCRINOLOGY, V136, P4195, DOI 10.1210/en.136.10.4195; SUDA T, 1970, J NUTR, V100, P1049, DOI 10.1093/jn/100.9.1049; Uskokovic MR, 2001, STEROIDS, V66, P463, DOI 10.1016/S0039-128X(00)00226-9	39	117	121	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15897	15907		10.1074/jbc.M311473200	http://dx.doi.org/10.1074/jbc.M311473200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757768	hybrid			2022-12-27	WOS:000220747900026
J	Li, GB; Yin, HS; Kuret, J				Li, GB; Yin, HS; Kuret, J			Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; GLYCOGEN-SYNTHASE KINASE-3-BETA; ALZHEIMERS-DISEASE BRAIN; PROTEIN PHOSPHATASE 2A; CENTRAL-NERVOUS-SYSTEM; BETA-CATENIN; 1 DELTA; SUBSTRATE DETERMINANTS; MOLECULAR-CLONING; MASS-SPECTROMETRY	Tau hyperphosphorylation precedes neuritic lesion formation in Alzheimer's disease, suggesting it participates in the tau fibrillization reaction pathway. Candidate tau protein kinases include members of the casein kinase 1 (CK1) family of phosphotransferases, which are highly overexpressed in Alzheimer's disease brain and colocalize with neuritic and granulovacuolar lesions. Here we characterized the contribution of one CK1 isoform, Ckidelta, to the phosphorylation of tau at residues Ser(202)/Thr(205) and Ser(396)/Ser(404) in human embryonic kidney 293 cells using immunodetection and fluorescence microscopy. Treatment of cells with membrane permeable CK1 inhibitor 3-[(2,3,6-trimethoxyphenyl) methylidenyl]indolin-2-one (IC261) lowered occupancy of Ser(396)/ Ser(404) phosphorylation sites by > 70% at saturation, suggesting that endogenous CK1 was the major source of basal phosphorylation activity at these sites. Overexpression of Ckidelta increased CK1 enzyme activity and further raised tau phosphorylation at residues Ser(202)/ Thr(205) and Ser(396)/Ser(404) in situ. Inhibitor IC261 reversed tau hyperphosphorylation induced by Ckidelta overexpression. Co-immunoprecipitation assays showed direct association of tau and Ckidelta in situ, consistent with tau being a Ckidelta substrate. Ckidelta overexpression also produced a decrease in the fraction of bulk tau bound to detergent-insoluble microtubules. These results suggest that Ckidelta phosphorylates tau at sites that modulate tau/ microtubule binding, and that the expression pattern of Ckidelta in Alzheimer's disease is consistent with it playing an important role in tau aggregation.	Ohio State Univ, Coll Med & Publ Hlth, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), Ctr Neurobiotechnol, 1060 Carmack Rd, Columbus, OH 43210 USA.	kuret.3@osu.edu	Li, Guibin/E-3507-2011		NIA NIH HHS [AG14452] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Chirita CN, 2004, BIOCHEMISTRY-US, V43, P1704, DOI 10.1021/bi036034b; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Galvan M, 2001, J ALZHEIMERS DIS, V3, P417, DOI 10.3233/JAD-2001-3409; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; Ghoshal N, 1999, AM J PATHOL, V155, P1163, DOI 10.1016/S0002-9440(10)65219-4; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1997, J CELL SCI, V110, P3083; Hamdane M, 2003, J BIOL CHEM, V278, P34026, DOI 10.1074/jbc.M302872200; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Hu JH, 2003, J NEUROCHEM, V85, P422, DOI 10.1046/j.1471-4159.2003.01669.x; Kitabayashi AN, 1997, GENOMICS, V46, P133, DOI 10.1006/geno.1997.4991; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuret J, 1997, J NEUROCHEM, V69, P2506; Liu F, 2001, P NATL ACAD SCI USA, V98, P11062, DOI 10.1073/pnas.191353898; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Lund ET, 2001, J NEUROCHEM, V76, P1221, DOI 10.1046/j.1471-4159.2001.00130.x; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P365, DOI 10.1016/0197-4580(95)00027-C; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Pulgar V, 1999, EUR J BIOCHEM, V260, P520, DOI 10.1046/j.1432-1327.1999.00195.x; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Schwab C, 2000, NEUROBIOL AGING, V21, P503, DOI 10.1016/S0197-4580(00)00110-X; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SIMKOWSKI KW, 1980, J BIOL CHEM, V255, P6456; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; Singh TJ, 1996, MOL CELL BIOCHEM, V154, P143, DOI 10.1007/BF00226782; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; Sun W, 2002, J BIOL CHEM, V277, P11933, DOI 10.1074/jbc.M107182200; Sygowski Linda A., 1993, Molecular Brain Research, V20, P221, DOI 10.1016/0169-328X(93)90044-P; Takahashi S, 2003, J BIOL CHEM, V278, P10506, DOI 10.1074/jbc.M211964200; Utton MA, 1997, BIOCHEM J, V323, P741, DOI 10.1042/bj3230741; Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200; Wada Y, 1998, J BIOCHEM-TOKYO, V124, P738, DOI 10.1093/oxfordjournals.jbchem.a022174; Wagner U, 1996, J CELL SCI, V109, P1537; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Yasojima K, 2000, BRAIN RES, V865, P116, DOI 10.1016/S0006-8993(00)02200-9; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	76	114	136	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15938	15945		10.1074/jbc.M314116200	http://dx.doi.org/10.1074/jbc.M314116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761950	hybrid			2022-12-27	WOS:000220747900030
J	Likhite, VS; Cass, EI; Anderson, SD; Yates, JR; Nardulli, AM				Likhite, VS; Cass, EI; Anderson, SD; Yates, JR; Nardulli, AM			Interaction of estrogen receptor alpha with 3-methyladenine DNA glycosylase modulates transcription and DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ALLOSTERIC MODULATION; HUMAN HOMOLOGS; MPG PROTEIN; ACETYLATION; COACTIVATOR; ACTIVATION; CELLS	Estrogen receptor alpha (ERalpha) interacts with basal transcription factors, coregulatory proteins, and chromatin modifiers to initiate transcription of the target genes. We have identified a novel interaction between ERalpha and the DNA repair protein 3-methyladenine DNA glycosylase (MPG) thereby providing a functional link between gene expression and DNA repair. Interestingly, the ERalpha-MPG interaction was enhanced by the presence of estrogen response element ( ERE)-containing DNA. In vitro pull-down assays indicated that the interaction of ERalpha with MPG was direct and occurred through the DNA- and ligand-binding domains and the hinge region of the receptor. More importantly, endogenously expressed ERalpha and MPG from MCF-7 cells coimmunoprecipitated with ERalpha- and MPG-specific antibodies. The ERalpha-MPG interaction had functional consequences on the activities of both proteins. ERalpha increased MPG acetylation, stabilized the binding of MPG with hypoxanthine-containing oligos, and enhanced MPG-catalyzed removal of hypoxanthine from DNA. In turn, MPG dramatically stabilized the interaction of ERalpha with ERE-containing oligos, decreased p300-mediated acetylation of the receptor, and reduced transcription of simple and complex ERE-containing reporter plasmids in a dose-dependent manner. Our studies suggest that recruitment of MPG to ERE-containing genes influences transcription and plays a role in maintaining integrity of the genome by recruiting DNA repair proteins to actively transcribing DNA.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Scripps Research Institute	Nardulli, AM (corresponding author), 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	anardull@life.uiuc.edu			NCRR NIH HHS [NCRR11823] Funding Source: Medline; NIDDK NIH HHS [DK 53884] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053884, R56DK053884] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Cerda SR, 1998, FEBS LETT, V431, P12, DOI 10.1016/S0014-5793(98)00697-8; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lindahl T, 1995, J CELL SCI, P73; Loven MA, 2003, MOL ENDOCRINOL, V17, P67, DOI 10.1210/me.2002-0280; Loven MA, 2001, J BIOL CHEM, V276, P45282, DOI 10.1074/jbc.M106211200; Loven MA, 2001, MOL CELL ENDOCRINOL, V181, P151, DOI 10.1016/S0303-7207(01)00491-9; MARNETT LJ, 1993, CHEM RES TOXICOL, V6, P771, DOI 10.1021/tx00036a005; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	50	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16875	16882		10.1074/jbc.M313155200	http://dx.doi.org/10.1074/jbc.M313155200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761960	hybrid			2022-12-27	WOS:000220747900140
J	Mahdi, F; Shariat-Madar, Z; Kuo, A; Carinato, M; Cines, DB; Schmaier, AH				Mahdi, F; Shariat-Madar, Z; Kuo, A; Carinato, M; Cines, DB; Schmaier, AH			Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING-SITE; WEIGHT KININOGEN; ENDOTHELIAL-CELLS; PREKALLIKREIN ACTIVATOR; CYTOKERATIN 1; DOMAIN-II; IDENTIFICATION; PROTEIN; PROLYLCARBOXYPEPTIDASE; ANGIOGENESIS	The urokinase plasminogen activator receptor (uPAR) is a multifunctional, GPI-linked receptor that modulates cell adhesion/migration and fibrinolysis. We mapped the interaction sites between soluble uPAR (suPAR) and high molecular mass kininogen (HK). Binding of biotin-HK to suPAR was inhibited by HK, 56HKa, and 46HKa with an IC50 of 60, 110, and 8 nM, respectively. We identified two suPAR-binding sites, a higher affinity site in the light chain of HK and 46HKa (His(477)-Gly(496)) and a lower affinity site within the heavy chain (Cys(333)-Lys(345)). HK predominantly bound to suPAR fragments containing domains 2 and 3 (S-D2D3). Binding of HK to domain 1 (S-D1) was also detected, and the addition of S-D1 to S-D2D3 completely inhibited biotin-HK or -46HKa binding to suPAR. Using sequential and overlapping 20-amino acid peptides prepared from suPAR, two regions for HK binding were identified. One on the carboxyl-terminal end of D2 (Leu(166)-Thr(195)) blocked HK binding to suPAR and to human umbilical vein endothelial cells (HUVEC). This site overlapped with the urokinase-binding region, and urokinase inhibited the binding of HK to suPAR. A second region on the amino-terminal portion of D3 (Gln(215)-Asn(255))also blocked HK binding to HUVEC. Peptides that blocked HK binding to uPAR also inhibited prekallikrein activation on HUVEC. Therefore, HK interacts with suPAR at several sites. HK binds to uPAR as part of its interaction with its multiprotein receptor complex on HUVEC, and the biological functions that depend upon this binding are modulated by urokinase.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	Schmaier, AH (corresponding author), Univ Michigan, Dept Internal Med, 5301 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	aschmaie@umich.edu	Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052779] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52779] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bdeir K, 2003, BLOOD, V102, P3600, DOI 10.1182/blood-2003-03-0949; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; Chavakis T, 2003, J BIOL CHEM, V278, P45375, DOI 10.1074/jbc.M304344200; Colman RW, 2003, J THROMB HAEMOST, V1, P164, DOI 10.1046/j.1538-7836.2003.00025.x; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Higazi AAR, 1997, J BIOL CHEM, V272, P5348, DOI 10.1074/jbc.272.8.5348; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; Joseph K, 2004, THROMB HAEMOSTASIS, V91, P61, DOI 10.1160/TH03-07-0471; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Li Y, 2003, J BIOL CHEM, V278, P29925, DOI 10.1074/jbc.M300751200; Mahdi F, 2003, J BIOL CHEM, V278, P43983, DOI 10.1074/jbc.M304239200; Mahdi F, 2002, BLOOD, V99, P3585, DOI 10.1182/blood.V99.10.3585; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; MELONI FJ, 1992, BLOOD, V79, P1233; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; MIZUKAMI IF, 1994, CLIN IMMUNOL IMMUNOP, V71, P96, DOI 10.1006/clin.1994.1057; Moreira CR, 2002, FEBS LETT, V523, P167, DOI 10.1016/S0014-5793(02)02980-0; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; SCHMAIER AH, 1988, J LAB CLIN MED, V112, P182; Shariat-Madar Z, 2002, J BIOL CHEM, V277, P17962, DOI 10.1074/jbc.M106101200; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; Walsh DA, 1997, KININ SYSTEM, P301; Zhang JC, 2000, FASEB J, V14, P2589, DOI 10.1096/fj.99-1025com; Zhang JC, 2002, P NATL ACAD SCI USA, V99, P12224, DOI 10.1073/pnas.192668299	31	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16621	16628		10.1074/jbc.M313850200	http://dx.doi.org/10.1074/jbc.M313850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764580	hybrid			2022-12-27	WOS:000220747900113
J	Chakravarty, K; Wu, SY; Chiang, CM; Samols, D; Hanson, RW				Chakravarty, K; Wu, SY; Chiang, CM; Samols, D; Hanson, RW			SREBP-1c and Sp1 interact to regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; LIPOPROTEIN RECEPTOR PROMOTER; STEROL REGULATION; TRANSGENIC MICE; NUCLEAR-PROTEIN; CULTURED-CELLS; IN-VITRO; EXPRESSION; INSULIN; IDENTIFICATION	The sterol regulatory element-binding protein-1c (SREBP-1c), as well as SREBP-1a and SREBP-2, inhibit transcription of the gene encoding the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) (PEPCK-C). There are two SREBP regulatory elements (SREs) in the PEPCK-C gene promoter (-322 to -313 and -590 to -581). The SRE at -590 overlaps an Sp1 site on the opposite strand of the DNA. These SREs bound SREBP-1a and SREBP-1c with low affinity but the addition of purified upstream stimulatory activity enhanced the binding of SREBP-1 to both of these sites. Mutating these SREs increased both unstimulated (5-fold) and protein kinase A-stimulated transcription (8-27-fold) from the PEPCK-C gene promoter; this was lost when both SREs were mutated. The SRE at -590 differs by a single base pair from the SRE in the low density lipoprotein (LDL) receptor gene (T in the PEPCK-C gene promoter at -582, compared with an A in the SRE of the gene for the LDL receptor promoter). Introduction of the LDL receptor SRE into the PEPCK-C gene promoter increased SREBP-1c binding and caused a 10-fold enhancement of basal transcription from the promoter, rather than an inhibition as observed with the SRE in the PEPCK-C gene promoter. The T/A change does not alter the binding of Sp1 to its site on the opposite strand of the DNA. Sp1 bound to the promoter independently of SREBP-1c but competed with SREBP-1c for binding. Sp1 does not bind to the SRE at -322. Chromatin immunoprecipitation analysis, using rat hepatocytes, demonstrated that SREBP-1 and Sp1 were associated in vivo with putative regulatory regions corresponding to the SREs in the PEPCK-C gene promoter. We propose that insulin represses transcription of the gene for PEPCK-C by inducing SREBP-1c production in the liver, which interferes with the stimulatory effect of Sp1 at -590 of the PEPCK-C gene promoter.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Chakravarty, K (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	kxc23@cwru.edu			NATIONAL CANCER INSTITUTE [R01CA081017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059643] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002467] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81017] Funding Source: Medline; NIA NIH HHS [AG 02467] Funding Source: Medline; NIDDK NIH HHS [DK 25541] Funding Source: Medline; NIGMS NIH HHS [GM 59643] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Becard D, 2001, DIABETES, V50, P2425, DOI 10.2337/diabetes.50.11.2425; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; KIM JB, 1995, MOL CELL BIOL, V15, P2582; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Lechner PS, 2001, J BIOL CHEM, V276, P22675, DOI 10.1074/jbc.M102422200; Leffert H L, 1979, Methods Enzymol, V58, P536; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Massillon D, 2003, J BIOL CHEM, V278, P40694, DOI 10.1074/jbc.M303182200; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WANG XD, 1993, J BIOL CHEM, V268, P14497; YAMAMOTO T, 2004, J BIOL CHEM     0113; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200	45	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15385	15395		10.1074/jbc.M309905200	http://dx.doi.org/10.1074/jbc.M309905200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744869	hybrid			2022-12-27	WOS:000220594700108
J	Hague, C; Uberti, MA; Chen, ZJ; Hall, RA; Minneman, KP				Hague, C; Uberti, MA; Chen, ZJ; Hall, RA; Minneman, KP			Cell surface expression of alpha(1D)-adrenergic receptors is controlled by heterodimerization with alpha(1B)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SUBTYPES MEDIATING CONTRACTIONS; ARTERIAL BLOOD-PRESSURE; VASCULAR SMOOTH-MUSCLE; ALPHA(1)-ADRENOCEPTOR SUBTYPES; ALPHA-1-ADRENERGIC RECEPTOR; ALPHA-1B-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; MESENTERIC-ARTERY; OPIOID RECEPTORS	alpha(1)-Adrenergic receptors (ARs) belong to the large Class I G protein-coupled receptor superfamily and comprise three subtypes (alpha(1A), alpha(1B), and alpha(1D)). Previous work with heterologously expressed C-terminal green fluorescent protein (GFP)-tagged alpha(1)-ARs showed that alpha(1A)- and alpha(1B)-ARs localize to the plasma membrane, whereas alpha(1D)-ARs accumulate intracellularly. We recently showed that alpha(1D)- and alpha(1B)-ARs form heterodimers, whereas alpha(1D)- and alpha(1A)-ARs do not. Here, we examined the role of heterodimerization in regulating alpha(1D)-AR localization using both confocal imaging of GFP- or CFP-tagged alpha(1)-ARs and a luminometer-based surface expression assay in HEK293 cells. Co-expression with alpha(1B)-ARs caused alpha(1D)-ARs to quantitatively translocate to the cell surface, but co-expression with alpha(1A)-ARs did not. Truncation of the alpha(1B)-AR extracellular N terminus or intracellular C terminus had no effect on surface expression of alpha(1D)-ARs, suggesting primary involvement of the hydrophobic core. Co-transfection with an uncoupled mutant alpha(1B)-AR (Delta12alpha(1B)) increased both alpha(1D)-AR surface expression and coupling to norepinephrine-stimulated Ca2+ mobilization. Finally, GFP-tagged alpha(1D)-ARs were not detected on the cell surface when expressed in rat aortic smooth muscle cells that express no endogenous ARs, but were almost exclusively localized on the surface when expressed in DDT1MF-2 cells, which express endogenous alpha(1B)-ARs. These studies demonstrate that alpha(1B)/alpha(1D)-AR heterodimerization controls surface expression and functional coupling of alpha(1D)-ARs, the N- and C-terminal domains are not involved in this interaction, and that alpha(1B)-AR G protein coupling is not required. These observations may be relevant to many other Class I G protein-coupled receptors, where the functional consequences of heterodimerization are still poorly understood.	Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Hague, C (corresponding author), Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA.	chague@emory.edu		Hall, Randy/0000-0002-8318-8728				Abbott KL, 2000, J MOL CELL CARDIOL, V32, P391, DOI 10.1006/jmcc.1999.1085; Andersson H, 2003, MOL PHARMACOL, V64, P570, DOI 10.1124/mol.64.3.570; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Boyd GW, 2003, J BIOL CHEM, V278, P27681, DOI 10.1074/jbc.M304938200; Buck LB, 2000, CELL, V100, P611, DOI 10.1016/S0092-8674(00)80698-4; Carrillo JJ, 2003, J BIOL CHEM, V278, P42578, DOI 10.1074/jbc.M306165200; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; Chalothorn D, 2002, MOL PHARMACOL, V61, P1008, DOI 10.1124/mol.61.5.1008; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Daly CJ, 2002, PHYSIOL GENOMICS, V9, P85, DOI 10.1152/physiolgenomics.00065.2001; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; ESBENSHADE TA, 1995, MOL PHARMACOL, V47, P977; Garcia-Sainz JA, 2001, BIOCHEM J, V353, P603, DOI 10.1042/0264-6021:3530603; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gonzalez-Cabrera PJ, 2003, MOL PHARMACOL, V63, P1104, DOI 10.1124/mol.63.5.1104; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hague C, 2003, LIFE SCI, V74, P411, DOI 10.1016/j.lfs.2003.07.008; HAGUE C, 2004, J PHARMACOL EXP THER, V309, P1; HAN C, 1992, EUR J PHARM-MOLEC PH, V226, P141, DOI 10.1016/0922-4106(92)90175-U; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRASAWA A, 1993, BIOCHEM BIOPH RES CO, V195, P902, DOI 10.1006/bbrc.1993.2130; Hirasawa A, 1997, MOL PHARMACOL, V52, P764, DOI 10.1124/mol.52.5.764; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; Hussain MB, 1997, BRIT J PHARMACOL, V122, P849, DOI 10.1038/sj.bjp.0701461; Hussain MB, 2000, EUR J PHARMACOL, V395, P69, DOI 10.1016/S0014-2999(00)00220-X; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kapoor M, 2003, J BIOL CHEM, V278, P6194, DOI 10.1074/jbc.M209132200; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Mackenzie JF, 2000, J PHARMACOL EXP THER, V294, P434; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Piascik MT, 2001, J PHARMACOL EXP THER, V298, P403; Piascik MT, 1995, J PHARMACOL EXP THER, V275, P1583; Pupo AS, 2003, EUR J PHARMACOL, V462, P1, DOI 10.1016/S0014-2999(03)01292-5; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rokosh DG, 2002, P NATL ACAD SCI USA, V99, P9474, DOI 10.1073/pnas.132552699; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; Tanoue A, 2002, J CLIN INVEST, V109, P765, DOI 10.1172/JCI200214001; Theroux TL, 1996, MOL PHARMACOL, V50, P1376; Toews ML, 2003, LIFE SCI, V74, P379, DOI 10.1016/j.lfs.2003.09.024; Turnbull L, 2003, AM J PHYSIOL-HEART C, V284, pH1104, DOI 10.1152/ajpheart.00441.2002; Uberti MA, 2003, MOL PHARMACOL, V64, P1379, DOI 10.1124/mol.64.6.1379; Vicentic A, 2002, J PHARMACOL EXP THER, V302, P58, DOI 10.1124/jpet.302.1.58; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; VON ZM, 1993, J BIOL CHEM, V268, P763; Wang JF, 2000, MOL PHARMACOL, V57, P687, DOI 10.1124/mol.57.4.687; Wang JF, 2002, J PHARMACOL EXP THER, V300, P134, DOI 10.1124/jpet.300.1.134; WILSON KM, 1990, J NEUROCHEM, V55, P691, DOI 10.1111/j.1471-4159.1990.tb04188.x; Wozniak M, 1996, J BIOL CHEM, V271, P5017; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; Xie XD, 1999, FEBS LETT, V456, P63, DOI 10.1016/S0014-5793(99)00918-7; Xu JG, 2003, J BIOL CHEM, V278, P10770, DOI 10.1074/jbc.M207968200; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8; Zhu SJ, 1996, EUR J PHARMACOL, V299, P205, DOI 10.1016/0014-2999(95)00838-1	71	145	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15541	15549		10.1074/jbc.M314014200	http://dx.doi.org/10.1074/jbc.M314014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736874	hybrid			2022-12-27	WOS:000220594700126
J	Caldarola, S; Amaldi, F; Proud, CG; Loreni, F				Caldarola, S; Amaldi, F; Proud, CG; Loreni, F			Translational regulation of terminal oligopyrimidine mRNAs induced by serum and amino acids involves distinct signaling events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; TUMOR-SUPPRESSOR PROTEIN; INHIBITS TRANSLATION; PYRIMIDINE TRACT; LA AUTOANTIGEN; 5 UTR; INITIATION; PHOSPHORYLATION; ACTIVATION; RAPAMYCIN	Various mitogenic or growth inhibitory stimuli induce a rapid change in the association of terminal oligopyrimidine (TOP) mRNAs with polysomes. It is generally believed that such translational control hinges on the mammalian target of rapamycin (mTOR)-S6 kinase pathway. Amino acid availability affects the translation of TOP mRNAs, although the signaling pathway involved in this regulation is less well characterized. To investigate both serum- and amino acid-dependent control of TOP mRNA translation and the signaling pathways involved, HeLa cells were subjected to serum and/or amino acid deprivation and stimulation. Our results indicate the following. 1) Serum and amino acid deprivation had additive effects on TOP mRNA translation. 2) The serum content of the medium specifically affected TOP mRNA translation, whereas amino acid availability affected both TOP and non-TOP mRNAs. 3) Serum signaling to TOP mRNAs involved only a rapamycin-sensitive pathway, whereas amino acid signaling depended on both rapamycin-sensitive and rapamycin-insensitive but wortmannin-sensitive events. 4) Eukaryotic initiation factor-2alpha phosphorylation increased during amino acid deprivation, but not following serum deprivation. Interestingly, rapamycin treatment suggests a novel connection between the mTOR pathway and eukaryotic initiation factor-2alpha phosphorylation in mammalian cells, which may not, however, be involved in TOP mRNA translational regulation.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee, Scotland	University of Rome Tor Vergata; University of Dundee	Loreni, F (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	loreni@uniroma2.it		Proud, Christopher/0000-0003-0704-6442				AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; Anthony TG, 2001, J NUTR, V131, P1171, DOI 10.1093/jn/131.4.1171; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fox Heather L., 1998, American Journal of Physiology, V275, pC1232; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Garcia-Barrio M, 2002, J BIOL CHEM, V277, P30675, DOI 10.1074/jbc.M203187200; GEYER PK, 1982, MOL CELL BIOL, V2, P685, DOI 10.1128/MCB.2.6.685; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kimball Sr, 2000, COLD SPRING HARBOR M, V39, P561; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; LANE HA, 1991, METHOD ENZYMOL, V200, P268; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Loreni F, 1997, FEBS LETT, V416, P239, DOI 10.1016/S0014-5793(97)01209-X; LORENI F, 1992, EUR J BIOCHEM, V205, P1027, DOI 10.1111/j.1432-1033.1992.tb16870.x; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas O, 2000, COLD SPRING HARBOR M, V39, P671; Pellizzoni L, 1996, J MOL BIOL, V259, P904, DOI 10.1006/jmbi.1996.0368; Pellizzoni L, 1997, J MOL BIOL, V267, P264, DOI 10.1006/jmbi.1996.0888; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shigemitsu K, 1999, FEBS LETT, V447, P303, DOI 10.1016/S0014-5793(99)00304-X; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Zhu JF, 2001, BBA-GENE STRUCT EXPR, V1521, P19, DOI 10.1016/S0167-4781(01)00277-9	52	30	39	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13522	13531		10.1074/jbc.M310574200	http://dx.doi.org/10.1074/jbc.M310574200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726531	hybrid			2022-12-27	WOS:000220478500031
J	Lukacova, V; Zhang, YF; Mackov, M; Baricic, P; Raha, S; Calvo, JA; Balaz, S				Lukacova, V; Zhang, YF; Mackov, M; Baricic, P; Raha, S; Calvo, JA; Balaz, S			Similarity of binding sites of human matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMELYSIN CATALYTIC DOMAIN; HUMAN NEUTROPHIL COLLAGENASE; X-RAY-STRUCTURE; SEQUENCE SPECIFICITIES; STRUCTURAL DIFFERENCES; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; INHIBITORS; DESIGN; POTENT	Tissue components hydrolyzing matrix metalloproteinases ( MMPs) exhibit a high sequence similarity (56 - 64% in catalytic domains) and yet a significant degree of functional specificity. The hexapeptide-binding sites of 24 known human MMPs were compared in terms of their force field interaction energies with five probes that are most frequently encountered in substrates and inhibitors. The probes moved along a grid enclosing partially flexible binding sites in rigid catalytic domains that were represented by published experimental structures and comparative models and new comparative models for nine most recently characterized MMPs. For individual MMPs, representative interaction energies were obtained as averages for all suitable experimental structures. Correlations of the representative energies for all MMP pairs were succinctly catalogued for individual probes, subsites, and correlation levels. Among the probes (neutral sp(3) carbon and sp3 oxygen, positive sp3 nitrogen and hydrogen, and negative carbonyl oxygen), the last probe is least distinctive. Similarities of subsites are decreasing as S1' > S2 > S3' > S1 similar to S3 > S2'. Most interesting, occupancies of subsites in published structures of MMP-inhibitor complexes follow an almost parallel trend, alluding to overall low selectivity of known MMP inhibitors. Flexible subsite S1' that appears as the specificity pocket in rigid x-ray structures is actually very similar among individual MMPs. Several correlations indicated that MMPs 3, 8, and 12 have similar binding sites. Modeling results are corroborated with published experimental data on MMP inhibition and substrate specificities. The results provide numerous clues for development of specific inhibitors and substrates, as well as for selection of MMPs for testing that provides maximum information without redundant experiments.	N Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Fargo, ND 58105 USA; N Dakota State Univ, Coll Pharm, Dept Comp Sci, Fargo, ND 58105 USA; N Dakota State Univ, Coll Pharm, Dept Math, Fargo, ND 58105 USA	North Dakota State University Fargo; North Dakota State University Fargo; North Dakota State University Fargo	Balaz, S (corresponding author), N Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Sudro Hall,Rm 8, Fargo, ND 58105 USA.	stefan.balaz@ndsu.nodak.edu	Balaz, Stefan/K-6776-2019; Balaz, Stefan/B-2965-2008	Balaz, Stefan/0000-0003-4378-8945; Balaz, Stefan/0000-0003-4378-8945	NCRR NIH HHS [1 PP20 RR15566, P20 RR015566, P20 RR016471, 1 P20 RR 16471] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016471, P20RR015566] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*ACC INC, 2003, DISC; *ACC INC, 2000, HOM MOD INS, V2; Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Almstead NG, 1999, J MED CHEM, V42, P4547, DOI 10.1021/jm990330y; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brandstetter H, 1998, PROTEIN SCI, V7, P1303, DOI 10.1002/pro.5560070605; Chen LY, 1999, J MOL BIOL, V293, P545, DOI 10.1006/jmbi.1999.3147; Cherney RJ, 2003, J MED CHEM, V46, P1811, DOI 10.1021/jm020475w; Esser CK, 1997, J MED CHEM, V40, P1026, DOI 10.1021/jm960465t; Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521; Finzel BC, 1998, PROTEIN SCI, V7, P2118, DOI 10.1002/pro.5560071008; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Hanessian S, 2001, J MED CHEM, V44, P3074, DOI 10.1021/jm010096n; Jacobsen EJ, 1999, J MED CHEM, V42, P1525, DOI 10.1021/jm9803222; Lang R, 2001, J MOL BIOL, V312, P731, DOI 10.1006/jmbi.2001.4954; Massova I, 1997, J MOL MODEL, V3, P17, DOI 10.1007/s008940050021; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Massova I, 1998, BIOORG MED CHEM LETT, V8, P853, DOI 10.1016/S0960-894X(98)00128-0; Matter H, 1999, J MED CHEM, V42, P1908, DOI 10.1021/jm980631s; Matter H, 1999, J MED CHEM, V42, P4506, DOI 10.1021/jm990250u; Moy FJ, 2000, J MOL BIOL, V302, P671, DOI 10.1006/jmbi.2000.4082; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Natchus MG, 2000, J MED CHEM, V43, P4948, DOI 10.1021/jm000246e; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; Pavlovsky AG, 1999, PROTEIN SCI, V8, P1455, DOI 10.1110/ps.8.7.1455; Pikul S, 1998, J MED CHEM, V41, P3568, DOI 10.1021/jm980253r; Reiter LA, 2003, BIOORG MED CHEM LETT, V13, P2331, DOI 10.1016/S0960-894X(03)00413-X; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; Sawa M, 2002, J MED CHEM, V45, P919, DOI 10.1021/jm0103211; Schroder J, 2001, J MED CHEM, V44, P3231, DOI 10.1021/jm010887p; Scozzafava A, 2000, J MED CHEM, V43, P1858, DOI 10.1021/jm990594k; Sternlicht MD, 2000, CANC DRUG DISC DEV, P1; Terp GE, 2002, J MED CHEM, V45, P2675, DOI 10.1021/jm0109053; Terp GE, 2000, J BIOMOL STRUCT DYN, V17, P933, DOI 10.1080/07391102.2000.10506582; *TRIP INC, 2003, HOM PROC BIOP MOD VE; *TRIP INC, 2003, SYB 6 9; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Woessner J.F., 2000, PROTEIN PROFILE SER; Zhang XL, 2000, J MOL BIOL, V301, P513, DOI 10.1006/jmbi.2000.3988	44	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14194	14200		10.1074/jbc.M313474200	http://dx.doi.org/10.1074/jbc.M313474200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732707	hybrid			2022-12-27	WOS:000220478500111
J	Sevetson, B; Taylor, S; Pan, Y				Sevetson, B; Taylor, S; Pan, Y			Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; OSTEOBLAST-LIKE CELLS; GROWTH-FACTOR BETA-1; VAN-BUCHEM-DISEASE; TRANSCRIPTION FACTOR; OSTEOCALCIN GENE; CLEIDOCRANIAL DYSPLASIA; EXTRACELLULAR-MATRIX; BINDING PROTEINS; STEM-CELLS	Loss-of-function mutations in the sclerosteosis gene (SOST) cause a rare sclerosing bone dysplasia characterized by skeletal overgrowth. Cbfa1/RUNX2 is a key transcriptional regulator of osteoblast function. Here we link these two pathways by demonstrating, via gel shift and transient transfection analyses, that Cbfa1 binding to the proximal SOST promoter contributes to differential SOST expression in two osteosarcoma cell lines. Additionally, an E-box binding motif in the 1.8-kb proximal SOST promoter appears to be functional in SAOS-2 cells, but does not account for SAOS-specific expression of SOST. The regulation of SOST expression by Cbfa1 suggests a potential role for the sclerosteosis gene in homeostatic regulation of osteoblast differentiation and function. Furthermore, the juxtaposition of Cbfa1, E-box, and C/EBP binding sites in the SOST proximal promoter bears an intriguing resemblance to the promoter for osteocalcin, another osteoblast-specific gene with a loss-of-function phenotype of bone overgrowth.	Amgen Corp, Funct Genom Dept, Seattle, WA 98101 USA; Amgen Corp, Bioinformat Dept, Seattle, WA 98101 USA		Pan, Y (corresponding author), Amgen Corp, Funct Genom Dept, Seattle, WA 98101 USA.	pany@amgen.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BEIGHTON P, 1977, CLIN GENET, V11, P1; BEIGHTON P, 1988, J MED GENET, V25, P200, DOI 10.1136/jmg.25.3.200; BEIGHTON P, 1984, CLIN GENET, V25, P175; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; EPSTEIN S, 1979, S AFR MED J, V55, P1105; GALLOP PM, 1980, NEW ENGL J MED, V302, P1460, DOI 10.1056/NEJM198006263022608; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563; Javed A, 1999, MOL CELL BIOL, V19, P7491; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo-124-2-612; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Sieron AL, 2002, CYTOKINE, V18, P214, DOI 10.1006/cyto.2002.1035; Staehling-Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401; STEIN SA, 1983, NEUROLOGY, V33, P267, DOI 10.1212/WNL.33.3.267; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Takazawa Y, 2000, J ENDOCRINOL, V165, P579, DOI 10.1677/joe.0.1650579; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; TRUSWELL AS, 1958, J BONE JOINT SURG BR, V40, P208, DOI 10.1302/0301-620X.40B2.208; VANBUCHE.FS, 1971, ACTA MED SCAND, V189, P257; Wada MR, 2002, DEVELOPMENT, V129, P2987; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	52	65	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13849	13858		10.1074/jbc.M306249200	http://dx.doi.org/10.1074/jbc.M306249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14739291	hybrid			2022-12-27	WOS:000220478500071
J	Tanaka, S; Maeda, Y; Tashima, Y; Kinoshita, T				Tanaka, S; Maeda, Y; Tashima, Y; Kinoshita, T			Inositol deacylation of glycosylphosphatidylinositol-anchored proteins is mediated by mammalian PGAP1 and yeast Bst1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOLICHOL-PHOSPHATE-MANNOSE; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; GLYCOINOSITOL PHOSPHOLIPID ANCHOR; ENDOPLASMIC-RETICULUM; GLUCOSAMINYL PHOSPHATIDYLINOSITOL; COENZYME-A; BIOSYNTHESIS; ACYLATION; LOCALIZATION; TRANSPORT	The inositol moiety of mammalian glycosylphosphatidylinositol (GPI) is acylated at an early step in GPI biosynthesis. The inositol acylation is essential for the generation of mature GPI capable of attachment to proteins. However, the acyl group is usually absent from GPI-anchored proteins (GPI-APs) on the cell surface due to inositol deacylation that occurs in the endoplasmic reticulum (ER) soon after GPI-anchor attachment. Mammalian GPI inositol-deacylase has not been cloned, and the biological significance of the deacylation has been unclear. Here we report a GPI inositol-deacylase-deficient Chinese hamster ovary cell line established by taking advantage of resistance to phosphatidylinositol-specific phospholipase C and the gene responsible, which was termed PGAP1 for Post GPI Attachment to Proteins 1. PGAP1 encoded an ER-associated, 922-amino acid membrane protein bearing a lipase consensus motif. Substitution of a conserved putative catalytic serine with alanine resulted in a complete loss of function, indicating that PGAP1 is the GPI inositol-deacylase. The mutant cells showed a clear delay in the maturation of GPI-APs in the Golgi and accumulation of GPI-APs in the ER. Thus, the GPI inositol deacylation is important for efficient transport of GPI-APs from the ER to the Golgi.	Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, Suita, Osaka 5650871, Japan	Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009					Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DEEG MA, 1992, J BIOL CHEM, V267, P18573; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Guther MLS, 2001, EMBO J, V20, P4923, DOI 10.1093/emboj/20.17.4923; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maeda Y, 2000, EMBO J, V19, P2475, DOI 10.1093/emboj/19.11.2475; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Murakami Y, 2003, MOL BIOL CELL, V14, P4285, DOI 10.1091/mbc.E03-03-0193; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; STEVENS VL, 1994, J BIOL CHEM, V269, P31397; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; TOUTANT JP, 1989, EUR J BIOCHEM, V180, P503, DOI 10.1111/j.1432-1033.1989.tb14674.x; Umemura M, 2003, J BIOL CHEM, V278, P23639, DOI 10.1074/jbc.M301044200; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; WALTER EI, 1990, J IMMUNOL, V144, P1030	31	125	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14256	14263		10.1074/jbc.M313755200	http://dx.doi.org/10.1074/jbc.M313755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734546	hybrid			2022-12-27	WOS:000220478500119
J	Chen, L; Rezaie, AR				Chen, L; Rezaie, AR			Proexosite-1-dependent recognition and activation of prothrombin by taipan venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VA; MOLECULAR-BASIS; THROMBIN; RESIDUES; HIRUDIN; COMPLEX; REGION	An activator complex from the venom of Oxyuranus scutellatus scutellatus (taipan venom) is known to rapidly activate prothrombin to thrombin. To determine whether, similar to prothrombinase, taipan venom utilizes proexosite-1 on prothrombin for a productive complex assembly, the activation of proexosite-1 mutants of prethrombin-1 by the partially purified venom was studied. It was discovered that basic residues of this site (Arg(35), Lys(36), Arg(67), Lys(70), Arg(73), Arg(75), and Arg(77)) are also crucial for recognition and rapid activation of the substrate by taipan venom. This was evidenced by the observation that the K-m and k(cat) values for the activation of the charge reversal mutants of prethrombin-1 (in particular K36E, R67E, and K70E) were markedly impaired. Competitive kinetic studies with the Tyr(63)-sulfated hirudin(54-65) peptide revealed that although the peptide inhibits the activation of the wild type zymogen by taipan venom with a K-D of similar to2 muM, it is ineffective in inhibiting the activation of mutant zymogens (K-D > 4-30 muM). Interestingly, an similar to50-kDa activator, isolated from the taipan venom complex, catalyzed the activation of prothrombin in a factor Va-dependent manner and exhibited identical activation kinetics toward the substrate in the presence of the hirudin peptide. These results suggest that, similar to prothrombinase, proexosite-1 is a cofactor-dependent recognition site for taipan venom.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S GRand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R01HL062565] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62565, HL 68571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HORTIN GL, 1990, BLOOD, V76, P946; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; LIU LW, 1991, J BIOL CHEM, V266, P16977; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MORITA T, 1981, METHOD ENZYMOL, V80, P303; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; Rao VS, 2003, BLOOD, V102, P1347, DOI 10.1182/blood-2002-12-3839; Rezaie AR, 2003, P NATL ACAD SCI USA, V100, P12051, DOI 10.1073/pnas.2135346100; Rezaie AR, 1998, PROTEIN SCI, V7, P349; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; ROSING J, 1980, J BIOL CHEM, V255, P274; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; SPEIJER H, 1986, J BIOL CHEM, V261, P3258; TRACY PB, 1983, J BIOL CHEM, V258, P7264; WALKER FJ, 1980, BIOCHEMISTRY-US, V19, P1020, DOI 10.1021/bi00546a029	24	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17869	17874		10.1074/jbc.M314285200	http://dx.doi.org/10.1074/jbc.M314285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769787	hybrid			2022-12-27	WOS:000220870400120
J	Salvioli, R; Scarpa, S; Ciaffoni, F; Tatti, M; Ramoni, C; Vanier, MT; Vaccaro, AM				Salvioli, R; Scarpa, S; Ciaffoni, F; Tatti, M; Ramoni, C; Vanier, MT; Vaccaro, AM			Glucosylceramidase mass and subcellular localization are modulated by cholesterol in Niemann-Pick disease type C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL-SENSING DOMAIN; ACTIVATOR PROTEIN; ENDOCYTIC PATHWAY; BETA-GLUCOSIDASE; SAPOSIN-C; FIBROBLASTS; STORAGE; GLUCOCEREBROSIDASE; SPHINGOMYELINASE; DEFICIENCY	Niemann-Pick disease type C (NPC) is characterized by the accumulation of cholesterol and sphingolipids in the late endosomal/lysosomal compartment. The mechanism by which the concentration of sphingolipids such as glucosylceramide is increased in this disease is poorly understood. We have found that, in NPC fibroblasts, the cholesterol storage affects the stability of glucosylceramidase (GCase), decreasing its mass and activity; a reduction of cholesterol raises the level of GCase to nearly normal values. GCase is activated and stabilized by saposin C (Sap C) and anionic phospholipids. Here we show by immunofluorescence microscopy that in normal fibroblasts, GCase, Sap C, and lysobisphosphatidic acid (LBPA), the most abundant anionic phospholipid in the endolysosomal system, reside in the same intracellular vesicular structures. In contrast, the colocalization of GCase, Sap C, and LBPA is markedly impaired in NPC fibroblasts but can be re-established by cholesterol depletion. These data show for the first time that the level of cholesterol modulates the interaction of GCase with its protein and lipid activators, namely Sap C and LBPA, regulating the GCase activity and stability.	Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Lyon Sud Hosp, Oullins & Fdn Gillet Merieux, Lyon Sud Med Sch, F-69495 Pierre Benite, France	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Sapienza University Rome; CHU Lyon	Vaccaro, AM (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	avaccaro@iss.it	tatti, Massimo/N-1382-2017					AERTS JMFG, 1990, BIOCHIM BIOPHYS ACTA, V1041, P55, DOI 10.1016/0167-4838(90)90122-V; BESLEY GTN, 1983, BIOCHIM BIOPHYS ACTA, V752, P54, DOI 10.1016/0005-2760(83)90232-1; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; JONSSON LMV, 1987, EUR J BIOCHEM, V164, P171, DOI 10.1111/j.1432-1033.1987.tb11008.x; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; MCMASTER MC, 1977, J LABELLED COMPD RAD, V13, P353, DOI 10.1002/jlcr.2580130309; Miaczynska M, 2002, EXP CELL RES, V272, P8, DOI 10.1006/excr.2001.5401; Millat G, 2001, AM J HUM GENET, V68, P1373, DOI 10.1086/320606; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Reagan JM, 2000, J BIOL CHEM, V275, P38104, DOI 10.1074/jbc.M005296200; Salvioi R, 2000, FEBS LETT, V472, P17, DOI 10.1016/S0014-5793(00)01417-4; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; Sun Y, 2003, J BIOL CHEM, V278, P31918, DOI 10.1074/jbc.M302752200; Taniguchi M, 2001, BRAIN DEV-JPN, V23, P414, DOI 10.1016/S0387-7604(01)00252-2; THOMAS GH, 1989, J INHERIT METAB DIS, V12, P139, DOI 10.1007/BF01800716; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; VACCARO AM, 1993, FEBS LETT, V336, P159, DOI 10.1016/0014-5793(93)81631-9; VACCARO AM, 1987, FEBS LETT, V216, P190, DOI 10.1016/0014-5793(87)80687-7; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Vaccaro AM, 1997, J BIOL CHEM, V272, P16862, DOI 10.1074/jbc.272.27.16862; Vanier MT, 1998, BRAIN PATHOL, V8, P163; VANIER MT, 1983, BIOCHIM BIOPHYS ACTA, V750, P178, DOI 10.1016/0005-2760(83)90218-7; Vanier MT, 1999, NEUROCHEM RES, V24, P481, DOI 10.1023/A:1022575511354; Watanabe Y, 1998, BRAIN DEV-JPN, V20, P95, DOI 10.1016/S0387-7604(97)00113-7; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	45	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17674	17680		10.1074/jbc.M313517200	http://dx.doi.org/10.1074/jbc.M313517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14757764	hybrid			2022-12-27	WOS:000220870400097
J	Soza, A; Norambuena, A; Cancino, J; de la Fuente, E; Henklein, P; Gonzalez, A				Soza, A; Norambuena, A; Cancino, J; de la Fuente, E; Henklein, P; Gonzalez, A			Sorting competition with membrane-permeable peptides in intact epithelial cells revealed discrimination of transmembrane proteins not only at the trans-Golgi network but also at pre-Golgi stages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS G-PROTEIN; ENDOPLASMIC-RETICULUM EXPORT; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; ER EXPORT; CARGO SELECTION; TRANSFERRIN RECEPTOR; BASOLATERAL SIGNALS; MAMMALIAN-CELLS; COPII VESICLES	Transmembrane proteins destined to the basolateral cell surface of epithelial cells contain in their cytosolic domain at least two classes of sorting signals: one class promotes exit from the endoplasmic reticulum (ER) and transport to the Golgi complex, and the other class operates at the trans-Golgi network (TGN) specifying segregation into basolateral exocytic pathways. Both kinds of addressing motifs are quite diverse among different proteins. It is unclear to what extent this feature reflects alternative decoding mechanisms or variations in motifs recognized by the same sorting factor. Here we applied a novel strategy based on permeable peptide technology and temperature-sensitive model proteins to study competition between cytosolic sorting motifs in the context of mammalian living cells. We used the transduction domain of HIV-1 Tat protein to make a membrane-permeable peptide of the cytosolic tail of GtsO45, which contains a well characterized ER exit di-acidic (DIE) motif and a tyrosine-based basolateral sorting signal (YTDI). This peptide added to the media inhibited transport of GtsO45 from both ER-to-Golgi and TGN-to-basolateral cell surface in transfected Madin-Darby canine kidney cells. Instead, it did not affect the exocytic trafficking of a GtsO45-derived chimeric protein bearing 30 juxtamembrane residues from the cytosolic domain of the epidermal growth factor receptor that contains a variant ER exit motif (ERE) and an unconventional proline-based basolateral sorting signal. These results not only proved the feasibility of competing for sorting events in intact cells but also showed that distinct plasma membrane proteins can be discriminated at pre-TGN stages, and that basolateral sorting involves different recognition elements for tyrosine-based motifs and an unconventional basolateral motif.	Pontificia Univ Catolica Chile, Fac Med, Dept Inmunol Clin & Reumatol, Santiago 6510260, Chile; Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Regulac Celular & Patol, Santiago 6510260, Chile; Millennium Inst Fundamental & Appl Biol, Santiago 7780344, Chile; Humboldt Univ, Fac Med, Inst Biochem, D-10117 Berlin, Germany	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Humboldt University of Berlin	Gonzalez, A (corresponding author), Pontificia Univ Catolica Chile, Fac Med, Dept Inmunol Clin & Reumatol, Santiago 6510260, Chile.	agonzara@med.puc.cl	de la Fuente Ortega, Erwin/S-6513-2019	de la Fuente Ortega, Erwin/0000-0001-8757-571X; Soza, Andrea/0000-0003-3783-5231				Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; Bravo-Zehnder M, 2000, P NATL ACAD SCI USA, V97, P13114, DOI 10.1073/pnas.240455697; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Gan YB, 2002, NAT CELL BIOL, V4, P605, DOI 10.1038/ncb827; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; He C, 2002, J BIOL CHEM, V277, P38284, DOI 10.1074/jbc.M104646200; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Keller P, 1997, J CELL SCI, V110, P3001; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2002, J CELL SCI, V115, P619; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Salazar G, 2002, MOL BIOL CELL, V13, P1677, DOI 10.1091/mbc.01-08-0403; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Stephens DJ, 2002, J CELL SCI, V115, P1149; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Sugimoto H, 2002, MOL BIOL CELL, V13, P2374, DOI 10.1091/mbc.E01-10-0096; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	57	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17376	17383		10.1074/jbc.M313197200	http://dx.doi.org/10.1074/jbc.M313197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14764609	hybrid			2022-12-27	WOS:000220870400061
J	Guo, Y; Yu, XM; Rihani, K; Wang, QY; Rong, LJ				Guo, Y; Yu, XM; Rihani, K; Wang, QY; Rong, LJ			The role of a conserved acidic residue in calcium-dependent protein folding for a low density lipoprotein (LDL)-A module - Implications in structure and function for the LDL receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOSIS VIRUS RECEPTOR; A AVIAN-LEUKOSIS; LIGAND-BINDING REPEAT; ROUS-SARCOMA-VIRUS; SUBGROUP-A; FAMILIAL HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN-E; CYSTEINE-RICH; VIRAL ENTRY; TVA	One common feature of the more than 1,000 complement-type repeats (or low density lipoprotein (LDL)-A modules) found in LDL receptor and the other members of the LDL receptor superfamily is a cluster of five highly conserved acidic residues in the C-terminal region, DXXXDXXDXXDE. However, the role of the third conserved aspartate of these LDL-A modules in protein folding and ligand recognition has not been elucidated. In this report, using a model LDL-A module and several experimental approaches, we demonstrate that this acidic residue, like the other four conserved acidic residues, is involved in calcium-dependent protein folding. These results suggest an alternative calcium coordination conformation for the LDL-A modules. The proposed model provides a plausible explanation for the conservation of this acidic residue among the LDL-A modules. Furthermore, the model can explain why mutations of this residue in human LDL receptor cause familial hypercholesterolemia.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rong, LJ (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, E829 MSB,835 S Wolcott Ave, Chicago, IL 60612 USA.	lijun@uic.edu			NATIONAL CANCER INSTITUTE [R01CA092459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI048056] Funding Source: NIH RePORTER; NCI NIH HHS [CA092459] Funding Source: Medline; NIAID NIH HHS [AI48056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balliet JW, 1999, J VIROL, V73, P3054, DOI 10.1128/JVI.73.4.3054-3061.1999; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; FEDERSPIEL MJ, 1994, P NATL ACAD SCI USA, V91, P11241, DOI 10.1073/pnas.91.23.11241; GILBERT JM, 1994, J VIROL, V68, P5623, DOI 10.1128/JVI.68.9.5623-5628.1994; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LOHSE P, 1991, J BIOL CHEM, V266, P10479; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Rai T, 2004, J VIROL, V78, P683, DOI 10.1128/JVI.78.2.683-691.2004; Rong LJ, 1997, J VIROL, V71, P3458, DOI 10.1128/JVI.71.5.3458-3465.1997; Rong LJ, 1998, J VIROL, V72, P4552, DOI 10.1128/JVI.72.6.4552-4559.1998; RONG LJ, 1995, J VIROL, V69, P4847, DOI 10.1128/JVI.69.8.4847-4853.1995; Rong LJ, 1998, P NATL ACAD SCI USA, V95, P8467, DOI 10.1073/pnas.95.15.8467; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Simonovic M, 2001, BIOCHEMISTRY-US, V40, P15127, DOI 10.1021/bi015688m; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; Tonelli M, 2001, FEBS LETT, V509, P161, DOI 10.1016/S0014-5793(01)03086-1; Wang QY, 2002, J VIROL, V76, P2848, DOI 10.1128/JVI.76.6.2848-2856.2002; Wang QY, 2001, J VIROL, V75, P2051, DOI 10.1128/JVI.75.5.2051-2058.2001; WARDELL MR, 1991, J LIPID RES, V32, P521; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Yu XM, 2003, J VIROL, V77, P7517, DOI 10.1128/JVI.77.13.7517-7526.2003; Zingler K, 1996, J VIROL, V70, P7510, DOI 10.1128/JVI.70.11.7510-7516.1996; ZINGLER K, 1995, J VIROL, V69, P4261, DOI 10.1128/JVI.69.7.4261-4266.1995	34	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16629	16637		10.1074/jbc.M400157200	http://dx.doi.org/10.1074/jbc.M400157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14749324	hybrid			2022-12-27	WOS:000220747900114
J	Lee, YT; Jacob, J; Michowski, W; Nowotny, M; Kuznicki, J; Chazin, WJ				Lee, YT; Jacob, J; Michowski, W; Nowotny, M; Kuznicki, J; Chazin, WJ			Human Sgt1 binds HSP90 through the CHORD-Sgt1 domain and not the tetratricopeptide repeat domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-RESISTANCE; ESSENTIAL COMPONENT; CRYSTAL-STRUCTURE; QUALITY-CONTROL; P23; COMPLEXES; CALCYCLIN; PROTEINS; DYNAMICS; PROGRAMS	Sgt1 has been identified as a subunit of both core kinetochore and SCF (Skp1-Cul1-F-box) ubiquitin ligase complexes and is also implicated in plant disease resistance. Sgt1 has two putative HSP90 binding domains, a tetratricopeptide repeat and a p23-like CHORD and Sgt1 (CS) domain. Using NMR spectroscopy, we show that only the CS domain of human Sgt1 physically interacts with HSP90. The tetratricopeptide repeat domain does not bind to either HSP90 or HSP70. Determination of the three-dimensional structure showed that the Sgt1-CS domain shares the same beta-sandwich fold as p23 but lacks the last highly conserved beta-strand in p23. Analysis of the structures of Sgt1-CS and p23 revealed a similar charge distribution on one of two opposing surfaces that suggests that it is the binding region for HSP90 in Sgt1. Although ATP is absolutely required for p23 binding to HSP90, Sgt1 binds to HSP90 also in the absence of the non-hydrolyzable analog ATPgammaS. Our findings suggest the CS domain is a binding module for HSP90 distinct from p23-like domains, which implies that Sgt1 and related proteins function in recruiting heat shock protein activities to multiprotein assemblies.	Int Inst Mol & Cell Biol, PL-02093 Warsaw, Poland; Vanderbilt Univ, Ctr Struct Biol, Dept Biochem, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Struct Biol, Dept Phys, Nashville, TN 37235 USA; M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, PL-02109 Warsaw, Poland	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Vanderbilt University; Vanderbilt University; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kuznicki, J (corresponding author), Int Inst Mol & Cell Biol, Trojdena 4, PL-02093 Warsaw, Poland.	jkuznicki@iimcb.gov.pl; walter.chazin@vanderbilt.edu	Kuznicki, Jacek/AAW-9239-2020	Kuznicki, Jacek/0000-0001-6486-0657; Lee, Young-Tae/0000-0002-3522-9361	FIC NIH HHS [R13 TW006005] Funding Source: Medline; NCI NIH HHS [P30 CA68485] Funding Source: Medline; NIGMS NIH HHS [R01 GM62112] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW006005] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062112] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Garcia-Ranea JA, 2002, FEBS LETT, V529, P162, DOI 10.1016/S0014-5793(02)03321-5; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Goddard T. D. and Kneller D. G ., 2002, SPARKY; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hubert DA, 2003, EMBO J, V22, P5679, DOI 10.1093/emboj/cdg547; Jacob J, 2002, J BIOMOL NMR, V24, P231, DOI 10.1023/A:1021662423490; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liu YL, 2004, J BIOL CHEM, V279, P2101, DOI 10.1074/jbc.M310029200; Lu R, 2003, EMBO J, V22, P5690, DOI 10.1093/emboj/cdg546; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1; Muskett P, 2003, MICROBES INFECT, V5, P969, DOI 10.1016/S1286-4579(03)00183-7; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nowotny M, 2000, J BIOL CHEM, V275, P31178, DOI 10.1074/jbc.M001622200; Nowotny M, 2003, J BIOL CHEM, V278, P26923, DOI 10.1074/jbc.M211518200; Oxelmark E, 2003, J BIOL CHEM, V278, P36547, DOI 10.1074/jbc.M305960200; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Shirasu K, 2003, TRENDS PLANT SCI, V8, P252, DOI 10.1016/S1360-1385(03)00104-3; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Smith JA, 1996, MAGN RESON CHEM, V34, pS147, DOI 10.1002/(SICI)1097-458X(199612)34:13<S147::AID-OMR47>3.0.CO;2-0; Stemmann O, 2002, P NATL ACAD SCI USA, V99, P8585, DOI 10.1073/pnas.082223899; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Sullivan WP, 2002, J BIOL CHEM, V277, P45942, DOI 10.1074/jbc.M207754200; Takahashi A, 2003, P NATL ACAD SCI USA, V100, P11777, DOI 10.1073/pnas.2033934100; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	40	95	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16511	16517		10.1074/jbc.M400215200	http://dx.doi.org/10.1074/jbc.M400215200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761955	hybrid			2022-12-27	WOS:000220747900100
J	Macri, V; Accili, EA				Macri, V; Accili, EA			Structural elements of instantaneous and slow gating in hyperpolarization-activated cyclic nucleotide-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-SENSING MECHANISM; PACEMAKER CHANNELS; MOLECULAR CHARACTERIZATION; CATION CURRENT; CELLS; FAMILY; POTASSIUM; CURRENTS; SHAKER; IDENTIFICATION	Hyperpolarization-activated cyclic nucleotide-gated (HCN) subunits produce a slowly activating current in response to hyperpolarization ( If) and an instantaneous voltage-independent current (I-inst) when expressed in Chinese hamster ovary (CHO) cells. Here we found that a mutation in the S4-S5 linker of HCN2 (Y331D) produced an additional mixed cationic instantaneous current. However, this current was inhibited by external Cs+ like I-f and unlike I-inst. Together with a concomitant reduction in If, the data suggest that the Y331D mutation disrupted channel closing placing the channel in a "I-f -like," and not an "I-inst-like," state. The " I-f-like" instantaneous current represented similar to 70% of total I-f over voltages ranging from +20 to - 150 mV in high K+ solutions. I-f activated at more depolarized potentials and the activation curve was less steep, whereas deactivation was significantly slowed, consistent with the idea that the mutation inhibited channel closing. The data suggest that the mutation produced allosteric effects on the activation gate (S6 segment) and/or on voltage-sensing elements. We also found that decreases in the ratio of external K+/Na+ further disrupted channel closing in the mutant channel. Finally, our data suggest that the structures involved in producing Iinst are similar between the HCN1 and HCN2 isoforms and that excess HCN protein on the plasma membrane of CHO cells relative to native cells is not responsible for Iinst. The data are consistent with Iinst flowing through a " leaky" closed state but do not rule out flow through a second configuration of recombinant HCN channels or up-regulated endogenous channels/subunits.	Simon Fraser Univ, Ion Channel Lab, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Accili, EA (corresponding author), Simon Fraser Univ, Ion Channel Lab, Burnaby, BC V5A 1S6, Canada.	eaaccili@sfu.ca		Macri, Vincenzo/0000-0003-3463-2877				Accili EA, 1997, AM J PHYSIOL-HEART C, V272, pH1549, DOI 10.1152/ajpheart.1997.272.3.H1549; Bal R, 2000, J NEUROPHYSIOL, V84, P806, DOI 10.1152/jn.2000.84.2.806; Bell DC, 2004, J GEN PHYSIOL, V123, P5, DOI 10.1085/jgp.200308918; Carroll RC, 1998, EMBO J, V17, P3036, DOI 10.1093/emboj/17.11.3036; Chaplan SR, 2003, J NEUROSCI, V23, P1169, DOI 10.1523/JNEUROSCI.23-04-01169.2003; Chen J, 2002, TRENDS CARDIOVAS MED, V12, P42, DOI 10.1016/S1050-1738(01)00141-4; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; Decher N, 2003, PFLUG ARCH EUR J PHY, V446, P633, DOI 10.1007/s00424-003-1127-7; DEMO SD, 1992, BIOPHYS J, V61, P639, DOI 10.1016/S0006-3495(92)81869-6; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P377, DOI 10.1113/jphysiol.1981.sp013714; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1982, J PHYSIOL-LONDON, V329, P485, DOI 10.1113/jphysiol.1982.sp014315; Dreyer I, 2001, FEBS LETT, V505, P233, DOI 10.1016/S0014-5793(01)02832-0; FRACE AM, 1992, PFLUG ARCH EUR J PHY, V421, P97; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; HAGIWARA N, 1992, J PHYSIOL-LONDON, V448, P53, DOI 10.1113/jphysiol.1992.sp019029; IRISAWA H, 1993, PHYSIOL REV, V73, P197, DOI 10.1152/physrev.1993.73.1.197; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Islas LD, 1999, J GEN PHYSIOL, V114, P723, DOI 10.1085/jgp.114.5.723; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Lacombe B, 1998, J MEMBRANE BIOL, V166, P91, DOI 10.1007/s002329900451; Liu ZW, 1996, J MOL CELL CARDIOL, V28, P2523, DOI 10.1006/jmcc.1996.0244; Lorincz A, 2002, NAT NEUROSCI, V5, P1185, DOI 10.1038/nn962; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; MacLean JN, 2003, NEURON, V37, P109, DOI 10.1016/S0896-6273(02)01104-2; Macri V, 2002, J BIOL CHEM, V277, P35939, DOI 10.1074/jbc.M203485200; Magee JC, 1998, J NEUROSCI, V18, P7613; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; Moroni A, 2001, J BIOL CHEM, V276, P29233, DOI 10.1074/jbc.M100830200; Moroni A, 2000, PFLUG ARCH EUR J PHY, V439, P618, DOI 10.1007/s004240050985; Muller F, 2003, EUR J NEUROSCI, V17, P2084, DOI 10.1046/j.1460-9568.2003.02634.x; Nie M, 1998, REGUL PEPTIDES, V75-6, P207, DOI 10.1016/S0167-0115(98)00070-6; NOBLE D, 1992, P ROY SOC B-BIOL SCI, V250, P199, DOI 10.1098/rspb.1992.0150; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Proenza C, 2002, J BIOL CHEM, V277, P29634, DOI 10.1074/jbc.M200504200; Proenza C, 2002, J BIOL CHEM, V277, P5101, DOI 10.1074/jbc.M106974200; Qu JH, 2002, PFLUG ARCH EUR J PHY, V444, P597, DOI 10.1007/s00424-002-0860-7; Qu JH, 2001, CIRC RES, V89, pE8, DOI 10.1161/hh1301.094395; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Rothberg BS, 2003, J GEN PHYSIOL, V122, P501, DOI 10.1085/jgp.200308928; Rothberg BS, 2002, J GEN PHYSIOL, V119, P83, DOI 10.1085/jgp.119.1.83; RYAN TA, 1988, SCIENCE, V239, P61, DOI 10.1126/science.2962287; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Shealy RT, 2003, BIOPHYS J, V84, P2929, DOI 10.1016/S0006-3495(03)70020-4; Shi WM, 1999, CIRC RES, V85, pE1; Soler-Llavina GJ, 2003, NEURON, V38, P61, DOI 10.1016/S0896-6273(03)00157-0; Sukhareva M, 2003, J GEN PHYSIOL, V122, P541, DOI 10.1085/jgp.200308905; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; Tran N, 2002, J BIOL CHEM, V277, P43588, DOI 10.1074/jbc.M208477200; Vemana S, 2004, J GEN PHYSIOL, V123, P21, DOI 10.1085/jgp.200308916; Wu JY, 2001, AM J PHYSIOL-HEART C, V280, pH1232, DOI 10.1152/ajpheart.2001.280.3.H1232; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9	57	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16832	16846		10.1074/jbc.M400518200	http://dx.doi.org/10.1074/jbc.M400518200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14752094	hybrid			2022-12-27	WOS:000220747900136
J	McEwen, DP; Meadows, LS; Chen, CL; Thyagarajan, V; Isom, LL				McEwen, DP; Meadows, LS; Chen, CL; Thyagarajan, V; Isom, LL			Sodium channel beta 1 subunit-mediated modulation of Na(v)1.2 currents and cell surface density is dependent on interactions with contactin and ankyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; GENERALIZED EPILEPSY; AUXILIARY SUBUNIT; FEBRILE SEIZURES; ALPHA-SUBUNITS; NA+ CHANNELS; TENASCIN-R; INACTIVATION	Voltage-gated sodium channels are composed of a pore-forming alpha subunit and at least one auxiliary beta subunit. Both beta1 and beta2 are cell adhesion molecules that interact homophilically, resulting in ankyrin recruitment. In contrast, beta1, but not beta2, interacts heterophilically with contactin, resulting in increased levels of cell surface sodium channels. We took advantage of these results to investigate the molecular basis of beta1-mediated enhancement of sodium channel cell surface density, including elucidating structure-function relationships for beta1 association with contactin, ankyrin, and Na(v)1.2. beta1/beta2 subunit chimeras were used to assign putative sites of contactin interaction to two regions of the beta1 Ig loop. Recent studies have shown that glutathione S-transferase fusion proteins containing portions of Na(v)1.2 intracellular domains interact directly with ankyrin(G). We show that native Na(v)1.2 associates with ankyrin(G) in cells in the absence of beta subunits and that this interaction is enhanced in the presence of beta1 but not beta1Y181E, a mutant that does not interact with ankyrinG. beta1Y181E does not modulate Na(v)1.2 channel function despite efficient association with Na(v)1.2 and contactin. beta1Y181E increases Na(v)1.2 cell surface expression, but not as efficiently as wild type beta1. beta1/beta2 chimeras exchanging various regions of the beta1 Ig loop were all ineffective in increasing Na(v)1.2 cell surface density. Our results demonstrate that full-length beta1 is required for channel modulation and enhancement of sodium channel cell surface expression.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1150 W Med Ctr Dr,1301 MSRB III, Ann Arbor, MI 48109 USA.	lisom@umich.edu		Isom, Lori/0000-0002-9479-6729; Hoffman, Veena/0000-0003-4932-0892	NIGMS NIH HHS [GM07767] Funding Source: Medline; NIMH NIH HHS [R01MH59980] Funding Source: Medline; NINDS NIH HHS [R01NS17965-17, NS43067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017965, F31NS043067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abriel H, 2000, CIRCULATION, V102, P921; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Berglund EO, 1999, NEURON, V24, P739, DOI 10.1016/S0896-6273(00)81126-5; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; Bouzidi M, 2002, J BIOL CHEM, V277, P28996, DOI 10.1074/jbc.M201760200; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen CL, 2002, P NATL ACAD SCI USA, V99, P17072, DOI 10.1073/pnas.212638099; Garrido JJ, 2003, SCIENCE, V300, P2091, DOI 10.1126/science.1085167; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; Isom LL, 2002, FRONT BIOSCI, V7, P12; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; Kizhatil K, 2002, J NEUROSCI, V22, P7948; Lemaillet G, 2003, J BIOL CHEM, V278, P27333, DOI 10.1074/jbc.M303327200; Makita N, 1996, J NEUROSCI, V16, P7117; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 2002, J BIOL CHEM, V277, P26681, DOI 10.1074/jbc.M202354200; MALHOTRA JD, 2003, SOC NEUROSCIENCE; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; McCormick KA, 1999, J BIOL CHEM, V274, P32638, DOI 10.1074/jbc.274.46.32638; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; Meadows L, 2001, J NEUROCHEM, V76, P1871, DOI 10.1046/j.1471-4159.2001.00192.x; Meadows LS, 2002, J NEUROSCI, V22, P10699; Morgan JR, 2000, J NEUROSCI, V20, P8667; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Yu FH, 2003, J NEUROSCI, V23, P7577; Zimmer T, 2002, J GEN PHYSIOL, V120, P887, DOI 10.1085/jgp.20028703	42	95	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16044	16049		10.1074/jbc.M400856200	http://dx.doi.org/10.1074/jbc.M400856200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761957	hybrid			2022-12-27	WOS:000220747900043
J	Ueno, T; Linder, S; Na, CL; Rice, WR; Johansson, J; Weaver, TE				Ueno, T; Linder, S; Na, CL; Rice, WR; Johansson, J; Weaver, TE			Processing of pulmonary surfactant protein B by napsin and cathepsin H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALVEOLAR EPITHELIAL-CELLS; RESPIRATORY-FAILURE; II PNEUMOCYTES; MICE; LUNG; EXPRESSION; LOCALIZATION; TISSUE; GENE; DEFICIENCY	Surfactant protein B (SP-B) is an essential constituent of pulmonary surfactant. SP-B is synthesized in alveolar type II cells as a preproprotein and processed to the mature peptide by the cleavage of NH2- and COOH-terminal peptides. An aspartyl protease has been suggested to cleave the NH2- terminal propeptide resulting in a 25-kDa intermediate. Napsin, an aspartyl protease expressed in alveolar type II cells, was detected in fetal lung homogenates as early as day 16 of gestation, 1 day before the onset of SP-B expression and processing. Napsin was localized to multivesicular bodies, the site of SP-B proprotein processing in type II cells. Incubation of SP-B proprotein from type II cells with a crude membrane extract from napsin-transfected cells resulted in enhanced levels of a 25-kDa intermediate. Purified napsin cleaved a recombinant SP-B/EGFP fusion protein within the NH2- terminal propeptide between Leu(178) and Pro(179), 22 amino acids upstream of the NH2 terminus of mature SP-B. Cathepsin H, a cysteine protease also implicated in pro-SP-B processing, cleaved SP-B/EGFP fusion protein 13 amino acids upstream of the NH2 terminus of mature SP-B. Napsin did not cleave the COOH-terminal peptide, whereas cathepsin H cleaved the boundary between mature SP-B and the COOH-terminal peptide and at several other sites within the COOH-terminal peptide. Knockdown of napsin by small interfering RNA resulted in decreased levels of mature SP-B and mature SP-C in type II cells. These results suggest that napsin, cathepsin H, and at least one other enzyme are involved in maturation of the biologically active SP-B peptide.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Karolinska Hosp & Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden; Swedish Univ Agr Sci, Biomed Ctr, Dept Mol Biosci, SE-75123 Uppsala, Sweden	Cincinnati Children's Hospital Medical Center; Karolinska Institutet; Karolinska University Hospital; Swedish University of Agricultural Sciences	Weaver, TE (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Tim.Weaver@cchmc.org		Johansson, Jan/0000-0002-8719-4703	NHLBI NIH HHS [R37-HL65285] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbi HT, 1997, J BIOL CHEM, V272, P9640; Brasch F, 2003, J BIOL CHEM, V278, P49006, DOI 10.1074/jbc.M306844200; Brasch F, 2002, AM J RESP CELL MOL, V26, P659, DOI 10.1165/ajrcmb.26.6.4744; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chuman Y, 1999, FEBS LETT, V462, P129, DOI 10.1016/S0014-5793(99)01493-3; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Cole FS, 2003, AM J PHYSIOL-LUNG C, V285, pL540, DOI 10.1152/ajplung.00111.2003; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Guttentag S, 2003, AM J RESP CELL MOL, V28, P69, DOI 10.1165/rcmb.2002-0111OC; HAMVAS A, 1994, J PEDIATR-US, V125, P356, DOI 10.1016/S0022-3476(05)83276-7; Hawgood S, 1998, BBA-MOL BASIS DIS, V1408, P150, DOI 10.1016/S0925-4439(98)00064-7; HAWGOOD S, 1993, AM J PHYSIOL, V264, pL290, DOI 10.1152/ajplung.1993.264.3.L290; Hirano T, 2000, JPN J CANCER RES, V91, P1015, DOI 10.1111/j.1349-7006.2000.tb00879.x; Holzinger A, 1996, BIOTECHNIQUES, V20, P804; ISHII Y, 1991, ANAT REC, V230, P519, DOI 10.1002/ar.1092300411; Korimilli A, 2000, J BIOL CHEM, V275, P8672, DOI 10.1074/jbc.275.12.8672; Lin S, 1999, J BIOL CHEM, V274, P19168, DOI 10.1074/jbc.274.27.19168; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; Melton KR, 2003, AM J PHYSIOL-LUNG C, V285, pL543, DOI 10.1152/ajplung.00011.2003; Mori K, 1997, FEBS LETT, V401, P218, DOI 10.1016/S0014-5793(96)01473-1; Mori K, 2002, ARCH HISTOL CYTOL, V65, P359, DOI 10.1679/aohc.65.359; Mori K, 2001, ARCH HISTOL CYTOL, V64, P319, DOI 10.1679/aohc.64.319; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OREILLY MA, 1989, BIOCHIM BIOPHYS ACTA, V1011, P140, DOI 10.1016/0167-4889(89)90201-2; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Ross GF, 1999, AM J PHYSIOL-LUNG C, V277, pL1104, DOI 10.1152/ajplung.1999.277.6.L1104; Schauer-Vukasinovic V, 2000, BBA-GENE STRUCT EXPR, V1492, P207, DOI 10.1016/S0167-4781(00)00069-5; Schauer-Vukasinovic V, 1999, FEBS LETT, V462, P135, DOI 10.1016/S0014-5793(99)01458-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stahlman MT, 2000, LAB INVEST, V80, P395, DOI 10.1038/labinvest.3780044; Tatnell PJ, 2000, EUR J BIOCHEM, V267, P6921, DOI 10.1046/j.1432-1033.2000.01795.x; Tokieda K, 1997, AM J PHYSIOL-LUNG C, V273, pL875, DOI 10.1152/ajplung.1997.273.4.L875; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; VORBROKER DK, 1995, AM J PHYSIOL, V268, P647; Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; Weaver TE, 2002, SEMIN CELL DEV BIOL, V13, P263, DOI 10.1016/S1084952102000551; WEAVER TE, 1989, AM J PHYSIOL, V257, P100; Yayoi Y, 2001, ARCH HISTOL CYTOL, V64, P89, DOI 10.1679/aohc.64.89	43	105	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16178	16184		10.1074/jbc.M312029200	http://dx.doi.org/10.1074/jbc.M312029200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14766755	hybrid			2022-12-27	WOS:000220747900060
J	Marshall, ASJ; Willment, JA; Lin, HH; Williams, DL; Gordon, S; Brown, GD				Marshall, ASJ; Willment, JA; Lin, HH; Williams, DL; Gordon, S; Brown, GD			Identification and characterization of a novel human Myeloid inhibitory c-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCAN RECEPTOR; SH2-CONTAINING INOSITOL PHOSPHATASE; INHIBITORY RECEPTOR; T-CELL; SPLICED FORM; GENE; DECTIN-1; LIGAND; GLYCOSYLATION; MACROPHAGES	Inhibitory and activatory C-type lectin-like receptors play an important role in immunity through the regulation of leukocytes. Here, we report the identification and characterization of a novel (m) under bar yeloid (i) under bar nhibitory (C) under bar -type (L) under bar ectin- like receptor (MICL) whose expression is primarily restricted to granulocytes and monocytes. This receptor, which contains a single C-type lectin-like domain and a cytoplasmic immunoreceptor tyrosine-based inhibitory motif, is related to LOX-1 ((l) under bar ectin- like receptor for (ox) under bar idized low density lipoprotein-(1) under bar) and the beta-glucan receptor (Dectin-1) and is variably spliced and highly N-glycosylated. We demonstrate that it preferentially associates with the signaling phosphatases SHP-1 and SHP-2, but not with SHIP. Novel chimeric analyses with a construct combining MICL and the beta-glucan receptor show that MICL can inhibit cellular activation through its cytoplasmic immunoreceptor tyrosine-based inhibitory motif. These data suggest that MICL is a negative regulator of granulocyte and monocyte function.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; E Tennessee State Univ, James H Quillen Coll Med, Dept Surg, Johnson City, TN 37614 USA	University of Oxford; East Tennessee State University	Brown, GD (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	gordon.brown@path.ox.ac.uk	brown, gordon/B-4249-2012	brown, gordon/0000-0002-0287-5383; Willment, Janet/0000-0002-7040-0857; Marshall, Andrew/0000-0003-0529-0425				Abramson J, 2002, MOL IMMUNOL, V38, P1307, DOI 10.1016/S0161-5890(02)00080-9; Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Bates EEM, 1999, J IMMUNOL, V163, P1973; BATRA SK, 1991, CELL GROWTH DIFFER, V2, P385; Bellon T, 1999, J IMMUNOL, V162, P3996; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; Colonna M, 2000, EUR J IMMUNOL, V30, P697; Colonna M, 2000, SEMIN IMMUNOL, V12, P121, DOI 10.1006/smim.2000.0214; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; Damen JE, 1998, BLOOD, V92, P1199, DOI 10.1182/blood.V92.4.1199.416k16_1199_1205; Diefenbach A, 2003, EUR J IMMUNOL, V33, P381, DOI 10.1002/immu.200310012; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; DRICKAMER K, 1993, BIOCHEM SOC T, V21, P456, DOI 10.1042/bst0210456; Evans EJ, 2003, IMMUNITY, V19, P213, DOI 10.1016/S1074-7613(03)00198-5; Fernandes MJ, 2000, GENOMICS, V69, P263, DOI 10.1006/geno.2000.6316; Fournier N, 2000, J IMMUNOL, V165, P1197, DOI 10.4049/jimmunol.165.3.1197; Furukawa H, 1998, IMMUNOGENETICS, V48, P87, DOI 10.1007/s002510050407; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hashimoto SI, 2003, BLOOD, V101, P3509, DOI 10.1182/blood-2002-06-1866; Henshall TL, 2001, J IMMUNOL, V166, P3098, DOI 10.4049/jimmunol.166.5.3098; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang X, 2001, BIOCHEM BIOPH RES CO, V281, P131, DOI 10.1006/bbrc.2001.4322; Huang ZY, 2003, J LEUKOCYTE BIOL, V73, P823, DOI 10.1189/jlb.0902454; Iizuka K, 2003, NAT IMMUNOL, V4, P801, DOI 10.1038/ni954; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; ISHIWATA N, 1994, J BIOL CHEM, V269, P23708; Iwaia Y, 2002, IMMUNOL LETT, V83, P215, DOI 10.1016/S0165-2478(02)00088-3; Kataoka H, 2000, J BIOL CHEM, V275, P6573, DOI 10.1074/jbc.275.9.6573; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kumagai H, 2003, BIOCHEM BIOPH RES CO, V307, P719, DOI 10.1016/S0006-291X(03)01245-2; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Latour S, 2001, J IMMUNOL, V167, P2547, DOI 10.4049/jimmunol.167.5.2547; Lazetic S, 1996, J IMMUNOL, V157, P4741; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; Lian RH, 1998, J IMMUNOL, V161, P2301; Liang SC, 2003, EUR J IMMUNOL, V33, P2706, DOI 10.1002/eji.200324228; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Lopez-Botet Miguel, 1996, Methods (Orlando), V9, P352, DOI 10.1006/meth.1996.0040; Lucas DM, 1999, BLOOD, V93, P1922, DOI 10.1182/blood.V93.6.1922.406k21_1922_1933; Mason LH, 2003, J IMMUNOL, V171, P4235, DOI 10.4049/jimmunol.171.8.4235; McQueen KL, 2002, CURR OPIN IMMUNOL, V14, P615, DOI 10.1016/S0952-7915(02)00380-1; Mehta JL, 2002, J AM COLL CARDIOL, V39, P1429, DOI 10.1016/S0735-1097(02)01803-X; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Muller A, 1996, J IMMUNOL, V156, P3418; Poggi A, 2000, EUR J IMMUNOL, V30, P2751, DOI 10.1002/1521-4141(200010)30:10<2751::AID-IMMU2751>3.0.CO;2-L; Richard M, 2002, J LEUKOCYTE BIOL, V71, P871; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shimaoka T, 2001, J IMMUNOL, V166, P5108, DOI 10.4049/jimmunol.166.8.5108; Sinclair NRS, 2000, CRIT REV IMMUNOL, V20, P89; Sobanov Y, 2001, EUR J IMMUNOL, V31, P3493, DOI 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9; SOTO EO, 1988, J IMMUNOL, V141, P4324; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; Uehara T, 2001, J CLIN INVEST, V108, P1041, DOI 10.1172/JCI200112195; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942; Washington AV, 2002, BLOOD, V100, P3822, DOI 10.1182/blood-2002-02-0523; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Willment JA, 2001, J BIOL CHEM, V276, P43818, DOI 10.1074/jbc.M107715200; Willment JA, 2003, J IMMUNOL, V171, P4569, DOI 10.4049/jimmunol.171.9.4569; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; Zocchi MR, 2001, EUR J IMMUNOL, V31, P3667, DOI 10.1002/1521-4141(200112)31:12<3667::AID-IMMU3667>3.0.CO;2-G	74	111	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14792	14802		10.1074/jbc.M313127200	http://dx.doi.org/10.1074/jbc.M313127200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739280	Green Published, hybrid			2022-12-27	WOS:000220594700039
J	Mayrose, M; Bonshtien, A; Sessa, G				Mayrose, M; Bonshtien, A; Sessa, G			LeMPK3 is a mitogen-activated protein kinase with dual specificity induced during tomato defense and wounding responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPESTRIS PV VESICATORIA; DISEASE RESISTANCE; MAP KINASE; HYPERSENSITIVE RESPONSE; MEDIATED RESISTANCE; BACTERIAL PATHOGEN; SIGNALING PATHWAYS; GENE; CONVERGENCE; CASCADES	Mitogen-activated protein (MAP) kinase cascades are readily activated during the response of plants to avirulent pathogens or to pathogen-derived elicitors. Here we show that the tomato MAP kinase LeMPK3 is specifically induced at the mRNA level during elicitation of the hypersensitive response in resistant plants infected by avirulent strains of the phytopathogenic bacteria Xanthomonas campestris pv. vesicatoria and Pseudomonas syringae pv. tomato, as well as upon treatment with the fungal elicitor ethylene-inducing xylanase. LeMPK3 gene expression was also induced very rapidly by mechanical stress and wounding much earlier than upon pathogen infection, but not in response to the defense-related plant hormones ethylene and jasmonic acid. Moreover, in resistant tomato plants infected by X. campestris pv. vesicatoria, transcript accumulation was followed by an increase in LeMPK3 kinase activity. Biochemical characterization of a glutathione S-transferase-LeMPK3 fusion protein revealed that the LeMPK3 MAP kinase autophosphorylates in vitro mainly on tyrosine and less so on threonine and serine, whereas it phosphorylates myelin basic protein on serine and threonine. In vitro phosphorylation of a poly(Glu-Tyr) copolymer by LeMPK3 demonstrated its capability to phosphorylate tyrosine residues on substrates as well. By mutagenesis and phosphoamino acid analysis, Tyr-201 in the kinase activation domain was identified as the main LeMPK3 autophosphorylation site and as critical for kinase activity. Finally, LeMPK3 autophosphorylation showed a preference for Mn2+ cations and proceeded via an intramolecular mechanism with an estimated Km value for ATP of 9.5 muM. These results define LeMPK3 as a MAP kinase with dual specificity and strongly suggest that it represents a convergence point for different signaling pathways inducing the activation of defense responses in tomato.	Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Sessa, G (corresponding author), Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	guidos@post.tau.ac.il						Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Astua-Monge G, 2000, MOL PLANT MICROBE IN, V13, P911, DOI 10.1094/MPMI.2000.13.9.911; Cardinale F, 2000, J BIOL CHEM, V275, P36734, DOI 10.1074/jbc.M007418200; Cardinale F, 2002, PLANT CELL, V14, P703, DOI 10.1105/tpc.010256; DEAN JFD, 1989, PHYTOPATHOLOGY, V79, P1071; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Dong XN, 1998, CURR OPIN PLANT BIOL, V1, P316, DOI 10.1016/1369-5266(88)80053-0; Ekengren SK, 2003, PLANT J, V36, P905, DOI 10.1046/j.1365-313X.2003.01944.x; Gomez-Gomez L, 2002, TRENDS PLANT SCI, V7, P251, DOI 10.1016/S1360-1385(02)02261-6; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; Heath MC, 2000, CURR OPIN PLANT BIOL, V3, P315, DOI 10.1016/S1369-5266(00)00087-X; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Holley SR, 2003, PLANT PHYSIOL, V132, P1728, DOI 10.1104/pp.103.024414; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; Huang YF, 2000, PLANT PHYSIOL, V122, P1301, DOI 10.1104/pp.122.4.1301; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Jin HL, 2002, DEV CELL, V3, P291, DOI 10.1016/S1534-5807(02)00205-8; Jin HL, 2003, PLANT J, V33, P719, DOI 10.1046/j.1365-313X.2003.01664.x; Jonak C, 2002, CURR OPIN PLANT BIOL, V5, P415, DOI 10.1016/S1369-5266(02)00285-6; JONES JB, 1986, PLANT DIS, V70, P337, DOI 10.1094/PD-70-337; Kim CY, 2003, PLANT CELL, V15, P2707, DOI 10.1105/tpc.011411; Kroj T, 2003, J BIOL CHEM, V278, P2256, DOI 10.1074/jbc.M208200200; Ligterink W, 1997, SCIENCE, V276, P2054, DOI 10.1126/science.276.5321.2054; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; Nurnberger T, 2001, TRENDS PLANT SCI, V6, P372, DOI 10.1016/S1360-1385(01)02019-2; O'Donnell PJ, 2003, PLANT PHYSIOL, V133, P1181, DOI 10.1104/pp.103.030379; Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Ron M, 2000, THEOR APPL GENET, V100, P184, DOI 10.1007/s001220050025; Rudrabhatla P, 2002, PLANT PHYSIOL, V130, P380, DOI 10.1104/pp.005173; SchulzeMuth P, 1996, J BIOL CHEM, V271, P26684, DOI 10.1074/jbc.271.43.26684; SCOTT JW, 1995, HORTSCIENCE, V30, P579, DOI 10.21273/HORTSCI.30.3.579; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sessa G, 2000, ADV BOT RES, V32, P379, DOI 10.1016/S0065-2296(00)32030-4; Sessa G, 1996, PLANT CELL, V8, P2223, DOI 10.1105/tpc.8.12.2223; Sharma PC, 2003, MOL GENET GENOMICS, V269, P583, DOI 10.1007/s00438-003-0872-9; Tao Y, 2003, PLANT CELL, V15, P317, DOI 10.1105/tpc.007591; Ulm R, 2002, EMBO J, V21, P6483, DOI 10.1093/emboj/cdf646; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WHALEN MC, 1993, MOL PLANT MICROBE IN, V6, P616, DOI 10.1094/MPMI-6-616; Yamakawa H, 2004, J BIOL CHEM, V279, P928, DOI 10.1074/jbc.M310277200; Yang KY, 2001, P NATL ACAD SCI USA, V98, P741, DOI 10.1073/pnas.98.2.741; YU ZH, 1995, GENETICS, V141, P675; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; Zhang SQ, 2001, TRENDS PLANT SCI, V6, P520, DOI 10.1016/S1360-1385(01)02103-3; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zhang SQ, 2001, PLANT CELL, V13, P1877, DOI 10.1105/tpc.13.8.1877; Zhang SQ, 2000, PLANT J, V23, P339, DOI 10.1046/j.1365-313x.2000.00780.x	48	64	69	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14819	14827		10.1074/jbc.M313388200	http://dx.doi.org/10.1074/jbc.M313388200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742423	hybrid			2022-12-27	WOS:000220594700042
J	Won, HS; Jung, SJ; Kim, HE; Seo, MD; Lee, BJ				Won, HS; Jung, SJ; Kim, HE; Seo, MD; Lee, BJ			Systematic peptide engineering and structural characterization to search for the shortest antimicrobial peptide analogue of gaegurin 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; PROTEIN SECONDARY STRUCTURE; TRYPTOPHANYL RESIDUES; BIOLOGICAL-ACTIVITIES; MEMBRANE-PROTEINS; NMR; MAGAININS; MICELLES; SKIN; DODECYLPHOSPHOCHOLINE	As part of an effort to develop new, low molecular mass peptide antibiotics, we searched for the shortest bioactive analogue of gaegurin 5 (GGN5), a 24-residue antimicrobial peptide. Thirty-one kinds of GGN5 analogues were synthesized, and their biological activities were analyzed against diverse microorganisms and human erythrocytes. The structural properties of the peptides in various solutions were characterized by spectroscopic methods. The N-terminal 13 residues of GGN5 were identified as the minimal requirement for biological activity. The helical stability, the amphipathic property, and the hydrophobic N terminus were characterized as the important structural factors driving the activity. To develop shorter antibiotic peptides, amino acid substitutions in an inactive 11-residue analogue were examined. Single tryptophanyl substitutions at certain positions yielded some active 11-residue analogues. The most effective site for the substitution was the hydrophobic-hydrophilic interface in the amphipathic helical structure. At this position, tryptophan was the most useful amino acid conferring favorable activity to the peptide. The introduced tryptophan played an important anchoring role for the membrane interaction of the peptides. Finally, two 11-residue analogues of GGN5, which exhibited strong bactericidal activity with little hemolytic activity, were obtained as property-optimized candidates for new peptide antibiotic development. Altogether, the present approach not only characterized some important factors for the antimicrobial activity but also provided useful information about peptide engineering to search for potent lead molecules for new peptide antibiotic development.	Seoul Natl Univ, Coll Pharm, Natl Res Lab Membrane Prot Struct, Seoul 151742, South Korea	Seoul National University (SNU)	Lee, BJ (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab Membrane Prot Struct, Seoul 151742, South Korea.	lbj@nmr.snu.ac.kr	Lee, Bong-Jin/AAQ-1609-2020	Lee, Bong-Jin/0000-0001-7896-2961				Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Chia CSB, 2002, FEBS LETT, V512, P47, DOI 10.1016/S0014-5793(01)03313-0; CSORDAS A, 1969, TOXICON, V7, P103, DOI 10.1016/0041-0101(69)90072-5; EFTINK MR, 1977, BIOCHEMISTRY-US, V16, P5546, DOI 10.1021/bi00644a024; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; Fernandez-Lopez S, 2001, NATURE, V412, P452, DOI 10.1038/35086601; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; Ge YG, 1999, ANTIMICROB AGENTS CH, V43, P782, DOI 10.1128/AAC.43.4.782; Golczak M, 2001, FEBS LETT, V496, P49, DOI 10.1016/S0014-5793(01)02402-4; Goraya J, 1999, PEPTIDES, V20, P159, DOI 10.1016/S0196-9781(98)00174-0; Goraya J, 2000, EUR J BIOCHEM, V267, P894, DOI 10.1046/j.1432-1327.2000.01074.x; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Houliston RS, 2003, FEBS LETT, V535, P39, DOI 10.1016/S0014-5793(02)03852-8; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; Jacqueline C, 2003, J ANTIMICROB CHEMOTH, V51, P857, DOI 10.1093/jac/dkg160; Jorgensen JH, 1998, CLIN INFECT DIS, V26, P973, DOI 10.1086/513938; Kim S, 1999, J BIOCHEM MOL BIOL, V32, P12; Lindberg M, 2001, FEBS LETT, V497, P39, DOI 10.1016/S0014-5793(01)02433-4; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MOR A, 1994, J BIOL CHEM, V269, P1934; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; Oren Z, 1998, BIOPOLYMERS, V47, P451; PARK JM, 1994, BIOCHEM BIOPH RES CO, V205, P948, DOI 10.1006/bbrc.1994.2757; Park S, 2001, FEBS LETT, V507, P95, DOI 10.1016/S0014-5793(01)02956-8; Park SH, 2000, EUR J BIOCHEM, V267, P2695, DOI 10.1046/j.1432-1327.2000.01287.x; Park SH, 2002, BIOCHEM J, V368, P171, DOI 10.1042/BJ20020385; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; Rozek A, 2000, BIOCHEMISTRY-US, V39, P15765, DOI 10.1021/bi000714m; Schibli DJ, 1999, BIOCHEMISTRY-US, V38, P16749, DOI 10.1021/bi990701c; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Subbalakshmi C, 2001, J PEPT RES, V57, P59, DOI 10.1034/j.1399-3011.2001.00800.x; Subbalakshmi C, 1999, FEBS LETT, V448, P62, DOI 10.1016/S0014-5793(99)00328-2; Townsley LE, 2001, BIOCHEMISTRY-US, V40, P11676, DOI 10.1021/bi010942w; Wade D, 2000, FEBS LETT, V479, P6, DOI 10.1016/S0014-5793(00)01754-3; Wang GS, 1996, BBA-LIPID LIPID MET, V1301, P174, DOI 10.1016/0005-2760(96)00037-9; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; Wienk HLJ, 1999, FEBS LETT, V453, P318, DOI 10.1016/S0014-5793(99)00653-5; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Won HS, 2002, EUR J BIOCHEM, V269, P4367, DOI 10.1046/j.1432-1033.2002.03139.x; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yoon MK, 2000, FEBS LETT, V484, P241, DOI 10.1016/S0014-5793(00)02160-8; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	46	65	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14784	14791		10.1074/jbc.M309822200	http://dx.doi.org/10.1074/jbc.M309822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739294	hybrid			2022-12-27	WOS:000220594700038
J	Li, CH; Buettger, C; Kwagh, J; Matter, A; Daikhin, Y; Nissim, IB; Collins, HW; Yudkoff, M; Stanley, CA; Matschinsky, FM				Li, CH; Buettger, C; Kwagh, J; Matter, A; Daikhin, Y; Nissim, IB; Collins, HW; Yudkoff, M; Stanley, CA; Matschinsky, FM			A signaling role of glutamine in insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL HYPERINSULINISM; SULFONYLUREA RECEPTOR; GLUCOSE; ISLETS; CHILDREN; LEUCINE; MICE; GLUCOKINASE; MESSENGER; MUTATIONS	Children with hypoglycemia due to recessive loss of function mutations of the beta-cell ATP-sensitive potassium (K-ATP) channel can develop hypoglycemia in response to protein feeding. We hypothesized that amino acids might stimulate insulin secretion by unknown mechanisms, because the K-ATP channel-dependent pathway of insulin secretion is defective. We therefore investigated the effects of amino acids on insulin secretion and intracellular calcium in islets from normal and sulfonylurea receptor 1 knockout (SUR1-/-) mice. Even though SUR1-/- mice are euglycemic, their islets are considered a suitable model for studies of the human genetic defect. SUR1-/- islets, but not normal islets, released insulin in response to an amino acid mixture ramp. This response to amino acids was decreased by 60% when glutamine was omitted. Insulin release by SUR1-/- islets was also stimulated by a ramp of glutamine alone. Glutamine was more potent than leucine or dimethyl glutamate. Basal intracellular calcium was elevated in SUR1-/- islets and was increased further by glutamine. In normal islets, methionine sulfoximine, a glutamine synthetase inhibitor, suppressed insulin release in response to a glucose ramp. This inhibition was reversed by glutamine or by 6-diazo-5-oxo-L-norleucine, a non-metabolizable glutamine analogue. High glucose doubled glutamine levels of islets. Methionine sulfoximine inhibition of glucose stimulated insulin secretion was associated with accumulation of glutamate and aspartate. We hypothesize that glutamine plays a critical role as a signaling molecule in amino acid- and glucose-stimulated insulin secretion, and that beta-cell depolarization and subsequent intracellular calcium elevation are required for this glutamine effect to occur.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Endocrinol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Child Dev & Pediat Rehabil, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Diabet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Matschinsky, FM (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	matsch@mail.med.upenn.edu		STANLEY, CHARLES/0000-0003-4881-9392	NICHD NIH HHS [HD 26979] Funding Source: Medline; NIDDK NIH HHS [DK 19525, R01 DK53012, R01 DK56268] Funding Source: Medline; NINDS NIH HHS [NS 37915] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK056268, R01DK053012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRICK BA, 1983, J CLIN INVEST, V71, P258, DOI 10.1172/JCI110766; Bertrand G, 2002, J BIOL CHEM, V277, P32883, DOI 10.1074/jbc.M205326200; Doliba NM, 2003, DIABETES, V52, P394, DOI 10.2337/diabetes.52.2.394; Dura E, 2002, INT J MOL MED, V9, P527; FOURTNER SH, 2003, END SOC 85 ANN M JUN; Gao Z, 1999, DIABETES, V48, P1535, DOI 10.2337/diabetes.48.8.1535; Grimberg A, 2001, DIABETES, V50, P322, DOI 10.2337/diabetes.50.2.322; Kelly A, 2001, J CLIN ENDOCR METAB, V86, P3724, DOI 10.1210/jc.86.8.3724; KELLY A, 2003, END SOC 85 ANN M JUN; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; Liu YJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE380, DOI 10.1152/ajpendo.00008.2003; MacDonald MJ, 2000, J BIOL CHEM, V275, P34025, DOI 10.1074/jbc.C000411200; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Matschinsky FM, 2002, DIABETES, V51, pS394, DOI 10.2337/diabetes.51.2007.S394; MEISTER A, 1985, METHOD ENZYMOL, V113, P185; Meister A., 1980, GLUTAMINE METABOLISM, P1; MICHALIK M, 1992, METABOLISM, V41, P1319, DOI 10.1016/0026-0495(92)90102-G; SCHWENK WF, 1984, ANAL BIOCHEM, V141, P101; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Shiota C, 2002, J BIOL CHEM, V277, P37176, DOI 10.1074/jbc.M206757200; Stanley CA, 2002, J CLIN ENDOCR METAB, V87, P4857, DOI 10.1210/jc.2002-021403; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Thornton PS, 2003, DIABETES, V52, P2403, DOI 10.2337/diabetes.52.9.2403; Vatamaniuk M, 2003, DIABETES, V52, pA374	25	117	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13393	13401		10.1074/jbc.M311502200	http://dx.doi.org/10.1074/jbc.M311502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736887	hybrid			2022-12-27	WOS:000220478500016
J	Stovall, SH; Yi, AK; Meals, EA; Talati, AJ; Godambe, SA; English, BK				Stovall, SH; Yi, AK; Meals, EA; Talati, AJ; Godambe, SA; English, BK			Role of vav1- and src-related tyrosine kinases in macrophage activation by CpG DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MURINE MACROPHAGES; CELL-ACTIVATION; BACTERIAL-DNA; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; INOS PRODUCTION; INHIBITOR PP1; LIPOPOLYSACCHARIDE; PHOSPHORYLATION	Macrophage activation by CpG DNA requires toll-like receptor 9 and the adaptor protein MyD88. Gram-negative bacterial lipopolysaccharide also activates macrophages via a toll-like receptor pathway (TLR-4), but we and others have reported that lipopolysaccharide also stimulates tyrosine phosphorylation in macrophages. Herein we report that exposure of RAW 264.7 murine macrophages to CpG DNA ( but not non-CpG DNA) provoked the rapid tyrosine phosphorylation of vav1. PP1, a selective inhibitor of src-related tyrosine kinases, blocked both the CpG DNA-mediated tyrosine phosphorylation of vav1 and the CpG DNA-mediated up-regulation of macrophage tumor necrosis factor secretion and inducible nitric-oxide synthase protein accumulation. Furthermore, we found that the inducible expression of any of three dominant interfering mutants of vav1 ( a truncated protein, vavC; a form containing a point mutation in the regulatory tyrosine residue, vavYF174; and a form with an in-frame deletion of six amino acids required for the guanidine nucleotide exchange factor (GEF) activity of vav1 for rac family GTPases, vavGEFmt) consistently inhibited CpG DNA-mediated up-regulation of tumor necrosis factor secretion and inducible nitric-oxide synthase protein accumulation in RAW-TT10 macrophages. Finally, we determined that CpG DNA-mediated up-regulation of NF-kappaB activity ( but not mitogen-activated protein kinase activation) was inhibited by preincubation with PP1 or by expression of the truncated vavC mutant. Taken together, our results indicate that the tyrosine phosphorylation of vav1 by a src-related tyrosine kinase or kinases plays an important role in the macrophage response to CpG DNA.	Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Dept Pediat, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Div Infect Dis, Memphis, TN 38103 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Div Emergency Med, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Obstet & Gynecol, Div Neonatol, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	English, BK (corresponding author), Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Dept Pediat, 50 N Dunlap, Memphis, TN 38103 USA.	kenglish@utmem.edu	Talati, Ajay/AGY-6999-2022	Talati, Ajay/0000-0003-1798-9970	NIAMS NIH HHS [1R03AR47757] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047757] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Akira S, 2003, J INFECT DIS, V187, pS356, DOI 10.1086/374749; BEATY CD, 1994, EUR J IMMUNOL, V24, P1278, DOI 10.1002/eji.1830240606; Beutler B, 2002, CURR OPIN HEMATOL, V9, P2, DOI 10.1097/00062752-200201000-00002; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Choi KS, 2001, J VIROL, V75, P1949, DOI 10.1128/JVI.75.4.1949-1957.2001; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; English BK, 1997, J LEUKOCYTE BIOL, V62, P859, DOI 10.1002/jlb.62.6.859; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Orlicek SL, 1999, SHOCK, V12, P350, DOI 10.1097/00024382-199911000-00004; Orlicek SL, 1996, J INFECT DIS, V174, P638, DOI 10.1093/infdis/174.3.638; Schnare M, 2000, CURR BIOL, V10, P1139, DOI 10.1016/S0960-9822(00)00700-4; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Stacey KJ, 1996, J IMMUNOL, V157, P2116; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Utaisincharoen P, 2002, CLIN EXP IMMUNOL, V128, P467, DOI 10.1046/j.1365-2249.2002.01866.x; Weiner GJ, 2000, J LEUKOCYTE BIOL, V68, P455; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WU J, 1995, MOL CELL BIOL, V15, P4337; Yeo SJ, 2003, J BIOL CHEM, V278, P40590, DOI 10.1074/jbc.M306280200; Yeo SJ, 2003, J IMMUNOL, V170, P1052, DOI 10.4049/jimmunol.170.2.1052	33	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13809	13816		10.1074/jbc.M311434200	http://dx.doi.org/10.1074/jbc.M311434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14749335	hybrid			2022-12-27	WOS:000220478500066
J	Jin, YT; Zeng, SX; Lee, H; Lu, H				Jin, YT; Zeng, SX; Lee, H; Lu, H			MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID-RECEPTOR; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; FEEDBACK LOOP; IN-VITRO; P53; ACTIVATION; PROMOTES	We recently reported that MDM2, a negative feedback regulator of the tumor suppressor p53, inhibits p300/CREB-binding protein-associated factor (PCAF)-mediated p53 acetylation. Our further study showed that MDM2 also regulates the stability of PCAF. MDM2 ubiquitinated PCAF in vitro and in cells. PCAF ubiquitination occurred at the N terminus and in the nucleus, as the nuclear localization signal sequence-deletion mutant of MDM2, which localized in the cytoplasm and degraded p53, was unable to degrade nuclear PCAF. Restriction of PCAF in the nucleus by leptomycin B did not affect MDM2-mediated PCAF degradation. Consistently, overexpression of MDM2 in p53 null cells caused the reduction of the protein level of PCAF, but not the mRNA level. Conversely, PCAF levels were higher in MDM2-deficient mouse p53(-/-)/mdm2(-/-) embryonic fibroblast (MEF) cells than that in MDM2-containing MEF cells. Furthermore, MDM2 reduced the half-life of PCAF by 50%. These results demonstrate that MDM2 regulates the stability of PCAF by ubiquitinating and degrading this protein.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Lu, H (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	luh@ohsu.edu			NCI NIH HHS [CA 079721, CA 95441, CA 93614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093614, R01CA079721, R01CA095441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Colledge M, 2003, NEURON, V40, P595, DOI 10.1016/S0896-6273(03)00687-1; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu L, 1999, MOL CELL BIOL, V19, P1202; LUNA RMD, 1995, NATURE, V378, P203; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 2000, CANCER RES, V60, P6184; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	60	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20035	20043		10.1074/jbc.M309916200	http://dx.doi.org/10.1074/jbc.M309916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14769800	hybrid			2022-12-27	WOS:000221164500079
J	Farr, CL; Matsushima, Y; Lagina, AT; Luo, NG; Kaguni, LS				Farr, CL; Matsushima, Y; Lagina, AT; Luo, NG; Kaguni, LS			Physiological and biochemical defects in functional interactions of mitochondrial DNA polymerase and DNA-binding mutants of single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SSB; DROSOPHILA-MELANOGASTER; REPLICATION BUBBLE; SUBUNIT; EMBRYOS; BURST; TETRAMERIZATION; PURIFICATION; INITIATION; NUCLEAR	Functional interactions between mitochondrial DNA polymerase (pol gamma) and mitochondrial single-stranded DNA-binding protein (mtSSB) from Drosophila embryos greatly enhance the overall activity of pol gamma by increasing primer recognition and binding and stimulating the rate of initiation of DNA strands (Farr, C. L., Wang, Y., and Kaguni, L. S. (1999) J. Biol. Chem. 274, 14779-14785). We show here that DNA-binding mutants of mtSSB are defective in stimulation of DNA synthesis by pol gamma. RNAi knock-down of mtSSB reduces expression to < 5% of its normal level in Schneider cells, resulting in growth defects and in the depletion of mitochondrial DNA (mtDNA). Overexpression of mtSSB restores cell growth rate and the copy number of mtDNA, whereas overexpression of a DNA-binding and functionally impaired form of mtSSB neither rescues the cell growth defect nor the mtDNA depletion phenotype. Further development of Drosophila animal models, in which induced mtDNA depletion is manipulated by controlling exogenous expression of wild-type or mutant forms, will offer new insight into the mechanism and progression of human mtDNA depletion syndromes and possible intervention schemes.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.		Lagina, Anthony/AAO-2806-2020	Lagina, Anthony/0000-0002-9121-8712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4; Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P404, DOI 10.1016/S0968-0004(03)00165-8; Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CURTH U, 1991, EUR J BIOCHEM, V196, P87, DOI 10.1111/j.1432-1033.1991.tb15789.x; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; CURTH U, 1993, BIOCHEMISTRY-US, V32, P2585, DOI 10.1021/bi00061a016; de Mena IR, 2000, J BIOL CHEM, V275, P13628, DOI 10.1074/jbc.275.18.13628; Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefai E, 2000, J BIOL CHEM, V275, P33123, DOI 10.1074/jbc.M003024200; Lefai E, 2000, MOL GEN GENET, V264, P37, DOI 10.1007/s004380000301; Li K, 1997, J BIOL CHEM, V272, P8686, DOI 10.1074/jbc.272.13.8686; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Maier D, 2001, MOL BIOL CELL, V12, P821, DOI 10.1091/mbc.12.4.821; MIGNOTTE B, 1985, NUCLEIC ACIDS RES, V13, P1703, DOI 10.1093/nar/13.5.1703; OLSON MW, 1992, J BIOL CHEM, V267, P23136; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; SRERE PA, 1980, TRENDS BIOCHEM SCI, V5, P120, DOI 10.1016/0968-0004(80)90051-1; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9; Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2	37	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17047	17053		10.1074/jbc.M400283200	http://dx.doi.org/10.1074/jbc.M400283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14754882	hybrid			2022-12-27	WOS:000220870400021
J	Li, HT; Samouilov, A; Liu, XP; Zweier, JL				Li, HT; Samouilov, A; Liu, XP; Zweier, JL			Characterization of the effects of oxygen on xanthine oxidase-mediated nitric oxide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; SUPEROXIDE-DISMUTASE; POSTISCHEMIC HEART; BIOLOGICAL-SYSTEMS; RELAXING FACTOR; ANOXIC TISSUES; PEROXYNITRITE; REDUCTION; SYNTHASE; INJURY	Under anaerobic conditions, xanthine oxidase (XO)-catalyzed nitrite reduction can be an important source of nitric oxide (NO). However, questions remain regarding whether significant XO-mediated NO generation also occurs under aerobic conditions. Therefore, electron paramagnetic resonance, chemiluminescence NO-analyzer, and NO-electrode studies were performed to characterize the kinetics and magnitude of XO-mediated nitrite reduction as a function of oxygen tension. With substrates xanthine or 2,3-dihydroxy-benz-aldehyde that provide electrons to XO at the molybdenum site, the rate of NO production followed Michaelis-Menten kinetics, and oxygen functioned as a competitive inhibitor of nitrite reduction. However, with flavin-adenine dinucleotide site-binding substrate NADH as electron donor, aerobic NO production was maintained at more than 70% of anaerobic levels, and binding of NADH to the flavin-adenine dinucleotide site seemed to prevent oxygen binding. Therefore, under aerobic conditions, NADH would be the main electron donor for XO-catalyzed NO production in tissues. Studies of the pH dependence of NO formation indicated that lower pH values decrease oxygen reduction but greatly increase nitrite reduction, facilitating NO generation. Isotope tracer studies demonstrated that XO-mediated NO formation occurs in normoxic and hypoxic heart tissue. Thus, XO-mediated NO generation occurs under aerobic conditions and is regulated by oxygen tension, pH, nitrite, and reducing substrate concentrations.	Davis Heart & Lung Res Inst, Ctr Biomed EPR Spect & Imaging, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Internal Med, Div Cardiovasc Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Zweier, JL (corresponding author), Davis Heart & Lung Res Inst 110G, 473 W 12th Ave, Columbus, OH 43210 USA.	zweier-1@medctr.osu.edu	Samouilov, Alexandre/E-4010-2011; Samouilov, Alexandre/B-5824-2014; Liu, Xiaoping/A-4516-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608, R29HL038324, R01HL063744, R01HL038324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL65608, HL63744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RF, 1986, J BIOL CHEM, V261, P5870; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; GREGORY EM, 1973, J BACTERIOL, V114, P1193, DOI 10.1128/JB.114.3.1193-1197.1973; HILLE R, 1981, J BIOL CHEM, V256, P9090; HILLE R, 1986, J BIOL CHEM, V261, P1241; Hiramoto K, 1997, FREE RADICAL RES, V27, P505, DOI 10.3109/10715769709065790; HUKKANEN M, 1995, ENDOCRINOLOGY, V136, P5445, DOI 10.1210/en.136.12.5445; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KINGENBERG M, 1960, BEDEUTUNG FREIEN NUC, V11, P82; Kirsch M, 1999, J BIOL CHEM, V274, P24664, DOI 10.1074/jbc.274.35.24664; KUROBE N, 1990, CLIN CHIM ACTA, V187, P11, DOI 10.1016/0009-8981(90)90257-S; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Lynch SM, 1997, ARTERIOSCL THROM VAS, V17, P2975, DOI 10.1161/01.ATV.17.11.2975; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; MONCADA S, 1991, PHARMACOL REV, V43, P109; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PETKAU A, 1975, BIOCHEM BIOPH RES CO, V65, P886, DOI 10.1016/S0006-291X(75)80468-2; Roy S, 2003, CIRC RES, V92, P264, DOI 10.1161/01.RES.0000056770.30922.E6; Salem JE, 2002, ANN BIOMED ENG, V30, P202, DOI 10.1114/1.1454133; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Torre D, 1996, CLIN INFECT DIS, V22, P650, DOI 10.1093/clinids/22.4.650; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; Tsuchiya K, 2000, J BIOL CHEM, V275, P1551, DOI 10.1074/jbc.275.3.1551; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	40	108	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16939	16946		10.1074/jbc.M314336200	http://dx.doi.org/10.1074/jbc.M314336200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766900	hybrid			2022-12-27	WOS:000220870400008
J	Lin, C; Lin, K; Luong, YP; Rao, BG; Wei, YY; Brennan, DL; Fulghum, JR; Hsiao, HM; Ma, S; Maxwell, JP; Cottrell, KM; Perni, RB; Gates, CA; Kwong, AD				Lin, C; Lin, K; Luong, YP; Rao, BG; Wei, YY; Brennan, DL; Fulghum, JR; Hsiao, HM; Ma, S; Maxwell, JP; Cottrell, KM; Perni, RB; Gates, CA; Kwong, AD			In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NS3 PROTEASE; CRYSTAL-STRUCTURE; NS4A COFACTOR; PROTEINASE; REPLICATION; CLEAVAGE; INTERFERON-ALPHA-2B; COMBINATION; RIBAVIRIN; VARIANTS	We have used a structure-based drug design approach to identify small molecule inhibitors of the hepatitis C virus (HCV) NS3.4A protease as potential candidates for new anti-HCV therapies. VX-950 is a potent NS3.4A protease inhibitor that was recently selected as a clinical development candidate for hepatitis C treatment. In this report, we describe in vitro resistance studies using a subgenomic replicon system to compare VX-950 with another HCV NS3.4A protease inhibitor, BILN 2061, for which the Phase I clinical trial results were reported recently. Distinct drug-resistant substitutions of a single amino acid were identified in the HCV NS3 serine protease domain for both inhibitors. The resistance conferred by these mutations was confirmed by characterization of the mutant enzymes and replicon cells that contain the single amino acid substitutions. The major BILN 2061-resistant mutations at Asp(168) are fully susceptible to VX-950, and the dominant resistant mutation against VX-950 at Ala(156) remains sensitive to BILN 2061. Modeling analysis suggests that there are different mechanisms of resistance to VX-950 and BILN 2061.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	Lin, C (corresponding author), Vertex Pharmaceut Inc, 130 Waverly St, Cambridge, MA 02139 USA.	chao_lin@vrtx.com						Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; BABINE R, 2002, Patent No. 0218369; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Blight KJ, 1998, ANTIVIR THER, V3, P71; Chander G, 2002, HEPATOLOGY, V36, pS135, DOI 10.1053/jhep.2002.37146; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; De Francesco R, 2003, ANTIVIR RES, V58, P1, DOI 10.1016/S0166-3542(03)00028-7; Di Marco S, 2000, J BIOL CHEM, V275, P7152, DOI 10.1074/jbc.275.10.7152; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Kenny-Walsh E, 2001, Clin Liver Dis, V5, P969, DOI 10.1016/S1089-3261(05)70204-X; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lai CL, 2003, CLIN INFECT DIS, V36, P687, DOI 10.1086/368083; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Nguyen TT, 2003, ANTIMICROB AGENTS CH, V47, P3525, DOI 10.1128/AAC.47.11.3525-3530.2003; Perni RB, 2004, BIOORG MED CHEM LETT, V14, P1441, DOI 10.1016/j.bmcl.2004.01.022; Perni RB, 2003, HEPATOLOGY, V38, p624A; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Tsantrizos YS, 2003, ANGEW CHEM INT EDIT, V42, P1355, DOI 10.1002/anie.200390347; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8	40	253	292	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17508	17514		10.1074/jbc.M313020200	http://dx.doi.org/10.1074/jbc.M313020200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766754	hybrid			2022-12-27	WOS:000220870400078
J	Zhong, XL; Safa, AR				Zhong, XL; Safa, AR			RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; POLYMERASE-II; DNA; PROTEIN; CBP; EXPRESSION; PROMOTER; DEATH; ACETYLTRANSFERASE; PHOSPHORYLATION	RNA helicase A (RHA) is a member of the DEAD/H family of RNA helicases and unwinds duplex RNA and DNA. Recent studies have shown that RHA regulates the activity of gene promoters. However, little information is available about the in vivo relevance of RHA in the regulation of natural genes. We previously characterized a nuclear protein (MEF1) that binds to the proximal promoter of the multidrug resistance gene (MDR1) and up-regulates the promoter activity. In the present study, we isolated and identified RHA as a component of the MEF1 complex by using DNA-affinity chromatography and mass spectrometry. The antibody against RHA specifically disrupted the complex formation in electrophoretic mobility shift assay, confirming the identity of RHA. Western blotting showed that RHA in drug-resistant cells had a higher molecular weight than that in drug-sensitive cells. Similar results were obtained when FLAG-tagged RHA was overexpressed in these cells. This size difference probably reflects posttranslational modification(s) of RHA in drug-resistant cells. Chromatin immunoprecipitation revealed that RHA occupies the MDR1 promoter in vivo. Overexpression of RHA enhanced expression of the MDR1 promoter/reporter construct and endogenous P-glycoprotein (P-gp), the MDR1 gene product, and increased drug resistance of drug-resistant cells but not the drug-sensitive counterpart. Introduction of short interfering RNA targeting the RHA gene sequence selectively knocked-down RHA expression and concomitantly reduced P-gp level. Thus, our study demonstrates, for the first time, the involvement of RHA in up-regulation of the MDR1 gene. Interactions of RHA with other protein factors in the MEF1 complex bound to the promoter element may contribute to P-gp overexpression and multidrug resistance phenotype in drug-resistant cancer cells.	Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Safa, AR (corresponding author), Dept Pharmacol & Toxicol, 1044 W Walnut R4-119, Indianapolis, IN 46202 USA.	asafa@iupui.edu			NATIONAL CANCER INSTITUTE [R01CA090878, R01CA101743, R01CA080734] Funding Source: NIH RePORTER; NCI NIH HHS [CA 101743, CA 90878, CA 080734] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; Fujita H, 2003, MOL CELL BIOL, V23, P2645, DOI 10.1128/MCB.23.8.2645-2657.2003; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUILD BC, 1988, P NATL ACAD SCI USA, V85, P1595, DOI 10.1073/pnas.85.5.1595; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5; LEE CG, 1993, J BIOL CHEM, V268, P16822; LEE CG, 1992, J BIOL CHEM, V267, P4398; Matarrese P, 2001, BIOCHEM J, V355, P587, DOI 10.1042/bj3550587; McManus KJ, 2001, BIOCHEM CELL BIOL, V79, P253, DOI 10.1139/bcb-79-3-253; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Ruefli A, 2002, CELL DEATH DIFFER, V9, P1266, DOI 10.1038/sj.cdd.4401081; Ruefli AA, 2002, INT J CANCER, V99, P292, DOI 10.1002/ijc.10327; Safa AR, 1998, METHOD ENZYMOL, V292, P289; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; SHEN DW, 1986, MOL CELL BIOL, V6, P4039, DOI 10.1128/MCB.6.11.4039; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Yang JP, 2001, J BIOL CHEM, V276, P30694, DOI 10.1074/jbc.M102809200; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; Zhang SS, 1997, J BIOL CHEM, V272, P11487; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o; Zhou K, 2003, NUCLEIC ACIDS RES, V31, P2253, DOI 10.1093/nar/gkg328	39	31	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17134	17141		10.1074/jbc.M311057200	http://dx.doi.org/10.1074/jbc.M311057200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769796	hybrid			2022-12-27	WOS:000220870400032
J	Ahmad, A; Millett, IS; Doniach, S; Uversky, VN; Fink, AL				Ahmad, A; Millett, IS; Doniach, S; Uversky, VN; Fink, AL			Stimulation of insulin fibrillation by urea-induced intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-FIBRIL; ALPHA-SYNUCLEIN; MONOMERIC INSULIN; X-RAY; CONFORMATIONAL BEHAVIOR; ASSOCIATION STATE; CALCIUM-BINDING; PROTEIN; AGGREGATION; ASSIGNMENT	Fibrillar deposits of insulin cause serious problems in implantable insulin pumps, commercial production of insulin, and for some diabetics. We performed a systematic investigation of the effect of urea-induced structural perturbations on the mechanism of fibrillation of insulin. The addition of as little as 0.5 M urea to zinc-bound hexameric insulin led to dissociation into dimers. Moderate concentrations of urea led to accumulation of a partially unfolded dimer state, which dissociates into an expanded, partially folded monomeric state. Very high concentrations of urea resulted in an unfolded monomer with some residual structure. The addition of even very low concentrations of urea resulted in increased fibrillation. Accelerated fibrillation correlated with population of the partially folded intermediates, which existed at up to 8 M urea, accounting for the formation of substantial amounts of fibrils under such conditions. Under monomeric conditions the addition of low concentrations of urea slowed down the rate of fibrillation, e. g. 5-fold at 0.75 M urea. The decreased fibrillation of the monomer was due to an induced non-native conformation with significantly increased alpha-helical content compared with the native conformation. The data indicate a close-knit relationship between insulin conformation and propensity to fibrillate. The correlation between fibrillation and the partially unfolded monomer indicates that the latter is a critical amyloidogenic intermediate in insulin fibrillation.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	University of California System; University of California Santa Cruz; Stanford University; Stanford University	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	fink@chemistry.ucsc.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857; Ahmad, Atta/0000-0002-6968-192X				Ahmad A, 2003, BIOCHEMISTRY-US, V42, P11404, DOI 10.1021/bi034868o; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Brange J, 1997, J PHARM SCI, V86, P517, DOI 10.1021/js960297s; Brange J, 1997, PROTEINS, V27, P507, DOI 10.1002/(SICI)1097-0134(199704)27:4<507::AID-PROT4>3.3.CO;2-H; Brange J, 1993, Pharm Biotechnol, V5, P315; BREMS DN, 1990, BIOCHEMISTRY-US, V29, P9289, DOI 10.1021/bi00491a026; BRYANT C, 1992, BIOCHEMISTRY-US, V31, P5692, DOI 10.1021/bi00140a002; BURKE MJ, 1972, BIOCHEMISTRY-US, V11, P2435, DOI 10.1021/bi00763a008; Burstein E. A., 1976, INTRINSIC PROTEIN FL; Bushmarina NA, 2001, CHEMBIOCHEM, V2, P813, DOI 10.1002/1439-7633(20011105)2:11<813::AID-CBIC813>3.0.CO;2-W; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Chang XQ, 1997, BIOCHEMISTRY-US, V36, P9409, DOI 10.1021/bi9631069; Chiti F, 2002, P NATL ACAD SCI USA, V99, P16419, DOI 10.1073/pnas.212527999; DISCHE FE, 1988, DIABETOLOGIA, V31, P158, DOI 10.1007/BF00276849; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Doniach S, 2001, CHEM REV, V101, P1763, DOI 10.1021/cr990071k; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Glatter O., 1982, SMALL ANGLE XRAY SCA; GLENNER GG, 1981, PROG HISTOCHEM CYTOC, V13, P1; Goers J, 2002, BIOCHEMISTRY-US, V41, P12546, DOI 10.1021/bi0262698; Hamada D, 2002, PROTEIN SCI, V11, P2417, DOI 10.1110/ps.0217702; Hasegawa K, 2003, BIOCHEM BIOPH RES CO, V304, P101, DOI 10.1016/S0006-291X(03)00543-6; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kuznetsova IM, 2002, BBA-PROTEIN STRUCT M, V1596, P138, DOI 10.1016/S0167-4838(02)00212-1; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Li J, 2002, NEUROTOXICOLOGY, V23, P553, DOI 10.1016/S0161-813X(02)00066-9; Malisauskas M, 2003, J MOL BIOL, V330, P879, DOI 10.1016/S0022-2836(03)00551-5; MILLICAN RL, 1994, BIOCHEMISTRY-US, V33, P1116, DOI 10.1021/bi00171a010; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nettleton EJ, 2000, BIOPHYS J, V79, P1053, DOI 10.1016/S0006-3495(00)76359-4; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P8397, DOI 10.1021/bi0105983; Nilsson MR, 2003, BIOCHEMISTRY-US, V42, P375, DOI 10.1021/bi0204746; PERMYAKOV EA, 1980, EUR J BIOCHEM, V109, P307, DOI 10.1111/j.1432-1033.1980.tb04796.x; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Roher AE, 2000, BBA-MOL BASIS DIS, V1502, P31, DOI 10.1016/S0925-4439(00)00030-2; Scrocchi LA, 2002, J MOL BIOL, V318, P697, DOI 10.1016/S0022-2836(02)00164-X; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SLUZKY V, 1992, BIOTECHNOL BIOENG, V40, P895, DOI 10.1002/bit.260400805; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; Souillac PO, 2002, J BIOL CHEM, V277, P12657, DOI 10.1074/jbc.M109230200; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Uversky V.N., 1999, MED SCI MONITOR, V5, P1001; Uversky V.N., 1999, MED SCI MONITOR, V5, P1238; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2003, J PHARM SCI, V92, P847, DOI 10.1002/jps.10355; Uversky VN, 2002, J BIOL CHEM, V277, P11970, DOI 10.1074/jbc.M109541200; WAUGH DF, 1953, J AM CHEM SOC, V75, P2592, DOI 10.1021/ja01107a013; WEISS MA, 1989, BIOCHEMISTRY-US, V28, P9855, DOI 10.1021/bi00451a046; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; Whittingham JL, 2002, J MOL BIOL, V318, P479, DOI 10.1016/S0022-2836(02)00021-9; Yao ZP, 1999, ACTA CRYSTALLOGR D, V55, P1524, DOI 10.1107/S0907444999008562; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x	61	93	93	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14999	15013		10.1074/jbc.M313134200	http://dx.doi.org/10.1074/jbc.M313134200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736893	hybrid			2022-12-27	WOS:000220594700064
J	Mikhailov, VS; Okano, K; Rohrmann, GF				Mikhailov, VS; Okano, K; Rohrmann, GF			Specificity of the endonuclease activity of the baculovirus alkaline nuclease for single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; BINDING PROTEIN ICP8; VIRAL-DNA; IN-VITRO; HOMOLOGOUS RECOMBINATION; BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; LATE FACTOR-1; 2 STRAINS; REPLICATION	The Autographa californica multiple nucleocapsid nucleopolyhedrovirus ( AcMNPV) alkaline nuclease ( AN) likely participates in the maturation of virus genomes and in DNA recombination. AcMNPV AN was expressed in a recombinant baculovirus as a His(6)-tagged fusion and obtained in pure form (*AN) or as a complex with the baculoviral single-stranded DNA-binding protein LEF-3 (*AN/L3). Both AN preparations possessed potent 5' --> 3'-exonuclease and weak endonuclease activities. Mutant *AN(S146A)/L3 with a change from serine to alanine at position 146 in a conservative motif was impaired in both activities. This proved that the endonuclease is an intrinsic activity of baculovirus AN. The AN endonuclease showed specificity for single-stranded DNA and converted supercoiled plasmid DNA ( replicative form I, RFI) into the open circular form (RFII) by a single strand break. Plasmid DNA relaxed with topoisomerase I was resistant to *AN/L3 indicating that the partially single-stranded regions in negatively supercoiled molecules served as targets for the endonuclease. Unwinding the supercoiled DNA with ethidium bromide also made DNA resistant to AN/L3. In reactions with nicked circular DNA ( RFII), AN and AN/L3 hydrolyzed exonucleolytically the broken strand or cut endonucleolytically the intact strand at the position opposite the nick ( gap). When LEF-3 was added to the assay, the balance between the exonucleolytic and endonucleolytic modes of hydrolysis shifted in favor of the exonuclease. The data suggest that the AN endonuclease may digest the intermediates in replication and recombination at positions of structural irregularities in DNA duplexes, whereas LEF-3 may further regulate processing of the intermediates by AN via the endonuclease and exonuclease pathways.	Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Russian Acad Sci, NK Koltsov Dev Biol Inst, Moscow 117808, Russia	Oregon State University; Russian Academy of Sciences	Mikhailov, VS (corresponding author), Oregon State Univ, Dept Microbiol, Nash Hall 220, Corvallis, OR 97331 USA.	Victor.Mikhailov@orst.edu	Mikhailov, Victor S/O-2063-2016	Mikhailov, Victor/0000-0002-3324-8921	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM099825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM9982536] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHRENS CH, 1995, VIROLOGY, V212, P650, DOI 10.1006/viro.1995.1523; Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; Bataille D, 1995, BIOCHIMIE, V77, P787, DOI 10.1016/0300-9084(96)88197-1; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; Bronstein JC, 1996, J VIROL, V70, P2008, DOI 10.1128/JVI.70.3.2008-2013.1996; Bujnicki JM, 2001, VIRUS GENES, V22, P219, DOI 10.1023/A:1008131810233; CROIZIER G, 1992, VIRUS RES, V26, P183, DOI 10.1016/0168-1702(92)90012-X; DEAN WW, 1971, NATURE-NEW BIOL, V231, P5; DRAPER KG, 1986, J VIROL, V57, P1023, DOI 10.1128/JVI.57.3.1023-1036.1986; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; DUTCH RE, 1995, J VIROL, V69, P3084, DOI 10.1128/JVI.69.5.3084-3089.1995; FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641; FRANCKE B, 1978, J VIROL, V26, P209, DOI 10.1128/JVI.26.2.209-213.1978; Fu XP, 2002, J VIROL, V76, P5866, DOI 10.1128/JVI.76.12.5866-5874.2002; Goldstein JN, 1998, J VIROL, V72, P8772, DOI 10.1128/JVI.72.11.8772-8781.1998; Hajos JP, 2000, ARCH VIROL, V145, P159, DOI 10.1007/s007050050012; Harwood SH, 1998, VIROLOGY, V250, P118, DOI 10.1006/viro.1998.9334; Hayakawa T, 2000, VIROLOGY, V278, P1, DOI 10.1006/viro.2000.0668; Herniou EA, 2001, J VIROL, V75, P8117, DOI 10.1128/JVI.75.17.8117-8126.2001; HOFFMANN PJ, 1981, J VIROL, V38, P1005, DOI 10.1128/JVI.38.3.1005-1014.1981; HOFFMANN PJ, 1979, J VIROL, V32, P449, DOI 10.1128/JVI.32.2.449-457.1979; Kehm E, 1998, INTERVIROLOGY, V41, P110, DOI 10.1159/000024922; KOOL M, 1994, P NATL ACAD SCI USA, V91, P11212, DOI 10.1073/pnas.91.23.11212; KOOL M, 1995, J GEN VIROL, V76, P2103, DOI 10.1099/0022-1317-76-9-2103; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISY DJ, 1993, VIROLOGY, V196, P722, DOI 10.1006/viro.1993.1529; Li LL, 2000, J VIROL, V74, P6401, DOI 10.1128/JVI.74.14.6401-6407.2000; LU A, 1995, J VIROL, V69, P975, DOI 10.1128/JVI.69.2.975-982.1995; LU A, 1997, BACULOVIRUSES, P171; Mainz D, 2002, J VIROL, V76, P5198, DOI 10.1128/JVI.76.10.5198-5207.2002; Maniatis T., 1989, MOL CLONING LAB MAN; Martinez R, 1996, J VIROL, V70, P2075, DOI 10.1128/JVI.70.4.2075-2085.1996; MCLACHLIN JR, 1994, J VIROL, V68, P7746, DOI 10.1128/JVI.68.12.7746-7756.1994; Mikhailov VS, 2000, VIROLOGY, V270, P180, DOI 10.1006/viro.2000.0270; Mikhailov VS, 2003, MOL BIOL+, V37, P250, DOI 10.1023/A:1023349706186; Mikhailov VS, 2003, J VIROL, V77, P2436, DOI 10.1128/JVI.77.4.2436-2444.2003; Mikhailov VS, 2002, BMC MOL BIOL, V3, DOI 10.1186/1471-2199-3-14; Munoz D, 1997, APPL ENVIRON MICROB, V63, P3025; Nimonkar AV, 2003, J BIOL CHEM, V278, P9678, DOI 10.1074/jbc.M212555200; Nimonkar AV, 2002, J BIOL CHEM, V277, P15182, DOI 10.1074/jbc.M109988200; Okano K, 1999, J VIROL, V73, P110, DOI 10.1128/JVI.73.1.110-119.1999; Oppenheimer DI, 1997, ARCH VIROL, V142, P2107, DOI 10.1007/s007050050229; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Poteete AR, 2001, FEMS MICROBIOL LETT, V201, P9, DOI 10.1016/S0378-1097(01)00242-7; Reuven NB, 2003, J VIROL, V77, P7425, DOI 10.1128/JVI.77.13.7425-7433.2003; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SCHAFFER PA, 1974, VIROLOGY, V58, P219, DOI 10.1016/0042-6822(74)90156-1; Stahl FW, 1998, GENE, V223, P95, DOI 10.1016/S0378-1119(98)00246-7; THOMAS MS, 1992, J VIROL, V66, P1152, DOI 10.1128/JVI.66.2.1152-1161.1992; UMENE K, 1985, J GEN VIROL, V66, P2659, DOI 10.1099/0022-1317-66-12-2659; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; VAUGHAN PJ, 1984, J GEN VIROL, V65, P2033, DOI 10.1099/0022-1317-65-11-2033; WELLER SK, 1990, J GEN VIROL, V71, P2941, DOI 10.1099/0022-1317-71-12-2941; Wu YT, 1999, J VIROL, V73, P5473, DOI 10.1128/JVI.73.7.5473-5480.1999; XIONG GM, 1991, VIRUS RES, V21, P65, DOI 10.1016/0168-1702(91)90072-4; Yang S, 1998, VIROLOGY, V245, P99, DOI 10.1006/viro.1998.9152; Yang S, 1999, J VIROL, V73, P3404, DOI 10.1128/JVI.73.4.3404-3409.1999	59	22	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14734	14745		10.1074/jbc.M311658200	http://dx.doi.org/10.1074/jbc.M311658200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736888	hybrid			2022-12-27	WOS:000220594700033
J	Reinke, A; Anderson, S; McCaffery, JM; Yates, J; Aronova, S; Chu, S; Fairclough, S; Iverson, C; Wedaman, KP; Powers, T				Reinke, A; Anderson, S; McCaffery, JM; Yates, J; Aronova, S; Chu, S; Fairclough, S; Iverson, C; Wedaman, KP; Powers, T			TOR complex 1 includes a novel component, Tco89p (YPL180w), and cooperates with Ssd1p to maintain cellular integrity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE PATHWAY; RAPAMYCIN TOR; ACTIN CYTOSKELETON; SIGNALING PATHWAY; PROTEIN COMPLEXES; YEAST; TARGET; GROWTH; TAP42; EXPRESSION	The Tor1p and Tor2p kinases, targets of the therapeutically important antibiotic rapamycin, function as components of two distinct protein complexes in yeast, termed TOR complex 1 (TORC1) and TORC2. TORC1 is responsible for a wide range of rapamycin-sensitive cellular activities and contains, in addition to Tor1p or Tor2p, two highly conserved proteins, Lst8p and Kog1p. By identifying proteins that co-purify with Tor1p, Tor2p, Lst8p, and Kog1p, we have characterized a comprehensive set of protein-protein interactions that define further the composition of TORC1 as well as TORC2. In particular, we have identified Tco89p (YPL180w) and Bit61p (YJL058c) as novel components of TORC1 and TORC2, respectively. Deletion of TOR1 or TCO89 results in two specific and distinct phenotypes, (i) rapamycin-hypersensitivity and (ii) decreased cellular integrity, both of which correlate with the presence of SSD1-d, an allele of SSD1 previously associated with defects in cellular integrity. Furthermore, we link Ssd1p to Tap42p, a component of the TOR pathway that is believed to act uniquely downstream of TORC1. Together, these results define a novel connection between TORC1 and Ssd1p-mediated maintenance of cellular integrity.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Div Biol Sci, Ctr Genet & Dev, Davis, CA 95616 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Johns Hopkins Univ, Integrated Imaging Ctr, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	University of California System; University of California Davis; University of California System; University of California Davis; Scripps Research Institute; Johns Hopkins University; Johns Hopkins University	Powers, T (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shield Ave, Davis, CA 95616 USA.	tpowers@ucdavis.edu		Reinke, Aaron/0000-0001-7612-5342	NCRR NIH HHS [S10 RR019409-01, RR-11823] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019409, P41RR011823] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Alarcon CM, 1996, GENE DEV, V10, P279, DOI 10.1101/gad.10.3.279; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Brachmann CB, 1998, YEAST, V14, P115; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; de la Torre-Ruiz MA, 2002, J BIOL CHEM, V277, P33468, DOI 10.1074/jbc.M203515200; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; Evans DRH, 1997, GENETICS, V145, P227; Garcia-Rodriguez LJ, 2000, J BACTERIOL, V182, P2428, DOI 10.1128/JB.182.9.2428-2437.2000; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Helliwell SB, 1998, GENETICS, V148, P99; Holst B, 2000, MOL MICROBIOL, V37, P108, DOI 10.1046/j.1365-2958.2000.01968.x; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kaeberlein M, 2002, GENETICS, V160, P83; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Krause SA, 2002, CURR BIOL, V12, P588, DOI 10.1016/S0960-9822(02)00760-1; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Pruyne D, 2000, J CELL SCI, V113, P571; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Rohde JR, 2003, MOL CELL BIOL, V23, P629, DOI 10.1128/MCB.23.2.629-635.2003; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmitz HP, 2002, MOL MICROBIOL, V44, P829, DOI 10.1046/j.1365-2958.2002.02925.x; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; Uesono Y, 1997, J BIOL CHEM, V272, P16103, DOI 10.1074/jbc.272.26.16103; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609	55	186	192	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14752	14762		10.1074/jbc.M313062200	http://dx.doi.org/10.1074/jbc.M313062200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736892	hybrid			2022-12-27	WOS:000220594700035
J	Rudolph, JA; Poccia, JL; Cohen, MB				Rudolph, JA; Poccia, JL; Cohen, MB			Cyclic AMP activation of the extracellular signal-regulated kinases 1 and 2 - Implications for intestinal cell survival through the transient inhibition of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CHLORIDE SECRETION; IN-VITRO; CAMP; DIFFERENTIATION; RECEPTOR; EXPRESSION; PATHWAY; PKA; ERK	The proliferative compartment of the intestinal crypt is critical in the process of intestinal epithelial cell homeostasis. The ability of these progenitor crypt cells to resist apoptosis and ensure restitution during a potentially lethal insult, but retain the ability to remove damaged or altered cells afterward, is necessary for preservation of the crypt-villus unit. We have examined the ability of cAMP to transiently inhibit apoptosis via the extracellular signal-regulated kinases 1 and 2 (ERK1/2), in T84 cells, an intestinal crypt-like cell line. Using the cAMP analog 8-bromo-cAMP and cholera toxin (CT), cAMP-mediated ERK1/2 activation was first measured by Western blot analysis of the phosphorylated (activated) and total (activated and inactivated) forms of ERK1/2. Cyclic AMP activated ERK1/2 in a time- and dose-dependent manner, and the effect was inhibited by PD098059, an inhibitor of the ERK1/2 signaling pathway. However, inhibition of protein kinase A (PKA) did not alter the activation of ERK1/2. CT transiently inhibited both staurosporine and Fas antibody mediated apoptosis as measured by a caspase-3 activation assay and the detection of nucleosomes in an apoptosis based enzyme-linked immunosorbent assay. This inhibitory effect was reversed by the simultaneous addition of PD098059. Our data suggest that in the T84 cell line, cAMP activates ERK1/2 in a PKA independent fashion and a physiological consequence of this activated pathway is the transient inhibition of apoptosis. These findings suggest a novel pathway that intestinal cells use to protect against injury while maintaining the overall ability to remove damaged cells and preserve intestinal homeostasis.	Cincinnati Childrens Hosp, Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University of Cincinnati	Rudolph, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA.	jeff.rudolph@cchmc.org		Cohen, Mitchell/0000-0002-4412-350X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047318, R56DK047318] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47318] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu MT, 2001, J BIOL CHEM, V276, P47563, DOI 10.1074/jbc.M106226200; Amelsberg M, 1996, SCAND J GASTROENTERO, V31, P233, DOI 10.3109/00365529609004872; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Boushey RP, 1999, AM J PHYSIOL-ENDOC M, V277, pE937, DOI 10.1152/ajpendo.1999.277.5.E937; Cancedda L, 2003, J NEUROSCI, V23, P7012, DOI 10.1523/JNEUROSCI.23-18-07012.2003; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, P204; Ding QM, 2001, BIOCHEM BIOPH RES CO, V284, P282, DOI 10.1006/bbrc.2001.4969; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; FORTE LR, 1992, AM J PHYSIOL, V263, P607; FRODIN M, 1994, J BIOL CHEM, V269, P6207; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; Gauthier R, 2001, J CELL BIOCHEM, V82, P339, DOI 10.1002/jcb.1172; Houchen CW, 2003, AM J PHYSIOL-GASTR L, V284, pG490, DOI 10.1152/ajpgi.00240.2002; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; Iwamoto M, 1996, J PATHOL, V180, P152; Keefe DMK, 2000, GUT, V47, P632, DOI 10.1136/gut.47.5.632; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; Li W, 2001, AM J PHYSIOL-GASTR L, V280, pG75, DOI 10.1152/ajpgi.2001.280.1.G75; Luongo D, 2002, MOL CELL BIOCHEM, V231, P43, DOI 10.1023/A:1014476706382; MAMAJIWALLA SN, 1995, ONCOGENE, V11, P377; Marandi S, 2001, AM J PHYSIOL-GASTR L, V280, pG229, DOI 10.1152/ajpgi.2001.280.2.G229; Moss SF, 1996, GUT, V39, P811, DOI 10.1136/gut.39.6.811; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; POTTEN CS, 1992, CARCINOGENESIS, V13, P2305, DOI 10.1093/carcin/13.12.2305; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rudolph JA, 2002, AM J PHYSIOL-GASTR L, V283, pG695, DOI 10.1152/ajpgi.00433.2001; Saavedra AP, 2002, ONCOGENE, V21, P778, DOI 10.1038/sj.onc.1205123; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Singh AE, 1998, AM J PHYSIOL-CELL PH, V275, pC562, DOI 10.1152/ajpcell.1998.275.2.C562; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stork PJS, 2002, CELL CYCLE, V1, P315, DOI 10.4161/cc.1.5.145; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Wallace DP, 2001, AM J PHYSIOL-RENAL, V280, pF1019, DOI 10.1152/ajprenal.2001.280.6.F1019; Wu T, 2003, TRANSPLANTATION, V75, P1241, DOI 10.1097/01.TP.0000062840.49159.2F; Yamaguchi T, 2000, KIDNEY INT, V57, P1460, DOI 10.1046/j.1523-1755.2000.00991.x; Yan F, 2001, CANCER RES, V61, P8668; Yan F, 2002, J BIOL CHEM, V277, P50959, DOI 10.1074/jbc.M207050200; Yusta B, 2000, J BIOL CHEM, V275, P35345, DOI 10.1074/jbc.M005510200	45	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14828	14834		10.1074/jbc.M310289200	http://dx.doi.org/10.1074/jbc.M310289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744867	hybrid			2022-12-27	WOS:000220594700043
J	Ruotolo, R; Peracchi, A; Bolchi, A; Infusini, G; Amoresano, A; Ottonello, S				Ruotolo, R; Peracchi, A; Bolchi, A; Infusini, G; Amoresano, A; Ottonello, S			Domain organization of phytochelatin synthase - Functional properties of truncated enzyme species identified by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-METAL DETOXIFICATION; ARABIDOPSIS-THALIANA; BINDING PEPTIDES; PLANTS; GLUTATHIONE; TOLERANCE; MUTANTS; GENE	Phytochelatin synthase (PCS) is a major determinant of heavy metal tolerance in plants and other organisms. No structural information on this enzyme is as yet available. It is generally believed, however, that the active site region is located in the more conserved N-terminal portion of PCS, whereas various, as yet unidentified ( but supposedly less critical) roles have been proposed for the C-terminal region. To gain insight into the structural/ functional organization of PCS, we have conducted a limited proteolysis analysis of the enzyme from Arabidopsis (AtPCS1), followed by functional characterization of the resulting polypeptide fragments. Two N-terminal fragments ending at positions 372 (PCS_Nt1) and 283 (PCS_Nt2) were produced sequentially upon V8 protease digestion, without any detectable accumulation of the corresponding C-terminal fragments. As revealed by the results of in vivo and in vitro functional assays, the core PCS_Nt2 fragment is biosynthetically active in the presence of cadmium ions and supports phytochelatin formation at a rate that is only similar to5-fold lower than that of full-length AtPCS1. The loss of the C-terminal region, however, substantially decreases the thermal stability of the enzyme and impairs phytochelatin formation in the presence of certain heavy metals ( e. g. mercury and zinc, but not cadmium or copper). The latter phenotype was shared by PCS_Nt2 and by its precursor fragment PCS_Nt1, which, on the other hand, was almost as stable and biosynthetically active ( in the presence of cadmium) as the full-length enzyme. AtPCS1 thus appears to be composed of a protease-resistant ( and hence presumably highly structured) N-terminal domain, flanked by an intrinsically unstable C-terminal region. The most upstream part of such a region ( positions 284 - 372) is important for enzyme stabilization, whereas its most terminal part ( positions 373 - 485) appears to be required to determine enzyme responsiveness to a broader range of heavy metals.	Univ Parma, Dipartimento Biochim & Biol Mol, I-43100 Parma, Italy; Univ Naples Federico II, Dipartimento Chim Organ & Biochim, I-80134 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); University of Parma; University of Naples Federico II	Ottonello, S (corresponding author), Univ Parma, Dipartimento Biochim & Biol Mol, I-43100 Parma, Italy.	s.ottonello@unipr.it	Bolchi, Angelo/GOJ-9730-2022; Ruotolo, Roberta/GVU-0360-2022; Peracchi, Alessio/G-5167-2012; Peracchi, Alessio/Q-5173-2019	Peracchi, Alessio/0000-0003-3254-4099; Peracchi, Alessio/0000-0003-3254-4099; AMORESANO, Angela/0000-0002-8386-655X				Clemens S, 2001, EUR J BIOCHEM, V268, P3640, DOI 10.1046/j.1432-1327.2001.02293.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Cobbett CS, 2000, CURR OPIN PLANT BIOL, V3, P211, DOI 10.1016/S1369-5266(00)00066-2; DEKNECHT JA, 1994, PLANT PHYSIOL, V104, P255, DOI 10.1104/pp.104.1.255; Di Toppi LS, 2002, PHYSIOLOGY AND BIOCHEMISTRY OF METAL TOXICITY AND TOLERANCE IN PLANTS, P59; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; GRILL E, 1987, P NATL ACAD SCI USA, V84, P439, DOI 10.1073/pnas.84.2.439; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; Heiss S, 2003, J EXP BOT, V54, P1833, DOI 10.1093/jxb/erg205; HOWDEN R, 1995, PLANT PHYSIOL, V107, P1059, DOI 10.1104/pp.107.4.1059; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanfranco L, 2002, PLANT PHYSIOL, V130, P58, DOI 10.1104/pp.003525; Maier T, 2003, PLANTA, V218, P300, DOI 10.1007/s00425-003-1091-7; Maitani T, 1996, PLANT PHYSIOL, V110, P1145, DOI 10.1104/pp.110.4.1145; MINET M, 1992, PLANT J, V2, P417; Oven M, 2002, J BIOL CHEM, V277, P4747, DOI 10.1074/jbc.M108254200; Rauser WE, 1999, CELL BIOCHEM BIOPHYS, V31, P19, DOI 10.1007/BF02738153; SCHELLER HV, 1987, PLANT PHYSIOL, V85, P1031, DOI 10.1104/pp.85.4.1031; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	25	65	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14686	14693		10.1074/jbc.M314325200	http://dx.doi.org/10.1074/jbc.M314325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729665	hybrid			2022-12-27	WOS:000220594700028
J	Thiery, L; Leprince, AS; Lefebvre, D; Ali Ghars, M; Debarbieux, E; Savoure, A				Thiery, L; Leprince, AS; Lefebvre, D; Ali Ghars, M; Debarbieux, E; Savoure, A			Phospholipase D is a negative regulator of proline biosynthesis in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SIGNAL-TRANSDUCTION; ABSCISIC-ACID; DELTA(1)-PYRROLINE-5-CARBOXYLATE SYNTHETASE; PHOSPHATIDIC-ACID; GENE-EXPRESSION; STRESS; DROUGHT; COLD; DEHYDROGENASE; OSMOREGULATION	Accumulation of proline has been observed in a large number of plant species in response to drought and salt stresses, suggesting a key role of this amino acid in plant stress adaptation. Upstream components of the proline biosynthesis signal transduction pathways are still poorly defined. We provide experimental evidence that phospholipase D (PLD) is involved in the regulation of proline metabolism in Arabidopsis thaliana. The application of primary butyl alcohols, which divert part of PLD-derived phosphatidic acid by transphosphatidylation, stimulated proline biosynthesis even without hyperosmotic constraints. Moreover, application of primary butyl alcohols enhanced the proline responsiveness of seedlings to mild hyperosmotic stress. These data indicate that some PLDs are negative regulators of proline biosynthesis and that plants present a higher proline responsiveness to hyperosmotic stress when this regulator is abolished. We clearly demonstrate that PLD signaling for proline biosynthesis is similar to RD29A gene expression and different from the abscisic acid-dependent RAB18 gene expression. Our data reveal that PLDs play positive and negative roles in hyperosmotic stress signal transduction in plants, contributing to a precise regulation of ion homeostasis and plant salt tolerance.	Univ Paris 06, CNRS, UMR 7632, UInite Physiol Cellulaire & Mol Plantes, F-75252 Paris 05, France; Inst Natl Rech Sci, Lab Adaptat Plantes Stress Abiot, Hammam Lif 2050, Tunisia	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de Recherche Scientifique et Technique	Savoure, A (corresponding author), Univ Paris 06, CNRS, UMR 7632, UInite Physiol Cellulaire & Mol Plantes, Case 156,4 Pl Jussieu, F-75252 Paris 05, France.	savoure@ccr.jussieu.fr	Savouré, Arnould/AAP-3094-2021	Savouré, Arnould/0000-0002-5002-7856				BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060; BOYER JS, 1982, SCIENCE, V218, P443, DOI 10.1126/science.218.4571.443; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELAUNEY AJ, 1993, PLANT J, V4, P215, DOI 10.1046/j.1365-313X.1993.04020215.x; Deuschle K, 2001, PLANT J, V27, P345, DOI 10.1046/j.1365-313X.2001.01101.x; El Maarouf H, 1999, PLANT MOL BIOL, V39, P1257, DOI 10.1023/A:1006165919928; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Frank W, 2000, PLANT CELL, V12, P111, DOI 10.1105/tpc.12.1.111; Gampala SSL, 2001, J BIOL CHEM, V276, P9855, DOI 10.1074/jbc.M009168200; Hallouin M, 2002, PLANT PHYSIOL, V130, P265, DOI 10.1104/pp.004168; Hare PD, 1999, J EXP BOT, V50, P413, DOI 10.1093/jexbot/50.333.413; Ishitani M, 1997, PLANT CELL, V9, P1935, DOI 10.1105/tpc.9.11.1935; Jacob T, 1999, P NATL ACAD SCI USA, V96, P12192, DOI 10.1073/pnas.96.21.12192; Katagiri T, 2001, PLANT J, V26, P595, DOI 10.1046/j.1365-313x.2001.01060.x; KISHOR PBK, 1995, PLANT PHYSIOL, V108, P1387, DOI 10.1104/pp.108.4.1387; Kiyosue T, 1996, PLANT CELL, V8, P1323, DOI 10.1105/tpc.8.8.1323; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG V, 1992, PLANT MOL BIOL, V20, P951, DOI 10.1007/BF00027165; Martinez-Garcia JF, 1999, PLANT J, V20, P251, DOI 10.1046/j.1365-313x.1999.00579.x; McNeil SD, 2001, P NATL ACAD SCI USA, V98, P10001, DOI 10.1073/pnas.171228998; Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Peng Z, 1996, MOL GEN GENET, V253, P334, DOI 10.1007/s004380050329; QUIN C, 2002, PLANT PHYSIOL, V128, P1057; Ritchie S, 1998, P NATL ACAD SCI USA, V95, P2697, DOI 10.1073/pnas.95.5.2697; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sang YM, 2001, PLANT J, V28, P135, DOI 10.1046/j.1365-313X.2001.01138.x; Savoure A, 1997, MOL GEN GENET, V254, P104, DOI 10.1007/s004380050397; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; Strizhov N, 1997, PLANT J, V12, P557, DOI 10.1046/j.1365-313X.1997.00557.x; SZOKE A, 1992, PLANT PHYSIOL, V99, P1642, DOI 10.1104/pp.99.4.1642; Verbruggen N, 1996, P NATL ACAD SCI USA, V93, P8787, DOI 10.1073/pnas.93.16.8787; VERBRUGGEN N, 1993, PLANT PHYSIOL, V103, P771, DOI 10.1104/pp.103.3.771; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; White PJ, 1996, J EXP BOT, V47, P713, DOI 10.1093/jxb/47.5.713; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251; Yoshiba Y, 1999, BIOCHEM BIOPH RES CO, V261, P766, DOI 10.1006/bbrc.1999.1112	41	67	79	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14812	14818		10.1074/jbc.M308456200	http://dx.doi.org/10.1074/jbc.M308456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742440	hybrid			2022-12-27	WOS:000220594700041
J	Walker, JM; Huster, D; Ralle, M; Morgan, CT; Blackburn, NJ; Lutsenko, S				Walker, JM; Huster, D; Ralle, M; Morgan, CT; Blackburn, NJ; Lutsenko, S			The N-terminal metal-binding site 2 of the Wilson's disease protein plays a key role in the transfer of copper from Atox1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTING ATPASE ATP7B; CATALYTIC-ACTIVITY; CHAPERONE HAH1; IN-VITRO; DOMAIN; METALLOCHAPERONES; HOMEOSTASIS; EXPRESSION; ACID	The Wilson's disease protein (WNDP) is a copper-transporting ATPase regulating distribution of copper in the liver. Mutations in WNDP lead to a severe metabolic disorder, Wilson's disease. The function of WNDP depends on Atox1, a cytosolic metallochaperone that delivers copper to WNDP. We demonstrate that the metal-binding site 2 (MBS2) in the N-terminal domain of WNDP (N-WNDP) plays an important role in this process. The transfer of one copper from Atox1 to N-WNDP results in selective protection of the metal-coordinating cysteines in MBS2 against labeling with a cysteine-directed probe. Such selectivity is not observed when free copper is added to N-WNDP. Similarly, site-directed mutagenesis of MBS2 eliminates stimulation of the catalytic activity of WNDP by the copper-Atox1 complex but not by free copper. The Atox1 preference toward MBS2 is likely due to specific protein-protein interactions and is not due to unique surface exposure of the metal-coordinating residues or higher copper binding affinity of MBS2 compared with other sites. Competition experiments using a copper chelator revealed that MBS2 retained copper much better than Atox1, and this may facilitate the metal transfer process. X-ray absorption spectroscopy of the isolated recombinant MBS2 demonstrated that this sub-domain coordinates copper with a linear biscysteinate geometry, very similar to that of Atox1. Therefore, non-coordinating residues in the vicinity of the metal-binding sites are responsible for the difference in the copper binding properties of MBS2 and Atox1. The intramolecular changes that accompany transfer of a single copper to N-WNDP are discussed.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Environm & Biomol Syst, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	lutsenko@ohsu.edu	Morgan, Clinton/AAM-7410-2021; Ralle, Martina/H-2936-2019					Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; Chen K, 2003, J AM CHEM SOC, V125, P12088, DOI 10.1021/ja036070y; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; GEORGE GN, 1995, EXAFSPAK; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; Jones CE, 2003, J STRUCT BIOL, V143, P209, DOI 10.1016/j.jsb.2003.08.008; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lockhart PJ, 2000, BBA-GENE STRUCT EXPR, V1490, P11, DOI 10.1016/S0167-4781(99)00230-4; Loudianos G, 2000, SEMIN LIVER DIS, V20, P353, DOI 10.1055/s-2000-9389; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lutsenko S, 2002, J BIOENERG BIOMEMBR, V34, P351, DOI 10.1023/A:1021297919034; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ralle M, 2003, J BIOL CHEM, V278, P23163, DOI 10.1074/jbc.M303474200; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766	34	93	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15376	15384		10.1074/jbc.M400053200	http://dx.doi.org/10.1074/jbc.M400053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14754885	hybrid			2022-12-27	WOS:000220594700107
J	Decher, N; Chen, J; Sanguinetti, MC				Decher, N; Chen, J; Sanguinetti, MC			Voltage-dependent gating of hyperpolarization-activated, cyclic nucleotide-gated pacemaker channels - Molecular coupling between the S4-S5 and C-linkers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNELS; POTASSIUM CHANNELS; STRUCTURAL BASIS; XENOPUS-OOCYTES; CATION CHANNEL; ION CHANNELS; MODULATION; SENSOR	Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels have a transmembrane topology that is highly similar to voltage-gated K+ channels, yet HCN channels open in response to membrane hyperpolarization instead of depolarization. The structural basis for the "inverted" voltage dependence of HCN gating and how voltage sensing by the S1-S4 domains is coupled to the opening of the intracellular gate formed by the S6 domain are unknown. Coupling could arise from interaction between specific residues or entire transmembrane domains. We previously reported that the mutation of specific residues in the S4-S5 linker of HCN2 (i.e. Tyr-331 and Arg-339) prevented normal channel closure presumably by disruption of a crucial interaction with the activation gate. Here we hypothesized that the Clinker, a carboxyl terminus segment that connects S6 to the cyclic nucleotide binding domain, interacts with specific residues of the S4-S5 linker to mediate coupling. The recently solved structure of the C-linker of HCN2 indicates that an alpha-helix (the A'-helix) is located near the end of each S6 domain, the presumed location of the activation gate. Ala-scanning mutagenesis of the end of S6 and the A'-helix identified five residues that were important for normal gating as mutations disrupted channel closure. However, partial deletion of the C-linker indicated that the presence of only two of these residues was required for normal coupling. Further mutation analyses suggested that a specific electrostatic interaction between Arg-339 of the S4-S5 linker and Asp-443 of the C-linker stabilizes the closed state and thus participates in the coupling of voltage sensing and activation gating in HCN channels.	Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Sanguinetti, MC (corresponding author), Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, 95 S 2000 E, Salt Lake City, UT 84112 USA.	michael.sanguinetti@hmbg.utah.edu	Decher, Niels/AAF-5002-2020; Sanguinetti, Michael/AAN-2615-2020		NHLBI NIH HHS [HL65299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; Chen J, 2001, P NATL ACAD SCI USA, V98, P11277, DOI 10.1073/pnas.201250598; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Larsson HP, 2002, J GEN PHYSIOL, V120, P475, DOI 10.1085/jgp.20028657; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Proenza C, 2002, J BIOL CHEM, V277, P5101, DOI 10.1074/jbc.M106974200; Rothberg BS, 2003, J GEN PHYSIOL, V122, P501, DOI 10.1085/jgp.200308928; Rothberg BS, 2002, J GEN PHYSIOL, V119, P83, DOI 10.1085/jgp.119.1.83; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Silverman WR, 2003, P NATL ACAD SCI USA, V100, P2935, DOI 10.1073/pnas.0636603100; STUEHMER W, 1992, METHOD ENZYMOL, V207, P319; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zong XG, 1998, EMBO J, V17, P353, DOI 10.1093/emboj/17.2.353	27	98	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13859	13865		10.1074/jbc.M313704200	http://dx.doi.org/10.1074/jbc.M313704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726518	hybrid			2022-12-27	WOS:000220478500072
J	Qin, XL; Sarnow, P				Qin, XL; Sarnow, P			Preferential translation of internal ribosome entry site-containing mRNAs during the mitotic cycle in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING PROTEIN; C-MYC; DEPENDENT TRANSLATION; INITIATION; INHIBITION; MITOSIS; COMPLEX; IDENTIFICATION; INVOLVEMENT; ASSOCIATION	A cell synchronization protocol was established in which global and individual mRNA translational efficiencies could be examined. While global translational efficiency was reduced in mitotic cells, similar to 3% of mRNAs remained predominantly associated with large polysomes during mitosis, as determined by cDNA microarray analyses. The 5'-non-coding regions of six mRNAs were shown to contain internal ribosome entry sites (IRES). However, not all known mRNAs that contain IRES elements were actively translated during mitosis, arguing that specific IRES sequences are differentially regulated during mitosis.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University	Sarnow, P (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Fairchild Sci Bldg, Stanford, CA 94305 USA.	psarnow@stanford.edu		Sarnow, Peter/0000-0002-2043-2770	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055979] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55979] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; Carter MS, 2000, J BIOL CHEM, V275, P28301; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; Gallaher B, 2000, CELL MOL BIOL, V46, P79; Gustin KE, 2002, J VIROL, V76, P8787, DOI 10.1128/JVI.76.17.8787-8796.2002; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Honda M, 2000, GASTROENTEROLOGY, V118, P152, DOI 10.1016/S0016-5085(00)70424-0; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; Kuhn KM, 2001, MOL CELL BIOL, V21, P916, DOI 10.1128/MCB.21.3.916-927.2001; McBratney S, 1996, MOL CELL BIOL, V16, P3523; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Puntoni F, 1999, BIOCHEM BIOPH RES CO, V266, P279, DOI 10.1006/bbrc.1999.1800; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Sella O, 1999, MOL CELL BIOL, V19, P5429; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	29	135	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13721	13728		10.1074/jbc.M312854200	http://dx.doi.org/10.1074/jbc.M312854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14739278	hybrid			2022-12-27	WOS:000220478500055
J	Shimizu, T; Nishihira, J; Watanabe, H; Abe, R; Honda, A; Ishibashi, T; Shimizu, H				Shimizu, T; Nishihira, J; Watanabe, H; Abe, R; Honda, A; Ishibashi, T; Shimizu, H			Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; FACTOR MIF; ACTIVATED RECEPTOR; CYTOKINE PRODUCTION; TISSUE FACTOR; FACTOR VIIA; EXPRESSION; IDENTIFICATION; FIBROBLASTS; GROWTH	Macrophage migration inhibitory factor (MIF), a proinflammatory cytokine, has been shown to play a role in wound-healing processes. In this study, we investigated whether protease-activated receptor (PAR)-1 and PAR-2 mediated MIF expression in human endothelial cells. Thrombin, factor Xa (FXa), and trypsin induced MIF expression in human dermal microvascular endothelial cells and human umbilical vein endothelial cells, but other proteases, including kallikrein and urokinase, failed to do so. Thrombin-induced MIF mRNA expression was significantly reduced by the thrombin-specific inhibitor hirudin. Thrombin receptor activation peptide-6, a synthetic PAR-1 peptide, induced MIF mRNA expression, suggesting that PAR-1 mediates MIF expression in response to thrombin. The effects of FXa were blocked by antithrombin III, but not by hirudin, indicating that FXa might enhance MIF production directly rather than via thrombin stimulation. The synthetic PAR-2 peptide SLIGRL-NH2 induced MIF mRNA expression, showing that PAR-2 mediated MIF expression in response to FXa. Concerning the signal transduction, a mitogen-activated protein kinase kinase inhibitor (PD98089) and a nuclear factor (NF)-kappaB inhibitor (SN50) suppressed the up-regulation of MIF mRNA in response to thrombin, FXa, and PAR-2 agonist stimulation, whereas a p38 inhibitor (SB203580) had little effect. These facts indicate that up-regulation of MIF by thrombin or FXa is regulated by p44/p42 mitogen-activated protein kinase-dependent pathways and NF-kappaB-dependent pathways. Moreover, we found that PAR-1 and PAR-2 mRNA expression in endothelial cells was enhanced by MIF. Furthermore, we examined the inflammatory response induced by PAR-1 and PAR-2 agonists injected into the mouse footpad. As shown by footpad thickness, an indicator of inflammation, MIF-deficient mice (C57BL/6) were much less sensitive to either PAR-1 or PAR-2 agonists than wild-type mice. Taken together, these results suggest that MIF contributes to the inflammatory phase of the wound healing process in concert with thrombin and FXa via PAR-1 and PAR-2.	Hokkaido Univ, Grad Sch Med, Dept Mol Biochem, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Nishihira, J (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Mol Biochem, Sapporo, Hokkaido 0608638, Japan.	j_nisihi@med.hokudai.ac.jp	Shimizu, Hiroshi/A-5193-2012; Abe, Riichiro/A-5450-2012	Shimizu, Tadamichi/0000-0002-3231-0279				Abe R, 2000, BBA-MOL BASIS DIS, V1500, P1, DOI 10.1016/S0925-4439(99)00080-0; Beishuizen A, 2001, J CLIN ENDOCR METAB, V86, P2811, DOI 10.1210/jc.86.6.2811; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; COLOTTA F, 1994, AM J PATHOL, V144, P975; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRANDALIANO G, 1994, J EXP MED, V179, P1737, DOI 10.1084/jem.179.5.1737; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; JONES A, 1990, IMMUNOLOGY, V71, P236; Joshi PC, 2000, RES COMMUN MOL PATH, V107, P13; Kaplanski G, 1997, J IMMUNOL, V158, P5435; Lidington EA, 2000, BLOOD, V96, P2784; MACKIE IJ, 1996, OXFORD TXB MED, P3613; MARAGANORE JM, 1993, THROMB HAEMOSTASIS, V70, P208; Marin V, 2001, J IMMUNOL, V167, P3435, DOI 10.4049/jimmunol.167.6.3435; Marin V, 2001, BLOOD, V98, P667, DOI 10.1182/blood.V98.3.667; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Maruyama I, 1997, ANN NY ACAD SCI, V811, P429, DOI 10.1111/j.1749-6632.1997.tb52024.x; Nishihira J, 1998, CYTOKINE, V10, P199, DOI 10.1006/cyto.1997.0276; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; Ollivier V, 2000, ARTERIOSCL THROM VAS, V20, P1374, DOI 10.1161/01.ATV.20.5.1374; Papapetropoulos A, 1998, P NATL ACAD SCI USA, V95, P4738, DOI 10.1073/pnas.95.8.4738; Senden NHM, 1998, J IMMUNOL, V161, P4318; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Shimizu T, 1997, BIOCHEM BIOPH RES CO, V240, P173, DOI 10.1006/bbrc.1997.7633; Shimizu T, 1996, FEBS LETT, V381, P199, DOI 10.1016/0014-5793(96)00120-2; Shimizu T, 1999, SEMIN THROMB HEMOST, V25, P569, DOI 10.1055/s-2007-994967; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; Yang YB, 2000, J CLIN ENDOCR METAB, V85, P4721, DOI 10.1210/jc.85.12.4721	36	79	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13729	13737		10.1074/jbc.M400150200	http://dx.doi.org/10.1074/jbc.M400150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736878	hybrid			2022-12-27	WOS:000220478500056
J	Enguita, FJ; Marcal, D; Martins, LO; Grenha, R; Henriques, AO; Lindley, PF; Carrondo, MA				Enguita, FJ; Marcal, D; Martins, LO; Grenha, R; Henriques, AO; Lindley, PF; Carrondo, MA			Substrate and doxygen binding to the endospore coat laccase from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRAMETES-VERSICOLOR; ASCORBATE OXIDASE; COPPER; INTERMEDIATE; RESOLUTION; REDUCTION; SITE; REFINEMENT; COMPONENT	The CotA laccase from the endospore coat of Bacillus subtilis has been crystallized in the presence of the noncatalytic co-oxidant 2,2 '-azinobis-(3-ethylbenzothiazoline-6- sulfonate) ( ABTS), and the structure was determined using synchrotron radiation. The binding site for this adduct is well defined and indicates how ABTS, in conjunction with laccases, could act as an oxidative mediator toward non-phenolic moieties. In addition, a dioxygen moiety is clearly defined within the solvent channel oriented toward one of the T3 copper atoms in the trinuclear center.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, Prot Crystallog Lab, P-2781901 Oeiras, Portugal; Univ Lusofona Humanidades & Tecnol, Dept Engn & Tecnol, P-1749024 Lisbon, Portugal	Universidade Nova de Lisboa; Lusofona University	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Prot Crystallog Lab, P-2781901 Oeiras, Portugal.	carrondo@itqb.unl.pt	Martins, Lígia O./C-2513-2009; Enguita, Francisco J./A-2347-2009	Martins, Lígia O./0000-0003-0082-9591; Enguita, Francisco J./0000-0002-8072-8557; Carrondo, Maria Armenia/0000-0002-1261-1162; Marcal, David/0000-0001-5152-788X; Henriques, Adriano/0000-0003-4292-4802				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertrand T, 2002, BIOCHEMISTRY-US, V41, P7325, DOI 10.1021/bi0201318; BOURBONNAIS R, 1995, APPL ENVIRON MICROB, V61, P1876, DOI 10.1128/AEM.61.5.1876-1880.1995; Bourbonnais R, 1998, BBA-GEN SUBJECTS, V1379, P381, DOI 10.1016/S0304-4165(97)00117-7; BOURBONNAIS R, 1990, FEBS LETT, V267, P99, DOI 10.1016/0014-5793(90)80298-W; Claus H, 2003, ARCH MICROBIOL, V179, P145, DOI 10.1007/s00203-002-0510-7; Cole AP, 1996, SCIENCE, V273, P1848, DOI 10.1126/science.273.5283.1848; DeLano WL, 2002, PYMOL USERS MANUAL; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Enguita FJ, 2003, J BIOL CHEM, V278, P19416, DOI 10.1074/jbc.M301251200; Enguita FJ, 2002, ACTA CRYSTALLOGR D, V58, P1490, DOI 10.1107/S0907444902011575; Fabbrini M, 2002, J MOL CATAL B-ENZYM, V16, P231, DOI 10.1016/S1381-1177(01)00067-4; Gianfreda L., 1999, BIOREMEDIAT J, V3, P1, DOI DOI 10.1080/10889869991219163; Hakulinen N, 2002, NAT STRUCT BIOL, V9, P601, DOI 10.1038/nsb823; Huang HW, 1999, J BIOL CHEM, V274, P32718, DOI 10.1074/jbc.274.46.32718; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee SK, 2002, J AM CHEM SOC, V124, P6180, DOI 10.1021/ja0114052; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Lindley PF, 2001, HANDBOOK ON METALLOPROTEINS, P763; MALMSTROM BG, 1982, ANNU REV BIOCHEM, V51, P21, DOI 10.1146/annurev.bi.51.070182.000321; Martins LO, 2002, J BIOL CHEM, V277, P18849, DOI 10.1074/jbc.M200827200; Mayer AM, 2002, PHYTOCHEMISTRY, V60, P551, DOI 10.1016/S0031-9422(02)00171-1; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Messerschmidt A., 1997, MULTICOPPER OXIDASES; Mousty C, 1997, NEW J CHEM, V21, P1321; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Piontek K, 2002, J BIOL CHEM, V277, P37663, DOI 10.1074/jbc.M204571200; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sundaram UM, 1997, J AM CHEM SOC, V119, P12525, DOI 10.1021/ja972039i; Tronrud D. W., 1996, P CCP4 STUD WEEK MAC, P1; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Weiss MS, 2001, J APPL CRYSTALLOGR, V34, P130, DOI 10.1107/S0021889800018227; Xu F, 1999, J BIOL CHEM, V274, P12372, DOI 10.1074/jbc.274.18.12372; Xu F., 1999, ENCY BIOPROCESS TECH, P1545; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	36	146	152	3	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 28	2004	279	22					23472	23476		10.1074/jbc.M314000200	http://dx.doi.org/10.1074/jbc.M314000200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	822WI	14764581	hybrid			2022-12-27	WOS:000221570900084
J	Chatterjee, D; Bai, Y; Wang, Z; Beach, S; Mott, S; Roy, R; Braastad, C; Sun, YP; Mukhopadhyay, A; Aggarwal, BB; Darnowski, J; Pantazis, P; Wyche, J; Fu, Z; Kitagwa, Y; Keller, ET; Sedivy, JM; Yeung, KC				Chatterjee, D; Bai, Y; Wang, Z; Beach, S; Mott, S; Roy, R; Braastad, C; Sun, YP; Mukhopadhyay, A; Aggarwal, BB; Darnowski, J; Pantazis, P; Wyche, J; Fu, Z; Kitagwa, Y; Keller, ET; Sedivy, JM; Yeung, KC			RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ONCOGENE-DEPENDENT APOPTOSIS; TOPOISOMERASE-I; PROTEIN; CAMPTOTHECIN; KINASE; DEATH; EXPRESSION; INDUCTION; INHIBITOR	Cancer cells are more susceptible to chemotherapeutic agent-induced apoptosis than their normal counterparts. Although it has been demonstrated that the increased sensitivity results from deregulation of oncoproteins during cancer development (Evan, G. I., and Vousden, K. H. (2001) Nature 411, 342-348; Green, D. R., and Evan, G. I. (2002) Cancer Cell 1, 19-30), little is known about the signaling pathways leading to changes in the apoptotic threshold in cancer cells. Here we show that low RKIP expression levels in tumorigenic human prostate and breast cancer cells are rapidly induced upon chemotherapeutic drug treatment, sensitizing the cells to apoptosis. We show that the maximal RKIP expression correlates perfectly with the onset of apoptosis. In cancer cells resistant to DNA-damaging agents, treatment with the drugs does not up-regulate RKIP expression. However, ectopic expression of RKIP resensitizes DNA-damaging agent-resistant cells to undergo apoptosis. This sensitization can be reversed by up-regulation of survival pathways. Down-regulation of endogenous RKIP by expression of antisense and small interfering RNA (siRNA) confers resistance on sensitive cancer cells to anticancer drug-induced apoptosis. Our studies suggest that RKIP may represent a novel effector of signal transduction pathways leading to apoptosis and a prognostic marker of the pathogenesis of human cancer cells and tumors after treatment with clinically relevant chemotherapeutic drugs.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Brown Univ, Dept Med, Providence, RI 02903 USA; Rhode Isl Hosp, Providence, RI 02903 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect, Houston, TX 77030 USA; Univ Miami, Dept Biol, Coral Gables, FL 33146 USA; Lab Pharmacol Pharmacotechnol, Athens 11527, Greece; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Miami; Brown University; University of Michigan System; University of Michigan	Yeung, KC (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, 3035 Arlington Ave, Toledo, OH 43614 USA.	kyeung@mco.edu	Keller, Evan T/M-1446-2016; Aggarwal, Bharat B/G-3388-2013	Keller, Evan T/0000-0002-7592-7535; 	NIGMS NIH HHS [R01 GM64767] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064767] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; Baichwal V. R., 1997, CURR BIOL, V7, P94; Chatterjee D, 1996, ANN NY ACAD SCI, V803, P143, DOI 10.1111/j.1749-6632.1996.tb26383.x; Chatterjee D, 2001, CANCER RES, V61, P7148; COVEY JM, 1989, CANCER RES, V49, P5016; Duelli DM, 2000, NAT CELL BIOL, V2, P859, DOI 10.1038/35041112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; MURAKAMI MS, 2001, SCI STKE; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pantazis P, 2003, ANTICANCER RES, V23, P3623; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Rashid MG, 2001, CANCER RES, V61, P489; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Urasaki Y, 2001, CANCER RES, V61, P1964; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	34	183	212	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17515	17523		10.1074/jbc.M313816200	http://dx.doi.org/10.1074/jbc.M313816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766752	hybrid			2022-12-27	WOS:000220870400079
J	Lee, MH; Rapti, M; Knauper, V; Murphy, G				Lee, MH; Rapti, M; Knauper, V; Murphy, G			Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; TNF-ALPHA; TERMINAL DOMAIN; ENZYME; EPITOPES	Tissue inhibitors of metalloproteinases (TIMPs) are the endogenous modulators of the zinc-dependent mammalian matrix metalloproteinases (MMPs) and their close associates, proteinases of the ADAM (a disintegrin and metalloproteinase) and ADAM with thrombospondin repeats families. There are four variants of TIMPs, and each has its defined set of metalloproteinase (MP) targets. TIMP-1, in particular, is inactive against several of the membrane-type MMPs (MT-MMPs), MMP-19, and the ADAM proteinase TACE (tumor necrosis factor-alpha-converting enzyme, ADAM-17). The molecular basis for such inactivity is unknown. Previously, we showed that TIMP-1 could be transformed into an active inhibitor against MT1-MMP by the replacement of threonine 98 residue with leucine (T98L). Here, we reveal that the T98L mutation has in fact transformed TIMP-1 into a versatile inhibitor against an array of MPs otherwise insensitive to wild-type TIMP-1; examples include TACE, MMP-19, and MT5-MMP. Using T98L as the scaffold, we created a TIMP-1 variant that is fully active against TACE. The binding affinity of the mutant (V4S/TIMP-3-AB-loop/V69L/T98L) (K-i(app) 0.14 nM) surpassed that of TIMP-3 (K(i)(app)0.22 nM), the only natural TIMP inhibitor of the enzyme. The requirement for leucine is absolute for the transformation in inhibitory pattern. On the other hand, the mutation has minimal impact on the MPs already well inhibited by wild-type TIMP-1, such as gelatinase-A and stromelysin-1. Not only have we unlocked the molecular basis for the inactivity of TIMP-1 against several of the MPs, but also our findings fundamentally modify the current beliefs on the molecular mechanism of TIMP-MP recognition and selectivity.	Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ York, Dept Biol, Biomed Tissue Res Grp, York YO10 5YW, N Yorkshire, England	University of Cambridge; University of York - UK	Murphy, G (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust Med Res Council Bldg, Cambridge CB2 2XY, England.	gm290@cam.ac.uk		Knauper, Vera/0000-0002-3965-9924				Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bode W, 2000, METH MOL B, V151, P45, DOI 10.1385/1-59259-046-2:045; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Gao G, 2000, J MOL BIOL, V301, P537, DOI 10.1006/jmbi.2000.3976; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Ikeda U, 2003, CLIN CARDIOL, V26, P55, DOI 10.1002/clc.4960260203; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Lee MH, 2002, PROTEIN SCI, V11, P2493, DOI 10.1110/ps.0216202; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lee MH, 2001, BIOCHEM BIOPH RES CO, V280, P945, DOI 10.1006/bbrc.2000.4192; Llano E, 1999, CANCER RES, V59, P2570; MORRISON JF, 1995, METHOD ENZYMOL, V248, P201; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Ohta S, 2001, J RHEUMATOL, V28, P1756; Seiki M, 2003, CANCER SCI, V94, P569, DOI 10.1111/j.1349-7006.2003.tb01484.x; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stracke JO, 2000, J BIOL CHEM, V275, P14809, DOI 10.1074/jbc.275.20.14809; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Williamson RA, 2001, J BIOL CHEM, V276, P32966, DOI 10.1074/jbc.M101843200; Woessner JF, 2002, MOL BIOTECHNOL, V22, P33, DOI 10.1385/MB:22:1:033	26	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17562	17569		10.1074/jbc.M312589200	http://dx.doi.org/10.1074/jbc.M312589200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14734567	hybrid			2022-12-27	WOS:000220870400084
J	Mansson, R; Tsapogas, P; Akerlund, M; Lagergren, A; Gisler, R; Sigvardsson, M				Mansson, R; Tsapogas, P; Akerlund, M; Lagergren, A; Gisler, R; Sigvardsson, M			Pearson correlation analysis of microarray data allows for the identification of genetic targets for early B-cell factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; LOOP-HELIX PROTEINS; LYMPHOCYTE DEVELOPMENT; IMMUNOGLOBULIN ENHANCER; E2A; EXPRESSION; DIFFERENTIATION; MOUSE; EBF; PROMOTER	B lymphocyte development is a complex biological process critically dependent on the transcription factor early B cell factor (EBF). To deepen understanding of the roles for EBF in this process, we have used Pearson correlation analysis to evaluate microarray data from a set of mouse B lymphoid cell lines representing different stages of development. Comparing the expression pattern of EBF to that of the other genes in the data set revealed that VpreB1, mb-1, and lambda5, all known target genes, presented high correlation values to EBF. High correlations were also seen for the VpreB3 and CD19 genes and biochemical as well as functional data supported that they are target genes for EBF even though the expression of CD19 was critically dependent of Pax-5. We also obtained evidence for extensive collaborative actions of EBF and E47 even though microarray analysis of hematopoetic progenitor cells ectopically expressing these proteins suggested that they activated only a subset of pre-B cell restricted genes.	Lund Univ, Stemcell Ctr, Dept Heamatopoet Stemcell Biol, S-22184 Lund, Sweden	Lund University	Sigvardsson, M (corresponding author), BMC B12, S-22184 Lund, Sweden.	mikael.sigvardsson@stemcell.lu.se	Mansson, Robert/D-4372-2014; Tsapogas, Panagiotis/AAN-2465-2020	Mansson, Robert/0000-0003-0738-0328; Tsapogas, Panagiotis/0000-0002-9450-2604; Sigvardsson, Mikael/0000-0001-8527-7276				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Akerblad P, 1999, MOL CELL BIOL, V19, P392; Akerblad P, 2002, MOL CELL BIOL, V22, P8015, DOI 10.1128/MCB.22.22.8015-8025.2002; Akerblad P, 1999, J IMMUNOL, V163, P5453; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAUER SR, 1988, CURR TOP MICROBIOL, V137, P130; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Ghia P, 1998, IMMUNOL TODAY, V19, P480, DOI 10.1016/S0167-5699(98)01330-9; Greenbaum S, 2002, P NATL ACAD SCI USA, V99, P15030, DOI 10.1073/pnas.232299999; Greicius G, 2003, J LEUKOCYTE BIOL, V74, P126, DOI 10.1189/jlb.1202594; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hoffmann R, 2003, CURR OPIN IMMUNOL, V15, P239, DOI 10.1016/S0952-7915(03)00047-5; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liberg D, 2002, MOL CELL BIOL, V22, P8389, DOI 10.1128/MCB.22.24.8389-8397.2002; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Persson C, 1998, EUR J IMMUNOL, V28, P787; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Romanow WJ, 2000, MOL CELL, V5, P343, DOI 10.1016/S1097-2765(00)80429-3; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIRASAWA T, 1993, EMBO J, V12, P1827, DOI 10.1002/j.1460-2075.1993.tb05831.x; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Sigvardsson M, 2002, MOL CELL BIOL, V22, P8539, DOI 10.1128/MCB.22.24.8539-8551.2002; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; Souabni A, 2002, IMMUNITY, V17, P781, DOI 10.1016/S1074-7613(02)00472-7; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; Tsapogas P, 2003, J LEUKOCYTE BIOL, V74, P102, DOI 10.1189/jlb.0103008; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Zhang Z, 2003, EMBO J, V22, P4759, DOI 10.1093/emboj/cdg464; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	51	54	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17905	17913		10.1074/jbc.M400589200	http://dx.doi.org/10.1074/jbc.M400589200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960572	hybrid			2022-12-27	WOS:000220870400124
J	Morales, M; Barcena, J; Ramirez, MA; Boga, JA; Parra, F; Torres, JM				Morales, M; Barcena, J; Ramirez, MA; Boga, JA; Parra, F; Torres, JM			Synthesis in vitro of rabbit hemorrhagic disease virus subgenomic RNA by internal initiation on (-)sense genomic RNA - Mapping of a subgenomic promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TURNIP CRINKLE VIRUS; MOSAIC-VIRUS; ESCHERICHIA-COLI; VIRAL-RNA; MUTATIONAL ANALYSIS; STRAND SYNTHESIS; POLYMERASE; SEQUENCES; IDENTIFICATION; TRANSCRIPTION	Rabbit hemorrhagic disease virus (RHDV), a positive-strand RNA virus, is the type species of the Lagovirus within the Caliciviridae. In addition to the genomic RNA of 7.4 kb, a subgenomic mRNA (sgRNA) of 2.2 kb, which is identical in sequence to the 3' one-third of the genomic RNA, is also synthesized in RHDV-infected cells. Numerous RNA viruses make sgRNA for expression of their 3'-proximal genes. A relevant mechanism for viral gene expression is the regulation of sgRNA synthesis by specific promoter elements. In this study, we have investigated in vitro the sgRNA synthesis mechanism using recombinant RHDV RNA-dependent RNA polymerase produced in baculovirus-infected insect cells and synthetic RHDV (-) RNAs of different lengths containing regions located upstream of the subgenomic start site. We report evidences supporting that the sgRNA of RHDV is synthesized in vitro by internal initiation (subgenomic promoter) on (-) RNA templates of genomic length. The deletion mapping of the subgenomic promoter starting from minus-strand genomic length RNA showed that a sequence of 50 nucleotides upstream of the sgRNA start site (+1) is sufficient for full subgenomic promoter activity in an in vitro assay using recombinant RHDV RNA-dependent RNA polymerase. This study reports the first description of a subgenomic promoter in a member of the Caliciviridae.	INIA, Ctr Invest Sanidad Anim, Madrid 28130, Spain; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Oviedo	Torres, JM (corresponding author), INIA, Ctr Invest Sanidad Anim, Madrid 28130, Spain.	jmtorres@inia.es	de Paz, Miguel Ángel Ramírez/H-3171-2015; Barcena, Juan/B-8855-2013; Torres, Juan Maria/L-8768-2013; Parra, Francisco/D-5401-2009; Boga, Jose Antonio/ABA-2719-2021; Camarzana, Monica Morales/E-6725-2015	de Paz, Miguel Ángel Ramírez/0000-0002-5868-2134; Barcena, Juan/0000-0001-6050-0654; Torres, Juan Maria/0000-0003-0443-9232; Parra, Francisco/0000-0002-1885-9521; Boga, Jose Antonio/0000-0002-5500-9972; Camarzana, Monica Morales/0000-0001-9786-9076				Adkins S, 1998, VIROLOGY, V252, P1, DOI 10.1006/viro.1998.9449; Alonso JMM, 1996, J VIROL, V70, P1261; BALMORI E, 1993, BIOCHIMIE, V75, P517, DOI 10.1016/0300-9084(93)90056-X; BOCCARD F, 1993, VIROLOGY, V193, P563, DOI 10.1006/viro.1993.1165; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; Clarke IN, 1997, J GEN VIROL, V78, P291, DOI 10.1099/0022-1317-78-2-291; CUBBIT D, 1995, ARCH VIROL         S, V10, P359; Dreher TW, 1999, ANNU REV PHYTOPATHOL, V37, P151, DOI 10.1146/annurev.phyto.37.1.151; FRENCH R, 1988, J VIROL, V62, P2411, DOI 10.1128/JVI.62.7.2411-2420.1988; Green KY, 2000, J INFECT DIS, V181, pS322, DOI 10.1086/315591; Guan HC, 1997, RNA, V3, P1401; Haasnoot PCJ, 2000, RNA, V6, P708, DOI 10.1017/S1355838200992471; JOHNSTON JC, 1995, VIROLOGY, V214, P100, DOI 10.1006/viro.1995.9950; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Koev G, 1999, J VIROL, V73, P2876, DOI 10.1128/JVI.73.4.2876-2885.1999; Konig M, 1998, J VIROL, V72, P4492; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIS R, 1990, J VIROL, V64, P1726, DOI 10.1128/JVI.64.4.1726-1733.1990; Machin A, 2001, J BIOL CHEM, V276, P27787, DOI 10.1074/jbc.M100707200; Marin MS, 2000, J VIROL, V74, P10846, DOI 10.1128/JVI.74.22.10846-10851.2000; MARSH LE, 1988, NUCLEIC ACIDS RES, V16, P981, DOI 10.1093/nar/16.3.981; MEYERS G, 1991, VIROLOGY, V184, P664, DOI 10.1016/0042-6822(91)90436-F; MEYERS G, 1991, VIROLOGY, V184, P677, DOI 10.1016/0042-6822(91)90437-G; Miller WA, 2000, VIROLOGY, V273, P1, DOI 10.1006/viro.2000.0421; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; OHLINGER VF, 1990, J VIROL, V64, P3331, DOI 10.1128/JVI.64.7.3331-3336.1990; Olsthoorn RCL, 1999, EMBO J, V18, P4856, DOI 10.1093/emboj/18.17.4856; Osman TAM, 2000, J VIROL, V74, P11671, DOI 10.1128/JVI.74.24.11671-11680.2000; Panavas T, 2002, VIROLOGY, V296, P263, DOI 10.1006/viro.2002.1423; PARRA F, 1993, VIRUS RES, V27, P219, DOI 10.1016/0168-1702(93)90034-K; PARRA F, 1990, J VIROL, V64, P4013, DOI 10.1128/JVI.64.8.4013-4015.1990; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANKAR S, 1991, J VIROL, V65, P2993, DOI 10.1128/JVI.65.6.2993-3000.1991; Singh RN, 1997, VIROLOGY, V233, P430, DOI 10.1006/viro.1997.8621; Sit TL, 1998, SCIENCE, V281, P829, DOI 10.1126/science.281.5378.829; SONG CZ, 1995, J MOL BIOL, V254, P6, DOI 10.1006/jmbi.1995.0594; SUMMERS MD, 1978, VIROLOGY, V84, P390, DOI 10.1016/0042-6822(78)90257-X; VANDERKUYL AC, 1990, VIROLOGY, V176, P346, DOI 10.1016/0042-6822(90)90004-B; VANDERVOSSEN EAG, 1995, VIROLOGY, V212, P663, DOI 10.1006/viro.1995.1524; Vazquez AL, 2001, ARCH VIROL, V146, P59, DOI 10.1007/s007050170191; Vazquez AL, 1998, J VIROL, V72, P2999; Wang JL, 1997, VIROLOGY, V232, P174, DOI 10.1006/viro.1997.8550; Wirblich C, 1996, J VIROL, V70, P7974, DOI 10.1128/JVI.70.11.7974-7983.1996; WIRBLICH C, 1995, J VIROL, V69, P7159, DOI 10.1128/JVI.69.11.7159-7168.1995	47	36	43	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17013	17018		10.1074/jbc.M313674200	http://dx.doi.org/10.1074/jbc.M313674200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14744857	hybrid			2022-12-27	WOS:000220870400017
J	Tashiro, S; Sumi, T; Uozumi, N; Shimizu, T; Nakamura, T				Tashiro, S; Sumi, T; Uozumi, N; Shimizu, T; Nakamura, T			B-Myb-dependent regulation of c-Myc expression by cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; ARACHIDONIC-ACID RELEASE; INDUCED APOPTOSIS; NUCLEAR-ENVELOPE; ALVEOLAR MACROPHAGES; GENE-PRODUCT; TRANSLOCATION; ACTIVATION; 5-LIPOXYGENASE; LOCALIZATION	Cytosolic phospholipase A(2) (cPLA(2)) cleaves membrane phospholipids to release arachidonic acid, initiating lipoxygenase and cyclooxygenase pathways. Mice lacking a gene for cPLA(2) suggested important roles of the protein in allergic responses, fertility, and neural cell death. Here we show that cPLA(2) negatively regulates c-Myc expression in a B-Myb-dependent manner. Overexpression of cPLA(2) protein but not a mutant cPLA(2) protein that lacks in vitro binding ability with B-Myb inhibits B-Myb-dependent c-myc gene expression. The inhibition was associated with physical interaction of B-Myb protein with cPLA(2) both in the cytoplasm and the nucleus. Binding site analysis demonstrated that both the N and C termini of cPLA(2) interact with B-Myb. Macrophage colony stimulating factor (MCSF) stimulated cPLA(2) redistribution into the nucleus and also association with B-Myb in human monocytes. Importantly, macrophages from mice with a disrupted cPLA(2) gene demonstrated significantly increased levels of c-Myc protein in the nucleus compared with cells from the wild-type mice, whereas B-Myb levels were similar in the cells from the cPLA(2)(+/+) and cPLA(2)(-/-) mice. Moreover, an introduction of cPLA(2) into cPLA(2)(-/-) mouse macrophages resulted in decreased c-Myc protein levels, and an inhibition of cPLA(2) expression by small interfering RNAs or antisense RNA increased the c-myc transcription in macrophage colony stimulating factor-activated human monocytes. These findings provide new insights into the function of cPLA(2) in B-Myb-dependent gene expression.	Nagasaki Univ, Sch Dent, Dept Radiol & Canc Biol, Nagasaki 8528588, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1130033, Japan	Nagasaki University; University of Tokyo; Japan Science & Technology Agency (JST)	Nakamura, T (corresponding author), Nagasaki Univ, Sch Dent, Dept Radiol & Canc Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	taku@net.nagasaki-u.ac.jp	Uozumi, Nobuyuki/AAG-3252-2019; Shimizu, Takao/AAV-7052-2021					Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Adam-Klages S, 1998, J IMMUNOL, V161, P5687; Amati B, 2001, NAT CELL BIOL, V3, pE112, DOI 10.1038/35074634; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Gresham A, 1996, AM J PHYSIOL-CELL PH, V270, pC1037, DOI 10.1152/ajpcell.1996.270.4.C1037; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Haq S, 2003, NAT MED, V9, P944, DOI 10.1038/nm891; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Pawliczak R, 2002, J BIOL CHEM, V277, P33153, DOI 10.1074/jbc.M200246200; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Pilane CM, 2002, J CELL PHYSIOL, V191, P191, DOI 10.1002/jcp.10090; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Sheridan AM, 2001, J BIOL CHEM, V276, P29899, DOI 10.1074/jbc.M103758200; SierraHonigmann R, 1996, LAB INVEST, V74, P684; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TASHIRO S, 1995, ONCOGENE, V10, P1699; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889	35	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17715	17722		10.1074/jbc.M310561200	http://dx.doi.org/10.1074/jbc.M310561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769798	hybrid			2022-12-27	WOS:000220870400102
J	Chao, SH; Harada, JN; Hyndman, F; Gao, XQ; Nelson, CG; Chanda, SK; Caldwell, JS				Chao, SH; Harada, JN; Hyndman, F; Gao, XQ; Nelson, CG; Chanda, SK; Caldwell, JS			PDX1, a cellular homeoprotein, binds to and regulates the activity of human cytomegalovirus immediate early promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITORS; CCAAT DISPLACEMENT PROTEIN; DNA-BINDING; POU-DOMAIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; P-TEFB; COOPERATIVE INTERACTIONS; REPRESSES TRANSCRIPTION; HOMEODOMAIN PROTEINS	Cellular homeoproteins have been shown to regulate the transcription of several viruses, including herpes simplex viruses, human papillomaviruses, and mouse mammary tumor viruses. Previous studies investigating the anti-viral mechanisms of several cyclin-dependent kinase inhibitors showed that the homeoproteins, pre B-cell leukemia transcription factor 1 (PBX1) and PBX-regulating protein-1 (PREP1), function as transcriptional activators of Moloney murine leukemia virus. Here, we examined the involvement of cellular homeoproteins in regulating the activity of the human cytomegalovirus immediate early (CMV IE) promoter. We identified a 45-bp element located at position - 593 to - 549 upstream of the transcription start site of the CMV IE gene, which contains multiple putative homeoprotein binding motifs. Gel shift assays demonstrated the physical association between a homeodomain protein, pancreatic-duodenal homeobox factor-1 (PDX1) and the 45-bp cytomegalovirus (CMV) region. We further determined that PDX1 represses the CMV IE promoter activity in 293 cells. Overexpression of PDX1 resulted in a decrease in transcription of the CMV IE gene. Conversely, blocking PDX1 protein synthesis and mutating the PDX1 binding sites enhanced CMV IE-dependent transcription. Collectively, our results represent the first work demonstrating that a cellular homeoprotein, PDX1, may be a repressor involved in regulation of human CMV gene expression.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Novartis	Caldwell, JS (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	caldwell@gnf.org	Barron, Francie/E-5870-2010	Barron, Francie/0000-0001-6568-7358				Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; Angulo A, 2000, J VIROL, V74, P2826, DOI 10.1128/JVI.74.6.2826-2839.2000; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2003, MOL CELL BIOL, V23, P831, DOI 10.1128/MCB.23.3.831-841.2003; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GHAZAL P, 1990, VIROLOGY, V174, P18, DOI 10.1016/0042-6822(90)90049-W; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Greaves RF, 1998, J VIROL, V72, P366, DOI 10.1128/JVI.72.1.366-379.1998; Hajduch M, 1999, ADV EXP MED BIOL, V457, P341; HENNIGHAUSEN L, 1986, EMBO J, V5, P1367, DOI 10.1002/j.1460-2075.1986.tb04368.x; Herr W, 1998, COLD SPRING HARB SYM, V63, P599, DOI 10.1101/sqb.1998.63.599; Iskenderian AC, 1996, J VIROL, V70, P383, DOI 10.1128/JVI.70.1.383-392.1996; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Liu Y, 2001, J BIOL CHEM, V276, P17985, DOI 10.1074/jbc.M100678200; Lu M, 1996, ENDOCRINOLOGY, V137, P2959, DOI 10.1210/en.137.7.2959; Lundquist CA, 1999, J VIROL, V73, P9039, DOI 10.1128/JVI.73.11.9039-9052.1999; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marchini A, 2001, J VIROL, V75, P1870, DOI 10.1128/JVI.75.4.1870-1878.2001; Meier JL, 1996, INTERVIROLOGY, V39, P331, DOI 10.1159/000150504; Mocarski ES, 1996, P NATL ACAD SCI USA, V93, P11321, DOI 10.1073/pnas.93.21.11321; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; O'Connor MJ, 2000, J VIROL, V74, P401, DOI 10.1128/JVI.74.1.401-410.2000; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pattison S, 1997, J VIROL, V71, P2013, DOI 10.1128/JVI.71.3.2013-2022.1997; Pedersen AA, 2002, BIOCHEM BIOPH RES CO, V295, P243, DOI 10.1016/S0006-291X(02)00674-5; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Perez-Villamil B, 1999, ENDOCRINOLOGY, V140, P3857, DOI 10.1210/en.140.8.3857; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; Sausville EA, 2000, ANN NY ACAD SCI, V910, P207; Schang LM, 1998, J VIROL, V72, P5626, DOI 10.1128/JVI.72.7.5626-5637.1998; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Shen WF, 1999, MOL CELL BIOL, V19, P3051; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; Turner EE, 1997, NUCLEIC ACIDS RES, V25, P2589, DOI 10.1093/nar/25.13.2589; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x; Zhu Q, 2000, J VIROL, V74, P6348, DOI 10.1128/JVI.74.14.6348-6357.2000; Zhu Q, 2002, J VIROL, V76, P2168, DOI 10.1128/JVI.76.5.2168-2179.2002	59	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16111	16120		10.1074/jbc.M312304200	http://dx.doi.org/10.1074/jbc.M312304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764605	hybrid			2022-12-27	WOS:000220747900052
J	Elliott, S; Chang, D; Delorme, E; Eris, T; Lorenzini, T				Elliott, S; Chang, D; Delorme, E; Eris, T; Lorenzini, T			Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIERYTHROPOIETIN MONOCLONAL-ANTIBODIES; CORE-GLYCOSYLATION EFFICIENCY; HYDROXY AMINO-ACID; ENDOPLASMIC-RETICULUM; BIOLOGICAL-ACTIVITY; CELL-SURFACE; ACTIVE-SITE; PROTEIN; PEPTIDES; SEQUON	N-Linked glycosylation is a post-translational event whereby carbohydrates are added to secreted proteins at the consensus sequence Asn-Xaa-Ser/Thr, where Xaa is any amino acid except proline. Some consensus sequences in secreted proteins are not glycosylated, indicating that consensus sequences are necessary but not sufficient for glycosylation. In order to understand the structural rules for N-linked glycosylation, we introduced N-linked consensus sequences by site-directed mutagenesis into the polypeptide chain of the recombinant human erythropoietin molecule. Some regions of the polypeptide chain supported N-linked glycosylation more effectively than others. N-Linked glycosylation was inhibited by an adjacent proline suggesting that sequence context of a consensus sequence could affect glycosylation. One N-linked consensus sequence (Asn(123) - Thr(125)) introduced into a position close to the existing O-glycosylation site (Ser(126)) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation. The presence of a consensus sequence on the protein surface of the folded molecule did not appear to be a prerequisite for oligosaccharide addition. However, it was noted that recombinant human erythropoietin analogs that were hyperglycosylated at sites that were normally buried had altered protein structures. This suggests that carbohydrate addition precedes polypeptide folding.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Elliott, S (corresponding author), Amgen Inc, 1 Amgen Ctr, Thousand Oaks, CA 91320 USA.	selliott@amgen.com						Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8; BAUSE E, 1979, FEBS LETT, V108, P341, DOI 10.1016/0014-5793(79)80559-1; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERG DT, 1993, PROTEIN SCI, V2, P126; Breuer W, 2001, FEBS LETT, V501, P106, DOI 10.1016/S0014-5793(01)02641-2; BROWNE JK, 1986, COLD SPRING HARB SYM, V51, P673; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cheetham JC, 1998, NAT STRUCT BIOL, V5, P861, DOI 10.1038/2302; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; DELORME E, 1992, BIOCHEMISTRY-US, V31, P9871, DOI 10.1021/bi00156a003; EGRIE JC, 1986, IMMUNOBIOLOGY, V172, P213, DOI 10.1016/S0171-2985(86)80101-2; Egrie JC, 2003, EXP HEMATOL, V31, P290, DOI 10.1016/S0301-472X(03)00006-7; EGRIE JC, 1987, J IMMUNOL METHODS, V99, P235, DOI 10.1016/0022-1759(87)90133-5; Egrie JC, 2001, BRIT J CANCER, V84, P3, DOI 10.1054/bjoc.2001.1746; Elliott S, 1997, BLOOD, V89, P493, DOI 10.1182/blood.V89.2.493; Elliott S, 1996, BLOOD, V87, P2714, DOI 10.1182/blood.V87.7.2714.bloodjournal8772714; Elliott S, 2003, NAT BIOTECHNOL, V21, P414, DOI 10.1038/nbt799; ELLIOTT S, 1994, BIOCHEMISTRY-US, V33, P11237, DOI 10.1021/bi00203a020; Elliott S, 1996, BLOOD, V87, P2702, DOI 10.1182/blood.V87.7.2702.bloodjournal8772702; ENDO Y, 1992, J BIOCHEM, V112, P700, DOI 10.1093/oxfordjournals.jbchem.a123961; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HANIU M, 1993, PROTEIN SCI, V2, P1441, DOI 10.1002/pro.5560020908; HIGUCHI M, 1992, J BIOL CHEM, V267, P7703; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; Hounsell Elizabeth F., 1994, Molecular Biotechnology, V2, P45, DOI 10.1007/BF02789289; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; Imperiali B, 1995, BIOORGAN MED CHEM, V3, P1565, DOI 10.1016/0968-0896(95)00142-5; Kalies KU, 1998, EUR J BIOCHEM, V254, P1, DOI 10.1046/j.1432-1327.1998.2540001.x; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; LIVI GP, 1991, J BIOL CHEM, V266, P15348; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; NARHI LO, 1991, J BIOL CHEM, V266, P23022; Nicolaes GAF, 1999, BIOCHEMISTRY-US, V38, P13584, DOI 10.1021/bi991165r; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NISHIKAWA A, 2001, BIOCHEM J, V355, P1; OConnor SE, 1996, CHEM BIOL, V3, P803, DOI 10.1016/S1074-5521(96)90064-2; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Toyoda T, 2000, J BIOCHEM-TOKYO, V128, P731, DOI 10.1093/oxfordjournals.jbchem.a022809; Ujvari A, 2001, J BIOL CHEM, V276, P5924, DOI 10.1074/jbc.M009203200; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	45	48	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16854	16862		10.1074/jbc.M311095200	http://dx.doi.org/10.1074/jbc.M311095200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757769	hybrid			2022-12-27	WOS:000220747900138
J	Gao, SJ; Chen, J; Brodsky, SV; Huang, H; Adler, S; Lee, JH; Dhadwal, N; Cohen-Gould, L; Gross, SS; Goligorsky, MS				Gao, SJ; Chen, J; Brodsky, SV; Huang, H; Adler, S; Lee, JH; Dhadwal, N; Cohen-Gould, L; Gross, SS; Goligorsky, MS			Docking of endothelial nitric oxide synthase (eNOS) to the mitochondrial outer membrane - A pentabasic amino acid sequence in the autoinhibitory domain of eNOS targets a proteinase K-cleavable peptide on the cytoplasmic face of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CYTOCHROME-C-OXIDASE; SKELETAL-MUSCLE; SUPEROXIDE; CAVEOLIN-1; IMPORT; PEROXYNITRITE; RELEASE; PHOSPHORYLATION; TRANSLOCATION	Despite growing evidence for a mitochondrial localization of nitric oxide ( NO) synthase and a broadening spectrum of NO actions on mitochondrial respiration and apoptosis, the basis for interaction between the enzyme and the organelle remain obscure. Here we investigated mitochondrial localization of endothelial nitric oxide synthase ( eNOS) in human umbilical vein endothelial cells and human embryonic kidney cells transfected or infected with eNOS expression vectors. Copurification of eNOS with mitochondria was observed in both human umbilical vein endothelial cells and eNOS-expressing human embryonic kidney cells. Immunodetectable eNOS was cleaved from mitochondria by proteinase K treatment, suggesting eNOS association with the outer mitochondrial membrane. Localization of eNOS to a proteinase K-cleavable site on the cytoplasmic face of the outer membrane was confirmed by immunogold labeling of non-permeabilized mitochondria. Markers for mitochondrial subfractions ruled out the possibility of eNOS association with an intramitochondrial site or inverted mitochondrial particles. Denaturation of eNOS did not attenuate association with mitochondria. Mutant eNOS lacking a pentabasic amino acid sequence within the autoinhibitory domain ( residues 628 - 632 of the bovine eNOS) showed dramatically reduced binding to the mitochondrial but not to the plasma membrane, which was associated with increased oxygen consumption. Collectively, these findings argue in favor of eNOS localization to the outer mitochondrial membrane in endothelial cells and identify elements of a novel anchoring mechanism.	SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; New York Med Coll, Dept Med & Pharmacol, Valhalla, NY 10595 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; New York Medical College; Cornell University	Gao, SJ (corresponding author), SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.	gao@pharm.sunysb.edu; Michael_Goligorsky@nymc.edu	brodsky, sergey/AAU-3507-2021; Brodsky, Sergey/E-2807-2011		NIDDK NIH HHS [DK52783, DK45462, DK54602] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054602, R01DK045462, R01DK052783] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Brodsky SV, 2002, AM J PHYSIOL-HEART C, V283, pH2130, DOI 10.1152/ajpheart.00196.2002; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Chow CK, 2001, BIOL SIGNAL RECEPT, V10, P112; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Frandsen U, 1996, BIOCHEM BIOPH RES CO, V227, P88, DOI 10.1006/bbrc.1996.1472; Fukuto JM, 2000, NITRIC OXIDE BIOL PA, P23, DOI DOI 10.1016/B978-012370420-7/50003-4; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GARTNER F, 1995, J BIOL CHEM, V270, P3788; Geissler A, 2000, MOL BIOL CELL, V11, P3977, DOI 10.1091/mbc.11.11.3977; Ghafourifar P, 1999, BIOL CHEM, V380, P1025, DOI 10.1515/BC.1999.127; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 2001, BIOL SIGNAL RECEPT, V10, P57; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Gratton J.-P., 2000, NITRIC OXIDE BIOL PA, P157; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; Li WP, 2001, J CELL SCI, V114, P1397; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Loke KE, 1999, CIRC RES, V84, P840; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Melino G, 2000, CELL MOL LIFE SCI, V57, P612, DOI 10.1007/PL00000723; Michel T, 1999, BRAZ J MED BIOL RES, V32, P1361, DOI 10.1590/S0100-879X1999001100006; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Reiner M, 2001, J HISTOCHEM CYTOCHEM, V49, P1605, DOI 10.1177/002215540104901214; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044	43	96	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15968	15974		10.1074/jbc.M308504200	http://dx.doi.org/10.1074/jbc.M308504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761967	hybrid			2022-12-27	WOS:000220747900034
J	Hoy, JA; Kundu, S; Trent, JT; Ramaswamy, S; Hargrove, MS				Hoy, JA; Kundu, S; Trent, JT; Ramaswamy, S; Hargrove, MS			The crystal structure of Synechocystis hemoglobin with a covalent heme linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(5); LIGAND-BINDING; MYCOBACTERIUM-TUBERCULOSIS; HEXACOORDINATE HEMOGLOBIN; TRUNCATED HEMOGLOBINS; SULFITE OXIDASE; NMR MODELS; HEMICHROME; MYOGLOBIN; LEGHEMOGLOBIN	The x-ray crystal structure of Synechocystis hemoglobin has been solved to a resolution of 1.8 Angstrom. The conformation of this structure is surprisingly different from that of the previously reported solution structure, probably due in part to a covalent linkage between the heme 2-vinyl and His(117) that is present in the crystal structure but not in the structure solved by NMR. Synechocystis hemoglobin is a hexacoordinate hemoglobin in which the heme iron is coordinated by both the proximal and distal histidines. It is also a member of the "truncated hemoglobin" family that is much shorter in primary structure than vertebrate and plant hemoglobins. In contrast to other truncated hemoglobins, the crystal structure of Synechocystis hemoglobin displays no "ligand tunnel" and shows that several important amino acid side chains extrude into the solvent instead of residing inside the heme pocket. The stereochemistry of hexacoordination is compared with other hexacoordinate hemoglobins and cytochromes in an effort to illuminate factors contributing to ligand affinity in hexacoordinate hemoglobins.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	Iowa State University; University of Iowa	Hargrove, MS (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	msh@iastate.edu	Subramanian, Ramaswamy/Q-8671-2019	Subramanian, Ramaswamy/0000-0002-6709-190X				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Brucker EA, 1996, J BIOL CHEM, V271, P25419, DOI 10.1074/jbc.271.41.25419; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burr AHJ, 2000, J BIOL CHEM, V275, P4810, DOI 10.1074/jbc.275.7.4810; Chen YW, 2000, ACTA CRYSTALLOGR D, V56, P1535, DOI 10.1107/S0907444900012002; Chen YW, 2001, ACTA CRYSTALLOGR D, V57, P1457, DOI 10.1107/S0907444901010824; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Das TK, 1999, BIOCHEMISTRY-US, V38, P15360, DOI 10.1021/bi991237e; DOU Y, 1995, J BIOL CHEM, V270, P15993, DOI 10.1074/jbc.270.27.15993; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Durley RCE, 1996, ACTA CRYSTALLOGR D, V52, P65, DOI 10.1107/S0907444995007827; Falzone CJ, 2002, J MOL BIOL, V324, P1015, DOI 10.1016/S0022-2836(02)01093-8; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kundu S, 2003, BIOPHYS J, V84, P3931, DOI 10.1016/S0006-3495(03)75121-2; Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8; Kundu S, 2003, PROTEINS, V50, P239, DOI 10.1002/prot.10277; Kundu S, 2002, PROTEINS, V46, P268, DOI 10.1002/prot.10048; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MITCHELL DT, 1995, J MOL BIOL, V251, P421, DOI 10.1006/jmbi.1995.0445; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Riccio A, 2002, P NATL ACAD SCI USA, V99, P9801, DOI 10.1073/pnas.132182099; RIFKIND JM, 1994, METHOD ENZYMOL, V231, P449; Robinson VL, 2003, BIOCHEMISTRY-US, V42, P10113, DOI 10.1021/bi030059t; RodriguezMaranon MJ, 1996, BIOCHEMISTRY-US, V35, P16378, DOI 10.1021/bi961895o; Rudolph MJ, 2003, ACTA CRYSTALLOGR D, V59, P1183, DOI 10.1107/S0907444903009934; Scott NL, 2002, BIOCHEMISTRY-US, V41, P6902, DOI 10.1021/bi025609m; Scott NL, 2000, PROTEIN SCI, V9, P587; Shakarji CM, 1998, J RES NATL INST STAN, V103, P633, DOI 10.6028/jres.103.043; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; Vu BC, 2002, J AM CHEM SOC, V124, P8544, DOI 10.1021/ja026569c; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679	58	59	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16535	16542		10.1074/jbc.M313707200	http://dx.doi.org/10.1074/jbc.M313707200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14736872	hybrid			2022-12-27	WOS:000220747900103
J	Koenderink, JB; Swarts, HGP; Willems, PHGM; Krieger, E; De Pont, JJHHM				Koenderink, JB; Swarts, HGP; Willems, PHGM; Krieger, E; De Pont, JJHHM			A conformation-specific interhelical salt bridge in the K+ binding site of gastric H,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-BINDING; DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; TRANSMEMBRANE DOMAINS; FUNCTIONAL EXPRESSION; H+,K+-ATPASE ACTIVITY; MUTATIONAL ANALYSIS; CALCIUM-PUMP; AMINO-ACID; NA,K-ATPASE	Homology modeling of gastric H, K-ATPase based on the E-2 model of sarcoplasmic reticulum Ca2+-ATPase (Toyoshima, C., and Nomura, H. (2002) Nature 392, 835-839) revealed the presence of a single high-affinity binding site for K+ and an E-2 form-specific salt bridge between Glu(820) (M6) and Lys(791) (M5). In the E820Q mutant this salt bridge is no longer possible, and the head group of Lys791, together with a water molecule, fills the position of the K+ ion and apparently mimics the K+-filled cation binding pocket. This gives an explanation for the K+-independent ATPase activity and dephosphorylation step of the E820Q mutant (Swarts, H. G. P., Hermsen, H. P. H., Koenderink, J. B., Schuurmans Stekhoven, F. M. A. H., and De Pont, J. J. H. H. M. ( 1998) EMBO J. 17, 3029 - 3035) and, indirectly, for its E-1 preference. The model is strongly supported by a series of reported mutagenesis studies on charged and polar amino acid residues in the membrane domain. To further test this model, Lys(791) was mutated alone and in combination with other crucial residues. In the K791A mutant, the K+ affinity was markedly reduced without altering the E-2 preference of the enzyme. The K791A mutation prevented, in contrast to the K791R mutation, the spontaneous dephosphorylation of the E820Q mutant as well as its conformational equilibrium change toward E-1. This indicates that the salt bridge is essential for high-affinity K+ binding and the E-2 preference of H,K-ATPase. Moreover, its breakage (E820Q) can generate a K+-insensitive activity and an E-1 preference. In addition, the study gives a molecular explanation for the electroneutrality of H, K-ATPases.	Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.dePont@ncmls.kun.nl	Koenderink, Jan/N-3578-2014; Willems, P.H.G.M./L-4759-2015	Willems, P.H.G.M./0000-0002-0915-1599				Asano S, 2000, J BIOCHEM, V127, P993, DOI 10.1093/oxfordjournals.jbchem.a022716; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; BROWN ID, 1976, ACTA CRYSTALLOGR B, V32, P1957, DOI 10.1107/S0567740876006869; Bukrinsky JT, 2001, FEBS LETT, V494, P6, DOI 10.1016/S0014-5793(01)02301-8; Burnay M, 2003, J BIOL CHEM, V278, P19237, DOI 10.1074/jbc.M300946200; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHINEA G, 1995, PROTEINS, V23, P415, DOI 10.1002/prot.340230315; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; Guerini D, 2000, J BIOL CHEM, V275, P31361, DOI 10.1074/jbc.M003474200; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; Hermsen HPH, 2001, BIOCHEMISTRY-US, V40, P6527, DOI 10.1021/bi002456z; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Koenderink JB, 2003, J BIOL CHEM, V278, P51213, DOI 10.1074/jbc.M306384200; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; RABON EC, 1982, J BIOL CHEM, V257, P6296; REENSTRA WW, 1981, J MEMBRANE BIOL, V61, P55, DOI 10.1007/BF01870752; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; Rulli SJ, 2001, ARCH BIOCHEM BIOPHYS, V387, P27, DOI 10.1006/abbi.2000.2243; SKRABANJA ATP, 1987, BIOCHIM BIOPHYS ACTA, V903, P434, DOI 10.1016/0005-2736(87)90050-2; SKRABANJA ATP, 1984, BIOCHIM BIOPHYS ACTA, V774, P91, DOI 10.1016/0005-2736(84)90278-5; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Swarts HGP, 1999, MOL PHARMACOL, V55, P541; Swarts HGP, 2003, ANN NY ACAD SCI, V986, P308, DOI 10.1111/j.1749-6632.2003.tb07196.x; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Swarts HGP, 2001, J BIOL CHEM, V276, P36909, DOI 10.1074/jbc.M103945200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vagin O, 2001, BIOCHEMISTRY-US, V40, P7480, DOI 10.1021/bi0105328; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, FEBS LETT, V333, P44, DOI 10.1016/0014-5793(93)80372-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F	45	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16417	16424		10.1074/jbc.M400020200	http://dx.doi.org/10.1074/jbc.M400020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761952	hybrid, Green Published			2022-12-27	WOS:000220747900089
J	Ng, KKS; Pendas-Franco, N; Rojo, J; Boga, JA; Machin, A; Alonso, JMM; Parra, F				Ng, KKS; Pendas-Franco, N; Rojo, J; Boga, JA; Machin, A; Alonso, JMM; Parra, F			Crystal structure of Norwalk virus polymerase reveals the carboxyl terminus in the active site cleft	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; REVERSE-TRANSCRIPTASE; IDENTIFICATION; COMPLEXES; MECHANISM; PROGRAM; OLIGOMERIZATION; PURIFICATION; POLYPROTEIN; INITIATION	Norwalk virus is a major cause of acute gastroenteritis for which effective treatments are sorely lacking. To provide a basis for the rational design of novel antiviral agents, the main replication enzyme in Norwalk virus, the virally encoded RNA-dependent RNA polymerase (RdRP), has been expressed in an enzymatically active form, and its structure has been crystallographically determined both in the presence and absence of divalent metal cations. Although the overall fold of the enzyme is similar to that seen previously in the RdRP from rabbit hemorrhagic disease virus, the carboxyl terminus, surprisingly, is located in the active site cleft in five independent copies of the protein in three distinct crystal forms. The location of this carboxyl-terminal segment appears to interfere with the binding of double-stranded RNA in the active site cleft and may play a role in the initiation of RNA synthesis or mediate interactions with accessory replication proteins.	Univ Calgary, Dept Biol Sci, Div Biochem, Calgary, AB T2N 1N4, Canada; Univ Oviedo, Inst Univ Biotecnol Asturias, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Hosp Univ Cent Asturias, Serv Microbiol 1, Oviedo 33006, Spain	University of Calgary; University of Oviedo; Central University Hospital Asturias	Ng, KKS (corresponding author), Univ Calgary, Dept Biol Sci, Div Biochem, Calgary, AB T2N 1N4, Canada.	ngk@ucalgary.ca	Martin Alonso, Jose Manuel/C-7763-2013; Parra, Francisco/D-5401-2009; Boga, Jose Antonio/ABA-2719-2021	Martin Alonso, Jose Manuel/0000-0003-1725-6216; Parra, Francisco/0000-0002-1885-9521; Boga, Jose Antonio/0000-0002-5500-9972; Ng, Kenneth K.S./0000-0001-7280-8445				Adachi T, 2002, BBA-PROTEINS PROTEOM, V1601, P38, DOI 10.1016/S1570-9639(02)00433-8; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belliot G, 2003, J VIROL, V77, P10957, DOI 10.1128/JVI.77.20.10957-10974.2003; Blakeney SJ, 2003, VIROLOGY, V308, P216, DOI 10.1016/S0042-6822(03)00004-7; Bougie I, 2003, J BIOL CHEM, V278, P52471, DOI 10.1074/jbc.M308917200; Bougie I, 2003, J BIOL CHEM, V278, P3868, DOI 10.1074/jbc.M209785200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cameron Craig E., 2002, P255; DeLano WL, 2002, PYMOL USERS MANUAL; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Green KY, 2002, J VIROL, V76, P8582, DOI 10.1128/JVI.76.17.8582-8595.2002; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; HEY TD, 1986, J VIROL, V58, P790, DOI 10.1128/JVI.58.3.790-796.1986; Hobson SD, 2001, EMBO J, V20, P1153, DOI 10.1093/emboj/20.5.1153; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kensch O, 2000, J MOL BIOL, V301, P1029, DOI 10.1006/jmbi.2000.3998; Koopmans M, 2004, INT J FOOD MICROBIOL, V90, P23, DOI 10.1016/S0168-1605(03)00169-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laurila MRL, 2002, J BIOL CHEM, V277, P17117, DOI 10.1074/jbc.M111220200; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Liu BL, 1999, J GEN VIROL, V80, P291, DOI 10.1099/0022-1317-80-2-291; Machin A, 2001, J BIOL CHEM, V276, P27787, DOI 10.1074/jbc.M100707200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATA JD, 1995, RNA, V1, P466; PLOTCH SJ, 1989, J VIROL, V63, P216, DOI 10.1128/JVI.63.1.216-225.1989; Ponstingl H, 2000, PROTEINS, V41, P47; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Ranjith-Kumar CT, 2003, J MOL BIOL, V330, P675, DOI 10.1016/S0022-2836(03)00613-2; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Sarafianos SG, 1999, CHEM BIOL, V6, pR137, DOI 10.1016/S1074-5521(99)80071-4; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Vazquez AL, 2001, ARCH VIROL, V146, P59, DOI 10.1007/s007050170191; Vazquez AL, 1998, J VIROL, V72, P2999; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Wei L, 2001, J VIROL, V75, P1211, DOI 10.1128/JVI.75.3.1211-1219.2001; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; YOUNG DC, 1985, J VIROL, V54, P256, DOI 10.1128/JVI.54.2.256-264.1985; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	56	104	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16638	16645		10.1074/jbc.M400584200	http://dx.doi.org/10.1074/jbc.M400584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764591	hybrid			2022-12-27	WOS:000220747900115
J	Xu, B; Bhattacharjee, A; Roy, B; Feldman, GM; Cathcart, MK				Xu, B; Bhattacharjee, A; Roy, B; Feldman, GM; Cathcart, MK			Role of protein kinase C isoforms in the regulation of interleukin-13-induced 15-lipoxygenase gene expression in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; STAT1 SERINE PHOSPHORYLATION; CENTRIFUGAL ELUTRIATION CCE; SUPEROXIDE ANION PRODUCTION; MONONUCLEAR CELL SUBSETS; POLAR STEROL ESTERS; TYROSINE PHOSPHORYLATION; ENRICHED FRACTIONS; ENDOTHELIAL-CELLS; HUMAN ATHEROMA	We reported previously that interleukin-13 (IL-13) induces tyrosine phosphorylation/activation of Jak2 and Tyk2 kinases and Stats 1, 3, 5, and 6 in primary human monocytes. We recently revealed that p38 MAPK-mediated serine phosphorylation of both Stat1 and Stat3 is required for the induction of 15-lipoxygenase (15-LO) expression by IL-13. In this study, we present data indicating that another serine/threonine kinase, PKCdelta, is also required for IL-13-induced 15-LO expression. PKCdelta, a member of the novel protein kinase C (PKC) subclass, was rapidly phosphorylated and activated upon exposure to IL-13. Treatment of cells with rottlerin, a PKCdelta inhibitor, blocked IL-13-induced 15-LO mRNA and protein expression, whereas Go6976, an inhibitor of the conventional PKC subclass, had no inhibitory effects. Down-regulation of cellular PKCdelta protein levels by PKCdelta-specific antisense oligodeoxyribonucleotides also inhibited 15-LO expression markedly. IL-13-induced 15-LO expression resulted in significant inhibition of synthesis of the potent chemotactic factor leukotriene B-4, and that process was reversed by rottlerin, presumably through the blockage of PKCdelta-dependent 15-LO expression. Furthermore, our data demonstrate that IL-13-mediated activation of PKCdelta and p38 MAPK are independent pathways, because inhibition of one kinase activity had no effect on the other, suggesting that the two pathways act in parallel to regulate the downstream targets necessary for 15-LO expression. Inhibition of PKCdelta activation by rottlerin also markedly attenuated IL-13-induced Stat3 DNA binding activity. Our findings indicate that PKCdelta plays an important role in regulating IL-13-induced 15-LO expression in human monocytes and subsequently modulates the inflammatory responses mediated by 15-LO products.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; US FDA, Ctr Biol Evaluat & Res, Div Monoclonal Antibodies, Off Therapeut Res & Review, Bethesda, MD 20892 USA	Cleveland Clinic Foundation; US Food & Drug Administration (FDA)	Cathcart, MK (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	cathcam@ccf.org			NHLBI NIH HHS [HL51068] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051068] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bey EA, 2000, J LIPID RES, V41, P489; Bey EA, 2002, METHOD ENZYMOL, V353, P421; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BROOKS CJW, 1971, ATHEROSCLEROSIS, V13, P223, DOI 10.1016/0021-9150(71)90025-6; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gollob JA, 1999, J IMMUNOL, V162, P4472; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HARLAND WA, 1971, ATHEROSCLEROSIS, V13, P239, DOI 10.1016/0021-9150(71)90026-8; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jimenez SA, 2001, J CLIN INVEST, V108, P1395, DOI 10.1172/JCI200112347; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Munger KA, 1999, P NATL ACAD SCI USA, V96, P13375, DOI 10.1073/pnas.96.23.13375; Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Page K, 2003, J IMMUNOL, V170, P5681, DOI 10.4049/jimmunol.170.11.5681; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Profita M, 2000, AM J PHYSIOL-CELL PH, V279, pC1249, DOI 10.1152/ajpcell.2000.279.4.C1249; Profita M, 2002, J PHARMACOL EXP THER, V300, P868, DOI 10.1124/jpet.300.3.868; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rhee SH, 2003, J BIOL CHEM, V278, P22506, DOI 10.1074/jbc.M208633200; Roy B, 1998, J BIOL CHEM, V273, P32023, DOI 10.1074/jbc.273.48.32023; Roy B, 2002, J LEUKOCYTE BIOL, V72, P580; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL SM, 1984, CELL IMMUNOL, V85, P384, DOI 10.1016/0008-8749(84)90252-1; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu B, 2003, MOL CELL BIOL, V23, P3918, DOI 10.1128/MCB.23.11.3918-3928.2003; XU JH, 1994, MOL CELL BIOL, V14, P8018, DOI 10.1128/MCB.14.12.8018; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	45	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15954	15960		10.1074/jbc.M400413200	http://dx.doi.org/10.1074/jbc.M400413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757756	hybrid			2022-12-27	WOS:000220747900032
J	Ando, H; Watabe, H; Valencia, JC; Yasumoto, K; Furumura, M; Funasaka, Y; Oka, M; Ichihashi, M; Hearing, VJ				Ando, H; Watabe, H; Valencia, JC; Yasumoto, K; Furumura, M; Funasaka, Y; Oka, M; Ichihashi, M; Hearing, VJ			Fatty acids regulate pigmentation via proteasomal degradation of tyrosinase - A new aspect of ubiquitin-proteasome function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LINOLEIC-ACID; MULTICATALYTIC PROTEINASE; MELANOMA-CELLS; MAMMALIAN TYROSINASE; ENDOTHELIAL-CELLS; CIS-FATTY; KAPPA-B; ACTIVATION; PATHWAY	Fatty acids are common components of biological membranes that are known to play important roles in intracellular signaling. We report here a novel mechanism by which fatty acids regulate the degradation of tyrosinase, a critical enzyme associated with melanin biosynthesis in melanocytes and melanoma cells. Linoleic acid ( unsaturated fatty acid, C18: 2) accelerated the spontaneous degradation of tyrosinase, whereas palmitic acid ( saturated fatty acid, C16:0) retarded the proteolysis. The linoleic acid-induced acceleration of tyrosinase degradation could be abrogated by inhibitors of proteasomes, the multicatalytic proteinase complexes that selectively degrade intracellular ubiquitinated proteins. Linoleic acid increased the ubiquitination of many cellular proteins, whereas palmitic acid decreased such ubiquitination, as compared with untreated controls, when a proteasome inhibitor was used to stabilize ubiquitinated proteins. Immunoprecipitation analysis also revealed that treatment with fatty acids modulated the ubiquitination of tyrosinase, i.e. linoleic acid increased the amount of ubiquitinated tyrosinase whereas, in contrast, palmitic acid decreased it. Furthermore, confocal immunomicroscopy showed that the colocalization of ubiquitin and tyrosinase was facilitated by linoleic acid and diminished by palmitic acid. Taken together, these data support the view that fatty acids regulate the ubiquitination of tyrosinase and are responsible for modulating the proteasomal degradation of tyrosinase. In broader terms, the function of the ubiquitin-proteasome pathway might be regulated physiologically, at least in part, by fatty acids within cellular membranes.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Kobe Univ, Sch Med, Dept Dermatol, Kobe, Hyogo 6500017, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kobe University	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov		Yasumoto, Ken-ichi/0000-0002-8090-1161	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Ando H, 1998, ARCH DERMATOL RES, V290, P375, DOI 10.1007/s004030050320; ANDO H, 1990, PIGM CELL RES, V3, P200, DOI 10.1111/j.1600-0749.1990.tb00290.x; Ando H, 1999, J LIPID RES, V40, P1312; ANDO H, 1995, J CELL PHYSIOL, V163, P608, DOI 10.1002/jcp.1041630322; Basrur V, 2003, J PROTEOME RES, V2, P69, DOI 10.1021/pr025562r; BELL RM, 1991, J BIOL CHEM, V266, P4661; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CHEN SG, 1992, BIOCHEM J, V282, P33, DOI 10.1042/bj2820033; Clinical trial group for linoleic acid-containing gel, 1998, NISHINIHON J DERMATO, V60, P537; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1993, ENZYME PROTEIN, V47, P274, DOI 10.1159/000468685; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Dichtl W, 2002, METABOLISM, V51, P327, DOI 10.1053/meta.2002.29963; Glasgow WC, 1997, J BIOL CHEM, V272, P19269, DOI 10.1074/jbc.272.31.19269; Glickman MH, 2000, SEMIN CELL DEV BIOL, V11, P149, DOI 10.1006/scdb.2000.0161; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; Hennig B, 1996, AM J CLIN NUTR, V63, P322, DOI 10.1093/ajcn/63.3.322; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; LAMPE MA, 1983, J LIPID RES, V24, P131; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; Meerarani P, 2003, METABOLISM, V52, P493, DOI 10.1053/meta.2003.50087; Mosse CA, 2001, BIOCHEM BIOPH RES CO, V285, P313, DOI 10.1006/bbrc.2001.5153; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAEKI H, 1980, J CELL PHYSIOL, V104, P171, DOI 10.1002/jcp.1041040206; SEIFERT R, 1988, BIOCHEM BIOPH RES CO, V154, P20, DOI 10.1016/0006-291X(88)90643-2; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Shono S., 1981, PIGMENT CELL, P263; Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195; TANAKA K, 1986, J BIOL CHEM, V261, P5197; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Watanabe N, 1996, PLANT CELL PHYSIOL, V37, P147, DOI 10.1093/oxfordjournals.pcp.a028925; Whitehouse AS, 2003, BRIT J CANCER, V89, P737, DOI 10.1038/sj.bjc.6601184; Zhao J, 2000, J CELL SCI, V113, P4363	50	114	118	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15427	15433		10.1074/jbc.M313701200	http://dx.doi.org/10.1074/jbc.M313701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739285	hybrid			2022-12-27	WOS:000220594700113
J	Danko, S; Yamasaki, K; Daiho, T; Suzuki, H				Danko, S; Yamasaki, K; Daiho, T; Suzuki, H			Distinct natures of beryllium fluoride-bound, aluminum fluoride-bound, and magnesium fluoride-bound stable analogues of an ADP-insensitive phosphoenzyme intermediate of sarcoplasmic reticulum Ca2+-ATPase - Changes in catalytic and transport sites during phosphoenzyme hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; MYOSIN MOTOR DOMAIN; CONFORMATIONAL TRANSITION; ADENOSINE-TRIPHOSPHATASE; CALCIUM-ATPASE; CRYSTAL-STRUCTURE; TIGHT-BINDING; PHOSPHOSERINE PHOSPHATASE; SENSITIVE PHOSPHOENZYME; PHOSPHORYL TRANSFER	The structural natures of stable analogues for the ADP-insensitive phosphoenzyme (E2P) of Ca2+-ATPase formed in sarcoplasmic reticulum vesicles, i.e. the enzymes with bound beryllium fluoride (BeF.E2), bound aluminum fluoride (AlF.E2), and bound magnesium fluoride (MgF.E2), were explored and compared with those of actual E2P formed from Pi without Ca2+. Changes in trinitrophenyl-AMP fluorescence revealed that the catalytic site is strongly hydrophobic in BeF.E2 as in E2P but hydrophilic in MgF.E2 and AlF.E2; yet, the three cytoplasmic domains are compactly organized in these states. Thapsigargin, which was shown in the crystal structure to fix the transmembrane helices and, thus, the postulated Ca2+ release pathway to lumen in a closed state, largely reduced the tryptophan fluorescence in BeF.E2 as in E2P, but only very slightly ( hence, the release pathway is likely closed without thapsigargin) in MgF.E2 and AlF.E2 as in dephosphorylated enzyme. Consistently, the completely suppressed Ca2+-ATPase activity in BeF-treated vesicles was rapidly restored in the presence of ionophore A23187 but not in its absence by incubation with Ca2+ ( over several millimolar concentrations) at pH 6, and, therefore, lumenal Ca2+ is accessible to reactivate the enzyme. In contrast, no or only very slow restoration was observed with vesicles treated with MgF and AlF even with A23187. BeF.E2 thus has the features very similar to those characteristic of the E2P ground state, although AlF.E2 and MgF.E2 most likely mimic the transition or product state for the E2P hydrolysis, during which the hydrophobic nature around the phosphorylation site is lost and the Ca2+ release pathway is closed. The change in hydrophobic nature is probably associated with the change in phosphate geometry from the covalently bound tetrahedral ground state (BeF3-) to trigonal bipyramidal transition state (AlF3 or AlF4-) and further to tetrahedral product state (MgF42-), and such change likely rearranges transmembrane helices to prevent access and leakage of lumenal Ca2+.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BELDA FF, 1986, BIOCHIM BIOPHYS ACTA, V854, P257, DOI 10.1016/0005-2736(86)90118-5; BISHOP JE, 1986, BIOCHEMISTRY-US, V25, P696, DOI 10.1021/bi00351a029; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHALOUB RM, 1980, J BIOL CHEM, V255, P6168; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; COLL RJ, 1992, J BIOL CHEM, V267, P21584; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 2001, J BIOL CHEM, V276, P32771, DOI 10.1074/jbc.M101229200; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Graham DL, 2002, CHEM BIOL, V9, P375, DOI 10.1016/S1074-5521(02)00112-6; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HASSELBACH W, 1983, Z NATURFORSCH C, V38, P1015; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; INESI G, 1980, J BIOL CHEM, V255, P6040; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; Lee SY, 2001, J BIOL CHEM, V276, P16425, DOI 10.1074/jbc.M101002200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARKUS S, 1989, BIOCHEMISTRY-US, V28, P793, DOI 10.1021/bi00428a057; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; MEDDA P, 1985, EUR J BIOCHEM, V146, P255, DOI 10.1111/j.1432-1033.1985.tb08647.x; MOLLER M, 1986, ADV PINEAL RES, V1, P51; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1993, J BIOL CHEM, V268, P23307; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PICK U, 1982, J BIOL CHEM, V257, P6111; PICK U, 1982, J BIOL CHEM, V257, P6120; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; Seekoe T, 2001, J BIOL CHEM, V276, P46737, DOI 10.1074/jbc.M106320200; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SUZUKI H, 1995, J BIOL CHEM, V270, P3089, DOI 10.1074/jbc.270.7.3089; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; VARGA S, 1985, EUR J BIOCHEM, V148, P119, DOI 10.1111/j.1432-1033.1985.tb08815.x; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WEBB MR, 1981, J BIOL CHEM, V256, P4884; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200; Yamasaki K, 2002, J BIOL CHEM, V277, P13615, DOI 10.1074/jbc.M200625200; Youngburg GE, 1930, J LAB CLIN MED, V16, P158	68	80	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14991	14998		10.1074/jbc.M313363200	http://dx.doi.org/10.1074/jbc.M313363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14754887	hybrid			2022-12-27	WOS:000220594700063
J	Hensbergen, PJ; Verzijl, D; Balog, CIA; Dijkman, R; van der Schors, RC; van der Raaij-Helmer, EMH; van der Plas, MJA; Leurs, R; Deelder, AM; Smit, MJ; Tensen, CP				Hensbergen, PJ; Verzijl, D; Balog, CIA; Dijkman, R; van der Schors, RC; van der Raaij-Helmer, EMH; van der Plas, MJA; Leurs, R; Deelder, AM; Smit, MJ; Tensen, CP			Furin is a chemokine-modifying enzyme - In vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOFILTRATE CC-CHEMOKINE-1; RECEPTOR CXCR3; CUTTING EDGE; IP-10; MIG; BINDING; ACTIVATION; INHIBITION; EXPRESSION; EPIDERMIS	Chemokines comprise a class of structurally related proteins that are involved in many aspects of leukocyte migration under basal and inflammatory conditions. In addition to the large number of genes, limited processing of these proteins by a variety of enzymes enhances the complexity of the total spectrum of chemokine variants. We have recently shown that the native chemokine CXCL10 is processed at the C terminus, thereby shedding the last four amino acids. The present study was performed to elucidate the mechanism in vivo and in vitro and to study the biological activity of this novel isoform of CXCL10. Using a combination of protein purification and mass spectrometric techniques, we show that the production of C-terminally truncated CXCL10 by primary keratinocytes is inhibited in vivo by a specific inhibitor of pro-protein convertases (e.g. furin) but not by inhibition of matrix metalloproteinases. Moreover, CXCL10 is processed by furin in vitro, which is abrogated by a mutation in the furin recognition site. Using GTPgammaS binding, Ca2+ mobilization, and chemotaxis assays, we demonstrate that the C-terminally truncated CXCL10 variant is a potent ligand for CXCR3. Moreover, the inverse agonist activity on the virally encoded receptor ORF74 and the direct antibacterial activity of CXCL10 are fully retained. Hence, we have identified furin as a novel chemokine-modifying enzyme in vitro and most probably also in vivo, generating a C-terminally truncated CXCL10, which fully retains its ( inverse) agonistic properties.	Leiden Univ, Med Ctr, Sylvius Lab, Dept Dermatol, NL-2333 AL Leiden, Netherlands; Free Univ Amsterdam, Div Med Chem, NL-1081 HV Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands; Free Univ Amsterdam, Dept Mol Neurobiol, NL-1081 HV Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Tensen, CP (corresponding author), Leiden Univ, Med Ctr, Sylvius Lab, Dept Dermatol, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	C.P.Tensen@lumc.nl	Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021; van der Plas, Mariena/GYV-3702-2022	Leurs, Rob/0000-0003-1354-2848; Tensen, Cornelis/0000-0002-5325-1888; Hensbergen, Paul/0000-0002-3193-5445; Dijkman, Remco/0000-0002-8325-879X; Verzijl, Dennis/0000-0002-7716-9838; van der Plas, Mariena/0000-0002-3233-2881; Smit, Martine/0000-0003-2713-0238				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Campanella GSV, 2003, J BIOL CHEM, V278, P17066, DOI 10.1074/jbc.M212077200; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; EHLERT JE, 1995, J BIOL CHEM, V270, P6338, DOI 10.1074/jbc.270.11.6338; Ehlert JE, 1998, J IMMUNOL, V161, P4975; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Flier J, 1999, J INVEST DERMATOL, V113, P574, DOI 10.1046/j.1523-1747.1999.00730.x; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hensbergen PJ, 2001, EUR J BIOCHEM, V268, P4992, DOI 10.1046/j.0014-2956.2001.02433.x; Hoover DM, 2002, J BIOL CHEM, V277, P37647, DOI 10.1074/jbc.M203907200; Krijgsveld J, 2000, J BIOL CHEM, V275, P20374, DOI 10.1074/jbc.275.27.20374; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Luster AD, 1998, P ASSOC AM PHYSICIAN, V110, P183; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Meyer M, 2001, EUR J IMMUNOL, V31, P2521, DOI 10.1002/1521-4141(200108)31:8<2521::AID-IMMU2521>3.0.CO;2-Q; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Pearton DJ, 2001, EXP DERMATOL, V10, P193, DOI 10.1034/j.1600-0625.2001.010003193.x; Ponec M, 1997, J INVEST DERMATOL, V109, P348, DOI 10.1111/1523-1747.ep12336024; Proost P, 2001, BLOOD, V98, P3554, DOI 10.1182/blood.V98.13.3554; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Schutyser E, 2000, J IMMUNOL, V165, P4470, DOI 10.4049/jimmunol.165.8.4470; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Soejima K, 2001, J IMMUNOL, V167, P6576, DOI 10.4049/jimmunol.167.11.6576; Tensen CP, 1999, BBA-GENE STRUCT EXPR, V1446, P167, DOI 10.1016/S0167-4781(99)00084-6; Tensen CP, 1999, J INVEST DERMATOL, V112, P716, DOI 10.1046/j.1523-1747.1999.00581.x; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Vakili J, 2001, J IMMUNOL, V167, P3406, DOI 10.4049/jimmunol.167.6.3406; Valenzuela-Fernandez A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Wolf M, 2003, AM J PATHOL, V162, P1183, DOI 10.1016/S0002-9440(10)63914-4; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127	45	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13402	13411		10.1074/jbc.M312814200	http://dx.doi.org/10.1074/jbc.M312814200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14739277	Green Published, hybrid			2022-12-27	WOS:000220478500017
J	Ono, S; Mohri, K; Ono, K				Ono, S; Mohri, K; Ono, K			Microscopic evidence that actin-interacting protein 1 actively disassembles actin-depolymerizing factor/cofilin-bound actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; COFILIN; ADF/COFILIN; GELSOLIN; FAMILY; DYNAMICS; FRAGMENTATION; ACTOPHORIN; TURNOVER; HOMOLOG	Actin-depolymerizing factor (ADF)/cofilin and gelsolin are the two major factors to enhance actin filament disassembly. Actin-interacting protein 1 (AIP1) enhances fragmentation of ADF/cofilin-bound filaments and caps the barbed ends. However, the mechanism by which AIP1 disassembles ADF/cofilin-bound filaments is not clearly understood. Here, we directly observed the effects of these proteins on filamentous actin by fluorescence microscopy and gained novel insight into the function of ADF/cofilin and AIP1. ADF/cofilin severed filaments and AIP1 strongly enhanced disassembly at nanomolar concentrations. However, gelsolin, gelsolin-actin complex, or cytochalasin D did not enhance disassembly by ADF/cofilin, suggesting that the strong activity of AIP1 cannot be explained by simple barbed end capping. Barbed end capping by ADF/cofilin and AIP1 was weak and allowed filament elongation, whereas gelsolin or gelsolin-actin complex strongly capped and inhibited elongation. These results suggest that AIP has an active role in filament severing or depolymerization and that ADF/cofilin and AIP1 are distinct from gelsolin in modulating filament elongation.	Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Emory University	Ono, S (corresponding author), Emory Univ, Dept Pathol, 615 Michael St,Whitehead Res Bldg,Rm 105N, Atlanta, GA 30322 USA.	sono@emory.edu	Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048615] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR48615] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aizawa H, 1999, GENES CELLS, V4, P311, DOI 10.1046/j.1365-2443.1999.00262.x; Allwood EG, 2002, PLANT CELL, V14, P2915, DOI 10.1105/tpc.005363; Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; Amann KJ, 2001, NAT CELL BIOL, V3, P306, DOI 10.1038/35060104; Balcer HI, 2003, CURR BIOL, V13, P2159, DOI 10.1016/S0960-9822(03)00907-2; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; BEARER EL, 1991, J CELL BIOL, V115, P1629, DOI 10.1083/jcb.115.6.1629; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; Ichetovkin I, 2000, CELL MOTIL CYTOSKEL, V45, P293, DOI 10.1002/(SICI)1097-0169(200004)45:4<293::AID-CM5>3.0.CO;2-1; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Maciver SK, 2002, GENOME BIOL, V3; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; Mohri K, 2003, J CELL SCI, V116, P4107, DOI 10.1242/jcs.00717; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; Okada K, 1999, J CELL SCI, V112, P1553; Okada K, 2002, J BIOL CHEM, V277, P43011, DOI 10.1074/jbc.M203111200; Ono S, 2003, BIOCHEMISTRY-US, V42, P13363, DOI 10.1021/bi034600x; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Ono S, 1998, J BIOL CHEM, V273, P3778, DOI 10.1074/jbc.273.6.3778; Ono S, 2001, J CELL BIOL, V152, P1313, DOI 10.1083/jcb.152.6.1313; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pope BJ, 2000, J MOL BIOL, V298, P649, DOI 10.1006/jmbi.2000.3688; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Southwick FS, 2000, P NATL ACAD SCI USA, V97, P6936, DOI 10.1073/pnas.97.13.6936; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179	35	83	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14207	14212		10.1074/jbc.M313418200	http://dx.doi.org/10.1074/jbc.M313418200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14742433	hybrid			2022-12-27	WOS:000220478500113
J	Wang, GY; Woods, A; Sabari, S; Pagnotta, L; Stanton, LA; Beier, F				Wang, GY; Woods, A; Sabari, S; Pagnotta, L; Stanton, LA; Beier, F			RhoA/ROCK signaling suppresses hypertrophic chondrocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-FACTOR RECEPTOR-3; BRACHYDACTYLY TYPE-B; RHO FAMILY GTPASES; RECESSIVE ROBINOW-SYNDROME; INTEGRIN-LINKED KINASE; BONE SIALOPROTEIN BSP; EZRIN-LIKE DOMAIN; PARATHYROID-HORMONE; TYROSINE KINASE; CELL-LINE	Coordinated proliferation and differentiation of growth plate chondrocytes is required for normal growth and development of the endochondral skeleton, but little is known about the intracellular signal transduction pathways regulating these processes. We have investigated the roles of the GTPase RhoA and its effector kinases ROCK1/2 in hypertrophic chondrocyte differentiation. RhoA, ROCK1, and ROCK2 are expressed throughout chondrogenic differentiation. RhoA overexpression in chondrogenic ATDC5 cells results in increased proliferation and a marked delay of hypertrophic differentiation, as shown by decreased induction of alkaline phosphatase activity, mineralization, and expression of the hypertrophic markers collagen X, bone sialoprotein, and matrix metalloproteinase 13. These effects are accompanied by activation of cyclin D1 transcription and repression of the collagen X promoter by RhoA. In contrast, inhibition of Rho/ROCK signaling by the pharmacological inhibitor Y27632 inhibits chondrocyte proliferation and accelerates hypertrophic differentiation. Dominant-negative RhoA also inhibits induction of the cyclin D1 promoter by parathyroid hormone-related peptide. Finally, Y27632 treatment partially rescues the effects of RhoA overexpression. In summary, we identify the RhoA/ROCK signaling pathway as a novel and important regulator of chondrocyte proliferation and differentiation.	Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res, Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada; Univ Western Ontario, Sch Dent, London, ON N6A 5C1, Canada	Institute for Work & Health; Western University (University of Western Ontario); Western University (University of Western Ontario)	Beier, F (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Canadian Inst Hlth Res, Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada.	fbeier@uwo.ca	Beier, Frank/G-4595-2013; Beier, Frank/T-4734-2019	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				Adamiak K, 2002, ADV BOUND ELEM SER, V13, P465; Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Ballock RT, 2000, ENDOCRINOLOGY, V141, P4552, DOI 10.1210/en.141.12.4552; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Beier F, 1999, MATRIX BIOL, V18, P109, DOI 10.1016/S0945-053X(99)00009-8; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Beier F, 2002, MOL ENDOCRINOL, V16, P2163, DOI 10.1210/me.2001-0103; Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Beier F, 1997, J CELL BIOCHEM, V66, P210, DOI 10.1002/(SICI)1097-4644(19970801)66:2<210::AID-JCB8>3.0.CO;2-T; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BENYA PD, 1993, EXP CELL RES, V204, P268, DOI 10.1006/excr.1993.1033; BENYA PD, 1988, PATHOL IMMUNOPATH R, V7, P51, DOI 10.1159/000157093; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bokoch GM, 2000, IMMUNOL RES, V21, P139, DOI 10.1385/IR:21:2-3:139; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; CHEN J, 1991, HISTOCHEM J, V23, P281, DOI 10.1007/BF01045047; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Cleverley S, 1999, CURR BIOL, V9, P657, DOI 10.1016/S0960-9822(99)80289-9; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; DerMardirossian C, 2001, DRUG NEWS PERSPECT, V14, P389, DOI 10.1358/dnp.2001.14.7.858421; Dib K, 2001, J IMMUNOL, V166, P6311, DOI 10.4049/jimmunol.166.10.6311; EnomotoIwamoto M, 1997, J BONE MINER RES, V12, P1124, DOI 10.1359/jbmr.1997.12.7.1124; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Hirsch MS, 1997, DEV DYNAM, V210, P249, DOI 10.1002/(SICI)1097-0177(199711)210:3<249::AID-AJA6>3.0.CO;2-G; Ionescu AM, 2001, J BIOL CHEM, V276, P11639, DOI 10.1074/jbc.M006564200; Karaplis AC, 1998, ENDOCRINOLOGY, V139, P5255, DOI 10.1210/en.139.12.5255; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; Koyano Y, 2001, OSTEOARTHR CARTILAGE, V9, pS64, DOI 10.1053/joca.2001.0446; Koyano Y, 1997, BIOCHEM BIOPH RES CO, V241, P369, DOI 10.1006/bbrc.1997.7826; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Loeser RF, 2002, BIORHEOLOGY, V39, P119; Long FX, 2001, DEVELOPMENT, V128, P5099; LuValle P, 2000, FRONT BIOSCI-LANDMRK, V5, pD493, DOI 10.2741/LuValle; Magie CR, 1999, DEVELOPMENT, V126, P5353; Marlow F, 2002, CURR BIOL, V12, P876, DOI 10.1016/S0960-9822(02)00864-3; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Negishi Y, 2000, BIOCHEM BIOPH RES CO, V268, P450, DOI 10.1006/bbrc.2000.2076; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; REICHENBERGER E, 1991, DEV BIOL, V148, P562, DOI 10.1016/0012-1606(91)90274-7; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schwabe GC, 2000, AM J HUM GENET, V67, P822, DOI 10.1086/303084; Segat D, 2002, J BIOL CHEM, V277, P31612, DOI 10.1074/jbc.M203471200; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012-1606(03)00321-X; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Thies E, 2003, J NEUROBIOL, V54, P358, DOI 10.1002/neu.10135; Tuckermann JP, 2000, J BONE MINER RES, V15, P1257, DOI 10.1359/jbmr.2000.15.7.1257; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; Von der Mark K., 1986, RHEUMATOLOGY, V10; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; Wei L, 2002, DEVELOPMENT, V129, P1705; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Wunnenberg-Stapleton K, 1999, DEVELOPMENT, V126, P5339; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhen XC, 2001, J BIOL CHEM, V276, P4879, DOI 10.1074/jbc.M004990200	103	105	108	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13205	13214		10.1074/jbc.M311427200	http://dx.doi.org/10.1074/jbc.M311427200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726536	hybrid			2022-12-27	WOS:000220334900142
J	Kaplan, DD; Meigs, TE; Kelly, P; Casey, PJ				Kaplan, DD; Meigs, TE; Kelly, P; Casey, PJ			Identification of a role for beta-catenin in the establishment of a bipolar mitotic spindle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; FUNCTIONAL INTERACTION; CELL-ADHESION; E-CADHERIN; PROTEIN; LOCALIZATION; PLAKOGLOBIN; CENTROSOME; MECHANISMS; COMPONENT	beta-Catenin is a multifunctional protein that is known to participate in two well defined cellular processes, cell-cell adhesion and Wnt-stimulated transcriptional activation. Here we report that beta-catenin participates in a third cellular process, the establishment of a bipolar mitotic spindle. During mitosis, beta-catenin relocalizes to mitotic spindle poles and to the midbody. Furthermore, biochemical fractionation demonstrates the presence of beta-catenin in purified centrosome preparations. Reduction of cellular beta-catenin by RNA interference leads to the failure of centrosomes to fully separate, resulting in a marked increase in the frequency of monoastral mitotic spindles. Our results define a new and important function for beta-catenin in mitosis and demonstrate that beta-catenin is involved in vital biological processes beyond cell adhesion and Wnt signaling.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309; Kaplan, Daniel/0000-0001-8297-560X	NCI NIH HHS [CA91159, CA100869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100869, R21CA091159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basyuk E, 2000, Nucleic Acids Res, V28, pE46, DOI 10.1093/nar/28.10.e46; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEROD A, 1981, J HISTOCHEM CYTOCHEM, V29, P844, DOI 10.1177/29.7.6167611; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Harborth J, 2001, J CELL SCI, V114, P4557; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; MITCHISON TJ, 1986, METHOD ENZYMOL, V134, P261; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Polakis P, 2000, GENE DEV, V14, P1837; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zipperlen P, 2001, EMBO J, V20, P3984, DOI 10.1093/emboj/20.15.3984	31	94	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10829	10832		10.1074/jbc.C400035200	http://dx.doi.org/10.1074/jbc.C400035200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14744872	hybrid			2022-12-27	WOS:000220157600001
J	Martins, A; Shuman, S				Martins, A; Shuman, S			Characterization of a baculovirus enzyme with RNA ligase, polynucleotide 5 '-kinase, and polynucleotide 3 '-phosphatase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS DNA-LIGASE; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; RIBONUCLEIC-ACID; DEOXYRIBONUCLEIC-ACID; ADENYLYLATION SITE; DOMAIN-STRUCTURE; CAPPING ENZYME; PHOSPHORYLATION; IDENTIFICATION	The end-healing and end-sealing steps of the phage T4-induced RNA restriction-repair pathway are performed by two separate enzymes, a bifunctional polynucleotide 5'-kinase/3'-phosphatase and an ATP-dependent RNA ligase. Here we show that a single trifunctional baculovirus enzyme, RNA ligase 1 (Rnl1), catalyzes the identical set of RNA repair reactions. Three enzymatic activities of baculovirus Rnl1 are organized in a modular fashion within a 694-amino acid polypeptide consisting of an autonomous N-terminal RNA-specific ligase domain, Rnl1-(1 -385), and a C-terminal kinase-phosphatase domain, Rnl1-(394 - 694). The ligase domain is itself composed of two functional units. The N-terminal module Rnl1-( 1 - 270) contains essential nucleotidyltransferase motifs I, IV, and V and suffices for both enzyme adenylylation ( step 1 of the ligation pathway) and phosphodiester bond formation at a preactivated RNA-adenylate end ( step 3). The downstream module extending to residue 385 is required for ligation of a phosphorylated RNA substrate, suggesting that it is involved specifically in the second step of the end-joining pathway, the transfer of AMP from the ligase to the 5'-PO4 end to form RNA-adenylate. The end-healing domain Rnl1( 394 - 694) consists of a proximal 5'-kinase module with an essential P-loop motif ((404)GSGKS(408)) and a distal 3'-phosphatase module with an essential acylphosphatase motif ((560)DLDGT(564)). Our findings have implications for the evolution of RNA repair systems and their potential roles in virus-host dynamics.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULJABBAR M, 1984, J VIROL, V51, P522; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; AYRES MD, 1994, VIROLOGY, V202, P586, DOI 10.1006/viro.1994.1380; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Durantel D, 1998, J GEN VIROL, V79, P629, DOI 10.1099/0022-1317-79-3-629; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; Miller ES, 2003, J BACTERIOL, V185, P5220, DOI 10.1128/JB.185.17.5220-5233.2003; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2933; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2923; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Pedulla ML, 2003, CELL, V113, P171, DOI 10.1016/S0092-8674(03)00233-2; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sawaya R, 2003, J BIOL CHEM, V278, P43928, DOI 10.1074/jbc.M307839200; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Wang LK, 2003, J BIOL CHEM, V278, P29454, DOI 10.1074/jbc.M304320200; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200	43	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18220	18231		10.1074/jbc.M313386200	http://dx.doi.org/10.1074/jbc.M313386200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14747466	hybrid			2022-12-27	WOS:000221041500017
J	Chen, Q; Liang, DC; Fromm, LD; Overbeek, PA				Chen, Q; Liang, DC; Fromm, LD; Overbeek, PA			Inhibition of lens fiber cell morphogenesis by expression of a mutant SV40 large T antigen that binds CREB-binding protein/p300 but not pRb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CBP-INDUCED STIMULATION; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA PROTEIN; MOUSE LENS; TRANSGENIC MICE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; DNA-BINDING; C-JUN; DIFFERENTIATION	Simian virus (SV) 40 large T antigen can both induce tumors and inhibit cellular differentiation. It is not clear whether these cellular changes are synonymous, sequential, or distinct responses to the protein. T antigen is known to bind to p53, to the retinoblastoma (Rb) family of tumor suppressor proteins, and to other cellular proteins such as p300 family members. To test whether SV40 large T antigen inhibits cellular differentiation in vivo in the absence of cell cycle induction, we generated transgenic mice that express in the lens a mutant version of the early region of SV40. This mutant, which we term E107KDelta, has a deletion that eliminates synthesis of small t antigen and a point mutation (E107K) that results in loss of the ability to bind to Rb family members. At embryonic day 15.5 (E15.5), the transgenic lenses show dramatic defects in lens fiber cell differentiation. The fiber cells become post-mitotic, but do not elongate properly. The cells show a dramatic reduction in expression of their beta- and gamma-crystallins. Because CBP and p300 are co-activators for crystallin gene expression, we assayed for interactions between E107KDelta and CBP/p300. Our studies demonstrate that cellular differentiation can be inhibited by SV40 large T antigen in the absence of pRb inactivation, and that interaction of large T antigen with CBP/p300 may be enhanced by a mutation that eliminates the binding to pRb.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Indiana Univ, Ball State Univ, Sch Med, Ctr Med Educ, Muncie, IN 47306 USA	Baylor College of Medicine; Ball State University; Indiana University System	Overbeek, PA (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	overbeek@bcm.tmc.edu		Overbeek, Paul/0000-0001-9784-2084	NATIONAL EYE INSTITUTE [R01EY010448, R01EY011348, R01EY010803] Funding Source: NIH RePORTER; NEI NIH HHS [EY11348, EY10448, EY10803] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Chen Q, 2000, INVEST OPHTH VIS SCI, V41, P4223; Chen Q, 2002, ONCOGENE, V21, P1028, DOI 10.1038/sj.onc.1205050; Chen Q, 2002, J BIOL CHEM, V277, P24081, DOI 10.1074/jbc.M201821200; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; Cho SY, 2001, J BIOL CHEM, V276, P33533, DOI 10.1074/jbc.M102906200; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Eckner R, 1996, MOL CELL BIOL, V16, P3454; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P321, DOI 10.1093/oxfordjournals.jbchem.a123899; Fromm L, 1996, ONCOGENE, V12, P69; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; Hogan B, 1994, MANIPULATING MOUSE E; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Reneker LW, 1996, DEV BIOL, V180, P554, DOI 10.1006/dbio.1996.0328; Ring BZ, 2000, DEVELOPMENT, V127, P307; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TRETON JA, 1991, DIFFERENTIATION, V47, P143, DOI 10.1111/j.1432-0436.1991.tb00232.x; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162	40	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17667	17673		10.1074/jbc.M311678200	http://dx.doi.org/10.1074/jbc.M311678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14742445	hybrid			2022-12-27	WOS:000220870400096
J	Gros, L; Maksimenko, AV; Privezentzev, CV; Laval, J; Saparbaev, MK				Gros, L; Maksimenko, AV; Privezentzev, CV; Laval, J; Saparbaev, MK			Hijacking of the human alkyl-N-purine-DNA glycosylase by 3,N-4-ethenocytosine, a lipid peroxidation-induced DNA adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 3-METHYLADENINE DNA; HUMAN ALKYLADENINE GLYCOSYLASE; ESCHERICHIA-COLI; BASE EXCISION; SACCHAROMYCES-CEREVISIAE; INCREASED SUSCEPTIBILITY; CISPLATIN ADDUCTS; MOLECULAR BEACONS; PRIMARY SUBSTRATE; POTENTIAL ROLE	Lipid peroxidation generates aldehydes, which react with DNA bases, forming genotoxic exocyclic etheno(epsilon)-adducts. E-bases have been implicated in vinyl chloride-induced carcinogenesis, and increased levels of these DNA lesions formed by endogenous processes are found in human degenerative disorders. E-adducts are repaired by the base excision repair pathway. Here, we report the efficient biological hijacking of the human alkyl-N-purine-DNA glycosylase (ANPG) by 3,N-4-ethenocytosine (epsilonC) when present in DNA. Unlike the ethenopurines, ANPG does not excise, but binds to epsilonC when present in either double-stranded or single-stranded DNA. We developed a direct assay, based on the fluorescence quenching mechanism of molecular beacons, to measure a DNA glycosylase activity. Molecular beacons containing modified residues have been used to demonstrate that the epsilonC. ANPG interaction inhibits excision repair both in reconstituted systems and in cultured human cells. Furthermore, we show that the epsilonC.ANPG complex blocks primer extension by the Klenow fragment of DNA polymerase I. These results suggest that epsilonC could be more genotoxic than 1,N-6-ethenoadenine (epsilonA) residues in vivo. The proposed model of ANPG-mediated genotoxicity of epsilonC provides a new insight in the molecular basis of lipid peroxidation-induced cell death and genome instability in cancer.	Inst Gustave Roussy, CNRS, UMR 8113,LBPA,ENS Cachan, Grp Reparat ADN, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Saparbaev, MK (corresponding author), Inst Gustave Roussy, CNRS, UMR 8113,LBPA,ENS Cachan, Grp Reparat ADN, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	smurat@igr.fr	Saparbaev, Murat/AAC-5478-2020; Saparbaev, Murat K/N-3225-2015	Saparbaev, Murat/0000-0002-4630-1074; Saparbaev, Murat K/0000-0002-4630-1074				Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; Asaeda A, 2000, BIOCHEMISTRY-US, V39, P1959, DOI 10.1021/bi9917075; Barbin A, 2000, MUTAT RES-REV MUTAT, V462, P55, DOI 10.1016/S1383-5742(00)00014-4; Bartsch H, 2002, CANCER DETECT PREV, V26, P308, DOI 10.1016/S0361-090X(02)00093-4; Bartsch H, 2002, BIOL CHEM, V383, P915, DOI 10.1515/BC.2002.098; Bartsch H, 2000, TOXICOLOGY, V153, P105, DOI 10.1016/S0300-483X(00)00307-3; BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; Cardinal JW, 2001, MOL CELL BIOL, V21, P5605, DOI 10.1128/MCB.21.16.5605-5613.2001; Cerda SR, 1998, FEBS LETT, V431, P12, DOI 10.1016/S0014-5793(98)00697-8; Chung FL, 1996, CARCINOGENESIS, V17, P2105, DOI 10.1093/carcin/17.10.2105; Cullinan D, 1997, BIOCHEMISTRY-US, V36, P11933, DOI 10.1021/bi9705725; Cullinan D, 2000, J MOL BIOL, V296, P851, DOI 10.1006/jmbi.1999.3490; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Gros L, 2003, MUTAT RES-FUND MOL M, V531, P219, DOI 10.1016/j.mrfmmm.2003.07.008; Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005; Guliaev AB, 2002, NUCLEIC ACIDS RES, V30, P3778, DOI 10.1093/nar/gkf494; Hang B, 1998, P NATL ACAD SCI USA, V95, P13561, DOI 10.1073/pnas.95.23.13561; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; Ishchenko AA, 2003, NUCLEIC ACIDS RES, V31, P6344, DOI 10.1093/nar/gkg812; Kartalou M, 2000, BIOCHEMISTRY-US, V39, P8032, DOI 10.1021/bi000417h; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; Kovtun IV, 2001, BIOCHEM CELL BIOL, V79, P325, DOI 10.1139/bcb-79-3-325; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; LEFEBVRE P, 1993, DNA CELL BIOL, V12, P233, DOI 10.1089/dna.1993.12.233; Levine RL, 2000, CANCER RES, V60, P4098; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; Marion MJ, 1999, IARC SCI PUBL, P315; MARNETT LJ, 1993, CHEM RES TOXICOL, V6, P771, DOI 10.1021/tx00036a005; Mertens A, 2003, CIRCULATION, V107, P1640, DOI 10.1161/01.CIR.0000056523.08033.9F; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Nair J, 1999, IARC SCI PUBL, P55; NAIR J, 1995, CARCINOGENESIS, V16, P613, DOI 10.1093/carcin/16.3.613; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; PENDLEBURY A, 1994, CARCINOGENESIS, V15, P2957, DOI 10.1093/carcin/15.12.2957; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; Pollack M, 2003, CHEM RES TOXICOL, V16, P893, DOI 10.1021/tx030009p; Rizzo J, 2002, MOL CELL PROBE, V16, P277, DOI 10.1006/mcpr.2002.0423; Roth RB, 2002, CANCER RES, V62, P656; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; Saparbaev M, 2002, J BIOL CHEM, V277, P26987, DOI 10.1074/jbc.M111100200; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; SIMHA D, 1994, MUTAT RES, V304, P265, DOI 10.1016/0027-5107(94)90219-4; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; Ye N, 1998, J MOL BIOL, V284, P269, DOI 10.1006/jmbi.1998.2138	65	36	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17723	17730		10.1074/jbc.M314010200	http://dx.doi.org/10.1074/jbc.M314010200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761949	hybrid			2022-12-27	WOS:000220870400103
J	Park, HJ; Park, IY; Kim, EJ; Youn, BY; Fields, K; Dunker, AK; Kang, CH				Park, HJ; Park, IY; Kim, EJ; Youn, BY; Fields, K; Dunker, AK; Kang, CH			Comparing skeletal and cardiac calsequestrin structures and their calcium binding - A proposed mechanism for coupled calcium binding and protein polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; TRANSGENIC MICE; OVEREXPRESSING CALSEQUESTRIN; MUSCLE CALSEQUESTRIN; RYANODINE RECEPTOR; CATION BINDING; CONFORMATION; ASSOCIATION; RELEASE; TRIADIN	Calsequestrin, the major calcium storage protein of both cardiac and skeletal muscle, binds and releases large numbers of Ca2+ ions for each contraction and relaxation cycle. Here we show that two crystal structures for skeletal and cardiac calsequestrin are nearly superimposable not only for their subunits but also their front-to-front-type dimers. Ca2+ binding curves were measured using atomic absorption spectroscopy. This method enables highly accurate measurements even for Ca2+ bound to polymerized protein. The binding curves for both skeletal and cardiac calsequestrin were complex, with binding increases that correlated with protein dimerization, tetramerization, and oligomerization. The Ca2+ binding capacities of skeletal and cardiac calsequestrin are directly compared for the first time, with similar to80 Ca2+ ions bound per skeletal calsequestrin and similar to60 Ca2+ ions per cardiac calsequestrin, as compared with net charges for these molecules of - 80 and - 69, respectively. Deleting the negatively charged and disordered C-terminal 27 amino acids of cardiac calsequestrin results in a 50% reduction of its calcium binding capacity and a loss of Ca2+-dependent tetramer formation. Based on the crystal structures of rabbit skeletal muscle calsequestrin and canine cardiac calsequestrin, Ca2+ binding capacity data, and previous light-scattering data, a mechanism of Ca2+ binding coupled with polymerization is proposed.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea; Indiana Univ, Ctr Computat Biol & Informat, Indianapolis, IN 46202 USA	Washington State University; Chungbuk National University; Indiana University System; Indiana University-Purdue University Indianapolis	Kang, CH (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	chkang@wsunix.wsu.edu		Kang, ChulHee/0000-0002-0693-7860				CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; COZENS B, 1984, J BIOL CHEM, V259, P6248; Eldar M, 2003, TRENDS CARDIOVAS MED, V13, P148, DOI 10.1016/S1050-1738(03)00025-2; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; IKEMOTO N, 1974, J BIOL CHEM, V249, P2357; Johnson LN, 1996, CURR OPIN STRUC BIOL, V6, P762, DOI 10.1016/S0959-440X(96)80005-4; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; KRAUSE KH, 1991, J BIOL CHEM, V266, P9453; Lahat H, 2001, AM J HUM GENET, V69, P1378, DOI 10.1086/324565; Langdown ML, 2003, BIOCHEM J, V371, P61, DOI 10.1042/BJ20021771; Linck B, 2000, J PHARMACOL EXP THER, V294, P648; MacLennan DH, 1998, NAT STRUCT BIOL, V5, P409, DOI 10.1038/nsb0698-409; MACLENNAN DH, 1974, J BIOL CHEM, V249, P980; MacLennan DH, 2002, J MOL CELL CARDIOL, V34, P897, DOI 10.1006/jmcc.2002.2031; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSTWALD TJ, 1974, J BIOL CHEM, V249, P5867; Park HJ, 2003, J BIOL CHEM, V278, P16176, DOI 10.1074/jbc.M300120200; Postma AV, 2002, CIRC RES, V91, pE21, DOI 10.1161/01.RES.0000038886.18992.6B; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Wang SR, 1998, NAT STRUCT BIOL, V5, P476, DOI 10.1038/nsb0698-476; Wang W, 2000, J PHYSIOL-LONDON, V524, P399, DOI 10.1111/j.1469-7793.2000.00399.x; WILLIAMS RJP, 1978, BIOCHIM BIOPHYS ACTA, V505, P1, DOI 10.1016/0304-4173(78)90007-1; WRIGHT DL, 1965, ANAL CHEM, V37, P884, DOI 10.1021/ac60226a025; Xie, 1998, Genome Inform Ser Workshop Genome Inform, V9, P193; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	35	119	122	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18026	18033		10.1074/jbc.M311553200	http://dx.doi.org/10.1074/jbc.M311553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14871888	hybrid			2022-12-27	WOS:000220870400138
J	Wang, CY; Liang, YJ; Lin, YS; Shih, HM; Jou, YS; Yu, WCY				Wang, CY; Liang, YJ; Lin, YS; Shih, HM; Jou, YS; Yu, WCY			YY1AP, a novel co-activator of YY1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; EARLY PROTEIN IE2; BINDING-PROTEIN; ADENOVIRUS E1A; HUMAN CYTOMEGALOVIRUS; XENOPUS OOCYTES; YIN YANG-1; REPRESSION; REGULATOR; PROMOTER	With the aim of identifying potential cellular proteins that mediate the transcriptional regulation of YY1, a HeLa cDNA library was screened using the yeast two-hybrid system. A previously unknown protein interacting with YY1 was identified and named YY1AP. By using the 5'-rapid amplification of cDNA ends technique, the full-length cDNA of YY1AP was cloned and sequenced. The cDNA was 2253 bp in length and encoded an open reading frame of 750 amino acids. The chromosomal gene was made up of 10 exons separated by nine introns and is localized on chromosome 1 (1q21.3). Northern blot analysis revealed that YY1AP is ubiquitously expressed in various human tissues and cancer cell lines. Co-immunoprecipitation and immunostaining of cells further indicated that YY1AP co-localizes with YY1 in the nucleus. Furthermore, YY1AP was shown to be capable of enhancing the transcriptional activation of an YY1 responsive promoter. Subsequent analysis by glutathione S-transferase pull-down assay showed that YY1AP contained two YY1 binding regions. The transactivation region of YY1AP would seem to be localized within the section of amino acids 260-345. It is proposed that YY1AP is a novel co-activator of YY1.	Natl Hlth Res Inst, Taipei 114, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center; Academia Sinica - Taiwan	Yu, WCY (corresponding author), Natl Hlth Res Inst, 3F,109 Min Chuan East Rd,Sec 6, Taipei 114, Taiwan.	Winston@nhri.org.tw	Yu, C.Y./E-3666-2010; Shih, Hsiu-Ming/S-7023-2018; Jou, Yuh-Shan/O-5921-2018	Jou, Yuh-Shan/0000-0001-5090-3732				Adams DJ, 2001, J CELL BIOL, V154, P25, DOI 10.1083/jcb.200010059; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Berndt JA, 2001, J NEUROCHEM, V77, P935, DOI 10.1046/j.1471-4159.2001.00307.x; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Ficzycz A, 2002, J BIOL CHEM, V277, P8382, DOI 10.1074/jbc.M110304200; Ficzycz A, 2001, J BIOL CHEM, V276, P22819, DOI 10.1074/jbc.M011188200; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Huang CF, 2000, J BIOL CHEM, V275, P12313, DOI 10.1074/jbc.275.16.12313; Jacobsen BM, 1999, J BIOL CHEM, V274, P29984, DOI 10.1074/jbc.274.42.29984; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LEE TC, 1994, ONCOGENE, V9, P1047; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Tan DP, 2002, NUCLEIC ACIDS RES, V30, P1213, DOI 10.1093/nar/30.5.1213; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Tsai HL, 1996, J BIOL CHEM, V271, P3534; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	30	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17750	17755		10.1074/jbc.M310532200	http://dx.doi.org/10.1074/jbc.M310532200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14744866	hybrid			2022-12-27	WOS:000220870400106
J	Abrams, KL; Xu, JW; Nativelle-Serpentini, C; Dabirshahsahebi, S; Rogers, MB				Abrams, KL; Xu, JW; Nativelle-Serpentini, C; Dabirshahsahebi, S; Rogers, MB			An evolutionary and molecular analysis of Bmp2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; EMBRYONAL CARCINOMA-CELLS; ACID RECEPTOR-ALPHA; RETINOIC-ACID; GENE-TRANSCRIPTION; NUCLEAR RECEPTORS; NONCODING SEQUENCES; IN-VIVO; SP1; INDUCTION	The coding regions of many metazoan genes are highly similar. For example, homologs to the key developmental factor bone morphogenetic protein (BMP) 2 have been cloned by sequence identity from arthropods, mollusks, cnidarians, and nematodes. Wide conservation of protein sequences suggests that differential gene expression explains many of the vast morphological differences between species. To test the hypothesis that the regulatory mechanisms controlling this evolutionarily ancient and critical gene are conserved, we compared sequences flanking Bmp2 genes of several species. We identified numerous conserved noncoding sequences including some retained because the fish lineage separated 450 million years ago. We tested the function of some of these sequences in the F9 cell model system of Bmp2 expression. We demonstrated that both mouse and primate Bmp2 promoters drive a reporter gene in an expression pattern resembling that of the endogenous transcript in F9 cells. A conserved Sp1 site contributes to the retinoic acid responsiveness of the Bmp2 promoter, which lacks a classical retinoic acid response element. We have also discovered a sequence downstream of the stop codon whose conservation between humans, rodents, deer, chickens, frogs, and fish is striking. A fragment containing this region influences reporter gene expression in F9 cells. The conserved region contains elements that may mediate the half-life of the Bmp2 transcript. Together, our molecular and evolutionary analysis has identified new regulatory elements controlling Bmp2 expression.	UMDNJ, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07101 USA; Univ S Florida, Dept Biol, Tampa, FL 33620 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; State University System of Florida; University of South Florida	Rogers, MB (corresponding author), UMDNJ, New Jersey Med Sch, Dept Biochem & Mol Biol, MSB E627,POB 1709, Newark, NJ 07101 USA.	rogersmb@umdnj.edu			NICHD NIH HHS [HD31117] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD031117, R01HD031117] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baur ST, 2000, DEVELOPMENT, V127, P605; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Beppu H, 2000, DEV BIOL, V221, P249, DOI 10.1006/dbio.2000.9670; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; CARPENTER ML, 1993, EUR J BIOCHEM, V215, P561, DOI 10.1111/j.1432-1033.1993.tb18066.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang H, 1999, DEVELOPMENT, V126, P1631; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Farboud B, 2003, MOL CELL BIOL, V23, P2844, DOI 10.1128/MCB.23.8.2844-2858.2003; FENG JQ, 1994, BBA-GENE STRUCT EXPR, V1218, P221, DOI 10.1016/0167-4781(94)90017-5; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Feng JQ, 1997, BBA-GENE STRUCT EXPR, V1350, P47, DOI 10.1016/S0167-4781(96)00178-9; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Frazer KA, 2003, GENOME RES, V13, P1, DOI 10.1101/gr.222003; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; Glozak MA, 2003, MOL ENDOCRINOL, V17, P27, DOI 10.1210/me.2002-0192; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hao H, 2003, BLOOD, V101, P4551, DOI 10.1182/blood-2002-10-3174; Hardison RC, 2000, TRENDS GENET, V16, P369, DOI 10.1016/S0168-9525(00)02081-3; Hauksdottir H, 2003, MOL ENDOCRINOL, V17, P373, DOI 10.1210/me.2002-0340; Heller LC, 1999, J BIOL CHEM, V274, P1394, DOI 10.1074/jbc.274.3.1394; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOGAN BLM, 1995, NATURE, V376, P210, DOI 10.1038/376210a0; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; Huang DY, 2002, DEV DYNAM, V223, P353, DOI 10.1002/dvdy.10057; Husmann M, 2000, BIOCHEM J, V352, P763, DOI 10.1042/0264-6021:3520763; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kelley KMM, 2003, GENE, V307, P87, DOI 10.1016/S0378-1119(03)00445-1; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAZEGA D, 1993, J CELL PHYSIOL, V157, P90, DOI 10.1002/jcp.1041570112; Lelong C, 2001, BIOCHIMIE, V83, P423, DOI 10.1016/S0300-9084(01)01260-3; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MartinezBarbera JP, 1997, GENE, V198, P53, DOI 10.1016/S0378-1119(97)00292-8; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; McCue LA, 2002, GENOME RES, V12, P1523, DOI 10.1101/gr.323602; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Newfeld SJ, 1997, GENETICS, V145, P297; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Rao J, 1998, J CELL PHYSIOL, V175, P121, DOI 10.1002/(SICI)1097-4652(199805)175:2<121::AID-JCP1>3.0.CO;2-Q; Reddi AH, 2001, J BONE JOINT SURG AM, V83A, pS1, DOI 10.2106/00004623-200100001-00001; Richter B, 1997, GENETICS, V145, P311; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P1; ROGERS MB, 1992, MOL BIOL CELL, V3, P189, DOI 10.1091/mbc.3.2.189; Rogers MB, 1996, CELL GROWTH DIFFER, V7, P115; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Shimada J, 2001, MOL ENDOCRINOL, V15, P1677, DOI 10.1210/me.15.10.1677; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069; Sugiura T, 1999, BIOCHEM J, V338, P433, DOI 10.1042/0264-6021:3380433; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Tremblay KD, 2001, DEVELOPMENT, V128, P3609; Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vaahtokari A, 1996, DEVELOPMENT, V122, P121; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yang X, 1999, DEVELOPMENT, V126, P1571; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yi SE, 2000, DEVELOPMENT, V127, P621; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002-0210; Zile MH, 1998, J NUTR, V128, p455S, DOI 10.1093/jn/128.2.455S; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	89	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15916	15928		10.1074/jbc.M313531200	http://dx.doi.org/10.1074/jbc.M313531200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757762	hybrid			2022-12-27	WOS:000220747900028
J	Buscaglia, CA; Campo, VA; Di Noia, JM; Torrecilhas, ACT; De Marchi, CR; Ferguson, MAJ; Frasch, ACC; Almeida, IC				Buscaglia, CA; Campo, VA; Di Noia, JM; Torrecilhas, ACT; De Marchi, CR; Ferguson, MAJ; Frasch, ACC; Almeida, IC			The surface coat of the mammal-dwelling infective trypomastigote stage of Trypanosoma cruzi is formed by highly diverse immunogenic mucins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GALACTOSYL ANTIBODIES; TRANS-SIALIDASE; CHAGAS-DISEASE; SUPER-FAMILY; GENES; GLYCOPROTEINS; MEMBRANE; OLIGOSACCHARIDES; ACCEPTORS; ANTIGENS	A thick coat of mucin-like glycoproteins covers the surface of Trypanosoma cruzi and plays a crucial role in parasite protection and infectivity and host immuno-modulation. The appealing candidate genes coding for the mucins of the mammal-dwelling stages define a heterogeneous family termed TcMUC, which comprises up to 700 members, thus precluding a genetic approach to address the protein core identity. Here, we demonstrate by multiple approaches that the TcMUC II genes code for the majority of trypomastigote mucins. These molecules display a variable, non-repetitive, highly O-glycosylated central domain, followed by a short conserved C terminus and a glycosylphosphatidylinositol anchor. A simultaneous expression of multiple TcMUC II gene products was observed. Moreover, the C terminus of TcMUC II mucins, but not their central domain, elicited strong antibody responses in patients with Chagas' disease and T. crusi infected animals. This highly diverse coat of mucins may represent a refined parasite strategy to elude the mammalian host immune system.	Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, BR-05508000 Sao Paulo, Brazil; Univ Nacl Gen San Martin, Inst Tecnol Chascomus, Inst Invest Biotecnol, RA-1650 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1650 Buenos Aires, DF, Argentina; Univ Sao Paulo, Hosp Clin, Dept Molestias Infecciosas, Inst Med Trop,Lab Invest Med Parasitol, BR-05508000 Sao Paulo, Brazil; Univ Dundee, Sch Life Sci, Welcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	Universidade de Sao Paulo; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidade de Sao Paulo; University of Dundee	Almeida, IC (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, ICB2,Av Prof Lineu Prestes 1374, BR-05508000 Sao Paulo, Brazil.	ialmeida@icb.usp.br	Torrecilhas, Ana Claudia/AFR-7084-2022; Di Noia, Javier Marcelo/D-2285-2012; Almeida, Igor C./AAF-9409-2019; /W-6163-2019; Ferguson, Michael A. J./F-7829-2010	Torrecilhas, Ana Claudia/0000-0001-5724-2199; Di Noia, Javier Marcelo/0000-0003-2896-0321; Almeida, Igor C./0000-0002-2443-8213; Ferguson, Michael A. J./0000-0003-1321-8714; Frasch, Alberto Carlos/0000-0001-7532-653X; Buscaglia, Carlos/0000-0001-6466-4138				Acosta-Serrano A, 2001, MOL BIOCHEM PARASIT, V114, P143, DOI 10.1016/S0166-6851(01)00245-6; Aguero F, 2000, GENOME RES, V10, P1996, DOI 10.1101/gr.GR-1463R; Allen CL, 2001, EXP PARASITOL, V97, P173, DOI 10.1006/expr.2001.4600; Almeida IC, 2001, J LEUKOCYTE BIOL, V70, P467; ALMEIDA IC, 1993, J CLIN LAB ANAL, V7, P307, DOI 10.1002/jcla.1860070603; ALMEIDA IC, 1994, BRAZ J MED BIOL RES, V27, P443; ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; ALVES MJM, 1975, FEBS LETT, V52, P188, DOI 10.1016/0014-5793(75)80803-9; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; ANDREWS NW, 1982, J PROTOZOOL, V29, P264, DOI 10.1111/j.1550-7408.1982.tb04024.x; Barros HC, 1996, J EUKARYOT MICROBIOL, V43, P275, DOI 10.1111/j.1550-7408.1996.tb03990.x; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; Buscaglia CA, 1998, J INFECT DIS, V177, P431, DOI 10.1086/514199; Buscaglia CA, 2003, MICROBES INFECT, V5, P419, DOI 10.1016/S1286-4579(03)00050-9; Campo V, 2004, MOL BIOCHEM PARASIT, V133, P81, DOI 10.1016/j.molbiopara.2003.09.006; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; Di Noia JM, 2002, J EXP MED, V195, P401, DOI 10.1084/jem.20011433; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; DINOIA JM, 2002, MOL MECH PATHOGENESI, P31; Ferguson M. A. J., 1993, GLYCOBIOLOGY, P349; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7; Freitas-Junior LHG, 1998, MOL BIOCHEM PARASIT, V93, P101, DOI 10.1016/S0166-6851(98)00025-5; GONCALVES MF, 1991, EXP PARASITOL, V72, P43, DOI 10.1016/0014-4894(91)90119-H; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; Millar AE, 1999, J IMMUNOL, V162, P6092; NUSSENZWEIG RS, 1984, PHILOS T ROY SOC B, V307, P117, DOI 10.1098/rstb.1984.0113; Pereira-Chioccola VL, 2000, J CELL SCI, V113, P1299; Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3; Pollevick GD, 2000, J BIOL CHEM, V275, P27671; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Salazar NA, 1996, MOL BIOCHEM PARASIT, V78, P127, DOI 10.1016/S0166-6851(96)02617-5; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Tyler KM, 2001, INT J PARASITOL, V31, P472, DOI 10.1016/S0020-7519(01)00153-9; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; World Health Organization (WHO), 2002, WHO TECH REP SER, V905, P1; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; Zingales B, 1997, ACTA TROP, V68, P159, DOI 10.1016/S0001-706X(97)00088-0	45	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15860	15869		10.1074/jbc.M314051200	http://dx.doi.org/10.1074/jbc.M314051200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14749325	hybrid			2022-12-27	WOS:000220747900022
J	Fabian, M; Jancura, D; Palmer, G				Fabian, M; Jancura, D; Palmer, G			Two sites of interaction of anions with cytochrome a in oxidized bovine cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-SPIN HEME; ESCHERICHIA-COLI; PARACOCCUS-DENITRIFICANS; ANGSTROM RESOLUTION; UBIQUINOL OXIDASE; BINDING-SITE; RHODOBACTER-SPHAEROIDES; ELECTRON-TRANSFER; NITRIC-OXIDE; CHLORIDE	An interaction between cytochrome a in oxidized cytochrome c oxidase (CcO) and anions has been characterized by EPR spectroscopy. Those anions that affect the EPR g=3 signal of cytochrome a can be divided into two groups. One group consists of halides (Cl-, Br-, and I-) and induces an upfield shift of the g=3 signal. Nitrogen-containing anions (CN-, NO2-, N-3(-), NO3-) are in the second group and shift the g=3 signal downfield. The shifts in the EPR spectrum of CcO are unrelated to ligand binding to the binuclear center. The binding properties of one representative from each group, azide and chloride, were characterized in detail. The dependence of the shift on chloride concentration is consistent with a single binding site in the isolated oxidized enzyme with a K-d of similar to3 mM. In mitochondria, the apparent K-d was found to be about four times larger than that of the isolated enzyme. The data indicate it is the chloride anion that is bound to CcO, and there is a hydrophilic size-selective access channel to this site from the cytosolic side of the mitochondrial membrane. An observed competition between azide and chloride is interpreted by azide binding to three sites: two that are apparent in the x-ray structure plus the chloride-binding site. It is suggested that either Mg2+ or Arg-438/Arg-439 is the chloride-binding site, and a mechanism for the ligand-induced shift of the g=3 signal is proposed.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Rice University	Fabian, M (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS 140,6100 Main, Houston, TX 77005 USA.	fabian@rice.edu			NIGMS NIH HHS [GM 55807] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; BEINERT H, 1976, BIOCHIM BIOPHYS ACTA, V423, P339, DOI 10.1016/0005-2728(76)90190-0; Butler CS, 1997, BIOCHEMISTRY-US, V36, P16259, DOI 10.1021/bi971481a; CHANCE B, 1965, J GEN PHYSIOL, V49, P163, DOI 10.1085/jgp.49.1.163; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; DEGN H, 1971, BIOCHIM BIOPHYS ACTA, V245, P347, DOI 10.1016/0005-2728(71)90153-8; ESPE MP, 1995, BIOCHEMISTRY-US, V34, P7593, DOI 10.1021/bi00023a005; Fabian M, 2001, BIOCHEMISTRY-US, V40, P6061, DOI 10.1021/bi010059y; Fabian M, 1998, FEBS LETT, V422, P1, DOI 10.1016/S0014-5793(97)01561-5; Fei MJ, 2000, ACTA CRYSTALLOGR D, V56, P529, DOI 10.1107/S0907444900002213; Florens L, 2001, BIOCHEMISTRY-US, V40, P7491, DOI 10.1021/bi0101188; Forte E, 2002, BIOCHEMISTRY-US, V41, P13046, DOI 10.1021/bi025917k; Giuffre A, 1998, J BIOL CHEM, V273, P32475, DOI 10.1074/jbc.273.49.32475; GREENWOOD NN, 1990, CHEM ELEMENTS, P952; GRIFFITH JS, 1957, NATURE, V180, P30, DOI 10.1038/180030a0; HALTIA T, 1992, BIOCHIM BIOPHYS ACTA, V1098, P343, DOI 10.1016/S0005-2728(09)91016-7; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; Hirano T, 1997, J BIOCHEM-TOKYO, V122, P430; HOGFELDT E, 1982, STABILITY CONSTANTS, P166; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JACOBS EE, 1960, J BIOL CHEM, V235, P531; Kannt A, 1998, J BIOENERG BIOMEMBR, V30, P81, DOI 10.1023/A:1020563629032; Kannt A, 1998, BIOPHYS J, V74, P708, DOI 10.1016/S0006-3495(98)73996-7; LENAZ G, 1967, METHOD ENZYMOL, V10, P499; LI WB, 1993, BIOCHEMISTRY-US, V32, P1833, DOI 10.1021/bi00058a018; Liao GL, 1996, BBA-BIOENERGETICS, V1274, P109, DOI 10.1016/0005-2728(96)00014-X; MARGALIT R, 1973, EUR J BIOCHEM, V32, P492, DOI 10.1111/j.1432-1033.1973.tb02633.x; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; MOODY AJ, 1994, BIOCHEM J, V302, P821, DOI 10.1042/bj3020821; MURAMATO K, 2002, BIOCHIM BIOPHYS ACTA, V12, P112; ORII Y, 1995, BIOCHEMISTRY-US, V34, P1127, DOI 10.1021/bi00004a004; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PIWNICAWORMS D, 1983, J GEN PHYSIOL, V81, P731, DOI 10.1085/jgp.81.5.731; Ralle M, 1999, BIOCHEMISTRY-US, V38, P7185, DOI 10.1021/bi982885l; RUMSEY WL, 1990, J BIOL CHEM, V265, P15392; SCHMIDT B, 2003, IN PRESS P NATL ACAD; SCHOONOVER JR, 1991, BIOCHEMISTRY-US, V30, P7541, DOI 10.1021/bi00244a025; SCOTT RA, 1988, ANN NY ACAD SCI, V550, P53, DOI 10.1111/j.1749-6632.1988.tb35322.x; SHIMOKATA K, 2002, BIOCHIM BIOPHYS ACTA, V12, P105; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SILLEN LG, 1964, STABILITY CONSTANTS, P257; SMITH RM, 1981, CRITICAL STABILITY C, V4, P96; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; SOULIMANE T, 1995, EUR J BIOCHEM, V227, P588, DOI 10.1111/j.1432-1033.1995.tb20429.x; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Tsukihara T, 2003, P NATL ACAD SCI USA, V100, P15304, DOI 10.1073/pnas.2635097100; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; WILSON DF, 1976, ARCH BIOCHEM BIOPHYS, V175, P160, DOI 10.1016/0003-9861(76)90495-1; WILSON DF, 1977, ARCH BIOCHEM BIOPHYS, V182, P749, DOI 10.1016/0003-9861(77)90557-4; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P9757; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zaric SD, 2001, BIOCHEMISTRY-US, V40, P7914, DOI 10.1021/bi010428q	57	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16170	16177		10.1074/jbc.M311834200	http://dx.doi.org/10.1074/jbc.M311834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14766756	hybrid			2022-12-27	WOS:000220747900059
J	Nogami, K; Lapan, KA; Zhou, Q; Wakabayashi, H; Fay, PJ				Nogami, K; Lapan, KA; Zhou, Q; Wakabayashi, H; Fay, PJ			Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	45th Annual Meeting and Exhibition of the American-Society-of-Hematology	DEC 06-09, 2003	San Diego, CA	Amer Soc Hematol			LENGTH CROSS-LINKING; A1 SUBUNIT; LIGHT-CHAIN; A2 SUBUNIT; FACTOR VA; CATALYZED CLEAVAGE; ACIDIC REGION; BINDING-SITE; FACTOR-IXA; ACTIVATION	We recently demonstrated that the residues 337-372, comprising the acidic C-terminal region in A1 subunit, interact with factor Xa during the proteolytic inactivation of factor VIIIa (Nogami, K., Wakabayashi, H., and Fay, P. J. (2003) J. Biol. Chem. 278, 16502-16509). We now show this sequence is important for factor Xa-catalyzed activation of factor VIII. Peptide 337-372 markedly inhibited cofactor activation, consistent with a delay in the rate of cleavage at the A1-A2 junction. Studies using the isolated factor VIII heavy chain indicated that the peptide completely blocked cleavage at the A1-A2 junction (IC50 = 11 muM) and partially blocked cleavage at the A2-B junction (IC50 = 100 muM). Covalent cross-linking was observed between the 337-372 peptide and factor Xa following reaction with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, and the peptide quenched the fluorescence of dansyl-Glu-Gly-Arg active site-modified factor Xa, suggesting that residues 337-372 directly interact with factor Xa. Studies using a monoclonal antibody recognizing residues 351-365 as well as the peptide to this sequence further restricted the interactive region. Mutant factor VIII molecules in which clustered acidic residues in the 337-372 segment were converted to alanine were evaluated for activation by factor Xa. Of the mutants tested, only factor Xa-catalyzed activation of the D361A/D362A/D363A mutant was inhibited with peak activity of similar to50% and an activation rate constant of similar to30% of the wild type values. These results indicate that the 337-372 acidic region separating A1 and A2 domains and, in particular, a cluster of acidic residues at position 361-363 contribute to a unique factor Xa-interactive site within the factor VIII heavy chain that promotes factor Xa docking during cofactor activation.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076213, P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30616, HL38199, HL76213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASILLAS G, 1971, COAGULATION, V4, P107; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; Jenkins PV, 2002, BLOOD, V100, P501, DOI 10.1182/blood-2001-12-0361; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Mumford AD, 2002, BRIT J HAEMATOL, V118, P589, DOI 10.1046/j.1365-2141.2002.03617.x; Nogami K, 2000, J BIOL CHEM, V275, P25774, DOI 10.1074/jbc.M002007200; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; Nogami K, 2003, J BIOL CHEM, V278, P16502, DOI 10.1074/jbc.M213044200; Nogami K, 2002, BRIT J HAEMATOL, V116, P868, DOI 10.1046/j.0007-1048.2002.03360.x; Nogami K, 2002, THROMB HAEMOSTASIS, V87, P459, DOI 10.1055/s-0037-1613026; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; Singh LS, 2003, J BIOL CHEM, V278, P28335, DOI 10.1074/jbc.M300233200; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WAKABAYASHI H, 2004, J BIOL CHEM     0113; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	35	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15763	15771		10.1074/jbc.M400568200	http://dx.doi.org/10.1074/jbc.M400568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	811BR	14764590	hybrid			2022-12-27	WOS:000220747900010
J	Santamaria-Araujo, JA; Fischer, B; Otte, T; Nimtz, M; Mendel, RR; Wray, V; Schwarz, GN				Santamaria-Araujo, JA; Fischer, B; Otte, T; Nimtz, M; Mendel, RR; Wray, V; Schwarz, GN			The tetrahydropyranopterin structure of the sulfur-free and metal-free molybdenum cofactor precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLYBDOPTERIN SYNTHASE; CRYSTAL-STRUCTURE; CONVERTING FACTOR; XANTHINE-OXIDASE; SULFITE OXIDASE; BIOSYNTHESIS; ENZYMES; REDUCTASE; OXIDOREDUCTASE	The molybdenum cofactor (Moco), a highly conserved pterin compound coordinating molybdenum (Mo), is required for the activity of all Mo-dependent enzymes with the exception of nitrogenase. Moco is synthesized by a unique and evolutionary old multi-step pathway with two intermediates identified so far, the sulfur-free and metal-free pterin derivative precursor Z and molybdopterin, a pterin with an enedithiolate function essential for Mo ligation. The latter pterin component is believed to form a tetrahydropyranopterin similar to the one found for Moco in the crystal structure of Mo as well as tungsten (W) enzymes. Here we report the spectroscopic characterization and structure elucidation of precursor Z purified from Escherichia coli overproducing MoaA and MoaC, two proteins essential for bacterial precursor Z synthesis. We have shown that purified precursor Z is as active as precursor Z present in E. coli cell extracts, demonstrating that no modifications during the purification procedure have occurred. High resolution electrospray ionization mass spectrometry afforded a [M + H](+) ion compatible with a molecular formula of C10H15N5O8P. Consequently H-1 NMR spectroscopy not only allowed structural characterization of the molecule but confirmed that this intermediate undergoes direct oxidation to the previously well characterized non-productive follow-up product compound Z. The H-1 chemical shift and coupling constant data are incompatible with previous structural proposals and indicate that precursor Z already is a tetrahydropyranopterin system and carries a geminal diol function in the C1' position.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38128 Braunschweig, Germany; German Res Ctr Biotechnol GBF, Dept Biol Struct, D-38124 Braunschweig, Germany; German Inst Sci & Technol, Singapore 118255, Singapore; Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore	Braunschweig University of Technology; Helmholtz Association; Helmholtz-Center for Infection Research; National University of Singapore	Schwarz, GN (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38128 Braunschweig, Germany.	g.schwarz@tu-bs.de	Schwarz, Guenter/ABE-9643-2021	Schwarz, Guenter/0000-0002-2118-9338; Fischer, Berthold/0000-0003-2840-9812				Bracher A, 1998, J BIOL CHEM, V273, P28132, DOI 10.1074/jbc.273.43.28132; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Doyle WA, 1996, EUR J BIOCHEM, V239, P782, DOI 10.1111/j.1432-1033.1996.0782u.x; Duran M, 1978, J Inherit Metab Dis, V1, P175, DOI 10.1007/BF01805591; Enemark JH, 2002, MET IONS BIOL SYST, V39, P621; Fischer B, 1998, J INORG BIOCHEM, V72, P13, DOI 10.1016/S0162-0134(98)10054-5; Fischer B, 2002, MET IONS BIOL SYST, V39, P265; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; Hanzelmann P, 2002, J BIOL CHEM, V277, P18303, DOI 10.1074/jbc.M200947200; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; IRBY RB, 1994, J BIOL CHEM, V269, P23981; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; Johnson JL., 2001, METABOLIC MOL BASES, P3163; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Kuper J, 2000, P NATL ACAD SCI USA, V97, P6475, DOI 10.1073/pnas.110568497; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Mendel RR, 1999, CRIT REV PLANT SCI, V18, P33, DOI 10.1016/S0735-2689(99)00386-X; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; Nichols J, 2002, J BIOL CHEM, V277, P24995, DOI 10.1074/jbc.M203238200; Pfleiderer W., 1996, COMPREHENSIVE HETERO, V7, P679; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; REISS J, 1987, MOL GEN GENET, V206, P352, DOI 10.1007/BF00333594; Reiss J, 2003, HUM MUTAT, V21, P569, DOI 10.1002/humu.10223; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; SCHAFER A, 1995, HELV CHIM ACTA, V78, P1763, DOI 10.1002/hlca.19950780710; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; SOYKA R, 1990, HELV CHIM ACTA, V73, P808, DOI 10.1002/hlca.19900730407; Stiefel EI, 1996, SCIENCE, V272, P1599, DOI 10.1126/science.272.5268.1599; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	41	75	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15994	15999		10.1074/jbc.M311815200	http://dx.doi.org/10.1074/jbc.M311815200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761975	hybrid			2022-12-27	WOS:000220747900037
J	Schechtman, D; Craske, ML; Kheifets, V; Meyer, T; Schechtman, J; Mochly-Rosen, D				Schechtman, D; Craske, ML; Kheifets, V; Meyer, T; Schechtman, J; Mochly-Rosen, D			A critical intramolecular interaction for protein kinase C epsilon translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAFFOLDING PROTEIN; SIGNAL-TRANSDUCTION; ANCHORING PROTEINS; REGULATORY DOMAIN; LIVING CELLS; BINDING; RACK1; BETA; DIACYLGLYCEROL; ISOZYME	Disruption of intramolecular interactions, translocation from one intracellular compartment to another, and binding to isozyme-specific anchoring proteins termed RACKs, accompany protein kinase C (PKC) activation. We hypothesized that in inactive epsilonPKC, the RACK-binding site is engaged in an intramolecular interaction with a sequence resembling its RACK, termed psiepsilonRACK. An amino acid difference between the psiepsilonRACK sequence in epsilonPKC and its homologous sequence in epsilonACK constitutes a change from a polar non-charged amino acid (asparagine) in epsilonRACK to a polar charged amino acid (aspartate) in epsilonPKC. Here we show that mutating the aspartate to asparagine in epsilonPKC increased intramolecular interaction as indicated by increased resistance to proteolysis, and slower hormone- or PMA-induced translocation in cells. Substituting aspartate for a non-polar amino acid (alanine) resulted in binding to epsilonRACK without activators, in vitro, and increased translocation rate upon activation in cells. Mathematical modeling suggests that translocation is at least a two-step process. Together our data suggest that intramolecular interaction between the psiRACK site and RACK-binding site within epsilonPKC is critical and rate limiting in the process of PKC translocation.	Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR 3145, Stanford, CA 94305 USA; Inst Matematica Pura & Aplicada, BR-22460320 Rio De Janeiro, Brazil	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR 3145, 269 Campus Dr, Stanford, CA 94305 USA.	mochly@stanford.edu	schechtman, deborah/B-7572-2012	Mochly-Rosen, Daria/0000-0002-6691-8733; Meyer, Tobias/0000-0003-4339-3804; Schechtman, Deborah/0000-0002-8874-7023	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011147] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA1117] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Banci L, 2002, J BIOL CHEM, V277, P12988, DOI 10.1074/jbc.M106875200; Bolsover SR, 2003, J BIOL CHEM, V278, P10282, DOI 10.1074/jbc.M212145200; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; LEE MH, 1986, J BIOL CHEM, V261, P4867; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; ORR JW, 1992, J BIOL CHEM, V267, P15263; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Slater SJ, 2002, J BIOL CHEM, V277, P15277, DOI 10.1074/jbc.M112207200; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	39	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15831	15840		10.1074/jbc.M310696200	http://dx.doi.org/10.1074/jbc.M310696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14739299	hybrid			2022-12-27	WOS:000220747900019
J	Cha, JY; Ishiwata, A; Mobashery, S				Cha, JY; Ishiwata, A; Mobashery, S			A novel beta-lactamase activity from a penicillin-binding protein of Treponema pallidum and why syphilis is still treatable with penicillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; MECHANISM; INHIBITION; ENZYME; CLASSIFICATION; LIPOPROTEIN; ANTIBIOTICS; RESISTANCE	Treponema pallidum, the causative agent of syphilis, is sensitive to penicillins. Yet, an abundant membrane-bound protein of this organism, Tp47, turns over penicillins. It is shown herein that the turnover process is a hydrolytic reaction that results in the corresponding penicilloates, products that have their beta-lactam bonds hydrolyzed. This is the reaction of beta-lactamases, bona fide resistance enzymes to beta-lactam antibiotics. Remarkably, the x-ray structure of Tp47 bears no resemblance to any other beta-lactamases or the related penicillin-binding proteins. Furthermore, evidence is presented that the reaction of Tp47 takes place in the absence of the zinc ion and does not involve intermediary acyl enzyme species. Hence, the beta-lactamase activity of Tp47 is the fifth known mechanism for turnover of beta-lactam antibiotics. Tp47 also exhibits a penicillin binding reaction, in the process of which the enzyme is covalently modified in the active site. The two reactions take place in two different active sites, and the events of the beta-lactamase activity are over 2,000-fold more rapid than the penicillin binding reaction. The level of beta-lactamase activity is high and is held back only by a strong product-inhibition component to the catalytic process. If natural selection would result in a mutant variant of Tp47 that overcomes product inhibition for the beta-lactamase activity, a novel bona fide resistance to penicillins will emerge in Treponema, which will be a disconcerting clinical development. The physiological functions of Tp47 are not known, but it is likely that this is at least a bifunctional enzyme involved in the processing of the Treponema peptidoglycan as a substrate.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Mobashery, S (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	mobashery@nd.edu	Ishiwata, Akihiro/B-4710-2015	Ishiwata, Akihiro/0000-0002-5542-2214	NIAID NIH HHS [AI 33170] Funding Source: Medline; NIGMS NIH HHS [GM 61629] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061629] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P264, DOI 10.1128/AAC.33.3.264; Bush K, 1998, ADV EXP MED BIOL, V456, P71; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Deka RK, 2002, J BIOL CHEM, V277, P41857, DOI 10.1074/jbc.M207402200; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; Golemi D, 2000, J ANTIBIOT, V53, P1022, DOI 10.7164/antibiotics.53.1022; Kotra L P., 2002, BACTERIAL RESISTANCE, P123; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Maveyraud L, 1996, J AM CHEM SOC, V118, P7435, DOI 10.1021/ja9609718; Maveyraud L, 2002, J AM CHEM SOC, V124, P2461, DOI 10.1021/ja016736t; MIYASHITA K, 1995, J AM CHEM SOC, V117, P11055, DOI 10.1021/ja00150a003; Mourey L, 1998, J AM CHEM SOC, V120, P9382, DOI 10.1021/ja9817996; Nagase T, 2001, BIOORG CHEM, V29, P140, DOI 10.1006/bioo.2001.1205; PAGE MI, 1998, J CHEM SOC CHEM COMM, V16, P1609; RADOLF JD, 1989, INFECT IMMUN, V57, P1248, DOI 10.1128/IAI.57.4.1248-1254.1989; Rolinson GN, 1998, J ANTIMICROB CHEMOTH, V41, P589, DOI 10.1093/jac/41.6.589; Swaren P, 1999, J AM CHEM SOC, V121, P5353, DOI 10.1021/ja990400q; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; WEIGEL LM, 1994, P NATL ACAD SCI USA, V91, P11611, DOI 10.1073/pnas.91.24.11611; Zhao GS, 1999, ANTIMICROB AGENTS CH, V43, P1124, DOI 10.1128/AAC.43.5.1124	23	31	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14917	14921		10.1074/jbc.M400666200	http://dx.doi.org/10.1074/jbc.M400666200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747460	hybrid			2022-12-27	WOS:000220594700053
J	Katoh, I; Tomimori, Y; Ikawa, Y; Kurata, S				Katoh, I; Tomimori, Y; Ikawa, Y; Kurata, S			Dimerization and processing of procaspase-9 by redox stress in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATING FACTOR-1; DEPENDENT ANION CHANNEL; CYTOCHROME-C; CELL-DEATH; OXIDATIVE STRESS; BCL-2 FAMILY; CASPASE-9 ACTIVATION; STRUCTURAL BASIS; APAF-1 CARD; APOPTOSIS	We studied the mechanism of intra-mitochondrial death initiator caspase-9 activation by a redox response, in which hydrogen peroxide (H2O2) caused a subtle decrease in the inner membrane potential (Deltapsim) with little evidence of cytochrome c release. Initiation of the intra-mitochondrial autocleavage of procaspase-9 preceded the onset of caspase cascade induction in the cytosol. Purified mitochondria demonstrated procaspase-9 processing and releasing abilities when exposed to H2O2. Bcl-2 overexpression caused accumulation of the active form caspase-9 in the mitochondria, rendering the cells resistant to the redox stress. Intriguingly, disulfide-bonded dimers of autoprocessed caspase-9 were generated in the mitochondria in the pre-apoptotic phase. Using a substrate- analog inhibitor, dimer formation of procaspase-9 was also detectable inside the mitochondria. Furthermore, thiol reductant thioredoxin blocked the caspase-9 activation step and the cell death induction. Thus, redox stress-responsive thiol-disulfide converting reactions in the mitochondrion seemed to mediate procaspase-9 assembly that allows autoprocessing. This study offers an explanation for the recent observation that Apaf-1-null cells can execute apoptosis, which can be blocked by Bcl-2, and supports the proposition that the cytochrome c-Apaf-1-procaspase-9 complex functions in the caspase amplification rather than in its initiation.	Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; RIKEN, Ikawa Lab, Wako, Saitama 3500198, Japan; Tokyo Med & Dent Univ, Med Res Inst, Grad Sch Allied Hlth Sci, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); RIKEN; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Kurata, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kushbgen@mri.tmd.ac.jp						Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Baker A, 2000, BIOCHEM BIOPH RES CO, V268, P78, DOI 10.1006/bbrc.1999.1908; Baliga B, 2003, CELL DEATH DIFFER, V10, P16, DOI 10.1038/sj.cdd.4401166; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Chandra D, 2003, J BIOL CHEM, V278, P17408, DOI 10.1074/jbc.M300750200; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; KATOH I, 1989, J VIROL, V63, P2226, DOI 10.1128/JVI.63.5.2226-2232.1989; KATOH I, 1987, NATURE, V329, P654, DOI 10.1038/329654a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Kurata SI, 1996, J BIOL CHEM, V271, P21798, DOI 10.1074/jbc.271.36.21798; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Robertson JD, 2003, CELL DEATH DIFFER, V10, P485, DOI 10.1038/sj.cdd.4401218; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scandalios J.G., 1997, OXIDATIVE STRESS MOL; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Tzung SP, 1997, AM J PATHOL, V150, P1985; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 2000, METHOD ENZYMOL, V322, P208; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265	54	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15515	15523		10.1074/jbc.M311819200	http://dx.doi.org/10.1074/jbc.M311819200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747474	hybrid			2022-12-27	WOS:000220594700123
J	Pak, SC; Kumar, V; Tsu, C; Luke, CJ; Askew, YS; Askew, DJ; Mills, DR; Bromme, D; Silverman, GA				Pak, SC; Kumar, V; Tsu, C; Luke, CJ; Askew, YS; Askew, DJ; Mills, DR; Bromme, D; Silverman, GA			SRP-2 is a cross-class inhibitor that participates in postembryonic development of the nematode Caenorhabditis elegans - Initial characterization of the clade L serpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITORS; TRANS-SPLICED LEADER; FUNCTIONAL EXPRESSION; MESSENGER-RNA; CATHEPSIN-L; MECHANISM; CHYMOTRYPSIN; SUPERFAMILY; OVALBUMIN; EVOLUTION	High molecular weight serpins are members of a large superfamily of structurally conserved proteins that inactivate target proteinases by a suicide substrate-like mechanism. In vertebrates, different clades of serpins distribute predominantly to either the intracellular or extracellular space. Although much is known about the function, structure, and inhibitory mechanism of circulating serpins such as alpha(1)-antitrypsin (SERPINA1) and antithrombin III (SERPINC1), relatively little is known about the function of the vertebrate intracellular (clade B) serpins. To gain a better understanding of the biology of the intracellular serpins, we initiated a comparative genomics study using Caenorhabditis elegans as a model system. A screen of the C. elegans genomic and cDNA databases revealed nine serpin genes, tandemly arrayed on chromosome V. Although the C. elegans serpins represent a unique clade ( L), they share significant functional homology with members of the clade B group of intracellular serpins, since they lack typical N-terminal signal peptides and reside intracellularly. To determine whether nematode serpins function as proteinase inhibitors, one family member, srp-2, was chosen for further characterization. Biochemical analysis of recombinant SRP-2 protein revealed SRP-2 to be a dual cross-class inhibitor of the apoptosis-related serine proteinase, granzyme B, and the lysosomal cysteine proteinases, cathepsins K, L, S, and V. Analysis of temporal and spatial expression indicated that SRP-2 was present during early embryonic development and highly expressed in the intestine and hypoderm of larval and adult worms. Transgenic animals engineered to overexpress SRP-2 were slow growing and/or arrested at the first, second, or third larval stages. These data suggest that perturbations of serpin-proteinase balance are critical for correct postembryonic development in C. elegans.	Harvard Univ, Childrens Hosp, Dept Pediat, Sch Med, Boston, MA 02115 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Silverman, GA (corresponding author), Harvard Univ, Childrens Hosp, Dept Pediat, Sch Med, 300 Longwood Ave,Enders 970, Boston, MA 02115 USA.	gary.silverman@tch.harvard.edu	Silverman, Gary/AAJ-1269-2020	Pak, Stephen/0000-0002-8089-3237	NATIONAL CANCER INSTITUTE [R01CA086007, R01CA087006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046182] Funding Source: NIH RePORTER; NCI NIH HHS [CA86007, CA87006] Funding Source: Medline; NIAMS NIH HHS [AR46182] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROMME D, 1994, J BIOL CHEM, V269, P30238; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Burglin TR, 1998, INT J PARASITOL, V28, P395, DOI 10.1016/S0020-7519(97)00208-7; Dougherty KM, 1999, P NATL ACAD SCI USA, V96, P686, DOI 10.1073/pnas.96.2.686; Ferguson KC, 1999, MOL CELL BIOL, V19, P1892; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GOODING LR, 1992, CELL, V71, P5; Hashmi S, 2002, J BIOL CHEM, V277, P3477, DOI 10.1074/jbc.M106117200; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Irving JA, 2002, MOL BIOL EVOL, V19, P1881, DOI 10.1093/oxfordjournals.molbev.a004012; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Kettle S, 1997, J GEN VIROL, V78, P677, DOI 10.1099/0022-1317-78-3-677; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Kruger O, 2002, GENE, V293, P97, DOI 10.1016/S0378-1119(02)00697-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; Mello C, 1995, METHOD CELL BIOL, V48, P451; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; Silverman GA, 2004, CELL MOL LIFE SCI, V61, P301, DOI 10.1007/s00018-003-3240-3; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Whisstock JC, 1999, PROTEINS, V36, P31, DOI 10.1002/(SICI)1097-0134(19990701)36:1&lt;31::AID-PROT3&gt;3.0.CO;2-Q; Zang XX, 1999, BLOOD, V94, P1418, DOI 10.1182/blood.V94.4.1418.416k03_1418_1428; Zang XX, 2001, TRENDS BIOCHEM SCI, V26, P191, DOI 10.1016/S0968-0004(00)01761-8; Zhang M, 2002, MED INTELL UNIT, P96	37	35	46	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15448	15459		10.1074/jbc.M400261200	http://dx.doi.org/10.1074/jbc.M400261200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739286	hybrid			2022-12-27	WOS:000220594700116
J	Rabel, D; Charlet, M; Ehret-Sabatier, L; Cavicchioli, L; Cudic, M; Otvos, L; Bulet, P				Rabel, D; Charlet, M; Ehret-Sabatier, L; Cavicchioli, L; Cudic, M; Otvos, L; Bulet, P			Primary structure and in vitro antibacterial properties of the Drosophila melanogaster attacin C pro-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; IMMUNE-RESPONSE; ANTIMICROBIAL PEPTIDES; MASS-SPECTROMETRY; HOST-DEFENSE; RECOGNITION; PROTEIN; ACTIVATION; BACTERIA; RANGE	In Drosophila melanogaster, seven distinct families of antimicrobial peptides with different structures and specificities are synthesized by the fat body and released into the hemolymph during the immune response. Using microscale high performance liquid chromatography, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and Edman degradation, we have isolated and characterized from immune-challenged Drosophila two novel induced molecules, under the control of the Imd pathway, that correspond to post-translationally modified antimicrobial peptides or peptide fragments. The first molecule is a doubly glycosylated form of drosocin, an O-glycosylated peptide that kills Gram-negative organisms. The second molecule represents a truncated form of the pro-domain of the Drosophila attacin C carrying two post-translational modifications and has significant structural similarities to proline-rich antibacterial peptides including drosocin. We have synthesized this peptide and found that it is active against Gram-negative bacteria. Furthermore, this activity is potentiated when the peptide is used in combination with the Drosophila antimicrobial peptide cecropin A. The synergistic action observed between these two molecules suggests that the truncated post-translationally modified pro-domain of attacin C by itself may play an important role in the antimicrobial defense of Drosophila.	CNRS, Inst Biol Mol & Cellulaire, UPR9022, F-67084 Strasbourg, France; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; The Wistar Institute	Bulet, P (corresponding author), Atheris Labs, Case Postale 314, CH-1233 Geneva, Switzerland.	philippe.bulet@atheris.ch	BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				Amsterdam D, 1996, ANTIBIOTICS LAB MED, V4, P52; ANDO K, 1988, J BIOCHEM-TOKYO, V103, P735, DOI 10.1093/oxfordjournals.jbchem.a122337; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; Bulet P, 1999, M S-MED SCI, V15, P23, DOI 10.4267/10608/1192; Bulet P, 1996, EUR J BIOCHEM, V238, P64, DOI 10.1111/j.1432-1033.1996.0064q.x; Bulet P, 2000, PROTEOME AND PROTEIN ANALYSIS, P157; BULET P, 1993, J BIOL CHEM, V268, P14893; Carte N, 2001, EUR J MASS SPECTROM, V7, P399, DOI 10.1255/ejms.450; Castle M, 1999, J BIOL CHEM, V274, P32555, DOI 10.1074/jbc.274.46.32555; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hedengren M, 2000, BIOCHEM BIOPH RES CO, V279, P574, DOI 10.1006/bbrc.2000.3988; Hetru C, 1997, Methods Mol Biol, V78, P35; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hoffmann R, 1999, BBA-GEN SUBJECTS, V1426, P459, DOI 10.1016/S0304-4165(98)00169-X; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Irving P, 2001, P NATL ACAD SCI USA, V98, P15119, DOI 10.1073/pnas.261573998; Kragol G, 2002, EUR J BIOCHEM, V269, P4226, DOI 10.1046/j.1432-1033.2002.03119.x; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Kurata S, 2004, DEV COMP IMMUNOL, V28, P89, DOI 10.1016/S0145-305X(03)00121-6; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Meister M, 2000, CURR TOP MICROBIOL, V248, P17; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Otvos L, 2002, CELL MOL LIFE SCI, V59, P1138, DOI 10.1007/s00018-002-8493-8; OTVOS L, 1994, BBA-MOL CELL RES, V1224, P68, DOI 10.1016/0167-4889(94)90114-7; Otvos L, 2000, BIOCHEMISTRY-US, V39, P14150, DOI 10.1021/bi0012843; Patrzykat A, 2001, ANTIMICROB AGENTS CH, V45, P1337, DOI 10.1128/AAC.45.5.1337-1342.2001; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Silva PI, 2000, J BIOL CHEM, V275, P33464, DOI 10.1074/jbc.M001491200; Uttenweiler-Joseph S, 1998, P NATL ACAD SCI USA, V95, P11342, DOI 10.1073/pnas.95.19.11342; Vizioli J, 2001, P NATL ACAD SCI USA, V98, P12630, DOI 10.1073/pnas.221466798	36	39	42	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14853	14859		10.1074/jbc.M313608200	http://dx.doi.org/10.1074/jbc.M313608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744858	hybrid			2022-12-27	WOS:000220594700046
J	Shin, DM; Jeon, JH; Kim, CW; Cho, SY; Kwon, JC; Lee, HJ; Choi, KH; Park, SC; Kim, IG				Shin, DM; Jeon, JH; Kim, CW; Cho, SY; Kwon, JC; Lee, HJ; Choi, KH; Park, SC; Kim, IG			Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation - Implications of transglutaminase 2 in age-related cataractogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; CROSS-LINKING; DIFFERENTIAL EXPRESSION; LENS TRANSGLUTAMINASE; MESSENGER-RNA; PROTEIN; CRYSTALLIN; BINDING; DISEASE; STABILIZE	Transglutaminase ( TGase) 2 is a ubiquitously expressed enzyme that modifies proteins by cross-linking or polyamination. An aberrant activity of TGase 2 has implicated its possible roles in a variety of diseases including age-related cataracts. However, the molecular mechanism by which TGase 2 is activated has not been elucidated. In this report, we showed that oxidative stress or UV irradiation elevates in situ TGase 2 activity. Neither the expression level nor the in vitro activity of TGase 2 appeared to correlate with the observed elevation of in situ TGase 2 activity. Screening a number of cell lines revealed that the level of TGase 2 activation depends on the cell type and also the environmental stress, suggesting that unrecognized cellular factor(s) may specifically regulate in situ TGase 2 activity. Concomitantly, we observed that human lens epithelial cells (HLE-B3) exhibited about 3-fold increase in in situ TGase 2 activity in response to the stresses. The activated TGase 2 catalyzed the formation of water-insoluble dimers or polymers of alphaB-crystallin, betaB(2)-crystallin, and vimentin in HLE-B3 cells, providing evidence that TGase 2 may play a role in cataractogenesis. Thus, our findings indicate that in situ TGase 2 activity must be evaluated instead of in vitro activity to study the regulation mechanism and function of TGase 2 in biological and pathological processes.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Aging & Apoptosis Res Ctr, Seoul 110799, South Korea	Seoul National University (SNU)	Kim, IG (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Aging & Apoptosis Res Ctr, 28 Yongon Dong, Seoul 110799, South Korea.	igkim@plaza.snu.ac.kr	Kim, In-Gyu/J-2747-2012; Jeon, Ju-Hong/D-5740-2012; Choi, Kyungho/J-5685-2012	Jeon, Ju-Hong/0000-0002-5603-2955; Choi, Kyungho/0000-0003-1635-173X; Kim, Chai-Wan/0000-0001-5105-2829				Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; BERBERS GAM, 1983, EUR J BIOCHEM, V135, P315, DOI 10.1111/j.1432-1033.1983.tb07655.x; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Clement S, 1998, J BIOL CHEM, V273, P7604, DOI 10.1074/jbc.273.13.7604; CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658; DEUSSEN A, 1989, EXP EYE RES, V48, P37, DOI 10.1016/0014-4835(89)90016-X; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREEN H, 1993, CELL, V74, P955, DOI 10.1016/0092-8674(93)90718-6; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; Jeon JH, 2003, EMBO J, V22, P5273, DOI 10.1093/emboj/cdg495; Jeon JH, 2003, FEBS LETT, V534, P180, DOI 10.1016/S0014-5793(02)03836-X; Jeon JH, 2002, BIOCHEM BIOPH RES CO, V294, P818, DOI 10.1016/S0006-291X(02)00582-X; Kalinin A, 2001, J CELL SCI, V114, P3069; Karpuj MV, 2002, NAT MED, V8, P143, DOI 10.1038/nm0202-143; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; KUCK JFR, 1990, EXP EYE RES, V50, P659, DOI 10.1016/0014-4835(90)90110-G; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Magabo KS, 2000, INVEST OPHTH VIS SCI, V41, P3056; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MUKHERJEE DC, 1983, SCIENCE, V219, P989, DOI 10.1126/science.6130601; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Peng XJ, 1999, FEBS LETT, V446, P35, DOI 10.1016/S0014-5793(99)00018-6; REDDY VN, 1990, EXP EYE RES, V50, P771, DOI 10.1016/0014-4835(90)90127-G; Shridas P, 2001, FEBS LETT, V499, P245, DOI 10.1016/S0014-5793(01)02565-0; SPORN MB, 1983, CANCER RES, V43, P3034; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	37	91	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15032	15039		10.1074/jbc.M308734200	http://dx.doi.org/10.1074/jbc.M308734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752105	hybrid			2022-12-27	WOS:000220594700067
J	Wimalasena, DS; Wimalasena, K				Wimalasena, DS; Wimalasena, K			Kinetic evidence for channeling of dopamine between monoamine transporter and membranous dopamine-beta-monooxygenase in chromaffin granule ghosts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-MEDULLA; REDUCING EQUIVALENTS; PH-GRADIENT; HYDROXYLASE; ASCORBATE; CATECHOLAMINES; QUANTITATION; DEPENDENCE; MECHANISMS; PROTEINS	The nature of coupling between the uptake and dopamine-beta-monooxygenase (DbetaM) catalyzed hydroxylation of dopamine (DA) was studied in bovine chromaffin granule ghosts. Initial rate and transient kinetics of DA uptake and conversion were determined under a variety of conditions. The uptake kinetics of DA, norepinephrine (NE), and epinephrine demonstrate that DA is a better substrate than NE and epinephrine under optimal uptake conditions. The transient kinetics of DA accumulation and NE production under both optimal uptake and uptake and conversion conditions were zero-order with no detectable lag or burst periods. The mathematical analyses of the data show that a normal sequential uptake followed by the conversion process could not explain the observed kinetics, under any condition. On the other hand, all experimental data are in agreement with a mechanism in which DA is efficiently channeled from the vesicular monoamine transporter to membranous DbetaM for hydroxylation, prior to the release into the bulk medium of the ghost interior. The slow accumulation of DA under optimal conversion conditions appears to be caused by the slow leakage of DA from the channeling pathway to the ghost interior. Because DbetaM activity in intact granules is equally distributed between soluble and membranous forms of DbetaM, if an efficient channeling mechanism is operative in vivo, soluble DbetaM may not have access to the substrate, making the catalytic activity of soluble DbetaM physiologically insignificant, which is consistent with the increasing experimental evidence that membranous DbetaM may be the physiologically functional form.	Wichita State Univ, Dept Chem, Wichita, KS 67260 USA	Wichita State University	Wimalasena, K (corresponding author), Wichita State Univ, Dept Chem, Wichita, KS 67260 USA.	kandatege.wimalasena@wichita.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039423] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 39423] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1989, J BIOL CHEM, V264, P12259; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; APPS DK, 1980, FEBS LETT, V111, P386, DOI 10.1016/0014-5793(80)80833-7; BEERS MF, 1986, J BIOL CHEM, V261, P2529; BELPAIRE F, 1968, BIOCHEM PHARMACOL, V17, P411, DOI 10.1016/0006-2952(68)90251-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HENRY JP, 1994, J EXP BIOL, V196, P251; Henry JP, 1998, NEUROCHEM INT, V32, P227, DOI 10.1016/S0197-0186(97)00092-2; HERMAN HH, 1988, J BIOL CHEM, V263, P666; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; HUYGHE BG, 1991, J BIOL CHEM, V266, P11544; ISAMBERT MF, 1985, BIOCHEMISTRY-US, V24, P3660, DOI 10.1021/bi00335a039; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KELLEY PM, 1988, J BIOL CHEM, V263, P3799; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KNOTH J, 1981, J BIOL CHEM, V256, P6541; KNOTH J, 1980, BIOCHEMISTRY-US, V19, P2938, DOI 10.1021/bi00554a019; LJONES T, 1984, COPPER PROTEINS COPP, V2, P131; MCCLURE WR, 1969, BIOCHEMISTRY-US, V8, P2782, DOI 10.1021/bi00835a014; MENNITI FS, 1987, J BIOL CHEM, V262, P7651; NJUS D, 1983, J BIOL CHEM, V258, P27; NJUS D, 1979, BIOCHEM J, V180, P579, DOI 10.1042/bj1800579; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PHILLIPS JH, 1974, BIOCHEM J, V144, P319, DOI 10.1042/bj1440319; Rosenberg R C, 1980, Essays Neurochem Neuropharmacol, V4, P163; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SALAMA G, 1980, J GEN PHYSIOL, V75, P109, DOI 10.1085/jgp.75.2.109; SCHERMAN D, 1980, BIOCHEM PHARMACOL, V29, P1883, DOI 10.1016/0006-2952(80)90098-2; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; Terland O, 2000, ADV EXP MED BIOL, V482, P55; VILLAFRANCA JJ, 1981, COPPER PROTEINS, P263; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WIMALASENA K, 1989, J BIOL CHEM, V264, P124; WIMALASENA K, 1995, J BIOL CHEM, V270, P27516, DOI 10.1074/jbc.270.46.27516; WINKLER H, 1970, BIOCHEM J, V118, P303, DOI 10.1042/bj1180303; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7	42	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15298	15304		10.1074/jbc.M313325200	http://dx.doi.org/10.1074/jbc.M313325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732710	hybrid			2022-12-27	WOS:000220594700098
J	Satagopan, S; Spreitzer, RJ				Satagopan, S; Spreitzer, RJ			Substitutions at the Asp-473 latch residue of chlamydomonas ribulosebisphosphate carboxylase/oxygenase cause decreases in carboxylation efficiency and CO2/O-2 specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; CHLOROPLAST RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; X-RAY-STRUCTURE; LARGE SUBUNIT; CRYSTAL-STRUCTURE; ACTIVE-SITE; DIRECTED MUTAGENESIS; THERMAL-STABILITY; SUPPRESSOR MUTATIONS; MUTANT FORMS	The loop between alpha-helix 6 and beta-strand 6 in the alpha/beta-barrel active site of ribulose-1,5-bisphosphate carboxylase/ oxygenase (Rubisco, EC 4.1.1.39) plays a key role in discriminating between gaseous substrates CO2 and O-2. Based on numerous x-ray crystal structures, loop 6 is either closed or open depending on the presence or absence, respectively, of substrate ligands. The carboxyl terminus folds over loop 6 in the closed conformation, prompting speculation that it may trigger or latch loop 6 closure. Because an x-ray crystal structure of tobacco Rubisco revealed that phosphate is located at a site in the open form that is occupied by the carboxyl group of Asp-473 in the closed form, it was proposed that Asp-473 may serve as the latch that holds the carboxyl terminus over loop 6. To assess the essentiality of Asp-473 in catalysis, we used directed mutagenesis and chloroplast transformation of the green alga Chlamydomonas reinhardtii to create D473A and D473E mutant enzymes. The D473A and D473E mutant strains can grow photoautotrophically, indicating that Asp-473 is not essential for catalysis. However, both substitutions caused 87% decreases in carboxylation catalytic efficiency (V-max/K-m) and similar to16% decreases in CO2/O-2 specificity. If the carboxyl terminus is required for stabilizing loop 6 in the closed conformation, there must be additional residues at the carboxyl terminus/loop 6 interface that contribute to this mechanism. Considering that substitutions at residue 473 can influence CO2/O-2 specificity, further study of interactions between loop 6 and the carboxyl terminus may provide clues for engineering an improved Rubisco.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Spreitzer, RJ (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rspreitzer1@unl.edu	Satagopan, Sriram/B-3198-2011	Satagopan, Sriram/0000-0002-4867-531X				Andersson I, 2003, ARCH BIOCHEM BIOPHYS, V414, P130, DOI 10.1016/S0003-9861(03)00164-4; Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews TJ, 1996, NAT STRUCT BIOL, V3, P3, DOI 10.1038/nsb0196-3; Bainbridge G, 1998, BIOCHEM J, V336, P387, DOI 10.1042/bj3360387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN ZX, 1992, PHOTOSYNTH RES, V31, P157, DOI 10.1007/BF00028792; CHEN ZX, 1991, PLANTA, V183, P597, DOI 10.1007/BF00194282; CHEN ZX, 1993, PLANT PHYSIOL, V101, P1189, DOI 10.1104/pp.101.4.1189; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; Cheng ZQ, 1998, PROTEIN ENG, V11, P457, DOI 10.1093/protein/11.6.457; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; Du YC, 2003, J BIOL CHEM, V278, P49401, DOI 10.1074/jbc.M309993200; Du YC, 2000, P NATL ACAD SCI USA, V97, P14206, DOI 10.1073/pnas.260503997; Du YC, 2000, J BIOL CHEM, V275, P19844, DOI 10.1074/jbc.M002321200; Duff AP, 2000, J MOL BIOL, V298, P903, DOI 10.1006/jmbi.2000.3724; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; Hansen S, 1999, J MOL BIOL, V288, P609, DOI 10.1006/jmbi.1999.2701; HOLLINGSHEAD S, 1985, PLASMID, V13, P17, DOI 10.1016/0147-619X(85)90052-6; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARSON EM, 1995, BIOCHEMISTRY-US, V34, P4531, DOI 10.1021/bi00014a005; Larson EM, 1997, J BIOL CHEM, V272, P17033, DOI 10.1074/jbc.272.27.17033; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; Okano Y, 2002, FEBS LETT, V527, P33, DOI 10.1016/S0014-5793(02)03148-4; Ott CM, 2000, J BIOL CHEM, V275, P26241, DOI 10.1074/jbc.M004580200; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; Parry MAJ, 2003, J EXP BOT, V54, P1321, DOI 10.1093/jxb/erg141; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; Portis AR, 2003, PHOTOSYNTH RES, V75, P11, DOI 10.1023/A:1022458108678; PORTIS AR, 1990, ARCH BIOCHEM BIOPHYS, V283, P397, DOI 10.1016/0003-9861(90)90660-Q; RANTY B, 1990, EMBO J, V9, P1365, DOI 10.1002/j.1460-2075.1990.tb08251.x; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Smith SA, 2003, J MOL BIOL, V331, P557, DOI 10.1016/S0022-2836(03)00786-1; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Spreitzer RJ, 2001, BIOCHEMISTRY-US, V40, P5615, DOI 10.1021/bi002943e; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1998, MOL BIOL CHLOROPLAST, P515; Sugawara H, 1999, J BIOL CHEM, V274, P15655, DOI 10.1074/jbc.274.22.15655; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; Taylor TC, 2001, J BIOL CHEM, V276, P48159, DOI 10.1074/jbc.M107765200; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; Wierenga RK, 2001, FEBS LETT, V492, P193, DOI 10.1016/S0014-5793(01)02236-0; Zhu GH, 1998, PHOTOSYNTH RES, V57, P71, DOI 10.1023/A:1006020424581; ZHU GH, 1990, PLANT PHYSIOL, V93, P244, DOI 10.1104/pp.93.1.244; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952	59	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14240	14244		10.1074/jbc.M313215200	http://dx.doi.org/10.1074/jbc.M313215200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734540	hybrid			2022-12-27	WOS:000220478500117
J	Towne, JE; Garka, KE; Renshaw, BR; Virca, GD; Sims, JE				Towne, JE; Garka, KE; Renshaw, BR; Virca, GD; Sims, JE			Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappa B and MAPKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN; MOLECULAR-CLONING; FAMILY-MEMBERS; T-CELLS; RECEPTOR; T1/ST2; CYTOKINE; IDENTIFICATION; IL-1H4/IL-1F7; EXPRESSION	Interleukin 1 (IL-1) plays a prominent role in immune and inflammatory reactions. Our understanding of the IL-1 family has recently expanded to include six novel members named IL-1F5 to IL-1F10. Recently, it was reported that IL-1F9 activated NF-kappaB through the orphan receptor IL-1 receptor (IL-1R)-related protein 2 (IL-1Rrp2) in Jurkat cells (Debets, R., Timans, J. C., Homey, B., Zurawski, S., Sana, T. R., Lo, S., Wagner, J., Edwards, G., Clifford, T., Menon, S., Bazan, J. F., and Kastelein, R. A. (2001) J. Immunol. 167, 1440 - 1446). In this study, we demonstrate that IL-1F6 and IL-1F8, in addition to IL-1F9, activate the pathway leading to NF-kappaB in an IL-1Rrp2-dependent manner in Jurkat cells as well as in multiple other human and mouse cell lines. Activation of the pathway leading to NF-kappaB by IL-1F6 and IL-1F8 follows a similar time course to activation by IL-1beta, suggesting that signaling by the novel family members occurs through a direct mechanism. In a mammary epithelial cell line, NCI/ADR-RES, which naturally expresses IL-1Rrp2, all three cytokines signal without further receptor transfection. IL-1Rrp2 antibodies block activation of the pathway leading to NF-kappaB by IL-1F6, IL-1F8, and IL-1F9 in both Jurkat and NCI/ADR-RES cells. In NCI/ ADR-RES cells, the three IL-1 homologs activated the MAPKs, JNK and ERK1/2, and activated downstream targets as well, including an IL- 8 promoter reporter and the secretion of IL-6. We also provide evidence that IL-1RAcP, in addition to IL-1Rrp2, is required for signaling by all three cytokines. Antibodies directed against IL-1RAcP and transfection of cytoplasmically deleted IL-1RAcP both blocked activation of the pathway leading to NF-kappaB by the three cytokines. We conclude that IL-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP.	Amgen Corp, Seattle, WA 98101 USA		Towne, JE (corresponding author), Amgen Corp, 51 Univ St, Seattle, WA 98101 USA.	townej@amgen.com		Sims, John/0000-0002-5667-9185				Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Born TL, 2000, J BIOL CHEM, V275, P41529; Bufler P, 2002, P NATL ACAD SCI USA, V99, P13723, DOI 10.1073/pnas.212519099; Carrie A, 1999, NAT GENET, V23, P25, DOI 10.1038/12623; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Daun JM, 2000, J INTERF CYTOK RES, V20, P843, DOI 10.1089/10799900050163217; Debets R, 2001, J IMMUNOL, V167, P1440, DOI 10.4049/jimmunol.167.3.1440; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dunn E, 2001, TRENDS IMMUNOL, V22, P533, DOI 10.1016/S1471-4906(01)02034-8; Dunn EF, 2003, BIOCHEMISTRY-US, V42, P10938, DOI 10.1021/bi0341197; DUNNE A, 2003, SCI STKE, V171, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Gao WT, 2003, J IMMUNOL, V170, P107, DOI 10.4049/jimmunol.170.1.107; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Kumar S, 2000, J BIOL CHEM, V275, P10308, DOI 10.1074/jbc.275.14.10308; Kumar S, 2002, CYTOKINE, V18, P61, DOI 10.1006/cyto.2002.0873; Li HJ, 2000, GENOMICS, V67, P284, DOI 10.1006/geno.2000.6269; Lin HS, 2001, J BIOL CHEM, V276, P20597, DOI 10.1074/jbc.M010095200; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nicklin MJH, 2002, GENOMICS, V79, P718, DOI 10.1006/geno.2002.6751; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pan GH, 2001, CYTOKINE, V13, P1, DOI 10.1006/cyto.2000.0799; Parnet P, 1996, J BIOL CHEM, V271, P3967; Radons J, 2002, J BIOL CHEM, V277, P16456, DOI 10.1074/jbc.M201000200; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; Sims JE, 2001, TRENDS IMMUNOL, V22, P536, DOI 10.1016/S1471-4906(01)02040-3; Sims JE, 2002, CURR OPIN IMMUNOL, V14, P117, DOI 10.1016/S0952-7915(01)00306-5; Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Taylor SL, 2002, GENOMICS, V79, P726, DOI 10.1006/geno.2002.6752; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Walzl G, 2001, J EXP MED, V193, P785, DOI 10.1084/jem.193.7.785; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Yoshimoto T, 1998, J IMMUNOL, V161, P3400	42	310	343	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13677	13688		10.1074/jbc.M400117200	http://dx.doi.org/10.1074/jbc.M400117200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734551	hybrid			2022-12-27	WOS:000220478500050
J	Wang, S; Ge, K; Roeder, RG; Hankinson, O				Wang, S; Ge, K; Roeder, RG; Hankinson, O			Role of mediator in transcriptional activation by the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P1-450 GENE-TRANSCRIPTION; NUCLEAR TRANSLOCATOR PROTEIN; SIGNAL-TRANSDUCTION PATHWAYS; ESTROGEN-RECEPTOR; WILD-TYPE; IN-VIVO; COACTIVATOR COMPLEX; TRAP220 COMPONENT; AH RECEPTOR; TRANSACTIVATION	The aryl hydrocarbon receptor (AHR) binds many aromatic hydrocarbon compounds and mediates their carcinogenesis. We demonstrate that the endogenous AHR physically associates with the endogenous TRAP/DRIP/ ARC/Mediator complex in a ligand-dependent manner. The Med220 subunit, which is known to interact with several nuclear hormone receptors through its LXXLL motifs, potentiates AHR-dependent reporter gene activity in an LXXLL-independent manner. Depletion of Med220 substantially reduces endogenous AHR-mediated transcription from the mouse cytochrome P4501A1 gene (CYP1A1). Both Med220 and CDK8 ( another subunit of TRAP/DRIP/ ARC/Mediator) are recruited to the CYP1A1 enhancer in a TCDD ( 2,3,7,8-tetrachlorodibenzop- dioxin)-dependent fashion in vivo, and Med220 LXXLL motifs are not required. Med220 rapidly and persistently associates with the enhancer but not the promoter of the CYP1A1 gene after TCDD treatment with similar kinetics as AHR and the coactivators p300 and p/CIP. Our findings demonstrate a novel role for Med220 in AHR-regulated transcription that differs mechanistically from its role in transcriptional regulation by other previously studied transcription factors.	Univ Calif Los Angeles, Inst Mol Biol, Jonsson Comprehens Canc Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Rockefeller University	Hankinson, O (corresponding author), Univ Calif Los Angeles, Med Ctr, Dept Pathol & Lab Med, Ctr Hlth Sci, Box 951732, Los Angeles, CA 90095 USA.	ohank@mednet.ucla.edu	Ge, Kai/H-2810-2019	Ge, Kai/0000-0002-7442-5138	NCI NIH HHS [R01 CA28868, R01 CA028868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK075003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander DL, 1998, J CELL SCI, V111, P3311; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Burakov D, 2002, J BIOL CHEM, V277, P14359, DOI 10.1074/jbc.C200099200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Devito Michael J., 1994, P139; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GIERTHY JF, 1994, J CELL BIOCHEM, V54, P231, DOI 10.1002/jcb.240540211; GIERTHY JF, 1993, CANCER RES, V53, P3149; Gradin K, 1999, J BIOL CHEM, V274, P13511, DOI 10.1074/jbc.274.19.13511; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jana NR, 1999, BIOCHEM BIOPH RES CO, V256, P462, DOI 10.1006/bbrc.1999.0367; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kuil CW, 1998, J BIOL CHEM, V273, P8829, DOI 10.1074/jbc.273.15.8829; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PROBST MR, 1993, MOL PHARMACOL, V44, P511; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; Safe S, 1998, TOXICOL LETT, V103, P343; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; ZACHAREWSKI T, 1991, BIOCHEM PHARMACOL, V41, P1931, DOI 10.1016/0006-2952(91)90133-P	55	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13593	13600		10.1074/jbc.M312274200	http://dx.doi.org/10.1074/jbc.M312274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729673	hybrid			2022-12-27	WOS:000220478500039
J	Choi, HS; Sreenivas, A; Han, GS; Carman, GM				Choi, HS; Sreenivas, A; Han, GS; Carman, GM			Regulation of phospholipid synthesis in the yeast cki1 Delta eki1 Delta mutant defective in the Kennedy pathway - The CHO1-encoded phosphatidylserine synthase is regulated by mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; DEPENDENT PROTEIN-KINASE; CDP-CHOLINE PATHWAY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; COORDINATE REGULATION; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; NUCLEOTIDE-SEQUENCE	In the yeast Saccharomyces cerevisiae, the most abundant phospholipid phosphatidylcholine is synthesized by the complementary CDP-diacylglycerol and Kennedy pathways. Using a cki1Delta eki1Delta mutant defective in choline kinase and ethanolamine kinase, we examined the consequences of a block in the Kennedy pathway on the regulation of phosphatidylcholine synthesis by the CDP-diacylglycerol pathway. The cki1Delta eki1Delta mutant exhibited increases in the synthesis of phosphatidylserine, phosphatidylethanolamine, and phosphatidylcholine via the CDP-diacylglycerol pathway. The increase in phospholipid synthesis correlated with increased activity levels of the CDPdiacylglycerol pathway enzymes phosphatidylserine synthase, phosphatidylserine decarboxylase, phosphatidylethanolamine methyltransferase, and phospholipid methyltransferase. However, other enzyme activities, including phosphatidylinositol synthase and phosphatidate phosphatase, were not affected in the cki1Delta eki1Delta mutant. For phosphatidylserine synthase, the enzyme catalyzing the committed step in the pathway, activity was regulated by increases in the levels of mRNA and protein. Decay analysis of CHO1 mRNA indicated that a dramatic increase in transcript stability was a major component responsible for the elevated level of phosphatidylserine synthase. These results revealed a novel mechanism that controls phospholipid synthesis in yeast.	Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboagye EO, 1999, CANCER RES, V59, P80; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAELEE M, 1990, J BIOL CHEM, V265, P7221; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; Birner R, 2003, INT REV CYTOL, V225, P273, DOI 10.1016/S0074-7696(05)25007-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; CULBERTSON MR, 1975, GENETICS, V80, P23; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; GAYNOR PM, 1990, BIOCHIM BIOPHYS ACTA, V1045, P156, DOI 10.1016/0005-2760(90)90145-N; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HAID A, 1983, METHOD ENZYMOL, V96, P192; HAMAMATSU S, 1994, FEBS LETT, V348, P33, DOI 10.1016/0014-5793(94)00576-1; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HROMY JM, 1986, J BIOL CHEM, V261, P5572; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KIYONO K, 1987, J BIOCHEM-TOKYO, V102, P1089, DOI 10.1093/oxfordjournals.jbchem.a122147; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; KOHLWEIN SD, 1988, J BACTERIOL, V170, P3778, DOI 10.1128/jb.170.8.3778-3781.1988; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; Kuzj AES, 1998, MICROBIOL-UK, V144, P739, DOI 10.1099/00221287-144-3-739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPING E, 1994, GENETICS, V137, P55; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; LEVY JR, 1992, J BIOL CHEM, V267, P25289; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; MinSeok R, 1996, J BIOCHEM, V120, P1040; MORASH SC, 1994, J BIOL CHEM, V269, P28769; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; Noga AA, 2003, J LIPID RES, V44, P1998, DOI 10.1194/jlr.M300226-JLR200; Noga AA, 2003, J BIOL CHEM, V278, P21851, DOI 10.1074/jbc.M301982200; Oshiro J, 2003, J BIOL CHEM, V278, P31495, DOI 10.1074/jbc.M305452200; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; Rose MD., 1990, METHODS YEAST GENETI; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; SPECTOR AA, 1985, J LIPID RES, V26, P1015; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; Street JC, 1997, MAGNET RESON MED, V38, P769, DOI 10.1002/mrm.1910380513; SUMMERS EF, 1988, GENETICS, V120, P909; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; Vance JE, 2003, PROG NUCLEIC ACID RE, V75, P69, DOI 10.1016/S0079-6603(03)75003-X; Vemula M, 2003, J BIOL CHEM, V278, P45269, DOI 10.1074/jbc.M308812200; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Wright MM, 2001, J BIOL CHEM, V276, P25254, DOI 10.1074/jbc.M011552200; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Yamashita S, 1997, BBA-LIPID LIPID MET, V1348, P228, DOI 10.1016/S0005-2760(97)00102-1	108	15	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12081	12087		10.1074/jbc.M400297200	http://dx.doi.org/10.1074/jbc.M400297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14739287	hybrid			2022-12-27	WOS:000220334900012
J	Szurmant, H; Muff, TJ; Ordal, GW				Szurmant, H; Muff, TJ; Ordal, GW			Bacillus subtilis CheC and FliY are members of a novel class of CheY-P-hydrolyzing proteins in the chemotactic signal transduction cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FLAGELLAR SWITCH; METHYLATION; PHOSPHOTRANSFER; PHOSPHORYLATION; EXPRESSION; ADAPTATION; REGULATOR; RESPONSES; BEHAVIOR	Rapid restoration of prestimulus levels of the chemotactic response regulator, CheY- P, is important for preparing bacteria and archaea to respond sensitively to new stimuli. In an extension of previous work ( Szurmant, H., Bunn, M. W., Cannistraro, V. J., and Ordal, G. W. ( 2003) J. Biol. Chem. 278, 48611 - 48616), we describe a new family of CheY- P phosphatases, the CYX family, that is widespread among the bacteria and archaea. These proteins provide another pathway, in addition to the ones involving CheZ of the gamma- and beta- proteobacteria ( e. g. Escherichia coli) or the alternative CheY that serves as a " phosphate sink" among the alpha- proteobacteria ( e. g. Sinorhizobium meliloti), for dephosphorylating CheY- P. In particular, we identify CheC, known previously to be involved in adaptation to stimuli in Bacillus subtilis, as a CheY- P phosphatase. Using an in vitro assay used previously to demonstrate that the switch protein FliY is a CheY- P phosphatase, we have shown that increasing amounts of CheC accelerate the hydrolysis of CheY- P. In vivo, a double mutant lacking cheC and the region of fliY that encodes the CheY- P binding domain is almost completely smooth swimming, implying that these cells contain very high levels of CheY- P. CheC appears to be primarily involved in restoring normal CheY- P levels following the addition of attractant, whereas FliY seems to act on CheY- P constitutively. The activity of CheC is relatively low compared to that of FliY, but we have shown that the chemotaxis protein CheD enhances the activity of CheC 5- fold. We suggest a model for how FliY, CheC, and CheD work together to regulate CheY- P levels in the bacterium.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Liberal Arts & Sci, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Ordal, GW (corresponding author), Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA.	ordal@uiuc.edu			NIGMS NIH HHS [R01 GM54365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; Aizawa S-I, 2002, BACILLUS SUBTILIS IT, P437; Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P2715, DOI 10.1111/j.1365-2958.1992.tb01448.x; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P23, DOI 10.1111/j.1365-2958.1992.tb00833.x; Boesch KC, 2000, J BACTERIOL, V182, P3544, DOI 10.1128/JB.182.12.3544-3552.2000; Cantwell BJ, 2003, J BACTERIOL, V185, P2354, DOI 10.1128/JB.185.7.2354-2361.2003; FUHRER DK, 1991, J BACTERIOL, V173, P7443, DOI 10.1128/jb.173.23.7443-7448.1991; Greene SR, 1999, GENE, V232, P59, DOI 10.1016/S0378-1119(99)00115-8; HARLOW E, 1988, ANTIBODIES LAB MANUA, P632; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; Karatan E, 2001, J BIOL CHEM, V276, P43618, DOI 10.1074/jbc.M104955200; Kirby JR, 1999, J BIOL CHEM, V274, P11092, DOI 10.1074/jbc.274.16.11092; Kirby JR, 2000, MOL MICROBIOL, V35, P44, DOI 10.1046/j.1365-2958.2000.01676.x; Kirby JR, 2001, MOL MICROBIOL, V42, P573, DOI 10.1046/j.1365-2958.2001.02581.x; KIRSCH ML, 1993, J BIOL CHEM, V268, P18610; KOFOID EC, 1991, J BACTERIOL, V173, P2116, DOI 10.1128/jb.173.6.2116-2119.1991; Kristich CJ, 2002, J BIOL CHEM, V277, P25356, DOI 10.1074/jbc.M201334200; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; Mowbray SL, 1999, MOL CELLS, V9, P115; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; Porter SL, 2002, J MOL BIOL, V324, P35, DOI 10.1016/S0022-2836(02)01031-8; RATHLEV T, 1956, ARCH BIOCHEM BIOPHYS, V65, P319, DOI 10.1016/0003-9861(56)90197-7; Rosario MML, 1996, MOL MICROBIOL, V21, P511, DOI 10.1111/j.1365-2958.1996.tb02560.x; ROSARIO MML, 1995, BIOCHEMISTRY-US, V34, P3823, DOI 10.1021/bi00011a040; ROSARIO MML, 1994, J BACTERIOL, V176, P2736, DOI 10.1128/JB.176.9.2736-2739.1994; SAULMON MM, 2004, MICROBIOLOGY, V150, P591; Sourjik V, 1998, BIOCHEMISTRY-US, V37, P2327, DOI 10.1021/bi972330a; Sourjik V, 2000, MOL MICROBIOL, V37, P740, DOI 10.1046/j.1365-2958.2000.02044.x; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Szurmant H, 2003, J BIOL CHEM, V278, P48611, DOI 10.1074/jbc.M306180200; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; Wang H, 1996, MOL MICROBIOL, V19, P695, DOI 10.1046/j.1365-2958.1996.393934.x; Zhao R, 2002, NAT STRUCT BIOL, V9, P570; Zhao RH, 1996, J MOL BIOL, V261, P195, DOI 10.1006/jmbi.1996.0452; Zimmer MA, 2002, MOL MICROBIOL, V45, P555, DOI 10.1046/j.1365-2958.2002.03035.x	39	79	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21787	21792		10.1074/jbc.M311497200	http://dx.doi.org/10.1074/jbc.M311497200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14749334	hybrid			2022-12-27	WOS:000221417100015
J	Tullai, JW; Schaffer, ME; Mullenbrock, S; Kasif, S; Cooper, GM				Tullai, JW; Schaffer, ME; Mullenbrock, S; Kasif, S; Cooper, GM			Identification of transcription factor binding sites upstream of human genes regulated by the phosphatidylinositol 3-kinase and MEK/ERK signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; ZINC-FINGER PROTEIN; C-FOS PROMOTER; NF-KAPPA-B; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; GROWTH-FACTORS; TARGET GENES; EXPRESSION; ACTIVATION	We have taken an integrated approach in which expression profiling has been combined with the use of small molecule inhibitors and computational analysis of transcription factor binding sites to characterize regulatory sequences of genes that are targets of specific signaling pathways in growth factor-stimulated human cells. T98G cells were stimulated with platelet-derived growth factor (PDGF) and analyzed by DNA microarrays, which identified 74 immediate-early gene transcripts. Cells were then treated with inhibitors to identify subsets of genes that are targets of the phosphatidylinositol 3-kinase (PI3K) and MEK/ERK signaling pathways. Four groups of PDGF-induced genes were defined: independent of PI3K and MEK/ERK signaling, dependent on PI3K signaling, dependent on MEK/ERK signaling, and dependent on both pathways. The upstream regions of all genes in the four groups were scanned using TRANSFAC for putative cis-elements as compared with a background set of non-induced genes. Binding sites for 18 computationally predicted transcription factors were over-represented in the four groups of co-expressed genes compared with the background sequences (p < 0.01). Many of the cis-elements identified were conserved in orthologous mouse genes, and many of the predicted elements and their cognate transcription factors were consistent with previous experimental data. In addition, chromatin immunoprecipitation assays experimentally verified nine predicted SRF binding sites in T98G cells, including a previously unknown SRF site upstream of DUSP5. These results indicate that groups of human genes regulated by discrete intracellular signaling pathways share common cis-regulatory elements.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Boston Univ, Bioinformat Program, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Cooper, GM (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gmcooper@bu.edu			NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM066401, F32GM067392] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 18689] Funding Source: Medline; NIGMS NIH HHS [F32 GM 067392, P20 GM 66401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; Blanchette M, 2002, J COMPUT BIOL, V9, P211, DOI 10.1089/10665270252935421; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; EWENS WJ, 2001, STAT METHODS BIOINFO, P119; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fickett JW, 2000, CURR OPIN BIOTECH, V11, P19, DOI 10.1016/S0958-1669(99)00049-X; Frith MC, 2002, NUCLEIC ACIDS RES, V30, P3214, DOI 10.1093/nar/gkf438; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Halfon MS, 2002, GENOME RES, V12, P1019, DOI 10.1101/gr.228902; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; Liu XD, 1999, J GEN VIROL, V80, P3073, DOI 10.1099/0022-1317-80-12-3073; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McEvoy AN, 2002, J IMMUNOL, V168, P2979, DOI 10.4049/jimmunol.168.6.2979; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morcinek JC, 2002, ONCOGENE, V21, P1668, DOI 10.1038/sj.onc.1205148; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Ohler U, 2001, TRENDS GENET, V17, P56, DOI 10.1016/S0168-9525(00)02174-0; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; Rebeiz M, 2002, P NATL ACAD SCI USA, V99, P9888, DOI 10.1073/pnas.152320899; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Santoro T, 1995, GENOMICS, V30, P558, DOI 10.1006/geno.1995.1277; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Takahashi Y, 2000, GENE DEV, V14, P804; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wasserman WW, 2000, NAT GENET, V26, P225, DOI 10.1038/79965; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Wolfsberg TG, 1999, GENOME RES, V9, P775; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Wyrick JJ, 2002, CURR OPIN GENET DEV, V12, P130, DOI 10.1016/S0959-437X(02)00277-0; Xi HK, 2003, J IMMUNOL, V170, P315, DOI 10.4049/jimmunol.170.1.315; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	72	81	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					20167	20177		10.1074/jbc.M309260200	http://dx.doi.org/10.1074/jbc.M309260200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14769801	hybrid			2022-12-27	WOS:000221164500093
J	Castro-Obregon, S; Rao, RV; del Rio, G; Chen, SF; Poksay, KS; Rabizadeh, S; Vesce, S; Zhang, XK; Swanson, RA; Bredesen, DE				Castro-Obregon, S; Rao, RV; del Rio, G; Chen, SF; Poksay, KS; Rabizadeh, S; Vesce, S; Zhang, XK; Swanson, RA; Bredesen, DE			Alternative, nonapoptotic programmed cell death - Mediation by arrestin 2, ERK2, AND Nur77	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; TACHYKININ NK1 RECEPTOR; NUCLEAR RECEPTOR; NEURONAL DEATH; SUBSTANCE-P; APOPTOSIS; ACTIVATION; INHIBITION; TRIGGERS; ANTAGONIST	Programmed cell death (pcd) may take the form of apoptosis or of nonapoptotic pcd. Whereas cysteine aspartyl-specific proteases (caspases) mediate apoptosis, the mediators of nonapoptotic cell death programs are much less well characterized. Here we report that alternative, nonapoptotic pcd induced by the neurokinin-1 receptor (NK1R) activated by its ligand Substance P, is mediated by a MAPK phosphorylation cascade recruited by the scaffold protein arrestin 2. The activation of the protein kinases Raf-1, MEK2, and ERK2 is essential for this form of nonapoptotic pcd, leading to the phosphorylation of the orphan nuclear receptor Nur77. NK1R-mediated cell death was inhibited by a dominant negative form of arrestin 2, Raf-1, or Nur77, by MEK1/2-specific inhibitors, and by RNA interference directed against ERK2 or MEK2 but not ERK1 or MEK1 and against Nur77. The MAPK pathway is also activated in neurons in primary culture undergoing NK1R-mediated death, since the MEK inhibitor PD98059 inhibited Substance P-induced death in primary striatal neurons. These results suggest that Nur77, which is regulated by a MAPK pathway activated via arrestin 2, modulates NK1R-mediated nonapoptotic pcd.	Buck Inst Age Res, Novato, CA 94945 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Buck Institute for Research on Aging; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bredesen, DE (corresponding author), Buck Inst Age Res, Novato, CA 94945 USA.	dbredesen@buckinstitute.org	Castro-Obregon, Susana/AAE-5105-2020	Castro-Obregon, Susana/0000-0003-0549-5690	NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER; NIA NIH HHS [AG12282] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; Bras A, 2000, CELL DEATH DIFFER, V7, P262, DOI 10.1038/sj.cdd.4400653; CALNAN BJ, 1995, IMMUNITY, V3, P273; Castilho RF, 1998, J NEUROSCI, V18, P10277; Castro-Obregon S, 2002, CELL DEATH DIFFER, V9, P807, DOI 10.1038/sj.cdd.4401035; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CUNNINGHAM TJ, 1982, INT REV CYTOL, V74, P163, DOI 10.1016/S0074-7696(08)61172-9; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DeFea K, 2000, BIOCHEM SOC T, V28, P419, DOI 10.1042/0300-5127:0280419; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FADOK VA, 1992, J IMMUNOL, V148, P2207; Honkaniemi J, 1999, EUR J NEUROSCI, V11, P10, DOI 10.1046/j.1460-9568.1999.00401.x; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kim SO, 2003, J EXP MED, V197, P1441, DOI 10.1084/jem.20021842; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li HZ, 1997, P NATL ACAD SCI USA, V94, P9475, DOI 10.1073/pnas.94.17.9475; Linford NJ, 2001, J PHARMACOL EXP THER, V299, P67; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOCKSHIN RA, 1964, J INSECT PHYSIOL, V10, P643, DOI 10.1016/0022-1910(64)90034-4; MAJNO G, 1995, AM J PATHOL, V146, P3; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; OPPENHEIM RW, 1985, TRENDS NEUROSCI, V8, P487, DOI 10.1016/0166-2236(85)90175-4; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Palma C, 2000, LIFE SCI, V67, P985, DOI 10.1016/S0024-3205(00)00692-5; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PILAR G, 1976, J CELL BIOL, V68, P339, DOI 10.1083/jcb.68.2.339; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; Quartara L, 1997, NEUROPEPTIDES, V31, P537, DOI 10.1016/S0143-4179(97)90001-9; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Regan RF, 1995, BRAIN RES, V705, P188, DOI 10.1016/0006-8993(95)01170-6; Regan RF, 2001, J NEUROCHEM, V79, P545, DOI 10.1046/j.1471-4159.2001.00590.x; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; Runden E, 1998, J NEUROSCI, V18, P7296; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; SCHWEICHEL JU, 1972, Z ANAT ENTWICKLUNGS, V136, P192, DOI 10.1007/BF00519177; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Suzuki S, 2003, P NATL ACAD SCI USA, V100, P8276, DOI 10.1073/pnas.0932598100; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Walton M, 1999, BRAIN RES REV, V29, P137, DOI 10.1016/S0165-0173(98)00053-8; Wang Q, 2001, Ophthalmic Genet, V22, P133, DOI 10.1076/opge.22.3.133.2224; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Yu ZF, 1997, NEUROREPORT, V8, P2117, DOI 10.1097/00001756-199707070-00006; Yuan JY, 1999, NAT CELL BIOL, V1, pE44, DOI 10.1038/10037; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zachrisson O, 1998, MOL BRAIN RES, V60, P291, DOI 10.1016/S0169-328X(98)00191-0; Zhang J, 1999, COLD SPRING HARB SYM, V64, P363, DOI 10.1101/sqb.1999.64.363; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	71	72	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17543	17553		10.1074/jbc.M312363200	http://dx.doi.org/10.1074/jbc.M312363200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769794	hybrid			2022-12-27	WOS:000220870400082
J	Doyle, SM; Anderson, E; Parent, KN; Teschke, CM				Doyle, SM; Anderson, E; Parent, KN; Teschke, CM			A concerted mechanism for the suppression of a folding defect through interactions with chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-P22 COAT PROTEIN; IN-VIVO; TAILSPIKE PROTEIN; OSTEOGENESIS IMPERFECTA; SCAFFOLDING PROTEIN; THERMAL-STABILITY; ESCHERICHIA-COLI; TRIPLE-HELIX; MUTATIONS; AGGREGATION	Specific amino acid substitutions confer a temperature-sensitive-folding (tsf) phenotype to bacteriophage P22 coat protein. Additional amino acid substitutions, called suppressor substitutions (su), relieve the tsf phenotype. These su substitutions are proposed to increase the efficiency of procapsid assembly, favoring correct folding over improper aggregation. Our recent studies indicate that the molecular chaperones GroEL/ES are more effectively recruited in vivo for the folding of tsf: su coat proteins than their tsf parents. Here, the tsf: su coat proteins are studied with in vitro equilibrium and kinetic techniques to establish a molecular basis for suppression. The tsf:su coat proteins were monomeric, as determined by velocity sedimentation analytical ultracentrifugation. The stability of the tsf: su coat proteins was ascertained by equilibrium urea titrations, which were best described by a three-state folding model, N double left right arrow I double left right arrow U. The tsf: su coat proteins either had stabilized native or intermediate states as compared with their tsf coat protein parents. The kinetics of the I double left right arrow U transition showed a decrease in the rate of unfolding and a small increase in the rate of refolding, thereby increasing the population of the intermediate state. The increased intermediate population may be the reason the tsf: su coat proteins are aggregation-prone and likely enhances GroEL-ES interactions. The N double right arrow I unfolding rate was slower for the tsf: su proteins than their tsf coat parents, resulting in an increase in the native state population, which may allow more competent interactions with scaffolding protein, an assembly chaperone. Thus, the suppressor substitution likely improves folding in vivo through increased efficiency of coat protein-chaperone interactions.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	University of Connecticut	Teschke, CM (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, U-125,91 N Eagleville Rd, Storrs, CT 06269 USA.	teschke@uconn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053567, R01GM053567] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53567] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson E, 2003, VIROLOGY, V313, P184, DOI 10.1016/S0042-6822(03)00240-X; ANFINSEN C, 1961, J BIOL CHEM, V236, P1361; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ARAKAWA T, 1985, METHOD ENZYMOL, V117, P60; Aramli LA, 2001, J BIOL CHEM, V276, P25372, DOI 10.1074/jbc.M101759200; Aramli LA, 1999, J BIOL CHEM, V274, P22217, DOI 10.1074/jbc.274.32.22217; BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BEISSINGER M, 1995, J MOL BIOL, V249, P185, DOI 10.1006/jmbi.1995.0288; Bhate M, 2002, BIOCHEMISTRY-US, V41, P6539, DOI 10.1021/bi020070d; Bilsel O, 1999, BIOCHEMISTRY-US, V38, P1018, DOI 10.1021/bi982365q; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BOTSTEIN D, 1972, VIROLOGY, V49, P268, DOI 10.1016/S0042-6822(72)80028-X; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; Doyle SM, 2003, J MOL BIOL, V332, P937, DOI 10.1016/S0022-2836(03)00955-0; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; FARRIS FJ, 1978, J AM CHEM SOC, V100, P4469, DOI 10.1021/ja00482a026; FINN BE, 1992, PROTEIN ENG PRACTICA, P168; FREIDFELDER D, 1982, PHYSICAL BIOCH APPL, P662; FULLER MT, 1980, BIOPHYS J, V32, P381, DOI 10.1016/S0006-3495(80)84963-0; GALISTEO ML, 1995, J BIOL CHEM, V270, P16595, DOI 10.1074/jbc.270.28.16595; Ghaemmaghami S, 1998, BIOCHEMISTRY-US, V37, P9179, DOI 10.1021/bi980356b; Gloss LM, 1998, BIOCHEMISTRY-US, V37, P15990, DOI 10.1021/bi981511p; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1993, J BIOL CHEM, V268, P9358; GORDON CL, 1994, GENETICS, V136, P427; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; Korepanova A, 2001, PROTEIN SCI, V10, P1905, DOI 10.1110/ps.14801; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P52; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liu XY, 1998, BIOCHEMISTRY-US, V37, P15528, DOI 10.1021/bi981147u; Milewski MI, 2002, J BIOL CHEM, V277, P34462, DOI 10.1074/jbc.M205420200; Miller S, 1998, PROTEIN SCI, V7, P2223, DOI 10.1002/pro.5560071021; Nakonechny WS, 1998, J BIOL CHEM, V273, P27236, DOI 10.1074/jbc.273.42.27236; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schuler B, 1998, J MOL BIOL, V281, P227, DOI 10.1006/jmbi.1998.1944; SECNIK J, 1992, BIOCHEMISTRY-US, V31, P2982, DOI 10.1021/bi00126a020; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; Sideraki V, 2001, P NATL ACAD SCI USA, V98, P283, DOI 10.1073/pnas.011454198; Teschke CM, 1999, BIOCHEMISTRY-US, V38, P2873, DOI 10.1021/bi982739f; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10839, DOI 10.1021/bi00091a040; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; ThumanCommike PA, 1996, J MOL BIOL, V260, P85, DOI 10.1006/jmbi.1996.0383; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; Van der Schueren J, 1998, PROTEIN ENG, V11, P1211, DOI 10.1093/protein/11.12.1211; ZITZEWITZ JA, 1995, BIOCHEMISTRY-US, V34, P12812, DOI 10.1021/bi00039a042	53	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17473	17482		10.1074/jbc.M400467200	http://dx.doi.org/10.1074/jbc.M400467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14764588	hybrid			2022-12-27	WOS:000220870400074
J	Lobsanov, YD; Romero, PA; Sleno, B; Yu, BM; Yip, P; Herscovics, A; Howell, PL				Lobsanov, YD; Romero, PA; Sleno, B; Yu, BM; Yip, P; Herscovics, A; Howell, PL			Structure of Kre2p/Mnt1p - A yeast alpha 1,2-mannosyltransferase involved in mannoprotein biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; SACCHAROMYCES-CEREVISIAE; BLOOD-GROUP; FAMILIES; COMPLEX; PROGRAM; GALACTOSYLTRANSFERASE; GLYCOSYLTRANSFERASES; GLYCOSYLATION	Kre2p/Mnt1p is a Golgi alpha1,2-mannosyltransferase involved in the biosynthesis of Saccharomyces cerevisiae cell wall glycoproteins. The protein belongs to glycosyltransferase family 15, a member of which has been implicated in virulence of Candida albicans. We present the 2.0 Angstrom crystal structures of the catalytic domain of Kre2p/Mnt1p and its binary and ternary complexes with GDP/Mn2+ and GDP/Mn2+/acceptor methyl-alpha-mannoside. The protein has a mixed alpha/beta fold similar to the glycosyltransferase-A (GT-A) fold. Although the GDP-mannose donor was used in the crystallization experiments and the GDP moiety is bound tightly to the active site, the mannose is not visible in the electron density. The manganese is coordinated by a modified DXD motif (EPD), with only the first glutamate involved in a direct interaction. The position of the donor mannose was modeled using the binary and ternary complexes of other GT-A enzymes. The C1" of the modeled donor mannose is within hydrogen-bonding distance of both the hydroxyl of Tyr(220) and the O2 of the acceptor mannose. The O2 of the acceptor mannose is also within hydrogen bond distance of the hydroxyl of Tyr(220). The structures, modeling, site-directed mutagenesis, and kinetic analysis suggest two possible catalytic mechanisms. Either a double-displacement mechanism with the hydroxyl of Tyr(220) as the potential nucleophile or alternatively, an S(N)i-like mechanism with Tyr(220) positioning the substrates for catalysis. The importance of Tyr(220) in both mechanisms is highlighted by a 3000-fold reduction in k(cat) in the Y220F mutant.	Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Toronto	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	howell@sickkids.ca			NIGMS NIH HHS [GM 31265] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boix E, 2001, J BIOL CHEM, V276, P48608, DOI 10.1074/jbc.M108828200; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; Charnock SJ, 2001, PLANT PHYSIOL, V125, P527, DOI 10.1104/pp.125.2.527; Chen Y, 2003, ANNU REV BIOPH BIOM, V32, P135, DOI 10.1146/annurev.biophys.32.110601.141732; Coutinho PM, 1999, ROY SOC CH, P3; Davies G. J., 1998, INCOMPREHENSIVE BIOL, P119; Franco OL, 2003, GLYCOBIOLOGY, V13, P707, DOI 10.1093/glycob/cwg098; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gibbons BJ, 2002, J MOL BIOL, V319, P463, DOI 10.1016/S0022-2836(02)00305-4; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gow NAR, 1999, BIOCHEM SOC T, V27, P512, DOI 10.1042/bst0270512; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HILL K, 1992, GENETICS, V130, P273; Kikuchi N, 2003, BIOCHEM BIOPH RES CO, V310, P574, DOI 10.1016/j.bbrc.2003.09.031; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Lussier M, 1997, J BIOL CHEM, V272, P15527, DOI 10.1074/jbc.272.24.15527; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Ly HD, 2002, BIOCHEMISTRY-US, V41, P5075, DOI 10.1021/bi012031s; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Ramakrishnan B, 2002, J MOL BIOL, V318, P491, DOI 10.1016/S0022-2836(02)00020-7; Romero PA, 1997, BIOCHEM J, V321, P289, DOI 10.1042/bj3210289; Shibayama K, 1998, J BACTERIOL, V180, P5313, DOI 10.1128/JB.180.20.5313-5318.1998; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Takayama S, 1999, BIOORGAN MED CHEM, V7, P401, DOI 10.1016/S0968-0896(98)00249-1; Thomson LM, 2000, J BIOL CHEM, V275, P18933, DOI 10.1074/jbc.M909699199; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; WANG P, 1993, J ORG CHEM, V58, P3985, DOI 10.1021/jo00067a035; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; Watts AG, 2003, J AM CHEM SOC, V125, P7532, DOI 10.1021/ja0344967; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zhang YN, 2001, J BIOL CHEM, V276, P11567, DOI 10.1074/jbc.M006530200; Zhang ZD, 2003, PROTEIN SCI, V12, P2291, DOI 10.1110/ps.03131303	56	55	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17921	17931		10.1074/jbc.M312720200	http://dx.doi.org/10.1074/jbc.M312720200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14752117	hybrid			2022-12-27	WOS:000220870400126
J	Che, TJ; You, Y; Wang, DH; Tanner, MJ; Dixit, VM; Lin, X				Che, TJ; You, Y; Wang, DH; Tanner, MJ; Dixit, VM; Lin, X			MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; KINASE-C-THETA; MAGUK FAMILY; MALT LYMPHOMA; IMMUNOLOGICAL SYNAPSE; IMMUNE-RESPONSES; PKC-THETA; PROTEIN; BCL10; ANTIGEN	T cell receptor (TCR) induces a series of signaling cascades and leads to activation of multiple transcription factors, including NF-kappaB. Although the mechanism of TCR-induced NF-kappaB activation is not fully understood, recent studies indicate that Bcl10 and CARMA1, two adaptor/scaffold proteins, play essential roles in mediating TCR-induced NF-kappaB activation. MALT1/para-caspase is a caspase-like protein that contains an N-terminal death domain, two Ig-like domains, and a C-terminal caspase-like domain. It binds to Bcl10 through its Ig-like domains and cooperates with Bcl10 to activate NF-kappaB. Recently, it has been shown that MALT1 is involved in mediating TCR signal transduction, leading to activation of NF-kappaB. In this study, we show that MALT1 is recruited into the lipid rafts of the immunological synapse following activation of the TCR and the CD28 coreceptor (CD3/CD28 costimulation). This recruitment of MALT1 is dependent on CARMA1 because CD3/CD28 costimulation failed to recruit MALT1 into lipid rafts in CARMA1-deficient T cells. In addition, we also found that MALT1 not only binds to Bcl10 directly, but also associates with CARMA1 in a Bcl10-independent manner. Therefore, MALT1, Bcl10, and CARMA1 form a trimolecular complex. Expression of a MALT1 deletion mutant containing only the N-terminal death domain and the two Ig-like domains completely blocked CD3/CD28 costimulation-induced, but not tumor necrosis factor-alpha-induced, NF-kappaB activation. Together, these results indicate that MALT1 is a crucial signaling component in the TCR signaling pathway.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roche Holding; Genentech	Lin, X (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol & Immunol, 138 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	xinlin@buffalo.edu	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Tanner, Matthew/0000-0002-4392-5535	NIAID NIH HHS [AI50848] Funding Source: Medline; NIGMS NIH HHS [GM65899] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI050848, R01AI050848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065899, R56GM065899] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dienz O, 2003, J IMMUNOL, V170, P365, DOI 10.4049/jimmunol.170.1.365; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205	35	95	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15870	15876		10.1074/jbc.M310599200	http://dx.doi.org/10.1074/jbc.M310599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754896	hybrid			2022-12-27	WOS:000220747900023
J	Goldshmit, Y; Walters, CE; Scott, HJ; Greenhalgh, CJ; Turnley, AM				Goldshmit, Y; Walters, CE; Scott, HJ; Greenhalgh, CJ; Turnley, AM			SOCS2 induces neurite outgrowth by regulation of epidermal growth factor receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN D1 PROMOTER; FACTOR-I RECEPTOR; C-SRC; PHEOCHROMOCYTOMA CELLS; CYTOKINE SIGNALING-2; ADAPTER PROTEIN; STAT ACTIVATION; SUPPRESSOR; DIFFERENTIATION; INHIBITION	Suppressor of cytokine signaling (SOCS) 2 is a negative regulator of growth hormone (GH) signaling that regulates body growth postnatally and neuronal differentiation during development. SOCS2 binds to the GH receptor and inhibits GH signaling, including attenuation of STAT5 activation. Here we describe a new function and mechanism of action for SOCS2. Overexpression of SOCS2 in central nervous system neurons promoted neurite outgrowth, and in PC12 cells, neurite outgrowth was induced under nondifferentiating conditions, leading to inhibition of the neurite-inhibitory GTPase Rho and activation of the neurite-promoting GTPase Rac1. Addition of the epidermal growth factor receptor ( EGFR) inhibitors PP3 or AG490 or the Src kinase inhibitor PP2 blocked the SOCS2-induced neurite outgrowth. The overexpressed SOCS2 bound to the EGFR, which was constitutively phosphorylated at Tyr(845), the Src binding site. Overexpression of the phosphatase SHP-2 reduced the constitutive EGFR phosphorylation and subsequent neurite outgrowth. SOCS2 expression also resulted in a modest 30% decrease in phosphorylation of STAT5b at Tyr(699), which is the primary site on STAT5 phosphorylated by GH; however, total tyrosine phosphorylation of STAT5 was decreased by 75 - 80% under basal and epidermal growth factor-stimulated conditions. Our findings suggest that SOCS2 regulates EGFR phosphorylation, leading to regulation of neurite outgrowth through a novel pathway that is distinct from GH.	Univ Melbourne, Ctr Neurosci, Neural Regenerat Lab, Parkville, Vic 3010, Australia; Univ Melbourne, Sch Physiotherapy, Parkville, Vic 3010, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3053, Australia	University of Melbourne; University of Melbourne; Walter & Eliza Hall Institute	Turnley, AM (corresponding author), Univ Melbourne, Ctr Neurosci, Neural Regenerat Lab, Grattan St, Parkville, Vic 3010, Australia.	turnley@unimelb.edu.au	Turnley, Ann/A-8125-2010	Turnley, Ann/0000-0002-8442-127X				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Da Silva JS, 2002, NAT REV NEUROSCI, V3, P694, DOI 10.1038/nrn918; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348; Greenhalgh CJ, 2002, MOL ENDOCRINOL, V16, P1394, DOI 10.1210/me.16.6.1394; Greenhalgh CJ, 2002, J BIOL CHEM, V277, P40181, DOI 10.1074/jbc.C200450200; Guren TK, 2003, J CELL PHYSIOL, V196, P113, DOI 10.1002/jcp.10282; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kloth MT, 2002, J BIOL CHEM, V277, P8693, DOI 10.1074/jbc.M111884200; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kusama T, 2001, CANCER RES, V61, P4885; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Polizzotto MN, 2000, J COMP NEUROL, V423, P348; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ramakers GJA, 2002, TRENDS NEUROSCI, V25, P191, DOI 10.1016/S0166-2236(00)02118-4; RIJKEN PJ, 1991, J CELL SCI, V100, P491; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Silva CM, 2002, ENDOCRINOLOGY, V143, P2610, DOI 10.1210/en.143.7.2610; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Traxler P, 1997, J MED CHEM, V40, P3601, DOI 10.1021/jm970124v; Turnley AM, 2002, NAT NEUROSCI, V5, P1155, DOI 10.1038/nn954; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Weinstein DE, 1999, DEV BRAIN RES, V116, P29, DOI 10.1016/S0165-3806(99)00072-3; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Yang LT, 2002, J BIOL CHEM, V277, P17406, DOI 10.1074/jbc.M111902200	48	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16349	16355		10.1074/jbc.M312873200	http://dx.doi.org/10.1074/jbc.M312873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764607	hybrid			2022-12-27	WOS:000220747900081
J	Roybal, CN; Yang, SJ; Sun, CW; Hurtado, D; Vander Jagt, DL; Townes, TM; Abcouwer, SF				Roybal, CN; Yang, SJ; Sun, CW; Hurtado, D; Vander Jagt, DL; Townes, TM; Abcouwer, SF			Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; MESSENGER-RNA STABILITY; PLASMA HOMOCYSTEINE; GENE-EXPRESSION; GLUCOSE DEPRIVATION; HYPOXIC REGULATION; UP-REGULATION; RISK-FACTOR; CELLS; RETINOPATHY	Vascular endothelial growth factor (VEGF) plays a key role in the development and progression of diabetic retinopathy. We previously demonstrated that amino acid deprivation and other inducers of endoplasmic reticulum-stress (ER stress) up-regulate the expression of VEGF in the retinal-pigmented epithelial cell line ARPE-19. Because homocysteine causes ER stress, we hypothesized that VEGF expression is increased by ambient homocysteine. DL-Homocysteine-induced VEGF expression was investigated in confluent ARPE-19 cultures. Northern analysis showed that homocysteine increased steady state VEGF mRNA levels 4.4-fold. Other thiol-containing compounds, including L-homocysteine thiolactone and DTT, induced VEGF expression 7.9- and 8.8-fold. Transcriptional run-on assays and mRNA decay studies demonstrated that the increase in VEGF mRNA levels was caused by increased transcription rather than mRNA stabilization. VEGF mRNA induction paralleled that of the ER-stress gene GRP78. Homocysteine treatment caused transient phosphorylation of eIF2alpha and an increase in ATF4 protein level. Overexpression of a dominant-negative ATF4 abolished the VEGF response to homocysteine treatment and to amino acid deprivation. VEGF mRNA expression by ATF4 -/- MEF did not respond to homocysteine treatment and the response was restored with expression of wild-type ATF4. These studies indicate that expression of the pro-angiogenic factor VEGF is increased by homocysteine and other thiol-containing reductive compounds via ATF4-dependent activation of VEGF transcription.	Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Sch Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Sch Dent, Birmingham, AL 35294 USA	University of New Mexico; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Abcouwer, SF (corresponding author), Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, MSC08-4670, Albuquerque, NM 87131 USA.	sabcouwer@salud.unm.edu		Yang, Shujie/0000-0003-1753-3068; Abcouwer, Steven F/0000-0003-2580-1288	NATIONAL CANCER INSTITUTE [R29CA072772] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY013695, F31EY014535] Funding Source: NIH RePORTER; NCI NIH HHS [CA72772] Funding Source: Medline; NEI NIH HHS [EY13695, EY014535] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791; AGARDH CD, 1994, SCAND J CLIN LAB INV, V54, P637, DOI 10.3109/00365519409087544; Agardh E, 2000, SCAND J CLIN LAB INV, V60, P169, DOI 10.1080/003655100750044811; AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012; Aiello LP, 2000, KIDNEY INT, V58, pS113, DOI 10.1046/j.1523-1755.2000.07718.x; Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X; Cahill MT, 2003, AM J OPHTHALMOL, V136, P1136, DOI 10.1016/S0002-9394(03)00571-3; Chambers JC, 2001, CIRC RES, V89, P187, DOI 10.1161/hh1401.093459; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; de Bruijne ELE, 1999, ANN INTERN MED, V130, P78, DOI 10.7326/0003-4819-130-1-199901050-00026; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kane KK, 2004, J ANIM SCI, V82, P283; Kevil CG, 1997, BIOCHEM BIOPH RES CO, V238, P277, DOI 10.1006/bbrc.1997.7284; Kokame K, 1998, METHODS, V16, P434, DOI 10.1006/meth.1998.0698; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; LENTZ SR, 1993, BLOOD, V81, P683; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Levy AP, 1997, KIDNEY INT, V51, P575, DOI 10.1038/ki.1997.82; Looker HC, 2003, DIABETOLOGIA, V46, P766, DOI 10.1007/s00125-003-1104-x; LOSCH A, 1995, J BIOL CHEM, V270, P11543, DOI 10.1074/jbc.270.19.11543; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Moore P, 2001, EXP EYE RES, V73, P45, DOI 10.1006/exer.2001.1009; Naggar H, 2003, EXP EYE RES, V77, P687, DOI 10.1016/j.exer.2003.08.013; Negroiu G, 2000, J BIOL CHEM, V275, P32200, DOI 10.1074/jbc.M005186200; Neugebauer S, 1997, LANCET, V349, P473, DOI 10.1016/S0140-6736(05)61185-3; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; PULIDO JS, 1999, PRESENT PROBLEM FUTU, V12, P564; Satake S, 1998, BIOL CELL, V90, P161, DOI 10.1016/S0248-4900(98)80337-7; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Sone H, 1996, BIOCHEM BIOPH RES CO, V221, P193, DOI 10.1006/bbrc.1996.0568; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; von Marschall Z, 2001, GUT, V48, P87, DOI 10.1136/gut.48.1.87; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	51	185	200	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14844	14852		10.1074/jbc.M312948200	http://dx.doi.org/10.1074/jbc.M312948200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747470	hybrid			2022-12-27	WOS:000220594700045
J	Yamaguchi, Y; Kurokawa, M; Imai, Y; Izutsu, K; Asai, T; Ichikawa, M; Yamamoto, G; Nitta, E; Yamagata, T; Sasaki, K; Mitani, K; Ogawa, S; Chiba, S; Hirai, H				Yamaguchi, Y; Kurokawa, M; Imai, Y; Izutsu, K; Asai, T; Ichikawa, M; Yamamoto, G; Nitta, E; Yamagata, T; Sasaki, K; Mitani, K; Ogawa, S; Chiba, S; Hirai, H			AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA SEGMENTATION GENE; STIMULATING FACTOR-RECEPTOR; T-CELL-RECEPTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASES; PROTEIN INTERFERES	AML1 (RUNX1) is one of the most frequently disrupted genes in human leukemias. AML1 encodes transcription factors, which play a pivotal role in hematopoietic differentiation, and their inappropriate expression is associated with leukemic transformation of hematopoietic cells. Previous studies demonstrated that the transcription cofactor p300 binds to the C-terminal region of AML1 and stimulates AML1-dependent transcription during myeloid cell differentiation. Here, we report that AML1 is specifically acetylated by p300 in vitro. Mutagenesis analyses reveal that p300 acetylates AML1 at the two conserved lysine residues (Lys-24 and Lys-43). AML1 is subject to acetylation at the same sites in vivo, and p300-mediated acetylation significantly augments the DNA binding activity of AML1. Disruption of these two lysines severely impairs DNA binding of AML1 and reduced the transcriptional activity and the transforming potential of AML1. Taken together, these data indicate that acetylation of AML1 through p300 is a critical manner of posttranslational modification and identify a novel mechanism for regulating the function of AML1.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Natl Canc Ctr, Res Inst, Div Growth Factor, Tokyo 1040045, Japan; Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan	University of Tokyo; National Cancer Center - Japan; Dokkyo Medical University	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Izutsu, Koji/AAI-1125-2019; Ogawa, Seishi/AAE-7088-2019	Imai, Yoichi/0000-0002-2938-6133; Izutsu, Koji/0000-0001-9129-8057; Ichikawa, Motoshi/0000-0001-6497-0848				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ERICKSON P, 1992, BLOOD, V80, P1825; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; Goodman RH, 2000, GENE DEV, V14, P1553; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurokawa M, 1996, ONCOGENE, V12, P883; KUROKAWA M, 1995, ONCOGENE, V11, P833; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NISSON PE, 1993, CANCER GENET CYTOGEN, V66, P81; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Prives C, 1999, J PATHOL, V187, P112; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rubnitz J E, 1998, Curr Opin Hematol, V5, P264; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	68	77	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15630	15638		10.1074/jbc.M400355200	http://dx.doi.org/10.1074/jbc.M400355200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752096	hybrid			2022-12-27	WOS:000220594700135
J	Cottrell, GS; Amadesi, S; Grady, EF; Bunnett, NW				Cottrell, GS; Amadesi, S; Grady, EF; Bunnett, NW			Trypsin IV, a novel agonist of protease-activated receptors 2 and 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL TRYPTASE; MOLECULAR-CLONING; THROMBIN RECEPTOR; INHIBITOR RESISTANCE; MYENTERIC NEURONS; EPITHELIAL-CELLS; SERINE PROTEASES; EXPRESSION; IDENTIFICATION; TISSUE	Certain serine proteases signal to cells by cleaving protease-activated receptors (PARs) and thereby regulate hemostasis, inflammation, pain and healing. However, in many tissues the proteases that activate PARs are unknown. Although pancreatic trypsin may be a physiological agonist of PAR(2) and PAR(4) in the small intestine and pancreas, these receptors are expressed by cells not normally exposed pancreatic trypsin. We investigated whether extrapancreatic forms of trypsin are PAR agonists. Epithelial cells lines from prostate, colon, and airway and human colonic mucosa expressed mRNA encoding PAR(2), trypsinogen IV, and enteropeptidase, which activates the zymogen. Immunoreactive trypsinogen IV was detected in vesicles in these cells. Trypsinogen IV was cloned from PC-3 cells and expressed in CHO cells, where it was also localized to cytoplasmic vesicles. We expressed trypsinogen IV with an N-terminal Igkappa signal peptide to direct constitutive secretion and allow enzymatic characterization. Treatment of conditioned medium with enteropeptidase reduced the apparent molecular mass of trypsinogen IV from 36 to 30 kDa and generated enzymatic activity, consistent with formation of trypsin IV. In contrast to pancreatic trypsin, trypsin IV was completely resistant to inhibition by polypeptide inhibitors. Exposure of cell lines expressing PAR(2) and PAR(4) to trypsin IV increased [Ca2+](i) and strongly desensitized cells to PAR agonists, whereas there were no responses in cells lacking these receptors. Thus, trypsin IV is a potential agonist of PAR(2) and PAR(4) in epithelial tissues where its resistance to endogenous trypsin inhibitors may permit prolonged signaling.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.	nigelb@itsa.ucsf.edu		Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627	NIDDK NIH HHS [DK52388, DK43207, DK57840] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057840, R01DK043207, R56DK043207, R01DK052388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alm AK, 2000, BIOCHEM BIOPH RES CO, V275, P77, DOI 10.1006/bbrc.2000.3267; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bohm SK, 1996, BIOCHEM J, V314, P1009; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ducroc R, 2002, LIFE SCI, V70, P1359, DOI 10.1016/S0024-3205(01)01519-3; EMI M, 1986, GENE, V41, P305; Ferris HA, 1997, PEPTIDES, V18, P663, DOI 10.1016/S0196-9781(97)00127-7; Gao CY, 2002, GASTROENTEROLOGY, V123, P1554, DOI 10.1053/gast.2002.36581; Hoogerwerf WA, 2002, BMC MOL BIOL, V3, DOI 10.1186/1471-2199-3-2; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; Kunitz M, 1939, J GEN PHYSIOL, V22, P429, DOI 10.1085/jgp.22.4.429; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Minn A, 1998, GLIA, V22, P338, DOI 10.1002/(SICI)1098-1136(199804)22:4<338::AID-GLIA3>3.0.CO;2-#; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; OSSOVSKAYA VS, 2004, IN PRESS PHYSL REV; Reed DE, 2003, J PHYSIOL-LONDON, V547, P531, DOI 10.1113/jphysiol.2002.032011; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SmithSwintosky VL, 1997, J NEUROCHEM, V69, P1890; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Szmola R, 2003, J BIOL CHEM, V278, P48580, DOI 10.1074/jbc.M310301200; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; YAMASHINA I, 1956, ACTA CHEM SCAND, V10, P739, DOI 10.3891/acta.chem.scand.10-0739	49	138	144	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13532	13539		10.1074/jbc.M312090200	http://dx.doi.org/10.1074/jbc.M312090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726524	hybrid			2022-12-27	WOS:000220478500032
J	O'Callaghan, DW; Burgoyne, RD				O'Callaghan, DW; Burgoyne, RD			Identification of residues that determine the absence of a Ca2+/myristoyl switch in neuronal calcium sensor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PROTEIN-1; BINDING PROTEIN; MEMBRANE ASSOCIATION; POTASSIUM CHANNELS; NEUROCALCIN-DELTA; CRYSTAL-STRUCTURE; MYRISTOYL GROUP; FREQUENIN; CHROMAFFIN; FAMILY	The neuronal calcium sensor (NCS) family of Ca2+-binding proteins regulates a number of different processes in neurons and photoreceptor cells. The first of these proteins to be characterized, recoverin, was shown to exhibit a Ca2+/myristoyl switch whereby its N-terminal myristoyl group is sequestered in the Ca2+-free form and is exposed on Ca2+ binding to allow the protein to become membrane-associated. It has subsequently been shown that certain other family members also exhibit this mechanism in living cells. In contrast, NCS-1 does not show the Ca2+/myristoyl switch and is membrane-associated even at low Ca2+ concentrations. We have used sequence comparison combined with information from structural analyses to attempt to identify candidate residues within the NCS proteins that determine whether or not the Ca2+/myristoyl switch operates in cells and have tested their functional significance by mutagenesis. The results show that NCS-1 possesses residues within its N terminus that lock the myristoyl group in an exposed conformation. In addition, other structural aspects within the C-terminal domains are required to allow the switch to operate. We have determined a key role for residues within the motif EELTRK in NCS-1 in keeping the myristoyl group exposed and allowing the protein to be constitutively membrane-associated.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liv.ac.uk	Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Burgoyne RD, 2001, BIOCHEM J, V353, P1; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; COX JA, 1994, J BIOL CHEM, V269, P32807; Gomez M, 2001, NEURON, V30, P241, DOI 10.1016/S0896-6273(01)00276-8; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Heo WD, 2003, CELL, V113, P315; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Hwang JY, 2002, BBA-PROTEINS PROTEOM, V1600, P111, DOI 10.1016/S1570-9639(02)00451-X; Hwang JY, 2002, BIOCHEMISTRY-US, V41, P13021, DOI 10.1021/bi026618y; Ivings L, 2002, BIOCHEM J, V363, P599, DOI 10.1042/0264-6021:3630599; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Koizumi S, 2002, J BIOL CHEM, V277, P30315, DOI 10.1074/jbc.M201132200; LADANT D, 1995, J BIOL CHEM, V270, P3179; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Martone ME, 1999, CELL TISSUE RES, V295, P395, DOI 10.1007/s004410051246; Matsuda S, 1999, BIOCHEMISTRY-US, V38, P1310, DOI 10.1021/bi982117u; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; O'Callaghan DW, 2003, J CELL SCI, V116, P4833, DOI 10.1242/jcs.00803; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Spilker C, 2000, NEUROSCIENCE, V96, P121, DOI 10.1016/S0306-4522(99)00536-9; Spilker C, 2002, J NEUROSCI, V22, P7331; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Weiss JL, 2002, TRENDS NEUROSCI, V25, P489, DOI 10.1016/S0166-2236(02)02247-6; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	42	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14347	14354		10.1074/jbc.M310152200	http://dx.doi.org/10.1074/jbc.M310152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726528	hybrid			2022-12-27	WOS:000220478500130
J	Trifonova, R; Small, D; Kacer, D; Kovalenko, D; Kolev, V; Mandinova, A; Soldi, R; Liaw, L; Prudovsky, I; Maciag, T				Trifonova, R; Small, D; Kacer, D; Kovalenko, D; Kolev, V; Mandinova, A; Soldi, R; Liaw, L; Prudovsky, I; Maciag, T			The non-transmembrane form of Delta1, but not of Jagged1, induces normal migratory behavior accompanied by fibroblast growth factor receptor 1-dependent transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOTCH LIGAND; INHIBITS DIFFERENTIATION; CELLULAR-TRANSFORMATION; NUCLEAR-LOCALIZATION; CELLS; ACTIVATION; CORTACTIN; PROTEIN; HOMOLOG; COMPLEX	The interactions between Notch (N) receptors and their transmembrane ligands, Jagged1 (JI) and Delta1 (Dl1), mediate signaling events between neighboring cells that are crucial during embryonal development and in adults. Since the non-transmembrane extracellular form of J1 acts as an antagonist of N activation in NIH 3T3 mouse fibroblast cells and induces fibroblast growth factor 1 (FGF1)-dependent transformation (Small, D., Kovalenko, D., Soldi, R., Mandinova, A., Kolev, V., Trifonova, R., Bagala, C., Kacer, D., Battelli, C., Liaw, L., Prudovsky, I., and Maciag, T. ( 2003) J. Biol. Chem. 278, 16405-16413), we examined the potential redundant functions of the two subfamilies of Notch ligands and report that while the soluble (s) forms of both Dl1 and J1 act as N signaling antagonists in NIH 3T3 cells, they do display disparate functions. While sJ1 induced an attenuation of cell motility which is accompanied by a decrease in actin stress fibers and an increase in adherence junctions, sDl1 does not. However, sJ1, like sDl1, induces a NIH 3T3 cell tranformed phenotype mediated by FGF signaling. Because the inhibition of N signaling by sJ1 and sDl1 is rescued by dominant-negative Src expression, we suggest that there may be cooperation between the Notch and Src signaling pathways.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA	Maine Medical Center	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	maciat@mmc.org	Prudovsky, Igor/GVU-1521-2022		NHLBI NIH HHS [HL32348, HL70865, HL35627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348, R01HL070865] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; Franklin JL, 1999, CURR BIOL, V9, P1448, DOI 10.1016/S0960-9822(00)80114-1; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; Han W, 2000, BLOOD, V95, P1616, DOI 10.1182/blood.V95.5.1616.005k31_1616_1625; Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Klueg KM, 1998, MOL BIOL CELL, V9, P1709, DOI 10.1091/mbc.9.7.1709; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morrissette JJD, 2001, HUM MOL GENET, V10, P405, DOI 10.1093/hmg/10.4.405; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Small D, 2003, J BIOL CHEM, V278, P16405, DOI 10.1074/jbc.M300464200; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Sun X, 1996, DEVELOPMENT, V122, P2465; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Weinmaster G, 1998, CURR OPIN GENET DEV, V8, P436, DOI 10.1016/S0959-437X(98)80115-9; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; ZHAN X, 1993, J BIOL CHEM, V268, P24427; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	30	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13285	13288		10.1074/jbc.C300564200	http://dx.doi.org/10.1074/jbc.C300564200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14769803	hybrid			2022-12-27	WOS:000220478500001
J	Jones, CE; Mueser, TC; Nossal, NG				Jones, CE; Mueser, TC; Nossal, NG			Bacteriophage T4 32 protein is required for helicase-dependent leading strand synthesis when the helicase is loaded by the T4 59 helicase-loading protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE 32 PROTEIN; DNA-BINDING-PROTEIN; POLAR BRANCH MIGRATION; REPLICATION FORK; ASSEMBLY PROTEIN; NUCLEIC-ACIDS; MACROMOLECULAR MACHINES; MINICIRCLE SUBSTRATE; CRYSTAL-STRUCTURE; POLYMERASE GP43	In the bacteriophage T4 DNA replication system, T4 gene 59 protein binds preferentially to fork DNA and accelerates the loading of the T4 41 helicase. 59 protein also binds the T4 32 single-stranded DNA-binding protein that coats the lagging strand template. Here we explore the function of the strong affinity between the 32 and 59 proteins at the replication fork. We show that, in contrast to the 59 helicase loader, 32 protein does not bind forked DNA more tightly than linear DNA. 32 protein displays a strong binding polarity on fork DNA, binding with much higher affinity to the 5' single-stranded lagging strand template arm of a model fork, than to the 3' single-stranded leading strand arm. 59 protein promotes the binding of 32 protein on forks too short for cooperative binding by 32 protein. We show that 32 protein is required for helicase-dependent leading strand DNA synthesis when the helicase is loaded by 59 protein. However, 32 protein is not required for leading strand synthesis when helicase is loaded, less efficiently, without 59 protein. Leading strand synthesis by wild type T4 polymerase is strongly inhibited when 59 protein is present without 32 protein. Because 59 protein can load the helicase on forks without 32 protein, our results are best explained by a model in which 59 helicase loader at the fork prevents the coupling of the leading strand polymerase and the helicase, unless the position of 59 protein is shifted by its association with 32 protein.	NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Toledo, Dept Chem, Toledo, OH 43606 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Ohio; University of Toledo	Nossal, NG (corresponding author), NIDDK, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.	ngn@helix.nih.gov	Jones, Charles/GVS-9497-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; BARRY J, 1994, J BIOL CHEM, V269, P33049; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CHA TA, 1989, J BIOL CHEM, V264, P12220; Chastain PD, 2000, MOL CELL, V6, P803, DOI 10.1016/S1097-2765(05)00093-6; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; Dong F, 1996, P NATL ACAD SCI USA, V93, P14456, DOI 10.1073/pnas.93.25.14456; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; JIANG H, 1993, J BIOL CHEM, V268, P7904; Jones CE, 2001, P NATL ACAD SCI USA, V98, P8312, DOI 10.1073/pnas.121009398; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; Klein HL, 2002, MOL CELL, V9, P471, DOI 10.1016/S1097-2765(02)00493-8; Kong DC, 1997, J BIOL CHEM, V272, P8380; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; Nossal NG, 2001, MOL CELL, V7, P31, DOI 10.1016/S1097-2765(01)00152-6; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; SPICER EK, 1979, J BIOL CHEM, V254, P6433; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; Waidner LA, 2001, J BIOL CHEM, V276, P2509, DOI 10.1074/jbc.M007778200; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; Yang JS, 2003, J BIOL CHEM, V278, P49828, DOI 10.1074/jbc.M307406200; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	54	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12067	12075		10.1074/jbc.M313840200	http://dx.doi.org/10.1074/jbc.M313840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729909	hybrid			2022-12-27	WOS:000220334900010
J	Bhattacharyya, SN; Adhya, S				Bhattacharyya, SN; Adhya, S			tRNA-triggered ATP hydrolysis and generation of membrane potential by the Leishmania mitochondrial tRNA import complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; INNER MEMBRANE; PROTEIN; DOMAINS; CELLS	Translocation of tRNAs across mitochondrial membranes is a receptor-mediated active transport process requiring ATP. A large tRNA import complex from the inner membrane of Leishmania mitochondria catalyzes translocation into phospholipid vesicles. In this reconstituted system, the import substrate tRNA(Tyr)(GUA) specifically stimulated hydrolysis of ATP within the vesicles, with the subsequent generation of a membrane potential by pumping out of protons, as shown by the protonophore-sensitive uptake of the potential-sensitive dye rhodamine 123. Generation of membrane potential was dependent on ATP hydrolysis, and inhibited by oligomycin, recalling the proton-translocation mechanism of the respiratory F-1-F-0-ATPase. For translocation of tRNA, ATP could be replaced by low pH of the medium, but proton-dependent import was resistant to oligomycin. Moreover, ATP hydrolysis, generation of membrane potential and tRNA uptake were inhibited by carboxyatractyloside, a specific inhibitor of mitochondrial ATP-ADP translocase, implying an ATP requirement within the vesicles. These observations imply a gating mechanism in which tRNA, on binding to its receptor, triggers the energetic activation of the complex, leading to the opening of import channels.	Indian Inst Chem Biol, Genet Engn Lab, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Adhya, S (corresponding author), Indian Inst Chem Biol, Genet Engn Lab, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	sadhya@iicb.res.in						Adhya S, 1997, J BIOL CHEM, V272, P21396, DOI 10.1074/jbc.272.34.21396; Bhattacharyya SN, 2003, MOL CELL BIOL, V23, P5217, DOI 10.1128/MCB.23.15.5217-5224.2003; Bhattacharyya SN, 2002, MOL CELL BIOL, V22, P4372, DOI 10.1128/MCB.22.12.4372-4382.2002; Bohme E, 1974, Methods Enzymol, V38, P27; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P113; Dorner M, 2001, MOL BIOL CELL, V12, P2688, DOI 10.1091/mbc.12.9.2688; Futai M, 2000, J EXP BIOL, V203, P107; Goswami S, 2003, NUCLEIC ACIDS RES, V31, P5552, DOI 10.1093/nar/gkg773; HANCOCK K, 1990, J BIOL CHEM, V265, P19203; Kumar R, 1996, MOL GEN GENET, V252, P404, DOI 10.1007/BF02173005; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1998, NUCLEIC ACIDS RES, V26, P2037, DOI 10.1093/nar/26.9.2037; MARTIN RP, 1979, BIOCHEMISTRY-US, V18, P4600, DOI 10.1021/bi00588a021; Mukherjee S, 1999, J BIOL CHEM, V274, P31249, DOI 10.1074/jbc.274.44.31249; PRINGLE MJ, 1990, J BIOL CHEM, V265, P7632; Rubio MAT, 2000, RNA, V6, P988, DOI 10.1017/S1355838200991519; Schneider A, 2000, TRENDS CELL BIOL, V10, P509, DOI 10.1016/S0962-8924(00)01854-7; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; TARRASOV I, 1992, NUCLEIC ACIDS RES, V20, P1277; Werbovetz KA, 1997, MOL BIOCHEM PARASIT, V85, P1, DOI 10.1016/S0166-6851(96)02820-4; Yermovsky-Kammerer AE, 1999, MOL CELL BIOL, V19, P6253	22	14	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11259	11263		10.1074/jbc.C300540200	http://dx.doi.org/10.1074/jbc.C300540200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14739289	hybrid			2022-12-27	WOS:000220157600053
J	Shang, T; Kotamraju, S; Kalivendi, SV; Hillard, CJ; Kalyanaraman, B				Shang, T; Kotamraju, S; Kalivendi, SV; Hillard, CJ; Kalyanaraman, B			1-methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; ENDOTHELIAL-CELLS; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; NO-PRODUCTION; L-ARGININE; GENERATION; ACCUMULATION	In this study, we investigated the molecular mechanisms of toxicity of 1-methyl-4-phenylpyridinium (MPP+), an ultimate toxic metabolite of a mitochondrial neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, that causes Parkinson-like symptoms in experimental animals and humans. We used rat cerebellar granule neurons as a model cell system for investigating MPP+ toxicity. Results show that MPP+ treatment resulted in the generation of reactive oxygen species from inhibition of complex I of the mitochondrial respiratory chain, and inactivation of aconitase. This, in turn, stimulated transferrin receptor (TfR)-dependent iron signaling via activation of the iron-regulatory protein/iron-responsive element interaction. MPP+ caused a time-dependent depletion of tetrahydrobiopterin (BH4) that was mediated by H2O2 and transferrin iron. Depletion of BH4 decreased the active, dimeric form of neuronal nitric-oxide synthase (nNOS). MPP+-mediated "uncoupling" of nNOS decreased .NO and increased superoxide formation. Pretreatment of cells with sepiapterin to promote BH4 biosynthesis or cell-permeable iron chelator and TfR antibody to prevent iron-catalyzed BH4 decomposition inhibited MPP+ cytotoxicity. Preincubation of cerebellar granule neurons with nNOS inhibitor exacerbated MPP+-induced iron uptake, BH4 depletion, proteasomal inactivation, and apoptosis. We conclude that MPP+-dependent aconitase inactivation, Tf-iron uptake, and oxidant generation result in the depletion of intracellular BH4, leading to the uncoupling of nNOS activity. This further exacerbates reactive oxygen species-mediated oxidative damage and apoptosis. Implications of these results in unraveling the molecular mechanisms of neurodegenerative diseases (Parkinson's and Alzheimer's disease) are discussed.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu	Hillard, Cecilia J/O-6693-2018		NHLBI NIH HHS [1P01HL68769-01] Funding Source: Medline; NINDS NIH HHS [R01 NS039958, NS39958] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039958] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barc S, 2001, NEUROSCI LETT, V314, P82, DOI 10.1016/S0304-3940(01)02273-X; Behl C, 2002, FREE RADICAL BIO MED, V33, P182, DOI 10.1016/S0891-5849(02)00883-3; Bishop GM, 2002, DEV NEUROSCI-BASEL, V24, P184, DOI 10.1159/000065696; Bonn D, 1996, LANCET, V347, P1614, DOI 10.1016/S0140-6736(96)91094-6; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Cho S, 1999, J NEUROSCI, V19, P878; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Delgado-Esteban M, 2002, J NEUROCHEM, V82, P1148, DOI 10.1046/j.1471-4159.2002.01055.x; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Habisch HJ, 2003, MOL PHARMACOL, V63, P682, DOI 10.1124/mol.63.3.682; Hausladen A, 1996, METHOD ENZYMOL, V269, P37; Hemmens B, 1998, METH MOL B, V100, P1; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Ihlemann N, 2003, AM J PHYSIOL-HEART C, V285, pH875, DOI 10.1152/ajpheart.00008.2003; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Kalivendi SV, 2003, BIOCHEM J, V371, P151, DOI 10.1042/BJ20021525; KALIVENDI SV, 2004, J BIOL CHEM     0123; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Kotamraju S, 2003, P NATL ACAD SCI USA, V100, P10653, DOI 10.1073/pnas.1933581100; Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200; KUIPER MA, 1994, J NEUROL SCI, V121, P46, DOI 10.1016/0022-510X(94)90155-4; LAGNSTON JW, 1983, SCIENCE, V219, P979; Lan J, 1997, J NEURAL TRANSM, V104, P649, DOI 10.1007/BF01291883; LANGSTON JW, 1984, NEUROSCI LETT, V48, P87, DOI 10.1016/0304-3940(84)90293-3; LOVENBERG W, 1979, SCIENCE, V204, P624, DOI 10.1126/science.432666; Madsen JT, 2003, J NEUROCHEM, V85, P214, DOI 10.1046/j.1471-4159.2003.01666.x; Matthews RT, 1997, NEUROBIOL DIS, V4, P114, DOI 10.1006/nbdi.1997.0141; Metodiewa D, 1999, NEUROTOX RES, V1, P197, DOI 10.1007/BF03033290; MOCHIZUKI H, 1994, NEUROSCI LETT, V168, P251, DOI 10.1016/0304-3940(94)90462-6; Mohanakumar KP, 2002, ANN NY ACAD SCI, V962, P389, DOI 10.1111/j.1749-6632.2002.tb04083.x; Mulero V, 1999, BLOOD, V94, P2383, DOI 10.1182/blood.V94.7.2383.419k20_2383_2389; Muramatsu Y, 2002, METAB BRAIN DIS, V17, P169, DOI 10.1023/A:1020025805287; NAGATSU T, 1981, CLIN CHIM ACTA, V109, P305, DOI 10.1016/0009-8981(81)90316-8; Nagatsu T, 1984, Adv Neurol, V40, P467; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Osawa Y, 2003, J PHARMACOL EXP THER, V304, P493, DOI 10.1124/jpet.102.035055; Panda K, 2002, J BIOL CHEM, V277, P31020, DOI 10.1074/jbc.M203749200; Paraskeva E, 1996, FEBS LETT, V389, P40, DOI 10.1016/0014-5793(96)00574-1; Perry G, 2002, FREE RADICAL BIO MED, V33, P1475, DOI 10.1016/S0891-5849(02)01113-9; Powers KM, 2003, NEUROLOGY, V60, P1761, DOI 10.1212/01.WNL.0000068021.13945.7F; Qian ZM, 1998, NEUROSCI LETT, V251, P9; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; Ryu SY, 2000, ANTICANCER RES, V20, P3331; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; Shang TS, 2003, J NEUROCHEM, V85, P358, DOI 10.1046/j.1471-4159.2003.01686.x; Sipe JC, 2002, DEV NEUROSCI-BASEL, V24, P188, DOI 10.1159/000065701; Song Y, 2002, BIOCHEMISTRY-US, V41, P10616, DOI 10.1021/bi026060u; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stewart VC, 2003, FREE RADICAL BIO MED, V34, P287, DOI 10.1016/S0891-5849(02)01327-8; Tampo Y, 2003, CIRC RES, V92, P56, DOI 10.1161/01.RES.0000048195.15637.AC; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Tiefenbacher CP, 2003, PFLUG ARCH EUR J PHY, V447, P1, DOI 10.1007/s00424-003-1131-y; Tiefenbacher CP, 1996, CIRCULATION, V94, P1423, DOI 10.1161/01.CIR.94.6.1423; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Vasquez-Vivar J, 2003, FREE RADICAL RES, V37, P121, DOI 10.1080/1071576021000040655; Vasquez-Vivar J, 2002, BIOCHEM J, V362, P733, DOI 10.1042/0264-6021:3620733; Vasquez-Vivar J, 2001, FREE RADICAL BIO MED, V31, P975, DOI 10.1016/S0891-5849(01)00680-3; Weikert S, 1997, BRAIN RES, V748, P1, DOI 10.1016/S0006-8993(96)01241-3; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	71	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19099	19112		10.1074/jbc.M400101200	http://dx.doi.org/10.1074/jbc.M400101200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14752097	hybrid			2022-12-27	WOS:000221041500123
J	Chuang, JL; Wynn, RM; Moss, CC; Song, JL; Li, J; Awad, N; Mandel, H; Chuang, DT				Chuang, JL; Wynn, RM; Moss, CC; Song, JL; Li, J; Awad, N; Mandel, H; Chuang, DT			Structural and biochemical basis for novel mutations in homozygous Israeli maple syrup urine disease patients - A proposed mechanism for the thiamin-responsive phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOACID DEHYDROGENASE; 2-OXO ACID DEHYDROGENASE; E2 MESSENGER-RNA; CHAPERONINS GROEL; ESCHERICHIA-COLI; MOLECULAR-BASIS; COMPLEX; DECARBOXYLASE; COMPONENT; SUBUNIT	Maple syrup urine disease (MSUD) results from mutations affecting different subunits of the mitochondrial branched-chain alpha-ketoacid dehydrogenase complex. In this study, we identified seven novel mutations in MSUD patients from Israel. These include C219W-alpha (TGC to TGG) in the E1alpha subunit; H156Y-beta (CAT to TAT), V69G-beta (GTT to GGT), IVS 9 del[-7:-4], and 1109 ins 8bp (exon 10) in the E1alpha subunit; and H391R (CAC to CGC) and S133stop (TCA to TGA) affecting the E2 subunit of the branched-chain alpha-ketoacid dehydrogenase complex. Recombinant E1 proteins carrying the C219W-alpha or H156Y-beta mutation show no catalytic activity with defective subunit assembly and reduced binding affinity for cofactor thiamin diphosphate. The mutant E1 harboring the V69G-beta substitution cannot be expressed, suggesting aberrant folding caused by this mutation. These E1 mutations are ubiquitously associated with the classic phenotype in homozygous-affected patients. The H391R substitution in the E2 subunit abolishes the key catalytic residue that functions as a general base in the acyltransfer reaction, resulting in a completely inactive E2 component. However, wild-type E1 activity is enhanced by E1 binding to this full-length mutant E2 in vitro. We propose that the augmented E1 activity is responsible for robust thiamin responsiveness in homozygous patients carrying the H391R E2 mutation and that the presence of a full-length mutant E2 is diagnostic of this MSUD phenotype. The present results offer a structural and biochemical basis for these novel mutations and will facilitate DNA-based diagnosis for MSUD in the Israeli population.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Technion Fac Med, Rambam Med Ctr, Meyers Childrens Hosp, Metab Unit, IL-31906 Haifa, Israel	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	h_mandel@rambam.health.gov.il		Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; Beaudet AL, 1996, HUM MUTAT, V8, P197; Blair PV, 1999, J NUTR, V129, P641, DOI 10.1093/jn/129.3.641; CHITAYAT D, 1992, J INHERIT METAB DIS, V15, P198, DOI 10.1007/BF01799631; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; CHUANG DT, 1988, METHOD ENZYMOL, V166, P146; CHUANG DT, 2001, ENCY MOL MED, V5, P393; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Chuang JL, 2002, J BIOL CHEM, V277, P36905, DOI 10.1074/jbc.C200430200; Chuang JL, 1997, J CLIN INVEST, V100, P736, DOI 10.1172/JCI119586; Chuang JL, 2000, METHOD ENZYMOL, V324, P413; Chuang JL, 1999, J BIOL CHEM, V274, P10395, DOI 10.1074/jbc.274.15.10395; DANCIS J, 1972, J PEDIATR-US, V81, P312, DOI 10.1016/S0022-3476(72)80301-9; EISENSTEIN RS, 1991, J INHERIT METAB DIS, V14, P37, DOI 10.1007/BF01804386; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FISHER CW, 1989, J BIOL CHEM, V264, P3448; FISHER CW, 1991, BIOCHEM BIOPH RES CO, V174, P804, DOI 10.1016/0006-291X(91)91489-Y; GRIFFIN TA, 1990, J BIOL CHEM, V265, P13174; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; HENNIG J, 1966, BIOCH PHYSL THIAMIN, P243; LAKOWICZ JR, 1983, BIOCHEMISTRY-US, V22, P1741, DOI 10.1021/bi00277a001; LAU KS, 1990, BIOCHIM BIOPHYS ACTA, V1038, P360, DOI 10.1016/0167-4838(90)90249-F; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MENG MH, 1994, BIOCHEMISTRY-US, V33, P12879, DOI 10.1021/bi00209a020; MENKES JH, 1954, PEDIATRICS, V14, P462; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; NOBUKUNI Y, 1993, BIOCHIM BIOPHYS ACTA, V1225, P64, DOI 10.1016/0925-4439(93)90123-I; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SCRIVER CR, 1971, LANCET, V1, P310; Shaag A, 1999, AM J MED GENET, V82, P177, DOI 10.1002/(SICI)1096-8628(19990115)82:2<177::AID-AJMG15>3.3.CO;2-0; SHIMOMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P210, DOI 10.1016/0003-9861(88)90252-4; Song JL, 2001, J BIOL CHEM, V276, P40241, DOI 10.1074/jbc.M107242200; TAYLOR J, 1978, PEDIATR RES, V12, P60, DOI 10.1203/00006450-197801000-00019; Wynn RM, 2000, METHOD ENZYMOL, V324, P179; Wynn RM, 2003, J BIOL CHEM, V278, P43402, DOI 10.1074/jbc.M306204200; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Wynn RM, 2001, J BIOL CHEM, V276, P36550, DOI 10.1074/jbc.M105862200; ZHANG B, 1990, AM J HUM GENET, V46, P843	41	36	39	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17792	17800		10.1074/jbc.M313879200	http://dx.doi.org/10.1074/jbc.M313879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14742428	hybrid			2022-12-27	WOS:000220870400111
J	Fleckenstein, B; Qiao, SW; Larsen, MR; Jung, G; Roepstorff, P; Sollid, LM				Fleckenstein, B; Qiao, SW; Larsen, MR; Jung, G; Roepstorff, P; Sollid, LM			Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-INTESTINAL MUCOSA; T-CELL EPITOPE; CELIAC-DISEASE; RECOGNIZE GLIADIN; IDENTIFICATION; DEAMIDATION; SPECIFICITY; TRANSAMIDATION; AUTOANTIGEN; PROTEINS	Tissue transglutaminase (TG2) modifies proteins and peptides by transamidation or deamidation of specific glutamine residues. TG2 also has a central role in the pathogenesis of celiac disease. The enzyme is both the target of disease-specific autoantibodies and generates deamidated gliadin peptides recognized by intestinal T cells from patients. Incubation of TG2 with gliadin peptides also results in the formation of covalent TG2-peptide complexes. Here we report the characterization of complexes between TG2 and two immunodominant gliadin peptides. Two types of covalent complexes were found; the peptides are either linked via a thioester bond to the active site cysteine of TG2 or via isopeptide bonds to particular lysine residues of the enzyme. We quantified the number of gliadin peptides bound to TG2 under different conditions. After 30 min of incubation of TG2 at 1 muM with an equimolar ratio of peptides to TG2, approximately equal amounts of peptides were bound by thioester and isopeptide linkage. At higher peptide to TG2 ratios, more than one peptide was linked to TG2, and isopeptide bond formation dominated. The lysine residues in TG2 that act as acyl acceptors were identified by matrix assisted laser desorption ionization and nanoelectrospray mass spectrometry and tandem mass spectrometry analysis of proteolytic digests of the TG2-peptide complexes. At a high molar excess of gliadin peptides to TG2 altogether six lysine residues of TG2 were found to participate in isopeptide bond formation. The results are relevant to the understanding of how antibodies to TG2 are formed in celiac disease.	Univ Oslo, Rikshosp, Inst Immunol, N-0027 Oslo, Norway; Univ So Denmark, Dept Biochem & Mol Biol, Prot Res Grp, DK-5230 Odense M, Denmark; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany	University of Oslo; National Hospital Norway; University of Southern Denmark; Eberhard Karls University of Tubingen	Fleckenstein, B (corresponding author), Univ Oslo, Rikshosp, Inst Immunol, N-0027 Oslo, Norway.	burkhard.fleckenstein@labmed.uio.no	Sollid, Ludvig/N-9691-2015; Qiao, Shuo-Wang/ABE-8148-2020; Larsen, Martin Rossel/F-1411-2015	Sollid, Ludvig/0000-0001-8860-704X; Qiao, Shuo-Wang/0000-0002-0935-8397; Larsen, Martin Rossel/0000-0001-6203-0123				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; BUUS S, 1995, BBA-GEN SUBJECTS, V1243, P453, DOI 10.1016/0304-4165(94)00172-T; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; EVANS DF, 1988, GUT, V29, P1035, DOI 10.1136/gut.29.8.1035; Fleckenstein B, 2002, J BIOL CHEM, V277, P34109, DOI 10.1074/jbc.M204521200; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Grenard P, 2001, J BIOL CHEM, V276, P33066, DOI 10.1074/jbc.M102553200; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; LUNDIN KEA, 1994, HUM IMMUNOL, V41, P285, DOI 10.1016/0198-8859(94)90047-7; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Molberg O, 2001, EUR J IMMUNOL, V31, P1317, DOI 10.1002/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Parameswaran KN, 1997, J BIOL CHEM, V272, P10311; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; Schuppan D, 1998, ANN NY ACAD SCI, V859, P121, DOI 10.1111/j.1749-6632.1998.tb11116.x; Sjostrom H, 1998, SCAND J IMMUNOL, V48, P111; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; Sollid LM, 1997, GUT, V41, P851, DOI 10.1136/gut.41.6.851; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; van de Wal Y, 1998, J IMMUNOL, V161, P1585	27	110	118	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17607	17616		10.1074/jbc.M310198200	http://dx.doi.org/10.1074/jbc.M310198200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14747475	hybrid			2022-12-27	WOS:000220870400089
J	Kaido, T; Perez, B; Yebra, M; Hill, J; Cirulli, V; Hayek, A; Montgomery, AM				Kaido, T; Perez, B; Yebra, M; Hill, J; Cirulli, V; Hayek, A; Montgomery, AM			alpha(v)-Integrin utilization in human beta-cell adhesion, spreading, and motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC-ISLETS; ALPHA-V INTEGRINS; LONG-TERM CULTURE; IN-VITRO; EXTRACELLULAR-MATRIX; DIFFERENTIATION; VITRONECTIN; ALPHA(V)BETA(1); EXPRESSION; RECEPTORS	The role of individual integrins in human beta-cell development and function is largely unknown. This study describes the contribution of alpha(v)-integrins to human beta-cell adhesion, spreading, and motility. Developmental differences in alpha(v)-integrin utilization are addressed by comparing the responses of adult and fetal beta-cells, and vitronectin is used as a substrate based on its unique pattern of expression in the developing pancreas. Fetal and adult beta-cells attached equally to vitronectin and integrin alpha(v)beta(5) was found to support the adhesion of both mature and immature beta-cell populations. Fetal beta-cells were also observed to spread and migrate on vitronectin, and integrin alpha(v)beta(1) was found to be essential for these responses. In contrast to their fetal counterparts, adult beta-cells failed to either spread or migrate and this deficit was associated with a marked down-regulation of alpha(v)beta(1) expression in adult islet preparations. The integrin alpha(v)beta(3) was not found to support significant beta-cell attachment or migration. Based on our findings, we conclude that integrins alpha(v)beta(5) and alpha(v)beta(1) are important mediators of human beta-cell adhesion and motility, respectively. By supporting fetal beta-cell migration, alpha(v)beta(1) could play an important role in early motile processes required for islet neogenesis.	Univ Calif San Diego, Dept Pediat, Whittier Inst Diabet, Islet Res Lab, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Montgomery, AM (corresponding author), Univ Calif San Diego, Dept Pediat, Whittier Inst Diabet, Islet Res Lab, 9894 Genesee Ave, La Jolla, CA 92037 USA.	ammontgo@ucsd.edu	Cirulli, Vincenzo/AFK-2791-2022; Cirulli, Vincenzo/AAG-1102-2022					Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BEATTIE GM, 1994, J CLIN ENDOCR METAB, V78, P1232, DOI 10.1210/jc.78.5.1232; Beattie GM, 1997, J CLIN ENDOCR METAB, V82, P1852, DOI 10.1210/jc.82.6.1852; Beattie GM, 2002, DIABETES, V51, P3435, DOI 10.2337/diabetes.51.12.3435; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Cirulli V, 2000, J CELL BIOL, V150, P1445, DOI 10.1083/jcb.150.6.1445; Dahm LM, 1998, J CELL SCI, V111, P1175; DAMSKY C, 1993, FASEB J, V7, P1320, DOI 10.1096/fasebj.7.14.8224605; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; Fierabracci A, 1999, VACCINE, V18, P342, DOI 10.1016/S0264-410X(99)00204-2; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Gullberg D, 1995, INT J DEV BIOL, V39, P845; HAYEK A, 1989, IN VITRO CELL DEV B, V25, P146; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jiang FX, 1999, DIABETES, V48, P722, DOI 10.2337/diabetes.48.4.722; Jiang FX, 2001, MOL MED, V7, P107, DOI 10.1007/BF03401944; Koistinen P, 2002, J BIOL CHEM, V277, P24835, DOI 10.1074/jbc.M203149200; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LUCASCLERC C, 1993, MOL CELL ENDOCRINOL, V94, P9, DOI 10.1016/0303-7207(93)90046-M; MARSHALL JF, 1995, J CELL SCI, V108, P1227; Milner R, 1996, J NEUROSCI, V16, P7240; MILNER R, 1994, DEVELOPMENT, V120, P3497; Milner R, 2001, MOL CELL NEUROSCI, V18, P108, DOI 10.1006/mcne.2001.1003; Oberg-Welsh C, 2001, PANCREAS, V22, P157; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; Ris F, 2002, DIABETOLOGIA, V45, P841, DOI 10.1007/s00125-002-0840-7; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; Seiffert D, 1997, HISTOL HISTOPATHOL, V12, P787; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Tarone G, 2000, INT J DEV BIOL, V44, P725; Thibault G, 2000, MOL PHARMACOL, V58, P1137, DOI 10.1124/mol.58.5.1137; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wada J, 1996, J CELL BIOL, V132, P1161, DOI 10.1083/jcb.132.6.1161; Wang RN, 1999, J ENDOCRINOL, V163, P181, DOI 10.1677/joe.0.1630181; Xu CS, 2001, ACTA BIOCH BIOPH SIN, V33, P153; Yamada S, 1995, CELL ADHES COMMUN, V3, P311, DOI 10.3109/15419069509081016	40	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17731	17737		10.1074/jbc.M308425200	http://dx.doi.org/10.1074/jbc.M308425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766759	hybrid			2022-12-27	WOS:000220870400104
J	O'Nuallain, B; Williams, AD; Westermark, P; Wetzel, R				O'Nuallain, B; Williams, AD; Westermark, P; Wetzel, R			Seeding specificity in amyloid growth induced by heterologous fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; IN-VITRO; PROTEIN AGGREGATION; SECONDARY STRUCTURE; BETA; POLYGLUTAMINE; PEPTIDE; AMYLOIDOGENICITY; POLYPEPTIDE; FEATURES	Over residues 15-36, which comprise the H-bonded core of the amyloid fibrils it forms, the Alzheimer's disease plaque peptide amyloid beta (Abeta) possesses a very similar sequence to that of another short, amyloidogenic peptide, islet amyloid polypeptide (IAPP). Using elongation rates to quantify seeding efficiency, we inquired into the relationship between primary sequence similarity and seeding efficiency between Abeta-(1-40) and amyloid fibrils produced from IAPP as well as other proteins. In both a solution phase and a microtiter plate elongation assay, IAPP fibrils are poor seeds for Abeta-(1 40) elongation, exhibiting weight-normalized efficiencies of only 1-2% compared with Abeta-(1-40) fibrils. Amyloid fibrils of peptides with sequences completely unrelated to Abeta also exhibit poor to negligible seeding ability for Abeta elongation. Fibrils from a number of point mutants of Abeta-(1-40) exhibit intermediate seeding abilities for wild-type Abeta elongation, with differing efficiencies depending on whether or not the mutation is in the amyloid core region. The results suggest that amyloid fibrils from different proteins exhibit structural differences that control seeding efficiencies. Preliminary results also suggest that identical sequences can grow into different conformations of amyloid fibrils as detected by seeding efficiencies. The results have a number of implications for amyloid structure and biology.	Univ Tennessee, Grad Sch Med, Knoxville, TN 37920 USA; Uppsala Univ, Dept Genet & Pathol, S-75185 Uppsala, Sweden	University of Tennessee System; University of Tennessee Health Science Center; Uppsala University	Wetzel, R (corresponding author), Univ Tennessee, Grad Sch Med, 1924 Alcoa Highway, Knoxville, TN 37920 USA.	rwetzel@mc.utmck.edu	Wetzel, Ronald/G-7453-2011		NATIONAL INSTITUTE ON AGING [R01AG018416] Funding Source: NIH RePORTER; NIA NIH HHS [AG18416] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berthelier V, 2001, ANAL BIOCHEM, V295, P227, DOI 10.1006/abio.2001.5217; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chen SM, 2001, PROTEIN SCI, V10, P887, DOI 10.1110/ps.42301; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; DIAMANDIS EP, 1988, CLIN BIOCHEM, V21, P139, DOI 10.1016/S0009-9120(88)80104-8; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Ferrone F, 1999, METHOD ENZYMOL, V309, P256; Galasko D, 2003, NEUROLOGY, V60, P1886, DOI 10.1212/WNL.60.12.1886; Gebre-Medhin S, 1998, BIOCHEM BIOPH RES CO, V250, P271, DOI 10.1006/bbrc.1998.9308; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; Higham CE, 2000, FEBS LETT, V470, P55, DOI 10.1016/S0014-5793(00)01287-4; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kheterpal I, 2003, BIOCHEMISTRY-US, V42, P14092, DOI 10.1021/bi0357816; Kheterpal I, 2000, P NATL ACAD SCI USA, V97, P13597, DOI 10.1073/pnas.250288897; LeVine H, 1999, METHOD ENZYMOL, V309, P274; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; Lundmark K, 2002, P NATL ACAD SCI USA, V99, P6979, DOI 10.1073/pnas.092205999; Ma Z, 2001, AMYLOID, V8, P242, DOI 10.3109/13506120108993820; McCampbell A, 2001, NAT MED, V7, P528, DOI 10.1038/87842; Moriarty DF, 1999, BIOCHEMISTRY-US, V38, P1811, DOI 10.1021/bi981658g; Morimoto A, 2002, BIOCHEM BIOPH RES CO, V295, P306, DOI 10.1016/S0006-291X(02)00670-8; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; Murakami K, 2002, BIOCHEM BIOPH RES CO, V294, P5, DOI 10.1016/S0006-291X(02)00430-8; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Naiki H, 1996, LAB INVEST, V74, P374; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; POTTER N. T., 2003, METHOD MOL BIOL, P295; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Sakagashira S, 2000, AM J PATHOL, V157, P2101, DOI 10.1016/S0002-9440(10)64848-1; Sakagashira S, 1996, DIABETES, V45, P1279, DOI 10.2337/diabetes.45.9.1279; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; WESTERMARK P, 1978, DIABETOLOGIA, V15, P417, DOI 10.1007/BF01219652; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, BIOCHEMISTRY-US, V35, P12623, DOI 10.1021/bi961074j	61	326	329	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17490	17499		10.1074/jbc.M311300200	http://dx.doi.org/10.1074/jbc.M311300200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14752113	hybrid			2022-12-27	WOS:000220870400076
J	Ali, V; Shigeta, Y; Tokumoto, U; Takahashi, Y; Nozaki, T				Ali, V; Shigeta, Y; Tokumoto, U; Takahashi, Y; Nozaki, T			An intestinal parasitic protist, Entamoeba histolytica, possesses a non-redundant nitrogen fixation-like system for iron-sulfur cluster assembly under anaerobic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIFS-LIKE PROTEIN; FE-S CLUSTER; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; SACCHAROMYCES-CEREVISIAE; AZOTOBACTER-VINELANDII; CHAPERONE SYSTEM; LATERAL TRANSFER; 2FE-2S CLUSTER; GENE-CLUSTER	We have characterized the iron-sulfur (Fe-S) cluster formation in an anaerobic amitochondrial protozoan parasite, Entamoeba histolytica, in which Fe-S proteins play an important role in energy metabolism and electron transfer. A genomewide search showed that E. histolytica apparently possesses a simplified and non-redundant NIF ( nitrogen fixation)-like system for the Fe-S cluster formation, composed of only a catalytic component, NifS, and a scaffold component, NifU. Amino acid alignment and phylogenetic analyses revealed that both amebic NifS and NifU (EhNifS and EhNifU, respectively) showed a close kinship to orthologs from epsilon-proteobacteria, suggesting that both of these genes were likely transferred by lateral gene transfer from an ancestor of epsilon-proteobacteria to E. histolytica. The EhNifS protein expressed in E. coli was present as a homodimer, showing cysteine desulfurase activity with a very basic optimum pH compared with NifS from other organisms. EhNifU protein existed as a tetramer and contained one stable [2Fe-2S](2+) cluster per monomer, revealed by spectroscopic and iron analyses. Fractionation of the whole parasite lysate by anion exchange chromatography revealed three major cysteine desulfurase activities, one of which corresponded to the EhNifS protein, verified by immunoblot analysis using the specific EhNifS antibody; the other two peaks corresponded to methionine gamma-lyase and cysteine synthase. Finally, ectopic expression of the EhNifS and EhNifU genes successfully complemented, under anaerobic but not aerobic conditions, the growth defect of an Escherichia coli strain, in which both the isc and suf operons were deleted, suggesting that EhNifS and EhNifU are necessary and sufficient for Fe-S clusters of non-nitrogenase Fe-S proteins to form under anaerobic conditions. This is the first demonstration of the presence and biological significance of the NIF-like system in eukaryotes.	Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Tokyo 1900012, Japan	National Institute of Infectious Diseases (NIID); Osaka University; Japan Science & Technology Agency (JST)	Nozaki, T (corresponding author), Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	nozaki@nih.go.jp	Takahashi, Yasuhiro/F-1119-2011	Takahashi, Yasuhiro/0000-0002-0588-6045				Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Ali V, 2003, BIOCHEM J, V375, P729, DOI 10.1042/BJ20030630; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Benci S, 1999, BBA-PROTEIN STRUCT M, V1429, P317, DOI 10.1016/S0167-4838(98)00229-5; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIAMOND LS, 1972, J VIROL, V9, P326, DOI 10.1128/JVI.9.2.326-341.1972; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; Field J, 2000, MOL MICROBIOL, V38, P446, DOI 10.1046/j.1365-2958.2000.02143.x; Flint DH, 1996, J BIOL CHEM, V271, P16068; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Nixon JEJ, 2002, EUKARYOT CELL, V1, P181, DOI 10.1128/EC.1.2.181-190.2002; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Olson JW, 2000, BIOCHEMISTRY-US, V39, P16213, DOI 10.1021/bi001744s; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; REEVES RE, 1980, EXP PARASITOL, V49, P83, DOI 10.1016/0014-4894(80)90059-4; Sambrook J., 2001, MOL CLONING LAB MANU; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Sellers VM, 1998, J BIOL CHEM, V273, P22311, DOI 10.1074/jbc.273.35.22311; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Tachezy J, 2001, MOL BIOL EVOL, V18, P1919, DOI 10.1093/oxfordjournals.molbev.a003732; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokoro M, 2003, J BIOL CHEM, V278, P42717, DOI 10.1074/jbc.M212414200; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Tovar J, 2003, NATURE, V426, P172, DOI 10.1038/nature01945; WOOD JL, 1987, METHOD ENZYMOL, V143, P25; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	55	98	100	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16863	16874		10.1074/jbc.M313314200	http://dx.doi.org/10.1074/jbc.M313314200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757765	hybrid			2022-12-27	WOS:000220747900139
J	Goto, M; Omi, R; Miyahara, I; Hosono, A; Mizuguchi, H; Hayashi, H; Kagamiyama, H; Hirotsu, K				Goto, M; Omi, R; Miyahara, I; Hosono, A; Mizuguchi, H; Hayashi, H; Kagamiyama, H; Hirotsu, K			Crystal structures of glutamine : phenylpyruvate aminotransferase from Thermus thermophilus HB8 - Induced fit and substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES; AMINO-ACID AMINOTRANSFERASE; ESCHERICHIA-COLI; TRANSAMINASE-K; KYNURENINE AMINOTRANSFERASE; MOLECULAR-CLONING; CLOSED-FORM; ENZYMES; BRAIN; SPECIFICITY	The following three-dimensional structures of three forms of glutamine: phenylpyruvate aminotransferase from Thermus thermophilus HB8 have been determined and represent the first x-ray analysis of the enzyme: the unliganded pyridoxal 5'-phosphate form at 1.9 Angstrom resolution and two complexes with 3-phenylpropionate and alpha-keto-gamma-methylthiobutyrate at 2.35 and 2.6 Angstrom resolution, respectively. The enzyme shows high activity toward phenylalanine, tyrosine, tryptophan, kynurenine, methionine, and glutamine. The enzyme is a homodimer, and each subunit is divided into an N-terminal arm and small and large domains. Based on its folding, the enzyme belongs to fold type I, aminotransferase subclass Ib. The subclass I aminotransferases whose structures have so far been determined exhibit a large movement of the small domain region upon binding of a substrate. Similarly, the glutamine: phenylpyruvate aminotransferase undergoes a large movement in part of the small domain to close the active site. The active-site pocket has a shape and size suitable to enclose the side chain of an aromatic amino acid or that of methionine. The inner side of the pocket is mostly hydrophobic, but also has polar sites. The kynurenine complex generated by computer modeling fits the pocket of the enzyme and its hydrophilic groups interact with the polar sites of the pocket.	Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; RIKEN, Inst Phys & Chem Res, Harima Inst SPring 8, Mikazuki, Hyogo 6795148, Japan; Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan	Osaka Metropolitan University; Osaka University; RIKEN; Osaka Medical College	Hirotsu, K (corresponding author), Osaka City Univ, Grad Sch Sci, Dept Chem, Osaka 5588585, Japan.	hirotsu@sci.osaka-cu.ac.jp	Mizuguchi, Hiroyuki/B-5676-2013	Mizuguchi, Hiroyuki/0000-0001-7055-316X; Mizuguchi, Hiroyuki/0000-0003-0594-8178				Abraham DG, 1996, ARCH BIOCHEM BIOPHYS, V335, P311, DOI 10.1006/abbi.1996.0512; BARAN H, 1994, J NEUROCHEM, V62, P730; Blankenfeldt W, 1999, PROTEIN SCI, V8, P2406; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christen P, 1985, TRANSAMINASES; COOPER AJL, 1981, COMP BIOCHEM PHYS B, V69, P137, DOI 10.1016/0305-0491(81)90223-6; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Goto M, 2003, BIOCHEMISTRY-US, V42, P3725, DOI 10.1021/bi026722f; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Haruyama K, 2001, BIOCHEMISTRY-US, V40, P4633, DOI 10.1021/bi002769u; Hayashi H, 1998, BIOCHEMISTRY-US, V37, P15076, DOI 10.1021/bi981517e; HAYASHI H, 1995, J BIOCHEM-TOKYO, V118, P463, DOI 10.1093/oxfordjournals.jbchem.a124931; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hosono A, 2003, J BIOCHEM, V134, P843, DOI 10.1093/jb/mvg210; INOUE K, 1991, J BIOCHEM, V109, P570, DOI 10.1093/oxfordjournals.jbchem.a123421; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESRF EESF; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MALHERBE P, 1995, FEBS LETT, V367, P141, DOI 10.1016/0014-5793(95)00546-L; Matsui I, 2000, J BIOL CHEM, V275, P4871, DOI 10.1074/jbc.275.7.4871; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIYAHARA I, 1994, J BIOCHEM, V116, P1001, DOI 10.1093/oxfordjournals.jbchem.a124620; Mizuguchi H, 2001, BIOCHEMISTRY-US, V40, P353, DOI 10.1021/bi001403e; MOSCA M, 1994, FEBS LETT, V353, P21, DOI 10.1016/0014-5793(94)01003-X; Nakai T, 1999, BIOCHEMISTRY-US, V38, P2413, DOI 10.1021/bi9819881; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Okada K, 2001, BIOCHEMISTRY-US, V40, P7453, DOI 10.1021/bi010384l; Okamoto A, 1996, J BIOCHEM-TOKYO, V119, P135; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY S, 1995, FEBS LETT, V360, P277, DOI 10.1016/0014-5793(95)00123-Q; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Schwarcz R, 2002, J PHARMACOL EXP THER, V303, P1, DOI 10.1124/jpet.102.034439; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712	45	24	25	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16518	16525		10.1074/jbc.M311575200	http://dx.doi.org/10.1074/jbc.M311575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761974	hybrid			2022-12-27	WOS:000220747900101
J	Lee, HY; Park, JB; Jang, IH; Chae, YC; Kim, JH; Kim, IS; Suh, PG; Ryu, SH				Lee, HY; Park, JB; Jang, IH; Chae, YC; Kim, JH; Kim, IS; Suh, PG; Ryu, SH			Munc-18-1 inhibits phospholipase D activity by direct interaction in an epidermal growth factor-reversible manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PX-DOMAIN; PLASMA-MEMBRANE; NERVOUS-SYSTEM; NEUROTRANSMITTER RELEASE; REGULATED EXOCYTOSIS; PHOSPHATIDIC-ACID; CHROMAFFIN CELLS; BINDING PROTEIN; SEC1 HOMOLOG	Mammalian phospholipase D (PLD) has been reported to be a key enzyme for epidermal growth factor (EGF)induced cellular signaling, however, the regulatory mechanism of PLD is still unclear. In this report, we found that Munc-18-1 is a potent negative regulator of PLD in the basal state and that its inhibition is abolished by EGF stimulation. We investigated PLD-binding proteins obtained from rat brain extract, and identified a 67-kDa protein as Munc-18-1 by peptide-mass fingerprinting. The direct association between PLD and Munc-18-1 was confirmed by in vitro binding analysis using the purified proteins, and their binding sites were identified as the phox homology domain of PLD and multiple sites of Munc-18-1. PLD activity was potently inhibited by Munc-18-1 in vitro (IC50 = 2 - 5 nM), and the cotransfection of COS-7 cells with Munc-18-1 and PLD inhibited basal PLD activity in vivo. In the basal state, Munc-18-1 coprecipitated with PLD and colocalized with PLD2 at the plasma membrane of COS-7 cells. EGF treatment triggered the dissociation of Munc-18-1 from PLD when PLD was activated by EGF. The dissociation of the endogenous interaction between Munc-18-1 and PLD, and the activation of PLD by EGF were also observed in primary cultured chromaffin cells. These results suggest that Munc-18-1 is a potent negative regulator of basal PLD activity and that EGF stimulation abolishes this interaction.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Ryu, SH (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea.	sungho@postech.ac.kr	Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Jang, Il Ho/0000-0002-0820-3035				Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DANNIEL LW, 1999, BIOCHIM BIOPHYS ACTA, V1439, P265; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; Frohman MA, 1999, CHEM PHYS LIPIDS, V98, P127, DOI 10.1016/S0009-3084(99)00025-0; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Han JM, 2002, MOL BIOL CELL, V13, P3976, DOI 10.1091/mbc.E02-02-0100; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hughes WE, 2002, J BIOL CHEM, V277, P22974, DOI 10.1074/jbc.M201391200; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; KILPATRICK DL, 1980, J NEUROCHEM, V35, P679, DOI 10.1111/j.1471-4159.1980.tb03707.x; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim JH, 1999, J IMMUNOL, V163, P5462; Kim SW, 2003, J BIOL CHEM, V278, P2661, DOI 10.1074/jbc.M205819200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee C, 2000, J BIOL CHEM, V275, P18751, DOI 10.1074/jbc.M001695200; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; Lee S, 2002, J BIOL CHEM, V277, P6542, DOI 10.1074/jbc.M108047200; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Ojeda SR, 1998, MOL CELL ENDOCRINOL, V140, P101, DOI 10.1016/S0303-7207(98)00036-7; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; OSULLIVAN C, 1993, LANCET, V342, P148, DOI 10.1016/0140-6736(93)91348-P; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Perez-Branguli F, 2002, MOL CELL NEUROSCI, V20, P169, DOI 10.1006/mcne.2002.1122; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PLATASALAMAN CR, 1991, PEPTIDES, V12, P653, DOI 10.1016/0196-9781(91)90115-6; PLATASALAMAN CR, 1988, NEUROSCI LETT, V94, P161, DOI 10.1016/0304-3940(88)90288-1; Rizzo MA, 2002, PHARMACOL THERAPEUT, V94, P35, DOI 10.1016/S0163-7258(02)00170-5; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Vitale N, 2002, ANN NY ACAD SCI, V971, P193, DOI 10.1111/j.1749-6632.2002.tb04463.x; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Xian CJ, 1999, MOL NEUROBIOL, V20, P157, DOI 10.1007/BF02742440; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; Yamaura T, 1981, Nihon Yakurigaku Zasshi, V78, P305; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	68	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16339	16348		10.1074/jbc.M310976200	http://dx.doi.org/10.1074/jbc.M310976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14744865	hybrid, Green Published			2022-12-27	WOS:000220747900080
J	Matsui, E; Abe, J; Yokoyama, H; Matsui, I				Matsui, E; Abe, J; Yokoyama, H; Matsui, I			Aromatic residues located close to the active center are essential for the catalytic reaction of flap endonuclease-1 from hyperthermophilic archaeon Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; REPAIR PROTEIN MUTS; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; REPLICATION FORK; EXCISION-REPAIR; CLEAVAGE; FEN-1; MUTAGENESIS; EXONUCLEASE	Flap endonuclease-1 (FEN-1) possessing 5'-flap endonuclease and 5'-->3' exonuclease activity plays important roles in DNA replication and repair. In this study, the kinetic parameters of mutants at highly conserved aromatic residues, Tyr(33), Phe(35), Phe(79), and Phe(278)-Phe(279), in the vicinity of the catalytic centers of FEN-1 were examined. The substitution of these aromatic residues with alanine led to a large reduction in k(cat) values, although these mutants retained K-m values similar to that of the wild-type enzyme. Notably, the k(cat) of Y33A and F79A decreased 333-fold and 71-fold, respectively, compared with that of the wild-type enzyme. The aromatic residues Tyr(33) and Phe(79), and the aromatic cluster Phe(278)-Phe(279) mainly contributed to the recognition of the substrates without the 3' projection of the upstream strand (the nick, 5'-recess-end, single-flap, and pseudo-Y substrates) for the both exo- and endo-activities, but played minor roles in recognizing the substrates with the 3' projection (the double flap substrate and the nick substrate with the 3' projection). The replacement of Tyr(33), Phe(79), and Phe(278)-Phe(279), with non-charged aromatic residues, but not with aliphatic hydrophobic residues, recovered the k(cat) values almost fully for the substrates without the 3' projection of the upstream strand, suggesting that the aromatic groups of Tyr(33), Phe(79), and Phe(278)-Phe(279) might be involved in the catalytic reaction, probably via multiple stacking interactions with nucleotide bases. The stacking interactions of Tyr(33) and Phe(79) might play important roles in fixing the template strand and the downstream strand, respectively, in close proximity to the active center to achieve the productive transient state leading to the hydrolysis.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, HIgashi 1-1-1, Tsukuba, Ibaraki 3058566, Japan.	ik-matsui@aist.go.jp		Yokoyama, Hideshi/0000-0002-3137-2793				Allawi HT, 2003, J MOL BIOL, V328, P537, DOI 10.1016/S0022-2836(03)00351-6; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Dervan JJ, 2002, P NATL ACAD SCI USA, V99, P8542, DOI 10.1073/pnas.082241699; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIROMI K, 1970, BIOCHEM BIOPH RES CO, V40, P1, DOI 10.1016/0006-291X(70)91037-5; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Matsui E, 2002, J BIOL CHEM, V277, P37840, DOI 10.1074/jbc.M205235200; Matsui E, 1999, J BIOL CHEM, V274, P18297, DOI 10.1074/jbc.274.26.18297; Matsui I, 1997, J BIOL CHEM, V272, P22456, DOI 10.1074/jbc.272.36.22456; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MATSUI I, 1992, BIOCHEMISTRY-US, V31, P5232, DOI 10.1021/bi00137a019; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Qiu JZ, 2002, J BIOL CHEM, V277, P24659, DOI 10.1074/jbc.M111941200; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; SAKODA M, 1976, J BIOCHEM-TOKYO, V80, P547, DOI 10.1093/oxfordjournals.jbchem.a131310; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Storici F, 2002, EMBO J, V21, P5930, DOI 10.1093/emboj/cdf587; Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Yoshikawa M, 2001, J BIOL CHEM, V276, P10432, DOI 10.1074/jbc.M010138200	42	8	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16687	16696		10.1074/jbc.M313695200	http://dx.doi.org/10.1074/jbc.M313695200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14742430	hybrid			2022-12-27	WOS:000220747900121
J	Melnyk, RA; Kim, S; Curran, AR; Engelman, DM; Bowie, JU; Deber, CM				Melnyk, RA; Kim, S; Curran, AR; Engelman, DM; Bowie, JU; Deber, CM			The affinity of GXXXG motifs in transmembrane helix-helix interactions is modulated by long-range communication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M13 COAT PROTEIN; GLYCOPHORIN-A; MEMBRANE-PROTEIN; POLAR RESIDUES; ALPHA-HELICES; CROSS-LINKING; ION-CHANNEL; DOMAIN; ASSOCIATION; DIMER	Sequence motifs are responsible for ensuring the proper assembly of transmembrane (TM) helices in the lipid bilayer. To understand the mechanism by which the affinity of a common TM-TM interactive motif is controlled at the sequence level, we compared two well characterized GXXXG motif-containing homodimers, those formed by human erythrocyte protein glycophorin A (GpA, high-affinity dimer) and those formed by bacteriophage M13 major coat protein (MCP, low affinity dimer). In both constructs, the GXXXG motif is necessary for TM-TM association. Although the remaining interfacial residues (underlined) in GpA ((LI) under bar XXG (V) under bar XXG (V) under bar XX (T) under bar) differ from those in MCP ( (VV) under bar XXG (A) under bar XXG (I) under bar XX (F) under bar), molecular modeling performed here indicated that GpA and MCP dimers possess the same overall fold. Thus, we could introduce GpA interfacial residues, alone and in combination, into the MCP sequence to help decrypt the determinants of dimer affinity. Using both in vivo TOXCAT assays and SDS-PAGE gel migration rates of synthetic peptides derived from TM regions of the proteins, we found that the most distal interfacial sites, 12 residues apart (and similar to18 Angstrom in structural space), work in concert to control TM-TM affinity synergistically.	Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, UCLA DOE Ctr Genom & Proteom, Los Angeles, CA 90095 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles; Yale University	Deber, CM (corresponding author), Hosp Sick Children, Res Inst, Div Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	donald.engelman@yale.edu; bowie@mbi.ucla.edu; deber@sickkids.ca	Melnyk, Roman/GQA-9908-2022	Kim, Sanguk/0000-0002-3449-3814	NIGMS NIH HHS [GM54160, R01 GM063919-08, R01 GM063919-06, GM063919, R01 GM063919-05, R01 GM063919-07, R01 GM063919-04, R01 GM063919] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063919] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, PROTEINS, V26, P257, DOI 10.1002/(SICI)1097-0134(199611)26:3<257::AID-PROT2>3.0.CO;2-B; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Bauer CM, 1999, VIROLOGY, V254, P196, DOI 10.1006/viro.1998.9552; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Brosig B, 1998, PROTEIN SCI, V7, P1052; CAVALIERI SJ, 1976, J MOL BIOL, V102, P713, DOI 10.1016/0022-2836(76)90287-4; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; DEBER CM, 1993, P NATL ACAD SCI USA, V90, P11648, DOI 10.1073/pnas.90.24.11648; Fisher LE, 1999, J MOL BIOL, V293, P639, DOI 10.1006/jmbi.1999.3126; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Haigh NG, 1998, J MOL BIOL, V279, P19, DOI 10.1006/jmbi.1998.1778; HENRY GD, 1990, J MOL BIOL, V212, P11, DOI 10.1016/0022-2836(90)90299-2; Karim CB, 2000, BIOCHEMISTRY-US, V39, P10892, DOI 10.1021/bi0003543; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Kim S, 2003, J MOL BIOL, V329, P831, DOI 10.1016/S0022-2836(03)00521-7; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Lau FW, 1999, J MOL BIOL, V290, P559, DOI 10.1006/jmbi.1999.2905; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MAKINO S, 1975, J BIOL CHEM, V250, P4327; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Melnyk RA, 2002, J MOL BIOL, V315, P63, DOI 10.1006/jmbi.2001.5214; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; Mingarro I, 1997, J MOL BIOL, V272, P633, DOI 10.1006/jmbi.1997.1276; Nagy JK, 2000, BIOCHEMISTRY-US, V39, P4154, DOI 10.1021/bi991781n; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Shortle D, 1998, P NATL ACAD SCI USA, V95, P11158, DOI 10.1073/pnas.95.19.11158; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; Smith SO, 2002, BIOPHYS J, V82, P2476, DOI 10.1016/S0006-3495(02)75590-2; Smith SO, 2001, BIOCHEMISTRY-US, V40, P6553, DOI 10.1021/bi010357v; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; Wang C, 2000, J BIOL CHEM, V275, P16155, DOI 10.1074/jbc.M000723200; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	43	100	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16591	16597		10.1074/jbc.M313936200	http://dx.doi.org/10.1074/jbc.M313936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14766751	hybrid			2022-12-27	WOS:000220747900109
J	Weigert, C; Brodbeck, K; Sawadogo, M; Haring, HU; Schleicher, ED				Weigert, C; Brodbeck, K; Sawadogo, M; Haring, HU; Schleicher, ED			Upstream stimulatory factor (USF) proteins induce human TGF-beta 1 gene activation via the glucose-response element-1013/-1002 in mesangial cells - Up-regulation of USF activity by the hexosamine biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; GROWTH-FACTOR-BETA; O-GLYCOSYLATION; CARBOHYDRATE REGULATION; MESSENGER-RNA; DNA-BINDING; EXPRESSION; SP1; PROMOTER; TRANSCRIPTION	The hyperglycemia-enhanced flux through the hexosamine biosynthetic pathway (HBP) has been implicated in the up-regulated gene expression of transforming growth factor-beta1 (TGF-beta1) in mesangial cells, thus leading to mesangial matrix expansion and diabetic glomerulosclerosis. Since the -1013 to -1002 region of the TGF-beta1 promoter shows high homology to glucose-response elements (GlRE) formerly described in genes involved in glucose metabolism, we studied the function of the GlRE in the high glucose-induced TGF-beta1 gene activation in mesangial cells. We found that high glucose concentrations enhanced the nuclear amount of upstream stimulatory factors (USF) and their binding to this sequence. Fusion of the GlRE to the thymidine kinase promoter resulted in glucose responsiveness of this promoter construct. Overexpression of either USF-1 or USF-2 increased TGF-beta1 promoter activity 2-fold, which was prevented by mutation or deletion of the GlRE. The high glucose-induced activation of the GlRE is mediated by the HBP; increased flux through the HBP induced by high glucose concentrations, by glutamine, or by overexpression of the rate-limiting enzyme glutamine: fructose-6-phosphate aminotransferase (GFAT) particularly activated USF-2 expression. GFAT-overexpressing cells showed higher USF binding activity to the GlRE and enhanced promoter activation via the GlRE. Increasing O-GlcNAc modification of proteins by streptozotocin, thereby mimicking HBP activation, also resulted in increased mRNA and nuclear protein levels of USF-2, leading to enhanced DNA binding activity to the GlRE. USF proteins themselves were not found to be O-GlcNAc-modified. Thus, we have provided evidence for a new molecular mechanism linking high glucose-enhanced HBP activity with increased nuclear USF protein levels and DNA binding activity and with up-regulated TGF-beta1 promoter activity.	Univ Tubingen, Dept Internal Med, Div Endocrinol Metab & Pathobiochem, D-72076 Tubingen, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Eberhard Karls University of Tubingen; University of Texas System; UTMD Anderson Cancer Center	Schleicher, ED (corresponding author), Univ Tubingen, Dept Internal Med, Div Endocrinol Metab & Pathobiochem, Otfried Muller Str 10, D-72076 Tubingen, Germany.	enschlei@med.uni-tuebingen.de						Akimoto Y, 2000, DIABETOLOGIA, V43, P1239, DOI 10.1007/s001250051519; AYO SH, 1990, AM J PATHOL, V136, P1339; AYO SH, 1991, AM J PHYSIOL, V261, pF571, DOI 10.1152/ajprenal.1991.261.4.F571; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Brasse-Lagnel C, 2003, J BIOL CHEM, V278, P52504, DOI 10.1074/jbc.M306752200; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Goldberg HJ, 2000, DIABETES, V49, P863, DOI 10.2337/diabetes.49.5.863; Groenen PMA, 1996, GENOMICS, V38, P141, DOI 10.1006/geno.1996.0609; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; Hoffman BB, 1998, KIDNEY INT, V54, P1107, DOI 10.1046/j.1523-1755.1998.00119.x; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Isono M, 2000, J AM SOC NEPHROL, V11, P2222, DOI 10.1681/ASN.V11122222; Iwano M, 1996, KIDNEY INT, V49, P1120, DOI 10.1038/ki.1996.162; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kolm V, 1996, AM J PHYSIOL-RENAL, V270, pF812, DOI 10.1152/ajprenal.1996.270.5.F812; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; Majumdar G, 2003, AM J PHYSIOL-ENDOC M, V285, pE584, DOI 10.1152/ajpendo.00140.2003; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; Nerlich AG, 1998, DIABETES, V47, P170, DOI 10.2337/diabetes.47.2.170; Netzker R, 1997, EUR J BIOCHEM, V245, P174, DOI 10.1111/j.1432-1033.1997.00174.x; OSTERBY R, 1992, DIABETOLOGIA, V35, P803, DOI 10.1007/BF00399925; Roos MD, 1998, P ASSOC AM PHYSICIAN, V110, P422; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wang HY, 2002, J BIOL CHEM, V277, P32746, DOI 10.1074/jbc.M201635200; Weigert C, 2003, DIABETOLOGIA, V46, P852, DOI 10.1007/s00125-003-1122-8; Weigert C, 2001, FEBS LETT, V488, P95, DOI 10.1016/S0014-5793(00)02395-4; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wilmer WA, 1998, KIDNEY INT, V53, P1172, DOI 10.1046/j.1523-1755.1998.00888.x; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	46	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15908	15915		10.1074/jbc.M313524200	http://dx.doi.org/10.1074/jbc.M313524200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757763	hybrid			2022-12-27	WOS:000220747900027
J	Bernardin-Fried, F; Kummalue, T; Leijen, S; Collector, MI; Ravid, K; Friedman, AD				Bernardin-Fried, F; Kummalue, T; Leijen, S; Collector, MI; Ravid, K; Friedman, AD			AML1/RUNX1 increases during G(1) to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; MYOSIN HEAVY-CHAIN; CBF-BETA-SMMHC; FETAL LIVER HEMATOPOIESIS; TRANSCRIPTION FACTOR; DNA-BINDING; IN-VIVO; GRANULOCYTIC DIFFERENTIATION; DEFINITIVE HEMATOPOIESIS	AML1/RUNX1, a member of the core binding factor (CBF) family stimulates myelopoiesis and lymphopoiesis by activating lineage-specific genes. In addition, AML1 induces S phase entry in 32Dcl3 myeloid or Ba/F3 lymphoid cells via transactivation. We now found that AML1 levels are regulated during the cell cycle. 32Dcl3 and Ba/F3 cell cycle fractions were prepared using elutriation. Western blotting and a gel shift/supershift assay demonstrated that endogenous CBF DNA binding and AML1 levels were increased 2-4-fold in S and G(2)/M phase cells compared with G(1) cells. In addition, G(1) arrest induced by mimosine reduced AML1 protein levels. In contrast, AML1 RNA did not vary during cell cycle progression relative to actin RNA. Analysis of exogenous Myc-AML1 or AML1-ER demonstrated a significant reduction in G(1) phase cells, whereas levels of exogenous DNA binding domain alone were constant, lending support to the conclusion that regulation of AML1 protein stability contributes to cell cycle variation in endogenous AML1. However, cytokine-dependent AML1 phosphorylation was independent of cell cycle phase, and an AML1 mutant lacking two ERK phosphorylation sites was still cell cycle-regulated. Inhibition of AML1 activity with the CBF beta-SMMHC or AML1-ETO oncoproteins reduced cyclin D3 RNA expression, and AML1 bound and activated the cyclin D3 promoter. Signals stimulating G(1) to S cell cycle progression or entry into the cell cycle in immature hematopoietic cells might do so in part by inducing AML1 expression, and mutations altering pathways regulating variation in AML1 stability potentially contribute to leukemic transformation.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02128 USA	Johns Hopkins University; Boston University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, CRB 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhmi.edu		Ravid, Katya/0000-0002-9918-3024	NCI NIH HHS [CA098805] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BAE SC, 1993, ONCOGENE, V8, P809; Bernardin F, 2002, CANCER BIOL THER, V1, P492, DOI 10.4161/cbt.1.5.163; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Bernardin F, 2002, CANCER RES, V62, P3904; Bjerregaard MD, 2003, BLOOD, V101, P4322, DOI 10.1182/blood-2002-03-0835; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Corsetti MT, 1997, BLOOD, V89, P2359, DOI 10.1182/blood.V89.7.2359; D'Costa J, 2003, BLOOD, V102, p352A; Dal Cin P, 2001, GENE CHROMOSOME CANC, V30, P407, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Fukushima-Nakase Y, 2003, BLOOD, V102, p133A; Gu L, 2003, FEBS LETT, V544, P218, DOI 10.1016/S0014-5793(03)00502-7; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kummalue T, 2002, MOL CELL BIOL, V22, P8278, DOI 10.1128/MCB.22.23.8278-8291.2002; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; LU J, 1995, MOL CELL BIOL, V15, P1651; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Miyazaki Y, 2001, J BIOL CHEM, V276, P40528, DOI 10.1074/jbc.M103051200; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Niini T, 2000, HAEMATOLOGICA, V85, P362; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; North T, 1999, DEVELOPMENT, V126, P2563; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Peterson LF, 2002, BLOOD, V100, p299A; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Rhoades KL, 2000, BLOOD, V96, P2108; Robinson C, 1996, ONCOGENE, V12, P1855; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sun WL, 2003, BLOOD, V102, p132A; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang QF, 2003, ONCOGENE, V22, P2548, DOI 10.1038/sj.onc.1206360; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Yang YD, 2002, CANCER RES, V62, P2232; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	59	72	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15678	15687		10.1074/jbc.M310023200	http://dx.doi.org/10.1074/jbc.M310023200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747476	hybrid			2022-12-27	WOS:000220594700141
J	daCosta, CJB; Wagg, ID; McKay, ME; Baenziger, JE				daCosta, CJB; Wagg, ID; McKay, ME; Baenziger, JE			Phosphatidic acid and phosphatidylserine have distinct structural and functional interactions with the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; EXCHANGE-RESISTANT CORE; LIPID RAFTS; RECONSTITUTED MEMBRANES; FTIR SPECTROSCOPY; BILAYERS; CONFORMATION; DYNAMICS	Bilayers containing phosphatidylcholine ( PC) and the anionic lipid phosphatidic acid (PA) are particularly effective at stabilizing the nicotinic acetylcholine receptor ( nAChR) in a functional conformation that undergoes agonist-induced conformational change. The physical properties of PC membranes containing PA are also substantially altered upon incorporation of the nAChR. To test whether or not the negative charge of PA is responsible for this "bi-directional coupling," the nAChR was reconstituted into membranes composed of PC with varying levels of the net negatively charged lipid phosphatidylserine ( PS). In contrast to PA, increasing levels of PS in PC membranes do not stabilize an increasing proportion of nAChRs in a functional resting conformation, nor do they slow nAChR peptide hydrogen exchange kinetics. Incorporation of the nAChR had little effect on the physical properties of the PC/PS membranes, as monitored by the gel-to-liquid crystal phase transition temperatures of the bilayers. These results show that a net negative charge alone is not sufficient to account for the unique interactions that occur between the nAChR and PC/PA membranes. Incorporation of the receptor into PC/PS membranes, however, did lead to an altered head group conformation of PS possibly by recruiting divalent cations to the membrane surface. The results show that the nAChR has complex and unique interactions with both PA and PS. The interactions between the nAChR and PS may be bridged by divalent cations, such as calcium.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Baenziger, JE (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jebaenz@uottawa.ca		Baenziger, John/0000-0002-2888-5328				Baenziger JE, 1999, BIOCHEMISTRY-US, V38, P4905, DOI 10.1021/bi990181l; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BAENZIGER JE, 1992, BIOCHEMISTRY-US, V31, P3377, DOI 10.1021/bi00128a011; BAENZIGER JE, 1995, J BIOL CHEM, V270, P29129, DOI 10.1074/jbc.270.49.29129; BARRANTES FJ, 1989, CRIT REV BIOCHEM MOL, V24, P437, DOI 10.3109/10409238909086961; BLUME A, 1988, BIOCHEMISTRY-US, V27, P8239, DOI 10.1021/bi00421a038; Bruses JL, 2001, J NEUROSCI, V21, P504, DOI 10.1523/JNEUROSCI.21-02-00504.2001; CASAL HL, 1987, BIOCHEMISTRY-US, V26, P7395, DOI 10.1021/bi00397a030; daCosta CJB, 2002, J BIOL CHEM, V277, P201, DOI 10.1074/jbc.M108341200; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; HUBNER W, 1994, BIOCHEMISTRY-US, V33, P320; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Marchand S, 2002, J NEUROSCI, V22, P8891; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; McNamee M., 1988, LIPID DOMAINS RELATI, P43; Mendelson R., 1986, PROGR PROTEIN LIPID, V2, P103; METHOT N, 1995, BIOCHEMISTRY-US, V34, P15142, DOI 10.1021/bi00046a021; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; OCHOA ELM, 1983, BIOCHIM BIOPHYS ACTA, V727, P151, DOI 10.1016/0005-2736(83)90379-6; Oshikawa J, 2003, AM J PHYSIOL-CELL PH, V285, pC567, DOI 10.1152/ajpcell.00422.2002; Poveda JA, 2002, BIOCHEMISTRY-US, V41, P12253, DOI 10.1021/bi0200099; Rankin SE, 1997, BIOPHYS J, V73, P2446, DOI 10.1016/S0006-3495(97)78273-0; Ryan SE, 1996, J BIOL CHEM, V271, P24590, DOI 10.1074/jbc.271.40.24590; Ryan SE, 1999, MOL PHARMACOL, V55, P348, DOI 10.1124/mol.55.2.348	24	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14967	14974		10.1074/jbc.M310037200	http://dx.doi.org/10.1074/jbc.M310037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752108	hybrid			2022-12-27	WOS:000220594700060
J	Otto, GP; Wu, MY; Kazgan, N; Anderson, OR; Kessin, RH				Otto, GP; Wu, MY; Kazgan, N; Anderson, OR; Kessin, RH			Dictyostelium macroautophagy mutants vary in the severity of their developmental defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN-ACTIVATING ENZYME; KINASE GENE; C-ELEGANS; AUTOPHAGY; DISCOIDEUM; AUTOPHAGOCYTOSIS; INDUCTION; CYTOPLASM; MEMBRANE	Macroautophagy is the major mechanism that eukaryotes use to recycle cellular components during stressful conditions. We have shown previously that the Atg12-Atg5 conjugation system, required for autophagosome formation in yeast, is necessary for Dictyostelium development. A second conjugation reaction, Aut7/Atg8 lipidation with phosphatidylethanolamine, as well as a protein kinase complex and a phosphatidylinositol 3-kinase complex are also required for macroautophagy in yeast. In this study, we characterize mutations in the putative Dictyostelium discoideum orthologues of budding yeast genes that are involved in one of each of these functions, ATG1, ATG6, and ATG8. All three genes are required for macroautophagy in Dictyostelium. Mutant amoebae display reduced survival during nitrogen starvation and reduced protein degradation during development. Mutations in the three genes produce aberrant development with defects of varying severity. As with other Dictyostelium macroautophagy mutants, development of atg1-1, atg6(-), and atg8(-) is more aberrant in plaques on bacterial lawns than on nitrocellulose filters. The most severe defect is observed in the atg1-1 mutant, which does not aggregate on bacterial lawns and arrests as loose mounds on nitrocellulose filters. The atg6(-) and atg8(-) mutants display almost normal development on nitrocellulose filters, producing multi-tipped aggregates that mature into small fruiting bodies. The distribution of a green fluorescent protein fusion of the autophagosome marker, Atg8, is aberrant in both atg1-1 and atg6(-) mutants.	Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Lamont Doherty Earth Observ, Dept Biol, Palisades, NY 10964 USA	Columbia University; Columbia University	Kessin, RH (corresponding author), Columbia Univ, Dept Anat & Cell Biol, P&S 12-517,630 W 168th St, New York, NY 10032 USA.	rhk2@columbia.edu		Otto, Grant/0000-0001-8709-3366; Wu, Mary Y./0000-0002-2074-6171	NIGMS NIH HHS [GM 33136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; ANDERSON OR, 1994, J EUKARYOT MICROBIOL, V41, P124, DOI 10.1111/j.1550-7408.1994.tb01484.x; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Juhasz G, 2003, FEBS LETT, V543, P154, DOI 10.1016/S0014-5793(03)00431-9; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Otto GP, 2004, MOL MICROBIOL, V51, P63, DOI 10.1046/j.1365-2958.2003.03826.x; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Pinan-Lucarre R, 2003, MOL MICROBIOL, V47, P321, DOI 10.1046/j.1365-2958.2003.03208.x; PODGORSKI GJ, 1989, MOL CELL BIOL, V9, P3938, DOI 10.1128/MCB.9.9.3938; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; WHITE GJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P285, DOI 10.1016/0006-3002(61)90441-3; Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040; Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546; Yan J, 1999, ONCOGENE, V18, P5850, DOI 10.1038/sj.onc.1202988; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	50	116	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15621	15629		10.1074/jbc.M311139200	http://dx.doi.org/10.1074/jbc.M311139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736886	hybrid			2022-12-27	WOS:000220594700134
J	Vaghefi, H; Hughes, AL; Neet, KE				Vaghefi, H; Hughes, AL; Neet, KE			Nerve growth factor withdrawal-mediated apoptosis in naive and differentiated PC12 cells through p53/caspase-3-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; DEVELOPMENTAL NEURON DEATH; TRANSGENIC MOUSE MODEL; P53-INDEPENDENT PATHWAY; SYMPATHETIC NEURONS; PHEOCHROMOCYTOMA CELLS; MOLECULAR MECHANISMS; CASPASE ACTIVATION; FACTOR DEPRIVATION; FAMILY-MEMBER	Programmed cell death is regulated in response to a variety of stimuli, including the tumor suppressor protein p53, that can mediate cell cycle arrest through p21/Waf1 and apoptosis through the Bcl-2/Bax equilibrium and caspases. Neuronal cell apoptosis has been reported to require p53, whereas other data suggest that neuronal cell death may be independent of p53. Comparison of wild type PC12 to a temperature-sensitive PC12 cell line that depresses the normal function of p53 has permitted investigation of the importance of p53 in a variety of cell functions. This study examined the role of p53 in trophic factor withdrawal-mediated apoptosis in both naive and differentiated PC12 cells. Our data show that as PC12 cells differentiate they are more poised to undergo apoptosis than their undifferentiated counterparts. Survival assays with XTT (sodium 3'-1-(phenylaminocarbonyl)-3,4-tetrazolium-bis(4-methoxy-6-nitro) benzene sulfonic acid) and TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) demonstrated that lack of p53 is initially protective against apoptosis. The window of protection is about 20 h for naive and 36 h for differentiated cells. Apoptosis involved caspases 3, 6, and 9. However, caspase 3 activation was absent in cells lacking p53, concomitant with the delayed apoptosis. When the expression of caspase 3 was silenced with interference RNA, wild type PC12 cells revealed a morphology and biochemistry similar to PC12[p53ts] cells, indicating that caspase 3 accounts for the observed delay in apoptosis in p53 dysfunction. These results suggest that p53 is important, but not essential, in factor withdrawal-mediated apoptosis. Parallel pathways of caspase-mediated apoptosis are activated later in the absence of functional p53.	Rosalind Franklin Univ Med & Sci, Dept Biochem & Mol Biol, Chicago Med Sch, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Neet, KE (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Biochem & Mol Biol, Chicago Med Sch, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	Kenneth.Neet@rosalindfranklin.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24380] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; BASNAKIAN AG, 1994, NUCLEIC ACIDS RES, V22, P2714, DOI 10.1093/nar/22.13.2714; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BAXTER GD, 1989, J PATHOL, V158, P123, DOI 10.1002/path.1711580207; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Carlile GW, 2000, MOL PHARMACOL, V57, P2; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Cooray S, 2003, J GEN VIROL, V84, P1275, DOI 10.1099/vir.0.18785-0; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 1999, J NEUROSCI, V19, P7860; Cummings BS, 2002, J PHARMACOL EXP THER, V302, P8, DOI 10.1124/jpet.302.1.8; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; DAVIES AM, 1994, NEUROSCI LETT, V182, P112, DOI 10.1016/0304-3940(94)90219-4; de Aguilar JLG, 2000, NEUROBIOL DIS, V7, P406, DOI 10.1006/nbdi.2000.0295; Deckwerth TL, 1998, EXP NEUROL, V152, P150, DOI 10.1006/exnr.1998.6846; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Eves EM, 1996, J NEUROCHEM, V67, P1908; FADOK VA, 1992, J IMMUNOL, V148, P2207; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gollapudi L, 1999, J NEUROSCI RES, V56, P471, DOI 10.1002/(SICI)1097-4547(19990601)56:5<471::AID-JNR3>3.3.CO;2-T; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guo Q, 1997, J NEUROSCI, V17, P4212; Haviv R, 1997, J NEUROSCI RES, V50, P69, DOI 10.1002/(SICI)1097-4547(19971001)50:1<69::AID-JNR8>3.0.CO;2-J; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Henshall DC, 2002, NEUROBIOL DIS, V10, P71, DOI 10.1006/nbdi.2002.0505; Hughes AL, 2000, J BIOL CHEM, V275, P37829, DOI 10.1074/jbc.M003146200; Humar B, 1997, INT J RADIAT BIOL, V72, P257, DOI 10.1080/095530097143257; Hwang SG, 2001, TOXICOLOGY, V165, P179, DOI 10.1016/S0300-483X(01)00432-2; Klockel BJ, 2002, CELL DEATH DIFFER, V9, P1063, DOI 10.1038/sj.cdd.4401067; Kuntz C, 2000, EXP NEUROL, V165, P184, DOI 10.1006/exnr.2000.7464; Lad SP, 2003, CNS NEUROL DISORD-DR, V2, P315, DOI 10.2174/1568007033482724; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Y, 2002, MOL VIS, V8, P341; LIU M, 1995, ONCOGENE, V10, P1955; Lo WD, 2003, MOL BRAIN RES, V113, P1, DOI 10.1016/S0169-328X(03)00052-4; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCKENBILLEDDS L, 1979, J NEUROCYTOL, V8, P493, DOI 10.1007/BF01214805; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARX J, 1993, SCIENCE, V262, P1644, DOI 10.1126/science.8259506; MCGUIRE JC, 1979, J BIOL CHEM, V254, P3362; Meller R, 2002, NEUROSCI LETT, V324, P33, DOI 10.1016/S0304-3940(02)00166-0; Merrick BA, 2001, BIOCHEMISTRY-US, V40, P4053, DOI 10.1021/bi002045i; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MICHIELI P, 1994, CANCER RES, V54, P3391; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Nakano H, 2002, CELL TISSUE RES, V310, P305, DOI 10.1007/s00441-002-0635-7; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; Osterhout DJ, 2002, J NEUROSCI RES, V69, P24, DOI 10.1002/jnr.10230; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Rocha S, 2000, CELL GROWTH DIFFER, V11, P491; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sadoul R, 1996, J NEUROSCI RES, V43, P594, DOI 10.1002/(SICI)1097-4547(19960301)43:5<594::AID-JNR9>3.3.CO;2-D; SLADEK TL, 1992, ONCOGENE, V7, P1305; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Takadera T, 1997, EUR J BIOCHEM, V249, P8, DOI 10.1111/j.1432-1033.1997.00008.x; Troy CM, 2002, J BIOL CHEM, V277, P34295, DOI 10.1074/jbc.M205167200; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; TSUKADA T, 1993, ONCOGENE, V8, P3313; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; Vyas S, 2002, MOL CELL NEUROSCI, V21, P1, DOI 10.1006/mcne.2002.1170; WOOD KA, 1995, J NEUROSCI, V15, P5851; Wosik K, 2003, J NEUROCHEM, V85, P635, DOI 10.1046/j.1471-4159.2003.01674.x; Wu J, 2001, MOL VIS, V7, P101; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001; ZHAN QM, 1994, ONCOGENE, V9, P3743	83	26	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15604	15614		10.1074/jbc.M311500200	http://dx.doi.org/10.1074/jbc.M311500200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739302	hybrid			2022-12-27	WOS:000220594700132
J	Walker, AK; Shi, Y; Blackwell, TK				Walker, AK; Shi, Y; Blackwell, TK			An extensive requirement for transcription factor IID-specific TAF-1 in Caenorhabditis elegans embryonic transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TBP-LIKE FACTOR; CELL-CYCLE PROGRESSION; C-TERMINAL DOMAIN; IN-VIVO; GENE-EXPRESSION; P-TEFB; SINGLE BLASTOMERE; SAGA COMPLEXES; YEAST	The general transcription factor TFIID sets the mRNA start site and consists of TATA-binding protein and associated factors (TAF(II)s), some of which are also present in SPT-ADA-GCN5 (SAGA)-related complexes. In yeast, results of multiple studies indicate that TFIID-specific TAFIIs are not required for the transcription of most genes, implying that intact TFIID may have a surprisingly specialized role in transcription. Relatively little is known about how TAFIIs contribute to metazoan transcription in vivo, especially at developmental and tissue-specific genes. Previously, we investigated functions of four shared TFIID/SAGA TAF(II)s in Caenorhabditis elegans. Whereas TAF-4 was required for essentially all embryonic transcription, TAF-5, TAF-9, and TAF-10 were dispensable at multiple developmental and other metazoan-specific promoters. Here we show evidence that in C. elegans embryos transcription of most genes requires TFIID-specific TAF-1. TAF-1 is not as universally required as TAF-4, but it is essential for a greater proportion of transcription than TAF-5, -9, or -10 and is important for transcription of many developmental and other metazoan-specific genes. TAF-2, which binds core promoters with TAF-1, appears to be required for a similarly substantial proportion of transcription. C. elegans TAF-1 overlaps functionally with the coactivator p300/CBP (CBP-1), and at some genes it is required along with the TBP-like protein TLF(TRF2). We conclude that during C. elegans embryogenesis TAF-1 and TFIID have broad roles in transcription and development and that TFIID and TLF may act together at certain promoters. Our findings imply that in metazoans TFIID may be of widespread importance for transcription and for expression of tissue-specific genes.	Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Blackwell, TK (corresponding author), Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, 1 Joslin Pl, Boston, MA 02115 USA.	keith.blackwell@joslin.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062891] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Andel F, 1999, SCIENCE, V286, P2153, DOI 10.1126/science.286.5447.2153; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; Baugh LR, 2003, DEVELOPMENT, V130, P889, DOI 10.1242/dev.00302; Bowerman B, 1997, DEVELOPMENT, V124, P3815; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Calvo D, 2001, EMBO J, V20, P7197, DOI 10.1093/emboj/20.24.7197; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; Durso RJ, 2001, MOL CELL BIOL, V21, P7331, DOI 10.1128/MCB.21.21.7331-7344.2001; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hardy S, 2002, J BIOL CHEM, V277, P32875, DOI 10.1074/jbc.M205860200; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Horner MA, 1998, GENE DEV, V12, P1947, DOI 10.1101/gad.12.13.1947; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Kalb JM, 1998, DEVELOPMENT, V125, P2171; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; Maduro MF, 2001, MOL CELL, V7, P475, DOI 10.1016/S1097-2765(01)00195-2; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Martianov I, 2002, DEVELOPMENT, V129, P945; Matangkasombut O, 2000, GENE DEV, V14, P951; Matangkasombut O, 2003, MOL CELL, V11, P353, DOI 10.1016/S1097-2765(03)00033-9; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Muller F, 2001, CURR BIOL, V11, P282, DOI 10.1016/S0960-9822(01)00076-8; Newman-Smith ED, 1998, CURR OPIN GENET DEV, V8, P472, DOI 10.1016/S0959-437X(98)80120-2; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Seydoux G, 1997, DEVELOPMENT, V124, P2191; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Shen WC, 2003, EMBO J, V22, P3395, DOI 10.1093/emboj/cdg336; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shim EY, 2002, J BIOL CHEM, V277, P30413, DOI 10.1074/jbc.C200305200; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Takagi T, 2003, J BIOL CHEM, V278, P14174, DOI 10.1074/jbc.M212101200; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Victor M, 2002, EMBO REP, V3, P50, DOI 10.1093/embo-reports/kvf006; Walker AK, 2003, J BIOL CHEM, V278, P6181, DOI 10.1074/jbc.M211056200; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wallenfang MR, 2002, P NATL ACAD SCI USA, V99, P5527, DOI 10.1073/pnas.082618399; Wassarman DA, 2000, P NATL ACAD SCI USA, V97, P1154, DOI 10.1073/pnas.97.3.1154; Wassarman DA, 2001, J CELL SCI, V114, P2895; Zhang F, 2003, GENE DEV, V17, P748, DOI 10.1101/gad.1068203	71	14	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15339	15347		10.1074/jbc.M310731200	http://dx.doi.org/10.1074/jbc.M310731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726532	hybrid			2022-12-27	WOS:000220594700103
J	Hyun, TS; Rao, DS; Saint-Dic, D; Michael, LE; Kumar, PD; Bradley, SV; Mizukami, IF; Oravecz-Wilson, KI; Ross, TS				Hyun, TS; Rao, DS; Saint-Dic, D; Michael, LE; Kumar, PD; Bradley, SV; Mizukami, IF; Oravecz-Wilson, KI; Ross, TS			HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTIN-INTERACTING PROTEIN; GROWTH-FACTOR RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; ENTH-DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; EARLY ENDOSOMES; COLON-CANCER; COATED PITS; CELLS; ACTIN	Huntingtin-interacting protein 1-related (HIP1r) is the only known mammalian relative of huntingtin-interacting protein 1 (HIP1), a protein that transforms fibroblasts via undefined mechanisms. Here we demonstrate that both HIP1r and HIP1 bind inositol lipids via their epsin N-terminal homology (ENTH) domains. In contrast to other ENTH domain-containing proteins, lipid binding is preferential to the 3-phosphate-containing inositol lipids, phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,5-bisphosphate. Furthermore, the HIP1r ENTH domain, like that of HIP1, is necessary for lipid binding, and expression of an ENTH domain-deletion mutant, HIP1r/DeltaE, induces apoptosis. Consistent with the ability of HIP1r and HIP1 to affect cell survival, full-length HIP1 and HIP1r stabilize pools of growth factor receptors by prolonging their half-life following ligand-induced endocytosis. Although HIP1r and HIP1 display only a partially overlapping pattern of protein interactions, these data suggest that both proteins share a functional homology by binding 3-phosphorylated inositol lipids and stabilizing receptor tyrosine kinases in a fashion that may contribute to their ability to alter cell growth and survival.	Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Grad Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ross, TS (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.	tsross@umich.edu	Rao, Dinesh/AAE-9625-2019	Ross, Theodora/0000-0002-9166-1802; Hyun, Teresa/0000-0002-9350-2733; Bradley, Sarah/0000-0001-8491-7809; Rao, Dinesh/0000-0002-0794-9337	NATIONAL CANCER INSTITUTE [R01CA082363, R01CA098730] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82363-01A1, R01 CA 098730-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen XM, 2001, EMBO REP, V2, P842, DOI 10.1093/embo-reports/kve179; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Friant S, 2003, DEV CELL, V5, P499, DOI 10.1016/S1534-5807(03)00238-7; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Hussain NK, 2003, J BIOL CHEM, V278, P28823, DOI 10.1074/jbc.M300995200; Itoh T, 2002, CELL SIGNAL, V14, P733, DOI 10.1016/S0898-6568(02)00028-1; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; Kari C, 2003, CANCER RES, V63, P1; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Legendre-Guillemin V, 2002, J BIOL CHEM, V277, P19897, DOI 10.1074/jbc.M112310200; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Metzler M, 2003, EMBO J, V22, P3254, DOI 10.1093/emboj/cdg334; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Rao DS, 2003, CANCER CELL, V3, P471, DOI 10.1016/S1535-6108(03)00107-7; Rao DS, 2002, J CLIN INVEST, V110, P351, DOI 10.1172/JCI200215529; Rao DS, 2001, MOL CELL BIOL, V21, P7796, DOI 10.1128/MCB.21.22.7796-7806.2001; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Ross TS, 1999, J BIOL CHEM, V274, P22328, DOI 10.1074/jbc.274.32.22328; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Scanlan MJ, 2002, CANCER RES, V62, P4041; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078	44	53	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14294	14306		10.1074/jbc.M312645200	http://dx.doi.org/10.1074/jbc.M312645200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732715	hybrid			2022-12-27	WOS:000220478500124
J	Sanna, MG; Liao, JY; Jo, EJ; Alfonso, C; Ahn, MY; Peterson, MS; Webb, B; Lefebvre, S; Chun, J; Gray, N; Rosen, H				Sanna, MG; Liao, JY; Jo, EJ; Alfonso, C; Ahn, MY; Peterson, MS; Webb, B; Lefebvre, S; Chun, J; Gray, N; Rosen, H			Sphingosine 1-phosphate (S1P) receptor subtypes S1P(1) and S1P(3), respectively, regulate lymphocyte recirculation and heart rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE-1-PHOSPHATE; FTY720; ACTIVATION; EDG-1; LYSOPHOSPHOLIPIDS; TRANSPLANTATION; TRAFFICKING; CELLS	Sphingosine 1-phosphate (S1P) influences heart rate, coronary artery caliber, endothelial integrity, and lymphocyte recirculation through five related high affinity G-protein-coupled receptors. Inhibition of lymphocyte recirculation by non-selective S1P receptor agonists produces clinical immunosuppression preventing transplant rejection but is associated with transient bradycardia. Understanding the contribution of individual receptors has been limited by the embryonic lethality of the S1P(1) knock-out and the unavailability of selective agonists or antagonists. A potent, S1P(1)-receptor selective agonist structurally unrelated to S1P was found to activate multiple signals triggered by S1P, including guanosine 5'-3-O-( thio) triphosphate binding, calcium flux, Akt and ERK1/2 phosphorylation, and stimulation of migration of S1P(1)- but not S1P(3)-expressing cells in vitro. The agonist also alters lymphocyte trafficking in vivo. Use of selective agonism together with deletant mice lacking S1P(3) receptor reveals that agonism of S1P(1) receptor alone is sufficient to control lymphocyte recirculation. Moreover, S1P(1) receptor agonist plasma levels are causally associated with induction and maintenance of lymphopenia. S1P(3), and not S1P(1), is directly implicated in sinus bradycardia. The sustained bradycardia induced by S1P receptor nonselective immunosuppressive agonists in wild-type mice is abolished in S1P(3)(-/-) mice, whereas S1P(1)-selective agonist does not produce bradycardia. Separation of receptor subtype usage for control of lymphocyte recirculation and heart rate may allow the identification of selective immunosuppressive S1P(1) receptor agonists with an enhanced therapeutic window. S1P(1)- selective agonists will be of broad utility in understanding cell functions in vitro, and vascular physiology in vivo, and the success of the chemical approach for S1P(1) suggests that selective tools for the resolution of function across this broad lipid receptor family are now possible.	Scripps Res Inst, Ctr Mass Spectrometry, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Novartis	Rosen, H (corresponding author), Scripps Res Inst, Ctr Mass Spectrometry, Dept Immunol, 10550 N torrey Pines Rd,ICND 118, La Jolla, CA 92037 USA.	hrosen@scripps.edu	Chun, Jerold/Y-4670-2019	Jo, Euijung/0000-0003-1131-2723				Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; Brinkmann V, 2001, TRANSPLANT P, V33, P530, DOI 10.1016/S0041-1345(00)02126-6; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Budde K, 2003, AM J TRANSPLANT, V3, P846, DOI 10.1034/j.1600-6143.2003.00130.x; Dantas APV, 2003, AM J PHYSIOL-HEART C, V284, pH2045, DOI 10.1152/ajpheart.01089.2002; DOHERTY G, 2003, Patent No. 03061567; English D, 2002, BBA-MOL CELL BIOL L, V1582, P228, DOI 10.1016/S1388-1981(02)00176-2; FORREST M, 2004, IN PRESS J PHARM EXP; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gowans J L, 1980, Ciba Found Symp, V71, P113, DOI 10.1002/9780470720547.ch7; GOWANS JL, 1971, INT ARCH ALLER A IMM, V41, P1; GOWANS JL, 1975, J RETICULOENDOTH SOC, V17, P97; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; GRAELER M, 2002, BIOCHIM BIOPHYS ACTA, V1582, P168; Himmel HM, 2000, MOL PHARMACOL, V58, P449, DOI 10.1124/mol.58.2.449; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Karliner JS, 2002, BBA-MOL CELL BIOL L, V1582, P216, DOI 10.1016/S1388-1981(02)00174-9; KLUCK MJ, 2002, BIOCHIM BIOPHYS ACTA, V1582, P72; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mazurais D, 2002, J HISTOCHEM CYTOCHEM, V50, P661, DOI 10.1177/002215540205000507; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Ohmori T, 2003, CARDIOVASC RES, V58, P170, DOI 10.1016/S0008-6363(03)00260-8; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Rosen H, 2003, IMMUNOL REV, V195, P160, DOI 10.1034/j.1600-065X.2003.00068.x; Rosen H, 2003, CURR OPIN CHEM BIOL, V7, P461, DOI 10.1016/S1367-5931(03)00085-1; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sugiyama A, 2000, CARDIOVASC RES, V46, P119, DOI 10.1016/S0008-6363(00)00013-4; Xie JH, 2003, J IMMUNOL, V170, P3662, DOI 10.4049/jimmunol.170.7.3662; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O	43	516	592	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13839	13848		10.1074/jbc.M311743200	http://dx.doi.org/10.1074/jbc.M311743200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732717	hybrid			2022-12-27	WOS:000220478500070
J	Kang, MR; Muller, MT; Chung, IK				Kang, MR; Muller, MT; Chung, IK			Telomeric DNA damage by topoisomerase I - A possible mechanism for cell killing by camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; CLEAVAGE; SEQUENCE; COMPLEXES; BREAKAGE; SITES; VITRO	Topoisomerase I adjusts torsional stress in the genome by breaking and resealing one strand of the helix through a transient covalent coupling between enzyme and DNA. Camptothecin, a specific topoisomerase I poison, traps this covalent intermediate, thereby damaging the genome. Here we examined the activity of topoisomerase I at telomeric repeats to determine whether telomere structures are targets for DNA damage. We show that topoisomerase I is catalytically active in cleaving the G-rich telomeric strand in vitro in the presence of camptothecin but not in cleaving the C-rich strand. The topoisomerase I cleavage site is 5'-TT down arrow AGGG-3' ( cleavage site marked by the 2). We also show that endogenous topoisomerase I can access telomeric DNA in vivo and form camptothecin-dependent covalent complexes. Therefore, each telomeric repeat represents a potential topoisomerase I cleavage site in vivo. Because telomere structures are comprised of a large number of repeats, telomeres in fact represent a high concentration of nested topoisomerase I sites. Therefore, more telomeric DNA damage by camptothecin could occur in cells with longer telomeres when cells possess equivalent levels of topoisomerase I. The evidence presented here suggests that DNA damage at telomeric repeats by topoisomerase I is a prominent feature of cell killing by camptothecin and triggers camptothecin-induced apoptosis.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Mol Aging Res Ctr, Seoul 120749, South Korea; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Yonsei University; Yonsei University; Ohio State University	Chung, IK (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, 134 Shinchon Dong, Seoul 120749, South Korea.	topoviro@yonsei.ac.kr						BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8463, DOI 10.1093/nar/17.21.8463; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Harrington L, 2002, ONCOGENE, V21, P592, DOI 10.1038/sj.onc.1205084; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HORWITZ SB, 1973, CANCER RES, V33, P2834; JAXEL C, 1991, J BIOL CHEM, V266, P20418; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Mao YH, 2000, CANCER RES, V60, P4538; MULLER MT, 1988, MOL CELL BIOL, V8, P3661, DOI 10.1128/MCB.8.9.3661; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Subramanian D, 2000, METH MOL B, V95, P137; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Subramanian D, 1998, CANCER RES, V58, P976; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yoon HJ, 1998, BBA-GENE STRUCT EXPR, V1395, P110, DOI 10.1016/S0167-4781(97)00139-5	35	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12535	12541		10.1074/jbc.M309779200	http://dx.doi.org/10.1074/jbc.M309779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729676	hybrid			2022-12-27	WOS:000220334900065
J	Pavlova, P; Shimabukuro, K; Hisabori, T; Groth, G; Lill, H; Bald, D				Pavlova, P; Shimabukuro, K; Hisabori, T; Groth, G; Lill, H; Bald, D			Complete inhibition and partial re-activation of single F-1-ATPase molecules by tentoxin - New properties of the re-activated enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST COUPLING FACTOR-1; INACTIVE STATE TRANSITIONS; ESCHERICHIA-COLI F1-ATPASE; ATP SYNTHASE; ALPHA(3)BETA(3)GAMMA COMPLEX; CATALYTIC SITE; KINETIC-ANALYSIS; BINDING-SITES; GAMMA-SUBUNIT; ROTATION	During hydrolysis of ATP, the gamma subunit of the rotary motor protein F-1-ATPase rotates within a ring of alpha(3)beta(3) subunits. Tentoxin is a phyto-pathogenic cyclic tetrapeptide, which influences F-1-ATPase activity of sensitive species. At low concentrations, tentoxin inhibits ATP hydrolysis of ensembles of F-1 molecules in solution. At higher concentrations, however, ATP hydrolysis recovers. Here we have examined how tentoxin acts on individual molecules of engineered F-1-ATPase from the thermophilic Bacillus PS3 (Groth, G., Hisabori, T., Lill, H., and Bald, D. ( 2002) J. Biol. Chem. 277, 20117 - 20119). We found that inhibition by tentoxin caused a virtually complete stop of rotation, which was partially relieved at higher tentoxin concentrations. Re-activation, however, was not simply a reversal of inhibition; while the torque appears unaffected as compared with the situation without tentoxin, F-1 under re-activating conditions was less susceptible to inhibitory ADP binding but displayed a large number of short pauses, indicating infringed energy conversion.	Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Biol Struct, NL-1181 HV Amsterdam, Netherlands; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Univ Dusseldorf, D-40225 Dusseldorf, Germany	Vrije Universiteit Amsterdam; Tokyo Institute of Technology; Heinrich Heine University Dusseldorf	Bald, D (corresponding author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Biol Struct, De Boelelaan 1085, NL-1181 HV Amsterdam, Netherlands.	dirkbald@bio.vu.nl	Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277; Lill, H./0000-0001-9336-5428				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARNTZEN CJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P539, DOI 10.1016/0005-2728(72)90273-3; Bald D, 1998, J BIOL CHEM, V273, P865, DOI 10.1074/jbc.273.2.865; Bald D, 2001, J BIOL CHEM, V276, P39505, DOI 10.1074/jbc.C100436200; Bald D, 1999, EUR J BIOCHEM, V262, P563, DOI 10.1046/j.1432-1327.1999.00410.x; Borsch M, 2002, FEBS LETT, V527, P147, DOI 10.1016/S0014-5793(02)03198-8; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Groth G, 2002, P NATL ACAD SCI USA, V99, P3464, DOI 10.1073/pnas.052546099; Groth G, 2002, J BIOL CHEM, V277, P20117, DOI 10.1074/jbc.C200168200; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; Mochimaru M, 1997, FEBS LETT, V419, P23, DOI 10.1016/S0014-5793(97)01421-X; MOYLE J, 1975, FEBS LETT, V56, P55, DOI 10.1016/0014-5793(75)80110-4; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Santolini J, 1998, J BIOL CHEM, V273, P3343, DOI 10.1074/jbc.273.6.3343; Santolini J, 1999, J BIOL CHEM, V274, P849, DOI 10.1074/jbc.274.2.849; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; SYROESHKIN AV, 1995, FEBS LETT, V366, P29, DOI 10.1016/0014-5793(95)00487-T; Tucker WC, 2001, BIOCHEMISTRY-US, V40, P7542, DOI 10.1021/bi0105227; Tucker WC, 2001, EUR J BIOCHEM, V268, P2179, DOI 10.1046/j.1432-1327.2001.02110.x; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	34	7	8	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9685	9688		10.1074/jbc.C400014200	http://dx.doi.org/10.1074/jbc.C400014200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14739290	Green Published, hybrid			2022-12-27	WOS:000220050400004
J	Jobling, AI; Nguyen, M; Gentle, A; McBrien, NA				Jobling, AI; Nguyen, M; Gentle, A; McBrien, NA			Isoform-specific changes in scleral transforming growth factor-beta expression and the regulation of collagen synthesis during myopia progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORM-DEPRIVATION MYOPIA; TREE SHREW SCLERA; TGF-BETA; GENE-EXPRESSION; RETINAL CONTROL; MESSENGER-RNA; AXIAL MYOPIA; EYE GROWTH; IN-VITRO; CHICKS	The development of high myopia is associated with altered scleral extracellular matrix biochemistry. Previous studies highlight the importance of collagen turnover in this process, yet it is unclear which factors control scleral remodeling. This study used a mammalian model of myopia to investigate the capacity of TGF (transforming growth factor)-beta1, -beta2, and -beta3 to influence scleral remodeling in myopia. RT-PCR confirmed the presence of all mammalian TGF-beta isoforms in scleral tissue and scleral fibroblasts. Myopia was experimentally induced via monocular deprivation of pattern vision, and animals were allocated to two groups depending on the duration of treatment ( 1 or 5 days). Downregulation of each isoform was apparent after only 1 day of myopia development (TGF-beta1, -32%; TGF-beta2, - 27%; TGF-beta3, - 42%). Whereas the decrease in TGF-beta1 and -beta3 expression was relatively constant between the two time points, differential down-regulation of TGF-beta2 was found between days 1 (-27%) and 5 (-50%). In vitro experiments, using primary scleral fibroblasts, demonstrated the capacity of all isoforms to increase collagen production in a dose-dependent manner. Changes in TGF-beta levels, which mimicked those during myopia induction, caused an similar to15% reduction in collagen synthesis, which is qualitatively similar to those previously reported in vivo. These data represent the first demonstration of TGF-beta3 expression in the sclera and implicate all three TGF-beta isoforms in the control of scleral remodeling during myopia development. In addition, the early alterations in TGF-beta expression levels may reflect a role for these cytokines in mediating the retinoscleral signal that controls myopic eye growth.	Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia	University of Melbourne	McBrien, NA (corresponding author), Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.	n.mcbrien@optometry.unimelb.edu.au	Jobling, Andrew/C-8221-2015	Jobling, Andrew/0000-0002-7827-3135				BIRK DE, 1990, J CELL SCI, V95, P649; BURGOWER W, 1985, MYOPIAS BASIC SCI CL; CHRISTENSEN AM, 1991, INVEST OPHTH VIS SCI, V32, P2143; Coker RK, 1997, AM J PATHOL, V150, P981; CURTIN BJ, 1979, ARCH OPHTHALMOL-CHIC, V97, P912, DOI 10.1001/archopht.1979.01020010470017; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gentle A, 1999, EXP EYE RES, V68, P155, DOI 10.1006/exer.1998.0587; Gentle A, 2003, J BIOL CHEM, V278, P16587, DOI 10.1074/jbc.M300970200; Gentle A, 2002, CYTOKINE, V18, P344, DOI 10.1006/cyto.2002.1046; Gentle A, 2001, CURR EYE RES, V23, P179, DOI 10.1076/ceyr.23.3.179.5466; Gentle A, 2001, BIOTECHNIQUES, V31, P502, DOI 10.2144/01313st03; Gordon-Thomson C, 1998, INVEST OPHTH VIS SCI, V39, P1399; GOTTLIEB MD, 1990, CURR EYE RES, V9, P1157, DOI 10.3109/02713689009003472; Guggenheim JA, 1996, INVEST OPHTH VIS SCI, V37, P1380; Honda S, 1996, INVEST OPHTH VIS SCI, V37, P2519; Kinbara T, 2002, J CELL PHYSIOL, V190, P375, DOI 10.1002/jcp.10046; Koyano Y, 1997, BIOTECHNIQUES, V22, P706; Kusakari T, 2001, EXP EYE RES, V73, P533, DOI 10.1006/exer.2001.1064; MARSHALL GE, 1993, INVEST OPHTH VIS SCI, V34, P1202; McBrien NA, 2000, INVEST OPHTH VIS SCI, V41, P3713; McBrien NA, 2003, PROG RETIN EYE RES, V22, P307, DOI 10.1016/S1350-9462(02)00063-0; MCBRIEN NA, 1992, VISION RES, V32, P843, DOI 10.1016/0042-6989(92)90027-G; McBrien NA, 2001, INVEST OPHTH VIS SCI, V42, P2179; Mietz H, 1998, GRAEF ARCH CLIN EXP, V236, P467, DOI 10.1007/s004170050107; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; NORTON TT, 1995, VISION RES, V35, P1271, DOI 10.1016/0042-6989(94)00243-F; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Phillips JR, 2000, INVEST OPHTH VIS SCI, V41, P2028; RADA JA, 1995, INVEST OPHTH VIS SCI, V36, P1555; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; ROHRER B, 1994, EXP EYE RES, V58, P553, DOI 10.1006/exer.1994.1049; Saika S, 2001, DEV BIOL, V240, P419, DOI 10.1006/dbio.2001.0480; SEKO Y, 1995, INVEST OPHTH VIS SCI, V36, P1183; SHAH M, 1995, J CELL SCI, V108, P985; Siegwart JT, 1999, VISION RES, V39, P387, DOI 10.1016/S0042-6989(98)00150-3; Siegwart JT, 2002, INVEST OPHTH VIS SCI, V43, P2067; SIEGWART JT, 1994, LAB ANIM SCI, V44, P213; Song QH, 2000, J CELL BIOCHEM, V77, P186, DOI 10.1002/(SICI)1097-4644(20000501)77:2<186::AID-JCB3>3.0.CO;2-M; Spindler KP, 2002, J ORTHOP RES, V20, P318, DOI 10.1016/S0736-0266(01)00107-3; Streilein JW, 2002, DNA CELL BIOL, V21, P453, DOI 10.1089/10445490260099746; Tredget EE, 2000, J INTERF CYTOK RES, V20, P143, DOI 10.1089/107999000312540; WALLMAN J, 1993, PROG RETIN RES, V12, P133, DOI 10.1016/0278-4327(93)90007-G; WESTERGRENTHORSSON G, 1991, MATRIX, V11, P177, DOI 10.1016/S0934-8832(11)80156-3; Yu L, 2003, KIDNEY INT, V64, P844, DOI 10.1046/j.1523-1755.2003.00162.x	44	102	115	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18121	18126		10.1074/jbc.M400381200	http://dx.doi.org/10.1074/jbc.M400381200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14752095	hybrid			2022-12-27	WOS:000221041500006
J	Rampazzo, C; Ferraro, P; Pontarin, G; Fabris, S; Reichard, P; Bianchi, V				Rampazzo, C; Ferraro, P; Pontarin, G; Fabris, S; Reichard, P; Bianchi, V			Mitochondrial deoxyribonucleotides, pool sizes, synthesis, and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE; DEOXYNUCLEOTIDE CARRIER; CELL-CYCLE; DNA; CLONING; GENE; TRIPHOSPHATES; EXPRESSION; MUTATIONS; TOXICITY	We quantify cytosolic and mitochondrial deoxyribo-nucleoside triphosphates (dNTPs) from four established cell lines using a recently described method for the separation of cytosolic and mitochondrial (mt) dNTPs from as little as 10 million cells in culture (Pontarin, G., Gallinaro, L., Ferraro, P., Reichard, P., and Bianchi, V. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 12159-12164). In cycling cells the concentrations of the phosphates of thymidine, deoxycytidine, and deoxyadenosine (combining mono-, di-, and triphosphates in each case) did not differ significantly between mitochondria and cytosol, whereas deoxyguanosine phosphates were concentrated to mitochondria. We study the source and regulation of the mt dTTP pool as an example of mt dNTPs. We suggest two pathways as sources for mt dTTP: (i) import from the cytosol of thymidine diphosphate by a deoxynucleotide transporter, predominantly in cells involved in DNA replication with an active synthesis of deoxynucleotides and (ii) import of thymidine followed by phosphorylation by the mt thymidine kinase, predominantly in resting cells. Here we demonstrate that the second pathway is regulated by a mt 5'-deoxyribo-nucleotidase (mdN). We modify the in situ activity of mdN and measure the transfer of radioactivity from [H-3]thymidine to mt thymidine phosphates. In cycling cells lacking the cytosolic thymidine kinase, a 30-fold overproduction of mdN decreases the specific radioactivity of mt dTTP to 25%, and an 80% decrease of mdN by RNA interference increases the specific radioactivity 2-fold. These results suggest that mdN modulates the synthesis of mt dTTP by counteracting in a substrate cycle the phosphorylation of thymidine by the mt thymidine kinase.	Univ Padua, Dept Biol, I-35131 Padua, Italy	University of Padua	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	vbianchi@mail.bio.unipd.it			Telethon [GP0140Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		BERK AJ, 1973, J BIOL CHEM, V248, P2722; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; Bianchi V, 1997, J BIOL CHEM, V272, P16118, DOI 10.1074/jbc.272.26.16118; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; ERECINSKA M, 1981, INHIBITORS MITOCHOND, P1; Gallinaro L, 2002, J BIOL CHEM, V277, P35080, DOI 10.1074/jbc.M203755200; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Lai YR, 2004, J BIOL CHEM, V279, P4490, DOI 10.1074/jbc.M307938200; Lambeth DO, 1997, J BIOL CHEM, V272, P24604, DOI 10.1074/jbc.272.39.24604; Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; NORDENSKJOLD BA, 1970, J BIOL CHEM, V245, P5360; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200; SPYROU G, 1988, MUTAT RES, V200, P37, DOI 10.1016/0027-5107(88)90069-3; Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Van Rompay AR, 2003, PHARMACOL THERAPEUT, V100, P119, DOI 10.1016/j.pharmthera.2003.07.001; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6	33	64	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17019	17026		10.1074/jbc.M313957200	http://dx.doi.org/10.1074/jbc.M313957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14747464	hybrid			2022-12-27	WOS:000220870400018
J	Secombe, J; Parkhurst, SM				Secombe, J; Parkhurst, SM			Drosophila topors is a RING finger-containing protein that functions as a ubiquitin-protein isopeptide ligase for the hairy basic helix-loop-helix repressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TRANSCRIPTIONAL REPRESSION; HERPES-SIMPLEX-VIRUS; TOPOISOMERASE-I; NUCLEAR-BODIES; HISTONE DEACETYLASE; SEX DETERMINATION; BINDING-PROTEIN; BHLH PROTEINS; FUSHI-TARAZU; SEGMENTATION	Transcriptional repression plays an essential role in many aspects of metazoan development. Drosophila hairy is a primary pair-rule gene encoding a basic helix-loop-helix class transcriptional repressor that is required for proper segmentation. Previous characterization of Hairy-binding proteins has implicated two different classes of histone deacetylase as mediators of Hairy repression. Here, we present the characterization of a novel Hairy-interacting protein (dTopors) that binds specifically to the basic region of Hairy, but does not affect the ability of Hairy to bind DNA. By reducing the gene dose of dtopors, we demonstrate that it acts genetically as an antagonist of Hairy-mediated transcriptional repression. Consistent with this genetic interaction, we show that that recombinant dTopors protein possesses ubiquitin-protein isopeptide ligase activity in vitro and that dTopors mediates Hairy polyubiquitination and can lead to Hairy degradation. This work provides the first evidence that regulated proteolysis of Hairy is required for correct segmentation.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Parkhurst, SM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, A1-162,1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA.	susanp@fhcrc.org		Parkhurst, Susan/0000-0001-5806-9930	NIGMS NIH HHS [GM47852] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM047852, R01GM047852] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Courey AJ, 2001, GENE DEV, V15, P2786; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Furuyama S, 2002, MOL CELL BIOL, V22, P5337, DOI 10.1128/MCB.22.15.5337-5346.2002; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; HOWARD KR, 1990, DEVELOPMENT, V110, P1223; INGHAM PW, 1985, GENETICS, V111, P463; ISHHOROWICZ D, 1987, CELL, V51, P401; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; Nibu Y, 2001, EMBO J, V20, P2246, DOI 10.1093/emboj/20.9.2246; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Pankratz Michael J., 1993, P467; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Phippen TM, 2000, J BIOL CHEM, V275, P37628, DOI 10.1074/jbc.M004234200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rosenberg MI, 2002, CELL, V109, P447, DOI 10.1016/S0092-8674(02)00732-8; Torok T, 1997, GENE DEV, V11, P213, DOI 10.1101/gad.11.2.213; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WAINWRIGHT SM, 1992, MOL CELL BIOL, V12, P2475, DOI 10.1128/MCB.12.6.2475; Weger S, 2002, J GEN VIROL, V83, P511, DOI 10.1099/0022-1317-83-3-511; Wieschaus E., 1986, P199; Zhang HL, 1999, P NATL ACAD SCI USA, V96, P535, DOI 10.1073/pnas.96.2.535; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	43	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17126	17133		10.1074/jbc.M310097200	http://dx.doi.org/10.1074/jbc.M310097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14871887	hybrid			2022-12-27	WOS:000220870400031
J	Turner, JH; Gelasco, AK; Raymond, JR				Turner, JH; Gelasco, AK; Raymond, JR			Calmodulin interacts with the third intracellular loop of the serotonin 5-hydroxytryptamine(1A) receptor at two distinct sites - Putative role in receptor phosphorylation by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 5-HT1A RECEPTOR; GROWTH-FACTOR RECEPTOR; MEDIATED ERK ACTIVATION; MEMBRANE CA2+ PUMP; RAT HIPPOCAMPUS; NA+/H+ EXCHANGE; COUPLING DOMAIN; BINDING DOMAINS; CHO-K1 CELLS; NEURONS	The serotonin 5-HT1A receptor couples to heterotrimeric G proteins and intracellular second messengers, yet no studies have investigated the possible role of additional receptor-interacting proteins in 5-HT1A receptor signaling. We have found that the ubiquitous Ca2+-sensor calmodulin (CaM) co-immunoprecipitates with the 5-HT1A receptor in Chinese hamster ovary fibroblasts. The human 5-HT1A receptor contains two putative CaM binding motifs, located in the N- and C-terminal juxtamembrane regions of the third intracellular loop of the receptor. Peptides encompassing both the N- terminal (i3N) and C-terminal (i3C) CaM-binding domains were tested for CaM binding. Using in vitro binding assays in combination with gel shift analysis, we demonstrated Ca2+-dependent formation of complexes between CaM and both peptides. We determined kinetic data using a combination of BIAcore surface plasmon resonance (SPR) and dansyl-CaM fluorescence. SPR analysis gave an apparent K-D of similar to110 nM for the i3N peptide and similar to700 nM for the i3C peptide. Both peptides also caused characteristic shifts in the fluorescence emission spectrum of dansyl-CaM, with apparent affinities of 87 +/- 23 nM and 1.70 +/- 0.16 muM. We used bioluminescence resonance energy transfer to show that CaM interacts with the 5-HT1A receptor in living cells, representing the first in vivo evidence of a G protein-coupled receptor interacting with CaM. Finally, we showed that CaM binding and phosphorylation of the 5-HT1A receptor i3 loop peptides by protein kinase C are antagonistic in vitro, suggesting a possible role for CaM in the regulation of 5-HT1A receptor phosphorylation and desensitization. These data suggest that the 5-HT1A receptor contains high and moderate affinity CaM binding regions that may play important roles in receptor signaling and function.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Raymond, JR (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA.	raymondj@musc.edu	Turner, Justin/AAD-8607-2020	Turner, Justin/0000-0002-5501-9900	NIDDK NIH HHS [DK52448, DK59950] Funding Source: Medline; NIGMS NIH HHS [GM63909] Funding Source: Medline; NIMH NIH HHS [MH64795] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052448, R01DK052448, K25DK059950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH064795] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albert PR, 1998, ANN NY ACAD SCI, V861, P146, DOI 10.1111/j.1749-6632.1998.tb10186.x; ANDRADE R, 1987, J PHYSIOL-LONDON, V394, P99, DOI 10.1113/jphysiol.1987.sp016862; Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; Balcells-Olivero M, 1998, J PHARMACOL EXP THER, V286, P742; Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Blier P, 1997, NEUROPSYCHOPHARMACOL, V16, P333, DOI 10.1016/S0893-133X(96)00242-4; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Chen Y, 1996, J PHYSIOL-LONDON, V496, P129, DOI 10.1113/jphysiol.1996.sp021670; CLAUSTRE Y, 1988, EUR J PHARMACOL, V149, P149, DOI 10.1016/0014-2999(88)90054-4; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; DEVIVO M, 1986, J PHARMACOL EXP THER, V238, P248; Edagawa Y, 1998, EUR J PHARMACOL, V349, P221, DOI 10.1016/S0014-2999(98)00286-6; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; Enrich C, 1996, Z Gastroenterol, V34 Suppl 3, P83; Enyedi A, 1997, J BIOL CHEM, V272, P27525, DOI 10.1074/jbc.272.44.27525; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; Garnovskaya MN, 1997, J BIOL CHEM, V272, P7770, DOI 10.1074/jbc.272.12.7770; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; IKEN K, 1995, CELL IMMUNOL, V163, P1, DOI 10.1006/cimm.1995.1092; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Lembo PMC, 1995, MOL PHARMACOL, V48, P1024; Li HB, 2002, BIOCHEM J, V362, P499, DOI 10.1042/bj3620499; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; MAEKAWA S, 1994, J BIOL CHEM, V269, P19462; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; Maswood N, 1998, BRAIN RES, V802, P98, DOI 10.1016/S0006-8993(98)00554-X; Melien O, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-5; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; NEBIGIL CG, 1995, BIOCHEMISTRY-US, V34, P11954, DOI 10.1021/bi00037a037; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; Ramboz S, 1998, P NATL ACAD SCI USA, V95, P14476, DOI 10.1073/pnas.95.24.14476; RAYMOND JR, 1994, BIOCHEMISTRY-US, V33, P11264, DOI 10.1021/bi00203a023; RAYMOND JR, 1989, J BIOL CHEM, V264, P21943; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; Robertson DN, 2003, MOL PHARMACOL, V64, P1239, DOI 10.1124/mol.64.5.1239; Scaloni A, 1998, J MOL BIOL, V277, P945, DOI 10.1006/jmbi.1998.1629; SELETTI B, 1995, NEUROPSYCHOPHARMACOL, V13, P93; Shiah IS, 1998, NEUROPSYCHOBIOLOGY, V38, P6, DOI 10.1159/000026510; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; WEISS S, 1986, EUR J PHARMACOL, V120, P227, DOI 10.1016/0014-2999(86)90544-3; WILLIAMS R, 1995, BIOCHEM BIOPH RES CO, V216, P90, DOI 10.1006/bbrc.1995.2596; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; ZGOMBICK JM, 1989, MOL PHARMACOL, V35, P484	57	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17027	17037		10.1074/jbc.M313919200	http://dx.doi.org/10.1074/jbc.M313919200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14752100	hybrid			2022-12-27	WOS:000220870400019
J	Augustin, R; Carayannopoulos, MO; Dowd, LO; Phay, JE; Moley, JF; Moley, KH				Augustin, R; Carayannopoulos, MO; Dowd, LO; Phay, JE; Moley, JF; Moley, KH			Identification and characterization of human glucose transporter-like protein-9 (GLUT9) - Alternative splicing alters trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-INTESTINE; ADIPOSE-TISSUE; FAMILY; EXPRESSION; CLONING; NOMENCLATURE; SURFACE; SLC2A11; KIDNEY; MEMBER	The recently cloned human GLUT9 gene, which maps to chromosome 4p15.3-p16, consists of 12 exons coding for a 540-amino acid protein. Based on a sequence entry (NCBI accession number BC018897) and screening of expressed sequence tags, we have cloned an alternative splice variant of GLUT9 from human kidney cDNA. The RNA of this splice variant consists of 13 exons and codes for a putative protein of 512 amino acids (GLUT9DeltaN). The predicted proteins differ only in their N terminus, suggesting a different subcellular localization and possible physiological role. Screening human tissue RNA by reverse transcription-PCR showed that GLUT9 is expressed mainly in kidney, liver, placenta, and leukocytes, whereas GLUT9DeltaN was detected only in kidney and placenta. The GLUT9 protein localized by immunohistochemistry to human kidney proximal tubules, and subcellular fractionation of human kidney revealed the GLUT9 protein in plasma membranes and high density microsomal membranes. Treatment of kidney membrane proteins with peptide N-glycosidase F showed that GLUT9 and GLUT9DeltaN are expressed in vivo. Localization of GLUT9 and GLUT9DeltaN in three kidney-derived cell lines revealed a plasma membrane distribution for GLUT9 in COS-7 and HEK293 cells, whereas GLUT9DeltaN showed a perinuclear pattern and plasma membrane staining in COS-7 and HEK293 cells, respectively. In polarized Madin-Darby canine kidney cells, GLUT9 trafficked to the basolateral membrane, whereas GLUT9DeltaN localized to the apical membrane. Using heterologous expression of GLUT9 in Xenopus oocytes, GLUT9 appears to be a functional isoform with low affinity for deoxyglucose. Deoxyglucose transport mediated by GLUT9 was not inhibited by cytochalasin B. GLUT9 did not bind cytochalasin B as shown by a cytochalasin B binding assay, indicating a similar behavior of GLUT9 compared with GLUT5.	Washington Univ, Sch Med, Dept Obstet Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA	Washington University (WUSTL); Washington University (WUSTL); Vanderbilt University	Moley, KH (corresponding author), Washington Univ, Sch Med, Dept Obstet Gynecol, 4911 Barnes Jewish Hosp Plaza,Campus Box 8064, St Louis, MO 63110 USA.	moleyk@msnotes.wustl.edu	Phay, John E/E-3861-2011; Phay, John/K-7348-2019	Phay, John/0000-0002-8482-2137	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040390] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK059518] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA91842] Funding Source: Medline; NICHD NIH HHS [R01 HD040390] Funding Source: Medline; NIDDK NIH HHS [R21DK59518] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURANT CF, 1992, J BIOL CHEM, V267, P14523; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; Doege H, 2001, BIOCHEM J, V359, P443, DOI 10.1042/0264-6021:3590443; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Ibberson M, 2000, J BIOL CHEM, V275, P4607, DOI 10.1074/jbc.275.7.4607; INUKAI K, 1995, ENDOCRINOLOGY, V136, P4850, DOI 10.1210/en.136.11.4850; Joost HG, 2002, AM J PHYSIOL-ENDOC M, V282, pE974, DOI 10.1152/ajpendo.00407.2001; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KELLER K, 1989, J BIOL CHEM, V264, P18884; Ladd AN, 2002, GENOME BIOL, V3; Lalioti V, 2001, MOL MEMBR BIOL, V18, P257, DOI 10.1080/09687680110090780; Lisinski I, 2001, BIOCHEM J, V358, P517, DOI 10.1042/0264-6021:3580517; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Pascoe WS, 1996, AM J PHYSIOL-CELL PH, V271, pC547, DOI 10.1152/ajpcell.1996.271.2.C547; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; Quinones B, 1999, J CELL SCI, V112, P4291; Rogers S, 2002, AM J PHYSIOL-ENDOC M, V282, pE733, DOI 10.1152/ajpendo.2002.282.3.E733; Sasaki T, 2001, BIOCHEM BIOPH RES CO, V289, P1218, DOI 10.1006/bbrc.2001.6101; Schurmann A, 1997, BIOCHEMISTRY-US, V36, P12897, DOI 10.1021/bi971173c; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; ULDRY M, 2003, PFLUEGERS ARCH, V447, P480; Wood IS, 2003, BRIT J NUTR, V89, P3, DOI 10.1079/BJN2002763; Wu XH, 2002, GENOMICS, V80, P553, DOI 10.1006/geno.2002.7010; Wu XH, 2002, MOL GENET METAB, V76, P37, DOI 10.1016/S1096-7192(02)00018-5	28	206	222	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16229	16236		10.1074/jbc.M312226200	http://dx.doi.org/10.1074/jbc.M312226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14739288	hybrid			2022-12-27	WOS:000220747900066
J	Kizhatil, K; Bennett, V				Kizhatil, K; Bennett, V			Lateral membrane biogenesis in human bronchial epithelial cells requires 190-kDa ankyrin-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXON INITIAL SEGMENTS; ADHESION MOLECULE UVOMORULIN; LETHAL-GIANT-LARVAE; BETA-IV-SPECTRIN; PLASMA-MEMBRANE; COMPLEX; KIDNEY; POLARITY; EXPRESSION; SKELETON	Ankyrin-G polypeptides are required for restriction of voltage-gated sodium channels, L1 cell adhesion molecules, and beta IV spectrin to axon initial segments and are believed to couple the Na/K-ATPase to the spectrin-actin network at the lateral membrane in epithelial cells. We report here that depletion of 190-kDa ankyrin-G in human bronchial epithelial cells by small interfering RNA results in nearly complete loss of lateral plasma membrane in interphase cells, and also blocks de novo lateral membrane biogenesis following mitosis. Loss of the lateral membrane domain is accompanied by an expansion of apical and basal plasma membranes and preservation of apical-basal polarity. Expression of rat 190-kDa ankyrin-G, which is resistant to human small interfering RNA, prevents loss of the lateral membrane following depletion of human 190-kDa ankyrin-G. Human 220-kDa ankyrin-B, a closely related ankyrin isoform, is incapable of preserving the lateral membrane following 190-kDa ankyrin-G depletion. Moreover, analysis of rat 190-kDa ankyrin G/ankyrin B chimeras shows that all three domains of 190-kDa ankyrin-G are required for preservation of the lateral membrane. These results demonstrate that 190-kDa ankyrin-G plays a pleiotropic role in assembly of lateral membranes of bronchial epithelial cells.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Kizhatil, K (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3892, Durham, NC 27710 USA.	k.kizhatil@cellbio.duke.edu	Kizhatil, Krish/AAR-5868-2021	Kizhatil, Krishnakumar/0000-0003-3755-6101				Andrews HK, 2002, TRAFFIC, V3, P906, DOI 10.1034/j.1600-0854.2002.31206.x; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; Huotari V, 1996, J CELL PHYSIOL, V167, P121, DOI 10.1002/(SICI)1097-4652(199604)167:1<121::AID-JCP14>3.0.CO;2-E; Jenkins SM, 2002, P NATL ACAD SCI USA, V99, P2303, DOI 10.1073/pnas.042601799; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Knust E, 2002, SCIENCE, V298, P1955, DOI 10.1126/science.1072161; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Lecuit T, 2003, NAT CELL BIOL, V5, P103, DOI 10.1038/ncb0203-103; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Muller HAJ, 2003, DEV CELL, V4, P1, DOI 10.1016/S1534-5807(02)00408-2; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Norman KR, 2002, J CELL BIOL, V157, P665, DOI 10.1083/jcb.200111051; Otsuka AJ, 2002, J NEUROBIOL, V50, P333, DOI 10.1002/neu.10036; OTSUKA AJ, 1995, J CELL BIOL, V129, P1081, DOI 10.1083/jcb.129.4.1081; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; Pradhan D, 2001, J BIOL CHEM, V276, P4175, DOI 10.1074/jbc.M009259200; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; Sheth B, 2000, MECH DEVELOP, V97, P93, DOI 10.1016/S0925-4773(00)00416-0; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; Thevananther S, 1998, J BIOL CHEM, V273, P23952, DOI 10.1074/jbc.273.37.23952; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Woroniecki R, 2003, AM J PHYSIOL-RENAL, V284, pF358, DOI 10.1152/ajprenal.00100.2002; Wu HJ, 1998, J CELL SCI, V111, P2365; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	46	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16706	16714		10.1074/jbc.M314296200	http://dx.doi.org/10.1074/jbc.M314296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757759	hybrid			2022-12-27	WOS:000220747900123
J	Coughlan, CM; Walker, JL; Cochran, JC; Wittrup, KD; Brodsky, JL				Coughlan, CM; Walker, JL; Cochran, JC; Wittrup, KD; Brodsky, JL			Degradation of mutated bovine pancreatic trypsin inhibitor in the yeast vacuole suggests post-endoplasmic reticulum protein quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRANSMEMBRANE CONDUCTANCE REGULATOR; GONADOTROPIN-BETA-SUBUNIT; DISULFIDE BOND FORMATION; IG LIGHT-CHAINS; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; CARBOXYPEPTIDASE-Y; MOLECULAR CHAPERONES; SORTING RECEPTOR	The rate-limiting step in protein secretion is folding, which occurs in the endoplasmic reticulum (ER) lumen, and almost all secreted proteins contain disulfide bonds that form in the ER and stabilize the native state. Secreted proteins unable to fold may aggregate or they may be subject to ER-associated protein degradation. To examine the fate of aberrant forms of a well characterized, disulfide-bonded secreted protein, we expressed bovine pancreatic trypsin inhibitor in yeast. Bovine pancreatic trypsin inhibitor is a single domain, 58-amino acid polypeptide containing three disulfide bonds, and yeast cells secrete the wild type protein. In contrast, the Y35L mutant, which folds rapidly but is unstable, remains soluble and is not secreted. Surprisingly, the proteolysis of Y35L is unaffected in yeast containing mutations in genes encoding factors required for ER-associated protein degradation and is stable if artificially retained in the ER. Rather, Y35L is diverted from the Golgi to the vacuole and degraded. Because only the mutant protein is quantitatively proteolyzed these data suggest that a post-ER quality control check-point diverts unstable proteins to the vacuole for degradation.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; Univ Denver, Dept Biol Sci, Denver, CO 80208 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Denver	Brodsky, JL (corresponding author), Univ Pittsburgh, Dept Biol Sci, 274 Crawford Hall, Pittsburgh, PA 15260 USA.	jbrodsky@pitt.edu						Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Coughlan Christina M, 2003, Methods Mol Biol, V232, P77; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; Davis DP, 1999, J IMMUNOL, V163, P3842; DUNN A, 1995, BIOCHEM SOC T, V23, pS78, DOI 10.1042/bst023078s; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Ferreira T, 2002, J BIOL CHEM, V277, P21027, DOI 10.1074/jbc.M112281200; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; Hagihara Y, 2002, P NATL ACAD SCI USA, V99, P6619, DOI 10.1073/pnas.102172099; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Harty C, 2001, MOL BIOL CELL, V12, P1093, DOI 10.1091/mbc.12.4.1093; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Holkeri H, 1998, FEBS LETT, V429, P162, DOI 10.1016/S0014-5793(98)00586-9; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; HURLE MR, 1992, PROTEIN SCI, V1, P91; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1982, GENETICS, V102, P665; JONES EW, 1997, MOL CELLULAR BIOL YE, P363; Jorgensen MU, 1999, EUR J BIOCHEM, V260, P461, DOI 10.1046/j.1432-1327.1999.00176.x; Kabani M, 2003, MOL BIOL CELL, V14, P3437, DOI 10.1091/mbc.E02-12-0847; KANE PM, 1989, J CELL SCI, P161; Kimata Y, 2003, MOL BIOL CELL, V14, P2559, DOI 10.1091/mbc.E02-11-0708; Kjeldsen T, 2002, J BIOL CHEM, V277, P18245, DOI 10.1074/jbc.C200137200; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Kowalski JM, 1998, J BIOL CHEM, V273, P19453, DOI 10.1074/jbc.273.31.19453; Li Y, 1999, MOL CELL BIOL, V19, P3588; Loayza D, 1998, MOL CELL BIOL, V18, P779, DOI 10.1128/MCB.18.2.779; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; NADERI HM, 1991, CONFORMATIONS FORCES, P86; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; OMURA F, 1992, EUR J BIOCHEM, V205, P551, DOI 10.1111/j.1432-1033.1992.tb16812.x; PAREKH R, 1995, PROTEIN EXPRES PURIF, V6, P537, DOI 10.1006/prep.1995.1071; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SCHONBERGER O, 1991, MOL MICROBIOL, V5, P2663, DOI 10.1111/j.1365-2958.1991.tb01975.x; Sifers RN, 2003, SCIENCE, V299, P1330, DOI 10.1126/science.1082718; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; Spear ED, 2003, MOL BIOL CELL, V14, P2756, DOI 10.1091/mbc.E02-11-0717; Srivastava A, 2000, GENETICS, V156, P105; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Sullivan ML, 2003, J HISTOCHEM CYTOCHEM, V51, P545, DOI 10.1177/002215540305100417; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; TEHEESEN S, 1994, EUR J BIOCHEM, V222, P631; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VANMIERLO CPM, 1991, J MOL BIOL, V222, P353, DOI 10.1016/0022-2836(91)90216-S; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; WAGNER G, 1987, J MOL BIOL, V196, P227, DOI 10.1016/0022-2836(87)90524-9; WEISSMAN JS, 1995, NAT STRUCT BIOL, V2, P1123, DOI 10.1038/nsb1295-1123; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WLODAWER A, 1987, J MOL BIOL, V198, P469, DOI 10.1016/0022-2836(87)90294-4; Zhang BY, 2003, J BIOL CHEM, V278, P3687, DOI 10.1074/jbc.M209474200; Zhang BY, 2001, J CELL BIOL, V153, P1187, DOI 10.1083/jcb.153.6.1187; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	85	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15289	15297		10.1074/jbc.M309673200	http://dx.doi.org/10.1074/jbc.M309673200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744871	hybrid			2022-12-27	WOS:000220594700097
J	DeLong, LJ; Bonamy, GMC; Fink, EN; Allison, LA				DeLong, LJ; Bonamy, GMC; Fink, EN; Allison, LA			Nuclear export of the oncoprotein v-ErbA is mediated by acquisition of a viral nuclear export sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; DOMINANT-NEGATIVE ACTIVITY; C-ERBA; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; ONCOGENE PROTEIN; XENOPUS OOCYTES; RETINOIC ACID; A PROTEIN; IN-VIVO	v-ErbA, an oncogenic derivative of the thyroid hormone receptor alpha(TRalpha) carried by the avian erythroblastosis virus, contains several alterations including fusion of a portion of avian erythroblastosis virus Gag to its N terminus, N- and C-terminal deletions, and 13 amino acid substitutions. Nuclear export of v-ErbA occurs through a CRM1-mediated pathway. In contrast, nuclear export of TRalpha and another isoform, TRbeta, is CRM1-independent. To determine which amino acid changes in v-ErbA confer CRM1-dependent nuclear export, we expressed a panel of green and yellow fluorescent protein-tagged mutant and chimeric proteins in mammalian cells. The sensitivity of subcellular trafficking of these mutants to leptomycin B (LMB), a specific inhibitor of CRM1, was assessed by fluorescence microscopy. Our data showed that a nuclear export sequence resides within a 70-amino acid domain in the C-terminal portion of the p10 region of Gag, and in vitro binding assays demonstrated that Gag interacts directly with CRM1. However, a panel of ligand-binding domain mutants of v-ErbA lacking the Gag sequence exhibited greater nuclear localization in the presence of LMB, suggesting that the various amino acid substitutions/deletions may cause a conformation shift, unmasking an additional CRM1-dependent nuclear export sequence. In contrast, the altered DNA-binding domain of the oncoprotein did not contribute to CRM1-dependent nuclear export. Heterokaryon experiments revealed that v-ErbA did not undergo nucleocytoplasmic shuttling when the CRM1 export pathway was blocked by LMB treatment, suggesting that the ability to follow the export pathway used by TRalpha has been lost by the oncoprotein during its evolution. Our findings thus point to the intriguing possibility that acquisition of altered nuclear export capabilities contributes to the oncogenic properties of v-ErbA.	Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA; Univ Paris 07, F-75251 Paris, France	William & Mary; UDICE-French Research Universities; Universite Paris Cite	Allison, LA (corresponding author), Coll William & Mary, Dept Biol, POB 8795,Millington Hall 116, Williamsburg, VA 23187 USA.	laalli@wm.edu		Bonamy, Ghislain/0000-0002-2826-5225	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK058028] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK058028-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson ML, 2000, ONCOGENE, V19, P3563, DOI 10.1038/sj.onc.1203692; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOUCHER P, 1990, ONCOGENE, V5, P1303; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; Braliou GG, 2001, ONCOGENE, V20, P775, DOI 10.1038/sj.onc.1204159; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; Busch K, 1997, MOL ENDOCRINOL, V11, P379, DOI 10.1210/me.11.3.379; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Ciana P, 1998, EMBO J, V17, P7382, DOI 10.1093/emboj/17.24.7382; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FORREST D, 1990, ONCOGENE, V5, P309; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; GANDRILLON O, 1994, ONCOGENE, V9, P749; Harbers M, 2001, J BIOL CHEM, V276, P48596, DOI 10.1074/jbc.M108077200; HERMANN T, 1993, ONCOGENE, V8, P55; Holaska JM, 2002, MOL CELL BIOL, V22, P6286, DOI 10.1128/MCB.22.17.6286-6297.2002; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Li YZ, 1998, P NATL ACAD SCI USA, V95, P4864, DOI 10.1073/pnas.95.9.4864; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Mey A, 2002, ONCOGENE, V21, P2864, DOI 10.1038/sj.onc.1205411; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAGL SB, 1995, MOL ENDOCRINOL, V9, P1522, DOI 10.1210/me.9.11.1522; Nagl SB, 1997, J CELL BIOCHEM, V67, P184, DOI 10.1002/(SICI)1097-4644(19971101)67:2<184::AID-JCB4>3.3.CO;2-F; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Scheifele LZ, 2002, P NATL ACAD SCI USA, V99, P3944, DOI 10.1073/pnas.062652199; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; Shen Q, 2000, J BIOL CHEM, V275, P41018, DOI 10.1074/jbc.M006111200; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STUNNENBERG HG, 1998, BIOCHIM BIOPHYS ACTA, V1423, pF15; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; THORAVAL P, 1987, NUCLEIC ACIDS RES, V15, P9612, DOI 10.1093/nar/15.22.9612; Trapasso F, 1996, ONCOGENE, V12, P1879; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WONG CW, 1995, MOL ENDOCRINOL, V9, P551, DOI 10.1210/me.9.5.551; YEN PM, 1994, MOL ENDOCRINOL, V8, P1450, DOI 10.1210/me.8.11.1450; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	59	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15356	15367		10.1074/jbc.M308214200	http://dx.doi.org/10.1074/jbc.M308214200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729678	hybrid, Green Published			2022-12-27	WOS:000220594700105
J	Jensen, KP; Ryde, U				Jensen, KP; Ryde, U			How O-2 binds to heme - Reasons for rapid binding and spin inversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-FUNCTIONAL THERMOCHEMISTRY; SPERM WHALE MYOGLOBIN; IRON-OXYGEN BOND; ELECTRONIC-STRUCTURE; DIOXYGEN COMPLEXES; CORRELATION-ENERGY; CRYSTAL-STRUCTURES; HUMAN HEMOGLOBIN; LOW-TEMPERATURE; EXCITED-STATES	We have used density functional methods to calculate fully relaxed potential energy curves of the seven lowest electronic states during the binding of O-2 to a realistic model of ferrous deoxyheme. Beyond a Fe-O distance of similar to 2.5 Angstrom, we find a broad crossing region with five electronic states within 15 kJ/mol. The almost parallel surfaces strongly facilitate spin inversion, which is necessary in the reaction of O-2 with heme ( deoxyheme is a quintet and O-2 a triplet, whereas oxyheme is a singlet). Thus, despite a small spin-orbit coupling in heme, the transition probability approaches unity. Using reasonable parameters, we estimate a transition probability of 0.06-1, which is at least 15 times larger than for the nonbiological Fe-O+ system. Spin crossing is anticipated between the singlet ground state of bound oxyheme, the triplet and septet dissociation states, and a quintet intermediate state. The fact that the quintet state is close in energy to the dissociation couple is of biological importance, because it explains how both spin states of O-2 may bind to heme, thereby increasing the overall efficiency of oxygen binding. The activation barrier is estimated to be < 15 kJ/mol based on our results and Mossbauer experiments. Our results indicate that both the activation energy and the spin-transition probability are tuned by the porphyrin as well as by the choice of the proximal heme ligand, which is a histidine in the globins. Together, they may accelerate O-2 binding to iron by similar to 10(11) compared with the Fe-O+ system. A similar near degeneracy between spin states is observed in a ferric deoxyheme model with the histidine ligand hydrogen bonded to a carboxylate group, i.e. a model of heme peroxidases, which bind H2O2 in this oxidation state.	Lund Univ, Ctr Chem, Dept Theoret Chem, S-22100 Lund, Sweden	Lund University	Ryde, U (corresponding author), Lund Univ, Ctr Chem, Dept Theoret Chem, POB 124, S-22100 Lund, Sweden.	Ulf.Ryde@teokem.lu.se	Kepp, Kasper P./AAA-4626-2021; Ryde, Ulf/D-5882-2017; Kepp, Kasper Planeta/G-1748-2013	Kepp, Kasper P./0000-0002-6754-7348; Ryde, Ulf/0000-0001-7653-8489; Kepp, Kasper Planeta/0000-0002-6754-7348				Alrichs R., 1989, CHEM PHYS LETT, V162, P165; BADE D, 1978, Z NATURFORSCH C, V33, P488; BAUSCHLICHER CW, 1995, CHEM PHYS LETT, V246, P40, DOI 10.1016/0009-2614(95)01089-R; BECKE AD, 1992, J CHEM PHYS, V96, P2155, DOI 10.1063/1.462066; BECKE AD, 1993, J CHEM PHYS, V98, P1372, DOI 10.1063/1.464304; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; BYTHEWAY I, 1994, CHEM REV, V94, P639, DOI 10.1021/cr00027a005; CASE DA, 1979, J AM CHEM SOC, V101, P4433, DOI 10.1021/ja00510a001; CERDONIO M, 1977, P NATL ACAD SCI USA, V74, P398, DOI 10.1073/pnas.74.2.398; Danovich D, 1997, J AM CHEM SOC, V119, P1773, DOI 10.1021/ja963033g; DEDIEU A, 1976, J AM CHEM SOC, V98, P3717, DOI 10.1021/ja00428a060; EICHER H, 1976, J CHEM PHYS, V64, P1446, DOI 10.1063/1.432414; EYRING H, 1944, QUANTUM CHEM, P330; Feis A, 1998, J RAMAN SPECTROSC, V29, P933, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<933::AID-JRS319>3.0.CO;2-P; Franzen S, 2002, P NATL ACAD SCI USA, V99, P16754, DOI 10.1073/pnas.252590999; Gajhede M., 2001, HDB METALLOPROTEINS, P195; Ghosh A, 1998, ACCOUNTS CHEM RES, V31, P189, DOI 10.1021/ar950033x; GISMELSEED A, 1990, INORG CHEM, V29, P2741, DOI 10.1021/ic00340a008; GLASSTONE S, 1941, THEORY RATE PROCESSE, P149; Harvey JN, 2000, J AM CHEM SOC, V122, P12401, DOI 10.1021/ja005543n; Hertwig RH, 1997, CHEM PHYS LETT, V268, P345, DOI 10.1016/S0009-2614(97)00207-8; Howes BD, 1999, BIOPHYS J, V77, P478, DOI 10.1016/S0006-3495(99)76905-5; Howes BD, 2000, J BIOL INORG CHEM, V5, P227, DOI 10.1007/s007750050367; HUYNH BH, 1974, J CHEM PHYS, V61, P3750, DOI 10.1063/1.1682561; Indiani C, 2000, J INORG BIOCHEM, V79, P269, DOI 10.1016/S0162-0134(99)00156-7; JENSEN F, 1999, INTRO COMPUTATIONAL, P188; Jensen KP, 2003, MOL PHYS, V101, P2003, DOI 10.1080/0026897031000109383; Jensen KP, 2003, CHEMBIOCHEM, V4, P413, DOI 10.1002/cbic.200200449; Johansson MP, 2002, J AM CHEM SOC, V124, P11771, DOI 10.1021/ja026523j; KAIM W, 1994, BIOINORGANIC CHEM IN, P93; KAIM W, 1994, BIOINORGANIC CHEM IN, P84; KOTANI M, 1963, REV MOD PHYS, V35, P717, DOI 10.1103/RevModPhys.35.717; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Liao MS, 2002, J CHEM PHYS, V116, P3635, DOI 10.1063/1.1447902; MALTEMPO MM, 1979, BIOCHEMISTRY-US, V18, P2935, DOI 10.1021/bi00581a003; MALTEMPO MM, 1974, J CHEM PHYS, V61, P2540, DOI 10.1063/1.1682376; Marian CM, 2001, REV COMP CH, V17, P99, DOI 10.1002/0471224413.ch3; MCCLURE DS, 1960, RAD RES S, V2, pS218; MOMENTEAU M, 1994, CHEM REV, V94, P659, DOI 10.1021/cr00027a006; Moore C. E., 1971, ATOMIC ENERGY LEVELS, P56; Nakatsuji H, 1996, CHEM PHYS LETT, V250, P379, DOI 10.1016/0009-2614(96)00033-4; Niu SQ, 2000, CHEM REV, V100, P353, DOI 10.1021/cr980404y; Ozaki SI, 2001, ACCOUNTS CHEM RES, V34, P818, DOI 10.1021/ar9502590; PAPAEEFTHYMIOU GC, 1974, J CHEM PHYS, V62, P2995; Pauling L, 1936, P NATL ACAD SCI USA, V22, P210, DOI 10.1073/pnas.22.4.210; PAULING L, 1964, NATURE, V203, P182, DOI 10.1038/203182b0; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Poli R, 2003, CHEM SOC REV, V32, P1, DOI 10.1039/b200675h; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; Reed CA, 1996, J AM CHEM SOC, V118, P3281, DOI 10.1021/ja954263i; REED CA, 1979, J AM CHEM SOC, V101, P2948, DOI 10.1021/ja00505a023; Rovira C, 1997, J PHYS CHEM A, V101, P8914, DOI 10.1021/jp9722115; Rovira C, 2000, INT J QUANTUM CHEM, V80, P1172, DOI 10.1002/1097-461X(2000)80:6<1172::AID-QUA4>3.0.CO;2-E; Rovira C, 1998, INT J QUANTUM CHEM, V70, P387, DOI 10.1002/(SICI)1097-461X(1998)70:2<387::AID-QUA16>3.0.CO;2-9; Ryde U, 2003, J AM CHEM SOC, V125, P14232, DOI 10.1021/ja0365328; Schafer A, 2000, PHYS CHEM CHEM PHYS, V2, P2187, DOI 10.1039/b000184h; SCHAFER A, 1992, J CHEM PHYS, V97, P2571, DOI 10.1063/1.463096; SCHEIDT WR, 1981, CHEM REV, V81, P543, DOI 10.1021/cr00046a002; Siegbahn PEM, 1999, ANNU REV PHYS CHEM, V50, P221, DOI 10.1146/annurev.physchem.50.1.221; Siegbahn PEM, 2000, CHEM REV, V100, P421, DOI 10.1021/cr980390w; Sigfridsson E, 1999, J BIOL INORG CHEM, V4, P99, DOI 10.1007/s007750050293; Slater JC, 1930, PHYS REV, V36, P0057, DOI 10.1103/PhysRev.36.57; TSAI TE, 1981, J CHEM PHYS, V74, P4306, DOI 10.1063/1.441662; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; WEISS JJ, 1964, NATURE, V202, P83, DOI 10.1038/202083b0; YAMAMOTO S, 1989, CHEM PHYS LETT, V161, P85, DOI 10.1016/S0009-2614(89)87036-8	70	160	161	3	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14561	14569		10.1074/jbc.M314007200	http://dx.doi.org/10.1074/jbc.M314007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752099	hybrid			2022-12-27	WOS:000220594700013
J	Lloyd, MD; Lipscomb, SJ; Hewitson, KS; Hensgens, CMH; Baldwin, JE; Schofield, CJ				Lloyd, MD; Lipscomb, SJ; Hewitson, KS; Hensgens, CMH; Baldwin, JE; Schofield, CJ			Controlling the substrate selectivity of deacetoxycephalosporin/deacetylcephalosporin C synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC RING EXPANSION; STREPTOMYCES-CLAVULIGERUS; CLAVAMINATE SYNTHASE; ACTIVE-SITE; PENICILLIN; PURIFICATION; CEPHALOSPORINS; BIOSYNTHESIS; DIOXYGENASES; HYDROXYLASE	Deacetoxycephalosporin/deacetylcephalosporin C synthase (DAOC/DACS) is an iron(II) and 2-oxoglutarate-dependent oxygenase involved in the biosynthesis of cephalosporin C in Cephalosporium acremonium. It catalyzes two oxidative reactions, oxidative ring-expansion of penicillin N to deacetoxycephalosporin C, and hydroxylation of the latter to give deacetylcephalosporin C. The enzyme is closely related to deacetoxycephalosporin C synthase (DAOCS) and DACS from Streptomyces clavuligerus, which selectively catalyze ring-expansion or hydroxylation reactions, respectively. In this study, structural models based on DAOCS coupled with site-directed mutagenesis were used to identify residues within DAOC/DACS that are responsible for controlling substrate and reaction selectivity. The M306I mutation abolished hydroxylation of deacetylcephalosporin C, whereas the W82A mutant reduced ring-expansion of penicillin G ( an "unnatural" substrate). Truncation of the C terminus of DAOC/DACS to residue 310 (Delta310 mutant) enhanced ring-expansion of penicillin G by similar to2-fold. A double mutant, Delta310/M306I, selectively catalyzed the ring-expansion reaction and had similar kinetic parameters to the wild-type DAOC/DACS. The Delta310/N305L/ M306I triple mutant selectively catalyzed ring-expansion of penicillin G and had improved kinetic parameters (K-m = 2.00 +/- 0.47 compared with 6.02 +/- 0.97 mM for the wild-type enzyme). This work demonstrates that a single amino acid residue side chain within the DAOC/DACS active site can control whether the enzyme catalyzes ring-expansion, hydroxylation, or both reactions. The catalytic efficiency of mutant enzymes can be improved by combining active site mutations with other modifications including C-terminal truncation and modification of Asn-305.	Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Dept Chem, Oxford OX1 3TA, England; Oxford Ctr Mol Sci, Oxford OX1 3TA, England	University of Bath; University of Oxford	Lloyd, MD (corresponding author), Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.	M.D.Lloyd@bath.ac.uk	Lloyd, Matthew/AAX-6048-2021	Lloyd, Matthew/0000-0002-4821-4361; Schofield, Christopher/0000-0002-0290-6565				AHARONOWITZ Y, 1992, ANNU REV MICROBIOL, V46, P461, DOI 10.1146/annurev.mi.46.100192.002333; BALDWIN JE, 1987, TETRAHEDRON, V43, P3009, DOI 10.1016/S0040-4020(01)86840-X; BALDWIN JE, 1992, TETRAHEDRON, V48, P6853, DOI 10.1016/S0040-4020(01)89876-8; BALDWIN JE, 1993, TETRAHEDRON, V49, P7499, DOI 10.1016/S0040-4020(01)87226-4; BALDWIN JE, 1992, BIOORG MED CHEM LETT, V2, P663, DOI 10.1016/S0960-894X(00)80386-8; BALDWIN JE, 1987, BIOCHEM J, V245, P831, DOI 10.1042/bj2450831; BALDWIN JE, 1987, J CHEM SOC CHEM COMM, P374, DOI 10.1039/c39870000374; BALDWIN JE, 1991, BIOORG MED CHEM LETT, V1, P421, DOI 10.1016/S0960-894X(00)80269-3; BALDWIN JE, 1989, J CHEM SOC CHEM COMM, P1141, DOI 10.1039/c39890001141; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Chin HS, 2003, FEMS MICROBIOL LETT, V218, P251, DOI 10.1111/j.1574-6968.2003.tb11525.x; Chin HS, 2001, BIOCHEM BIOPH RES CO, V287, P507, DOI 10.1006/bbrc.2001.5552; Dubus A, 2001, CELL MOL LIFE SCI, V58, P835, DOI 10.1007/PL00000904; Hamilton CS, 2001, BIOORG MED CHEM LETT, V11, P2511, DOI 10.1016/S0960-894X(01)00470-X; Hedden P, 2000, TRENDS PLANT SCI, V5, P523, DOI 10.1016/S1360-1385(00)01790-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOVACEVIC S, 1989, J BACTERIOL, V171, P754, DOI 10.1128/jb.171.2.754-760.1989; KOVACEVIC S, 1991, J BACTERIOL, V173, P398, DOI 10.1128/jb.173.1.398-400.1991; Lee HJ, 2003, EUR J BIOCHEM, V270, P1301, DOI 10.1046/j.1432-1033.2003.03500.x; Lee HJ, 2002, BIOCHEM BIOPH RES CO, V292, P66, DOI 10.1006/bbrc.2002.6620; Lee HJ, 2000, BIOCHEM BIOPH RES CO, V267, P445, DOI 10.1006/bbrc.1999.1957; Lee HJ, 2001, J BIOL CHEM, V276, P18290, DOI 10.1074/jbc.M100085200; Lee HJ, 2001, J MOL BIOL, V308, P937, DOI 10.1006/jmbi.2001.4649; Lipscomb SJ, 2002, EUR J BIOCHEM, V269, P2735, DOI 10.1046/j.1432-1033.2002.02945.x; Lloyd MD, 1999, TETRAHEDRON, V55, P10201, DOI 10.1016/S0040-4020(99)00547-5; Lloyd MD, 1999, J MOL BIOL, V287, P943, DOI 10.1006/jmbi.1999.2594; Pavel EG, 1998, J AM CHEM SOC, V120, P743, DOI 10.1021/ja972408a; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Price JC, 2003, BIOCHEMISTRY-US, V42, P7497, DOI 10.1021/bi030011f; Price JC, 2003, J AM CHEM SOC, V125, P13008, DOI 10.1021/ja037400h; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEIDEGGER A, 1984, J ANTIBIOT, V37, P522, DOI 10.7164/antibiotics.37.522; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Shibata N, 1996, BIOORG MED CHEM LETT, V6, P1579, DOI 10.1016/S0960-894X(96)00278-8; TOWNSEND CA, 1984, J CHEM SOC CHEM COMM, P1586, DOI 10.1039/c39840001586; TOWNSEND CA, 1985, J AM CHEM SOC, V107, P4760, DOI 10.1021/ja00302a026; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Wei CL, 2003, APPL ENVIRON MICROB, V69, P2306, DOI 10.1128/AEM.69.4.2306-2312.2003; Zhou J, 1998, J AM CHEM SOC, V120, P13539, DOI 10.1021/ja983534x	43	23	26	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15420	15426		10.1074/jbc.M313928200	http://dx.doi.org/10.1074/jbc.M313928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14734549	hybrid			2022-12-27	WOS:000220594700112
J	Takezako, T; Gogonea, C; Saad, Y; Noda, K; Karnik, SS				Takezako, T; Gogonea, C; Saad, Y; Noda, K; Karnik, SS			''Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; AT(1) RECEPTOR; BINDING; INTERNALIZATION; ACTIVATION; RHODOPSIN; DISTINCT; PHOSPHORYLATION; CONFORMATION	A mechanistic understanding of the insurmountable antagonism of the angiotensin II type 1 (AT(1)) receptor could be fundamental in the quest for discovery and improvement of drugs. Candesartan and EXP3174 are competitive, reversible insurmountable antagonists of the AT(1) receptor. They contain di-acidic substitutions, whereas the surmountable antagonist, losartan, contains only one acidic group. We tested the hypothesis that these two classes of ligands interact with the AT(1) receptor through similar but not identical bonds and that the differences in the acid-base group contacts are critical for insurmountable antagonism. By pharmacological characterization of site-directed AT(1) receptor mutants expressed in COS1 cells we show that specific interactions with Gln(257) in transmembrane 6 distinguishes insurmountable antagonists and that abolishing these interactions transforms insurmountable to surmountable antagonism. In the Q257A mutant, the dissociation rate of [H-3] candesartan is 2.8-fold more than the rate observed with wild type, and the association rate was reduced 4-fold lower than the wild type. The pattern of antagonism of angiotensin II concentration-response in the Q257A mutant pretreated with EXP3174 and candesartan is surmountable. We propose that leaning ability of insurmountable antagonists on Gln(257) in the wildtype receptor is the basis of an antagonist-mediated conformational transition, which is responsible for both slow dissociation and inhibition of maximal IP response.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; Fukuoka Univ, Sch Med, Dept Cardiol, Jonan Ku, Fukuoka 8140180, Japan	Cleveland Clinic Foundation; Fukuoka University	Karnik, SS (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	karniks@ccf.org	Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057490] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL064845, R01 HL057470, HL57490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; CROZAT A, 1986, ENDOCRINOLOGY, V118, P2312, DOI 10.1210/endo-118-6-2312; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Fierens F, 1999, EUR J PHARMACOL, V367, P413, DOI 10.1016/S0014-2999(98)00965-0; GADDUM J H, 1955, Q J Exp Physiol Cogn Med Sci, V40, P49; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; Kenakin T, 2001, FASEB J, V15, P598, DOI 10.1096/fj.00-0438rev; KIVLIGHN SD, 1995, AM J PHYSIOL-REG I, V268, pR820, DOI 10.1152/ajpregu.1995.268.3.R820; Lew MJ, 2000, TRENDS PHARMACOL SCI, V21, P376, DOI 10.1016/S0165-6147(00)01523-6; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Morsing P, 1999, J AM SOC NEPHROL, V10, pS248; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Peleg G, 2001, P NATL ACAD SCI USA, V98, P8469, DOI 10.1073/pnas.151239698; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; Surya A, 1998, TRENDS PHARMACOL SCI, V19, P243; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; TIMMERMANS PB, 1999, CAN J CARDIOL S, VF, P26; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; WONG PC, 1990, J PHARMACOL EXP THER, V255, P211	27	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15248	15257		10.1074/jbc.M312728200	http://dx.doi.org/10.1074/jbc.M312728200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14754891	hybrid			2022-12-27	WOS:000220594700092
J	Gao, ZQ; Joseph, E; Ruden, DM; Lu, XY				Gao, ZQ; Joseph, E; Ruden, DM; Lu, XY			Drosophila Pkd2 is haploid-insufficient for mediating optimal smooth muscle contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; RYANODINE-RECEPTOR; CATION CHANNEL; VASCULAR EXPRESSION; SKELETAL-MUSCLE; MALE-FERTILITY; 2-HIT MODEL; PKD2; CELLS; GENE	Humans heterozygous for PKD1 or PKD2 develop autosomal dominant polycystic kidney disease, a common genetic disorder characterized by renal cyst formation and extrarenal complications such as hypertension and vascular aneurysms. Cyst formation requires the somatic inactivation of the wild type allele. However, it is unknown whether this recessive mechanism applies to life-threatening vascular aneurysms, which could involve weakening of the endothelial lining or surrounding vascular smooth muscle cells (SMCs). Drosophila Pkd2 at 33E3 (Pkd2) encodes a PKD2 family of Ca2+-activated Ca2+-permeable cation channels. We show here that loss-of-function Pkd2 mutations severely reduced the contractility of the visceral SMCs, which was restored by expressing wild type Pkd2 cDNA via a muscle-specific Gal4 driver. The effect of Pkd2 mutations alone on the skeletal muscle was minimal but was exacerbated by ryanodine-induced perturbation of intracellular Ca2+ stores. Consistent with this, Pkd2 interacted strongly with a ryanodine receptor mutation, causing a synergistic reduction of larval body wall contraction rate that is normally regulated through Ca2+ oscillation during excitation-contraction coupling in the skeletal muscle. These results suggest that PKD2 cooperates with the ryanodine receptor to promote optimal muscle contractility through intracellular Ca2+ homeostasis. Further genetic analysis indicated that Pkd2 is strongly haploinsufficient for normal SMC contractility. Since Ca2+ homeostasis is a conserved mechanism for optimal muscle performance, our results raise the possibility that inactivation of just one PKD2 copy is sufficient to compromise vascular SMC contractility and function in PKD2 heterozygous patients, thus explaining their increased susceptibility to hypertension and vascular aneurysms.	Univ Alabama, Dept Environm Hlth Sci, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Lu, XY (corresponding author), Univ Alabama, Dept Environm Hlth Sci, RPHB 623A,1530 3rd Ave S, Birmingham, AL 35294 USA.	xlu@uab.edu	Ruden, Douglas/ABE-1418-2021; Ruden, Douglas/A-5008-2016	Ruden, Douglas/0000-0002-0070-437X	NCI NIH HHS [R01 CA105349] Funding Source: Medline; NIAAA NIH HHS [R01 AA012276] Funding Source: Medline; NIDDK NIH HHS [P50-DK57301, R21-DK60821] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060821, P50DK057301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnaout MA, 2000, KIDNEY INT, V58, P2599, DOI 10.1046/j.1523-1755.2000.00446.x; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098; BRAND AH, 1993, DEVELOPMENT, V118, P401; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; Chen XZ, 2001, BIOCHEM BIOPH RES CO, V282, P1251, DOI 10.1006/bbrc.2001.4720; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gao ZQ, 2003, CURR BIOL, V13, P2175, DOI 10.1016/j.cub.2003.11.053; Gonzalez-Perrett S, 2002, J BIOL CHEM, V277, P24959, DOI 10.1074/jbc.M105084200; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Griffin MD, 1997, J AM SOC NEPHROL, V8, P616; Haycraft CJ, 2001, DEVELOPMENT, V128, P1493; Hoskins RA, 2001, GENOME RES, V11, P1100, DOI 10.1101/gr.GR-1780R; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Maryon EB, 1998, J CELL SCI, V111, P2885; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Pei Y, 1999, J AM SOC NEPHROL, V10, P1524; Perrone RD, 1997, KIDNEY INT, V51, P2022, DOI 10.1038/ki.1997.276; Perrone RD, 2001, AM J KIDNEY DIS, V38, P777, DOI 10.1053/ajkd.2001.27720; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian Q, 2003, J AM SOC NEPHROL, V14, P2280, DOI 10.1097/01.ASN.0000080185.38113.A3; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; Sharma Y, 2002, GENESIS, V34, P115, DOI 10.1002/gene.10127; Sullivan KMC, 2000, P NATL ACAD SCI USA, V97, P5942, DOI 10.1073/pnas.110145997; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Torres VE, 2001, J AM SOC NEPHROL, V12, P1, DOI 10.1681/ASN.V1211; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Watnick TJ, 2003, CURR BIOL, V13, P2179, DOI 10.1016/S0960-9822(03)00913-8; Watnick TJ, 1998, MOL CELL, V2, P247, DOI 10.1016/S1097-2765(00)80135-5; Wernig F, 2002, PROG BIOPHYS MOL BIO, V78, P105, DOI 10.1016/S0079-6107(02)00008-1; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161	38	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14225	14231		10.1074/jbc.M312223200	http://dx.doi.org/10.1074/jbc.M312223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732716	hybrid			2022-12-27	WOS:000220478500115
J	Gazo, BM; Murphy, P; Gatchel, JR; Browning, KS				Gazo, BM; Murphy, P; Gatchel, JR; Browning, KS			A novel interaction of cap-binding protein complexes eukaryotic initiation factor (eIF) 4F and eIF(iso)4F with a region in the 3 '-untranslated region of satellite tobacco necrosis virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL ENHANCER DOMAIN; RIBOSOME ENTRY SITE; MESSENGER-RNA; WHEAT-GERM; ARABIDOPSIS-THALIANA; ISOZYME FORM; NUCLEOTIDE-SEQUENCE; INDEPENDENT TRANSLATION; STIMULATES TRANSLATION; UNTRANSLATED REGIONS	Satellite tobacco necrosis virus (STNV) RNA is naturally uncapped at its 5' end and lacks polyadenylation at its 3' end. Despite lacking these two hallmarks of eukaryotic mRNAs, STNV-1 RNA is translated very efficiently. A similar to 130-nucleotide translational enhancer (TED), located 3' to the termination codon, is necessary for efficient cap-independent translation of STNV-1 RNA. The STNV-1 TED RNA fragment binds to the eukaryotic cap-binding complexes, initiation factor (eIF) 4F and eIF(iso) 4F, as measured by nitrocellulose binding and fluorescence titration. STNV-1 TED is a potent inhibitor of in vitro translation when added in trans. This inhibition is reversed by the addition of eIF4F or eIF( iso) 4F, and the subunits of eIF4F and eIF( iso) 4F cross-link to STNV-1 TED, providing additional evidence that these factors interact directly with STNV-1 TED. Deletion mutagenesis of the STNV-1 TED indicates that a minimal region of similar to100 nucleotides is necessary to promote cap-independent translation primarily through interaction with the cap binding subunits (eIF4E or eIF(iso) 4E) of eIF4F or eIF(iso) 4F.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Browning, KS (corresponding author), Univ Texas, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.	kbrowning@mail.utexas.edu		Gatchel, Jennifer/0000-0002-3892-9742				ALLEN ML, 1992, J BIOL CHEM, V267, P23232; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; BOKROS CL, 1995, P NATL ACAD SCI USA, V92, P7120, DOI 10.1073/pnas.92.15.7120; Bringloe DH, 1998, J GEN VIROL, V79, P1539, DOI 10.1099/0022-1317-79-6-1539; BROWNING KS, 1980, BIOCHEMISTRY-US, V19, P2276, DOI 10.1021/bi00551a044; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1988, J BIOL CHEM, V263, P8380; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; Bushell M, 2002, J CELL BIOL, V158, P395, DOI 10.1083/jcb.200205044; DANTHINNE X, 1991, VIROLOGY, V185, P605, DOI 10.1016/0042-6822(91)90531-F; DANTHINNE X, 1993, MOL CELL BIOL, V13, P3340, DOI 10.1128/MCB.13.6.3340; De Quinto SL, 2001, RNA, V7, P1213, DOI 10.1017/S1355838201010433; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; Gallie DR, 2002, PLANT MOL BIOL, V50, P949, DOI 10.1023/A:1021220910664; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Groft CM, 2002, MOL CELL, V9, P1273, DOI 10.1016/S1097-2765(02)00555-5; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Guo L, 2001, MOL CELL, V7, P1103, DOI 10.1016/S1097-2765(01)00252-0; Guo L, 2000, RNA, V6, P1808, DOI 10.1017/S1355838200001539; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HORST J, 1971, BIOCHEMISTRY-US, V10, P4748, DOI 10.1021/bi00801a022; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; KAEMPFER R, 1981, P NATL ACAD SCI-BIOL, V78, P1542, DOI 10.1073/pnas.78.3.1542; KASSANIS B, 1961, J GEN MICROBIOL, V25, P459, DOI 10.1099/00221287-25-3-459; KASSANIS B, 1970, J GEN VIROL, V9, P119, DOI 10.1099/0022-1317-9-2-119; KASSANIS B, 1962, J GEN MICROBIOL, V27, P477, DOI 10.1099/00221287-27-3-477; Kraemer B, 2000, METHOD ENZYMOL, V328, P297, DOI 10.1016/S0076-6879(00)28404-8; LAX SR, 1986, METHOD ENZYMOL, V118, P109; Lellis AD, 2002, CURR BIOL, V12, P1046, DOI 10.1016/S0960-9822(02)00898-9; Leonard S, 2000, J VIROL, V74, P7730, DOI 10.1128/JVI.74.17.7730-7737.2000; Leonard S, 2002, J GEN VIROL, V83, P2085, DOI 10.1099/0022-1317-83-8-2085; LEUNG DW, 1979, BIOCHEMISTRY-US, V18, P1361, DOI 10.1021/bi00574a036; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Marcotrigiano J, 2003, ADV PROTEIN CHEM, V61, P269; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; Mathews MB, 2002, TRENDS BIOCHEM SCI, V27, P267, DOI 10.1016/S0968-0004(02)02087-X; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; Metz AM, 1999, BIOCHEM BIOPH RES CO, V266, P314, DOI 10.1006/bbrc.1999.1814; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; Meulewaeter F, 1998, RNA, V4, P1347, DOI 10.1017/S135583829898092X; Meulewaeter F, 1998, PLANT J, V14, P169, DOI 10.1046/j.1365-313X.1998.00104.x; Nicaise V, 2003, PLANT PHYSIOL, V132, P1272, DOI 10.1104/pp.102.017855; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Rodriguez CM, 1998, PLANT J, V13, P465, DOI 10.1046/j.1365-313X.1998.00047.x; Ruffel S, 2002, PLANT J, V32, P1067, DOI 10.1046/j.1365-313X.2002.01499.x; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Sarnow P, 2003, J VIROL, V77, P2801, DOI 10.1128/JVI.77.5.2801-2806.2003; Schaad MC, 2000, VIROLOGY, V273, P300, DOI 10.1006/viro.2000.0416; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SMITH RE, 1979, BIOCHEMISTRY-US, V18, P1366, DOI 10.1021/bi00574a037; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; Urcuqui-Inchima S, 2001, VIRUS RES, V74, P157, DOI 10.1016/S0168-1702(01)00220-9; Van Lipzig R, 2002, RNA, V8, P229, DOI 10.1017/S1355838202018071; van Lipzig R, 2001, NUCLEIC ACIDS RES, V29, P1080, DOI 10.1093/nar/29.5.1080; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; Varani G, 2002, NAT STRUCT BIOL, V9, P158, DOI 10.1038/nsb0302-158; WANG SP, 1995, J BIOL CHEM, V270, P13446, DOI 10.1074/jbc.270.22.13446; Wang SP, 1999, RNA, V5, P728, DOI 10.1017/S1355838299981979; Wang SP, 1997, EMBO J, V16, P4107, DOI 10.1093/emboj/16.13.4107; Wittmann S, 1997, VIROLOGY, V234, P84, DOI 10.1006/viro.1997.8634; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; YSEBAERT M, 1980, J MOL BIOL, V143, P273, DOI 10.1016/0022-2836(80)90190-4	70	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13584	13592		10.1074/jbc.M311361200	http://dx.doi.org/10.1074/jbc.M311361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729906	hybrid			2022-12-27	WOS:000220478500038
J	Lai, WL; Chou, LY; Ting, CY; Kirby, R; Tsai, YC; Wang, AHJ; Liaw, SH				Lai, WL; Chou, LY; Ting, CY; Kirby, R; Tsai, YC; Wang, AHJ; Liaw, SH			The functional role of the binuclear metal center in D-aminoacylase - One-metal activation and second-metal attenuation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-FAECALIS DA1; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; STRUCTURAL-ANALYSIS; D-HYDANTOINASE; UREASE; PROTEINS; ZINC	Our structural comparison of the TIM barrel metal-dependent hydrolase(- like) superfamily suggests a classification of their divergent active sites into four types: alphabeta-binuclear, alpha-mononuclear, beta-mononuclear, and metal-independent subsets. The D-aminoacylase from Alcaligenes faecalis DA1 belongs to the beta-mononuclear subset due to the fact that the catalytically essential Zn2+ is tightly bound at the beta site with coordination by Cys(96), His(220), and His(250), even though it possesses a binuclear active site with a weak alpha binding site. Additional Zn2+, Cd2+, and Cu2+, but not Ni2+, Co2+, Mg2+, Mn2+, and Ca2+, can inhibit enzyme activity. Crystal structures of these metal derivatives show that Zn2+ and Cd2+ bind at the alpha(1) subsite ligated by His(67), His(69), and Asp(366), while Cu2+ at the alpha(2) subsite is chelated by His(67), His(69) and Cys96. Unexpectedly, the crystal structure of the inactive H220A mutant displays that the endogenous Zn2+ shifts to the alpha(3) subsite coordinated by His(67), His(69), Cys(96), and Asp(366), revealing that elimination of the beta site changes the coordination geometry of the alpha ion with an enhanced affinity. Kinetic studies of the metal ligand mutants such as C96D indicate the uniqueness of the unusual bridging cysteine and its involvement in catalysis. Therefore, the two metal-binding sites in the D-aminoacylase are interactive with partially mutual exclusion, thus resulting in widely different affinities for the activation/attenuation mechanism, in which the enzyme is activated by the metal ion at the beta site, but inhibited by the subsequent binding of the second ion at the alpha site.	Natl Yang Ming Univ, Dept Life Sci, Inst Biochem, Struct Biol Program, Taipei 11221, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 11221, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Liaw, SH (corresponding author), Natl Yang Ming Univ, Dept Life Sci, Inst Biochem, Struct Biol Program, Taipei 11221, Taiwan.	shliaw@ym.edu.tw						Abendroth J, 2002, J MOL BIOL, V320, P143, DOI 10.1016/S0022-2836(02)00422-9; Abendroth J, 2002, BIOCHEMISTRY-US, V41, P8589, DOI 10.1021/bi0157722; ASHWELL G, 1960, J BIOL CHEM, V235, P1559; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Benning MM, 2001, BIOCHEMISTRY-US, V40, P2712, DOI 10.1021/bi002661e; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchbinder JL, 1998, BIOCHEMISTRY-US, V37, P5096, DOI 10.1021/bi971707+; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; Cheon YH, 2002, BIOCHEMISTRY-US, V41, P9410, DOI 10.1021/bi0201567; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Dudev T, 2003, CHEM REV, V103, P773, DOI 10.1021/cr020467n; El Yazal J, 1999, J PHYS CHEM B, V103, P8773, DOI 10.1021/jp991787m; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; GomezOrtiz M, 1997, FEBS LETT, V400, P336, DOI 10.1016/S0014-5793(96)01412-3; HOLLAND DR, 1995, PROTEIN SCI, V4, P1955, DOI 10.1002/pro.5560041001; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; Hsu CS, 2002, PROTEIN SCI, V11, P2545, DOI 10.1110/ps.0220902; Hsu CS, 2002, ACTA CRYSTALLOGR D, V58, P1482, DOI 10.1107/S0907444902011046; Ireton GC, 2002, J MOL BIOL, V315, P687, DOI 10.1006/jmbi.2001.5277; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14225, DOI 10.1073/pnas.94.26.14225; Liaw SH, 2003, J BIOL CHEM, V278, P4957, DOI 10.1074/jbc.M210795200; Nitanai Y, 2002, J MOL BIOL, V321, P177, DOI 10.1016/S0022-2836(02)00632-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park IS, 1996, J BIOL CHEM, V271, P18632, DOI 10.1074/jbc.271.31.18632; Schwarzenbacher R, 2003, PROTEINS, V53, P142, DOI 10.1002/prot.10462; Thoden JB, 2003, BIOCHEMISTRY-US, V42, P4874, DOI 10.1021/bi034233p; Thoden JB, 2001, BIOCHEMISTRY-US, V40, P6989, DOI 10.1021/bi010682i; TSAI YC, 1992, ENZYME MICROB TECH, V14, P384, DOI 10.1016/0141-0229(92)90007-B; Vincent F, 2004, J BIOL CHEM, V279, P2809, DOI 10.1074/jbc.M310165200; Wakayama M, 2000, BIOSCI BIOTECH BIOCH, V64, P1, DOI 10.1271/bbb.64.1; WILLIAMS RJP, 1995, EUR J BIOCHEM, V234, P363, DOI 10.1111/j.1432-1033.1995.363_b.x; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Xu Z, 2003, J BACTERIOL, V185, P4038, DOI 10.1128/JB.185.14.4038-4049.2003; Yang W, 2002, PROTEINS, V47, P344, DOI 10.1002/prot.10093; YANG YB, 1992, BIOSCI BIOTECH BIOCH, V56, P1392, DOI 10.1271/bbb.56.1392; YANG YB, 1991, APPL ENVIRON MICROB, V57, P1259, DOI 10.1128/AEM.57.4.1259-1260.1991	39	40	40	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13962	13967		10.1074/jbc.M308849200	http://dx.doi.org/10.1074/jbc.M308849200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736882	hybrid			2022-12-27	WOS:000220478500083
J	Just, VJ; Stevenson, CEM; Bowater, L; Tanner, A; Lawson, DM; Bornemann, S				Just, VJ; Stevenson, CEM; Bowater, L; Tanner, A; Lawson, DM; Bornemann, S			A closed conformation of Bacillus subtilis oxalate decarboxylase OxdC provides evidence for the true identity of the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLYBIA-VELUTIPES; CARBON-DIOXIDE; OXALIC-ACID; OXIDASE; MANGANESE; OVEREXPRESSION; RESISTANCE; EVOLUTION; COMPLEX; CLONING	Oxalate decarboxylase (EC 4.1.1.2) catalyzes the conversion of oxalate to formate and carbon dioxide and utilizes dioxygen as a cofactor. By contrast, the evolutionarily related oxalate oxidase (EC 1.2.3.4) converts oxalate and dioxygen to carbon dioxide and hydrogen peroxide. Divergent free radical catalytic mechanisms have been proposed for these enzymes that involve the requirement of an active site proton donor in the decarboxylase but not the oxidase reaction. The oxidase possesses only one domain and manganese binding site per subunit, while the decarboxylase has two domains and two manganese sites per subunit. A structure of the decarboxylase together with a limited mutagenesis study has recently been interpreted as evidence that the C-terminal domain manganese binding site (site 2) is the catalytic site and that Glu-333 is the crucial proton donor (Anand, R., Dorrestein, P. C., Kinsland, C., Begley, T. P., and Ealick, S. E. (2002) Biochemistry 41, 7659-7669). The N-terminal binding site (site 1) of this structure is solvent-exposed (open) and lacks a suitable proton donor for the decarboxylase reaction. We report a new structure of the decarboxylase that shows a loop containing a 310 helix near site 1 in an alternative conformation. This loop adopts a "closed" conformation forming a lid covering the entrance to site 1. This conformational change brings Glu-162 close to the manganese ion, making it a new candidate for the crucial proton donor. Site-directed mutagenesis of equivalent residues in each domain provides evidence that Glu-162 performs this vital role and that the N-terminal domain is either the sole or the dominant catalytically active domain.	John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Bornemann, S (corresponding author), John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	Stephen.Bornemann@bbsrc.ac.uk	Bornemann, Stephen/K-2938-2012; Lawson, David M/D-1810-2009	Bornemann, Stephen/0000-0001-5930-9473; Bowater, Laura/0000-0003-3232-8062				Anand R, 2002, BIOCHEMISTRY-US, V41, P7659, DOI 10.1021/bi0200965; Azam M, 2002, BIOCHEM J, V367, P67, DOI 10.1042/BJ20011573; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; Cruickshank DWJ, 1996, MACROMOLECULAR REFIN, P11; DAHLENBURG L, 1986, J ORGANOMET CHEM, V308, P63, DOI 10.1016/S0022-328X(00)99522-6; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; Dutton MV, 1996, CAN J MICROBIOL, V42, P881, DOI 10.1139/m96-114; EMILIANI E, 1964, ARCH BIOCHEM BIOPHYS, V105, P488, DOI 10.1016/0003-9861(64)90040-2; HAYWARD PJ, 1970, J AM CHEM SOC, V92, P5873, DOI 10.1021/ja00723a010; Hodgkinson A., 1977, OXALIC ACID BIOL MED; Isse AA, 1999, ACTA CHEM SCAND, V53, P1013, DOI 10.3891/acta.chem.scand.53-1013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kesarwani M, 2000, J BIOL CHEM, V275, P7230, DOI 10.1074/jbc.275.10.7230; Khan S. R., 1995, CALCIUM OXALATE BIOL; Khuri S, 2001, MOL BIOL EVOL, V18, P593, DOI 10.1093/oxfordjournals.molbev.a003840; LANE BG, 1993, J BIOL CHEM, V268, P12239; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang HY, 2001, PLANT MOL BIOL, V45, P619, DOI 10.1023/A:1010631318831; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MASTRORILLI P, 1992, INORG CHIM ACTA, V192, P189, DOI 10.1016/S0020-1693(00)80758-6; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEHTA A, 1991, J BIOL CHEM, V266, P23548; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reinhardt LA, 2003, J AM CHEM SOC, V125, P1244, DOI 10.1021/ja0286977; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; Shimada M, 1997, J BIOTECHNOL, V53, P103, DOI 10.1016/S0168-1656(97)01679-9; SHIMAZONO H, 1955, J BIOCHEM-TOKYO, V42, P321, DOI 10.1093/oxfordjournals.jbchem.a126533; Tanner A, 2000, J BACTERIOL, V182, P5271, DOI 10.1128/JB.182.18.5271-5273.2000; Tanner A, 2001, J BIOL CHEM, V276, P43627, DOI 10.1074/jbc.M107202200; Whittaker MM, 2002, J BIOL INORG CHEM, V7, P136, DOI 10.1007/s007750100281; Woo EJ, 2000, NAT STRUCT BIOL, V7, P1036	35	75	79	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19867	19874		10.1074/jbc.M313820200	http://dx.doi.org/10.1074/jbc.M313820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14871895	hybrid			2022-12-27	WOS:000221164500060
J	Bornes, S; Boulard, M; Hieblot, C; Zanibellato, C; Iacovoni, JS; Prats, H; Touriol, C				Bornes, S; Boulard, M; Hieblot, C; Zanibellato, C; Iacovoni, JS; Prats, H; Touriol, C			Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; 3'-UNTRANSLATED REGION; FACTOR ISOFORMS; ERYTHROID-DIFFERENTIATION; BIOLOGICAL-PROPERTIES; VEGF ISOFORMS; FACTOR FAMILY; CUG CODONS; HNRNP-K; ANGIOGENESIS	The vascular endothelial growth factor-A ( VEGF) gene locus contains eight exons that span 14 kb. Alternative splicing generates multiple, different mRNAs that in turn translate into at least five protein isoforms. While the canonical AUG start codon is located at position 1039 in exon 1, there also exists an upstream, in-frame CUG initiation codon that drives expression of L-VEGF, containing an additional 180 amino acids. Two separate internal ribosome entry sites (IRES) regulate the activity of each initiation codon. Thus the 5'-UTR of VEGF, which comprises the majority of exon 1, consists of IRES B, the CUG, IRES A, and the AUG, from 5' to 3'. Previously, it has been shown that IRES B regulates initiation at the CUG and IRES A regulates AUG usage. In this study, we have found evidence that the exon content of the VEGF mRNA, determined through alternative splicing, controls IRES A activity. While the CUG is most efficient at initiating translation, transcripts that lack both exons 6 and 7 and therefore contain an exon 5/8 junction lack AUG-initiated translation. The process of splicing is not responsible for this start codon selection since transfection of genomic and cDNA VEGF sequences give the same expression pattern. We hypothesize that long range tertiary interactions in the VEGF mRNA regulate IRES activity and thus control start codon selection. This is the first report describing the influence of alternatively spliced coding sequences on codon selection by modulating IRES activity.	CHU Rangueil, Inst Federatif Rech Louis Bugnard, INSERM, U589, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, H (corresponding author), CHU Rangueil, Inst Federatif Rech Louis Bugnard, INSERM, U589, F-31403 Toulouse 04, France.	pratsh@toulouse.inserm.fr	Bornes, Stephanie/C-2142-2015; TOURIOL, Christian/O-8949-2014; Hieblot, Corinne/O-4734-2019; Boulard, Matthieu/H-8923-2017	TOURIOL, Christian/0000-0003-1219-4693; Prats, Herve/0000-0002-4861-2167; Bornes, Stephanie/0000-0003-3944-6192; Boulard, Matthieu/0000-0001-5135-8529				ANTHONY FW, 1994, PLACENTA, V15, P557, DOI 10.1016/S0143-4004(05)80424-2; Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; BRUCCOLERI RE, 1988, COMPUT APPL BIOSCI, V4, P167; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Galambos C, 2002, AM J RESP CELL MOL, V27, P194, DOI 10.1165/ajrcmb.27.2.4703; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Guo P, 2001, CANCER RES, V61, P8569; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Huez I, 2001, MOL ENDOCRINOL, V15, P2197, DOI 10.1210/me.15.12.2197; Iacovoni JS, 2003, BIOINFORMATICS, V19, P2316, DOI 10.1093/bioinformatics/btg304; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P7134, DOI 10.1073/pnas.92.15.7134; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; Lei JX, 1998, BBA-GENE STRUCT EXPR, V1443, P400, DOI 10.1016/S0167-4781(98)00240-1; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy NS, 1997, BBA-GENE STRUCT EXPR, V1352, P167, DOI 10.1016/S0167-4781(97)00052-3; Macke TJ, 2001, NUCLEIC ACIDS RES, V29, P4724, DOI 10.1093/nar/29.22.4724; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; Meiron M, 2001, BIOCHEM BIOPH RES CO, V282, P1053, DOI 10.1006/bbrc.2001.4684; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Stalmans I, 2003, NAT MED, V9, P173, DOI 10.1038/nm819; Stimpfl M, 2002, CLIN CANCER RES, V8, P2253; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Tee MK, 2001, BIOCHEM J, V359, P219, DOI 10.1042/0264-6021:3590219; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Touriol C, 1999, J BIOL CHEM, V274, P21402, DOI 10.1074/jbc.274.30.21402; Touriol C, 2000, J BIOL CHEM, V275, P19361, DOI 10.1074/jbc.M908431199; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; White FC, 1995, GROWTH FACTORS, V12, P289, DOI 10.3109/08977199509028967; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yue XP, 2001, AM J PHYSIOL-HEART C, V280, pH2240, DOI 10.1152/ajpheart.2001.280.5.H2240; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	52	50	61	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18717	18726		10.1074/jbc.M308410200	http://dx.doi.org/10.1074/jbc.M308410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14764596	hybrid			2022-12-27	WOS:000221041500078
J	Apetri, AC; Surewicz, K; Surewicz, WK				Apetri, AC; Surewicz, K; Surewicz, WK			The effect of disease-associated mutations on the folding pathway of human prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; CELL-FREE FORMATION; CONFORMATIONAL CONVERSION; THERMODYNAMIC STABILITY; STRUCTURAL CLUES; N-TERMINUS; INTERMEDIATE; YEAST; TRANSITION; MECHANISM	Propagation of transmissible spongiform encephalopathies is believed to involve the conversion of cellular prion protein, PrPC, into a misfolded oligomeric form, PrPSc. An important step toward understanding the mechanism of this conversion is to elucidate the folding pathway(s) of the prion protein. We reported recently (Apetri, A. C., and Surewicz, W. K. (2002) J. Biol. Chem. 277, 44589 - 44592) that the folding of wild-type prion protein can best be described by a three-state sequential model involving a partially folded intermediate. Here we have performed kinetic stopped-flow studies for a number of recombinant prion protein variants carrying mutations associated with familial forms of prion disease. Analysis of kinetic data clearly demonstrates the presence of partially structured intermediates on the refolding pathway of each PrP variant studied. In each case, the partially folded state is at least one order of magnitude more populated than the fully unfolded state. The present study also reveals that, for the majority of PrP variants tested, mutations linked to familial prion diseases result in a pronounced increase in the thermodynamic stability, and thus the population, of the folding intermediate. These data strongly suggest that partially structured intermediates of PrP may play a crucial role in prion protein conversion, serving as direct precursors of the pathogenic PrPSc isoform.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	wks3@po.cwru.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38604] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apetri AC, 2002, J BIOL CHEM, V277, P44589, DOI 10.1074/jbc.C200507200; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Caughey B, 2001, ADV VIRUS RES, V56, P277, DOI 10.1016/S0065-3527(01)56031-5; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; Fersht AR, 2000, P NATL ACAD SCI USA, V97, P14121, DOI 10.1073/pnas.260502597; Gambetti P, 1999, COLD SPRING HARBOR M, V38, P509; Holscher C, 1998, J VIROL, V72, P1153; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Khan F, 2003, J MOL BIOL, V333, P169, DOI 10.1016/j.jmb.2003.08.024; KHORASANIZADEH S, 1993, BIOCHEMISTRY-US, V32, P7054, DOI 10.1021/bi00078a034; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Krantz BA, 2000, BIOCHEMISTRY-US, V39, P11696, DOI 10.1021/bi000792+; Krantz BA, 2002, J MOL BIOL, V324, P359, DOI 10.1016/S0022-2836(02)01029-X; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Kuwata K, 2002, BIOCHEMISTRY-US, V41, P12277, DOI 10.1021/bi026129y; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Martins SM, 2003, J BIOL CHEM, V278, P50449, DOI 10.1074/jbc.M307354200; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Nicholson EM, 2002, J MOL BIOL, V316, P807, DOI 10.1006/jmbi.2001.5347; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Priola SA, 2001, ADV PROTEIN CHEM, V57, P1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raschke TM, 1999, NAT STRUCT BIOL, V6, P825; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; Sanchez IE, 2003, J MOL BIOL, V325, P367, DOI 10.1016/S0022-2836(02)01230-5; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Silow M, 1997, BIOCHEMISTRY-US, V36, P7633, DOI 10.1021/bi970210x; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Takei L, 2000, P NATL ACAD SCI USA, V97, P10796, DOI 10.1073/pnas.190265797; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Vanik DL, 2002, J BIOL CHEM, V277, P49065, DOI 10.1074/jbc.M207511200; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zhang YB, 2000, J BIOL CHEM, V275, P33650, DOI 10.1074/jbc.C000483200	57	128	128	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18008	18014		10.1074/jbc.M313581200	http://dx.doi.org/10.1074/jbc.M313581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761942	hybrid			2022-12-27	WOS:000220870400136
J	Bakouh, N; Benjelloun, F; Hulin, P; Brouillard, F; Edelman, A; Cherif-Zahar, B; Planelles, G				Bakouh, N; Benjelloun, F; Hulin, P; Brouillard, F; Edelman, A; Cherif-Zahar, B; Planelles, G			NH3 is involved in the NH4(+) transport induced by the functional expression of the human RhC glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; NH4+; SODIUM; IDENTIFICATION; DIFFUSION; NH3/NH4+; FAMILY; KIDNEY; ATPASE; RHAG	Renal ammonium (NH3 + NH4+) transport is a key process for body acid-base balance. It is well known that several ionic transport systems allow NH4+ transmembrane translocation without high specificity for NH4+, but it is still debated whether NH3, and more generally, gas, may be transported by transmembrane proteins. The human Rh glycoproteins have been proposed to mediate ammonium transport. Transport of NH4+ and/or NH3 by the epithelial Rh C glycoprotein (RhCG) may be of physiological importance in renal ammonium excretion because RhCG is mainly expressed in the distal nephron. However, RhCG function is not yet established. In the present study, we search for ammonium transport by RhCG. RhCG function was investigated by electrophysiological approaches in RhCG-expressing Xenopus laevis oocytes. In the submillimolar concentration range, NH4Cl exposure induced inward currents (I-AM) in voltage-clamped RhCG-expressing cells, but not in control cells. At physiological extracellular pH (pH(o)) = 7.5, the amplitude of I-AM increased with NH4Cl concentration and membrane hyperpolarization. The amplitude of I-AM was independent of external Na+ or K+ concentrations but was enhanced by alkaline pHo and decreased by acid pHo. The apparent affinity of RhCG for NH4+ was affected by NH3 concentration and by changing pHo, whereas the apparent affinity for NH3 was unchanged by pHo, consistent with direct NH3 involvement in RhCG function. The enhancement of methylammonium-induced current by NH3 further supported this conclusion. Exposure to 500 muM NH4Cl induced a biphasic intracellular pH change in RhCG-expressing oocytes, consistent with both NH3 and NH4+ enhanced influx. Our results support the hypothesis of a specific role for RhCG in NH3 and NH4+ transport.	Univ Paris 05, Fac Med Necker Enfants Malad, INSERM, U467, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Planelles, G (corresponding author), Univ Paris 05, Fac Med Necker Enfants Malad, INSERM, U467, 156 Rue Vaugirard, F-75015 Paris, France.	planelle@necker.fr	Planelles, Gabrielle/F-9603-2013	Planelles, Gabrielle/0000-0002-7314-8837; Cherif-Zahar, Baya/0000-0002-4965-7252				ANAGNOSTOPOULOS T, 1987, J PHYSIOL-LONDON, V393, P73, DOI 10.1113/jphysiol.1987.sp016811; Bissig KD, 2001, BIOL CHEM, V382, P711, DOI 10.1515/BC.2001.085; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BURCKHARDT BC, 1995, PFLUG ARCH EUR J PHY, V429, P306, DOI 10.1007/BF00374144; Chaudhry FA, 2001, EMBO J, V20, P7041, DOI 10.1093/emboj/20.24.7041; Chernova MN, 2003, AM J PHYSIOL-CELL PH, V284, pC1235, DOI 10.1152/ajpcell.00522.2002; Cooper GJ, 2002, J PHYSIOL-LONDON, V542, P17, DOI 10.1113/jphysiol.2002.023218; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; Cougnon M, 2002, AM J PHYSIOL-CELL PH, V282, pC1445, DOI 10.1152/ajpcell.00410.2001; Cougnon M, 1996, PFLUG ARCH EUR J PHY, V431, P658, DOI 10.1007/BF02191917; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; Eladari D, 2002, J AM SOC NEPHROL, V13, P1999, DOI 10.1097/01.ASN.0000025280.02386.9D; Liu Z, 2000, J BIOL CHEM, V275, P25641, DOI 10.1074/jbc.M003353200; Liu Z, 2001, J BIOL CHEM, V276, P1424, DOI 10.1074/jbc.M007528200; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Ludewig U, 2002, J BIOL CHEM, V277, P13548, DOI 10.1074/jbc.M200739200; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Matassi G, 1999, J MOL EVOL, V48, P151, DOI 10.1007/PL00006453; Matassi G, 1998, GENOMICS, V47, P286, DOI 10.1006/geno.1997.5112; Nakhoul NL, 2001, AM J PHYSIOL-RENAL, V281, pF255, DOI 10.1152/ajprenal.2001.281.2.F255; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; Prie D, 2002, NEW ENGL J MED, V347, P983, DOI 10.1056/NEJMoa020028; Rettinger J, 1999, PFLUG ARCH EUR J PHY, V437, P917, DOI 10.1007/s004240050863; Soupene E, 2002, P NATL ACAD SCI USA, V99, P7769, DOI 10.1073/pnas.112225599; Soupene E, 2002, P NATL ACAD SCI USA, V99, P3926, DOI 10.1073/pnas.062043799; Soupene E, 2001, MOL CELL BIOL, V21, P5733, DOI 10.1128/MCB.21.17.5733-5741.2001; Verlander JW, 2003, AM J PHYSIOL-RENAL, V284, pF323, DOI 10.1152/ajprenal.00050.2002; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200	32	101	102	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15975	15983		10.1074/jbc.M308528200	http://dx.doi.org/10.1074/jbc.M308528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761968	hybrid			2022-12-27	WOS:000220747900035
J	Cemazar, M; Zahariev, S; Pongor, S; Hore, PJ				Cemazar, M; Zahariev, S; Pongor, S; Hore, PJ			Oxidative folding of Amaranthus alpha-amylase inhibitor - Disulfide bond formation and conformational folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC RIBONUCLEASE-A; POTATO CARBOXYPEPTIDASE INHIBITOR; TICK ANTICOAGULANT PEPTIDE; CYSTINE KNOT MOTIF; GROWTH-FACTOR-I; TRYPSIN-INHIBITOR; HEN LYSOZYME; PHOTO-CIDNP; RESONANCE ASSIGNMENTS; STRUCTURAL-ANALYSIS	Oxidative folding is the fusion of native disulfide bond formation with conformational folding. This complex process is guided by two types of interactions: first, covalent interactions between cysteine residues, which transform into native disulfide bridges, and second, non-covalent interactions giving rise to secondary and tertiary protein structure. The aim of this work is to understand both types of interactions in the oxidative folding of Amaranthus alpha-amylase inhibitor (AAI) by providing information both at the level of individual disulfide species and at the level of amino acid residue conformation. The cystine-knot disulfides of AAI protein are stabilized in an interdependent manner, and the oxidative folding is characterized by a high heterogeneity of one-, two-, and three-disulfide intermediates. The formation of the most abundant species, the main folding intermediate, is favored over other species even in the absence of non-covalent sequential preferences. Time-resolved NMR and photochemically induced dynamic nuclear polarization spectroscopies were used to follow the oxidative folding at the level of amino acid residue conformation. Because this is the first time that a complete oxidative folding process has been monitored with these two techniques, their results were compared with those obtained at the level of an individual disulfide species. The techniques proved to be valuable for the study of conformational developments and aromatic accessibility changes along oxidative folding pathways. A detailed picture of the oxidative folding of AAI provides a model study that combines different biochemical and biophysical techniques for a fuller understanding of a complex process.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Oxford, Phys & Theoret Chem Lab, Oxford OX1 3QZ, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QZ, England	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Oxford; University of Oxford	Cemazar, M (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	cemazar@icgeb.org	Hore, Peter/R-1923-2017	Hore, Peter/0000-0002-8863-570X				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BIELY P, 1988, ANAL BIOCHEM, V172, P176, DOI 10.1016/0003-2697(88)90428-9; Carugo O, 2001, PROTEIN ENG, V14, P639, DOI 10.1093/protein/14.9.639; Cemazar M, 2003, P NATL ACAD SCI USA, V100, P5754, DOI 10.1073/pnas.2225470100; CHAGOLLALOPEZ A, 1994, J BIOL CHEM, V269, P23675; Chang JY, 2001, J BIOL CHEM, V276, P4845, DOI 10.1074/jbc.M005160200; Chang JY, 2000, J BIOL CHEM, V275, P8287, DOI 10.1074/jbc.275.12.8287; Chang JY, 1999, J BIOL CHEM, V274, P123, DOI 10.1074/jbc.274.1.123; CHANG JY, 1995, J BIOL CHEM, V270, P11992, DOI 10.1074/jbc.270.20.11992; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHANG JY, 1995, J BIOL CHEM, V270, P25661; Chang JY, 2002, J PROTEIN CHEM, V21, P203, DOI 10.1023/A:1015380902094; Chang JY, 2002, J BIOL CHEM, V277, P120, DOI 10.1074/jbc.M108057200; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; Chen HJ, 2000, BIOCHEMISTRY-US, V39, P12140, DOI 10.1021/bi000976o; Ciaffi M, 2001, GENE, V265, P147, DOI 10.1016/S0378-1119(01)00348-1; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; Escher SE, 1999, J PEPT RES, V54, P505, DOI 10.1034/j.1399-3011.1999.00125.x; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Goransson U, 2003, J BIOL CHEM, V278, P48188, DOI 10.1074/jbc.M308771200; Han YX, 1997, J ORG CHEM, V62, P4307, DOI 10.1021/jo9622744; HEITZ A, 1995, EUR J BIOCHEM, V233, P837, DOI 10.1111/j.1432-1033.1995.837_3.x; HORE PJ, 1993, PROG NUCL MAG RES SP, V25, P345, DOI 10.1016/0079-6565(93)80002-B; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Jarrett NM, 2002, PROTEIN SCI, V11, P2584, DOI 10.1110/ps.0221802; KAINUMA K, 1995, J BIOCHEM, V117, P208, DOI 10.1093/oxfordjournals.jbchem.a124712; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Kubo S, 1996, BIOPOLYMERS, V38, P733, DOI 10.1002/(SICI)1097-0282(199606)38:6<733::AID-BIP5>3.0.CO;2-S; Laity JH, 1997, BIOCHEMISTRY-US, V36, P12683, DOI 10.1021/bi970878b; Li CP, 1996, PLANT MOL BIOL, V30, P873, DOI 10.1007/BF00020800; Lozanov V, 1997, J PEPT RES, V50, P65; Lu SY, 1999, J BIOL CHEM, V274, P20473, DOI 10.1074/jbc.274.29.20473; Maeda K, 2000, J BIOMOL NMR, V16, P235, DOI 10.1023/A:1008351128089; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; Narayan M, 2000, ACCOUNTS CHEM RES, V33, P805, DOI 10.1021/ar000063m; Pearson MA, 1998, PROTEIN SCI, V7, P1255, DOI 10.1002/pro.5560070522; Pereira PJB, 1999, STRUCTURE, V7, P1079, DOI 10.1016/S0969-2126(99)80175-0; Peti W, 2001, J BIOMOL NMR, V19, P153, DOI 10.1023/A:1008307323283; Redfield C, 1999, NAT STRUCT BIOL, V6, P948, DOI 10.1038/13318; SCHEFFLER JE, 1985, J MAGN RESON, V63, P199, DOI 10.1016/0022-2364(85)90169-6; Scheraga HA, 2001, METHOD ENZYMOL, V341, P189, DOI 10.1016/S0076-6879(01)41153-0; Schultz CP, 2000, NAT STRUCT BIOL, V7, P7, DOI 10.1038/71197; SHIMONI Y, 1995, PLANT PHYSIOL, V108, P327, DOI 10.1104/pp.108.1.327; Shimotakahara S, 1997, BIOCHEMISTRY-US, V36, P6915, DOI 10.1021/bi963024k; SOFFE N, 1995, J MAGN RESON SER A, V116, P117, DOI 10.1006/jmra.1995.1197; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; TACHIBANA H, 1994, BIOCHEMISTRY-US, V33, P15008, DOI 10.1021/bi00254a009; Takemoto Y, 2002, PLANT PHYSIOL, V128, P1212, DOI 10.1104/pp.010624; van den Berg B, 1999, J MOL BIOL, V290, P781, DOI 10.1006/jmbi.1999.2915; van den Berg P, 1999, EMBO J, V18, P4794, DOI 10.1093/emboj/18.17.4794; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Welker E, 1999, FEBS LETT, V460, P477, DOI 10.1016/S0014-5793(99)01391-5; Welker E, 2001, P NATL ACAD SCI USA, V98, P2312, DOI 10.1073/pnas.041615798	59	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16697	16705		10.1074/jbc.M312328200	http://dx.doi.org/10.1074/jbc.M312328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14749333	hybrid			2022-12-27	WOS:000220747900122
J	Hoffmann, C; Pop, M; Leemhuis, J; Schirmer, J; Aktories, K; Schmidt, G				Hoffmann, C; Pop, M; Leemhuis, J; Schirmer, J; Aktories, K; Schmidt, G			The Yersinia pseudotuberculosis cytotoxic necrotizing factor (CNFY) selectively activates RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACTIVATION; DEAMIDATION; RAC	The cytotoxic necrotizing factors (CNF) 1 and CNF2 from pathogenic Escherichia coli strains activate RhoA, Rac1, and Cdc42 by deamidation of Gln(63) (RhoA) or Gln(61) (Rac and Cdc42). Recently, a novel cytotoxic necrotizing factor termed CNFY was identified in Yersinia pseudotuberculosis strains (Lockman, H. A., Gillespie, R. A., Baker, B. D., and Shakhnovich, E. (2002) Infect. Immun. 70, 2708 - 2714). We amplified the cnfy gene from genomic DNA of Y. pseudotuberculosis, cloned and expressed the recombinant protein, and studied its activity. Recombinant GST-CNFY induced morphological changes in HeLa cells and caused an upward shift of RhoA in SDS-PAGE, as is known for GST-CNF1 and GST-CNF2. Mass spectrometric analysis of GST-CNFY-treated RhoA confirmed deamidation at Glu(63). Treatment of RhoA, Rac1, and Cdc42 with GST-CNFY decreased their GTPase activities, indicating that all of these Rho proteins could serve as substrates for GST-CNFY in vitro. In contrast, RhoA, but not Rac or Cdc42, was the substrate of GST-CNFY in culture cells. GST-CNFY caused marked stress fiber formation in HeLa cells after 2 h. In contrast to GST-CNF1, formation of filopodia or lamellipodia was not induced with GST-CNFY. Accordingly, effector pull-down experiments with lysates of toxin-treated cells revealed strong activation of RhoA but no activation of Rac1 or Cdc42 after 6 h of GST-CNFY-treatment. Moreover, in rat hippocampal neurons, GST-CNFY results in the retraction of neurites, indicating RhoA activation. In contrast, no activation of Rac or Cdc42 was found. Altogether, our data suggest that CNFY from Y. pseudotuberculosis is a strong, selective activator of RhoA, which can be used as a powerful tool for constitutive RhoA activation without concomitant activation of Rac1 or Cdc42.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Schmidt, G (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albert Str 25, D-79104 Freiburg, Germany.	Gudula.Schmidt@uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Aktories K, 2003, TRENDS MICROBIOL, V11, P152, DOI 10.1016/S0966-842X(03)00042-8; Andor A, 2001, CELL MICROBIOL, V3, P301, DOI 10.1046/j.1462-5822.2001.00114.x; Benz I, 1998, J MEMBRANE BIOL, V161, P275, DOI 10.1007/s002329900334; Boutillier S, 2003, N-S ARCH PHARMACOL, V368, P513, DOI 10.1007/s00210-003-0830-4; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; COBURN J, 1989, J BIOL CHEM, V264, P9004; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Csosz E, 2002, MINERVA BIOTECNOL, V14, P149; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Lockman HA, 2002, INFECT IMMUN, V70, P2708, DOI 10.1128/IAI.70.5.2708-2714.2002; Ridley AJ, 2000, FR MOLEC B, V24, P89; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735	18	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16026	16032		10.1074/jbc.M313556200	http://dx.doi.org/10.1074/jbc.M313556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761941	hybrid			2022-12-27	WOS:000220747900041
J	Ishiyama, K; Inoue, E; Watanabe-Takahashi, A; Obara, M; Yamaya, T; Takahashi, H				Ishiyama, K; Inoue, E; Watanabe-Takahashi, A; Obara, M; Yamaya, T; Takahashi, H			Kinetic properties and ammonium-dependent regulation of cytosolic isoenzymes of glutamine synthetase in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; MEDIATED TRANSFORMATION; TRANSPORTER GENES; SPATIAL-PATTERNS; AMINO-ACIDS; ROOT HAIRS; LEAVES; THALIANA; NITROGEN; FAMILY	Glutamine synthetase (GS; EC 6.3.1.2) is a key enzyme of nitrogen assimilation, catalyzing the synthesis of glutamine from ammonium and glutamate. In Arabidopsis, cytosolic GS (GS1) was accumulated in roots when plants were excessively supplied with ammonium; however, the GS activity was controlled at a constant level. The discrepancy between the protein content and enzyme activity of GS1 was attributable to the kinetic properties and expression of four distinct isoenzymes encoded by GLN1;1, GLN1;2, GLN1;3 and GLN1;4, genes that function complementary to each other in Arabidopsis roots. GLN1;2 was the only isoenzyme significantly up-regulated by ammonium, which correlated with the rapid increase in total GS1 protein. GLN1;2 was localized in the vasculature and exhibited low affinities to ammonium (K-m=2450+/-150 muM) and glutamate (K-m=3.8+/-0.2 mM). The expression of the counterpart vascular tissue-localizing low affinity isoenzyme, GLN1; 3, was not stimulated by ammonium; however, the enzyme activity of GLN1;3 was significantly inhibited by a high concentration of glutamate. By contrast, the high affinity isoenzyme, GLN1;1 (K-m for ammonium < 10 mu M; K-m for glutamate=1.1 +/- 0.4 mM) was abundantly accumulated in the surface layers of roots during nitrogen limitation and was down-regulated by ammonium excess. GLN1;4 was another high affinity-type GS1 expressed in nitrogen-starved plants but was 10-fold less abundant than GLN1;1. These results suggested that dynamic regulations of high and low affinity GS1 isoenzymes at the levels of mRNA and enzyme activities are dependent on nitrogen availabilities and may contribute to the homeostatic control of glutamine synthesis in Arabidopsis roots.	RIKEN Plant Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Tohoku Univ, Grad Sch Agr Sci, Aoba Ku, Sendai, Miyagi 9818555, Japan	RIKEN; Tohoku University	Takahashi, H (corresponding author), RIKEN Plant Sci Ctr, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	hideki@postman.riken.go.jp	ISHIYAMA, Keiki/AAE-3978-2020; Takahashi, Hideki/D-4531-2009	ISHIYAMA, Keiki/0000-0001-9259-1271; Takahashi, Hideki/0000-0001-8439-0533; OBARA, Mitsuhiro/0000-0002-3728-9050				Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; COCK JM, 1990, PLANT MOL BIOL, V14, P549, DOI 10.1007/BF00027500; Dubois F, 1996, PLANT MOL BIOL, V31, P803, DOI 10.1007/BF00019468; EDWARDS JW, 1990, P NATL ACAD SCI USA, V87, P3459, DOI 10.1073/pnas.87.9.3459; FORDE BG, 1989, PLANT CELL, V1, P391, DOI 10.1105/tpc.1.4.391; Gazzarrini S, 1999, PLANT CELL, V11, P937, DOI 10.1105/tpc.11.5.937; GEBHARDT C, 1986, EMBO J, V5, P1429, DOI 10.1002/j.1460-2075.1986.tb04379.x; HIREL B, 1987, EMBO J, V6, P1167, DOI 10.1002/j.1460-2075.1987.tb02350.x; HOFGEN R, 1988, NUCLEIC ACIDS RES, V16, P9877, DOI 10.1093/nar/16.20.9877; INABA K, 1994, PLANT PHYSIOL, V104, P881, DOI 10.1104/pp.104.3.881; Ireland RJ, 1999, BOOK SOIL P, P49; KAMACHI K, 1992, PLANT PHYSIOL, V98, P1323, DOI 10.1104/pp.98.4.1323; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Lam HM, 1996, ANNU REV PLANT PHYS, V47, P569, DOI 10.1146/annurev.arplant.47.1.569; Lauter FR, 1996, P NATL ACAD SCI USA, V93, P8139, DOI 10.1073/pnas.93.15.8139; LI MG, 1993, PLANT MOL BIOL, V23, P401, DOI 10.1007/BF00029015; Mathur J, 1998, PLANT J, V13, P707, DOI 10.1046/j.1365-313X.1998.00059.x; MIAO GH, 1991, PLANT CELL, V3, P11, DOI 10.1105/tpc.3.1.11; Morey KJ, 2002, PLANT PHYSIOL, V128, P182, DOI 10.1104/pp.010380; OAKS A, 1985, ANNU REV PLANT PHYS, V36, P345; Oliveira IC, 1999, PLANT PHYSIOL, V121, P301, DOI 10.1104/pp.121.1.301; PETERMAN TK, 1991, MOL GEN GENET, V230, P145, DOI 10.1007/BF00290662; Rawat SR, 1999, PLANT J, V19, P143, DOI 10.1046/j.1365-313X.1999.00505.x; ROCHE D, 1993, PLANT MOL BIOL, V22, P971, DOI 10.1007/BF00028970; SAKAKIBARA H, 1992, PLANT CELL PHYSIOL, V33, P49; Sakakibara H, 1996, J BIOL CHEM, V271, P29561, DOI 10.1074/jbc.271.47.29561; SAKAMOTO A, 1989, PLANT MOL BIOL, V13, P611, DOI 10.1007/BF00027323; Sakurai N, 1996, PLANTA, V200, P306, DOI 10.1007/BF00200297; Sakurai N, 2001, PHYSIOL PLANTARUM, V113, P400, DOI 10.1034/j.1399-3054.2001.1130314.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sonoda Y, 2003, PLANT CELL PHYSIOL, V44, P726, DOI 10.1093/pcp/pcg083; Terce-Laforgue T, 1999, PLANT MOL BIOL, V39, P551, DOI 10.1023/A:1006169018296; TINGEY SV, 1987, EMBO J, V6, P1; Tobin AK, 2001, J EXP BOT, V52, P591, DOI 10.1093/jexbot/52.356.591; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; von Wiren N, 2000, PLANT J, V21, P167, DOI 10.1046/j.1365-313x.2000.00665.x; von Wiren N, 2000, CURR OPIN PLANT BIOL, V3, P254, DOI 10.1016/S1369-5266(00)00073-X; Wang RC, 2003, PLANT PHYSIOL, V132, P556, DOI 10.1104/pp.103.021253; Yoshimoto N, 2003, PLANT PHYSIOL, V131, P1511, DOI 10.1104/pp.014712	41	150	170	5	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16598	16605		10.1074/jbc.M313710200	http://dx.doi.org/10.1074/jbc.M313710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757761	hybrid			2022-12-27	WOS:000220747900110
J	Koo, AJK; Ohlrogge, JB; Pollard, M				Koo, AJK; Ohlrogge, JB; Pollard, M			On the export of fatty acids from the chloroplast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; COENZYME-A SYNTHETASE; BOVINE SERUM-ALBUMIN; OUTER-MEMBRANE; SACCHAROMYCES-CEREVISIAE; GLYCEROLIPID METABOLISM; PHOSPHOLIPID-BILAYERS; SPINACH-CHLOROPLASTS; ENVELOPE MEMBRANES; TRANSPORT PROTEIN	The model for export of fatty acids from plastids proposes that the acyl-ACP ( acyl carrier protein) product of de novo fatty acid synthesis is hydrolyzed in the stroma by acyl-ACP thioesterases and the free fatty acid (FFA) released is then transferred to the outer envelope of the plastid where it is reactivated to acyl-CoA for utilization in cytosolic glycerolipid synthesis. Experiments were performed to assess whether the delivery of nascent FFA from the stroma for long chain acyl-CoA synthesis (LACS) occurs via simple diffusion or a more complex mechanism. The flux through the in vivo FFA pool was estimated using kinetic labeling experiments with spinach and pea leaves. The maximum half-life for FFA in the export pool was less than or equal to 1 s. Isolated pea chloroplasts incubated in the light with [C-14] acetate gave a linear accumulation of FFA. When CoASH and ATP were present there was also a linear accumulation of acyl-CoA thioesters ( plus derived polar lipids), with no measurable lag phase (< 30 s), indicating that the FFA pool supplying LACS rapidly reached steady state. The LACS reaction was also measured independently in the dark after in situ generated FFA had accumulated yielding estimates of LACS substrate-velocity relationships. Based on these experiments the LACS reaction with in situ generated FFA as substrate is only about 3% of the LACS activity required in vivo at the very low concentrations of the FFA export pool calculated from the in vivo experiment. Furthermore, bovine serum albumin rapidly removed in situ generated FFA from chloroplasts, but could not compete effectively for "nascent" FFA substrates of LACS. Together the data suggest a locally channeled pool of exported FFA that is closely linked to LACS.	Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University	Pollard, M (corresponding author), Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA.	pollard9@msu.edu	Koo, Abraham J/H-9721-2017	Koo, Abraham/0000-0003-2162-2987				Abumrad N, 1998, J LIPID RES, V39, P2309; ANDREWS J, 1983, PLANT PHYSIOL, V72, P735, DOI 10.1104/pp.72.3.735; [Anonymous], METHODS CHLOROPLAST; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Bao XM, 2000, PLANT J, V22, P39, DOI 10.1046/j.1365-313x.2000.00712.x; BLOCK MA, 1983, FEBS LETT, V153, P377, DOI 10.1016/0014-5793(83)80647-4; BROWSE J, 1981, BIOCHEM J, V196, P347, DOI 10.1042/bj1960347; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; Engeseth NJ, 1996, ARCH BIOCHEM BIOPHYS, V331, P55, DOI 10.1006/abbi.1996.0282; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; GARDINER SE, 1984, PLANT PHYSIOL, V74, P890, DOI 10.1104/pp.74.4.890; HAMILTON JA, 1984, P NATL ACAD SCI-BIOL, V81, P3718, DOI 10.1073/pnas.81.12.3718; Hamilton JA, 1998, J LIPID RES, V39, P467; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HEBER U, 1981, ANNU REV PLANT PHYS, V32, P139, DOI 10.1146/annurev.pp.32.060181.001035; HEINZ E, 1983, PLANT PHYSIOL, V72, P273, DOI 10.1104/pp.72.2.273; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; Hettema EH, 2000, BBA-MOL CELL BIOL L, V1486, P18, DOI 10.1016/S1388-1981(00)00045-7; Johnson PE, 2002, PLANTA, V215, P515, DOI 10.1007/s00425-002-0788-3; JOYARD J, 1981, PLANT PHYSIOL, V67, P250, DOI 10.1104/pp.67.2.250; KAHN MU, 1977, J CHROMATOGR, V140, P179; Kamp F, 2003, J BIOL CHEM, V278, P7988, DOI 10.1074/jbc.M206648200; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kleinfeld AM, 1998, BIOCHEMISTRY-US, V37, P8011, DOI 10.1021/bi980301+; KLEINFELD AM, 1997, BIOCHEMISTRY-US, V36, P14140; Koo AJK, 2002, PLANT PHYSIOL, V130, P823, DOI 10.1104/pp.008052; KUMAR GB, 1993, J BIOL CHEM, V268, P15469; LILLEY RM, 1975, NEW PHYTOL, V75, P1, DOI 10.1111/j.1469-8137.1975.tb01365.x; MANGROO D, 1992, J BIOL CHEM, V267, P17095; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; OHLROGGE JB, 1979, P NATL ACAD SCI USA, V76, P1194, DOI 10.1073/pnas.76.3.1194; PARKS JS, 1983, J BIOL CHEM, V258, P9262; Pollard M, 1999, PLANT PHYSIOL, V121, P1217, DOI 10.1104/pp.121.4.1217; ROUGHAN PG, 1980, BIOCHEM J, V188, P17, DOI 10.1042/bj1880017; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; Roughan PG, 1996, PLANT PHYSIOL, V110, P1239, DOI 10.1104/pp.110.4.1239; ROUGHAN PG, 1977, BIOCHEM J, V162, P457, DOI 10.1042/bj1620457; ROUGHAN PG, 1981, FEBS LETT, V135, P182, DOI 10.1016/0014-5793(81)80972-6; ROUGHAN PG, 1980, PLANT SCI LETT, V18, P221; ROUGHAN PG, 1979, BIOCHEM J, V184, P193, DOI 10.1042/bj1840193; ROUGHAN PG, 1987, METHOD ENZYMOL, V148, P327; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schnurr JA, 2002, PLANT PHYSIOL, V129, P1700, DOI 10.1104/pp.003251; SHINE WE, 1976, ARCH BIOCHEM BIOPHYS, V172, P110, DOI 10.1016/0003-9861(76)90054-0; Shockey JM, 2002, PLANT PHYSIOL, V129, P1710, DOI 10.1104/pp.003269; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; Thelen JJ, 2002, ARCH BIOCHEM BIOPHYS, V400, P245, DOI 10.1016/S0003-9861(02)00025-5; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	54	106	117	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16101	16110		10.1074/jbc.M311305200	http://dx.doi.org/10.1074/jbc.M311305200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764601	hybrid			2022-12-27	WOS:000220747900051
J	Noorwez, SM; Malhotra, R; McDowell, JH; Smith, KA; Krebs, MP; Kaushal, S				Noorwez, SM; Malhotra, R; McDowell, JH; Smith, KA; Krebs, MP; Kaushal, S			Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN MUTATIONS; AGGRESOME FORMATION; INTRADISCAL DOMAIN; BOVINE RHODOPSIN; METARHODOPSIN-II; POINT MUTANTS; G-PROTEIN; DISEASE; CHROMOPHORE; STABILITY	The clinically common mutant opsin P23H, associated with autosomal dominant retinitis pigmentosa, yields low levels of rhodopsin when retinal is added following induction of the protein in stably transfected HEK-293 cells. We previously showed that P23H rhodopsin levels could be increased by providing a 7-membered ring, locked analog of 11-cis-retinal during expression of P23H opsin in vivo. Here we demonstrate that the mutant opsin is effectively rescued by 9- or 11-cis-retinal, the native chromophore. When retinal was added during expression, P23H rhodopsin levels were 5-fold (9-cis) and 6-fold (11-cis) higher than when retinal was added after opsin was expressed and cells were harvested. Levels of P23H opsin were increased similar to3.5-fold with both compounds, but wild-type protein levels were only slightly increased. Addition of retinal during induction promoted the Golgi-specific glycosylation of P23H opsin and transport of the protein to the cell surface. P23H rhodopsins containing 9- or 11-cis-retinal had blue-shifted absorption maxima and altered photo-bleaching properties compared with the corresponding wild-type proteins. Significantly, P23H rhodopsins were more thermally unstable than the wild-type proteins and more rapidly bleached by hydroxylamine in the dark. We suggest that P23H opsin is similarly unstable and that retinal binds and stabilizes the protein early in its biogenesis to promote its cellular folding and trafficking. The implications of this study for treating retinitis pigmentosa and other protein conformational disorders are discussed.	Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA	State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; Illinois State University	Kaushal, S (corresponding author), Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.	skaushal@ufl.edu		Krebs, Mark/0000-0001-9017-6066				Andres A, 2003, BIOCHEM BIOPH RES CO, V303, P294, DOI 10.1016/S0006-291X(03)00328-0; Bicknell IR, 2002, MOL VIS, V8, P333; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; DEFOE DM, 1983, INVEST OPHTH VIS SCI, V24, P1211; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P256; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; Dryja TP, 2000, AM J OPHTHALMOL, V130, P547, DOI 10.1016/S0002-9394(00)00737-6; Farrar GJ, 2002, EMBO J, V21, P857, DOI 10.1093/emboj/21.5.857; Garriga P, 2002, FEBS LETT, V528, P17, DOI 10.1016/S0014-5793(02)03241-6; GROENENDIJK GWT, 1980, BIOCHIM BIOPHYS ACTA, V617, P430, DOI 10.1016/0005-2760(80)90009-0; HALL MO, 1969, J MOL BIOL, V45, P397, DOI 10.1016/0022-2836(69)90114-4; Harada M, 2001, GASTROENTEROLOGY, V120, P967, DOI 10.1053/gast.2001.22543; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KHAN SMA, 1991, EUR J BIOCHEM, V200, P53, DOI 10.1111/j.1432-1033.1991.tb21047.x; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KITO Y, 1968, NATURE, V218, P955, DOI 10.1038/218955a0; Landin JS, 2001, BIOCHEMISTRY-US, V40, P11176, DOI 10.1021/bi0100539; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; Morello JP, 2000, TRENDS PHARMACOL SCI, V21, P466, DOI 10.1016/S0165-6147(00)01575-3; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; OBRIEN PJ, 1972, BIOCHEMISTRY-US, V11, P64, DOI 10.1021/bi00751a012; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; Saliba RS, 2002, J CELL SCI, V115, P2907; SMITH WC, 1990, J MOL EVOL, V30, P72, DOI 10.1007/BF02102454; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; STJULES RS, 1989, EXP EYE RES, V48, P653, DOI 10.1016/0014-4835(89)90007-9; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Wang WJ, 2003, J CELL SCI, V116, P683, DOI 10.1242/jcs.00267	41	126	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16278	16284		10.1074/jbc.M312101200	http://dx.doi.org/10.1074/jbc.M312101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14769795	hybrid			2022-12-27	WOS:000220747900072
J	Wagner, CT; Lu, IY; Hoffman, MH; Sun, WQ; Trent, JD; Connor, J				Wagner, CT; Lu, IY; Hoffman, MH; Sun, WQ; Trent, JD; Connor, J			T-complex polypeptide-1 interacts with the erythrocyte cytoskeleton in response to elevated temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GROUP-II CHAPERONIN; EUKARYOTIC CHAPERONIN; MOLECULAR CHAPERONE; MEMBRANE SKELETON; YEAST TCP1; IN-VIVO; THERMOTOLERANCE; CELL; LOCALIZATION	Chaperonins are double ring complexes composed of highly conserved 60-kDa protein subunits that are divided into two subgroups. Group II chaperonins are found in archaea and the cytoplasm of eukarya and are believed to function like other chaperonins as part of a protein folding system. We report here that human erythrocytes contain the group II chaperonin T-complex polypeptide 1 (TCP-1) and that this complex translocates from the cytoplasm to the cytoskeleton in response to heat treatment in the absence of overt cell damage. Identification as TCP-1 was determined by immunodetection for TCP-1alpha and corroborated by mass spectroscopy peptide sequencing. Direct visualization by immunofluorescence confirmed peripherally localized TCP-1 in response to heat treatment. Temperatures ranging from 37-50degreesC were demonstrated to have distinct kinetic profiles of induced translocation. Heat-induced binding was shown by Triton shell analysis to be specifically associated with the cytoskeletal proteins. Furthermore, the binding was reversible following removal of the stimulatory condition. A stabilizing process is hypothesized based on the known interactions of chaperonins.	LifeCell Corp, Branchburg, NJ 08876 USA; NASA, Astrobiol & Technol Branch, Ames Res Ctr, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Wagner, CT (corresponding author), LifeCell Corp, 1 Millennium Way, Branchburg, NJ 08876 USA.	cwagner@lifecell.com						BRECHER ME, 2002, TECHNICAL MANUAL, P733; Chow KC, 1998, BIOCHEM BIOPH RES CO, V253, P502, DOI 10.1006/bbrc.1998.9766; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; Ellis RJ, 1999, CURR BIOL, V9, pR137; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FISHER B, 1992, CANCER RES, V52, P2854; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Garduno RA, 1998, J BACTERIOL, V180, P505; GERSHFELD NL, 1988, J MEMBRANE BIOL, V101, P67, DOI 10.1007/BF01872821; Greenwalt TJ, 1997, TRANSFUSION, V37, P269, DOI 10.1046/j.1537-2995.1997.37397240208.x; GROMOV PS, 1991, EXP CELL RES, V195, P556, DOI 10.1016/0014-4827(91)90412-N; Gross C, 1996, BIOCHEM BIOPH RES CO, V220, P766, DOI 10.1006/bbrc.1996.0478; GUDI SRP, 1990, BIOCHIM BIOPHYS ACTA, V1023, P63, DOI 10.1016/0005-2736(90)90010-L; GUDI T, 1993, J BIOL CHEM, V268, P21344; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HO KC, 1991, RADIAT RES, V125, P20, DOI 10.2307/3577977; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; Kagawa HK, 2003, MOL MICROBIOL, V48, P143, DOI 10.1046/j.1365-2958.2003.03418.x; KIFOR G, 1993, J MEMBRANE BIOL, V134, P169; KOTER M, 1989, INT J RADIAT BIOL, V56, P59, DOI 10.1080/09553008914551181; KOTER M, 1993, CELL BIOL INT, V17, P665, DOI 10.1006/cbir.1993.1116; KOZWIAK Z, 1991, INT J RADIAT BIOL, V59, P479; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; KUBOTA H, 1997, GUIDEBOOK MOL CHAPER, P207; KUMAR A, 1990, BIOCHIM BIOPHYS ACTA, V1030, P269, DOI 10.1016/0005-2736(90)90303-6; LASZLO A, 1988, EXP CELL RES, V178, P401, DOI 10.1016/0014-4827(88)90409-0; LEE YJ, 1987, J CELL PHYSIOL, V132, P41, DOI 10.1002/jcp.1041320106; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; Mohandas N., 1978, RED CELL, P453; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Norcum MT, 1996, PROTEIN SCI, V5, P1366, DOI 10.1002/pro.5560050715; PARKES JL, 1989, ARCH BIOCHEM BIOPHYS, V275, P459, DOI 10.1016/0003-9861(89)90392-5; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Ruggero D, 1998, EMBO J, V17, P3471, DOI 10.1093/emboj/17.12.3471; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANDERS BM, 1993, CRIT REV TOXICOL, V23, P49, DOI 10.3109/10408449309104074; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schluter A, 2000, BBA-GENE STRUCT EXPR, V1491, P65, DOI 10.1016/S0167-4781(00)00028-2; Schoehn G, 2000, J MOL BIOL, V301, P323, DOI 10.1006/jmbi.2000.3952; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Stoldt V, 1996, YEAST, V12, P523, DOI 10.1002/(SICI)1097-0061(199605)12:6<523::AID-YEA962>3.3.CO;2-3; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; Torok Z, 1997, P NATL ACAD SCI USA, V94, P2192, DOI 10.1073/pnas.94.6.2192; Trent JD, 1997, P NATL ACAD SCI USA, V94, P5383, DOI 10.1073/pnas.94.10.5383; Trent JD, 2003, P NATL ACAD SCI USA, V100, P15589, DOI 10.1073/pnas.2136795100; Trent JD, 1998, ANN NY ACAD SCI, V851, P36, DOI 10.1111/j.1749-6632.1998.tb08974.x; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; URSIC D, 1992, NATURE, V356, P392; VANBOGELEN RA, 1987, GENE DEV, V1, P525, DOI 10.1101/gad.1.6.525; VANDERWALT JH, 1978, BRIT J ANAESTH, V50, P815, DOI 10.1093/bja/50.8.815; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; Wagner CT, 2003, TRANSFUSION, V43, p66A; Wagner CT, 2002, CRYOBIOLOGY, V45, P153, DOI 10.1016/S0011-2240(02)00124-4; Wagner CT, 2000, CRYOBIOLOGY, V41, P178, DOI 10.1006/cryo.2000.2279; WATSON K, 1990, ADV MICROB PHYSIOL, V31, P183; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zaric J, 1998, MOL CELL BIOCHEM, V178, P119, DOI 10.1023/A:1006877026611	62	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16223	16228		10.1074/jbc.M310730200	http://dx.doi.org/10.1074/jbc.M310730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14729905	hybrid			2022-12-27	WOS:000220747900065
J	Papadakis, M; Hawkins, LM; Stephenson, FA				Papadakis, M; Hawkins, LM; Stephenson, FA			Appropriate NR1-NR1 disulfide-linked homodimer formation is requisite for efficient expression of functional, cell surface N-methyl-D-aspartate NR1/NR2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-BINDING-SITE; NMDA-RECEPTOR; GLUTAMATE-RECEPTOR; CYSTEINE RESIDUES; MOLECULAR DETERMINANTS; BIOCHEMICAL-EVIDENCE; CRYSTAL-STRUCTURES; SUBUNITS; PROTEIN; NR1	A c-Myc epitope-tagged N-methyl-D-aspartate receptor NR1-2a subunit was generated, NR1-2a(c-Myc), where the tag was inserted after amino acid 81. NR1-2a(c-Myc)/NR2A receptors when expressed in mammalian cells are not trafficked to the cell surface nor do they yield cell cytotoxicity post-transfection. NR1-2a(c-Myc) was, however, shown to assemble with NR2A subunits by immunoprecipitation and [H-3] MK801 radioligand binding assays. Immunoblots of cells co-transfected with wild-type NR1-2a/ NR2A subunits yielded two NR1-2a immunoreactive species with molecular masses of 115 and 226 kDa. Two-dimensional electrophoresis under non-reducing and reducing conditions revealed that the 226-kDa band contained disulfide-linked NR1-2a subunits. Only the 115-kDa NR1-2a species was detected for NR1-2a(c-Myc)/NR2A. The c-Myc epitope is inserted adjacent to cysteine 79 of the NR1-2a subunit; therefore, it is possible that the tag may prevent the formation of NR1 disulfide bridges. A series of cysteine --> alanine NR1-2a mutants was generated, and the NR1-2a mutants were co-expressed with NR2A or NR2B subunits in mammalian cells and characterized with respect to cell surface expression, cell cytotoxicity post-transfection, co-association by immunoprecipitation, and immunoblotting following SDS-PAGE under both reducing and non-reducing conditions. When co-expressed with NR2A in mammalian cells, NR1-2a(C79A)/NR2A displayed similar properties to NR1-2a(c-Myc)/NR2A in that the 226-kDa NR1 immunoreactive species was not detectable, and trafficking to the cell surface was impaired compared with wild-type NR1/NR2 receptors. These results provide the first biochemical evidence for the formation of NR1-NR1 intersubunit disulfide-linked homodimers involving cysteine 79. They suggest that disulfide bridging and structural integrity within the NR1 N-terminal domain is requisite for cell surface N-methyl-D-aspartate receptor expression.	Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Stephenson, FA (corresponding author), Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, 29-39 Brunswick Sq, London WC1N 1AX, England.	anne.stephenson@ulsop.ac.uk						Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; Chazot PL, 1997, J NEUROCHEM, V68, P507; Chazot PL, 1995, MOL MEMBR BIOL, V12, P331, DOI 10.3109/09687689509072435; Cho HC, 2000, BIOCHEMISTRY-US, V39, P4649, DOI 10.1021/bi992469g; Choi YB, 2001, J NEUROSCI, V21, P392, DOI 10.1523/JNEUROSCI.21-02-00392.2001; CHOPRA B, 2000, BRIT J PHARMACOL, V30, P65; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; Dingledine R, 1999, PHARMACOL REV, V51, P7; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; Hughes PD, 2001, DEV BRAIN RES, V129, P135, DOI 10.1016/S0165-3806(01)00192-4; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Lipton SA, 2002, TRENDS NEUROSCI, V25, P474, DOI 10.1016/S0166-2236(02)02245-2; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Rutter AR, 2000, J NEUROCHEM, V75, P2501, DOI 10.1046/j.1471-4159.2000.0752501.x; Rutter AR, 2002, J NEUROCHEM, V81, P1298, DOI 10.1046/j.1471-4159.2002.00923.x; Sandhu S, 1999, J NEUROCHEM, V72, P1694, DOI 10.1046/j.1471-4159.1999.721694.x; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; SHENG M, 1996, NEURON, V17, P576; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Wu TY, 1996, BIOCHEM J, V319, P731, DOI 10.1042/bj3190731	39	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14703	14712		10.1074/jbc.M313446200	http://dx.doi.org/10.1074/jbc.M313446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732708	hybrid			2022-12-27	WOS:000220594700030
J	Segal, DJ; Goncalves, J; Eberhardy, S; Swan, CH; Torbett, BE; Li, XL; Barbas, CF				Segal, DJ; Goncalves, J; Eberhardy, S; Swan, CH; Torbett, BE; Li, XL; Barbas, CF			Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CONTROLLING GENE-EXPRESSION; INFECTIOUS MOLECULAR CLONE; DNA-BINDING PROTEINS; INTRACELLULAR IMMUNIZATION; TYPE-1 REPLICATION; RNA INTERFERENCE; REVERSE TRANSCRIPTION; LENTIVIRUS VECTOR; LTR PROMOTER	Small molecule inhibitors of human immunodeficiency virus, type 1 (HIV-1) have been extremely successful but are associated with a myriad of undesirable effects and require lifelong daily dosing. In this study we explore an alternative approach, that of inducing intracellular immunity using designed, zinc finger-based transcription factors. Three transcriptional repression proteins were engineered to bind sites in the HIV-1 promoter that were expected to be both accessible in chromatin structure and highly conserved in sequence structure among the various HIV-1 subgroups. Transient transfection assays identified one factor, KRAB-HLTR3, as being able to achieve 100-fold repression of an HIV-1 promoter. Specificity of repression was demonstrated by the lack of repression of other promoters. This factor was further shown to repress the replication of several HIV-1 viral strains 10- to 100-fold in T-cell lines and primary human peripheral blood mononuclear cells. Repression was observed for at least 18 days with no significant cytotoxicity. Stable T-cell lines expressing the factor also do not show obvious signs of cytotoxicity. These characteristics present KRAB-HLTR3 as an attractive candidate for development in an intracellular immunization strategy for anti-HIV-1 therapy.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Lisbon, Fac Farm, Ctr Patogenese Mol, URIA, P-1649019 Lisbon, Portugal	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Universidade de Lisboa	Barbas, CF (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-550,N Torrey Pines Rd, La Jolla, CA 92037 USA.	carlos@scripps.edu	iMed.ULisboa, M2B/B-5277-2014; Segal, David/V-9126-2019; Goncalves, Joao/B-2013-2008; Segal, David/B-6646-2013	iMed.ULisboa, M2B/0000-0002-1245-3715; Segal, David/0000-0001-8962-3105; Goncalves, Joao/0000-0002-1245-3715; Segal, David/0000-0001-8962-3105	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065059] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49165] Funding Source: Medline; NIGMS NIH HHS [GM065059] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Amado RG, 1999, HUM GENE THER, V10, P2255, DOI 10.1089/10430349950017239; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; Beerli RR, 2000, J BIOL CHEM, V275, P32617, DOI 10.1074/jbc.M005108200; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794; Boden D, 2003, J VIROL, V77, P11531, DOI 10.1128/JVI.77.21.11531-11535.2003; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Davis BR, 1998, HUM GENE THER, V9, P1197, DOI 10.1089/hum.1998.9.8-1197; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gea-Banacloche JC, 1999, AIDS, V13, pS25; Goncalves J, 2002, J BIOL CHEM, V277, P32036, DOI 10.1074/jbc.M201906200; Guan X, 2002, P NATL ACAD SCI USA, V99, P13296, DOI 10.1073/pnas.192412899; He GC, 2002, DNA CELL BIOL, V21, P697, DOI 10.1089/104454902760599672; HUANG LM, 1993, J VIROL, V67, P6937, DOI 10.1128/JVI.67.12.6937-6944.1993; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Kim JS, 1997, J BIOL CHEM, V272, P29795, DOI 10.1074/jbc.272.47.29795; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Kuiken C, 2001, HIV SEQUENCE COMPEND; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Pierson T, 2000, J VIROL, V74, P7824, DOI 10.1128/JVI.74.17.7824-7833.2000; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Reynolds L, 2003, P NATL ACAD SCI USA, V100, P1615, DOI 10.1073/pnas.252770699; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67; Segal DJ, 2002, METHODS, V26, P76, DOI 10.1016/S1046-2023(02)00009-9; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Segal DJ, 2001, CURR OPIN BIOTECH, V12, P632, DOI 10.1016/S0958-1669(01)00272-5; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; Stege JT, 2002, PLANT J, V32, P1077, DOI 10.1046/j.1365-313X.2002.01492.x; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Vashee S, 1998, BIOCHEM BIOPH RES CO, V247, P530, DOI 10.1006/bbrc.1998.8820; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; Wong-Staal F, 1998, HUM GENE THER, V9, P2407, DOI 10.1089/hum.1998.9.16-2407; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	57	73	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14509	14519		10.1074/jbc.M400349200	http://dx.doi.org/10.1074/jbc.M400349200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14734553	hybrid			2022-12-27	WOS:000220594700008
J	Wilson, HL; Rajagopalan, KV				Wilson, HL; Rajagopalan, KV			The role of tyrosine 343 in substrate binding and catalysis by human sulfite oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; RAY-ABSORPTION-SPECTROSCOPY; MOLECULAR-CLONING; ESCHERICHIA-COLI; CYSTEINE 207; ACTIVE-SITE; MOLYBDENUM; IDENTIFICATION; EXPRESSION; MOLYBDOPTERIN	In the crystal structure of chicken sulfite oxidase, the residue Tyr(322) (Tyr(343) in human sulfite oxidase) was found to directly interact with a bound sulfate molecule and was proposed to have an important role in mediating the substrate specificity and catalytic activity of this molybdoprotein. In order to understand the role of this residue in the catalytic mechanism of sulfite oxidase, steady-state and stopped-flow analyses were performed on wild-type and Y343F human sulfite oxidase over the pH range 6 - 10. In steady-state assays of Y343F sulfite oxidase using cytochrome c as the electron acceptor, k(cat) was somewhat impaired ( similar to 34% wild-type activity at pH 8.5), whereas the K-m(sulfite) showed a 5-fold increase over wild type. In rapid kinetic assays of the reductive half-reaction of wild-type human sulfite oxidase, k(red)(heme) changed very little over the entire pH range, with a significant increase in K-d(sulfite) at high pH. The k(red)(heme) of the Y343F variant was significantly impaired across the entire pH range, and unlike the wildtype protein, both k(red)(heme) and K-d(sulfite) were dependent on pH, with a significant increase in both kinetic parameters at high pH. Additionally, reduction of the molybdenum center by sulfite was directly measured for the first time in rapid reaction assays using sulfite oxidase lacking the N-terminal heme-containing domain. Reduction of the molybdenum center was quite fast (k(red)(Mo) = 972 s(-1) at pH 8.65 for wild-type protein), indicating that this is not the rate-limiting step in the catalytic cycle. Reduction of the molybdenum center of the Y343F variant by sulfite was more significantly impaired at high pH than at low pH. These results demonstrate that the Tyr(343) residue is important for both substrate binding and oxidation of sulfite by sulfite oxidase.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu			NIGMS NIH HHS [GM 44283] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astashkin AV, 2002, J AM CHEM SOC, V124, P6109, DOI 10.1021/ja0115417; Brody MS, 1999, BIOCHEMISTRY-US, V38, P6668, DOI 10.1021/bi9902539; BRODY MS, 1995, BBA-PROTEIN STRUCT M, V1253, P133, DOI 10.1016/0167-4838(95)00194-4; Codd R, 2002, J BIOL INORG CHEM, V7, P338, DOI 10.1007/s00775-001-0303-5; COHEN HJ, 1971, J BIOL CHEM, V246, P374; Davis J.R.E., 2002, WILEY ENCY MOL MED, DOI [10.1002/0471203076.emm1201, DOI 10.1002/0471203076.EMM1201]; Enemark JH, 2002, MET IONS BIOL SYST, V39, P621; Feng CJ, 2003, BIOCHEMISTRY-US, V42, P12235, DOI 10.1021/bi0350194; Feng CJ, 2003, J BIOL CHEM, V278, P2913, DOI 10.1074/jbc.M210374200; Feng CJ, 2002, BIOCHEMISTRY-US, V41, P5816, DOI 10.1021/bi016059f; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; Garrett RM, 1998, P NATL ACAD SCI USA, V95, P6394, DOI 10.1073/pnas.95.11.6394; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Garton SD, 1997, J AM CHEM SOC, V119, P2590, DOI 10.1021/ja963931c; George GN, 1996, J AM CHEM SOC, V118, P8588, DOI 10.1021/ja961218h; GEORGE GN, 1989, BIOCHEMISTRY-US, V28, P5075, DOI 10.1021/bi00438a026; Johnson Jean L, 2002, Hum Mutat, V20, P74, DOI 10.1002/humu.9038; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; JOHNSON JL, 1988, METHOD ENZYMOL, V158, P371, DOI 10.1016/0076-6879(88)58069-2; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; JOHNSON JL, 1988, BIOCHEM MED METAB B, V40, P86, DOI 10.1016/0885-4505(88)90108-9; KESSLER DL, 1974, BIOCHIM BIOPHYS ACTA, V370, P389, DOI 10.1016/0005-2744(74)90100-4; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; RAJAGOPALAN KV, 1958, MOLYBDENUM MOLYBDENU, P241; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; Schrader N, 2003, STRUCTURE, V11, P1251, DOI 10.1016/j.str.2003.09.001; STIEFEL EI, 1973, P NATL ACAD SCI USA, V70, P988, DOI 10.1073/pnas.70.4.988; SULLIVAN EP, 1992, J AM CHEM SOC, V114, P9662, DOI 10.1021/ja00050a058; SULLIVAN EP, 1993, BIOCHEMISTRY-US, V32, P12465, DOI 10.1021/bi00097a026; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200	33	58	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15105	15113		10.1074/jbc.M314288200	http://dx.doi.org/10.1074/jbc.M314288200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729666	hybrid			2022-12-27	WOS:000220594700076
J	Shang, J; Lehrman, MA				Shang, J; Lehrman, MA			Activation of glycogen phosphorylase with 5-aminoimidazole-4-carboxamide riboside (AICAR) - Assessment of glycogen as a precursor of mannosyl residues in glycoconjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; 5-AMINO-4-IMIDAZOLECARBOXAMIDE RIBOSIDE; SKELETAL-MUSCLE; GLYCOSYLATION; METABOLISM; SUBSTRATE; STRESS	The experimental evaluation of the contribution of glycogen phosphorylase ( GP) to biochemical pathways is limited to methods that raise cAMP, activating the cAMP-dependent protein kinase/phosphorylase kinase/ GP cascade. Such methods convert the unphosphorylated form, "GPb," which catalyzes glycogenolysis only in the presence of appropriate allosteric activators such as AMP, to the phosphorylated, constitutively activated form, "GPa." However, activation of GP in this way is indirect, requires a functional cAMP kinase cascade, and is complicated by other actions of cAMP. Here, we demonstrate a strategy for the experimental manipulation of GP in intact dermal fibroblasts, involving activation by the membrane-permeable adenosine analog 5-aminoimidazole-4-carboxamide riboside ( AICAR) and inhibition by caffeine and Pfizer compound CP-91149, which bind to GP at distinct sites. Potential complications because of activation of AMP-activated protein kinase by AICAR were assessed with metformin, which activates this kinase but does not activate GP. Using this strategy, we show that glycogen can be a significant and regulatable precursor of mannosyl units in lipid-linked oligosaccharides and glycoproteins.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	mark.lehrman@utsouthwestern.edu			NIGMS NIH HHS [R01 GM038545, GM 38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; Beyer A, 2000, BIOL CHEM, V381, P457, DOI 10.1515/BC.2000.060; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Doerrler WT, 1999, P NATL ACAD SCI USA, V96, P13050, DOI 10.1073/pnas.96.23.13050; Gill A, 2002, J BIOL CHEM, V277, P44747, DOI 10.1074/jbc.M205001200; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Henin N, 1996, BBA-GEN SUBJECTS, V1290, P197, DOI 10.1016/0304-4165(96)00021-9; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Longnus SL, 2003, AM J PHYSIOL-REG I, V284, pR936, DOI 10.1152/ajpregu.00319.2002; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; McMahon RJ, 1996, AM J PHYSIOL-ENDOC M, V270, pE640, DOI 10.1152/ajpendo.1996.270.4.E640; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Rath VL, 2000, CHEM BIOL, V7, P677, DOI 10.1016/S1074-5521(00)00004-1; SABINA RL, 1982, J BIOL CHEM, V257, P178; SABINA RL, 1985, J BIOL CHEM, V260, P6107; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Young ME, 1996, FEBS LETT, V382, P43, DOI 10.1016/0014-5793(96)00129-9; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	25	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12076	12080		10.1074/jbc.M400431200	http://dx.doi.org/10.1074/jbc.M400431200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729664	hybrid			2022-12-27	WOS:000220334900011
J	Maytum, R; Bathe, F; Konrad, M; Geeves, MA				Maytum, R; Bathe, F; Konrad, M; Geeves, MA			Tropomyosin exon 6b is troponin-specific and required for correct acto-myosin regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVELY SPLICED EXONS; ALPHA-TROPOMYOSIN; MUSCLE-CONTRACTION; HYPERTROPHIC CARDIOMYOPATHY; COOPERATIVE REGULATION; FUNCTIONAL DOMAINS; CARDIAC TROPONIN; BINDING-SITES; MODEL; SUBFRAGMENT-1	The specificity of tropomyosin (Tm) exon 6b for interaction with and functioning of troponin (Tn) has been studied using recombinant fibroblast Tm isoforms 5a and 5b. These isoforms differ internally by exons 6a/6b and possess non-muscle exons 1b/9d at the termini, hence they lack the primary TnT(1)-tropomyosin interaction, allowing study of exon 6 exchange in isolation from this. Using kinetic techniques to measure regulation of myosin S1 binding to actin and fluorescently labeled Tm to directly measure Tn binding, we show that binding of Tn to both isoforms is similar (0.1 - 0.5 muM) and both produce well regulated systems. Calcium has little effect on Tn binding to the actin . Tm complex and both exons produce a 3-fold reduction in the S1 binding rate to actin . Tm . Tn in its absence. This confirms previous results that show exon 6 has little influence on Tn affinity to actin . Tm or its ability to fully inhibit the acto-myosin interaction. Thin filaments reconstituted with Tn and Tm5a or skeletal Tm ( containing exon 6b) show nearly identical calcium dependence of acto-myosin regulation. However, Tm5b produces a dramatic increase in calcium sensitivity, shifting the activation mid-point by almost an order of magnitude. This shows that exon 6 sequence and, hence, Tm structure in this region have a significant effect upon the calcium regulation of Tn. This finding supports evidence that familial hypertrophic cardiomyopathy mutations occurring adjacent to this region can effect calcium regulation.	Univ Kent, Canterbury CT2 7NJ, Kent, England; Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany; Adolf Butenandt Inst, D-80336 Munich, Germany	University of Kent; Max Planck Society; University of Munich	Maytum, R (corresponding author), Univ Kent, Canterbury CT2 7NJ, Kent, England.	rmm@ukc.ac.uk	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898; Maytum, Robin/0000-0003-0395-403X				BURTNICK LD, 1988, ARCH BIOCHEM BIOPHYS, V266, P622, DOI 10.1016/0003-9861(88)90295-0; Chen YD, 2001, BIOPHYS J, V80, P2338, DOI 10.1016/S0006-3495(01)76204-2; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; COTE GP, 1983, MOL CELL BIOCHEM, V57, P127, DOI 10.1007/BF00849190; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; Earing MG, 2003, J AM SOC ECHOCARDIOG, V16, P698, DOI 10.1016/S0894-7317(03)00285-2; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREASER ML, 1971, J BIOL CHEM, V246, P4226; Hammell RL, 1996, J BIOL CHEM, V271, P4236; Hammell RL, 1997, J BIOL CHEM, V272, P22409, DOI 10.1074/jbc.272.36.22409; Harada K, 2001, J MOL CELL CARDIOL, V33, P593, DOI 10.1006/jmcc.2000.1313; HARRISON SM, 1989, J GEN PHYSIOL, V93, P411, DOI 10.1085/jgp.93.3.411; HEAD JG, 1995, EUR J BIOCHEM, V227, P694, DOI 10.1111/j.1432-1033.1995.tb20190.x; HILL LE, 1992, J BIOL CHEM, V267, P16106; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HITCHCOCK SE, 1973, BIOCHEMISTRY-US, V12, P2509; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; Jongbloed RJ, 2003, J AM COLL CARDIOL, V41, P981, DOI 10.1016/S0735-1097(02)03005-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Lehman W, 2001, J MOL BIOL, V307, P739, DOI 10.1006/jmbi.2001.4514; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; LEWIS WG, 1983, FEBS LETT, V156, P269, DOI 10.1016/0014-5793(83)80511-0; Li MX, 2000, BIOCHEMISTRY-US, V39, P8782, DOI 10.1021/bi000473i; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Maytum R, 2000, BIOCHEMISTRY-US, V39, P11913, DOI 10.1021/bi000977g; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Maytum R, 2001, BIOPHYS J, V80, p87A; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Michele DE, 1999, NAT MED, V5, P1413; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Naimi B, 2001, MOL BIOL CELL, V12, P1529, DOI 10.1091/mbc.12.5.1529; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; Palm T, 2003, BIOPHYS J, V84, P3181, DOI 10.1016/S0006-3495(03)70042-3; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; POOLE KJV, 1995, BIOPHYS J, V68, pS348; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; Regnier M, 1995, AM J PHYSIOL-CELL PH, V269, pC1532, DOI 10.1152/ajpcell.1995.269.6.C1532; Resetar AM, 2002, BIOPHYS J, V83, P1039, DOI 10.1016/S0006-3495(02)75229-6; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Smith DA, 2003, BIOPHYS J, V84, P3155, DOI 10.1016/S0006-3495(03)70040-X; Smith DA, 2003, BIOPHYS J, V84, P3168, DOI 10.1016/S0006-3495(03)70041-1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WATSON MH, 1990, J BIOL CHEM, V265, P18860; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; Zhou X, 2000, BIOCHEMISTRY-US, V39, P1128, DOI 10.1021/bi992327m	64	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18203	18209		10.1074/jbc.M311636200	http://dx.doi.org/10.1074/jbc.M311636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14752114	Green Published, hybrid			2022-12-27	WOS:000221041500015
J	Russell, SJ; Ruddock, LW; Salo, KEH; Oliver, JD; Roebuck, QP; Llewellyn, DH; Roderick, HL; Koivunen, P; Myllyharju, J; High, S				Russell, SJ; Ruddock, LW; Salo, KEH; Oliver, JD; Roebuck, QP; Llewellyn, DH; Roderick, HL; Koivunen, P; Myllyharju, J; High, S			The primary substrate binding site in the b ' domain of ERp57 is adapted for endoplasmic reticulum lectin association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE-ISOMERASE; CALRETICULIN P-DOMAIN; IN-VIVO; PEPTIDE-BINDING; CALNEXIN; LOCALIZATION; CHAPERONES; SUBUNIT	ERp57 is a member of the protein disulfide isomerase (PDI) family that is located in the endoplasmic reticulum ( ER) and characterized by its specificity for glycoproteins. Substrate selection by ERp57 is dependent upon its formation of discrete complexes with two ER resident lectins, soluble calreticulin and membrane-bound calnexin. It is these two lectins that directly associate with glycoproteins bearing correctly trimmed oligosaccharide side chains. Thus, ERp57 is presented with a preselected set of substrates upon which it can act, and the specific binding of calreticulin and calnexin to ERp57 is pivotal to the functions of the resulting complexes. To gain further insights into the formation of these ERp57-ER lectin complexes, we have investigated the regions of ERp57 that are specifically required for its binding to calreticulin. Using a quantitative pull-down assay to investigate the binding of ERp57/PDI chimeras to calreticulin, we define the b and b' domains of ERp57 as the minimal elements that are sufficient for complex formation. This analysis further identifies a novel role for the distinctive C-terminal extension of ERp57 in reconstituting complex formation to wild type levels. Using our understanding of substrate binding to the b' domain of PDI as a paradigm, we show that alterations to specific residues in the b' domain of ERp57 dramatically reduce or completely abolish its binding to calreticulin. On the basis of these data, we propose a model where the region of ERp57 equivalent to the primary substrate binding site of archetypal PDI is occupied by calreticulin and suggest that the ER lectins act as adaptor molecules that define the substrate specificity of ERp57.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Wales Coll Cardiff, Coll Med, Dept Med Biochem, Cardiff CF14 1LB, S Glam, Wales; Univ Oulu, Dept Med Biochem & Mol Biol, Oulu FIN-90014, Finland	University of Manchester; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; Cardiff University; University of Oulu	High, S (corresponding author), Univ Manchester, Sch Biol Sci, Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	stephen.high@man.ac.uk		High, Stephen/0000-0002-4532-8152; Ruddock, Lloyd/0000-0002-6247-686X; Roderick, Hywel/0000-0001-7065-3523	Biotechnology and Biological Sciences Research Council [SF16973] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Ellgaard L, 2002, J MOL BIOL, V322, P773, DOI 10.1016/S0022-2836(02)00812-4; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Klappa P, 2000, J BIOL CHEM, V275, P13213, DOI 10.1074/jbc.275.18.13213; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; Leach MR, 2004, J BIOL CHEM, V279, P9072, DOI 10.1074/jbc.M310788200; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pirneskoski A, 2001, J BIOL CHEM, V276, P11287, DOI 10.1074/jbc.M010656200; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; Ruddock LW, 2000, PROTEIN SCI, V9, P758; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	28	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18861	18869		10.1074/jbc.M400575200	http://dx.doi.org/10.1074/jbc.M400575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14871899	hybrid, Green Published			2022-12-27	WOS:000221041500095
J	Chen, YR; Chen, CL; Chen, WG; Zweier, JL; Augusto, O; Radi, R; Mason, RP				Chen, YR; Chen, CL; Chen, WG; Zweier, JL; Augusto, O; Radi, R; Mason, RP			Formation of protein tyrosine ortho-semiquinone radical and nitrotyrosine from cytochrome c-derived tyrosyl radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; HYDROGEN-PEROXIDE; RIBONUCLEOTIDE REDUCTASE; SPIN-STABILIZATION; INDUCED APOPTOSIS; CATECHOL ESTROGENS; OXIDATIVE STRESS; ANION RADICALS; PHOTOSYSTEM-II; TUMOR-CELLS	Oxidative alteration of mitochondrial cytochrome c (cyt c) has been linked to disease pathophysiology and is one of the causative factors for pro-apoptotic events. Hydrogen peroxide induces a short-lived cyt c-derived tyrosyl radical as detected by the electron spin resonance (ESR) spin-trapping technique. This investigation was undertaken to characterize the fate and consequences of the cyt c-derived tyrosyl radical. The direct ESR spectrum from the reaction of cyt c with H2O2 revealed a single-line signal with a line width of similar to10 G. The detected ESR signal could be prevented by pretreatment of cyt c with iodination, implying that the tyrosine residue of cyt c was involved. The ESR signal can be enhanced and stabilized by a divalent metal ion such as Zn2+, indicating the formation of the protein tyrosine ortho-semiquinone radical (ToQ(radical anion)). The production of cyt c-derived ToQ(radical anion) is inhibited by the spin trap, 2- methyl-2-nitrosopropane (MNP), suggesting the participation of tyrosyl radical in the formation of the ortho-semiquinone radical. The endothelium relaxant factor nitric oxide is well known to mediate mitochondrial respiration and apoptosis. The consumption of NO by cyt c was enhanced by addition of H2O2 as verified by inhibition electrochemical detection using an NO electrode. The rate of NO consumption in the system containing cyt c/NO/H2O2 was decreased by the spin traps 5,5-dimethyl pyrroline N-oxide and MNP, suggesting NO trapping of the cyt c-derived tyrosyl radical. The above result was further confirmed by NO quenching of the ESR signal of the MNP adduct of cyt c tyrosyl radical. Immunoblotting analysis of cyt c after exposure to NO in the presence of H2O2 revealed the formation of 3-nitrotyrosine. The addition of superoxide dismutase did not change the cyt c nitration, indicating that it is peroxynitrite-independent. The results of this study may provide useful information in understanding the interconnection among cyt c, H2O2, NO, and apoptosis.	Ohio State Univ, Coll Med, Dept Internal Med,Div Cardiovasc Med, Davis Heart & Lung Res Inst 607, Columbus, OH 43210 USA; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05513970 Sao Paulo, Brazil; Univ Republica, Fac Med, Dept Biochem, Montevideo 11800, Uruguay; Univ Republica, Fac Med, Ctr Free Rad & Biomed Res, Montevideo 11800, Uruguay; NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	University System of Ohio; Ohio State University; Universidade de Sao Paulo; Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Chen, YR (corresponding author), Ohio State Univ, Coll Med, Dept Internal Med,Div Cardiovasc Med, Davis Heart & Lung Res Inst 607, 473 W 12th Ave, Columbus, OH 43210 USA.	chen-12@medctr.osu.edu	Augusto, Ohara/D-3839-2012; Mason, Ronald P/G-5967-2019	Augusto, Ohara/0000-0002-7220-4286; Mason, Ronald P/0000-0002-1859-9109	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R01HL063744, P01HL065608, R29HL038324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050139, ZIAES050139, K22ES011031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63744, HL65608, R01S-HL38324] Funding Source: Medline; NIEHS NIH HHS [K22 ES011031, K22-ES11031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1990, J BIOL CHEM, V265, P20139; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Chen YR, 2002, J BIOL CHEM, V277, P29781, DOI 10.1074/jbc.M200709200; Cruthirds DL, 2003, ARCH BIOCHEM BIOPHYS, V412, P27, DOI 10.1016/S0003-9861(03)00039-0; de Menezes SL, 2001, J BIOL CHEM, V276, P39879, DOI 10.1074/jbc.M104012200; DeGray JA, 1997, J BIOL CHEM, V272, P2359; Deterding LJ, 1998, J BIOL CHEM, V273, P12863, DOI 10.1074/jbc.273.21.12863; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Filosa A, 2001, J BIOL CHEM, V276, P21022, DOI 10.1074/jbc.M100644200; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; Glover RE, 1999, NITRIC OXIDE-BIOL CH, V3, P439, DOI 10.1006/niox.1999.0256; Gunther MR, 1998, BIOCHEM J, V330, P1293; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; KALYANARAMAN B, 1985, ENVIRON HEALTH PERSP, V64, P185, DOI 10.2307/3430009; KALYANARAMAN B, 1989, J BIOL CHEM, V264, P11014; KALYANARAMAN B, 1987, J BIOL CHEM, V262, P11080; Kanno S, 2000, BIOL PHARM BULL, V23, P37; Kanno S, 1999, BIOL PHARM BULL, V22, P1296; KORYTOWSKI W, 1987, BIOCHIM BIOPHYS ACTA, V924, P383, DOI 10.1016/0304-4165(87)90152-8; Lawrence A, 2003, J BIOL CHEM, V278, P29410, DOI 10.1074/jbc.M300054200; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; MacMillan-Crow LA, 2001, FREE RADICAL BIO MED, V31, P1603, DOI 10.1016/S0891-5849(01)00750-X; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; Rossig L, 2000, J BIOL CHEM, V275, P25502, DOI 10.1074/jbc.M002283200; Sanakis Y, 1997, BIOCHEMISTRY-US, V36, P1411, DOI 10.1021/bi9622074; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Sturgeon BE, 2001, J BIOL CHEM, V276, P45516, DOI 10.1074/jbc.M106835200; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; WELLS K, 1991, ANAL BIOCHEM, V194, P237, DOI 10.1016/0003-2697(91)90224-H; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	51	78	80	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18054	18062		10.1074/jbc.M307706200	http://dx.doi.org/10.1074/jbc.M307706200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761966	hybrid			2022-12-27	WOS:000220870400141
J	Curtin, JF; Cotter, TG				Curtin, JF; Cotter, TG			JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; DEATH DOMAIN PROTEIN; JUN KINASE; SERINE/THREONINE KINASE; TUMOR-GROWTH; PHOSPHORYLATION; ACTIVATION; INHIBITOR; IDENTIFICATION; SENSITIZATION	Elevated endogenous JNK activity and resistance to Fas receptor-mediated apoptosis have recently been implicated in progression of prostate cancer and can promote resistance to apoptosis in response to chemotherapeutic drugs. In addition, JNK has been demonstrated to promote transformation of epithelial cells by increasing both proliferation and survival. Although numerous studies have reported a role for JNK in promoting Fas receptor-mediated apoptosis, there is a paucity in the literature studying the antiapoptotic function of JNK during Fas receptor-mediated apoptosis. Consequently, we have used the recently described specific JNK inhibitor SP600125 and RNA interference to inhibit endogenous JNK activity in the prostate carcinoma cell line DU 145. We demonstrated that endogenous JNK activity increased the expression of a kinase, HIPK3, that has previously been implicated in multidrug resistance in a number of tumors. HIPK3 has also been reported to phosphorylate FADD. The interaction between FADD and caspase-8 was inhibited, but abrogation of JNK activity or HIPK3 expression was found to restore this interaction and increased the sensitivity of DU 145 cells to Fas receptor-mediated apoptosis. In conclusion, we present novel evidence that JNK regulates the expression of HIPK3 in prostate cancer cells, and this contributes to increased resistance to Fas receptor-mediated apoptosis by reducing the interaction between FADD and caspase-8.	Unic Coll Cork, Biosci Res Inst, Dept Biochem, Tumor Biol Lab, Cork, Ireland	University College Cork	Cotter, TG (corresponding author), Unic Coll Cork, Biosci Res Inst, Dept Biochem, Tumor Biol Lab, Cork, Ireland.	t.cotter@ucc.ie	Curtin, James/B-1669-2008	Curtin, James/0000-0002-9320-9254; Cotter, Thomas/0000-0003-4626-5613				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; Bagowski CP, 2003, CURR BIOL, V13, P315, DOI 10.1016/S0960-9822(03)00083-6; Bagowski CP, 2001, CURR BIOL, V11, P1176, DOI 10.1016/S0960-9822(01)00330-X; Begley DA, 1997, GENE, V200, P35, DOI 10.1016/S0378-1119(97)00350-8; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Chakraborty M, 2001, CANCER RES, V61, P7255; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Costa-Pereira AP, 2000, BRIT J CANCER, V82, P1827, DOI 10.1054/bjoc.2000.1149; Curtin JF, 2002, BRIT J CANCER, V87, P1188, DOI 10.1038/sj.bjc.6600612; de Thonel A, 2001, BLOOD, V98, P3770, DOI 10.1182/blood.V98.13.3770; deSouza PL, 1997, CLIN CANCER RES, V3, P287; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; Gjerset R, 2001, METH MOL B, V175, P495; Han SY, 2002, J BIOL CHEM, V277, P47167, DOI 10.1074/jbc.M204270200; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Hedlund TE, 1998, PROSTATE, V36, P92, DOI 10.1002/(SICI)1097-0045(19980701)36:2<92::AID-PROS4>3.0.CO;2-G; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; Li X, 2000, BIOCHEM BIOPH RES CO, V277, P513, DOI 10.1006/bbrc.2000.3700; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Meng XW, 2003, J BIOL CHEM, V278, P47326, DOI 10.1074/jbc.M304793200; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; O'Hagan RC, 1998, ONCOGENE, V16, P301, DOI 10.1038/sj.onc.1201547; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Petrylak DP, 1999, UROLOGY, V54, P30, DOI 10.1016/S0090-4295(99)00452-5; Potapova O, 2002, CANCER RES, V62, P3257; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Rennefahrt UEE, 2002, J BIOL CHEM, V277, P29510, DOI 10.1074/jbc.M203010200; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; SAMPSON KE, 1993, J CELL BIOCHEM, V52, P384, DOI 10.1002/jcb.240520403; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Yang YM, 2003, CLIN CANCER RES, V9, P391; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	45	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17090	17100		10.1074/jbc.M307629200	http://dx.doi.org/10.1074/jbc.M307629200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766760	Green Submitted, hybrid			2022-12-27	WOS:000220870400027
J	Guo, SL; Presnell, SR; Yuan, FH; Zhang, YB; Gu, LY; Li, GM				Guo, SL; Presnell, SR; Yuan, FH; Zhang, YB; Gu, LY; Li, GM			Differential requirement for proliferating cell nuclear antigen in 5 ' and 3 ' nick-directed excision in human mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DNA MISMATCH; MUTATION AVOIDANCE; IN-VITRO; PCNA; CANCER; P21; INHIBITION; MECHANISM; COMPLEXES	Proliferating cell nuclear antigen (PCNA) is involved in mammalian mismatch repair at a step prior to or at mismatch excision, but the molecular mechanism of this process is not fully understood. To examine the role of PCNA in mismatch-provoked and nick-directed excision, orientation-specific mismatch removal of hetero-duplexes with a pre-existing nick was monitored in human nuclear extracts supplemented with the PCNA inhibitor protein p21. We show here that, whereas 3' nick-directed mismatch excision was completely inhibited by low concentrations of p21 or a p21 C-terminal fusion protein, 5' nick-directed excision was only partially blocked under the same conditions. No further reduction of the 5' excision was detected when a much higher concentration of p21 C-terminal protein was used. These results suggest the following. (i) There is a differential requirement for PCNA in 3' and 5' nick-directed excision; and (ii) 5' nick-directed excision is conducted by a manner either dependent on or independent of PCNA. Our in vitro reconstitution experiments indeed identified a 5' nick-directed excision pathway that is dependent on PCNA, hMutSalpha, and a partially purified fraction from a HeLa nuclear extract.	Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Li, GM (corresponding author), Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lucille P Markey Canc Ctr, 800 Rose St, Lexington, KY 40536 USA.	gmli@uky.edu	Yuan, Fenghua/F-8736-2011; Zhang, Yanbin/F-2998-2011; Li, Guo-Min/I-5016-2014	Zhang, Yanbin/0000-0002-7263-5510; Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R01CA085377, R29CA072956] Funding Source: NIH RePORTER; NCI NIH HHS [CA85377, CA72956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; FANG WH, 1993, J BIOL CHEM, V268, P11838; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Genschel J, 2003, MOL CELL, V12, P1077, DOI 10.1016/S1097-2765(03)00428-3; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Johnson RE, 1998, CURR GENET, V34, P21, DOI 10.1007/s002940050362; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Li GM, 2003, FRONT BIOSCI-LANDMRK, V8, pD997, DOI 10.2741/1121; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Longley MJ, 1997, J BIOL CHEM, V272, P10917; McCulloch SD, 2003, J BIOL CHEM, V278, P50803, DOI 10.1074/jbc.M309025200; McCulloch SD, 2003, J BIOL CHEM, V278, P3891, DOI 10.1074/jbc.M210687200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Ramilo C, 2002, MOL CELL BIOL, V22, P2037, DOI 10.1128/MCB.22.7.2037-2046.2002; SU SS, 1988, J BIOL CHEM, V263, P6829; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wei KC, 2003, GENE DEV, V17, P603, DOI 10.1101/gad.1060603; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869	34	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16912	16917		10.1074/jbc.M313213200	http://dx.doi.org/10.1074/jbc.M313213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14871894	hybrid			2022-12-27	WOS:000220870400005
J	Rodriguez, P; Jackson, WA; Colyer, J				Rodriguez, P; Jackson, WA; Colyer, J			Critical evaluation of cardiac Ca2+-ATPase phosphorylation on serine 38 using a phosphorylation site-specific antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; RETICULUM CALCIUM-PUMP; TWITCH SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; HEART-FAILURE; PHOSPHOLAMBAN PHOSPHORYLATION; DEPENDENT PHOSPHORYLATION; CALMODULIN; ATPASE	The phosphorylation of the cardiac muscle isoform of the sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) on serine 38 has been described as a regulatory event capable of very significant enhancement of enzyme activity (Hawkins, C., Xu, A., and Narayanan, N. (1994) J. Biol. Chem. 269, 31198 - 31206). Independent confirmation of these observations has not been forthcoming. This study has utilized a polyclonal antibody specific for the phosphorylated serine 38 epitope on the Ca2+-ATPase to evaluate the phosphorylation of SERCA2a in isolated sarcoplasmic reticulum vesicles and isolated rat ventricular myocytes. A quantitative Western blot approach failed to detect serine 38-phosphorylated Ca2+-ATPase in either kinase-treated sarcoplasmic reticulum vesicles or suitably stimulated cardiac myocytes. Calibration standards confirmed that the detection sensitivity of assays was adequate to detect Ser-38 phosphorylation if it occurred on at least 1% of Ca2+-ATPase molecules in SR vesicle experiments or on at least 0.1% of Ca2+-ATPase molecules in cardiac myocytes. The failure to detect a phosphorylated form of the Ca2+-ATPase in either preparation ( isolated myocyte, purified sarcoplasmic reticulum vesicles) suggests that Ser-38 phosphorylation of the Ca2+-ATPase is not a significant regulatory feature of cardiac Ca2+ homeostasis.	Badrilla Ltd, Leeds LS17 9WA, W Yorkshire, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Colyer, J (corresponding author), Badrilla Ltd, POB 251, Leeds LS17 9WA, W Yorkshire, England.	j.colyer@leeds.ac.uk						Al-Khalili L, 2003, ANN NY ACAD SCI, V986, P449, DOI 10.1111/j.1749-6632.2003.tb07228.x; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Brette F, 2000, AM J PHYSIOL-HEART C, V279, pH1963, DOI 10.1152/ajpheart.2000.279.4.H1963; Brockwell DJ, 2002, BIOPHYS J, V83, P458, DOI 10.1016/S0006-3495(02)75182-5; Calaghan S, 1998, BIOCHEM BIOPH RES CO, V248, P701, DOI 10.1006/bbrc.1998.9036; Carafoli E, 1997, BASIC RES CARDIOL, V92, P59, DOI 10.1007/BF00794069; COLYER J, 1991, J BIOL CHEM, V266, P17486; DeSantiago J, 2002, J MOL CELL CARDIOL, V34, P975, DOI 10.1006/jmcc.2002.2034; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; FRAMPTON JE, 1992, J PHYSIOL-LONDON, V453, P385, DOI 10.1113/jphysiol.1992.sp019234; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hasenfuss G, 2002, J MOL CELL CARDIOL, V34, P951, DOI 10.1006/jmcc.2002.2037; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; Houser SR, 2003, CIRC RES, V92, P350, DOI 10.1161/01.RES.0000060027.40275.A6; HUDSON L, 1980, PRACTICAL INMUNOLOGY, P348; INESI G, 1980, J BIOL CHEM, V255, P3025; Jackson WA, 1996, BIOCHEM J, V316, P201, DOI 10.1042/bj3160201; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CF, 1990, BIOCHEMISTRY-US, V29, P4535, DOI 10.1021/bi00471a005; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; Liu YW, 1997, AM J PHYSIOL-CELL PH, V273, pC1915, DOI 10.1152/ajpcell.1997.273.6.C1915; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; MundinaWeilenmann C, 1996, J BIOL CHEM, V271, P33561, DOI 10.1074/jbc.271.52.33561; Netticadan T, 1999, AM J PHYSIOL-CELL PH, V277, pC384, DOI 10.1152/ajpcell.1999.277.3.C384; Netticadan T, 2000, CIRC RES, V86, P596, DOI 10.1161/01.RES.86.5.596; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; Osada M, 1998, AM J PHYSIOL-HEART C, V274, pH2025, DOI 10.1152/ajpheart.1998.274.6.H2025; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; Rodriguez P, 2003, J BIOL CHEM, V278, P38593, DOI 10.1074/jbc.C301180200; Shannon TR, 2001, J BIOL CHEM, V276, P7195, DOI 10.1074/jbc.M007085200; SIMMERMAN HKB, 1989, BIOCHIM BIOPHYS ACTA, V997, P322, DOI 10.1016/0167-4838(89)90203-3; TADA M, 1980, J BIOL CHEM, V255, P1985; TIKHONOV VN, 1965, ZH ANAL KHIM, V20, P390; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; XU A, 1993, J BIOL CHEM, V268, P8394; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	48	12	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17111	17119		10.1074/jbc.M400462200	http://dx.doi.org/10.1074/jbc.M400462200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766745	hybrid			2022-12-27	WOS:000220870400029
J	Carrigan, PE; Nelson, GM; Roberts, PJ; Stoffer, JN; Riggs, DL; Smith, DF				Carrigan, PE; Nelson, GM; Roberts, PJ; Stoffer, JN; Riggs, DL; Smith, DF			Multiple domains of the co-chaperone Hop are important for Hsp70 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; STRESS-INDUCIBLE PROTEIN-1; HEAT-SHOCK PROTEINS; ATPASE ACTIVITY; MUTATIONAL ANALYSIS; SUBSTRATE-BINDING; HSP90; IDENTIFICATION; SITE; IMMUNOPHILINS	The Hop/Sti1 co-chaperone binds to both Hsp70 and Hsp90. Biochemical and co-crystallographic studies have suggested that the EEVD-containing C terminus of Hsp70 or Hsp90 binds specifically to one of the Hop tetratricopeptide repeat domains, TPR1 or TPR2a, respectively. Mutational analyses of Hsp70 and Hop were undertaken to better characterize interactions between the C terminus of Hsp70 and Hop domains. Surprisingly, truncation of EEVD plus as many as 34 additional amino acids from the Hsp70 C terminus did not reduce the ability of Hsp70 mutants to co-immunoprecipitate with Hop, although further truncation eliminated Hop binding. Hop point mutations targeting a carboxylate clamp position in TPR1 disrupted Hsp70 binding, as was expected; however, similar point mutations in TPR2a or TPR2b also inhibited Hsp70 binding in some settings. Using a yeast-based in vivo assay for Hop function, wild type Hop and TPR2b mutants could fully complement deletion of Sti1p; TPR1 and TPR2a point mutants could partially restore activity. Conformations of Hop and Hop mutants were probed by limited proteolysis. The TPR1 mutant digested in a similar manner to wild type; however, TPR2a and TPR2b mutants each displayed greater resistance to chymotryptic digestion. All point mutants retained an ability to dimerize, and none appeared to be grossly misfolded. These results raise questions about current models for Hop/Hsp70 interaction.	Mayo Clin Scottsdale, Samuel C Johnson Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix	Smith, DF (corresponding author), Mayo Clin Scottsdale, Samuel C Johnson Res Ctr, Scottsdale, AZ 85259 USA.	smith.david26@mayo.edu	Nelson, Gregory M./H-6315-2011	Nelson, Gregory M./0000-0002-8382-910X	NIDDK NIH HHS [R01-DK44923] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044923] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Chou CC, 2003, J BIOL CHEM, V278, P30311, DOI 10.1074/jbc.M304563200; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; GUELMAN R, 2002, BONE, V30, P23; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; HOHFELD J, 1995, CELL, V83, P589; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Konigsberg WH, 1995, METHOD ENZYMOL, V262, P331; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Nelson GM, 2003, CELL STRESS CHAPERON, V8, P125, DOI 10.1379/1466-1268(2003)008<0125:COTCDR>2.0.CO;2; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; van der Spuy J, 2000, BIOCHEM J, V345, P645, DOI 10.1042/0264-6021:3450645; van der Spuy J, 2001, PROTEIN EXPRES PURIF, V21, P462, DOI 10.1006/prep.2001.1399; Ward BK, 2002, J BIOL CHEM, V277, P40799, DOI 10.1074/jbc.M207097200	39	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16185	16193		10.1074/jbc.M314130200	http://dx.doi.org/10.1074/jbc.M314130200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14960564	hybrid, Green Published			2022-12-27	WOS:000220747900061
J	Bate, C; Salmona, M; Diomede, L; Williams, A				Bate, C; Salmona, M; Diomede, L; Williams, A			Squalestatin cures prion-infected neurons and protects against prion neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA REDUCTASE INHIBITORS; PROSTAGLANDIN E-2; CHOLESTEROL-METABOLISM; MICROGLIAL ACTIVATION; DAMAGED NEURONS; MURINE SCRAPIE; IN-VIVO; PRP; CELLS; PROTEINS	A key feature of prion diseases is the conversion of the normal, cellular prion protein (PrPC) into beta-sheet-rich disease-related isoforms (PrPSc), the deposition of which is thought to lead to neurodegeneration. In the present study, the squalene synthase inhibitor squalestatin reduced the cholesterol content of cells and prevented the accumulation of PrPSc in three prion-infected cell lines (ScN2a, SMB, and ScGT1 cells). ScN2a cells treated with squalestatin were also protected against microglia-mediated killing. Treatment of neurons with squalestatin resulted in a redistribution of PrPC away from Triton X-100 insoluble lipid rafts. These effects of squalestatin were dose-dependent, were evident at nanomolar concentrations, and were partially reversed by cholesterol. In addition, uninfected neurons treated with squalestatin became resistant to the otherwise toxic effect of PrP peptides, a synthetic miniprion (sPrP106) or partially purified prion preparations. The protective effect of squalestatin, which was reversed by the addition of water-soluble cholesterol, correlated with a reduction in prostaglandin E-2 production that is associated with neuronal injury in prion disease. These studies indicate a pivotal role for cholesterol-sensitive processes in controlling PrPSc formation, and in the activation of signaling pathways associated with PrP-induced neuronal death.	Univ Glasgow, Sch Vet, Inst Comparat Med, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland; Ist Ric Farmacol Mario Negri, Dept Mol Biochem & Pharmacol, I-20157 Milan, Italy; Univ London Royal Vet Coll, Dept Pathol & Infect Dis, N Mymms AL9 7TA, Herts, England	University of Glasgow; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of London; University of London Royal Veterinary College	Bate, C (corresponding author), Univ Glasgow, Sch Vet, Inst Comparat Med, Dept Vet Pathol, Bearsdon Rd, Glasgow G61 1QH, Lanark, Scotland.	c.bate@vet.gla.ac.uk	salmona, mario/ABI-4066-2020; salmona, mario/AAA-7116-2020; Diomede, Luisa/P-3417-2014	salmona, mario/0000-0002-9098-9873; Diomede, Luisa/0000-0002-2258-0531				ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Bate C, 2001, NEUROREPORT, V12, P2589, DOI 10.1097/00001756-200108080-00059; Bate C, 2002, NEUROREPORT, V13, P1695, DOI 10.1097/00001756-200209160-00025; BAXTER A, 1992, J BIOL CHEM, V267, P11705; Beranger F, 2002, J BIOL CHEM, V277, P38972, DOI 10.1074/jbc.M205110200; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bonetto V, 2002, J BIOL CHEM, V277, P31327, DOI 10.1074/jbc.M203275200; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Chilton R, 2001, CURR PROB CARDIOLOGY, V26, P734, DOI 10.1067/mcd.2001.119386; Danesh FR, 2003, ARCH IMMUNOL THER EX, V51, P139; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Diomede L, 2001, ARTERIOSCL THROM VAS, V21, P1327, DOI 10.1161/hq0801.094222; Fassbender K, 2002, NEUROLOGY, V59, P1257, DOI 10.1212/WNL.59.8.1257; FOLCH J, 1957, J BIOL CHEM, V226, P497; Forloni G, 1996, MOL CHEM NEUROPATHOL, V28, P163, DOI 10.1007/BF02815218; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Giese A, 1998, BRAIN PATHOL, V8, P449; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Jeffrey M, 2000, NEUROPATH APPL NEURO, V26, P41, DOI 10.1046/j.1365-2990.2000.00216.x; Jones SP, 2001, ACTA PHYSIOL SCAND, V173, P139, DOI 10.1046/j.1365-201X.2001.00899.x; Kalinowski L, 2002, J PHYSIOL PHARMACOL, V53, P585; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Locatelli S, 2002, ARCH NEUROL-CHICAGO, V59, P213, DOI 10.1001/archneur.59.2.213; Magalhaes AC, 2002, J BIOL CHEM, V277, P33311, DOI 10.1074/jbc.M203661200; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; Marella M, 2002, J BIOL CHEM, V277, P25457, DOI 10.1074/jbc.M203248200; Minghetti L, 2002, NEUROLOGY, V58, P127, DOI 10.1212/WNL.58.1.127; Minghetti L, 2000, J NEUROPATH EXP NEUR, V59, P866, DOI 10.1093/jnen/59.10.866; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Peyrin JM, 1999, NEUROREPORT, V10, P723, DOI 10.1097/00001756-199903170-00012; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shogomori H, 2001, J NEUROCHEM, V78, P991, DOI 10.1046/j.1471-4159.2001.00489.x; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; VISTICA DT, 1991, CANCER RES, V51, P2515; Williams A, 1997, EXP NEUROL, V144, P433, DOI 10.1006/exnr.1997.6424; Williams A, 1997, BRAIN RES, V754, P171, DOI 10.1016/S0006-8993(97)00067-X; Yagami T, 2001, BRIT J PHARMACOL, V134, P673, DOI 10.1038/sj.bjp.0704261	53	115	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14983	14990		10.1074/jbc.M313061200	http://dx.doi.org/10.1074/jbc.M313061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14754889	hybrid			2022-12-27	WOS:000220594700062
J	Chang, WT; Huang, AM				Chang, WT; Huang, AM			alpha-Pal/NRF-1 regulates the promoter of the human integrin-associated protein/CD47 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-2-ALPHA; RESPIRATORY FACTOR-I; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; MEMORY RETENTION; CD47; EXPRESSION; RECEPTOR; CELLS	Integrin-associated protein (IAP or CD47) is expressed in a variety of tissues, including the nervous system and immune system. To understand how cells control the expression of the IAP gene, we cloned the 5'-proximal region of the human IAP gene and investigated IAP promoter activity by transient transfection. RT-PCR confirmed the expression of IAP transcripts in human neuroblastoma IMR-32 and hepatoma HepG2 cells. Deletion analysis identified a core promoter of the human IAP gene located between nucleotide positions -232 and - 12 relative to the translation initiation codon in these two cell lines. Site-directed mutagenesis and gel electrophoretic mobility shift assay identified a alpha-Pal/ NRF-1 binding element within the IAP core promoter. Supershift assays using the alpha-Pal/NRF-1 antiserum confirmed the binding of this transcription factor on the alpha-Pal/NRF-1 site. Overexpression of the DNA binding domain of alpha-Pal/NRF-1 in cells enhanced DNA-alpha-Pal/ NRF-1 binding in vitro. Furthermore, overexpression of full-length alpha-Pal/NRF-1 significantly enhanced IAP promoter activity while overexpression of dominant-negative mutant reduced promoter activity both in the cultured human cell lines and primary mouse cortical cells. These results revealed that alpha-Pal/NRF-1 is an essential transcription factor in the regulation of human IAP gene expression.	Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University	Huang, AM (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan.	amhuang@mail.ncku.edu.tw						Aiyar A, 1996, Methods Mol Biol, V57, P177; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Becker TS, 1998, DEVELOPMENT, V125, P4369; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CALZONE FJ, 1991, DEVELOPMENT, V112, P335; Chang HP, 2001, NEUROSCIENCE, V102, P289, DOI 10.1016/S0306-4522(00)00478-4; Chang HP, 1999, LEARN MEMORY, V6, P448, DOI 10.1101/lm.6.5.448; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; DICHTER MA, 1978, BRAIN RES, V149, P279, DOI 10.1016/0006-8993(78)90476-6; EFIOK BJS, 1994, J BIOL CHEM, V269, P18921; Efiok BJS, 2000, BBA-MOL CELL RES, V1495, P51, DOI 10.1016/S0167-4889(99)00138-X; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; GOMEZCUADRADO A, 1995, MOL CELL BIOL, V15, P6670; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; Huang AM, 1998, J NEUROSCI, V18, P4305; JACOB WF, 1989, J BIOL CHEM, V264, P20372; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; Kumari D, 2001, J BIOL CHEM, V276, P4357, DOI 10.1074/jbc.M009629200; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Myers SJ, 1998, J NEUROSCI, V18, P6723; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Schickel J, 2002, BIOCHEM CELL BIOL, V80, P169, DOI 10.1139/O01-210; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; Shahein YEA, 2002, IMMUNOLOGY, V106, P564, DOI 10.1046/j.1365-2567.2002.01465.x; Silva AJ, 1996, CURR BIOL, V6, P1509, DOI 10.1016/S0960-9822(96)00756-7; Ticchioni M, 1997, J IMMUNOL, V158, P677; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865	36	32	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14542	14550		10.1074/jbc.M309825200	http://dx.doi.org/10.1074/jbc.M309825200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747477	hybrid			2022-12-27	WOS:000220594700011
J	Harndahl, L; Wierup, N; Enerback, S; Mulder, H; Manganiello, VC; Sundler, F; Degerman, E; Ahren, B; Holst, LS				Harndahl, L; Wierup, N; Enerback, S; Mulder, H; Manganiello, VC; Sundler, F; Degerman, E; Ahren, B; Holst, LS			beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROTEIN-KINASE; PANCREATIC-ISLETS; DEFICIENT MICE; CAMP; ACTIVATION; EXPRESSION; RELEASE; ARCHITECTURE; POLYPEPTIDE	The second messenger cAMP mediates potentiation of glucose-stimulated insulin release. Use of inhibitors of cAMP-hydrolyzing phosphodiesterase (PDE) 3 and overexpression of PDE3B in vitro have demonstrated a regulatory role for this enzyme in insulin secretion. In this work, the physiological significance of PDE3B-mediated degradation of cAMP for the regulation of insulin secretion in vivo and glucose homeostasis was investigated in transgenic mice overexpressing PDE3B in pancreatic beta-cells. A 2-fold overexpression of PDE3B protein and activity blunted the insulin response to intravenous glucose, resulting in reduced glucose disposal. The effects were "dose"-dependent because mice overexpressing PDE3B 7-fold failed to increase insulin in response to glucose and hence exhibited pronounced glucose intolerance. Also, the insulin secretory response to intravenous glucagon-like peptide 1 was reduced in vivo. Similarly, islets stimulated in vitro exhibited reduced insulin secretory capacity in response to glucose and glucagon-like peptide 1. Perifusion experiments revealed that the reduction specifically affected the first phase of glucose-stimulated insulin secretion. Furthermore, morphological examinations demonstrated deranged islet cytoarchitecture. In conclusion, these results are consistent with an essential role for PDE3B in cAMP-mediated regulation of insulin release and glucose homeostasis.	Biomed Ctr, Dept Cell & Mol Biol, SE-22184 Lund, Sweden; Biomed Ctr, Dept Physiol Sci, SE-22184 Lund, Sweden; Gothenburg Univ, Dept Med Biochem, SE-40530 Gothenburg, Sweden; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	University of Gothenburg; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Holst, LS (corresponding author), Biomed Ctr, Dept Cell & Mol Biol, C11, SE-22184 Lund, Sweden.	Lena.Stenson-Holst@medkem.lu.se	Mulder, Hindrik/E-1045-2012	Mulder, Hindrik/0000-0002-6593-8417	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002540, ZIAHL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad M, 2000, BRIT J PHARMACOL, V129, P1228, DOI 10.1038/sj.bjp.0703165; Ahren B, 1998, BIOESSAYS, V20, P642, DOI 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K; Bratanova-Tochkova TK, 2002, DIABETES, V51, pS83, DOI 10.2337/diabetes.51.2007.S83; DEGERMAN E, 2000, DIABETES MELLITUS FU, P284; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; ElMetwally M, 1997, EUR J PHARMACOL, V324, P227, DOI 10.1016/S0014-2999(97)00076-9; ENGFELDT P, 1982, J CLIN ENDOCR METAB, V55, P983, DOI 10.1210/jcem-55-5-983; Eppig JT, 2002, GENESIS, V32, P63, DOI 10.1002/gene.10055; Filipsson K, 2001, DIABETES, V50, P1959, DOI 10.2337/diabetes.50.9.1959; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Gannon M, 2000, DEVELOPMENT, V127, P2883; Gebre-Medhin S, 1998, BIOCHEM BIOPH RES CO, V250, P271, DOI 10.1006/bbrc.1998.9308; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Han P, 1999, J BIOL CHEM, V274, P22337, DOI 10.1074/jbc.274.32.22337; Harndahl L, 2002, J BIOL CHEM, V277, P37446, DOI 10.1074/jbc.M205401200; Harris TE, 1997, BIOCHEM BIOPH RES CO, V232, P648, DOI 10.1006/bbrc.1997.6344; Houslay MD, 1998, SEMIN CELL DEV BIOL, V9, P161, DOI 10.1006/scdb.1997.0221; HOWELL SL, 1994, DIABETOLOGIA, V37, pS30, DOI 10.1007/BF00400823; Jamen F, 2000, J CLIN INVEST, V105, P1307, DOI 10.1172/JCI9387; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Jorns A, 1996, VIRCHOWS ARCH, V428, P177; Jorns A, 2002, VIRCHOWS ARCH, V440, P63, DOI 10.1007/s004280100490; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; MURAD F, 1971, P NATL ACAD SCI USA, V68, P736, DOI 10.1073/pnas.68.4.736; Nakazaki M, 2002, DIABETES, V51, P3440, DOI 10.2337/diabetes.51.12.3440; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Pacini G, 2001, AM J PHYSIOL-ENDOC M, V281, pE693, DOI 10.1152/ajpendo.2001.281.4.E693; Parker JC, 1997, BIOCHEM BIOPH RES CO, V236, P665, DOI 10.1006/bbrc.1997.7034; PERSAUD SJ, 1990, BIOCHEM BIOPH RES CO, V173, P833, DOI 10.1016/S0006-291X(05)80862-9; Reisz-Porszasz S, 2003, AM J PHYSIOL-ENDOC M, V285, pE876, DOI 10.1152/ajpendo.00107.2003; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; SIEGEL EG, 1980, J CLIN INVEST, V65, P233, DOI 10.1172/JCI109665; SKOGLUND G, 1988, ACTA PHYSIOL SCAND, V132, P289, DOI 10.1111/j.1748-1716.1988.tb08332.x; SNYDER PB, 1999, EMERGING THERAPEUTIC, V3, P587; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Winarto A, 2001, ARCH HISTOL CYTOL, V64, P59, DOI 10.1679/aohc.64.59; Wollheim CB, 2002, DIABETES, V51, pS37, DOI 10.2337/diabetes.51.2007.S37; Yamagata K, 2002, DIABETES, V51, P114, DOI 10.2337/diabetes.51.1.114; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zhao AZ, 1997, P NATL ACAD SCI USA, V94, P3223, DOI 10.1073/pnas.94.7.3223	45	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15214	15222		10.1074/jbc.M308952200	http://dx.doi.org/10.1074/jbc.M308952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736883	hybrid			2022-12-27	WOS:000220594700088
J	Sekiya, M; Osuga, JI; Okazaki, H; Yahagi, N; Harada, K; Shen, WJ; Tamura, Y; Tomita, S; Iizuka, Y; Ohashi, K; Okazaki, M; Sata, M; Nagai, R; Fujita, T; Shimano, H; Kraemer, FB; Yamada, N; Ishibashi, S				Sekiya, M; Osuga, JI; Okazaki, H; Yahagi, N; Harada, K; Shen, WJ; Tamura, Y; Tomita, S; Iizuka, Y; Ohashi, K; Okazaki, M; Sata, M; Nagai, R; Fujita, T; Shimano, H; Kraemer, FB; Yamada, N; Ishibashi, S			Absence of hormone-sensitive lipase inhibits obesity and adipogenesis in Lep(ob/ob) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL-DIFFERENTIATION; ACID SYNTHASE INHIBITOR; AP2 GENE-EXPRESSION; FATTY-ACIDS; OB/OB MICE; DEFICIENT MICE; FOOD-INTAKE; ADIPOCYTE DIFFERENTIATION; TARGETED DISRUPTION; INSULIN-RESISTANCE	Hormone-sensitive lipase (HSL) plays a crucial role in the hydrolysis of triacylglycerol and cholesteryl ester in various tissues including adipose tissues. To explore the role of HSL in the metabolism of fat and carbohydrate, we have generated mice lacking both leptin and HSL (Lep(ob/ob)/HSL-/-) by cross-breeding HSL-/- mice with genetically obese Lep(ob/ob) mice. Unexpectedly, Lep(ob/ob)/ HSL-/- mice ate less food, gained less weight, and had lower adiposity than Lep(ob/ob)/HSL+/+ mice. Lep(ob/ob)/ HSL-/- mice had massive accumulation of preadipocytes in white adipose tissues with increased expression of preadipocyte-specific genes (CAAT/enhancer-binding protein beta and adipose differentiation-related protein) and decreased expression of genes characteristic of mature adipocytes (CCAAT/enhancer-binding protein alpha, peroxisome proliferator activator receptor gamma, and adipocyte determination and differentiation factor 1/sterol regulatory element-binding protein-1). Consistent with the reduced food intake, hypothalamic expression of neuropeptide Y and agouti-related peptide was decreased. Since HSL is expressed in hypothalamus, we speculate that defective generation of free fatty acids in the hypothalamus due to the absence of HSL mediates the altered expression of these orexigenic neuropeptides. Thus, deficiency of both leptin and HSL has unmasked novel roles of HSL in adipogenesis as well as in feeding behavior.	Jichi Med Sch, Div Endocrinol & Metab, Dept Med, Minami Kawachi, Tochigi 3290498, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Stanford Univ, Div Endocrinol, Palo Alto, CA 94304 USA; Tokyo Med & Dent Univ, Chem Lab, Coll Liberal Arts & Sci, Chiba 2720827, Japan; Univ Tsukuba, Inst Clin Med, Ibaraki 3058575, Japan	Jichi Medical University; University of Tokyo; University of Tokyo; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Tokyo Medical & Dental University (TMDU); University of Tsukuba	Ishibashi, S (corresponding author), Jichi Med Sch, Div Endocrinol & Metab, Dept Med, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	ishibash@jichi.ac.jp	Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/AAI-5648-2020; Kraemer, Fredric/AAC-3633-2019; Harada, Kenji/J-2230-2016; Shimano, Hitoshi/V-1761-2019	Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572; Kraemer, Fredric/0000-0003-2468-7807; Shen, Wen-Jun/0000-0001-5150-1698				AMRI EZ, 1994, J LIPID RES, V35, P930; AMRI EZ, 1991, J LIPID RES, V32, P1457; AMRI EZ, 1991, J LIPID RES, V32, P1449; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Chung SR, 2001, ENDOCRINOLOGY, V142, P4272, DOI 10.1210/en.142.10.4272; CINTI S, 1989, ANAT REC, V224, P466, DOI 10.1002/ar.1092240403; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; GOODE N, 1992, J BIOL CHEM, V267, P16878; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; Haemmerle G, 2002, J BIOL CHEM, V277, P12946, DOI 10.1074/jbc.M108640200; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; Harada K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1182, DOI 10.1152/ajpendo.00259.2003; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Janke J, 2002, DIABETES, V51, P1699, DOI 10.2337/diabetes.51.6.1699; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Kraemer FB, 2002, ENDOCRINOLOGY, V143, P801, DOI 10.1210/en.143.3.801; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Kumar MV, 2002, P NATL ACAD SCI USA, V99, P1921, DOI 10.1073/pnas.042683699; Li H, 2002, ENDOCRINOLOGY, V143, P3333, DOI 10.1210/en.2002-220341; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Loftus TM, 1998, P NATL ACAD SCI USA, V95, P14168, DOI 10.1073/pnas.95.24.14168; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; Makimura H, 2000, DIABETES, V49, P1917, DOI 10.2337/diabetes.49.11.1917; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sainsbury A, 2002, DIABETES, V51, P3420, DOI 10.2337/diabetes.51.12.3420; SAITO M, 1984, AM J PHYSIOL, V246, pR20, DOI 10.1152/ajpregu.1984.246.1.R20; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200	46	47	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15084	15090		10.1074/jbc.M310985200	http://dx.doi.org/10.1074/jbc.M310985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752112	hybrid			2022-12-27	WOS:000220594700073
J	Ma, YJ; Hendershot, LM				Ma, YJ; Hendershot, LM			Herp is dually regulated by both the endoplasmic reticulum stress-specific branch of the unfolded protein response and a branch that is shared with other cellular stress pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ER STRESS; MESSENGER-RNA; TRANSLATIONAL CONTROL; MAMMALIAN-CELLS; GENE-EXPRESSION; ALPHA-SUBUNIT; CHOP; IDENTIFICATION; ELEMENT	The mammalian unfolded protein response (UPR) includes two major branches: one(s) specific to ER stress (Ire1/XBP-1 and ATF6-dependent), and one( s) shared by other cellular stresses (PERK/eIF-2alpha phosphorylation-dependent). Here, we demonstrate that the ER-localized protein Herp represents a second target, in addition to CHOP, that is dually regulated by both the shared and the ER stress-specific branches during UPR activation. For the first time, we are able to assess the contribution of each branch of the UPR in the induction of these targets. We demonstrate that activation of the shared branch of the UPR alone was sufficient to induce Herp and CHOP. ATF4 was not required during ER stress when both branches were used but did contribute significantly to their induction. Conversely, stresses that activated only the shared branch of the UPR were completely dependent on ATF4 for CHOP and Herp induction. Thus, the shared and the ER stress-specific branches of the UPR diverge to regulate two groups of targets, one that is ATF6 and Ire1/XBP-1-dependent, which includes BiP and XBP-1, and another that is eIF-2alpha kinase-dependent, which includes ATF4 and GADD34. The two branches also converge to maximally up-regulate targets like Herp and CHOP. Finally, our studies reveal that a PERK-dependent target other than ATF4 is contributing to the cross-talk between the two branches of the UPR that has previously been demonstrated.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hendershot, LM (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	linda.hendershot@stjude.org	Longo, Kenneth A/A-5631-2010; Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NCI NIH HHS [CA23099, CA21765] Funding Source: Medline; NIGMS NIH HHS [GM54068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHOI SY, 1992, J BIOL CHEM, V267, P286; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; PRICE BD, 1992, CANCER RES, V52, P3814; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Southwood CM, 2002, NEURON, V36, P585, DOI 10.1016/S0896-6273(02)01045-0; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; van Laar T, 2001, CURR PROTEIN PEPT SC, V2, P169; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	48	130	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13792	13799		10.1074/jbc.M313724200	http://dx.doi.org/10.1074/jbc.M313724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14742429	hybrid			2022-12-27	WOS:000220478500064
J	Simons, PC; Biggs, SM; Waller, A; Foutz, T; Cimino, DF; Guo, Q; Neubig, RR; Tang, WJ; Prossnitz, ER; Sklar, LA				Simons, PC; Biggs, SM; Waller, A; Foutz, T; Cimino, DF; Guo, Q; Neubig, RR; Tang, WJ; Prossnitz, ER; Sklar, LA			Real-time analysis of ternary complex on particles - Direct evidence for partial agonism at the agonist-receptor-G protein complex assembly step of signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; LIGAND-BINDING; AFFINITY; PHOSPHORYLATION; RECONSTITUTION; DOMAIN; FULL	We developed a novel and generalized approach to investigate G protein-coupled receptor molecular assemblies. We solubilized a fusion protein consisting of the beta(2)-adrenergic receptor and green fluorescent protein (GFP) for bead-based flow cytometric analysis. beta(2)-Adrenergic receptor GFP bound to dihydroalprenolol-conjugated beads, providing a K-d for the fusion protein and, in competition with beta(2)-adrenergic receptor ligands, K-d values for agonists and antagonists. Beads displaying chelated nickel bound purified hexahistidine-tagged G protein heterotrimers and, subsequently, the binary complex of agonist with beta(2)-adrenergic receptor GFP. The dose-response curves of ternary complex formation revealed maximal assembly for ligands previously classified as full agonists and reduced assembly for ligands previously classified as partial agonists. Guanosine 5'-3-O-( thio) triphosphate-induced dissociation rates of the ternary complex were the same for full and partial agonists. Soluble G protein, competing with ternary complexes on beads provided an affinity estimate of agonist-receptor complexes to G protein. When performed simultaneously, the two assemblies discriminated between agonist, antagonist or inactive molecule in a manner appropriate for high throughput, small volume drug discovery. The assemblies can be further generalized to other G protein coupled receptor protein-protein interactions.	Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Ctr Canc, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ Chicago, Ben May Canc Res Inst, Chicago, IL 60637 USA; Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of Chicago; University of Michigan System; University of Michigan	Sklar, LA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Ctr Canc, Albuquerque, NM 87131 USA.	lsklar@salud.unm.edu	Prossnitz, Eric R./B-4543-2008	Tang, Wei-Jen/0000-0002-8267-8995; Waller, Anna/0000-0003-3676-2501; Neubig, Richard/0000-0003-0501-0008	NHLBI NIH HHS [HL-476417] Funding Source: Medline; NIBIB NIH HHS [EB00264] Funding Source: Medline; NIGMS NIH HHS [GM60799, GM53459] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R24EB000264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459, R24GM060799] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT TE, 1995, AM J RESP CRIT CARE, V151, P574, DOI 10.1164/ajrccm.151.2.7842223; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Bennett TA, 2001, J BIOL CHEM, V276, P22453, DOI 10.1074/jbc.M009679200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bremner P, 1996, CHEST, V109, P957, DOI 10.1378/chest.109.4.957; BYLUND DB, 1978, BRAIN RES, V152, P391, DOI 10.1016/0006-8993(78)90270-6; CARON MG, 1979, J BIOL CHEM, V254, P2923; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Clark RB, 1999, TRENDS PHARMACOL SCI, V20, P279, DOI 10.1016/S0165-6147(99)01351-6; Cussac D, 2002, MOL PHARMACOL, V62, P578, DOI 10.1124/mol.62.3.578; DELEAN A, 1980, J BIOL CHEM, V255, P7108; GETHER U, 1995, J BIOL CHEM, V270, P28268; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; GREEN SA, 1993, J BIOL CHEM, V268, P23116; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; KENT RS, 1980, MOL PHARMACOL, V17, P14; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; LEYSEN JE, 1988, J PHARMACOL EXP THER, V247, P661; MUKHERJEE C, 1976, MOL PHARMACOL, V12, P16; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nolan John P., 1998, P19; Nolan JP, 1998, NAT BIOTECHNOL, V16, P633, DOI 10.1038/nbt0798-633; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Simons PC, 2003, MOL PHARMACOL, V64, P1227, DOI 10.1124/mol.64.5.1227; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; TOTA MR, 1990, MOL PHARMACOL, V37, P996; UPRICHARD DC, 1978, J BIOL CHEM, V253, P5090; Waller A, 2003, COMB CHEM HIGH T SCR, V6, P389; Wise A, 2002, DRUG DISCOV TODAY, V7, P235, DOI 10.1016/S1359-6446(01)02131-6	31	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13514	13521		10.1074/jbc.M310306200	http://dx.doi.org/10.1074/jbc.M310306200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726530	hybrid			2022-12-27	WOS:000220478500030
J	Cannistraro, VJ; Taylor, JS				Cannistraro, VJ; Taylor, JS			DNA-thumb interactions and processivity of T7 DNA polymerase in comparison to yeast polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; ALANINE-SCANNING MUTAGENESIS; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MINOR-GROOVE; ANGSTROM RESOLUTION; FRAMESHIFT FIDELITY; REACTION-MECHANISM; RIBONUCLEASE-II	The replicative polymerase of bacteriophage T7 is structurally and mechanistically well characterized. The crystal structure of T7 DNA polymerase or gene 5 protein complexed to its processivity factor, Escherichia coli thioredoxin, a primer-template, and a dideoxynucleotide reveals how this enzyme interacts with the 3'-end of the primer-template, but does not show how thioredoxin confers processivity to the polymerase. In the crystal structure highly conserved amino acids Asn(335) and Ser(338) of the thumb subdomain of T7 DNA polymerase are seen to interact with phosphates 7 and 8 of the DNA template strand. Results with a mutant T7 DNA polymerase in which aliphatic residues are substituted for these amino acids and experiments with different length and methylphosphonate-modified primer-templates demonstrate that these interactions are essential for processive synthesis and d(A.T)(n) tract bypass. Our data with methylphosphonate-modified DNA suggests that thioredoxin confers processivity to T7 DNA polymerase in part by causing an interaction with the phosphate backbone or minor groove of DNA. Residues Asn(335) and Ser(338) may also function with a nearby helix-loop-helix motif located at residues 339 - 372 to enclose the DNA during processive synthesis. Our results suggest that this structure must be held close to the DNA by ionic interactions to function. These interactions also allow for DNA sliding but physically block the passage of a 3T bulge in the template. In contrast, yeast polymerase eta, a polymerase that non-mutagenically repairs cis-syn thymidine dimers, allows the same bulge to slide past its thumb subdomain during synthesis. A relaxed thumb interaction with the DNA could account for the notably low processivity of polymerase eta.	Washington Univ, Dept Chem, St Louis, MO 63130 USA	Washington University (WUSTL)	Taylor, JS (corresponding author), Washington Univ, Dept Chem, 1 Brookings Dr,Campus Box 1134, St Louis, MO 63130 USA.	taylor@wustl.edu	Taylor, John-Stephen/AAA-3218-2020	Taylor, John-Stephen/0000-0002-8615-7257	NCI NIH HHS [CA-40463] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040463, R01CA040463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allawi HT, 2003, J MOL BIOL, V328, P537, DOI 10.1016/S0022-2836(03)00351-6; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; Cannistraro VJ, 1999, BBA-PROTEIN STRUCT M, V1433, P170, DOI 10.1016/S0167-4838(99)00136-3; CANNISTRARO VJ, 1994, J MOL BIOL, V243, P930, DOI 10.1006/jmbi.1994.1693; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Hamelberg D, 2002, NUCLEIC ACIDS RES, V30, P3615, DOI 10.1093/nar/gkf472; Hermann T, 1996, EUR J BIOCHEM, V242, P98, DOI 10.1111/j.1432-1033.1996.0098r.x; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; Lavigne M, 1999, J MOL BIOL, V285, P977, DOI 10.1006/jmbi.1998.2367; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; Milan S, 1999, BIOCHEMISTRY-US, V38, P218, DOI 10.1021/bi9818422; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PRASAD R, 1994, J BIOL CHEM, V269, P18096; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SAENGER W, 1984, PRINCIPLES NUCL ACID, P300; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; StraussSoukup JK, 1997, BIOCHEMISTRY-US, V36, P8692, DOI 10.1021/bi9705467; Sun LP, 2000, BIOCHEMISTRY-US, V39, P14603, DOI 10.1021/bi001446v; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; TABOR S, 1987, J BIOL CHEM, V262, P16212; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233	41	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18288	18295		10.1074/jbc.M400282200	http://dx.doi.org/10.1074/jbc.M400282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14871898	hybrid			2022-12-27	WOS:000221041500025
J	Das, AT; Zhou, X; Vink, M; Klaver, B; Verhoef, K; Marzio, G; Berkhout, B				Das, AT; Zhou, X; Vink, M; Klaver, B; Verhoef, K; Marzio, G; Berkhout, B			Viral evolution as a tool to improve the tetracycline-regulated gene expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TET REPRESSOR; DIRECTED EVOLUTION; ANTIBIOTIC-RESISTANCE; MAMMALIAN-CELLS; REPLICATION; TRANSCRIPTION; TAT; EUKARYOTES; COMPLEX	We present viral evolution as a novel and powerful method to optimize non-viral proteins. We used this approach to optimize the tetracycline (Tc)-regulated gene expression system (Tet system) for its function in mammalian cells. The components of the Tet system were incorporated in the human immunodeficiency virus (HIV)-1 virus such that viral replication is controlled by this regulatory system. Upon long term replication of this HIV-rtTA virus in human T cells, we obtained a virus variant with an enhanced replication potential resulting from an improved rtTA component of the introduced Tet system. We identified a single amino acid exchange, F86Y, which enhances the transcriptional activity and doxycycline (dox) sensitivity of rtTA. We generated a new rtTA variant that is 5-fold more active at high dox levels than the initial rtTA, and 25-fold more sensitive to dox, whereas the background activity in the absence of dox is not increased. This new rtTA variant will be very useful in biological applications that require a more sensitive or active Tet system. Our results demonstrate that the viral evolution strategy can be used to improve the activity of genes by making them an integral and essential part of the virus.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.berkhout@amc.uva.nl						AUERSPERG N, 1964, J NATL CANCER I, V32, P135; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BAUMEISTER R, 1992, J MOL BIOL, V226, P1257, DOI 10.1016/0022-2836(92)91065-W; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Camps M, 2003, P NATL ACAD SCI USA, V100, P9727, DOI 10.1073/pnas.1333928100; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; Ghadessy FJ, 2001, P NATL ACAD SCI USA, V98, P4552, DOI 10.1073/pnas.071052198; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gossen Manfred, 2001, P139; Hasty J, 2002, P NATL ACAD SCI USA, V99, P16516, DOI 10.1073/pnas.012694899; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krueger C, 2003, NUCLEIC ACIDS RES, V31, P3050, DOI 10.1093/nar/gkg421; Leong SR, 2003, P NATL ACAD SCI USA, V100, P1163, DOI 10.1073/pnas.0237327100; Marzio G, 2002, J VIROL, V76, P3084, DOI 10.1128/JVI.76.6.3084-3088.2002; Marzio G, 2001, P NATL ACAD SCI USA, V98, P6342, DOI 10.1073/pnas.111031498; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Orth P, 1998, J MOL BIOL, V279, P439, DOI 10.1006/jmbi.1998.1775; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; Powell SK, 2000, NAT BIOTECHNOL, V18, P1279, DOI 10.1038/82391; Smith SM, 2001, J BIOL CHEM, V276, P32184, DOI 10.1074/jbc.M101604200; Sutherland JD, 2000, CURR OPIN CHEM BIOL, V4, P263, DOI 10.1016/S1367-5931(00)00087-9; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Verhoef K, 2001, J VIROL, V75, P979, DOI 10.1128/JVI.75.2.979-987.2001; Xiao Y, 2000, VIROLOGY, V269, P268, DOI 10.1006/viro.2000.0213; Yokobayashi Y, 2002, P NATL ACAD SCI USA, V99, P16587, DOI 10.1073/pnas.252535999	35	104	122	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18776	18782		10.1074/jbc.M313895200	http://dx.doi.org/10.1074/jbc.M313895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14761948	hybrid			2022-12-27	WOS:000221041500085
J	Charlesworth, A; Cox, LL; MacNicol, AM				Charlesworth, A; Cox, LL; MacNicol, AM			Cytoplasmic polyadenylation element (CPE)- and CPE-binding protein (CPEB)-independent mechanisms regulate early class maternal mRNA translational activation in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-SPECIFIC POLYADENYLATION; C-MOS; MEIOTIC MATURATION; POLY(A) ADDITION; CELL-CYCLE; AURORA-A; KINASE; PATHWAY; EG2; PHOSPHORYLATION	Meiotic cell cycle progression during vertebrate oocyte maturation requires the correct temporal translation of maternal mRNAs encoding key regulatory proteins. The mechanism by which specific mRNAs are temporally activated is unknown, although both cytoplasmic polyadenylation elements (CPE) within the 3'-untranslated region (3'-UTR) of mRNAs and the CPE-binding protein (CPEB) have been implicated. We report that in progesterone-stimulated Xenopus oocytes, the early cytoplasmic polyadenylation and translational activation of multiple maternal mRNAs occur in a CPE- and CPEB-independent manner. We demonstrate that polyadenylation response elements, originally identified in the 3'-UTR of the mRNA encoding the Mos protooncogene, direct CPE- and CPEB-independent polyadenylation of an early class of Xenopus maternal mRNAs. Our findings refute the hypothesis that CPE sequences alone account for the range of temporal inductions of maternal mRNAs observed during Xenopus oocyte maturation. Rather, our data indicate that the sequential action of distinct 3'-UTR-directed translational control mechanisms coordinates the complex temporal patterns and extent of protein synthesis during vertebrate meiotic cell cycle progression.	Univ Arkansas Med Sci, ACRC, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Neurobiol & Dev Sci, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	MacNicol, AM (corresponding author), Univ Arkansas Med Sci, ACRC, Slot 814,4301 W Markham, Little Rock, AR 72205 USA.	Angus@UAMS.edu			NICHD NIH HHS [R01 HD035688] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035688] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Ballantyne S, 1997, MOL BIOL CELL, V8, P1633, DOI 10.1091/mbc.8.8.1633; Barkoff AF, 2000, DEV BIOL, V220, P97, DOI 10.1006/dbio.2000.9613; Castro A, 2003, J BIOL CHEM, V278, P2236, DOI 10.1074/jbc.M207894200; Charlesworth A, 2002, EMBO J, V21, P2798, DOI 10.1093/emboj/21.11.2798; Charlesworth A, 2000, DEV BIOL, V227, P706, DOI 10.1006/dbio.2000.9922; Culp PA, 1998, DEV BIOL, V193, P63, DOI 10.1006/dbio.1997.8785; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; Dupre A, 2002, EMBO J, V21, P4026, DOI 10.1093/emboj/cdf400; Ferby I, 1999, GENE DEV, V13, P2177, DOI 10.1101/gad.13.16.2177; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; Frank-Vaillant M, 2000, J CELL SCI, V113, P1127; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Howard EL, 1999, MOL CELL BIOL, V19, P1990; HYMAN LE, 1988, GENE DEV, V2, P598, DOI 10.1101/gad.2.5.598; Machaca K, 2002, J CELL BIOL, V156, P75, DOI 10.1083/jcb.200110059; Maton G, 2003, J BIOL CHEM, V278, P21439, DOI 10.1074/jbc.M300811200; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Minshall N, 1999, RNA, V5, P27, DOI 10.1017/S1355838299981220; Nakajo N, 2000, GENE DEV, V14, P328; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335; Rassa JC, 2000, VIROLOGY, V274, P438, DOI 10.1006/viro.2000.0494; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SMITH RC, 1988, GENE DEV, V2, P1296, DOI 10.1101/gad.2.10.1296; STANDART N, 1993, DEV GENET, V14, P492, DOI 10.1002/dvg.1020140610; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Stutz A, 1998, GENE DEV, V12, P2535, DOI 10.1101/gad.12.16.2535; Tay J, 2000, DEV BIOL, V221, P1, DOI 10.1006/dbio.2000.9669; Welk JF, 2001, GENE, V263, P113, DOI 10.1016/S0378-1119(00)00588-6	45	83	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17650	17659		10.1074/jbc.M313837200	http://dx.doi.org/10.1074/jbc.M313837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14752101	hybrid, Green Accepted			2022-12-27	WOS:000220870400094
J	de Alvaro, C; Teruel, T; Hernandez, R; Lorenzo, M				de Alvaro, C; Teruel, T; Hernandez, R; Lorenzo, M			Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappa B kinase in a p38 MAPK-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; SIGNALING PATHWAYS; 3T3-L1 ADIPOCYTES; C2C12 MYOBLASTS; TARGETED DISRUPTION; GLUT4 TRANSLOCATION; BROWN ADIPOCYTES; PROTEIN-KINASES; DOWN-REGULATION; ADIPOSE-TISSUE	Insulin stimulation produced a reliable 3-fold increase in glucose uptake in primary neonatal rat myotubes, which was accompanied by a similar effect on GLUT4 translocation to plasma membrane. Tumor necrosis factor (TNF)-alpha caused insulin resistance on glucose uptake and GLUT4 translocation by impairing insulin stimulation of insulin receptor (IR) and IR substrate (IRS)-1 and IRS-2 tyrosine phosphorylation, IRS-associated phosphatidylinositol 3-kinase activation, and Akt phosphorylation. Because this cytokine produced sustained activation of stress and proinflammatory kinases, we have explored the hypothesis that insulin resistance by TNF-alpha could be mediated by these pathways. In this study we demonstrate that pretreatment with PD169316 or SB203580, inhibitors of p38 MAPK, restored insulin signaling and normalized insulin-induced glucose uptake in the presence of TNF-alpha. However, in the presence of PD98059 or SP600125, inhibitors of p42/p44 MAPK or JNK, respectively, insulin resistance by TNF-alpha was still produced. Moreover, TNF-alpha produced inhibitor kappaB kinase (IKK)-beta activation and inhibitor kappaB-beta and -alpha degradation in a p38 MAPK-dependent manner, and treatment with salicylate (an inhibitor of IKK) completely restored insulin signaling. Furthermore, TNF-alpha produced serine phosphorylation of IR and IRS-1 (total and on Ser(307) residue), and these effects were completely precluded by pretreatment with either PD169316 or salicylate. Consequently, TNF-alpha, through activation of p38 MAPK and IKK, produces serine phosphorylation of IR and IRS-1, impairing its tyrosine phosphorylation by insulin and the corresponding activation of phosphatidylinositol 3-kinase and Akt, leading to insulin resistance on glucose uptake and GLUT4 translocation.	Univ Complutense, Fac Farm, Dept Bioquim & Biol Mol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Lorenzo, M (corresponding author), Univ Complutense, Fac Farm, Dept Bioquim & Biol Mol 2, E-28040 Madrid, Spain.	mlorenzo@farm.ucm.es						Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Ciaraldi TP, 1998, ENDOCRINOLOGY, V139, P4793, DOI 10.1210/en.139.12.4793; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Conejo R, 2002, ONCOGENE, V21, P3739, DOI 10.1038/sj.onc.1205469; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; Del Aguila LF, 1999, AM J PHYSIOL-ENDOC M, V276, pE849, DOI 10.1152/ajpendo.1999.276.5.E849; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Fujishiro M, 2003, MOL ENDOCRINOL, V17, P487, DOI 10.1210/me.2002-0131; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hernandez R, 2001, FEBS LETT, V494, P225, DOI 10.1016/S0014-5793(01)02353-5; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Nolte LA, 1998, DIABETES, V47, P721, DOI 10.2337/diabetes.47.5.721; Patiag D, 2000, CLIN SCI, V99, P303, DOI 10.1042/cs0990303; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Ranganathan S, 1996, METABOLISM, V45, P1089, DOI 10.1016/S0026-0495(96)90007-4; Rosenzweig T, 2002, DIABETES, V51, P1921, DOI 10.2337/diabetes.51.6.1921; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Uysal KT, 1998, ENDOCRINOLOGY, V139, P4832, DOI 10.1210/en.139.12.4832; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vollenweider P, 2002, DIABETES, V51, P1052, DOI 10.2337/diabetes.51.4.1052; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Watson RT, 2001, EXP CELL RES, V271, P75, DOI 10.1006/excr.2001.5375; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	47	293	309	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17070	17078		10.1074/jbc.M312021200	http://dx.doi.org/10.1074/jbc.M312021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14764603	hybrid			2022-12-27	WOS:000220870400024
J	Gronberg, KLC; Watmough, NJ; Thomson, AJ; Richardson, DJ; Field, SJ				Gronberg, KLC; Watmough, NJ; Thomson, AJ; Richardson, DJ; Field, SJ			Redox-dependent open and closed forms of the active site of the bacterial respiratory nitric-oxide reductase revealed by cyanide binding studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-COPPER OXIDASES; TERMINAL OXIDASES; ESCHERICHIA-COLI; CARBON-MONOXIDE; ENZYME; NO	The bacterial respiratory nitric-oxide reductase (NOR) catalyzes the respiratory detoxification of nitric oxide in bacteria and Archaea. It is a member of the well known super-family of heme-copper oxidases but has a [heme Fe-non-heme Fe] active site rather than the [heme Fe-Cu-B] active site normally associated with oxygen reduction. Paracoccus denitrificans NOR is spectrally characterized by a ligand-to-metal charge transfer absorption band at 595 nm, which arises from the high spin ferric heme iron of a mu-oxo-bridged [heme Fe(III)-O-Fe(III)] active site. On reduction of the nonheme iron, the mu-oxo bridge is broken, and the ferric heme iron is hydroxylated or hydrated, depending on the pH. At present, the catalytic cycle of NOR is a matter of much debate, and it is not known to which redox state(s) of the enzyme nitric oxide can bind. This study has used cyanide to probe the nature of the active site in a number of different redox states. Our observations suggest that the mu-oxo-bridged [heme Fe(III)-O-Fe(III)] active site represents a closed or resting state of NOR that can be opened by reduction of the non-heme iron.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci & Pharm, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of East Anglia	Field, SJ (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	sarah.field@uea.ac.uk	Richardson, David J/E-2275-2011; Watmough, Nicholas J/A-6643-2010	Watmough, Nicholas J/0000-0001-5901-6750				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BELL LC, 1992, J GEN MICROBIOL, V138, P437, DOI 10.1099/00221287-138-3-437; Busch A, 2002, APPL ENVIRON MICROB, V68, P668, DOI 10.1128/AEM.68.2.668-672.2002; Butland G, 2001, J BACTERIOL, V183, P189, DOI 10.1128/JB.183.1.189-199.2001; Cheesman MR, 1998, BIOCHEMISTRY-US, V37, P3994, DOI 10.1021/bi972437y; Field SJ, 2002, J BIOL CHEM, V277, P20146, DOI 10.1074/jbc.M112202200; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Girsch P, 1997, BBA-BIOENERGETICS, V1318, P202, DOI 10.1016/S0005-2728(96)00138-7; Gronberg KLC, 1999, BIOCHEMISTRY-US, V38, P13780, DOI 10.1021/bi9916426; Hendriks J, 1998, J BIOENERG BIOMEMBR, V30, P15, DOI 10.1023/A:1020547225398; Hendriks J, 2000, BBA-BIOENERGETICS, V1459, P266, DOI 10.1016/S0005-2728(00)00161-4; Hendriks JHM, 2001, BIOCHEMISTRY-US, V40, P13361, DOI 10.1021/bi011428t; MITCHELL R, 1995, BIOCHEMISTRY-US, V34, P7576, DOI 10.1021/bi00023a003; Moody AJ, 1996, BBA-BIOENERGETICS, V1276, P6; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; Pinakoulaki E, 2002, J BIOL CHEM, V277, P23407, DOI 10.1074/jbc.M201913200; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; Suharti, 2001, BIOCHEMISTRY-US, V40, P2632, DOI 10.1021/bi0020067; SUKURAI N, 1997, BIOCHEMISTRY-US, V36, P13809; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8	22	27	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17120	17125		10.1074/jbc.M400824200	http://dx.doi.org/10.1074/jbc.M400824200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766741	hybrid			2022-12-27	WOS:000220870400030
J	Le Stunff, H; Auger, R; Kanellopoulos, J; Raymond, MN				Le Stunff, H; Auger, R; Kanellopoulos, J; Raymond, MN			The Pro-451 to leu polymorphism within the C-terminal tail of P2X7 receptor impairs cell death but not phospholipase D activation in murine thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P(2Z) PURINERGIC RECEPTORS; EXTRACELLULAR ATP; NUCLEOTIDE RECEPTOR; P2X(7) RECEPTOR; INDUCED APOPTOSIS; PC12 CELLS; BAC1.2F5 MACROPHAGES; CYTOKINE PRODUCTION; PHOSPHATIDIC-ACID; HUMAN-LYMPHOCYTES	The P2X family of ATP receptors (P2XR) are ligand-gated channels that have been proposed to regulate cell death of immature thymocytes. However, the nature of the P2XR subtype involved has been controversial until recently. In agreement with previous studies, we found that extracellular ATP (ATPe) induces a caspase-dependent apoptosis of BALB/c thymocytes, as observed by DNA fragmentation. Additionally, ATPe induces a predominant caspase-independent thymocytes lysis characterized by plasma membrane disruption. Both responses to ATPe can be induced by a potent P2X7R agonist, benzoylbenzoyl-ATP, whereas P2X7R antagonists, oxidized ATP and pyridoxalphosphate-6-azophenyl-2' 4'-disulfonic acid, inhibited the effect of ATPe. These results are further supported by observations where disruption of the P2X7R gene (P2X7R (-/-) mice) completely abolishes thymocytes death induced by ATPe. Interestingly, the natural P451L mutation in the C-terminal tail of P2X7R present in C57BL/6 mice, which impairs ATPe-dependent pore formation in T lymphocytes, significantly reduces thymocytes death triggered by ATPe. Furthermore, we found that P2X7R from BW5147 thymoma cells also harbors this point mutation, accounting for their insensitivity to ATPe-induced cell death. Concentrations of ATPe effective in inducing cell death also increase phosphatidylcholine-hydrolyzing phospholipase D (PC-PLD) activity in BALB/c thymocytes through the stimulation of P2X7R. However, in contrast to ATPe-induced cell death, PC-PLD activation is totally Ca2+-dependent. Moreover, the stimulation of PC-PLD by ATPe is not affected by the P451L mutation present in C57BL/6 thymocytes and BW5147 cells, suggesting that cell death and PC-PLD activity are regulated through distinct domains of the P2X7R. Finally, the inhibition of ATPe-induced PC-PLD stimulation does not affect thymocytes death. Altogether, these data suggest that P2X7R-induced thymocytes death is independent of the stimulation of PC-PLD activity.	Univ Paris 11, CNRS, UMR 8619,Inst Biochim & Biophys Mol & Cellulaire, Lab Activat Cellulaire & Transduct Signaux, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Raymond, MN (corresponding author), Univ Paris 11, CNRS, UMR 8619,Inst Biochim & Biophys Mol & Cellulaire, Lab Activat Cellulaire & Transduct Signaux, Batiment 430, F-91405 Orsay, France.	marie-noelle.raymond@bbmpc.u-psud.fr	LE STUNFF, Hervé/AAA-6882-2019					Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Apasov SG, 1997, J IMMUNOL, V158, P5095; Auger R, 1999, J BIOL CHEM, V274, P28652, DOI 10.1074/jbc.274.40.28652; Budagian V, 2003, J BIOL CHEM, V278, P1549, DOI 10.1074/jbc.M206383200; Cario-Toumaniantz C, 1998, CIRC RES, V83, P196, DOI 10.1161/01.RES.83.2.196; Chiozzi P, 1996, BIOCHEM BIOPH RES CO, V218, P176, DOI 10.1006/bbrc.1996.0031; Chvatchko Y, 1996, IMMUNITY, V5, P275, DOI 10.1016/S1074-7613(00)80322-2; Courageot MP, 2002, ANN NY ACAD SCI, V973, P186, DOI 10.1111/j.1749-6632.2002.tb04630.x; Coutinho-Silva R, 2003, IMMUNITY, V19, P403, DOI 10.1016/S1074-7613(03)00235-8; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Fernando KC, 1999, ARCH BIOCHEM BIOPHYS, V362, P197, DOI 10.1006/abbi.1998.1045; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Freedman BD, 1999, EUR J IMMUNOL, V29, P1635, DOI 10.1002/(SICI)1521-4141(199905)29:05<1635::AID-IMMU1635>3.3.CO;2-2; FREEMAN EJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P84, DOI 10.1006/abbi.1995.1269; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; Gendron FP, 2003, AM J PHYSIOL-CELL PH, V284, pC571, DOI 10.1152/ajpcell.00286.2002; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Humphreys BD, 1998, MOL PHARMACOL, V54, P22, DOI 10.1124/mol.54.1.22; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; KANAHO Y, 1993, J BIOL CHEM, V268, P12492; Kang JH, 1998, EXP MOL MED, V30, P21, DOI 10.1038/emm.1998.3; Koshiba M, 1997, P NATL ACAD SCI USA, V94, P831, DOI 10.1073/pnas.94.3.831; Le Feuvre RA, 2002, J BIOL CHEM, V277, P3210, DOI 10.1074/jbc.M104388200; Lee CS, 2001, NEUROSCI LETT, V313, P117, DOI 10.1016/S0304-3940(01)02233-9; Lee SD, 2000, J NEUROCHEM, V75, P1053, DOI 10.1046/j.1471-4159.2000.0751053.x; Lee Y, 2002, IMMUNOLOGY, V107, P435, DOI 10.1046/j.1365-2567.2002.01532.x; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; McConkey DJ, 1998, TOXICOL LETT, V99, P157, DOI 10.1016/S0378-4274(98)00155-6; Nagy PV, 2000, IMMUNOL LETT, V72, P23, DOI 10.1016/S0165-2478(00)00168-1; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; O'Sullivan W.J., 1969, DATA BIOCH RES, P423; Rizzo MA, 2002, PHARMACOL THERAPEUT, V94, P35, DOI 10.1016/S0163-7258(02)00170-5; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Smart ML, 2002, AM J PHYSIOL-CELL PH, V283, pC77, DOI 10.1152/ajpcell.00456.2001; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sun SH, 1999, J NEUROCHEM, V73, P334, DOI 10.1046/j.1471-4159.1999.0730334.x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; vanMeerwijk JPM, 1997, J EXP MED, V185, P377, DOI 10.1084/jem.185.3.377; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Yamakawa H, 2000, NEUROREPORT, V11, P3647, DOI 10.1097/00001756-200011090-00049; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	55	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16918	16926		10.1074/jbc.M313064200	http://dx.doi.org/10.1074/jbc.M313064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761980	hybrid			2022-12-27	WOS:000220870400006
J	Gidalevitz, T; Biswas, C; Ding, H; Schneidman-Duhovny, D; Wolfson, HJ; Stevens, F; Radford, S; Argon, Y				Gidalevitz, T; Biswas, C; Ding, H; Schneidman-Duhovny, D; Wolfson, HJ; Stevens, F; Radford, S; Argon, Y			Identification of the N-terminal peptide binding site of glucose-regulated protein 94	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90 MOLECULAR CHAPERONE; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; VIRAL PEPTIDE; GP96; GRP94; AFFINITY; DOMAIN; HSP70; BETA(2)-MICROGLOBULIN	Because the stress protein GRP94 can augment presentation of peptides to T cells, it is important to define how it, as well as all other HSP90 family members, binds peptides. Having previously shown that the N-terminal half of GRP94 can account for the peptide binding activity of the full-length protein, we now locate this binding site by testing predictions of a molecular docking model. The best predicted site was on the opposite face of the beta sheet from the pan-HSP90 radicicol-binding pocket, in close proximity to a deep hydrophobic pocket. The peptide and radicicol-binding sites are distinct, as shown by the ability of a radicicol-refractive mutant to bind peptide. When the fluorophore acrylodan is attached to Cys(117) within the hydrophobic pocket, its fluorescence is reduced upon peptide binding, consistent with proximity of the two ligands. Substitution of His(125), which contacts the bound peptide, compromises peptide-binding activity. We conclude that peptide binds to the concave face of the beta sheet of the N-terminal domain, where binding is regulated during the action cycle of the chaperone.	Univ Penn, Childrens Hosp Philadelphia, Div Cell Pathol, Philadelphia, PA 19104 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Comp Sci, IL-69978 Tel Aviv, Israel; Argonne Natl Lab, Argonne, IL 60439 USA; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Chicago; Tel Aviv University; United States Department of Energy (DOE); Argonne National Laboratory; University of Leeds	Argon, Y (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Div Cell Pathol, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	yargon@mail.med.upenn.edu	Schneidman, Dina/ABH-6654-2020; Wolfson, Haim/A-1837-2011; Gidalevitz, Tali/C-9217-2009	Schneidman, Dina/0000-0003-0480-0438; Wolfson, Haim/0000-0002-7600-2702; Gidalevitz, Tali/0000-0002-9178-6648; Radford, Sheena/0000-0002-3079-8039	NATIONAL CANCER INSTITUTE [P01CA074182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030178] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043757] Funding Source: NIH RePORTER; NCI NIH HHS [CA-74182] Funding Source: Medline; NIAID NIH HHS [AI-30178] Funding Source: Medline; NIDDK NIH HHS [DK43757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; Baker-LePain JC, 2003, CURR OPIN IMMUNOL, V15, P89, DOI 10.1016/S0952791502000067; Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Breloer M, 1998, EUR J IMMUNOL, V28, P1016, DOI 10.1002/(SICI)1521-4141(199803)28:03<1016::AID-IMMU1016>3.0.CO;2-G; Burkholder WF, 1996, P NATL ACAD SCI USA, V93, P10632, DOI 10.1073/pnas.93.20.10632; Collins EJ, 1998, IMMUNOL REV, V163, P151, DOI 10.1111/j.1600-065X.1998.tb01194.x; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; IMARAI M, 1995, CELL IMMUNOL, V160, P33, DOI 10.1016/0008-8749(95)80006-5; Ishii T, 1999, J IMMUNOL, V162, P1303; Kalkum M, 1998, BIOCONJUGATE CHEM, V9, P226, DOI 10.1021/bc970162t; Liu CL, 2004, METHODS, V32, P32, DOI 10.1016/S1046-2023(03)00185-3; Meng SD, 2001, LANCET, V357, P528, DOI 10.1016/S0140-6736(00)04050-2; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Rai SS, 1998, J BIOL CHEM, V273, P31131, DOI 10.1074/jbc.273.47.31131; Robert J, 2001, EUR J IMMUNOL, V31, P186, DOI 10.1002/1521-4141(200101)31:1<186::AID-IMMU186>3.0.CO;2-D; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schneidman-Duhovny D, 2003, PROTEINS, V52, P107, DOI 10.1002/prot.10397; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Shields MJ, 1998, J IMMUNOL, V160, P2297; Shields MJ, 1998, J BIOL CHEM, V273, P28010, DOI 10.1074/jbc.273.43.28010; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Smith RA, 2002, J IMMUNOL, V169, P3105, DOI 10.4049/jimmunol.169.6.3105; SOLDANO KL, 2003, J BIOL CHEM; Spee P, 1997, EUR J IMMUNOL, V27, P2441, DOI 10.1002/eji.1830270944; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Vogen S, 2002, J BIOL CHEM, V277, P40742, DOI 10.1074/jbc.M205323200; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	45	52	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16543	16552		10.1074/jbc.M313060200	http://dx.doi.org/10.1074/jbc.M313060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754890	hybrid, Green Accepted			2022-12-27	WOS:000220747900104
J	Law, R; Harper, S; Speicher, DW; Discher, DE				Law, R; Harper, S; Speicher, DW; Discher, DE			Influence of lateral association on forced unfolding of antiparallel spectrin heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN ROD DOMAIN; CELL MEMBRANE; PROTEINS; MOLECULE; REPEATS; SPECTROSCOPY; TEMPERATURE; INITIATION; MICROSCOPY; SKELETON	Protein extensibility appears to be based broadly on conformational changes that can in principle be modulated by protein-protein interactions. Spectrin family proteins, with their extensible three-helix folds, enable evaluation of dimerization effects at the single molecule level by atomic force microscopy. Although some spectrin family members function physiologically only as homodimers (e.g. alpha-actinin) or are strictly monomers (e.g. dystrophin), alpha- and beta-spectrins are stable as monomeric forms but occur physiologically as alpha,beta-heterodimers bound laterally lengthwise. For short constructs of alpha- and beta-spectrin, either as monomers or as alpha,beta-dimers, sawtooth patterns in atomic force microscopy-forced extension show that unfolding stochastically extends repeats similar to4-5-fold greater in length than native conformations. For both dimers and monomers, distributions of unfolding lengths appear bimodal; major unfolding peaks reflect single repeats, and minor unfolding peaks at twice the length reflect tandem repeats. Cooperative unfolding thus propagates through helical linkers between serial repeats (1, 2). With lateral heterodimers, however, the force distribution is broad and shifted to higher forces. The associated chains in a dimer can stay together and unfold simultaneously in addition to unfolding independently. Weak lateral interactions do not inhibit unfolding, but strong lateral interactions facilitate simultaneous unfolding analogous to serial repeat coupling within spectrin family proteins.	Univ Penn, Sch Engn & Appl Sci, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Struct Biol Program, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute	Discher, DE (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA.	discher@seas.upenn.edu		discher, dennis/0000-0001-6163-2229				An XL, 2002, J BIOL CHEM, V277, P31796, DOI 10.1074/jbc.M204567200; Begg GE, 2000, J BIOL CHEM, V275, P3279, DOI 10.1074/jbc.275.5.3279; Broderick MJF, 2002, J STRUCT BIOL, V137, P184, DOI 10.1006/jsbi.2002.4465; Calvert R, 1996, BIOPHYS J, V71, P1605, DOI 10.1016/S0006-3495(96)79363-3; Carl P, 2001, P NATL ACAD SCI USA, V98, P1565, DOI 10.1073/pnas.031409698; FLOOD G, 1995, J MOL BIOL, V252, P227, DOI 10.1006/jmbi.1995.0490; Flood G, 1997, EUR BIOPHYS J BIOPHY, V25, P431, DOI 10.1007/s002490050057; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Kahana E, 1997, CELL MOTIL CYTOSKEL, V36, P246; Kreis T., 1999, GUIDEBOOK CYTOSKELET, V2nd; Law R, 2003, BIOPHYS J, V85, P3286, DOI 10.1016/S0006-3495(03)74747-X; Law R, 2003, BIOPHYS J, V84, P533, DOI 10.1016/S0006-3495(03)74872-3; Lee JCM, 2001, BIOPHYS J, V81, P3178, DOI 10.1016/S0006-3495(01)75954-1; Lenne PF, 2000, FEBS LETT, V476, P124, DOI 10.1016/S0014-5793(00)01704-X; Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697; LIU SC, 1981, J CLIN INVEST, V68, P597, DOI 10.1172/JCI110293; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; Paci E, 2000, P NATL ACAD SCI USA, V97, P6521, DOI 10.1073/pnas.100124597; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SHAHBAKHTI F, 1986, BIOCHEMISTRY-US, V25, P5969, DOI 10.1021/bi00368a020; Shao JY, 1999, BIOPHYS J, V77, P587, DOI 10.1016/S0006-3495(99)76915-8; Thomas GH, 1999, J CELL SCI, V112, P2843; Thomas GH, 2001, BIOESSAYS, V23, P152, DOI 10.1002/1521-1878(200102)23:2<152::AID-BIES1022>3.0.CO;2-1; Trottier M, 2000, RNA, V6, P1257, DOI 10.1017/S1355838200992501; Ursitti JA, 1996, J BIOL CHEM, V271, P6636, DOI 10.1074/jbc.271.12.6636; Yip CM, 1998, BIOCHEMISTRY-US, V37, P5439, DOI 10.1021/bi9722756	27	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16410	16416		10.1074/jbc.M313107200	http://dx.doi.org/10.1074/jbc.M313107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761982	hybrid			2022-12-27	WOS:000220747900088
J	Moreno, E; Tovar-Palacio, C; de los Heros, P; Guzman, B; Bobadilla, NA; Vazquez, N; Riccardi, D; Poch, E; Gamba, G				Moreno, E; Tovar-Palacio, C; de los Heros, P; Guzman, B; Bobadilla, NA; Vazquez, N; Riccardi, D; Poch, E; Gamba, G			A single nucleotide polymorphism alters the activity of the renal Na+: Cl- cotransporter and reveals a role for transmembrane segment 4 in chloride and thiazide affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NACL-COTRANSPORTER; NA+-K+-2CL(-) COTRANSPORTER; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; ESCHERICHIA-COLI; ION-TRANSPORT; BETA-SUBUNIT; RAT; SODIUM; BINDING	The thiazide-sensitive Na+: Cl- cotransporter is the major salt transport pathway in the distal convoluted tubule of the kidney, and a role of this cotransporter in blood pressure homeostasis has been defined by physiological studies on pressure natriuresis and by its involvement in monogenic diseases that feature arterial hypotension or hypertension. Data base analysis revealed that 135 single nucleotide polymorphisms along the human SLC12A3 gene that encodes the Na+: Cl- cotransporter have been reported. Eight are located within the coding region, and one results in a single amino acid change; the residue glycine at the position 264 is changed to alanine (G264A). This residue is located within the fourth transmembrane domain of the predicted structure. Because Gly-264 is a highly conserved residue, we studied the functional properties of this polymorphism by using in vitro mutagenesis and the heterologous expression system in Xenopus laevis oocytes. G264A resulted in a significant and reproducible reduction (similar to50%) in Na-22(+) uptake when compared with the wild type cotransporter. The affinity for extracellular Cl- and for thiazide diuretics was increased in G264A. Western blot analysis showed similar immunoreactive bands between the wild type and the G264A cotransporters, and confocal images of oocytes injected with enhanced green fluorescent protein-tagged wild type and G264A cotransporter showed no differences in the protein surface expression level. These observations suggest that the G264A polymorphism is associated with reduction in the substrate translocation rate of the cotransporter, due to a decrease in the intrinsic activity. Our study also reveals a role of the transmembrane segment 4 in defining the affinity for extracellular Cl- and thiazide diuretics.	Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mol Physiol Unit, Mexico City 14000, DF, Mexico; Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City 14000, DF, Mexico; IDIBAPS, Serv Nefrol, Barcelona 08036, Spain; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Universidad Nacional Autonoma de Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Manchester	Gamba, G (corresponding author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mol Physiol Unit, Vasco Quiroga 15, Mexico City 14000, DF, Mexico.	gamba@sni.conacyt.mx	Riccardi, Daniela/A-4674-2010; Tovar-Palacio, Claudia/AAE-4572-2022; Gamba, Gerardo/P-4873-2016	Riccardi, Daniela/0000-0002-7322-3163; Moreno Martinez, Reyna Erika/0000-0002-7563-0379; Gamba, Gerardo/0000-0002-4378-9043; Tovar-Palacio, Claudia/0000-0001-7965-6421				Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; BRANICA M, 1991, MAR CHEM, V1, P1; Cheng BK, 2004, J BIOL CHEM, V279, P8648, DOI 10.1074/jbc.M312095200; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COSTANZO LS, 1985, AM J PHYSIOL, V248, pF527, DOI 10.1152/ajprenal.1985.248.4.F527; De Jong JC, 2003, J AM SOC NEPHROL, V14, P2428, DOI 10.1097/01.ASN.0000089832.52063.F5; de Jong JC, 2003, J BIOL CHEM, V278, P24302, DOI 10.1074/jbc.M303101200; De Jong JC, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017904.77985.03; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; ELLISON DH, 1987, AM J PHYSIOL, V253, pF546, DOI 10.1152/ajprenal.1987.253.3.F546; Feskanich D, 1997, OSTEOPOROSIS INT, V7, P79, DOI 10.1007/BF01623465; Gagnon E, 2004, J BIOL CHEM, V279, P5648, DOI 10.1074/jbc.M311218200; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; GESEK FA, 1995, AM J PHYSIOL-RENAL, V268, pF89, DOI 10.1152/ajprenal.1995.268.1.F89; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gimenez I, 2002, J BIOL CHEM, V277, P8767, DOI 10.1074/jbc.C200021200; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; HAAS M, 1983, AM J PHYSIOL, V245, pC235, DOI 10.1152/ajpcell.1983.245.3.C235; Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Isenring P, 2001, COMP BIOCHEM PHYS A, V130, P487, DOI 10.1016/S1095-6433(01)00420-2; JONES G, 1995, J BONE MINER RES, V10, P106; KUCHAPARTY S, 1999, AM J PHYSIOL, V277, pF643; KUNAU RT, 1975, J CLIN INVEST, V56, P401, DOI 10.1172/JCI108105; Mastroianni N, 1996, GENOMICS, V35, P486, DOI 10.1006/geno.1996.0388; Mastroianni N, 1996, AM J HUM GENET, V59, P1019; Mayan H, 2002, J CLIN ENDOCR METAB, V87, P3248, DOI 10.1210/jc.87.7.3248; Meade P, 2003, AM J PHYSIOL-RENAL, V284, pF1145, DOI 10.1152/ajprenal.00421.2002; Melander O, 2000, HYPERTENSION, V36, P389, DOI 10.1161/01.HYP.36.3.389; Monroy A, 2000, AM J PHYSIOL-RENAL, V279, pF161, DOI 10.1152/ajprenal.2000.279.1.F161; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Okuda T, 2002, J BIOL CHEM, V277, P45315, DOI 10.1074/jbc.M207742200; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; Plotkin MD, 1996, KIDNEY INT, V50, P174, DOI 10.1038/ki.1996.300; Rafferty JA, 1997, BBA-PROTEIN STRUCT M, V1342, P90, DOI 10.1016/S0167-4838(97)00095-2; Schoofs MWCJ, 2003, ANN INTERN MED, V139, P476, DOI 10.7326/0003-4819-139-6-200309160-00010; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; STOKES JB, 1984, J CLIN INVEST, V74, P7, DOI 10.1172/JCI111420; TRAN JM, 1990, AM J PHYSIOL, V258, pF908, DOI 10.1152/ajprenal.1990.258.4.F908; Vazquez N, 2002, AM J PHYSIOL-RENAL, V282, pF599, DOI 10.1152/ajprenal.00284.2001; Velazquez H, 1998, KIDNEY INT, V54, P464, DOI 10.1046/j.1523-1755.1998.00036.x; VELAZQUEZ H, 1984, AM J PHYSIOL, V247, pF904, DOI 10.1152/ajprenal.1984.247.6.F904; VERMERSCH PS, 1990, J BIOL CHEM, V265, P16592; Wang XY, 2001, J CLIN INVEST, V108, P215, DOI 10.1172/JCI200110366; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443; ZHAO GP, 1993, J BIOL CHEM, V268, P14921; Zhu HD, 2003, J HYPERTENS, V21, P87, DOI 10.1097/00004872-200301000-00018	53	33	36	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16553	16560		10.1074/jbc.M400602200	http://dx.doi.org/10.1074/jbc.M400602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14766743	hybrid			2022-12-27	WOS:000220747900105
J	Bibillo, A; Eickbush, TH				Bibillo, A; Eickbush, TH			End-to-end template jumping by the reverse transcriptase encoded by the R2 retrotransposon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONTEMPLATED NUCLEOTIDE ADDITION; STRAND TRANSFER; IN-VITRO; RNA-POLYMERASE; TARGET SITE; MECHANISM; RECOMBINATION; REQUIREMENTS; INITIATION; SEQUENCES	The reverse transcriptase encoded by the non-long terminal repeat retrotransposon R2 has been shown to be able to jump from the 5'-end of one RNA template (the donor) to the 3'-end of a second RNA template (the acceptor) in the absence of preexisting sequence identity between the two templates. These jumps between RNA templates have similarity to the end-to-end template jumps described for the RNA-directed RNA polymerases encoded by certain RNA viruses. Here we describe for the first time the mechanism by which such end-to-end template jumps can occur. Most template jumps by the R2 reverse transcriptase are brought about by the enzyme's ability to add nontemplated (overhanging) nucleotides to the cDNA when it reaches the end of the donor RNA. The enzyme then anneals these overhanging nucleotides to sequences at the 3'-end of the acceptor RNA. The annealing is most efficient if it involves the terminal nucleotide(s) of the acceptor RNA but can occur to sites at least 5 nucleotides from the 3'-end. These end-to-end jumps are similar to steps proposed to be part of the integration reaction of non-long terminal repeat retrotransposons and can explain chimeric integration products derived from multiple RNA templates.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Eickbush, TH (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	eick@mail.rochester.edu						Arnold JJ, 1999, J BIOL CHEM, V274, P2706, DOI 10.1074/jbc.274.5.2706; Bibillo A, 2002, J BIOL CHEM, V277, P34836, DOI 10.1074/jbc.M204345200; Bibillo A, 2002, J MOL BIOL, V316, P459, DOI 10.1006/jmbi.2001.5369; Boeke JD, 2003, GENOME RES, V13, P1975, DOI 10.1101/gr.1392003; Burke WD, 1999, MOL BIOL EVOL, V16, P502, DOI 10.1093/oxfordjournals.molbev.a026132; Buzdin A, 2003, NUCLEIC ACIDS RES, V31, P4385, DOI 10.1093/nar/gkg496; Chen B, 1997, J MOL BIOL, V271, P311, DOI 10.1006/jmbi.1997.1185; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Dang Q, 2001, J VIROL, V75, P809, DOI 10.1128/JVI.75.2.809-820.2001; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Eickbush T.H., 2002, MOBILE DNA, P813; Golinelli MP, 2002, BIOCHEMISTRY-US, V41, P5894, DOI 10.1021/bi0160415; Kao C, 1999, RNA, V5, P1268, DOI 10.1017/S1355838299991033; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KENNELL JC, 1994, MOL CELL BIOL, V14, P3094, DOI 10.1128/MCB.14.5.3094; Kim MJ, 2001, P NATL ACAD SCI USA, V98, P4972, DOI 10.1073/pnas.081077198; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; Luan DD, 1996, MOL CELL BIOL, V16, P4726; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mules EH, 1998, J VIROL, V72, P6490, DOI 10.1128/JVI.72.8.6490-6503.1998; Nagy PD, 1998, EMBO J, V17, P2392, DOI 10.1093/emboj/17.8.2392; Nagy PD, 1997, P NATL ACAD SCI USA, V94, P1113, DOI 10.1073/pnas.94.4.1113; Negroni M, 2001, NAT REV MOL CELL BIO, V2, P151, DOI 10.1038/35052098; Ostertag EM, 2001, GENOME RES, V11, P2059, DOI 10.1101/gr.205701; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Pfeiffer JK, 2001, J VIROL, V75, P11263, DOI 10.1128/JVI.75.23.11263-11274.2001; Takahashi H, 2002, EMBO J, V21, P408, DOI 10.1093/emboj/21.3.408; Tayon R, 2001, NUCLEIC ACIDS RES, V29, P3576, DOI 10.1093/nar/29.17.3576; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; Volloch VZ, 1995, DNA CELL BIOL, V14, P991, DOI 10.1089/dna.1995.14.991; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; Yang J, 1998, MOL CELL BIOL, V18, P3455, DOI 10.1128/MCB.18.6.3455	38	55	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14945	14953		10.1074/jbc.M310450200	http://dx.doi.org/10.1074/jbc.M310450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752111	hybrid			2022-12-27	WOS:000220594700057
J	Clark, LB; Viswanathan, P; Quigley, G; Chiang, YC; McMahon, JS; Yao, G; Chen, JJ; Nelsbach, A; Denis, CL				Clark, LB; Viswanathan, P; Quigley, G; Chiang, YC; McMahon, JS; Yao, G; Chen, JJ; Nelsbach, A; Denis, CL			Systematic mutagenesis of the leucine-rich repeat (LRR) domain of CCR4 reveals specific sites for binding to CAF1 and a separate critical role for the LRR in CCR4 deadenylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLASE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; RIBONUCLEASE INHIBITOR; TRANSCRIPTION FACTOR; PROTEIN; COMPLEX; IDENTIFICATION; DETERMINANTS; PURIFICATION	CCR4, a poly(A) deadenylase of the exonuclease III family, is a component of the multiprotein CCR4-NOT complex of Saccharomyces cerevisiae that is involved in mRNA degradation. CCR4, unlike all other exonuclease III family members, contains a leucine-rich repeat (LRR) motif through which it makes contact to CAF1 and other factors. The LRR residues important in contacting CAF1 were identified by constructing 29 CCR4 mutations encompassing a majority ( 47 of 81) of residues interstitial to the conserved structural residues. Two-hybrid and immunoprecipitation data revealed that physical contact between CAF1 and the LRR is blocked by mutation of just two alpha-helix/beta-helix strand loop residues linking the first and second repeats. In contrast, CAF16, a potential ligand of CCR4, was abrogated in its binding to the LRR by mutations in the N terminus of the second beta-strand. The LRR domain was also found to contact the deadenylase domain of CCR4, and deletion of the LRR region completely inhibited CCR4 enzymatic activity. Mutations throughout the beta-sheet surface of the LRR, including those that did not specifically interfere with contacts to CAF1 or CAF16, significantly reduced CCR4 deadenylase activity. These results indicate that the CCR4-LRR, in addition to binding to CAF1, plays an essential role in the CCR4 deadenylation of mRNA.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Denis, CL (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, Rudman Hall,46 Coll Rd, Durham, NH 03824 USA.	cldenis@cisunix.unh.edu			NIGMS NIH HHS [1 F32 GM20235-01, GM41215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041215, F32GM020235] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; Bai YL, 1999, MOL CELL BIOL, V19, P6642; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Chen CZ, 1997, P NATL ACAD SCI USA, V94, P1761, DOI 10.1073/pnas.94.5.1761; Chen JJ, 2001, J MOL BIOL, V314, P683, DOI 10.1006/jmbi.2001.5162; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; CORMACK B, 1999, SHORT PROTOCOLS MOL, P15; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Haberland J, 1999, BIOCHEM J, V343, P653, DOI 10.1042/0264-6021:3430653; Hadi MZ, 2002, J MOL BIOL, V316, P853, DOI 10.1006/jmbi.2001.5382; Ho DN, 2002, P NATL ACAD SCI USA, V99, P1888, DOI 10.1073/pnas.042698599; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Leckie F, 1999, EMBO J, V18, P2352, DOI 10.1093/emboj/18.9.2352; Liker E, 2000, EMBO J, V19, P5587, DOI 10.1093/emboj/19.21.5587; Liu HY, 2001, J BIOL CHEM, V276, P7541, DOI 10.1074/jbc.M009112200; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MALVAR T, 1992, GENETICS, V132, P951; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200	45	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13616	13623		10.1074/jbc.M313202200	http://dx.doi.org/10.1074/jbc.M313202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734555	hybrid			2022-12-27	WOS:000220478500042
J	Eckhardt, ERM; Cai, L; Sun, B; Webb, NR; van der Westhuyzen, DR				Eckhardt, ERM; Cai, L; Sun, B; Webb, NR; van der Westhuyzen, DR			High density lipoprotein uptake by scavenger receptor SR-BII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TYPE-I; MICROVILLAR CHANNEL FORMATION; CHOLESTERYL ESTER UPTAKE; SELECTIVE LIPID UPTAKE; HDL PARTICLE UPTAKE; APOPROTEIN-A-I; CELL-SURFACE; APOLIPOPROTEIN-E; ADRENAL-CELLS; METABOLISM	Scavenger receptor class B, type I (SR-BI) mediates selective uptake of high density lipoprotein (HDL) lipids. It is unclear whether this process occurs at the cell membrane or via endocytosis. Our group previously identified an alternative mRNA splicing variant of SR-BI, named SR-BII, with an entirely different, yet highly conserved cytoplasmic C terminus. In this study we aimed to compare HDL uptake by both isoforms. Whereas SR-BI was mainly (similar to70%) localized on the surface of transfected Chinese hamster ovary cells, as determined by biotinylation, HDL binding at 4 degreesC, and studies of enhanced green fluorescent protein-tagged SR-BI/II fusion proteins, the majority of SR-BII ( similar to 80-90%) was expressed intracellularly. The cellular distribution of SR-BI was not affected by deletion of the C terminus, which suggests that the distinct C terminus of SR-BII is responsible for its intracellular expression. Pulse-chase experiments showed that SR-BII rapidly internalized HDL protein, whereas in the case of SR-BI most HDL protein remained surface bound. Like its ligand, SR-BII was more rapidly endocytosed compared with SR-BI. Despite more rapid HDL uptake by SR-BII than SR-BI, selective cholesteryl ether uptake was significantly lower. Relative to their levels of expression at the cell surface, however, both isoforms mediated selective uptake with similar efficiency. HDL protein that was internalized by SR-BII largely co-localized with transferrin in the endosomal recycling compartment. Within the endosomal recycling compartment of SR-BII cells, there was extensive co-localization of internalized HDL lipid and protein. These results do not support a model that selective lipid uptake by SR-BI requires receptor/ligand recycling within the cell. We conclude that SR-BII may influence cellular cholesterol trafficking and homeostasis in a manner that is distinct from SR-BI.	Univ Kentucky, Med Ctr, Dept Internal Med, MN 520, Lexington, KY 40536 USA; Dept Vet Affairs Med Ctr, Lexington, KY 40536 USA	University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	van der Westhuyzen, DR (corresponding author), Univ Kentucky, Med Ctr, Dept Internal Med, MN 520, 800 Rose St, Lexington, KY 40536 USA.	dvwest1@uky.edu	Webb, Nancy/AAL-7030-2021; Sun, Bing/D-3758-2009; Eckhardt, Erik/G-1567-2010	Eckhardt, Erik/0000-0002-3015-5180	NHLBI NIH HHS [HL63763] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063763] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALAM R, 1989, BIOCHIM BIOPHYS ACTA, V1004, P292, DOI 10.1016/0005-2760(89)90076-3; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Connelly MA, 2001, BIOCHEMISTRY-US, V40, P5249, DOI 10.1021/bi002825r; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756; Farkas MH, 2003, J BIOL CHEM, V278, P9412, DOI 10.1074/jbc.M208026200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; Graf GA, 2001, J LIPID RES, V42, P1444; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; Heeren J, 2001, J BIOL CHEM, V276, P42333, DOI 10.1074/jbc.M107461200; HEROLD G, 1994, LIPIDS, V29, P735, DOI 10.1007/BF02536694; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Liu B, 2002, J BIOL CHEM, V277, P34125, DOI 10.1074/jbc.M204265200; Mardones P, 2001, J LIPID RES, V42, P170; McGwire GB, 1999, J BIOL CHEM, V274, P31632, DOI 10.1074/jbc.274.44.31632; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Reaven E, 2000, J LIPID RES, V41, P343; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; RINNINGER F, 1994, ATHEROSCLEROSIS, V105, P145, DOI 10.1016/0021-9150(94)90044-2; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; ROGLER G, 1992, GASTROENTEROLOGY, V103, P469, DOI 10.1016/0016-5085(92)90836-N; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Trigatti BL, 2003, ARTERIOSCL THROM VAS, V23, P1732, DOI 10.1161/01.ATV.0000091363.28501.84; Vishnyakova TG, 2003, J BIOL CHEM, V278, P22771, DOI 10.1074/jbc.M211032200; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Webb NR, 1997, J LIPID RES, V38, P1490; Williams DL, 2002, J LIPID RES, V43, P544	44	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14372	14381		10.1074/jbc.M313793200	http://dx.doi.org/10.1074/jbc.M313793200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726519	hybrid			2022-12-27	WOS:000220478500133
J	Fu, Y; Hoang, A; Escher, G; Parton, RG; Krozowski, Z; Sviridov, D				Fu, Y; Hoang, A; Escher, G; Parton, RG; Krozowski, Z; Sviridov, D			Expression of caveolin-1 enhances cholesterol efflux in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; RECEPTOR CLASS-B; CELLULAR CHOLESTEROL; PLASMA-MEMBRANE; SR-BI; INTRACELLULAR CHOLESTEROL; ENDOPLASMIC-RETICULUM; SELECTIVE UPTAKE; MEDIATED EXPRESSION	HepG2 cells were stably transfected with human caveolin-1 (HepG2/cav cells). Transfection resulted in expression of caveolin-1 mRNA, a high abundance of caveolin-1 protein, and the formation of caveolae on the plasma membrane. Cholesterol efflux from HepG2/cav cells was 280 and 45% higher than that from parent HepG2 cells when human plasma and human apoA-I, respectively, were used as acceptors. The difference in efflux was eliminated by treatment of cells with progesterone. There was no difference in cholesterol efflux to cyclodextrin. Cholesterol efflux from plasma membrane vesicles was similar for the two cell types. Transfection led to a 40% increase in the amount of plasma membrane cholesterol in cholesterol-rich domains ( caveolae and/or rafts) and a 67% increase in the rate of cholesterol trafficking from intracellular compartments to these domains. Cholesterol biosynthesis in HepG2/cav cells was increased by 2-fold, and cholesterol esterification was reduced by 50% compared with parent HepG2 cells. The proliferation rate of transfected cells was significantly lower than that of non-transfected cells. Transfection did not affect expression of ABCA1 or the abundance of ABCA1 protein, but decreased secretion of apoA-I. We conclude that overexpression of caveolin-1 in hepatic cells stimulates cholesterol efflux by enhancing transfer of cholesterol to cholesterol-rich domains in the plasma membrane.	Baker Heart Res Inst, Melbourne, Vic 8008, Australia; Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	Baker Heart and Diabetes Institute; University of Queensland; University of Queensland	Sviridov, D (corresponding author), Baker Heart Res Inst, Wynn Domain,St Kilda Rd Cent,POB 6492, Melbourne, Vic 8008, Australia.	Dmitri.Sviridov@Baker.edu.au	Sviridov, Dmitri/E-7943-2010; Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; fu, ying/0000-0002-1261-3336; Escher, Genevieve/0000-0002-5125-2262				Arakawa R, 2000, J LIPID RES, V41, P1952; Barter P, 2003, ATHEROSCLEROSIS, V168, P195, DOI 10.1016/S0021-9150(03)00006-6; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; Briand O, 2003, BBA-MOL CELL BIOL L, V1631, P42, DOI 10.1016/S1388-1981(02)00354-2; Chao WT, 2003, J LIPID RES, V44, P1094, DOI 10.1194/jlr.M300033-JLR200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Escher G, 2003, J BIOL CHEM, V278, P11015, DOI 10.1074/jbc.M212780200; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; Fielding PE, 2002, BIOCHEMISTRY-US, V41, P4929, DOI 10.1021/bi012091y; Frank PG, 2002, BIOCHEMISTRY-US, V41, P11931, DOI 10.1021/bi0257078; Frank PG, 2001, AM J PHYSIOL-CELL PH, V280, pC1204, DOI 10.1152/ajpcell.2001.280.5.C1204; Frank PG, 2001, BIOCHEMISTRY-US, V40, P10892, DOI 10.1021/bi0106437; Fujimoto T, 2000, J CELL SCI, V113, P3509; Gargalovic P, 2003, J LIPID RES, V44, P11, DOI 10.1194/jlr.R200005-JLR200; Gaus K, 2001, BIOCHEMISTRY-US, V40, P13002, DOI 10.1021/bi010833h; Hailstones D, 1998, J LIPID RES, V39, P369; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Ishiguro H, 2001, J BIOL CHEM, V276, P36742, DOI 10.1074/jbc.M106027200; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; Major AS, 2001, ARTERIOSCL THROM VAS, V21, P1790, DOI 10.1161/hq1101.097798; Matveev S, 2001, EUR J BIOCHEM, V268, P5609, DOI 10.1046/j.1432-1033.2001.02496.x; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; Okazaki H, 2002, J BIOL CHEM, V277, P31893, DOI 10.1074/jbc.M204016200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peterson TE, 2003, ARTERIOSCL THROM VAS, V23, P1521, DOI 10.1161/01.ATV.0000081743.35125.05; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020-JLR200; SVIRIDOV D, 1995, BBA-LIPID LIPID MET, V1256, P210, DOI 10.1016/0005-2760(95)00028-B; Sviridov D, 1999, PROTEIN EXPRES PURIF, V17, P231, DOI 10.1006/prep.1999.1114; SVIRIDOV D, 1995, J LIPID RES, V36, P1887; Sviridov D, 2002, ATHEROSCLEROSIS, V161, P245, DOI 10.1016/S0021-9150(01)00677-3; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; Sviridov D, 2001, BIOCHEM J, V358, P79, DOI 10.1042/0264-6021:3580079; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; URBANI L, 1990, J BIOL CHEM, V265, P1919; Wang LB, 2003, J LIPID RES, V44, P807, DOI 10.1194/jlr.M200449-JLR200; Williams DL, 2002, J LIPID RES, V43, P544; Zhang ZY, 2001, ATHEROSCLEROSIS, V159, P67, DOI 10.1016/S0021-9150(01)00490-7	48	92	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14140	14146		10.1074/jbc.M311061200	http://dx.doi.org/10.1074/jbc.M311061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729661	hybrid			2022-12-27	WOS:000220478500104
J	Srichai, MB; Konieczkowski, M; Padiyar, A; Konieczkowski, DJ; Mukherjee, A; Hayden, PS; Kamat, S; El-Meanawy, MA; Khan, S; Mundel, P; Lee, SB; Bruggeman, LA; Schelling, JR; Sedor, JR				Srichai, MB; Konieczkowski, M; Padiyar, A; Konieczkowski, DJ; Mukherjee, A; Hayden, PS; Kamat, S; El-Meanawy, MA; Khan, S; Mundel, P; Lee, SB; Bruggeman, LA; Schelling, JR; Sedor, JR			A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL SEGMENTAL GLOMERULOSCLEROSIS; TUMOR SUPPRESSOR WT1; DENYS-DRASH-SYNDROME; CONGENITAL NEPHROTIC SYNDROME; HIV-ASSOCIATED NEPHROPATHY; GLOMERULAR SLIT DIAPHRAGM; CELL-CELL ADHESION; WILMS-TUMOR; TRANSCRIPTIONAL ACTIVATION; CD2-ASSOCIATED PROTEIN	Glomerular podocyte differentiation state is critical for filtration barrier function and is regulated by WT1, a zinc finger transcription factor. A yeast two-hybrid assay identified a novel, WT1-interacting protein (WTIP) that maps to human chromosome 19q13.1, a region with genes linked to familial focal segmental glomerulosclerosis. The domain structure of WTIP is similar to the zyxin subfamily of cytosolic LIM domain-containing proteins, which contain three carboxyl-terminal LIM protein-protein interaction domains and a proline-rich, pre-LIM region with a nuclear export signal. Other LIM domain-containing proteins ( zyxin and mouse muscle LIM protein) did not interact with WT1 in two-hybrid assays, and WTIP did not interact with an unrelated transcription factor, LMX1B. WTIP mRNA was detected in cultured podocytes and was developmentally regulated, with expression peaking in mouse kidney at embryonic day 15 - 16 (E15 - E16) in kidney but persisting into adulthood. In situ hybridization demonstrated WTIP expression in developing E15 glomeruli and in cultured podocytes. The partial WTIP clone, which interacted with WTIP in the two-hybrid assay, co-localized with WT1 in nuclei, co-precipitated with WT1, and inhibited WT1-dependent transcriptional activation of the amphiregulin promoter. In contrast, full-length WTIP was excluded from cell nuclei, but after the addition of leptomycin B, an inhibitor of Crm1-mediated nuclear export, it accumulated in the nucleus and co-precipitated with WT1 in whole cell lysates. Epitope-tagged WTIP co-localized with the adaptor protein CD2AP (CMS) in podocyte actin spots and with Mena at cell-cell junctions. We propose that WTIP monitors slit diaphragm protein assembly as part of a multiple protein complex, linking this specialized adhesion junction to the actin cytoskeleton, and shuttles into the nucleus after podocyte injury, providing a mechanism whereby changes in slit diaphragm structure modulate gene expression.	Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44109 USA; Rammelkamp Ctr Res & Educ, Cleveland, OH 44109 USA; Albert Einstein Coll Med, Dept Anat, Bronx, NY 10461 USA; NIDDK, Dept Genet Dev, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; Case Western Reserve University; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sedor, JR (corresponding author), Metrohlth Med Ctr, Dept Med, BG 531, 2500 Metrohlth Dr, Cleveland, OH 44109 USA.	jrs4@po.cwru.edu	Mukherjee, Amitava/AAK-4002-2020; Padiyar, Aparna/X-4884-2019	Mukherjee, Amitava/0000-0001-5603-5147; Lee, Sean/0000-0001-6211-3498	NIDDK NIH HHS [DK064719, P50 DK054178, DK07470, DK038558] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038558, ZIADK056002, P50DK054178, T32DK007470, R01DK064719, Z01DK056002] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Barisoni L, 1999, J AM SOC NEPHROL, V10, P51; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079, DOI 10.1681/ASN.V11112079; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dharnidharka VR, 2001, PEDIATR NEPHROL, V16, P227, DOI 10.1007/s004670000537; DRENCKHAHN D, 1988, LAB INVEST, V59, P673; Du XJ, 2002, BBA-GENE STRUCT EXPR, V1577, P93, DOI 10.1016/S0167-4781(02)00414-1; Guo JK, 2002, HUM MOL GENET, V11, P651, DOI 10.1093/hmg/11.6.651; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hastie ND, 2001, CELL, V106, P391, DOI 10.1016/S0092-8674(01)00469-X; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Huber TB, 2001, J BIOL CHEM, V276, P41543, DOI 10.1074/jbc.C100452200; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; Kanungo J, 2000, MOL BIOL CELL, V11, P3299, DOI 10.1091/mbc.11.10.3299; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kerjaschki D, 2001, J CLIN INVEST, V108, P1583, DOI 10.1172/JCI200114629; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kriz W, 2002, MICROSC RES TECHNIQ, V57, P189, DOI 10.1002/jemt.10072; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Little NA, 2000, HUM MOL GENET, V9, P2231, DOI 10.1093/oxfordjournals.hmg.a018914; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Ohtaka A, 2002, AM J KIDNEY DIS, V39, P475, DOI 10.1053/ajkd.2002.31391; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Patek CE, 1999, P NATL ACAD SCI USA, V96, P2931, DOI 10.1073/pnas.96.6.2931; Patek CE, 2003, HUM MOL GENET, V12, P2379, DOI 10.1093/hmg/ddg240; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Quaggin SE, 2002, MICROSC RES TECHNIQ, V57, P208, DOI 10.1002/jemt.10076; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Renfranz PJ, 2003, GENE, V305, P13, DOI 10.1016/S0378-1119(02)01173-3; Richard DJ, 2001, GENE DEV, V15, P328, DOI 10.1101/gad.185901; Ross MD, 2003, J BIOL CHEM, V278, P33248, DOI 10.1074/jbc.M301299200; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Shirato I, 2002, MICROSC RES TECHNIQ, V57, P241, DOI 10.1002/jemt.10082; Singh R, 1997, J CLIN INVEST, V100, P419, DOI 10.1172/JCI119549; Singh R, 1999, J CLIN INVEST, V103, P1561, DOI 10.1172/JCI5754; Smoyer WE, 2002, FASEB J, V16, DOI 10.1096/fj.01-0681com; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Wagner KD, 2003, J CELL SCI, V116, P1653, DOI 10.1242/jcs.00405; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769	59	72	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14398	14408		10.1074/jbc.M314155200	http://dx.doi.org/10.1074/jbc.M314155200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736876	hybrid			2022-12-27	WOS:000220478500136
J	Wear, MA; Cooper, JA				Wear, MA; Cooper, JA			Capping protein binding to S100B - Implications for the "tentacle" model for capping the actin filament barbed end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ACTIN; CAPZ; TARGET; LOCALIZATION; SITE; BETA; MYOFIBRILLOGENESIS; IDENTIFICATION; EXPRESSION; MECHANISM	S100B binds tightly to a 12-amino acid peptide derived from heterodimeric capping protein. In native intact capping protein, this sequence is in the C terminus of the alpha-subunit, which is important for capping the actin filament. This C-terminal region is proposed to act as a flexible "tentacle," extending away from the body of capping protein in order to bind actin. To this hypothesis, we analyzed the interaction between S100B and capping protein in solution. The C-terminal 28 amino acids of the alpha-subunit, the proposed tentacle, bound to S100B as a free synthetic peptide or a glutathione S-transferase fusion (K-d similar to 0.4 - 1 muM). In contrast, S100B did not bind to whole native capping protein or functionally affect its capping activity. S100B does not bind, with any significant affinity, to the proposed alpha-tentacle sequence of whole native capping protein in solution. In the NMR structure of S100B complexed with the alpha-subunit-derived 12-amino acid peptide, the hydrophobic side of a short alpha-helix in the peptide, containing an important tryptophan residue, contacts S100B. In the x-ray structure of native capping protein, the corresponding sequence of the alpha-subunit C terminus, including Trp(271), interacts closely with the body of the protein. Therefore, our results suggest the alpha-subunit C terminus is not mobile as predicted by the tentacle model. Addition of nonionic detergent allowed whole capping protein to bind weakly to S100B, indicating that the alpha-subunit C terminus can be mobilized from the surface of the capping protein molecule, presumably by weakening the hydrophobic binding at the contact site.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Cooper, JA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	jcooper@wustl.edu	Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Cooper, John/0000-0002-0933-4571	NIGMS NIH HHS [GM38542, R01 GM038542-16, R01 GM038542] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038542] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBURGEY JC, 1995, J BIOMOL NMR, V6, P171, DOI 10.1007/BF00211781; Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; COOPER JA, 1999, GUIDEBOOK CYTOSKELET, P62; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Hart MC, 1999, J CELL BIOL, V147, P1287, DOI 10.1083/jcb.147.6.1287; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hopmann R, 1996, J CELL BIOL, V133, P1293, DOI 10.1083/jcb.133.6.1293; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; Inman KG, 2002, J MOL BIOL, V324, P1003, DOI 10.1016/S0022-2836(02)01152-X; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Ivanenkov VV, 1996, BIOCHEM BIOPH RES CO, V221, P46, DOI 10.1006/bbrc.1996.0542; Kim K, 2004, J CELL BIOL, V164, P567, DOI 10.1083/jcb.200308061; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Palmgren S, 2001, J CELL BIOL, V155, P251, DOI 10.1083/jcb.200106157; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; SAFER D, 1989, ANAL BIOCHEM, V178, P32, DOI 10.1016/0003-2697(89)90351-5; SCHAFER DA, 1993, CELL MOTIL CYTOSKEL, V25, P317, DOI 10.1002/cm.970250403; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; SCHAFER DA, 1995, J CELL BIOL, V128, P61, DOI 10.1083/jcb.128.1.61; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Smith SP, 1998, BIOCHEM CELL BIOL, V76, P324, DOI 10.1139/bcb-76-2-3-324; Soeno Y, 1998, J MUSCLE RES CELL M, V19, P639, DOI 10.1023/A:1005329114263; Sorci G, 1999, CELL CALCIUM, V25, P93, DOI 10.1054/ceca.1998.0012; VANELDIK LJ, 1988, J BIOL CHEM, V263, P7830; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P2613, DOI 10.1021/bi00307a012; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167; ZIMMER DB, 1991, CELL MOTIL CYTOSKEL, V20, P325, DOI 10.1002/cm.970200408	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14382	14390		10.1074/jbc.M313412200	http://dx.doi.org/10.1074/jbc.M313412200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736868	hybrid, Green Accepted			2022-12-27	WOS:000220478500134
J	Maeda, T; Inoue, M; Koshiba, S; Yabuki, T; Aoki, M; Nunokawa, E; Seki, E; Matsuda, T; Motoda, Y; Kobayashi, A; Hiroyasu, F; Shirouzu, M; Terada, T; Hayami, N; Ishizuka, Y; Shinya, N; Tatsuguchi, A; Yoshida, M; Hirota, H; Matsuo, Y; Tani, K; Arakawa, T; Carninci, P; Kawai, J; Hayashizaki, Y; Kigawa, T; Yokoyama, S				Maeda, T; Inoue, M; Koshiba, S; Yabuki, T; Aoki, M; Nunokawa, E; Seki, E; Matsuda, T; Motoda, Y; Kobayashi, A; Hiroyasu, F; Shirouzu, M; Terada, T; Hayami, N; Ishizuka, Y; Shinya, N; Tatsuguchi, A; Yoshida, M; Hirota, H; Matsuo, Y; Tani, K; Arakawa, T; Carninci, P; Kawai, J; Hayashizaki, Y; Kigawa, T; Yokoyama, S			Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; MOLECULAR-CLONING; SCALAR COUPLINGS; SH3 DOMAIN; IG-HEPTA; PROTEIN; IDENTIFICATION; MUCIN; RECEPTOR	Human CA125, encoded by the MUC16 gene, is an ovarian cancer antigen widely used for a serum assay. Its extracellular region consists of tandem repeats of SEA domains. In this study we determined the three-dimensional structure of the SEA domain from the murine MUC16 homologue using multidimensional NMR spectroscopy. The domain forms a unique alpha/beta sandwich fold composed of two alpha helices and four antiparallel beta strands and has a characteristic turn named the TY-turn between alpha1 and alpha2. The internal mobility of the main chain is low throughout the domain. The residues that form the hydrophobic core and the TY-turn are fully conserved in all SEA domain sequences, indicating that the fold is common in the family. Interestingly, no other residues are conserved throughout the family. Thus, the sequence alignment of the SEA domain family was refined on the basis of the three-dimensional structure, which allowed us to classify the SEA domains into several subfamilies. The residues on the surface differ between these subfamilies, suggesting that each subfamily has a different function. In the MUC16 SEA domains, the conserved surface residues, Asn-10, Thr-12, Arg-63, Asp-75, Asp-112, Ser-115, and Phe-117, are clustered on the beta sheet surface, which may be functionally important. The putative epitope ( residues 58 - 77) for anti-MUC16 antibodies is located around the beta2 and beta3 strands. On the other hand the tissue tumor marker MUC1 has a SEA domain belonging to another subfamily, and its GSVVV motif for proteolytic cleavage is located in the short loop connecting beta2 and beta3.	RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; SPring8, Harima Inst, RIKEN, Sayo, Hyogo 6795148, Japan	RIKEN; University of Tokyo; Japan Synchrotron Radiation Research Institute; RIKEN	Yokoyama, S (corresponding author), RIKEN, Genom Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Kigawa, Takanori/A-7679-2010; Kawai, Jun/A-6451-2016; Carninci, Piero/K-1568-2014; Shirouzu, Mikako/A-6521-2016; Hayashizaki, Yoshihide/N-6590-2015; Yokoyama, Shigeyuki/N-6911-2015; Tani, Kazutoshi/B-3705-2008; Hirota, Hiroshi/C-3634-2017	Kigawa, Takanori/0000-0003-0146-9719; Carninci, Piero/0000-0001-7202-7243; Yokoyama, Shigeyuki/0000-0003-3133-7338; Tani, Kazutoshi/0000-0003-4835-154X; Hirota, Hiroshi/0000-0002-6600-9775; Matsuda, Takayoshi/0000-0002-6746-7639				Abe J, 2002, J BIOL CHEM, V277, P23391, DOI 10.1074/jbc.M110877200; Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Baruch A, 1999, CANCER RES, V59, P1552; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BORK P, 1995, PROTEIN SCI, V4, P1421, DOI 10.1002/pro.5560040716; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAVANAGH J, 1996, PROTEIN NMR SPECTROS, P478; Cordier F, 1999, J AM CHEM SOC, V121, P1601, DOI 10.1021/ja983945d; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1999, J AM CHEM SOC, V121, P2949, DOI 10.1021/ja9902221; Croce Maria V., 2001, Pathology and Oncology Research, V7, P284; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; FARROW NA, 1995, BIOCHEMISTRY-US, V34, P868, DOI 10.1021/bi00003a021; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hovig E, 2001, TUMOR BIOL, V22, P345, DOI 10.1159/000050637; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Lloyd KO, 1997, INT J CANCER, V71, P842, DOI 10.1002/(SICI)1097-0215(19970529)71:5<842::AID-IJC24>3.0.CO;2-8; Lloyd KO, 2001, TUMOR BIOL, V22, P77, DOI 10.1159/000050600; MARKLEY JL, 1989, METHOD ENZYMOL, V176, P12; Meden H, 1998, INT J BIOL MARKER, V13, P231, DOI 10.1177/172460089801300411; Nap M, 1996, TUMOR BIOL, V17, P325; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; O'Brien TJ, 2001, TUMOR BIOL, V22, P348, DOI 10.1159/000050638; Parry S, 2001, BIOCHEM BIOPH RES CO, V283, P715, DOI 10.1006/bbrc.2001.4775; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; Smorodinsky N, 1996, BIOCHEM BIOPH RES CO, V228, P115, DOI 10.1006/bbrc.1996.1625; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wang RQ, 2002, BIOCHEM J, V366, P623, DOI 10.1042/BJ20020289; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502; Yin BWT, 2002, INT J CANCER, V98, P737, DOI 10.1002/ijc.10250; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200	41	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13174	13182		10.1074/jbc.M309417200	http://dx.doi.org/10.1074/jbc.M309417200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14764598	hybrid			2022-12-27	WOS:000220334900139
J	Barnett, AC; Tsvetanov, S; Gamage, N; Martin, JL; Duggleby, RG; McManus, ME				Barnett, AC; Tsvetanov, S; Gamage, N; Martin, JL; Duggleby, RG; McManus, ME			Active site mutations and substrate inhibition in human sulfotransferase 1A1 and 1A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN SULFOTRANSFERASE; HUMAN DOPAMINE SULFOTRANSFERASE; FORM PHENOL SULFOTRANSFERASES; CRYSTAL-STRUCTURE; BREAST-CANCER; CYTOSOLIC SULFOTRANSFERASES; BACTERIAL EXPRESSION; HETEROCYCLIC AMINES; SULFURYL TRANSFER; SPECIFICITY	Human SULT1A1 is primarily responsible for sulfonation of xenobiotics, including the activation of promutagens, and it has been implicated in several forms of cancer. Human SULT1A3 has been shown to be the major sulfotransferase that sulfonates dopamine. These two enzymes shares 93% amino acid sequence identity and have distinct but overlapping substrate preferences. The resolution of the crystal structures of these two enzymes has enabled us to elucidate the mechanisms controlling their substrate preferences and inhibition. The presence of two p-nitrophenol (pNP) molecules in the crystal structure of SULT1A1 was postulated to explain cooperativity at low and inhibition at high substrate concentrations, respectively. In SULT1A1, substrate inhibition occurs with pNP as the substrate but not with dopamine. For SULT1A3, substrate inhibition is found for dopamine but not with pNP. We investigated how substrate inhibition occurs in these two enzymes using molecular modeling, site-directed mutagenesis, and kinetic analysis. The results show that residue Phe-247 of SULT1A1, which interacts with both p-nitrophenol molecules in the active site, is important for substrate inhibition. Mutation of phenylalanine to leucine at this position in SULT1A1 results in substrate inhibition by dopamine. We also propose, based on modeling and kinetic studies, that substrate inhibition by dopamine in SULT1A3 is caused by binding of two dopamine molecules in the active site.	Univ Queensland, Fac Biol & Chem Sci, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	McManus, ME (corresponding author), Univ Queensland, Fac Biol & Chem Sci, Sch Biomed Sci, Comp Sci Bldg Bldg 69,Rm 304, Brisbane, Qld 4072, Australia.	m.mcmanus@uq.edu.au	Martin, Jennifer L./A-6039-2010	Martin, Jennifer L./0000-0002-9225-8863				Banoglu E, 2000, CURR DRUG METAB, V1, P1, DOI 10.2174/1389200003339234; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; Blanchard RL, 2004, PHARMACOGENETICS, V14, P199, DOI 10.1097/00008571-200403000-00009; Brix LA, 1999, BIOCHEMISTRY-US, V38, P10474, DOI 10.1021/bi990795q; Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen GP, 2003, J BIOL CHEM, V278, P36358, DOI 10.1074/jbc.M306045200; Chen GP, 2000, BIOCHEMISTRY-US, V39, P16000, DOI 10.1021/bi0021479; CHOU HC, 1995, CANCER RES, V55, P525; Dajani R, 1998, MOL PHARMACOL, V54, P942, DOI 10.1124/mol.54.6.942; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Falany CN, 1997, FASEB J, V11, P1; FOLDES A, 1973, BIOCHIM BIOPHYS ACTA, V327, P365, DOI 10.1016/0005-2744(73)90419-1; Gaedigk A, 1997, GENOMICS, V40, P242, DOI 10.1006/geno.1996.4575; Gamage NU, 2003, J BIOL CHEM, V278, P7655, DOI 10.1074/jbc.M207246200; GANGULY TC, 1995, DRUG METAB DISPOS, V23, P945; Glatt H, 2000, CHEM-BIOL INTERACT, V129, P141, DOI 10.1016/S0009-2797(00)00202-7; Harris RM, 2000, J BIOL CHEM, V275, P159, DOI 10.1074/jbc.275.1.159; Honma W, 2001, DRUG METAB DISPOS, V29, P274; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kester MHA, 1999, J CLIN ENDOCR METAB, V84, P1357, DOI 10.1210/jc.84.4.1357; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis AJ, 1996, DRUG METAB DISPOS, V24, P1180; Li X, 2001, J ENDOCRINOL, V171, P525, DOI 10.1677/joe.0.1710525; Liu MC, 2000, J BIOL CHEM, V275, P13460, DOI 10.1074/jbc.275.18.13460; NAGATA K, 2000, ANN REV PHARM TOXICO, V40, P59; Nowell S, 2002, J NATL CANCER I, V94, P1635; Pai TG, 2003, J BIOL CHEM, V278, P1525, DOI 10.1074/jbc.M203108200; Pai TG, 2002, J BIOL CHEM, V277, P43813, DOI 10.1074/jbc.M200785200; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Raftogianis RB, 1999, BIOCHEM PHARMACOL, V58, P605, DOI 10.1016/S0006-2952(99)00145-8; Rehse PH, 2002, BIOCHEM J, V364, P165, DOI 10.1042/bj3640165; REITER C, 1983, N-S ARCH PHARMACOL, V324, P140, DOI 10.1007/BF00497020; Rikke BA, 1996, BBA-GENE STRUCT EXPR, V1307, P331, DOI 10.1016/0167-4781(96)00065-6; Sakakibara Y, 1998, J BIOL CHEM, V273, P6242, DOI 10.1074/jbc.273.11.6242; Seth P, 2000, CANCER RES, V60, P6859; Wang YF, 2002, LUNG CANCER, V35, P137, DOI 10.1016/S0169-5002(01)00406-8; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Yamazoe Y, 1999, CANCER LETT, V143, P103, DOI 10.1016/S0304-3835(99)00136-6; Yoshinari K, 2001, J BIOCHEM MOL TOXIC, V15, P67, DOI 10.1002/jbt.1; Zhang HP, 1998, J BIOL CHEM, V273, P10888, DOI 10.1074/jbc.273.18.10888; Zheng W, 2001, CANCER EPIDEM BIOMAR, V10, P89	45	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18799	18805		10.1074/jbc.M312253200	http://dx.doi.org/10.1074/jbc.M312253200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14871892	Green Published, hybrid			2022-12-27	WOS:000221041500088
J	Tartaix, PH; Doulaverakis, M; George, A; Fisher, LW; Butler, WT; Qin, CL; Salih, E; Tan, ML; Fujimoto, Y; Spevak, L; Boskey, AL				Tartaix, PH; Doulaverakis, M; George, A; Fisher, LW; Butler, WT; Qin, CL; Salih, E; Tan, ML; Fujimoto, Y; Spevak, L; Boskey, AL			In vitro effects of dentin matrix protein-1 on hydroxyapatite formation provide insights into in vivo functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PHOSPHOPROTEIN; OSTEOPONTIN; GENE; SIALOPROTEIN; BIOMINERALIZATION; IDENTIFICATION; INHIBITION; EXPRESSION; GROWTH; CALCIFICATION	Dentin matrix protein-1 (DMP1) is a mineralized tissue matrix protein synthesized by osteoblasts, hypertrophic chondrocytes, and ameloblasts as well as odontoblasts. DMP1 is believed to have multiple in vivo functions, acting both as a signaling molecule and a regulator of biomineralization. Using a cell-free system in vitro, we evaluated the action of DMP1 in the regulation of hydroxylapatite ( HA) formation and crystal growth. The non-phosphorylated recombinant protein acted as an HA nucleator, increasing the amount of mineral formed in a gelatin gel HA growth system relative to protein-free controls. The recombinant protein phosphorylated in vitro had no detectable effect on HA formation and growth. In contrast, phosphorylated bovine DMP1 expressed in marrow stromal cells with an adenovirus vector containing 29.7 phosphates/mol was an effective inhibitor of HA formation and growth. The native full-length protein appeared to be absent or present in only small amounts in the extracellular matrix of bones and teeth. However, two highly phosphorylated fragments representing the N- and C-terminal portions of DMP1 have been identified, apparently arising from proteolytic cleavage of four X - Asp bonds. The highly phosphorylated C-terminal 57-kDa fragment ( containing 42 phosphates/mol), like the non-phosphorylated DMP1, was an HA nucleator. These data suggest that, in its native form, DMP1 inhibits mineralization, but when cleaved or dephosphorylated, it initiates mineralization. These in vitro data are consistent with the findings in the DMP1 knockout mouse.	Hosp Special Surg, Div Res, Mineralized Tissues Lab, Musculoskeletal Integr Program, New York, NY 10021 USA; Columbia Univ, Sch Dent & Oral Surg, New York, NY 10032 USA; Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA; NIDCR, Matrix Biochem Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Texas, Hlth Sci Ctr, Dept Basic Sci, Houston, TX 77030 USA; Harvard Univ, Sch Med, Lab Study Skeletal Dis & Rehabil, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Columbia University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Texas System; University of Texas Health Science Center Houston; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Cornell University	Boskey, AL (corresponding author), Hosp Special Surg, Div Res, Mineralized Tissues Lab, Musculoskeletal Integr Program, 535 E 70th St, New York, NY 10021 USA.	boskeya@hss.edu		GEORGE, ANNE/0000-0002-9008-7642; Boskey, Adele/0000-0002-6181-2219; Salih, Erdjan/0000-0003-3322-2323	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657, R01DE005092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004141, Z01DE000074, R56DE011657, R37DE005092, R01DE004141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017969] Funding Source: NIH RePORTER; NIA NIH HHS [AG17969] Funding Source: Medline; NIDCR NIH HHS [DE05092, DE11657, DE04141] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BLUMENTHAL NC, 1981, CALCIFIED TISSUE INT, V33, P111, DOI 10.1007/BF02409422; Boskey A, 2000, CALCIFIED TISSUE INT, V67, P472, DOI 10.1007/s002230001169; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; BOSKEY AL, 1990, BONE MINER, V11, P55, DOI 10.1016/0169-6009(90)90015-8; BOSKEY AL, 1995, ANN NY ACAD SCI, V760, P249, DOI 10.1111/j.1749-6632.1995.tb44635.x; BOSKEY AL, 1989, J PHYS CHEM-US, V93, P1628, DOI 10.1021/j100341a086; Butler WT, 2002, CONNECT TISSUE RES, V43, P301, DOI 10.1080/03008200290000682; Chaplet M, 2003, J BONE MINER RES, V18, P1506, DOI 10.1359/jbmr.2003.18.8.1506; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Drezner MK, 2000, KIDNEY INT, V57, P9, DOI 10.1046/j.1523-1755.2000.00807.x; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003; Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; GEORGE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1527, DOI 10.1177/42.12.7983353; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945-053X(00)00108-6; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; He G, 2003, CONNECT TISSUE RES, V44, P240, DOI 10.1080/03008200390181726; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; Hirst KL, 1997, J DENT RES, V76, P754, DOI 10.1177/00220345970760030701; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; Jain A, 2002, J BIOL CHEM, V277, P13700, DOI 10.1074/jbc.M110757200; Jono S, 2000, J BIOL CHEM, V275, P20197, DOI 10.1074/jbc.M909174199; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Qin CL, 2003, J BIOL CHEM, V278, P34700, DOI 10.1074/jbc.M305315200; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; Septier D, 2001, EUR J ORAL SCI, V109, P198, DOI 10.1034/j.1600-0722.2001.00892.x; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017; Wiesmann HP, 1995, CONNECT TISSUE RES, V32, P501; WILLIS JB, 1993, CLIN CHEM, V39, P155	38	139	146	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18115	18120		10.1074/jbc.M314114200	http://dx.doi.org/10.1074/jbc.M314114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14769788	hybrid			2022-12-27	WOS:000221041500005
J	Frasch, SC; Henson, PM; Nagaosa, K; Fessler, MB; Borregaard, N; Bratton, DL				Frasch, SC; Henson, PM; Nagaosa, K; Fessler, MB; Borregaard, N; Bratton, DL			Phospholipid flip-flop and phospholipid scramblase 1 (PLSCR1) co-localize to uropod rafts in formylated Met-Leu-Phe-stimulated neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; LIPID RAFTS; TRANSBILAYER MOVEMENT; SUBCELLULAR FRACTIONATION; PHOSPHATIDYLSERINE; CELLS; ACTIVATION; EXPRESSION; ASYMMETRY; APOPTOSIS	Movement of phosphatidylserine (PS) to the plasma membrane outer leaflet is a nearly universal marker of apoptosis and occurs during activation of many cells. Neutrophils stimulated with the chemotactic peptide formylated Met-Leu-Phe (fMLP) demonstrated transient PS exposure. Stimulated outward movement of PS was accompanied by enhanced inward movement of several phosphorylcholine lipid probes and was associated with enhanced FM 1-43 staining indicative of phospholipid packing changes. Unlike apoptosis, inward movement of exogenously added fluorescent PS did not decline, and DNA was not cleaved during fMLP stimulation. Movement of phospholipids occurred within minutes following stimulation, was independent of endocytosis/pinocytosis, and was consistent with bidirectional, transbilayer phospholipid flip-flop. While the role of phospholipid scramblase 1 (PLSCR1) is controversial in flip-flop, we sought evidence for its role in enhanced phospholipid movements during fMLP stimulation. Using antibodies to the carboxyl-terminal domain of PLSCR1, its presence in the plasma membranes of non-permeabilized neutrophils was confirmed by flow cytometry. Additionally subcellular fractionation demonstrated that PLSCR1 was also located in secretory vesicles and tertiary and secondary granules. Activation of neutrophils with fMLP, however, did not significantly alter surface labeling suggesting that stimulated phospholipid flip-flop does not require additional mobilization of PLSCR1 to the plasma membrane. As expected for palmitoylated proteins, PLSCR1 was enriched in detergent-insoluble membranes and co-localized with raft markers at the neutrophil uropod after stimulation. Of note, PS exposure, phospholipid uptake, and FM 1-43 staining also localized to the uropod following stimulation demonstrating that both PLSCR1 and phospholipid flip-flop characterize this specialized domain of polarized neutrophils.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Div Cell Biol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol & Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Med, Denver, CO 80262 USA; Rigshosp 4042, Dept Hematol, DK-2100 Copenhagen, Denmark	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Rigshospitalet	Bratton, DL (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Rm D506,1400 Jackson St, Denver, CO 80206 USA.	brattond@njc.org	Nagaosa, Kaz/G-3857-2014; Fessler, Michael B/C-6323-2019	Nagaosa, Kaz/0000-0002-1695-2562; Fessler, Michael B/0000-0002-8262-8613	NHLBI NIH HHS [HL34303] Funding Source: Medline; NIAID NIH HHS [AI058228] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI058228, R01AI058228] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso-Lebrero JL, 2000, BLOOD, V95, P2413, DOI 10.1182/blood.V95.7.2413.007k17_2413_2419; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; Borisenko GG, 2003, ARCH BIOCHEM BIOPHYS, V413, P41, DOI 10.1016/S0003-9861(03)00083-3; Borset M, 2000, BLOOD, V96, P2528; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRATTON DL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P24, DOI 10.1016/0005-2736(91)90330-B; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; BRATTON DL, 1992, J IMMUNOL, V148, P514; Bruhl H, 2003, EUR J IMMUNOL, V33, P3028, DOI 10.1002/eji.200324163; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; de Vries KJ, 2003, BIOL REPROD, V68, P2122, DOI 10.1095/biolreprod.102.012500; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Diaz C, 2001, ARCH BIOCHEM BIOPHYS, V391, P56, DOI 10.1006/abbi.2001.2386; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; FITTSCHEN C, 1994, J CLIN INVEST, V93, P247, DOI 10.1172/JCI116952; Flesch FM, 2001, J CELL SCI, V114, P3543; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gargalovic P, 2003, J LIPID RES, V44, P1622, DOI 10.1194/jlr.M300140-JLR200; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Halleck MS, 1999, PHYSIOL GENOMICS, V1, P139, DOI 10.1152/physiolgenomics.1999.1.3.139; Hannigan M, 2002, P NATL ACAD SCI USA, V99, P3603, DOI 10.1073/pnas.052010699; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; HASLETT C, 1985, AM J PATHOL, V119, P101; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Kagan VE, 2000, FEBS LETT, V477, P1, DOI 10.1016/S0014-5793(00)01707-5; Kato N, 2002, BIOCHEMISTRY-US, V41, P8068, DOI 10.1021/bi016022v; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; Kjeldsen L, 1999, J IMMUNOL METHODS, V232, P131, DOI 10.1016/S0022-1759(99)00171-4; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Manes S, 2003, TRENDS IMMUNOL, V24, P320, DOI 10.1016/S1471-4906(03)00137-6; Manno S, 2002, P NATL ACAD SCI USA, V99, P1943, DOI 10.1073/pnas.042688399; MCEVOY L, 1988, J LEUKOCYTE BIOL, V44, P337, DOI 10.1002/jlb.44.5.337; Millan J, 2002, BLOOD, V99, P978, DOI 10.1182/blood.V99.3.978; MOHANDAS N, 1978, J SUPRAMOL STR CELL, V9, P453, DOI 10.1002/jss.400090315; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200; Pierini LM, 2000, BLOOD, V95, P2471; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Sengelov H, 1999, J IMMUNOL METHODS, V232, P145, DOI 10.1016/S0022-1759(99)00172-6; Seveau S, 2001, MOL BIOL CELL, V12, P3550, DOI 10.1091/mbc.12.11.3550; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Tseng CC, 2000, FEBS LETT, V475, P232, DOI 10.1016/S0014-5793(00)01700-2; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; Van der Luit AH, 2003, BIOCHEM J, V374, P747, DOI 10.1042/BJ20030179; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; WILLIAMSON P, 1983, BIOCHIM BIOPHYS ACTA, V732, P387, DOI 10.1016/0005-2736(83)90055-X; Williamson P, 2001, BIOCHEMISTRY-US, V40, P8065, DOI 10.1021/bi001929z; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; Windmiller DA, 2003, J BIOL CHEM, V278, P11874, DOI 10.1074/jbc.M211787200; Yu A, 2003, J BIOL CHEM, V278, P9706, DOI 10.1074/jbc.M204614200; Zhai X, 2002, BIOCHEMISTRY-US, V41, P5675, DOI 10.1021/bi011844d; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121; Zweifach A, 2000, BIOCHEM J, V349, P255, DOI 10.1042/0264-6021:3490255	73	95	100	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17625	17633		10.1074/jbc.M313414200	http://dx.doi.org/10.1074/jbc.M313414200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766753	hybrid			2022-12-27	WOS:000220870400091
J	Goyer, A; Johnson, TL; Olsen, LJ; Collakova, E; Shachar-Hill, Y; Rhodes, D; Hanson, AD				Goyer, A; Johnson, TL; Olsen, LJ; Collakova, E; Shachar-Hill, Y; Rhodes, D; Hanson, AD			Characterization and metabolic function of a peroxisomal sarcosine and pipecolate oxidase from Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-METHYLTRYPTOPHAN OXIDASE; ONE-CARBON METABOLISM; FORMATE DEHYDROGENASE; HIGHER-PLANTS; AMINO-ACID; DELTA1-PIPERIDEINE-6-CARBOXYLIC ACID; PYRROLINE-5-CARBOXYLATE REDUCTASE; MOLECULAR CHARACTERIZATION; LYSINE CATABOLISM; ESCHERICHIA-COLI	Sarcosine oxidase (SOX) is known as a peroxisomal enzyme in mammals and as a sarcosine-inducible enzyme in soil bacteria. Its presence in plants was unsuspected until the Arabidopsis genome was found to encode a protein (AtSOX) with similar to33% sequence identity to mammalian and bacterial SOXs. When overexpressed in Escherichia coli, AtSOX enhanced growth on sarcosine as sole nitrogen source, showing that it has SOX activity in vivo, and the recombinant protein catalyzed the oxidation of sarcosine to glycine, formaldehyde, and H2O2 in vitro. AtSOX also attacked other N-methyl amino acids and, like mammalian SOXs, catalyzed the oxidation of L-pipecolate to Delta(1)-piperideine-6-carboxylate. Like bacterial monomeric SOXs, AtSOX was active as a monomer, contained FAD covalently bound to a cysteine residue near the C terminus, and was not stimulated by tetrahydrofolate. Although AtSOX lacks a typical peroxisome-targeting signal, in vitro assays established that it is imported into peroxisomes. Quantitation of mRNA showed that AtSOX is expressed at a low level throughout the plant and is not sarcosine-inducible. Consistent with a low level of AtSOX expression, Arabidopsis plantlets slowly metabolized supplied [C-14] sarcosine to glycine and serine. Gas chromatography-mass spectrometry analysis revealed low levels of pipecolate but almost no sarcosine in wild type Arabidopsis and showed that pipecolate but not sarcosine accumulated 6-fold when AtSOX expression was suppressed by RNA interference. Moreover, the pipecolate catabolite alpha-aminoadipate decreased 30-fold in RNA interference plants. These data indicate that pipecolate is the endogenous substrate for SOX in plants and that plants can utilize exogenous sarcosine opportunistically, sarcosine being a common soil metabolite.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA	State University System of Florida; University of Florida; University of Michigan System; University of Michigan; Michigan State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	adha@mail.ifas.ufl.edu	Rhodes, David/L-4602-2019; Goyer, Aymeric/AAW-2617-2021; Shachar-Hill, Yair/B-6165-2013	Shachar-Hill, Yair/0000-0001-8793-5084; Goyer, Aymeric/0000-0003-0714-6750; Collakova, Eva/0000-0003-3476-6701	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arruda P, 2000, TRENDS PLANT SCI, V5, P324, DOI 10.1016/S1360-1385(00)01688-5; ASPEN AJ, 1962, BIOCHEMISTRY-US, V1, P600, DOI 10.1021/bi00910a009; BALAGHI M, 1993, BIOCHEM J, V291, P145, DOI 10.1042/bj2910145; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brickner DG, 1997, PLANT PHYSIOL, V113, P1213, DOI 10.1104/pp.113.4.1213; Chikayama M, 2000, HISTOCHEM CELL BIOL, V113, P489; Farres J, 2002, TRANSGENIC RES, V11, P49, DOI 10.1023/A:1013957819596; Fujii T, 2002, BIOSCI BIOTECH BIOCH, V66, P622, DOI 10.1271/bbb.66.622; Galili G, 2002, ANNU REV PLANT BIOL, V53, P27, DOI 10.1146/annurev.arplant.53.091401.110929; Galili G, 2001, CURR OPIN PLANT BIOL, V4, P261, DOI 10.1016/S1369-5266(00)00170-9; Gibeaut DM, 1997, PLANT PHYSIOL, V115, P317, DOI 10.1104/pp.115.2.317; Hanson AD, 2001, ANNU REV PLANT PHYS, V52, P119, DOI 10.1146/annurev.arplant.52.1.119; Hanson AD, 2000, TRENDS PLANT SCI, V5, P206, DOI 10.1016/S1360-1385(00)01599-5; HARBORNE JB, 1993, INTRO ECOLOGICAL BIO, P73; Hourton-Cabassa C, 1998, PLANT PHYSIOL, V116, P627, DOI 10.1104/pp.116.2.627; Hunt S., 1985, CHEM BIOCH AMINO ACI, P55; Job V, 2002, J BIOL CHEM, V277, P6985, DOI 10.1074/jbc.M111095200; Johnson TL, 2001, PLANT PHYSIOL, V127, P731, DOI 10.1104/pp.010262; Khanna P, 2001, BIOCHEMISTRY-US, V40, P1441, DOI 10.1021/bi0024411; Khanna P, 2001, BIOCHEMISTRY-US, V40, P1451, DOI 10.1021/bi002442t; Kvalnes-Krick K., 1991, CHEM BIOCH FLAVOENZY, P425; Li R, 2001, CAN J BOT, V79, P796, DOI 10.1139/cjb-79-7-796; Liu LH, 2003, PLANT CELL, V15, P790, DOI 10.1105/tpc.007120; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; MIHALIK SJ, 1991, J BIOL CHEM, V266, P4822; Mullen RT, 1997, PLANT PHYSIOL, V115, P881, DOI 10.1104/pp.115.3.881; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Newton-Vinson P, 2000, PROTEIN EXPRES PURIF, V20, P334, DOI 10.1006/prep.2000.1309; Olsen LJ, 1998, PLANT MOL BIOL, V38, P163, DOI 10.1023/A:1006092830670; Olson BJSC, 2000, PLANT SCI, V159, P205, DOI 10.1016/S0168-9452(00)00337-X; PAHLICH E, 1981, Z PFLANZENPHYSIOL, V101, P137, DOI 10.1016/S0044-328X(81)80048-7; Rebeille F, 1999, PR PHYT SOC, V42, P53; REITZER LJ, 1996, ESCHERICHIA COLI SAL, P380; Reuber BE, 1997, J BIOL CHEM, V272, P6766, DOI 10.1074/jbc.272.10.6766; RHODES D, 1986, PLANT PHYSIOL, V82, P890, DOI 10.1104/pp.82.4.890; Rontein D, 2003, PLANT PHYSIOL, V132, P1678, DOI 10.1104/pp.103.023242; Rontein D, 2002, METAB ENG, V4, P49, DOI 10.1006/mben.2001.0208; RUMBERO A, 1995, BIOORGAN MED CHEM, V3, P1237, DOI 10.1016/0968-0896(95)00110-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SODA K, 1968, BIOCHEMISTRY-US, V7, P4102, DOI 10.1021/bi00851a045; Trickey P, 1999, STRUCTURE, V7, P331, DOI 10.1016/S0969-2126(99)80043-4; Venci D, 2002, BIOCHEMISTRY-US, V41, P15795, DOI 10.1021/bi020515y; VERBRUGGEN N, 1993, PLANT PHYSIOL, V103, P771, DOI 10.1104/pp.103.3.771; Wagner MA, 2000, BIOCHEMISTRY-US, V39, P8825, DOI 10.1021/bi000350y; Wagner MA, 1999, BIOCHEMISTRY-US, V38, P5588, DOI 10.1021/bi982955o; Wagner MA, 1997, ARCH BIOCHEM BIOPHYS, V342, P176, DOI 10.1006/abbi.1997.0106; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; Yeo EJ, 1999, J BIOL CHEM, V274, P37559, DOI 10.1074/jbc.274.53.37559	51	53	54	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16947	16953		10.1074/jbc.M400071200	http://dx.doi.org/10.1074/jbc.M400071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766747	hybrid			2022-12-27	WOS:000220870400009
J	Arcus, VL; Backbro, K; Roos, A; Daniel, EL; Baker, EN				Arcus, VL; Backbro, K; Roos, A; Daniel, EL; Baker, EN			Distant structural homology leads to the functional characterization of an archaeal PIN domain as an exonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; CRYSTAL-STRUCTURE; DNA-REPAIR; PROTEIN-STRUCTURE; GENOME SEQUENCE; RECOGNITION; POLYMERASE; PREDICTION; STRATEGIES; EVOLUTION	Genome sequencing projects have focused attention on the problem of discovering the functions of protein domains that are widely distributed throughout living species but which are, as yet, largely uncharacterized. One such example is the PIN domain, found in eukaryotes, bacteria, and Archaea, and with suggested roles in signaling, RNase editing, and/or nucleotide binding. The first reported crystal structure of a PIN domain ( open reading frame PAE2754, derived from the crenarchaeon, Pyrobaculum aerophilum) has been determined to 2.5 Angstrom resolution and is presented here. Mapping conserved residues from a multiple sequence alignment onto the structure identifies a putative active site. The discovery of distant structural homology with several exonucleases, including T4 phage RNase H and flap endonuclease (FEN1), further suggests a likely function for PIN domains as Mg2+-dependent exonucleases, a hypothesis that we have confirmed in vitro. The tetrameric structure of PAE2754, with the active sites inside a tunnel, suggests a mechanism for selective cleavage of single-stranded overhangs or flap structures. These results indicate likely DNA or RNA editing roles for prokaryotic PIN domains, which are strikingly numerous in thermophiles, and in organisms such as Mycobacterium tuberculosis. They also support previous hypotheses that eukaryotic PIN domains participate in RNA(i) and nonsense-mediated RNA degradation.	Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, AgRes Struct Biol Lab, Auckland 1, New Zealand; Univ Auckland, Ctr Mol Biodiscovery, Auckland 1, New Zealand	University of Auckland; University of Auckland; University of Auckland	Arcus, VL (corresponding author), Univ Auckland, Sch Biol Sci, Private Bag 92019, Auckland 1, New Zealand.	v.arcus@auckland.ac.nz	Scotter, Emma/C-4833-2012	Scotter, Emma/0000-0003-4064-3599; Baker, Edward/0000-0003-2456-7661				Adams MWW, 2003, ACCOUNTS CHEM RES, V36, P191, DOI 10.1021/ar0101382; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; ARCUS VL, 2004, IN PRESS ACTA CRYS D, V60; BARBER MJ, 1992, J BIOL CHEM, V267, P6611; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Clissold PM, 2000, CURR BIOL, V10, pR888, DOI 10.1016/S0960-9822(00)00858-7; DeLano W.L, PYMOL MOL GRAPHICS S; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Gonzalez A, 2003, ACTA CRYSTALLOGR D, V59, P315, DOI 10.1107/S0907444902022138; Goulding Celia W., 2002, Current Drug Targets - Infectious Disorders, V2, P121, DOI 10.2174/1568005023342551; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Holton T, 2000, ACTA CRYSTALLOGR D, V56, P722, DOI 10.1107/S0907444900003450; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Ioerger TR, 2002, ACTA CRYSTALLOGR D, V58, P2043, DOI 10.1107/S0907444902016724; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karunakaran P, 2000, J BACTERIOL, V182, P3331, DOI 10.1128/JB.182.12.3331-3335.2000; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Makarova KS, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-115; Makarova KS, 2002, NUCLEIC ACIDS RES, V30, P482, DOI 10.1093/nar/30.2.482; Makarova KS, 1999, GENOME RES, V9, P608; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Miura R, 1997, J BIOCHEM-TOKYO, V122, P825; Mizrahi V, 1998, MOL MICROBIOL, V29, P1331, DOI 10.1046/j.1365-2958.1998.01038.x; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Stevens RC, 2001, SCIENCE, V294, P89, DOI 10.1126/science.1066011; Teichmann SA, 2001, CURR OPIN STRUC BIOL, V11, P354, DOI 10.1016/S0959-440X(00)00215-3; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Wall D, 1999, MOL MICROBIOL, V32, P1, DOI 10.1046/j.1365-2958.1999.01339.x	40	93	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16471	16478		10.1074/jbc.M313833200	http://dx.doi.org/10.1074/jbc.M313833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14734548	hybrid			2022-12-27	WOS:000220747900095
J	Onodera, J; Ohsumi, Y				Onodera, J; Ohsumi, Y			Ald6p is a preferred target for autophagy in yeast, Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ALDEHYDE DEHYDROGENASE; MULTIFUNCTIONAL PROTEINASE; ACETALDEHYDE DEHYDROGENASE; DEFICIENT MUTANTS; INVIVO FUNCTION; VACUOLE; PATHWAY; CYTOPLASM; DEGRADATION; GENE	Macroautophagy is the process of intracellular bulk protein degradation induced by nutrient starvation and is generally considered to be a nonselective degradation of cytosolic enzymes and organelles. However, it remains a possibility that some proteins may be preferentially degraded by autophagy. In this study, we have performed a systematic analysis on the substrate selectivity of autophagy in yeast, Saccharomyces cerevisiae, using two-dimensional PAGE. We performed a differential screen on wild-type and Deltaatg7/apg7 autophagy-deficient cells and found that cytosolic acetaldehyde dehydrogenase (Ald6p) decreased under nitrogen starvation. As assessed by immunoblot, Ald6p was reduced by greater than 82% after 24 h of nitrogen starvation. This reduction was dependent on Atg/Apg proteins and vacuolar proteases but was not dependent on the proteasome or the cytoplasm to vacuole targetting (Cvt) pathway. Using pulse-chase and subcellular fractionation, we have also demonstrated that Ald6p was preferentially transported to vacuoles via autophagosomes. Deltaatg7 Deltaald6 double mutant cells were able to maintain higher rates of viability than Deltaatg7 cells under nitrogen starvation, and Ald6p-overexpressing cells were not able to maintain high rates of viability. Furthermore, the Ald6p(C306S) mutant, which lacks enzymatic activity, had viability rates similar to Deltaald6 cells. Ald6p enzymatic activity may be disadvantageous for survival under nitrogen starvation; therefore, yeast cells may preferentially eliminate Ald6p via autophagy.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Nishigonaka 38, Okazaki, Aichi 4448585, Japan.	yohsumi@nibb.ac.jp	Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166				ASHFORD TP, 1962, J CELL BIOL, V12, P198, DOI 10.1083/jcb.12.1.198; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Barth H, 2001, FEBS LETT, V508, P23, DOI 10.1016/S0014-5793(01)03016-2; BETZ H, 1976, EUR J BIOCHEM, V70, P385, DOI 10.1111/j.1432-1033.1976.tb11028.x; Brejning J, 2002, INT J FOOD MICROBIOL, V75, P27, DOI 10.1016/S0168-1605(01)00726-7; Brown CR, 2002, J CELL SCI, V115, P655; BRUKE D, 2000, METHOD YEAST GENETIC; FARRES J, 1995, BIOCHEMISTRY-US, V34, P2592, DOI 10.1021/bi00008a025; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Grabowska D, 2003, J BIOL CHEM, V278, P13984, DOI 10.1074/jbc.M210076200; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hoffman M, 1996, GENETICS, V143, P1555; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Khalfan WA, 2002, CURR OPIN CELL BIOL, V14, P468, DOI 10.1016/S0955-0674(02)00343-5; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kurita O, 1999, FEMS MICROBIOL LETT, V181, P281, DOI 10.1111/j.1574-6968.1999.tb08856.x; Meaden PG, 1997, YEAST, V13, P1319, DOI 10.1002/(SICI)1097-0061(199711)13:14<1319::AID-YEA183>3.0.CO;2-T; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mukaiyama H, 2002, GENES CELLS, V7, P75, DOI 10.1046/j.1356-9597.2001.00499.x; Murray RK, 2003, HARPERS ILLUSTRATED, V26th; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; SIKORSKI RS, 1989, GENETICS, V122, P19; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tessier WD, 1998, FEMS MICROBIOL LETT, V164, P29, DOI 10.1111/j.1574-6968.1998.tb13063.x; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; White WH, 2003, GENETICS, V163, P69	43	89	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16071	16076		10.1074/jbc.M312706200	http://dx.doi.org/10.1074/jbc.M312706200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761979	hybrid			2022-12-27	WOS:000220747900047
J	Walisser, JA; Bunger, MK; Glover, E; Harstad, EB; Bradfield, CA				Walisser, JA; Bunger, MK; Glover, E; Harstad, EB; Bradfield, CA			Patent ductus venosus and dioxin resistance in mice harboring a hypomorphic Arnt allele	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; AH RECEPTOR; MOLECULAR CHARACTERIZATION; RETINOBLASTOMA PROTEIN; PAS SUPERFAMILY; HYPOXIA; TRANSCRIPTION; COMPETITION; EXPRESSION; GENE	The Ah receptor nuclear translocator (ARNT) is the dimeric partner of hypoxia-inducible factors and thus plays a pivotal role in cellular adaptation to low oxygen environments. ARNT is also a dimeric partner for the Ah receptor (AHR), and this complex is essential in regulating the adaptive metabolic response to polycyclic aromatic hydrocarbons. Because of the essential role of ARNT in hypoxia-driven developmental events, it has been difficult to study the physiological significance of AHR.ARNT heterodimers in vivo. To address this issue, we developed a hypomorphic Arnt allele that displayed normal development and allowed the examination of the role of ARNT in AHR biology. In this regard, the AHR is also known to mediate two additional biological processes: the toxicological response to compounds such as 2,3,7,8-tetrachlorodibenzo- p-dioxin (dioxin) and the developmental closure of a fetal vascular structure known as the ductus venosus. Although the mechanism of the adaptive pathway has been well described, the mechanism of AHR-mediated signal transduction in the toxic and developmental pathways is not well understood. Liver perfusion studies demonstrated that ARNT hypomorphs have a patent ductus venosus, identical to that observed in the Ahr null mice. Parallel dioxin toxicity studies demonstrated that the ARNT hypomorphs exhibited resistance to the end points of dioxin exposure. Moreover, we observed that toxicity could be segregated from the classical adaptive responses such as P4501A induction. Taken in sum, these experiments demonstrate that ARNT is an essential component of AHR developmental signaling and shed light on the mechanism of dioxin toxicity.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	bradfield@oncology.wisc.edu			NATIONAL CANCER INSTITUTE [P01CA022484, P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006883] Funding Source: NIH RePORTER; NCI NIH HHS [CA022484, CA014520, P01 CA022484] Funding Source: Medline; NIEHS NIH HHS [R01 ES006883, ES006881] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Blankenship A, 1997, MOL PHARMACOL, V52, P667, DOI 10.1124/mol.52.4.667; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P229; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V267, P184, DOI 10.1006/bbrc.1999.1913; Drutel G, 1996, BIOCHEM BIOPH RES CO, V225, P333, DOI 10.1006/bbrc.1996.1176; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Gu YZ, 1998, GENE EXPRESSION, V7, P205; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; HOLSAPPLE MP, 1991, ANNU REV PHARMACOL, V31, P73; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; Klinge CM, 2000, ARCH BIOCHEM BIOPHYS, V373, P163, DOI 10.1006/abbi.1999.1552; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Liang HCL, 1996, P NATL ACAD SCI USA, V93, P1671, DOI 10.1073/pnas.93.4.1671; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1980, MOL PHARMACOL, V17, P86; Pollenz RS, 1999, MOL PHARMACOL, V56, P1127, DOI 10.1124/mol.56.6.1127; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Reiners JJ, 1999, J BIOL CHEM, V274, P2502, DOI 10.1074/jbc.274.4.2502; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tomita S, 2003, J IMMUNOL, V171, P4113, DOI 10.4049/jimmunol.171.8.4113; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245	35	95	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16326	16331		10.1074/jbc.M400784200	http://dx.doi.org/10.1074/jbc.M400784200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764592	hybrid			2022-12-27	WOS:000220747900078
J	Allende, ML; Dreier, JL; Mandala, S; Proia, RL				Allende, ML; Dreier, JL; Mandala, S; Proia, RL			Expression of the sphingosine 1-phosphate receptor, S1P(1), on T-cells controls thymic emigration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; THYMOCYTE EMIGRATION; VASCULAR MATURATION; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE; FTY720; LYSOPHOSPHOLIPIDS; EDG-1; IMMUNOSUPPRESSANT; PHOSPHORYLATION	S1P1 is a widely distributed G protein-coupled receptor whose ligand, sphingosine 1-phosphate, is present in high concentrations in the blood. The sphingosine 1-phosphate receptor-signaling pathway is believed to have potent effects on cell trafficking in the immune system. To determine the precise role of the S1P1 receptor on T-cells, we established a T-cell-specific S1P1 knock-out mouse. The mutant mice showed a block in the egress of mature T-cells into the periphery. The expression of the S1P1 receptor was up-regulated in mature thymocytes, and its deletion altered the chemotactic responses of thymocytes to sphingosine 1-phosphate. The results indicated that the expression of the S1P1 receptor on T-cells controls their exit from the thymus and entry into the blood and, thus, has a central role in regulating the numbers of peripheral T-cells.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Merck Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Merck & Company	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bldg 10,Rm 9N-314,10 Ctr Dr, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; An SZ, 1998, J CELL BIOCHEM, P147; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Chiba K, 1998, J IMMUNOL, V160, P5037; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Gabor MJ, 1997, EUR J IMMUNOL, V27, P2010, DOI 10.1002/eji.1830270827; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Hakomori S, 2003, CURR OPIN HEMATOL, V10, P16, DOI 10.1097/00062752-200301000-00004; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HLA T, 1990, J BIOL CHEM, V265, P9308; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Lee CK, 2001, BLOOD, V97, P1360, DOI 10.1182/blood.V97.5.1360; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; Shayman JA, 2000, KIDNEY INT, V58, P11, DOI 10.1046/j.1523-1755.2000.00136.x; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	37	362	380	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15396	15401		10.1074/jbc.M314291200	http://dx.doi.org/10.1074/jbc.M314291200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732704	hybrid			2022-12-27	WOS:000220594700109
J	Gooch, JL; Gorin, Y; Zhang, BX; Abboud, HE				Gooch, JL; Gorin, Y; Zhang, BX; Abboud, HE			Involvement of calcineurin in transforming growth factor-beta-mediated regulation of extracellular matrix accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESANGIAL CELLS; TGF-BETA; HYDROGEN-PEROXIDE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; INTRACELLULAR CA2+; LUNG FIBROBLASTS; MESSENGER-RNA; T-LYMPHOCYTES; HIGH GLUCOSE	Calcineurin is a calcium-dependent, serine/threonine phosphatase that functions as a signaling intermediate. In this study, we investigated the role of calcineurin in transforming growth factor-beta (TGF-beta)-mediated cellular effects and examined the signaling pathway involved in activation of calcineurin. Calcineurin is activated by TGF-beta in a time- and dose-dependent manner. Consistent with increased phosphatase activity, the calcineurin substrate, NFATc1, is dephosphorylated and transported to the nucleus. Inhibition of calcineurin prior to the addition of TGF-beta revealed that calcineurin is required for TGF-beta-mediated accumulation of extracellular matrix (ECM) proteins but not cell hypertrophy. Conversely, overexpression of constitutively active calcineurin was sufficient to induce ECM protein expression. The mechanism of calcineurin activation by TGF-beta was found to be induction of a low, sustained increase of intracellular calcium. Chelation of extracellular calcium blocked both TGF-beta-mediated calcium influx and calcineurin activity. Finally, calcium entry was found to be dependent upon generation of reactive oxygen species (ROS) including superoxide anion and hydrogen peroxide. Accordingly, inhibition of ROS generation also blocked TGF-beta-mediated calcineurin phosphatase activity and decreased ECM accumulation. In conclusion, this study describes a new pathway for TGF-beta-mediated regulation of ECM via generation of ROS, calcium influx, and activation of calcineurin.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78284 USA; S Texas Vet Adm, Audie Murphy Mem Hosp, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Gooch, JL (corresponding author), UTHSCSA, Div Renal, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	Gooch@uthscsa.edu		Gorin, Yves/0000-0003-4048-6925	NIDDK NIH HHS [DK439888] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alevizopoulos A, 1997, J BIOL CHEM, V272, P23597, DOI 10.1074/jbc.272.38.23597; Bogumil R, 2000, EUR J BIOCHEM, V267, P1407, DOI 10.1046/j.1432-1327.2000.01133.x; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cao Q, 2002, AM J PHYSIOL-GASTR L, V283, pG1051, DOI 10.1152/ajpgi.00128.2002; Chiu C, 2001, INT J MOL MED, V8, P251; CHOI ME, 1993, KIDNEY INT, V44, P948, DOI 10.1038/ki.1993.336; Delorme N, 2002, J ENDOCRINOL, V173, P345, DOI 10.1677/joe.0.1730345; DOLMETSCH R, 1997, NATURE, V6627, P855; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; Gooch JL, 2003, AM J PHYSIOL-RENAL, V284, pF144, DOI 10.1152/ajprenal.00158.2002; Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200; Gorin Y, 2001, FASEB J, V15, P1909, DOI 10.1096/fj..01-0165com; Ha HJ, 2000, KIDNEY INT, V58, pS19, DOI 10.1046/j.1523-1755.2000.07704.x; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; Ishiyama N, 1996, MOL CELL ENDOCRINOL, V117, P1, DOI 10.1016/0303-7207(95)03726-8; Islam M, 2001, KIDNEY INT, V59, P498, DOI 10.1046/j.1523-1755.2001.059002498.x; Jaimes EA, 1998, KIDNEY INT, V54, P775, DOI 10.1046/j.1523-1755.1998.00068.x; Johnson DW, 1999, J PHARMACOL EXP THER, V289, P535; JOHNSTON RB, 1984, METHOD ENZYMOL, V105, P365; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; Lee ZW, 1998, J BIOL CHEM, V273, P12710, DOI 10.1074/jbc.273.21.12710; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McGowan TA, 2002, AM J PHYSIOL-RENAL, V282, pF910, DOI 10.1152/ajprenal.00252.2001; Miyashita T, 2001, JPN CIRC J, V65, P815, DOI 10.1253/jcj.65.815; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Palmer S, 2001, J CELL BIOL, V153, P985, DOI 10.1083/jcb.153.5.985; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Reiter TA, 2002, J BIOL INORG CHEM, V7, P823, DOI 10.1007/s00775-002-0367-x; Sharma K, 1999, AM J PHYSIOL-RENAL, V276, pF54, DOI 10.1152/ajprenal.1999.276.1.F54; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; Sharma K, 1997, J BIOL CHEM, V272, P14617, DOI 10.1074/jbc.272.23.14617; Sharma K, 2000, AM J PHYSIOL-RENAL, V278, pF1022, DOI 10.1152/ajprenal.2000.278.6.F1022; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Tanimura A, 2000, J BIOL CHEM, V275, P27488; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Tudor KSRS, 2001, CYTOKINE, V15, P196, DOI 10.1006/cyto.2001.0922; Wolf G, 1996, EXP NEPHROL, V4, P304; WOLF G, 1990, J AM SOC NEPHROL, V1, P918; Zhang BX, 2002, J BIOL CHEM, V277, P48165, DOI 10.1074/jbc.M208077200; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	51	89	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15561	15570		10.1074/jbc.M308759200	http://dx.doi.org/10.1074/jbc.M308759200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742441	hybrid			2022-12-27	WOS:000220594700128
J	Iwabu, A; Smith, K; Allen, FD; Lauffenburger, DA; Wells, A				Iwabu, A; Smith, K; Allen, FD; Lauffenburger, DA; Wells, A			Epidermal growth factor induces fibroblast contractility and motility via a protein kinase C delta-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONMUSCLE MYOSIN-II; SMOOTH-MUSCLE-CELLS; CALPAIN CALPAIN-II; FACTOR RECEPTOR; LIGHT-CHAIN; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; HEPATOCYTE GROWTH; PKC-DELTA; PHOSPHORYLATION	Myosin-based cell contractile force is considered to be a critical process in cell motility. However, for epidermal growth factor (EGF)-induced fibroblast migration, molecular links between EGF receptor ( EGFR) activation and force generation have not been clarified. Herein, we demonstrate that EGF stimulation increases myosin light chain (MLC) phosphorylation, a marker for contractile force, concomitant with protein kinase C (PKC) activity in mouse fibroblasts expressing human EGFR constructs. Interestingly, PKCdelta is the most strongly phosphorylated isoform, and the preferential PKCdelta inhibitor rottlerin largely prevented EGF-induced phosphorylation of PKC substrates and MARCKS. The pathway through which EGFR activates PKCdelta is suggested by the fact that the MEK-1 inhibitor U0126 and the phosphatidylinositol 3-kinase inhibitor LY294002 had no effect on PKCdelta activation, whereas lack of PLCgamma signaling resulted in delayed PKCdelta activation. EGF-enhanced MLC phosphorylation was prevented by a specific MLC kinase inhibitor ML-7 and the PKC inhibitors chelerythrine chloride and rottlerin. Further indicating that PKCdelta is required, a dominant-negative PKCdelta construct or RNAi-mediated PKCdelta depletion also prevented MLC phosphorylation. In the absence of PLC signaling, MLC phosphorylation and cell force generation were delayed similarly to PKCdelta activation. All of the interventions that blocked PKCdelta activation or MLC phosphorylation abrogated EGF-induced cell contractile force generation and motility. Our results suggest that PKCdelta activation is responsible for a major part of EGF-induced fibroblast contractile force generation. Hence, we identify here a new pathway helping to govern cell motility, with PLC signaling playing a role in activation of PKCdelta to promote the acute phase of EGF-induced MLC activation.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; MIT, Dept Biol, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Drexel University	Wells, A (corresponding author), Univ Pittsburgh, Dept Pathol, S713 Scaife Hall, Pittsburgh, PA 15261 USA.	wellsa@msx.upmc.edu		Wells, Alan/0000-0002-1637-8150	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069668] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM069668] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Allen FD, 2002, WOUND REPAIR REGEN, V10, P67, DOI 10.1046/j.1524-475X.2002.10701.x; ANDO Y, 1993, J CELL PHYSIOL, V156, P487, DOI 10.1002/jcp.1041560308; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Ben-Ya'acov A, 2003, J BIOL CHEM, V278, P40032, DOI 10.1074/jbc.M306948200; Bhatt A, 2002, J CELL SCI, V115, P3415; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Cai WY, 2000, INVEST OPHTH VIS SCI, V41, P1885; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chou J, 2003, EXP CELL RES, V287, P47, DOI 10.1016/S0014-4827(03)00119-8; Chou J, 2002, INT J BIOCHEM CELL B, V34, P776, DOI 10.1016/S1357-2725(01)00177-7; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; CONRAD AH, 1995, CELL MOTIL CYTOSKEL, V31, P93, DOI 10.1002/cm.970310203; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Eto M, 2000, CELL MOTIL CYTOSKEL, V46, P222, DOI 10.1002/1097-0169(200007)46:3<222::AID-CM6>3.3.CO;2-2; Gauthier ML, 2003, BIOCHEM BIOPH RES CO, V307, P839, DOI 10.1016/S0006-291X(03)01273-7; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Haase I, 2003, J CELL SCI, V116, P3227, DOI 10.1242/jcs.00610; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; IKEBE M, 1987, J BIOL CHEM, V262, P9569; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; Maheshwari G, 1999, BIOPHYS J, V76, P2814, DOI 10.1016/S0006-3495(99)77435-7; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Murakami M, 2002, J BIOL CHEM, V277, P20367, DOI 10.1074/jbc.M202501200; Murthy KS, 2000, AM J PHYSIOL-GASTR L, V279, pG201, DOI 10.1152/ajpgi.2000.279.1.G201; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; OHNO S, 1994, J BIOL CHEM, V269, P17495; Palecek SP, 1998, J CELL SCI, V111, P929; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pollard TD, 2003, NATURE, V422, P741, DOI 10.1038/nature01598; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Straussman R, 2001, J CELL SCI, V114, P3047; Ware MF, 1998, J CELL SCI, V111, P2423; Watanabe Y, 2001, BLOOD, V97, P3798, DOI 10.1182/blood.V97.12.3798; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	72	119	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14551	14560		10.1074/jbc.M311981200	http://dx.doi.org/10.1074/jbc.M311981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747473	hybrid			2022-12-27	WOS:000220594700012
J	Abe, H; Matsubara, T; Iehara, N; Nagai, K; Takahashi, T; Arai, H; Kita, T; Doi, T				Abe, H; Matsubara, T; Iehara, N; Nagai, K; Takahashi, T; Arai, H; Kita, T; Doi, T			Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-LIKE KINASE-1; MESANGIAL CELLS; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; EXPRESSION; MICE; GENE; COMPLICATIONS; ACTIVIN	Prolonged exposure to hyperglycemia is now recognized as the most significant causal factor of diabetic complications. Excessive advanced glycation end products (AGEs) as a result of hyperglycemia in tissues or in the circulation may critically affect the progression of diabetic nephropathy. In diabetic nephropathy, glomerulosclerosis is a typical pathologic feature characterized by the increase of the extracellular matrix (ECM). We have reported previously that alpha1 type IV collagen (Col4) is one of the major components of ECM, which is up-regulated by AGEs, and that the overexpression of Col4 is transcriptionally regulated by an unknown transcription factor binding to the promoter. Here we identified this protein as Smad1 by yeast one-hybrid screening. Using chromatin immunoprecipitation and reporter assay, we observed that Smad1 directly regulated transcription for Col4 through the binding of Smad1 to the promoter of Col4. Smad1 was significantly induced along with Col4 in AGE-treated mesangial cells. Moreover, suppression of Smad1 by antisense morpholino resulted in a decrease of AGE-induced Col4 overproduction. To elucidate the interaction between transforming growth factor-beta and Smad1, we investigated whether activin receptor-liked kinase1 (ALK1) was involved in this regulation. AGE stimulation significantly increased the expression of the ALK1 mRNA in mesangial cells. We also demonstrated that Smad1 and ALK1 were highly expressed in human diabetic nephropathy. These results suggest that the modulation of Smad1 expression is responsible for the initiation and progression of diabetic nephropathy and that blocking Smad1 signaling may be beneficial in preventing diabetic nephropathy and other various diabetic complications.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Artificial Kidney, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Doi, T (corresponding author), Univ Tokushima, Dept Clin Biol & Med, Course Biol Med, Tokushima 7708503, Japan.	doi@clin.med.tokushima-u.ac.jp	Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849				Abe H, 1999, J BIOL CHEM, V274, P20874, DOI 10.1074/jbc.274.30.20874; Ahn DG, 2002, NATURE, V417, P754, DOI 10.1038/nature00814; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BRUGGEMAN LA, 1992, ONCOGENE, V7, P1497; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; Chappey O, 1997, EUR J CLIN INVEST, V27, P97, DOI 10.1046/j.1365-2362.1997.710624.x; Chen S, 2003, BIOCHEM BIOPH RES CO, V300, P16, DOI 10.1016/S0006-291X(02)02708-0; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; DAVIES M, 1994, KIDNEY INT, V45, P320, DOI 10.1038/ki.1994.41; Dick A, 1998, DEV DYNAM, V211, P293, DOI 10.1002/(SICI)1097-0177(199804)211:4<293::AID-AJA1>3.0.CO;2-C; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; FLOEGE J, 1991, KIDNEY INT, V40, P477, DOI 10.1038/ki.1991.235; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang SX, 2000, GENE, V258, P43, DOI 10.1016/S0378-1119(00)00396-6; HUIJBERTS MSP, 1993, J CLIN INVEST, V92, P1407, DOI 10.1172/JCI116716; Iehara N, 1996, KIDNEY INT, V50, P1166, DOI 10.1038/ki.1996.424; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; THROCKMORTON DC, 1995, KIDNEY INT, V48, P111, DOI 10.1038/ki.1995.274; Tremblay KD, 2001, DEVELOPMENT, V128, P3609; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; YANG CW, 1994, P NATL ACAD SCI USA, V91, P9436, DOI 10.1073/pnas.91.20.9436; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	40	72	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14201	14206		10.1074/jbc.M310427200	http://dx.doi.org/10.1074/jbc.M310427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732718	hybrid			2022-12-27	WOS:000220478500112
J	Hao, MM; Mukherjee, S; Sun, Y; Maxfield, FR				Hao, MM; Mukherjee, S; Sun, Y; Maxfield, FR			Effects of cholesterol depletion and increased lipid unsaturation on the properties of endocytic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; CELL-SURFACE; PLASMA-MEMBRANE; LIVING CELLS; DOMAIN FORMATION; TRAFFICKING; TRANSPORT; PATHWAY; RAFTS; SPHINGOLIPIDS	Lipid analogs with dialkylindocarbocyanine (DiI) head groups and short or unsaturated hydrocarbon chains (e.g. DiIC(12) and FAST DiI) enter the endocytic recycling compartment efficiently, whereas lipid analogs with long, saturated tails (e.g. DiIC(16) and DiIC(18)) are sorted out of this pathway and targeted to the late endosomes/lysosomes (Mukherjee, S., Soe, T. T., and Maxfield, F. R. ( 1999) J. Cell Biol. 144, 1271 - 1284). This differential trafficking of lipid analogs with the same polar head group was interpreted to result from differential partitioning to different types of domains with varying membrane order and/or curvature. Here we investigate the system further by monitoring the trafficking behavior of these lipid analogs under conditions that alter domain properties. There was a marked effect of cholesterol depletion on the cell-surface distribution and degree of internalization of the lipid probes. Furthermore, instead of going to the late endosomes/lysosomes as in control cells, long chain DiI analogs, such as DiIC16, were sorted to the recycling pathway in cholesterol-depleted cells. We confirmed that this difference was due to a change in overall membrane properties, and not cholesterol levels per se, by utilizing a Chinese hamster ovary cell line that overexpressed transfected stearoyl-CoA desaturase 1, a rate-limiting enzyme in the production of monounsaturated fatty acids. These cells have a decrease in membrane order because they contain a much larger fraction of unsaturated fatty acids. These cells showed alteration of DiI trafficking very similar to cholesterol-depleted cells. By using cold Triton X-100 extractability of different lipids as a criterion to determine the membrane properties of intracellular organelles, we found that the endocytic recycling compartment has abundant detergent-resistant membranes, in contrast to the late endosomes and lysosomes.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Columbia Univ, Dept Med, New York, NY 10032 USA	Cornell University; Columbia University	Maxfield, FR (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	frmaxfie@med.cornell.edu	Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011; Eckhardt, Erik/G-1567-2010	Maxfield, Fred/0000-0003-4396-8866; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027083, R01DK027083] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Feigenson GW, 2001, BIOPHYS J, V80, P2775, DOI 10.1016/S0006-3495(01)76245-5; Gennis R. B., 1989, BIOMEMBRANES MOL STR, DOI [10.1007/978-1-4757-2065-5, DOI 10.1007/978-1-4757-2065-5]; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Johnson RA, 2003, BIOCHEMISTRY-US, V42, P1637, DOI 10.1021/bi0264465; Julicher F, 1996, PHYS REV E, V53, P2670, DOI 10.1103/PhysRevE.53.2670; KOK JW, 1991, J CELL BIOL, V114, P231, DOI 10.1083/jcb.114.2.231; KOK JW, 1990, EUR J CELL BIOL, V53, P173; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Maier O, 2001, SEMIN CELL DEV BIOL, V12, P149, DOI 10.1006/scdb.2000.0232; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SCHROEDER F, 1995, MOL MEMBR BIOL, V12, P113, DOI 10.3109/09687689509038505; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; SPINK CH, 1990, BIOCHIM BIOPHYS ACTA, V1023, P25, DOI 10.1016/0005-2736(90)90005-9; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; Watanabe R, 2002, J BIOL CHEM, V277, P49538, DOI 10.1074/jbc.M206209200; Wustner D, 2002, J BIOL CHEM, V277, P30325, DOI 10.1074/jbc.M202626200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G	44	79	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14171	14178		10.1074/jbc.M309793200	http://dx.doi.org/10.1074/jbc.M309793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734557	hybrid			2022-12-27	WOS:000220478500108
J	Heim, N; Griesbeck, O				Heim, N; Griesbeck, O			Genetically encoded indicators of cellular calcium dynamics based on troponin C and green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE; CALMODULIN; BINDING; DOMAIN; PROBE	Genetic calcium probes offer tremendous potential in the fields of neuroscience, cell biology, and pharmaceutical screening. Previously, ratiometric and non-ratio-metric indicators of cellular calcium dynamics have been described that consist of mutants of the green fluorescent protein (GFP) as fluorophores and calmodulin as calcium-binding moiety in several configurations. However, these calmodulin-based types of probes have a series of deficiencies, such as reduced dynamic ranges, when expressed within transgenic organisms and lack of calcium sensitivity in certain targetings. We developed novel types of calcium probes based on troponin C variants from skeletal and cardiac muscle. These indicators have ratio changes up to 140%, K(d)s ranging from 470 nM to 29 muM, and improved subcellular targeting properties. We targeted the indicators to the plasma membrane of HEK293 cells and primary hippocampal neurons. Upon long lasting depolarization, submembrane calcium levels in hippocampal neurons were found to be in equilibrium with bulk cytosolic calcium levels, suggesting no standing gradient persists from the membrane toward the cytosol. We expect that such novel indicators using specialized calcium sensing proteins will be minimally interacting with the cellular biochemical machinery.	Max Planck Inst Neurobiol, AG Zellulare Dynam, D-82152 Martinsried, Germany	Max Planck Society	Griesbeck, O (corresponding author), Max Planck Inst Neurobiol, AG Zellulare Dynam, Klopferspitz 18A, D-82152 Martinsried, Germany.	griesbeck@neuro.mpg.de		Griesbeck, Oliver/0000-0001-5883-5594				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Benaim G, 2002, EUR J BIOCHEM, V269, P3619, DOI 10.1046/j.1432-1033.2002.03038.x; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHEUNG HC, 2000, TOPICS FLUORESCENCE, V6, P257; Fiala A, 2002, CURR BIOL, V12, P1877, DOI 10.1016/S0960-9822(02)01239-3; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kerr R, 2000, NEURON, V26, P583, DOI 10.1016/S0896-6273(00)81196-4; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Mercier P, 2000, BIOCHEMISTRY-US, V39, P2902, DOI 10.1021/bi992579n; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; Pearlstone JR, 2000, J BIOL CHEM, V275, P35106, DOI 10.1074/jbc.M001000200; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; Reiff DF, 2002, J NEUROSCI, V22, P9399; REINACH FC, 1988, J BIOL CHEM, V263, P2371; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; SORENSON MM, 1995, J BIOL CHEM, V270, P9770, DOI 10.1074/jbc.270.17.9770; Truong K, 2001, NAT STRUCT BIOL, V8, P1069, DOI 10.1038/nsb728; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	27	187	193	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14280	14286		10.1074/jbc.M312751200	http://dx.doi.org/10.1074/jbc.M312751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14742421	hybrid			2022-12-27	WOS:000220478500122
J	Lengqvist, J; Svensson, R; Evergren, E; Morgenstern, R; Griffiths, WJ				Lengqvist, J; Svensson, R; Evergren, E; Morgenstern, R; Griffiths, WJ			Observation of an intact noncovalent homotrimer of detergent-solubilized rat microsomal glutathione transferase-1 by electrospray mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6 ANGSTROM RESOLUTION; S-TRANSFERASE; PROTEIN COMPLEXES; MEMBRANE-PROTEIN; HYDROGEN/DEUTERIUM EXCHANGE; TRANSMEMBRANE PEPTIDES; PROJECTION STRUCTURE; LIPID-BILAYERS; IONIZATION; CRYSTALS	Microsomal glutathione transferase-1 (MGST1) is a membrane-bound enzyme involved in the detoxification of xenobiotics and the protection of cells against oxidative stress. The proposed active form of the enzyme is a noncovalently associated homotrimer that binds one substrate glutathione molecule/trimer. In this study, this complex has been directly observed by electrospray mass spectrometry analysis of active rat liver MGST1 reconstituted in a minimum amount of detergent. The measured mass of the homotrimer is 53 kDa, allowing for the mass of three MGST molecules in complex with one glutathione molecule. Collision-induced dissociation of the trimer complex resulted in the formation of monomer and homodimer ion species. Two distinct species of homodimer were observed, one unliganded and one identified as a homodimer . glutathione complex. Activation of the enzyme by N-ethylmaleimide through modification of Cys(49) (Svensson, R., Rinaldi, R., Swedmark, S., and Morgenstern, R. (2000) Biochemistry 39, 15144 - 15149) was monitored by the observation of an appropriate increase in mass in both the denatured monomeric and native trimeric forms of MGST1. Together, the data correspond well with the proposed functional organization of MGST1. These results also represent the first example of direct electrospray mass spectrometry analysis of a detergent-solubilized multimeric membrane protein complex in its native state.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Karolinska Inst, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, Ctr Excellence Dev Biol, SE-17177 Stockholm, Sweden; Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska Institutet; University of London; University College London; University of London School of Pharmacy	Griffiths, WJ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	william.griffiths@ulsop.ac.uk	Morgenstern, Ralf/GZH-0158-2022; Griffiths, William/N-4641-2016; Evergren, Emma/X-3677-2019	Griffiths, William/0000-0002-4129-6616; Evergren, Emma/0000-0002-0775-2921				ANDERSSON C, 1994, BBA-PROTEIN STRUCT M, V1204, P298, DOI 10.1016/0167-4838(94)90021-3; Barnidge DR, 1999, ANAL BIOCHEM, V269, P1, DOI 10.1006/abio.1999.4012; BOYER TD, 1986, J BIOL CHEM, V261, P6963; Chung EW, 1997, PROTEIN SCI, V6, P1316, DOI 10.1002/pro.5560060620; Codreanu SG, 2002, BIOCHEMISTRY-US, V41, P15161, DOI 10.1021/bi026776p; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; Demmers JAA, 2000, P NATL ACAD SCI USA, V97, P3189, DOI 10.1073/pnas.050444797; Demmers JAA, 2002, J AM CHEM SOC, V124, P11191, DOI 10.1021/ja0125927; Demmers JAA, 2003, FEBS LETT, V541, P28, DOI 10.1016/S0014-5793(03)00282-5; Demmers JAA, 2001, J BIOL CHEM, V276, P34501, DOI 10.1074/jbc.M101401200; Fandrich M, 2000, P NATL ACAD SCI USA, V97, P14151, DOI 10.1073/pnas.240326597; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; Green BN, 2001, J MOL BIOL, V309, P553, DOI 10.1006/jmbi.2001.4704; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hanson CL, 2003, J BIOL CHEM, V278, P1259, DOI 10.1074/jbc.M208966200; Hebert H, 1997, J MOL BIOL, V271, P751, DOI 10.1006/jmbi.1997.1216; Holm PJ, 2002, BBA-PROTEIN STRUCT M, V1594, P276, DOI 10.1016/S0167-4838(01)00311-9; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; Kelner MJ, 2000, J BIOL CHEM, V275, P13000, DOI 10.1074/jbc.275.17.13000; Loo JA, 1997, MASS SPECTROM REV, V16, P1; LUNDQVIST G, 1992, BIOCHIM BIOPHYS ACTA, V1159, P103, DOI 10.1016/0167-4838(92)90081-N; Miranker AD, 2000, CURR OPIN STRUC BIOL, V10, P601, DOI 10.1016/S0959-440X(00)00137-8; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; Moniatte M, 1997, INT J MASS SPECTROM, V169, P179, DOI 10.1016/S0168-1176(97)00213-9; Morgenstern R, 2001, BIOCHEMISTRY-US, V40, P3378, DOI 10.1021/bi0023394; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; Rostom AA, 1999, J AM CHEM SOC, V121, P4718, DOI 10.1021/ja990238r; Rundlett KL, 1996, ANAL CHEM, V68, P3493, DOI 10.1021/ac960472p; Schmidt-Krey I, 2000, EMBO J, V19, P6311, DOI 10.1093/emboj/19.23.6311; Schmidt-Krey I, 1999, J MOL BIOL, V288, P243, DOI 10.1006/jmbi.1999.2683; SHORE LJ, 1995, BIOCHEM PHARMACOL, V49, P181, DOI 10.1016/S0006-2952(94)00488-9; Sobott F, 2002, CURR OPIN STRUC BIOL, V12, P729, DOI 10.1016/S0959-440X(02)00400-1; Sun TH, 1997, BIOCHEM J, V326, P193, DOI 10.1042/bj3260193; Svensson R, 2000, BIOCHEMISTRY-US, V39, P15144, DOI 10.1021/bi001764u; Torres J, 2003, TRENDS BIOCHEM SCI, V28, P137, DOI 10.1016/S0968-0004(03)00026-4; Werten PJL, 2002, FEBS LETT, V529, P65, DOI 10.1016/S0014-5793(02)03290-8; Whitelegge JP, 1999, P NATL ACAD SCI USA, V96, P10695, DOI 10.1073/pnas.96.19.10695; Whitelegge JP, 2002, MOL CELL PROTEOMICS, V1, P816, DOI 10.1074/mcp.M200045-MCP200; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619	42	40	41	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13311	13316		10.1074/jbc.M310958200	http://dx.doi.org/10.1074/jbc.M310958200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726533	hybrid			2022-12-27	WOS:000220478500007
J	Yamamura, H; Ugawa, S; Ueda, T; Nagao, M; Shimada, S				Yamamura, H; Ugawa, S; Ueda, T; Nagao, M; Shimada, S			Protons activate the delta-subunit of the epithelial Na+ channel in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; ION CHANNELS; MOLECULAR-CLONING; PH SENSITIVITY; EXPRESSION; NEURODEGENERATION; NEURONS; FAMILY	The amiloride-sensitive epithelial Na+ channel (ENaC) controls Na+ transport into cells and across epithelia. So far, four homologous subunits of mammalian ENaC have been isolated and are denoted as alpha, beta, gamma, and delta. ENaCdelta can associate with beta and gamma subunits and generate a constitutive current that is 2 orders of magnitude larger than that of homomeric ENaCdelta. However, the distribution pattern of ENaCdelta is not consistent with that of the beta and gamma subunits. ENaCdelta is expressed mainly in the brain in contrast to beta and gamma subunits, which are expressed in non-neuronal tissues. To explain this discrepancy, we searched for novel functional properties of homomeric ENaCdelta and investigated the detailed tissue distribution in humans. When human ENaCdelta was expressed in Xenopus oocytes and Chinese hamster ovary cells, a reduction of extracellular pH activated this channel (half-maximal pH for an activation of 5.0), and the acid-induced current was abolished by amiloride. The most striking finding was that the desensitization of the acid-evoked current was much slower ( by similar to 10% 120 s later), dissociating from the kinetics of acid-sensing ion channels in the degenerin/epithelial Na+ channel family, which were rapidly desensitized during acidification. RNA dot-blot analyses showed that ENaCdelta mRNA was widely distributed throughout the brain and was also expressed in the heart, kidney, and pancreas in humans. Northern blotting confirmed that ENaCdelta was expressed in the cerebellum and the hippocampus. In conclusion, human ENaCdelta activity is regulated by protons, indicating that it may contribute to the pH sensation and/or pH regulation in the human brain.	Nagoya City Univ, Grad Sch Med Sci, Dept Mol Morphol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Forens Med Sci, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Yamamura, H (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Mol Morphol, Mizuho Ku, 1 Kawasumi Mizuhocho, Nagoya, Aichi 4678601, Japan.	yamamura@med.nagoya-cu.ac.jp						Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Ugawa S, 1998, NATURE, V395, P555, DOI 10.1038/26882; Ugawa S, 2001, NEUROREPORT, V12, P2141, DOI 10.1097/00001756-200107200-00020; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1996, GENOMICS, V34, P262, DOI 10.1006/geno.1996.0282; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Zhang P, 1999, BIOPHYS J, V77, P3043, DOI 10.1016/S0006-3495(99)77135-3	22	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12529	12534		10.1074/jbc.M400274200	http://dx.doi.org/10.1074/jbc.M400274200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726523				2022-12-27	WOS:000220334900064
J	Hama, K; Aoki, J; Fukaya, M; Kishi, Y; Sakai, T; Suzuki, R				Hama, K; Aoki, J; Fukaya, M; Kishi, Y; Sakai, T; Suzuki, R			Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; RHO-ASSOCIATED KINASE; PHOSPHODIESTERASE-I; LYSOPHOSPHOLIPASE-D; EDG-FAMILY; IDENTIFICATION; EXPRESSION; INVASION; CANCER; MIGRATION	Autotaxin (ATX) is a tumor cell motility-stimulating factor originally isolated from melanoma cell supernatant that has been implicated in regulation of invasive and metastatic properties of cancer cells. Recently, we showed that ATX is identical to lysophospholipase D, which converts lysophosphatidylcholine to a potent bioactive phospholipid mediator, lysophosphatidic acid (LPA), raising the possibility that autocrine or paracrine production of LPA by ATX contributes to tumor cell motility. Here we demonstrate that LPA and ATX mediate cell motility-stimulating activity through the LPA receptor, LPA(1). In fibroblasts isolated from lpa(1)(-/-) mice, but not from wild-type or lpa(2)(-/-), cell motility stimulated with LPA and ATX was completely absent. In the lpa(1)(-/-) cells, LPA-stimulated lamellipodia formation was markedly diminished with a concomitant decrease in Rac1 activation. LPA stimulated the motility of multiple human cancer cell lines expressing LPA1, and the motility was attenuated by an LPA(1)-selective antagonist, Ki16425. The present study suggests that ATX and LPA(1) represent potential targets for cancer therapy.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 0608638, Japan; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Takasaki, Gumma 3701295, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Toshima Ku, Tokyo 1708455, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Tokyo; Hokkaido University; Kirin Brewery Company Limited; Japanese Foundation for Cancer Research; Scripps Research Institute	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp	WATANABE, Masahiko/A-4055-2012; Watanabe, Masahiko/S-3614-2019	WATANABE, Masahiko/0000-0001-5037-7138; Watanabe, Masahiko/0000-0001-5037-7138; Aoki, Junken/0000-0001-9435-1896				An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fox MA, 2003, MOL CELL NEUROSCI, V23, P507, DOI 10.1016/S1044-7431(03)00073-3; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Fuss B, 1997, J NEUROSCI, V17, P9095; Hasegawa Y, 2003, J BIOL CHEM, V278, P11962, DOI 10.1074/jbc.M209168200; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Shida D, 2003, CANCER RES, V63, P1706; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Weiner JA, 1998, J COMP NEUROL, V398, P587; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yamori T, 1999, CANCER RES, V59, P4042; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Yang Y, 1999, AM J RESP CELL MOL, V21, P216, DOI 10.1165/ajrcmb.21.2.3667; Zhang GX, 1999, CHINESE MED J-PEKING, V112, P330	38	236	243	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17634	17639		10.1074/jbc.M313927200	http://dx.doi.org/10.1074/jbc.M313927200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14744855	hybrid			2022-12-27	WOS:000220870400092
J	Hattori, N; Nishino, K; Ko, YG; Hattori, N; Ohgane, J; Tanaka, S; Shiota, K				Hattori, N; Nishino, K; Ko, YG; Hattori, N; Ohgane, J; Tanaka, S; Shiota, K			Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING PROTEIN; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; DNA METHYLTRANSFERASES; POU-DOMAIN; N-COR; METHYLATION; REPRESSION; SP1; MECP2	The first cell differentiation event in mammalian embryogenesis segregates inner cell mass lineage from the trophectoderm at the blastocyst stage. Oct-4, a member of the POU family of transcription factors, is necessary for the pluripotency of the inner cell mass lineage. Embryonic stem (ES) cells, which contribute to all of embryonic lineages, express the Oct-4 gene. Trophoblast stem (TS) cells, which have the ability to differentiate into trophoblast lineage in vitro, never contribute to embryonic proper tissues in chimeras and differentiate only into trophoblastic cells in the placenta. Expression of the Oct-4 gene was undetectable and severely repressed in trophoblastic lineage, including the stem cells. We found that the culture of TS cells with 5-aza-2'-deoxycytidine or trichostatin A caused the activation of the Oct-4 gene. Analysis of the DNA methylation status of mouse Oct-4 gene upstream region revealed that Oct-4 enhancer/promoter region was hypomethylated in ES cells but hypermethylated in TS cells. Furthermore, in vitro methylation suppressed Oct-4 enhancer/promoter activity in reporter assay. In the placenta of Dnmt1(n/n) mutant mice, most of the CpGs in the enhancer/promoter region were unmethylated, and Oct-4 gene expression was aberrantly detected. Chromatin immuno-precipitation assay revealed that Oct-4 enhancer/promoter region was hyperacetylated in ES cells compared with TS cells, thus demonstrating that DNA methylation status is closely linked to the chromatin structure of the Oct-4 gene. Here we propose that the epigenetic mechanism, consisting of DNA methylation and chromatin remodeling, underlies the developmental stage- and cell type-specific mechanism of Oct-4 gene expression.	Univ Tokyo, Dept Anim Resource Sci Vet Med Sci, Lab Cellular Biochem, Bunkyo Ku, Tokyo 1138657, Japan; Natl Inst Genet, Div Appl Genet, Mishima, Shizuoka 4118540, Japan	University of Tokyo; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Shiota, K (corresponding author), Univ Tokyo, Dept Anim Resource Sci Vet Med Sci, Lab Cellular Biochem, Bunkyo Ku, Tokyo 1138657, Japan.	ashiota@mail.ecc.u-tokyo.ac.jp	Ohgane, Jun/AAV-3548-2020	Tanaka, Satoshi/0000-0002-4745-550X; Hattori, Naoko/0000-0002-0901-4869				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Barnea E, 2000, J BIOL CHEM, V275, P6608, DOI 10.1074/jbc.275.9.6608; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Cho JH, 2001, ENDOCRINOLOGY, V142, P3389, DOI 10.1210/en.142.8.3389; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Fuhrmann G, 1999, CELL MOL BIOL, V45, P717; Hata K, 2002, DEVELOPMENT, V129, P1983; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAWASE E, 1994, INT J DEV BIOL, V38, P385; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MATISE MP, 2000, GENE TARGETING PRACT, P102; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Ohgane J, 1998, DEV GENET, V22, P132, DOI 10.1002/(SICI)1520-6408(1998)22:2<132::AID-DVG3>3.0.CO;2-7; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pesce M, 1999, CELL MOL BIOL, V45, P709; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; SYLVESTER I, 1994, NUCLEIC ACIDS RES, V22, P901, DOI 10.1093/nar/22.6.901; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yeom YI, 1996, DEVELOPMENT, V122, P881; Yoshimizu T, 1999, DEV GROWTH DIFFER, V41, P675	52	326	358	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17063	17069		10.1074/jbc.M309002200	http://dx.doi.org/10.1074/jbc.M309002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761969	hybrid			2022-12-27	WOS:000220870400023
J	Leonardi, R; Roach, PL				Leonardi, R; Roach, PL			Thiamine biosynthesis in Escherichia coli - In vitro reconstitution of the thiazole synthase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; FE-S CLUSTER; SALMONELLA-TYPHIMURIUM; 5-AMINOIMIDAZOLE RIBOTIDE; PYRIMIDINE MOIETY; NIFS GENE; PROTEIN; IDENTIFICATION; PRECURSOR; COMPLEX	The biosynthesis of thiamine in Escherichia coli requires the formation of an intermediate thiazole from tyrosine, 1-deoxy-D-xylulose-5-phosphate (Dxp), and cysteine using at least six structural proteins, ThiFSGH, IscS, and ThiI. We describe for the first time the reconstitution of thiazole synthase activity using cell-free extracts and proteins derived from adenosine-treated E. coli 83-1 cells. The addition of adenosine or adenine to growing cultures of Aerobacter aerogenes, Salmonella typhimurium, and E. coli has been shown previously to relieve the repression by thiamine of its own biosynthesis and increase the expression levels of the thiamine biosynthetic enzymes. By exploiting this effect, we show that the in vitro thiazole synthase activity of cleared lysates or desalted proteins from E. coli 83-1 cells is dependent upon the addition of purified ThiGH-His complex, tyrosine (but not cysteine or 1-deoxy-D-xylulose-5- phosphate), and an as yet unidentified intermediate present in the protein fraction from these cells. The activity is strongly stimulated by the addition of S-adenosylmethionine and NADPH.	Univ Southampton, Sch Chem, Southampton SO17 1BJ, Hants, England	University of Southampton	Roach, PL (corresponding author), Univ Southampton, Sch Chem, Univ Rd, Southampton SO17 1BJ, Hants, England.	plr2@soton.ac.uk	Roach, Peter/C-6248-2013; Roach, Peter/AAW-7071-2021	Roach, Peter/0000-0001-9880-2877				ANDERSAG H, 1937, CHEM BER           B, V70, P2035; BAXTER RL, 1990, J CHEM SOC PERK T 1, P2963, DOI 10.1039/p19900002963; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BELLION E, 1976, BIOCHIM BIOPHYS ACTA, V437, P229, DOI 10.1016/0304-4165(76)90364-0; BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVID S, 1982, J CHEM SOC PERK T, V1, P2131; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; ESTRAMAREIX B, 1984, J AM CHEM SOC, V106, P3857, DOI 10.1021/ja00325a025; ESTRAMAREIX B, 1990, BIOCHIM BIOPHYS ACTA, V1035, P154, DOI 10.1016/0304-4165(90)90110-I; ESTRAMAREIX B, 1972, BIOCHIM BIOPHYS ACTA, V192, P375; Flint DH, 1996, J BIOL CHEM, V271, P16068; FUJIWARA M, 1953, ANAL CHEM, V25, P810, DOI 10.1021/ac60077a040; Gerrits J, 1997, METHOD ENZYMOL, V279, P74; Gralnick J, 2000, J BACTERIOL, V182, P5180, DOI 10.1128/JB.182.18.5180-5187.2000; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hecht S, 2001, J ORG CHEM, V66, P3948, DOI 10.1021/jo0100300; Himmeldirk K, 1996, CHEM COMMUN, P1187, DOI 10.1039/cc9960001187; IWASHIMA A, 1971, J VITAMINOL, V17, P43, DOI 10.5925/jnsv1954.17.43; JULLIARD JH, 1991, P NATL ACAD SCI USA, V88, P2042, DOI 10.1073/pnas.88.6.2042; KAWASAKI T, 1969, J BIOCHEM-TOKYO, V65, P417, DOI 10.1093/oxfordjournals.jbchem.a129029; KAWASAKI T, 1969, J BIOCHEM-TOKYO, V65, P407, DOI 10.1093/oxfordjournals.jbchem.a129028; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; LEDER IG, 1970, METHOD ENZYMOL, V18, P166; Leonardi R, 2003, FEBS LETT, V539, P95, DOI 10.1016/S0014-5793(03)00204-7; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; MOYED HS, 1964, J BACTERIOL, V88, P1024, DOI 10.1128/JB.88.4.1024-1029.1964; NEWELL PC, 1966, BIOCHEM J, V100, P517, DOI 10.1042/bj1000517; NEWELL PC, 1966, BIOCHEM J, V100, P512, DOI 10.1042/bj1000512; NEWELL PC, 1968, BIOCHEM J, V106, P279, DOI 10.1042/bj1060279; Padovani D, 2001, BIOCHEMISTRY-US, V40, P6713, DOI 10.1021/bi002936q; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Park JH, 2003, BIOCHEMISTRY-US, V42, P12430, DOI 10.1021/bi034902z; Petersen LA, 1997, J BACTERIOL, V179, P4894, DOI 10.1128/jb.179.15.4894-4900.1997; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; Settembre EC, 2003, BIOCHEMISTRY-US, V42, P2971, DOI 10.1021/bi026916v; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Skovran E, 2003, J BACTERIOL, V185, P98, DOI 10.1128/JB.185.1.98-106.2003; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Spenser ID, 1997, ANGEW CHEM INT EDIT, V36, P1033; Taylor SV, 1998, J ORG CHEM, V63, P2375, DOI 10.1021/jo971933p; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; TAZUYA K, 1987, BIOCHIM BIOPHYS ACTA, V924, P210, DOI 10.1016/0304-4165(87)90089-4; THERISOD M, 1977, NOUVEAU J CHIM, V2, P119; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Webb E, 1996, J BACTERIOL, V178, P2533, DOI 10.1128/jb.178.9.2533-2538.1996; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997; WHITE RH, 1978, BIOCHIM BIOPHYS ACTA, V542, P340, DOI 10.1016/0304-4165(78)90029-6; WHITE RH, 1979, BIOCHIM BIOPHYS ACTA, V583, P55, DOI 10.1016/0304-4165(79)90309-X; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698; ZALKIN H, 1996, ESCHERICHIA COLI SAL, V1, P561; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	55	46	49	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17054	17062		10.1074/jbc.M312714200	http://dx.doi.org/10.1074/jbc.M312714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14757766	hybrid			2022-12-27	WOS:000220870400022
J	Pluskota, E; Soloviev, DA; Bdeir, K; Cines, DB; Plow, EF				Pluskota, E; Soloviev, DA; Bdeir, K; Cines, DB; Plow, EF			Integrin alpha(M)beta(2) orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE-BINDING-SITES; MAC-1 CD11B/CD18; CELL-SURFACE; MEDIATED ENHANCEMENT; CLOT LYSIS; IN-VITRO; A-DOMAIN; T-PA; UROKINASE; RECEPTOR	Plasmin, the pivotal thrombolytic enzyme, is generated on the surface of many cell types, where urokinase receptor (uPAR)-bound urokinase (uPA) activates cell-bound plasminogen (Plg). It has been reported that neutrophils mediate endogenous thrombolysis involving a uPA-dependent mechanism, and we previously demonstrated that both uPAR and integrin alpha(M)beta(2) recognize uPA to control cell migration and adhesion. In the present study, we report that the alpha(M)beta(2) regulates neutrophil-dependent fibrinolysis. Phorbol 12-myristate 13-acetate (PMA)-stimulated but not resting neutrophils dissolved fibrin clots, and this activity was not only uPA- and Plg-dependent but also alpha(M)beta(2)-dependent. Purified alpha(M)beta(2) directly bound uPA (K-d = 40 nM) and Plg (K-d = 1 muM) in a dose-dependent and saturable manner. In Plg activation assays, addition of purified alpha(M)beta(2), but not a control protein, to a single chain uPA (sc-uPA)/Plg mixture, decreased the K-m from 2 to 0.1 muM, thereby augmenting the overall reaction efficiency by 50-fold. The binding of sc-uPA to alpha(M)beta(2) was critical for the alpha(M)beta(2)-mediated enhancement of plasmin (Plm) generation, because this effect was lost when WT-sc-uPA was replaced with a kringle-less mutant (DeltaK-sc-uPA), which does not bind to alpha(M)beta(2). Plm inactivation by alpha(2)-antiplasmin was significantly delayed when Plm was preincubated with purified, soluble alpha(M)beta(2). When Plg was added to PMA-stimulated neutrophils, both uPA and Plg were co-immunoprecipitated with alpha(M)beta(2). Thus, assembly of Plg and uPA on integrin alpha(M)beta(2) regulates Plm activity and, thereby, plays a crucial role in neutrophil-mediated thrombolysis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Cleveland Clinic Foundation; University of Pennsylvania; Pennsylvania Medicine	Plow, EF (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	plowe@ccf.org			NHLBI NIH HHS [HL60169, HL66197, HL17964] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066197, R01HL060169, R01HL017964] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; Bhat GJ, 1999, AM J PHYSIOL-LUNG C, V277, pL301, DOI 10.1152/ajplung.1999.277.2.L301; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOUTAUD A, 1993, ARCH BIOCHEM BIOPHYS, V303, P222, DOI 10.1006/abbi.1993.1276; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Falcone DJ, 2001, BLOOD, V97, P777, DOI 10.1182/blood.V97.3.777; FALCONE DJ, 1995, FASEB J, V9, pA412; Fan ZQ, 1998, BLOOD, V91, P1987, DOI 10.1182/blood.V91.6.1987.1987_1987_1998; Gyetko MR, 1999, J LAB CLIN MED, V133, P274, DOI 10.1016/S0022-2143(99)90084-7; Haj-Yehia A, 2000, FASEB J, V14, P1411, DOI 10.1096/fj.14.10.1411; HEIPLE JM, 1986, J EXP MED, V164, P826, DOI 10.1084/jem.164.3.826; HENRY RL, 1965, THROMB DIATH HAEMOST, V13, P35; HOOVERPLOW JL, 1993, BIOCHEMISTRY-US, V32, P13681, DOI 10.1021/bi00212a037; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; LANGUINO LR, 1995, P NATL ACAD SCI USA, V92, P1505, DOI 10.1073/pnas.92.5.1505; LERCH PG, 1980, BIOCHIM BIOPHYS ACTA, V625, P374, DOI 10.1016/0005-2795(80)90302-5; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; Lopez-Alemany R, 2003, AM J HEMATOL, V72, P234, DOI 10.1002/ajh.10299; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1986, J CLIN INVEST, V77, P2001, DOI 10.1172/JCI112529; Miles LA, 2003, TRENDS CARDIOVAS MED, V13, P21, DOI 10.1016/S1050-1738(02)00190-1; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; MILLER LJ, 1987, J IMMUNOL, V138, P2381; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; Moir E, 2001, BRIT J HAEMATOL, V113, P72, DOI 10.1046/j.1365-2141.2001.02696.x; MORRIS JP, 1983, BIOCHIM BIOPHYS ACTA, V744, P99, DOI 10.1016/0167-4838(83)90345-X; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Nassar T, 2002, J BIOL CHEM, V277, P40499, DOI 10.1074/jbc.M207172200; NIEUWENHUIZEN W, 1990, ADV EXP MED BIOL, V281, P83; NILSSON T, 1982, BIOCHIM BIOPHYS ACTA, V705, P264, DOI 10.1016/0167-4838(82)90187-X; PLESNER T, 1994, BLOOD, V83, P808; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; PLOW EF, 1983, J LAB CLIN MED, V102, P858; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; RYAN TJ, 1992, J CELL PHYSIOL, V151, P255, DOI 10.1002/jcp.1041510206; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; SIMON DI, 1993, BLOOD, V82, P2414; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; SMITH JW, 1994, J BIOL CHEM, V269, P960; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wu SC, 2003, J BIOL CHEM, V278, P18199, DOI 10.1074/jbc.M210919200; XUE W, 1994, J IMMUNOL, V152, P4630; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558	61	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18063	18072		10.1074/jbc.M310462200	http://dx.doi.org/10.1074/jbc.M310462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769799	hybrid			2022-12-27	WOS:000220870400142
J	Zilberberg, A; Yaniv, A; Gazit, A				Zilberberg, A; Yaniv, A; Gazit, A			The low density lipoprotein receptor-1, LRP1, interacts with the human Frizzled-1 (HFz1) and down-regulates the canonical wnt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LRP; TYROSINE PHOSPHORYLATION; BETA-CATENIN; GENE FAMILY; LIGAND-BINDING; CELLS; TRANSFORMATION; ENDOCYTOSIS; INHIBITION; MECHANISMS	Members of the low density lipoprotein receptor family (LDLR), LRP5/6, were shown to interact with the Frizzled (Fz) receptors and to function as Wnt coreceptors. Here we show that mLRP4T100, a minireceptor of LRP1, another member of the LDLR family, interacts with the human Fz-1 (HFz1), previously shown to serve as a receptor transmitting the canonical Wnt-3a-induced signaling cascade. However, in contrast to LRP5/6, mLRP4T100, as well as the full-length LRP1, did not cooperate with HFz1 in transmitting the Wnt-3a signaling but rather repressed it. mLRP4T100 inhibitory effect was displayed also by endocytosis-defective mLRP4T100 mutants, suggesting that LRP1 repressive effect is not attributable to LRP1-mediated enhanced HFz1 internalization and subsequent degradation. Enforced expression of mLRP4T100 decreased the capacity of HFz1 cysteine-rich domain (CRD) to interact with LRP6, in contrast to HFz1-CRD/Wnt-3a interaction that was not disrupted by overexpressing mLRP4T100. These data suggest that LRP1, by sequestering HFz1, disrupts the receptor/coreceptor complex formation, leading to the repression of the canonical Wnt signaling. Thus, this study implies that the ability to interact with Fz receptors is shared by several members of the LDLR family. However, whereas some members of the LDLR family, such as LRP5/6, interact with Fz and serve as Wnt coreceptors, others negatively regulate Wnt signaling, presumably by sequestering Fz.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Gazit, A (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.	micro1@post.tau.ac.il						Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bejsovec A, 2000, CURR BIOL, V10, pR919, DOI 10.1016/S0960-9822(00)00852-6; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1994, J BIOL CHEM, V269, P29874; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Gliemann J, 1998, BIOL CHEM, V379, P951; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, TRENDS NEUROSCI, V24, P193, DOI 10.1016/S0166-2236(00)01768-9; HOVSEP SM, 1997, P NATL ACAD SCI USA, V94, P13636; Howell BW, 2001, CURR OPIN NEUROBIOL, V11, P74, DOI 10.1016/S0959-4388(00)00176-8; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; MAY P, 2003, SCI STKE; Mikhailenko I, 1999, J CELL SCI, V112, P3269; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	53	97	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17535	17542		10.1074/jbc.M311292200	http://dx.doi.org/10.1074/jbc.M311292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14739301	hybrid			2022-12-27	WOS:000220870400081
J	Ellis, TP; Helfenbein, KG; Tzagoloff, A; Dieckmann, CL				Ellis, TP; Helfenbein, KG; Tzagoloff, A; Dieckmann, CL			Aep3p stabilizes the mitochondrial bicistronic mRNA encoding subunits 6 and 8 of the H+-translocating ATP synthase of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR GENES; YEAST MITOCHONDRIA; ESCHERICHIA-COLI; PROTEIN; SEQUENCE; MEMBRANE; TRANSLATION; TRANSCRIPTS; COMPLEX; MUTANT	Subunits 6 and 8 of the mitochondrial ATPase in Saccharomyces cerevisiae are encoded by the mitochondrial genome and translated from bicistronic mRNAs containing both reading frames. The stability of the two major species of ATP8/6 mRNA, which differ in the length of the 5'-untranslated region, depends on the expression of several nuclear-encoded factors. In the present study, the product of the gene designated AEP3 (open reading frame YPL005W) is shown to be required for stabilization and/or processing of both ATP8/6 mRNA species. In an aep3-disruptant strain, the shorter ATP8/6 mRNA was undetectable, and the level of the longer mRNA was reduced to similar to35% that of wild type. Localization of a hemagglutinin-tagged version of Aep3p showed that the protein is an extrinsic constituent of the mitochondrial inner membrane facing the matrix.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Arizona; Columbia University	Dieckmann, CL (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA.	dieckman@u.arizona.edu			NHLBI NIH HHS [R01 HL022174, HL2274] Funding Source: Medline; NIGMS NIH HHS [GM34893] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034893] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BENASHER E, 1989, MOL GEN GENET, V215, P517; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CAMOUGRAND N, 1995, J MOL BIOL, V247, P588, DOI 10.1006/jmbi.1995.0165; CHEN W, 1994, J BIOL CHEM, V269, P16574; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GROUDINSKY O, 1993, MOL GEN GENET, V240, P419, DOI 10.1007/BF00280396; Helfenbein KG, 2003, J BIOL CHEM, V278, P19751, DOI 10.1074/jbc.M301679200; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Islas-Osuna MA, 2002, J BIOL CHEM, V277, P37987, DOI 10.1074/jbc.M206132200; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANON S, 1988, EUR J BIOCHEM, V174, P399, DOI 10.1111/j.1432-1033.1988.tb14111.x; MANON S, 1989, BIOCHIM BIOPHYS ACTA, V985, P127, DOI 10.1016/0005-2736(89)90356-8; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; MAYER SA, 1989, MOL CELL BIOL, V9, P4161, DOI 10.1128/MCB.9.10.4161; MIN JJ, 1993, MOL CELL BIOL, V13, P4167, DOI 10.1128/MCB.13.7.4167; MITTELMEIER TM, 1993, MOL CELL BIOL, V13, P4203, DOI 10.1128/MCB.13.7.4203; NAKAGAWA K, 1991, J BIOL CHEM, V266, P1977; Nevill-Manning CG, 1998, P NATL ACAD SCI USA, V95, P5865, DOI 10.1073/pnas.95.11.5865; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PELISSIER P, 1995, CURR GENET, V27, P409, DOI 10.1007/BF00311209; PELISSIER PP, 1992, J BIOL CHEM, V267, P2467; Rodeheffer MS, 2001, J BIOL CHEM, V276, P8616, DOI 10.1074/jbc.M009901200; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; SIMON M, 1984, P NATL ACAD SCI-BIOL, V81, P8, DOI 10.1073/pnas.81.1.8; SIMON M, 1984, MOL GEN GENET, V196, P266, DOI 10.1007/BF00328059; Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0; STAPLES RR, 1993, GENETICS, V135, P981; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Wiesenberger G, 1997, MOL CELL BIOL, V17, P2816, DOI 10.1128/MCB.17.5.2816	45	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15728	15733		10.1074/jbc.M314162200	http://dx.doi.org/10.1074/jbc.M314162200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14742425	hybrid			2022-12-27	WOS:000220747900006
J	Huang, J; Teng, L; Li, LX; Liu, T; Li, LY; Chen, DY; Xu, LG; Zhai, ZH; Shu, HB				Huang, J; Teng, L; Li, LX; Liu, T; Li, LY; Chen, DY; Xu, LG; Zhai, ZH; Shu, HB			ZNF216 is an A20-like and I kappa B kinase gamma-interacting inhibitor of NF kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; IKK-GAMMA; A20; RIP; COMPLEX; ALPHA; IDENTIFICATION; PHOSPHORYLATION; RECRUITMENT; GENE	The transcription factor NFkappaB plays important roles in immune regulation, inflammatory responses, and antiapoptosis. Activation of NFkappaB requires the activity of IkappaB kinase, a kinase complex that contains two catalytic subunits, IKKalpha and IKKbeta, and a non-enzymatic regulatory subunit, IKKgamma. To understand how NFkappaB activation is regulated at the IKKgamma level, we searched for IKKgamma-interacting proteins by the yeast two-hybrid system. This search identified ZNF216, a zinc finger protein with unknown biological functions. ZNF216 contains an A20-like zinc finger domain (ZnF-A20) at its N terminus and an AN1-like domain (ZnF-AN1) at its C terminus. Similar to A20, ZNF216 interacted with IKKgamma, RIP, and TRAF6 in co-immunoprecipitation experiments. Domain mapping experiments indicated that the ZnF-A20 domain was responsible for interacting with IKKgamma and RIP, whereas the ZnF-AN1 domain interacted with TRAF6. ZNF216 inhibited NFkappaB activation triggered by overexpression of RIP and TRAF6 but not of p65. ZNF216 also inhibited tumor necrosis factor (TNF)-, interleukin-1-, and Toll-like receptor 4-induced NFkappaB activation in a dose-dependent manner. The ZnF-A20 domain was essential for ZNF216-mediated inhibition of NFkappaB activation. The ZnF-A20 and ZnF-AN1 domains of ZNF216 could interact with each other, whereas ZNF216 could form homo-oligomers or hetero-oligomers with A20. Unlike A20, which inhibits TNF-induced apoptosis, overexpression of ZNF216 sensitized cells to TNF-induced apoptosis. Our findings suggest that ZNF216 and A20 have redundant and distinct roles in regulating NFkappaB activation and apoptosis.	Peking Univ, Dept Cell Biol & Genet, Coll Life Sci, Beijing 100871, Peoples R China; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Integrated Dept Immunol, Denver, CO 80206 USA	Peking University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Shu, HB (corresponding author), Peking Univ, Dept Cell Biol & Genet, Coll Life Sci, Beijing 100871, Peoples R China.	shuh@pku.edu.cn		Xu, Liangguo/0000-0003-1991-2889; Li, Lianyun/0000-0003-4194-3059	NIAID NIH HHS [AI49992] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; HSU H, 1996, CELL, V104, P487; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jaattela M, 1996, J IMMUNOL, V156, P1166; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Klinkenberg M, 2001, FEBS LETT, V498, P93, DOI 10.1016/S0014-5793(01)02504-2; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; LINNEN JM, 1993, GENE, V128, P181, DOI 10.1016/0378-1119(93)90561-G; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; O'Reilly SM, 2003, BIOCHEM BIOPH RES CO, V303, P586, DOI 10.1016/S0006-291X(03)00389-9; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scott DA, 1998, GENE, V215, P461, DOI 10.1016/S0378-1119(98)00316-3; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	33	93	111	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16847	16853		10.1074/jbc.M309491200	http://dx.doi.org/10.1074/jbc.M309491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754897	hybrid			2022-12-27	WOS:000220747900137
J	Liu, JF; Maurel, D; Etzol, S; Brabet, I; Ansanay, H; Pin, JP; Rondard, P				Liu, JF; Maurel, D; Etzol, S; Brabet, I; Ansanay, H; Pin, JP; Rondard, P			Molecular determinants involved in the allosteric control of agonist affinity in the GABA(B) receptor by the GABA(B2) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; AMINOBUTYRIC ACID(B) RECEPTORS; PROTEIN-COUPLED RECEPTOR; LIGAND-BINDING; B-RECEPTOR; ACTIVATION PROCESS; TERMINAL DOMAINS; ENERGY-TRANSFER; GB2 SUBUNITS; TRAFFICKING	The gamma-aminobutyric acid type B (GABA(B)) receptor is an allosteric complex made of two subunits, GABA(B1) (GB1) and GABA(B2) (GB2). Both subunits are composed of an extracellular Venus flytrap domain (VFT) and a heptahelical domain (HD). GB1 binds GABA, and GB2 plays a major role in G-protein activation as well as in the high agonist affinity state of GB1. How agonist affinity in GB1 is regulated in the receptor remains unknown. Here, we demonstrate that GB2 VFT is a major molecular determinant involved in this control. We show that isolated versions of GB1 and GB2 VFTs in the absence of the HD and C-terminal tail can form hetero-oligomers as shown by time-resolved fluorescence resonance energy transfer (based on HTRF(R) technology). GB2 VFT and its association with GB1 VFT controlled agonist affinity in GB1 in two ways. First, GB2 VFT exerted a direct action on GB1 VFT, as it slightly increased agonist affinity in isolated GB1 VFT. Second and most importantly, GB2 VFT prevented inhibitory interaction between the two main domains (VFT and HD) of GB1. According to this model, we propose that GB1 HD prevents the possible natural closure of GB1 VFT. In contrast, GB2 VFT facilitates this closure. Finally, such inhibitory contacts between HD and VFT in GB1 could be similar to those important to maintain the inactive state of the receptor.	Dept Mol Pharmacol, Lab Funct Genom, CNRS, UPR2580, F-34094 Montpellier 5, France; Cis Bio Int, F-30204 Bagnols Sur Ceze, France; Huazhong Univ Sci & Technol, Inst Biochem & Biophys, Wuhan 430074, Hubei, Peoples R China	Centre National de la Recherche Scientifique (CNRS); Huazhong University of Science & Technology	Rondard, P (corresponding author), Dept Mol Pharmacol, Lab Funct Genom, CNRS, UPR2580, 141 Rue Cardonille, F-34094 Montpellier 5, France.	prondard@ccipe.cnrs.fr	Liu, Jianfeng/E-2786-2012; Pin, Jean-Philippe/Y-6668-2019; Rondard, Philippe/N-9720-2018	Pin, Jean-Philippe/0000-0002-1423-345X; RONDARD, Philippe/0000-0003-1134-2738				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Bazin H, 2002, J Biotechnol, V82, P233, DOI 10.1016/S1389-0352(01)00040-X; Bernard P, 2001, J MED CHEM, V44, P27, DOI 10.1021/jm000915o; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; Calver AR, 2001, J NEUROSCI, V21, P1203; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Costantino G, 2001, J MED CHEM, V44, P1827, DOI 10.1021/jm0100133; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Franek M, 1999, NEUROPHARMACOLOGY, V38, P1657, DOI 10.1016/S0028-3908(99)00135-5; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Galvez T, 2000, MOL PHARMACOL, V57, P419, DOI 10.1124/mol.57.3.419; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Havlickova M, 2002, MOL PHARMACOL, V62, P343, DOI 10.1124/mol.62.2.343; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; MATHIS G, 1995, CLIN CHEM, V41, P1391; MAUREL D, 2004, IN PRESS ANAL BIOCH; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Pagano A, 2001, J NEUROSCI, V21, P1189; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Peltekova V, 2000, MOL BRAIN RES, V76, P180, DOI 10.1016/S0169-328X(00)00029-2; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Pin JP, 2001, MOL PHARMACOL, V60, P881, DOI 10.1124/mol.60.5.881; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Urwyler S, 2001, MOL PHARMACOL, V60, P963, DOI 10.1124/mol.60.5.963; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	44	64	72	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15824	15830		10.1074/jbc.M313639200	http://dx.doi.org/10.1074/jbc.M313639200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14736871	Green Submitted, hybrid			2022-12-27	WOS:000220747900018
J	Stamenova, SD; Dunn, R; Adler, AS; Hicke, L				Stamenova, SD; Dunn, R; Adler, AS; Hicke, L			The Rsp5 ubiquitin ligase binds to and ubiquitinates members of the yeast CIN85-endophilin complex, Sla1-Rvs167	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; EPIDERMAL-GROWTH-FACTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; CORTICAL ACTIN CYTOSKELETON; SACCHAROMYCES-CEREVISIAE; DOWN-REGULATION; RECEPTOR ENDOCYTOSIS; INTERNALIZATION STEP; NERVE-TERMINALS	Sla1 and Rvs167 are yeast proteins required for receptor internalization and organization of the actin cytoskeleton. Here we provide evidence that Sla1 and Rvs167 are orthologues of the mammalian CIN85 and endophilin proteins, respectively, which are required for ligand-stimulated growth factor receptor internalization. Sla1 is similar in domain structure to CIN85 and binds directly to the endophilin-like Rvs167. Akin to CIN85, Sla1 interacts with synaptojanins and a ubiquitin ligase that regulates endocytosis. This ubiquitin ligase, Rsp5, binds directly to both Sla1 and Rvs167. The interaction between Rsp5 and Rvs167 is mediated through Rsp5 WW domains and PXY motifs in the central Gly-Pro-Ala-rich domain of Rvs167. Rvs167 PXY motifs are required for Rsp5-dependent monoubiquitination of Rvs167 on Lys(481) in the Src homology 3 (SH3) domain. Mutation of Lys(481) --> Arg causes cells to grow slowly on medium containing 1 M NaCl, although this phenotype is not due to the defect in ubiquitination caused by the K481R mutation. We propose that Rsp5 interaction with Sla1-Rvs167 promotes Rvs167 ubiquitination and regulates activity of this protein complex. Rvs167 ubiquitination is not required for general function of Rvs167, but may control specific Rvs167 SH3 domain-protein interactions or negatively regulate SH3 domain activity.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Hicke, L (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	l-hicke@northwestern.edu		Adler, Adam/0000-0001-9301-0037	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK061299, R01DK061299] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61299] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGERS A, 2003, MOL BIOL CELL, V14, pA360; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Bon E, 2000, YEAST, V16, P1229, DOI 10.1002/1097-0061(20000930)16:13<1229::AID-YEA618>3.0.CO;2-Q; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Colwill K, 1999, GENETICS, V152, P881; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Gourlay CW, 2003, J CELL SCI, V116, P2551, DOI 10.1242/jcs.00454; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hitchcock AL, 2003, P NATL ACAD SCI USA, V100, P12735, DOI 10.1073/pnas.2135500100; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Howard JP, 2002, J CELL BIOL, V157, P315, DOI 10.1083/jcb.200110027; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Navarro P, 1997, BBA-PROTEIN STRUCT M, V1343, P187, DOI 10.1016/S0167-4838(97)00108-8; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Otsuki M, 2003, J BIOL CHEM, V278, P6461, DOI 10.1074/jbc.M207433200; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sehgal BU, 2000, ANAL BIOCHEM, V281, P232, DOI 10.1006/abio.2000.4569; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smythe E, 2003, EMBO REP, V4, P246, DOI 10.1038/sj.embor.embor776; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; Verdier F, 2002, EUR J BIOCHEM, V269, P3402, DOI 10.1046/j.1432-1033.2002.03031.x; Warren DT, 2002, J CELL SCI, V115, P1703; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Yeung BG, 1999, MOL BIOL CELL, V10, P3643, DOI 10.1091/mbc.10.11.3643; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x	64	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16017	16025		10.1074/jbc.M313479200	http://dx.doi.org/10.1074/jbc.M313479200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761940	hybrid			2022-12-27	WOS:000220747900040
J	Chang, ZZ; Kuchar, J; Hausinger, RP				Chang, ZZ; Kuchar, J; Hausinger, RP			Chemical cross-linking and mass spectrometric identification of sites of interaction for UreD, UreF, and urease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-AEROGENES UREASE; HELICOBACTER-PYLORI; ACCESSORY PROTEINS; NICKEL METALLOCHAPERONE; APOPROTEIN COMPLEXES; BACILLUS-PASTEURII; MICROBIAL UREASES; CRYSTAL-STRUCTURE; GENE-CLUSTER; ACTIVE-SITE	Synthesis of active Klebsiella aerogenes urease requires four accessory proteins to generate, in a GTP-dependent process, a dinuclear nickel active site with the metal ions bridged by a carbamylated lysine residue. The UreD and UreF accessory proteins form stable complexes with urease apoprotein, comprised of UreA, UreB, and UreC. The sites of protein-protein interactions were explored by using homobifunctional amino group-specific chemical cross-linkers with reactive residues being identified by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) of tryptic peptides. On the basis of studies of the UreABCD complex, UreD is capable of cross-linking with UreB Lys(9), UreB Lys(76), and UreC Lys(401). Furthermore UreD appears to be positioned over UreC Lys(515) according to decreased reactivity of this residue compared with its reactivity in UreD-free apoprotein. Several UreB-UreC and UreC-UreC cross-links also were observed within this complex; e.g. UreB Lys(76) with the UreC amino terminus, UreB Lys(9) with UreC Lys(20), and UreC Lys(515) with UreC Lys(89). These interactions are consistent with the proximate surface locations of these residues observed in the UreABC crystal structure. MALDI-TOF MS analyses of UreABCDF are consistent with a cross-link between the UreF amino terminus and UreB Lys(76). On the basis of an unexpected cross-link between UreB Lys(76) and UreC Lys(382) (distant from each other in the UreABC structure) along with increased side chain reactivities for UreC Lys(515) and Lys(522), UreF is proposed to induce a conformational change within urease that repositions UreB and potentially could increase the accessibility of nickel ions and CO2 to residues that form the active site.	Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Hausinger, RP (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.	hausinge@msu.edu		Hausinger, Robert/0000-0002-3643-2054	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK045686, DK 45686] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bacanamwo M, 2002, MOL GENET GENOMICS, V268, P525, DOI 10.1007/s00438-002-0769-z; Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; Colpas GJ, 2000, J BIOL CHEM, V275, P10731, DOI 10.1074/jbc.275.15.10731; Ha NC, 2001, NAT STRUCT BIOL, V8, P505, DOI 10.1038/88563; Hausinger R.P., 2001, HDB METALLOPROTEINS, P867; Heimer SR, 2001, J BACTERIOL, V183, P1423, DOI 10.1128/JB.183.4.1423-1433.2001; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Jabri E, 1996, BIOCHEMISTRY-US, V35, P10616, DOI 10.1021/bi960424z; Kansau I, 1996, MOL MICROBIOL, V22, P1013, DOI 10.1046/j.1365-2958.1996.01536.x; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; MCLEAN RJC, 1988, CRC CR REV MICROBIOL, V16, P37, DOI 10.3109/10408418809104467; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; Moncrief MBC, 1996, J BACTERIOL, V178, P5417, DOI 10.1128/jb.178.18.5417-5421.1996; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; Mulrooney SB, 2003, FEMS MICROBIOL REV, V27, P239, DOI 10.1016/S0168-6445(03)00042-1; Park IS, 1996, BIOCHEMISTRY-US, V35, P5345, DOI 10.1021/bi952894j; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; PARK IS, 1995, J BACTERIOL, V177, P1947, DOI 10.1128/jb.177.8.1947-1951.1995; Pearson KM, 2002, RAPID COMMUN MASS SP, V16, P149, DOI 10.1002/rcm.554; Pearson MA, 1997, BIOCHEMISTRY-US, V36, P8164, DOI 10.1021/bi970514j; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Remaut H, 2001, J BIOL CHEM, V276, P49365, DOI 10.1074/jbc.M108304200; Sheridan L, 2002, ACTA CRYSTALLOGR D, V58, P374, DOI 10.1107/S0907444901021503; Song HK, 2001, J BIOL CHEM, V276, P49359, DOI 10.1074/jbc.M108619200; Soriano A, 1999, P NATL ACAD SCI USA, V96, P11140, DOI 10.1073/pnas.96.20.11140; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o; Stingl K, 2002, TRENDS MICROBIOL, V10, P70, DOI 10.1016/S0966-842X(01)02287-9; TAKISHIMA K, 1988, EUR J BIOCHEM, V175, P151, DOI 10.1111/j.1432-1033.1988.tb14177.x; TODD MJ, 1987, J BIOL CHEM, V262, P5963; Voland P, 2003, AM J PHYSIOL-GASTR L, V284, pG96, DOI 10.1152/ajpgi.00160.2002; ZONIA LE, 1995, PLANT PHYSIOL, V107, P1097, DOI 10.1104/pp.107.4.1097	36	54	65	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15305	15313		10.1074/jbc.M312979200	http://dx.doi.org/10.1074/jbc.M312979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749331	hybrid			2022-12-27	WOS:000220594700099
J	Jones, HM; Hamilton, KL; Papworth, GD; Syme, CA; Watkins, SC; Bradbury, NA; Devor, DC				Jones, HM; Hamilton, KL; Papworth, GD; Syme, CA; Watkins, SC; Bradbury, NA; Devor, DC			Role of the NH2 terminus in the assembly and trafficking of the intermediate conductance Ca2+-activated K+ channel hIK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; ACTIVATED POTASSIUM CHANNEL; DEPENDENT ACTIVATION; ARACHIDONIC-ACID; BINDING-SITE; CL-SECRETION; DI-LEUCINE; PROTEIN; CELLS; INHIBITION	The role of the NH2-terminal leucine zipper and dileucine motifs of hIK1 in the assembly, trafficking, and function of the channel was investigated using cell surface immunoprecipitation, co-immunoprecipitation (Co-IP), immunoblot, and whole-cell patch clamp techniques. Mutation of the NH2-terminal leucine zipper at amino acid positions 18 and 25 (L18A/L25A) resulted in a complete loss of steady-state protein expression, cell surface expression, and whole-cell current density. Inhibition of proteasomal degradation with lactacystin restored L18A/L25A protein expression, although this channel was not expressed at the cell surface as assessed by cell surface immunoprecipitation and whole-cell patch clamp. In contrast, inhibitors of lysosomal degradation (leupeptin/pepstatin) and endocytosis ( chloroquine) had little effect on L18A/L25A protein expression or localization. Further studies confirmed the rapid degradation of this channel, having a time constant of 19.0 +/- 1.3 min compared with 3.2 +/- 0.8 h for wild type hIK1. Co-expression studies demonstrated that the L18A/L25A channel associates with wild type channel, thereby attenuating its expression at the cell surface. Co-IP studies confirmed this association. However, L18A/L25A channels failed to form homotetrameric channels, as assessed by Co-IP, suggesting the NH2 terminus plays a role in tetrameric channel assembly. As with the leucine zipper, mutation of the dileucine motif to alanines, L18A/L19A, resulted in a near complete loss in steady-state protein expression with the protein being similarly targeted to the proteasome for degradation. In contrast to our results on the leucine zipper, however, both chloroquine and growing the cells at the permissive temperature of 27 degreesC restored expression of L18A/L19A at the cell surface, suggesting that the defect in the channel trafficking is the result of a subtle folding error. In conclusion, we demonstrate that the NH2 terminus of hIK1 contains overlapping leucine zipper and dileucine motifs essential for channel assembly and trafficking to the plasma membrane.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Otago, Dept Physiol, Dunedin, New Zealand	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Otago	Devor, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S312 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	dd2@pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NIDDK NIH HHS [DK54941] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054941] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P83; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC138, DOI 10.1152/ajpcell.1998.274.1.C138; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Dong K, 2001, J BIOL CHEM, V276, P44347, DOI 10.1074/jbc.M108072200; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Francis MJ, 1999, J CELL SCI, V112, P1721; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; Hamilton KL, 2003, J BIOL CHEM, V278, P16690, DOI 10.1074/jbc.M212959200; Hoffman JF, 2003, P NATL ACAD SCI USA, V100, P7366, DOI 10.1073/pnas.1232342100; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen B S, 2002, Expert Opin Ther Targets, V6, P623, DOI 10.1517/14728222.6.6.623; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kohler R, 2000, CIRC RES, V87, P496; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; MACFARLANE SN, 2001, SCI STKE; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Saito T, 2002, CLIN EXP PHARMACOL P, V29, P324, DOI 10.1046/j.1440-1681.2002.03652.x; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; SHEN NV, 1993, NEURON, V11, P67; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Stockklausner C, 2003, J BIOL CHEM, V278, P17000, DOI 10.1074/jbc.M212243200; Storey N, 2002, J CELL BIOL, V158, P1251, DOI 10.1083/jcb.200204010; Syme CA, 2003, J BIOL CHEM, V278, P8476, DOI 10.1074/jbc.M210072200; Syme CA, 2000, AM J PHYSIOL-CELL PH, V278, pC570, DOI 10.1152/ajpcell.2000.278.3.C570; Takahata T, 2003, AM J PHYSIOL-CELL PH, V284, pC127, DOI 10.1152/ajpcell.00250.2002; TIETZE C, 1980, BIOCHEM BIOPH RES CO, V93, P1, DOI 10.1016/S0006-291X(80)80237-3; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; Wulf A, 2002, J MEMBRANE BIOL, V187, P71, DOI 10.1007/s00232-001-0149-3; Wulff H, 2001, J BIOL CHEM, V276, P32040, DOI 10.1074/jbc.M105231200; Zhou JS, 2000, CIRC RES, V87, P33, DOI 10.1161/01.RES.87.1.33; ZOON KC, 1983, VIROLOGY, V130, P195, DOI 10.1016/0042-6822(83)90127-7	39	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15531	15540		10.1074/jbc.M400069200	http://dx.doi.org/10.1074/jbc.M400069200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14754884	hybrid			2022-12-27	WOS:000220594700125
J	Kao, HI; Veeraraghavan, J; Polaczek, P; Campbell, JL; Bambara, RA				Kao, HI; Veeraraghavan, J; Polaczek, P; Campbell, JL; Bambara, RA			On the roles of Saccharomyces cerevisiae Dna2p and flap endonuclease 1 in Okazaki fragment processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; CELL NUCLEAR ANTIGEN; SINGLE-STRANDED-DNA; STRUCTURE-SPECIFIC CLEAVAGE; ESSENTIAL IN-VIVO; POLYMERASE-DELTA; SECONDARY STRUCTURE; RNASE H(35); YEAST; HELICASE	Short DNA segments designated Okazaki fragments are intermediates in eukaryotic DNA replication. Each contains an initiator RNA/DNA primer (iRNA/DNA), which is converted into a 5'-flap and then removed prior to fragment joining. In one model for this process, the flap endonuclease 1 (FEN1) removes the iRNA. In the other, the single-stranded binding protein, replication protein A (RPA), coats the flap, inhibits FEN1, but stimulates cleavage by the Dna2p helicase/nuclease. RPA dissociates from the resultant short flap, allowing FEN1 cleavage. To determine the most likely process, we analyzed cleavage of short and long 5'-flaps. FEN1 cleaves 10-nucleotide fixed or equilibrating flaps in an efficient reaction, insensitive to even high levels of RPA or Dna2p. On 30-nucleotide fixed or equilibrating flaps, RPA partially inhibits FEN1. CTG flaps can form foldback structures and were inhibitory to both nucleases, however, addition of a dT(12) to the 5'-end of a CTG flap allowed Dna2p cleavage. The presence of high Dna2p activity, under reaction conditions favoring helicase activity, substantially stimulated FEN1 cleavage of tailed-foldback flaps and also 30-nucleotide unstructured flaps. Our results suggest Dna2p is not used for processing of most flaps. However, Dna2p has a role in a pathway for processing structured flaps, in which it aids FEN1 using both its nuclease and helicase activities.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; CALTECH, Braun Labs 147 75, Pasadena, CA 91125 USA	University of Rochester; California Institute of Technology	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urme.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508, R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25508, GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bae SH, 2002, J BIOL CHEM, V277, P26632, DOI 10.1074/jbc.M111026200; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Budd ME, 2000, MUTAT RES-DNA REPAIR, V459, P173, DOI 10.1016/S0921-8777(99)00072-5; Callahan JL, 2003, MOL CELL BIOL, V23, P7849, DOI 10.1128/MCB.23.21.7849-7860.2003; Choe W, 2002, MOL CELL BIOL, V22, P4202, DOI 10.1128/MCB.22.12.4202-4217.2002; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; Eki T, 1996, GENOMICS, V37, P408, DOI 10.1006/geno.1996.0581; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; Frank P, 1998, FEBS LETT, V421, P23, DOI 10.1016/S0014-5793(97)01528-7; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Gould KL, 1998, GENETICS, V149, P1221; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; GOULIAN M, 1987, PROCESSIVE DISCONTIN, P101; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Higashibata H, 2003, J BIOL CHEM, V278, P15983, DOI 10.1074/jbc.M207748200; HUANG L, 1994, J BIOL CHEM, V269, P25922; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Imamura O, 2003, P NATL ACAD SCI USA, V100, P8193, DOI 10.1073/pnas.1431624100; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Jin YH, 2003, J BIOL CHEM, V278, P1626, DOI 10.1074/jbc.M209803200; Kang HY, 2000, GENETICS, V155, P1055; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; KORNBERG A, 1992, DNA REPLICATION, P140; KUO CL, 1983, P NATL ACAD SCI-BIOL, V80, P6465, DOI 10.1073/pnas.80.21.6465; Lee KH, 2003, MOL CELLS, V15, P81; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; Lopes J, 2002, EMBO J, V21, P3201, DOI 10.1093/emboj/cdf310; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; McMurray CT, 1999, P NATL ACAD SCI USA, V96, P1823, DOI 10.1073/pnas.96.5.1823; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; Rumbaugh JA, 1999, J BIOL CHEM, V274, P14602, DOI 10.1074/jbc.274.21.14602; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Weitao T, 2003, J BIOL CHEM, V278, P22513, DOI 10.1074/jbc.M301610200; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	61	87	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15014	15024		10.1074/jbc.M313216200	http://dx.doi.org/10.1074/jbc.M313216200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747468	hybrid			2022-12-27	WOS:000220594700065
J	Petrich, BG; Eloff, BC; Lerner, DL; Kovacs, A; Saffitz, JE; Rosenbaum, DS; Wang, YB				Petrich, BG; Eloff, BC; Lerner, DL; Kovacs, A; Saffitz, JE; Rosenbaum, DS; Wang, YB			Targeted activation of c-Jun N-terminal kinase in vivo induces restrictive cardiomyopathy and conduction defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA(1); MESSENGER-RNA EXPRESSION; CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; OXIDATIVE STRESS; PROTEIN-KINASES; TRANSGENIC MICE; MYOCARDIAL-INFARCTION; DIASTOLIC DYSFUNCTION; NH2-TERMINAL KINASE	The stress-activated protein kinase, c-Jun N-terminal kinase (JNK), has been implicated in the process of cardiac hypertrophy and apoptosis, yet the specific roles of JNK in heart failure are unclear. To determine the effects of JNK activation in intact heart, we established transgenic animals using a Cre/loxP-mediated gene switch approach to achieve targeted expression of an upstream activator, mitogen-activated protein kinase kinase 7 (D) (MKK7D), in ventricular myocytes. MKK7D expression led to significant JNK activation, robust induction of the fetal gene program, and contractile dysfunction. The animals died similar to7 weeks after birth with signs of congestive heart failure. Doppler mode echocardiography revealed a marked stiffening of JNK-activated hearts that was associated with the remodeling of specific extracellular matrix components. Gene expression analysis of MKK7D hearts revealed up-regulation of transforming growth factor beta signaling, offering a potential molecular mechanism underlying changes in extracellular matrix composition. In addition, we demonstrated that JNK activation led to specific loss of connexin 43 protein and gap junctions without affecting the expression or localization of other key intercalated disc proteins. This specific and localized gap junction remodeling resulted in significant slowing of ventricular electrical conduction in JNK-activated hearts. These results represent the first characterization of JNK-mediated cardiac pathology in vivo and support an important role for JNK signaling in specific aspects of cardiac remodeling in the pathogenesis of cardiac disease.	Univ Calif Los Angeles, Div Mol Med, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Case Western Reserve Univ, Heart & Vasc Res Ctr, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44109 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Case Western Reserve University; Case Western Reserve University; Washington University (WUSTL); Washington University (WUSTL)	Wang, YB (corresponding author), Univ Calif Los Angeles, Div Mol Med, Dept Anesthesiol, 650 Charles E Young Dr,Rm 569-CSH, Los Angeles, CA 90095 USA.	yibinwang@mednet.ucla.edu		Wang, Yibin/0000-0003-0852-0767				AHUMADA GG, 1984, J HISTOCHEM CYTOCHEM, V32, P383, DOI 10.1177/32.4.6707462; Ammarguellat FZ, 2002, HYPERTENSION, V39, P679, DOI 10.1161/hy0202.103481; Andreka P, 2001, CIRC RES, V88, P305, DOI 10.1161/01.RES.88.3.305; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; APPLETON CP, 1988, J AM COLL CARDIOL, V11, P757, DOI 10.1016/0735-1097(88)90208-2; Barker RJ, 2002, CIRC RES, V91, P556, DOI 10.1161/01.RES.0000036861.37203.2F; Barker RJ, 2002, CIRC RES, V90, P317, DOI 10.1161/hh0302.104471; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Borer JS, 2002, CIRCULATION, V105, P1837, DOI 10.1161/01.CIR.0000014419.71706.85; BRAND T, 1995, J MOL CELL CARDIOL, V27, P5, DOI 10.1016/S0022-2828(08)80003-X; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Chow JFC, 2001, MOL HUM REPROD, V7, P1047, DOI 10.1093/molehr/7.11.1047; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DOLBER PC, 1993, J HISTOCHEM CYTOCHEM, V41, P465, DOI 10.1177/41.3.7679127; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Eloff BC, 2001, CARDIOVASC RES, V51, P681, DOI 10.1016/S0008-6363(01)00341-8; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Girouard SD, 1996, J CARDIOVASC ELECTR, V7, P1024, DOI 10.1111/j.1540-8167.1996.tb00478.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Gutstein DE, 2003, J CELL SCI, V116, P875, DOI 10.1242/jcs.00258; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; Heling A, 2000, CIRC RES, V86, P846, DOI 10.1161/01.RES.86.8.846; Hreniuk D, 2001, MOL PHARMACOL, V59, P867, DOI 10.1124/mol.59.4.867; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KLEBER AG, 2002, HDB PHYSL, V1, P455; Kucera JP, 2002, CIRC RES, V91, P1176, DOI 10.1161/01.RES.0000046237.54156.0A; Kuwahara F, 2002, CIRCULATION, V106, P130, DOI 10.1161/01.CIR.0000020689.12472.E0; Li H, 2001, ARCH BIOCHEM BIOPHYS, V394, P1, DOI 10.1006/abbi.2001.2518; Li WG, 1998, BIOCHEM BIOPH RES CO, V246, P816, DOI 10.1006/bbrc.1998.8662; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Lijnen PJ, 2000, MOL GENET METAB, V71, P418, DOI 10.1006/mgme.2000.3032; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; Nakajima H, 2000, CIRC RES, V86, P571, DOI 10.1161/01.RES.86.5.571; Pellieux C, 2000, J HYPERTENS, V18, P1307, DOI 10.1097/00004872-200018090-00017; Peters NS, 1997, CIRCULATION, V95, P988; Petrich BG, 2003, FASEB J, V17, P749, DOI 10.1096/fj.02-0438fje; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Rosendahl A, 2001, AM J RESP CELL MOL, V25, P60, DOI 10.1165/ajrcmb.25.1.4396; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Saffitz JE, 2000, AM J PHYSIOL-HEART C, V278, pH1662, DOI 10.1152/ajpheart.2000.278.5.H1662; SAMUEL JL, 1991, J CLIN INVEST, V88, P1737, DOI 10.1172/JCI115492; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sato M, 2001, FREE RADICAL BIO MED, V31, P729, DOI 10.1016/S0891-5849(01)00626-8; Shaddy RE, 1996, BIOCHEM MOL MED, V57, P10, DOI 10.1006/bmme.1996.0002; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Spray DC, 2002, HDB PHYSL CARDIOVASC, V1, P169; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; WANG N, 1994, BIOPHYS J, V66, P2181, DOI 10.1016/S0006-3495(94)81014-8; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Weber Karl T., 1997, P13; Weber KT, 2000, CURR OPIN CARDIOL, V15, P264, DOI 10.1097/00001573-200007000-00010; Young RL, 1998, CARDIOVASC RES, V37, P187, DOI 10.1016/S0008-6363(97)00205-8; Zheng MZ, 2004, AM J PHYSIOL-HEART C, V286, pH424, DOI 10.1152/ajpheart.00110.2003	68	86	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15330	15338		10.1074/jbc.M314142200	http://dx.doi.org/10.1074/jbc.M314142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742426	hybrid			2022-12-27	WOS:000220594700102
J	Aamodt, RM; Falnes, PO; Johansen, RF; Seeberg, E; Bjoras, M				Aamodt, RM; Falnes, PO; Johansen, RF; Seeberg, E; Bjoras, M			The Bacillus subtilis counterpart of the mammalian 3-methyladenine DNA glycosylase has hypoxanthine and 1,N-6-ethenoadenine as preferred substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; OXIDATIVE DEMETHYLATION; ADAPTIVE RESPONSE; ALKYLATED DNA; BASE EXCISION; REPAIR; PURIFICATION; CDNA; GENE	The AAG family of 3-methyladenine DNA glycosylases was initially thought to be limited to mammalian cells, but genome sequencing efforts have revealed the presence of homologous proteins in certain prokaryotic species as well. Here, we report the first molecular characterization of a functional prokaryotic AAG homologue, i.e. YxlJ, termed bAag, from Bacillus subtilis. The B. subtilis aag gene was expressed in Escherichia coli, and the protein was purified to homogeneity. As expected, B. subtilis Aag was found to be a DNA glycosylase, which releases 3-alkylated purines and hypoxanthine, as well as the cyclic etheno adduct 1, N-6-ethenoadenine from DNA. However, kinetic analysis showed that bAag removed hypoxanthine much faster than human AAG with a 10-fold higher value for k(cat), whereas the rate of excision of 1, N-6-ethenoadenine was found to be similar. In contrast, it was found that bAag removes 3-methyladenine and 3-methylguanine similar to 10 - 20 times more slowly than human AAG, and there was hardly any detectable excision of 7-methylguanine. It thus appears that bAag has a minor role in the repair of DNA alkylation damage and an important role in preventing the mutagenic effects of deaminated purines and cyclic etheno adducts in Bacillus subtilis.	Univ Oslo, Natl Hosp, Inst Med Microbiol, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway; Univ Oslo, Natl Hosp, Inst Med Microbiol, Dept Mol Biol, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Bjoras, M (corresponding author), Univ Oslo, Natl Hosp, Inst Med Microbiol, Ctr Mol Biol & Neurosci, N-0027 Oslo, Norway.	magnar.bjoras@labmed.uio.no	Bjørås, Magnar/N-9286-2017; Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; BJELLAND S, 1993, NUCLEIC ACIDS RES, V21, P2045, DOI 10.1093/nar/21.9.2045; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BJORAS M, 1995, BIOCHEMISTRY-US, V34, P4577, DOI 10.1021/bi00014a010; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; EVENSEN G, 1982, NATURE, V296, P773, DOI 10.1038/296773a0; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Guo GM, 1998, J BACTERIOL, V180, P46, DOI 10.1128/JB.180.1.46-51.1998; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883; KARRAN P, 1980, J MOL BIOL, V140, P101, DOI 10.1016/0022-2836(80)90358-7; KARRAN P, 1982, NATURE, V296, P770, DOI 10.1038/296770a0; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; NAIR J, 1995, CARCINOGENESIS, V16, P613, DOI 10.1093/carcin/16.3.613; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SAMSON L, 1977, NATURE, V267, P281, DOI 10.1038/267281a0; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SEDGWICK B, 1991, MUTAT RES, V250, P211, DOI 10.1016/0027-5107(91)90178-Q; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Winterling KW, 1998, J BACTERIOL, V180, P2201, DOI 10.1128/JB.180.8.2201-2211.1998; Winterling KW, 1997, J BACTERIOL, V179, P1698, DOI 10.1128/jb.179.5.1698-1703.1997; YAO M, 1994, J BIOL CHEM, V269, P16260	37	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13601	13606		10.1074/jbc.M314277200	http://dx.doi.org/10.1074/jbc.M314277200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729667	hybrid			2022-12-27	WOS:000220478500040
J	Chumanevich, AA; Krupenko, SA; Davies, C				Chumanevich, AA; Krupenko, SA; Davies, C			The crystal structure of the hydrolase domain of 10-formyltetrahydrofolate dehydrogenase - Mechanism of hydrolysis and its interplay with the dehydrogenase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; ALDEHYDE DEHYDROGENASE; ESCHERICHIA-COLI; ACTIVE-SITE; TERMINAL DOMAIN; FORMYLTRANSFERASE; ENZYMES; LIVER; GENE; CYCLOHYDROLASE	10-Formyltetrahydrofolate dehydrogenase (FDH) converts 10-formyltetrahydrofolate, a precursor for nucleotide biosynthesis, to tetrahydrofolate. The protein comprises two functional domains: a hydrolase domain that removes a formyl group from 10-formyltetrahydrofolate and a NADP(+)-dependent dehydrogenase domain that reduces the formyl to carbon dioxide. As a first step toward deciphering the catalytic mechanism of the enzyme, we have determined the crystal structure of the hydrolase domain of FDH from rat, solved to 2.3-Angstrom resolution. The structure comprises two domains. As expected, domain 1 shares the same Rossmann fold as the related enzymes, methionyl-tRNA-formyltransferase and glycinamide ribonucleotide formyltransferase, but, unexpectedly, the structural similarity between the amino-terminal domain of 10-formyltetrahydrofolate dehydrogenase and methionyl-tRNA-formyltransferase extends to the C terminus of both proteins. The active site contains a molecule of beta-mercaptoethanol that is positioned between His-106 and Asp-142 and that appears to mimic the formate product. We propose a catalytic mechanism for the hydrolase reaction in which Asp-142 polarizes the catalytic water molecule and His-106 orients the carbonyl group of formyl. The structure also provides clues as to how, in the native enzyme, the hydrolase domain transfers its product to the dehydrogenase domain.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	krupenko@musc.edu			NIDDK NIH HHS [DK54388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; BENKOVIC SJ, 1984, TRENDS BIOCHEM SCI, V9, P320, DOI 10.1016/0968-0004(84)90302-5; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHEN P, 1992, J MOL BIOL, V227, P283, DOI 10.1016/0022-2836(92)90698-J; Chu E., 1996, CANC CHEMOTHERAPY BI, P109; Chumanevich AA, 2002, ACTA CRYSTALLOGR D, V58, P1841, DOI 10.1107/S0907444902012155; COOK RJ, 1991, J BIOL CHEM, V266, P4965; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; GREENBAU.AL, 1965, BIOCHEM J, V95, P161, DOI 10.1042/bj0950161; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisliuk RL, 2000, PHARMACOL THERAPEUT, V85, P183, DOI 10.1016/S0163-7258(99)00056-X; KLEIN C, 1995, J MOL BIOL, V249, P153, DOI 10.1006/jmbi.1995.0286; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; Krupenko SA, 1997, J BIOL CHEM, V272, P10273; Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227; Krupenko SA, 1998, PROTEIN EXPRES PURIF, V14, P146, DOI 10.1006/prep.1998.0937; Krupenko SA, 2001, J BIOL CHEM, V276, P24030, DOI 10.1074/jbc.M009257200; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; Krupenko SA, 1999, J BIOL CHEM, V274, P35777, DOI 10.1074/jbc.274.50.35777; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu XW, 2000, BIOCHEMISTRY-US, V39, P11523, DOI 10.1021/bi000665d; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAGY PL, 1993, J BACTERIOL, V175, P7066, DOI 10.1128/jb.175.21.7066-7073.1993; NAGY PL, 1995, J BACTERIOL, V177, P1292, DOI 10.1128/jb.177.5.1292-1298.1995; Newton DT, 1999, BIOCHEM J, V339, P63, DOI 10.1042/0264-6021:3390063; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Reuland SN, 2003, J BIOL CHEM, V278, P22894, DOI 10.1074/jbc.M302948200; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; SMITH JM, 1987, J BIOL CHEM, V262, P10565; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Su Y, 1998, J MOL BIOL, V281, P485, DOI 10.1006/jmbi.1998.1931; TEPHLY TR, 1991, LIFE SCI, V48, P1031, DOI 10.1016/0024-3205(91)90504-5; Wagner C, 1995, FOLATE HLTH DIS, P23; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715	52	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14355	14364		10.1074/jbc.M313934200	http://dx.doi.org/10.1074/jbc.M313934200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729668	hybrid			2022-12-27	WOS:000220478500131
J	Kounosu, A; Li, ZR; Cosper, NJ; Shokes, JE; Scott, RA; Imai, T; Urushiyama, A; Iwasaki, T				Kounosu, A; Li, ZR; Cosper, NJ; Shokes, JE; Scott, RA; Imai, T; Urushiyama, A; Iwasaki, T			Engineering a three-cysteine, one-histidine ligand environment into a new hyperthermophilic archaeal Rieske-type [2Fe-2S] ferredoxin from Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; RESONANCE RAMAN-SPECTRA; SP STRAIN 7; ABSORPTION SPECTROSCOPIC ANALYSIS; PYRROLIDONE CARBOXYL PEPTIDASE; NORMAL COORDINATE ANALYSIS; SITE-DIRECTED MUTAGENESIS; ECHO ENVELOPE MODULATION; WATER-SOLUBLE FRAGMENT; BLUE COPPER PROTEINS	We heterologously overproduced a hyperthermostable archaeal low potential (E-m = - 62 mV) Rieske-type ferredoxin (ARF) from Sulfolobus solfataricus strain P-1 and its variants in Escherichia coli to examine the influence of ligand substitutions on the properties of the [2Fe-2S] cluster. While two cysteine ligand residues (Cys(42) and Cys(61)) are essential for the cluster assembly and/or stability, the contributions of the two histidine ligands to the cluster assembly in the archaeal Rieske-type ferredoxin appear to be inequivalent as indicated by much higher stability of the His(64) --> Cys variant (H64C) than the His(44) --> Cys variant (H44C). The x-ray absorption and resonance Raman spectra of the H64C variant firmly established the formation of a novel, oxidized [2Fe-2S] cluster with one histidine and three cysteine ligands in the archaeal Rieske-type protein moiety. Comparative resonance Raman features of the wildtype, natural abundance and uniformly N-15-labeled ARF and its H64C variant showed significant mixing of the Fe-S and Fe-N stretching characters for an oxidized biological [2Fe-2S] cluster with partial histidine ligation.	Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Rikkyo St Pauls Univ, Dept Chem, Toshima Ku, Tokyo 1718501, Japan	Nippon Medical School; University System of Georgia; University of Georgia	Iwasaki, T (corresponding author), Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	tiwasaki@nms.ac.jp	Li, Zhongrui/AAB-9111-2019; Li, Zhongrui/I-4872-2017	Li, Zhongrui/0000-0001-5371-7628; Iwasaki, Toshio/0000-0001-9562-4649; Scott, Robert/0000-0003-2236-1336	NIGMS NIH HHS [GM 42025] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; Beharry ZM, 2003, BIOCHEMISTRY-US, V42, P13625, DOI 10.1021/bi035385n; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Bonisch H, 2002, J MOL BIOL, V319, P791, DOI 10.1016/S0022-2836(02)00323-6; Brugna M, 1999, J BIOL CHEM, V274, P16766, DOI 10.1074/jbc.274.24.16766; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Cavagnero S, 1998, BIOCHEMISTRY-US, V37, P3369, DOI 10.1021/bi9721795; CLINE JF, 1985, J BIOL CHEM, V260, P3251; Colbert CL, 2000, STRUCTURE, V8, P1267, DOI 10.1016/S0969-2126(00)00536-0; COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; Cosper NJ, 2002, PROTEIN SCI, V11, P2969, DOI 10.1110/ps.0222402; Cosper NJ, 2001, J BIOCHEM, V130, P191, DOI 10.1093/oxfordjournals.jbchem.a002972; Couture MMJ, 2001, BIOCHEMISTRY-US, V40, P84, DOI 10.1021/bi001780r; Crouse BR, 1996, BIOCHEMISTRY-US, V35, P16222, DOI 10.1021/bi9620114; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; Degli Esposti M, 1987, Biochem J, V241, P285; Dikanov SA, 1996, J AM CHEM SOC, V118, P8408, DOI 10.1021/ja960781x; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; FEE JA, 1984, J BIOL CHEM, V259, P124; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; FU WG, 1992, J BIOL CHEM, V267, P15502; GASSNER GT, 1995, BIOCHEMISTRY-US, V34, P13460, DOI 10.1021/bi00041a025; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAN J, 1991, BIOCHEMISTRY-US, V30, P10904, DOI 10.1021/bi00109a014; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; Holz RC, 1997, BIOCHEMISTRY-US, V36, P14690, DOI 10.1021/bi971831t; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; Hunsicker-Wang LM, 2003, BIOCHEMISTRY-US, V42, P7303, DOI 10.1021/bi0342719; Iwasaki T, 2000, J BIOL CHEM, V275, P25391, DOI 10.1074/jbc.M909243199; IWASAKI T, 1995, J BACTERIOL, V177, P2576, DOI 10.1128/jb.177.9.2576-2582.1995; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; Iwasaki T, 2002, EPR IN THE 21ST CENTURY: BASICS AND APPLICATIONS TO MATERIAL, LIFE AND EARTH SCIENCES, P488, DOI 10.1016/B978-044450973-4/50083-4; Iwasaki T, 2002, J BIOL CHEM, V277, P39642, DOI 10.1074/jbc.M207312200; Iwasaki T, 2001, METHOD ENZYMOL, V334, P3; Iwasaki T, 1996, J BIOL CHEM, V271, P27659, DOI 10.1074/jbc.271.44.27659; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Kaushik JK, 2002, J MOL BIOL, V316, P991, DOI 10.1006/jmbi.2001.5355; KUILA D, 1987, J AM CHEM SOC, V109, P1559, DOI 10.1021/ja00239a041; KUILA D, 1992, BIOCHIM BIOPHYS ACTA, V1140, P175, DOI 10.1016/0005-2728(92)90007-O; Li ZR, 2003, BIOCHEMISTRY-US, V42, P15003, DOI 10.1021/bi035078h; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; Link TA, 1999, ADV INORG CHEM, V47, P83, DOI 10.1016/S0898-8838(08)60077-X; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Meyer J, 1997, BIOCHEMISTRY-US, V36, P13374, DOI 10.1021/bi971775w; MEYER J, 1994, BIOCHEMISTRY-US, V33, P13642, DOI 10.1021/bi00250a014; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PALMER G, 1967, BIOCHEMISTRY-US, V6, P1658, DOI 10.1021/bi00858a012; RANDALL CR, 1995, INORG CHEM, V34, P1036, DOI 10.1021/ic00109a007; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; Rotsaert FAJ, 2003, J BIOL INORG CHEM, V8, P318, DOI 10.1007/s00775-002-0417-4; SAITO H, 1991, B CHEM SOC JPN, V64, P829, DOI 10.1246/bcsj.64.829; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Samoilova RI, 2002, J BIOL CHEM, V277, P4605, DOI 10.1074/jbc.C100664200; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shergill JK, 1995, BIOCHEMISTRY-US, V34, P16533, DOI 10.1021/bi00051a001; Suzuki T, 2002, EXTREMOPHILES, V6, P39, DOI 10.1007/s007920100221; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; URUSHIYAMA A, 1990, B CHEM SOC JPN, V63, P1563, DOI 10.1246/bcsj.63.1563; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P8083, DOI 10.1021/bi00083a005; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; Xia B, 1999, BIOCHEMISTRY-US, V38, P727, DOI 10.1021/bi981851a; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	76	45	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12519	12528		10.1074/jbc.M305923200	http://dx.doi.org/10.1074/jbc.M305923200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726526	hybrid			2022-12-27	WOS:000220334900063
J	Gardai, SJ; Hildeman, DA; Frankel, SK; Whitlock, BB; Frasch, SC; Borregaard, N; Marrack, P; Bratton, DL; Henson, PM				Gardai, SJ; Hildeman, DA; Frankel, SK; Whitlock, BB; Frasch, SC; Borregaard, N; Marrack, P; Bratton, DL; Henson, PM			Phosphorylation of Bax Ser(184) by Akt regulates its activity and apoptosis in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CYTOCHROME-C RELEASE; MCL-1 EXPRESSION; SURVIVAL SIGNALS; BH3 DOMAIN; MITOCHONDRIA; ACTIVATION; PROTEIN; KINASE	Although important for apoptosis, the mechanism of Bax regulation is poorly understood. This study demonstrates that phosphorylation of Ser(184) regulates Bax activity. The phosphorylation required phosphatidylinositol 3-kinase/Akt activation and appeared to be mediated by Akt itself. In the serine-phosphorylated form, Bax was detected in the cytoplasm, could not be immunoprecipitated with the activation-specific antibody 6A7, and promoted heterodimerization with Mcl-1, Bcl-x(L), and A1. Apoptotic neutrophils possessed reduced levels of serine-phosphorylated Bax correlating with an increase in activated Bax as well as an increase in the amount of Bax found translocated to the mitochondria. We suggest that Bax is regulated by phosphorylation of Ser(184) in an Akt-dependent manner and that phosphorylation inhibits Bax effects on the mitochondria by maintaining the protein in the cytoplasm, heterodimerized with antiapoptotic Bcl-2 family members.	Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Cincinnati Childrens Hosp, Dept Immunobiol, Cincinnati, OH 45229 USA; W Virginia Wesleyan Coll, Dept Biol, Buckhannon, WV 26201 USA; Natl Univ Hosp, Dept Hematol, Finsen Ctr, Rigshosp, Copenhagen, Denmark	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cincinnati Children's Hospital Medical Center; Rigshospitalet; University of Copenhagen	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, D508,1400 Jackson St, Denver, CO 80206 USA.	hensonp@NJC.org	Hildeman, David/I-4884-2015; Marrack, Philippa/AHE-6316-2022; Hildeman, David/AAA-1757-2020	Hildeman, David/0000-0002-0421-8483; Hildeman, David/0000-0002-0421-8483; Marrack, Philippa/0000-0003-1883-3687				Aikin R, 2000, BIOCHEM BIOPH RES CO, V277, P455, DOI 10.1006/bbrc.2000.3664; Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; ANDREWS PC, 1983, BLOOD, V61, P333; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dewson G, 2001, BLOOD, V98, P2239, DOI 10.1182/blood.V98.7.2239; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Frankel SK, 2001, BIOCHEM BIOPH RES CO, V288, P313, DOI 10.1006/bbrc.2001.5761; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Granville DJ, 1999, AM J PATHOL, V155, P1021, DOI 10.1016/S0002-9440(10)65202-9; Haslett C, 1999, AM J RESP CRIT CARE, V160, pS5, DOI 10.1164/ajrccm.160.supplement_1.4; HASLETT C, 1985, AM J PATHOL, V119, P101; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kjeldsen L, 1999, J IMMUNOL METHODS, V232, P131, DOI 10.1016/S0022-1759(99)00171-4; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; Leuenroth SJ, 2000, SURGERY, V128, P171, DOI 10.1067/msy.2000.107609; Leuenroth SJ, 2000, J LEUKOCYTE BIOL, V68, P158; Lewis S, 1998, PROTEIN EXPRES PURIF, V13, P120, DOI 10.1006/prep.1997.0871; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McDonald PP, 1998, BIOCHEMISTRY-US, V37, P13165, DOI 10.1021/bi972539o; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pryde JG, 2000, J BIOL CHEM, V275, P33574, DOI 10.1074/jbc.M001008200; SAVIGE JA, 1984, CLIN EXP IMMUNOL, V58, P737; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Shinoura N, 1999, ONCOGENE, V18, P5703, DOI 10.1038/sj.onc.1202966; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Sweeney JF, 1999, J SURG RES, V81, P108, DOI 10.1006/jsre.1998.5471; Tudan C, 2000, J IMMUNOL, V165, P5798, DOI 10.4049/jimmunol.165.10.5798; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Weinmann P, 1999, BLOOD, V93, P3106; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou J, 1998, J Tongji Med Univ, V18, P42	57	325	333	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21085	21095		10.1074/jbc.M400063200	http://dx.doi.org/10.1074/jbc.M400063200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14766748	hybrid			2022-12-27	WOS:000221273800066
J	Ikeda, W; Kakunaga, S; Takekuni, K; Shingai, T; Satoh, K; Morimoto, K; Takeuchi, M; Imai, T; Takai, Y				Ikeda, W; Kakunaga, S; Takekuni, K; Shingai, T; Satoh, K; Morimoto, K; Takeuchi, M; Imai, T; Takai, Y			Nectin-like molecule-5/Tage4 enhances cell migration in an integrin-dependent, Nectin-3-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL G-PROTEINS; POLIOVIRUS RECEPTOR CD155; GTP-BINDING PROTEINS; IMMUNOGLOBULIN SUPERFAMILY; ADHESION MOLECULE; ALPHA(V)BETA(3) INTEGRIN; CONTACT INHIBITION; ALPHA-V-BETA-3 INTEGRINS; ADHERENS JUNCTIONS; TRANS-INTERACTIONS	Cell migration plays roles in invasion of transformed cells and scattering of embryonic mesenchymal cells into surrounding tissues. We have found that Ig-like Necl-5/Tage4 is up-regulated in NIH3T3 cells transformed by an oncogenic Ras (V12Ras-NIH3T3 cells) and heterophilically trans-interacts with a Ca2+-independent Ig-like cell adhesion molecule nectin-3, eventually enhancing their intercellular motility. We show here that Necl-5 furthermore enhances cell migration in a nectin-3-independent manner. Studies using L fibroblasts expressing various mutants of Necl-5, NIH3T3 cells, and V12Ras-NIH3T3 cells have revealed that Necl-5 enhances serum- and platelet-derived growth factor-induced cell migration. The extracellular region of Necl-5 is necessary for directional cell migration, but not for random cell motility. The cytoplasmic region of Necl-5 is necessary for both directional and random cell movement. Necl-5 colocalizes with integrin alpha(V)beta(3) at leading edges of migrating cells. Analyses using an inhibitor or an activator of integrin alpha(V)beta(3) or a dominant negative mutant of Necl-5 have shown the functional association of Necl-5 with integrin alpha(V)beta(3) in cell motility. Cdc42 and Rac small G proteins are activated by the action of Necl-5 and required for the serum-induced, Necl-5-enhanced cell motility. These results indicate that Necl-5 regulates serum- and platelet-derived growth factor-induced cell migration in an integrin-dependent, nectin3- independent manner, when cells do not contact other cells. We furthermore show here that enhanced motility and metastasis of V12Ras-NIH3T3 cells are at least partly the result of up-regulated Necl-5.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1970, IN VITRO CELL DEV B, V6, P128; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; BASARA ML, 1985, CANCER RES, V45, P2487; Baury B, 2001, GENE, V265, P185, DOI 10.1016/S0378-1119(01)00343-2; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BROWN C, 1991, J INVEST DERMATOL, V96, P724, DOI 10.1111/1523-1747.ep12470960; Chadeneau C, 1996, MAMM GENOME, V7, P636, DOI 10.1007/s003359900194; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; Chadeneau C, 1997, MAMM GENOME, V8, P157, DOI 10.1007/s003359900636; Freistadt MS, 1997, MOL IMMUNOL, V34, P1247, DOI 10.1016/S0161-5890(98)00003-0; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lange R, 2001, VIROLOGY, V285, P218, DOI 10.1006/viro.2001.0943; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; MARTZ E, 1972, J CELL PHYSIOL, V79, P189, DOI 10.1002/jcp.1040790205; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Mueller S, 2003, J BIOL CHEM, V278, P31251, DOI 10.1074/jbc.M304166200; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ravens I, 2003, BIOCHEM BIOPH RES CO, V312, P1364, DOI 10.1016/j.bbrc.2003.11.067; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Takenawa T, 2001, J CELL SCI, V114, P1801; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; Urase K, 2001, NEUROREPORT, V12, P3217, DOI 10.1097/00001756-200110290-00015; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; Woodard AS, 1998, J CELL SCI, V111, P469; Yasuda T, 2000, GENES CELLS, V5, P583, DOI 10.1046/j.1365-2443.2000.00349.x	72	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18015	18025		10.1074/jbc.M312969200	http://dx.doi.org/10.1074/jbc.M312969200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14871893	hybrid			2022-12-27	WOS:000220870400137
J	Kremer, W; Steiner, G; Beraud-Dufour, S; Kalbitzer, HR				Kremer, W; Steiner, G; Beraud-Dufour, S; Kalbitzer, HR			Conformational states of the small G protein Arf-1 in complex with the guanine nucleotide exchange factor ARNO-Sec7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR ARNO; BINDING; SEC7; GDP; P-31; PHOSPHOLIPIDS; ACTIVATION; DOMAINS; FAMILY; GTPASE	Arfl is a small G protein involved in vesicular trafficking, and although it is only distantly related to Ras, it adopts a similar three-dimensional structure. In the present work, we study Arfl bound to GDP and GTP and its interactions with one of its guanosine nucleotide exchange factors, ARNO-Sec7. The P-31 NMR spectra of Arfl.GDP.Mg2+ and Arfl.GTP.Mg2+ share the general features typical for all small G proteins studied so far. Especially, the beta-phosphate resonances of the bound nucleotide are shifted strongly downfield compared with the resonance positions of the free magnesium complexes of GDP and GTP. However, no evidence for an equilibrium between two conformational states of Arfl.GDP.Mg-2 or Arfl.GTP.Mg2+ could be observed as it was described earlier for Ras and Ran. Glu(156) of ARNO-Sec7 has been suggested to play as "glutamic acid finger" an important role in the nucleotide exchange mechanism. In the millimolar concentration range used in the NMR experiments, wild type ARNO-Sec7 and ARNO-Sec7(E156D) do weakly interact with Arfl.GDP.Mg2+ but do not form a strong complex with magnesium-free Arfl.GDP. Only wild type ARNO-Sec7 competes weakly with GDP on Arfl.GDP.Mg2+ and leads to a release of GDP when added to the solution. The catalytically inactive mutants ARNO-Sec7(E156A) and ARNO-Sec7(E156K) induce a release of magnesium from Arfl.GDP.Mg2+ but do not promote GDP release. In addition, ARNO-Sec7 does not interact or only very weakly interacts with the GTP-bound form of Arf1, opposite to the observation made earlier for Ran, where the nucleotide exchange factor RCC1 forms a complex with Ran.GTP.Mg2+ and is able to displace the bound GTP.	Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	University of Regensburg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Kalbitzer, HR (corresponding author), Univ Regensburg, Inst Biophys & Phys Biochem, Univ Str 31, D-93053 Regensburg, Germany.	hans-robert.kalbitzer@biologie.uni-regensburg.de	BERAUD-DUFOUR, Sophie/M-4641-2016	BERAUD-DUFOUR, Sophie/0000-0002-0062-6842; Kalbitzer, Hans Robert/0000-0002-6514-2355				Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; ARMOR JC, 1994, NATURE, V372, P704; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Geyer M, 1999, BIOCHEMISTRY-US, V38, P11250, DOI 10.1021/bi9904306; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Maurer T, 1996, J MAGN RESON SER B, V113, P177, DOI 10.1006/jmrb.1996.0172; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NAKANO A, 1980, FEBS LETT, V116, P72, DOI 10.1016/0014-5793(80)80531-X; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Renault L, 2002, BIOCHEMISTRY-US, V41, P3605, DOI 10.1021/bi012123h; Rohrer M, 2001, BIOCHEMISTRY-US, V40, P1884, DOI 10.1021/bi002164y; Spoerner M, 2001, P NATL ACAD SCI USA, V98, P4944, DOI 10.1073/pnas.081441398; WITTINGHOFER A, 1982, EUR J BIOCHEM, V124, P109, DOI 10.1111/j.1432-1033.1982.tb05912.x	20	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17004	17012		10.1074/jbc.M312780200	http://dx.doi.org/10.1074/jbc.M312780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14739276	hybrid			2022-12-27	WOS:000220870400016
J	Wild, AC; Yu, JW; Lemmon, MA; Blumer, KJ				Wild, AC; Yu, JW; Lemmon, MA; Blumer, KJ			The p21-activated protein kinase-related kinase Cla4 is a coincidence detector of signaling by Cdc42 and phosphatidylinositol 4-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL POLARITY; PLASMA-MEMBRANE; ACTIN POLARIZATION; YEAST HOMOLOG; MITOTIC EXIT; ALPHA-PAK; N-WASP; GTPASE; BINDING; LOCALIZATION	Signal transduction pathways that co-regulate a given biological process often are organized into networks by molecules that act as coincidence detectors. Phosphoinositides and the Rho-type GTPase Cdc42 regulate overlapping processes in all eukaryotic cells. However, the coincidence detectors that link these pathways into networks remain unknown. Here we show that the p21-activated protein kinase-related kinase Cla4 of yeast integrates signaling by Cdc42 and phosphatidylinositol 4-phosphate (PI4P). We found that the Cla4 pleckstrin homology (PH) domain binds in vitro to several phosphoinositide species. To determine which phosphoinositides regulate Cla4 in vivo, we analyzed phosphatidylinositol kinase mutants (stt4, mss4, and pik1). This indicated that the plasma membrane pool of PI4P, but not phosphatidylinositol 4,5-bisphosphate or the Golgi pool of PI4P, is required for localization of Cla4 to sites of polarized growth. A combination of the Cdc42-binding and PH domains of Cla4 was necessary and sufficient for localization to sites of polarized growth. Point mutations affecting either domain impaired the ability of Cla4 to regulate cell morphogenesis and the mitotic exit network ( localization of Lte1). Therefore, Cla4 must retain the ability to bind both Cdc42 and phosphoinositides, the hallmark of a coincidence detector. PI4P may recruit Cla4 to the plasma membrane where Cdc42 activates its kinase activity and refines its localization to cortical sites of polarized growth. In mammalian cells, the myotonic dystrophy-related Cdc42-binding kinase possesses p21-binding and PH domains, suggesting that this kinase may be a coincidence detector of signaling by Cdc42 and phosphoinositides.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Washington University (WUSTL); University of Pennsylvania	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	kblumer@cellbio.wustl.edu	Blumer, Kendall J/C-5268-2012	Lemmon, Mark/0000-0002-3379-5319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056846, F32GM020643, R01GM044592] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44592, GM56846, R01 GM056846, F32 GM20643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Bender L, 1996, J CELL BIOL, V133, P879, DOI 10.1083/jcb.133.4.879; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Bi EF, 2000, MOL BIOL CELL, V11, P773, DOI 10.1091/mbc.11.2.773; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Castillon GA, 2003, CURR BIOL, V13, P654, DOI 10.1016/S0960-9822(03)00247-1; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Chiroli E, 2003, J CELL BIOL, V160, P857, DOI 10.1083/jcb.200209097; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Gladfelter AS, 2002, J CELL BIOL, V156, P315, DOI 10.1083/jcb.200109062; Hallett MA, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-16; Han GS, 2002, J BIOL CHEM, V277, P47709, DOI 10.1074/jbc.M207996200; Hofken T, 2002, EMBO J, V21, P4851, DOI 10.1093/emboj/cdf481; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Keniry ME, 2003, MOL CELL BIOL, V23, P1569, DOI 10.1128/MCB.23.5.1569-1580.2003; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Lamson RE, 2002, MOL CELL BIOL, V22, P2939, DOI 10.1128/MCB.22.9.2939-2951.2002; Leberer E, 1997, CURR BIOL, V7, P539, DOI 10.1016/S0960-9822(06)00252-1; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Muller O, 2001, EMBO J, V20, P5657, DOI 10.1093/emboj/20.20.5657; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Osman MA, 1998, J CELL BIOL, V142, P443, DOI 10.1083/jcb.142.2.443; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Prehoda KE, 2002, CURR OPIN CELL BIOL, V14, P149, DOI 10.1016/S0955-0674(02)00307-1; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Richman TJ, 1999, J BIOL CHEM, V274, P16861, DOI 10.1074/jbc.274.24.16861; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Seshan A, 2002, CURR BIOL, V12, P2098, DOI 10.1016/S0960-9822(02)01388-X; Shelton SN, 2003, BIOCHEM J, V371, P533, DOI 10.1042/BJ20021407; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith GR, 2002, EUKARYOT CELL, V1, P469, DOI 10.1128/EC.1.3.469-480.2002; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	68	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17101	17110		10.1074/jbc.M314035200	http://dx.doi.org/10.1074/jbc.M314035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14766750	hybrid			2022-12-27	WOS:000220870400028
J	Di Carlo, A; De Mori, R; Martelli, F; Pompilio, G; Capogrossi, MC; Germani, A				Di Carlo, A; De Mori, R; Martelli, F; Pompilio, G; Capogrossi, MC; Germani, A			Hypoxia inhibits myogenic differentiation through accelerated MyoD degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; SKELETAL-MUSCLE DIFFERENTIATION; INDUCIBLE FACTOR 1-ALPHA; TERMINAL DIFFERENTIATION; SATELLITE CELLS; GENE-EXPRESSION; NITRIC-OXIDE; IN-VITRO; PHOSPHORYLATION; PROLIFERATION	Cells undergo a variety of biological responses when placed in hypoxic conditions, including alterations in metabolic state and growth rate. Here we investigated the effect of hypoxia on the ability of myogenic cells to differentiate in culture. Exposure of myoblasts to hypoxia strongly inhibited multinucleated myotube formation and the expression of differentiation markers. We showed that hypoxia reversibly inhibited MyoD, Myf5, and myogenin expression. One key step in skeletal muscle differentiation involves the up-regulation of the cell cycle-dependent kinase inhibitors p21 and p27 as well as the product of the retinoblastoma gene (pRb). Myoblasts cultured under hypoxic conditions in differentiation medium failed to up-regulate both p21 and pRb despite the G(1) cell cycle arrest, as evidenced by p27 accumulation and pRb hypophosphorylation. Hypoxia-dependent inhibition of differentiation was associated with MyoD degradation by the ubiquitin-proteasome pathway. MyoD overexpression in C2C12 myoblasts overrode the differentiation block imposed by hypoxic conditions. Thus, hypoxia by inducing MyoD degradation blocked accumulation of early myogenic differentiation markers such as myogenin and p21 and pRb, preventing both permanent cell cycle withdraw and terminal differentiation. Our study revealed a novel anti-differentiation effect exerted by hypoxia in myogenic cells and identified MyoD degradation as a relevant target of hypoxia.	Ist Ricovero & Cura Carattere Sci, Lab Patol Vasc, Ist Dermopat Immacolata, I-00167 Rome, Italy; Ist Ricovero & Cura Carattere Sci, Ctr Cardiol Monzino, Lab Biol Vasc & Terapia Gen, I-20138 Milan, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Centro Cardiologico Monzino	Germani, A (corresponding author), Ist Ricovero & Cura Carattere Sci, Lab Patol Vasc, Ist Dermopat Immacolata, Via Monti Creta 104, I-00167 Rome, Italy.	a.germani@idi.it	Martelli, Fabio/AAL-3788-2020; de mori, roberta/H-2982-2018; Di Carlo, Anna/AAY-4368-2021; Pompilio, Giulio/J-6701-2014	Martelli, Fabio/0000-0002-8624-7738; de mori, roberta/0000-0002-1197-4308; Di Carlo, Anna/0000-0002-6037-6160; Pompilio, Giulio/0000-0003-2581-5735				Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Amellem O, 1998, BRIT J CANCER, V77, P862, DOI 10.1038/bjc.1998.143; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859; Benayoun B, 1998, FEBS LETT, V437, P39, DOI 10.1016/S0014-5793(98)01192-2; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; Chakravarthy MV, 2001, CELL MOL LIFE SCI, V58, P1150, DOI 10.1007/PL00000929; Csete M, 2001, J CELL PHYSIOL, V189, P189, DOI 10.1002/jcp.10016; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Greenbaum AR, 1997, J MUSCLE RES CELL M, V18, P149, DOI 10.1023/A:1018653521686; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HOLLENBERG M, 1981, J CELL PHYSIOL, V106, P209, DOI 10.1002/jcp.1041060206; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LEE KH, 1994, J BIOL CHEM, V269, P14371; Li Q, 1999, MOL CELL BIOL, V19, P5339; Magenta A, 2003, MOL CELL BIOL, V23, P2893, DOI 10.1128/MCB.23.8.2893-2906.2003; MARTELLI F, 1994, ONCOGENE, V9, P3579; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STERN MD, 1985, CIRC RES, V56, P899, DOI 10.1161/01.RES.56.6.899; STERN MD, 1988, P NATL ACAD SCI USA, V85, P6954, DOI 10.1073/pnas.85.18.6954; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; Walsh K, 1997, Prog Cell Cycle Res, V3, P53; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1	49	98	106	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16332	16338		10.1074/jbc.M313931200	http://dx.doi.org/10.1074/jbc.M313931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754880	hybrid			2022-12-27	WOS:000220747900079
J	Fuchs, S; Xiao, HD; Cole, JM; Adams, JW; Frenzel, K; Michaud, A; Zhao, H; Keshelava, G; Capecchi, MR; Corvol, P; Bernstein, KE				Fuchs, S; Xiao, HD; Cole, JM; Adams, JW; Frenzel, K; Michaud, A; Zhao, H; Keshelava, G; Capecchi, MR; Corvol, P; Bernstein, KE			Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASP-LYS-PRO; 2 HOMOLOGOUS DOMAINS; HEMATOPOIETIC PROGENITOR CELLS; BONE-MARROW CULTURES; BLOOD-PRESSURE; TETRAPEPTIDE ACSDKP; GENE POLYMORPHISM; DEFICIENT MICE; ACTIVE-SITES; PLASMA-LEVEL	Angiotensin-converting enzyme (ACE) produces the vasoconstrictor angiotensin II. The ACE protein is composed of two homologous domains, each binding zinc and each independently catalytic. To assess the physiologic significance of the two ACE catalytic domains, we used gene targeting in mice to introduce two point mutations (H395K and H399K) that selectively inactivated the ACE N-terminal catalytic site. This modification does not affect C-terminal enzymatic activity or ACE protein expression. In addition, the testis ACE isozyme is not affected by the mutations. Analysis of homozygous mutant mice ( termed ACE 7/7) showed normal plasma levels of angiotensin II but an elevation of plasma and urine N-acetyl-Ser-Asp-Lys-Pro, a peptide suggested to inhibit bone marrow maturation. Despite this, ACE 7/7 mice had blood pressure, renal function, and hematocrit that were indistinguishable from wild-type mice. We also studied compound heterozygous mice in which one ACE allele was null ( no ACE expression) and the second allele encoded the mutations selectively inactivating the N-terminal catalytic domain. These mice produced approximately half the normal levels of ACE, with the ACE protein lacking N-terminal catalytic activity. Despite this, the mice have a phenotype indistinguishable from wild-type animals. This study shows that, in vivo, the presence of the C-terminal ACE catalytic domain is sufficient to maintain a functional renin-angiotensin system. It also strongly suggests that the anemia present in ACE null mice is not due to the accumulation of the peptide N-acetyl-Ser-Asp-Lys-Pro.	Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Univ Utah, Howard Hughes Med Inst, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Coll France, INSERM, U36, F-75005 Paris, France	Emory University; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Bernstein, KE (corresponding author), Emory Univ, Dept Pathol, Rm 7107A WMB, Atlanta, GA 30322 USA.	kbernst@emory.edu		Bernstein, Kenneth/0000-0001-8097-3272	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055503, R37DK039777, R01DK044280, R01DK051445, R01DK039777] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39777, DK55503, DK51445, DK44280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azizi M, 2000, HYPERTENSION, V35, P1226, DOI 10.1161/01.HYP.35.6.1226; Azizi M, 2002, J MOL MED-JMM, V80, P492, DOI 10.1007/s00109-002-0357-z; Azizi M, 1997, HYPERTENSION, V30, P1015, DOI 10.1161/01.HYP.30.5.1015; Azizi M, 1996, J CLIN INVEST, V97, P839, DOI 10.1172/JCI118484; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; CASHMAN JD, 1994, BLOOD, V84, P1534, DOI 10.1182/blood.V84.5.1534.bloodjournal8451534; Cole J, 2000, J CLIN INVEST, V106, P1391, DOI 10.1172/JCI10557; Cole J, 2002, CIRC RES, V90, P87, DOI 10.1161/hh0102.102360; Cole JM, 2003, AM J PHYSIOL-RENAL, V284, pF599, DOI 10.1152/ajprenal.00308.2002; CORVOL P, 1995, J HYPERTENS, V13, pS3, DOI 10.1097/00004872-199509003-00002; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; Esther CR, 1996, LAB INVEST, V74, P953; Esther CR, 1997, J CLIN INVEST, V99, P2375, DOI 10.1172/JCI119419; FRINDEL E, 1977, EXP HEMATOL, V5, P74; Fuchs S, 2002, AM J PATHOL, V161, P717, DOI 10.1016/S0002-9440(10)64227-7; GUIGON M, 1990, EXP HEMATOL, V18, P1112; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; Jackson JD, 1996, EXP HEMATOL, V24, P475; Jackson JD, 2000, J HEMATOTH STEM CELL, V9, P489, DOI 10.1089/152581600419152; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; LACHURIE ML, 1995, CIRCULATION, V91, P2933, DOI 10.1161/01.CIR.91.12.2933; LENFANT M, 1989, P NATL ACAD SCI USA, V86, P779, DOI 10.1073/pnas.86.3.779; Liu JM, 2003, BLOOD, V101, P3014, DOI 10.1182/blood-2002-07-2315; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; Nandurkar HH, 1997, BLOOD, V90, P2148; Papaioannou Virginia, 1993, V126, P107; PRADELLES P, 1990, BIOCHEM BIOPH RES CO, V170, P986, DOI 10.1016/0006-291X(90)90489-A; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; RIORDAN JF, 1991, BIOMED BIOCHIM ACTA, V50, P809; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002	38	81	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15946	15953		10.1074/jbc.M400149200	http://dx.doi.org/10.1074/jbc.M400149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757757	hybrid			2022-12-27	WOS:000220747900031
J	Kumaraswami, M; Howe, MM; Park, HW				Kumaraswami, M; Howe, MM; Park, HW			Crystal structure of the mor protein of bacteriophage Mu, a member of the Mor/C family of transcription activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; COLI RNA-POLYMERASE; TARGET SITE; DNA-BINDING; C-PROTEIN; P-M; REPRESSOR; PROMOTER; OPERATOR; ALIGNMENT	Transcription from the middle promoter, P-m, of bacteriophage Mu requires the phage-encoded activator protein Mor and bacterial RNA polymerase. Mor is a sequence-specific DNA-binding protein that mediates transcription activation through its interactions with the C-terminal domains of the alpha and sigma subunits of bacterial RNA polymerase. Here we present the first structure for a member of the Mor/C family of transcription activators, the crystal structure of Mor to 2.2-Angstrom resolution. Each monomer of the Mor dimer is composed of two domains, the N-terminal dimerization domain and C-terminal DNA-binding domain, which are connected by a linker containing a beta strand. The N-terminal dimerization domain has an unusual mode of dimerization; helices alpha1 and alpha2 of both monomers are intertwined to form a four-helix bundle, generating a hydrophobic core that is further stabilized by antiparallel interactions between the two beta strands. Mutational analysis of key leucine residues in helix alpha1 demonstrated a role for this hydrophobic core in protein solubility and function. The C-terminal domain has a classical helix-turn-helix DNA-binding motif that is located at opposite ends of the elongated dimer. Since the distance between the two helix-turn-helix motifs is too great to allow binding to two adjacent major grooves of the 16-bp Mor-binding site, we propose that conformational changes in the protein and DNA will be required for Mor to interact with the DNA. The highly conserved glycines flanking the beta strand may act as pivot points, facilitating the conformational changes of Mor, and the DNA may be bent.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Park, HW (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	hee-won.park@stjude.org			NCI NIH HHS [CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Artsimovitch I, 1996, J BIOL CHEM, V271, P32343, DOI 10.1074/jbc.271.50.32343; Artsimovitch I, 1996, P NATL ACAD SCI USA, V93, P9408, DOI 10.1073/pnas.93.18.9408; Artsimovitch I, 1996, NUCLEIC ACIDS RES, V24, P450, DOI 10.1093/nar/24.3.450; ARTSIMOVITCH I, 1996, ACTIVATION MIDDLE TR; Bell CE, 2001, J MOL BIOL, V312, P921, DOI 10.1006/jmbi.2001.5024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Casjens S, 2003, MOL MICROBIOL, V49, P277, DOI 10.1046/j.1365-2958.2003.03580.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Duchaud E, 2003, NAT BIOTECHNOL, V21, P1307, DOI 10.1038/nbt886; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Heidelberg JF, 2002, NAT BIOTECHNOL, V20, P1118, DOI 10.1038/nbt749; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hochschild A, 1998, CELL, V92, P597, DOI 10.1016/S0092-8674(00)81126-5; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; HOWE MM, 1973, VIROLOGY, V54, P93, DOI 10.1016/0042-6822(73)90118-9; HOWE MM, 1997, MOL MICROBIOL, P65; JIANG Y, 1999, THESIS U TENNESSEE M; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KahmeyerGabbe M, 1996, J BACTERIOL, V178, P1585, DOI 10.1128/jb.178.6.1585-1592.1996; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 1997, MICROBIOL-UK, V143, P705, DOI 10.1099/00221287-143-3-705; Luscombe NM, 2000, GENOME BIOL, V1; MARGOLIN W, 1990, J BACTERIOL, V172, P1424, DOI 10.1128/jb.172.3.1424-1429.1990; MARGOLIN W, 1989, J BACTERIOL, V171, P2003, DOI 10.1128/jb.171.4.2003-2018.1989; Maris AE, 2002, NAT STRUCT BIOL, V9, P771, DOI 10.1038/nsb845; MARRS CF, 1990, VIROLOGY, V174, P192, DOI 10.1016/0042-6822(90)90068-3; MATHEE K, 1990, J BACTERIOL, V172, P6641, DOI 10.1128/jb.172.12.6641-6650.1990; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; McPherson A., 1989, PREPARATION ANAL PRO; Miller J. H, 1972, EXPT MOL GENETICS; Morgan GJ, 2002, J MOL BIOL, V317, P337, DOI 10.1006/jmbi.2002.5437; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkhill J, 2001, NATURE, V413, P848, DOI 10.1038/35101607; Paul BD, 2003, PROTEINS, V52, P272, DOI 10.1002/prot.10413; POUDEROYEN VG, 1997, EMBO J, V16, P6044; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.ge.19.120185.002035; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sun WY, 1997, J MOL BIOL, V273, P765, DOI 10.1006/jmbi.1997.1349; Symonds N., 1987, PHAGE MU; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P501, DOI 10.1107/S0907444998012657; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VASCONCELOS ATR, 2003, P NATL ACAD SCI USA, V100, P11660, DOI 10.1073/pnas.1832124100; WILSON CM, 1983, METHOD ENZYMOL, V91, P236; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; ZHANG H, 1994, J MOL BIOL, V238, P592, DOI 10.1006/jmbi.1994.1317; ZHAO Z, 1999, THESIS U TENNESSEE M	62	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16581	16590		10.1074/jbc.M313555200	http://dx.doi.org/10.1074/jbc.M313555200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14729670	hybrid			2022-12-27	WOS:000220747900108
J	Massiello, A; Salas, A; Pinkerman, RL; Roddy, P; Roesser, JR; Chalfant, CE				Massiello, A; Salas, A; Pinkerman, RL; Roddy, P; Roesser, JR; Chalfant, CE			Identification of two RNA cis-elements that function to regulate the 5 ' splice site selection of Bcl-x pre-mRNA in response to ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR PROTEINS; CELL-DIFFERENTIATION; SPHINGOMYELIN TURNOVER; PHOSPHATASE-1; DEPENDENCE; EXPRESSION; GENERATION; ACTIVATION; APOPTOSIS; MECHANISM	Two splice variants derived from the BCL-x gene, proapoptotic Bcl-x(s) and anti-apoptotic Bcl-x(L), are produced via alternative 5' splice site selection within exon 2 of Bcl-x pre-mRNA. In previous studies, our laboratory demonstrated that ceramide regulated this 5' splice site selection, inducing the production of Bcl-x(s) mRNA with a concomitant decrease in Bcl-x(L) correlating with sensitization to chemotherapy (Chalfant, C. E., Rathman, K., Pinkerman, R. L., Wood, R. E., Obeid, L. M., Ogretmen, B., and Hannun, Y. A. (2002) J. Biol. Chem. 277, 12587-12595). We have now identified several possible RNA cis-elements within exon 2 of Bcl-x pre-mRNA by sequence analysis. To study the possible roles of these RNA cis-elements in regulating the alternative 5' splice site selection of Bcl-x pre-mRNA, we developed a BCL-x minigene construct which conferred the same ratio of Bcl-x(L)/Bcl-x(s) mRNA as the endogenous Bcl-x and was responsive to ceramide treatment. Mutagenesis of either a purine-rich splicing enhancer or a pyrimidine tract element within exon 2 induced a change in the ratio of Bcl-x(L)/Bcl-x(s) mRNA from 7 to 1 and 0.23, thereby diminishing the selection of the Bcl-x(L) 5' splice site with a concomitant increase in Bcl-x(s) 5' splice site selection. Furthermore, mutagenesis of these cis-elements abolished the ability of ceramide to affect the 5' splice site selection. In vitro binding assays coupled with competitor studies demonstrated specific binding of RNA trans-activating proteins to these regions. SDS-PAGE analysis of cross-linked RNA trans-activating factors with these RNA cis-elements revealed the binding of 215-, 120-, and 30-kDa proteins to the purine-rich element and 120- and 76-kDa proteins to the pyrimidine tract element. In addition, exogenous treatment of A549 cells with ceramide increased the formation of protein complexes with these RNA cis-elements. Therefore, we have identified two ceramide-responsive RNA cis-elements within exon 2 of Bcl-x pre-mRNA, and this is the first report of an RNA cis-element responsive to a bioactive lipid.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA; Massey Canc Ctr, Richmond, VA 23232 USA	Virginia Commonwealth University; Medical University of South Carolina; Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Rm 2-003,Sanger Hall,1101 E Marshall St,POB 98061, Richmond, VA 23298 USA.	cechalfant@vcu.edu						BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Eperon IC, 2000, MOL CELL BIOL, V20, P8303, DOI 10.1128/MCB.20.22.8303-8318.2000; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KIM MY, 1991, J BIOL CHEM, V266, P484; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; LIN CH, 1995, RNA, V1, P234; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lopato S, 1996, P NATL ACAD SCI USA, V93, P3074, DOI 10.1073/pnas.93.7.3074; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Shav-Tal Y, 2001, MOL BIOL CELL, V12, P2328, DOI 10.1091/mbc.12.8.2328; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zahler AM, 1999, METH MOL B, V118, P419	40	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15799	15804		10.1074/jbc.M313950200	http://dx.doi.org/10.1074/jbc.M313950200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14734550	hybrid			2022-12-27	WOS:000220747900015
J	Botos, J; Xian, WJ; Smith, DF; Smith, CL				Botos, J; Xian, WJ; Smith, DF; Smith, CL			Progesterone receptor deficient in chromatin binding has an altered cellular state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; TUMOR VIRUS TEMPLATES; C-TERMINAL DOMAIN; GLUCOCORTICOID-RECEPTOR; SUBNUCLEAR TRAFFICKING; ESTROGEN-RECEPTOR; HSP90; TRANSCRIPTION; P23; PHOSPHORYLATION	Our previous work has shown that the progesterone receptor (PR) can exist in two distinct functional states in mammary adenocarcinoma cells. The differences in function included the ability to activate a promoter in organized chromatin, sensitivity to ligand, and ligand-independent activation. To determine whether these functional differences were because of altered cellular processing, we carried out biochemical analyses of the functionally distinct PRs. Although the majority of PR is localized to the nucleus, biochemical partitioning resulted in a loosely bound (cytosolic) fraction, and a tightly bound (nuclear) fraction. In the absence of progestins, the functionally distinct PRs differed significantly in partitioning between the two fractions. To characterize these fractions further, we analyzed interactions of unliganded PR with chaperones by coimmunoprecipitation. We determined that PR in the cytosolic fraction associated with hsp90 and p23. In contrast, PR in the nuclear fraction consisted of complexes containing hsp90, p23, and FKBP51 as well as PR that was dimerized and highly phosphorylated. Hormone treatment significantly reduced the formation of all PR-chaperone complexes. The hsp90 inhibitor, geldanamycin, similarly blocked transcriptional activity of both functionally distinct receptors. However, the two forms of the PR differed in their ability to associate with the mouse mammary tumor virus promoter in organized chromatin. These findings provide new information about the composition and distribution of mature progesterone receptor complexes in mammary adenocarcinoma cells, and suggest that differences in receptor subcellular distribution have a significant impact on their function. These findings also reveal that transiently expressed steroid receptors may not always be processed like their endogenous counterparts.	NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Mayo Clin, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Mayo Clinic Phoenix	Smith, CL (corresponding author), NCI, Lab Receptor Biol & Gene Express, NIH, 41 Lib Dr, Bethesda, MD 20892 USA.	smithcat@exchange.nih.gov		Botos, Jennifer/0000-0002-6961-8808	NATIONAL CANCER INSTITUTE [Z01BC010279] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; Gorski J, 1968, Recent Prog Horm Res, V24, P45; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; Hubler TR, 2003, ENDOCRINOLOGY, V144, P2380, DOI 10.1210/en.2003-0092; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Leonhardt SA, 1998, MOL ENDOCRINOL, V12, P1914, DOI 10.1210/me.12.12.1914; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; LOGEAT F, 1985, BIOCHEMISTRY-US, V24, P1029, DOI 10.1021/bi00325a034; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Muller WG, 2001, J CELL BIOL, V154, P33, DOI 10.1083/jcb.200011069; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RENOIR JM, 1990, J BIOL CHEM, V265, P14402; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Smith DF, 2000, SEMIN CELL DEV BIOL, V11, P45, DOI 10.1006/scdb.1999.0350; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Wilson MA, 2002, J BIOL CHEM, V277, P15171, DOI 10.1074/jbc.M200349200; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523	51	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15231	15239		10.1074/jbc.M309718200	http://dx.doi.org/10.1074/jbc.M309718200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744870	hybrid			2022-12-27	WOS:000220594700090
J	Cornelie, S; Hoebeke, J; Schacht, AM; Bertin, B; Vicogne, J; Capron, M; Riveau, G				Cornelie, S; Hoebeke, J; Schacht, AM; Bertin, B; Vicogne, J; Capron, M; Riveau, G			Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CPG-DNA; INNATE IMMUNE-RESPONSE; CELL WALL COMPONENTS; IMMUNOSTIMULATORY DNA; SIGNALING PATHWAYS; DENDRITIC CELLS; CUTTING EDGE; ACTIVATION; IDENTIFICATION; FAMILY	Cytosine-phosphate-guanine (CpG) motifs in bacterial DNA are known to activate the mammalian immune system, and this activation is thought to depend on the Toll-like receptor 9 (TLR9) signaling pathway. Previous studies strongly suggested that TLR9 is involved as the specific receptor for CpG motifs but did not provide direct evidence of their interaction. In this study, we demonstrate for the first time that murine TLR9 binds an unmethylated CpG-containing plasmid. This interaction is sequence-specific and is influenced by the methylation status of the plasmid. Furthermore, we demonstrate that this interaction leads to the activation of the NF-kappaB pathway in mTLR9-expressing cells. Our results provide a molecular basis for the interaction between CpG-DNA and TLR9.	Inst Pasteur, INSERM, U547, F-59019 Lille, France; Inst Biol Mol & Cellulaire, CNRS, Unite Propre Rech 9021, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Riveau, G (corresponding author), Inst Pasteur, INSERM, U547, 1 Rue Prof Calmette,BP 245, F-59019 Lille, France.	gilles.riveau@pasteur-lille.fr	; Bertin, Benjamin/M-8300-2016	cornelie, sylvie/0000-0003-3662-1450; Bertin, Benjamin/0000-0002-9160-3717; Vicogne, Jerome/0000-0001-8360-7497				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Bandholtz L, 2003, CELL MOL LIFE SCI, V60, P422, DOI 10.1007/s000180300035; Bauer S, 2002, CURR TOP MICROBIOL, V270, P145; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Beutler B, 2002, CURR OPIN HEMATOL, V9, P2, DOI 10.1097/00062752-200201000-00002; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; CARDON LR, 1994, P NATL ACAD SCI USA, V91, P3799, DOI 10.1073/pnas.91.9.3799; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Daun JM, 2000, J INTERF CYTOK RES, V20, P843, DOI 10.1089/10799900050163217; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, GENE THER, V6, P893, DOI 10.1038/sj.gt.3300880; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jakob T, 1998, J IMMUNOL, V161, P3042; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Krieg AM, 2000, CURR TOP MICROBIOL, V247, P1; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; MESSINA JP, 1991, J IMMUNOL, V147, P1759; Mizel SB, 2003, J BIOL CHEM, V278, P23624, DOI 10.1074/jbc.M303481200; Muzio M, 2000, EUR CYTOKINE NETW, V11, P489; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Pisetsky DS, 2000, SPRINGER SEMIN IMMUN, V22, P21, DOI 10.1007/s002810000021; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schnare M, 2000, CURR BIOL, V10, P1139, DOI 10.1016/S0960-9822(00)00700-4; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Stacey KJ, 1996, J IMMUNOL, V157, P2116; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Ulevitch RJ, 1999, NATURE, V401, P755, DOI 10.1038/44490; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Verthelyi D, 2003, TRENDS IMMUNOL, V24, P519, DOI 10.1016/S1471-4906(03)00243-6; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Yamamoto S, 2000, CURR TOP MICROBIOL, V247, P23; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yi AK, 1998, J IMMUNOL, V160, P1240; Yi AK, 1998, J IMMUNOL, V160, P4755; Yoshimura A, 1999, J IMMUNOL, V163, P1	52	90	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15124	15129		10.1074/jbc.M313406200	http://dx.doi.org/10.1074/jbc.M313406200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736866	hybrid			2022-12-27	WOS:000220594700078
J	Goel, A; Janknecht, R				Goel, A; Janknecht, R			Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ER81; HUMAN BREAST-CANCER; UP-REGULATION; HISTONE ACETYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; PEA3 SUBFAMILY; FACTOR FAMILY; C-JUN	Activator of thyroid and retinoic acid receptor (ACTR) is overexpressed in similar to60% of primary human breast tumors and belongs to the p160 steroid receptor coactivator family. In this study, we identified a novel interaction partner of ACTR, the ETS transcription factor ER81 that is also heavily implicated in mammary tumor formation. ACTR and related p160 family members (steroid receptor coactivator-1 and glucocorticoid receptor-interacting protein-1 (GRIP-1)) augment ER81-mediated transcription. Although ACTR and GRIP-1 can acetylate ER81, this posttranslational modification of ER81 is not required for its stimulation by ACTR or GRIP-1. In addition, ACTR collaborates with the p300 coactivator, a joint interaction partner of ACTR and ER81, to stimulate ER81 function and the ability of p300 to acetylate ER81 is indispensable for this collaboration. Furthermore, the receptor tyrosine kinase HER2/Neu, an oncoprotein particularly found overexpressed in breast tumors, cooperates with both ACTR and p300 to stimulate ER81-mediated transcription. Thus, oncogenic HER2/Neu and ACTR may synergize to orchestrate mammary tumorigenesis through the dysregulation of the transcription factor ER81 and its target genes.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Guggenheim Bldg 1501A,200 1st St SW, Rochester, MN 55905 USA.	janknecht.ralf@mayo.edu		Janknecht, Ralf/0000-0003-1741-1562	NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER; NCI NIH HHS [CA085257, R01 CA085257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bosc DG, 2002, J CELL BIOCHEM, V86, P174, DOI 10.1002/jcb.10205; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Bouras T, 2001, CANCER RES, V61, P903; Chan HM, 2001, J CELL SCI, V114, P2363; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen Q, 2002, J BIOL CHEM, V277, P24081, DOI 10.1074/jbc.M201821200; Chen SL, 2000, GENE DEV, V14, P1209; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; De Haro L, 2002, NUCLEIC ACIDS RES, V30, P2972; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Fuchs B, 2003, FEBS LETT, V553, P104, DOI 10.1016/S0014-5793(03)00984-0; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Glass CK, 2000, GENE DEV, V14, P121; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Goueli BS, 2004, MOL CELL BIOL, V24, P25, DOI 10.1128/MCB.24.1.25-35.2004; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Horton John, 2002, Cancer Control, V9, P499; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Janknecht R, 2001, J BIOL CHEM, V276, P41856, DOI 10.1074/jbc.M106630200; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Lee KC, 2003, MOL ENDOCRINOL, V17, P908, DOI 10.1210/me.2002-0308; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Reiter R, 2001, J BIOL CHEM, V276, P39736, DOI 10.1074/jbc.M104744200; Sakakura C, 2000, INT J CANCER, V89, P217; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Xu Jianming, 2002, Rev Endocr Metab Disord, V3, P185, DOI 10.1023/A:1020016208071; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yuan YH, 2002, CIRCULATION, V105, P2653, DOI 10.1161/01.CIR.0000018947.95555.65	65	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14909	14916		10.1074/jbc.M400036200	http://dx.doi.org/10.1074/jbc.M400036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747462	hybrid			2022-12-27	WOS:000220594700052
J	Kalivendi, SV; Cunningham, S; Kotamraju, S; Joseph, J; Hillard, CJ; Kalyanaraman, B				Kalivendi, SV; Cunningham, S; Kotamraju, S; Joseph, J; Hillard, CJ; Kalyanaraman, B			alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells - Intermediacy of transferrin receptor iron and hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MITOCHONDRIAL COMPLEX-I; PARKINSONS-DISEASE; DEPENDENT IRON; LEWY BODIES; EXPRESSION; BRAIN; PROTEASOME; ALZHEIMERS; MODEL	1-Methyl-4-phenylpyridinium (MPP+) is a neurotoxin that causes Parkinson's disease in experimental animals and humans. Despite the fact that intracellular iron was shown to be crucial for MPP+-induced apoptotic cell death, the molecular mechanisms for the iron requirement remain unclear. We investigated the role of transferrin receptor (TfR) and iron in modulating the expression of alpha-synuclein (alpha-syn) in MPP+-induced oxidative stress and apoptosis. Results show that MPP+ inhibits mitochondrial complex-1 and aconitase activities leading to enhanced H2O2 generation, TfR expression and alpha-syn expression/aggregation. Pretreatment with cell-permeable iron chelators, TfR antibody (that inhibits TfR-mediated iron uptake), or transfection with glutathione peroxidase (GPx1) enzyme inhibits intracellular oxidant generation, alpha-syn expression/aggregation, and apoptotic signaling as measured by caspase-3 activation. Cells overexpressing alpha-syn exacerbated MPP+ toxicity, whereas antisense alpha-syn treatment totally abrogated MPP+-induced apoptosis in neuroblastoma cells without affecting oxidant generation. The increased cytotoxic effects of alpha-syn in MPP+-treated cells were attributed to inhibition of mitogen-activated protein kinase and proteasomal function. We conclude that MPP+-induced iron signaling is responsible for intracellular oxidant generation, alpha-syn expression, proteasomal dysfunction, and apoptosis. Relevance to Parkinson's disease is discussed.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Radical Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu	Hillard, Cecilia J/O-6693-2018		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039958] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39958, R01 NS039958] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; BATES TE, 1994, J NEUROCHEM, V63, P640; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Berg D, 2002, NEUROTOX RES, V4, P637, DOI 10.1080/1029842021000045444; Berg D, 2001, J NEUROCHEM, V79, P225, DOI 10.1046/j.1471-4159.2001.00608.x; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; FAHAN S, 2000, MERRITTS NEUROLOGY, P679; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; Hashimoto M, 2003, NEUROMOL MED, V4, P21, DOI 10.1385/NMM:4:1-2:21; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Kakimura J, 2001, EUR J PHARMACOL, V417, P59, DOI 10.1016/S0014-2999(01)00902-5; Kalivendi SV, 2003, BIOCHEM J, V371, P151, DOI 10.1042/BJ20021525; Kalyanaraman B, 2002, MOL CELL BIOCHEM, V234, P119, DOI 10.1023/A:1015976430790; Kaur D, 2002, AGING CELL, V1, P17, DOI 10.1046/j.1474-9728.2002.00001.x; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; Ke Y, 2003, LANCET NEUROL, V2, P246, DOI 10.1016/S1474-4422(03)00353-3; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Schmidt N, 2001, J NEURAL TRANSM, V108, P1263, DOI 10.1007/s007020100004; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sherer TB, 2002, J NEUROSCI, V22, P7006; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Tampo Y, 2003, CIRC RES, V92, P56, DOI 10.1161/01.RES.0000048195.15637.AC; Tanimoto Y, 2002, J BIOCHEM, V131, P319, DOI 10.1093/oxfordjournals.jbchem.a003106; Tong XJ, 2002, BRIT J HAEMATOL, V116, P458, DOI 10.1046/j.0007-1048.2001.03289.x; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yen HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P59, DOI 10.1006/abbi.1998.1011; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	48	104	113	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15240	15247		10.1074/jbc.M312497200	http://dx.doi.org/10.1074/jbc.M312497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742448	hybrid			2022-12-27	WOS:000220594700091
J	Majumder, S; Varadharaj, S; Ghoshal, K; Monani, U; Burghes, AHM; Jacob, ST				Majumder, S; Varadharaj, S; Ghoshal, K; Monani, U; Burghes, AHM; Jacob, ST			RETRACTED: Identification of a novel cyclic AMP-response element (CRE-II) and the role of CREB-1 in the cAMP-induced expression of the survival motor neuron (SMN) gene (Retracted article. See vol. 293, pg. 12946, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							SPINAL MUSCULAR-ATROPHY; TRANSCRIPTION FACTOR; MESSENGER-RNA; SPLICING ENHANCER; SINGLE NUCLEOTIDE; SOMATOSTATIN GENE; COPY NUMBER; IN-VIVO; PROTEIN; MOUSE	Spinal muscular atrophy, an autosomal recessive disorder, is caused by loss of the SMN1 (survival motor neuron) gene while retaining the SMN2 gene. SMN1 produces a majority of full-length SMN transcript, whereas SMN2 generates mostly an isoform lacking exon 7. Here, we demonstrate a novel cAMP-response element, CRE-II, in the SMN promoter that interacts with the cAMP-response element-binding (CREB) family of proteins. In vitro DNase I protection analysis and in vivo genomic foot-printing of the SMN promoter using the brain and liver nuclei from SMN2 transgenic mice revealed footprinting at the CRE-II site. Site-directed mutation of the CRE-II element caused a marked reduction in the SMN promoter activity revealed by transient transfection assay. Activation of the cAMP pathway by dibutyryl cAMP (0.5 mM) alone or in combination with forskolin (20 muM) caused a 2-5-fold increase in the SMN promoter activity but had no effect on the CRE-II mutated promoter. Electrophoretic mobility shift assay and a UV-induced DNA-protein cross-linking experiment confirmed that CREB1 binds specifically to the CRE-II site. Transient overexpression of CREB1 protein resulted in a 4-fold increase of the SMN promoter activity. Intraperitoneal injection of epinephrine in mice expressing two copies of the human SMN2 gene resulted in a 2-fold increase in full-length SMN transcript in the liver. Combined treatment with dibutyryl cAMP and forskolin significantly increased the level of both the full-length and exon 7-deleted SMN (exonDelta7SMN) transcript in primary hepatocytes from mice expressing two copies of human SMN2 gene. Similar treatments of type I spinal muscular atrophy mouse and human fibroblasts as well as HeLa cells resulted in an augmented level of SMN transcript. These findings suggest that the CRE-II site in SMN promoter positively regulates the expression of the SMN gene, and treatment with cAMP-elevating agents increases expression of both the full-length and exonDelta7SMN transcript.	Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Neurol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	jacob.42@osu.edu	Jacob, Samson/H-3135-2011	Burghes, Arthur/0000-0001-9031-1555	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041649] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS041649, NS 41649] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Andreassi C, 2001, HUM MOL GENET, V10, P2841, DOI 10.1093/hmg/10.24.2841; Andreassi C, 2002, NEUROGENETICS, V4, P29, DOI 10.1007/s10048-001-0128-y; Baron-Delage S, 2000, MOL MED, V6, P957, DOI 10.1007/BF03401830; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Chang JG, 2001, P NATL ACAD SCI USA, V98, P9808, DOI 10.1073/pnas.171105098; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Echaniz-Laguna A, 2002, J NEUROL, V249, P290, DOI 10.1007/s004150200007; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Germain-Desprez D, 2001, GENE, V279, P109, DOI 10.1016/S0378-1119(01)00758-2; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; Le TT, 2000, NEUROGENETICS, V3, P7, DOI 10.1007/s100480000090; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEVITZKI A, 1988, SCIENCE, V241, P800, DOI 10.1126/science.2841758; Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LIU ZJ, 1994, J BIOL CHEM, V269, P16618; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Majumder S, 2001, GENE EXPRESSION, V9, P203, DOI 10.3727/000000001783992588; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465; Monani UR, 2000, HUM MOL GENET, V9, P2451, DOI 10.1093/hmg/9.16.2451; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333; Monani UR, 1999, BBA-GENE STRUCT EXPR, V1445, P330, DOI 10.1016/S0167-4781(99)00060-3; Monti B, 2002, EUR J NEUROSCI, V16, P1490, DOI 10.1046/j.1460-9568.2002.02232.x; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUNSAT TL, 1992, NEUROMUSCULAR DISORD, V2, P423, DOI 10.1016/S0960-8966(06)80015-5; NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101; Parsons DW, 1996, HUM MOL GENET, V5, P1727, DOI 10.1093/hmg/5.11.1727; Parsons DW, 1998, AM J HUM GENET, V63, P1712, DOI 10.1086/302160; PEARN J, 1978, J MED GENET, V15, P414, DOI 10.1136/jmg.15.6.414; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; Rossoll W, 2002, HUM MOL GENET, V11, P93, DOI 10.1093/hmg/11.1.93; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; Sambrook J, 1989, MOL CLONING LAB MANU, V2; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Skordis LA, 2003, P NATL ACAD SCI USA, V100, P4114, DOI 10.1073/pnas.0633863100; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Wirth B, 1999, AM J HUM GENET, V64, P1340, DOI 10.1086/302369; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858; Zhang ML, 2001, GENE THER, V8, P1532, DOI 10.1038/sj.gt.3301550	66	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14803	14811		10.1074/jbc.M308225200	http://dx.doi.org/10.1074/jbc.M308225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742439	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000220594700040
J	Sik, A; Passer, BJ; Koonin, EV; Pellegrini, L				Sik, A; Passer, BJ; Koonin, EV; Pellegrini, L			Self-regulated cleavage of the mitochondrial intramembrane-cleaving protease PARL yields P beta, a nuclear-targeted peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; ESTABLISHMENT; MECHANISM; APOPTOSIS; NEURONS; PATHWAY; COMPLEX; FAMILY; AXIS; OPA1	Regulated intramembrane proteolysis (RIP) is an emerging paradigm in signal transduction. RIP is mediated by intramembrane-cleaving proteases (I-CliPs), which liberate biologically active nuclear or secreted domains from their membrane-tethered precursor proteins. The yeast Pcp1p/Rbd1p protein is a Rhomboid-like I-CliP that regulates mitochondrial membrane remodeling and fusion through cleavage of Mgm1p, a regulator of these essential activities. Although this ancient function is conserved in PARL ((P) under bar resenilins-(a) under bar ssociated (R) double under bar homboid-(l) under bar ike protein), the mammalian ortholog of Pcp1p/Rbd1p, the two proteins show a strong divergence at their N termini. However, the N terminus of PARL is significantly conserved among vertebrates, particularly among mammals, suggesting that this domain evolved a distinct but still unknown function. Here, we show that the cytosolic N-terminal domain of PARL is cleaved at positions 52-53(alpha-site) and 77-78 (beta-site). Whereas alpha-cleavage is constitutive and removes the mitochondrial targeting sequence, beta-cleavage appears to be developmentally controlled and dependent on PARL I-CliP activity supplied in trans. The beta-cleavage of PARL liberates Pbeta, a nuclear targeted peptide whose sequence is conserved only in mammals. Thus, in addition to its evolutionarily conserved function in regulating mitochondrial dynamics, PARL might mediate a mammalian-specific, developmentally regulated mitochondria-to-nuclei signaling through regulated proteolysis of its N terminus and release of the Pbeta peptide.	Univ Laval, Ctr Rech Robert Giffard, Quebec City, PQ G1J 2G3, Canada; Univ Laval, Dept Psychiat, Quebec City, PQ G1J 2G3, Canada; Mol Engines Labs, F-75011 Paris, France; Natl Lib Med, NCBI, NIH, Bethesda, MD 20894 USA	Laval University; Laval University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Pellegrini, L (corresponding author), CRULRG, Mol Neurobiol Lab, 2601 Chemin Canardiere, Quebec City, PQ G1J 2G3, Canada.	Luca.Pellegrini@crulrg.ulaval.ca		Pellegrini, Luca/0000-0002-4235-7708	NATIONAL LIBRARY OF MEDICINE [Z01LM000061, ZIALM000061] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeKoninck P, 1995, J NEUROSCI, V15, P7966; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; Gay F, 2003, GENE DEV, V17, P717, DOI 10.1101/gad.1042403; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Jeffery CJ, 2003, ANN MED, V35, P28, DOI 10.1080/07853890310004101; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Koonin EV, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r19; Koonin EV, 2002, NATURE, V420, P218, DOI 10.1038/nature01256; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Moliaka YK, 2004, FEBS LETT, V557, P185, DOI 10.1016/S0014-5793(03)01489-3; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Pellegrini L, 2001, J ALZHEIMERS DIS, V3, P181; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; Rakic P, 2002, PROG BRAIN RES, V138, P3, DOI 10.1016/S0079-6123(02)38067-1; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Re RN, 2002, REGUL PEPTIDES, V106, P1, DOI 10.1016/S0167-0115(02)00031-9; Rossi V, 1997, J BIOL CHEM, V272, P13758, DOI 10.1074/jbc.272.21.13758; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Sik A, 1998, P NATL ACAD SCI USA, V95, P3245, DOI 10.1073/pnas.95.6.3245; Tandon A, 2002, GENOME BIOL, V3; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6	33	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15323	15329		10.1074/jbc.M313756200	http://dx.doi.org/10.1074/jbc.M313756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732705	hybrid			2022-12-27	WOS:000220594700101
J	Biesiadecki, BJ; Schneider, KL; Bin Yu, Z; Chong, SM; Jin, JP				Biesiadecki, BJ; Schneider, KL; Bin Yu, Z; Chong, SM; Jin, JP			An R111C polymorphism in wild turkey cardiac troponin I accompanying the dilated cardiomyopathy-related abnormal splicing variant of cardiac troponin T with potentially compensatory effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDNA-CLONE; DEVELOPMENTAL EXPRESSION; MUSCLE; PROTEINS; ISOFORMS; HEART; EVOLUTION; REGION; RNA	Cardiac muscle contraction is regulated by Ca2+ through the troponin complex consisting of three subunits: troponin C (TnC), troponin T (TnT), and troponin I (TnI). We reported previously that the abnormal splicing of cardiac TnT in turkeys with dilated cardiomyopathy resulted in a greater binding affinity to TnI. In the present study, we characterized a polymorphism of cardiac TnI in the heart of wild turkeys. cDNA cloning and sequencing of the novel turkey cardiac TnI revealed a single amino acid substitution, R111C. Arg(111) in avian cardiac TnI corresponds to a Lys in mammals. This residue is conserved in cardiac and skeletal muscle TnIs across the vertebrate phylum, implying a functional importance. In the partial crystal structure of cardiac troponin, this amino acid resides in an alpha-helix that directly contacts with TnT. Structural modeling indicates that the substitution of Cys for Arg or Lys at this position would not disrupt the global structure of troponin. To evaluate the functional significance of the different size and charge between the Arg and Cys side chains, protein-binding assays using purified turkey cardiac TnI expressed in Escherichia coli were performed. The results show that the R111C substitution lowered binding affinity to TnT, which is potentially compensatory to the increased TnI-binding affinity of the cardiomyopathy-related cardiac TnT splicing variant. Therefore, the fixation of the cardiac TnI Cys(111) allele in the wild turkey population and the corresponding functional effect reflect an increased fitness value, suggesting a novel target for the treatment of TnT myopathies.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	jxj12@po.cwru.edu		Jin, JP/0000-0001-9932-1063	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048816] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 048816] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARMOUR KL, 1993, GENE, V131, P287, DOI 10.1016/0378-1119(93)90308-P; AUSONI S, 1994, J BIOL CHEM, V269, P339; Biesiadecki BJ, 2002, J BIOL CHEM, V277, P50275, DOI 10.1074/jbc.M206369200; Biesiadecki BJ, 2002, J BIOL CHEM, V277, P18459, DOI 10.1074/jbc.M200788200; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; Hodgson PA, 1996, BBA-GENE STRUCT EXPR, V1306, P142, DOI 10.1016/0167-4781(96)00033-4; Huang QQ, 1999, J MOL EVOL, V49, P780, DOI 10.1007/PL00006600; HUNSAKER WG, 1971, POULTRY SCI, V50, P1720, DOI 10.3382/ps.0501720; Jackman DM, 1998, BBA-PROTEIN STRUCT M, V1387, P478, DOI 10.1016/S0167-4838(98)00165-4; Jin JP, 2001, J MOL EVOL, V52, P103, DOI 10.1007/s002390010139; Jin JP, 2001, BIOCHEMISTRY-US, V40, P2623, DOI 10.1021/bi002423j; Jin JP, 1996, GENE, V168, P217, DOI 10.1016/0378-1119(95)00803-9; Jin JP, 1996, BIOCHEM BIOPH RES CO, V225, P883, DOI 10.1006/bbrc.1996.1267; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; MARTIN AF, 1991, J MOL CELL CARDIOL, V23, P583, DOI 10.1016/0022-2828(91)90050-V; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Stanley SE, 1999, MOL BIOL EVOL, V16, P1575, DOI 10.1093/oxfordjournals.molbev.a026070; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; WU QL, 1993, DNA SEQUENCE, V4, P113, DOI 10.3109/10425179309020150; Yu ZB, 2001, J BIOL CHEM, V276, P15753, DOI 10.1074/jbc.M011048200; [No title captured]	35	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13825	13832		10.1074/jbc.M314225200	http://dx.doi.org/10.1074/jbc.M314225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736877	hybrid			2022-12-27	WOS:000220478500068
J	Cao, J; Kozarekar, P; Pavlaki, M; Chiarelli, C; Bahou, WF; Zucker, S				Cao, J; Kozarekar, P; Pavlaki, M; Chiarelli, C; Bahou, WF; Zucker, S			Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; PRO-GELATINASE; PERICELLULAR PROTEOLYSIS; PROPEPTIDE DOMAIN; PROGELATINASE-A; TUMOR INVASION; RHO GTPASES; ACTIVATION	Substrate degradation and cell migration are key steps in cancer metastasis. Membrane-type 1-matrix metalloproteinase (MT1-MMP) has been linked with these processes. Using the fluorescein isothiocyanate (FITC)-labeled fibronectin degradation assay combined with the phagokinetic cell migration assay, structure-function relationships of MT1-MMP were studied. Our data indicate that MT1-MMP initiates substrate degradation and enhances cell migration; cell migration occurs as a concurrent but independent event. Using recombinant DNA approaches, we demonstrated that the hemopexin-like domain and a nonenzymatic component of the catalytic domain of MT1-MMP are essential for MT1-MMP-mediated cell migration. Because the cytoplasmic domain of MT1-MMP was not required for MT1-MMP-mediated fibronectin degradation and cell migration, it is proposed that cross-talk between the hemopexin domain of MT1-MMP and adjacent cell surface molecules is responsible for outside-in signaling. Employing cDNAs encoding dominant negative mutations, we demonstrated that Rac1 participates in the MT1-MMP signal transduction pathway. These data demonstrated that each domain of MT1-MMP plays a distinct role in substrate degradation and cell migration.	Vet Affairs Med Ctr, Dept Res, Northport, NY 11768 USA; SUNY Stony Brook, Sch Med, Dept Med, Stony Brook, NY 11794 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zucker, S (corresponding author), Vet Affairs Med Ctr, Dept Res, Mail Code 151, Northport, NY 11768 USA.	s_zucker@yahoo.com			NHLBI NIH HHS [HL49141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049141] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Chen Wen-Tien, 1994, Journal of Tissue Culture Methods, V16, P177, DOI 10.1007/BF01540646; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P95; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Murphy G, 2000, FIBRINOLYSIS PROTEOL, V14, P165, DOI 10.1054/fipr.2000.0068; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Pavlaki M, 2002, J BIOL CHEM, V277, P2740, DOI 10.1074/jbc.M108987200; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Silletti S, 1998, INT J CANCER, V76, P129, DOI 10.1002/(SICI)1097-0215(19980330)76:1<129::AID-IJC20>3.0.CO;2-6; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	51	74	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14129	14139		10.1074/jbc.M312120200	http://dx.doi.org/10.1074/jbc.M312120200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729674	hybrid			2022-12-27	WOS:000220478500103
J	Fritsch, RM; Saur, D; Kurjak, M; Oesterle, D; Schlossmann, J; Geiselhoringer, A; Hofmann, F; Allescher, HD				Fritsch, RM; Saur, D; Kurjak, M; Oesterle, D; Schlossmann, J; Geiselhoringer, A; Hofmann, F; Allescher, HD			InsP(3)R-associated cGMP kinase substrate (IRAG) is essential for nitric oxide-induced inhibition of calcium signaling in human colonic smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SOLUBLE GUANYLATE-CYCLASE; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; PHOSPHORYLATION; COMPLEX; CELLS; TRANSDUCTION; VARIANTS	Nitric oxide (NO)-mediated relaxation of colonic smooth muscle is crucial for the maintenance of human gut function. The molecular mechanisms of NO-dependent smooth muscle relaxation involve cyclic GMP-mediated inhibition of store-dependent calcium signaling. Recently, IRAG (inositol 1,4,5-trisphophate receptor-associated cGMP kinase substrate) has been characterized as a novel target molecule of cGMP-dependent protein kinase (cGKI) mediating NO-/cGMP-dependent inhibition of inositol 1,4,5-trisphosphate (InsP(3))-dependent calcium release in transfected COS cells. The aim of the present study was to characterize IRAG expression and its functional role in NO-dependent signaling in human colonic smooth muscle. Reverse transcriptase-PCR revealed IRAG mRNA expression in human colon, rectum, and cultured colonic smooth muscle cells. In cultured human colonic smooth muscle cells, bradykinin (BK) elicited InsP(3)-dependent calcium transients that were repeatable and independent of extracellular calcium. The NO donor sodium nitroprusside and the specific cGK activator 8-(4-chlorophenylthio) guanosine-3', 5'-cyclicmonophosphate (8-pCPT-cGMP) significantly inhibited BK-induced increase in intracellular calcium. Cells transfected with antisense oligonucleotides raised against IRAG (IRAG-AS) showed strongly decreased IRAG protein expression. In these cells, sodium nitroprusside and 8-pCPT-cGMP both failed to modulate BK-induced calcium transients. Thus, endogenous IRAG appears to be essentially involved in the NO/cGK-dependent inhibition of InsP(3)-dependent Ca2+-signaling in colonic smooth muscle.	Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-81675 Munich, Germany	Technical University of Munich; Technical University of Munich	Fritsch, RM (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, Ismaninger Str 22, D-81675 Munich, Germany.	ralph.fritsch@lrz.tum.de	Saur, Dieter/G-4629-2011; Schlossmann, Jens/I-7743-2016; Saur, Dieter/O-8355-2015; Fritsch, Ralph/Q-8836-2019	Schlossmann, Jens/0000-0002-2550-6839; Saur, Dieter/0000-0001-5874-0210; Fritsch, Ralph/0000-0001-9639-3213				Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Bielefeldt K, 1997, AM J PHYSIOL-GASTR L, V272, pG1439, DOI 10.1152/ajpgi.1997.272.6.G1439; BROOKES SJH, 1993, J GASTROEN HEPATOL, V8, P590, DOI 10.1111/j.1440-1746.1993.tb01658.x; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; DANIEL EE, 1994, AM J PHYSIOL, V266, pG31, DOI 10.1152/ajpgi.1994.266.1.G31; Feil R, 2002, CIRC RES, V90, P1080, DOI 10.1161/01.RES.0000019586.95768.40; Fritsch RM, 2001, GASTROENTEROLOGY, V120, pA499; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; Hofmann F, 2000, J CELL SCI, V113, P1671; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG1146, DOI 10.1152/ajpgi.1998.275.5.G1146; HYMAN PE, 1992, GASTROENTEROLOGY, V102, P1597, DOI 10.1016/0016-5085(92)91719-K; Kannan MS, 1997, AM J PHYSIOL-LUNG C, V272, pL1, DOI 10.1152/ajplung.1997.272.1.L1; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Lucas KA, 2000, PHARMACOL REV, V52, P375; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Murr MM, 1999, J SURG RES, V84, P8, DOI 10.1006/jsre.1999.5590; MURTHY KS, 1993, AM J PHYSIOL, V264, pG967, DOI 10.1152/ajpgi.1993.264.5.G967; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Porter AJ, 1997, GASTROENTEROLOGY, V113, P1916, DOI 10.1016/S0016-5085(97)70011-8; RAEYMAEKERS L, 1990, CELL CALCIUM, V11, P261, DOI 10.1016/0143-4160(90)90002-C; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Saur D, 2002, AM J PHYSIOL-GASTR L, V282, pG349, DOI 10.1152/ajpgi.00226.2001; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shuttleworth CWR, 1999, BRIT J PHARMACOL, V127, P1495, DOI 10.1038/sj.bjp.0702674; Shuttleworth CWR, 1996, P SOC EXP BIOL MED, V211, P16, DOI 10.3181/00379727-211-43950C; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STARK ME, 1992, GASTROENTEROLOGY, V103, P1928, DOI 10.1016/0016-5085(92)91454-C; Tao M, 1999, FEBS LETT, V454, P312, DOI 10.1016/S0014-5793(99)00814-5; Tertyshnikova X, 1998, J PHYSIOL-LONDON, V512, P89, DOI 10.1111/j.1469-7793.1998.089bf.x; Tomita R, 2001, J GASTROENTEROL, V36, P386, DOI 10.1007/s005350170082; Wassdal I, 1999, ACTA PHYSIOL SCAND, V165, P259; Zhao YD, 2000, BIOCHEMISTRY-US, V39, P10848, DOI 10.1021/bi9929296; Zholos AV, 2000, J PHYSIOL-LONDON, V528, P521, DOI 10.1111/j.1469-7793.2000.00521.x	42	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12551	12559		10.1074/jbc.M313365200	http://dx.doi.org/10.1074/jbc.M313365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14729908	hybrid			2022-12-27	WOS:000220334900067
J	Sallette, J; Bohler, S; Benoit, P; Soudant, M; Pons, S; Le Novere, N; Changeux, JP; Corringer, PJ				Sallette, J; Bohler, S; Benoit, P; Soudant, M; Pons, S; Le Novere, N; Changeux, JP; Corringer, PJ			An extracellular protein microdomain controls up-regulation of neuronal nicotinic acetylcholine receptors by nicotine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-BINDING; M10 CELLS; RAT-BRAIN; CHRONIC EXPOSURE; BETA-2 SUBUNIT; SITES; DESENSITIZATION; IDENTIFICATION; EXPRESSION; AFFINITY	In smoker's brain, rodent brain, and in cultured cells expressing nicotinic receptors, chronic nicotine treatment induces an increase in the total number of high affinity receptors for acetylcholine and nicotine, a process referred to as up-regulation. Up-regulation induced by 1 mM nicotine reaches 6-fold for alpha3beta2 nicotinic receptors transiently expressed in HEK 293 cells, whereas it is much smaller for alpha3beta4 receptors, offering a rationale to investigate the molecular mechanism underlying upregulation. In this expression system binding sites are mainly intracellular, as shown by [H-3] epibatidine binding experiments and competition with the impermeant ligand carbamylcholine. Systematic analysis of beta2/beta4 chimeras demonstrates the following. (i) The extracellular domain critically contributes to up-regulation. (ii) Only residues belonging to two beta2 segments, 74 - 89 and 106 - 115, confer up-regulation to beta4, mainly by decreasing the amount of binding sites in the absence of nicotine; on an atomic three-dimensional model of the alpha3beta2 receptor these amino acids form a compact microdomain that mainly contributes to the subunit interface and also faces the acetylcholine binding site. (iii) The beta4 microdomain is sufficient to confer to beta2 a beta4-like upregulation. (iv) This microdomain makes an equivalent contribution to the up-regulation differences between alpha4beta2 and alpha4beta4. We propose that nicotine, by binding to immature oligomers, elicits a conformational reorganization of the microdomain, strengthening the interaction between adjacent subunits and, thus, facilitating maturation processes toward high affinity receptors. This mechanism may be central to nicotine addiction, since alpha4beta2 is the subtype exhibiting the highest degree of up-regulation in the brain.	Inst Pasteur, CNRS, UIRA D2182 Recepteurs & Cognit, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Corringer, PJ (corresponding author), Inst Pasteur, CNRS, UIRA D2182 Recepteurs & Cognit, 25 Rue Docteur Roux, F-75724 Paris 15, France.	changeux@pasteur.fr; pjcorrin@pasteur.fr	Le Novère, Nicolas/F-9973-2010	Le Novère, Nicolas/0000-0002-6309-7327				BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BHAT RV, 1991, J NEUROCHEM, V56, P1932, DOI 10.1111/j.1471-4159.1991.tb03450.x; Bohler S, 2001, BIOCHEMISTRY-US, V40, P2066, DOI 10.1021/bi0020022; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Buisson B, 2002, TRENDS PHARMACOL SCI, V23, P130, DOI 10.1016/S0165-6147(00)01979-9; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Chiara DC, 1998, FEBS LETT, V423, P223, DOI 10.1016/S0014-5793(98)00093-3; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; Corringer PJ, 1998, J NEUROSCI, V18, P648; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Fenster CP, 1999, J NEUROSCI, V19, P4804; FLORES CM, 1992, MOL PHARMACOL, V41, P31; Gopalakrishnan M, 1996, J PHARMACOL EXP THER, V276, P289; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; Green WN, 1997, J BIOL CHEM, V272, P20945, DOI 10.1074/jbc.272.33.20945; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harkness PC, 2002, J NEUROSCI, V22, P10172; Hsu YN, 1996, J NEUROCHEM, V66, P667; Ke L, 1998, J PHARMACOL EXP THER, V286, P825; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; Kuryatov A, 2000, EUR J PHARMACOL, V393, P11, DOI 10.1016/S0014-2999(00)00027-3; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8; MARKS MJ, 1992, J NEUROSCI, V12, P2765; Molinari EJ, 1998, EUR J PHARMACOL, V347, P131, DOI 10.1016/S0014-2999(98)00084-3; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nelson ME, 2003, MOL PHARMACOL, V63, P332, DOI 10.1124/mol.63.2.332; Nguyen HN, 2003, J PHARMACOL EXP THER, V307, P1090, DOI 10.1124/jpet.103.056408; Parker MJ, 1998, MOL PHARMACOL, V54, P1132, DOI 10.1124/mol.54.6.1132; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peng X, 1997, MOL PHARMACOL, V51, P776, DOI 10.1124/mol.51.5.776; PENG X, 1994, MOL PHARMACOL, V46, P523; Perry DC, 1999, J PHARMACOL EXP THER, V289, P1545; Peto R, 1999, NAT MED, V5, P15, DOI 10.1038/4691; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Ramanathan VK, 1999, J BIOL CHEM, V274, P20513, DOI 10.1074/jbc.274.29.20513; ROWELL PP, 1990, J NEUROCHEM, V55, P2105, DOI 10.1111/j.1471-4159.1990.tb05802.x; Rowell PP, 1997, J NEUROCHEM, V68, P1982; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Tomizawa M, 2000, TOXICOL APPL PHARM, V169, P114, DOI 10.1006/taap.2000.9057; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; Warpman U, 1998, J NEUROCHEM, V70, P2028; Whiteaker P, 1998, MOL PHARMACOL, V53, P950; ZHANG X, 1995, NEUROREPORT, V6, P313, DOI 10.1097/00001756-199501000-00022	50	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18767	18775		10.1074/jbc.M308260200	http://dx.doi.org/10.1074/jbc.M308260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14764595	hybrid			2022-12-27	WOS:000221041500084
J	Mitsutake, S; Kim, TJ; Inagaki, Y; Kato, M; Yamashita, T; Igarashi, Y				Mitsutake, S; Kim, TJ; Inagaki, Y; Kato, M; Yamashita, T; Igarashi, Y			Ceramide kinase is a mediator of calcium-dependent degranulation in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; TYROSINE PHOSPHORYLATION; HIGH-AFFINITY; SPHINGOSINE 1-PHOSPHATE; MOLECULAR-CLONING; LIPID KINASE; RECEPTOR; SPHINGOSINE-1-PHOSPHATE; CERAMIDE-1-PHOSPHATE; MIGRATION	Ceramide kinase (CERK) catalyzes the conversion of ceramide to ceramide 1-phosphate (C1P) and is known to be activated by calcium. Although several groups have examined the functions of CERK and its product C1P, the functions of C1P and CERK are not understood. We studied the RBL-2H3 cell line, a widely used model for mast cells, and found that CERK and C1P are required for activation of the degranulation process in mast cells. We found that C1P formation was enhanced during activation induced by IgE/antigen or by Ca2+ ionophore A23187. The formation of C1P required the intracellular elevation of Ca2+. We generated RBL-2H3 cells that stably express CERK, and when these cells were treated with A23187, a concomitant C1P formation was observed and degranulation increased 4-fold, compared with mock transfectants. The cell-permeable N-acetylsphingosine (C-2-ceramide), a poor substrate of CERK, inhibited both the formation of C1P and degranulation, indicating that C1P formation was necessary for degranulation. Exogenous introduction of CERK into permeabilized RBL-2H3 cells caused degranulation. We identified a cytosolic localization of CERK that provides exposure to cytosolic Ca2+. Taken together, these results indicate that C1P formation is a necessary step in the degranulation pathway in RBL-2H3 cells.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University; Hokkaido University	Igarashi, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	yigarash@pharm.hokudai.ac.jp	Mitsutake, Susumu/A-4082-2012					Abousalham A, 1997, J BIOL CHEM, V272, P1069, DOI 10.1074/jbc.272.2.1069; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; Blank U, 2002, MOL IMMUNOL, V38, P1341, DOI 10.1016/S0161-5890(02)00085-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUDKER O, 1993, J BIOL CHEM, V268, P22150; Burow ME, 2000, J BIOL CHEM, V275, P9628, DOI 10.1074/jbc.275.13.9628; Choi OH, 1996, NATURE, V380, P634; Choi WS, 2002, ANN NY ACAD SCI, V968, P198, DOI 10.1111/j.1749-6632.2002.tb04336.x; CINQUE B, 2003, PHARM RES, V1132, P1; Cohen JS, 2001, BIOCHEMISTRY-US, V40, P6589, DOI 10.1021/bi0103011; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Gijsbers S, 1999, FEBS LETT, V453, P269, DOI 10.1016/S0014-5793(99)00735-8; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; HOWELL TW, 1987, BIOCHIM BIOPHYS ACTA, V927, P177, DOI 10.1016/0167-4889(87)90132-7; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Kohno T, 2003, GENES CELLS, V8, P685, DOI 10.1046/j.1365-2443.2003.00667.x; KOHNO T, 2002, FASEB J, V13, P893; KUMADA T, 1995, BBA-LIPID LIPID MET, V1258, P107, DOI 10.1016/0005-2760(95)00106-M; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mansfield PJ, 2002, BLOOD, V99, P1434, DOI 10.1182/blood.V99.4.1434; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Min DS, 2000, J NEUROCHEM, V75, P274, DOI 10.1046/j.1471-4159.2000.0750274.x; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; Murakami K, 2000, INT IMMUNOL, V12, P169, DOI 10.1093/intimm/12.2.169; Nakamura Y, 1996, J IMMUNOL, V156, P256; Ohyama A, 2002, J NEUROSCI, V22, P3342; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Rile G, 2003, ACTA HAEMATOL-BASEL, V109, P76, DOI 10.1159/000068491; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wightman RM, 2002, ANN NY ACAD SCI, V971, P620, DOI 10.1111/j.1749-6632.2002.tb04540.x; Yamashita T, 2001, J BIOCHEM-TOKYO, V129, P861, DOI 10.1093/oxfordjournals.jbchem.a002930	42	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17570	17577		10.1074/jbc.M312885200	http://dx.doi.org/10.1074/jbc.M312885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769792	hybrid			2022-12-27	WOS:000220870400085
J	Towler, P; Staker, B; Prasad, SG; Menon, S; Tang, J; Parsons, T; Ryan, D; Fisher, M; Williams, D; Dales, NA; Patane, MA; Pantoliano, MW				Towler, P; Staker, B; Prasad, SG; Menon, S; Tang, J; Parsons, T; Ryan, D; Fisher, M; Williams, D; Dales, NA; Patane, MA; Pantoliano, MW			ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; CRYSTAL-STRUCTURE; ACTIVE-SITE; BLOOD-PRESSURE; THERMOLYSIN; DEPENDENCE; CARBOXYPEPTIDASE; GLYCOPROTEIN; EXPRESSION; CAPTOPRIL	The angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE2, is a type I integral membrane protein of 805 amino acids that contains one HEXXH + E zinc-binding consensus sequence. ACE2 has been implicated in the regulation of heart function and also as a functional receptor for the coronavirus that causes the severe acute respiratory syndrome (SARS). To gain further insights into this enzyme, the first crystal structures of the native and inhibitor-bound forms of the ACE2 extracellular domains were solved to 2.2- and 3.0-Angstrom resolution, respectively. Comparison of these structures revealed a large inhibitor-dependent hinge-bending movement of one catalytic subdomain relative to the other (similar to16degrees) that brings important residues into position for catalysis. The potent inhibitor MLN-4760 ((S, S)- 2-{1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol4-yl]- ethylamino}-4-methylpentanoic acid) makes key binding interactions within the active site and offers insights regarding the action of residues involved in catalysis and substrate specificity. A few active site residue substitutions in ACE2 relative to ACE appear to eliminate the S-2' substrate-binding subsite and account for the observed reactivity change from the peptidyl dipeptidase activity of ACE to the carboxypeptidase activity of ACE2.	Millennium Pharmaceut Inc, Drug Discovery, Cambridge, MA 02139 USA; Millennium Pharmaceut Inc, Prot Sci, Cambridge, MA 02139 USA; Emerald BioStruct Inc, Bainbridge Isl, WA 98110 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Pantoliano, MW (corresponding author), Millennium Pharmaceut Inc, Drug Discovery, 270 Albany St, Cambridge, MA 02139 USA.	pantoliano@mpi.com		Staker, Bart/0000-0001-9570-5086				Abrahams JP, 1998, CURR OPIN STRUC BIOL, V8, P601, DOI 10.1016/S0959-440X(98)80151-6; Arndt JW, 2002, STRUCTURE, V10, P215, DOI 10.1016/S0969-2126(02)00698-6; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERNSTEIN KE, 1990, BIOCHEM BIOPH RES CO, V167, P310, DOI 10.1016/0006-291X(90)91766-L; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brown CK, 2001, P NATL ACAD SCI USA, V98, P3127, DOI 10.1073/pnas.051633198; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Dales NA, 2002, J AM CHEM SOC, V124, P11852, DOI 10.1021/ja0277226; Danilczyk U, 2003, J MOL MED, V81, P227, DOI 10.1007/s00109-003-0419-x; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; Esther CR, 1996, LAB INVEST, V74, P953; Fernandez M, 2001, J BIOL CHEM, V276, P4998, DOI 10.1074/jbc.M009009200; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Gerstein M, 1998, NUCLEIC ACIDS RES, V26, P4280, DOI 10.1093/nar/26.18.4280; Gordon K, 2003, BIOCHEM J, V371, P437, DOI 10.1042/BJ20021842; Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671; Guy JL, 2003, BIOCHEMISTRY-US, V42, P13185, DOI 10.1021/bi035268s; Hauptman HA, 1997, METHOD ENZYMOL, V277, P3, DOI 10.1016/S0076-6879(97)77003-4; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; HOLLAND DR, 1992, BIOCHEMISTRY-US, V31, P11310, DOI 10.1021/bi00161a008; Kim HM, 2003, FEBS LETT, V538, P65, DOI 10.1016/S0014-5793(03)00128-5; KNOWLES JR, 1991, PHILOS T ROY SOC B, V332, P115, DOI 10.1098/rstb.1991.0039; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liu XF, 2001, J BIOL CHEM, V276, P33518, DOI 10.1074/jbc.M101495200; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mcree D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Oudit GY, 2003, TRENDS CARDIOVAS MED, V13, P93, DOI 10.1016/S1050-1738(02)00233-5; PANTOLIANO MW, 1984, BIOCHEMISTRY-US, V23, P1037, DOI 10.1021/bi00300a036; PATCHETT AA, 1980, NATURE, V288, P280, DOI 10.1038/288280a0; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rockel B, 2002, EMBO J, V21, P5979, DOI 10.1093/emboj/cdf601; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5234, DOI 10.1021/bi00317a022; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054; Zhang H, 2001, J BIOL CHEM, V276, P17132, DOI 10.1074/jbc.M006723200	51	438	472	4	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17996	18007		10.1074/jbc.M311191200	http://dx.doi.org/10.1074/jbc.M311191200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14754895	hybrid, Green Published			2022-12-27	WOS:000220870400135
J	Ahn, JY; Rong, R; Kroll, TG; Van Meir, EG; Snyder, SH; Ye, KQ				Ahn, JY; Rong, R; Kroll, TG; Van Meir, EG; Snyder, SH; Ye, KQ			PIKE (Phosphatidylinositol 3-Kinase Enhancer)-A GTPase stimulates akt activity and mediates cellular invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; POSTSYNAPTIC DENSITY PROTEINS; HUMAN-MALIGNANT GLIOMAS; NERVE GROWTH-FACTOR; PHOSPHOLIPASE C-GAMMA-1; KINASE-ACTIVITY; NUCLEAR GTPASE; HUMAN CANCERS; AMPLIFICATION; BINDING	Akt/PKB is a crucial regulator of diverse cellular processes and contributes to cancer progression. Activation of Akt is essentially dependent on phosphatidylinositol ( PI) 3-kinase signaling. Here, we describe a novel mediator of Akt that is independent of PI 3-kinase. This mediator, PIKE-A, is a PIKE isoform and contains GTPase, pleckstrin homology, ArfGAP, and ankyrin repeats domains. PIKE-A directly binds to activated Akt but not PI 3-kinase in a guanine nucleotide-dependent way and stimulates the kinase activity of Akt. Overexpression of PIKE-A enhances Akt activity and promotes cancer cell invasion, whereas dominant-negative PIKE-A and PIKE-A knockdown markedly inhibit these processes. Our results demonstrate that PIKE-A is a physiologic regulator of Akt and an oncogenic effector of cell invasion.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol Surg & Hematol Oncol, Winship Canc Inst, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Emory University; Emory University; Johns Hopkins University	Ye, KQ (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.	kye@emory.edu		Van Meir, Erwin G./0000-0003-2444-7707	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045627] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS045627] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cherfils J, 2001, FEBS LETT, V507, P280, DOI 10.1016/S0014-5793(01)02970-2; Coffer PJ, 1998, BIOCHEM J, V335, P1; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Elkahloun AG, 1997, GENOMICS, V42, P295, DOI 10.1006/geno.1997.4727; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Kalman D, 1999, NAT CELL BIOL, V1, P389, DOI 10.1038/14087; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kroll TG, 2002, AM J PATHOL, V160, P1941, DOI 10.1016/S0002-9440(10)61142-X; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nakanishi K, 2002, CANCER RES, V62, P2971; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SMITH SH, 1992, CANCER RES, V52, P3746; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xia CZ, 2003, MOL CELL BIOL, V23, P2476, DOI 10.1128/MCB.23.7.2476-2488.2003; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Ye KQ, 1999, J NEUROSCI, V19, P10747, DOI 10.1523/JNEUROSCI.19-24-10747.1999; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	44	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16441	16451		10.1074/jbc.M312175200	http://dx.doi.org/10.1074/jbc.M312175200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761976	hybrid			2022-12-27	WOS:000220747900092
J	Carven, GJ; Chitta, S; Hilgert, I; Rushe, MM; Baggio, RF; Palmer, M; Arenas, JE; Strominger, JL; Horejsi, V; Santambrogio, L; Stern, LJ				Carven, GJ; Chitta, S; Hilgert, I; Rushe, MM; Baggio, RF; Palmer, M; Arenas, JE; Strominger, JL; Horejsi, V; Santambrogio, L; Stern, LJ			Monoclonal antibodies specific for the empty conformation of HLA-DR1 reveal aspects of the conformational change associated with peptide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II MHC; MYELIN BASIC-PROTEIN; HLA-DM; ANTIGENIC PEPTIDE; ESCHERICHIA-COLI; STRUCTURAL BASIS; DENDRITIC CELLS; ALPHA-CHAIN; ACIDIC PH	Class II major histocompatibility complex (MHC) proteins bind peptides and present them at the cell surface for interaction with CD4(+) T cells as part of the system by which the immune system surveys the body for signs of infection. Peptide binding is known to induce conformational changes in class II MHC proteins on the basis of a variety of hydrodynamic and spectroscopic approaches, but the changes have not been clearly localized within the overall class II MHC structure. To map the peptide-induced conformational change for HLA-DR1, a common human class II MHC variant, we generated a series of monoclonal antibodies recognizing the beta subunit that are specific for the empty conformation. Each antibody reacted with the empty but not the peptide-loaded form, for both soluble recombinant protein and native protein expressed at the cell surface. Antibody binding epitopes were characterized using overlapping peptides and alanine scanning substitutions and were localized to two distinct regions of the protein. The pattern of key residues within the epitopes suggested that the two epitope regions undergo substantial conformational alteration during peptide binding. These results illuminate aspects of the structure of the empty forms and the nature of the peptide-induced conformational change.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Acad Sci Czech Republ, Inst Genet Mol, CZ-16637 Prague, Czech Republic; Appl Biosyst Cell Biol & Funct Proteom, Bedford, MA 01730 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	University of Massachusetts System; University of Massachusetts Worcester; Massachusetts Institute of Technology (MIT); Czech Academy of Sciences; Thermo Fisher Scientific; Applied Biosystems; Harvard University; Harvard University; Dana-Farber Cancer Institute; Yeshiva University; Albert Einstein College of Medicine	Stern, LJ (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Rm S2-127, Worcester, MA 01655 USA.	lawrence.stern@umassmed.edu	Horejsi, Vaclav/G-3113-2014	Horejsi, Vaclav/0000-0003-4925-0142; Carven, Gregory/0000-0002-8468-6323	NIAID NIH HHS [AI-48832, AI-48833, AI-49524] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048832, R01AI048833, R01AI049524] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beeson C, 1996, J EXP MED, V184, P777, DOI 10.1084/jem.184.2.777; BEESON C, 1994, P NATL ACAD SCI USA, V91, P8842, DOI 10.1073/pnas.91.19.8842; Bolin DR, 2000, J MED CHEM, V43, P2135, DOI 10.1021/jm000034h; Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; Cameron TO, 2002, J IMMUNOL METHODS, V268, P51, DOI 10.1016/S0022-1759(02)00200-4; Chou CL, 2000, J EXP MED, V192, P1697, DOI 10.1084/jem.192.12.1697; Cochran JR, 2000, CHEM BIOL, V7, P683, DOI 10.1016/S1074-5521(00)00019-3; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Doebele RC, 2000, IMMUNITY, V13, P517, DOI 10.1016/S1074-7613(00)00051-0; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; FU XT, 1994, HUM IMMUNOL, V39, P253, DOI 10.1016/0198-8859(94)90268-2; Gampfer JM, 2002, VACCINE, V20, P3675, DOI 10.1016/S0264-410X(02)00400-0; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; GORGA JC, 1986, CELL IMMUNOL, V103, P160, DOI 10.1016/0008-8749(86)90077-8; Hansen BE, 1998, TISSUE ANTIGENS, V51, P119; Jardetzky TS, 1996, P NATL ACAD SCI USA, V93, P734, DOI 10.1073/pnas.93.2.734; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; Joshi RV, 2000, BIOCHEMISTRY-US, V39, P3751, DOI 10.1021/bi9923656; KABAT EA, 1970, ANN NY ACAD SCI, V169, P43; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; LAPAN KE, 1992, HYBRIDOMA, V11, P217, DOI 10.1089/hyb.1992.11.217; Li YL, 2000, J MOL BIOL, V304, P177, DOI 10.1006/jmbi.2000.4198; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; Maeda H, 2000, FEMS IMMUNOL MED MIC, V28, P219, DOI 10.1111/j.1574-695X.2000.tb01480.x; MASON K, 1995, J IMMUNOL, V154, P5216; MASON K, 1994, P NATL ACAD SCI USA, V91, P12463, DOI 10.1073/pnas.91.26.12463; MATSUSHITA K, 1994, INFECT IMMUN, V62, P4034, DOI 10.1128/IAI.62.9.4034-4042.1994; McFarland BJ, 2002, MED RES REV, V22, P168, DOI 10.1002/med.10006; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; Natarajan SK, 1999, J IMMUNOL, V162, P4030; Natarajan SK, 1999, J IMMUNOL, V162, P3463; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; Robinson J, 2003, NUCLEIC ACIDS RES, V31, P311, DOI [10.1093/nar/gkg070, 10.1093/nar/GKG070]; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Runnels HA, 1996, J EXP MED, V183, P127, DOI 10.1084/jem.183.1.127; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SADEGHNASSERI S, 1992, IMMUNOL TODAY, V13, P43, DOI 10.1016/0167-5699(92)90131-P; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15050, DOI 10.1073/pnas.96.26.15050; Sato AK, 2000, J BIOL CHEM, V275, P2165, DOI 10.1074/jbc.275.3.2165; SCHEIRLE A, 1992, J IMMUNOL, V149, P1994; Schmitt L, 1999, J MOL BIOL, V286, P207, DOI 10.1006/jmbi.1998.2463; Schmitt L, 1999, P NATL ACAD SCI USA, V96, P6581, DOI 10.1073/pnas.96.12.6581; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; Scott CA, 1998, PROTEIN SCI, V7, P413; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STOCKEL J, 1994, J BIOL CHEM, V269, P29571; Stratikos E, 2004, J IMMUNOL, V172, P1109, DOI 10.4049/jimmunol.172.2.1109; Stratmann T, 2000, J IMMUNOL, V165, P3214, DOI 10.4049/jimmunol.165.6.3214; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wu SH, 1997, J IMMUNOL, V158, P3221; Zarutskie JA, 2001, P NATL ACAD SCI USA, V98, P12450, DOI 10.1073/pnas.211439398; Zarutskie JA, 1999, BIOCHEMISTRY-US, V38, P5878, DOI 10.1021/bi983048m	62	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16561	16570		10.1074/jbc.M314315200	http://dx.doi.org/10.1074/jbc.M314315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757758	hybrid			2022-12-27	WOS:000220747900106
J	Gervois, P; Kleemann, R; Pilon, A; Percevault, F; Koenig, W; Staels, B; Kooistra, T				Gervois, P; Kleemann, R; Pilon, A; Percevault, F; Koenig, W; Staels, B; Kooistra, T			Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; TRANSCRIPTION FACTORS; PPAR-ALPHA; INTERLEUKIN-6 FAMILY; INFLAMMATION CONTROL; KAPPA-B; FIBRINOGEN; STAT3; PROMOTER	The peroxisome proliferator-activated receptor alpha (PPARalpha), which is highly expressed in liver, plays key roles in lipid metabolism and inflammation. Interleukin-6 (IL-6) is the principal inducer of acute phase response (APR) gene expression. In the present study, we demonstrate that chronic treatment with the PPARalpha agonist fenofibrate fully prevents the IL-6-induced APR gene expression in wild-type but not in PPARalpha-deficient mice. PPARalpha prevents the IL-6-induced expression of the positive APR genes fibrinogen-alpha, -beta, -gamma, haptoglobulin, and serum amyloid A and the IL-6-induced suppression of the negative APR gene, major urinary protein. Furthermore, the effect of PPARalpha on the APR gene expression does not simply consist in a delayed systemic response to IL-6 but occurs directly at the transcriptional level. This global suppression of acute phase gene transcription may be explained by two PPARalpha-dependent in vivo effects: 1) PPARalpha activation results in the down-regulation of the IL-6 receptor components gp80 and gp130 in the liver, thereby reducing the phosphorylation and activation of the downstream transcription factors STAT3 and c-Jun that transduce the IL-6 signal; and 2) PPARalpha reduces the basal expression of the transcription factors CCAAT enhancer-binding protein-alpha, -beta, -delta, which are responsible for immediate and maintained transcription of APR genes. A similar global effect of fenofibrate on acute phase protein expression is observed in hyperlipidemic patients chronically treated with fenofibrate, which displayed decreased plasma concentrations of the positive APR proteins fibrinogen, C-reactive protein, serum amyloid A, plasminogen, and alpha2-macroglobulin and increased plasma concentrations of the negative APR albumin, underlining the clinical significance of our findings.	Univ Lille 2, Fac Pharm, Biochim Lab, F-59006 Lille, France; TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Inst Pasteur, Dept Atherosclerose, INSERM, U545, F-59006 Lille, France; Univ Ulm, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany	Universite de Lille - ISITE; Universite de Lille; Netherlands Organization Applied Science Research; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Ulm University	Gervois, P (corresponding author), Univ Lille 2, Fac Pharm, Biochim Lab, 3 Rue Prof Laguesse,BP83, F-59006 Lille, France.	pgervois@pharma.univ-lille2.fr	Staels, Bart/N-9497-2016; percevault, frederic/K-1836-2015; Pilon, Antoine/S-5585-2018	Staels, Bart/0000-0002-3784-1503; 				Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Delerive P, 2000, J BIOL CHEM, V275, P36703, DOI 10.1074/jbc.M004045200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dhainaut JF, 2001, CRIT CARE MED, V29, pS42, DOI 10.1097/00003246-200107001-00016; ERNST E, 1992, J CLIN PATHOL, V45, P534, DOI 10.1136/jcp.45.6.534; Fattori E, 1995, ANN NY ACAD SCI, V762, P262; Gervois P, 2000, CLIN CHEM LAB MED, V38, P3, DOI 10.1515/CCLM.2000.002; Gervois P, 2001, J BIOL CHEM, V276, P33471, DOI 10.1074/jbc.M102839200; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hoffmeister A, 2001, AM J CARDIOL, V87, P262, DOI 10.1016/S0002-9149(00)01355-2; Jonkers IJ, 2002, AM J MED, V112, P275, DOI 10.1016/S0002-9343(01)01123-8; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kockx M, 1999, BLOOD, V93, P2991; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Marx N, 2002, CIRC RES, V90, P703, DOI 10.1161/01.RES.0000014225.20727.8F; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Rizos E, 2002, ANGIOLOGY, V53, P273, DOI 10.1177/000331970205300304; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schuringa JJ, 2001, CYTOKINE, V14, P78, DOI 10.1006/cyto.2001.0856; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; STAELS B, 1992, DEVELOPMENT, V115, P1035; Streetz KL, 2001, CELL MOL BIOL, V47, P661; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takata Y, 2002, CIRC RES, V91, P427, DOI 10.1161/01.RES.0000031271.20771.4F; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503	38	165	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16154	16160		10.1074/jbc.M400346200	http://dx.doi.org/10.1074/jbc.M400346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764586	hybrid			2022-12-27	WOS:000220747900057
J	Qin, P; Haberbusch, JM; Zhang, ZP; Soprano, KJ; Soprano, DR				Qin, P; Haberbusch, JM; Zhang, ZP; Soprano, KJ; Soprano, DR			Pre-b cell leukemia transcription factor (PBX) proteins are important mediators for retinoic acid-dependent endodermal and neuronal differentiation of mouse embryonal carcinoma P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; HOX GENES; HOMEOBOX GENES; RECEPTOR-ALPHA; DNA-BINDING; PROTEOGLYCAN SYNTHESIS; HOMEODOMAIN PROTEINS; PROMOTER REGION; DECORIN GENE; E-BOX	Pre-B cell leukemia transcription factors (PBXs) act as cofactors in the transcriptional regulation mediated by Homeobox proteins during embryonic development and cellular differentiation. PBX1 protein is expressed throughout murine embryonic development, and its deletion in mice disrupts chondrogenesis. PBX protein levels are also increased in mouse embryonal carcinoma P19 cells during retinoic acid (RA)-induced differentiation. To elucidate the role of PBX proteins in this process, we stably overexpressed PBX1b antisense mRNA in P19 cells (PBX1b-AS cells). PBX1b-AS cells did not differentiate to neuronal or endodermal cells following treatment with RA suggesting PBX proteins are required for both processes. Furthermore we demonstrated that PBX proteins regulate the RA-dependent induction in the mRNA levels of bone morphogenetic protein 4 (BMP4) and Decorin (DCN) in P19 cells using both PBX1b-AS cells and PBX1 small interfering RNA. Chromatin immunoprecipitation assays further demonstrated that PBX proteins directly bind to the promoter of Bmp4 and Dcn in vivo in a RA-dependent fashion. In addition, type I and type II BMP receptor mRNA levels were also increased in P19 cells following RA treatment; however, this was PBX-independent. Taken together these data demonstrate that PBX proteins are required for RA-induced differentiation of P19 cells and that PBX proteins regulate the expression of BMP4 and DCN during this differentiation process.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, DR (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3420 N Broad St, Philadelphia, PA 19140 USA.	dsoprano@temple.edu			NATIONAL CANCER INSTITUTE [R01CA082770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517] Funding Source: NIH RePORTER; NCI NIH HHS [CA82770] Funding Source: Medline; NIDDK NIH HHS [DK44517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonja O, 2000, LEUKEMIA RES, V24, P849, DOI 10.1016/S0145-2126(00)00059-X; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/00007632-200208151-00004; Ebara S, 1997, BIOCHEM BIOPH RES CO, V240, P136, DOI 10.1006/bbrc.1997.7618; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Ferretti E, 2000, DEVELOPMENT, V127, P155; Gao X, 2001, BIOCHEM BIOPH RES CO, V284, P1098, DOI 10.1006/bbrc.2001.5089; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; Glozak MA, 1998, EXP CELL RES, V242, P165, DOI 10.1006/excr.1998.4075; Glozak MA, 2001, EXP CELL RES, V268, P128, DOI 10.1006/excr.2001.5281; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kawasaki S, 1999, BIOCHEM BIOPH RES CO, V263, P560, DOI 10.1006/bbrc.1999.1402; Knoepfler PS, 1997, MECH DEVELOP, V63, P5, DOI 10.1016/S0925-4773(97)00669-2; Knudson CB, 2001, SEMIN CELL DEV BIOL, V12, P69, DOI 10.1006/scdb.2000.0243; Kobayashi E, 2003, KIDNEY INT, V64, P1179, DOI 10.1046/j.1523-1755.2003.00202.x; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kuroda M, 2002, KIDNEY INT, V62, P780, DOI 10.1046/j.1523-1755.2002.00524.x; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lyu J, 2003, J BIOL CHEM, V278, P13487, DOI 10.1074/jbc.M300591200; MALY P, 1992, FEBS LETT, V311, P102, DOI 10.1016/0014-5793(92)81377-X; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; Mauviel A, 1996, J BIOL CHEM, V271, P24824, DOI 10.1074/jbc.271.40.24824; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; POPPERL H, 1993, MOL CELL BIOL, V13, P257; PRATT MAC, 1993, DIFFERENTIATION, V53, P105, DOI 10.1111/j.1432-0436.1993.tb00650.x; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; Qin P, 2002, TERATOLOGY, V66, P224, DOI 10.1002/tera.10082; QIN P, 2004, IN PRESS J CELL BIOC; ROGERS MB, 1992, MOL BIOL CELL, V3, P189, DOI 10.1091/mbc.3.2.189; Rogers MB, 1996, CELL GROWTH DIFFER, V7, P115; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Schnabel CA, 2001, MECH DEVELOP, V100, P131, DOI 10.1016/S0925-4773(00)00516-5; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; Selleri L, 2001, DEVELOPMENT, V128, P3543; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Soprano DR, 1996, ONCOGENE, V12, P577; Soprano DR, 2001, TOXICOL APPL PHARM, V174, P153, DOI 10.1006/taap.2001.9209; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Weston AD, 2000, J CELL BIOL, V148, P679, DOI 10.1083/jcb.148.4.679; ZWARTKRUIS F, 1993, EXP CELL RES, V205, P422, DOI 10.1006/excr.1993.1108	59	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16263	16271		10.1074/jbc.M313938200	http://dx.doi.org/10.1074/jbc.M313938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14742427	hybrid			2022-12-27	WOS:000220747900070
J	Watanabe, Y; Yoshida, M				Watanabe, Y; Yoshida, M			Trigonal Dnak-DnaJ complex versus free DnaK and DnaJ - Heat stress converts the former to the latter, and only the latter can do disaggregation in cooperation with ClpB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITES; THERMUS-THERMOPHILUS; CHAPERONE SYSTEM; SACCHAROMYCES-CEREVISIAE; INACTIVATED PROTEINS; MITOCHONDRIAL HSP78; ESCHERICHIA-COLI; HSP104; GRPE; OLIGOMERIZATION	DnaK from Thermus thermophilus (TDnaK) is unique because significant fractions of cellular TDnaK exist as a trigonal K.J complex that consists of three copies each of TDnaK, TDnaJ, and an assembly factor TDafA. Here, chaperone functions of the K.J complex and free TDnaK plus free TDnaJ (K+J) were compared. Substrate proteins were completely denatured at 72-73 degreesC or 89 degreesC in the absence or the presence of K.J complex or K+J and were subsequently incubated at a moderate temperature of 55 degreesC. TGrpE and ATP were always included in the K.J complex and K+J, and TClpB was supplemented at 55 degreesC. At 72-73 degreesC, both the K.J complex and K+J suppressed heat aggregation of substrate proteins. During the next incubation at 55 degreesC, K+J, assisted by TClpB, was able to disaggregate the heat aggregates and efficiently reactivate activities of the proteins, whereas the K.J complex was not; it reactivated only the soluble inactivated proteins. When substrate proteins were heated to 89 degreesC, both the K.J complex and K+J were no longer able to prevent heat aggregation, and because of selective, irreversible denaturation of TDafA the K.J complex dissociated into K+J, which then exhibited disaggregation activity during the next incubation at 55 degreesC. Thus, TClpB-assisted disaggregation activity belongs only to K+J, and TDafA is a potential thermosensor for converting the K.J complex to K+J in response to heat stress.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan	Tokyo Institute of Technology	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp						Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Klostermeier D, 1998, J MOL BIOL, V279, P841, DOI 10.1006/jmbi.1998.1816; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; Motohashi K, 1996, J BIOL CHEM, V271, P17343, DOI 10.1074/jbc.271.29.17343; Motohashi K, 1997, FEBS LETT, V412, P633, DOI 10.1016/S0014-5793(97)00847-8; OKUNO H, 1985, Journal of Applied Biochemistry, V7, P192; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Watanabe YH, 2000, J BIOL CHEM, V275, P12388, DOI 10.1074/jbc.275.17.12388; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; YAMADA T, 1990, J BIOCHEM-TOKYO, V108, P449, DOI 10.1093/oxfordjournals.jbchem.a123220; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	26	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15723	15727		10.1074/jbc.M308782200	http://dx.doi.org/10.1074/jbc.M308782200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14729677	hybrid			2022-12-27	WOS:000220747900005
J	Zambrano, N; Gianni, D; Bruni, P; Passaro, F; Telese, F; Russo, T				Zambrano, N; Gianni, D; Bruni, P; Passaro, F; Telese, F; Russo, T			Fe65 is not involved in the platelet-derived growth factor-induced processing of Alzheimer's amyloid precursor protein, which activates its caspase-directed cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; DEPENDENT REGULATION; SIGNAL-TRANSDUCTION; AXONAL-TRANSPORT; WILD-TYPE; APP; DISEASE; BINDING; SECRETION	The proteolytic processing of the precursor of the beta-amyloid peptides (APP) is believed to be a key event in the pathogenesis of Alzheimer's disease. This processing is activated through a pathway involving the PDGF receptor, Src, and Rac1. In this paper, we demonstrate that this pathway specifically acts on APP and requires the YENPTY motif present in the APP cytosolic domain. Considering that several results indicate that the adaptor proteins interacting with this domain affect the processing of APP, we examined their possible involvement in the PDGF-induced pathway. By using an APP-Gal4 reporter system, we observed that the overexpression of Fe65 activates APP-Gal4 cleavage, whereas X11 stabilizes APP. Although mDab1 and Jip1 have no effect, Shc induces a strong activation of APP cleavage, and the contemporary exposure of cells to PDGF causes a dramatic cooperative effect. The analysis of point mutations of the APP YENPTY motif indicates that Fe65 and PDGF function through different mechanisms. In fact, Fe65 requires the integrity of APP695 Tyr(682) residue, whereas PDGF effect is dependent upon the integrity of Asn(684). Furthermore, the mutation of Asp(664) of APP, which is the target site for the caspase-directed APP cleavage, strongly decreases the effect of Fe65. This suggests that Fe65 activates the cleavage of APP by caspases, and in fact, caspase inhibitor Z-VEVD decreases the APP cleavage induced by Fe65. On the contrary, the effects of Shc overexpression, like those of PDGF, are completely absent in the presence of compound X and require the integrity of the Asn(684) residue of APP695. The involvement of Shc in the pathway regulating APP processing is confirmed by the effects of constitutively active and dominant negative mutants of Src and Rac1.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Ceinge Biotecnol Avanzate, I-80131 Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Ceinge Biotecnol Avanzate, Via S Pansini 5, I-80131 Naples, Italy.	russot@dbbm.unina.it	Passaro, Fabiana/I-5941-2012; Zambrano, Nicola/B-9352-2014; Russo, Tommaso/K-1331-2016	Passaro, Fabiana/0000-0003-0150-5302; Zambrano, Nicola/0000-0001-9395-3481; Russo, Tommaso/0000-0003-4426-0106; Telese, Francesca/0000-0003-3877-0628				Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Biederer T, 2002, J NEUROSCI, V22, P7340; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bruni P, 2002, J BIOL CHEM, V277, P35481, DOI 10.1074/jbc.M205227200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 2000, J CELL SCI, V113, P1857; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Netzer WJ, 2003, P NATL ACAD SCI USA, V100, P12444, DOI 10.1073/pnas.1534745100; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; St George-Hyslop PH, 2000, ANN NY ACAD SCI, V924, P1; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	43	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16161	16169		10.1074/jbc.M311027200	http://dx.doi.org/10.1074/jbc.M311027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14766758	hybrid			2022-12-27	WOS:000220747900058
J	Han, KJ; Su, XQ; Xu, LG; Bin, LH; Zhang, J; Shu, HB				Han, KJ; Su, XQ; Xu, LG; Bin, LH; Zhang, J; Shu, HB			Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappa B activation and apoptosis pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING ADAPTER; REGULATORY FACTOR-3; SENDAI-VIRUS; IL-1; PROTEIN; MYD88; MOLECULE; DISTINCT; IRF-3; TIRAP	Toll-like receptor-3 is critically involved in host defense against viruses through induction of type I interferons (IFNs). Recent studies suggest that a Toll/interleukin-1 receptor domain-containing adapter protein (TRIF) and two protein kinases (TANK-binding kinase-1 (TBK1) and IbetaB kinase (IKK)-epsilon) are critically involved in Toll-like receptor-3-mediated IFN-beta production through activation of IFN regulatory factor (IRF)-3 and IRF-7. In this study, we demonstrate that TRIF interacts with both IRF-7 and IRF-3. In addition to TBK1 and IKKepsilon, our results indicate that IKKbeta can also phosphorylate IRF-3 and activate the IFN-stimulated response element. TRIF-induced IRF-3 and IRF-7 activation was mediated by TBK1 and its downstream kinases IKKbeta and IKKepsilon. TRIF induced NF-kappaB activation through an IKKbeta- and tumor necrosis factor receptor-associated factor-6-dependent (but not TBK1- and IKKepsilon-dependent) pathway. In addition, TRIF also induced apoptosis through a RIP/FADD/caspase-8-dependent and mitochondrion-independent pathway. Furthermore, our results suggest that the TRIF-induced IFN-stimulated response element and NF-kappaB activation and apoptosis pathways are uncoupled and provide a molecular explanation for the divergent effects induced by the adapter protein TRIF.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St,K516C, Denver, CO 80206 USA.	shuh@njc.org		Xu, Liangguo/0000-0003-1991-2889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49992] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bin LH, 2003, J BIOL CHEM, V278, P24526, DOI 10.1074/jbc.M303451200; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Servant MJ, 2002, J INTERF CYTOK RES, V22, P49, DOI 10.1089/107999002753452656; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TROPEA F, 1995, EXP CELL RES, V218, P63, DOI 10.1006/excr.1995.1131; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Zhang LW, 2002, J INTERF CYTOK RES, V22, P95, DOI 10.1089/107999002753452700	37	204	224	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15652	15661		10.1074/jbc.M311629200	http://dx.doi.org/10.1074/jbc.M311629200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739303	hybrid			2022-12-27	WOS:000220594700138
J	Mashanov, GI; Tacon, D; Peckham, M; Molloy, JE				Mashanov, GI; Tacon, D; Peckham, M; Molloy, JE			The spatial and temporal dynamics of pleckstrin homology domain binding at the plasma membrane measured by Imaging single molecules in live mouse myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL-REFLECTION-FLUORESCENCE; MYOSIN-X; PHOTOBLEACHING RECOVERY; ACTIN DYNAMICS; MICROSCOPY; DIFFUSION; PROTEINS; REGIONS; CELLS	Pleckstrin homology (PH) domains act to target proteins to the plasma membrane and intracellular vesicles by binding to specific phosphoinositol phospholipids. We have investigated the binding kinetics of PH domains found in the tail region of the molecular motor, myosin X. Using total internal reflection fluorescence microscopy, we observed binding and release of individual PH domains fused to green fluorescent protein at the plasma membrane of living cells. Individual spots of light corresponding to single fluorescently tagged molecules were imaged onto a sensitive camera system, and digital image processing was then used to identify each fluorophore and store its trajectory in time and space. The PH domains bound with an apparent on-rate of 0.03 muM(-1) mum(-2) s(-1) and a detachment rate constant of 0.05 s(-1). The average residency time of the domains at the plasma membrane was about 20s. We found very limited movement of the membrane-bound PH domains in the mouse myoblast cells that we studied. This implies that the PH domains must either be attached to the cytoskeleton or corralled in a lipid compartment. Localization of the PH domains together with their rapid detachment rate is probably important in controlling the response of myosin X to signaling events and in regulating its cellular function.	Natl Inst Med Res, MRC, Div Phys Biochem, London NW7 1AA, England; Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	MRC National Institute for Medical Research; University of Leeds	Molloy, JE (corresponding author), Natl Inst Med Res, MRC, Div Phys Biochem, Ridgeway,Mill Hill, London NW7 1AA, England.	jmolloy@nimr.mrc.ac.uk	Peckham, Michelle/J-4991-2015	Peckham, Michelle/0000-0002-3754-2028; Molloy, Justin/0000-0002-8307-2450				Axelrod D, 1992, TOPICS FLUORESCENCE, P289; Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; BURGHARDT TP, 1981, BIOPHYS J, V33, P455, DOI 10.1016/S0006-3495(81)84906-5; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Czech MP, 2003, P NATL ACAD SCI USA, V100, P11198, DOI 10.1073/pnas.2135308100; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Garcia-Parajo MF, 2000, P NATL ACAD SCI USA, V97, P7237, DOI 10.1073/pnas.97.13.7237; Harms GS, 2001, BIOPHYS J, V80, P2396, DOI 10.1016/S0006-3495(01)76209-1; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Mashanov GI, 2003, METHODS, V29, P142, DOI 10.1016/S1046-2023(02)00305-5; Peckham M, 2001, J CELL SCI, V114, P1367; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Sund SE, 2000, BIOPHYS J, V79, P1655, DOI 10.1016/S0006-3495(00)76415-0; THOMPSON NL, 1981, BIOPHYS J, V33, P435, DOI 10.1016/S0006-3495(81)84905-3; van Rheenen J, 2002, MOL BIOL CELL, V13, P3257, DOI 10.1091/mbc.E02-04-0231; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; Yonezawa S, 2000, BIOCHEM BIOPH RES CO, V271, P526, DOI 10.1006/bbrc.2000.2669; Yonezawa S, 2003, DEV GROWTH DIFFER, V45, P175	25	61	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15274	15280		10.1074/jbc.M312140200	http://dx.doi.org/10.1074/jbc.M312140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729907	hybrid			2022-12-27	WOS:000220594700095
J	Sheehan, JK; Kirkham, S; Howard, M; Woodman, P; Kutay, S; Brazeau, C; Buckley, J; Thornton, DJ				Sheehan, JK; Kirkham, S; Howard, M; Woodman, P; Kutay, S; Brazeau, C; Buckley, J; Thornton, DJ			Identification of molecular intermediates in the assembly pathway of the MUC5AC mucin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSICAL-CHARACTERIZATION; MUCUS GLYCOPROTEINS; FORMS; GLYCOSYLATION; TERMINUS; PROTEINS; COMPLEX; DIMERS; MOTIF	MUC5AC mucins secreted by HT-29 cells in culture are oligomeric glycoproteins with characteristics similar to the MUC5AC mucins isolated from human airway sputum (Sheehan, J. K., Brazeau, C., Kutay, S., Pigeon, H., Kirkham, S., Howard, M., and Thornton, D. J. (2000) Biochem. J. 347, 37-44). Therefore we have used this cell line as a model system to investigate the biosynthesis of this major airway mucin. Initial experiments showed that the MUC5AC mucins isolated from the cells were liable to depolymerization depending on the conditions used for their solubilization. Prevention against reduction resulted in large oligomers associated with the cells, similar to those secreted into the medium. Using a combination of density gradient centrifugation and agarose gel electrophoresis coupled with probes specific for different forms of the mucin we identified five major intracellular populations of the MUC5AC polypeptide (unglycosylated monomer and dimer, GalNAc-substituted dimer, fully glycosylated dimer, and higher order oligomers). Pulse-chase studies were performed to follow the flow of radioactivity through these various intracellular forms into the mature oligomeric mucin secreted into the medium (a process taking similar to2-4 h). The results show that the mucin polypeptide undergoes dimerization and then becomes substituted with GalNAc residues prior to glycan elaboration to produce a mature mucin dimer, which then undergoes multimerization. These data indicate that this oligomeric mucin follows a similar assembly to the von Willebrand factor glycoprotein to yield long linear disulfide-linked chains.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Thornton, DJ (corresponding author), Univ Manchester, Sch Biol Sci, Michael Smith Bldg, Manchester M13 9PT, Lancs, England.	dave.thornton@man.ac.uk		Thornton, David/0000-0001-7148-1970				Aksoy N, 1999, GLYCOBIOLOGY, V9, P739, DOI 10.1093/glycob/9.7.739; Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; Bell SL, 2001, BIOCHEM J, V357, P203, DOI 10.1042/0264-6021:3570203; CARLSTEDT I, 1984, BIOCHEM SOC T, V12, P615, DOI 10.1042/bst0120615; CARLSTEDT I, 1983, BIOCHEM J, V211, P13, DOI 10.1042/bj2110013; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; Godl K, 2002, J BIOL CHEM, V277, P47248, DOI 10.1074/jbc.M208483200; GUPTA R, 1992, J BIOL CHEM, V267, P3160; GUPTA R, 1990, BIOPOLYMERS, V29, P347, DOI 10.1002/bip.360290207; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; Khatri IA, 1998, BIOCHEM J, V331, P323, DOI 10.1042/bj3310323; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1998, J BIOL CHEM, V273, P34527, DOI 10.1074/jbc.273.51.34527; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; Sheehan JK, 1999, BIOCHEM J, V338, P507, DOI 10.1042/0264-6021:3380507; Sheehan JK, 2000, BIOCHEM J, V347, P37, DOI 10.1042/0264-6021:3470037; Thornton DJ, 1996, BIOCHEM J, V316, P967, DOI 10.1042/bj3160967; THORNTON DJ, 1990, BIOCHEM J, V265, P179, DOI 10.1042/bj2650179; THORNTON DJ, 1989, ANAL BIOCHEM, V182, P160, DOI 10.1016/0003-2697(89)90735-5; Thornton DJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1118, DOI 10.1152/ajplung.2000.278.6.L1118; THORNTON DJ, 1997, AIRWAY MUCUS BASIC M, P19; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Wickstrom C, 2001, J BIOL CHEM, V276, P47116, DOI 10.1074/jbc.M106593200	29	73	73	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15698	15705		10.1074/jbc.M313241200	http://dx.doi.org/10.1074/jbc.M313241200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749330	hybrid			2022-12-27	WOS:000220594700143
J	Tanaka, K; Xu, W; Zhou, FF; You, GF				Tanaka, K; Xu, W; Zhou, FF; You, GF			Role of glycosylation in the organic anion transporter OAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS	Organic anion transporters (OAT) play essential roles in the body disposition of clinically important anionic drugs, including antiviral drugs, antitumor drugs, antibiotics, antihypertensives, and anti-inflammatories. We reported previously (Kuze, K., Graves, P., Leahy, A., Wilson, P., Stuhlmann, H., and You, G. (1999) J. Biol. Chem. 274, 1519-1524) that tunicamycin, an inhibitor of asparagine-linked glycosylation, significantly inhibited organic anion transport in COS-7 cells expressing a mouse organic anion transporter (mOAT1), suggesting an important role of glycosylation in mOAT1 function. In the present study, we investigated the effect of disrupting putative glycosylation sites in mOAT1 as well as its human counterpart, hOAT1, by mutating asparagine to glutamine and assessing mutant transporters in HeLa cells. We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated. Disrupting Asp-39 resulted in a complete loss of transport activity in both mOAT1 and hOAT1 without affecting their cell surface expression, suggesting that the loss of function is not because of deglycosylation of Asp-39 per se but rather is likely because of the change of this important amino acid critically involved in the substrate binding. Single replacement of asparagines at other sites had no effect on transport activity indicating that glycosylation at individual sites is not essential for OAT function. In contrast, a simultaneous replacement of all asparagines in both mOAT1 and hOAT1 impaired the trafficking of the transporters to the plasma membrane. In summary, we provided the evidence that 1) Asp-39 is crucially involved in substrate recognition of OAT1, 2) glycosylation at individual sites is not required for OAT1 function, and 3) glycosylation plays an important role in the targeting of OAT1 onto the plasma membrane. This study is the first molecular identification and characterization of glycosylation of OAT1 and may provide important insights into the structure-function relationships of the organic anion transporter family.	Rutgers State Univ, Dept Pharmaceut, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	You, GF (corresponding author), Rutgers State Univ, Dept Pharmaceut, 160 Frelinhuysen Rd, Piscataway, NJ 08854 USA.	gyou@cop.rutgers.edu	Zhou, Fanfan/M-4404-2013; Zhou, Fanfan/J-2327-2019	Zhou, Fanfan/0000-0002-1982-1541; Zhou, Fanfan/0000-0002-1982-1541	NIDDK NIH HHS [R01-DK 60034] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060034] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; GENG L, 1999, 32 ANN M MIAM BEACH; Kuze K, 1999, J BIOL CHEM, V274, P1519, DOI 10.1074/jbc.274.3.1519; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; You GF, 2004, CURR DRUG METAB, V5, P55, DOI 10.2174/1389200043489207; You GF, 2000, J BIOL CHEM, V275, P10278, DOI 10.1074/jbc.275.14.10278; You GF, 2002, MED RES REV, V22, P602, DOI 10.1002/med.10019	7	89	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14961	14966		10.1074/jbc.M400197200	http://dx.doi.org/10.1074/jbc.M400197200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749323	hybrid			2022-12-27	WOS:000220594700059
J	Corna, G; Santambrogio, P; Minotti, G; Cairo, G				Corna, G; Santambrogio, P; Minotti, G; Cairo, G			Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity - Role of reactive oxygen species and ferritin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN-2; TRANSFERRIN RECEPTOR; OXIDATIVE STRESS; GENE-EXPRESSION; HEAVY SUBUNIT; NITRIC-OXIDE; RAT-LIVER; INDUCTION; BINDING; CARDIOTOXICITY	The cardiotoxicity induced by the anticancer anthracycline doxorubicin (DOX) is attributed to reactions between iron and reactive oxygen species (ROS) that lead to oxidative damage. We found that DOX forms ROS in H9c2 cardiomyocytes, as shown by dichlorodihydrofluorescein oxidation and the expression of stress-responsive genes such as catalase or aldose reductase. DOX also increased ferritin levels in these cells, particularly the H subunit. A considerable increase in ferritin mRNA levels showed that DOX acted at transcriptional level, but an additional potential mechanism was identified as the down-regulation of iron regulatory protein-2, post-transcriptional inhibitor of ferritin synthesis. Pretreatment with DOX protected H9c2 cells against the damage induced by subsequent exposure to ferric ammonium citrate, and experiments with Fe-55 revealed that the protection was due to the deposition of iron in ferritin. Cytoprotection was also observed when DOX was replaced by glucose/glucose oxidase, a source of H2O2, thus suggesting that DOX increases ferritin synthesis through the action of ROS. This concept was supported by three more lines of evidence. (i) DOX-induced ferritin synthesis was blocked by N-acetylcysteine, a scavenger of ROS. (ii) Mitoxantrone, a ROS-forming analogue, similarly induced ferritin expression and protected the cells against iron toxicity. (iii) 5-Iminodaunorubicin, an analogue lacking ROS-forming activity, did not induce ferritin synthesis or protect the cells against iron toxicity. These results characterize a paradoxically beneficial link between anthracycline-derived ROS, increased ferritin synthesis, and resistance to iron-mediated damage. The role of iron and ROS in anthracycline-induced cardiotoxicity may, therefore, be more complex than previously believed.	Univ Milan, Inst Gen Pathol, I-20133 Milan, Italy; IRCCS HS Raffaele, Prot Engn Unit Dibit, I-20132 Milan, Italy; Univ G DAnnunzio, Dept Drug Sci, Sch Med, I-66013 Chieti, Italy; Univ G DAnnunzio, Sch Med, Ctr Studi Invecchiamento, I-66013 Chieti, Italy	University of Milan; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Cairo, G (corresponding author), Univ Milan, Inst Gen Pathol, Via Mangiagalli 31, I-20133 Milan, Italy.	gaetano.cairo@unimi.it	Santambrogio, Paolo/AAN-3837-2020; Cairo, Gaetano/M-5104-2016	Santambrogio, Paolo/0000-0002-5481-2130; Cairo, Gaetano/0000-0002-8147-4720; Minotti, Giorgio/0000-0002-5678-6175				Barisani D, 2000, FEBS LETT, V469, P208, DOI 10.1016/S0014-5793(00)01280-1; Bradley SJ, 1997, BRIT J HAEMATOL, V99, P337, DOI 10.1046/j.1365-2141.1997.4143221.x; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; da Silva MM, 2003, AM J PHYSIOL-HEART C, V285, pH154, DOI 10.1152/ajpheart.00955.2002; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Gianni L, 1997, J CLIN ONCOL, V15, P1906, DOI 10.1200/JCO.1997.15.5.1906; HALLIWELL B, 1988, FEBS LETT, V241, P202, DOI 10.1016/0014-5793(88)81061-5; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Kalyanaraman B, 2002, MOL CELL BIOCHEM, V234, P119, DOI 10.1023/A:1015976430790; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; Kwok JC, 2002, MOL PHARMACOL, V62, P888, DOI 10.1124/mol.62.4.888; LEIBOLD EA, 1984, J BIOL CHEM, V259, P4327; MINOTTI G, 1990, ARCH BIOCHEM BIOPHYS, V277, P268, DOI 10.1016/0003-9861(90)90578-M; Minotti G, 1998, FASEB J, V12, P541, DOI 10.1096/fasebj.12.7.541; Minotti G, 2001, CANCER RES, V61, P8422; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MURRAY MT, 1987, P NATL ACAD SCI USA, V84, P7438, DOI 10.1073/pnas.84.21.7438; Myers C, 1998, SEMIN ONCOL, V25, P10; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; Recalcati S, 1998, BLOOD, V91, P1059, DOI 10.1182/blood.V91.3.1059.1059_1059_1066; Reszka KJ, 1997, CHEM RES TOXICOL, V10, P1325, DOI 10.1021/tx970039q; Santambrogio P, 2000, PROTEIN EXPRES PURIF, V19, P212, DOI 10.1006/prep.2000.1212; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Tacchini L, 1997, GASTROENTEROLOGY, V113, P946, DOI 10.1016/S0016-5085(97)70191-4; Tacchini L, 1996, REDOX REP, V2, P273, DOI 10.1080/13510002.1996.11747061; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VISTICA DT, 1991, CANCER RES, V51, P2515	32	73	80	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13738	13745		10.1074/jbc.M310106200	http://dx.doi.org/10.1074/jbc.M310106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14739295	hybrid			2022-12-27	WOS:000220478500057
J	Pederson, BA; Wilson, WA; Roach, PJ				Pederson, BA; Wilson, WA; Roach, PJ			Glycogen synthase sensitivity to glucose-6-P is important for controlling glycogen accumulation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; YEAST; PHOSPHORYLATION; METABOLISM; IDENTIFICATION; MUTANTS; CELLS	Glycogen is a storage form of glucose utilized as an energy reserve by many organisms. Glycogen synthase, which is essential for synthesizing this glucose polymer, is regulated by both covalent phosphorylation and the concentration of glucose-6-P. With the yeast glycogen synthase Gsy2p, we recently identified two mutants, R579A/R581A/R582A and R586A/R588A/R591A, in which multiple arginine residues were mutated to alanine that were completely insensitive to activation by glucose-6-P in vitro (Pederson, B. A., Cheng, C., Wilson, W. A., and Roach, P. J. (2000) J. Biol. Chem. 275, 27753 - 27761). We report here the expression of these mutants in Saccharomyces cerevisiae and, as expected from our findings in vitro, they were not activated by glucose-6-P. The R579A/ R581A/R582A mutant, which is also resistant to inhibition by phosphorylation, caused hyperaccumulation of glycogen. In contrast, the mutant R586A/R588A/R591A, which retains the ability to be inactivated by phosphorylation, resulted in lower glycogen accumulation when compared with wild-type cells. When intracellular glucose-6-P levels were increased by mutating the PFK2 gene, glycogen storage due to the wild-type enzyme was increased, whereas that associated with R579A/R581A/ R582A was not greatly changed. This is the first direct demonstration that activation of glycogen synthase by glucose-6-P in vivo is necessary for normal glycogen accumulation.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Roach, PJ (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.	proach@iupui.edu		Wilson, Wayne/0000-0003-2417-5756	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542, R01DK042576] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20542, DK42576] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson C, 2001, J BACTERIOL, V183, P821, DOI 10.1128/JB.183.3.821-829.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; CIRIACY M, 1979, J BACTERIOL, V139, P152, DOI 10.1128/JB.139.1.152-160.1979; COROMINAS J, 1992, FEBS LETT, V310, P182, DOI 10.1016/0014-5793(92)81325-G; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1016/S0168-6445(00)00059-0; Hanashiro I, 2002, ARCH BIOCHEM BIOPHYS, V397, P286, DOI 10.1006/abbi.2001.2623; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Huang DQ, 1997, J BIOL CHEM, V272, P22495, DOI 10.1074/jbc.272.36.22495; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; Jensen PR, 1998, BIOTECHNOL BIOENG, V58, P191, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<191::AID-BIT11>3.0.CO;2-G; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; LOBO Z, 1983, J BIOL CHEM, V258, P1444; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; Pederson BA, 2000, J BIOL CHEM, V275, P27753; ROACH PJ, 1977, MOL CELL BIOCHEM, V15, P179, DOI 10.1007/BF01734108; Roach PJ, 2001, HDB PHYSL 7, VII, P609, DOI DOI 10.1002/CPHY.CP070219; SAGARDIA F, 1971, BIOCHEM BIOPH RES CO, V42, P829, DOI 10.1016/0006-291X(71)90505-5; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001	29	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13764	13768		10.1074/jbc.M312335200	http://dx.doi.org/10.1074/jbc.M312335200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14742447	hybrid			2022-12-27	WOS:000220478500060
J	Petersen, SV; Oury, TD; Ostergaard, L; Valnickova, Z; Wegrzyn, J; Thogersen, IB; Jacobsen, C; Bowler, RP; Fattman, CL; Crapo, JD; Enghild, JJ				Petersen, SV; Oury, TD; Ostergaard, L; Valnickova, Z; Wegrzyn, J; Thogersen, IB; Jacobsen, C; Bowler, RP; Fattman, CL; Crapo, JD; Enghild, JJ			Extracellular superoxide dismutase (EC-SOD) binds to type I collagen and protects against oxidative fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-CATALYZED OXIDATION; HEPARIN-BINDING; FREE-RADICALS; PROTEINS; OXYGEN; DOMAIN; LOCALIZATION; POLYPEPTIDES; DEGRADATION; RADIOLYSIS	The antioxidant enzyme extracellular superoxide dismutase (EC-SOD) is mainly found in the extracellular matrix of tissues. EC-SOD participates in the detoxification of reactive oxygen species by catalyzing the dismutation of superoxide radicals. The tissue distribution of the enzyme is particularly important because of the reactive nature of its substrate, and it is likely essential that EC-SOD is positioned at the site of superoxide production to prevent adventitious oxidation. EC-SOD contains a C-terminal heparin-binding region thought to be important for modulating its distribution in the extracellular matrix. This paper demonstrates that, in addition to binding heparin, EC-SOD specifically binds to type I collagen with a dissociation constant (K-d) of 200 nM. The heparin-binding region was found to mediate the interaction with collagen. Notably, the bound EC-SOD significantly protects type I collagen from oxidative fragmentation. This expands the known repertoire of EC-SOD binding partners and may play an important physiological role in preventing oxidative fragmentation of collagen during oxidative stress.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15261 USA; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	Aarhus University; Aarhus University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Jewish Health	Enghild, JJ (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds vej 10C, DK-8000 Aarhus C, Denmark.	jje@mb.au.dk	Ostergaard, Lars/AAA-3020-2020; Bowler, Russell P/J-8283-2015	Ostergaard, Lars/0000-0003-2459-0511; Bowler, Russell P/0000-0003-4651-363X; Vang Petersen, Steen/0000-0002-9338-911X; Ostergaard, Lars/0000-0002-7619-605X; Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [R01 HL63700, P01 HL31992E] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031992, R01HL063700] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI T, 1989, J BIOL CHEM, V264, P8537; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; Bowler RP, 2002, J BIOL CHEM, V277, P16505, DOI 10.1074/jbc.M105409200; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; DOOLITTLE RF, 1986, URFS ORFS, P55; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; Fattman CL, 2003, FREE RADICAL BIO MED, V35, P763, DOI 10.1016/S0891-5849(03)00402-7; Fattman CL, 2003, FREE RADICAL BIO MED, V35, P236, DOI 10.1016/S0891-5849(03)00275-2; Fattman CL, 2001, FREE RADICAL BIO MED, V31, P1198, DOI 10.1016/S0891-5849(01)00699-2; FORMAN HJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P396, DOI 10.1016/0003-9861(73)90636-X; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; KATO Y, 1992, J BIOL CHEM, V267, P23646; Kato Y, 2001, FREE RADICAL BIO MED, V31, P624, DOI 10.1016/S0891-5849(01)00623-2; LASKIN DL, 1994, AM J RESP CELL MOL, V10, P58, DOI 10.1165/ajrcmb.10.1.8292381; LASKIN DL, 1986, J LEUKOCYTE BIOL, V39, P255, DOI 10.1002/jlb.39.3.255; Lookene A, 2000, BIOCHEMISTRY-US, V39, P230, DOI 10.1021/bi991512x; MALONE JD, 1991, MATRIX, V11, P289; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; Monboisse J C, 1992, EXS, V62, P323; MONBOISSE JC, 1983, BIOCHEM PHARMACOL, V32, P53, DOI 10.1016/0006-2952(83)90651-2; MONBOISSE JC, 1988, BIOCHIM BIOPHYS ACTA, V965, P29, DOI 10.1016/0304-4165(88)90147-X; OURY TD, 1994, LAB INVEST, V70, P889; Oury TD, 1996, BIOCHEM J, V317, P51, DOI 10.1042/bj3170051; Oury TD, 2002, AM J PHYSIOL-LUNG C, V283, pL777, DOI 10.1152/ajplung.00011.2002; Petersen SV, 2003, P NATL ACAD SCI USA, V100, P13875, DOI 10.1073/pnas.2436143100; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; SCHUESSLER H, 1984, INT J RADIAT BIOL, V45, P267, DOI 10.1080/09553008414550381; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stenlund P, 2002, BIOCHEMISTRY-US, V41, P3168, DOI 10.1021/bi011454r; UCHIDA K, 1990, BIOCHEM BIOPH RES CO, V169, P265, DOI 10.1016/0006-291X(90)91463-3; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; Zhao F, 1997, J BIOL CHEM, V272, P9019	44	142	152	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13705	13710		10.1074/jbc.M310217200	http://dx.doi.org/10.1074/jbc.M310217200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736885	hybrid			2022-12-27	WOS:000220478500053
J	Bateman, NW; Tan, DF; Pestell, RG; Black, JD; Black, AR				Bateman, NW; Tan, DF; Pestell, RG; Black, JD; Black, AR			Intestinal tumor progression is associated with altered function of KLF5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; BTEB2 TRANSCRIPTION FACTOR; COLONIC CELL-GROWTH; KINASE-C ISOZYMES; EPITHELIAL-CELLS; PROSTATE-CANCER; FACTOR FAMILY; GENE; EXPRESSION; PROMOTER	Kruppel-like transcription factors have been linked to cell growth regulation and tumorigenesis in a number of systems. In the intestinal epithelium, expression of KLF5 (IKLF/BTEB2) is limited to proliferating crypt cells, indicating a growth-promoting role. Consistent with this role, we demonstrate that expression of KLF5 in non-transformed intestinal epithelial cells ( ileal IEC-18 and Immorto-Min Colon Epithelial (IMCE) cells) enhances colony formation, cyclin D1 transcription, and cell growth. However, in contrast to these effects in non-transformed cells, KLF5 reduced colony number, failed to enhance cyclin D1 transcription, and was negatively correlated with cell growth in colon cancer cell lines. The relationship between tumor progression and KLF5 was further investigated using Ras-mediated transformation of IEC-18 and IMCE cells as syngeneic models. Ras-transformation recapitulated differences in the effects of KLF5 on cell growth and cyclin D1 transcription, providing a direct link between intestinal tumor progression and altered function of KLF5. Ras-transformation also markedly down-regulated KLF5; further analysis indicated that reduced expression of KLF5 mRNA and destabilization of KLF5 protein occur in intestinal tumors. Reduced levels of KLF5 mRNA were also detected in APC(min) mouse and human familial adenomatous polyposis adenomas compared with normal crypt epithelium, indicating that down-regulation of KLF5 is an early event in intestinal tumorigenesis in vivo. Collectively, these data indicate that intestinal tumor progression is associated with a change in the growth-related functions of KLF5 and that intestinal tumors down-regulate KLF5 expression by multiple mechanisms.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; Georgetown Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20057 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Georgetown University	Black, AR (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	adrian.black@roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054909, R56DK060632, R01DK060632] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056] Funding Source: Medline; NIDDK NIH HHS [DK 54909, DK 60632] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Black AR, 1996, CANCER RES, V56, P700; Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Burgess AW, 1998, PHILOS T ROY SOC B, V353, P903, DOI 10.1098/rstb.1998.0254; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Goodman RH, 2000, GENE DEV, V14, P1553; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Katz JP, 2002, DEVELOPMENT, V129, P2619; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Muraoka M, 1996, ONCOGENE, V12, P1565; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Ogata T, 2000, TRANSPLANTATION, V70, P1653, DOI 10.1097/00007890-200012150-00019; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Rak J, 2000, CANCER RES, V60, P490; Rozenblum E, 2002, HUM GENET, V110, P111, DOI 10.1007/s00439-001-0646-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Stone CD, 2002, FEBS LETT, V530, P147, DOI 10.1016/S0014-5793(02)03449-X; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Sur I, 2002, EUR J CELL BIOL, V81, P323, DOI 10.1078/0171-9335-00257; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; WARD JM, 1973, JNCI-J NATL CANCER I, V51, P1997, DOI 10.1093/jnci/51.6.1997; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	44	111	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12093	12101		10.1074/jbc.M311532200	http://dx.doi.org/10.1074/jbc.M311532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726538	hybrid			2022-12-27	WOS:000220334900014
J	Khosravani, H; Altier, C; Simms, B; Hamming, KS; Snutch, TP; Mezeyova, J; McRory, JE; Zamponi, GW				Khosravani, H; Altier, C; Simms, B; Hamming, KS; Snutch, TP; Mezeyova, J; McRory, JE; Zamponi, GW			Gating effects of mutations in the Ca(v)3.2 T-type calcium channel associated with childhood absence epilepsy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; MOLECULAR CHARACTERIZATION; LOW-THRESHOLD; EXPRESSION; ALPHA(1G); NEURONS; FAMILY; INACTIVATION; SEIZURES; CLONING	Childhood absence epilepsy (CAE) is a type of generalized epilepsy observed in 2 - 10% of epileptic children. In a recent study by Chen et al. ( Chen, Y., Lu, J., Pan, H., Zhang, Y., Wu, H., Xu, K., Liu, X., Jiang, Y., Bao, X., Yao, Z., Ding, K., Lo, W. H., Qiang, B., Chan, P., Shen, Y., and Wu, X. ( 2003) Ann. Neurol. 54, 239 - 243) 12 missense mutations were identified in the CACNA1H (Ca(v)3.2) gene in 14 of 118 patients with CAE but not in 230 control individuals. We have functionally characterized five of these mutations (F161L, E282K, C456S, V831M, and D1463N) using rat Ca(v)3.2 and whole-cell patch clamp recordings in transfected HEK293 cells. Two of the mutations, F161L and E282K, mediated an similar to10-mV hyperpolarizing shift in the half-activation potential. Mutation V831M caused a similar to 50% slowing of inactivation relative to control and shifted half-inactivation potential similar to 10 mV toward more depolarized potentials. Mean time to peak was significantly increased by mutation V831M but was unchanged for all others. No resolvable changes in the parameters of the IV relation or current kinetics were observed with the remaining mutations. The findings suggest that several of the Cav3.2 mutants allow for greater calcium influx during physiological activation and in the case of F161L and E282K can result in channel openings at more hyperpolarized ( close to resting) potentials. This may underlie the propensity for seizures in patients with CAE.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada	University of Calgary; University of British Columbia	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	zamponi@ucalgary.ca	Khosravani, Houman/X-2391-2019; Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Zamponi, Gerald W./0000-0002-0644-9066				Adams R, 1998, PRINCIPLES NEUROLOGY, V6th; Avoli M, 2001, EPILEPSIA, V42, P445, DOI 10.1046/j.1528-1157.2001.39800.x; Beedle AM, 2002, J MEMBRANE BIOL, V187, P225, DOI 10.1007/s00232-001-0166-2; Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269; Chemin J, 2001, BIOPHYS J, V80, P1238, DOI 10.1016/S0006-3495(01)76100-0; Chen YC, 2003, ANN NEUROL, V54, P239, DOI 10.1002/ana.10607; COULTER DA, 1989, ANN NEUROL, V25, P582, DOI 10.1002/ana.410250610; Cribbs LL, 2000, FEBS LETT, V466, P54, DOI 10.1016/S0014-5793(99)01756-1; Crunelli V, 2002, NAT REV NEUROSCI, V3, P371, DOI 10.1038/nrn811; da Silva MRD, 2002, CLIN ENDOCRINOL, V56, P367; Goetz C.G., 1999, TXB CLIN NEUROLOGY; Gomora JC, 2002, BIOPHYS J, V83, P229, DOI 10.1016/S0006-3495(02)75164-3; JASPER HH, 1947, RES PUBL ASS NERV ME, V26, P272; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; KOSTYUK PG, 1992, NEUROSCIENCE, V51, P755, DOI 10.1016/0306-4522(92)90515-4; Kozlov AS, 1999, EUR J NEUROSCI, V11, P4149, DOI 10.1046/j.1460-9568.1999.00841.x; Kumar PP, 2002, MOL PHARMACOL, V61, P649, DOI 10.1124/mol.61.3.649; Lee JH, 1999, J NEUROSCI, V19, P1912; Marksteiner R, 2001, J PHYSIOL-LONDON, V537, P27, DOI 10.1111/j.1469-7793.2001.0027k.x; McRory JE, 2001, J BIOL CHEM, V276, P3999, DOI 10.1074/jbc.M008215200; MCRORY JE, 2004, IN PRESS J NEUROSCI, V24; Meeren HKM, 2002, J NEUROSCI, V22, P1480, DOI 10.1523/JNEUROSCI.22-04-01480.2002; Melliti K, 2003, J PHYSIOL-LONDON, V546, P337, DOI 10.1113/jphysiol.2002.026716; Park JY, 2003, FEBS LETT, V547, P37, DOI 10.1016/S0014-5793(03)00665-3; Perez-Reyes E, 1998, J BIOENERG BIOMEMBR, V30, P313, DOI 10.1023/A:1021981420839; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; POLLEN DA, 1963, ELECTROEN CLIN NEURO, V15, P1017, DOI 10.1016/0013-4694(63)90145-7; SONG I, 2001, ANN M SOC NEUR NOV 1; Staes M, 2001, J PHYSIOL-LONDON, V530, P35, DOI 10.1111/j.1469-7793.2001.0035m.x; STERIADE M, 1995, J NEUROSCI, V15, P623; Steriade M, 1998, J NEUROPHYSIOL, V80, P1439, DOI 10.1152/jn.1998.80.3.1439; Stotz SC, 2004, J PHYSIOL-LONDON, V554, P263, DOI 10.1113/jphysiol.2003.047068; Talley EM, 1999, J NEUROSCI, V19, P1895; Talley EM, 2000, MOL BRAIN RES, V75, P159, DOI 10.1016/S0169-328X(99)00307-1	34	139	152	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9681	9684		10.1074/jbc.C400006200	http://dx.doi.org/10.1074/jbc.C400006200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14729682	hybrid			2022-12-27	WOS:000220050400003
J	Prybylowski, K; Wenthold, RJ				Prybylowski, K; Wenthold, RJ			N-methyl-D-aspartate receptors: Subunit assembly and trafficking to the synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ER RETENTION SIGNAL; NMDA GLUTAMATE RECEPTORS; CELL-SURFACE EXPRESSION; PROTEIN-KINASE-C; MOLECULAR-BASIS; AMPA RECEPTORS; PSD-95; COMPLEX; TRANSMISSION; SENSITIVITY		NIDCD, Neurochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Prybylowski, K (corresponding author), NIDCD, Neurochem Lab, NIH, Bldg 50,Rm 4148, Bethesda, MD 20892 USA.	prybylow@nidcd.nih.gov			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000003, Z01DC000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chavis P, 2001, NATURE, V411, P317, DOI 10.1038/35077101; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; Dunah AW, 2003, J NEUROCHEM, V85, P935, DOI 10.1046/j.1471-4159.2003.01744.x; Fong DK, 2002, J NEUROSCI, V22, P2153, DOI 10.1523/JNEUROSCI.22-06-02153.2002; Gottmann K, 1997, J NEUROSCI, V17, P2766; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Guillaud L, 2003, J NEUROSCI, V23, P131; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kuner T, 2003, TRENDS NEUROSCI, V26, P27, DOI 10.1016/S0166-2236(02)00010-3; Lan JY, 2001, J NEUROSCI, V21, P6058, DOI 10.1523/JNEUROSCI.21-16-06058.2001; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Li B, 2002, NAT NEUROSCI, V5, P833, DOI 10.1038/nn912; Liao GY, 2000, J NEUROCHEM, V75, P282, DOI 10.1046/j.1471-4159.2000.0750282.x; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; MacDonald JF, 2001, CURR DRUG TARGETS, V2, P299, DOI 10.2174/1389450013348452; McGee AW, 2003, CURR OPIN NEUROBIOL, V13, P111, DOI 10.1016/S0959-4388(03)00008-4; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; McIlhinney RAJ, 2003, BIOCHEM SOC T, V31, P865, DOI 10.1042/BST0310865; Mok H, 2002, J NEUROSCI, V22, P5253; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Nicoll RA, 2003, PHILOS T R SOC B, V358, P721, DOI 10.1098/rstb.2002.1228; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; Okabe S, 1999, J NEUROSCI, V19, P7781; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; Philpot BD, 2001, NEURON, V29, P157, DOI 10.1016/S0896-6273(01)00187-8; Prybylowski K, 2002, J NEUROSCI, V22, P8902; Regalado MP, 2001, NEURON, V32, P1085, DOI 10.1016/S0896-6273(01)00539-6; Riefler GM, 2003, BIOCHEM J, V373, P49, DOI 10.1042/BJ20021838; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rumbaugh G, 1999, J NEUROSCI, V19, P10603, DOI 10.1523/JNEUROSCI.19-24-10603.1999; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Seabold GK, 2003, J BIOL CHEM, V278, P15040, DOI 10.1074/jbc.M212825200; Skeberdis VA, 2001, P NATL ACAD SCI USA, V98, P3561, DOI 10.1073/pnas.051634698; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Stephenson FA, 2001, CURR DRUG TARGETS, V2, P233, DOI 10.2174/1389450013348461; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tovar KR, 2002, NEURON, V34, P253; Townsend M, 2003, P NATL ACAD SCI USA, V100, P1340, DOI 10.1073/pnas.0335786100; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Watt AJ, 2000, NEURON, V26, P659, DOI 10.1016/S0896-6273(00)81202-7; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Yaka R, 2003, J NEUROSCI, V23, P3623; Yamada Y, 1999, J BIOL CHEM, V274, P6647, DOI 10.1074/jbc.274.10.6647; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	60	95	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9673	9676		10.1074/jbc.R300029200	http://dx.doi.org/10.1074/jbc.R300029200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14742424	hybrid			2022-12-27	WOS:000220050400001
J	Fitzgerald, JB; Jin, M; Dean, D; Wood, DJ; Zheng, MH; Grodzinsky, AJ				Fitzgerald, JB; Jin, M; Dean, D; Wood, DJ; Zheng, MH; Grodzinsky, AJ			Mechanical compression of cartilage explants induces multiple time-dependent gene expression patterns and involves intracellular calcium and cyclic AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TRANSCRIPTION FACTORS; ARTICULAR-CARTILAGE; MATRIX-METALLOPROTEINASE; PROTEOGLYCAN DEGRADATION; CHONDROCYTE AGGRECAN; DYNAMIC COMPRESSION; MAP KINASES; BOVINE; COLLAGEN; PROTEIN	Chondrocytes are influenced by mechanical forces to remodel cartilage extracellular matrix. Previous studies have demonstrated the effects of mechanical forces on changes in biosynthesis and mRNA levels of particular extracellular matrix molecules, and have identified certain signaling pathways that may be involved. However, the broad extent and kinetics of mechano-regulation of gene transcription has not been studied in depth. We applied static compressive strains to bovine cartilage explants for periods between 1 and 24 h and measured the response of 28 genes using real time PCR. Compression time courses were also performed in the presence of an intracellular calcium chelator or an inhibitor of cyclic AMP-activated protein kinase A. Cluster analysis of the data revealed four main expression patterns: two groups containing either transiently up-regulated or duration-enhanced expression profiles could each be subdivided into genes that did or did not require intracellular calcium release and cyclic AMP-activated protein kinase A for their mechano-regulation. Transcription levels for aggrecan, type II collagen, and link protein were up-regulated similar to2-3-fold during the first 8 h of 50% compression and subsequently down-regulated to levels below that of free-swelling controls by 24 h. Transcription levels of matrix metalloproteinases-3, -9, and -13, aggrecanase-1, and the matrix protease regulator cyclooxygenase-2 increased with the duration of 50% compression 2-16-fold by 24 h. Thus, transcription of proteins involved in matrix remodeling and catabolism dominated over anabolic matrix proteins as the duration of static compression increased. Immediate early genes c-fos and c-jun were dramatically up-regulated 6-30-fold, respectively, during the first 8 h of 50% compression and remained up-regulated after 24 h.	MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Orthopaed Surg, Nedlands, WA 6009, Australia	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Western Australia	Grodzinsky, AJ (corresponding author), MIT, Biol Engn Div, NE47-377,77 Massachusetts Ave, Cambridge, MA 02139 USA.	alg@mit.edu	Dean, Delphine/AAZ-7907-2021; Jin, Moonsoo/D-6128-2011; Dean, Delphine/F-3391-2010	Dean, Delphine/0000-0002-8631-2640; Dean, Delphine/0000-0002-8631-2640; Zheng, Minghao/0000-0003-1185-4768	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033236, R37AR033236] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 33236] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; ARMITAGE P, 2002, STAT METHODS MED RES, P455; BEHRENS F, 1989, J ORTHOPAED RES, V7, P335, DOI 10.1002/jor.1100070305; Blain EJ, 2001, ARCH BIOCHEM BIOPHYS, V396, P49, DOI 10.1006/abbi.2001.2575; Bonassar LJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P57, DOI 10.1006/abbi.2000.1820; Bonassar LJ, 2001, J ORTHOP RES, V19, P11, DOI 10.1016/S0736-0266(00)00004-8; Davisson T, 2002, J ORTHOPAED RES, V20, P842, DOI 10.1016/S0736-0266(01)00160-7; Dougherty ER, 2002, J COMPUT BIOL, V9, P105, DOI 10.1089/10665270252833217; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Fermor B, 2002, OSTEOARTHR CARTILAGE, V10, P792, DOI 10.1053/joca.2002.0832; GENG Y, 1995, J IMMUNOL, V155, P796; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; Guilak F, 1994, Osteoarthritis Cartilage, V2, P91, DOI 10.1016/S1063-4584(05)80059-7; Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356; Hascall VC, 2002, MANY FACES OF OSTEOARTHRITIS, P177; Herberhold C, 1999, J BIOMECH, V32, P1287, DOI 10.1016/S0021-9290(99)00130-X; HODGE WA, 1986, P NATL ACAD SCI USA, V83, P2879, DOI 10.1073/pnas.83.9.2879; Holter NS, 2000, P NATL ACAD SCI USA, V97, P8409, DOI 10.1073/pnas.150242097; Hui A, 1998, ARTHRITIS RHEUM, V41, P869, DOI 10.1002/1529-0131(199805)41:5<869::AID-ART15>3.0.CO;2-3; Hui W, 2001, CYTOKINE, V16, P31, DOI 10.1006/cyto.2001.0950; Hunter CJ, 2002, BIOMATERIALS, V23, P1249, DOI 10.1016/S0142-9612(01)00245-9; Ikenoue T, 2003, J ORTHOPAED RES, V21, P110, DOI 10.1016/S0736-0266(02)00091-8; Jin M, 2001, ARCH BIOCHEM BIOPHYS, V395, P41, DOI 10.1006/abbi.2001.2543; Kaarniranta K, 2001, OSTEOARTHR CARTILAGE, V9, P7, DOI 10.1053/joca.2000.0354; Kim YJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P331, DOI 10.1006/abbi.1996.0181; KIM YJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P1, DOI 10.1006/abbi.1994.1201; Kisiday JD, 2004, J BIOMECH, V37, P595, DOI 10.1016/j.jbiomech.2003.10.005; Li KW, 2003, ARTHRITIS RHEUM-US, V48, P689, DOI 10.1002/art.10849; Liacini A, 2003, EXP CELL RES, V288, P208, DOI 10.1016/S0014-4827(03)00180-0; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; LOHMANDER LS, 1993, J RHEUMATOL, V20, P1362; Lowe GN, 1996, ENDOCRINOLOGY, V137, P2208, DOI 10.1210/en.137.6.2208; Mauck RL, 2000, J BIOMECH ENG-T ASME, V122, P252, DOI 10.1115/1.429656; Millward-Sadler SJ, 2000, ARTHRITIS RHEUM, V43, P2091, DOI 10.1002/1529-0131(200009)43:9<2091::AID-ANR21>3.0.CO;2-C; Millward-Sadler SJ, 1999, J CELL BIOL, V145, P183, DOI 10.1083/jcb.145.1.183; Mizuno S, 2002, J CELL PHYSIOL, V193, P319, DOI 10.1002/jcp.10180; Murata M, 2003, ARCH BIOCHEM BIOPHYS, V413, P229, DOI 10.1016/S0003-9861(03)00129-2; PARKKINEN JJ, 1993, ANN RHEUM DIS, V52, P192, DOI 10.1136/ard.52.3.192; Patwari P, 2003, ARTHRITIS RHEUM-US, V48, P1292, DOI 10.1002/art.10892; Ragan PM, 1999, J ORTHOPAED RES, V17, P836, DOI 10.1002/jor.1100170608; SAAMAMEN AM, 1994, CONNECT TISSUE RES, V30, P191, DOI 10.3109/03008209409061971; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; Sironen RK, 2002, BIORHEOLOGY, V39, P111; SLOWMAN SD, 1986, ARTHRITIS RHEUM, V29, P88, DOI 10.1002/art.1780290112; Thibault M, 2002, J ORTHOP RES, V20, P1265, DOI 10.1016/S0736-0266(02)00070-0; Tsuji M, 1996, FEBS LETT, V381, P222, DOI 10.1016/0014-5793(96)00118-4; Tsuzaki M, 2003, J ORTHOP RES, V21, P256, DOI 10.1016/S0736-0266(02)00141-9; Valhmu WB, 1998, ARCH BIOCHEM BIOPHYS, V353, P29, DOI 10.1006/abbi.1998.0633; Valhmu WB, 2002, BIOCHEM J, V361, P689, DOI 10.1042/0264-6021:3610689; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; Vincenti MP, 2001, ARTHRITIS RES, V3, P381, DOI 10.1186/ar331; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401	54	182	186	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2004	279	19					19502	19511		10.1074/jbc.M400437200	http://dx.doi.org/10.1074/jbc.M400437200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	817FX	14960571	hybrid			2022-12-27	WOS:000221164500017
J	Ma, YJ; Wang, TS; Villemain, JL; Giedroc, DP; Morrical, SW				Ma, YJ; Wang, TS; Villemain, JL; Giedroc, DP; Morrical, SW			Dual functions of single-stranded DNA-binding protein in helicase loading at the bacteriophage T4 DNA replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-DESTABILIZING PROTEIN; NUCLEIC-ACID COMPLEXES; T4 GENE-32 PROTEIN; ASSEMBLY PROTEIN; COOPERATIVITY DOMAIN; MEDIATOR PROTEINS; CRYSTAL-STRUCTURE; DDA HELICASE; PURIFICATION; PHAGE	Semi-conservative DNA synthesis reactions catalyzed by the bacteriophage T4 DNA polymerase holoenzyme are initiated by a strand displacement mechanism requiring gp32, the T4 single-stranded DNA (ssDNA)-binding protein, to sequester the displaced strand. After initiation, DNA helicase acquisition by the nascent replication fork leads to a dramatic increase in the rate and processivity of leading strand DNA synthesis. In vitro studies have established that either of two T4-encoded DNA helicases, gp41 or dda, is capable of stimulating strand displacement synthesis. The acquisition of either helicase by the nascent replication fork is modulated by other protein components of the fork including gp32 and, in the case of the gp41 helicase, its mediator/ loading protein gp59. Here, we examine the relationships between gp32 and the gp41/gp59 and dda helicase systems, respectively, during T4 replication using altered forms of gp32 defective in either protein-protein or protein-ssDNA interactions. We show that optimal stimulation of DNA synthesis by gp41/gp59 helicase requires gp32-gp59 interactions and is strongly dependent on the stability of ssDNA binding by gp32. Fluorescence assays demonstrate that gp59 binds stoichiometrically to forked DNA molecules; however, gp59-forked DNA complexes are destabilized via protein-protein interactions with the C-terminal "A-domain" fragment of gp32. These and previously published results suggest a model in which a mobile gp59-gp32 cluster bound to lagging strand ssDNA is the target for gp41 helicase assembly. In contrast, stimulation of DNA synthesis by dda helicase requires direct gp32-dda protein-protein interactions and is relatively unaffected by mutations in gp32 that destabilize its ssDNA binding activity. The latter data support a model in which protein-protein interactions with gp32 maintain dda in a proper active state for translocation at the replication fork. The relationship between dda and gp32 proteins in T4 replication appears similar to the relationship observed between the UL9 helicase and ICP8 ssDNA-binding protein in herpesvirus replication.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	University of Vermont; Texas A&M University System; Texas A&M University College Station	Morrical, SW (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.	smorrica@zoo.uvm.edu	Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [GM42569, GM48847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM048847, R01GM042569, R29GM042569, R01GM048847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; Arana ME, 2001, J BIOL CHEM, V276, P6840, DOI 10.1074/jbc.M007219200; BARRY J, 1994, J BIOL CHEM, V269, P33049; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; BEHME MT, 1975, J VIROL, V15, P50, DOI 10.1128/JVI.15.1.50-54.1975; BITTNER M, 1979, J BIOL CHEM, V254, P9565; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1989, J BIOL CHEM, V264, P12220; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; DOTTO GP, 1981, P NATL ACAD SCI-BIOL, V78, P5421, DOI 10.1073/pnas.78.9.5421; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HACKER KJ, 1992, J BIOL CHEM, V267, P20674; He XD, 2000, J VIROL, V74, P5726, DOI 10.1128/JVI.74.12.5726-5728.2000; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Jones CE, 2000, J BIOL CHEM, V275, P27145; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2933; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; MORRICAL SW, 1991, J BIOL CHEM, V266, P14031; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nanduri B, 2002, P NATL ACAD SCI USA, V99, P14722, DOI 10.1073/pnas.232401899; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; Villemain JL, 1996, BIOCHEMISTRY-US, V35, P14395, DOI 10.1021/bi961482n; Villemain JL, 1996, J BIOL CHEM, V271, P27623, DOI 10.1074/jbc.271.44.27623; Villemain JL, 2000, J BIOL CHEM, V275, P31496, DOI 10.1074/jbc.M002902200; WILLIAMS KR, 1994, MOL BIOL BACTERIOP T, V4, P301; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	52	38	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19035	19045		10.1074/jbc.M311738200	http://dx.doi.org/10.1074/jbc.M311738200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14871889	hybrid			2022-12-27	WOS:000221041500116
J	Hong, SH; Choi, HM; Park, MJ; Kim, YH; Choi, YH; Kim, HH; Choi, YH; Cheong, JH				Hong, SH; Choi, HM; Park, MJ; Kim, YH; Choi, YH; Kim, HH; Choi, YH; Cheong, JH			Activation and interaction of ATF2 with the coactivator ASC-2 are responsive for granulocytic differentiation by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; TRANSCRIPTION FACTOR-2; RECEPTOR COACTIVATOR; GENE-EXPRESSION; MELANOMA-CELLS; NUCLEAR-FACTOR; C/EBP-ALPHA; CYCLIN D1; PROTEIN; BINDING	Terminal differentiation of hematopoietic cells follows a precisely orchestrated program of transcriptional regulatory events at the promoters of both lineage-specific and ubiquitous genes. Here we show that the transcription factor ATF2 is associated with the induction of granulocytic differentiation, and the molecular interaction of ATF2 with a tissue-specific coactivator activating signal cointegator-2 (ASC-2) potentiates the differentiation procedure. All-trans retinoic acid (RA) induced the phosphorylation and expression of ATF2 in the early and middle phase of granulocyte differentiation, respectively. The activation of granulocyte-specific gene expression is increased with the concerted action of another basic region-leucine zipper factor, CCAAT/enhancer-binding protein (C/EBPalpha), and ASC-2, which function in a cooperative manner. The interaction between ATF2 and C/EBPalpha in RA-treated cells was enhanced by the ectopic expression of ASC-2. ATF2-mediated transactivation was also increased by co-transfection of ASC-2. This resulted from the direct protein interaction that the N-terminal transactivation domain of ATF2 interacts with the central region of ASC-2. Furthermore, the molecular interaction of ATF2 and ASC-2 was stimulated by RA treatment and inhibited by p38beta kinase inhibitor. Taking these results together, these results suggest that the differentiation-dependent expression and phosphorylation of ATF2 protein physically and functionally interacts with C/EBPalpha and coativator ASC-2 and synergizes to induce target gene transcription during granulocytic differentiation.	Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; Pusan Natl Univ, Coll Med, Dept Clin Pathol, Pusan 602739, South Korea; Dong Eui Univ, Coll Oriental Med, Dept Biochem, Pusan 614054, South Korea	Pusan National University; Pusan National University; Dong-Eui University	Cheong, JH (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	molecule85@pusan.ac.kr						Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; AUSUBEL FM, 2002, SHORT PROTOCOLS MOL, P9; Ban N, 2000, DIABETES, V49, P1142, DOI 10.2337/diabetes.49.7.1142; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3461; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hong S, 2001, BIOCHEM BIOPH RES CO, V282, P1257, DOI 10.1006/bbrc.2001.4727; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Lee MY, 2002, DIABETES, V51, P3400; Lee MY, 2001, BIOCHEM BIOPH RES CO, V281, P1241, DOI 10.1006/bbrc.2001.4494; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Yamanaka R, 1998, INT J MOL MED, V1, P213; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510	34	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16996	17003		10.1074/jbc.M311752200	http://dx.doi.org/10.1074/jbc.M311752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14734562	hybrid			2022-12-27	WOS:000220870400015
J	Golan, T; Yaniv, A; Bafico, A; Liu, GZ; Gazit, A				Golan, T; Yaniv, A; Bafico, A; Liu, GZ; Gazit, A			The human frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt center dot beta-Catenin signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; PROTEIN-KINASE-II; WNT/BETA-CATENIN; MAMMALIAN-CELLS; C-MYC; PATHWAY; RECEPTOR; TRANSCRIPTION; TCF; TRANSFORMATION	Previously we have cloned the human Frizzled 1 (HFz1) and shown that it transmits the Wnt-3a-induced canonical pathway. We also cloned the human Frizzled 6 (HFz6) and show in the present study that, as opposed to HFz1, HFz6 did not activate the canonical Wnt pathway following exposure to various Wnts, whether belonging to the Wnt-1 or to the Wnt-5a group. Moreover we show that HFz6 repressed Wnt-3a-induced canonical signaling when co-expressed with HFz1. HFz6 repressed the canonical Wnt cascade activated also by various Wnt signaling intracellular mediators such as Dishevelled-1, a stabilized beta-catenin(S33Y) mutant, and LiCl-mediated repression of glycogen synthase kinase-3beta activity. Removal of HFz6 N'- or C'-terminal sequences abolished HFz6 repressive activity. As the HFz6 repressive effect was not associated with a decrease in the level of beta-catenin, it is suggested that HFz6 does not affect beta-catenin stabilization, implying that HFz6 transmits a repressive signaling that cross-talks with and inhibits the canonical Wnt pathway downstream of beta-catenin destruction complex. HFz6 did not affect the level of nuclear T-cell factor 4 (TCF4) nor did it affect beta-catenin.TCF4 complex formation. However, electrophoretic mobility shift assays indicated that HFz6 repressed the binding of TCF/lymphoid enhancer factor transcription factors to target DNA. Moreover we present data suggesting that HFz6 activates the transforming growth factor-beta-activated kinase-NEMO-like kinase pathway that blocks TCF/lymphoid enhancer factor binding to target promoters, thereby inhibiting the ability of beta-catenin to activate transcription of Wnt target genes.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Tel Aviv University; Sackler Faculty of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Gazit, A (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.	micro1@post.tau.ac.il						Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Holmen SL, 2002, J BIOL CHEM, V277, P34727, DOI 10.1074/jbc.M204989200; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; LORENZI MV, 1995, ONCOGENE, V10, P2051; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Sato A, 1999, DEVELOPMENT, V126, P4421; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tokuhara M, 1998, BIOCHEM BIOPH RES CO, V243, P622, DOI 10.1006/bbrc.1998.8143; Tolwinski NS, 2001, DEVELOPMENT, V128, P2107; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Weidinger G, 2003, J CELL BIOL, V162, P753, DOI 10.1083/jcb.200307181; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	51	111	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14879	14888		10.1074/jbc.M306421200	http://dx.doi.org/10.1074/jbc.M306421200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747478	hybrid			2022-12-27	WOS:000220594700049
J	Golding, SE; Rosenberg, E; Khalil, A; McEwen, A; Holmes, M; Neill, S; Povirk, LF; Valerie, K				Golding, SE; Rosenberg, E; Khalil, A; McEwen, A; Holmes, M; Neill, S; Povirk, LF; Valerie, K			Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAFFEINE-INDUCED RADIOSENSITIZATION; DEPENDENT PROTEIN-KINASE; DNA-DAMAGE CHECKPOINT; DIRECTED REPAIR; HISTONE H2AX; IN-VIVO; MAMMALIAN CHROMOSOME; IONIZING-RADIATION; GENE CONVERSION; HIGH-FREQUENCY	To investigate double strand break (DSB) repair and signaling in human glioma cells, we stably transfected human U87 (ATM(+), p53(+)) glioma cells with a plasmid having a single I-SceI site within an inactive green fluorescent protein (GFP) expression cassette, allowing for the detection of homologous recombination repair (HRR) by GFP expression. HRR and nonhomologous end joining (NHEJ) were also determined by PCR. DSB repair was first detected at 12 h postinfection with an adenovirus expressing I-SceI with repair reaching plateau levels between 24 and 48 h. Within this time frame, NHEJ predominated over HRR in the range of 3-50-fold. To assess the involvement of ATM in DSB repair, we first examined whether ATM was associated with the DSB. Chromatin immunoprecipitation showed that ATM was present at the site of the DSB as early as 18 h postinfection. In cells treated with caffeine, an inhibitor of ATM, HRR was reduced, whereas NHEJ was not. In support of this finding, GFP flow cytometry demonstrated that caffeine reduced HRR by 90% under conditions when ATM kinase activity was inhibited. Dominant-negative ATM expressed from adenovirus inhibited HRR by 45%, also having little to no effect on NHEJ. Furthermore, HRR was inhibited by caffeine in serum-starved cells arrested in G(0)/G(1), suggesting that ATM is also important for HRR outside of the S and G(2) cell cycle phases. Altogether, these results demonstrate that HRR contributes substantially to DSB repair in human glioma cells, and, importantly, ATM plays a critical role in regulating HRR but not NHEJ throughout the cell cycle.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Univ W England, Fac Sci Appl, Bristol BS16 1QY, Avon, England	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of West England	Valerie, K (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.	KVALERIE@MAIL2.VCU.EDU	Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [P01CA072955, P30CA016059] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 72955, P30 CA 16059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Anderson CW, 2000, RADIAT RES, V154, P473, DOI 10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2; Anglana M, 1999, NUCLEIC ACIDS RES, V27, P4276, DOI 10.1093/nar/27.21.4276; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; HaasKogan DA, 1996, INT J RADIAT ONCOL, V36, P95, DOI 10.1016/S0360-3016(96)00244-1; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jackson SP, 1999, BIOCHEM SOC T, V27, P1; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Luo CM, 1996, J BIOL CHEM, V271, P4497; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pluth JM, 2001, CANCER RES, V61, P2649; POWELL SN, 1995, CANCER RES, V55, P1643; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosenberg E, 2003, BIOTECHNIQUES, V34, P476, DOI 10.2144/03343bm05; Rosenberg E, 2002, INT J RADIAT ONCOL, V52, P831, DOI 10.1016/S0360-3016(01)02754-7; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shiloh Y, 2001, BIOCHEM SOC T, V29, P661, DOI 10.1042/0300-5127:0290661; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; Tsuchida R, 2002, RADIAT RES, V158, P195, DOI 10.1667/0033-7587(2002)158[0195:DOAGMI]2.0.CO;2; Valerie K, 2000, CANCER GENE THER, V7, P879, DOI 10.1038/sj.cgt.7700185; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; Wang X, 2003, J BIOL CHEM, V278, P30869, DOI 10.1074/jbc.M301876200; Wang X, 2003, RADIAT RES, V159, P426, DOI 10.1667/0033-7587(2003)159[0426:CIRIIO]2.0.CO;2; Wiese C, 2002, CANCER RES, V62, P1279; Yoshida M, 2002, INT J RADIAT BIOL, V78, P503, DOI [10.1080/095530002317577321, 10.1080/09553000210123685]; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	71	102	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15402	15410		10.1074/jbc.M314191200	http://dx.doi.org/10.1074/jbc.M314191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744854	hybrid			2022-12-27	WOS:000220594700110
J	Hinsch, KD; De Pinto, V; Aires, VA; Schneider, X; Messina, A; Hinsch, E				Hinsch, KD; De Pinto, V; Aires, VA; Schneider, X; Messina, A; Hinsch, E			Voltage-dependent anion-selective channels VDAC2 and VDAC3 are abundant proteins in bovine outer dense fibers, a cytoskeletal component of the sperm flagellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-LYMPHOCYTES; MITOCHONDRIAL-MEMBRANE; LIGHT-CHAIN; SKELETAL-MUSCLE; PORIN; IDENTIFICATION; PURIFICATION; ISOFORMS; YEAST; EXPRESSION	Outer dense fibers (ODF) are specific subcellular components of the sperm flagellum. The functions of ODF have not yet been clearly elucidated. We have investigated the protein composition of purified ODF from bovine spermatozoa and found that one of the most abundant proteins is a 30-32-kDa polypeptide. This protein was analyzed by sequencing peptides derived following limited proteolysis. Peptide sequences were found to match VDAC2 and VDAC3. VDACs (voltage-dependent, anion-selective channels) or eukaryotic porins are a group of proteins first identified in the mitochondrial outer membrane that are able to form hydrophilic pore structures in membranes. In mammals, three VDAC isoforms (VDAC1, -2, -3) have been identified by cDNA cloning and sequencing. Antibodies against synthetic peptides specific for the three mammal VDAC isoforms were generated in rabbits. Their specificity was demonstrated by immunoblotting using recombinant VDAC1, -2, and -3. In protein extracts of bovine spermatozoa, VDAC1, -2, and -3 were detected by specific antibodies, while only VDAC2 and -3 were found as solubilized proteins derived from purified bovine ODFs. Immunofluorescence microscopy of spermatozoa revealed that anti-VDAC2 and anti-VDAC3 antibodies clearly bound to the sperm flagellum, in particular to the ODF. Transmission electron immunomicroscopy supported the finding that VDAC2 protein is abundant in the ODF. Since the ODF does not have any known membranous structure, it is tempting to speculate that VDAC2 and VDAC3 might have an alternative structural organization and different functions in ODF than in mitochondria.	Univ Giessen, Ctr Dermatol & Androl, D-35392 Giessen, Germany; Univ Catania, Dept Chem, Biochem & Mol Biol Lab, I-95125 Catania, Italy	Justus Liebig University Giessen; University of Catania	Hinsch, KD (corresponding author), Univ Giessen, Ctr Dermatol & Androl, Gaffystr 14, D-35392 Giessen, Germany.	Klaus-Dieter.Hinsch@derma.med.uni-giessen.de	De Pinto, Vito/AAC-2634-2019; Messina, Angela/ABC-9518-2020	De Pinto, Vito/0000-0001-5513-2906; MESSINA, Angela Anna/0000-0002-5745-9846				Abrecht H, 2000, PLANT PHYSIOL, V124, P1181, DOI 10.1104/pp.124.3.1181; BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; BENZ R, 1992, J BIOENERG BIOMEMBR, V24, P33, DOI 10.1007/BF00769528; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bhullar B, 2003, J BIOL CHEM, V278, P16159, DOI 10.1074/jbc.M213126200; BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BRITO M, 1986, GAMETE RES, V15, P327, DOI 10.1002/mrd.1120150406; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; FLORKE H, 1994, BIOL CHEM H-S, V375, P513, DOI 10.1515/bchm3.1994.375.8.513; Gonzalez-Gronow M, 2003, J BIOL CHEM, V278, P27312, DOI 10.1074/jbc.M303172200; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HEINS L, 1994, J BIOL CHEM, V269, P26402; HENKEL R, 1992, BIOL CHEM H-S, V373, P685, DOI 10.1515/bchm3.1992.373.2.685; Hinsch E, 1996, ANDROLOGIA, V28, P9; Hinsch E, 2003, REPROD DOMEST ANIM, V38, P155, DOI 10.1046/j.1439-0531.2003.00408.x; Hinsch E, 1998, ANDROLOGIA, V30, P281; Hinsch E, 1997, ADV EXP MED BIOL, V424, P313; Hinsch KD, 2001, BBA-GENE STRUCT EXPR, V1518, P329, DOI 10.1016/S0167-4781(01)00199-3; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; LINDEN M, 1982, BIOCHEM J, V208, P77, DOI 10.1042/bj2080077; MANN T, 1982, CRC CR REV TOXICOL, V11, P1, DOI 10.3109/10408448209089846; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; OKO R, 1988, BIOL REPROD, V39, P169, DOI 10.1095/biolreprod39.1.169; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Rostovtseva TK, 1998, BIOPHYS J, V74, P2365, DOI 10.1016/S0006-3495(98)77945-7; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; Schwarzer C, 2002, INT J BIOCHEM CELL B, V34, P1059, DOI 10.1016/S1357-2725(02)00026-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; UNGEWICKELL E, 1994, EUR J BIOCHEM, V222, P33, DOI 10.1111/j.1432-1033.1994.tb18838.x; Xu X, 1999, J MEMBRANE BIOL, V170, P89, DOI 10.1007/s002329900540; Xu X, 2001, J MEMBRANE BIOL, V180, P73, DOI 10.1007/s002320010060	46	97	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15281	15288		10.1074/jbc.M313433200	http://dx.doi.org/10.1074/jbc.M313433200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739283	hybrid			2022-12-27	WOS:000220594700096
J	Verho, R; Putkonen, M; Londesborough, J; Penttila, M; Richard, P				Verho, R; Putkonen, M; Londesborough, J; Penttila, M; Richard, P			A novel NADH-linked L-xylulose reductase in the L-arabinose catabolic pathway of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ARABINITOL DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; PICHIA-STIPITIS; XYLOSE REDUCTASE; XYLITOL-DEHYDROGENASE; CANDIDA-TROPICALIS; MOLECULAR-CLONING; ASPERGILLUS-NIGER; GENE; EXPRESSION	An NADH-dependent L-xylulose reductase and the corresponding gene were identified from the yeast Ambrosiozyma monospora. The enzyme is part of the yeast pathway for L-arabinose catabolism. A fungal pathway for L-arabinose utilization has been described previously for molds. In this pathway L-arabinose is sequentially converted to L-arabinitol, L-xylulose, xylitol, and D-xylulose and enters the pentose phosphate pathway as D-xylulose 5-phosphate. In molds the reductions are NADPH-linked, and the oxidations are NAD(+)-linked. Here we show that in A. monospora the pathway is similar, i.e. it has the same two reduction and two oxidation reactions, but the reduction by L-xylulose reductase is not performed by a strictly NADPH-dependent enzyme as in molds but by a strictly NADH-dependent enzyme. The ALX1 gene encoding the NADH-dependent L-xylulose reductase is strongly expressed during growth on L-arabinose as shown by Northern analysis. The gene was functionally overexpressed in Saccharomyces cerevisiae and the purified His-tagged protein characterized. The reversible enzyme converts L-xylulose to xylitol. It also converts D-ribulose to D-arabinitol but has no activity with L-arabinitol or adonitol, i.e. it is specific for sugar alcohols where, in a Fischer projection, the hydroxyl group of the C-2 is in the L-configuration and the hydroxyl group of C-3 is in the D-configuration. It also has no activity with C-6 sugars or sugar alcohols. The Km values for L-xylulose and D-ribulose are 9.6 and 4.7 mM, respectively. To our knowledge this is the first report of an NADH-linked L-xylulose reductase.	VTT Biotechnol, FIN-02044 Espoo, Finland	VTT Technical Research Center Finland	Richard, P (corresponding author), VTT Biotechnol, Tietotie 2,POB 1500, FIN-02044 Espoo, Finland.	Peter.Richard@vtt.fi	Richard, Peter/A-4229-2009; Penttilä, Merja E/A-4710-2013	Richard, Peter/0000-0003-0922-6092; Penttila, Merja/0000-0002-6929-1032				Becker J, 2003, APPL ENVIRON MICROB, V69, P4144, DOI 10.1128/AEM.69.7.4144-4150.2003; CHIANG C, 1960, BIOCHEM BIOPH RES CO, V3, P554, DOI 10.1016/0006-291X(60)90174-1; Dien BS, 1996, APPL BIOCHEM BIOTECH, V57-8, P233, DOI 10.1007/BF02941704; HALLBORN J, 1995, YEAST, V11, P839, DOI 10.1002/yea.320110906; Harhangi HR, 2003, ARCH MICROBIOL, V180, P134, DOI 10.1007/s00203-003-0565-0; HICKMAN J, 1959, J BIOL CHEM, V234, P758; Ishikura S, 2001, CHEM-BIOL INTERACT, V130, P879, DOI 10.1016/S0009-2797(00)00315-X; Jin YS, 2002, APPL ENVIRON MICROB, V68, P1232, DOI 10.1128/AEM.68.3.1232-1239.2002; KUHN A, 1995, APPL ENVIRON MICROB, V61, P1580, DOI 10.1128/AEM.61.4.1580-1585.1995; Lee JK, 2003, APPL ENVIRON MICROB, V69, P6179, DOI 10.1128/AEM.69.10.6179-6188.2003; MINET M, 1990, CURR GENET, V18, P287, DOI 10.1007/BF00318209; MURRAY JS, 1995, GENE, V155, P123, DOI 10.1016/0378-1119(94)00900-D; Richard P, 2000, FEMS MICROBIOL LETT, V190, P39, DOI 10.1016/S0378-1097(00)00312-8; Richard P, 2003, FEMS YEAST RES, V3, P185, DOI 10.1016/S1567-1356(02)00184-8; Richard P, 2002, BIOCHEMISTRY-US, V41, P6432, DOI 10.1021/bi025529i; Richard P, 2001, J BIOL CHEM, V276, P40631, DOI 10.1074/jbc.M104022200; Richard P, 1999, FEBS LETT, V457, P135, DOI 10.1016/S0014-5793(99)01016-9; RIZZI M, 1989, J FERMENT BIOENG, V67, P20, DOI 10.1016/0922-338X(89)90080-9; RIZZI M, 1988, APPL MICROBIOL BIOT, V29, P148; RUOHONEN L, 1995, J BIOTECHNOL, V39, P193, DOI 10.1016/0168-1656(95)00024-K; SHERMAN F, 1983, METHODS YEAST GENETI, P62; Shi NQ, 2000, APPL BIOCHEM BIOTECH, V84-6, P201, DOI 10.1385/ABAB:84-86:1-9:201; VERDUYN C, 1985, BIOCHEM J, V226, P669, DOI 10.1042/bj2260669; Verho R, 2002, BIOCHEMISTRY-US, V41, P13833, DOI 10.1021/bi0265325; WITTEVEEN CFB, 1989, J GEN MICROBIOL, V135, P2163; WITTEVEEN CFB, 1994, MICROBIOL-SGM, V140, P1679, DOI 10.1099/13500872-140-7-1679; WONG B, 1993, J BACTERIOL, V175, P6314, DOI 10.1128/JB.175.19.6314-6320.1993	27	65	70	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14746	14751		10.1074/jbc.M312533200	http://dx.doi.org/10.1074/jbc.M312533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736891	hybrid			2022-12-27	WOS:000220594700034
J	Voets, T; Janssens, A; Droogmans, G; Nilius, B				Voets, T; Janssens, A; Droogmans, G; Nilius, B			Outer pore architecture of a Ca2+-selective TRP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CA2+ CHANNEL; ACTIVATED CALCIUM-CHANNEL; K+ CHANNEL; POTASSIUM CHANNEL; ION-CHANNEL; PERMEATION; CELLS; IDENTIFICATION; PERMEABILITY; EXPRESSION	The TRP superfamily forms a functionally important class of cation channels related to the product of the Drosophila trp gene. TRP channels display an unusual diversity in activation mechanisms and permeation properties, but the basis of this diversity is unknown, as the structure of these channels has not been studied in detail. To obtain insight in the pore architecture of TRPV6, a Ca2+-selective member of the TRPV subfamily, we probed the dimensions of its pore and determined pore-lining segments using cysteine-scanning mutagenesis. Based on the permeability of the channel to organic cations, we estimated a pore diameter of 5.4 Angstrom. Mutating Asp(541), a residue involved in high affinity Ca2+ binding, altered the apparent pore diameter, indicating that this residue lines the narrowest part of the pore. Cysteines introduced in a region preceding Asp(541) displayed a cyclic pattern of reactivity to Ag+ and cationic methylthiosulfanate reagents, indicative of a pore helix. The anionic methanethiosulfonate ethylsulfonate showed only limited reactivity in this region, consistent with the presence of a cation-selective filter at the outer part of the pore helix. Based on these data and on homology with the bacterial KcsA channel, we present the first structural model of a TRP channel pore. We conclude that main structural features of the outer pore, namely a selectivity filter preceded by a pore helix, are conserved between K+ channels and TRPV6. However, the selectivity filter of TRPV6 is wider than that of K+ channels and lined by amino acid side chains rather than main chain carbonyls.	Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, B-3000 Louvain, Belgium	KU Leuven	Voets, T (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	thomas.voets@med.kuleuven.ac.be	Voets, Thomas/E-2466-2012; Voets, Thomas/AAD-4389-2019	Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821; Janssens, Annelies/0000-0002-6735-8248				Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Cataldi M, 2002, J BIOL CHEM, V277, P45969, DOI 10.1074/jbc.M203922200; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; den Dekker E, 2003, CELL CALCIUM, V33, P497, DOI 10.1016/S0143-4160(03)00065-4; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Montell C., 2001, SCI STKE; Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143-4160(03)00042-3; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Peng JB, 2003, J PHYSIOL-LONDON, V551, P729, DOI 10.1113/jphysiol.2003.043349; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2003, J MEMBRANE BIOL, V192, P1, DOI 10.1007/s00232-002-1059-8; Voets T, 2003, CELL CALCIUM, V33, P299, DOI 10.1016/S0143-4160(03)00044-7; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	38	94	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15223	15230		10.1074/jbc.M312076200	http://dx.doi.org/10.1074/jbc.M312076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736889	hybrid			2022-12-27	WOS:000220594700089
J	Hoja, U; Marthol, S; Hofmann, J; Stegner, S; Schulz, R; Meier, S; Greiner, E; Schweizer, E				Hoja, U; Marthol, S; Hofmann, J; Stegner, S; Schulz, R; Meier, S; Greiner, E; Schweizer, E			HFA1 encoding an organelle-specific acetyl-CoA carboxylase controls mitochondrial fatty acid synthesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ACYL CARRIER PROTEIN; YEAST; GENE; TRANSLATION; INITIATION; ENZYME; SITES; IDENTIFICATION; BIOSYNTHESIS	The Saccharomyces cerevisiae gene, HFA1, encodes a > 250- kDa protein, which is required for mitochondrial function. Hfa1p exhibits 72% overall sequence similarity ( 54% identity) to ACC1- encoded yeast cytoplasmic acetyl- CoA carboxylase. Nevertheless, HFA1 and ACC1 functions are not overlapping because mutants of the two genes have different phenotypes and do not complement each other. Whereas ACC1 is involved in cytoplasmic fatty acid synthesis, the phenotype of hfa1Delta disruptants resembles that of mitochondrial fatty- acid synthase mutants. They fail to grow on lactate or glycerol, and the mitochondrial cofactor, lipoic acid, is reduced to < 10% of its normal cellular concentration. Other than Acc1p, the N- terminal sequence of Hfa1p comprises a canonical mitochondrial targeting signal together with a matrix protease cleavage site. Accordingly, the HFA1- encoded protein was specifically assigned by Western blotting of appropriate cell fractions to the mitochondrial compartment. Removal of the mitochondrial targeting sequence abolished the competence of HFA1 DNA to complement hfal null mutants. Conversely and in contrast to the intact HFA1 sequence, the signal sequence- free HFA1 gene complemented the mutational loss of cytoplasmic acetyl- CoA carboxylase. Expression of HFA1 under the control of the ACC1 promoter restored cellular ACC activity in ACC1- defective yeast mutants to wild type levels. From this finding, it is concluded that HFA1 encodes a specific mitochondrial acetyl- CoA carboxylase providing malonyl- CoA for intraorganellar fatty acid and, in particular, lipoic acid synthesis.	Univ Erlangen Nurnberg, Lehrstuhl Biochem, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Schweizer, E (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Biochem, Staudtstr 5, D-91058 Erlangen, Germany.	eschweiz@biologie.uni-erlangen.de	Schulz, Rainer/ABD-5069-2021	Schulz, Rainer/0000-0003-3017-0476; Hofmann, Joerg/0000-0001-7387-1569				ALBAN C, 1994, BIOCHEM J, V300, P557, DOI 10.1042/bj3000557; ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Dalphin ME, 1996, NUCLEIC ACIDS RES, V24, P216, DOI 10.1093/nar/24.1.216; Drabkin HJ, 1998, MOL CELL BIOL, V18, P5140, DOI 10.1128/MCB.18.9.5140; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; HARINGTON A, 1993, MOL MICROBIOL, V9, P545, DOI 10.1111/j.1365-2958.1993.tb01715.x; HARRER R, 1993, CURR GENET, V24, P136, DOI 10.1007/BF00324677; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KEARSEY SE, 1993, DNA SEQUENCE, V4, P69, DOI 10.3109/10425179309015625; KEARSEY SE, 1987, MOL GEN GENET, V210, P509, DOI 10.1007/BF00327205; Konishi T, 1996, PLANT CELL PHYSIOL, V37, P117, DOI 10.1093/oxfordjournals.pcp.a028920; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; Matsuhashi M., 1969, METHOD ENZYMOL, V14, P3; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; MISHINA M, 1976, EUR J BIOCHEM, V71, P295, DOI 10.1111/j.1432-1033.1976.tb11115.x; Ohlrogge JB, 1997, ANNU REV PLANT PHYS, V48, P109, DOI 10.1146/annurev.arplant.48.1.109; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Rossler H, 2003, MOL GENET GENOMICS, V269, P290, DOI 10.1007/s00438-003-0836-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SADDIK M, 1993, J BIOL CHEM, V268, P25836; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Stuible HP, 1998, J BIOL CHEM, V273, P22334, DOI 10.1074/jbc.273.35.22334; TOH H, 1993, EUR J BIOCHEM, V215, P687, DOI 10.1111/j.1432-1033.1993.tb18080.x; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591	39	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21779	21786		10.1074/jbc.M401071200	http://dx.doi.org/10.1074/jbc.M401071200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	14761959	hybrid			2022-12-27	WOS:000221417100014
J	Brown, K; Long, JM; Vial, SCM; Dedi, N; Dunster, NJ; Renwick, SB; Tanner, AJ; Frantz, JD; Fleming, MA; Cheetham, GMT				Brown, K; Long, JM; Vial, SCM; Dedi, N; Dunster, NJ; Renwick, SB; Tanner, AJ; Frantz, JD; Fleming, MA; Cheetham, GMT			Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; MICE LACKING; TEC; FAMILY; ITK; PHOSPHORYLATION; ACTIVATION; INSIGHTS; DOMAINS; PATHWAY	Interleukin-2 tyrosine kinase, Itk, is an important member of the Tec family of non-receptor tyrosine kinases that play a central role in signaling through antigen receptors such as the T-cell receptor, B-cell receptor, and Fcepsilon. Selective inhibition of Itk may be an important way of modulating many diseases involving heightened or inappropriate activation of the immune system. In addition to an unliganded nonphophorylated Itk catalytic kinase domain, we determined the crystal structures of the phosphorylated and nonphosphorylated kinase domain bound to staurosporine, a potent broad-spectrum kinase inhibitor. These structures are useful for the design of novel, highly potent and selective Itk inhibitors and provide insight into the influence of inhibitor binding and phosphorylation on the conformation of Itk.	Vertex Pharmaceut Europe Ltd, Abingdon OX14 4RY, Oxon, England; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals; Vertex Pharmaceuticals	Cheetham, GMT (corresponding author), Vertex Pharmaceut Europe Ltd, 88 Milton Pk, Abingdon OX14 4RY, Oxon, England.	graham_cheetham@vrtx.com						Backesjo CM, 2002, BIOCHEM BIOPH RES CO, V299, P510, DOI 10.1016/S0006-291X(02)02643-8; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brazin KN, 2000, J MOL BIOL, V302, P607, DOI 10.1006/jmbi.2000.4091; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Ellmeier W, 2000, J EXP MED, V192, P1611, DOI 10.1084/jem.192.11.1611; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hawkins J, 2001, PROTEIN EXPRES PURIF, V22, P211, DOI 10.1006/prep.2001.1447; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; Kawakami Y, 1999, J LEUKOCYTE BIOL, V65, P286, DOI 10.1002/jlb.65.3.286; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Mao C, 2001, J BIOL CHEM, V276, P41435, DOI 10.1074/jbc.M104828200; Marquez JA, 2003, EMBO J, V22, P4616, DOI 10.1093/emboj/cdg448; Matsumoto Y, 2002, INT ARCH ALLERGY IMM, V129, P327, DOI 10.1159/000067589; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; Pursglove SE, 2002, J BIOL CHEM, V277, P755, DOI 10.1074/jbc.M108318200; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V81, P86; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Schaeffer EM, 2001, NAT IMMUNOL, V2, P1183, DOI 10.1038/ni734; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; Wilcox HM, 2003, J BIOL CHEM, V278, P37112, DOI 10.1074/jbc.M304811200; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	35	51	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18727	18732		10.1074/jbc.M400031200	http://dx.doi.org/10.1074/jbc.M400031200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14766749	hybrid			2022-12-27	WOS:000221041500079
J	Leonoudakis, D; Conti, LR; Radeke, CM; McGuire, LMM; Vandenberg, CA				Leonoudakis, D; Conti, LR; Radeke, CM; McGuire, LMM; Vandenberg, CA			A multiprotein trafficking complex composed of SAP97, CASK, Veli, and Mint1 is associated with inward rectifier Kir2 potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; SYNAPTIC VESICLE EXOCYTOSIS; GUANYLATE KINASE DOMAINS; DENSITY PROTEIN PSD-95; EPITHELIAL-CELLS; BASOLATERAL MEMBRANE; NMDA RECEPTOR; HUMAN HOMOLOG; PDZ PROTEINS; INTRAMOLECULAR INTERACTION	Strong inward rectifier potassium (Kir2) channels are important in the control of cell excitability, and their functions are modulated by interactions with intracellular proteins. Here we identified a complex of scaffolding/trafficking proteins in brain that associate with Kir2.1, Kir2.2, and Kir2.3 channels. By using a combination of affinity interaction pulldown assays and co-immunoprecipitations from brain and transfected cells, we demonstrated that a complex composed of SAP97, CASK, Veli, and Mint1 associates with Kir2 channels via the C-terminal PDZ-binding motif. We further demonstrated by using in vitro protein interaction assays that SAP97, Veli-1, or Veli-3 binds directly to the Kir2.2 C terminus and recruits CASK. Co-immunoprecipitations indicated that specific Veli isoforms participate in forming distinct protein complexes in brain, where Veli-1 stably associates with CASK and SAP97, Veli-2 associates with CASK and Mint1, and Veli-3 associates with CASK, SAP97, and Mint1. Additionally, immunocytochemistry of rat cerebellum revealed overlapping expression of Kir2.2, SAP97, CASK, Mint1, with Veli-1 in the granule cell layer and Veli-3 in the molecular layer. We propose a model whereby Kir2.2 associates with distinct SAP97-CASK-Veli-Mint1 complexes. In one complex, SAP97 interacts directly with the Kir2 channels and recruits CASK, Veli, and Mint1. Alternatively, Veli-1 or Veli-3 interacts directly with the Kir2 channels and recruits CASK and SAP97; association of Mint1 with the complex requires Veli-3. Expression of Kir2.2 in polarized epithelial cells resulted in targeting of the channels to the basolateral membrane and co-localization with SAP97 and CASK, whereas a dominant interfering form of CASK caused the channels to mislocalize. Therefore, CASK appears to be a central protein of a macromolecular complex that participates in trafficking and plasma membrane localization of Kir2 channels.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Vandenberg, CA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	vandenbe@lifesci.ucsb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043377] Funding Source: NIH RePORTER; NINDS NIH HHS [NS43377] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berthier C, 1997, BIOL CELL, V89, P413, DOI 10.1016/S0248-4900(97)89313-6; Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Firestein BL, 1999, NEURON, V24, P659, DOI 10.1016/S0896-6273(00)81120-4; Firestein BL, 2001, MOL BIOL CELL, V12, P3465, DOI 10.1091/mbc.12.11.3465; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Hata Y, 1996, J NEUROSCI, V16, P2488; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Karschin C, 1996, J NEUROSCI, V16, P3559; Karschin C, 1997, MOL CELL NEUROSCI, V10, P131, DOI 10.1006/mcne.1997.0655; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonoudakis D, 2001, J CELL SCI, V114, P987; LEONOUDAKIS D, 2004, IN PRESS J BIOL CHEM, V279; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Misawa H, 2001, J BIOL CHEM, V276, P9264, DOI 10.1074/jbc.M009334200; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Purves D., 2001, NEUROSCIENCE; Raab-Graham KF, 1998, J BIOL CHEM, V273, P19699, DOI 10.1074/jbc.273.31.19699; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Straight SW, 2001, MOL BIOL CELL, V12, P1329, DOI 10.1091/mbc.12.5.1329; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Wu HJ, 1998, J CELL SCI, V111, P2365; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	60	122	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					19051	19063		10.1074/jbc.M400284200	http://dx.doi.org/10.1074/jbc.M400284200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14960569	hybrid			2022-12-27	WOS:000221041500118
J	Burgdorf, S; Leister, P; Scheidtmann, KH				Burgdorf, S; Leister, P; Scheidtmann, KH			TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; ACTIVATION DOMAIN; NUCLEAR RECEPTORS; DLK/ZIP KINASE; CELL-GROWTH; PROTEIN; UBIQUITIN; GENE; PROTEASOME; TRANSACTIVATION	Apoptosis-antagonizing transcription factor (AATF), also termed Che-1, was identified as interacting protein of Dlk/ZIP kinase and RNA polymerase II, respectively. Che-1 has additionally been shown to bind Rb, thereby activating transcription factor E2F and promoting cell cycle progression. Moreover, AATF enhances steroid receptor-mediated transactivation in a hormone- and dose-dependent manner (Leister, P., Burgdorf, S., and Scheidtmann, K. H., (2003) Signal Transduction 3, 18-25). These data suggest that AATF exerts its functions through interaction with different transcription factors. In search of novel interaction partners of AATF, we identified the tumor susceptibility gene product TSG101, which had also been recognized as a co-regulator of nuclear hormone receptors. Interestingly, TSG101 and AATF functioned as cooperative coactivators in androgen receptor-mediated transcription. Because TSG101 was also shown to play a role in regulation of ubiquitin conjugation, we asked whether its coactivating function might be linked to ubiquitination. Indeed, TSG101 enhanced monoubiquitination of the androgen receptor in a ligand-dependent manner, and this correlated with enhanced transactivating capacity. Furthermore, a dominant-negative mutant of ubiquitin preventing polyubiquitination also stimulated androgen receptor-mediated transcription, which in this case could not be enhanced by TSG101. We propose that TSG101 activates androgen receptor-induced transcription by transient stabilization of the monoubiquitinated state, thus revealing a novel regulatory mechanism for nuclear receptors.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany	University of Bonn	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, D-53117 Bonn, Germany.	kh.scheidtmann@uni-bonn.de						Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Dupre S, 2001, CURR BIOL, V11, pR932, DOI 10.1016/S0960-9822(01)00558-9; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Feng GH, 2000, CANCER RES, V60, P1736; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Leister P., 2003, SIGNAL TRANSDUCTION, V3, P17, DOI [10.1002/sita.200300020, DOI 10.1002/SITA.200300020]; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lindfors K, 2000, BIOCHEM BIOPH RES CO, V276, P660, DOI 10.1006/bbrc.2000.3480; Lohrum M, 1996, ONCOGENE, V13, P2527; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Myers EL, 2002, J VIROL, V76, P11226, DOI 10.1128/JVI.76.22.11226-11235.2002; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Oh H, 2002, P NATL ACAD SCI USA, V99, P5430, DOI 10.1073/pnas.082123999; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Preuss U, 2003, NUCLEIC ACIDS RES, V31, P878, DOI 10.1093/nar/gkg176; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Saji S, 2001, BIOCHEM BIOPH RES CO, V281, P259, DOI 10.1006/bbrc.2001.4339; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Thomas T, 2000, DEV BIOL, V227, P324, DOI 10.1006/dbio.2000.9915; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1998, CANCER RES, V58, P2699	55	85	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17524	17534		10.1074/jbc.M313703200	http://dx.doi.org/10.1074/jbc.M313703200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14761944	hybrid			2022-12-27	WOS:000220870400080
J	Liu, GC; Jin, CS; Jin, C				Liu, GC; Jin, CS; Jin, C			CMP-N-acetylneuraminic acid synthetase from Escherichia coli K1 is a bifunctional enzyme - Identification of minimal catalytic domain for synthetase activity and novel functional domain for platelet-activating factor acetylhydrolase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLNEURAMINATE CYTIDYLYLTRANSFERASE; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; GROUP-B; PURIFICATION; EXPRESSION; SUBUNIT; PROTEIN; MENINGITIS; MIGRATION	Escherichia coli CMP-NeuAc synthetase (EC 2.7.7.43) catalyzes the synthesis of CMP-NeuAc from CTP and NeuAc, which is essential for the formation of capsule polysialylate for strain K1. Alignment of the amino acid sequence of E. coli CMP-NeuAc synthetase with those from other bacterial species revealed that the conserved motifs were located in its N termini, whereas the C terminus appeared to be redundant. Based on this information, a series of deletions from the 3'-end of the CMP-NeuAc synthetase coding region was constructed and expressed in E. coli. As a result, the catalytic domain required for CMP-NeuAc synthetase was found to be in the N-terminal half consisting of amino acids 1-229. Using the strategy of tertiary structure prediction based on the homologous search of the secondary structure, the C-terminal half was recognized as an alpha1-subunit of bovine brain platelet-activating factor acetylhydrolase isoform I. The biochemical analyses showed that the C-terminal half consisting of amino acids 228-418 exhibited platelet-activating factor acetylhydrolase activity. The enzyme properties and substrate specificity were similar to that of bovine brain alpha1-subunit. Although its physiological function is still unclear, it has been proposed that the alpha1-subunit-like domain of E. coli may be involved in the traversal of the blood-brain barrier.	Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS	Jin, C (corresponding author), Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China.	jinc@sun.im.ac.cn		jin, cheng/0000-0002-1514-6374				ADACHI H, 1995, BIOCHEM BIOPH RES CO, V214, P180, DOI 10.1006/bbrc.1995.2272; Adachi T, 1997, NEUROSCI LETT, V235, P133, DOI 10.1016/S0304-3940(97)00742-8; Arai H, 2002, J BIOCHEM, V131, P635, DOI 10.1093/oxfordjournals.jbchem.a003145; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bravo IG, 2001, BIOCHEM J, V358, P585, DOI 10.1042/bj3580585; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Brick DJ, 1995, FEBS LETT, V377, P475, DOI 10.1016/0014-5793(95)01405-5; DIETZMAN DE, 1974, J PEDIATR-US, V85, P128, DOI 10.1016/S0022-3476(74)80308-2; EDWARDS U, 1992, FEMS MICROBIOL LETT, V96, P161; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; FEIGIN R D, 1977, Clinics in Perinatology, V4, P103; Gilbert M, 1998, NAT BIOTECHNOL, V16, P769, DOI 10.1038/nbt0898-769; GLADSTONE IM, 1990, PEDIATR INFECT DIS J, V9, P819, DOI 10.1097/00006454-199011000-00009; Grigg ME, 1996, BIOCHEM J, V317, P541, DOI 10.1042/bj3170541; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; Haft RF, 1996, MOL MICROBIOL, V19, P555, DOI 10.1046/j.1365-2958.1996.395931.x; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Ho YS, 1999, PROTEIN ENG, V12, P693, DOI 10.1093/protein/12.8.693; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; Hoffman JA, 1999, INFECT IMMUN, V67, P3566, DOI 10.1128/IAI.67.7.3566-3570.1999; HUANG SH, 1995, INFECT IMMUN, V63, P4470, DOI 10.1128/IAI.63.11.4470-4475.1995; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; Kim KS, 2001, INFECT IMMUN, V69, P5217, DOI 10.1128/IAI.69.9.5217-5222.2001; KIM KS, 1992, J CLIN INVEST, V90, P897, DOI 10.1172/JCI115965; Kishimoto K, 2001, BIOCHEM BIOPH RES CO, V281, P657, DOI 10.1006/bbrc.2001.4404; Koedel U, 1999, INFECT DIS CLIN N AM, V13, P549, DOI 10.1016/S0891-5520(05)70094-5; Leib SL, 1999, INFECT DIS CLIN N AM, V13, P527, DOI 10.1016/S0891-5520(05)70093-3; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Manya H, 1999, J BIOL CHEM, V274, P31827, DOI 10.1074/jbc.274.45.31827; McMullen TWP, 2000, PROTEIN ENG, V13, P865, DOI 10.1093/protein/13.12.865; Min JH, 2001, BIOCHEMISTRY-US, V40, P4539, DOI 10.1021/bi002600g; Mosimann SC, 2001, J BIOL CHEM, V276, P8190, DOI 10.1074/jbc.M007235200; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; Pan XM, 2001, PROTEINS, V43, P256, DOI 10.1002/prot.1036; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; PRASADARAO NV, 1999, INFECT IMMUN, V67, P6423; Ringenberg M, 2001, GLYCOBIOLOGY, V11, P533, DOI 10.1093/glycob/11.7.533; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; RODRIGUEZAPARICIO LB, 1992, J BIOL CHEM, V267, P9257; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAUER R, 1980, H-S Z PHYSIOL CHEM, V361, P641, DOI 10.1515/bchm2.1980.361.1.641; SHAMES S L, 1991, Glycobiology, V1, P187, DOI 10.1093/glycob/1.2.187; Sheffield PJ, 2001, PROTEIN ENG, V14, P513, DOI 10.1093/protein/14.7.513; Steenbergen SM, 2003, J BIOL CHEM, V278, P15349, DOI 10.1074/jbc.M208837200; STINS MF, 1994, AM J PATHOL, V145, P1228; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; Tullius MV, 1996, J BIOL CHEM, V271, P15373, DOI 10.1074/jbc.271.26.15373; UNHANAND M, 1993, J PEDIATR-US, V122, P15, DOI 10.1016/S0022-3476(05)83480-8; UPTON C, 1995, TRENDS BIOCHEM SCI, V20, P178, DOI 10.1016/S0968-0004(00)89002-7; VANN WF, 1987, J BIOL CHEM, V262, P17556; Xia GQ, 2000, J MOL CATAL B-ENZYM, V10, P199, DOI 10.1016/S1381-1177(00)00115-6; Yan W, 2003, P NATL ACAD SCI USA, V100, P7189, DOI 10.1073/pnas.1236145100; ZAPATA G, 1989, J BIOL CHEM, V264, P14769	60	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17738	17749		10.1074/jbc.M400143200	http://dx.doi.org/10.1074/jbc.M400143200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960566	hybrid			2022-12-27	WOS:000220870400105
J	Won, HS; Lee, YH; Kim, JH; Shin, IS; Lee, MH; Lee, BJ				Won, HS; Lee, YH; Kim, JH; Shin, IS; Lee, MH; Lee, BJ			Structural characterization of the nickel-binding properties of Bacillus pasteurii urease accessory protein (Ure)E in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-AEROGENES UREE; AMP RECEPTOR PROTEIN; TRIPLE-RESONANCE EXPERIMENTS; BACKBONE NMR ASSIGNMENTS; MULTIDIMENSIONAL NMR; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; GENE-CLUSTER; ACTIVE-SITE	Urease activation is critical to the virulence of many human and animal pathogens. Urease possesses multiple, nickel-containing active sites, and UreE, the only nickel-binding protein among the urease accessory proteins, activates urease by transporting nickel ions. We performed NMR experiments to investigate the solution structure and the nickel-binding properties of Bacillus pasteurii (Bp) UreE. The secondary structures and global folds of BpUreE were determined for its metal-free and nickel-bound forms. The results indicated that no major structural change of BpUreE arises from the nickel binding. In addition to the previously identified nickel-binding site (Gly(97)-Cys(103)), the C-terminal tail region (Lys(141)-His(147)) was confirmed for the first time to be involved in the nickel binding. The C-terminally conserved sequence ((144)GHQH(147)) was confirmed to have an inherent nickel-binding ability. Nickel addition to 1.6 mM subunit, a concentration where BpUreE predominantly forms a tetramer upon the nickel binding, induced a biphasic spectral change consistent with binding of up to at least three nickel ions per tetrameric unit. In contrast, nickel addition to 0.1 mM subunit, a concentration at which the protein is primarily a dimer, caused a monophasic spectral change consistent with more than 1 equivalent per dimeric unit. Combined with the equilibrium dialysis results, which indicated 2.5 nickel equivalents binding per dimer at a micromolar protein concentration, the nickel-binding stoichiometry of BpUreE at a physiological concentration could be three nickel ions per dimer. Altogether, the present results provide the first detailed structural data concerning the nickel-binding properties of intact, wild-type BpUreE in solution.	Seoul Natl Univ, Coll Pharm, Natl Res Lab Membrane Prot Struct, Seoul 151742, South Korea; Catholic Univ Daegu, Coll Pharm, Gyongsan 712702, Gyongbook, South Korea	Seoul National University (SNU); Catholic University of Daegu	Lee, BJ (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab Membrane Prot Struct, Seoul 151742, South Korea.	lbj@nmr.snu.ac.kr	Lee, Bong-Jin/AAQ-1609-2020	Lee, Bong-Jin/0000-0001-7896-2961				Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Bonvin AMJJ, 2001, J BIOMOL NMR, V21, P221, DOI 10.1023/A:1012935005256; Brayman TG, 1996, J BACTERIOL, V178, P5410, DOI 10.1128/jb.178.18.5410-5416.1996; Ciurli S, 1999, COORDIN CHEM REV, V190, P331, DOI 10.1016/S0010-8545(99)00093-4; Ciurli S, 2002, J BIOL INORG CHEM, V7, P623, DOI 10.1007/s00775-002-0341-7; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeRose EF, 2002, BIOCHEMISTRY-US, V41, P94, DOI 10.1021/bi0114170; Dunn BE, 2001, NAT STRUCT BIOL, V8, P480, DOI 10.1038/88527; Gardner KH, 1997, BIOCHEMISTRY-US, V36, P1389, DOI 10.1021/bi9624806; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; Ha NC, 2001, NAT STRUCT BIOL, V8, P505, DOI 10.1038/88563; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; Lee YH, 2002, J BIOMOL NMR, V24, P361, DOI 10.1023/A:1021645605881; Lee YH, 2002, FEBS LETT, V522, P135, DOI 10.1016/S0014-5793(02)02919-8; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; Okon M, 2001, FEBS LETT, V487, P390, DOI 10.1016/S0014-5793(00)02375-9; PARK IS, 1995, J BACTERIOL, V177, P1947, DOI 10.1128/jb.177.8.1947-1951.1995; Park SH, 2002, BIOCHEM J, V368, P171, DOI 10.1042/BJ20020385; Remaut H, 2001, J BIOL CHEM, V276, P49365, DOI 10.1074/jbc.M108304200; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Sebbane F, 2002, J BACTERIOL, V184, P5706, DOI 10.1128/JB.184.20.5706-5713.2002; Song HK, 2001, J BIOL CHEM, V276, P49359, DOI 10.1074/jbc.M108619200; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o; SRIWANTHANA B, 1994, J BACTERIOL, V176, P6836, DOI 10.1128/JB.176.22.6836-6841.1994; Venters RA, 1996, J MOL BIOL, V264, P1101, DOI 10.1006/jmbi.1996.0699; Wakabayashi H, 2002, BIOCHEMISTRY-US, V41, P8485, DOI 10.1021/bi025589o; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Won HS, 2000, BIOCHEMISTRY-US, V39, P13953, DOI 10.1021/bi000012x; Won HS, 2002, EUR J BIOCHEM, V269, P4367, DOI 10.1046/j.1432-1033.2002.03139.x; Won HS, 2002, J BIOL CHEM, V277, P11450, DOI 10.1074/jbc.M112411200; Won HS, 2000, J BIOMOL NMR, V16, P79, DOI 10.1023/A:1008398103476; Yoon MK, 2000, FEBS LETT, V484, P241, DOI 10.1016/S0014-5793(00)02160-8; YOU JH, 1995, MOL CELLS, V5, P359	40	16	17	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17466	17472		10.1074/jbc.M308390200	http://dx.doi.org/10.1074/jbc.M308390200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769802	hybrid			2022-12-27	WOS:000220870400073
J	del Castillo-Olivares, A; Campos, JA; Pandak, WM; Gil, G				del Castillo-Olivares, A; Campos, JA; Pandak, WM; Gil, G			The role of alpha(1)-fetoprotein transcription factor/LRH-1 in bile acid biosynthesis - A known nuclear receptor activator that can act as a suppressor of bile acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; NEGATIVE FEEDBACK-REGULATION; PRIMARY RAT HEPATOCYTES; STEROL 12-ALPHA-HYDROXYLASE; FACTOR 4-ALPHA; X-RECEPTOR; EXPRESSION; MECHANISM; PROMOTER; PATHWAY	Two key regulatory enzymes in the bile acid biosynthesis pathway are cholesterol 7alpha-hydroxylase/CYP7A1 (7alpha-hydroxylase) and sterol 12alpha-hydroxylase/CYP8B1 (12alpha-hydroxylase). It has been shown previously that hepatocyte nuclear factor-4alpha (HNF-4) and the alpha(1)-fetoprotein transcription factor (FTF) are activators of 7alpha-and 12alpha-hydroxylase transcription and that the small heterodimer partner (SHP) suppresses bile acid biosynthesis by heterodimerizing with FTF. However, the role of FTF in bile acid biosynthesis has been studied only in tissue culture systems. In heterozygous FTF knockout mice, 7alpha- and 12alpha-hydroxylase genes were expressed at 5-7-fold higher levels than in wild-type mice, an apparent direct contradiction to previous in vitro observations. This higher expression of the 7alpha- and 12alpha-hydroxylase genes resulted in a 33% higher bile acid pool in their gallbladders, bile more enriched in cholic acid, and a 13% decrease in plasma cholesterol levels. Adenovirus-mediated FTF overexpression in wild-type mice resulted in 10-fold lower expression of the 7alpha- and 12alpha-hydroxylase genes and up to 8-fold higher SHP expression, highlighting the dual role that FTF plays in different promoters. Shorter overexpression times still resulted in lower 7alpha- and 12alpha-hydroxylase expression, but unchanged SHP expression, suggesting that two different mechanisms are involved in the FTF-mediated suppression of 7alpha- and 12alpha-hydroxylase expression. This FTF-mediated suppression of the expression of two bile acid biosynthesis genes resulted in a 3-fold lower rate of bile acid synthesis in a rat bile fistula animal model. Based on these observations and on protein binding studies performed in vitro and by chromatin immunoprecipitation, we hypothesize that FTF has two synergetic effects that contribute to its role in bile acid biosynthesis: 1) it has the ability to activate the expression of SHP, which in turn heterodimerizes and suppresses FTF transactivation activity; and 2) it occupies the FTF/ HNF-4 recognition site within the 7alpha- and 12alpha-hydroxylase promoters, which can otherwise be occupied by a factor (HNF-4) that cannot be suppressed by SHP.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Gil, G (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Med Sci Bldg,Rm 540,1217 E Marschall St,POB 98061, Richmond, VA 23298 USA.	ggil@vcu.edu	Campos-Sandoval, José/I-7375-2018	Campos-Sandoval, José/0000-0002-2457-9884	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK65049, DK39030] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auwerx J, 1999, CELL, V97, P161; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Crestani M, 1998, J LIPID RES, V39, P2192; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; DECASTILLOOLIVA.A, 2001, NUCLEIC ACIDS RES, V29, P4035; del Castill-Olivares A, 2002, J BIOL CHEM, V277, P6750, DOI 10.1074/jbc.M106785200; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; Falender AE, 2003, ENDOCRINOLOGY, V144, P3598, DOI 10.1210/en.2002-0137; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gafvels M, 1999, GENOMICS, V56, P184, DOI 10.1006/geno.1998.5606; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Gerbod-Giannone MC, 2002, J BIOL CHEM, V277, P42973, DOI 10.1074/jbc.M205089200; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; HEUMAN DM, 1989, J LIPID RES, V30, P1161; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2001, J BIOL CHEM, V276, P24767, DOI 10.1074/jbc.M100912200; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; Pandak WM, 2002, J BIOL CHEM, V277, P48158, DOI 10.1074/jbc.M205244200; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Schoonjans K, 2002, EMBO REP, V3, P1181, DOI 10.1093/embo-reports/kvf238; SHAW R, 1979, J BIOL CHEM, V254, P7177; Stroup D, 2000, J LIPID RES, V41, P1; Subramanian A, 1998, NUCLEIC ACIDS RES, V26, P2173, DOI 10.1093/nar/26.9.2173; TZUNG KW, 1994, GENOMICS, V21, P244, DOI 10.1006/geno.1994.1250; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; Vlahcevic ZR, 1997, GASTROENTEROLOGY, V113, P1949, DOI 10.1016/S0016-5085(97)70015-5; Wang DQH, 1999, J LIPID RES, V40, P2066; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yang YZ, 2002, BBA-MOL CELL BIOL L, V1583, P63, DOI 10.1016/S1388-1981(02)00186-5; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200	46	64	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16813	16821		10.1074/jbc.M400646200	http://dx.doi.org/10.1074/jbc.M400646200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14766742	hybrid			2022-12-27	WOS:000220747900134
J	Einholm, AP; Vilsen, B; Andersen, JP				Einholm, AP; Vilsen, B; Andersen, JP			Importance of transmembrane segment M1 of the sarcoplasmic reticulum Ca2(+)-ATPase in Ca2+ occlusion and phosphoenzyme processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; FUNCTIONAL CONSEQUENCES; ADENOSINE-TRIPHOSPHATASE; CRYSTAL-STRUCTURE; CA2+-ATPASE; ATPASE; MECHANISM; TRANSPORT; SITES; CA-2+-ATPASE	The functional consequences of a series of point mutations in transmembrane segment M1 of sarcoplasmic reticulum Ca2+ -ATPase were analyzed in steady-state and transient kinetic experiments examining the partial reaction steps involved in Ca2+ interaction and phosphoenzyme turnover. Arginine or leucine substitution of Glu(51), Glu(55), or Glu(58), located in the N-terminal third of M1, did not affect these functions. Arginine or leucine substitution of Asp(59), located right at the bend of M1 seen in the crystal structure of the thapsigargin-bound form, caused a 10-fold increase of the rate of Ca2+ dissociation toward the cytoplasmic side. Mutation of Leu(60) to alanine or pro-line and of Val(62) to alanine also enhanced Ca2+ dissociation, whereas an 11-fold reduction of the rate of Ca2+ dissociation was observed upon alanine substitution of Leu(65), thus providing evidence for a relation of the middle part of M1 to a gating mechanism controlling the dissociation of occluded Ca2+ from its membranous binding sites. Moreover, phosphoenzyme processing was affected by some of the latter mutations, in particular leucine substitution of Asp(59), and alanine substitution of Leu(65) accelerated the transition to ADP-insensitive phosphoenzyme and blocked its dephosphorylation, thus demonstrating that this part of M1, besides being important in Ca2+ interaction, furthermore, is a critical element in the long range signaling between the transmembrane domain and the cytoplasmic catalytic site.	Aarhus Univ, Inst Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, JP (corresponding author), Aarhus Univ, Inst Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dode L, 2002, J BIOL CHEM, V277, P45579, DOI 10.1074/jbc.M207778200; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; FORGE V, 1993, J BIOL CHEM, V268, P10961; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; Lipkind GM, 2001, BIOCHEMISTRY-US, V40, P6786, DOI 10.1021/bi010269a; LUND S, 1988, J BIOL CHEM, V263, P1654; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Menguy T, 2002, J BIOL CHEM, V277, P13016, DOI 10.1074/jbc.M108899200; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1982, J BIOL CHEM, V257, P6111; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Stokes DL, 2003, ANNU REV BIOPH BIOM, V32, P445, DOI 10.1146/annurev.biophys.32.110601.142433; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1	39	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15888	15896		10.1074/jbc.M400158200	http://dx.doi.org/10.1074/jbc.M400158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754883	hybrid			2022-12-27	WOS:000220747900025
J	Naus, S; Richter, M; Wildeboer, D; Moss, M; Schachner, M; Bartsch, JW				Naus, S; Richter, M; Wildeboer, D; Moss, M; Schachner, M; Bartsch, JW			Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; BIOCHEMICAL-CHARACTERIZATION; CLOSE HOMOLOG; L1 CHL1; ADHESION; PROTEINS; SURFACE; EXPRESSION; PATTERNS	The neural cell adhesion molecule "close homologue of L1," termed CHL1, has functional importance in the nervous system. CHL1 is expressed as a transmembrane protein of 185 kDa, and ectodomain shedding releases soluble fragments relevant for its physiological function. Here we describe that ADAM8, a member of the family of metalloprotease disintegrins cleaves a CHL1-Fc fusion protein in vitro at two sites corresponding to release of the extracellular domain of CHL1 in fibronectin (FN) domains II ( 125 kDa) and V ( 165 kDa), inhibited by batimastat (BB-94). Cleavage of CHL1-Fc in the 125-kDa fragment was not detectable under nonreducing conditions arguing that cleavage resulting in the 165-kDa fragment is more relevant in releasing soluble CHL1 in vivo. In cells transfected with full-length ADAM8, membrane proximal cleavage of CHL1 was similar and not stimulated by phorbol ester 12-O-tetradecanoylphorbol-13-acetate and pervanadate. No cleavage of CHL1 was observed in cells expressing either inactive ADAM8 with a Glu(330) to Gln exchange (EQ-A8), or active ADAM10 and ADAM17. Consequently, processing of CHL1 was hardly detectable in brain extracts of ADAM8-deficient mice but enhanced in a neurodegenerative mouse mutant. CHL1 processed by ADAM8 in supernatants of COS-7 cells and in co-culture with cerebellar granule neurons was very potent in stimulating neurite outgrowth and suppressing neuronal cell death, not observed in cells co-transfected with CHL1/EQ-A8, CHL1/ ADAM10, or CHL1/ ADAM17. Taken together, we propose that ADAM8 plays an important role in physiological and pathological cell interactions by a specific release of functional CHL1 from the cell surface.	Univ Bielefeld, D-33501 Bielefeld, Germany; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; Biozyme Inc, Apex, NC 27523 USA	University of Bielefeld; University of Hamburg; University Medical Center Hamburg-Eppendorf	Bartsch, JW (corresponding author), Univ Bielefeld, W7, D-33501 Bielefeld, Germany.	joerg.bartsch@uni-bielefeld.de	Bartsch, Joerg Walter/AAB-2951-2020	Bartsch, Prof. Joerg Walter/0000-0002-2773-3357; Richter, Matthias/0000-0003-3898-3332; Richter, Melanie/0000-0003-0575-9625				Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buhusi M, 2003, J BIOL CHEM, V278, P25024, DOI 10.1074/jbc.M303084200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chaisuksunt V, 2000, NEUROSCIENCE, V100, P87, DOI 10.1016/S0306-4522(00)00254-2; CHANTRY A, 1989, J BIOL CHEM, V264, P21603; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; FISCHER G, 1986, J NEUROSCI, V6, P605; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Hillenbrand R, 1999, EUR J NEUROSCI, V11, P813, DOI 10.1046/j.1460-9568.1999.00496.x; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; RATHJEN FG, 1984, EMBO J, V3, P1; Rolf B, 2003, J NEUROSCI RES, V71, P835, DOI 10.1002/jnr.10533; Rudiger M, 1997, BIOTECHNIQUES, V23, P96, DOI 10.2144/97231bm20; SADOUL K, 1988, J NEUROCHEM, V50, P510, DOI 10.1111/j.1471-4159.1988.tb02941.x; Schlomann U, 2000, J NEUROSCI, V20, P7964; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Szelenyi J, 2001, BRAIN RES BULL, V54, P329, DOI 10.1016/S0361-9230(01)00428-2; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Wheeler DL, 2003, CANCER RES, V63, P6547; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	34	104	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16083	16090		10.1074/jbc.M400560200	http://dx.doi.org/10.1074/jbc.M400560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761956	hybrid			2022-12-27	WOS:000220747900049
J	Pernot, L; Chesnel, L; Le Gouellec, A; Croize, J; Vernet, T; Dideberg, O; Dessen, A				Pernot, L; Chesnel, L; Le Gouellec, A; Croize, J; Vernet, T; Dideberg, O; Dessen, A			A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism for reduction of susceptibility to beta-lactam antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN 2X; PENICILLIN-RESISTANT; CRYSTAL-STRUCTURE; GENES; KINETICS; 2B; TRANSPEPTIDASE; DEACYLATION; MUTATIONS; DIVERSITY	The human pathogen Streptococcus pneumoniae is one of the main causative agents of respiratory tract infections. At present, clinical isolates of S. pneumoniae often exhibit decreased susceptibility toward beta-lactams, a phenomenon linked to multiple mutations within the penicillin-binding proteins (PBPs). PBP2x, one of the six PBPs of S. pneumoniae, is the first target to be modified under antibiotic pressure. By comparing 89 S. pneumoniae PBP2x sequences from clinical and public data bases, we have identified one major group of sequences from drug-sensitive strains as well as two distinct groups from drug-resistant strains. The first group includes proteins that display high similarity to PBP2x from the well characterized resistant strain Sp328. The second group includes sequences in which a signature mutation, Q552E, is found adjacent to the third catalytic motif. In this work, a PBP2x from a representative strain from the latter group ( S. pneumoniae 5259) was biochemically and structurally characterized. Phenotypical analyses of transformed pneumococci show that the Q552E substitution is responsible for most of the reduction of strain susceptibility toward beta-lactams. The crystal structure of 5259-PBP2x reveals a change in polarity and charge distribution around the active site cavity, as well as rearrangement of strand beta3, emulating structural changes observed for other PBPs that confer drug resistance to Gram-positive pathogens. Interestingly, the active site of 5259-PBP2x is in closed conformation, whereas that of Sp328-PBP2x is open. Consequently, S. pneumoniae has evolved to employ the same protein in two distinct mechanisms of antibiotic resistance.	UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, F-38027 Grenoble, France; UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, F-38027 Grenoble, France; CHU Grenoble, Bacteriol Lab, F-38400 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Dessen, A (corresponding author), UJF, CNRS,CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.	dessen@ibs.fr	Le Gouellec, audrey/AAC-3013-2019; le gouellec, audrey/M-6072-2014; Vernet, Thierry/G-1118-2012	Le Gouellec, audrey/0000-0002-4905-3854; Dessen, Andrea/0000-0001-6487-4020; chesnel, laurent/0000-0002-4947-5029				Appelbaum PC, 2002, CLIN INFECT DIS, V34, P1613, DOI 10.1086/340400; Asahi Y, 1999, ANTIMICROB AGENTS CH, V43, P1252, DOI 10.1128/AAC.43.5.1252; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chesnel L, 2003, J BIOL CHEM, V278, P44448, DOI 10.1074/jbc.M305948200; COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x; Dessen A, 2001, J BIOL CHEM, V276, P45106, DOI 10.1074/jbc.M107608200; Di Guilmi AM, 2000, ANAL BIOCHEM, V284, P240, DOI 10.1006/abio.2000.4735; Di Guilmi AM, 2003, J BACTERIOL, V185, P4418, DOI 10.1128/JB.185.15.4418-4423.2003; du Plessis M, 2002, ANTIMICROB AGENTS CH, V46, P2349, DOI 10.1128/AAC.46.8.2349-2357.2002; FRERE JM, 1975, EUR J BIOCHEM, V57, P343, DOI 10.1111/j.1432-1033.1975.tb02307.x; Ghuysen Jean-Marie, 1994, Trends in Microbiology, V2, P372, DOI 10.1016/0966-842X(94)90614-9; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gordon E, 2000, J MOL BIOL, V299, P477, DOI 10.1006/jmbi.2000.3740; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; HAKENBECK R, 1986, EUR J BIOCHEM, V157, P101, DOI 10.1111/j.1432-1033.1986.tb09644.x; Hakenbeck R, 2001, INFECT IMMUN, V69, P2477, DOI 10.1128/IAI.69.4.2477-2486.2001; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; JAMIN M, 1993, BIOCHEM J, V292, P735, DOI 10.1042/bj2920735; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krauss J, 1996, MICROB DRUG RESIST, V2, P183, DOI 10.1089/mdr.1996.2.183; LAIBLE G, 1991, MOL MICROBIOL, V5, P1993, DOI 10.1111/j.1365-2958.1991.tb00821.x; LAIBLE G, 1991, J BACTERIOL, V173, P6986, DOI 10.1128/jb.173.21.6986-6990.1991; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; Lu WP, 2001, J BIOL CHEM, V276, P31494, DOI 10.1074/jbc.M102499200; McCormick AW, 2003, NAT MED, V9, P424, DOI 10.1038/nm839; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; Mouz N, 1999, J BIOL CHEM, V274, P19175, DOI 10.1074/jbc.274.27.19175; Nagai K, 2002, ANTIMICROB AGENTS CH, V46, P1273, DOI 10.1128/AAC.46.5.1273-1280.2002; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pares S, 1996, NAT STRUCT BIOL, V3, P284, DOI 10.1038/nsb0396-284; Sauvage E, 2002, CELL MOL LIFE SCI, V59, P1223, DOI 10.1007/s00018-002-8500-0; Thomas B, 2001, BIOCHEMISTRY-US, V40, P15811, DOI 10.1021/bi011368r; van Heijenoort J, 1998, CELL MOL LIFE SCI, V54, P300, DOI 10.1007/s000180050155; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; Zhao GS, 1997, J BACTERIOL, V179, P4901, DOI 10.1128/jb.179.15.4901-4908.1997	42	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16463	16470		10.1074/jbc.M313492200	http://dx.doi.org/10.1074/jbc.M313492200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14734544	hybrid			2022-12-27	WOS:000220747900094
J	Pottekat, A; Menon, AK				Pottekat, A; Menon, AK			Subcellular localization and targeting of N-acetylglucosaminyl phosphatidylinositol de-N-acetylase, the second enzyme in the glycosylphosphatidylinositol biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; ANCHOR BIOSYNTHESIS; RAT-LIVER; INTERMEDIATE COMPARTMENT; TRANSMEMBRANE DOMAINS; MEMBRANE-FRACTION; RETENTION SIGNAL; PROTEIN; MITOCHONDRIA	The second step in glycosylphosphatidylinositol biosynthesis is the de-N-acetylation of N-acetylglucosaminylphosphatidylinositol (GlcNAc-PI) catalyzed by N-acetylglucosaminylphosphatidylinositol deacetylase (PIG-L). Previous studies of mouse thymoma cells showed that GlcNAc-PI de-N-acetylase activity is localized to the endoplasmic reticulum ( ER) but enriched in a mitochondria-associated ER membrane (MAM) domain. Because PIG-L has no readily identifiable ER sorting determinants, we were interested in learning how PIG-L is localized to the ER and possibly enriched in MAM. We used HeLa cells transiently or stably expressing epitope-tagged PIG-L variants or chimeric constructs composed of elements of PIG-L fused to Tac antigen, a cell surface protein. We first analyzed the subcellular distribution of PIG-L and GlcNAc-PI-de-N-acetylase activity and then studied the localization of Tac-PIG-L chimeras to identify sequence elements in PIG-L responsible for its subcellular localization. We show that human PIG-L is a type I membrane protein with a large cytoplasmic domain and that, unlike the result with mouse thymoma cells, both PIG-L and GlcNAc-PI-de-N-acetylase activity are uniformly distributed between ER and MAM in HeLa cells. Analyses of a series of Tac-PIG-L chimeras indicated that PIG-L contains two ER localization signals, an independent retention signal located between residues 60 and 88 of its cytoplasmic domain and another weak signal in the luminal and transmembrane domains that functions autonomously in the presence of membrane proximal residues of the cytoplasmic domain that themselves lack any retention information. We conclude that PIG-L, like a number of other ER membrane proteins, is retained in the ER through a multi-component localization signal rather than a discrete sorting motif.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Menon, AK (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	menon@biochem.wisc.edu	Pottekat, Anita/P-2719-2014	Pottekat, Anita/0000-0002-2117-6887; Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; Baumann NA, 2000, J BIOL CHEM, V275, P7378, DOI 10.1074/jbc.275.10.7378; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CUI Z, 1993, J BIOL CHEM, V268, P16655; Eisenhaber B, 2003, BIOESSAYS, V25, P367, DOI 10.1002/bies.10254; Fu J, 2000, EUR J CELL BIOL, V79, P219, DOI 10.1078/S0171-9335(04)70025-4; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEWIS JA, 1973, J CELL SCI, V13, P447; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Murakami Y, 2003, MOL BIOL CELL, V14, P4285, DOI 10.1091/mbc.E03-03-0193; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; OHTA Y, 1992, BIOCHEMISTRY-US, V31, P12680, DOI 10.1021/bi00165a019; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; Sharma DK, 1999, GLYCOBIOLOGY, V9, P415, DOI 10.1093/glycob/9.4.415; Shields DJ, 2003, J BIOL CHEM, V278, P2956, DOI 10.1074/jbc.M210904200; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; Smith TK, 2001, EMBO J, V20, P3322, DOI 10.1093/emboj/20.13.3322; Stevens VL, 1999, BIOCHEM J, V341, P577, DOI 10.1042/0264-6021:3410577; Stevens VL, 1996, BIOCHEM J, V313, P253, DOI 10.1042/bj3130253; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Stornaiuolo M, 2003, MOL BIOL CELL, V14, P889, DOI 10.1091/mbc.E02-08-0468; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; Szczesna-Skorupa E, 2001, J BIOL CHEM, V276, P45009, DOI 10.1074/jbc.M104676200; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Vainauskas S, 2004, J BIOL CHEM, V279, P6540, DOI 10.1074/jbc.M312191200; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; Watanabe R, 1999, BIOCHEM J, V339, P185, DOI 10.1042/0264-6021:3390185	47	18	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15743	15751		10.1074/jbc.M313537200	http://dx.doi.org/10.1074/jbc.M313537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14742432	hybrid			2022-12-27	WOS:000220747900008
J	Asin-Cayuela, J; Helm, M; Attardi, G				Asin-Cayuela, J; Helm, M; Attardi, G			A monomer-to-trimer transition of the human mitochondrial transcription termination factor (mTERF) is associated with a loss of in vitro activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; RNA-POLYMERASE-I; CRYSTAL-STRUCTURE; LEUCINE-ZIPPER; SEQUENCE; ACTIVATION; IDENTIFICATION; HEMAGGLUTININ; PURIFICATION; INVITRO	The human mitochondrial transcription termination factor (mTERF) is a nuclear-encoded 39-kDa protein that recognizes a mtDNA segment within the mitochondrial tRNA(Leu(UUR)) gene immediately adjacent to and downstream of the 16 S rRNA gene. Binding of mTERF to this site promotes termination of rDNA transcription. Despite the fact that mTERF binds DNA as a monomer, the presence in its sequence of three leucine-zipper motifs suggested the possibility of mTERF establishing intermolecular interactions with proteins of the same or different type. When a mitochondrial lysate from HeLa cells was submitted to gel filtration chromatography, mTERF was eluted in two peaks, as detected by immunoblotting. The first peak, which varied in proportion between 30 and 50%, appeared at the position expected from the molecular mass of the monomer (41+/-2 kDa), and the gel filtration fractions that contained it exhibited DNA binding activity. Most interestingly, the material in this peak had a strong stimulating activity on in vitro transcription of the mitochondrial rDNA. The second peak eluted at a position corresponding to an estimated molecular mass of 111+/-5 kDa. No mTERF DNA binding activity could be detected in the corresponding gel filtration fractions. Therefore, we propose that mTERF exists in mitochondria in two forms, an active monomer and an inactive large size complex. The estimated molecular weight of this complex and the fact that purified mTERF can be eluted from a gel filtration column as a complex of the same molecular weight strongly suggest that this inactive complex is a homotrimer of mTERF.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Attardi, G (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	attardi@caltech.edu	Helm, Mark/AAD-5433-2022	Helm, Mark/0000-0002-0154-0928	NIGMS NIH HHS [GM 11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ATTARDI G, 1990, BIOCHEM SOC T, V18, P509, DOI 10.1042/bst0180509; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHOMYN A, 1992, MOL MECHANISMS BIOEN, P483; CHRISTIANSON TW, 1986, P NATL ACAD SCI USA, V83, P6277, DOI 10.1073/pnas.83.17.6277; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DAGA A, 1993, J BIOL CHEM, V268, P8123; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; FERNANDEZSILVA P, 1996, METHOD ENZYMOL, V264, P158; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GRUMMT I, 1986, CELL, V45, P837, DOI 10.1016/0092-8674(86)90558-1; Hames BD., 1990, GEL ELECTROPHORESIS, P1; Harlow E., 1988, ANTIBODIES LAB MANUA; HURST HC, 1995, PROTEIN PROFILE, V2, P105; Jansa P, 1998, EMBO J, V17, P2855, DOI 10.1093/emboj/17.10.2855; Jansa P, 2001, NUCLEIC ACIDS RES, V29, P423, DOI 10.1093/nar/29.2.423; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; Puranam RS, 2001, MOL CELL BIOL, V21, P548, DOI 10.1128/MCB.21.2.548-561.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SKOLNICK J, 1985, MACROMOLECULES, V18, P1549, DOI 10.1021/ma00150a005; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	31	22	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15670	15677		10.1074/jbc.M312537200	http://dx.doi.org/10.1074/jbc.M312537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744862	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000220594700140
J	Butler, GS; Tam, EM; Overall, CM				Butler, GS; Tam, EM; Overall, CM			The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity - Probing the role of the methionine-turn in the metzincin metalloprotease superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; C-TERMINAL DOMAIN; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; BINDING-PROPERTIES; IV COLLAGENASE; ACTIVATION; TIMP-2; MODULES; IDENTIFICATION	Matrix metalloproteinases (MMPs) are an important family of extracellular proteases that process a variety of biologically significant molecules. MMPs are members of the metzincin superfamily of >770 zinc endopeptidases, which includes astacins, serralysins, adamalysins, leishmanolysins, and snapalysins. Metzincins are characterized by an absolutely conserved methionine residue COOH-terminal to the third histidine in the consensus sequence HEXXHXXGXX(H/D), where the histidine residues chelate a catalytic zinc ion. The canonical methionine is part of a tight 1,4-beta-turn that loops the polypeptide chain beneath the catalytic zinc ion, forming a hydrophobic floor to the Zn2+ ion binding site. The role of this methionine is uncertain, but its absolute conservation indicates an essential catalytic or structural function. To investigate this hypothesis, we replaced Met-392 that forms the Met-turn of human MMP-2 (gelatinase A) by site-directed mutagenesis. The catalytic competence of leucine and serine mutants was assessed. (M392L) MMP-2 and (M392S) MMP-2 cleaved the physiological substrates gelatin, native type I collagen, and the chemokine monocyte chemoattractant protein-3 with similar efficiency to wild-type MMP-2. These mutants also cleaved two quenched fluorescent peptide substrates with a k(cat)/K-m comparable to wild-type MMP-2 and underwent 4-aminophenylmercuric acetate-induced autoactivation with similar kinetics. (M392L) MMP-2 and (M392S) MMP-2 were inhibited by tissue inhibitor of metalloproteinases (TIMP)-1, -2, and -4 and by the zinc chelators 1,10-phenanthroline and a synthetic hydroxamate inhibitor, Batimastat, similar to the wild-type protein, indicating an unaltered active site topography. A tryptic susceptibility assay also suggested that (M392L) MMP-2 and (M392S) MMP-2 were correctly folded. These results challenge the dogma that this methionine residue and the Met-turn, which are absolutely conserved in all of the subfamilies of the metzincins, play an essential role in catalysis or active site structure.	Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Dept Oral Biol & Med Sci, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bigg HF, 2001, CANCER RES, V61, P3610; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Butler GS, 2002, J BIOL CHEM, V277, P17511, DOI 10.1074/jbc.M201461200; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fingleton B, 2003, EXPERT OPIN THER TAR, V7, P385, DOI 10.1517/14728222.7.3.385; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hege T, 2001, J MOL BIOL, V314, P181, DOI 10.1006/jmbi.2001.5125; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; PIELAK GJ, 1985, NATURE, V313, P152, DOI 10.1038/313152a0; Pieper M, 1997, J PROTEIN CHEM, V16, P637, DOI 10.1023/A:1026327125333; QORONFLEH MW, 1995, J BIOTECHNOL, V39, P119, DOI 10.1016/0168-1656(94)00149-7; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119	38	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15615	15620		10.1074/jbc.M312727200	http://dx.doi.org/10.1074/jbc.M312727200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14732714	hybrid			2022-12-27	WOS:000220594700133
J	Kwa, LG; Garcia-Martin, A; Vegh, AP; Strohmann, B; Robert, B; Braun, P				Kwa, LG; Garcia-Martin, A; Vegh, AP; Strohmann, B; Robert, B; Braun, P			Hydrogen bonding in a model bacteriochlorophyll-binding site drives assembly of light harvesting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY ELECTRON-DONOR; RHODOBACTER-SPHAEROIDES; REACTION CENTERS; PHOTOSYSTEM-I; TRANSMEMBRANE HELIX; CIRCULAR-DICHROISM; MEMBRANE-PROTEINS; PIGMENT BINDING; POLAR RESIDUES; ASSOCIATION	In this study, the contribution of intramembrane hydrogen bonding at the interface between polypeptide and cofactor is explored in the native lipid environment by use of model bacteriochlorophyll proteins. In the peripheral antenna complex, LH2, large portions of the transmembrane helices, which make up the dimeric bacteriochlorophyll-binding site, are replaced by simplified, alternating alanine-leucine stretches. Replacement of either one of the two helices with the helices containing the model sequence at a time results in the assembly of complexes with nearly native light harvesting properties. In contrast, replacement of both helices results in the loss of antenna complexes from the membrane. The assembly of such doubly modified complexes is restored by a single intramembrane serine residue at position -4 relative to the liganding histidine of the alpha-subunit. In situ analysis of the spectral properties in a series of site-directed mutants reveals a critical dependence of the model complex assembly on the side chain of the residue at this position in the helix. A hydrogen bond between the hydroxy group of the serine and the 131 keto group of one of the central bacteriochlorophylls of the complexes is identified by Raman spectroscopy in the model antenna complex containing one of the alanine-leucine helices. The additional OH group of the serine residue, which participates in hydrogen bonding, increases the thermal stability of the model complexes in the native membrane. Intramembrane hydrogen bonding is thus shown to be a key factor for the binding of bacteriochlorophyll and assembly of this model cofactor-polypeptide site.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany; CE Saclay, Sect Biophys Fonct Membranaires, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Semmelweis Univ, Inst Biophys & Radiat Biol, Fac Med, H-1088 Budapest, Hungary	University of Munich; CEA; Centre National de la Recherche Scientifique (CNRS); Semmelweis University	Braun, P (corresponding author), Univ Munich, Dept Biol 1, D-80638 Munich, Germany.	braun@botanik.biologie.uni-muenchen.de	Robert, Bruno/D-1264-2012	Robert, Bruno/0000-0001-5999-4538; GARCIA MARTIN, ADELA MARIA/0000-0001-7054-7907				Adamian L, 2003, J MOL BIOL, V327, P251, DOI 10.1016/S0022-2836(03)00041-X; Adamian L, 2002, PROTEINS, V47, P209, DOI 10.1002/prot.10071; Bandilla M, 1998, BBA-BIOENERGETICS, V1364, P390, DOI 10.1016/S0005-2728(98)00086-3; BRAUN P, 1991, BIOCHEMISTRY-US, V30, P5177, DOI 10.1021/bi00235a010; Braun P, 2003, BBA-BIOENERGETICS, V1607, P19, DOI 10.1016/j.bbabio.2003.08.004; Braun P, 2002, J MOL BIOL, V318, P1085, DOI 10.1016/S0022-2836(02)00192-4; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Cogdell R. J., 1995, ANOXYGENIC PHOTOSYNT, P315; COGDELL RJ, 1985, PHOTOCHEM PHOTOBIOL, V42, P669, DOI 10.1111/j.1751-1097.1985.tb01629.x; DAVIS CM, 1995, J BIOL CHEM, V270, P5793, DOI 10.1074/jbc.270.11.5793; Dawson JP, 2003, J MOL BIOL, V331, P255, DOI 10.1016/S0022-2836(03)00714-9; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; DeGrado WF, 2003, PROTEIN SCI, V12, P647, DOI 10.1110/ps.0236503; Desiraju GR, 2002, ACCOUNTS CHEM RES, V35, P565, DOI 10.1021/ar010054t; FOWLER GJS, 1994, BIOCHEM J, V299, P695, DOI 10.1042/bj2990695; FOWLER GJS, 1995, J BIOL CHEM, V270, P23875, DOI 10.1074/jbc.270.40.23875; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Gall A, 2003, BIOCHEMISTRY-US, V42, P7252, DOI 10.1021/bi0268293; Gall A, 1997, BIOCHEMISTRY-US, V36, P16282, DOI 10.1021/bi9717237; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Horn R, 2002, J MOL BIOL, V318, P547, DOI 10.1016/S0022-2836(02)00115-8; Hu QH, 1998, BIOCHEMISTRY-US, V37, P10006, DOI 10.1021/bi980036s; Ivancich A, 1998, BIOCHEMISTRY-US, V37, P11812, DOI 10.1021/bi9806908; JONES MR, 1992, MOL MICROBIOL, V6, P1173, DOI 10.1111/j.1365-2958.1992.tb01556.x; KIM J, 1994, PLANT PHYSIOL, V104, P907, DOI 10.1104/pp.104.3.907; Koolhaas MHC, 1998, BIOCHEMISTRY-US, V37, P4693, DOI 10.1021/bi973036l; Lapouge K, 1998, J RAMAN SPECTROSC, V29, P977, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<977::AID-JRS325>3.0.CO;2-K; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Liebl U, 1996, PHOTOCHEM PHOTOBIOL, V64, P38, DOI 10.1111/j.1751-1097.1996.tb02419.x; MATTIOLI TA, 1991, BIOCHEMISTRY-US, V30, P1715, DOI 10.1021/bi00220a038; MATTIOLI TA, 1995, BIOCHEMISTRY-US, V34, P6142, DOI 10.1021/bi00018a017; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MOENNELOCCOZ P, 1990, BIOCHEMISTRY-US, V29, P4740, DOI 10.1021/bi00471a031; PLUMLEY FG, 1995, PLANT CELL, V7, P689, DOI 10.2307/3870172; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; Prince SM, 1997, J MOL BIOL, V268, P412, DOI 10.1006/jmbi.1997.0966; Rau HK, 2001, EUR J BIOCHEM, V268, P3284, DOI 10.1046/j.1432-1327.2001.02231.x; ROBERT B, 1985, BIOCHIM BIOPHYS ACTA, V807, P10, DOI 10.1016/0005-2728(85)90048-9; Robert B., 1996, BIOPHYSICAL TECHNIQU, P161; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Shan SO, 1996, P NATL ACAD SCI USA, V93, P14474, DOI 10.1073/pnas.93.25.14474; SNIGULA H, 2001, PS2001 P 12 INT C PH; Spiedel D, 2002, FEBS LETT, V527, P171, DOI 10.1016/S0014-5793(02)03203-9; Sturgis JN, 1997, J PHYS CHEM B, V101, P7227, DOI 10.1021/jp963363n; STURGIS JN, 1995, BIOCHEMISTRY-US, V34, P517, DOI 10.1021/bi00002a016; Takano K, 2003, J BIOL CHEM, V278, P31790, DOI 10.1074/jbc.M304177200; VANGRONDELLE R, 1985, BIOCHIM BIOPHYS ACTA, V811, P147, DOI 10.1016/0304-4173(85)90017-5; Witt H, 2002, BIOCHEMISTRY-US, V41, P8557, DOI 10.1021/bi025822i; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	51	19	23	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15067	15075		10.1074/jbc.M312429200	http://dx.doi.org/10.1074/jbc.M312429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742420	hybrid			2022-12-27	WOS:000220594700071
J	Qiu, JM; Pintel, DJ				Qiu, JM; Pintel, DJ			Alternative polyadenylation of adeno-associated virus type 5 RNA within an internal intron is governed by the distance between the promoter and the intron and is inhibited by U1 small nuclear RNP binding to the intervening donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SNRNP-A PROTEIN; 5' SPLICE-SITE; POLY(A) SITE; REGULATED PRODUCTION; HUMAN PARVOVIRUS; POLYMERASE-II; COMPLEX; EXPRESSION; GENE	Adeno-associated virus type 5 is unique among adeno-associated virus serotypes in that it uses a polyadenylation site in the center of the genome. The great majority of transcripts generated from the upstream P7 and P19 promoters are polyadenylated at a site in the central intron ((pA)p); however, most of the viral transcripts generated by the proximal P41 promoter are polyadenylated at the distal polyadenylation site at the 3' end of the genome (pA)d and subsequently spliced. Polyadenylation at (pA) p increases as the distance between the RNA initiation site and the intron and (pA) p site is increased. The steady-state level of RNAs polyadenylated at (pA) p is independent of the promoter used or of the intervening sequence but is dependent upon competition with splicing, inhibition by U1 snRNP binding to the intron donor, and the intrinsic efficiency of the cleavage/polyadenylation reaction. Each of these determinants shows a marked dependence on the distance between the RNA initiation site and the intron and (pA) p. Finally, unlike other reported systems, inhibition of (pA) p by U1 snRNP binding to the intron donor is decreased as the distance between the donor and (pA) p is increased.	Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Pintel, DJ (corresponding author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA.	pinteld@missouri.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021302, R01AI046458] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI46458, R01 AI21302] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashe MP, 1997, EMBO J, V16, P5752, DOI 10.1093/emboj/16.18.5752; ASHE MP, 1995, GENE DEV, V9, P3008, DOI 10.1101/gad.9.23.3008; Ashe MP, 2000, RNA, V6, P170, DOI 10.1017/S1355838200991957; BANTELSCHAAL U, 1984, VIROLOGY, V134, P52, DOI 10.1016/0042-6822(84)90271-X; BARKSDALE SK, 1995, J VIROL, V69, P6553, DOI 10.1128/JVI.69.10.6553-6556.1995; Beckley SA, 2001, MOL CELL BIOL, V21, P2815, DOI 10.1128/MCB.21.8.2815-2825.2001; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; Colot HV, 1996, GENE DEV, V10, P1699, DOI 10.1101/gad.10.13.1699; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; Fortes P, 2003, P NATL ACAD SCI USA, V100, P8264, DOI 10.1073/pnas.1332669100; FURTH PA, 1994, MOL CELL BIOL, V14, P5278, DOI 10.1128/MCB.14.8.5278; GALLI G, 1988, P NATL ACAD SCI USA, V85, P2439, DOI 10.1073/pnas.85.8.2439; GEORGFRIES B, 1984, VIROLOGY, V134, P64, DOI 10.1016/0042-6822(84)90272-1; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Lewis JD, 1996, NUCLEIC ACIDS RES, V24, P3332, DOI 10.1093/nar/24.17.3332; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Mouw MB, 2000, J VIROL, V74, P9878, DOI 10.1128/JVI.74.21.9878-9888.2000; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; Phillips C, 2001, EMBO J, V20, P6443, DOI 10.1093/emboj/20.22.6443; Qiu JM, 2004, J VIROL, V78, P83, DOI 10.1128/JVI.78.1.83-93.2004; Qiu JM, 2002, MOL CELL BIOL, V22, P3639, DOI 10.1128/MCB.22.11.3639-3652.2002; Qiu JM, 2002, J VIROL, V76, P12435, DOI 10.1128/JVI.76.24.12435-12447.2002; SCHOBORG RV, 1991, VIROLOGY, V181, P22, DOI 10.1016/0042-6822(91)90466-O; SIEGL G, 1985, INTERVIROLOGY, V23, P61, DOI 10.1159/000149587; Vagner S, 2000, RNA, V6, P178, DOI 10.1017/S1355838200991854; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	36	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14889	14898		10.1074/jbc.M312734200	http://dx.doi.org/10.1074/jbc.M312734200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749332	hybrid			2022-12-27	WOS:000220594700050
J	Sakurai, T; Itoh, K; Higashitsuji, H; Nagao, T; Nonoguchi, K; Chiba, T; Fujita, J				Sakurai, T; Itoh, K; Higashitsuji, H; Nagao, T; Nonoguchi, K; Chiba, T; Fujita, J			A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; HUMAN-MELANOMA; P53; GANKYRIN; MYC; DEATH; INHIBITOR; PROTEINS; MITOCHONDRIA; ONCOPROTEIN	Gankyrin, a recently discovered oncoprotein, is a promising target for drug therapy because it is overexpressed in most hepatocellular carcinomas. Since gankyrin interacts with MAGE-A4, we made several MAGE-A4 mutants and assessed their effects on cell growth. We found that the C-terminal 107 amino acids of MAGE-A4 (MAGE-A4DeltaN1) induced p53-dependent and p53-independent apoptosis. MAGE-A4DeltaN1 increased the p53 protein level, but decreased the p21(Cip1) transcript and protein levels. During apoptosis Bcl-xL was down-regulated and mitochondrial integrity was disrupted. A yeast two-hybrid screen identified Miz-1 as a MAGE-A4DeltaN1-binding protein. MAGE-A4DeltaN1 was recruited through association with Miz-1 to the p21Cip1 promoter and down-regulated transcription of p21(Cip1). In 293T cells and U-2 OS cells, full-length MAGE-A4 was processed to generate a C-terminal fragment of 104 amino acids with activities similar to MAGE-A4DeltaN1. Processing was inhibited with a broad range caspase inhibitor Z-VAD-FMK, but not by site-directed mutagenesis of aspartic acids in MAGE-A4, suggesting an indirect involvement of caspase(s) in the processing. The amount of the processed form was increased by exposure of cells to adriamycin. Transduction with a HIV Tat-MAGE-A4DeltaN1 fusion protein suppressed anchorage-independent growth of gankyrin-overexpressing cells in vitro and in vivo. These results demonstrate that the C-terminal fragment of MAGE-A4 induces apoptosis at least partly by binding to Miz-1, and that the fragment may be exploited as an anticancer agent. Furthermore, the finding that a C-terminal fragment with pro-apoptotic activity is generated from full-length MAGE-A4 after genotoxic stress in human cells suggests a novel function for MAGE-A4.	Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Med,Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Fujita, J (corresponding author), Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	jfujita@virus.kyoto-u.ac.jp						Alarcon R, 1999, CANCER RES, V59, P6046; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Castelli C, 2000, J CELL PHYSIOL, V182, P323, DOI 10.1002/(SICI)1097-4652(200003)182:3<323::AID-JCP2>3.0.CO;2-#; Chomez P, 2001, CANCER RES, V61, P5544; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Forslund KO, 2001, EXP CELL RES, V265, P185, DOI 10.1006/excr.2001.5173; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Krzywda S, 2004, J BIOL CHEM, V279, P1541, DOI 10.1074/jbc.M310265200; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Manfredi JJ, 2003, MOL CELL, V11, P552, DOI 10.1016/S1097-2765(03)00106-0; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nagao T, 2003, J BIOL CHEM, V278, P10668, DOI 10.1074/jbc.M206104200; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicholson DW, 2003, SCIENCE, V299, P214, DOI 10.1126/science.1081274; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Park TJ, 2001, MOL CARCINOGEN, V30, P138, DOI 10.1002/mc.1022; Pati D, 2002, MOL CELL BIOL, V22, P8267, DOI 10.1128/MCB.22.23.8267-8277.2002; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XD, 2001, GENE DEV, V15, P2922; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034	47	48	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15505	15514		10.1074/jbc.M310437200	http://dx.doi.org/10.1074/jbc.M310437200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14739298	hybrid, Green Submitted			2022-12-27	WOS:000220594700122
J	Surana, NK; Cutter, D; Barenkamp, SJ; St Geme, JW				Surana, NK; Cutter, D; Barenkamp, SJ; St Geme, JW			The Haemophilus influenzae Hia autotransporter contains an unusually short trimeric translocator domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROCOLONY FORMATION; ESCHERICHIA-COLI; MEMBRANE PROTEIN; IDENTIFICATION; PREDICTION; SECRETION; TRANSPORT; DETERMINANTS; ADHERENCE; ADHESIN	Gram-negative bacterial autotransporter proteins are a growing group of virulence factors that are characterized by their ability to cross the outer membrane without the help of accessory proteins. A conserved C-terminal beta-domain is critical for targeting of autotransporters to the outer membrane and for translocation of the N-terminal "passenger" domain to the bacterial surface. We have demonstrated previously that the Haemophilus influenzae Hia adhesin belongs to the autotransporter family, with translocator activity residing in the C-terminal 319 residues. To gain further insight into the mechanism of autotransporter protein translocation, we performed a structure-function analysis on Hia. In initial experiments, we generated a series of in-frame deletions and a set of chimeric proteins containing varying regions of the Hia C terminus fused to a heterologous passenger domain and discovered that the final 76 residues of Hia are both necessary and sufficient for translocation. Analysis by flow cytometry revealed that the region N-terminal to this shortened translocator domain is surface localized, further suggesting that this region is not involved in beta-barrel formation or in translocation of the passenger domain. Western analysis demonstrated that the translocation-competent regions of the C terminus migrated at masses consistent with trimers, suggesting that the Hia C terminus oligomerizes. Furthermore, fusion proteins containing a heterologous passenger domain demonstrated that similarly small C-terminal regions of Yersinia sp. YadA and Neisseria meningitidis NhhA are translocation-competent. These data provide experimental support for a unique subclass of autotransporters characterized by a short trimeric translocator domain.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pediat, St Louis, MO 63104 USA	Washington University (WUSTL); Washington University (WUSTL); Saint Louis University	St Geme, JW (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	stgeme@borcim.wustl.edu	Barenkamp, Stephen J./I-9390-2019	Barenkamp, Stephen J./0000-0002-3054-8910	NIAID NIH HHS [R01 AI44167, R01 AI48066, T32 AI0717223] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172, R01AI044167, R01AI048066] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1972, J CLIN INVEST, V51, P31, DOI 10.1172/JCI106793; Barenkamp SJ, 1996, MOL MICROBIOL, V19, P1215, DOI 10.1111/j.1365-2958.1996.tb02467.x; Brandon LD, 2001, J BACTERIOL, V183, P951, DOI 10.1128/JB.183.3.951-958.2001; CARLONE GM, 1986, J CLIN MICROBIOL, V24, P330, DOI 10.1128/JCM.24.3.330-332.1986; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Fink DL, 2003, CELL MICROBIOL, V5, P175, DOI 10.1046/j.1462-5822.2003.00266.x; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Hendrixson DR, 1998, MOL CELL, V2, P841, DOI 10.1016/S1097-2765(00)80298-1; Hendrixson DR, 1997, MOL MICROBIOL, V26, P505, DOI 10.1046/j.1365-2958.1997.5921965.x; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; Hoiczyk E, 2000, EMBO J, V19, P5989, DOI 10.1093/emboj/19.22.5989; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; KLAUSER T, 1992, EMBO J, V11, P2327, DOI 10.1002/j.1460-2075.1992.tb05292.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Laarmann S, 2002, MOL MICROBIOL, V46, P731, DOI 10.1046/j.1365-2958.2002.03189.x; Loveless BJ, 1997, MOL MEMBR BIOL, V14, P113, DOI 10.3109/09687689709048171; Maurer J, 1999, J BACTERIOL, V181, P7014, DOI 10.1128/JB.181.22.7014-7020.1999; Oliver DC, 2003, MOL MICROBIOL, V47, P1367, DOI 10.1046/j.1365-2958.2003.03377.x; Peak IRA, 2000, FEMS IMMUNOL MED MIC, V28, P329, DOI 10.1111/j.1574-695X.2000.tb01494.x; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Roggenkamp A, 2003, J BACTERIOL, V185, P3735, DOI 10.1128/JB.185.13.3735-3744.2003; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 2001, MOL CLONING LAB MANU; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; Schulz GE, 2000, CURR OPIN STRUC BIOL, V10, P443, DOI 10.1016/S0959-440X(00)00120-2; SETLOW JK, 1968, J BACTERIOL, V95, P546, DOI 10.1128/JB.95.2.546-558.1968; Shannon JL, 1999, J BACTERIOL, V181, P5838, DOI 10.1128/JB.181.18.5838-5842.1999; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; St Geme JW, 1998, INFECT IMMUN, V66, P364; St Geme JW, 2000, J BACTERIOL, V182, P6005, DOI 10.1128/JB.182.21.6005-6013.2000; Stathopoulos C, 2000, MICROBES INFECT, V2, P1061, DOI 10.1016/S1286-4579(00)01260-0; STGEME JW, 1993, P NATL ACAD SCI USA, V90, P2875, DOI 10.1073/pnas.90.7.2875; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; Veiga E, 1999, MOL MICROBIOL, V33, P1232, DOI 10.1046/j.1365-2958.1999.01571.x; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; YEO HJ, 2004, IN PRESS EMBO J	40	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14679	14685		10.1074/jbc.M311496200	http://dx.doi.org/10.1074/jbc.M311496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726537	hybrid			2022-12-27	WOS:000220594700027
J	Wain, R; Redfield, C; Ferguson, SJ; Smith, LJ				Wain, R; Redfield, C; Ferguson, SJ; Smith, LJ			NMR analysis shows that a b-type variant of Hydrogenobacter thermophilus cytochrome c(552) retains its native structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROME; IN-VITRO FORMATION; CHEMICAL-SHIFTS; HEME; PROTEIN; MATURATION; ASSIGNMENT; BIOGENESIS; CONVERSION; FORMS	Conversion of Hydrogenobacter thermophilus cytochrome c(552) into a b-type cytochrome by mutagenesis of both heme-binding cysteines to alanines significantly reduces the stability of the protein ( Tomlinson, E. J., and Ferguson, S. J. ( 2000) Proc. Natl. Acad. Sci. U. S. A. 97, 5156 - 5160). To understand the effects of this change on the structure and dynamics of the protein, heteronuclear N-15-edited NMR techniques have been used to characterize this b-type variant. The backbone N-15, H-1(N), and H-1(alpha), and H-1(beta) resonances of the protein have been assigned. Analysis of (3)J(HN)alpha coupling constants, nuclear Overhauser enhancement intensities, and chemical shift index data demonstrates that the four alpha-helices present in the wild-type protein are retained in the b-type variant. Comparison of the chemical shifts for the b-type and wild-type proteins indicates that the tertiary structures of the two proteins are closely similar. Some subtle differences are, however, observed for residues in the N-terminal region and in the vicinity of the heme-binding pocket. Hydrogen exchange studies show that there are 25 backbone amide protons that exchange very slowly in the b-type variant and confirm that the fluctuations within the b-type protein are of a similar extent to those in the wild-type protein. These data demonstrate the notable retention of the native secondary structure and tertiary fold despite the absence of covalent linkages between the heme group and the protein.	Univ Oxford, Chem Res Lab, Oxford Ctr Mol Sci, Oxford OX1 3TA, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Smith, LJ (corresponding author), Univ Oxford, Chem Res Lab, Oxford Ctr Mol Sci, Mansfield Rd, Oxford OX1 3TA, England.	lorna.smith@chem.ox.ac.uk		Redfield, Christina/0000-0001-7297-7708				Allen JWA, 2003, J BIOL CHEM, V278, P52075, DOI 10.1074/jbc.M307196200; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Arnesano F, 2000, BIOCHEMISTRY-US, V39, P1499, DOI 10.1021/bi991831o; AVIRAM I, 1972, BIOPOLYMERS, V11, P2141, DOI 10.1002/bip.1972.360111014; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Case DA, 2000, CURR OPIN STRUC BIOL, V10, P197, DOI 10.1016/S0959-440X(00)00068-3; Clarke J, 1998, CURR OPIN STRUC BIOL, V8, P112, DOI 10.1016/S0959-440X(98)80018-3; Daltrop O, 2003, J BIOL CHEM, V278, P24308, DOI 10.1074/jbc.M301967200; Daltrop O, 2003, J BIOL CHEM, V278, P4404, DOI 10.1074/jbc.M211124200; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11310, DOI 10.1021/bi9603736; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Karan EF, 2002, J BIOL INORG CHEM, V7, P260, DOI 10.1007/s007750100292; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MCLACHLAN SJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P274, DOI 10.1016/0167-4838(86)90026-9; McRee DE, 2001, J BIOL CHEM, V276, P6537, DOI 10.1074/jbc.M008421200; Oldfield E, 2002, ANNU REV PHYS CHEM, V53, P349, DOI 10.1146/annurev.physchem.53.082201.124235; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PETTIGREW GW, 1991, CYTOCHROMES C EVOLUT, P1; REDFIELD C, 1993, NMR MACROMOLECULES P, P71; Rosell FI, 2002, BIOCHEMISTRY-US, V41, P7811, DOI 10.1021/bi016060e; Sambongi Y, 2002, EUR J BIOCHEM, V269, P3355, DOI 10.1046/j.1432-1033.2002.03045.x; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; Wain R, 2001, J BIOL CHEM, V276, P45813, DOI 10.1074/jbc.M107572200; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P13	30	17	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15177	15182		10.1074/jbc.M311869200	http://dx.doi.org/10.1074/jbc.M311869200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14726539	hybrid			2022-12-27	WOS:000220594700084
J	Hayes, MJ; Merrifield, CJ; Shao, DM; Ayala-Sanmartin, J; D'Souza-Schorey, C; Levine, TP; Proust, J; Curran, J; Bailly, M; Moss, SE				Hayes, MJ; Merrifield, CJ; Shao, DM; Ayala-Sanmartin, J; D'Souza-Schorey, C; Levine, TP; Proust, J; Curran, J; Bailly, M; Moss, SE			Annexin 2 binding to phosphatidylinositol 4,5-bisphosphate on endocytic vesicles is regulated by the stress response pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ACTIN DYNAMICS; ENDOSOMES; PHOSPHOINOSITIDES; PHOSPHORYLATION; TRANSLOCATION; PHAGOCYTOSIS; ASSOCIATION; REQUIRES; ALPHA	Annexin 2 is a Ca2+-binding protein that has an essential role in actin-dependent macropinosome motility. We show here that macropinosome rocketing can be induced by hyperosmotic shock, either alone or synergistically when combined with phorbol ester or pervanadate. Rocketing was blocked by inhibitors of phosphatidylinositol-3-kinase( s), p38 mitogen-activated protein ( MAP) kinase, and calcium, suggesting the involvement of phosphoinositide signaling. Since various phosphoinositides are enriched on inwardly mobile vesicles, we examined whether or not annexin 2 binds to any of this class of phospholipid. In liposome sedimentation assays, we show that recombinant annexin 2 binds to phosphatidylinositol 4,5-bisphosphate (PtdIns-4,5P(2)) but not to other poly- and mono-phosphoinositides. The affinity of annexin 2 for PtdIns-4,5P(2) (K-D similar to 5 muM) is comparable with those reported for a variety of PtdIns-4,5P(2)-binding proteins and is enhanced in the presence of Ca2+. Although annexin 1 also bound to PtdIns-4,5P(2), annexin 5 did not, indicating that this is not a generic annexin property. To test whether annexin 2 binds to PtdIns-4,5P(2) in vivo, we microinjected rat basophilic leukemia cells stably expressing annexin 2-green fluorescent protein (GFP) with fluorescently tagged antibodies to PtdIns-4,5P(2). Annexin 2-GFP and anti-PtdIns- 4,5P(2) IgG co-localize at sites of pinosome formation, and annexin 2-GFP relocalizes to intracellular membranes in Ptk cells microinjected with Arf6Q67L, which has been shown to stimulate PtdIns- 4,5P(2) synthesis on pinosomes through activation of phosphatidylinositol 5 kinase. These results establish a novel phospholipid-binding specificity for annexin 2 consistent with a role in mediating the interaction between the macropinosome surface and the polymerized actin tail.	UCL, Inst Ophthalmol, Div Cell Biol, 11-43 Bath St, London EC1V 9EL, England; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; CHU St Antoine, INSERM, U538, F-75012 Paris, France; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Toulouse 3, CNRS, UMR 5546, F-31326 Castanet Tolosan, France	University of London; University College London; Yale University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Notre Dame; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Moss, SE (corresponding author), UCL, Inst Ophthalmol, Div Cell Biol, 11-43 Bath St, London EC1V 9EL, England.	s.moss@ucl.ac.uk	Bailly, Maryse/C-1663-2008	Levine, Timothy/0000-0002-7231-0775; Bailly, Maryse/0000-0002-0593-6356	Wellcome Trust [063736] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15190, DOI 10.1021/bi000764r; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Castellano F, 2001, SEMIN IMMUNOL, V13, P347, DOI 10.1006/smim.2001.0331; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Guay J, 1997, J CELL SCI, V110, P357; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Ma L, 1998, J CELL BIOL, V140, P1125; May RC, 2001, J CELL SCI, V114, P1061; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Moreau V, 1998, FEBS LETT, V427, P353, DOI 10.1016/S0014-5793(98)00443-8; RA C, 1989, EUR J IMMUNOL, V19, P1771, DOI 10.1002/eji.1830191002; REGNOUF F, 1991, J NEUROCHEM, V56, P1985, DOI 10.1111/j.1471-4159.1991.tb03457.x; Sakai E, 2001, J BIOCHEM, V130, P823, DOI 10.1093/oxfordjournals.jbchem.a003054; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Sciorra VA, 2002, J CELL BIOL, V159, P1039, DOI 10.1083/jcb.200205056; Sechi AS, 2000, J CELL SCI, V113, P3685; SJOLIN C, 1994, BIOCHEM J, V300, P325; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Tomas A, 2003, J BIOL CHEM, V278, P20210, DOI 10.1074/jbc.M212669200; Zeuschner D, 2001, EUR J CELL BIOL, V80, P499, DOI 10.1078/0171-9335-00184	35	92	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14157	14164		10.1074/jbc.M313025200	http://dx.doi.org/10.1074/jbc.M313025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734570	Green Accepted, hybrid			2022-12-27	WOS:000220478500106
J	Lai, KO; Chen, Y; Po, HM; Lok, KC; Gong, K; Ip, NY				Lai, KO; Chen, Y; Po, HM; Lok, KC; Gong, K; Ip, NY			Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle - Implications in the regulation of acetylcholinesterase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; EPIDERMAL-GROWTH-FACTOR; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTION; NEURAL DEVELOPMENT; GENE-EXPRESSION; EPHB2 RECEPTOR; JAK FAMILY; ACTIVATION; PHOSPHORYLATION	Eph receptors and their cognate ligands ephrins are important players in axon guidance and neural patterning during development of the nervous system. Much of our knowledge about the signal transduction pathways triggered by Eph receptors has been related to the modulation of actin cytoskeleton, which is fundamental in mediating the cellular responses in growth cone navigation, cell adhesion, and cell migration. In contrast, little was known about whether long term activation of Eph receptor would regulate gene expression. Here we report a novel signaling pathway of EphA4, which involves activation of the tyrosine kinase Jak2 and the transcriptional activator Stat3. Transfection of COS7 cells with EphA4, but not the kinase-dead mutant, induced tyrosine phosphorylation of Jak2, Stat1, and Stat3. Treatment of cultured C2C12 myotubes with ephrin-A1 also induced tyrosine phosphorylation of Stat3, which was abolished by the Jak2 inhibitor AG490. Moreover, Jak2 was co-immunoprecipitated with EphA4 in muscle, and both proteins were concentrated at the neuromuscular junction (NMJ) of adult muscle. By using microarray analysis, we have identified acetylcholinesterase, the critical enzyme that hydrolyzed the neurotransmitter acetylcholine at the NMJ, as a downstream target gene of the Jak/Stat pathway in muscle. More importantly, ephrin-A1 increased the expression of acetylcholinesterase protein in C2C12 myotubes, which was abolished by AG490. In contrast, ephrin-A1 reduced the expression of fibronectin mRNA in C2C12 myotubes independently of Jak2. Finally, the expression level of acetylcholinesterase in limb muscle of EphA4 null mice was significantly reduced compared with the wild-type control. Taken together, these results have identified Jak/Stat proteins as the novel downstream targets of EphA4 signaling. In addition, the present study provides the first demonstration of a potential function of Eph receptors and Jak/Stat proteins at the NMJ.	Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Clear Water Bay, Hong Kong, Peoples R China.	BOIP@UST.HK	Lai, Kwok-On/L-7468-2019; Lai, Kwok-On/E-5182-2011; Lai, Kwok On/ABC-8046-2021	Lai, Kwok-On/0000-0002-4069-054X; Ip, Nancy Yuk-Yu/0000-0002-2763-8907				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; CHIU AY, 1984, DEV BIOL, V103, P456, DOI 10.1016/0012-1606(84)90333-6; Choi S, 1999, ONCOGENE, V18, P5413, DOI 10.1038/sj.onc.1202917; Coonan JR, 2003, J COMP NEUROL, V458, P98, DOI 10.1002/cne.10571; Coonan JR, 2001, J COMP NEUROL, V436, P248; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Ellis C, 1996, ONCOGENE, V12, P1727; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Frost RA, 2002, ENDOCRINOLOGY, V143, P492, DOI 10.1210/en.143.2.492; Fu AKY, 1999, MOL CELL NEUROSCI, V14, P241, DOI 10.1006/mcne.1999.0784; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gerlai R, 1999, J NEUROSCI, V19, P9538; Gerlai R, 2001, NAT REV NEUROSCI, V2, P205, DOI 10.1038/35058582; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; HARPUR AG, 1992, ONCOGENE, V7, P1347; He W, 2002, FEBS LETT, V514, P214, DOI 10.1016/S0014-5793(02)02367-0; Ip FCF, 1996, J NEUROCHEM, V67, P1607; Irie F, 2002, NAT NEUROSCI, V5, P1117, DOI 10.1038/nn964; Kami K, 2002, J HISTOCHEM CYTOCHEM, V50, P1579, DOI 10.1177/002215540205001202; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lai KO, 2003, TRENDS GENET, V19, P395, DOI 10.1016/S0168-9525(03)00147-1; Lai KO, 2001, MOL CELL NEUROSCI, V17, P1034, DOI 10.1006/mcne.2001.0997; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; Massoulie J, 2002, NEUROSIGNALS, V11, P130, DOI 10.1159/000065054; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; Murai KK, 2002, NEURON, V33, P159, DOI 10.1016/S0896-6273(02)00565-2; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Murata S, 2000, MOL BRAIN RES, V78, P80, DOI 10.1016/S0169-328X(00)00077-2; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Spangenburg EE, 2002, AM J PHYSIOL-CELL PH, V283, pC204, DOI 10.1152/ajpcell.00574.2001; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	55	66	66	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13383	13392		10.1074/jbc.M313356200	http://dx.doi.org/10.1074/jbc.M313356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729671	hybrid			2022-12-27	WOS:000220478500015
J	Rungroj, N; Devonald, MAJ; Cuthbert, AW; Reimann, F; Akkarapatumwong, V; Yenchitsomanus, P; Bennett, WM; Karet, FE				Rungroj, N; Devonald, MAJ; Cuthbert, AW; Reimann, F; Akkarapatumwong, V; Yenchitsomanus, P; Bennett, WM; Karet, FE			A novel missense mutation in AE1 causing autosomal dominant distal renal tubular acidosis retains normal transport function but is mistargeted in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGER KAE1; HEREDITARY SPHEROCYTOSIS; ANION-EXCHANGER-1 GENE; IMPAIRED TRAFFICKING; ASIAN OVALOCYTOSIS; XENOPUS OOCYTES; GLYCOPHORIN-A; BAND-3; MEMBRANE; BICARBONATE	Mutations in SLC4A1, encoding the chloride-bicarbonate exchanger AE1, cause distal renal tubular acidosis (dRTA), a disease of defective urinary acidification by the distal nephron. In this study we report a novel missense mutation, G609R, causing dominant dRTA in affected members of a large Caucasian pedigree who all exhibited metabolic acidosis with alkaline urine, prominent nephrocalcinosis, and progressive renal impairment. To investigate the potential disease mechanism, the consequent effects of this mutation were determined. We first assessed anion transport function of G609R by expression in Xenopus oocytes. Western blotting and immunofluorescence demonstrated that the mutant protein was expressed at the oocyte cell surface. Measuring chloride and bicarbonate fluxes revealed normal 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid-inhibitable anion exchange, suggesting that loss-of-function of kAE1 cannot explain the severe disease phenotype in this kindred. We next expressed epitope-tagged wild-type or mutant kAE1 in Madin-Darby canine kidney cells. In monolayers grown to polarity, mutant kAE1 was detected subapically and at the apical membrane, as well as at the basolateral membrane, in contrast to the normal basolateral appearance of wildtype kAE1. These findings suggest that the seventh transmembrane domain that contains Gly-609 plays an important role in targeting kAE1 to the correct cell surface compartment. They confirm that dominant dRTA is associated with non-polarized trafficking of the protein, with no significant effect on anion transport function in vitro, which remains an unusual mechanism of human disease.	Univ Cambridge, Dept Med Genet, Cambridge CB2 2XY, England; Univ Cambridge, Dept Med, Cambridge CB2 2XY, England; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Cambridge, Div Nephrol, Cambridge CB2 2XY, England; Mahidol Univ, Inst Mol Biol & Genet, Salaya 73170, Thailand; Mahidol Univ, Siriraj Hosp, Fac Med, BIOTEC Med Biotechnol Unit, Bangkok 10700, Thailand; Mahidol Univ, Div Med Mol Biol, Bangkok 10700, Thailand; NW Renal Clin, Portland, OR 97210 USA	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Mahidol University; Mahidol University; Mahidol University	Karet, FE (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med Genet, Box 139, Cambridge CB2 2XY, England.	fek1000@cam.ac.uk	Rungroj, Nanyawan/O-4481-2015; Rungroj, Nanyawan/GYR-2610-2022; Rungroj, Nanyawan/AAU-3374-2020	Rungroj, Nanyawan/0000-0002-2379-9658; Karet, Fiona/0000-0002-2457-2869; Reimann, Frank/0000-0001-9399-6377				Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; Batlle D, 2001, ANNU REV MED, V52, P471, DOI 10.1146/annurev.med.52.1.471; Bruce LJ, 2000, BIOCHEM J, V350, P41, DOI 10.1042/0264-6021:3500041; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Cheidde L, 2003, PEDIATRICS, V112, P1361, DOI 10.1542/peds.112.6.1361; Devonald MAJ, 2003, NAT GENET, V33, P125, DOI 10.1038/ng1082; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; GEERING K, 1989, AM J PHYSIOL, V257, P851; GROVES JD, 1992, J BIOL CHEM, V267, P22163; Jarolim P, 1996, BLOOD, V88, P4366; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; Karet FE, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000023433.08833.88; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Koivisto UM, 2001, CELL, V105, P575, DOI 10.1016/S0092-8674(01)00371-3; Koomoa DLT, 2002, J MEMBRANE BIOL, V185, P57, DOI 10.1007/s00232-001-0109-y; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; Quilty JA, 2002, BIOCHEM J, V368, P895, DOI 10.1042/BJ20020574; Quilty JA, 2002, AM J PHYSIOL-RENAL, V282, pF810, DOI 10.1152/ajprenal.00216.2001; Ribeiro ML, 2000, BLOOD, V96, P1602; Rodriguez-Soriano J, 2000, PEDIATR NEPHROL, V14, P1121, DOI 10.1007/s004670000407; Sritippayawan S, 2003, PEDIATR NEPHROL, V18, P644, DOI 10.1007/s00467-003-1112-6; Tanner MJA, 1996, NATURE, V382, P209, DOI 10.1038/382209a0; Tanphaichitr VS, 1998, J CLIN INVEST, V102, P2173, DOI 10.1172/JCI4836; Toye AM, 2002, BLOOD, V99, P342, DOI 10.1182/blood.V99.1.342; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; Vasuvattakul S, 1999, KIDNEY INT, V56, P1674, DOI 10.1046/j.1523-1755.1999.00756.x; Weber S, 2000, PEDIATR NEPHROL, V15, P201, DOI 10.1007/s004670000454; Yenchitsomanus PT, 2002, AM J KIDNEY DIS, V40, P21, DOI 10.1053/ajkd.2002.33909; Zhang DC, 2000, BLOOD, V96, P2925; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200	34	65	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13833	13838		10.1074/jbc.M400188200	http://dx.doi.org/10.1074/jbc.M400188200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734552	hybrid			2022-12-27	WOS:000220478500069
J	Larsen, F; Madsen, HO; Sim, RB; Koch, C; Garred, P				Larsen, F; Madsen, HO; Sim, RB; Koch, C; Garred, P			Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE DOMAIN; CORE-SPECIFIC LECTIN; COMPLEMENT ACTIVATION; POSTTRANSLATIONAL MODIFICATIONS; GENE; SERUM; EXPRESSION; POLYMORPHISMS; COMPONENT; VARIANT	Deficiency of human mannose-binding lectin (MBL) caused by mutations in the coding part of the MBL2 gene is associated with increased risk and severity of infections and autoimmunity. To study the biological consequences of MBL mutations, we expressed wild type MBL and mutated MBL in Chinese hamster ovary cells. The normal MBL cDNA (WT MBL-A) was cloned, and the three known natural and two artificial variants were expressed in Chinese hamster ovary cells. When analyzed, WT MBL-A formed covalently linked higher oligomers with a molecular mass of about 300-450 kDa, corresponding to 12-18 single chains or 4-6 structural units. By contrast, all MBL variants formed a dominant band of about 50 kDa, with increasingly weaker bands at 75, 100, and 125 kDa corresponding to two, three, four, and five chains, respectively. In contrast to WT MBL-A, variant MBL formed noncovalent oligomers containing up to six chains (two structural units). MBL variants bound ligands with a markedly reduced capacity compared with WT MBL-A. Mutations in the collagenous region of human MBL compromise assembly of higher order oligomers, resulting in reduced ligand binding capacity and thus reduced capability to activate complement.	Univ Copenhagen, Rigshosp, Dept Clin Immunol, DK-2100 Copenhagen O, Denmark; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Statens Serum Inst, Dept Immunol, DK-2300 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Oxford; Statens Serum Institut	Larsen, F (corresponding author), Univ Copenhagen, Rigshosp, Dept Clin Immunol, Sect 7631,Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.	flar@biobase.dk	Sim, Bob/A-1354-2008; Madsen, Hans O/Q-2035-2015	Sim, Bob/0000-0002-2855-7455; Madsen, Hans O/0000-0001-5551-4787; Garred, Peter/0000-0002-2876-8586				ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Butler GS, 2002, J BIOL CHEM, V277, P17511, DOI 10.1074/jbc.M201461200; Chanock SJ, 1999, J CLIN INVEST, V104, P369, DOI 10.1172/JCI7986; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; COLLEY KJ, 1987, J BIOL CHEM, V262, P10290; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; DAVIES EJ, 1995, ARTHRITIS RHEUM, V38, P110, DOI 10.1002/art.1780380117; Davies Monique V., 1992, Current Opinion in Biotechnology, V3, P512, DOI 10.1016/0958-1669(92)90079-X; Eda S, 1998, BIOSCI BIOTECH BIOCH, V62, P1326, DOI 10.1271/bbb.62.1326; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; Foster CB, 1998, J CLIN INVEST, V102, P2146, DOI 10.1172/JCI5084; Gadjeva M, 2001, CURR OPIN IMMUNOL, V13, P74, DOI 10.1016/S0952-7915(00)00185-0; Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1; Garred P, 2003, J INFECT DIS, V188, P1394, DOI 10.1086/379044; GARRED P, 1992, CLIN EXP IMMUNOL, V90, P517; Garred P, 1999, ARTHRITIS RHEUM, V42, P2145, DOI 10.1002/1529-0131(199910)42:10<2145::AID-ANR15>3.0.CO;2-#; Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x; Graudal NA, 2000, ARTHRITIS RHEUM, V43, P515, DOI 10.1002/1529-0131(200003)43:3<515::AID-ANR6>3.0.CO;2-T; GREEN PJ, 1994, MOL BIOCHEM PARASIT, V66, P319, DOI 10.1016/0166-6851(94)90158-9; Guo N, 1998, MAMM GENOME, V9, P246, DOI 10.1007/s003359900735; Hansen S, 2000, J IMMUNOL, V164, P2610, DOI 10.4049/jimmunol.164.5.2610; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; HAURUM JS, 1993, AIDS, V7, P1307, DOI 10.1097/00002030-199310000-00002; Heise CT, 2000, J IMMUNOL, V165, P1403, DOI 10.4049/jimmunol.165.3.1403; HOLMSKOV U, 1995, BIOCHEM J, V305, P889, DOI 10.1042/bj3050889; Ip WK, 2000, ARTHRITIS RHEUM, V43, P1679, DOI 10.1002/1529-0131(200008)43:8<1679::AID-ANR3>3.3.CO;2-4; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; Kawasaki T, 1999, BBA-GEN SUBJECTS, V1473, P186, DOI 10.1016/S0304-4165(99)00178-6; Kelly P, 2000, GASTROENTEROLOGY, V119, P1236, DOI 10.1053/gast.2000.19573; Koch A, 2001, JAMA-J AM MED ASSOC, V285, P1316, DOI 10.1001/jama.285.10.1316; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; KURATA H, 1993, BIOCHEM BIOPH RES CO, V191, P1204, DOI 10.1006/bbrc.1993.1345; KURATA H, 1994, J BIOCHEM-TOKYO, V115, P1148, DOI 10.1093/oxfordjournals.jbchem.a124471; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Lipscombe RJ, 1996, EUR J HUM GENET, V4, P13; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; LU J, 1990, J IMMUNOL, V144, P2287; Ma Y, 1997, J BIOCHEM-TOKYO, V122, P810; Ma Y, 1996, BIOCHEM MOL BIOL INT, V40, P965; Ma Y, 1999, P NATL ACAD SCI USA, V96, P371, DOI 10.1073/pnas.96.2.371; Madsen HO, 1998, J IMMUNOL, V161, P3169; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Naito H, 1999, BIOCHEM BIOPH RES CO, V256, P231, DOI 10.1006/bbrc.1999.0307; Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000; NIELSEN PH, 2001, THESIS U SO DENMARK; Petry F, 1997, IMMUNOPHARMACOLOGY, V38, P189, DOI 10.1016/S0162-3109(97)00065-9; SASTRY K, 1989, J EXP MED, V170, P1175, DOI 10.1084/jem.170.4.1175; SATO T, 1994, INT IMMUNOL, V6, P665, DOI 10.1093/intimm/6.4.665; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH MH, 2001, HDB BIOCH SELECTED D, pC3; Stover CM, 1999, J IMMUNOL, V162, P3481; Sullivan KE, 1996, ARTHRITIS RHEUM, V39, P2046, DOI 10.1002/art.1780391214; Summerfield JA, 1997, BRIT MED J, V314, P1229, DOI 10.1136/bmj.314.7089.1229; SUPER M, 1992, NAT GENET, V2, P50, DOI 10.1038/ng0992-50; Takahashi M, 1999, INT IMMUNOL, V11, P859, DOI 10.1093/intimm/11.5.859; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; TENNER AJ, 1995, IMMUNITY, V3, P485, DOI 10.1016/1074-7613(95)90177-9; Terai I, 2003, EUR J IMMUNOL, V33, P2755, DOI 10.1002/eji.200323955; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Townsend R, 2001, CLIN EXP IMMUNOL, V124, P223, DOI 10.1046/j.1365-2249.2001.01549.x; TURNER MW, 2001, REV IMMUNOGENET, V2, P305; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; Valdimarsson H, 1998, SCAND J IMMUNOL, V48, P116; Vorup-Jensen T, 2001, MOL THER, V3, P867, DOI 10.1006/mthe.2001.0335; Vorup-Jensen T, 2001, INT IMMUNOPHARMACOL, V1, P677, DOI 10.1016/S1567-5769(00)00052-7; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1999, J IMMUNOL, V163, P4953; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WON N, 1997, BIOCHEM SOC T, V25, pS41; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414	78	180	187	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 14	2004	279	20					21302	21311		10.1074/jbc.M400520200	http://dx.doi.org/10.1074/jbc.M400520200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	818VY	14764589	hybrid			2022-12-27	WOS:000221273800092
J	McCoy, SL; Kurtz, SE; Hausman, FA; Trune, DR; Bennett, RM; Hefeneider, SH				McCoy, SL; Kurtz, SE; Hausman, FA; Trune, DR; Bennett, RM; Hefeneider, SH			Activation of RAW264.7 macrophages by bacterial DNA and lipopolysaccharide increases cell surface DNA binding and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; TOLL-LIKE RECEPTORS; AIDED CROSS-PRESENTATION; CPG-DNA; DENDRITIC CELLS; MEMBRANE DNA; PROTEIN-KINASES; MAMMALIAN-CELLS; GENE-EXPRESSION; CUTTING EDGE	Bacterial DNA containing unmethylated CpG motifs is a pathogen-associated molecular pattern ( PAMP) that interacts with host immune cells via a toll-like receptor (TLR) to induce immune responses. DNA binding and internalization into cells is independent of TLR expression, receptor-mediated, and required for cell activation. The objective of this study was to determine whether exposure of immune cells to bacterial DNA affects DNA binding and internalization. Treatment of RAW264.7 cells with CpG oligodeoxynucleotide (ODN) for both 18 and 42 h resulted in a significant increase in DNA binding, whereas non-CpG ODN had no effect on DNA binding. Enhanced DNA binding was non-sequence-specific, inhibited by unlabeled DNA, showed saturation, was consistent with increased cell surface DNA receptors, and resulted in enhanced internalization of DNA. Treatment with Escherichia coli DNA or lipopolysaccharide (LPS) also resulted in a significant increase in DNA binding, but treatment with interleukin-1alpha, tumor necrosis factor-alpha, or phorbol 12-myristate 13-acetate had no effect on DNA binding. Soluble factors produced in response to treatment with CpG ODN or LPS did not affect DNA binding. These studies demonstrate that one consequence of activating the host innate immune response by bacterial infection is enhanced binding and internalization of DNA. During this period of increased DNA internalization, RAW264.7 cells were hypo-responsive to continued stimulation by CpG ODN, as assessed by tumor necrosis factor-alpha activity. We speculate the biological significance of increasing DNA binding and internalization following interaction with bacterial PAMPs may provide a mechanism to limit an ongoing immune inflammatory response by enhancing clearance of bacterial DNA from the extracellular environment.	Vet Affairs Med Ctr, Dept Immunol, Portland, OR 97201 USA; Targeted Gene Delivery Inc, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Div Rheumatol, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University	Hefeneider, SH (corresponding author), Vet Affairs Med Ctr, Dept Immunol, R&D-18,3710 SW,US Vet Hosp Rd, Portland, OR 97201 USA.	Hefeneid@OHSU.edu		Bennett, Robert/0000-0002-7526-3425	NIDCD NIH HHS [R01 DC03573, 1R43 DC05882-01] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003573, R43DC005882] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Bennett R M, 1993, Antisense Res Dev, V3, P235; BENNETT RM, 1991, CLIN EXP IMMUNOL, V86, P374; BENNETT RM, 1987, J EXP MED, V166, P850, DOI 10.1084/jem.166.4.850; BENNETT RM, 1986, LANCET, V1, P186; BENNETT RM, 1983, J CLIN INVEST, V71, P611, DOI 10.1172/JCI110807; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; EHRLICH M, 1976, BIOCHIM BIOPHYS ACTA, V454, P397, DOI 10.1016/0005-2787(76)90266-5; EMLEN W, 1988, AM J PATHOL, V133, P54; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; GASPARRO FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P315, DOI 10.1111/j.1751-1097.1990.tb04187.x; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hawley P, 1996, ANTISENSE NUCLEIC A, V6, P185, DOI 10.1089/oli.1.1996.6.185; HEFENEIDER SH, 1992, CLIN IMMUNOL IMMUNOP, V63, P245, DOI 10.1016/0090-1229(92)90229-H; HEFENEIDER SH, 1992, LUPUS, V1, P167, DOI 10.1177/096120339200100308; Heit A, 2003, J IMMUNOL, V170, P2802, DOI 10.4049/jimmunol.170.6.2802; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983; KABAKOV AE, 1991, CLIN EXP IMMUNOL, V83, P359; Klinman DM, 2003, CLIN EXP IMMUNOL, V133, P227, DOI 10.1046/j.1365-2249.2003.02216.x; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lu QL, 2003, GENE THER, V10, P131, DOI 10.1038/sj.gt.3301874; Marshall JD, 2003, J LEUKOCYTE BIOL, V73, P781, DOI 10.1189/jlb.1202630; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; McCoy SL, 2000, J IMMUNOL METHODS, V241, P141, DOI 10.1016/S0022-1759(00)00205-2; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Mizel SB, 2002, J BIOL CHEM, V277, P22414, DOI 10.1074/jbc.M201762200; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Ozato K, 2002, BIOTECHNIQUES, V33, pS66; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; RAZ E, 1993, EUR J IMMUNOL, V23, P383, DOI 10.1002/eji.1830230213; RIEBER M, 1989, BIOCHEM BIOPH RES CO, V159, P1441, DOI 10.1016/0006-291X(89)92271-7; RUSSELL JL, 1980, J IMMUNOL, V125, P2328; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Siess DC, 2000, J BIOL CHEM, V275, P33655, DOI 10.1074/jbc.M004461200; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; STEIN CA, 1993, BIOCHEMISTRY-US, V32, P4855, DOI 10.1021/bi00069a022; Trinchieri G, 1998, ADV IMMUNOL, V70, P83, DOI 10.1016/S0065-2776(08)60387-9; YAKUBOV L, 1991, NUCLEIC ACIDS RES S, V24, P311; Yeo SJ, 2003, J IMMUNOL, V170, P1052, DOI 10.4049/jimmunol.170.2.1052; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1996, J IMMUNOL, V156, P558; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711	50	34	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17217	17223		10.1074/jbc.M303837200	http://dx.doi.org/10.1074/jbc.M303837200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14757773	hybrid			2022-12-27	WOS:000220870400042
J	Sun, JR; Bird, CH; Thia, KY; Matthews, AY; Trapani, JA; Bird, PI				Sun, JR; Bird, CH; Thia, KY; Matthews, AY; Trapani, JA; Bird, PI			Granzyme B encoded by the commonly occurring human RAH allele retains pro-apoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH PATHWAY; TARGET-CELLS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; CYTOTOXIC LYMPHOCYTES; MEDIATED APOPTOSIS; DNA FRAGMENTATION; INHIBITOR; PROTEINASE-INHIBITOR-9; PROTECTS; RECEPTOR	A key function of human granzyme B (GrB) is to induce apoptosis of target cells in conjunction with perforin. The RAH allele is the first documented variant of the human GrB gene, occurs at a frequency of 25-30%, and encodes three amino acid substitutions (Q48R, P88A, and Y245H). It was initially reported that RAH GrB is incapable of inducing apoptosis, but here we show that it has essentially identical proteolytic and cytotoxic properties to wild type GrB. Recombinant RAH and wild type GrB cleave peptide substrates with similar kinetics, are both capable of cleaving Bid and procaspase 3, and are equally inhibited by proteinase inhibitor 9, an endogenous regulator of GrB. Furthermore, cytotoxic lymphocytes from RAH heterozygotes and homozygotes have no defect in target cell killing, and in vitro RAH GrB and wild type GrB kill cells equally well in the presence of perforin. We conclude that the RAH allele represents a neutral polymorphism in the GrB gene.	Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia; Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 8006, Australia	Monash University; Peter Maccallum Cancer Center	Bird, PI (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Bldg 13D,Rm D320, Melbourne, Vic 3800, Australia.	phil.bird@med.monash.edu.au		Trapani, Joseph/0000-0003-0983-1532; Bird, Phillip/0000-0002-6695-606X				Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Buzza MS, 2001, CELL IMMUNOL, V210, P21, DOI 10.1006/cimm.2001.1806; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; Ericson KG, 2003, HUM GENET, V112, P98, DOI 10.1007/s00439-002-0841-0; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Griffiths G M, 1997, Semin Immunol, V9, P109, DOI 10.1006/smim.1997.0059; Hayashi K, 1991, PCR Methods Appl, V1, P34; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hirst CE, 2003, J IMMUNOL, V170, P805, DOI 10.4049/jimmunol.170.2.805; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; LIU CC, 1994, BIOCHEM BIOPH RES CO, V201, P318, DOI 10.1006/bbrc.1994.1704; McIlroy D, 2003, P NATL ACAD SCI USA, V100, P2562, DOI 10.1073/pnas.0437935100; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Pinkoski MJ, 1998, BLOOD, V92, P1044; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; Song E, 2001, TRANSPLANT P, V33, P3274, DOI 10.1016/S0041-1345(01)02391-0; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Sun J, 2001, J BIOL CHEM, V276, P15177, DOI 10.1074/jbc.M006645200; Sun JR, 1999, BIOCHEM BIOPH RES CO, V261, P251, DOI 10.1006/bbrc.1999.0989; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911	27	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16907	16911		10.1074/jbc.M400563200	http://dx.doi.org/10.1074/jbc.M400563200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14752093	hybrid			2022-12-27	WOS:000220870400004
J	Zhang, J; Xu, LG; Han, KJ; Shu, HB				Zhang, J; Xu, LG; Han, KJ; Shu, HB			Identification of a ZU5 and death domain-containing inhibitor of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; TRANSCRIPTIONAL ACTIVITY; CELL-DEATH; PROTEIN; RIP; ACTIVATION; INTERACTS; TRAF2; FADD; PHOSPHORYLATION	The transcription factor NF-kappaB plays important roles in inflammation and cell survival. NF-kappaB is composed of homodimeric and heterodimeric complexes of Rel/NF-kappaB family members, including p65 (RelA), c-Rel (Rel), RelB, NF- kappaB1/p50, and NF-kappaB2/p52. Here we report the identification and characterization of a novel ZU5 and death domain-containing protein designated ZUD. In reporter gene assays, overexpression of ZUD inhibited NF-kappaB-dependent transcription induced by both tumor necrosis factor (TNF) and interleukin-1 and their downstream signaling proteins. Gel shift assays indicated that the overexpression of ZUD inhibited binding of NF-kappaB to its target sequence. ZUD is a cytoplasmic protein, and coimmunoprecipitation assays indicated that ZUD interacted with the NF-kappaB subunit p105 and transactivator p65. Consistent with its role in inhibition of NF-kappaB-dependent transcription, ZUD sensitized cells to apoptosis induced by TNF and the TNF-related apoptosis-inducing ligand (TRAIL). Our findings suggest that ZUD is an inhibitor of NF-kappaB activation and that this protein may provide an alternative regulatory mechanism for NF-kappaB-mediated transcription.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St,k516c, Denver, CO 80206 USA.	shuh@njc.org		Xu, Liangguo/0000-0003-1991-2889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49992] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Min W, 1996, MOL CELL BIOL, V16, P359; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Xu LG, 2002, J LEUKOCYTE BIOL, V72, P410; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	45	17	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17819	17825		10.1074/jbc.M310737200	http://dx.doi.org/10.1074/jbc.M310737200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14769797	hybrid			2022-12-27	WOS:000220870400114
J	Ford, S; Antoniou, A; Butcher, GW; Powis, SJ				Ford, S; Antoniou, A; Butcher, GW; Powis, SJ			Competition for access to the rat major histocompatibility complex class I peptide-loading complex reveals optimization of peptide cargo in the absence of transporter associated with antigen processing (TAP) association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CALRETICULIN P-DOMAIN; ENDOPLASMIC-RETICULUM; OXIDOREDUCTASE ERP57; ASSEMBLY COMPLEX; QUALITY-CONTROL; ALPHA-2 DOMAIN; MOLECULES; TAPASIN; CALNEXIN	Major histocompatibility complex (MHC) class I molecules load peptides in the endoplasmic reticulum in a process during which the peptide cargo is normally optimized in favor of stable MHC-peptide interactions. A dynamic multimolecular assembly termed the peptide-loading complex ( PLC) participates in this process and is composed of MHC class I molecules, calreticulin, ERp57, and tapasin bound to the transporter associated with antigen processing ( TAP) peptide transporter. We have exploited the observation that the rat MHC class I allele RT1-A(a), when expressed in the rat C58 thymoma cell line, effectively competes and prevents the endogenous RT1-A(u) molecule from associating with TAP. However, stable RT1-A(u) molecules are assembled efficiently in competition with RT1-A(a), demonstrating that cargo optimization can occur in the absence of TAP association. Defined mutants of RT1-A(a), which do not allow formation of the PLC, fail to become thermostable in C58 cells. Wild-type RT1-A(a), which does allow PLC formation, also fails to become thermostable in this cell line, which carries the rat TAPB transporter that supplies peptides incompatible for RT1-A(a) binding. Full optimization of RT1-A(a) requires the presence of the TAP2A allele, which is capable of supplying suitable peptides. Thus, formation of the PLC alone is not sufficient for optimization of the MHC class I peptide cargo.	Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England	University of Dundee; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Powis, SJ (corresponding author), Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	s.j.powis@dundee.ac.uk		Powis, Simon/0000-0003-4218-2984; Antoniou, Antony/0000-0002-6536-7781				Antoniou AN, 2003, ANTIOXID REDOX SIGN, V5, P375, DOI 10.1089/152308603768295104; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Deverson EV, 2001, GENES IMMUN, V2, P48, DOI 10.1038/sj.gene.6363727; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; FRASER JD, 1987, IMMUNOGENETICS, V26, P31, DOI 10.1007/BF00345451; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Harris MR, 1998, J IMMUNOL, V160, P5404; Harris MR, 2001, INT IMMUNOL, V13, P1275, DOI 10.1093/intimm/13.10.1275; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Knittler MR, 1998, J IMMUNOL, V161, P5967; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Lindquist JA, 2001, FASEB J, V15, P1448, DOI 10.1096/fj.00-0720fje; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; LIVINGSTONE AM, 1991, IMMUNOGENETICS, V34, P157, DOI 10.1007/BF00205818; LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Park B, 2003, J IMMUNOL, V170, P961, DOI 10.4049/jimmunol.170.2.961; POWIS SJ, 1990, TRANSPLANT P, V22, P2517; POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SILVA A, 1983, IMMUNOL REV, V76, P105, DOI 10.1111/j.1600-065X.1983.tb01099.x; Speir JA, 2001, IMMUNITY, V14, P81, DOI 10.1016/S1074-7613(01)00091-7; Stevens J, 2000, J BIOL CHEM, V275, P29217, DOI 10.1074/jbc.M002565200; SWIEDLER SJ, 1985, J BIOL CHEM, V260, P4046; Tan P, 2002, J IMMUNOL, V168, P1950, DOI 10.4049/jimmunol.168.4.1950; Turnquist HR, 2002, TISSUE ANTIGENS, V59, P18, DOI 10.1034/j.1399-0039.2002.590104.x; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Yu YYL, 1999, J IMMUNOL, V163, P4427; Zhang Q, 1998, J IMMUNOL, V160, P831	45	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16077	16082		10.1074/jbc.M400456200	http://dx.doi.org/10.1074/jbc.M400456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764587	hybrid			2022-12-27	WOS:000220747900048
J	Greene, EC; Mizuuchi, K				Greene, EC; Mizuuchi, K			Visualizing the assembly and disassembly mechanisms of the MuB transposition targeting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-MU; B-PROTEIN; STRAND-TRANSFER; PHAGE-MU; DNA; IMMUNITY; REFLECTS; PATHWAY; FORM; ENDS	MuB, a protein essential for replicative DNA transposition by the bacteriophage Mu, is an ATPase that assembles into a polymeric complex on DNA. We used total internal reflection fluorescence microscopy to observe the behavior of MuB polymers on single molecules of DNA. We demonstrate that polymer assembly is initiated by a stochastic nucleation event. After nucleation, polymer assembly occurs by a mechanism involving the sequential binding of small units of MuB. MuB that bound to A/T-rich regions of the DNA assembled into large polymeric complexes. In contrast, MuB that bound outside of the A/T-rich regions failed to assemble into large oligomeric complexes. Our data also show that MuB does not catalyze multiple rounds of ATP hydrolysis while remaining bound to DNA. Rather, a single ATP is hydrolyzed, then MuB dissociates from the DNA. Finally, we show that "capping" of the enhanced green fluorescent protein-MuB polymer ends with unlabeled MuB dramatically slows, but does not halt, dissociation. This suggests that MuB dissociation occurs through both an end-dependent mechanism and a slower mechanism wherein subunits dissociate from the polymer interior.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Mizuuchi, K (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bldg 5,Rm 237,5 Ctr Dr MSC0540, Bethesda, MD 20892 USA.	kmizu@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK033006, Z01DK033006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1985, CELL, V41, P857, DOI 10.1016/S0092-8674(85)80066-0; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; Greene EC, 2002, MOL CELL, V9, P1079, DOI 10.1016/S1097-2765(02)00514-2; Greene EC, 2002, EMBO J, V21, P1477, DOI 10.1093/emboj/21.6.1477; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; Manna D, 1999, MOL MICROBIOL, V32, P595, DOI 10.1046/j.1365-2958.1999.01377.x; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TEPLOW DB, 1988, J BIOL CHEM, V263, P10851; Yamauchi M, 1998, EMBO J, V17, P5509, DOI 10.1093/emboj/17.18.5509	19	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16736	16743		10.1074/jbc.M311883200	http://dx.doi.org/10.1074/jbc.M311883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14871890	hybrid			2022-12-27	WOS:000220747900126
J	Xu, P; LaVallee, PA; Lin, JJ; Hoidal, JR				Xu, P; LaVallee, PA; Lin, JJ; Hoidal, JR			Characterization of proteins binding to E-box/Ku86 sites and function of Ku86 in transcriptional regulation of the human xanthine oxidoreductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; RENAL EPITHELIAL-CELLS; ZINC-FINGER PROTEIN; URIC-ACID; DEHYDROGENASE GENE; OXIDASE ACTIVITY; MOLECULAR-CLONING; DNA-BINDING; E-BOX; EXPRESSION	We reported previously that E-box and TATA-like elements repress human xanthine oxidoreductase gene (hXOR) expression. In the present investigation, we determined the means by which the E-box site functions in this basal repression. DNA affinity purification demonstrated that at least five proteins are involved in the nuclear protein complex binding to the E-box and adjacent Ku86-binding sites. Amino acid sequence analysis demonstrated that three proteins, DNA-PK catalytic subunit, Ku86, and Ku70 are components of DNA-dependent protein kinase (DNA-PK). By electrophoretic mobility shift assays, gel-shift, and site-directed mutagenesis, we confirmed Ku86 binding to the Ku86 site. Studies indicated that the other two proteins of the complex are AREB6-like proteins binding to the E-box. Pull-down and immunoprecipitation analyses demonstrated the binding of Ku86 to AREB6-like proteins. The functional loss of Ku86 increases hXOR promoter activity and transcript expression. Based on the findings, we propose that DNA-PK/AREB6-like proteins play a central role in repression of basal hXOR activity. AREB6-like proteins specifically bind to the E-box, whereas Ku86 binds an adjacent site and recruits DNA-PK catalytic subunit and Ku70 proteins. A working model is presented to account for the role of DNA-PK and AREB6-like proteins in regulating hXOR activity.	Univ Utah, Hlth Sci Ctr, Dept Internal Med, Div Resp Crit Care & Occupat Med, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hoidal, JR (corresponding author), Univ Utah, Div Pulm, Hlth Sci Ctr, Wintrobe Bldg,Rm 743A,50 N Med Dr, Salt Lake City, UT 84132 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040665] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R01HL40665] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABADEH S, 1992, BIOCHIM BIOPHYS ACTA, V1117, P25, DOI 10.1016/0304-4165(92)90157-P; AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATHAR M, 1989, J CLIN INVEST, V83, P1137, DOI 10.1172/JCI113993; BECKER BF, 1989, PFLUG ARCH EUR J PHY, V415, P127, DOI 10.1007/BF00370582; BONIFACINO JS, 2003, CURRENT PROTOCOLS MO; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DAVIES KJA, 1986, BIOCHEM J, V235, P747, DOI 10.1042/bj2350747; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DIAMOND JR, 1986, KIDNEY INT, V29, P478, DOI 10.1038/ki.1986.24; DUPONT GP, 1992, J CLIN INVEST, V89, P197, DOI 10.1172/JCI115563; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Errami A, 1996, MOL CELL BIOL, V16, P1519; FALCIANI F, 1992, BIOCHEM J, V285, P1001, DOI 10.1042/bj2851001; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; FRANKLIN AJ, 1994, MOL CELL BIOL, V14, P6773, DOI 10.1128/MCB.14.10.6773; GABRIELSEN OS, 1993, METHOD ENZYMOL, V218, P508; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Harrison R, 1997, BIOCHEM SOC T, V25, P786, DOI 10.1042/bst0250786; HASSOUN PM, 1994, AM J PHYSIOL, V266, pL163, DOI 10.1152/ajplung.1994.266.2.L163; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HOWELL RR, 1960, J BIOL CHEM, V235, P3544; IKEDA K, 1995, EUR J BIOCHEM, V233, P73, DOI 10.1111/j.1432-1033.1995.073_1.x; KAWAMURA T, 1991, KIDNEY INT, V40, P291, DOI 10.1038/ki.1991.213; KELLOGG EW, 1977, J BIOL CHEM, V252, P6721; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LINAS SL, 1990, AM J PHYSIOL, V258, pF711, DOI 10.1152/ajprenal.1990.258.3.F711; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Miyamoto Y, 1996, P SOC EXP BIOL MED, V211, P366; MUXFELDT M, 1987, BASIC RES CARDIOL, V82, P486, DOI 10.1007/BF01907096; PALLER MS, 1991, KIDNEY INT, V40, P1041, DOI 10.1038/ki.1991.312; PEDEN DB, 1990, P NATL ACAD SCI USA, V87, P7638, DOI 10.1073/pnas.87.19.7638; PFEFFER KD, 1994, J IMMUNOL, V153, P1789; RODELL TC, 1987, J APPL PHYSIOL, V63, P2159, DOI 10.1152/jappl.1987.63.5.2159; Sanders SA, 1997, EUR J BIOCHEM, V245, P541, DOI 10.1111/j.1432-1033.1997.00541.x; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SLOT O, 1994, UGESKRIFT LAEGER, V156, P23960; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; SULCINER DJ, 1996, BIOCHEM J, V318, P379; WAJNER M, 1989, BIOCHIM BIOPHYS ACTA, V991, P79, DOI 10.1016/0304-4165(89)90031-7; WATANABE Y, 1993, J BIOCHEM-TOKYO, V114, P849, DOI 10.1093/oxfordjournals.jbchem.a124267; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; Xu P, 2000, J BIOL CHEM, V275, P5918, DOI 10.1074/jbc.275.8.5918; XU P, 1994, GENOMICS, V23, P289, DOI 10.1006/geno.1994.1498; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; XU P, 1994, BIOCHEM BIOPH RES CO, V199, P998, DOI 10.1006/bbrc.1994.1328; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239	53	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16057	16063		10.1074/jbc.M305856200	http://dx.doi.org/10.1074/jbc.M305856200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761964	hybrid			2022-12-27	WOS:000220747900045
J	Giraud, E; Hannibal, L; Fardoux, J; Jaubert, M; Jourand, P; Dreyfus, B; Sturgis, JN; Vermeglio, A				Giraud, E; Hannibal, L; Fardoux, J; Jaubert, M; Jourand, P; Dreyfus, B; Sturgis, JN; Vermeglio, A			Two distinct crt gene clusters for two different functional classes of carotenoid in Bradyrhizobium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC PHOTOSYNTHETIC BACTERIUM; PHYTOENE DESATURASE; RHODOBACTER-SPHAEROIDES; RUBRIVIVAX-GELATINOSUS; ERYTHROBACTER-LONGUS; BIOSYNTHESIS GENES; BETA-CAROTENE; EXPRESSION; BACTERIOPHYTOCHROMES; BACTERIOCHLOROPHYLL	Aerobic photosynthetic bacteria possess the unusual characteristic of producing different classes of carotenoids. In this study, we demonstrate the presence of two distinct crt gene clusters involved in the synthesis of spirilloxanthin and canthaxanthin in a Bradyrhizobium strain. Each cluster contains the genes crtE, crtB, and crtI leading to the common precursor lycopene. We show that spirilloxanthin is associated with the photosynthetic complexes, while canthaxanthin protects the bacteria from oxidative stress. Only the spirilloxanthin crt genes are regulated by light via the control of a bacteriophytochrome. Despite this difference in regulation, the biosyntheses of both carotenoids are strongly interconnected at the level of the common precursors. Phylogenetic analysis suggests that the canthaxanthin crt gene cluster has been acquired by a lateral gene transfer. This acquisition may constitute a major selective advantage for this class of bacteria, which photosynthesize only under conditions where harmful reactive oxygen species are generated.	Univ Montpellier 2, Lab Symbioses Trop & Mediterraneennes, Ctr Cooperat Int Rech Agron Dev Agro Montpellier, Inst Rech Dev,INRA, F-34398 Montpellier 5, France; Inst Biol Struct & Microbiol, Lab Ingn Syst Macromol, UPR 9027, CNRS, F-13402 Marseille 20, France; CEA Cadarache, Dept Ecophysiol Vegetale & Microbiol, Lab Bioenerget Cellulaire, UMR 163,CNRS, F-13108 St Paul Les Durance, France	CIRAD; INRAE; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS)	Giraud, E (corresponding author), Inst Rech Dev, LSTM, TA 10-J,Campus Baillaeguet, F-34398 Montpellier 1, France.	Giraud@mpl.ird.fr	Sturgis, James/F-6051-2011; Giraud, Eric/GLS-1036-2022; Sturgis, James/AAU-8103-2020	Sturgis, James/0000-0001-5125-7699				ALBERTI M, 1995, ANOXYGENIC PHOTOSYNT, P775; ARMSTRONG GA, 1994, J BACTERIOL, V176, P4795, DOI 10.1128/jb.176.16.4795-4802.1994; Armstrong GA, 1997, ANNU REV MICROBIOL, V51, P629, DOI 10.1146/annurev.micro.51.1.629; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; BRAMLEY PM, 1988, CURR TOP CELL REGUL, V29, P291; Choudhary M, 2000, NUCLEIC ACIDS RES, V28, P862, DOI 10.1093/nar/28.4.862; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fleischman D, 1998, BBA-BIOENERGETICS, V1364, P17, DOI 10.1016/S0005-2728(98)00011-5; Garcia-Asua G, 2002, MOL MICROBIOL, V44, P233, DOI 10.1046/j.1365-2958.2002.02871.x; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Giraud E, 2000, P NATL ACAD SCI USA, V97, P14795, DOI 10.1073/pnas.250484097; Gradinaru CC, 2001, P NATL ACAD SCI USA, V98, P2364, DOI 10.1073/pnas.051501298; Hannibal L, 2000, J BACTERIOL, V182, P3850, DOI 10.1128/JB.182.13.3850-3853.2000; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Igarashi N, 2001, J MOL EVOL, V52, P333, DOI 10.1007/s002390010163; KOKOTEK W, 1989, GENE, V84, P467, DOI 10.1016/0378-1119(89)90522-2; Lorquin J, 1997, APPL ENVIRON MICROB, V63, P1151, DOI 10.1128/AEM.63.3.1151-1154.1997; MARTINEZLABORDA A, 1990, MOL GEN GENET, V223, P205; Masuda S, 2002, CELL, V110, P613, DOI 10.1016/S0092-8674(02)00876-0; Matsumura H, 1997, GENE, V189, P169, DOI 10.1016/S0378-1119(96)00788-3; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; Molouba F, 1999, APPL ENVIRON MICROB, V65, P3084; Montecchia MS, 2002, SYST APPL MICROBIOL, V25, P423, DOI 10.1078/0723-2020-00123; Ouchane S, 1997, J BIOL CHEM, V272, P1670, DOI 10.1074/jbc.272.3.1670; Paulsen H, 1999, ADV PHOTOSYNTH, V8, P123; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; Pinta V, 2003, ARCH MICROBIOL, V179, P354, DOI 10.1007/s00203-003-0538-3; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANDMANN G, 1989, BIOCHEM BIOPH RES CO, V163, P916, DOI 10.1016/0006-291X(89)92309-7; Shimada K., 1995, ANOXYGENIC PHOTOSYNT, P105; TAKAICHI S, 1990, ARCH MICROBIOL, V153, P118, DOI 10.1007/BF00247807; TAKAICHI S, 1999, PHOTOCHEMISTRY CAROT, P40; TERAO J, 1989, LIPIDS, V24, P659, DOI 10.1007/BF02535085; vonLintig J, 1997, PLANT J, V12, P625, DOI 10.1046/j.1365-313X.1997.00625.x; Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X; YILDIZ FH, 1992, MOL MICROBIOL, V6, P2683, DOI 10.1111/j.1365-2958.1992.tb01445.x; YOUNG JPW, 1991, J BACTERIOL, V173, P2271; Yurkov VV, 1998, MICROBIOL MOL BIOL R, V62, P695, DOI 10.1128/MMBR.62.3.695-724.1998	42	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15076	15083		10.1074/jbc.M312113200	http://dx.doi.org/10.1074/jbc.M312113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14734565	hybrid			2022-12-27	WOS:000220594700072
J	Kaiser, RA; Bueno, OF; Lips, DJ; Doevendans, PA; Jones, F; Kimball, TF; Molkentin, JD				Kaiser, RA; Bueno, OF; Lips, DJ; Doevendans, PA; Jones, F; Kimball, TF; Molkentin, JD			Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED APOPTOSIS; TRANSGENIC MICE; ISCHEMIA/REPERFUSION INJURY; CARDIOMYOCYTE APOPTOSIS; MYOCARDIAL-ISCHEMIA; SIGNALING PATHWAYS; HYDROGEN-PEROXIDE; HEART-FAILURE; NEONATAL-RAT	The p38 branch of the mitogen-activated protein kinase ( MAPK) signaling cascade has been implicated as a regulator of cardiomyocyte apoptosis in culture as well as in the adult heart. However, considerable disagreement persists as to the functional effects attributed to p38 signaling, given that both pro- and anti-apoptotic regulatory roles have been reported. To address this area of uncertainty in the literature, we investigated the cell death effects associated with p38 inactivation in both cultured neonatal cardiomyocytes and the adult heart. In vitro, adenoviral-mediated gene transfer of two different dominant-negative-encoding p38 vectors reduced apoptosis induced by 2-deoxyglucose treatment, whereas overexpression of wild-type p38alpha or an activated mitogen-activated protein kinase kinase (MKK) 6 mutant each enhanced cell death. In vivo, transgenic mice expressing a dominant-negative MKK6 mutant or a dominant-negative p38alpha mutant were each significantly protected from ischemia-reperfusion injury, as assessed by infarct area measurements, DNA laddering, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling, and functional assessment of ventricular performance. Similarly, transgenic mice overexpressing the p38-inactivating dual specificity phosphatase MAPK phosphatase-1 (MKP-1) were also partially protected, whereas MKP-1 gene-targeted mice showed greater injury after ischemia-reperfusion injury. Mechanistically, inhibition of p38 signaling promoted a dramatic up-regulation of Bcl-2 in the hearts of transgenic mice. In primary neonatal cardiomyocyte cultures, adenoviral-mediated gene transfer of a p38 inhibitory mutant upregulated Bcl-2, whereas expression of an activated p38 mutant down-regulated Bcl-2 protein levels. Collectively, these results indicate that p38 functions as a prodeath signaling effector in both cultured myocytes as well as in the intact heart.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat,Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Hosp Maastricht, Cardiovasc Res Inst Maastricht, Dept Cardiol, NL-6202 AZ Maastricht, Netherlands; Dept Cardiol Heart Lung Ctr, NL-3508 GA Utrecht, Netherlands	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Maastricht University; Maastricht University Medical Centre (MUMC)	Molkentin, JD (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org		Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [HL 073550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL073550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Barancik M, 2000, J CARDIOVASC PHARM, V35, P474, DOI 10.1097/00005344-200003000-00019; Bernaudin M, 2002, J BIOL CHEM, V277, P39728, DOI 10.1074/jbc.M204619200; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Brocheriou V, 2000, J GENE MED, V2, P326, DOI 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Dorfman K, 1996, ONCOGENE, V13, P925; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Gorog DA, 2003, J MOL CELL CARDIOL, V35, P705, DOI 10.1016/S0022-2828(03)00082-8; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hochhauser E, 2003, AM J PHYSIOL-HEART C, V284, pH2351, DOI 10.1152/ajpheart.00783.2002; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; Huang JH, 2003, BIOCHEM BIOPH RES CO, V311, P64, DOI 10.1016/j.bbrc.2003.09.160; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Kang YJ, 2000, J BIOL CHEM, V275, P13690, DOI 10.1074/jbc.275.18.13690; Lemke LE, 2001, J MOL CELL CARDIOL, V33, P1527, DOI 10.1006/jmcc.2001.1415; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Mackay K, 2000, J MOL CELL CARDIOL, V32, P1585, DOI 10.1006/jmcc.2000.1194; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; McGowan Brian S, 2003, Cardiovasc Toxicol, V3, P191, DOI 10.1385/CT:3:3:191; Meldrum DR, 1998, SURGERY, V124, P291, DOI 10.1067/msy.1998.90570; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Otsu K, 2003, BIOCHEM BIOPH RES CO, V302, P56, DOI 10.1016/S0006-291X(03)00096-2; Parasrampuria DA, 2003, J CLIN PHARMACOL, V43, P406, DOI 10.1177/0091270002250615; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Ping PP, 2000, CIRC RES, V86, P921, DOI 10.1161/01.RES.86.9.921; Schneider S, 2001, AM J PHYSIOL-HEART C, V280, pH499; Sharov VG, 2003, EUR J HEART FAIL, V5, P121, DOI 10.1016/S1388-9842(02)00254-4; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	44	188	202	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15524	15530		10.1074/jbc.M313717200	http://dx.doi.org/10.1074/jbc.M313717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14749328	hybrid			2022-12-27	WOS:000220594700124
J	Kasahara, H; Takei, K; Ueda, N; Hishiyama, S; Yamaya, T; Kamiya, Y; Yamaguchi, S; Sakakibara, H				Kasahara, H; Takei, K; Ueda, N; Hishiyama, S; Yamaya, T; Kamiya, Y; Yamaguchi, S; Sakakibara, H			Distinct isoprenoid origins of cis- and trans-zeatin biosyntheses in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKININ BIOSYNTHESIS; ABSCISIC-ACID; PATHWAY; IDENTIFICATION; MEVALONATE; DIPHOSPHATE; METABOLISM; ENCODES; GENE; ISOPENTENYLTRANSFERASE	Plants produce the common isoprenoid precursors isopentenyl diphosphate and dimethylallyl diphosphate ( DMAPP) through the methylerythritol phosphate (MEP) pathway in plastids and the mevalonate (MVA) pathway in the cytosol. To assess which pathways contribute DMAPP for cytokinin biosynthesis, metabolites from each isoprenoid pathway were selectively labeled with C-13 in Arabidopsis seedlings. Efficient C-13 labeling was achieved by blocking the endogenous pathway genetically or chemically during the feed of a C-13 labeled precursor specific to the MEP or MVA pathways. Liquid chromatography-mass spectrometry analysis demonstrated that the prenyl group of trans-zeatin (tZ) and isopentenyladenine is mainly produced through the MEP pathway. In comparison, a large fraction of the prenyl group of cis-zeatin (cZ) derivatives was provided by the MVA pathway. When expressed as fusion proteins with green fluorescent protein in Arabidopsis cells, four adenosine phosphate-isopentenyltransferases (AtIPT1, AtIPT3, AtIPT5, and AtIPT8) were found in plastids, in agreement with the idea that the MEP pathway primarily provides DMAPP to tZ and isopentenyladenine. On the other hand, AtIPT2, a tRNA isopentenyltransferase, was detected in the cytosol. Because the prenylated adenine moiety of tRNA is usually of the cZ type, the formation of cZ in Arabidopsis seedlings might involve the transfer of DMAPP from the MVA pathway to tRNA. Distinct origins of large proportions of DMAPP for tZ and cZ biosynthesis suggest that plants are able to separately modulate the level of these cytokinin species.	RIKEN, Plant Sci Ctr, Lab Commun Mech, Yokohama, Kanagawa 2300045, Japan; RIKEN, Plant Sci Ctr, Lab Cellular Growth & Dev, Yokohama, Kanagawa 2300045, Japan; Forestry & Forest Prod Res Inst, Ibaraki 3058687, Japan	RIKEN; RIKEN; Forestry & Forest Products Research Institute - Japan	Sakakibara, H (corresponding author), RIKEN, Plant Sci Ctr, Lab Commun Mech, Suehiro 1-7-22, Yokohama, Kanagawa 2300045, Japan.	sakaki@postman.riken.go.jp	Yamaguchi, Shinjiro/F-9684-2010; Kasahara, Hiroyuki/F-6445-2012; Sakakibara, Hitoshi/A-6040-2010; Barickman, Thomas/I-6993-2012; Kamiya, Yuji/F-9420-2010	Kasahara, Hiroyuki/0000-0002-4858-0978; Sakakibara, Hitoshi/0000-0001-5449-6492; Kamiya, Yuji/0000-0003-4415-520X				AKIYOSHI DE, 1984, P NATL ACAD SCI-BIOL, V81, P5994, DOI 10.1073/pnas.81.19.5994; Astot C, 2000, P NATL ACAD SCI USA, V97, P14778, DOI 10.1073/pnas.260504097; BARRY GF, 1984, P NATL ACAD SCI-BIOL, V81, P4776, DOI 10.1073/pnas.81.15.4776; CHEN CM, 1969, PHYTOCHEMISTRY, V8, P1687, DOI 10.1016/S0031-9422(00)85955-5; CHEN CM, 1981, PLANT PHYSIOL, V68, P1020, DOI 10.1104/pp.68.5.1020; CHEN CM, 1981, PLANT PHYSIOL, V67, P494, DOI 10.1104/pp.67.3.494; CHEN CM, 1984, PLANT PHYSIOL, V75, P442, DOI 10.1104/pp.75.2.442; Cheng WH, 2002, PLANT CELL, V14, P2723, DOI 10.1105/tpc.006494; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CROWELL DN, 1992, PLANT PHYSIOL, V100, P2090, DOI 10.1104/pp.100.4.2090; Disch A, 1998, BIOCHEM J, V331, P615, DOI 10.1042/bj3310615; Dobrev PI, 2002, J CHROMATOGR A, V950, P21, DOI 10.1016/S0021-9673(02)00024-9; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Estevez JM, 2000, PLANT PHYSIOL, V124, P95, DOI 10.1104/pp.124.1.95; Giner JL, 1998, TETRAHEDRON LETT, V39, P2479, DOI 10.1016/S0040-4039(98)00310-4; Golovko A, 2002, PLANT MOL BIOL, V49, P161, DOI 10.1023/A:1014958816241; Hecht S, 2001, P NATL ACAD SCI USA, V98, P14837, DOI 10.1073/pnas.201399298; Helliwell CA, 2001, PLANT J, V28, P201, DOI 10.1046/j.1365-313X.2001.01150.x; Hemmerlin A, 2003, J BIOL CHEM, V278, P26666, DOI 10.1074/jbc.M302526200; Hirai N, 2000, BIOSCI BIOTECH BIOCH, V64, P1448, DOI 10.1271/bbb.64.1448; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; Kakimoto T, 2001, PLANT CELL PHYSIOL, V42, P677, DOI 10.1093/pcp/pce112; Kasahara H, 2002, J BIOL CHEM, V277, P45188, DOI 10.1074/jbc.M208659200; Krall L, 2002, FEBS LETT, V527, P315, DOI 10.1016/S0014-5793(02)03258-1; Laureys F, 1998, FEBS LETT, V426, P29, DOI 10.1016/S0014-5793(98)00297-X; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Murai N, 1994, CYTOKININS CHEM ACTI, P87; NICANDER B, 1993, PLANTA, V189, P312, DOI 10.1007/BF00194427; Niwa Y, 1999, PLANT J, V18, P455, DOI 10.1046/j.1365-313X.1999.00464.x; Piaggesi A, 1997, PLANT SCI, V129, P131, DOI 10.1016/S0168-9452(97)00186-6; RAUSCHENBACH P, 1974, MESSUNG RADIOAKTIVEN, P360; Rohmer M, 2003, PURE APPL CHEM, V75, P375, DOI 10.1351/pac200375020375; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; Sun JQ, 2003, PLANT PHYSIOL, V131, P167, DOI 10.1104/pp.011494; Takei K, 2003, J PLANT RES, V116, P265, DOI 10.1007/s10265-003-0099-1; Takei K, 2001, J BIOL CHEM, V276, P26405, DOI 10.1074/jbc.M102130200; TAYA Y, 1978, NATURE, V271, P545, DOI 10.1038/271545a0; Yamada H, 2001, PLANT CELL PHYSIOL, V42, P1017, DOI 10.1093/pcp/pce127	41	142	153	1	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14049	14054		10.1074/jbc.M314195200	http://dx.doi.org/10.1074/jbc.M314195200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726522	hybrid			2022-12-27	WOS:000220478500094
J	Zhou, J; Schmid, T; Frank, R; Brune, B				Zhou, J; Schmid, T; Frank, R; Brune, B			PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1 alpha from pVHL-independent degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR EXPRESSION; NECROSIS-FACTOR-ALPHA; FACTOR 1-ALPHA; 3-KINASE/AKT PATHWAY; SPOT-SYNTHESIS; NITRIC-OXIDE; HIF-ALPHA; ACTIVATION; HYDROXYLATION; TRANSCRIPTION	Hypoxia inducible factor 1 (HIF-1), a heterodimeric transcription factor composed of HIF-1alpha and HIF-1beta subunits, serves as a key regulator of metabolic adaptation to hypoxia. The amount of HIF-1alpha protein is regulated either by attenuating von Hippel-Lindau protein (pVHL)-dependent ubiquitination and subsequent 26 S proteasomal degradation or by enhancing cap-dependent mRNA translation, presumably involving a phosphatidyinositol 3-kinase (PI3K)/Akt-regulated pathway. In addition, it became apparent that Hsp90 protects HIF-1alpha from oxygen-independent degradation. Here we present evidence that PI3K/Akt is required for heat shock proteins to stabilize HIF-1alpha. In pVHL-deficient renal cell carcinoma cells, PI3K inhibition by LY294002 and wortmannin or transfection of either a dominant negative PI3K or a kinase-dead Akt mutant substantially lowered constitutively expressed HIF-1alpha without altering HIF-1alpha mRNA. Inhibitors of mitogen-activated protein kinase kinase (MAPKK) such as PD98059 or the p38 MAPK inhibitor SB203580 showed no interference. Considering that PI3K inhibitors down-regulated heat shock protein 90 ( Hsp90) as well as Hsp70 expression and moreover attenuated heat- or hypoxia-induced Hsp70 as well as hypoxia-induced Hsp90 up-regulation we conclude that PI3K inhibition promoted degradation of HIF-1alpha indirectly by reducing steady state concentrations of Hsp90 and/or Hsp70. HIF-1alpha co-immunoprecipitated with Hsp90/Hsp70 and direct binding of Hsp70 to the oxygen-dependent degradation domain ( ODD) of HIF-1alpha was proven by a pull-down assay and a peptide array. PI3K-mediated degradation of HIF-1alpha was confirmed in HEK 293 cells under hypoxia, suggesting that heat shock proteins constitute an integral component for HIF-1alpha accumulation. We conclude that PI3K/Akt contributes to HIF-1alpha stabilization by provoking expression of heat shock proteins.	Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany; German Res Ctr Biotechnol, GBF, Res Grp Mol Recognit, D-38124 Braunschweig, Germany	University of Kaiserslautern; Helmholtz Association; Helmholtz-Center for Infection Research	Brune, B (corresponding author), Univ Kaiserslautern, Fac Biol, Dept Cell Biol, Erwin Schroedinger Str 13-4, D-67663 Kaiserslautern, Germany.	bruene@rhrk.uni-kl.de		Schmid, Tobias/0000-0002-1952-5259				Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Baek SH, 2001, J CELL PHYSIOL, V188, P223, DOI 10.1002/jcp.1117; Blancher C, 2001, CANCER RES, V61, P7349; Bornfeldt KE, 2000, CIRC RES, V86, P1101, DOI 10.1161/01.RES.86.11.1101; Chen EY, 2001, CANCER RES, V61, P2429; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fujii T, 2002, INT J ONCOL, V20, P955; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Hur E, 2002, MOL PHARMACOL, V62, P975, DOI 10.1124/mol.62.5.975; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kasuno K, 2004, J BIOL CHEM, V279, P2550, DOI 10.1074/jbc.M308197200; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Kiang JG, 2000, MOL CELL BIOCHEM, V204, P169, DOI 10.1023/A:1007016822939; Kim H, 2001, TOXICOLOGY, V167, P135, DOI 10.1016/S0300-483X(01)00426-7; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee JE, 2001, EXP NEUROL, V170, P129, DOI 10.1006/exnr.2000.7614; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Tomita M, 2000, J RADIAT RES, V41, P93, DOI 10.1269/jrr.41.93; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhong H, 2000, CANCER RES, V60, P1541; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598	41	195	202	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13506	13513		10.1074/jbc.M310164200	http://dx.doi.org/10.1074/jbc.M310164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726529	hybrid			2022-12-27	WOS:000220478500029
J	Peleg-Shulman, T; Roisman, LC; Zupkovitz, G; Schreiber, G				Peleg-Shulman, T; Roisman, LC; Zupkovitz, G; Schreiber, G			Optimizing the binding affinity of a carrier protein - A case study on the interaction between soluble ifnar2 and interferon beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR COMPONENTS; LIGAND-BINDING; CLONING; ALPHA; PHARMACOKINETICS; SPECTROSCOPY; RESOLUTION; MECHANISMS; INTERFACE; CYTOKINES	Prolonging the circulatory half-life of low mass protein drugs can be achieved either by administration of a pro-drug or through co-injection with a carrier protein that will slowly release the active protein. The rate of release is concentration and affinity dependent. The optimal relationship between these two in prolonging the half-life of a pro-drug is the focus of this work. Interferon (IFN) beta is one of the most widely used protein drugs in the clinic. Here, we show that the circulatory half-life of IFNbeta can be significantly extended by coadministration with the extracellular domain of the IFN receptor ifnar2 (ifnar2-EC). To investigate the concentration/ affinity relation, a range of tighter binding ifnar2-EC mutants was designed that bind IFNbeta, but not IFNalpha2, up to 50-fold tighter compared with the wild-type ifnar2-EC. This increased affinity is related to a slower dissociation rate, whereas the association of IFNbeta with ifnar2-EC is already near optimum. Using the wild-type and mutant receptors, we investigated their potential in occluding IFNbeta from circulation in a tissue culture assay, as well as in rats. To determine the potential of ifnar2-EC as a carrier protein, we co-administered a mixture of IFNbeta and ifnar2-EC to rats both intravenously and subcutaneously, and followed the blood plasma concentrations of IFNbeta over time. The tighter binding ifnar2-EC mutant had a clear advantage in prolonging the half-life of IFNbeta in circulation, even when lower protein concentrations were administered. A numerical simulation of the in vivo data demonstrates that the optimal binding affinity of a carrier protein is around the concentration needed to obtain optimal activity of the ligand.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Schreiber, G (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	gideon.schreiber@weizmann.ac.il	Roisman, Laila/D-1827-2010; Schreiber, Gideon/C-7332-2008; Roisman, Laila C./P-9129-2019	Roisman, Laila/0000-0001-8455-9327; Roisman, Laila C./0000-0001-8455-9327; Zupkovitz, Gordin/0000-0001-8101-4524				Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; Calderara S, 2001, VIROLOGY, V279, P22, DOI 10.1006/viro.2000.0689; CHIANG J, 1993, PHARMACEUT RES, V10, P567, DOI 10.1023/A:1018902120023; Chill JH, 2003, STRUCTURE, V11, P791, DOI 10.1016/S0969-2126(03)00120-5; COHEN B, 1995, MOL CELL BIOL, V15, P4208; Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Dupont SA, 2002, J INTERF CYTOK RES, V22, P491, DOI 10.1089/10799900252952280; Han CS, 2001, P NATL ACAD SCI USA, V98, P6138, DOI 10.1073/pnas.111139598; Jacobson KA, 1996, DRUG DEVELOP RES, V39, P289, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<289::AID-DDR8>3.0.CO;2-N; Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; Kollewe C, 2000, FEBS LETT, V487, P189, DOI 10.1016/S0014-5793(00)02345-0; Kotenko SV, 2001, J IMMUNOL, V166, P7096, DOI 10.4049/jimmunol.166.12.7096; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Munafo A, 1998, EUR J NEUROL, V5, P187, DOI 10.1046/j.1468-1331.1998.520187.x; Noseworthy JH, 2003, CURR OPIN NEUROL, V16, P289, DOI 10.1097/00019052-200306000-00007; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; NOVICK D, 1992, FEBS LETT, V314, P445, DOI 10.1016/0014-5793(92)81523-O; Oppenheim JJ, 2001, INT J HEMATOL, V74, P3, DOI 10.1007/BF02982543; Pepinsky RB, 2001, J PHARMACOL EXP THER, V297, P1059; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 2001, ANAL BIOCHEM, V289, P173, DOI 10.1006/abio.2000.4920; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Piehler J, 1999, J MOL BIOL, V294, P223, DOI 10.1006/jmbi.1999.3230; Reddy KR, 2002, ADV DRUG DELIVER REV, V54, P571, DOI 10.1016/S0169-409X(02)00028-5; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; Runkel L, 2000, BIOCHEMISTRY-US, V39, P2538, DOI 10.1021/bi991631c; Schmitt HM, 1997, BIOSENS BIOELECTRON, V12, P809, DOI 10.1016/S0956-5663(97)00046-8; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 2001, PROTEINS, V45, P190, DOI 10.1002/prot.1139; Sporri B, 2001, CYTOKINE GROWTH F R, V12, P27, DOI 10.1016/S1359-6101(00)00020-4; TEPPER M, 1998, Patent No. 6372207	37	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					18046	18053		10.1074/jbc.M400033200	http://dx.doi.org/10.1074/jbc.M400033200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960565	hybrid			2022-12-27	WOS:000220870400140
J	Ban, R; Irino, Y; Fukami, K; Tanaka, H				Ban, R; Irino, Y; Fukami, K; Tanaka, H			Human mitotic spindle-associated protein PRC1 inhibits MgcRacGAP activity toward Cdc42 during the metaphase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RHO-GTPASES; AURORA-B; CLEAVAGE FURROW; CITRON-KINASE; CYTOKINESIS; PHOSPHORYLATION; BINDING; INCENP; MICROTUBULES	Although many proteins have been shown to participate in mitotic events, including cytokinesis, their specific roles and interactions remain unclear. A novel interaction of proteins is demonstrated in this report. Yeast two-hybrid screening using PRC1 (protein-regulating cytokinesis 1) cDNA, a human mitotic spindle-associated cyclin-dependent kinase (CDK) substrate, which is involved in cytokinesis, as bait was performed. Data show that the PRC1 bait bound to MgcRacGAP, which is a GTPase-activating protein ( GAP) for the Rho family GTPases also involved in cytokinesis. In addition, the two proteins showed similar localization during the Mphase. PRC1 was shown to bind to the COOH-terminal GAP-conserved domain of MgcRacGAP and to inhibit its GAP activity toward Cdc42. This binding and/or inhibition of MgcRacGAP GAP activity was found to depend on further binding of PRC1 to the basic region ( 125 - 285 amino acids) of MgcRacGAP. Furthermore, the basic region was phosphorylated with Aurora B kinase, and this phosphorylation prevented the inhibition of GAP activity by PRC1. Cells overexpressing a phosphorylation mimic mutant of MgcRacGAP exhibited an abnormality of spindle morphology in the metaphase. Cdc42 showed high activity and was localized to the mitotic spindles and centrosomes during the metaphase. We propose that PRC1 down-regulates the GAP activity of MgcRacGAP during the metaphase and thereby contributes to the correct formation of the spindle.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Mol Life Sci, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences	Tanaka, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Mol Life Sci, 1432-1 Horinouchi, Tokyo 1920392, Japan.	tanaka@ls.toyaku.ac.jp						Adams RR, 2001, CHROMOSOMA, V110, P65, DOI 10.1007/s004120100130; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Cotteret S, 2002, GENOME BIOL, V3; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Dutartre H, 1996, J CELL SCI, V109, P367; Eckley DM, 1997, J CELL BIOL, V136, P1169, DOI 10.1083/jcb.136.6.1169; Eda M, 2001, J CELL SCI, V114, P3273; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Gavet O, 1998, J CELL SCI, V111, P3333; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Kawashima T, 2000, BLOOD, V96, P2116; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kitamura T, 2001, CELL STRUCT FUNCT, V26, P645, DOI 10.1247/csf.26.645; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsumura F, 2001, CELL STRUCT FUNCT, V26, P639, DOI 10.1247/csf.26.639; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Mistry SJ, 2002, MT SINAI J MED, V69, P299; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Terada Y, 2001, CELL STRUCT FUNCT, V26, P653, DOI 10.1247/csf.26.653; Toure A, 1998, J BIOL CHEM, V273, P6019, DOI 10.1074/jbc.273.11.6019; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Wittmann T, 2001, J CELL SCI, V114, P3795	42	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16394	16402		10.1074/jbc.M313257200	http://dx.doi.org/10.1074/jbc.M313257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14744859	hybrid			2022-12-27	WOS:000220747900086
J	Mackey, SL; Darlington, GJ				Mackey, SL; Darlington, GJ			CCAAT enhancer-binding protein alpha is required for interleukin-6 receptor alpha signaling in newborn hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; SERUM AMYLOID-A; STIMULATING FACTOR; C/EBP-ALPHA; TRANSDUCER GP130; GENE-EXPRESSION; IL-6 RECEPTOR; IN-VIVO; ACTIVATION; MICE	The acute phase response is an evolutionarily conserved response of the liver to inflammatory stimuli, which aids the body in host defense and homeostasis. We have previously reported that CCAAT enhancer-binding protein alpha(C/EBPalpha) is required for the induction of acute phase protein (APP) genes in newborn mice in response to lipopolysaccharide. In this paper, we describe a mechanism by which C/EBPalpha knock-out mice are unable to induce APP gene expression in response to inflammatory stimuli. We demonstrate that the lack of acute phase response in C/EBPalpha knock-out mice is because of a hepatocyte autonomous defect. C/EBPalpha knock-out hepatocytes do not activate STAT3 in response to recombinant interleukin (IL)-6, indicating a defect in the IL-6 pathway. C/EBPalpha knock-out hepatocytes also do not show activation of other IL-6 receptor (IL-6R)-mediated Janus kinase substrates, gp130, SHP-2, and Tyk2. Further examination of the IL-6 pathway demonstrated that C/EBPalpha knock-out hepatocytes have decreased IL-6Ralpha protein levels caused, in part, by reduced protein stability. However, other components of the IL-6 pathway are intact, as demonstrated by rescue of STAT3 activation and APP gene induction with recombinant-soluble IL-6R linked to IL-6 cytokine (Hyper-IL-6) or with another gp130 signaling cytokine, Oncostatin M. In conclusion, C/EBPalpha is required for the proper regulation of IL-6Ralpha protein in hepatocytes resulting in a lack of acute phase protein gene induction in newborn C/EBPalpha null mice in response to lipopolysaccharide or cytokines.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Darlington, GJ (corresponding author), Baylor Coll Med, Huffington Ctr Aging, 1 Baylor Plaza, Houston, TX 77030 USA.	gretchen@bcm.tmc.edu			NIDDK NIH HHS [DK53045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053045] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM T, 1992, J BIOL CHEM, V267, P5021; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Alonzi T, 1998, CYTOKINE, V10, P13, DOI 10.1006/cyto.1997.0250; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Benigni F, 1996, BLOOD, V87, P1851, DOI 10.1182/blood.V87.5.1851.bloodjournal8751851; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GERHARTZ C, 1994, EUR J BIOCHEM, V223, P265, DOI 10.1111/j.1432-1033.1994.tb18991.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; LI XX, 1991, J BIOL CHEM, V266, P15192; MIRANDA L E V, 1977, Clinics in Perinatology, V4, P351; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; NESBITT JE, 1992, J BIOL CHEM, V267, P5739; Peters M, 1996, IMMUNOL LETT, V54, P177, DOI 10.1016/S0165-2478(96)02669-7; Rakemann T, 1999, J BIOL CHEM, V274, P1257, DOI 10.1074/jbc.274.3.1257; RAY BK, 1993, EUR J BIOCHEM, V216, P127, DOI 10.1111/j.1432-1033.1993.tb18124.x; SHIMIZU H, 1994, GENE, V149, P305; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Thorn CF, 2002, J IMMUNOL, V169, P399, DOI 10.4049/jimmunol.169.1.399; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6	33	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16206	16213		10.1074/jbc.M400737200	http://dx.doi.org/10.1074/jbc.M400737200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14960573	hybrid			2022-12-27	WOS:000220747900063
J	Sathish, HA; Koteiche, HA; Mchaourab, HS				Sathish, HA; Koteiche, HA; Mchaourab, HS			Binding of destabilized beta B2-crystallin mutants to alpha-crystallin - The role of a folding intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; EYE LENS BETA-B2-CRYSTALLIN; AGE-RELATED-CHANGES; T4 LYSOZYME; CHAPERONE FUNCTION; BETA-CRYSTALLIN; B-CRYSTALLIN; 2-DIMENSIONAL ELECTROPHORESIS; SEQUENCE EXTENSIONS; SECONDARY STRUCTURE	Age-related changes in protein-protein interactions in the lens play a critical role in the temporal evolution of its optical properties. In the relatively non-regenerating environment of the fiber cells, a critical determinant of these interactions is partial or global unfolding as a consequence of post-translational modifications or chemical damage to individual crystallins. One type of attractive force involves the recognition by alpha-crystallins of modified proteins prone to unfolding and aggregation. In this paper, we explore the energetic threshold and the structural determinants for the formation of a stable complex between alpha-crystallin and betaB2-crystallin as a consequence of destabilizing mutations in the latter. The mutations were designed in the framework of a folding model that proposes the equilibrium population of a monomeric intermediate. Binding to alpha-crystallin is detected through changes in the emission properties of a bimane fluorescent probe site-specifically introduced at a solvent exposed site in betaB2-crystallin. alpha-Crystallin binds the various betaB2-crystallin mutants, although with a significantly lower affinity relative to destabilized T4 lysozyme mutants. The extent of binding, while reflective of the overall destabilization, is determined by the dynamic population of a folding intermediate. The existence of the intermediate is inferred from the biphasic bimane emission unfolding curve of a mutant designed to disrupt interactions at the dimer interface. The results of this paper are consistent with a model in which the interaction of alpha-crystallins with substrates is not solely triggered by an energetic threshold but also by the population of excited states even under favorable folding conditions. The ability of alpha-crystallin to detect subtle changes in the population of betaB2-crystallin excited states supports a central role for this chaperone in delaying aggregation and scattering in the lens.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	hassane.mchaourab@vanderbilt.edu			NEI NIH HHS [EY-R0112018] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012018] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; Clout NJ, 2001, STRUCTURE, V9, P115, DOI 10.1016/S0969-2126(01)00573-1; Clout NJ, 2000, J MOL BIOL, V304, P253, DOI 10.1006/jmbi.2000.4197; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DAVID LL, 1994, INVEST OPHTH VIS SCI, V35, P785; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Hejtmancik JF, 1997, PROTEIN ENG, V10, P1347, DOI 10.1093/protein/10.11.1347; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; JAENICKE R, 1994, NATURWISSENSCHAFTEN, V81, P423; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; KROONE RC, 1994, PROTEIN ENG, V7, P1395, DOI 10.1093/protein/7.11.1395; Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481; Lampi KJ, 2002, INVEST OPHTH VIS SCI, V43, P216; Lampi KJ, 2001, EXP EYE RES, V72, P279, DOI 10.1006/exer.2000.0950; LAPATTO R, 1991, J MOL BIOL, V222, P1067, DOI 10.1016/0022-2836(91)90594-V; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Llinas M, 1999, NAT STRUCT BIOL, V6, P1072; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Norledge BV, 1997, PROTEIN SCI, V6, P1612, DOI 10.1002/pro.5560060802; Pace CN, 2000, PROTEINS, P1; Rajaraman K, 1998, BIOCHEM BIOPH RES CO, V249, P917, DOI 10.1006/bbrc.1998.9242; Sathish HA, 2003, J BIOL CHEM, V278, P44214, DOI 10.1074/jbc.M307578200; Sergeev YV, 2000, BIOCHEMISTRY-US, V39, P15799, DOI 10.1021/bi001882h; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Shih M, 1998, Mol Vis, V4, P4; Shih M, 2001, CURR EYE RES, V22, P458, DOI 10.1076/ceyr.22.6.458.5483; SLINGSBY C, 1990, BIOCHEMISTRY-US, V29, P6592, DOI 10.1021/bi00480a007; SLINGSBY C, 1994, EXP EYE RES, V58, P761, DOI 10.1006/exer.1994.1073; Slingsby C, 1999, EYE, V13, P395, DOI 10.1038/eye.1999.113; TARDIEU A, 1988, ANNU REV BIOPHYS BIO, V17, P47; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; Weinreb O, 2000, INVEST OPHTH VIS SCI, V41, P3893; Weinreb O, 2001, EUR J BIOCHEM, V268, P536, DOI 10.1046/j.1432-1327.2001.01885.x; Wieligmann K, 1998, J MOL BIOL, V280, P721, DOI 10.1006/jmbi.1998.1887; Wieligmann K, 1999, J MOL BIOL, V286, P989, DOI 10.1006/jmbi.1999.2554	47	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16425	16432		10.1074/jbc.M313402200	http://dx.doi.org/10.1074/jbc.M313402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761939	hybrid			2022-12-27	WOS:000220747900090
J	Jack, MT; Woo, RA; Motoyama, N; Takai, H; Lee, PWK				Jack, MT; Woo, RA; Motoyama, N; Takai, H; Lee, PWK			DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; LI-FRAUMENI-SYNDROME; ATAXIA-TELANGIECTASIA; TUMOR-SUPPRESSOR; P53-DEPENDENT APOPTOSIS; INDUCED PHOSPHORYLATION; IONIZING-RADIATION; CHK2; THREONINE-68; OLIGOMERIZATION	The role of the checkpoint kinase 2 (Chk2) as an upstream activator of p53 following DNA damage has been controversial. We have recently shown that Chk2 and the DNA-dependent protein kinase (DNA-PK) are both involved in DNA damage-induced apoptosis but not G(1) arrest in mouse embryo fibroblasts. Here we demonstrate that Chk2 is required to activate p53 in vitro as measured by its ability to bind its consensus DNA target sequence following DNA damage and is in fact the previously unidentified factor working synergistically with DNA-PK to activate p53. The gene mutated in ataxia telangiectasia is not involved in this p53 activation. Using wortmannin, serine 15 mutants of p53, DNA-PK null cells and Chk2 null cells, we demonstrate that DNA-PK and Chk2 act independently and sequentially on p53. Furthermore, the p53 target of these two kinases represents a latent (preexisting) population of p53. Taken together, the results from these studies are consistent with a model in which DNA damage causes an immediate and sequential modification of latent p53 by DNA-PK and Chk2, which under appropriate conditions can lead to apoptosis.	Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lee, PWK (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, 7-P,Sir Charles Tupper Med Bldg,5850 Coll St, Halifax, NS B3H 1X5, Canada.	patrick.lee@dal.ca	Takai, Hiroyuki/B-8352-2011					Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lee SB, 2001, CANCER RES, V61, P8062; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Vahteristo P, 2001, CANCER RES, V61, P5718; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	29	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15269	15273		10.1074/jbc.M309917200	http://dx.doi.org/10.1074/jbc.M309917200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14752107	hybrid			2022-12-27	WOS:000220594700094
J	McCain, DF; Wu, L; Nickel, P; Kassack, MU; Kreimeyer, A; Gagliardi, A; Collins, DC; Zhang, ZY				McCain, DF; Wu, L; Nickel, P; Kassack, MU; Kreimeyer, A; Gagliardi, A; Collins, DC; Zhang, ZY			Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC25 PHOSPHATASE; CATALYTIC DOMAINS; 2-PHENYLBENZIMIDAZOLE MOIETY; INTERMOLECULAR INTERACTIONS; VIRULENCE DETERMINANT; INSULIN SENSITIVITY; NEGATIVE REGULATION; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; FOCAL ADHESIONS	Protein-tyrosine phosphatases (PTPs) are important signaling enzymes that have emerged within the last decade as a new class of drug targets. It has previously been shown that suramin is a potent, reversible, and competitive inhibitor of PTP1B and Yersinia PTP ( YopH). We therefore screened 45 suramin analogs against a panel of seven PTPs, including PTP1B, YopH, CD45, Cdc25A, VHR, PTPalpha, and LAR, to identify compounds with improved potency and specificity. Of the 45 compounds, we found 11 to have inhibitory potency comparable or significantly improved relative to suramin. We also found suramin to be a potent inhibitor (IC50 = 1.5 muM) of Cdc25A, a phosphatase that mediates cell cycle progression and a potential target for cancer therapy. In addition we also found three other compounds, NF201, NF336, and NF339, to be potent (IC50 < 5 mu M) and specific ( at least 20-30-fold specificity with respect to the other human PTPs tested) inhibitors of Cdc25A. Significantly, we found two potent and specific inhibitors, NF250 and NF290, for YopH, the phosphatase that is an essential virulence factor for bubonic plague. Two of the compounds tested, NF504 and NF506, had significantly improved potency as PTP inhibitors for all phosphatases tested except for LAR and PTP alpha. Surprisingly, we found that a significant number of these compounds activated the receptor-like phosphatases, PTP alpha and LAR. In further characterizing this activation phenomenon, we reveal a novel role for the membrane-distal cytoplasmic PTP domain (D2) of PTP alpha: the direct intramolecular regulation of the activity of the membrane-proximal cytoplasmic PTP domain (D1). Binding of certain of these compounds to PTP alpha disrupts D1-D2 basal state contacts and allows new contacts to occur between D1 and D2, which activates D1 by as much as 12-14-fold when these contacts are optimized.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Univ Bonn, Inst Pharmaceut, D-53121 Bonn, Germany; Univ Kentucky, Coll Med, Dept Obstet & Gynecol, Lexington, KY 40536 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Bonn; University of Kentucky	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NIAID NIH HHS [AI48506, 1U54 AI057158] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057158, R01AI048506] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Bergnes G, 1999, BIOORG MED CHEM LETT, V9, P2849, DOI 10.1016/S0960-894X(99)00497-7; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Blanchard JL, 1999, BIOORG MED CHEM LETT, V9, P2537, DOI 10.1016/S0960-894X(99)00431-X; Blanchetot C, 2002, J BIOL CHEM, V277, P47263, DOI 10.1074/jbc.M205810200; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOJANOWSKI K, 1994, BIOCHEM BIOPH RES CO, V203, P1574, DOI 10.1006/bbrc.1994.2366; Brandt DT, 2003, J BIOL CHEM, V278, P34073, DOI 10.1074/jbc.M211650200; Broggini M, 2000, ANTICANCER RES, V20, P4835; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; CARDINALI M, 1992, J CLIN INVEST, V89, P1242, DOI 10.1172/JCI115708; Cebula RE, 1997, BIOORG MED CHEM LETT, V7, P2015, DOI 10.1016/S0960-894X(97)00357-0; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Ding XL, 2000, AM J PATHOL, V157, P1983, DOI 10.1016/S0002-9440(10)64837-7; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Felberg J, 2000, BIOCHEM BIOPH RES CO, V271, P292, DOI 10.1006/bbrc.2000.2623; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Fraser CM, 2001, NAT GENET, V29, P253, DOI 10.1038/ng763; Fritzen EL, 2000, BIOORG MED CHEM LETT, V10, P649, DOI 10.1016/S0960-894X(00)00069-X; Gagliardi ART, 1998, CANCER CHEMOTH PHARM, V41, P117; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gunasekera SP, 1996, J AM CHEM SOC, V118, P8759, DOI 10.1021/ja961961+; Ham SW, 1998, BIOORG MED CHEM LETT, V8, P2507, DOI 10.1016/S0960-894X(98)00411-9; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; HOFFMANN I, 1994, J CELL SCI, P75; HOLZMANN G, 1985, BIOMED MASS SPECTROM, V12, P659, DOI 10.1002/bms.1200121106; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Ito Y, 2002, BRIT J CANCER, V86, P1909, DOI 10.1038/sj.bjc.6600364; ITOH M, 1992, J BIOL CHEM, V267, P12356; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Kassack M, 1996, ARCH PHARM, V329, P225, DOI 10.1002/ardp.19963290502; Kassack M, 1996, J CHROMATOGR B, V686, P275, DOI 10.1016/S0378-4347(96)00214-9; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kreimeyer A, 1997, PHARMAZIE, V52, P268; Kreimeyer A, 1998, ARCH PHARM, V331, P97, DOI 10.1002/(SICI)1521-4184(199803)331:3<97::AID-ARDP97>3.0.CO;2-F; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Liang FB, 2003, J BIOL CHEM, V278, P41734, DOI 10.1074/jbc.M307152200; Loukaci A, 2001, BIOORGAN MED CHEM, V9, P3049, DOI 10.1016/S0968-0896(01)00208-5; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; McCain DF, 2002, J BIOL CHEM, V277, P11190, DOI 10.1074/jbc.M109636200; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; NICKEL P, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1153; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nishioka K, 2001, BRIT J CANCER, V85, P412, DOI 10.1054/bjoc.2001.1934; Peng HR, 2001, J MED CHEM, V44, P834, DOI 10.1021/jm0004401; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; Rudolph J, 2001, ANAL BIOCHEM, V289, P43, DOI 10.1006/abio.2000.4906; SARTOR O, 1992, J CLIN INVEST, V90, P2166, DOI 10.1172/JCI116102; Sasaki H, 2001, CANCER LETT, V173, P187, DOI 10.1016/S0304-3835(01)00669-3; Sasaki T, 2001, INT J BIOCHEM CELL B, V33, P1041, DOI 10.1016/S1357-2725(01)00075-9; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; Sodeoka M, 2001, J MED CHEM, V44, P3216, DOI 10.1021/jm0100741; Sonnenburg ED, 2003, BIOCHEMISTRY-US, V42, P7904, DOI 10.1021/bi0340503; STEIN CA, 1993, CANCER RES, V53, P2239; Taing M, 1999, BIOCHEMISTRY-US, V38, P3793, DOI 10.1021/bi9813781; Takahashi M, 2000, BIOORG MED CHEM LETT, V10, P2571, DOI 10.1016/S0960-894X(00)00527-8; Tamura K, 1999, ONCOGENE, V18, P6989, DOI 10.1038/sj.onc.1203179; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; Toledano-Katchalski H, 2003, MOL CELL BIOL, V23, P5460, DOI 10.1128/MCB.23.15.5460-5471.2003; Vincent I, 2001, NEUROSCIENCE, V105, P639, DOI 10.1016/S0306-4522(01)00219-6; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu FYH, 1999, EUR J CANCER, V35, P1388, DOI 10.1016/S0959-8049(99)00156-2; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	87	59	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14713	14725		10.1074/jbc.M312488200	http://dx.doi.org/10.1074/jbc.M312488200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14734566	hybrid			2022-12-27	WOS:000220594700031
J	Shimoaka, T; Kamekura, S; Chikuda, H; Hoshi, K; Chung, UI; Akune, T; Maruyama, Z; Komori, T; Matsumoto, M; Ogawa, W; Terauchi, Y; Kadowaki, T; Nakamura, K; Kawaguchi, H				Shimoaka, T; Kamekura, S; Chikuda, H; Hoshi, K; Chung, UI; Akune, T; Maruyama, Z; Komori, T; Matsumoto, M; Ogawa, W; Terauchi, Y; Kadowaki, T; Nakamura, K; Kawaguchi, H			Impairment of bone healing by insulin receptor substrate-1 deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; IGF-I; PARATHYROID-HORMONE; SIGNALING PATHWAYS; DIABETES-MELLITUS; MINERAL DENSITY; FRACTURE REPAIR; GENE-TRANSFER; CELL-SIZE; MICE	Insulin receptor substrate-1 (IRS-1) is an essential molecule for intracellular signaling of insulin-like growth factor (IGF)-I and insulin, both of which are potent anabolic regulators of bone and cartilage metabolism. To investigate the role of IRS-1 in bone regeneration, fracture was introduced in the tibia, and its healing was compared between wild-type (WT) mice and mice lacking the IRS-1 gene (IRS-1(-/-) mice). Among 15 IRS-1(-/-) mice, 12 remained in a non-union state even at 10 weeks after the operation, whereas all 15 WT mice showed a rigid bone union at 3 weeks. This impairment was because of the suppression of callus formation with a decrease in chondrocyte proliferation and increases in hypertrophic differentiation and apoptosis. Reintroduction of IRS-1 to the IRS-1(-/-) fractured site using an adenovirus vector significantly restored the callus formation. In the culture of chondrocytes isolated from the mouse growth plate, IRS-1(-/-) chondrocytes showed less mitogenic ability and Akt phosphorylation than WT chondrocytes. An Akt inhibitor decreased the IGF-I-stimulated DNA synthesis of chondrocytes more potently in the WT culture than in the IRS-1(-/-) culture. We therefore conclude that IRS-1 deficiency impairs bone healing at least partly by inhibiting chondrocyte proliferation through the phosphatidylinositol 3-kinase/Akt pathway, and we propose that IRS-1 can be a target molecule for bone regenerative medicine.	Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Tissue Engn, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Osaka Univ, Sch Med, Dept Mol Med, Osaka 5650871, Japan; Kobe Univ, Div Diabet Digest & Kidney Dis, Grad Sch Med, Kobe, Hyogo 6500017, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Osaka University; Kobe University	Kawaguchi, H (corresponding author), Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Hongo 7-3-1, Tokyo 1138655, Japan.	kawaguchi-ort@h.u-tokyo.ac.jp	OGAWA, Wataru/AAQ-9586-2020; Terauchi, Yasuo/AAO-4347-2020					Akune T, 2002, J CELL BIOL, V159, P147, DOI 10.1083/jcb.200204046; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; CANALIS E, 1993, BONE, V14, P273, DOI 10.1016/8756-3282(93)90151-Y; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; Caverzasio J, 1997, J BONE MINER RES, V12, P1975, DOI 10.1359/jbmr.1997.12.12.1975; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584; Gori F, 1999, ENDOCRINOLOGY, V140, P5579, DOI 10.1210/en.140.12.5579; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hoshi K, 2004, J BONE MINER RES, V19, P214, DOI 10.1359/JBMR.0301221; Huang BK, 2000, J BONE MINER RES, V15, P188, DOI 10.1359/jbmr.2000.15.2.188; Itaka K, 2002, BIOMACROMOLECULES, V3, P841, DOI 10.1021/bm025527d; KADOWAKI T, 1996, ENDOCR J, V43, P33; KATO Y, 1984, J CELL PHYSIOL, V120, P354, DOI 10.1002/jcp.1041200314; KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774; Krakauer JC, 1997, DIABETES CARE, V20, P1339, DOI 10.2337/diacare.20.8.1339b; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Laron Z, 1999, J BONE MINER RES, V14, P156, DOI 10.1359/jbmr.1999.14.1.156; Laron Z, 2001, J CLIN PATHOL-MOL PA, V54, P311; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; LODER RT, 1988, CLIN ORTHOP RELAT R, V232, P210; Lopaczynski W, 1999, ACTA BIOCHIM POL, V46, P51, DOI 10.18388/abp.1999_4183; MACEY LR, 1989, J BONE JOINT SURG AM, V71A, P722, DOI 10.2106/00004623-198971050-00014; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349; Morrione A, 2001, ONCOGENE, V20, P4842, DOI 10.1038/sj.onc.1204649; Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017; Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s-2007-979106; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Schmidmaier G, 2002, BONE, V31, P165, DOI 10.1016/S8756-3282(02)00798-6; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Shimoaka T, 2002, J BIOL CHEM, V277, P7493, DOI 10.1074/jbc.M108653200; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Smink JJ, 2003, J ENDOCRINOL, V177, P381, DOI 10.1677/joe.0.1770381; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Thomas DM, 1997, ENDOCRINOL METAB, V4, P5; TRIPPEL SB, 1998, CLIN ORTHOP S, V355, P301; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Uusitalo H, 2001, J BONE MINER RES, V16, P1837, DOI 10.1359/jbmr.2001.16.10.1837; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; van Griensven M, 2002, LAB ANIM-UK, V36, P455, DOI 10.1258/002367702320389134; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681	54	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15314	15322		10.1074/jbc.M312525200	http://dx.doi.org/10.1074/jbc.M312525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14736890	hybrid			2022-12-27	WOS:000220594700100
J	Stoeckman, AK; Ma, L; Towle, HC				Stoeckman, AK; Ma, L; Towle, HC			Mlx is the functional heteromeric partner of the carbohydrate response element-binding protein in glucose regulation of lipogenic enzyme genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; FATTY-ACID SYNTHASE; WILLIAMS-BEUREN-SYNDROME; TRANSCRIPTION FACTOR; RAT-LIVER; S-14 GENE; C-MYC; EXPRESSION; PROMOTER; INSULIN	The expression of genes encoding enzymes involved in de novo triglyceride synthesis (lipogenesis) is transcriptionally induced in the liver in response to increased glucose metabolism. The carbohydrate response element-binding protein (ChREBP) is a newly identified basic helix-loop-helix/leucine zipper transcription factor proposed to regulate the expression of the glucose-responsive gene pyruvate kinase. This gene contains a carbohydrate response element (ChoRE) consisting of two E box motifs separated by 5 bp that is necessary and sufficient for glucose regulation. We demonstrate that overexpression of ChREBP in primary rat hepatocytes activates other ChoRE-containing promoters in a manner consistent with their ability to respond to glucose. In vitro binding of ChREBP to ChoRE sequences was not detected. Because E box-binding proteins function as obligate dimers, we performed a yeast two-hybrid screen of a mouse liver cDNA library to identify potential heteromeric partners. Mlx ((M) under bar ax-(l) under bar ike protein (X) under bar) was selected as the only basic helix-loop-helix/leucine zipper interaction partner in this screen. When a plasmid expressing either Mlx or ChREBP was cotransfected with a ChoRE-containing reporter plasmid into human embryonic kidney 293 cells, no increase in promoter activity was observed. However, the expression of both proteins dramatically enhanced promoter activity. This activation was observed with reporters containing ChoREs from several different lipogenic enzyme genes. In contrast, reporters containing non-glucose-responsive E box elements were not activated by ChREBP-Mlx expression. In vitro binding of ChREBP to ChoRE-containing oligonucleotides was observed only in the presence of Mlx. ChREBP-Mlx binding discriminated between E box sites that are glucose-responsive and those that are not. We conclude that Mlx is a functional heteromeric partner of ChREBP in regulating the expression of glucose-responsive genes.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Towle, HC (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	towle@mail.ahc.umn.edu		Stoeckman, Angela/0000-0002-2009-0424	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050456, R01DK026919] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 26919, P30 DK 50456] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cairo S, 2001, HUM MOL GENET, V10, P617, DOI 10.1093/hmg/10.6.617; Collier JJ, 2003, J BIOL CHEM, V278, P6588, DOI 10.1074/jbc.M208011200; de Luis O, 2000, EUR J HUM GENET, V8, P215, DOI 10.1038/sj.ejhg.5200435; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Lou DQ, 1999, J BIOL CHEM, V274, P28385, DOI 10.1074/jbc.274.40.28385; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; O'Callaghan BL, 2001, J BIOL CHEM, V276, P16033, DOI 10.1074/jbc.M101557200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1994, J BIOL CHEM, V269, P9380; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wang HY, 2002, J BIOL CHEM, V277, P32746, DOI 10.1074/jbc.M201635200; Yamada K, 1999, BIOCHEM BIOPH RES CO, V257, P44, DOI 10.1006/bbrc.1999.0410; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298	42	163	179	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15662	15669		10.1074/jbc.M311301200	http://dx.doi.org/10.1074/jbc.M311301200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14742444	hybrid			2022-12-27	WOS:000220594700139
J	Wang, P; Tortorella, M; England, K; Malfait, AM; Thomas, G; Arner, EC; Pei, DQ				Wang, P; Tortorella, M; England, K; Malfait, AM; Thomas, G; Arner, EC; Pei, DQ			Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (aggrecanase-1) in the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; INTRACELLULAR ACTIVATION; FRAGMENTS; MEMBRANE; LOCALIZATION; DEGRADATION; INHIBITION; PORTLAND; CLONING; FAMILY	A member of the A disintegrin and metalloproteinase domain with thrombospondin type-1 motifs (ADAMTS-4) protease family can efficiently cleave aggrecan at several sites detected in joints of osteoarthritic patients. Although recent studies have shown that removal of the prodomain of ADAMTS4 is critical for its ability to degrade aggrecan, the cellular mechanisms for its processing and trafficking remain unclear. In this study, by using both furin-specific inhibitor and RNA interference technique, we demonstrate that furin plays an important role in the intracellular removal of ADAMTS4 prodomain. Further, we demonstrate that proADAMTS4 can be processed by means of multiple furin recognition sites: (RPRR209)-R-206, (209)RAKR(212), or (KR212)-K-211. The processing of proADAMTS4 was completely blocked by brefeldin A treatment, suggesting that processing occurs in the trans-Golgi network. Indeed, ADAMTS4 is co-localized with furin in trans-Golgi network. Interestingly, the pro form of ADAMTS4, not its mature one, co-precipitates with furin, suggesting that furin physically interacts with the prodomain of ADAMTS-4. In addition, our evidence suggests that a furin-independent pathway may also contribute to the activation of ADAMTS4. These results indicate that the activation mechanism for ADAMTS4 can be targeted for therapeutical intervention against this enzyme.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Pfizer Discovery Res, Joint Biol, St Louis, MO 63017 USA; Vollum Inst, Portland, OR 97201 USA	University of Minnesota System; University of Minnesota Twin Cities; Pfizer	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	peixx003@umn.edu		Malfait, Anne-Marie/0000-0003-1428-0384	NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076308, R01CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 2002, CURR OPIN PHARMACOL, V2, P322, DOI 10.1016/S1471-4892(02)00148-0; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Cherney RJ, 2003, BIOORG MED CHEM LETT, V13, P1297, DOI 10.1016/S0960-894X(03)00124-0; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Inocencio NM, 1997, J BIOL CHEM, V272, P1344, DOI 10.1074/jbc.272.2.1344; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Kang TB, 2002, CANCER RES, V62, P675; Leighton M, 2003, J BIOL CHEM, V278, P18478, DOI 10.1074/jbc.M213021200; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Sucic JF, 1999, BIOCHEM J, V339, P639, DOI 10.1042/0264-6021:3390639; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	37	93	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15434	15440		10.1074/jbc.M312797200	http://dx.doi.org/10.1074/jbc.M312797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14744861	hybrid			2022-12-27	WOS:000220594700114
J	Cobine, PA; Ojeda, LD; Rigby, KM; Winge, DR				Cobine, PA; Ojeda, LD; Rigby, KM; Winge, DR			Yeast contain a non-proteinaceous pool of copper in the mitochondrial matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; MANGANESE-SUPEROXIDE DISMUTASE; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; MUTATIONAL ANALYSIS; PHYSIOLOGICAL-ROLE; GENE; METALLOCHAPERONE; SCO1; METALLOTHIONEIN	The yeast mitochondrion is shown to contain a pool of copper that is distinct from that associated with the two known mitochondrial cuproenzymes, superoxide dismutase (Sod1) and cytochrome c oxidase (CcO) and the copper-binding CcO assembly proteins Cox11, Cox17, and Sco1. Only a small fraction of mitochondrial copper is associated with these cuproproteins. The bulk of the remainder is localized within the matrix as a soluble, anionic, low molecular weight complex. The identity of the matrix copper ligand is unknown, but the bulk of the matrix copper fraction is not protein-bound. The mitochondrial copper pool is dynamic, responding to changes in the cytosolic copper level. The addition of copper salts to the growth medium leads to an increase in mitochondrial copper, yet the expansion of this matrix pool does not induce any respiration defects. The matrix copper pool is accessible to a heterologous cuproenzyme. Co-localization of human Sod1 and the metallochaperone CCS within the mitochondrial matrix results in suppression of growth defects of sod2Delta cells. However, in the absence of CCS within the matrix, the activation of human Sod1 can be achieved by the addition of copper salts to the growth medium.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010; Cobine, Paul/AAH-6619-2020; Cobine, Paul A/G-3107-2011	Cobine, Paul/0000-0001-6012-0985; Cobine, Paul A/0000-0001-6012-0985	NCI NIH HHS [5P30-CA 42014] Funding Source: Medline; NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Balzan R, 1999, BIOCHEM BIOPH RES CO, V256, P63, DOI 10.1006/bbrc.1999.0285; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; El Meskini R, 2003, J BIOL CHEM, V278, P12278, DOI 10.1074/jbc.M211413200; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; Field LS, 2002, J BIOENERG BIOMEMBR, V34, P373, DOI 10.1023/A:1021202119942; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Luk E, 2003, P NATL ACAD SCI USA, V100, P10353, DOI 10.1073/pnas.1632471100; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reichert AS, 2002, BBA-MOL CELL RES, V1592, P41, DOI 10.1016/S0167-4889(02)00263-X; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 2002, NEUROBIOL DIS, V10, P100, DOI 10.1006/nbdi.2002.0493; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WRIGHT CF, 1987, J BIOL CHEM, V262, P12912; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	60	163	167	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14447	14455		10.1074/jbc.M312693200	http://dx.doi.org/10.1074/jbc.M312693200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729672	hybrid			2022-12-27	WOS:000220478500141
J	D'Anjou, FO; Bergeron, LJ; Ben Larbi, N; Fournier, I; Salzet, M; Perreault, JP; Day, R				D'Anjou, FO; Bergeron, LJ; Ben Larbi, N; Fournier, I; Salzet, M; Perreault, JP; Day, R			Silencing of SPC2 expression using an engineered delta ribozyme in the mouse beta TC-3 endocrine cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASES PC1; MESSENGER-RIBONUCLEIC-ACID; PRO-PROTEIN CONVERTASES; IN-VITRO; SEQUENCE; RNA; SPECIFICITY; CLEAVAGE; BIOSYNTHESIS; LOCALIZATION	Endoproteolytic processing is carried out by subtilase-like pro-protein convertases in mammalian cells. In order to understand the distinct roles of a member of this family (SPC2), gene silencing in cultured cells is an ideal approach. Previous studies showed limited success in either the degree of inhibition obtained or the stability of the cell lines. Here we demonstrate the high potential of delta ribozyme as a post-transcriptional gene silencing tool in cultured cells. We used an expression vector based on the RNA polymerase III promoter to establish betaTC-3 stable cell lines expressing the chimeric tRNA(Val)-delta ribozyme transcript targeting SPC2 mRNA. Northern and Western blot hybridizations showed a specific reduction of SPC2 mRNA and protein. Validation of processing effects was tested by measuring the levels of dynorphin A-(1-8), which are present in betaTC-3 cells as a result of the unique cleavage of dynorphin A-(1 - 17) by SPC2. Moreover, a differential proteomic analysis confirmed these results and allowed identification of secretogranin II as a potential substrate of SPC2. The development of efficient, specific, and durable silencing tools, such as described in the present work, will be of great importance in elucidating the functions of the subtilase-like pro-protein convertases in regard to peptide processing and derived cellular events.	Univ Sherbrooke, Inst Pharmacol, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; Univ Sci & Technol Lille, CNRS, UMR 8017, Lab Neuroimmunol Annelides, F-59650 Villeneuve Dascq, France	University of Sherbrooke; University of Sherbrooke; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Perreault, JP (corresponding author), Univ Sherbrooke, Inst Pharmacol, Dept Pharmacol, 3001 12 Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	jean-pierre.perreault@usherbrooke.ca; robert.day@usherbrooke.ca	Salzet, Michel/A-7675-2011; FOURNIER, Isabelle/H-9195-2015	Salzet, Michel/0000-0003-4318-0817; FOURNIER, Isabelle/0000-0003-1096-5044	Canadian Institutes of Health Research [38322] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Al-Anouti F, 2002, ANTISENSE NUCLEIC A, V12, P275, DOI 10.1089/108729002320351593; Ananvoranich S, 1998, J BIOL CHEM, V273, P13182, DOI 10.1074/jbc.273.21.13182; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Bergeron LJ, 2003, CURR MED CHEM, V10, P2589, DOI 10.2174/0929867033456486; Bergeron LJ, 2002, NUCLEIC ACIDS RES, V30, P4682, DOI 10.1093/nar/gkf598; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; Deschenes P, 2000, ANTISENSE NUCLEIC A, V10, P53, DOI 10.1089/oli.1.2000.10.53; DITTIE AS, 1995, BIOCHEM J, V310, P777, DOI 10.1042/bj3100777; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; Fugere M, 2002, CURR PHARM DESIGN, V8, P549, DOI 10.2174/1381612023395736; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; JOSHI D, 1995, ENDOCRINOLOGY, V136, P2721, DOI 10.1210/en.136.6.2721; Kato Y, 2001, J BIOL CHEM, V276, P15378, DOI 10.1074/jbc.M010570200; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; Lebedeva I, 2001, ANNU REV PHARMACOL, V41, P403, DOI 10.1146/annurev.pharmtox.41.1.403; Levesque D, 2002, RNA, V8, P464, DOI 10.1017/S1355838202020289; Mathews DH, 1999, RNA, V5, P1458, DOI 10.1017/S1355838299991148; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Shih IH, 2002, ANNU REV BIOCHEM, V71, P887, DOI 10.1146/annurev.biochem.71.110601.135349; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VIEAU D, 1995, ENDOCRINOLOGY, V136, P1187, DOI 10.1210/en.136.3.1187; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10299, DOI 10.1073/pnas.162352799	31	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14232	14239		10.1074/jbc.M310632200	http://dx.doi.org/10.1074/jbc.M310632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734558	hybrid, Green Accepted			2022-12-27	WOS:000220478500116
J	Kakimoto, T; Katoh, H; Negishi, M				Kakimoto, T; Katoh, H; Negishi, M			Identification of splicing variants of rapostlin, a novel Rnd2 effector that interacts with neural Wiskott-Aldrich syndrome protein and induces neurite branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; GROWTH CONE; ACTIN CYTOSKELETON; PC12 CELLS; BINDING; RAC1; RETRACTION; ACTIVATION; ADHESION; PARTNER	Rho family GTPases regulate neuronal morphology. Rnd subfamily is a new branch of Rho family GTPases. Of these GTPases, Rnd2 is specifically expressed in brain. We recently identified Rapostlin as a novel effector of Rnd2. Rapostlin induces neurite branching in response to Rnd2 in PC12 cells. During the cloning of Rapostlin, we have found two mainly expressed splicing variants of Rapostlin (renamed as RapostlinL), Rapost-linM and RapostlinS, lacking 29 residues and 61 residues within the unique insert region at the center, respectively, and three minor variants, RapostlinLd, RapostlinMd, and RapostlinSd, each with the identical five-amino acid deletion from RapostlinL, RapostlinM, and RapostlinS, respectively. RapostlinL is predominantly expressed in brain, whereas RapostlinS is expressed ubiquitously. In a dot-blot assay, all splicing variants bind to Rnd2 in a GTP-dependent manner. However, RapostlinM and RapostlinS induce less neurite branching when coexpressed with Rnd2 in PC12 cells, indicating that the insert region is important for the branching activity of RapostlinL. All splicing variants bind to N-WASP in vitro and in vivo through the SH3 domain at the carboxyl terminus, and the SH3 domain is essential for branching activity of RapostlinL. In immunoprecipitation experiments, Rnd2 reduces Ra-postlinL-N-WASP interaction, whereas it has little effect on the interaction of RapostlinM or RapostlinS with N-WASP. Therefore, we found that functionally different splicing variants of Rapostlin have different responses to Rnd2 in association with N-WASP.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.	mnegishi@pharm.kyoto-u.ac.jp	kakimoto, tetsuhiro/W-1403-2019	Kakimoto, Tetsuhiro/0000-0003-1349-5690; Katoh, Hironori/0000-0002-8191-8117				Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Foster R, 1996, MOL CELL BIOL, V16, P2689; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Fujita H, 2002, J BIOL CHEM, V277, P45428, DOI 10.1074/jbc.M208090200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishikawa Y, 2003, J NEUROSCI, V23, P11065; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kalil K, 2000, J NEUROBIOL, V44, P145, DOI 10.1002/1097-4695(200008)44:2<145::AID-NEU5>3.0.CO;2-X; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Linder S, 2000, J CELL SCI, V113, P4165; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Miki H, 2003, J BIOCHEM, V134, P309, DOI 10.1093/jb/mvg146; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Nishi M, 1999, MOL BRAIN RES, V67, P74, DOI 10.1016/S0169-328X(99)00039-X; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Szebenyi G, 1998, J NEUROSCI, V18, P7930; Tanaka H, 2002, BIOCHEM J, V365, P349, DOI 10.1042/BJ20020062; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	33	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14104	14110		10.1074/jbc.M312763200	http://dx.doi.org/10.1074/jbc.M312763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14732713	hybrid			2022-12-27	WOS:000220478500100
J	Kim, HC; Gottesman, ME				Kim, HC; Gottesman, ME			Transcription termination by phage HK022 nun is facilitated by COOH-terminal lysine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ANTITERMINATION PROTEIN; ESCHERICHIA-COLI; RNA-POLYMERASE; NASCENT RNA; LAMBDA; MUTATIONS; BINDING; GENE; RECOGNITION; REPRESSION	The 109-amino acid Nun protein of prophage HK022 excludes superinfecting bacteriophage lambda by blocking transcription elongation on the lambda chromosome. Multiple interactions between Nun and the transcription elongation complex are involved in this reaction. The Nun NH2-terminal arginine-rich motif binds BOXB sequence in nascent lambda transcripts, whereas the COOH terminus binds RNA polymerase and contacts DNA template. Nun Trp(108) is required for interaction with DNA and transcription arrest. We analyzed the role of the adjacent Lys(106) and Lys(107) residues in the Nun reaction. Substitution of the lysine residues with arginine (K106R/ K107R) had no effect on transcription arrest in vitro or in vivo. Nun K106A/K107A was partially active, whereas Nun K106D/K107D was defective in vitro and failed to exclude lambda. All mutants bound RNA polymerase and BOXB. In contrast to Nun K106R/ K107R and K106A/ K107A, Nun K106D/K107D did not cross-link DNA template. These results suggest that transcription arrest is facilitated by electrostatic interactions between positively charged Nun residues Lys(106) and Lys(107) and negatively charged DNA phosphate groups. These may assist intercalation of Trp(108) into template.	Columbia Univ, Med Ctr, Inst Canc Res, New York, NY 10032 USA; Columbia Univ, Med Ctr, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Columbia University	Gottesman, ME (corresponding author), Columbia Univ, Med Ctr, Inst Canc Res, 701 W 168th St,Hammer Bldg,Rm 916, New York, NY 10032 USA.	gottesma@cancercenter.columbia.edu			NIGMS NIH HHS [GM37219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM037219, R01GM037219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; BARON J, 1992, J BACTERIOL, V174, P1983, DOI 10.1128/jb.174.6.1983-1989.1992; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burova E, 1999, MOL MICROBIOL, V31, P1783, DOI 10.1046/j.1365-2958.1999.01315.x; Chattopadhyay S, 1995, P NATL ACAD SCI USA, V92, P12131, DOI 10.1073/pnas.92.26.12131; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; Henthorn KS, 1996, J MOL BIOL, V257, P9, DOI 10.1006/jmbi.1996.0142; Hung SC, 1997, GENE DEV, V11, P2670, DOI 10.1101/gad.11.20.2670; HUNG SC, 1995, J MOL BIOL, V247, P428; KAMEYAMA L, 1991, MOL MICROBIOL, V5, P2953, DOI 10.1111/j.1365-2958.1991.tb01855.x; Kim HC, 2003, P NATL ACAD SCI USA, V100, P5308, DOI 10.1073/pnas.0430995100; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LOZERON HA, 1976, VIROLOGY, V71, P262, DOI 10.1016/0042-6822(76)90111-2; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MODGRIDGE J, 1995, GENE DEV, V9, P2831; OBERTO J, 1989, J MOL BIOL, V207, P675, DOI 10.1016/0022-2836(89)90237-4; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; ROBLEDO R, 1991, J MOL BIOL, V220, P613, DOI 10.1016/0022-2836(91)90104-E; ROBLEDO R, 1990, J MOL BIOL, V212, P635, DOI 10.1016/0022-2836(90)90226-C; Silhavy T. J., 1984, EXPT GENE FUSIONS; STEEGE DA, 1987, J BIOL CHEM, V262, P17651; Washburn RS, 2003, J MOL BIOL, V329, P655, DOI 10.1016/S0022-2836(03)00465-0; Watnick RS, 2000, GENE DEV, V14, P731; Watnick RS, 1999, SCIENCE, V286, P2337, DOI 10.1126/science.286.5448.2337; Watnick RS, 1998, P NATL ACAD SCI USA, V95, P1546, DOI 10.1073/pnas.95.4.1546; Weiss MA, 1998, BIOPOLYMERS, V48, P167, DOI 10.1002/(SICI)1097-0282(1998)48:2<167::AID-BIP6>3.0.CO;2-8; Wilson HR, 1997, GENE DEV, V11, P2204, DOI 10.1101/gad.11.17.2204	27	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13412	13417		10.1074/jbc.M313206200	http://dx.doi.org/10.1074/jbc.M313206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14742436	hybrid			2022-12-27	WOS:000220478500018
J	Li, BM; Navarro, S; Kasahara, N; Comai, L				Li, BM; Navarro, S; Kasahara, N; Comai, L			Identification and biochemical characterization of a Werner's syndrome protein complex with Ku70/80 and poly(ADP-ribose) polymerase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL INTERACTION; ADP-RIBOSYLATION; SYNDROME GENE; DNA HELICASE; EXONUCLEASE ACTIVITY; GENOMIC STABILITY; TOPOISOMERASE-I; AGING PROCESS; WRN HELICASE; CELL-DEATH	Werner's syndrome (WS) is an inherited disease characterized by genomic instability and premature aging. The WS gene encodes a protein (WRN) with helicase and exonuclease activities. We have previously reported that WRN interacts with Ku70/80 and this interaction strongly stimulates WRN exonuclease activity. To gain further insight on the function of WRN and its relationship with the Ku heterodimer, we established a cell line expressing tagged WRNH, a WRN point mutant lacking helicase activity, and used affinity purification, immunoblot analysis and mass spectroscopy to identify WRN-associated proteins. To this end, we identified three proteins that are stably associated with WRN in nuclear extracts. Two of these proteins, Ku70 and Ku80, were identified by immunoblot analysis. The third polypeptide, which was identified by mass spectrometry analysis, is identical to poly(ADP-ribose) polymerase-1(PARP-1), a 113-kDa enzyme that functions as a sensor of DNA damage. Biochemical fractionation studies and immunoprecipitation assays and studies confirmed that endogenous WRN is associated with subpopulations of PARP-1 and Ku70/80 in the cell. Protein interaction assays with purified proteins further indicated that PARP-1 binds directly to WRN and assembles in a complex with WRN and Ku70/80. In the presence of DNA and NAD(+), PARP-1 poly( ADP-ribosyl) ates itself and Ku70/80 but not WRN, and gel-shift assays showed that poly( ADP-ribosyl) ation of Ku70/80 decreases the DNA-binding affinity of this factor. Significantly, (ADP-ribosyl) ation of Ku70/80 reduces the ability of this factor to stimulate WRN exonuclease, suggesting that covalent modification of Ku70/80 by PARP-1 may play a role in the regulation of the exonucleolytic activity of WRN.	Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Comai, L (corresponding author), Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.	comai@usc.edu	Comai, Lucio/L-5905-2019; Comai, Lucio/H-9524-2019	Comai, Lucio/0000-0003-3109-1841; Kasahara, Noriyuki/0000-0002-6069-9082				Adelfalk C, 2003, FEBS LETT, V554, P55, DOI 10.1016/S0014-5793(03)01088-3; ADOLPH KW, 1985, BIOCHEM BIOPH RES CO, V126, P840, DOI 10.1016/0006-291X(85)90261-X; ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Baynton K, 2003, J BIOL CHEM, V278, P36476, DOI 10.1074/jbc.M303885200; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Bohr VA, 2002, BIOGERONTOLOGY, V3, P89, DOI 10.1023/A:1015223917491; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Burkle A, 2001, CHEMBIOCHEM, V2, P725, DOI 10.1002/1439-7633(20011001)2:10<725::AID-CBIC725>3.0.CO;2-3; Cooper MP, 2000, GENE DEV, V14, P907; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dyer CAE, 1998, AGE AGEING, V27, P73, DOI 10.1093/ageing/27.1.73; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; FRY M, 2002, SCI AGING KNOWLEDGE, pRE2; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/pnas.89.24.11759; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KRUPITZA G, 1989, BIOCHEMISTRY-US, V28, P4054, DOI 10.1021/bi00435a063; KRUPITZA G, 1989, BIOCHEMISTRY-US, V28, P2034, DOI 10.1021/bi00431a011; Kun E, 2002, J BIOL CHEM, V277, P39066, DOI 10.1074/jbc.C200410200; Lebel M, 2003, AM J PATHOL, V162, P1559, DOI 10.1016/S0002-9440(10)64290-3; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OGATA N, 1981, J BIOL CHEM, V256, P4135; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sakoda T, 1999, J MOL CELL CARDIOL, V31, P2037, DOI 10.1006/jmcc.1999.1035; SASTRY SS, 1989, BIOCHEMISTRY-US, V28, P5670, DOI 10.1021/bi00439a050; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; WesierskaGadek J, 1996, J CELL BIOCHEM, V62, P90, DOI 10.1002/(SICI)1097-4644(199607)62:1<90::AID-JCB10>3.0.CO;2-J; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	58	108	114	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13659	13667		10.1074/jbc.M311606200	http://dx.doi.org/10.1074/jbc.M311606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734561	hybrid			2022-12-27	WOS:000220478500048
J	Linke, S; Stojkoski, C; Kewley, RJ; Booker, GW; Whitelaw, ML; Peet, DJ				Linke, S; Stojkoski, C; Kewley, RJ; Booker, GW; Whitelaw, ML; Peet, DJ			Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor-inhibiting hypoxia-inducible factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYL-BETA-HYDROXYLASE; VON-HIPPEL-LINDAU; TRANSCRIPTIONAL ACTIVITY; MOLECULAR-DYNAMICS; STRUCTURAL BASIS; HIF-ALPHA; PROLYL; FACTOR-1-ALPHA; HIF-1-ALPHA; PROTEIN	The hypoxia-inducible factor alpha subunits 1 and 2 (HIF-1alpha and HIF-2alpha) are subjected to oxygen-dependent asparaginyl hydroxylation, a modification that represses the carboxyl-terminal transactivation domain (CAD) at normoxia by preventing recruitment of the p300/cAMP-response element-binding protein coactivators. This hydroxylation is performed by the novel asparaginyl hydroxylase, factor-inhibiting HIF-1' (FIH-1), of which HIF-1alpha and HIF-2alpha are the only reported substrates. Here we investigated the substrate requirements of FIH-1 by characterizing its subcellular localization and by examining amino acids within the HIF-1alpha substrate for their importance in recognition and catalysis by FIH-1. Using immunohistochemistry, we showed that both endogenous and transfected FIH-1 are primarily confined to the cytoplasm and remain there under normoxia and following treatment with the hypoxia mimetic, dipyridyl. Individual alanine mutations of seven conserved amino acids flanking the hydroxylated asparagine in HIF-1alpha revealed the importance of the valine (Val-802) adjacent to the targeted asparagine. The HIF-1alpha CAD V802A mutant exhibited a 4-fold lower V-max in enzyme assays, whereas all other mutants were hydroxylated as efficiently as the wild type HIF-1alpha CAD. Furthermore, in cell-based assays the transcriptional activity of V802A was constitutive, suggesting negligible normoxic hydroxylation in HEK293T cells, whereas the wild type and other mutants were repressed under normoxia. Molecular modeling of the HIF-1alpha CAD V802A in complex with FIH-1 predicted an alteration in asparagine positioning compared with the wild type HIF-1alpha CAD, providing an explanation for the impaired catalysis observed and confirming the importance of Val-802 in asparaginyl hydroxylation by FIH-1.	Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Peet, DJ (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	daniel.peet@adelaide.edu.au	Peet, Daniel/AAE-6698-2020	Peet, Daniel/0000-0002-6085-8936; Prior, Robyn/0000-0001-5673-3914				Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; Dinchuk JE, 2000, J BIOL CHEM, V275, P39543, DOI 10.1074/jbc.M006753200; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; *TRIP INC, 2003, SYBYL VERS 6 9; WANG QP, 1991, J BIOL CHEM, V266, P14004; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Zhang JH, 1999, ANAL BIOCHEM, V271, P137, DOI 10.1006/abio.1999.4135; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6	35	63	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14391	14397		10.1074/jbc.M313614200	http://dx.doi.org/10.1074/jbc.M313614200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734545	hybrid			2022-12-27	WOS:000220478500135
J	Motycka, TA; Bessho, T; Post, SM; Sung, P; Tomkinson, AE				Motycka, TA; Bessho, T; Post, SM; Sung, P; Tomkinson, AE			Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; REPLICATION PROTEIN-A; BREAK-INDUCED RECOMBINATION; YEAST DNA-REPAIR; RAD52 PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE; RAD10; XPF-ERCC1; ERCC1-XPF	The XPF/ERCC1 heterodimer is a DNA structure-specific endonuclease that participates in nucleotide excision repair and homology-dependent recombination reactions, including DNA single strand annealing and gene targeting. Here we show that XPF/ERCC1 is stably associated with hRad52, a recombinational repair protein, in human cell-free extracts and that these factors interact directly via the N-terminal domain of hRad52 and the XPF protein. Complex formation between hRad52 and XPF/ERCC1 concomitantly stimulates the DNA structure-specific endonuclease activity of XPF/ ERCC1 and attenuates the DNA strand annealing activity of hRad52. Our results reveal a novel role for hRad52 as a subunit of a DNA structure-specific endonuclease and are congruent with evidence implicating both hRad52 and XPF/ ERCC1 in a number of homologous recombination reactions. We propose that the ternary complex of hRad52 and XPF/ ERCC1 is the active species that processes recombination intermediates generated during the repair of DNA double strand breaks and in homology-dependent gene targeting events.	Univ Maryland, Dept Radiat Oncol, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Mol Med Grad Program, San Antonio, TX 78245 USA; Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68198 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Health San Antonio; University of Nebraska System; University of Nebraska Medical Center; Yale University	Tomkinson, AE (corresponding author), Univ Maryland, Dept Radiat Oncol, Radiat Oncol Res Lab, 655 W Baltimore St, Baltimore, MD 21201 USA.	atomkinson@som.umaryland.edu			NCI NIH HHS [P30 CA54174, T32 CA86800, P01 CA81020] Funding Source: Medline; NIEHS NIH HHS [R01 ES07061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA086800, P30CA054174, P01CA081020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adair GR, 2000, EMBO J, V19, P5552, DOI 10.1093/emboj/19.20.5552; AGUILERA A, 1989, GENETICS, V122, P503; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, P3; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BENSON FE, 1998, NATURE, V335, P337; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HOY CA, 1985, CANCER RES, V45, P1737; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Krejci L, 2003, PROG NUCLEIC ACID RE, V74, P159, DOI 10.1016/S0079-6603(03)01013-4; Krejci L, 2002, J BIOL CHEM, V277, P40132, DOI 10.1074/jbc.M206511200; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Niedernhofer LJ, 2001, EMBO J, V20, P6540, DOI 10.1093/emboj/20.22.6540; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Rodriguez K, 1996, J BIOL CHEM, V271, P20551, DOI 10.1074/jbc.271.34.20551; RON D, 1992, BIOTECHNIQUES, V13, P866; Sargent RG, 1997, P NATL ACAD SCI USA, V94, P13122, DOI 10.1073/pnas.94.24.13122; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	48	70	73	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13634	13639		10.1074/jbc.M313779200	http://dx.doi.org/10.1074/jbc.M313779200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734547	hybrid			2022-12-27	WOS:000220478500044
J	Sharma, C; Pradeep, A; Pestell, RG; Rana, B				Sharma, C; Pradeep, A; Pestell, RG; Rana, B			Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATE GENE-EXPRESSION; CELL-CYCLE; PPAR-GAMMA; HEPATOCELLULAR-CARCINOMA; CANCER CELLS; FATTY-ACIDS; DIFFERENTIAL ACTIVATION; KINASE INHIBITORS; NUCLEAR RECEPTORS; COLON-CARCINOMA	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) following exposure to PPARgamma-specific ligands resulted in growth inhibition in various carcinoma cell lines. Our aim was to elucidate the pathway of PPARgamma2 activation-mediated modulation of cyclin D1 transcription in mouse hepatocytes. To address this we utilized stable control and PPARgamma hepatocyte cell lines created via retroviral overexpression utilizing AML-12 hepatocytes. Addition of PPARgamma ligand troglitazone (TZD) activated PPARgamma2 in proliferating hepatocytes and resulted in growth arrest accompanied by a down-regulation of proliferating cell nuclear antigen, cyclin D1, and beta-catenin expression. Furthermore activation of PPARgamma2 attenuated cyclin D1 promoter activity indicating a transcriptional regulation of cyclin D1. Since beta-catenin plays a pivotal role in regulating cyclin D1 transcription, we studied whether PPARgamma2-mediated inhibition of cyclin D1 transcription involved beta-catenin. Interestingly overexpression of either wild-type or S37A mutant beta-catenin was unable to rescue PPARgamma2-mediated suppression of cyclin D1 transcription, whereas overexpression of cAMP-response element-binding protein (CREB) was capable of antagonizing this inhibitory effect of PPARgamma2. Additionally pretreatment with okadaic acid antagonized PPARgamma2-mediated inhibition of cyclin D1 transcription without any effect on beta-catenin expression. These studies also showed a TZD-mediated inhibition of total and phospho-CREBSer133 levels, CREB promoter activity, and cAMP-response element-mediated transcription in PPARgamma hepatocytes. Pretreatment of PPARgamma hepatocytes with okadaic acid, however, maintained higher total and phospho-CREBSer133 levels in the presence of TZD. These results indicated that PPARgamma2 activation inhibited cyclin D1 transcription in hepatocytes via CREB-dependent and beta-catenin-independent pathways.	Texas A&M Univ, Coll Med,Syst Hlth Sci Ctr, Cardiovasc Res Inst, Div Mol Cardiol, Temple, TX 76504 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Georgetown University	Rana, B (corresponding author), Texas A&M Univ, Coll Med,Syst Hlth Sci Ctr, Cardiovasc Res Inst, Div Mol Cardiol, 1901 S 1st St,Bldg 205, Temple, TX 76504 USA.	brana@medicine.tamu.edu			NCI NIH HHS [R01CA86072, R01CA86071, R01CA75503, R01CA70896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086072, R01CA075503, R01CA070896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Cadoret A, 2001, CANCER RES, V61, P3245; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Deane NG, 2001, CANCER RES, V61, P5389; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Delfino FJ, 1999, J BIOL CHEM, V274, P35607, DOI 10.1074/jbc.274.50.35607; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gelman L, 1999, CELL MOL LIFE SCI, V55, P932, DOI 10.1007/s000180050345; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lazzereschi D, 1997, EXP CELL RES, V234, P425, DOI 10.1006/excr.1997.3627; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Moriuchi A, 2003, BIOCHEM BIOPH RES CO, V300, P415, DOI 10.1016/S0006-291X(02)02867-X; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Qin CH, 2003, CANCER RES, V63, P958; Rahimian R, 2001, MOL CELL BIOCHEM, V224, P29, DOI 10.1023/A:1011927113563; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Rumi MAK, 2001, BRIT J CANCER, V84, P1640, DOI 10.1054/bjoc.2001.1821; Schoonjans K, 1996, J LIPID RES, V37, P907; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wahli W, 1999, ADV EXP MED BIOL, V447, P199; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	57	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					16927	16938		10.1074/jbc.M309045200	http://dx.doi.org/10.1074/jbc.M309045200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14764597	hybrid			2022-12-27	WOS:000220870400007
J	Battaile, KP; Nguyen, TV; Vockley, J; Kim, JJP				Battaile, KP; Nguyen, TV; Vockley, J; Kim, JJP			Structures of isobutyryl-CoA dehydrogenase and enzyme-product complex - Comparison with isovaleryl- and short-chain acyl-CoA dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; COENZYME-A; IDENTIFICATION; DEFICIENCY; MECHANISM; DEFECT; PURIFICATION; POLYPEPTIDE; ISOLEUCINE; RESOLUTION	The acyl-CoA dehydrogenases are a family of mitochondrial flavoproteins involved in the catabolism of fatty and amino acids. Isobutyryl-CoA dehydrogenase (IBD) is involved in the catabolism of valine and catalyzes the conversion of isobutyryl-CoA to methacrylyl-CoA. The crystal structure of IBD with and without substrate has been determined to 1.76-Angstrom resolution. The asymmetric unit contains a homotetramer with substrate/product bound in two monomers. The overall structure of IBD is similar to those of previously determined acyl-CoA dehydrogenases and consists of an NH2-terminal alpha-helical domain, a medial beta-strand domain and a C-terminal alpha-helical domain. The enzyme-bound ligand has been modeled in as the reaction product, methacrylyl-CoA. The location of Glu-376 with respect to the C-2-C-3 of the bound product and FAD confirms Glu-376 to be the catalytic base. IBD has a shorter and wider substrate-binding cavity relative to short-chain acyl-CoA dehydrogenase, permitting the optimal binding of the isobutyryl-CoA substrate. The dramatic lateral expansion of the binding cavity seen in isovaleryl-CoA dehydrogenase is not observed in IBD. The conserved tyrosine or phenylalanine that defines a side of the binding cavity in other acyl-CoA dehydrogenases is replaced by a leucine (Leu-375) in the current structure. Substrate binding changes the position of some residues lining the binding pocket as well as the position of the loop containing the catalytic glutamate and subsequent helix. Three clinical mutations have been modeled to the structure. The mutations do not affect substrate binding but instead appear to disrupt protein folding and/or stability.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA	Medical College of Wisconsin; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank, Milwaukee, WI 53226 USA.	jjkim@mcw.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457; Battaile, Kevin/0000-0003-0833-3259	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029076] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07707] Funding Source: Medline; NIDDK NIH HHS [DK54936] Funding Source: Medline; NIGMS NIH HHS [GM29076] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andresen BS, 2000, AM J HUM GENET, V67, P1095, DOI 10.1086/303105; Andresen BS, 1996, HUM MOL GENET, V5, P461, DOI 10.1093/hmg/5.4.461; Andresen BS, 1996, J INHERIT METAB DIS, V19, P169, DOI 10.1007/BF01799421; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battaile KP, 2002, J BIOL CHEM, V277, P12200, DOI 10.1074/jbc.M111296200; Beinert H., 1963, ENZYMES, P447; BESRAT A, 1969, J BIOL CHEM, V244, P1461; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CRANE FL, 1956, J BIOL CHEM, V218, P717; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; Engel P. C., 1992, CHEM BIOCH FLAVOENZY, P597; Engst S, 1999, BIOCHEMISTRY-US, V38, P257, DOI 10.1021/bi9815041; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; GHISLA S, 1984, BIOCHEMISTRY-US, V23, P3154, DOI 10.1021/bi00309a008; Gibson KM, 2000, PEDIATR RES, V47, P830, DOI 10.1203/00006450-200006000-00025; HASHIMOTO T, 1992, NEW DEV FATTY ACID O, P19; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IZAI K, 1992, J BIOL CHEM, V267, P1027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KIM JJP, 1988, P NATL ACAD SCI USA, V85, P6677, DOI 10.1073/pnas.85.18.6677; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McPherson A., 1999, CRYSTALLIZATION BIOL; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mohsen AA, 1998, BIOCHEMISTRY-US, V37, P10325, DOI 10.1021/bi973096r; Nguyen TV, 2002, MOL GENET METAB, V77, P68, DOI 10.1016/S1096-7192(02)00152-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POHL B, 1986, EUR J BIOCHEM, V160, P109, DOI 10.1111/j.1432-1033.1986.tb09946.x; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Roe CR, 1998, MOL GENET METAB, V65, P264, DOI 10.1006/mgme.1998.2758; TANAKA K, 1966, P NATL ACAD SCI USA, V56, P236, DOI 10.1073/pnas.56.1.236; TANAKA K, 1967, J BIOL CHEM, V242, P2966; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; Zhang J, 2002, BIOCHEM BIOPH RES CO, V297, P1033, DOI 10.1016/S0006-291X(02)02336-7	39	50	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16526	16534		10.1074/jbc.M400034200	http://dx.doi.org/10.1074/jbc.M400034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14752098	hybrid			2022-12-27	WOS:000220747900102
J	Dart, DA; Adams, KE; Akerman, I; Lakin, ND				Dart, DA; Adams, KE; Akerman, I; Lakin, ND			Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S-phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; EARLY EMBRYONIC LETHALITY; SINGLE-STRANDED-DNA; REPLICATION CHECKPOINT; FORK PROGRESSION; PROTEIN COMPLEX; RAD9; STRESS; MEC1; HUS1	The ataxia telangiectasia-mutated (ATM) and Rad3-related kinase (ATR) is a central component of the cell cycle checkpoint machinery required to induce cell cycle arrest in response to DNA damage. Accumulating evidence suggests a role for ATR in signaling DNA damage during S-phase. Here we show that ATR is recruited to nuclear foci induced by replication fork stalling in a manner that is dependent on the single stranded binding protein replication protein A (RPA). ATR associates with chromatin in asynchronous cell cultures, and we use a variety of approaches to examine the association of ATR with chromatin in the absence of agents that cause genotoxic stress. Under our experimental conditions, ATR exhibits a decreased affinity for chromatin in quiescent cells and cells synchronized at mitosis but an increased affinity for chromatin as cells re-enter the cell cycle. Using centrifugal elutriation to obtain cells enriched at various stages of the cell cycle, we show that ATR associates with chromatin in a cell cycle-dependent manner, specifically during S-phase. Cell cycle association of ATR with chromatin mirrors that of RPA in addition to claspin, a cell cycle checkpoint protein previously shown to be a component of the replication machinery. Furthermore, association of ATR with chromatin occurs in the absence of detectable DNA damage and cell cycle checkpoint activation. These data are consistent with a model whereby ATR is recruited to chromatin during the unperturbed cell cycle and points to a role of ATR in monitoring genome integrity during normal S-phase progression.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Lakin, ND (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	nicholas.lakin@bioch.ox.ac.uk		Akerman, Ildem/0000-0002-9875-1421				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Rothstein R, 2000, GENE DEV, V14, P1; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	44	100	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16433	16440		10.1074/jbc.M314212200	http://dx.doi.org/10.1074/jbc.M314212200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14871897	hybrid			2022-12-27	WOS:000220747900091
J	Davies, WL; Vandenberg, JI; Sayeed, RA; Trezise, AEO				Davies, WL; Vandenberg, JI; Sayeed, RA; Trezise, AEO			Cardiac expression of the cystic fibrosis transmembrane conductance regulator involves novel Exon 1 usage to produce a unique amino-terminal protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; OPEN READING FRAME; DECARBOXYLASE MESSENGER-RNA; SECONDARY STRUCTURE; MULTIDRUG-RESISTANCE; CL-CHANNELS; ANTISENSE OLIGODEOXYNUCLEOTIDE; DEVELOPMENTAL REGULATION; TRANSLATIONAL CONTROL; VENTRICULAR MYOCYTES	Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a chloride channel present in many cells. In cardiomyocytes, we report that multiple exon 1 usage and alternative splicing produces four CFTR transcripts, with different 5'-untranslated regions, CFTRTRAD-139, CFTR-1C/-1A, CFTR-1C, and CFTR-1B. CFTR transcripts containing the novel upstream exons (exons -1C, -1B, and -1A) represent more than 90% of cardiac expressed CFTR mRNA. Regulation of cardiac CFTR expression, in response to developmental and pathological stimuli, is exclusively due to the modulation of CFTR-1C and CFTR-1C/-1A expression. Upstream open reading frames have been identified in the 5'-untranslated regions of all CFTR transcripts that, in conjunction with adjacent stem-loop structures, modulate the efficiency of translation initiation at the AUG codon of the main CFTR coding region in CFTRTRAD-139 and CFTR-1C/-1A transcripts. Exon(-1A), only present in CFTR-1C/-1A transcripts, encodes an AUG codon that is in-frame with the main CFTR open reading frame, the efficient translation of which produces a novel CFTR protein isoform with a curtailed amino terminus. As the expression of this CFTR transcript parallels the spatial and temporal distribution of the cAMP-activated whole-cell current density in normal and diseased hearts, we suggest that CFTR-1C/-1A provides the molecular basis for the cardiac cAMP-activated chloride channel. Our findings provide further insight into the complex nature of in vivo CFTR expression, to which multiple mRNA transcripts, protein isoforms, and post-transcriptional regulatory mechanisms are now added.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Victor Chang Cardiac Res Inst, Sydney, NSW 2010, Australia	University of Queensland; University of Cambridge; Victor Chang Cardiac Research Institute	Trezise, AEO (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	ann.trezise@uq.edu.au	Davies, Wayne/I-1547-2014; Sayeed, Rana/S-7736-2019; Vandenberg, Jamie I/B-6608-2013	Davies, Wayne/0000-0003-0232-1812; Sayeed, Rana/0000-0002-2887-1874; Vandenberg, Jamie I/0000-0002-3859-3716				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Antzelevitch C, 1995, CARDIAC ELECTROPHYSI; BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CARROLL TP, 1995, J BIOL CHEM, V270, P11941, DOI 10.1074/jbc.270.20.11941; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; CHERON G, 1984, ACTA PAEDIATR SCAND, V73, P697, DOI 10.1111/j.1651-2227.1984.tb09999.x; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES W, 2002, THESIS U CAMBRIDGE C; GADSBY DC, 1995, ANNU REV PHYSIOL, V57, P387; Ganeshan R, 2003, J BIOL CHEM, V278, P2876, DOI 10.1074/jbc.M211790200; Guarnieri C, 1985, Adv Myocardiol, V5, P191; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HART G, 1994, CARDIOVASC RES, V28, P933, DOI 10.1093/cvr/28.7.933; Hart P, 1996, P NATL ACAD SCI USA, V93, P6343, DOI 10.1073/pnas.93.13.6343; HILL JR, 1993, J BIOL CHEM, V268, P726; HOROWITZ B, 1993, AM J PHYSIOL, V264, pH2214, DOI 10.1152/ajpheart.1993.264.6.H2214; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; James AF, 1996, CIRC RES, V79, P201, DOI 10.1161/01.RES.79.2.201; Jin XP, 2003, J BIOL CHEM, V278, P25716, DOI 10.1074/jbc.M300316200; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KOPELMAN H, 1993, J CLIN INVEST, V91, P1253, DOI 10.1172/JCI116289; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee J, 2002, NUCLEIC ACIDS RES, V30, P5110, DOI 10.1093/nar/gkf664; LEVESQUE PC, 1995, CARDIOVASC RES, V29, P336, DOI 10.1016/0008-6363(96)88590-7; LEVESQUE PC, 1992, CIRC RES, V71, P1002, DOI 10.1161/01.RES.71.4.1002; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; LYDFORD S, 2001, 44 MOL DEV; MARBAN E, 1999, MOL BASIS CARDIOVASC; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCGOWN E, 1999, 30 MOL DEV; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; Mouchel N, 2003, HUM MOL GENET, V12, P759, DOI 10.1093/hmg/ddg079; MOUNT SM, 1982, NUCLEIC ACIDS RES, V14, P1319; MULBERG AE, 1994, NEUROREPORT, V5, P1684, DOI 10.1097/00001756-199408150-00035; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 2000, NEWS PHYSIOL SCI, V15, P57; OLENYCH SG, 1999, PEDIATR PULM, V19, P185; Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roden DM, 2002, ANNU REV PHYSIOL, V64, P431, DOI 10.1146/annurev.physiol.64.083101.145105; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SOROTA S, 1991, J MOL CELL CARDIOL, V23, P1191, DOI 10.1016/0022-2828(91)90207-3; SORSCHER EJ, 1991, P NATL ACAD SCI USA, V88, P7759, DOI 10.1073/pnas.88.17.7759; SULLIVAN MM, 1986, CHEST, V90, P239, DOI 10.1378/chest.90.2.239; TAKANO M, 1992, PFLUG ARCH EUR J PHY, V420, P223, DOI 10.1007/BF00374995; TOMASELLI GF, 1994, CIRCULATION, V90, P2534, DOI 10.1161/01.CIR.90.5.2534; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; TREZISE AEO, 1993, HUM MOL GENET, V2, P801, DOI 10.1093/hmg/2.6.801; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; Vega Laso Maria R., 1993, Journal of Biological Chemistry, V268, P6453; Vilela C, 1999, EMBO J, V18, P3139, DOI 10.1093/emboj/18.11.3139; Vuillaumier S, 1997, MOL BIOL EVOL, V14, P372, DOI 10.1093/oxfordjournals.molbev.a025773; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; Wallis W., 2001, Archives of Physiology and Biochemistry, V109, P117, DOI 10.1076/apab.109.2.117.4266; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; Warth JD, 1996, CARDIOVASC RES, V31, P615; WELSH M, 1995, METABOLIC BASIS INHE; Weyler RT, 1999, AM J PHYSIOL-CELL PH, V277, pC563, DOI 10.1152/ajpcell.1999.277.3.C563; White NL, 1998, HUM MOL GENET, V7, P363, DOI 10.1093/hmg/7.3.363; Wiestner A, 1998, NAT GENET, V18, P49, DOI 10.1038/ng0198-49; Wong KR, 2000, BIOCHEM BIOPH RES CO, V278, P144, DOI 10.1006/bbrc.2000.3754; Wong KR, 2000, MECH DEVELOP, V94, P195, DOI 10.1016/S0925-4773(00)00312-9; Wong KR, 1999, AM J PHYSIOL-HEART C, V277, pH1403, DOI 10.1152/ajpheart.1999.277.4.H1403; ZHANG K, 1994, CIRC RES, V75, P133, DOI 10.1161/01.RES.75.1.133; Zuker M., 1999, RNA BIOCH BIOTECHNOL	78	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15877	15887		10.1074/jbc.M313628200	http://dx.doi.org/10.1074/jbc.M313628200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14754881	hybrid			2022-12-27	WOS:000220747900024
J	Igarashi, J; Sato, A; Kitagawa, T; Yoshimura, T; Yamauchi, S; Sagami, I; Shimizu, T				Igarashi, J; Sato, A; Kitagawa, T; Yoshimura, T; Yamauchi, S; Sagami, I; Shimizu, T			Activation of heme-regulated eukaryotic initiation factor 2 alpha kinase by nitric oxide is induced by the formation of a five-coordinate NO-heme complex - Optical absorption, electron spin resonance, and resonance raman spectral studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; CYSTATHIONINE BETA-SYNTHASE; IRON COORDINATION STRUCTURES; CYTOCHROME-C PEROXIDASE; SENSING COOA PROTEIN; X-RAY-ABSORPTION; PARAMAGNETIC-RESONANCE; EIF2-ALPHA KINASE; PROXIMAL LIGAND; CARBON-MONOXIDE	Heme-regulated eukaryotic initiation factor 2alpha kinase (HRI) regulates the synthesis of hemoglobin in reticulocytes in response to heme availability. HRI contains a tightly bound heme at the N-terminal domain. Earlier reports show that nitric oxide (NO) regulates HRI catalysis. However, the mechanism of this process remains unclear. In the present study, we utilize in vitro kinase assays, optical absorption, electron spin resonance (ESR), and resonance Raman spectra of purified full-length HRI for the first time to elucidate the regulation mechanism of NO. HRI was activated via heme upon NO binding, and the Fe(II)-HRI(NO) complex displayed 5-fold greater eukaryotic initiation factor 2alpha kinase activity than the Fe(III)-HRI complex. The Fe(III)-HRI complex exhibited a Soret peak at 418 nm and a rhombic ESR signal with g values of 2.49, 2.28, and 1.87, suggesting coordination with Cys as an axial ligand. Interestingly, optical absorption, ESR, and resonance Raman spectra of the Fe(II)-NO complex were characteristic of five-coordinate NO-heme. Spectral findings on the coordination structure of full-length HRI were distinct from those obtained for the isolated N-terminal heme-binding domain. Specifically, six-coordinate NO-Fe(II)-His was observed but not Cys-Fe(III) coordination. It is suggested that significant conformational change(s) in the protein induced by NO binding to the heme lead to HRI activation. We discuss the role of NO and heme in catalysis by HRI, focusing on heme-based sensor proteins.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Okazaki Natl Res Inst, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan; Yamagata Publ Corp Dev Ind, Inst Life Support Technol, Yamagata 9902473, Japan	Tohoku University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB)	Shimizu, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp	Igarashi, Jotaro/B-4550-2008; Igarashi, Jotaro/ABC-9207-2021	Igarashi, Jotaro/0000-0002-6165-3350; Igarashi, Jotaro/0000-0002-6165-3350				ADDISON AW, 1986, BIOCHEMISTRY-US, V25, P4104, DOI 10.1021/bi00362a018; Andrew CR, 2003, J AM CHEM SOC, V125, P9548, DOI 10.1021/ja035105r; Andrew CR, 2001, BIOCHEMISTRY-US, V40, P4115, DOI 10.1021/bi0023652; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200; Ballou DP, 2002, P NATL ACAD SCI USA, V99, P12097, DOI 10.1073/pnas.192209799; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Bauer BN, 2001, BIOCHEMISTRY-US, V40, P11543, DOI 10.1021/bi010983s; Berlanga JJ, 1998, J BIOL CHEM, V273, P32340, DOI 10.1074/jbc.273.48.32340; BOHAN TL, 1977, J MAGN RESON, V26, P109, DOI 10.1016/0022-2364(77)90240-2; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; Coyle CM, 2003, J BIOL CHEM, V278, P35384, DOI 10.1074/jbc.M301000200; Coyle CM, 2003, BIOCHEMISTRY-US, V42, P4896, DOI 10.1021/bi026395b; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; FAGARD R, 1981, P NATL ACAD SCI-BIOL, V78, P866, DOI 10.1073/pnas.78.2.866; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; Franzen S, 2002, EUR J BIOCHEM, V269, P4879, DOI 10.1046/j.1432-1033.2002.03193.x; GADSBY PMA, 1982, FEBS LETT, V150, P59, DOI 10.1016/0014-5793(82)81304-5; Green EL, 2001, BIOCHEMISTRY-US, V40, P459, DOI 10.1021/bi0010874; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Igarashi J, 2003, BBA-PROTEINS PROTEOM, V1650, P99, DOI 10.1016/S1570-9639(03)00205-X; IKEDA M, 1974, BIOCHIM BIOPHYS ACTA, V336, P15, DOI 10.1016/0005-2795(74)90378-X; Ishikawa H, 2002, J AM CHEM SOC, V124, P13696, DOI 10.1021/ja0272336; Jain R, 2003, J BIOL INORG CHEM, V8, P1, DOI 10.1007/s00775-002-0405-8; KIM IC, 1982, J BIOL CHEM, V257, P1063; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; Lawson DM, 2003, BIOCHEM SOC T, V31, P553, DOI 10.1042/BST0310553; LU Y, 1993, P NATL ACAD SCI USA, V90, P11456, DOI 10.1073/pnas.90.24.11456; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; MASKALL CS, 1977, BIOCHEM J, V167, P435, DOI 10.1042/bj1670435; Miyatake H, 1999, J BIOL CHEM, V274, P23176, DOI 10.1074/jbc.274.33.23176; Ojha S, 2000, BIOCHEMISTRY-US, V39, P10542, DOI 10.1021/bi000831h; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; OMURA T, 1984, J BIOCHEM-TOKYO, V96, P1491, DOI 10.1093/oxfordjournals.jbchem.a134978; Othman S, 1996, BIOCHEMISTRY-US, V35, P9224, DOI 10.1021/bi952818g; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; Petrov T, 2003, J NEUROL SCI, V209, P31, DOI 10.1016/S0022-510X(02)00461-6; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; Rafie-Kolpin M, 2003, BIOCHEMISTRY-US, V42, P6536, DOI 10.1021/bi034005v; Rafie-Kolpin M, 2000, J BIOL CHEM, V275, P5171, DOI 10.1074/jbc.275.7.5171; Reynolds MF, 1998, J AM CHEM SOC, V120, P9080, DOI 10.1021/ja981146p; Reynolds MF, 2000, BIOCHEMISTRY-US, V39, P388, DOI 10.1021/bi991378g; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; RUF HH, 1984, BIOCHEMISTRY-US, V23, P5300, DOI 10.1021/bi00317a031; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; Schelvis JPM, 2000, J PHYS CHEM B, V104, P10844, DOI 10.1021/jp0016434; SCHOLLER DM, 1979, J BIOL CHEM, V254, P4072; Seibold SA, 2000, BIOCHEMISTRY-US, V39, P6616, DOI 10.1021/bi0002333; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5486, DOI 10.1021/bi00415a015; SPIRO TG, 1990, BIOCHEMISTRY-US, V29, P4497, DOI 10.1021/bi00471a001; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 2001, J INORG BIOCHEM, V87, P245, DOI 10.1016/S0162-0134(01)00335-X; Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831; Tomita T, 1997, BIOCHEMISTRY-US, V36, P10155, DOI 10.1021/bi9710131; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x; Uma S, 2001, J BIOL CHEM, V276, P14875, DOI 10.1074/jbc.M011476200; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Vogel KM, 1999, J BIOL INORG CHEM, V4, P804, DOI 10.1007/s007750050354; WHYSNER JA, 1970, J BIOL CHEM, V245, P5441; YONETANI T, 1971, J BIOL CHEM, V246, P7683; YOSHIMURA T, 1991, B CHEM SOC JPN, V64, P2819, DOI 10.1246/bcsj.64.2819; YOSHIMURA T, 1986, BIOCHEMISTRY-US, V25, P2436, DOI 10.1021/bi00357a021; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	91	72	73	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15752	15762		10.1074/jbc.M310273200	http://dx.doi.org/10.1074/jbc.M310273200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14752110	Green Submitted, hybrid			2022-12-27	WOS:000220747900009
J	Saadatzadeh, MR; Bijangi-Vishehsaraei, K; Hong, P; Bergmann, H; Haneline, LS				Saadatzadeh, MR; Bijangi-Vishehsaraei, K; Hong, P; Bergmann, H; Haneline, LS			Oxidant hypersensitivity of Fanconi anemia type C-deficient cells is dependent on a redox-regulated apoptotic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE 1 ASK1; METABOLIC OXIDATIVE STRESS; S-TRANSFERASE-MU; MITOMYCIN-C; COMPLEMENTATION GROUP; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; NUCLEAR-COMPLEX; FREE-RADICALS; GENE-PRODUCT	Fanconi anemia is a genetic disorder characterized by bone marrow failure. Significant evidence supports enhanced apoptosis of hematopoietic stem/progenitor cells as a critical factor in the pathogenesis of bone marrow failure in Fanconi anemia. However, the molecular mechanism(s) responsible for the apoptotic phenotype are incompletely understood. Here, we tested whether alterations in the activation of a redox-dependent pathway may participate in the pro-apoptotic phenotype of primary Fancc -/- cells in response to oxidative stress. Our data indicate that Fancc -/- cells are highly sensitive to oxidant stimuli and undergo enhanced oxidant-mediated apoptosis compared with wild type controls. In addition, antioxidants preferentially enhanced the survival of Fancc -/- cells. Because oxidative stress activates the redox-dependent ASK1 pathway, we assessed whether Fancc -/- cells exhibited increased oxidant-induced ASK1 activation. Our results revealed ASK1 hyperactivation in H2O2-treated Fancc -/- cells. Furthermore, using small interfering RNAs to decrease ASK1 expression and a dominant negative ASK1 mutant to inhibit ASK1 kinase activity, we determined that H2O2-induced apoptosis was ASK1-dependent. Collectively, these data argue that the predisposition of Fancc -/- hematopoietic stem/progenitor cells to apoptosis is mediated in part through altered redox regulation and ASK1 hyperactivation.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Dept Immunol Microbiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Haneline, LS (corresponding author), Canc Res Inst, 1044 W Walnut St,Rm 476, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004071, P01HL053586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK049218] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL53586, K08 HLDK04071-01] Funding Source: Medline; NIDDK NIH HHS [P30 DK49218] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; ALTER B, 1998, HEMATOLOGY INFANCY C, V1, P27; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; BLIGH HFJ, 1990, CANCER RES, V50, P7789; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Clarke AA, 1997, BRIT J HAEMATOL, V96, P240, DOI 10.1046/j.1365-2141.1997.d01-2023.x; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; D'Andrea AD, 2001, NAT MED, V7, P1259, DOI 10.1038/nm1201-1259a; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Fagerlie S, 2001, EXP HEMATOL, V29, P1371, DOI 10.1016/S0301-472X(01)00755-X; Faivre L, 2000, BLOOD, V96, P4064; Freie B, 2003, BLOOD, V102, P4146, DOI 10.1182/blood-2003-03-0971; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GILLE JJP, 1987, HUM GENET, V77, P28; Gillio AP, 1997, BLOOD, V90, P105; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; GOEPTAR AR, 1994, CANCER RES, V54, P2411; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Hadjur S, 2001, BLOOD, V98, P1003, DOI 10.1182/blood.V98.4.1003; Haneline LS, 2003, BLOOD, V101, P1299, DOI 10.1182/blood-2002-08-2404; Haneline LS, 1999, BLOOD, V94, P1; Haneline LS, 1998, BLOOD, V91, P4092; Heinrich MC, 2000, BLOOD, V95, P3970; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Joenje H, 1995, BLOOD CELL MOL DIS, V21, P182, DOI 10.1006/bcmd.1995.0021; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; KORKINA LG, 1992, J LEUKOCYTE BIOL, V52, P357, DOI 10.1002/jlb.52.3.357; Kruyt FAE, 1998, BLOOD, V92, P3050, DOI 10.1182/blood.V92.9.3050.421k56_3050_3056; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Kupfer GM, 1996, BLOOD, V88, P1019; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Liebetrau W, 1997, Recent Results Cancer Res, V143, P353; Liebetrau W, 1997, MUTAGENESIS, V12, P69, DOI 10.1093/mutage/12.2.69; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LIU JM, 2000, BONE MARROW FAILURE, P47; LO TF, 1996, NAT GENET, V14, P320; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pagano G, 2003, BIOESSAYS, V25, P589, DOI 10.1002/bies.10283; Pang QS, 2002, J BIOL CHEM, V277, P49638, DOI 10.1074/jbc.M209386200; Pang QS, 2001, BLOOD, V98, P1392, DOI 10.1182/blood.V98.5.1392; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Pearl-Yafe M, 2003, BIOCHEM PHARMACOL, V65, P833, DOI 10.1016/S0006-2952(02)01620-9; Powis G, 1997, Adv Pharmacol, V38, P329; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Rhee S G, 2000, Sci STKE, V2000, ppe1; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Ruppitsch W, 1998, FEBS LETT, V422, P99, DOI 10.1016/S0014-5793(97)01608-6; SAITO H, 1993, MUTAT RES, V294, P255, DOI 10.1016/0921-8777(93)90008-5; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHINDLER D, 1988, AM J HUM GENET, V43, P429; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; TAKEUCHI T, 1993, CARCINOGENESIS, V14, P1115, DOI 10.1093/carcin/14.6.1115; Tao W, 2002, BLOOD, V100, P1679, DOI 10.1182/blood.V100.5.1679.h81702001679_1679_1688; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Yin ZM, 2000, CANCER RES, V60, P4053; Youssoufian H, 1996, J CLIN INVEST, V97, P2003, DOI 10.1172/JCI118635; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975	79	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16805	16812		10.1074/jbc.M313721200	http://dx.doi.org/10.1074/jbc.M313721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764578	hybrid			2022-12-27	WOS:000220747900133
J	Shimizu, A; Matsushita, T; Kondo, T; Inden, Y; Kojima, T; Saito, H; Hirai, M				Shimizu, A; Matsushita, T; Kondo, T; Inden, Y; Kojima, T; Saito, H; Hirai, M			Identification of the amino acid residues of the platelet glycoprotein Ib (GPIb) essential for the von Willebrand factor binding by clustered charged-to-alanine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; LEUCINE-RICH REPEATS; TYROSINE SULFATION; LIGAND-BINDING; ALPHA-CHAIN; IX COMPLEX; MUTATIONAL ANALYSES; TERMINAL DOMAIN; A1 DOMAIN; RECEPTOR	At the site of vascular injury, von Willebrand factor (VWF) mediates platelet adhesion to subendothelial connective tissue through binding to the N-terminal domain of the alpha chain of platelet glycoprotein Ib (GPIbalpha). To elucidate the molecular mechanisms of the binding, we have employed charged-to-alanine scanning mutagenesis of the soluble fragment containing the N-terminal 287 amino acids of GPIbalpha. Sixty-two charged amino acids were changed singly or in small clusters, and 38 mutant constructs were expressed in the supernatant of 293T cells. Each mutant was assayed for binding to several monoclonal antibodies for human GPIbalpha and for ristocetin-induced and botrocetin-induced binding of I-125-labeled human VWF. Mutations at Glu(128), Glu(172), and Asp(175) specifically decreased both ristocetin- and botrocetin-induced VWF binding, suggesting that these sites are important for VWF binding of platelet GPIb. Monoclonal antibody 6D1 inhibited ristocetin- and botrocetin-induced VWF binding, and a mutation at Glu(125) specifically reduced the binding to 6D1. In contrast, antibody HPL7 had no effect for VWF binding, and mutant E121A reduced the HPL7 binding. Mutations at His(12) and Glu(14) decreased the ristocetin- induced VWF binding with normal botrocetin-induced binding. Crystallographic modeling of the VWF-GPIbalpha complex indicated that Glu(128) and Asp(175) form VWF binding sites; the binding of 6D1 to Glu(125) interrupts the VWF binding of Glu(128), but HPL7 binding to Glu(121) has no effect on VWF binding. Moreover, His(12) and Glu(14) contact with Glu(613) and Arg(571) of VWF A1 domain, whose mutations had shown similar phenotype. These findings indicated the novel binding sites required for VWF binding of human GPIbalpha.	Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Nagoya Natl Hosp, Naka Ku, Nagoya, Aichi 4610001, Japan; Aichi Blood Dis Res Fdn, Moriyama Ku, Nagoya, Aichi 4630074, Japan	Nagoya University; Nagoya University	Matsushita, T (corresponding author), Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tmatsu@med.nagoya-u.ac.jp	Kojima, Tetsuhito/I-6271-2014; Kondo, Takahisa/M-4918-2014; Matsushita, Tadadshi/I-7349-2014	Kojima, Tetsuhito/0000-0002-1905-1065; 				Afshar-Kharghan V, 2000, BIOCHEMISTRY-US, V39, P3384, DOI 10.1021/bi992061j; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Clemetson KJ, 1997, THROMB HAEMOSTASIS, V78, P266; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; Fukuda K, 2002, STRUCTURE, V10, P943, DOI 10.1016/S0969-2126(02)00787-6; HANDA M, 1986, J BIOL CHEM, V261, P2579; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Li CQ, 2001, PROTEIN EXPRES PURIF, V22, P200, DOI 10.1006/prep.2001.1441; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Matsushita T, 2000, J BIOL CHEM, V275, P11044, DOI 10.1074/jbc.275.15.11044; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; MILLER JL, 1992, BLOOD, V79, P439; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; Moshfegh K, 1998, BIOCHEM BIOPH RES CO, V249, P903, DOI 10.1006/bbrc.1998.9125; MURATA M, 1991, J BIOL CHEM, V266, P15474; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Ruggeri ZM, 1997, J CLIN INVEST, V100, pS41; RUSSELL SD, 1993, BLOOD, V81, P1787; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; YUN HY, 1994, J BIOL CHEM, V269, P10946	40	12	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16285	16294		10.1074/jbc.M307230200	http://dx.doi.org/10.1074/jbc.M307230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757772	hybrid			2022-12-27	WOS:000220747900073
J	Sun, AQ; Balasubramaniyan, N; Liu, CJ; Shahid, M; Suchy, FJ				Sun, AQ; Balasubramaniyan, N; Liu, CJ; Shahid, M; Suchy, FJ			Association of the 16-kDa subunit c of vacuolar proton pump with the ileal Na+-dependent bile acid transporter - Protein-protein interaction and intracellular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; EPITHELIAL-CELLS; V-ATPASE; APICAL MEMBRANE; RAT-LIVER; RETROGRADE TRANSPORT; CYTOPLASMIC TAIL; COATED VESICLE; BINDING; CYTOSKELETON	The rat ileal apical sodium-dependent bile acid transporter (Asbt) transports conjugated bile acids in a Na+-dependent fashion and localizes specifically to the apical surface of ileal enterocytes. The mechanisms that target organic anion transporters to different domains of the ileal enterocyte plasma membrane have not been well defined. Previous studies (Sung, A.-Q., Arresa, M. A., Zeng, L., Swaby, I'K., Zhou, M. M., and Suchy, F.J. (2001) J.Biol. Chem. 276, 6825-6833) from our laboratory demonstrated that rat Asbt follows an apical sorting pathway that is brefeldin A-sensitive and insensitive to protein glycosylation, monensin treatment, and low temperature shift. Furthermore, a 14-mer signal sequence that adopts a beta-turn conformation is required for apical localization of rat Asbt. In this study, a vacuolar proton pump subunit (VPP-c, the 16-kDa subunit c of vacuolar H+-ATPase) has been identified as an interacting partner of Asbt by a bacterial two-hybrid screen. A direct protein-protein interaction between Asbt and VPP-c was confirmed in an in vitro pull-down assay and in an in vivo mammalian two-hybrid analysis. Indirect immunofluorescence confocal microscopy demonstrated that the Asbt and VPP-c colocalized in transfected COS-7 and MDCK cells. Moreover, bafilomycin A1 (a specific inhibitor of VPP) interrupted the colocalization of Asbt and VPP-c. A taurocholate influx assay and membrane biotinylation analysis showed that treatment with bafilomycin A1 resulted in a significant decrease in bile acid transport activity and the apical membrane localization of Asbt in transfected cells. Thus, these results suggest that the apical membrane localization of Asbt is mediated in part by the vacuolar proton pump associated apical sorting machinery.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; NYU, Dept Orthopaed Surg, New York, NY 10003 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University	Sun, AQ (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Box 1664,1 Gustave L Levy Pl, New York, NY 10029 USA.	An-Qiang.Sun@mssm.edu		liu, chuanju/0000-0002-7181-8032	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR09145-01] Funding Source: Medline; NICHD NIH HHS [HD20632] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adam JL, 2000, VIROLOGY, V272, P315, DOI 10.1006/viro.2000.0376; ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Brown D, 2000, J EXP BIOL, V203, P137; Caplan MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1304, DOI 10.1152/ajpgi.1997.272.6.G1304; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Forgac M, 2000, J EXP BIOL, V203, P71; Geyer M, 2002, J BIOL CHEM, V277, P28521, DOI 10.1074/jbc.M200522200; Geyer M, 2002, MOL BIOL CELL, V13, P2045, DOI 10.1091/mbc.02-02-0026; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; Jansen EJR, 1998, J CELL SCI, V111, P2999; Kamal A, 2000, CURR OPIN CELL BIOL, V12, P503, DOI 10.1016/S0955-0674(00)00123-X; Karpen SJ, 2002, J HEPATOL, V36, P832, DOI 10.1016/S0168-8278(02)00129-0; Kipp H, 2000, SEMIN LIVER DIS, V20, P339, DOI 10.1055/s-2000-9388; KORALNIK IJ, 1995, J GEN VIROL, V76, P1909, DOI 10.1099/0022-1317-76-8-1909; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Mandic R, 2001, MOL BIOL CELL, V12, P463, DOI 10.1091/mbc.12.2.463; Maquoi E, 2003, BIOCHEM J, V373, P19, DOI 10.1042/BJ20030170; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; Milewski MI, 2001, J CELL SCI, V114, P719; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; Montagnani M, 2001, SCAND J GASTROENTERO, V36, P1077, DOI 10.1080/003655201750422693; NAKHOUL NL, 2002, J NEPHROL S5, V15, P22; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; Riento K, 2000, J BIOL CHEM, V275, P13476, DOI 10.1074/jbc.275.18.13476; Saunders C, 1997, J BIOL CHEM, V272, P19035, DOI 10.1074/jbc.272.30.19035; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Sun AQ, 1998, AM J PHYSIOL-GASTR L, V275, pG1045, DOI 10.1152/ajpgi.1998.275.5.G1045; Sun AQ, 2003, J BIOL CHEM, V278, P4000, DOI 10.1074/jbc.M207163200; Sun AQ, 2001, J BIOL CHEM, V276, P6825, DOI 10.1074/jbc.M008797200; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; Takeda T, 2003, AM J PHYSIOL-CELL PH, V284, pC1105, DOI 10.1152/ajpcell.00514.2002; vanWeert AWM, 1997, EUR J CELL BIOL, V74, P417; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; YILLA M, 1993, J BIOL CHEM, V268, P19092; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	44	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16295	16300		10.1074/jbc.M312838200	http://dx.doi.org/10.1074/jbc.M312838200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14752118	hybrid			2022-12-27	WOS:000220747900074
J	van den Burg, HA; Spronk, CAEM; Boeren, S; Kennedy, MA; Vissers, JPC; Vuister, GW; de Wit, PJGM; Vervoort, J				van den Burg, HA; Spronk, CAEM; Boeren, S; Kennedy, MA; Vissers, JPC; Vuister, GW; de Wit, PJGM; Vervoort, J			Binding of the AVR4 elicitor of Cladosporium fulvum to chitotriose units is facilitated by positive allosteric protein-protein interactions - The chitin-binding site of AVR4 represents a novel binding site on the folding scaffold shared between the invertebrate and the plant chitin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; URTICA-DIOICA AGGLUTININ; PATHOGENESIS-RELATED PROTEINS; NUCLEAR MAGNETIC-RESONANCE; N-ACETYLGLUCOSAMINE; CARBOHYDRATE INTERACTIONS; ANTIFUNGAL ACTIVITY; CF-4-MEDIATED RESISTANCE; CONFORMATIONAL-ANALYSIS; TOBACCO CHITINASES	The attack of fungal cell walls by plant chitinases is an important plant defense response to fungal infection. Anti-fungal activity of plant chitinases is largely restricted to chitinases that contain a noncatalytic, plant-specific chitin-binding domain (ChBD) ( also called Hevein domain). Current data confirm that the race-specific elicitor AVR4 of the tomato pathogen Cladosporium fulvum can protect fungi against plant chitinases, which is based on the presence of a novel type of ChBD in AVR4 that was first identified in invertebrates. Although these two classes of ChBDs ( Hevein and invertebrate) are sequentially unrelated, they share structural homology. Here, we show that the chitin-binding sites of these two classes of ChBDs have different topologies and characteristics. The K(D), DeltaH, and DeltaS values obtained for the interaction between AVR4 and chito-oligomers are comparable with those obtained for Hevein. However, the binding site of AVR4 is larger than that of Hevein, i.e. AVR4 interacts strictly with chitotriose, whereas Hevein can also interact with the monomer N-acetylglucosamine. Moreover, binding of additional AVR4 molecules to chitin occurs through positive cooperative protein-protein interactions. By this mechanism AVR4 is likely to effectively shield chitin on the fungal cell wall, preventing the cell wall from being degraded by plant chitinases.	Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Univ Wageningen & Res Ctr, Phytopathol Lab, NL-6703 HA Wageningen, Netherlands; Univ Nijmegen, Dept Biophys Chem, NL-6252 ED Nijmegen, Netherlands; Waters corp, MS Technol, NL-1320 AC Almere, Netherlands	Wageningen University & Research; Wageningen University & Research; Radboud University Nijmegen	Vervoort, J (corresponding author), Univ Wageningen & Res Ctr, Biochem Lab, Dreyenlaan 3, NL-6703 HA Wageningen, Netherlands.	Jacques.vervoort@wur.nl	de Wit, Pierre/A-1998-2013; de Wit, Pierre J. G.M./CAI-9966-2022	de Wit, Pierre/0000-0002-4208-288X; van den Burg, Harrold/0000-0003-4142-374X; Vuister, Geerten/0000-0001-6172-5097				Asensio JL, 2000, CHEM BIOL, V7, P529, DOI 10.1016/S1074-5521(00)00136-8; ASENSIO JL, 1995, EUR J BIOCHEM, V230, P621; Asensio JL, 2000, PROTEINS, V40, P218, DOI 10.1002/(SICI)1097-0134(20000801)40:2<218::AID-PROT50>3.3.CO;2-G; BAINS G, 1992, BIOCHEMISTRY-US, V31, P12624, DOI 10.1021/bi00165a012; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BEINTEMA JJ, 1994, FEBS LETT, V350, P159, DOI 10.1016/0014-5793(94)00753-5; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; BROEKAERT WF, 1989, SCIENCE, V245, P1100, DOI 10.1126/science.245.4922.1100; Brunner F, 1998, PLANT J, V14, P225, DOI 10.1046/j.1365-313X.1998.00116.x; Cai XZ, 2001, MOL PLANT PATHOL, V2, P77, DOI 10.1046/j.1364-3703.2001.00053.x; Chaires JB, 1997, BIOPHYS CHEM, V64, P15, DOI 10.1016/S0301-4622(96)02205-3; Chen YL, 1998, RAPID COMMUN MASS SP, V12, P1003, DOI 10.1002/(SICI)1097-0231(19980815)12:15<1003::AID-RCM275>3.0.CO;2-#; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; Coutinho PM, 1999, ROY SOC CH, P3; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; Espinosa JF, 2000, EUR J BIOCHEM, V267, P3965, DOI 10.1046/j.1432-1327.2000.01415.x; GarciaHernandez E, 1997, PROTEINS, V29, P467, DOI 10.1002/(SICI)1097-0134(199712)29:4<467::AID-PROT7>3.0.CO;2-5; Harata K, 2000, J MOL BIOL, V297, P673, DOI 10.1006/jmbi.2000.3594; Hemmi H, 2003, J BIOL CHEM, V278, P22820, DOI 10.1074/jbc.M301025200; HEUSING JE, 1991, PHYTOCHEMISTRY, V30, P3565; HOM K, 1995, FEBS LETT, V361, P157, DOI 10.1016/0014-5793(95)00133-T; Horn JR, 2001, BIOCHEMISTRY-US, V40, P1774, DOI 10.1021/bi002408e; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; JOOSTEN MHAJ, 1995, PHYSIOL MOL PLANT P, V46, P45, DOI 10.1006/pmpp.1995.1004; Joosten MHAJ, 1997, PLANT CELL, V9, P367; Joosten MHAJ, 1999, ANNU REV PHYTOPATHOL, V37, P335, DOI 10.1146/annurev.phyto.37.1.335; JOOSTEN MHAJ, 1989, PLANT PHYSIOL, V89, P945, DOI 10.1104/pp.89.3.945; KRONIS KA, 1985, BIOCHEMISTRY-US, V24, P834, DOI 10.1021/bi00325a004; KRONIS KA, 1985, BIOCHEMISTRY-US, V24, P826, DOI 10.1021/bi00325a003; Lee RT, 1998, GLYCOCONJUGATE J, V15, P649, DOI 10.1023/A:1006976129458; LIAN Y, 1993, NMR MARCOMOLECULES; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Mahe E, 1998, J PEPT RES, V52, P482; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MELCHERS LS, 1994, PLANT J, V5, P469, DOI 10.1046/j.1365-313X.1994.5040469.x; Muraki M, 2002, PROTEIN PEPTIDE LETT, V9, P195, DOI 10.2174/0929866023408751; Nesatyy VJ, 2001, J MASS SPECTROM, V36, P950, DOI 10.1002/jms.199; Neuhaus JM, 1999, PATHOGENESIS-RELATED PROTEINS IN PLANTS, P77; Ohno T, 1996, J BACTERIOL, V178, P5065, DOI 10.1128/jb.178.17.5065-5070.1996; PASSARINHO P, 2002, ARABIDOPSIS BOOK, P25; PONSTEIN AS, 1994, PLANT PHYSIOL, V104, P109, DOI 10.1104/pp.104.1.109; PRIVAT JP, 1974, EUR J BIOCHEM, V47, P5, DOI 10.1111/j.1432-1033.1974.tb03661.x; Punja ZK, 2001, CAN J PLANT PATHOL, V23, P216; Saul FA, 2000, STRUCTURE, V8, P593, DOI 10.1016/S0969-2126(00)00142-8; SEARLE MS, 1992, J AM CHEM SOC, V114, P10690, DOI 10.1021/ja00053a002; SELABUURLAGE MB, 1993, PLANT PHYSIOL, V101, P857, DOI 10.1104/pp.101.3.857; Shen ZC, 1999, J MOL EVOL, V48, P341, DOI 10.1007/PL00006478; STINTZI A, 1993, BIOCHIMIE, V75, P687, DOI 10.1016/0300-9084(93)90100-7; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; van den Burg HA, 2003, J BIOL CHEM, V278, P27340, DOI 10.1074/jbc.M212196200; van den Burg HA, 2001, J BIOMOL NMR, V20, P251, DOI 10.1023/A:1011206701288; van den Hooven HW, 1999, EUR J BIOCHEM, V264, P9, DOI 10.1046/j.1432-1327.1999.00503.x; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; Westerink N, 2002, MOL PLANT MICROBE IN, V15, P1219, DOI 10.1094/MPMI.2002.15.12.1219; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; Wuthrich K, 1986, NMR PROTEINS NUCL AC	61	62	62	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16786	16796		10.1074/jbc.M312594200	http://dx.doi.org/10.1074/jbc.M312594200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14769793	hybrid			2022-12-27	WOS:000220747900131
J	Tsukiyama-Kohara, K; Tone, S; Maruyama, I; Inoue, K; Katsume, A; Nuriya, H; Ohmori, H; Ohkawa, J; Taira, K; Hoshikawa, Y; Shibasaki, F; Reth, M; Minatogawa, Y; Kohara, M				Tsukiyama-Kohara, K; Tone, S; Maruyama, I; Inoue, K; Katsume, A; Nuriya, H; Ohmori, H; Ohkawa, J; Taira, K; Hoshikawa, Y; Shibasaki, F; Reth, M; Minatogawa, Y; Kohara, M			Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITORS; TRANSFORMS NIH3T3 CELLS; RAT EMBRYO FIBROBLASTS; CORE PROTEIN; HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA PROTEIN; INTERFERON-ALPHA; MAMMALIAN-CELLS; CYCLE CONTROL; LIVER-CANCER	Hepatitis C virus (HCV) causes persistent infection in hepatocytes, and this infection is, in turn, strongly associated with the development of hepatocellular carcinoma. To clarify the mechanisms underlying these effects, we established a Cre/loxP conditional expression system for the precisely self-trimmed HCV genome in human liver cells. Passage of hepatocytes expressing replicable full-length HCV (HCR6-Rz) RNA caused upregulation of anchorage-independent growth after 44 days. In contrast, hepatocytes expressing HCV structural, nonstructural, or all viral proteins showed no significant changes after passage for 44 days. Only cells expressing HCR6-Rz passaged for 44 days displayed acceleration of CDK activity, hyperphosphorylation of Rb, and E2F activation. These results demonstrate that full genome HCV expression up-regulates the CDK-Rb-E2F pathway much more effectively than HCV proteins during passage.	Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Cell Physiol, Bunkyo Ku, Tokyo 1138613, Japan; Kawasaki Med Sch, Dept Biochem, Kurashiki, Okayama 7010192, Japan; Showa Univ, Fujigaoka Hosp, Div Gastroenterol, Aoba Ku, Yokohama, Kanagawa 2278501, Japan; Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Lab, Gotemba, Shizuoka 412, Japan; NIH, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Kawasaki Medical School; Showa University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; National Institute of Health Sciences - Japan; University of Tokyo; Max Planck Society	Kohara, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	mkohara@rinshoken.or.jp	Tone, Shigenobu/L-2694-2019					Blight KJ, 2003, J VIROL, V77, P3181, DOI 10.1128/JVI.77.5.3181-3190.2003; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; Friebe P, 2001, J VIROL, V75, P12047, DOI 10.1128/JVI.75.24.12047-12057.2001; GRANA X, 1995, ONCOGENE, V11, P211; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Honda A, 1999, J MED VIROL, V59, P281, DOI 10.1002/(SICI)1096-9071(199911)59:3<281::AID-JMV4>3.0.CO;2-S; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Hui AM, 1998, HEPATO-GASTROENTEROL, V45, P1635; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kirch HC, 1997, EUR J BIOCHEM, V246, P736, DOI 10.1111/j.1432-1033.1997.00736.x; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma Y, 1999, CANCER RES, V59, P5341; Machida K, 2001, J BIOL CHEM, V276, P12140, DOI 10.1074/jbc.M010137200; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; O'Brien V, 1998, ONCOGENE, V17, P293, DOI 10.1038/sj.onc.1201937; Park JS, 2000, BIOCHEM BIOPH RES CO, V267, P581, DOI 10.1006/bbrc.1999.1999; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Servant MJ, 2002, BIOCHEM PHARMACOL, V64, P985, DOI 10.1016/S0006-2952(02)01165-6; Shibata M, 1998, LANCET, V351, P1773, DOI 10.1016/S0140-6736(97)08002-1; SHIMAYAMA T, 1995, BIOCHEMISTRY-US, V34, P3649, DOI 10.1021/bi00011a020; SUH YA, 1992, NUCLEIC ACIDS RES, V20, P747, DOI 10.1093/nar/20.4.747; Takeuchi T, 1999, GASTROENTEROLOGY, V116, P636, DOI 10.1016/S0016-5085(99)70185-X; Tanaka T, 1995, J HEPATOL, V23, P742, DOI 10.1016/0168-8278(95)80043-3; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; Wakita T, 1998, J BIOL CHEM, V273, P9001, DOI 10.1074/jbc.273.15.9001; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Yin MB, 1997, MOL PHARMACOL, V51, P630, DOI 10.1124/mol.51.4.630; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	51	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14531	14541		10.1074/jbc.M312822200	http://dx.doi.org/10.1074/jbc.M312822200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747471	hybrid			2022-12-27	WOS:000220594700010
J	Chen, WJ; Lin, JK				Chen, WJ; Lin, JK			Induction of G(1) arrest and apoptosis in human Jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27(Kip1), p21(Cip1/WAF1), and Bax proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBERS; BETA-D-GLUCOSE; DOWN-REGULATION; CALPAIN INHIBITOR; IN-VITRO; 20 S; ACTIVATION; PATHWAY	Pentagalloylglucose, which is found in many medicinal plants, can arrest the cell cycle at G(1) phase through down-regulation of cyclin-dependent kinases 2 and 4 and up-regulation of the cyclin-dependent kinase inhibitors p27(Kip1) and p21(Cip1/WAF1) in human breast cancer cells. Pentagalloylglucose also induces apoptosis in human leukemic cells. However, the mechanisms by which pentagalloylglucose induces these effects is unclear. We now show that pentagalloylglucose inhibits the activities of purified 20 and 26 S proteasomes in vitro, the 26 S proteasome in Jurkat T cell lysates, and chymotrypsin-like activity of the 26 S proteasome in intact Jurkat T cells. The turnover of p27(Kip1) and p21(Cip1/WAF1), which is necessary for cell cycle progression mediated by proteasome degradation, was disrupted by treatment of human Jurkat T cells with pentagalloylglucose. This was shown by cycloheximide treatment and in vivo pulse-chase labeling experiments, and this effect correlated with the arrest of proliferation of Jurkat T cells at G(1). Inhibition of the proteasome by pentagalloylglucose and by the proteasome inhibitor MG132 caused accumulation of ubiquitin-tagged proteins in Jurkat T cells. The addition of pentagalloylglucose to Jurkat T cells enhanced the stability of the proteasome substrate Bax and increased cytochrome c release and apoptosis. Our findings suggest a mechanism for the effect of pentagalloylglucose on the cell cycle in human leukemic cells: that pentagalloylglucose down-regulates proteasome-mediated pathways because it is a proteasome inhibitor.	Natl Taiwan Univ, Coll Med, Inst Biochem & Cell Biol, Taipei, Taiwan	National Taiwan University	Lin, JK (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Cell Biol, No 1,Sect 1,Jen Ai Rd, Taipei, Taiwan.	jklin@ha.mc.ntu.edu.tw						ADACHI H, 1989, CHEM PHARM BULL, V37, P1341; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adams J, 1998, BIOORG MED CHEM LETT, V8, P333, DOI 10.1016/S0960-894X(98)00029-8; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CANNELL RJP, 1998, BIOCHEM J, V255, P937; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN WJ, BIOCH PHARM, V65, P1777; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Feldman KS, 2001, BIOORG MED CHEM LETT, V11, P1813, DOI 10.1016/S0960-894X(01)00332-8; Gardner RC, 2000, BIOCHEM J, V346, P447, DOI 10.1042/0264-6021:3460447; Goto H, 1996, PLANTA MED, V62, P436, DOI 10.1055/s-2006-957934; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAYASHI T, 1989, J NAT PROD, V52, P210, DOI 10.1021/np50061a035; Hideshima T, 2001, CANCER RES, V61, P3071; Ho LL, 2002, EUR J PHARMACOL, V453, P149, DOI 10.1016/S0014-2999(02)02340-3; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Ikebe T, 1998, INT J CANCER, V77, P578; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Konishi K, 1999, BIOL PHARM BULL, V22, P240, DOI 10.1248/bpb.22.240; KONISHI K, 1990, CHEM PHARM BULL, V38, P474, DOI 10.1248/cpb.38.474; KONISHI K, 1993, BIOL PHARM BULL, V16, P716; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; LIN JH, 1990, CHEM PHARM BULL, V38, P1218, DOI 10.1248/cpb.38.1218; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Nam S, 2001, CANCER EPIDEM BIOMAR, V10, P1083; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Niedermann G, 1999, IMMUNOL REV, V172, P29, DOI 10.1111/j.1600-065X.1999.tb01354.x; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Oikawa T, 1998, BIOCHEM BIOPH RES CO, V246, P243, DOI 10.1006/bbrc.1998.8604; Ono K, 2000, CLIN CHIM ACTA, V290, P159, DOI 10.1016/S0009-8981(99)00184-9; Orlowski M, 2000, ARCH BIOCHEM BIOPHYS, V383, P1, DOI 10.1006/abbi.2000.2036; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pan MH, 2000, BIOCHEM PHARMACOL, V59, P357, DOI 10.1016/S0006-2952(99)00335-4; Pan MH, 1999, EUR J PHARMACOL, V381, P171, DOI 10.1016/S0014-2999(99)00549-X; Pan MH, 2001, J AGR FOOD CHEM, V49, P1464, DOI 10.1021/jf001129v; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PINTER M, 1994, NEUROSCI LETT, V170, P91, DOI 10.1016/0304-3940(94)90246-1; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; SUGAYA A, 1991, J ETHNOPHARMACOL, V33, P159, DOI 10.1016/0378-8741(91)90174-C; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Wang IK, 2000, PHARMACOL TOXICOL, V86, P83, DOI 10.1034/j.1600-0773.2000.d01-16.x	62	49	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13496	13505		10.1074/jbc.M212390200	http://dx.doi.org/10.1074/jbc.M212390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726525	hybrid			2022-12-27	WOS:000220478500028
J	Kesti, T; McDonald, WH; Yates, JR; Wittenberg, C				Kesti, T; McDonald, WH; Yates, JR; Wittenberg, C			Cell cycle-dependent phosphorylation of the DNA polymerase epsilon subunit, Dpb2, by the Cdc28 cyclin-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PRIMASE B-SUBUNIT; S-PHASE; CHROMOSOMAL DNA; SCHIZOSACCHAROMYCES-POMBE; LIGASE-I; CATALYTIC DOMAINS; FISSION YEAST; BUDDING YEAST; 3RD SUBUNIT	DNA polymerase epsilon (Polepsilon), one of the three major eukaryotic replicative polymerases, is comprised of the essential catalytic subunit, called Pol2 in budding yeast, and three accessory subunits, only one of which, Dpb2, is essential. Polepsilon is recruited to replication origins during late G(1) phase prior to activation of replication. In this work we show that the budding yeast Dpb2 is phosphorylated in a cell cycle-dependent manner during late G(1) phase. Phosphorylation results in the appearance of a lower mobility species. The appearance of that species in vivo is dependent upon the Cdc28 cyclin-dependent protein kinase (CDK), which can directly phosphorylate Dpb2 in vitro. Either G(1) cyclin (Cln) or B-type cyclin (Clb)-associated CDK is sufficient for phosphorylation. Mapping of phosphorylation sites by mass spectrometry using a novel gel-based proteolysis protocol shows that, of the three consensus CDK phosphorylation sites, at least two, Ser-144 and Ser-616, are phosphorylated in vivo. The Cdc28 CDK phosphorylates only Ser-144 in vitro. Using site-directed mutagenesis, we show that Ser-144 is sufficient for the formation of the lower mobility form of Dpb2 in vivo. In contrast, Ser-616 appears not to be phosphorylated by Cdc28. Finally, inactivation of all three CDK consensus sites in Dpb2 results in a synthetic phenotype with the pol2-11 mutation, leading to decreased spore viability, slow growth, and increased thermosensitivity. We suggest that phosphorylation of Dpb2 during late G(1) phase at CDK consensus sites facilitates the interaction with Pol2 or the activity of Polepsilon.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wittenberg, C (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-3,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		McDonald, W. Hayes/B-4109-2016	McDonald, W. Hayes/0000-0002-3510-426X				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Dehde S, 2001, MOL CELL BIOL, V21, P2581, DOI 10.1128/MCB.21.7.2581-2593.2001; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; DESHAIES RJ, 1995, P NATL ACAD SCI USA, V92, P1182, DOI 10.1073/pnas.92.4.1182; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; Edwards S, 2003, MOL CELL BIOL, V23, P2733, DOI 10.1128/MCB.23.8.2733-2748.2003; Feng WY, 2003, MOL BIOL CELL, V14, P3427, DOI 10.1091/mbc.E03-02-0088; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Ferrari G, 2003, J BIOL CHEM, V278, P37761, DOI 10.1074/jbc.M304462200; Ferrari M, 1996, J BIOL CHEM, V271, P8661, DOI 10.1074/jbc.271.15.8661; FOIANI M, 1995, MOL CELL BIOL, V15, P883; Haase SB, 2002, CELL CYCLE, V1, P132, DOI 10.4161/cc.1.2.114; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Henneke G, 2003, EMBO REP, V4, P252, DOI 10.1038/sj.embor.embor774; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; Ishimi Y, 2003, J BIOL CHEM, V278, P24644, DOI 10.1074/jbc.M213252200; Kawasaki Y, 2001, MOL CELLS, V12, P277; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Makiniemi M, 1999, TRENDS BIOCHEM SCI, V24, P14, DOI 10.1016/S0968-0004(98)01327-9; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masuda T, 2003, GENES CELLS, V8, P145, DOI 10.1046/j.1365-2443.2003.00621.x; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Noguchi E, 2002, CURR BIOL, V12, P599, DOI 10.1016/S0960-9822(02)00739-X; Ohya T, 2000, NUCLEIC ACIDS RES, V28, P3846, DOI 10.1093/nar/28.20.3846; Ohya T, 2002, J BIOL CHEM, V277, P28099, DOI 10.1074/jbc.M111573200; PARK H, 1995, NUCLEIC ACIDS RES, V23, P4337, DOI 10.1093/nar/23.21.4337; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Sugino A, 1998, GENES CELLS, V3, P99, DOI 10.1046/j.1365-2443.1998.00169.x; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; ZENG XR, 1994, J BIOL CHEM, V269, P24027; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	62	28	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14245	14255		10.1074/jbc.M313289200	http://dx.doi.org/10.1074/jbc.M313289200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14747467	hybrid			2022-12-27	WOS:000220478500118
J	Murray, DS; Schumacher, MA; Brennan, RG				Murray, DS; Schumacher, MA; Brennan, RG			Crystal structures of QacR-diamidine complexes reveal additional multidrug-binding modes and a novel mechanism of drug charge neutralization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; EFFLUX PUMP; DNA-BINDING; PROTEIN; RECOGNITION; RESISTANCE; CHEMISTRY; RESIDUES	The Staphylococcus aureus multidrug-binding protein QacR represses transcription of the plasmid-encoded membrane protein QacA, a multidrug efflux transporter. QacR is induced by multiple structurally dissimilar monovalent and bivalent cationic lipophilic compounds, many of which are effluxed from the cell by QacA via the proton motive force. The multidrug-binding pocket of QacR has been shown to be quite extensive and features several glutamates and multiple aromatic residues. To date, the structure of only one QacR-bivalent cationic drug complex ( that of QacR bound to dequalinium) has been determined, and how other longer or shorter bivalent cationic compounds bind is unknown. Here we report the crystal structures of QacR bound to two cytotoxic bivalent diamidines, pentamidine and hexamidine. These compounds are structurally similar, differing by only one methylene carbon in the alkyl chain linker. However, this small difference results in very dissimilar binding modes. Similar to dequalinium, hexamidine spans the multidrug-binding pocket, and its positively charged benzamidine groups are neutralized by residues Glu-57 and Glu-120. Pentamidine binds QacR in a novel fashion whereby one of its benzamidine groups interacts with residue Glu-63, and the other is neutralized by carbonyl and side chain oxygen atoms. Thus, these structures demonstrate that a formal negative charge is not a prerequisite for binding positively charged drugs and underscore the versatility of the QacR and, likely, all multidrug-binding pockets.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Brennan, RG (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	brennanr@ohsu.edu		Brennan, Richard/0000-0001-7647-485X	NIAID NIH HHS [AI48593] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048593] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casewell M, 2003, J ANTIMICROB CHEMOTH, V52, P159, DOI 10.1093/jac/dkg313; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Levy SB, 2001, CLIN INFECT DIS, V33, pS124, DOI 10.1086/321837; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; LITTLEJOHN TG, 1992, FEMS MICROBIOL LETT, V95, P259; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McKeegan KS, 2003, TRENDS MICROBIOL, V11, P21, DOI 10.1016/S0966-842X(02)00010-0; Mitchell BA, 1998, ANTIMICROB AGENTS CH, V42, P475; Neyfakh AA, 2002, MOL MICROBIOL, V44, P1123, DOI 10.1046/j.1365-2958.2002.02965.x; Rayment I, 1997, METHOD ENZYMOL, V276, P171, DOI 10.1016/S0076-6879(97)76058-0; Saier MH, 1998, FASEB J, V12, P265, DOI 10.1096/fasebj.12.3.265; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2002, MOL MICROBIOL, V45, P885, DOI 10.1046/j.1365-2958.2002.03039.x; Tegoni M, 2000, BBA-PROTEIN STRUCT M, V1482, P229, DOI 10.1016/S0167-4838(00)00167-9; Tsuzuki S, 2000, J AM CHEM SOC, V122, P11450, DOI 10.1021/ja001901a; Vincent F, 2000, J MOL BIOL, V300, P127, DOI 10.1006/jmbi.2000.3820; Yu EW, 2003, J BACTERIOL, V185, P5657, DOI 10.1128/JB.185.19.5657-5664.2003; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6; ZHELEZNOVAHELDW.EE, 2001, NATURE, V409, P378; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	33	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14365	14371		10.1074/jbc.M313870200	http://dx.doi.org/10.1074/jbc.M313870200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726520	hybrid			2022-12-27	WOS:000220478500132
J	Sprague, ER; Martin, WL; Bjorkman, PJ				Sprague, ER; Martin, WL; Bjorkman, PJ			pH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE-gI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARICELLA-ZOSTER-VIRUS; TRANS-GOLGI NETWORK; I-RELATED RECEPTOR; PLASMON RESONANCE BIOSENSORS; IMMUNOGLOBULIN-G IGG; PSEUDORABIES VIRUS; VIRAL GLYCOPROTEINS; CRYSTAL-STRUCTURE; CYTOPLASMIC TAIL; INFECTED-CELLS	Herpes simplex virus type 1 encodes two glycoproteins, gE and gI, that form a heterodimer on the surface of virions and infected cells. The gE-gI heterodimer has been implicated in cell-to-cell spread of virus and is a receptor for the Fc fragment of IgG. Previous studies localized the gE-gI-binding site on human IgG to a region near the interface between the C(H)2 and C(H)3 domains of Fc, which also serves as the binding site for bacterial and mammalian Fc receptors. Although there are two potential gE-gI-binding sites per Fc homodimer, only one gE-gI heterodimer binds per IgG in gel filtration experiments. Here we report production of recombinant human Fc molecules that contain zero, one, or two potential gE-gI-binding sites and use them in analytical ultracentrifugation experiments to show that two gE-gI heterodimers can bind to each Fc. Further characterization of the gE-gI interaction with Fc reveals a sharp pH dependence of binding, with K-D values of similar to 340 and similar to 930 nM for the first and second binding events, respectively, at the slightly basic pH of the cell surface (pH 7.4), but undetectable binding at pH 6.0. This strongly pH-dependent interaction suggests a physiological role for gE-gI dissociation from IgG within acidic intracellular compartments, consistent with a mechanism whereby herpes simplex virus promotes intracellular degradation of anti-viral antibodies.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Bjorkman, PJ (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	bjorkman@caltech.edu		Sprague, Elizabeth/0000-0002-1603-3750				ADLER R, 1978, INFECT IMMUN, V21, P442, DOI 10.1128/IAI.21.2.442-447.1978; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Alconada A, 1999, J VIROL, V73, P377, DOI 10.1128/JVI.73.1.377-387.1999; Bebbington C. R., 1987, DNA CLONING PRACTICA, P163; BROWN VI, 1991, DNA CELL BIOL, V10, P399, DOI 10.1089/dna.1991.10.399; Chapman TL, 1999, J BIOL CHEM, V274, P6911, DOI 10.1074/jbc.274.11.6911; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; DOWLER KW, 1984, J MED VIROL, V13, P251, DOI 10.1002/jmv.1890130307; DUBIN G, 1991, J VIROL, V65, P7046, DOI 10.1128/JVI.65.12.7046-7050.1991; DUBIN G, 1990, J VIROL, V64, P2725, DOI 10.1128/JVI.64.6.2725-2731.1990; Favoreel HW, 2000, VIROLOGY, V267, P151, DOI 10.1006/viro.1999.0132; Favoreel HW, 1997, J VIROL, V71, P8254, DOI 10.1128/JVI.71.11.8254-8261.1997; FRANK I, 1989, J VIROL, V63, P4479, DOI 10.1128/JVI.63.11.4479-4488.1989; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; GHIRLANDO R, 1995, BIOCHEMISTRY-US, V34, P13320, DOI 10.1021/bi00041a007; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; JOHANSSON PJH, 1994, IMMUNOLOGY, V83, P631; JOHANSSON PJH, 1984, J VIROL, V50, P796, DOI 10.1128/JVI.50.3.796-804.1984; JOHANSSON PJH, 1989, IMMUNOLOGY, V66, P8; JOHANSSON PJH, 1985, J VIROL, V56, P489, DOI 10.1128/JVI.56.2.489-494.1985; JOHANSSON PJH, 1986, IMMUNOLOGY, V58, P251; JOHNSON DC, 1987, J VIROL, V61, P2208, DOI 10.1128/JVI.61.7.2208-2216.1987; JOHNSON DC, 1988, J VIROL, V62, P1347, DOI 10.1128/JVI.62.4.1347-1354.1988; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; LITWIN V, 1992, J VIROL, V66, P3643, DOI 10.1128/JVI.66.6.3643-3651.1992; Martin WL, 1999, BIOCHEMISTRY-US, V38, P12639, DOI 10.1021/bi9913505; Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Nagashunmugam T, 1998, J VIROL, V72, P5351, DOI 10.1128/JVI.72.7.5351-5359.1998; Olson JK, 1997, J VIROL, V71, P4042, DOI 10.1128/JVI.71.5.4042-4054.1997; Olson JK, 1998, J VIROL, V72, P1542, DOI 10.1128/JVI.72.2.1542-1551.1998; Olson JK, 1997, J VIROL, V71, P110, DOI 10.1128/JVI.71.1.110-119.1997; Pasieka TJ, 2003, J VIROL, V77, P4191, DOI 10.1128/JVI.77.7.4191-4204.2003; Popov S, 1996, MOL IMMUNOL, V33, P521, DOI 10.1016/0161-5890(96)00004-1; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; Rizvi SM, 2001, J VIROL, V75, P11897, DOI 10.1128/JVI.75.23.11897-11901.2001; Sanchez LM, 1999, BIOCHEMISTRY-US, V38, P9471, DOI 10.1021/bi9907330; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SIMISTER NE, 1989, COLD SPRING HARB SYM, V54, P571, DOI 10.1101/SQB.1989.054.01.068; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Simister NE, 1997, BIOCHEM SOC T, V25, P481, DOI 10.1042/bst0250481; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Stryer L., 1988, BIOCHEMISTRY-US, P21; Tirabassi RS, 1998, J VIROL, V72, P4571, DOI 10.1128/JVI.72.6.4571-4579.1998; Tirabassi RS, 1999, J VIROL, V73, P2717, DOI 10.1128/JVI.73.4.2717-2728.1999; Van de Walle GR, 2003, J GEN VIROL, V84, P939, DOI 10.1099/vir.0.18663-0; VANVLIET KE, 1992, IMMUNOLOGY, V77, P109; Vaughn DE, 1997, J MOL BIOL, V274, P597, DOI 10.1006/jmbi.1997.1388; WESTMORELAND D, 1974, J GEN VIROL, V24, P167, DOI 10.1099/0022-1317-24-1-167; Whitbeck JC, 1996, J VIROL, V70, P7878, DOI 10.1128/JVI.70.11.7878-7884.1996; WIGER D, 1985, IMMUNOLOGY, V54, P565; YAO ZB, 1993, J VIROL, V67, P305, DOI 10.1128/JVI.67.1.305-314.1993; Zhu ZL, 1996, J VIROL, V70, P6563, DOI 10.1128/JVI.70.10.6563-6575.1996; ZHU ZL, 1995, J VIROL, V69, P7951, DOI 10.1128/JVI.69.12.7951-7959.1995; ZUCKERMANN FA, 1988, J VIROL, V62, P4622, DOI 10.1128/JVI.62.12.4622-4626.1988	68	36	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14184	14193		10.1074/jbc.M313281200	http://dx.doi.org/10.1074/jbc.M313281200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734541	hybrid, Green Accepted			2022-12-27	WOS:000220478500110
J	Varela, D; Simon, F; Riveros, A; Jorgensen, F; Stutzin, A				Varela, D; Simon, F; Riveros, A; Jorgensen, F; Stutzin, A			NAD(P)H oxidase-derived H2O2 signals chloride channel activation in cell volume regulation and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ORGANIC OSMOLYTE; ANION CHANNELS; APOPTOSIS; CONDUCTANCE; MECHANISMS; MEMBRANE; EFFLUX; INVOLVEMENT; EXPRESSION	Cellular swelling triggers the activation of Cl- channels (volume-sensitive outwardly rectifying (VSOR) Cl- channels) in many cell types. Ensuing regulatory volume decrease has been considered the primary function of these channels. However, Cl- channels, which share functional properties with volume-sensitive Cl- channels, have been shown to be involved in other physiological processes, including cell proliferation and apoptosis, raising the question of their physiological roles and the signal transduction pathways involved in their activation. Here we report that exogenously applied H2O2 elicited VSOR Cl- channel activation. Furthermore, activation of these channels was found to be coupled to NAD(P) H oxidase activity. Also, epidermal growth factor, known to increase H2O2 production, activated Cl- channels with properties identical to swelling-sensitive Cl- channels. It is concluded that NAD(P) H oxidase-derived H2O2 is the common signal transducing molecule that mediates the activation of these ubiquitously expressed anion channels under a variety of physiological conditions.	Univ Chile, Fac Med, Ctr Estudios Mol Celula, Santiago 6530499, Chile; Univ Chile, Fac Med, Inst Ciencias Biomed, Santiago 6530499, Chile; So Univ Denmark, IMB, DK-5230 Odense, Denmark	Universidad de Chile; Universidad de Chile; University of Southern Denmark	Stutzin, A (corresponding author), Univ Chile, Fac Med, Ctr Estudios Mol Celula, Santiago 6530499, Chile.	astutzin@bitmed.med.uchile.cl	Stutzin, Andrés/I-7605-2013; riveros, ana/AAD-2134-2020; Varela, Diego/AAG-7489-2019	Stutzin, Andrés/0000-0002-7264-066X; Varela, Diego/0000-0002-9352-414X; Simon, Felipe/0000-0002-2653-9798; Riveros, Ana Luisa/0000-0002-1926-4562				Abdullaev IF, 2003, J PHYSIOL-LONDON, V549, P749, DOI 10.1113/jphysiol.2003.039784; ALVAREZLEEFMANS FJ, 1995, METH NEUROSCI, V27, P361; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Chen LX, 2002, AM J PHYSIOL-CELL PH, V283, pC1313, DOI 10.1152/ajpcell.00182.2002; DeCoursey TE, 2002, J GEN PHYSIOL, V120, P773, DOI 10.1085/jgp.20028704; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P711, DOI 10.1113/jphysiol.1991.sp018575; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Hill, 2001, ION CHANNELS EXCITAB, P441; HOFFMANN EK, 1988, RENAL PHYSIOL BIOCH, V11, P221; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lambert IH, 2003, J MEMBRANE BIOL, V192, P19, DOI 10.1007/s00232-002-1061-1; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Moore AL, 2002, J BIOL CHEM, V277, P34030, DOI 10.1074/jbc.M205945200; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Okada Y, 2001, COMP BIOCHEM PHYS A, V130, P377, DOI 10.1016/S1095-6433(01)00424-X; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; PANUS PC, 1993, FREE RADICAL BIO MED, V14, P217, DOI 10.1016/0891-5849(93)90013-K; Rhee S G, 2000, Sci STKE, V2000, ppe1; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Schroder RL, 2000, PFLUG ARCH EUR J PHY, V440, P809, DOI 10.1007/s004240000364; SCHUMACHER PA, 1995, J MEMBRANE BIOL, V145, P217; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; STRANGE K, 1995, KIDNEY INT, V48, P994, DOI 10.1038/ki.1995.381; Stutzin A, 1999, AM J PHYSIOL-CELL PH, V277, pC392, DOI 10.1152/ajpcell.1999.277.3.C392; Stutzin A, 1997, AM J PHYSIOL-CELL PH, V273, pC999, DOI 10.1152/ajpcell.1997.273.3.C999; Suzuki YJ, 1999, J MOL CELL CARDIOL, V31, P345, DOI 10.1006/jmcc.1998.0872; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Voets T, 1996, J PHYSIOL-LONDON, V497, P95, DOI 10.1113/jphysiol.1996.sp021752; WERNER E, 2003, SCI STKE; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x	42	127	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13301	13304		10.1074/jbc.C400020200	http://dx.doi.org/10.1074/jbc.C400020200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14761962	hybrid			2022-12-27	WOS:000220478500005
J	D'hoedt, D; Hirzel, K; Pedarzani, P; Stocker, M				D'hoedt, D; Hirzel, K; Pedarzani, P; Stocker, M			Domain analysis of the calcium-activated potassium channel SK1 from rat brain - Functional expression and toxin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; SMALL-CONDUCTANCE; PHARMACOLOGICAL CHARACTERIZATION; SURFACE EXPRESSION; HEK-293 CELLS; NEURONS; CALMODULIN; APAMIN; AFTERHYPERPOLARIZATION; DETERMINANTS	Two small conductance, calcium-activated potassium channels (SK channels), SK2 and SK3, have been shown to contribute to the afterhyperpolarization (AHP) and to shape the firing behavior in neurons for example in the hippocampal formation, the dorsal vagal nucleus, the subthalamic nucleus, and the cerebellum. In heterologous expression systems, SK2 and SK3 currents are blocked by the bee venom toxin apamin, just as well as the corresponding neuronal AHP currents. However, the functional role and pharmacological profile of SK1 channels from rat brain (rSK1) is still largely unknown, as so far rSK1 homomeric channels could not be functionally expressed. We have performed a domain analysis to elucidate the pharmacological profile and the molecular determinants of rSK1 channel expression by using channel chimeras in combination with immunocytochemistry, immunoblot analysis, and electrophysiology. Our results reveal that the rSK1 subunit is synthesized in cells but does not form functional homomeric channels. Exchanging the carboxyl terminus of rSK1 for that of hSK1 or rSK2 is sufficient to rescue the functional expression of rSK1 channels. Additionally, transplantation of both amino and carboxyl termini of rSK1 onto hSK1 subunits, normally forming functional homomeric channel, hinders their functional expression, while hSK1 channels containing only the rSK1 carboxyl terminus are functional. These results suggest that the lack of functional expression of rSK1 channels is probably due to problems in their assembly and tetramerization but not in their calmodulin-dependent gating. Finally, we show that chimeric channels containing the core domain (S1 - S6) of rSK1, unlike hSK1, are apamin-insensitive.	UCL, Wellcome Lab Mol Pharmacol, Dept Pharmacol, London WC1E 6BT, England; UCL, Dept Physiol, London WC1E 6BT, England; Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany	University of London; University College London; University of London; University College London; Max Planck Society	Stocker, M (corresponding author), UCL, Wellcome Lab Mol Pharmacol, Dept Pharmacol, Gower St, London WC1E 6BT, England.	m.stocker@ucl.ac.uk	Stocker, Martin/C-1844-2008		MRC [G0100066] Funding Source: UKRI; Medical Research Council [G0100066] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Benton DCH, 2003, J PHYSIOL-LONDON, V553, P13, DOI 10.1113/jphysiol.2003.054551; Bruening-Wright A, 2002, J NEUROSCI, V22, P6499; Cingolani LA, 2002, J NEUROSCI, V22, P4456, DOI 10.1523/JNEUROSCI.22-11-04456.2002; Desai R, 2000, J BIOL CHEM, V275, P39954, DOI 10.1074/jbc.M001562200; Dror V, 1999, MOL PSYCHIATR, V4, P254, DOI 10.1038/sj.mp.4000508; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Grunnet M, 2001, NEUROPHARMACOLOGY, V40, P879, DOI 10.1016/S0028-3908(01)00028-4; Grunnet M, 2001, PFLUG ARCH EUR J PHY, V441, P544, DOI 10.1007/s004240000447; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Hosseini R, 2001, J PHYSIOL-LONDON, V535, P323, DOI 10.1111/j.1469-7793.2001.00323.x; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Kerschensteiner D, 1999, BIOPHYS J, V77, P248, DOI 10.1016/S0006-3495(99)76886-4; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Lee WS, 2003, J BIOL CHEM, V278, P25940, DOI 10.1074/jbc.M302091200; LORENZON NM, 1992, J NEUROPHYSIOL, V67, P350, DOI 10.1152/jn.1992.67.2.350; Monaghan AS, 2004, J BIOL CHEM, V279, P1003, DOI 10.1074/jbc.M308070200; Pedarzani P, 2000, J PHYSIOL-LONDON, V527, P283, DOI 10.1111/j.1469-7793.2000.t01-1-00283.x; Pedarzani P, 2002, J BIOL CHEM, V277, P46101, DOI 10.1074/JBC.m206465200; Sah P, 2002, PROG NEUROBIOL, V66, P345, DOI 10.1016/S0301-0082(02)00004-7; Sailer CA, 2002, J NEUROSCI, V22, P9698; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Shah M, 2000, BRIT J PHARMACOL, V129, P627, DOI 10.1038/sj.bjp.0703111; Shakkottai VG, 2001, J BIOL CHEM, V276, P43145, DOI 10.1074/jbc.M106981200; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; STOCKER M, 2004, IN PRESS TOXICON; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; Terstappen GC, 2001, NEUROPHARMACOLOGY, V40, P772, DOI 10.1016/S0028-3908(01)00007-7; Vogalis F, 2003, EUR J NEUROSCI, V18, P3155, DOI 10.1111/j.1460-9568.2003.03040.x; Wissmann R, 2002, J BIOL CHEM, V277, P4558, DOI 10.1074/jbc.M109240200; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	38	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12088	12092		10.1074/jbc.C300382200	http://dx.doi.org/10.1074/jbc.C300382200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14761961	hybrid			2022-12-27	WOS:000220334900013
J	Encinas, M; Crowder, RJ; Milbrandt, J; Johnson, EM				Encinas, M; Crowder, RJ; Milbrandt, J; Johnson, EM			Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-1; NEUROTROPHIC FACTOR; GDNF FAMILY; DOCKING SITE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING COMPLEXES; ENTERIC NEURON; SH2 DOMAIN; KINASE; IDENTIFICATION	The glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) are neurotrophic factors that influence several aspects of the developing and injured nervous system. GFLs signal through a common receptor tyrosine kinase (Ret) and one of the four ligand-binding co-receptors (GFRalpha1 to 4). Ligand-induced translocation of Ret to lipid rafts, where it interacts with the nonreceptor tyrosine kinase Src, is a prerequisite for full biological activity of these neurotrophic factors. This interaction and subsequent activation of Src are required for GFL-mediated neuronal survival, neurite outgrowth, or cell proliferation. Here we show by multiple approaches that Ret tyrosine 981 constitutes the major binding site of the Src homology 2 domain of Src and therefore the primary residue responsible for Src activation upon Ret engagement. Other tyrosines such as 1015 and 1029 may contribute to the overall interaction between Ret and Src, as judged by overexpression experiments. By generating a phosphospecific antibody, we demonstrate that tyrosine 981 is a novel autophosphorylation site in Ret. Importantly, we also show that this tyrosine becomes phosphorylated in dissociated sympathetic neurons after ligand stimulation. Mutation of tyrosine 981 to phenylalanine reduces GDNF-mediated survival in a transfected cerebellar granule neuron paradigm.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Johnson, EM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Campus Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.	emjohnson@msnotes.wustl.edu	Encinas, Mario/B-5600-2009	Encinas, Mario/0000-0003-3509-7431; Milbrandt, Jeffrey/0000-0002-5477-7689	NIA NIH HHS [AG13730, AG13729] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013730, R01AG013729] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Enomoto H, 2001, DEVELOPMENT, V128, P3963; Gay B, 1997, BIOCHEMISTRY-US, V36, P5712, DOI 10.1021/bi962642y; Gianino S, 2003, DEVELOPMENT, V130, P2187, DOI 10.1242/dev.00433; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Heuckeroth RO, 1998, DEV BIOL, V200, P116, DOI 10.1006/dbio.1998.8955; Kato M, 2002, CANCER RES, V62, P2414; Kilkenny DM, 2003, J BIOL CHEM, V278, P17448, DOI 10.1074/jbc.M209698200; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; LANDGREN E, 1995, ONCOGENE, V10, P2027; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Melillo RM, 1999, CANCER RES, V59, P1120; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Miller TM, 1996, J NEUROSCI, V16, P7487; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Moulder KL, 1999, J NEUROSCI, V19, P705; Nollau P, 2001, P NATL ACAD SCI USA, V98, P13531, DOI 10.1073/pnas.241215998; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Postigo A, 2002, GENE DEV, V16, P633, DOI 10.1101/gad.217902; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Xia ZG, 1996, J NEUROSCI, V16, P5425; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 30	2004	279	18					18262	18269		10.1074/jbc.M400505200	http://dx.doi.org/10.1074/jbc.M400505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	815KP	14766744	hybrid			2022-12-27	WOS:000221041500022
J	Chao, Y; Fu, D				Chao, Y; Fu, D			Thermodynamic studies of the mechanism of metal binding to the Escherichia coli zinc transporter YiiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; DIFFUSION FACILITATOR FAMILY; ANTIPORT MECHANISM; CONFERS RESISTANCE; PROTEIN; HOMEOSTASIS; INSIGHTS; EXCHANGE; MEMBER; ZITB	Sequence homology of the Escherichia coli YiiP places it within the family of cation diffusion facilitators, a family of membrane transporters that play a central role in regulating cellular zinc homeostasis. Here we describe the first thermodynamic and mechanistic studies of metal binding to a cation diffusion facilitator. Isothermal titration calorimetric analyses of the purified YiiP and binding competitions among Zn2+, Cd2+, and Hg2+ revealed a mutually competitive binding site common to three metal ions and a set of noncompetitive binding sites, including one Cd2+ site, one Hg2+ site, and at least one Zn2+ site, to which the binding of Zn2+ exhibited partial inhibitions of both Cd2+ and Hg2+ bindings. Lowering the pH from 7.0 to 5.5 inhibited binding of Zn2+ and Cd2+ to the common site. Further, the enthalpy change of the Cd2+ binding to the common site was found to be related linearly to the ionization enthalpy of the pH buffer with a slope corresponding to the release of 1.23 H+ for each Cd2+ binding. These H+ effects are consistent with a coupled deprotonation process upon binding of Zn2+ and Cd2+. Modification of histidine residues by diethyl pyrocarbonate specifically inhibited Zn2+ binding to the common binding site, indicating that the mechanism of binding-deprotonation coupling involves a histidine residue(s).	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Fu, D (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	dax@bnl.gov		Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065137] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM65137] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Baker BM, 1996, BIOPHYS J, V71, P2049, DOI 10.1016/S0006-3495(96)79403-1; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; Blencowe DK, 2003, FEMS MICROBIOL REV, V27, P291, DOI 10.1016/S0168-6445(03)00041-X; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Chao Y, 2004, J BIOL CHEM, V279, P12043, DOI 10.1074/jbc.M313510200; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Coleman JE, 1998, CURR OPIN CHEM BIOL, V2, P222, DOI 10.1016/S1367-5931(98)80064-1; daSilva J.J.R.F., 2001, INORGANIC CHEM LIFE; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Farrer BT, 2003, P NATL ACAD SCI USA, V100, P3760, DOI 10.1073/pnas.0336055100; Farrer BT, 2002, CURR OPIN DRUG DISC, V5, P937; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; GOLDBERG RN, 2001, J PHYS CHEM REF DATA, V30, P1; GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501; Grass G, 2001, J BACTERIOL, V183, P4664, DOI 10.1128/JB.183.15.4664-4667.2001; Grossman TH, 1998, GENE, V209, P95, DOI 10.1016/S0378-1119(98)00020-1; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Guffanti AA, 2002, MOL MICROBIOL, V45, P145, DOI 10.1046/j.1365-2958.2002.02998.x; Harris ED, 2002, NUTR REV, V60, P121, DOI 10.1301/00296640260085877; Jin XR, 2003, BIOCHEMISTRY-US, V42, P12927, DOI 10.1021/bi0350809; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X	31	84	86	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17173	17180		10.1074/jbc.M400208200	http://dx.doi.org/10.1074/jbc.M400208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14960568	hybrid			2022-12-27	WOS:000220870400037
J	Mercer, BA; Kolesnikova, N; Sonett, J; D'Armiento, J				Mercer, BA; Kolesnikova, N; Sonett, J; D'Armiento, J			Extracellular regulated kinase/mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALVEOLAR MACROPHAGES; AIRWAY INFLAMMATION; POSSIBLE MECHANISMS; CELL APOPTOSIS; GUINEA-PIGS; EXPRESSION; INHIBITION; ELASTASE; COLLAGEN; RELEASE	The interstitial collagenase matrix metalloproteinase-1 (MMP-1) is up-regulated in the lung during pulmonary emphysema. The mechanisms underlying this aberrant expression are poorly understood. Although cigarette smoking is the predominant cause of emphysema, only 15-20% of smokers develop the disease. To define the signaling pathways activated by smoke and to identify molecules responsible for emphysema-associated MMP-1 expression, we performed several in vitro and in vivo experiments. In this study, we showed that cigarette smoke directly induced MMP-1 mRNA and protein expression and increased the collagenolytic activity of human airway cells. Treatment with various chemical kinase inhibitors revealed that this response was dependent on the extracellular regulated kinase-1/2 (ERK) mitogen activated protein kinase pathway. Cigarette smoke increased phosphorylation of residues Thr-202 and Tyr-204 of ERK in airway lining cells and alveolar macrophages in mice at 10 days and 6 months of exposure. Moreover, analysis of lung tissues from emphysema patients revealed significantly increased ERK activity compared with lungs of control subjects. This ERK activity was evident in airway lining and alveolar cells. The identification of active ERK in the lungs of emphysema patients and the finding that induction of MMP-1 by cigarette smoke in pulmonary epithelial cells is ERK-dependent reveal a molecular mechanism and potential therapeutic target for excessive matrix remodeling in smokers who develop emphysema.	Columbia Univ Coll Phys & Surg, Dept Med, Div Mol Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Div Pulm Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	D'Armiento, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Div Mol Med, 630 W 168th St,P&S 9-449, New York, NY 10032 USA.	jmd12@columbia.edu						BLUE ML, 1978, AM REV RESPIR DIS, V117, P317; Brenneisen P, 2002, BIOCHEM J, V365, P31, DOI 10.1042/BJ20020110; Carnevali S, 1998, AM J PHYSIOL-LUNG C, V274, pL591, DOI 10.1152/ajplung.1998.274.4.L591; CARP H, 1978, AM REV RESPIR DIS, V118, P617; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Choudhury BK, 2002, J IMMUNOL, V169, P5955, DOI 10.4049/jimmunol.169.10.5955; Cosio MG, 1999, AM J RESP CRIT CARE, V160, pS21, DOI 10.1164/ajrccm.160.supplement_1.7; Croxton TL, 2003, AM J RESP CRIT CARE, V167, P1142, DOI 10.1164/rccm.200207-756WS; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fini ME, 1998, BIOL EXTRAC, P299; Finkelstein EI, 2001, AM J PHYSIOL-LUNG C, V281, pL732, DOI 10.1152/ajplung.2001.281.3.L732; Finlay GA, 1997, AM J RESP CRIT CARE, V156, P240, DOI 10.1164/ajrccm.156.1.9612018; FLETCHER C, 1976, NATURAL HIST CHRONIC, P82; Foronjy RF, 2003, AM J PHYSIOL-LUNG C, V284, pL727, DOI 10.1152/ajplung.00349.2002; GADEK J, 1979, SCIENCE; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hellermann GR, 2002, RESP RES, V3, DOI 10.1186/rr172; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Imai K, 2001, AM J RESP CRIT CARE, V163, P786, DOI 10.1164/ajrccm.163.3.2001073; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kashyap R, 2002, J INVEST MED, V50, P46, DOI 10.2310/6650.2002.33517; Kling DE, 2002, AM J PHYSIOL-LUNG C, V282, pL370, DOI 10.1152/ajplung.00200.2001; Kuschner WG, 1996, EUR RESPIR J, V9, P1989, DOI 10.1183/09031936.96.09101989; LAURENT P, 1983, AM REV RESPIR DIS, V127, P189; Majo J, 2001, EUR RESPIR J, V17, P946, DOI 10.1183/09031936.01.17509460; OGUSHI F, 1991, J CLIN INVEST, V87, P1060, DOI 10.1172/JCI115066; Ohnishi K, 1998, LAB INVEST, V78, P1077; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; Reunanen N, 2000, J BIOL CHEM, V275, P34634, DOI 10.1074/jbc.C000175200; RODRIGUEZ RJ, 1977, SCIENCE, V198, P313, DOI 10.1126/science.910131; Saetta M, 1999, AM J RESP CRIT CARE, V160, pS17, DOI 10.1164/ajrccm.160.supplement_1.6; Segura-Valdez L, 2000, CHEST, V117, P684, DOI 10.1378/chest.117.3.684; Selman M, 1996, AM J PHYSIOL-LUNG C, V271, pL734, DOI 10.1152/ajplung.1996.271.5.L734; Shaw RJ, 2002, RESP MED, V96, P67, DOI 10.1053/rmed.2001.1216; Shiomi T, 2003, EXP LUNG RES, V29, P1, DOI 10.1080/01902140303761; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; Takeyama K, 2000, J IMMUNOL, V164, P1546, DOI 10.4049/jimmunol.164.3.1546; THURLBECK WM, 1999, CHRONIC AIRFLOW OBST; Turato G, 2002, AM J RESP CRIT CARE, V166, P105, DOI 10.1164/rccm.2111084; *US DEP HEW, 1979, DHEW PUBL PHS; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; Vlahos CJ, 2003, NAT REV DRUG DISCOV, V2, P99, DOI 10.1038/nrd1009; WHITE RR, 1979, J LAB CLIN MED, V94; WRIGHT JL, 1995, AM J PHYSIOL-LUNG C, V268, pL17, DOI 10.1152/ajplung.1995.268.1.L17; WRIGHT JL, 1990, AM REV RESPIR DIS, V142, P1422, DOI 10.1164/ajrccm/142.6_Pt_1.1422	48	136	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 23	2004	279	17					17690	17696		10.1074/jbc.M313842200	http://dx.doi.org/10.1074/jbc.M313842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	812WU	14764579	hybrid			2022-12-27	WOS:000220870400099
J	Cho, SY; Ko, HM; Kim, JM; Lee, JA; Park, JE; Jang, MS; Park, SG; Lee, DH; Ryu, SE; Park, BC				Cho, SY; Ko, HM; Kim, JM; Lee, JA; Park, JE; Jang, MS; Park, SG; Lee, DH; Ryu, SE; Park, BC			Positive regulation of apoptosis signal-regulating kinase 1 by hD53L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC OXIDATIVE STRESS; ACTIVATED PROTEIN-KINASE; CELL-DEATH; ACINAR-CELLS; GENE FAMILY; 1 ASK1; IDENTIFICATION; THIOREDOXIN; INHIBITOR; CLONING	Apoptosis signal-regulating kinase 1 (ASK1) is a mitogen-activated protein kinase kinase kinase family member that plays a central role in cytokine- and stress-induced apoptosis by activating c-Jun N-terminal kinase and p38 signaling cascades. ASK1-induced apoptotic activity is up-regulated by two cellular factors, Daxx and TRAF2, through direct protein-protein interactions. Daxx and TRAF2 are death receptor-associated proteins in Fas and tumor necrosis factor-alpha pathways, respectively. Recent studies suggest that calcium signaling may regulate ASK1 pathway. Here we report that human D53L1, a member of the tumor protein D52 family involved in cell proliferation and calcium signaling, up-regulates the ASK1-induced apoptosis. The human D53L1 physically interacts with the C-terminal regulatory domain of ASK1 and promotes ASK1-induced apoptotic activity by activating caspase signaling in mammalian cells. In luciferase reporter assays, hD53L1 activates c-Jun N-terminal kinase-mediated transactivation in the presence of ASK1. Expression of hD53L1 enhances autophosphorylation and kinase activity of ASK1 but has no effect on ASK1 oligomerization that is necessary for kinase activity and on binding of ASK1 to MKK6, a downstream factor of ASK1. Taken together, these results suggest that activation of ASK1 by hD53L1 may provide a novel mechanism for ASK1 regulation.	Korea Res Inst Biosci & Biotechnol, Res Ctr System Proteom, Taejon 305600, South Korea; Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Taejon 305600, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Cho, SY (corresponding author), Korea Res Inst Biosci & Biotechnol, Res Ctr System Proteom, POB 115, Taejon 305600, South Korea.	scho@kribb.re.kr; parkbc@kribb.re.kr						Boutros R, 2003, J MOL BIOL, V332, P675, DOI 10.1016/S0022-2836(03)00944-6; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Byrne JA, 1998, ONCOGENE, V16, P873, DOI 10.1038/sj.onc.1201604; Byrne JA, 1998, CYTOGENET CELL GENET, V81, P199, DOI 10.1159/000015029; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harvey N L, 1998, Adv Biochem Eng Biotechnol, V62, P107; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kaspar KM, 2003, AM J PHYSIOL-GASTR L, V285, pG1300, DOI 10.1152/ajpgi.00534.2002; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nourse CR, 1998, BBA-GENE STRUCT EXPR, V1443, P155, DOI 10.1016/S0167-4781(98)00211-5; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Sagasti A, 2001, CELL, V105, P221, DOI 10.1016/S0092-8674(01)00313-0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sathasivam P, 2001, BIOCHEM BIOPH RES CO, V288, P56, DOI 10.1006/bbrc.2001.5721; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Thomas DDH, 2002, J BIOL CHEM, V277, P35496, DOI 10.1074/jbc.M110917200; Thomas DDH, 2001, J BIOL CHEM, V276, P28866, DOI 10.1074/jbc.M102214200; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilson SHD, 2001, GENOMICS, V76, P81, DOI 10.1006/geno.2001.6610; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang QG, 2003, NEUROSCI LETT, V337, P51, DOI 10.1016/S0304-3940(02)01295-8	45	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16050	16056		10.1074/jbc.M305758200	http://dx.doi.org/10.1074/jbc.M305758200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761963	hybrid			2022-12-27	WOS:000220747900044
J	Glauser, DA; Bourquin, F; Manieri, W; Schurmann, P				Glauser, DA; Bourquin, F; Manieri, W; Schurmann, P			Characterization of ferredoxin : thioredoxin reductase modified by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SPINACH FERREDOXIN; FERREDOXINTHIOREDOXIN REDUCTASE; DISULFIDE; SUBUNIT; CLUSTER	Ferredoxin: thioredoxin reductase (FTR) is a key regulatory enzyme of oxygenic photosynthetic cells involved in the reductive regulation of important target enzymes. It catalyzes the two-electron reduction of the disulfide of thioredoxins with electrons from ferredoxin involving a 4Fe-4S cluster and an adjacent active-site disulfide. We replaced Cys-57, Cys-87, and His-86 in the active site of Synechocystis FTR by site-directed mutagenesis and studied the properties of the mutated proteins. Mutation of either of the active-site cysteines yields inactive enzymes, which have different spectral properties, indicating a reduced Fe-S cluster when the inaccessible Cys-87 is replaced and an oxidized cluster when the accessible Cys-57 is replaced. The oxidized cluster in the latter mutant can be reversibly reduced with dithionite showing that it is functional. The C57S mutant is a very stable protein, whereas the C87A mutant is more labile because of the missing interaction with the cluster. The replacement of His-86 greatly reduces its catalytic activity supporting the proposal that His-86 increases the nucleophilicity of the neighboring cysteine. Ferredoxin forms non-covalent complexes with wild type (WT) and mutant FTRs, which are stable except with the C87A mutant. WT and mutant FTRs form stable covalent heteroduplexes with active-site modified thioredoxins. In particular, heteroduplexes formed with WT FTR represent interesting one-electron-reduced reaction intermediates, which can be split by reduction of the Fe-S cluster. Heteroduplexes form non-covalent complexes with ferredoxin demonstrating the ability of FTR to simultaneously dock thioredoxin and ferredoxin, which is in accord with the proposed reaction mechanism and the structural analyses.	Univ Neuchatel, Lab Biochim Vegetale, CH-2007 Neuchatel, Switzerland	University of Neuchatel	Schurmann, P (corresponding author), Univ Neuchatel, Lab Biochim Vegetale, Rue Emile Argand 11, CH-2007 Neuchatel, Switzerland.	peter.schurmann@unine.ch	Glauser, Dominique/B-3918-2012	Glauser, Dominique/0000-0002-3228-7304				Balmer Y, 2001, FEBS LETT, V492, P58, DOI 10.1016/S0014-5793(01)02229-3; Buchanan BB, 2002, PHOTOSYNTH RES, V73, P215, DOI 10.1023/A:1020407432008; Capitani G, 2000, J MOL BIOL, V302, P135, DOI 10.1006/jmbi.2000.4006; CHOW LP, 1995, EUR J BIOCHEM, V231, P149, DOI 10.1111/j.1432-1033.1995.tb20681.x; Chueca A, 2002, PHOTOSYNTH RES, V74, P235, DOI 10.1023/A:1021243110495; Dai SD, 2000, Q REV BIOPHYS, V33, P67, DOI 10.1017/S0033583500003607; Dai SD, 2000, SCIENCE, V287, P655, DOI 10.1126/science.287.5453.655; DEPASCALIS AR, 1994, FEBS LETT, V337, P217, DOI 10.1016/0014-5793(94)80194-0; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HIRASAWA M, 1988, BIOCHIM BIOPHYS ACTA, V935, P1, DOI 10.1016/0005-2728(88)90101-6; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; Jameson GNL, 2003, J AM CHEM SOC, V125, P1146, DOI 10.1021/ja029338e; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Manieri W, 2003, FEBS LETT, V549, P167, DOI 10.1016/S0014-5793(03)00811-1; MANIERI W, 2002, THESIS U NEUCHATEL; Miginiac-Maslow M, 2000, PHYSIOL PLANTARUM, V110, P322, DOI 10.1034/j.1399-3054.2000.1100306.x; SCHURMANN P, 1993, CHIMIA, V47, P245; Schurmann P, 1995, PHOTOSYNTH RES, V46, P309, DOI 10.1007/BF00020445; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; Schurmann P, 2002, METHOD ENZYMOL, V347, P403; Schurmann P, 2001, ADV PHOTOSYNTH, V11, P331; Schwendtmayer C, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1927; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Staples CR, 1998, BIOCHEMISTRY-US, V37, P4612, DOI 10.1021/bi9729763; WEDEL N, 1992, PLANT MOL BIOL, V18, P527, DOI 10.1007/BF00040668	27	21	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16662	16669		10.1074/jbc.M313851200	http://dx.doi.org/10.1074/jbc.M313851200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14769790	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000220747900118
J	Isaacs, JS; Jung, YJ; Neckers, L				Isaacs, JS; Jung, YJ; Neckers, L			Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1 alpha by modulating an Hsp90-dependent regulatory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTION FACTOR; MOLECULAR CHAPERONE; DIOXIN RECEPTOR; HIF-ALPHA; HSP90; COMPLEX; IDENTIFICATION; DEGRADATION	Hypoxia-inducible factor-1 (HIF-1) is a potent cellular survival factor contributing to tumorigenesis in a broad range of cancers. The functional transcription factor exists as a heterodimeric complex consisting of HIF-1alpha and the aryl hydrocarbon receptor nuclear translocator (ARNT). Association of HIF-1 with ARNT is required for its activity; however, no other role has been ascribed to this interaction. We demonstrated previously that pharmacologic inhibition of Hsp90 by geldanamycin (GA) impairs HIF transcription and promotes VHL ((V) under bar on (H) under bar ippel-(L) under bar indau)-independent degradation of the protein, thus implicating Hsp90 as an essential interacting partner for HIF. In this study, we further explore the physiological role for Hsp90 in HIF function. We establish that the PAS ((P) under bar er-(A) under bar RNT-(S) under bar im) domain of HIF is required both to promote association with Hsp90 and confer sensitivity to GA. Coincidentally, this domain also associates with ARNT. Overexpression of ARNT in a VHL-deficient background resulted in substantially increased HIF-1 protein concomitant with increased protein stability. Conversely, down-regulation of endogenous ARNT protein by RNA interference decreased the steady-state HIF protein. ARNT-mediated stabilization of HIF is specific for the Hsp90-dependent pathway, as ARNT was unable to protect HIF from VHL-mediated degradation. We establish that the ability of ARNT to up-regulate HIF and diminish HIF sensitivity to GA is due to its ability to compete for the Hsp90 binding site on HIF. These data elucidate novel functions for ARNT and Hsp90 in regulating HIF function and further illustrate that cofactor association may significantly impact upon the sensitivity of Hsp90 clients to chaperone inhibitors.	NCI, Urol Oncol Branch, Ctr Canc Res, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Isaacs, JS (corresponding author), NCI, Urol Oncol Branch, Ctr Canc Res, NIH, 9610 Med Ctr Dr,KWC Ste 300, Rockville, MD 20850 USA.	isaacsj@mail.nih.gov; len@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01SC010074, ZIASC010074] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Cowden KD, 2002, BIOCHEM BIOPH RES CO, V290, P1228, DOI 10.1006/bbrc.2001.6309; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McGuire J, 1995, J BIOL CHEM, V270, P31353, DOI 10.1074/jbc.270.52.31353; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wiesener MS, 2001, CANCER RES, V61, P5215; Zhong H, 1999, CANCER RES, V59, P5830	33	68	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16128	16135		10.1074/jbc.M313342200	http://dx.doi.org/10.1074/jbc.M313342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764593	hybrid			2022-12-27	WOS:000220747900054
J	Nakatani, T; Mizuhara, E; Minaki, Y; Sakamoto, Y; Ono, Y				Nakatani, T; Mizuhara, E; Minaki, Y; Sakamoto, Y; Ono, Y			Helt, a novel basic-helix-loop-helix transcriptional repressor expressed in the developing central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN NEURONAL DIFFERENTIATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; NEURAL DEVELOPMENT; DROSOPHILA HAIRY; PRIMARY TARGET; FEEDBACK LOOP; WRPW MOTIF; HEY GENES; PROTEINS; NOTCH	Neuronal differentiation is regulated by many basic-helix-loop- helix ( bHLH) family transcriptional activators and repressors, and the balance of activity between these factors is important for the differentiation process. Here, we report the identification of a novel transcriptional repressor, designated Helt. Helt encoded a Hey-related bHLH protein containing the bHLH and Orange domains. Helt could homodimerize, and heterodimerize with Hes5 or Hey2. Both the bHLH and Orange domains were involved in the homodimerization. In contrast, only the bHLH domain was required for the heterodimerization with Hey2, whereas only the Orange domain mediated the interaction between Helt and Hes5. Thus, Helt has two dimerization domains, and these domains independently select a partner. Identification of preferred recognition sequences by CASTing experiments revealed that Helt bound to the E box, which was distinct from the Hes1 optimal sequence around the E box core. Not only the core sequence but also sequences flanking the E box were essential for the recognition by Helt and Hes1. Furthermore, Helt repressed transcription from an artificial promoter through binding to the optimal E box elements, as well as transcription from its own promoter. Using in situ hybridization and immunohistochemistry, Helt expression in embryos was investigated. Helt was mainly expressed in undifferentiated neural progenitors in some of the developing brain regions, including the mesencephalon and diencephalon, at the neurogenesis stage. These results suggest that Helt acts as a transcriptional repressor to regulate neuronal differentiation and/ or identity.	KAN Res Associate Inc, Shimogyo Ku, Kyoto 6008815, Japan		Ono, Y (corresponding author), KAN Res Associate Inc, Shimogyo Ku, 93 Chudoji Awata Cho, Kyoto 6008815, Japan.	y-ono@kan.gr.jp		Minaki, Yasuko/0000-0001-5926-4746				Bae SK, 2000, DEVELOPMENT, V127, P2933; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Fedtsova N, 2001, MECH DEVELOP, V105, P129, DOI 10.1016/S0925-4773(01)00399-9; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Gratton MO, 2003, MOL CELL BIOL, V23, P6922, DOI 10.1128/MCB.23.19.6922-6935.2003; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Hirata H, 2001, EMBO J, V20, P4454, DOI 10.1093/emboj/20.16.4454; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kageyama R, 1997, INT J BIOCHEM CELL B, V29, P1389, DOI 10.1016/S1357-2725(97)89968-2; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Koyano-Nakagawa N, 2000, DEVELOPMENT, V127, P4203; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Leimeister C, 2000, DEV BIOL, V227, P91, DOI 10.1006/dbio.2000.9884; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Licht JD, 1996, ONCOGENE, V12, P323; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Muller T, 2002, NEURON, V34, P551, DOI 10.1016/S0896-6273(02)00689-X; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; Ono Y, 1998, MOL CELL BIOL, V18, P6939, DOI 10.1128/MCB.18.12.6939; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SAKAMOTO M, 2003, J BIOL CHEM; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Satow T, 2001, J NEUROSCI, V21, P1265; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	44	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16356	16367		10.1074/jbc.M311740200	http://dx.doi.org/10.1074/jbc.M311740200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14764602	hybrid			2022-12-27	WOS:000220747900082
J	Peralavarez-Marin, A; Marquez, M; Bourdelande, JL; Querol, E; Padros, E				Peralavarez-Marin, A; Marquez, M; Bourdelande, JL; Querol, E; Padros, E			Thr-90 plays a vital role in the structure and function of bacteriorhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTRA; ANGSTROM RESOLUTION; PURPLE MEMBRANE; SCHIFF-BASE; ARCHAEAL RHODOPSINS; CYSTEINE RESIDUES; THERMAL-STABILITY; LOW-TEMPERATURE; PROTEIN; INTERMEDIATE	The role of Thr-90 in the bacteriorhodopsin structure and function was investigated by its replacement with Ala and Val. The mutant D115A was also studied because Asp-115 in helix D forms a hydrogen bond with Thr-90 in helix C. Differential scanning calorimetry showed a decreased thermal stability of all three mutants, with T90A being the least stable. Light-dark adaptation of T90A was found to be abnormal and salt-dependent. Proton transport monitored using pyranine signals was similar to 10% of wild type for T90A, 20% for T90V, and 50% for D115A. At neutral or alkaline pH, the M rise of these mutants was faster than that of wild type, whereas M decay was slower in T90A. Overall, Fourier transform infrared ( FTIR) difference spectra of T90A were strongly pH-dependent. Spectra recorded on films adjusted at the same pH at 243 or 277 K, dry or wet, showed similar features. The D115A and T90V FTIR spectra were closer to WT, showing minor structural differences. The band at 1734 cm(-1) of the deconvoluted FTIR spectrum, corresponding to the carboxylate of Asp-115, was absent in all mutants. In conclusion, Thr-90 plays a critical role in maintaining the operative location and structure of helix C through three complementary interactions, namely an interhelical hydrogen bond with Asp-115, an intrahelical hydrogen bond with the peptide carbonyl oxygen of Trp-86, and a steric contact with the retinal. The interactions established by Thr-90 emerge as a general feature of archaeal rhodopsin proteins.	Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Fac Ciencies, Dept Quim Quim Organ, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain	Autonomous University of Barcelona; University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona	Padros, E (corresponding author), Univ Autonoma Barcelona, Fac Med, Dept Bioquim & Biol Mol, Unitat Biofis, E-08193 Barcelona, Spain.	esteve.padros@uab.es	Peralvarez-Marin, Alex/AAH-4305-2020; Peralvarez-Marin, Alex/A-8958-2017	Peralvarez-Marin, Alex/0000-0002-3457-0875				Azuaga AI, 1996, BIOCHEMISTRY-US, V35, P16328, DOI 10.1021/bi961845j; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; BRAIMAN MS, 1987, P NATL ACAD SCI USA, V84, P5221, DOI 10.1073/pnas.84.15.5221; CLADERA J, 1992, EUR J BIOCHEM, V207, P581, DOI 10.1111/j.1432-1033.1992.tb17084.x; Curran AR, 1999, BIOCHEMISTRY-US, V38, P9328, DOI 10.1021/bi982322+; Edman K, 2004, J BIOL CHEM, V279, P2147, DOI 10.1074/jbc.M300709200; Facciotti MT, 2001, BIOPHYS J, V81, P3442, DOI 10.1016/S0006-3495(01)75976-0; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; GRZESIEK S, 1986, FEBS LETT, V208, P337, DOI 10.1016/0014-5793(86)81045-6; HE YW, 1993, BIOCHEMISTRY-US, V32, P2282, DOI 10.1021/bi00060a021; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; Heyes CD, 2002, J BIOL CHEM, V277, P29437, DOI 10.1074/jbc.M203435200; Ihara K, 1999, J MOL BIOL, V285, P163, DOI 10.1006/jmbi.1998.2286; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P8829, DOI 10.1021/bi00152a020; KAUPPINEN JK, 1981, ANAL CHEM, V53, P1454, DOI 10.1021/ac00232a034; Kolbe M, 2000, SCIENCE, V288, P1390, DOI 10.1126/science.288.5470.1390; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Lazarova T, 1996, BIOCHEMISTRY-US, V35, P8354, DOI 10.1021/bi9601161; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MAEDA A, 1991, PHOTOCHEM PHOTOBIOL, V54, P911, DOI 10.1111/j.1751-1097.1991.tb02111.x; MARTI T, 1991, J BIOL CHEM, V266, P6919; MITAKU S, 1995, PROTEINS, V22, P350, DOI 10.1002/prot.340220406; MOGI T, 1989, J BIOL CHEM, V264, P14192; Moller C, 2000, J MOL BIOL, V301, P869, DOI 10.1006/jmbi.2000.3995; Neutze R, 2002, BBA-BIOMEMBRANES, V1565, P144, DOI 10.1016/S0005-2736(02)00566-7; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; Padros E, 2001, NATO SCI SER I LIFE, V335, P120; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Peralvarez A, 2001, FEBS LETT, V508, P399, DOI 10.1016/S0014-5793(01)03080-0; Sanz C, 1999, FEBS LETT, V456, P191, DOI 10.1016/S0014-5793(99)00950-3; SASAKI J, 1994, BIOCHEMISTRY-US, V33, P3178, DOI 10.1021/bi00177a006; Weik M, 1998, MOL CELL, V1, P411, DOI 10.1016/S1097-2765(00)80041-6; Zhai YF, 2001, BBA-BIOMEMBRANES, V1511, P206, DOI 10.1016/S0005-2736(00)00389-8; ZHANG YN, 1993, PHOTOCHEM PHOTOBIOL, V57, P1027, DOI 10.1111/j.1751-1097.1993.tb02966.x; Zscherp C, 1997, J PHYS CHEM B, V101, P10542, DOI 10.1021/jp971047i	40	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16403	16409		10.1074/jbc.M313988200	http://dx.doi.org/10.1074/jbc.M313988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14757760	hybrid			2022-12-27	WOS:000220747900087
J	Poveda, A; Pamblanco, M; Tafrov, S; Tordera, V; Sternglanz, R; Sendra, R				Poveda, A; Pamblanco, M; Tafrov, S; Tordera, V; Sternglanz, R; Sendra, R			Hif1 is a component of yeast histone acetyltransferase B, a complex mainly localized in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACETYLATION SITES; GENE-EXPRESSION; MAIZE EMBRYOS; H4; NUCLEOSOME; H3; IDENTIFICATION; PROTEINS; PURIFICATION	Hat1 is the catalytic subunit of the only type B histone acetyltransferase known (HAT-B). The enzyme specifically acetylates lysine 12, and to a lesser extent lysine 5, of free, non-chromatin-bound histone H4. The complex is usually isolated with cytosolic fractions and is thought to be involved in chromatin assembly. The Saccharomyces cerevisiae HAT-B complex also contains Hat2, a protein stimulating Hat1 catalytic activity. We have now identified by two-hybrid experiments Hif1 as both a Hat1- and a histone H4-interacting protein. These interactions were dependent on HAT2, indicating a mediating role for Hat2. Biochemical fractionation and coimmunoprecipitation assays demonstrated that Hif1 is a component of a yeast heterotrimeric HAT-B complex, in which Hat2 bridges Hat1 and Hif1 proteins. In contrast to Hat2, this novel subunit does not appear to regulate Hat1 enzymatic activity. Nevertheless, similarly to Hat1, Hif1 influences telomeric silencing. In a localization analysis by immunofluorescence microscopy on yeast strains expressing tagged versions of Hat1, Hat2, and Hif1, we have found that all three HAT-B proteins are mainly localized in the nucleus. Thus, we propose that the distinction between A- and B-type enzymes should henceforth be based on their capacity to acetylate histones bound to nucleosomes and not on their location within the cell. Finally, by Western blotting assays, we have not detected differences in the in vivo acetylation of H4 lysine 12 (acK12H4) between wild-type and hat1Delta, hat2Delta, or hif1Delta mutant strains, suggesting that the level of HAT-B-dependent acK12H4 may be very low under normal growth conditions.	Univ Valencia, Dept Bioquim & Biol Mol, Fac Ciencias Biol, E-46100 Valencia, Spain; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	University of Valencia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sendra, R (corresponding author), Univ Valencia, Dept Bioquim & Biol Mol, Fac Ciencias Biol, C Dr Moliner 50, E-46100 Valencia, Spain.	ramon.sendra@uv.es	Sendra, Ramón/K-3549-2014; Pamblanco, Merce/H-6688-2015; Poveda, Ana M/J-3338-2014	Sendra, Ramón/0000-0002-5519-4362; Pamblanco, Merce/0000-0003-0180-5751; Poveda, Ana M/0000-0003-1505-1372	NIGMS NIH HHS [GM28220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R56GM028220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Eberharter A, 1996, FEBS LETT, V386, P75, DOI 10.1016/0014-5793(96)00401-2; Georgieva EI, 1999, ANAL BIOCHEM, V269, P399, DOI 10.1006/abio.1999.4050; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Grant PA, 1999, SEMIN CELL DEV BIOL, V10, P169, DOI 10.1006/scdb.1999.0298; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Imhof A, 1999, BIOCHEMISTRY-US, V38, P13085, DOI 10.1021/bi9912490; James P, 1996, GENETICS, V144, P1425; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kolle D, 1998, FEBS LETT, V421, P109, DOI 10.1016/S0014-5793(97)01544-5; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOPEZRODAS G, 1991, BIOCHEMISTRY-US, V30, P3728, DOI 10.1021/bi00229a020; LOPEZRODAS G, 1985, ARCH BIOCHEM BIOPHYS, V239, P184, DOI 10.1016/0003-9861(85)90825-2; Lorch Y, 2000, MOL CELL, V6, P197, DOI 10.1016/S1097-2765(00)00021-6; Lusser A, 1999, NUCLEIC ACIDS RES, V27, P4427, DOI 10.1093/nar/27.22.4427; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; Makowski AM, 2001, J BIOL CHEM, V276, P43499, DOI 10.1074/jbc.C100549200; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; MINGARRO I, 1993, J BIOL CHEM, V268, P13248; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Pamblanco M, 2001, FEBS LETT, V496, P31, DOI 10.1016/S0014-5793(01)02397-3; Park H, 1999, YEAST, V15, P35, DOI 10.1002/(SICI)1097-0061(19990115)15:1<35::AID-YEA340>3.0.CO;2-R; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Shibahara K, 2000, P NATL ACAD SCI USA, V97, P7766, DOI 10.1073/pnas.97.14.7766; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; THIRIET C, 1995, ELECTROPHORESIS, V16, P357, DOI 10.1002/elps.1150160161; TORDERA V, 1993, EXPERIENTIA, V49, P780, DOI 10.1007/BF01923548; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; Van Leeuwen F, 2002, METHOD ENZYMOL, V350, P165, DOI 10.1016/S0076-6879(02)50962-9; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 2000, GENE DEV, V14, P1430; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	64	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16033	16043		10.1074/jbc.M314228200	http://dx.doi.org/10.1074/jbc.M314228200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14761951	hybrid			2022-12-27	WOS:000220747900042
J	Rouet-Benzineb, R; Aparicio, T; Guilmeau, S; Pouzet, C; Descatoire, V; Buyse, M; Bado, A				Rouet-Benzineb, R; Aparicio, T; Guilmeau, S; Pouzet, C; Descatoire, V; Buyse, M; Bado, A			Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappa B signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; LARGE-BOWEL CANCER; EPITHELIAL-CELLS; DIETARY FIBER; GROWTH-FACTOR; CYCLIN D1; SMALL-INTESTINE; LUMINAL LEPTIN; DIFFERENTIATION; ACTIVATION	This study shows that leptin induced a rapid phosphorylation of p42/44 mitogen-activated protein kinase, an enhancement of both NF-kappaB DNA binding and transcriptional activities, and a concentration-dependent increase of HT-29 cell proliferation. These effects are consistent with the presence of leptin receptors on cell membranes. The leptin induction of cell growth was associated with an increase of cell population in S and G(2)/M phase compared with control cells found in G(0)/G(1) phase of the cell cycle. Moreover, cyclin D1 immunoreactivity was enhanced in leptin-treated HT-29 cells and this increase was essentially associated with cell population in G(0)/G(1) phase. On the other hand, we observed that sodium butyrate inhibited cell proliferation by blocking HT-29 cells in G(0)/G(1) phase of the cell cycle. Interestingly, at physiological concentration, leptin prevented sodium butyrate-induced morphological nucleus changes, DNA laddering and suppressed butyrate-induced cell cycle arrest. This anti-apoptotic effect of leptin was associated with HT-29 cell proliferation and activation NF-kappaB pathways. However, the phosphorylation of p42/44 MAP kinase in response to leptin was reduced in butyrate-treated cells. These data demonstrated that leptin is a potent mitogenic factor for intestinal epithelial cells through the MAP kinase and NF-kappaB pathways. They also showed, for the first time, that leptin promotes colon cancer HT-29 cell survival upon butyrate challenge by counteracting the apoptotic programs initiated by this short chain fatty acid probably through the NF-kappaB pathways. Although further studies are required to unravel the precise mechanism, these data may have significance in the pathogenesis of colorectal cancer and ulcerative colitis diseases.	Univ Paris 07, Lab Neuroendocrinol & Biol Cellulaire Digest, INSERM, U410, F-75860 Paris 18, France; IFR 02, Serv Confocale, F-75860 Paris 18, France; IFR 02, Serv Cytometrie Flux Digest, F-75860 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bado, A (corresponding author), Univ Paris 07, Lab Neuroendocrinol & Biol Cellulaire Digest, INSERM, U410, 16 Rue Henri Huchard, F-75860 Paris 18, France.	bado@bichat.nserm.fr	Buyse, Marc/J-4658-2013; Guilmeau, Sandra/P-2318-2017	Guilmeau, Sandra/0000-0002-8260-1218; BADO, Andre/0000-0002-8007-1460				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Alavi K, 2002, J PEDIATR SURG, V37, P327, DOI 10.1053/jpsu.2002.30805; Andoh A, 2003, CURR PHARM DESIGN, V9, P347, DOI 10.2174/1381612033391973; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Berti L, 1999, MOL CELL ENDOCRINOL, V157, P121, DOI 10.1016/S0303-7207(99)00154-9; Buyse M, 2002, J BIOL CHEM, V277, P28182, DOI 10.1074/jbc.M203281200; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI13219; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Coradini D, 2000, CELL PROLIFERAT, V33, P139, DOI 10.1046/j.1365-2184.2000.00173.x; Della-Fera MA, 2003, BIOCHEM BIOPH RES CO, V303, P1053, DOI 10.1016/S0006-291X(03)00474-1; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1996, P NUTR SOC, V55, P937, DOI 10.1079/PNS19960090; Hardwick JCH, 2001, GASTROENTEROLOGY, V121, P79, DOI 10.1053/gast.2001.25490; HEERDT BG, 1994, CANCER RES, V54, P3288; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kim GS, 2003, J BIOL CHEM, V278, P21920, DOI 10.1074/jbc.M204598200; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liu ZH, 2001, INT J ONCOL, V19, P1009; Lollmann B, 1997, BIOCHEM BIOPH RES CO, V238, P648, DOI 10.1006/bbrc.1997.7205; Martin-Romero C, 2001, CELL IMMUNOL, V212, P83, DOI 10.1006/cimm.2001.1851; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Morton NM, 1999, J MOL ENDOCRINOL, V22, P173, DOI 10.1677/jme.0.0220173; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Najib S, 2001, J MOL ENDOCRINOL, V27, P85, DOI 10.1677/jme.0.0270085; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; SCHEPPACH W, 1995, EUR J CANCER, V31A, P1077, DOI 10.1016/0959-8049(95)00165-F; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Schwartz MW, 1999, AM J CLIN NUTR, V69, P584; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Tabuchi Y, 2002, BIOCHEM BIOPH RES CO, V293, P1287, DOI 10.1016/S0006-291X(02)00365-0; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	43	119	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16495	16502		10.1074/jbc.M312999200	http://dx.doi.org/10.1074/jbc.M312999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14752104	hybrid			2022-12-27	WOS:000220747900098
J	Ueoka-Nakanishi, H; Nakanishi, Y; Konno, H; Motohashi, K; Bald, D; Hisabori, T				Ueoka-Nakanishi, H; Nakanishi, Y; Konno, H; Motohashi, K; Bald, D; Hisabori, T			Inverse regulation of rotation of F-1-ATPase by the mutation at the regulatory region on the gamma subunit of chloroplast ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; DISULFIDE BOND; SITE; THIOREDOXIN; ACTIVATION; CATALYSIS; SYNECHOCYSTIS-6803; MITOCHONDRIAL	In F-1-ATPase, the rotation of the central axis subunit gamma relative to the surrounding alpha(3)beta(3) subunits is coupled to ATP hydrolysis. We previously reported that the introduced regulatory region of the gamma subunit of chloroplast F-1-ATPase can modulate rotation of the gamma subunit of the thermophilic bacterial F-1-ATPase (Bald, D., Noji, H., Yoshida, M., Hirono-Hara, Y., and Hisabori, T. (2001) J. Biol. Chem. 276, 39505-39507). The attenuated enzyme activity of this chimeric enzyme under oxidizing conditions was characterized by frequent and long pauses of rotation of gamma. In this study, we report an inverse regulation of the gamma subunit rotation in the newly engineered F-1-chimeric complex whose three negatively charged residues Glu(210)-Asp(211)-Glu(212) adjacent to two cysteine residues of the regulatory region derived from chloroplast F-1-ATPase gamma were deleted. ATP hydrolysis activity of the mutant complex was stimulated up to 2-fold by the formation of the disulfide bond at the regulatory region by oxidation. We successfully observed inverse redox switching of rotation of gamma using this mutant complex. The complex exhibited long and frequent pauses in its gamma rotation when reduced, but the rotation rates between pauses remained unaltered. Hence, the suppression or activation of the redox-sensitive F-1-ATPase can be explained in terms of the change in the rotation behavior at a single molecule level. These results obtained by the single molecule analysis of the redox regulation provide further insights into the regulation mechanism of the rotary enzyme.	Japan Sci & Technol Agcy, ERATO, ATP Syst Project, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan; Free Univ Amsterdam, Dept Biol Struct, NL-1081 Amsterdam, Netherlands	Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Nagoya University; Vrije Universiteit Amsterdam	Hisabori, T (corresponding author), Japan Sci & Technol Agcy, ERATO, ATP Syst Project, Midori Ku, 5800-3 Nagatsuta Cho, Yokohama, Kanagawa 2260026, Japan.	thisabor@res.titech.ac.jp	Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Bald D, 2001, J BIOL CHEM, V276, P39505, DOI 10.1074/jbc.C100436200; Bald D, 2000, J BIOL CHEM, V275, P12757, DOI 10.1074/jbc.275.17.12757; Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; Groth G, 2001, J BIOL CHEM, V276, P1345, DOI 10.1074/jbc.M008015200; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; Jacquot JP, 2002, ANN NY ACAD SCI, V973, P508, DOI 10.1111/j.1749-6632.2002.tb04692.x; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Konno H, 2000, BIOCHEM J, V352, P783, DOI 10.1042/0264-6021:3520783; Krenn BE, 1997, BIOCHEM J, V323, P841, DOI 10.1042/bj3230841; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; Mellwig C, 2003, J BIOL CHEM, V278, P18544, DOI 10.1074/jbc.M212852200; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MILLS JD, 1980, FEBS LETT, V112, P173, DOI 10.1016/0014-5793(80)80173-6; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; ROSS SA, 1995, J BIOL CHEM, V270, P9813, DOI 10.1074/jbc.270.17.9813; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shimabukuro K, 2003, P NATL ACAD SCI USA, V100, P14731, DOI 10.1073/pnas.2434983100; Stumpp MT, 1999, BIOCHEM J, V341, P157, DOI 10.1042/0264-6021:3410157; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WERNERGRUNE S, 1994, MOL GEN GENET, V244, P144; YOSHIDA M, 1979, J BIOL CHEM, V254, P9525; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	34	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16272	16277		10.1074/jbc.M400607200	http://dx.doi.org/10.1074/jbc.M400607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14747461	hybrid, Green Published			2022-12-27	WOS:000220747900071
J	Le Bras, S; Foucault, I; Foussat, A; Brignone, C; Acuto, O; Deckert, M				Le Bras, S; Foucault, I; Foussat, A; Brignone, C; Acuto, O; Deckert, M			Recruitment of the actin-binding protein HIP-55 to the immunological synapse regulates T cell receptor signaling and endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE ANTIGEN RECEPTORS; NEGATIVE REGULATION; ADAPTER PROTEINS; FUNCTIONAL-ANALYSIS; DOWN-MODULATION; LINKER PROTEIN; C-CBL; ACTIVATION; CYTOSKELETON; TRANSDUCTION	Actin cytoskeleton dynamics critically regulate T cell activation. We found that the cytoplasmic adaptor HIP-55, a Src/Syk-kinases substrate and member of the drebrin/ Abp1 family of actin-binding proteins, localized to the T cell-antigen-presenting cell (APC) contact site in an antigen-dependent manner. Using green fluorescent protein fusion proteins, both Src homology 3 (SH3) and actin binding domains were found necessary for recruitment at the T cell-APC interface. HIP-55 was not implicated in conjugate formation and actin polymerization but regulated distal signaling events through binding and activation of hematopoietic progenitor kinase 1 (HPK1), a germinal center kinase (GCK) family kinase involved in negative signaling in T cells. Using RNA interference and overexpression experiments, the HIP-55- HPK1 complex was found to negatively regulate nuclear factor of activated T cell ( NFAT) activation by the T cell antigen receptor. Moreover, we show that HIP-55, which partly co-localized with early endocytic compartments, promoted both basal and ligand-dependent T cell receptor (TCR) down-modulation, resulting in a decreased TCR expression. SH3 and actin-depolymerizing factor homology domains were required for this function. As controls, the expression of CD28 and the glycosylphosphatidylinositol-linked protein CD59 was not affected by HIP-55 overexpression. These results suggest that, in addition to binding to HPK1, HIP-55 might negatively regulate TCR signaling through down-regulation of TCR expression. Our findings show that HIP-55 is a key novel component of the immunological synapse that modulates T cell activation by connecting actin cytoskeleton and TCRs to gene activation and endocytic processes.	INSERM, U576, Hop Archet, F-06202 Nice 3, France; Inst Pasteur, CNRS, URA 1961, Unite Immunol Mol, F-75015 Paris, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Deckert, M (corresponding author), INSERM, U576, Hop Archet, F-06202 Nice 3, France.	deckert@unice.fr	Deckert, Marcel/T-3566-2019; Deckert, Marcel/M-4998-2016	Deckert, Marcel/0000-0003-2094-559X; 				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; CALLEWAERT DM, 1991, CYTOMETRY, V12, P666, DOI 10.1002/cyto.990120711; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; Egen JG, 2002, IMMUNITY, V16, P23, DOI 10.1016/S1074-7613(01)00259-X; Ensenat D, 1999, J BIOL CHEM, V274, P33945, DOI 10.1074/jbc.274.48.33945; Fazi B, 2002, J BIOL CHEM, V277, P5290, DOI 10.1074/jbc.M109848200; Fuller CL, 2003, IMMUNOL REV, V191, P220, DOI 10.1034/j.1600-065X.2003.00004.x; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; ISHIKAWA R, 1994, J BIOL CHEM, V269, P29928; Jang IK, 2003, CURR OPIN IMMUNOL, V15, P315, DOI 10.1016/S0952-7915(03)00048-7; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Lanzavecchia A, 2001, NAT IMMUNOL, V2, P487, DOI 10.1038/88678; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Larbolette O, 1999, MOL CELL BIOL, V19, P1539; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Loreto MP, 2002, MOL CELL BIOL, V22, P4241, DOI 10.1128/MCB.22.12.4241-4255.2002; Mise-Omata S, 2003, BIOCHEM BIOPH RES CO, V301, P704, DOI 10.1016/S0006-291X(02)02972-8; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Olazabal IM, 2001, J CELL BIOL, V154, P679, DOI 10.1083/jcb.200105061; Putnam MA, 2003, J IMMUNOL, V170, P905, DOI 10.4049/jimmunol.170.2.905; Ramjaun AR, 2001, J BIOL CHEM, V276, P28913, DOI 10.1074/jbc.M103198200; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; van der Merwe PA, 2002, CURR OPIN IMMUNOL, V14, P293, DOI 10.1016/S0952-7915(02)00350-3; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	47	67	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15550	15560		10.1074/jbc.M312659200	http://dx.doi.org/10.1074/jbc.M312659200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14729663	hybrid			2022-12-27	WOS:000220594700127
J	Neufeld, EB; Stonik, JA; Demosky, SJ; Knapper, CL; Combs, CA; Cooney, A; Comly, M; Dwyer, N; Blanchette-Mackie, J; Remaley, AT; Santamarina-Fojo, S; Brewer, HB				Neufeld, EB; Stonik, JA; Demosky, SJ; Knapper, CL; Combs, CA; Cooney, A; Comly, M; Dwyer, N; Blanchette-Mackie, J; Remaley, AT; Santamarina-Fojo, S; Brewer, HB			The ABCA1 transporter modulates late endocytic trafficking - Insights from the correction of the genetic defect in Tangier Disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; CHOLESTEROL EFFLUX; LIPID EFFLUX; CELLULAR CHOLESTEROL; PATHWAY; MEMBRANE; LOCALIZATION; REMOVAL; SURFACE; PHOSPHOLIPIDS	We have previously established that the ABCA1 transporter, which plays a critical role in the lipidation of extracellular apolipoprotein acceptors, traffics between late endocytic vesicles and the cell surface (Neufeld, E. B., Remaley, A. T., Demosky, S. J., Jr., Stonik, J. A., Cooney, A. M., Comly, M., Dwyer, N. K., Zhang, M., Blanchette-Mackie, J., Santamarina-Fojo, S., and Brewer, H. B., Jr. (2001) J. Biol. Chem. 276, 27584-27590). The present study provides evidence that ABCA1 in late endocytic vesicles plays a role in cellular lipid efflux. Late endocytic trafficking was defective in Tangier disease fibroblasts that lack functional ABCA1. Consistent with a late endocytic protein trafficking defect, the hydrophobic amine U18666A retained NPC1 in abnormally tubulated, cholesterol-poor, Tangier disease late endosomes, rather than cholesterol-laden lysosomes, as in wild type fibroblasts. Consistent with a lipid trafficking defect, Tangier disease late endocytic vesicles accumulated both cholesterol and sphingomyelin and were immobilized in a perinuclear localization. The excess cholesterol in Tangier disease late endocytic vesicles retained massive amounts of NPC1, which traffics lysosomal cholesterol to other cellular sites. Exogenous apoA-I abrogated the cholesterol-induced retention of NPC1 in wild type but not in Tangier disease late endosomes. Adenovirally mediated ABCA1-GFP expression in Tangier disease fibroblasts corrected the late endocytic trafficking defects and restored apoA-I-mediated cholesterol efflux. ABCA1-GFP expression in wild type fibroblasts also reduced late endosome-associated NPC1, induced a marked uptake of fluorescent apoA-I into ABCA1-GFP-containing endosomes (that shuttled between late endosomes and the cell surface), and enhanced apoA-I-mediated cholesterol efflux. The combined results of this study suggest that ABCA1 converts pools of late endocytic lipids that retain NPC1 to pools that can associate with endocytosed apoA-I, and be released from the cell as nascent high density lipoprotein.	NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Light Microscopy Core Facil, Bethesda, MD 20892 USA; NIDDK, Lab Cellular Biol & Biochem, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Neufeld, EB (corresponding author), NHLBI, Mol Dis Branch, NIH, 10-7N115,10 Ctr Dr, Bethesda, MD 20892 USA.	neufelde@mail.nih.gov	Neufeld, Edward/R-3819-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, ZIADK060003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], METABOLIC MOL BASES; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Assmann G, 2001, METABOLIC MOL BASES, P2937; Blom TS, 2003, HUM MOL GENET, V12, P257, DOI 10.1093/hmg/ddg025; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hovingh GK, 2003, J LIPID RES, V44, P1251, DOI 10.1194/jlr.M300080-JLR200; Johansson M, 2003, MOL BIOL CELL, V14, P903, DOI 10.1091/mbc.E02-08-0459; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Mendez AJ, 1997, J LIPID RES, V38, P1807; Neufeld EB, 2002, BIOCHEM BIOPH RES CO, V297, P974, DOI 10.1016/S0006-291X(02)02274-X; Neufeld EB, 2001, CIRCULATION, V104, P147; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Pagano RE, 1998, ANN NY ACAD SCI, V845, P152, DOI 10.1111/j.1749-6632.1998.tb09668.x; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	39	157	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					15571	15578		10.1074/jbc.M314160200	http://dx.doi.org/10.1074/jbc.M314160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14747463	hybrid			2022-12-27	WOS:000220594700129
J	Surguladze, N; Thompson, KM; Beard, JL; Connor, JR; Fried, MG				Surguladze, N; Thompson, KM; Beard, JL; Connor, JR; Fried, MG			Interactions and reactions of ferritin with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL EPITHELIAL-CELLS; GLOBIN GENE-EXPRESSION; IRON-SULFUR CENTER; RAT-LIVER NUCLEI; GEL-ELECTROPHORESIS; RIBONUCLEOTIDE REDUCTASE; LIPID-PEROXIDATION; PROTECTS DNA; K562 CELLS; BINDING	Ferritin, normally considered a cytoplasmic iron-storage protein, is also found in the nuclei of some cells. There is no current agreement about its function(s) in this environment. Proposals include DNA protection, provision of iron to nuclear enzymes, and regulation of transcription initiation, but evidence for these functions is scanty. We have shown previously that H-ferritin subunits can be cross-linked to chromosomal DNA in vivo (Thompson, K. J., Fried, M. G., Ye, Z., Boyer, P., and Connor, J. R. ( 2002) J. Cell Sci. 115, 2165 - 2177). Here we describe systematic analyses of DNA binding and the covalent stability of DNA in the presence of ferritins from several different sources. Our data show that the H-subunit of human ferritin binds DNA, whereas neither the L-subunit nor the ferroxidase-deficient 222-mutant of the H-subunit has detectable binding activity. DNA binding is without significant preference for base composition, sequence, or the nature of DNA ends. Hand L-ferritins and ferritins of mixed subunit composition stimulate the conversion of superhelical plasmid DNA to the relaxed form. The sensitivity of this conversion to glycerol suggests that DNA is nicked by a free radical mechanism. The rate of nicking correlates with the iron content of the ferritin and is strongly inhibited by chelators. Ferritin-dependent nicking is characterized by a kinetic lag that is not seen in control reactions containing free iron species. These results suggest that the release of iron from ferritin is an important part of the nicking mechanism. The potential role of ferritin as a protector of the genome is discussed in the context of these results.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA; Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Fried, MG (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	mfried@psu.edu			NIDDK NIH HHS [DK54289] Funding Source: Medline; NIGMS NIH HHS [R01 GM070662, R01 GM070662-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070662] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRONIKASHVILI EL, 1974, CANCER RES, V34, P271; BAUER WR, 1978, ANNU REV BIOPHYS BIO, V7, P287, DOI 10.1146/annurev.bb.07.060178.001443; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; BRODERSEN R, 1987, EUR J BIOCHEM, V169, P487, DOI 10.1111/j.1432-1033.1987.tb13636.x; Broyles RH, 2001, P NATL ACAD SCI USA, V98, P9145, DOI 10.1073/pnas.151147098; BROYLES RH, 1995, COLLOQ INSE, V234, P43; Cai CX, 1997, J BIOL CHEM, V272, P12831, DOI 10.1074/jbc.272.19.12831; Cai CX, 2001, J CELL SCI, V114, P2327; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; CHASTEEN ND, 1994, ADV EXP MED BIOL, V356, P23; Cheepsunthorn P, 2001, J COMP NEUROL, V431, P382, DOI 10.1002/1096-9861(20010319)431:4<382::AID-CNE1077>3.0.CO;2-#; Erikson KM, 1997, J NUTR, V127, P2030, DOI 10.1093/jn/127.10.2030; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; Fried MG, 1997, ELECTROPHORESIS, V18, P6, DOI 10.1002/elps.1150180103; Fried MG, 1998, ELECTROPHORESIS, V19, P1247, DOI 10.1002/elps.1150190804; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Gurgueira SA, 1996, J BIOL CHEM, V271, P13616, DOI 10.1074/jbc.271.23.13616; Gutfreund H, 1995, KINETICS LIFE SCI, P103; HADDOW A, 1960, J NATL CANCER I, V24, P109; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HILL TL, 1986, INTRO STAT THERMODYN, P59; HURTA RAR, 1991, BIOCHEM CELL BIOL, V69, P635, DOI 10.1139/o91-094; IANCU TC, 1985, J HEPATOL, V1, P261, DOI 10.1016/S0168-8278(85)80054-4; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Kurien BT, 1997, ANAL BIOCHEM, V245, P123, DOI 10.1006/abio.1996.9971; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Orino K, 2002, BIOMETALS, V15, P59, DOI 10.1023/A:1013102012234; Pountney D, 1999, J CELL SCI, V112, P825; PRINCE RC, 1993, TRENDS BIOCHEM SCI, V18, P153; *PROM CORP, 2000, PROM TECHN B, V33; REIF DW, 1988, ARCH BIOCHEM BIOPHYS, V264, P238, DOI 10.1016/0003-9861(88)90590-5; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; Romeo AM, 2001, J BIOL CHEM, V276, P24301, DOI 10.1074/jbc.M010806200; SAMOKYSZYN VM, 1988, DRUG METAB REV, V19, P283, DOI 10.3109/03602538808994137; SHIRES TK, 1982, BIOCHEM J, V205, P321, DOI 10.1042/bj2050321; SMITH AG, 1990, HEPATOLOGY, V12, P1399, DOI 10.1002/hep.1840120622; SPRAGUE ED, 1980, ANAL BIOCHEM, V101, P175, DOI 10.1016/0003-2697(80)90057-3; TACHON P, 1989, FREE RADICAL RES COM, V7, P1, DOI 10.3109/10715768909088155; Theil EC, 2003, J NUTR, V133, p1549S, DOI 10.1093/jn/133.5.1549S; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; Thompson KJ, 2002, J CELL SCI, V115, P2165; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; VACA CE, 1989, BIOCHIM BIOPHYS ACTA, V1001, P35, DOI 10.1016/0005-2760(89)90304-4; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WHITING RF, 1981, CANCER RES, V41, P1628; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; WU YJ, 1991, J BIOL CHEM, V266, P17566; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	54	58	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14694	14702		10.1074/jbc.M313348200	http://dx.doi.org/10.1074/jbc.M313348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14734543	hybrid			2022-12-27	WOS:000220594700029
J	Grosset, C; Boniface, R; Duchez, P; Solanilla, A; Cosson, B; Ripoche, J				Grosset, C; Boniface, R; Duchez, P; Solanilla, A; Cosson, B; Ripoche, J			In vivo studies of translational repression mediated by the granulocyte-macrophage colony-stimulating factor AU-rich element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; POLY(A) TAIL; POLY(A)-BINDING PROTEIN; UNTRANSLATED REGION; BINDING-PROTEIN; C-FOS; TURNOVER; DECAY; INITIATION; EUKARYOTES	The AU-rich element (ARE) controls the turnover of many unstable mRNAs and their translation. The granulocyte-macrophage colony-stimulating factor (GMCSF) ARE is known to be a destabilizing element, but its role in translation remains unclear. Here we studied in vivo the role of the GM-CSF ARE on the mRNA and protein expressions of an enhanced green fluorescent protein reporter gene. The GM-CSF ARE had a repressor effect on translation independently of its effect on mRNA levels. In the context of an internal ribosome entry site, the GM-CSF ARE still repressed translation but was no longer functional as a destabilizing element. Gel retardation assays showed that poly(A)-binding protein is displaced from the poly(A) tail when the ARE is present in the 3'-untranslated region. These data suggest that the GM-CSF ARE controls translation and mRNA decay by interfering with poly(A)-binding protein-mediated mRNA circularization.	Univ Bordeaux 2, CNRS, FRE 2617, F-33076 Bordeaux, France; Univ Rennes 1, CNRS, UMR 6061, F-35043 Rennes, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Grosset, C (corresponding author), Univ Bordeaux 2, CNRS, FRE 2617, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	christophe.grosset@umr5540.u-bordeaux2.fr	Grosset, Christophe/I-5059-2016; Grosset, Christophe/P-9864-2019	Grosset, Christophe/0000-0002-0479-6291; Grosset, Christophe/0000-0002-0479-6291; DUCHEZ, PASCALE/0000-0003-1474-3764; Cosson, Bertrand/0000-0003-3401-7137				BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Bollig F, 2003, BIOCHEM BIOPH RES CO, V301, P665, DOI 10.1016/S0006-291X(03)00015-9; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; D'Orso I, 2002, J BIOL CHEM, V277, P50520, DOI 10.1074/jbc.M209092200; Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Houzet L, 2001, BLOOD, V98, P1281, DOI 10.1182/blood.V98.5.1281; Jarzembowski JA, 1999, NUCLEIC ACIDS RES, V27, P3660, DOI 10.1093/nar/27.18.3660; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699; Mazumder B, 2001, MOL CELL BIOL, V21, P6440, DOI 10.1128/MCB.21.19.6440-6449.2001; Metcalf D, 1997, CIBA F SYMP, V204, P40; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Svitkin YV, 2001, RNA, V7, P1743; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wiklund L, 2002, J BIOL CHEM, V277, P40462, DOI 10.1074/jbc.M205929200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001	35	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13354	13362		10.1074/jbc.M308003200	http://dx.doi.org/10.1074/jbc.M308003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14726527	hybrid			2022-12-27	WOS:000220478500012
J	Jin, P; Walther, D; Zhang, J; Rowe-Teeter, C; Fu, GK				Jin, P; Walther, D; Zhang, J; Rowe-Teeter, C; Fu, GK			Serine 171, a conserved residue in the gamma-aminobutyric acid type A (GABA(A)) receptor gamma 2 subunit, mediates subunit interaction and cell surface localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNITS; INTERSUBUNIT CONTACTS; ALPHA-SUBUNITS; IDENTIFICATION; EXPRESSION; SUBTYPES; CLONING	Serine 171 in the GABA(A) receptor gamma2 subunit is highly conserved in the ligand-gated ion channel superfamily. In this paper, we report that mutating serine 171 within gamma2 to glycine or cysteine prevents the interaction of gamma2 with alpha2 and beta1 when these subunits are co-expressed in human embryo kidney 293 cells, resulting in intracellular retention of gamma2. Structure analysis based on a three-dimensional homology model of gamma2 (Ernst, M., Brauchart, D., Boresch, S., and Sieghart, W. (2003) Neuroscience 119, 933 - 943) reveals that serine 171 may play a critical role in the formation and stabilization of an exposed turn structure that is part of the subunit interaction site. Mutation of serine 171 in the gamma2 subunit could therefore result in alteration of the structure of the subunit interaction site, preventing correct subunit assembly.	Incyte Corp, Palo Alto, CA 94304 USA	Incyte	Jin, P (corresponding author), Incyte Corp, 3160 Porter Dr, Palo Alto, CA 94304 USA.	pjin@incyte.com		Walther, Dirk/0000-0002-5755-9265				BLOOM FE, 2001, GOODMAN GILMANS PHAR; Bollan K, 2003, J BIOL CHEM, V278, P4747, DOI 10.1074/jbc.M210229200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Ernst M, 2003, NEUROSCIENCE, V119, P933, DOI 10.1016/S0306-4522(03)00288-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Jin P, 2004, J BIOL CHEM, V279, P1408, DOI 10.1074/jbc.M308656200; JIN P, 2004, IN PRESS GENETICS; Klausberger T, 2000, J BIOL CHEM, V275, P8921, DOI 10.1074/jbc.275.12.8921; Klausberger T, 2001, J BIOL CHEM, V276, P16024, DOI 10.1074/jbc.M009508200; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; NAYEEM N, 1994, J NEUROCHEM, V62, P815; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PREGENZER JF, 1993, MOL PHARMACOL, V43, P801; Russell RB, 1997, J MOL BIOL, V269, P423, DOI 10.1006/jmbi.1997.1019; Taylor PM, 2000, J NEUROSCI, V20, P1297; Taylor PM, 1999, J NEUROSCI, V19, P6360; Trudell JR, 2002, BBA-BIOMEMBRANES, V1565, P91, DOI 10.1016/S0005-2736(02)00512-6; Whiting PJ, 1997, J NEUROSCI, V17, P5027	24	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14179	14183		10.1074/jbc.M313411200	http://dx.doi.org/10.1074/jbc.M313411200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14736867	hybrid			2022-12-27	WOS:000220478500109
J	Kramer, G; Patzelt, H; Rauch, T; Kurz, TA; Vorderwulbecke, S; Bukau, B; Deuerling, E				Kramer, G; Patzelt, H; Rauch, T; Kurz, TA; Vorderwulbecke, S; Bukau, B; Deuerling, E			Trigger factor peptidyl-prolyl cis/trans isomerase activity is not essential for the folding of cytosolic proteins in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASCENT POLYPEPTIDES; ENZYMATIC CATALYSIS; MUTATIONAL ANALYSIS; DNAK; DOMAIN; SUBSTRATE; BINDING; SITE; IDENTIFICATION; ISOMERIZATION	The ribosome-associated Trigger Factor (TF) cooperates with the DnaK system to assist the folding of newly synthesized polypeptides in Escherichia coli. TF unifies two functions in one to promote proper protein folding in vitro. First, as a chaperone it binds to unfolded protein substrates, thereby preventing aggregation and supporting productive folding. Second, TF catalyzes the cis/trans isomerization of peptidyl-prolyl bonds, which can be a rate-limiting step in protein folding. Here, we investigated whether the peptidyl-prolyl cis/trans isomerase ( PPIase) function is essential for the folding activity of TF in vitro and in vivo by separating these two TF activities through site-directed mutagenesis of the PPIase catalytic center. Of the four different TF variants carrying point mutations in the PPIase domain, only the exchange of the conserved residue Phe-198 to Ala (TF F198A) abolished the PPIase activity of TF toward both a tetrapeptide and the model protein substrate RNase T1 in vitro. In contrast, all other activities of TF F198A tested were comparable with wild type TF. TF F198A retained a similar binding specificity toward membrane-bound peptides, assisted the refolding of denatured D-glyceraldehyde-3-phosphate dehydrogenase in vitro, and associated with nascent polypeptides in an in vitro transcription/translation system. Importantly, expression of the TF F198A encoding gene complemented the synthetic lethality of DeltatigDeltadnaK cells and prevented global protein misfolding at temperatures between 20 and 34 degreesC in these cells. We conclude that the PPIase activity is not required for the function of TF in folding of newly synthesized proteins.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Deuerling, E (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	e.deuerling@zmbh.uni-heidelberg.de		Patzelt, Holger/0000-0001-9886-8374; Bukau, Bernd/0000-0003-0521-7199; Kramer, Gunter/0000-0001-7552-8393				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; CALLEBAUT I, 1995, FEBS LETT, V374, P211, DOI 10.1016/0014-5793(95)01109-R; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeCenzo MT, 1996, PROTEIN ENG, V9, P173, DOI 10.1093/protein/9.2.173; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; FISCHER G, 1992, MOL MICROBIOL, V6, P1375, DOI 10.1111/j.1365-2958.1992.tb00858.x; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; Hesterkamp T, 1996, FEBS LETT, V385, P67, DOI 10.1016/0014-5793(96)00351-1; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Huang GC, 2000, PROTEIN SCI, V9, P1254, DOI 10.1110/ps.9.6.1254; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lyon WR, 2003, J BACTERIOL, V185, P3661, DOI 10.1128/JB.185.12.3661-3667.2003; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; MUCKE M, 1992, BIOCHEMISTRY-US, V31, P7848; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Ramm K, 2001, J MOL BIOL, V310, P485, DOI 10.1006/jmbi.2001.4747; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schaffitzel E, 2001, BIOL CHEM, V382, P1235, DOI 10.1515/BC.2001.154; Schiene-Fischer C, 2002, BIOL CHEM, V383, P1865, DOI 10.1515/BC.2002.210; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; Scholz C, 1997, FEBS LETT, V414, P69, DOI 10.1016/S0014-5793(97)00979-4; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Stoller G, 1996, FEBS LETT, V384, P117, DOI 10.1016/0014-5793(96)00282-7; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x	33	81	83	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14165	14170		10.1074/jbc.M313635200	http://dx.doi.org/10.1074/jbc.M313635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729669	Green Published, hybrid			2022-12-27	WOS:000220478500107
J	Li, SS; Smerdon, MJ				Li, SS; Smerdon, MJ			Dissecting transcription-coupled and global genomic repair in the chromatin of yeast GAL1-10 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; RNA-POLYMERASE-II; CYCLOBUTANE PYRIMIDINE DIMERS; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; PREFERENTIAL REPAIR; CONTROL REGION; SACCHAROMYCES-CEREVISIAE-MFA2 GENE; NONTRANSCRIBED STRAND; XERODERMA-PIGMENTOSUM	Transcription-coupled repair (TCR) and global genomic repair (GGR) of UV-induced cyclobutane pyrimidine dimers were investigated in the yeast GAL1-10 genes. Both Rpb9- and Rad26-mediated TCR are confined to the transcribed strands, initiating at upstream sites similar to 100 nucleotides from the upstream activating sequence shared by the two genes. However, TCR initiation sites do not correlate with either transcription start sites or TATA boxes. Rad16-mediated GGR tightly correlates with nucleosome positioning when the genes are repressed and are slow in the nucleosome core and fast in linker DNA. Induction of transcription enhanced GGR in nucleosome core DNA, especially in the nucleosomes around and upstream of the transcription start sites. Furthermore, when the genes were induced, GGR was slower in the transcribed regions than in the upstream regions. Finally, simultaneous deletion of RAD16, RAD26, and RPB9 resulted in no detectable repair in all sites along the region analyzed. Our results suggest that ( a) TCR may be initiated by a transcription activator, presumably through the loading of RNA polymerase II, rather than by transcription initiation or elongation per se; (b) TCR and nucleosome disruption-enhanced GGR are the major causes of rapid repair in regions around and upstream of transcription start sites; ( c) transcription machinery may hinder access of NER factors to a DNA lesion in the absence of a transcription-repair coupling factor; and (d) other than GGR mediated by Rad16 and TCR mediated by Rad26 and Rpb9, no other nucleotide excision repair pathway exists in these RNA polymerase II-transcribed genes.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	smerdon@mail.wsu.edu	Li, Shisheng/H-9126-2012		NIEHS NIH HHS [ES04106, R01 ES002614, R37 ES002614, ES02614, R01 ES004106] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R01ES004106, R37ES002614] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; Conconi A, 2002, P NATL ACAD SCI USA, V99, P649, DOI 10.1073/pnas.022373099; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Feng ZH, 2002, J BIOL CHEM, V277, P12777, DOI 10.1074/jbc.M112297200; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P13117, DOI 10.1021/bi00040a024; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; Hu WW, 2002, J BIOL CHEM, V277, P38305, DOI 10.1074/jbc.M206375200; Jansen LET, 2000, EMBO J, V19, P6498, DOI 10.1093/emboj/19.23.6498; KUNALA S, 1995, J MOL BIOL, V246, P264, DOI 10.1006/jmbi.1994.0082; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Li SS, 1996, CARCINOGENESIS, V17, P1549, DOI 10.1093/carcin/17.8.1549; Li SS, 2000, METHODS, V22, P170, DOI 10.1006/meth.2000.1058; Li SS, 1997, J MOL BIOL, V271, P31, DOI 10.1006/jmbi.1997.1154; Li SS, 1999, NUCLEIC ACIDS RES, V27, P3610, DOI 10.1093/nar/27.17.3610; Li SS, 2002, J BIOL CHEM, V277, P44651, DOI 10.1074/jbc.M206623200; Li SS, 2002, EMBO J, V21, P5921, DOI 10.1093/emboj/cdf589; Liu XQ, 2000, J BIOL CHEM, V275, P23729, DOI 10.1074/jbc.M002206200; Lloyd RS, 1998, MUTAT RES-DNA REPAIR, V408, P159, DOI 10.1016/S0921-8777(98)00032-9; LOHR D, 1987, J BIOL CHEM, V262, P15589; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Meier A, 2002, J BIOL CHEM, V277, P11845, DOI 10.1074/jbc.M110941200; Powell NG, 2003, DNA REPAIR, V2, P375, DOI 10.1016/S1568-7864(02)00239-2; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1591, DOI 10.1093/carcin/14.8.1591; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Teng YM, 1997, J MOL BIOL, V267, P324, DOI 10.1006/jmbi.1996.0908; Teng YM, 2000, NUCLEIC ACIDS RES, V28, P1114, DOI 10.1093/nar/28.5.1114; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tijsterman M, 1999, MOL CELL BIOL, V19, P934; Tijsterman M, 1997, P NATL ACAD SCI USA, V94, P8027, DOI 10.1073/pnas.94.15.8027; Tommasi S, 2000, NUCLEIC ACIDS RES, V28, P3991, DOI 10.1093/nar/28.20.3991; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; Tu YQ, 1998, MUTAT RES-FUND MOL M, V400, P143, DOI 10.1016/S0027-5107(98)00038-4; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; VONHOLDE KE, 1989, CHROMATIN, P289; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; WOLFFE AP, 1999, CHROMATIN STRUCTURE, P7; Zheng Y, 2001, J BIOL CHEM, V276, P16786, DOI 10.1074/jbc.M010973200	53	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					14418	14426		10.1074/jbc.M312004200	http://dx.doi.org/10.1074/jbc.M312004200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734564	hybrid, Green Accepted			2022-12-27	WOS:000220478500138
J	Sounni, NE; Roghi, C; Chabottaux, V; Janssen, M; Munaut, C; Maquoi, E; Galvez, BG; Gilles, C; Frankenne, F; Murphy, G; Foidart, JM; Noel, AS				Sounni, NE; Roghi, C; Chabottaux, V; Janssen, M; Munaut, C; Maquoi, E; Galvez, BG; Gilles, C; Frankenne, F; Murphy, G; Foidart, JM; Noel, AS			Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; FACTOR GENE-EXPRESSION; TISSUE INHIBITOR; TUMOR-GROWTH; INTEGRIN ALPHA-V-BETA-3; MAMMARY-CARCINOMA; ANGIOGENIC SWITCH; DOWN-REGULATION; CANCER-CELLS; C-SRC	Membrane-type 1 matrix metalloproteinase (MT1-MMP) and vascular endothelial growth factor ( VEGF) are two key molecules involved in pericellular proteolysis and cell proliferation during tumor growth and angiogenesis. Our previous data showed that MT1-MMP overexpression in human breast carcinoma MCF7 cells induced an up-regulation of VEGF expression. This effect was associated in vivo with accelerated tumor growth and angiogenesis. We now provide evidence that MT1-MMP overexpression specifically affected VEGF-A production and failed to influence that of other VEGF family members ( VEGF, B, C, D, or PlGF) or their receptors. The up-regulation of VEGF-A by MT1-MMP was related to an increased transcriptional activation rather than to a modification of mRNA stability. It was blocked by synthetic MMP inhibitors, TIMP2, but not TIMP-1 and abolished by a partial deletion of the catalytic domain or the cytoplasmic tail of MT1-MMP. Analysis of the signal transduction mechanisms demonstrated that MT1-MMP acts through a signaling pathway involving Src tyrosine kinases. Thus, our results provide new insight into the mechanisms of action of MT1-MMP during angiogenesis and suggest that the full enzymatic activity of MT1-MMP is required for a specific up-regulation of VEGF-A through an activation of Src tyrosine kinase pathways.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Cambridge, Cambridge Inst Med Res, Dept Oncol, Cambridge CB2 2XY, England; Hosp Princesa, Dept Inmunol, Madrid 28006, Spain	University of Liege; University of Cambridge; Hospital de La Princesa	Noel, AS (corresponding author), Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be	Munaut, Carine/K-8138-2019; Sounni, Nor Eddine/AAY-8766-2021; Gálvez, Beatriz G./H-1644-2015; Roghi, Christian/F-3228-2012	Sounni, Nor Eddine/0000-0001-9962-9236; Gálvez, Beatriz G./0000-0002-8082-9323; Roghi, Christian/0000-0002-4109-6382; Noel, Agnes/0000-0002-7670-6179				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; Arlt M, 2002, CANCER RES, V62, P5543; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Eccles SA, 1996, CANCER RES, V56, P2815; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; Fukuda R, 2003, CANCER RES, V63, P2330; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Goffin F, 2003, BIOL REPROD, V69, P976, DOI 10.1095/biolreprod.103.015933; Grams F, 2001, BIOL CHEM, V382, P1277, DOI 10.1515/BC.2001.159; Hajitou A, 2001, CANCER RES, V61, P3450; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Lafleur MA, 2002, J CELL SCI, V115, P3427; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Llano E, 1999, CANCER RES, V59, P2570; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Munaut C, 2003, INT J CANCER, V106, P848, DOI 10.1002/ijc.11313; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Sounni NE, 2003, MATRIX BIOL, V22, P55, DOI 10.1016/S0945-053X(03)00003-9; Sounni NE, 2002, INT J CANCER, V98, P23, DOI 10.1002/ijc.10134; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Velasco G, 2000, CANCER RES, V60, P877; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	55	121	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13564	13574		10.1074/jbc.M307688200	http://dx.doi.org/10.1074/jbc.M307688200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14729679	hybrid, Green Submitted, Green Published			2022-12-27	WOS:000220478500036
J	Wang, LH; Weng, LX; Dong, YH; Zhang, LH				Wang, LH; Weng, LX; Dong, YH; Zhang, LH			Specificity and enzyme kinetics of the quorum-quenching N-acyl homoserine lactone lactonase (AHL-lactonase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA VIRULENCE GENES; TO-CELL COMMUNICATION; PSEUDOMONAS-AERUGINOSA; ERWINIA-CAROTOVORA; AGROBACTERIUM-TUMEFACIENS; EXOENZYME PRODUCTION; SENSING SIGNAL; BETA-LACTAMASE; GLYOXALASE-II; AUTOINDUCER	N-Acyl homoserine lactone (AHL) quorum-sensing signals are the vital elements of bacterial quorum-sensing systems, which regulate diverse biological functions, including virulence. The AHL-lactonase, a quorum-quenching enzyme encoded by aiiA from Bacillus sp., inactivates AHLs by hydrolyzing the lactone bond to produce corresponding N-acyl homoserines. To characterize the enzyme, the recombinant AHL-lactonase and its four variants were purified. Kinetic and substrate specificity analysis showed that AHL-lactonase had no or little residue activity to non-acyl lactones and noncyclic esters, but displayed strong enzyme activity toward all tested AHLs, varying in length and nature of the substitution at the C3 position of the acyl chain. The data also indicate that the amide group and the ketone at the C1 position of the acyl chain of AHLs could be important structural features in enzyme-substrate interaction. Surprisingly, although carrying a (HX)-H-104-HXDH109 short sequence identical to the zinc-binding motif of several groups of metallohydrolytic enzymes, AHL-lactonase does not contain or require zinc or other metal ions for enzyme activity. Except for the amino acid residue His-104, which was shown previously to not be required for catalysis, kinetic study and conformational analysis using circular dichroism spectrometry showed that substitution of the other key residues in the motif (His-106, Asp-108, and His-109), as well as His-169 with serine, respectively, caused conformational changes and significant loss of enzyme activity. We conclude that AHL-lactonase is a highly specific enzyme and that the (HXDH109)-H-106 similar to H-169 of AHL-lactonase represents a novel catalytic motif, which does not rely on zinc or other metal ions for activity.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Wang, LH (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	lianhui@imcb.nus.edu.sg	Wang, Lianhui/D-6826-2016					Byers JT, 2002, J BACTERIOL, V184, P1163, DOI 10.1128/jb.184.4.1163-1171.2002; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Costa JM, 1997, CAN J MICROBIOL, V43, P1164, DOI 10.1139/m97-165; Crowder MW, 1997, FEBS LETT, V418, P351, DOI 10.1016/S0014-5793(97)01416-6; Dong YH, 2000, P NATL ACAD SCI USA, V97, P3526, DOI 10.1073/pnas.060023897; Dong YH, 2002, APPL ENVIRON MICROB, V68, P1754, DOI 10.1128/AEM.68.4.1754-1759.2002; Dong YH, 2001, NATURE, V411, P813, DOI 10.1038/35081101; Dunphy G, 1997, J BACTERIOL, V179, P5288, DOI 10.1128/jb.179.17.5288-5291.1997; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; Givskov M, 1996, J BACTERIOL, V178, P6618, DOI 10.1128/jb.178.22.6618-6622.1996; Gursky O, 2001, BIOCHEMISTRY-US, V40, P12178, DOI 10.1021/bi0111505; HUCHO F, 1972, BIOCHIM BIOPHYS ACTA, V276, P176, DOI 10.1016/0005-2744(72)90018-6; JONES S, 1993, EMBO J, V12, P2477, DOI 10.1002/j.1460-2075.1993.tb05902.x; JONG YJ, 1986, J BIOL CHEM, V261, P5112; Kobayashi M, 1998, P NATL ACAD SCI USA, V95, P12787, DOI 10.1073/pnas.95.22.12787; Leadbetter JR, 2000, J BACTERIOL, V182, P6921, DOI 10.1128/JB.182.24.6921-6926.2000; Lee SJ, 2002, APPL ENVIRON MICROB, V68, P3919, DOI 10.1128/AEM.68.8.3919-3924.2002; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P198; Lin YH, 2003, MOL MICROBIOL, V47, P849, DOI 10.1046/j.1365-2958.2003.03351.x; Manefield M, 2002, MICROBIOL-SGM, V148, P1119, DOI 10.1099/00221287-148-4-1119; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; Menguy T, 1998, ANAL BIOCHEM, V264, P141, DOI 10.1006/abio.1998.2854; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Mochizuki K, 2001, ARCH MICROBIOL, V175, P430, DOI 10.1007/s002030100283; Nasser W, 1998, MOL MICROBIOL, V29, P1391, DOI 10.1046/j.1365-2958.1998.01022.x; PASSADOR L, 1993, SCIENCE, V260, P1127, DOI 10.1126/science.8493556; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; PIRHONEN M, 1993, EMBO J, V12, P2467, DOI 10.1002/j.1460-2075.1993.tb05901.x; Reimmann C, 2002, MICROBIOL-SGM, V148, P923, DOI 10.1099/00221287-148-4-923; ROBERTS BD, 1978, BIOCHEM BIOPH RES CO, V84, P322, DOI 10.1016/0006-291X(78)90173-0; SHIMIZU S, 1992, EUR J BIOCHEM, V209, P383, DOI 10.1111/j.1432-1033.1992.tb17300.x; VONBODMAN SB, 1995, J BACTERIOL, V177, P5000, DOI 10.1128/JB.177.17.5000-5008.1995; Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Winans SC, 1998, TRENDS MICROBIOL, V6, P382, DOI 10.1016/S0966-842X(98)01338-9; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yates EA, 2002, INFECT IMMUN, V70, P5635, DOI 10.1128/IAI.70.10.5635-5646.2002; Zhang HB, 2002, P NATL ACAD SCI USA, V99, P4638, DOI 10.1073/pnas.022056699; Zhang LH, 2003, TRENDS PLANT SCI, V8, P238, DOI 10.1016/S1360-1385(03)00063-3; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0	41	154	177	2	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13645	13651		10.1074/jbc.M311194200	http://dx.doi.org/10.1074/jbc.M311194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14734559	hybrid			2022-12-27	WOS:000220478500046
J	Hiniker, A; Bardwell, JCA				Hiniker, A; Bardwell, JCA			In vivo substrate specificity of periplasmic disulfide oxidoreductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-BINDING PROTEIN; BOND FORMATION INVIVO; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-EXPRESSION; SHIGELLA-FLEXNERI; RIBONUCLEASE-I; DSBA; TRANSPORT; VITRO	In Escherichia coli, a family of periplasmic disulfide oxidoreductases catalyzes correct disulfide bond formation in periplasmic and secreted proteins. Despite the importance of native disulfide bonds in the folding and function of many proteins, a systematic investigation of the in vivo substrates of E. coli periplasmic disulfide oxidoreductases, including the well characterized oxidase DsbA, has not yet been performed. We combined a modified osmotic shock periplasmic extract and two-dimensional gel electrophoresis to identify substrates of the periplasmic oxidoreductases DsbA, DsbC, and DsbG. We found 10 cysteine- containing periplasmic proteins that are substrates of the disulfide oxidase DsbA, including PhoA and FlgI, previously established DsbA substrates. This technique did not detect any in vivo substrates of DsbG, but did identify two substrates of DsbC, RNase I and MepA. We confirmed that RNase I is a substrate of DsbC both in vivo and in vitro. This is the first time that DsbC has been shown to affect the in vivo function of a native E. coli protein, and the results strongly suggest that DsbC acts as a disulfide isomerase in vivo. We also demonstrate that DsbC, but not DsbG, is critical for the in vivo activity of RNase I, indicating that DsbC and DsbG do not function identically in vivo. The absence of substrates for DsbG suggests either that the in vivo substrate specificity of DsbG is more limited than that of DsbC or that DsbG is not active under the growth conditions tested. Our work represents one of the first times the in vivo substrate specificity of a folding catalyst system has been systematically investigated. Because our methodology is based on the simple assumption that the absence of a folding catalyst should cause its substrates to be present at decreased steady- state levels, this technique should be useful in analyzing the substrate specificity of any folding catalyst or chaperone for which mutations are available.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Sci Training Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu			NIGMS NIH HHS [GM 57039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Bohin JP, 2000, FEMS MICROBIOL LETT, V186, P11, DOI 10.1016/S0378-1097(00)00110-5; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; FORST S, 1987, J BIOL CHEM, V262, P16433; GESTELAND RF, 1966, J MOL BIOL, V16, P67, DOI 10.1016/S0022-2836(66)80263-2; Hiniker A, 2003, BIOCHEMISTRY-US, V42, P1179, DOI 10.1021/bi027141t; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; KANG CH, 1991, J BIOL CHEM, V266, P23893; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Kreimer DI, 2000, EUR J BIOCHEM, V267, P4242; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Li MS, 2001, BIOCHEM BIOPH RES CO, V288, P91, DOI 10.1006/bbrc.2001.5734; LOUBENS I, 1993, MOL MICROBIOL, V10, P329, DOI 10.1111/j.1365-2958.1993.tb01959.x; MEYER SE, 1990, J BACTERIOL, V172, P5501, DOI 10.1128/jb.172.9.5501-5502.1990; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NEU HC, 1965, J BIOL CHEM, V240, P3685; Nickitenko AV, 1995, BIOCHEMISTRY-US, V34, P16585, DOI 10.1021/bi00051a006; OXENDER DL, 1980, P NATL ACAD SCI-BIOL, V77, P1412, DOI 10.1073/pnas.77.3.1412; Padmanabhan S, 2001, ARCH BIOCHEM BIOPHYS, V390, P42, DOI 10.1006/abbi.2001.2359; Page F, 2001, J BACTERIOL, V183, P3134, DOI 10.1128/JB.183.10.3134-3141.2001; Pittman MS, 2002, J BIOL CHEM, V277, P49841, DOI 10.1074/jbc.M205615200; PUGSLEY AP, 1993, MOL GEN GENET, V237, P407, DOI 10.1007/BF00279445; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; Skorko-Glonek J, 2003, BBA-PROTEINS PROTEOM, V1649, P171, DOI 10.1016/S1570-9639(03)00170-5; Sone M, 1997, J BIOL CHEM, V272, P10349; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Tanaka N, 2000, J MOL BIOL, V298, P859, DOI 10.1006/jmbi.2000.3707; Waheed A, 1997, PROTEIN EXPRES PURIF, V9, P279, DOI 10.1006/prep.1996.0691; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; WATARAI M, 1995, P NATL ACAD SCI USA, V92, P4927, DOI 10.1073/pnas.92.11.4927; WURTZEL ET, 1982, J BIOL CHEM, V257, P13685; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; YIM HH, 1992, J BACTERIOL, V174, P3637, DOI 10.1128/JB.174.11.3637-3644.1992; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zhao Z, 2003, J BIOL CHEM, V278, P43292, DOI 10.1074/jbc.M306945200	54	134	136	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12967	12973		10.1074/jbc.M311391200	http://dx.doi.org/10.1074/jbc.M311391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14726535	hybrid			2022-12-27	WOS:000220334900115
